<SEC-DOCUMENT>0000912057-18-000251.txt : 20180618
<SEC-HEADER>0000912057-18-000251.hdr.sgml : 20180618
<ACCEPTANCE-DATETIME>20180611094028
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0000912057-18-000251
CONFORMED SUBMISSION TYPE:	DRS
PUBLIC DOCUMENT COUNT:		20
FILED AS OF DATE:		20180611
<PUBLIC-REL-DATE>20180618
DATE AS OF CHANGE:		20180611

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			RHYTHM PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001649904
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				462159271
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DRS
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	377-02110
		FILM NUMBER:		18891119

	BUSINESS ADDRESS:	
		STREET 1:		500 BOYLSTON STREET
		STREET 2:		11TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116
		BUSINESS PHONE:		857-264-4280

	MAIL ADDRESS:	
		STREET 1:		500 BOYLSTON STREET
		STREET 2:		11TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RHYTHM METABOLIC, INC.
		DATE OF NAME CHANGE:	20150803
</SEC-HEADER>
<DOCUMENT>
<TYPE>DRS
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<P><FONT SIZE=3 >
Use these links to rapidly review the document<BR>
<A HREF="#bg44601_table_of_contents">  TABLE OF CONTENTS</A> <BR>
<A HREF="#fa1"> TABLE OF CONTENTS 2</A><BR></font>
</P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>As confidentially submitted with the Securities and Exchange Commission on June&nbsp;11, 2018<BR>
This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains strictly confidential.  </B></FONT></P>

<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><B> Registration No.&nbsp;333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=1><B> &nbsp;<BR>  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=1><B> <div style="width:100%;border-top:solid #000000 3.0pt;padding:0in 0in 0in 0in;font-size:3.0pt;"></div>
<div style="width:100%;border-top:solid #000000 1.0pt;padding:0in 0in 0in 0in;font-size:4.0pt;"></div>  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>  </B></FONT><FONT SIZE=1><B>Washington, D.C. 20549  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="20%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="20%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=1><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>FORM S-1<BR>  </B></FONT><FONT SIZE=1><B>REGISTRATION STATEMENT<BR>
UNDER<BR>
THE SECURITIES ACT OF&nbsp;1933  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="20%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="20%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=1><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>RHYTHM PHARMACEUTICALS,&nbsp;INC.<BR>  </B></FONT><FONT SIZE=1>(Exact name of Registrant as specified in its charter) </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="20%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="20%" ALIGN="CENTER" >


 </I></FONT><FONT SIZE=1>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>
 <!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="31%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="31%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="31%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Delaware</B></FONT><FONT SIZE=1><BR>
(State or Other Jurisdiction of<BR>
Incorporation or Organization)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B> 2834</B></FONT><FONT SIZE=1><BR>
(Primary Standard Industrial<BR>
Classification Code Number)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B> 46-2159271</B></FONT><FONT SIZE=1><BR>
(I.R.S. Employer<BR>
Identification Number)</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="20%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="20%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=1>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>500 Boylston Street<BR>
11<SUP>th</SUP>&nbsp;Floor<BR>
Boston, MA 02116<BR>
(857)&nbsp;264-4280</B></FONT><FONT SIZE=1><BR>
(Address, including zip code, and telephone number, including area code, of Registrant's principal executive offices) </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="20%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="20%" ALIGN="CENTER" >


 </I></FONT><FONT SIZE=1>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Keith M. Gottesdiener, M.D.<BR>
Chief Executive Officer and President<BR>
Rhythm Pharmaceuticals,&nbsp;Inc.<BR>
500 Boylston Street<BR>
11<SUP>th</SUP>&nbsp;Floor<BR>
Boston, MA 02116<BR>
(857)&nbsp;264-4280<BR>  </B></FONT><FONT SIZE=1>(Name, address, including zip code, and telephone number, including area code, of agent for service) </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="20%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="20%" ALIGN="CENTER" >


 </I></FONT><FONT SIZE=1>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>
 <!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="46%" style="font-family:times;"></TD>
<TD WIDTH="30pt" style="font-family:times;"></TD>
<TD WIDTH="46%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD COLSPAN=3 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Please send copies of all communications to:</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=1><B>Julio E. Vega<BR>
Laurie A. Cerveny<BR>
Morgan, Lewis&nbsp;&amp; Bockius&nbsp;LLP<BR>
One Federal Street<BR>
Boston, MA 02110<BR>
(617)&nbsp;951-8000</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=1><B> Patrick O'Brien<BR>
Thomas J. Danielski<BR>
Ropes&nbsp;&amp; Gray&nbsp;LLP<BR>
Prudential Tower<BR>
800 Boylston Street<BR>
Boston, MA 02116<BR>
(617)&nbsp;951-7527</B></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Approximate date of commencement of the proposed sale to the public:<BR>
As soon as practicable after the effective date of this Registration Statement.  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule&nbsp;415 under the Securities Act,
check the following box.&nbsp;&nbsp;&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If this Form is filed to register additional securities for an offering pursuant to Rule&nbsp;462(b) under the Securities Act, check the following box and list
the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If this Form is a post-effective amendment filed pursuant to Rule&nbsp;462(c) under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If this Form is a post-effective amendment filed pursuant to Rule&nbsp;462(d) under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&nbsp;&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT> </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company, or an
emerging growth company. See the definitions of "large accelerated filer," "accelerated filer" "smaller reporting company" and "emerging growth company" in Rule&nbsp;12b-2 of the Exchange Act.
(Check one): </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:62%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"130%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="130%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="110pt" style="font-family:times;"></TD>
<TD WIDTH="10%" style="font-family:times;"></TD>
<TD WIDTH="84pt" style="font-family:times;"></TD>
<TD WIDTH="10%" style="font-family:times;"></TD>
<TD WIDTH="103pt" style="font-family:times;"></TD>
<TD WIDTH="10%" style="font-family:times;"></TD>
<TD WIDTH="128pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Large&nbsp;accelerated&nbsp;filer&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Accelerated&nbsp;filer&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Non-accelerated&nbsp;filer&nbsp;<FONT FACE="WINGDINGS">&#253;</FONT><BR></FONT> <FONT SIZE=1>(Do not check if a<BR>
smaller reporting company)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;text-align:center;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"text-align:center;" -->


 Smaller&nbsp;reporting&nbsp;company&nbsp;<FONT FACE="WINGDINGS">&#111;</FONT></font> <p align=center style="font-family:times;margin-top:0pt;margin-left:0pt;"> <FONT SIZE=1> Emerging growth company&nbsp;<FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section&nbsp;13(a) of the Exchange Act.&nbsp;<FONT FACE="WINGDINGS">&#253;</FONT> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="20%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="20%" ALIGN="CENTER" >


 </I></FONT><FONT SIZE=1>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>CALCULATION OF REGISTRATION FEE  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>
 <!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="65%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="96" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="96" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:3pt;text-indent:-3pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=5 VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;">&nbsp;</TD>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Title of Each Class of Securities<BR>
to be Registered</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Proposed Maximum<BR>
Aggregate Offering<BR>
Price<SUP>(1)(2)</SUP></B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>Amount of<BR>
Registration Fee<SUP>(3)</SUP></B></FONT><BR></TH>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=5 VALIGN="BOTTOM" style="font-family:times;border-bottom:solid #000000 1.0pt;">&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:3pt;text-indent:-3pt;"><FONT SIZE=1><B> </B></FONT><FONT SIZE=1>Common Stock, $0.001 par value per share</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
</TR>
<TR style="font-size:1.5pt;" VALIGN="TOP">
<TD COLSPAN=5 VALIGN="BOTTOM" style="font-family:times;border-bottom:double #000000 2.25pt;"><p style="font-family:times;margin-left:3pt;text-indent:-3pt;"> &nbsp;</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->

<DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Includes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional
shares of common stock which the underwriters have the option to purchase in connection with this offering.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(2)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Estimated
solely for the purpose of calculating the registration fee pursuant to Rule&nbsp;457(o) under the Securities Act of 1933, as amended.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(3)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Calculated
based on Rule&nbsp;457(o) based on an estimate of the proposed maximum offering price.  </FONT></DD></DL>


<P style="font-family:times;text-align:justify"><FONT SIZE=1>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=1><B>The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall
file&nbsp;a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933, as
amended, or until the Registration Statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section&nbsp;8(a), may determine.  </B></FONT></P>
 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=1>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p>
 <P style="font-family:times;text-align:justify"><FONT SIZE=1><div
style="width:100%;border-top:solid #000000 1.0pt;padding:0in 0in 0in 0in;font-size:3.0pt;"></div>
<div style="width:100%;border-top:solid #000000 3.0pt;padding:0in 0in 0in 0in;font-size:4.0pt;"></div> </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=627912,FOLIO='blank',FILE='DISK109:[18ZBU1.18ZBU44601]BA44601A.;14',USER='CHE105614',CD='10-JUN-2018;18:07' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;text-align:justify"><FONT COLOR="#F1665F" SIZE=2>The information in this preliminary prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and
Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and it is not soliciting offers to buy these securities in any state or other jurisdiction where
the offer or sale is not permitted.</FONT></P>

<P style="font-family:times;text-align:justify"><FONT COLOR="#F1665F" SIZE=3><I>SUBJECT TO COMPLETION, DATED&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018<BR>  </I></FONT><FONT
COLOR="#F1665F" SIZE=2><I>Preliminary Prospectus</I></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g460244.jpg" ALT="LOGO" WIDTH="204" HEIGHT="94">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=5><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares  </I></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=5><I> Rhythm Pharmaceuticals,&nbsp;Inc.  </I></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=3><I>Common Stock  </I></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=3>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="21%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="21%" ALIGN="CENTER" >


</FONT> <FONT SIZE=3><I>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </I></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B><I>Rhythm Pharmaceuticals,&nbsp;Inc. is offering&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock in this offering.  </I></B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="21%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="21%" ALIGN="CENTER" >


</FONT> <FONT SIZE=2><B><I>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B><I> Our common stock is listed on the Nasdaq Global Market under the symbol "RYTM." The last reported sale price of our common stock on the Nasdaq Global Market
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018 was
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. The final public offering price will be determined through negotiation between us and the lead underwriters in the offering and the recent market
price used throughout the
prospectus may not be indicative of the final offering price.  </I></B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="21%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="21%" ALIGN="CENTER" >


 </FONT> <FONT SIZE=2><B><I>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=3><B><I>We are an "emerging growth company" as defined by the Jumpstart Our Business Startups Act of 2012 and, as such, we have elected to comply with certain reduced
public company reporting requirements for this prospectus and future filings. Investing in our common stock involves risks. See "Risk Factors" beginning on page&nbsp;16 of this prospectus before
making a decision to invest in our common stock.  </I></B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=3>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="21%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="21%" ALIGN="CENTER" >


</FONT> <FONT SIZE=3><B><I>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> </i></font></p><div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <P style="font-family:times;text-align:justify"><FONT SIZE=2><I>


<!-- COMMAND=ADD_TABLEWIDTH,"100%" -->


  </I></FONT></P>

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="111pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="111pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH NOWRAP  ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B><I>Per Share

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </I></B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH NOWRAP  ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B><I>Total

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </I></B></FONT></DIV></TH>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:4pt;text-indent:-4pt;"><FONT SIZE=1><B><I> </I></B></FONT><FONT SIZE=2><I>Public Offering Price </I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><I>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><I>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:5pt;text-indent:-5pt;"><FONT SIZE=2><I> </I></FONT><FONT SIZE=2><I>Underwriting Discount and Commissions<SUP>(1)</SUP> </I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><I>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><I>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:5pt;text-indent:-5pt;"><FONT SIZE=2><I> </I></FONT><FONT SIZE=2><I>Proceeds, before expenses, to us </I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><I>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><I>$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2><I>(1)</I></FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2><I>We refer you to "Underwriting" beginning on page&nbsp;218 for additional information regarding underwriter
compensation.</I></FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="21%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="21%" ALIGN="CENTER" >


 </I></FONT><FONT SIZE=2>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I>We have granted the underwriters an option for a period of up to 30&nbsp;days to purchase up to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional shares of common stock.</I></FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><I>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful
or complete. Any representation to the contrary is a criminal offense.</I></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I>The underwriters expect to deliver the shares to purchasers on or about&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018.  </I></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="21%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="21%" ALIGN="CENTER" >


</FONT> <FONT SIZE=2><I>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </I></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> </i></font></p><div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
 <P style="font-family:times;text-align:justify"><FONT SIZE=2><I>


<!-- COMMAND=ADD_TABLEWIDTH,"150%" -->


  </I></FONT></P>

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="199pt" style="font-family:times;"></TD>
<TD WIDTH="7%" style="font-family:times;"></TD>
<TD WIDTH="229pt" style="font-family:times;"></TD>
<TD WIDTH="7%" style="font-family:times;"></TD>
<TD WIDTH="81pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=4><I>MORGAN&nbsp;STANLEY</I></FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="TOP" style="font-family:times;"><FONT SIZE=4><I> BofA&nbsp;MERRILL&nbsp;LYNCH</I></FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=4><I> COWEN</I></FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD COLSPAN=5 ALIGN="CENTER" VALIGN="TOP" style="font-family:times;"><FONT SIZE=4><I>NEEDHAM &amp; COMPANY<BR> </I></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=2,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=201617,FOLIO='blank',FILE='DISK109:[18ZBU1.18ZBU44601]BC44601A.;38',USER='CHE109875',CD='11-JUN-2018;05:04' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A> </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="BG44601A_main_toc"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="bg44601_table_of_contents"> </A>
<BR></FONT><FONT SIZE=2><B>  TABLE OF CONTENTS    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>
<A NAME="BG44601_TOC"></A> </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- COMMAND=ADD_START_LINKTABLE -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="23pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#ca44601_prospectus_summary"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Prospectus Summary</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#ca44601_prospectus_summary"><FONT SIZE=2>1</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#ci44601_corporate_background_and_distribution"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Corporate Background and Distribution</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#ci44601_corporate_background_and_distribution"><FONT SIZE=2>15</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#ck44601_risk_factors"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Risk Factors</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#ck44601_risk_factors"><FONT SIZE=2>16</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#cw44601_special_note_regarding_forward-looking_statements"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Special Note Regarding Forward-Looking Statements</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#cw44601_special_note_regarding_forward-looking_statements"><FONT SIZE=2>73</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#cw44601_market,_industry_and_other_data"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Market, Industry and Other Data</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#cw44601_market,_industry_and_other_data"><FONT SIZE=2>74</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#cw44601_use_of_proceeds"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Use of Proceeds</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#cw44601_use_of_proceeds"><FONT SIZE=2>76</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#CW1"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Market Price of Common Stock</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#CW1"><FONT SIZE=2>78</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#cw44601_dividend_policy"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Dividend Policy</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#cw44601_dividend_policy"><FONT SIZE=2>78</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#cy44601_capitalization"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Capitalization</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#cy44601_capitalization"><FONT SIZE=2>79</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#cy44601_dilution"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Dilution</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#cy44601_dilution"><FONT SIZE=2>81</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#cy44601_selected_financial_data"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Selected Financial Data</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#cy44601_selected_financial_data"><FONT SIZE=2>83</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#da44601_management_s_discussion_and_an__man03466"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Management's Discussion and Analysis of Financial Condition and Results of
Operations</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da44601_management_s_discussion_and_an__man03466"><FONT SIZE=2>85</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#de44601_business"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Business</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#de44601_business"><FONT SIZE=2>100</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#du44601_management"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Management</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#du44601_management"><FONT SIZE=2>173</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dw44601_executive_and_director_compensation"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Executive and Director Compensation</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dw44601_executive_and_director_compensation"><FONT SIZE=2>183</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dy44601_transactions_with_related_persons"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Transactions with Related Persons</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dy44601_transactions_with_related_persons"><FONT SIZE=2>200</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#ea44601_principal_stockholders"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Principal Stockholders</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#ea44601_principal_stockholders"><FONT SIZE=2>202</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#ea44601_description_of_capital_stock"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Description of Capital Stock</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#ea44601_description_of_capital_stock"><FONT SIZE=2>205</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#ec44601_material_united_states_federal__mat04124"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Material United States Federal Income and Estate Tax Consequences to
Non-U.S.&nbsp;Holders of our Common Stock</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#ec44601_material_united_states_federal__mat04124"><FONT SIZE=2>211</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#ec44601_shares_eligible_for_future_sale"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Shares Eligible for Future Sale</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#ec44601_shares_eligible_for_future_sale"><FONT SIZE=2>216</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#ee44601_underwriting"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Underwriting</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#ee44601_underwriting"><FONT SIZE=2>218</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#ee44601_legal_matters"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Legal Matters</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#ee44601_legal_matters"><FONT SIZE=2>225</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#ee44601_experts"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Experts</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#ee44601_experts"><FONT SIZE=2>225</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#ee44601_where_you_can_find_more_information"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Where You Can Find More Information</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#ee44601_where_you_can_find_more_information"><FONT SIZE=2>225</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#FA1"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Index to Financial Statements</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#FA1"><FONT SIZE=2>F-1</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
<!-- COMMAND=ADD_END_LINKTABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>We and the underwriters have not authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in
any free writing prospectuses we have prepared. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may provide
you. We are offering to sell, and
seeking offers to buy, shares of common stock only in jurisdictions where offers and sales are permitted. The information contained in this prospectus is accurate only as of the date of this
prospectus, regardless of the time of delivery of this prospectus or of any sale of the common stock.</B></FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=3,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=820814,FOLIO='blank',FILE='DISK109:[18ZBU1.18ZBU44601]BG44601A.;10',USER='CHE108055',CD='11-JUN-2018;03:39' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_ca44601_1_1"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->


<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><BR></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ca44601_prospectus_summary"> </A>
<A NAME="toc_ca44601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PROSPECTUS SUMMARY    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>This summary highlights information contained elsewhere in this prospectus and does not contain all of the information
that you should consider in making your investment decision. Before investing in our common stock, you should carefully read this entire prospectus, including our financial statements and the related
notes included elsewhere in this prospectus. You should also consider, among other things, the matters described under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition
and Results of Operations," in each case appearing elsewhere in this prospectus. Unless otherwise stated, all references to "us," "our," "RYTM," "we," the "Company" and similar designations refer to
Rhythm Pharmaceuticals,&nbsp;Inc. or our predecessor company, as the context may require. See "Corporate Background and Distribution."</I></FONT></P>


<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Overview  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic disorders
that result in severe, life-threatening metabolic disorders. Our lead product candidate is setmelanotide, a potent, first-in-class melanocortin-4 receptor, or MC4R, agonist peptide for the treatment
of rare genetic disorders of obesity. We believe setmelanotide, for which we have exclusive worldwide rights, has the potential to serve as replacement therapy for the treatment of melanocortin-4, or
MC4, pathway deficiencies. MC4 pathway deficiencies result in the disruption of satiety signals and energy homeostasis in the body, which, in turn, leads to intense feelings of hunger and to obesity.
Our development efforts are initially focused on obesity related to six single gene-related, or monogenic, MC4 pathway deficiencies&#151;pro-opiomelanocortin, or POMC, leptin receptor, or LepR,
Bardet-Biedl syndrome, Alstr&ouml;m syndrome, POMC heterozygous, and POMC epigenetic disorders&#151;for which there are currently no effective or approved treatments. We believe that
the MC4 pathway is a compelling target for treating these genetic disorders because of its critical role in regulating appetite and weight by promoting satiety and weight control, and that peptide
therapeutics are uniquely suited for activating this target. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have demonstrated proof of concept in Phase&nbsp;2 clinical trials in POMC deficiency obesity, LepR deficiency obesity, Bardet-Biedl syndrome, and Alstr&ouml;m syndrome,
four genetic disorders of extreme and unrelenting appetite and obesity, in which setmelanotide dramatically reduced both weight and hunger. The U.S. Food and Drug Administration, or the FDA, has
acknowledged the importance of these results by giving setmelanotide Breakthrough Therapy designation for the treatment of obesity associated with genetic defects upstream of the MC4 receptor in the
leptin-melanocortin pathway. This designation currently covers four Breakthrough Therapy designation indications: POMC deficiency
obesity, LepR deficiency obesity, Bardet-Biedl syndrome, and Alstr&ouml;m syndrome. Setmelanotide is currently in Phase&nbsp;3 development for POMC deficiency obesity and LepR deficiency
obesity, and we are initiating a combined Phase&nbsp;3 trial for Bardet-Biedl syndrome and Alstr&ouml;m syndrome. We are close to completing enrollment in the pivotal cohorts for both our
POMC deficiency obesity Phase&nbsp;3 clinical trial and our LepR deficiency obesity Phase&nbsp;3 clinical trial. We expect to report initial Phase&nbsp;3 data from these trials in the third
quarter of 2019, and subsequently plan to file for regulatory approval for these two indications concurrently. We believe that we have demonstrated proof of concept in our Phase&nbsp;2 clinical
trial in Bardet-Biedl syndrome and in Alstr&ouml;m syndrome, and met with the FDA in May 2018 to discuss a combined pivotal Phase&nbsp;3 clinical trial in these indications. Based on these
preliminary discussions with the FDA, we currently plan to initiate this trial and enroll patients in 2018. We have an ongoing Phase&nbsp;2 clinical trial in POMC heterozygous deficiency obesity and
POMC epigenetic disorders, expect to report initial, preliminary results in these additional Phase&nbsp;2 indications in the second quarter of 2018, and plan to provide a further update for these
indications early in 2019. In total, approximately 300 obese subjects and patients have been treated with setmelanotide in previous and ongoing clinical trials in which setmelanotide demonstrated
statistically significant weight loss with good tolerability. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Obesity
is epidemic in the United States and current treatment approaches have demonstrated limited long-term success for most obese patients. We are taking a different approach to
obesity drug development </FONT></P>
 </DIV>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>1</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=4,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=352427,FOLIO='1',FILE='DISK109:[18ZBU1.18ZBU44601]CA44601A.;16',USER='CHE105614',CD='10-JUN-2018;18:07' -->
<A NAME="page_ca44601_1_2"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>by
leveraging new understanding of the genetic causes of severe obesity to develop innovative therapies that we believe have the potential for compelling efficacy. Setmelanotide's unique mechanism of
action at MC4R enables a targeted approach to treating very severe obesity in patients with specific, monogenic defects in the MC4 signaling pathway. By restoring impaired function in this pathway,
setmelanotide can serve as replacement therapy for genetic deficiencies, with the potential for dramatic improvements in weight and appetite. We believe we are at the forefront of improving treatment
outcomes in subtypes of severe obesity that are caused by genetically-defined defects in the MC4 pathway. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Our Product Pipeline  </I></B></FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following chart depicts key information regarding the development of setmelanotide, including the indications we are pursuing within MC4
pathway deficiencies, the current state of development and our expected upcoming milestones: </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g952280.jpg" ALT="GRAPHIC" WIDTH="651" HEIGHT="399">
  </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Setmelanotide: A First-in-Class MC4R Agonist  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Setmelanotide is a potent, first-in-class, MC4R agonist peptide administered by daily subcutaneous, or SC, injection. Setmelanotide activates
MC4R, which is part of the key pathway that can independently regulate energy homeostasis, which refers to the body's energy balance, and appetite. The critical role of the MC4 pathway in weight
regulation was validated with the discovery that single genetic defects along this pathway result in early onset and severe obesity. An expanding set of severe obesity genetic defects are now
identified that involve genes in the pathway which are either upstream of MC4R&#151;for example POMC deficiency obesity and LepR deficiency obesity&#151;or genes that are downstream of
MC4R or affect MC4R itself. We are focusing setmelanotide clinical development on patients with monogenic upstream genetic defects in which obesity is life-threatening but the downstream MC4 pathway
is fully functional. We believe setmelanotide has the potential to restore lost activity in the MC4 pathway by bypassing the defects upstream of MC4R, and activating the MC4 pathway below such
defects. In this way, setmelanotide may </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=5,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=604899,FOLIO='2',FILE='DISK109:[18ZBU1.18ZBU44601]CA44601A.;16',USER='CHE105614',CD='10-JUN-2018;18:07' -->
<A NAME="page_ca44601_1_3"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">

<P style="font-family:times;text-align:justify"><FONT SIZE=2>serve
as replacement therapy to reestablish weight and appetite control in patients with these genetic disorders. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
first generation of MC4R agonists were predominantly small molecules that failed in clinical trials due to safety issues, particularly increases in blood pressure, in addition to
having limited efficacy. In contrast, setmelanotide, a novel eight amino acid peptide, retains the specificity and functionality of the naturally occurring hormone that activates MC4R. </FONT></P>


<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Clinical Development in Rare Genetic Disorders of Obesity Caused by MC4 Pathway Deficiencies  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The figure below summarizes the indications on which we are focusing for the development of setmelanotide, including our clinical epidemiology
estimates for the addressable patient populations within these indications. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g250777.jpg" ALT="GRAPHIC" WIDTH="654" HEIGHT="397">
  </B></FONT></P>


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" >


<DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>*</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>The patient numbers above are based on Company estimates from clinical publications.  </FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>&#134;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Epidemiological
estimates are not yet available for POMC epigenetic disorders.</FONT></DD></DL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have estimated the patient populations for our rare genetic disorders of obesity primarily by identifying patients or by estimating from clinical epidemiology information. Another
method to estimate the size of these ultra-rare populations is by genetic epidemiology using newly available large genomic databases. Our preliminary genetic epidemiology estimates suggest a total of
approximately 13,000 patients in the United States with POMC deficiency obesity and LepR deficiency obesity, representing a 5-fold increase relative to our clinical epidemiology based estimates. We
believe the separate analyses that we have completed using clinical epidemiology and genetic epidemiology provide a robust range of patient population estimates for these rare disorders. However, to
be conservative, we reference the clinical epidemiology figures in our descriptions of our target indications. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe that the patient populations in the European Union, or EU, are at least as large as those in the United States. However, we do not have comparable epidemiological data from
the EU and these </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=6,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=233723,FOLIO='3',FILE='DISK109:[18ZBU1.18ZBU44601]CA44601A.;16',USER='CHE105614',CD='10-JUN-2018;18:07' -->
<A NAME="page_ca44601_1_4"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">


<P style="font-family:times;text-align:justify"><FONT SIZE=2>estimates
are therefore based solely on applying relative population percentages to the Company-derived United States estimates described above. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


POMC Deficiency Obesity  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;POMC deficiency obesity is a life-threatening, ultra-rare orphan disease, with approximately 50 patients reported to date. Ultra-rare orphan
diseases are generally categorized as those that affect fewer than 20 patients per million. We estimate that our addressable patient population for this disorder is approximately 100 to 500 patients
in the United States. Patients with POMC deficiency have unrelenting hunger, or hyperphagia, that begins in infancy and they develop severe, early onset obesity. POMC deficiency obesity results from
two different homozygous genetic defects, both upstream of MC4R, that result in loss of function in the MC4 pathway. Currently, there is no approved treatment for the obesity and hyperphagia
associated with this genetic disorder. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are close to completing enrollment of the pivotal cohort in our Phase&nbsp;3 open label, single arm, multinational trial to evaluate the safety and efficacy of setmelanotide for
POMC deficiency obesity, with setmelanotide administered once daily by SC injection for 12&nbsp;months, and we plan to report initial Phase&nbsp;3 data in the third quarter of 2019. Previously, we
completed a positive Phase&nbsp;2 clinical trial in which two patients were enrolled and received treatment. These results were published in the New England Journal of Medicine in July 2016. The
first patient in this trial lost 146.6 lbs. over 118&nbsp;weeks, from a baseline weight of 341.7 lbs., and the second patient lost 89.3 lbs. over 64&nbsp;weeks, from a baseline weight of 336.9
lbs. Both patients experienced substantial reductions in hunger, with hunger scores falling to one to two from baseline scores of nine to 10. Hunger scores were measured using a Likert score of zero
to 10, where zero represents no hunger and 10 represents extreme hunger. Setmelanotide was generally well tolerated in this Phase&nbsp;2 trial. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Leptin Receptor Deficiency Obesity  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;LepR deficiency obesity is an ultra-rare orphan disease that results in hyperphagia and severe early-onset obesity, with an estimated prevalence
of 1% of subjects with severe, early-onset obesity. We estimate that our addressable patient population for this disorder is approximately 500 to 2,000 patients in the United States. Like other
deficiencies upstream in the MC4 pathway, LepR deficiency results in loss of function in the MC4 pathway. Therefore, patients with this indication also manifest hyperphagia and severe obesity from
early childhood. Currently, there is no approved treatment for the obesity and hyperphagia associated with LepR deficiency obesity. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are close to completing enrollment of the pivotal cohort in our Phase&nbsp;3 open label, single arm, multinational trial to evaluate the safety and efficacy of setmelanotide for
LepR deficiency obesity, with setmelanotide administered once daily by SC injection for 12&nbsp;months, and we plan to report initial Phase&nbsp;3 data in the third quarter of 2019. Previously, we
completed a positive Phase&nbsp;2 clinical trial in which three patients were enrolled and received treatment in this trial each experiencing significant
weight loss and substantial reductions in hunger. These results were published in Nature Medicine in May 2018. Setmelanotide was generally well tolerated in this Phase&nbsp;2 trial. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
on our POMC deficiency obesity and LepR deficiency obesity Phase&nbsp;2 results, the FDA granted setmelanotide Breakthrough Therapy designation for the treatment of obesity
associated with genetic defects upstream of the MC4 receptor in the leptin-melanocortin pathway, which includes both POMC deficiency obesity and LepR deficiency obesity, enabling an expedited path to
approval of setmelanotide for these two indications. The FDA has granted orphan drug designation for setmelanotide for the treatment of POMC deficiency obesity and LepR deficiency obesity. </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>4</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=7,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=64481,FOLIO='4',FILE='DISK109:[18ZBU1.18ZBU44601]CA44601A.;16',USER='CHE105614',CD='10-JUN-2018;18:07' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_cc44601_1_5"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A> </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><BR></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Bardet-Biedl Syndrome  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Bardet-Biedl syndrome is a life-threatening, ultra-rare orphan disease with a prevalence of approximately one in 100,000 in North America. We
estimate that our addressable patient population for Bardet-Biedl syndrome obesity is approximately 1,500 to 2,500 patients in the United States. Bardet-Biedl syndrome is a monogenic disorder that
causes severe obesity and hyperphagia as well as vision loss, polydactyly, kidney abnormalities, and other signs and symptoms. Currently there are no approved or effective therapies for Bardet-Biedl
syndrome. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have demonstrated proof of concept based on data from five patients in our Phase&nbsp;2 clinical trial in Bardet-Biedl syndrome, indicating that this is also a
setmelanotide-responsive, upstream MC4 pathway disorder. Four of these five patients showed early, but significant weight loss and all five patients showed clear improvements in every hunger
assessment. We reported preliminary Phase&nbsp;2 results in the fourth quarter of 2017, and expect to provide an update on these patients in the second quarter of 2018. Based on these results, the
FDA recently included Bardet-Biedl syndrome under our existing Breakthrough Therapy designation for setmelanotide. Setmelanotide has been generally well tolerated in this trial. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Alstr&ouml;m Syndrome  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Alstr&ouml;m syndrome is a life-threatening, ultra-rare orphan disease with a prevalence of approximately one in one million in North
America. We estimate that our addressable patient population for Alstr&ouml;m syndrome is approximately 500 to 1,000 patients worldwide. Alstr&ouml;m syndrome is a monogenic
disorder, closely related to Bardet-Biedl syndrome, that causes childhood obesity and hyperphagia as well as progressive vision loss, deafness, cardiomegaly, insulin resistance and other signs and
symptoms. Currently there are no approved or effective therapies for Alstr&ouml;m syndrome. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe we have recently demonstrated proof of concept in our Phase&nbsp;2 clinical trial in Alstr&ouml;m syndrome, indicating that this is also a setmelanotide
responsive, upstream MC4 pathway disorder. Based on these results, the FDA recently included Alstr&ouml;m syndrome in our existing Breakthrough Therapy designation for setmelanotide.
Setmelanotide has so far been generally well tolerated in this trial. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
met with the FDA in May 2018 to discuss a combined pivotal Phase&nbsp;3 clinical trial in both Bardet-Biedl syndrome and Alstr&ouml;m syndrome. Based on these preliminary
discussions with the FDA, we currently plan to initiate this trial and enroll patients in 2018. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Other Upstream Genetic Defects in the MC4 Pathway  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are also focusing on additional monogenic, upstream MC4 pathway deficiencies for which setmelanotide can function as replacement therapy and
provide activation of the pathway downstream of the defect, promoting satiety and weight control. We have enrolled patients in Phase&nbsp;2 proof of concept trials for POMC epigenetic disorders, and
for POMC heterozygous deficiency obesity, for which we estimate our addressable population is approximately 4,000 patients in the United States. For all of these patients, hyperphagia and obesity can
have significant health consequences for which there is currently no approved treatment. We expect to report initial, preliminary results from these trials in the second quarter of 2018, and plan to
provide a further update for these indications early in 2019. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Expanding Attention to the Diagnosis of Genetic Obesity  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are supporting several initiatives to expand the diagnosis of genetic obesity, including The Genetic Obesity Project. The Genetic Obesity
Project has initiated a genotyping study, called GO-ID, and a patient registry, called TEMPO, both focusing initially on identifying people with POMC deficiency obesity and LepR deficiency obesity and
which we intend to expand to include other MC4 pathway deficiencies. We will be expanding our panel of obesity-related genes used in our GO-ID study in the second half of 2018. The preliminary
results, in 560 patients, from the GO-ID study suggest that patients with these disorders </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=8,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=264982,FOLIO='5',FILE='DISK109:[18ZBU1.18ZBU44601]CC44601A.;10',USER='CHE105614',CD='10-JUN-2018;18:07' -->
<A NAME="page_cc44601_1_6"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>can
be successfully identified. We are also conducting genetic obesity epidemiology analysis of MC4 pathway genetic defects in a large representative sample of the U.S. population, and we expect to
expand the genetic databases in our research efforts on an ongoing basis. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


RM-853: A Potent Ghrelin O-Acyltransferase Inhibitor  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition to our development of setmelanotide, in April 2018, we announced that we had acquired exclusive, worldwide rights from Takeda
Pharmaceutical Company Limited, or Takeda, to develop and commercialize T-3525770, now called RM-853. RM-853 is a potent, orally available ghrelin o-acyltransferase, or GOAT, inhibitor currently in
preclinical development for Prader-Willi Syndrome, or PWS. PWS is a rare genetic disorder that results in hyperphagia and early-onset, life-threatening obesity, for which there are no approved
therapeutic options. RM-853 is currently in pre-clinical development. We anticipate filing an Investigational New Drug application, or IND, for RM-853 with the FDA in 2020. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Company History  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our company was founded in November 2008 by former biopharmaceutical executives who have successfully developed, commercialized and in-licensed
innovative pharmaceutical products, and we have subsequently expanded our senior management team to further broaden our team's experience in developing, registering and commercializing new drugs. In
addition, our scientific advisory board, or SAB, members have extensive clinical expertise in obesity, endocrinology and metabolic diseases. We intend to leverage the experience of our senior
management team and SAB to develop and commercialize setmelanotide. Through our senior management team's network of industry contacts, we will continue to evaluate additional product candidate
licensing and acquisition opportunities. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
setmelanotide patent portfolio includes composition of matter patents for setmelanotide that expire in the United States in 2027, with possible patent term extension to 2032 under
the Hatch-Waxman Act. Additional patent coverage may be provided due to pending formulation patent applications, if such pending formulation applications were issued. </FONT></P>


<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Our Strategy  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our goal is to be a leader in developing and commercializing targeted therapies for genetic deficiencies that result in life-threatening
metabolic disorders. The key components of our strategy are: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2><B> Rapidly develop setmelanotide for rare genetic disorders of obesity caused by MC4
pathway deficiencies.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;We are aiming to dramatically improve patient outcomes in severe obesity by targeting setmelanotide's mechanism of action
to the treatment of patients with genetically-defined defects in the MC4 pathway. We are focusing setmelanotide clinical development on monogenic upstream genetic defects in which obesity is
life-threatening but where the downstream MC4 pathway is fully functional.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2><B> Advance setmelanotide for POMC deficiency obesity and LepR deficiency obesity as our
first indications in upstream MC4 pathway deficiencies.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;We are close to completing enrollment of the pivotal cohorts in our Phase&nbsp;3 trials
in POMC deficiency obesity and LepR deficiency obesity, and plan to report initial data from these trials in the third quarter of 2019. We are working with the FDA, based on our Breakthrough Therapy
designation, to prepare concurrent New Drug Application, or NDA, filings for these two indications as part of an expedited path to approval for POMC deficiency obesity and LepR deficiency obesity. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2><B> Advance setmelanotide for Bardet-Biedl syndrome and Alstr&ouml;m syndrome as
our second set of indications in upstream MC4 pathway deficiencies.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;We have demonstrated proof of concept in Bardet-Biedl syndrome and
Alstr&ouml;m syndrome, indicating that these are also setmelanotide responsive, upstream MC4 pathway disorders. Based on these results, the FDA recently included </FONT></DD></DL>
</UL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>6</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=9,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=343329,FOLIO='6',FILE='DISK109:[18ZBU1.18ZBU44601]CC44601A.;10',USER='CHE105614',CD='10-JUN-2018;18:07' -->
<A NAME="page_cc44601_1_7"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <UL>
<UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>these
disorders under our existing Breakthrough Therapy designation for setmelanotide. In May 2018, we met with the FDA to discuss a combined pivotal Phase&nbsp;3 clinical trial in both Bardet-Biedl
syndrome and Alstr&ouml;m syndrome. Based on these preliminary discussions with the FDA, we currently plan to initiate this trial and enroll patients in 2018.  </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2><B> Expand setmelanotide development to additional upstream MC4 pathway deficiencies,
including POMC heterozygous deficiency obesity and POMC epigenetic disorders.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;We have an ongoing Phase&nbsp;2 clinical trial that includes
patients with these rare genetic disorders, and expect to report initial, preliminary results in these indications in the second quarter of 2018. We continue to investigate other potential indications
that may result from MC4 pathway deficiencies, in which we may study treatment with setmelanotide in the future.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2><B> Commercialize setmelanotide for rare disease indications in core strategic
markets.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;We intend to establish our own commercial sales and marketing organization in the United States and other core strategic markets. We
expect this sales organization will target physicians treating these rare genetic disorders of obesity, including pediatric and adult endocrinologists. We believe that building our own commercial
operations will deliver a greater return on our product investment than if we license the rights to commercialize these products to third parties. We may also selectively establish partnerships in
markets outside the United States for sales, marketing, and distribution.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2><B> Leverage the broad experience of our team in clinical and commercial drug development,
and product acquisitions.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;We will apply our team's extensive experience in developing and commercializing innovative medicines to the development
and launch of setmelanotide. We will apply similar expertise to advance our second product candidate, RM-853, from pre-clinical to clinical development. In addition, we intend to identify and acquire
new pipeline product candidates in related diseases. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks Associated with Our Business  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our business is subject to a number of risks of which you should be aware before making an investment decision. These risks are discussed more
fully in the "Risk Factors" section beginning on page&nbsp;16 of this prospectus. These risks include the following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> We are a development stage biopharmaceutical company with a limited operating history and have not generated any revenue from product sales. We
have incurred significant operating losses since our inception, anticipate that we will incur continued losses for the foreseeable future and may never achieve profitability. As of March&nbsp;31,
2018, we had an accumulated deficit of $126.7&nbsp;million. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Even if this offering is successful, we will need to raise additional funding, which may not be available on acceptable terms, or at all.
Failure to obtain this necessary capital when needed may force us to delay, limit or terminate our product development efforts or other operations. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> We have only one product candidate in clinical development and we may not be successful in any future efforts to identify and develop
additional product candidates. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Positive results from early clinical trials of setmelanotide may not be predictive of the results of later clinical trials of setmelanotide. If
we cannot generate positive results in our later clinical trials of setmelanotide, we may be unable to successfully develop, obtain regulatory approval for and commercialize setmelanotide. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> The number of patients suffering from each of the MC4 pathway deficiencies is small and has not been established with precision. If the actual
number of patients with any of these conditions is smaller than we had estimated, our revenue and ability to achieve profitability will be materially adversely affected. </FONT></DD></DL>
</UL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>7</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=10,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=656172,FOLIO='7',FILE='DISK109:[18ZBU1.18ZBU44601]CC44601A.;10',USER='CHE105614',CD='10-JUN-2018;18:07' -->
<A NAME="page_cc44601_1_8"> </A>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Failures or delays in the commencement or completion of our planned clinical trials of setmelanotide could result in increased costs to us and
could delay, prevent or limit our ability to generate revenue and continue our business. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Changes in regulatory requirements, FDA guidance or unanticipated events during our clinical trials of setmelanotide may occur, which may
result in changes to clinical trial protocols or additional clinical trial requirements, which could result in increased costs to us and could delay our development timeline. Additionally, it may be
necessary to validate different or additional instruments for measuring subjective symptoms, and to show that setmelanotide has a clinically meaningful impact on those endpoints in order to obtain
regulatory approval. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Even if we complete the necessary clinical trials, the regulatory and marketing approval process is expensive, time consuming and uncertain and
may prevent us from obtaining approvals for the commercialization of setmelanotide. We depend almost entirely on the success of setmelanotide, which is still in clinical development. We cannot be
certain that we will be able to obtain regulatory approval for, or successfully commercialize setmelanotide. If we are not able to obtain, or if there are delays in obtaining, required regulatory
approvals, we will not be able to commercialize setmelanotide and our ability to generate revenue will be materially impaired. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could
be delayed or prevented. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Setmelanotide may cause undesirable side effects that could delay or prevent its regulatory approval, limit the commercial profile of an
approved labeling or result in significant negative consequences following marketing approval, if any. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Even if approved, reimbursement policies could limit our ability to sell setmelanotide. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Competing products and technologies could emerge, adversely affecting our opportunity to generate revenue from the sale of setmelanotide. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> If we are unable to obtain and maintain patent protection for setmelanotide and its related technology, or if the scope of the patent
protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully commercialize our
technology and setmelanotide may be impaired. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Since we have only a limited history of operating as an independent company, we may incur unforeseen expenses associated with doing so. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Corporate Background and Distribution  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are a Delaware corporation organized in February 2013 under the name Rhythm Metabolic,&nbsp;Inc. and as of October 2015, under the name
Rhythm Pharmaceuticals,&nbsp;Inc. See "</FONT><FONT SIZE=2><I>Corporate Background and Distribution</I></FONT><FONT SIZE=2>." </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="21%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="21%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=2>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
principal executive offices are located at 500 Boylston Street, 11<SUP>th</SUP>&nbsp;Floor, Boston, MA 02116, and our telephone number is (857)&nbsp;264-4280. Our corporate
website address is www.rhythmtx.com. Information contained on or accessible through our website is not a part of this prospectus, and the inclusion of our website address in this prospectus is an
inactive textual reference only. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
prospectus contains references to our trademarks and to trademarks belonging to other entities. Solely for convenience, trademarks and trade names referred to in this prospectus,
including logos, artwork and other visual displays, may appear without the &reg; or <SUP>TM</SUP> symbols, but such references are not intended to indicate, in any way, that we will not
assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensor to these trademarks and trade names. We do not intend our use or display </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>8</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=11,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=35374,FOLIO='8',FILE='DISK109:[18ZBU1.18ZBU44601]CC44601A.;10',USER='CHE105614',CD='10-JUN-2018;18:07' -->
<A NAME="page_cc44601_1_9"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">


<P style="font-family:times;text-align:justify"><FONT SIZE=2>of
other companies' trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Implications of Being an Emerging Growth Company  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are an "emerging growth company" as that term is used in the Jumpstart Our Business Startups (JOBS) Act of 2012 and, as such, have elected to
comply with certain reduced public company reporting requirements. These reduced reporting requirements include reduced disclosure about Rhythm's executive compensation arrangements and no non-binding
advisory votes on executive compensation. We will remain an emerging growth company until the earlier of (1)&nbsp;December&nbsp;31, 2022, and (2)&nbsp;the last day of the fiscal year
(a)&nbsp;in which we have total annual gross revenue of at least $1.07&nbsp;billion, or (b)&nbsp;in which we are deemed to be a large accelerated filer, which means the market value of our
common stock that is held by non-affiliates exceeds $700&nbsp;million as of the prior June&nbsp;30th, and (3)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in
non-convertible debt during the prior three year period. We refer to the Jumpstart Our Business Startups Act of 2012 in this prospectus as the "JOBS Act," and references in this prospectus to
"emerging growth company" shall have the meaning ascribed to it in the JOBS Act. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;An
emerging growth company may take advantage of reduced reporting requirements that are otherwise applicable to public companies. These provisions include, but are not limited
to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the ability to present only two years of audited financial statements and only two years of related Management's Discussion and Analysis of
Financial Condition and Results of Operations in this prospectus; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> an exemption from the requirements to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act of 2002,
as amended; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> reduced disclosure obligations regarding executive compensation in our periodic reports, proxy statements and registration statements; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> exemptions from the requirement to hold a nonbinding advisory vote on executive compensation and to obtain stockholder approval of any golden
parachute payments not previously approved. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may use these provisions until such time as we cease to be an emerging growth company. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have elected to take advantage of certain of the reduced disclosure obligations in the registration statement of which this prospectus forms&nbsp;a part and may elect to take
advantage of other reduced reporting requirements in future filings. As a result, the information that we provide to our stockholders may be different from the information that you might receive from
other public reporting companies in which you hold equity interests. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. We have irrevocably
elected not to avail ourselves of this exemption and, therefore, we will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>9</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=12,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=571352,FOLIO='9',FILE='DISK109:[18ZBU1.18ZBU44601]CC44601A.;10',USER='CHE105614',CD='10-JUN-2018;18:07' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_ce44601_1_10"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->


<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><BR></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ce44601_the_offering"> </A>
<A NAME="toc_ce44601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  THE OFFERING    <BR>    </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="218pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Common stock offered by us</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;text-align:justify;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Common stock to be outstanding after this offering</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Option to purchase additional common stock offered by us</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Use of proceeds</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;text-align:justify;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 We intend to use the net proceeds from this offering, together with our existing cash resources, as follows:</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;text-align:justify;"><p align=left style="font-family:times;margin-top:12pt;margin-bottom:-12pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> &#149;</font></p> <p align=justify style="font-family:times;margin-top:0pt;margin-left:10pt;"><font size=2></FONT><FONT SIZE=2> approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million for the development of setmelanotide through the completion of our Phase&nbsp;3 studies in POMC deficiency obesity and LepR deficiency obesity, as well as
preparation for regulatory filing for these indications and initial preparation for the commercialization of setmelanotide in the United States;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;text-align:justify;"><p align=left style="font-family:times;margin-top:12pt;margin-bottom:-12pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> &#149;</font></p> <p align=justify style="font-family:times;margin-top:0pt;margin-left:10pt;"><font size=2></FONT><FONT SIZE=2> approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million for the development of setmelanotide through the completion of our Phase&nbsp;3 studies in Bardet-Biedl syndrome and Alstr&ouml;m syndrome, as well as preparation
for regulatory filing for these indications;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;text-align:justify;"><p align=left style="font-family:times;margin-top:12pt;margin-bottom:-12pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> &#149;</font></p> <p align=justify style="font-family:times;margin-top:0pt;margin-left:10pt;"><font size=2></FONT><FONT SIZE=2> approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million to expand the clinical development of setmelanotide in new indications, including POMC heterozygous deficiency obesity and POMC epigenetics, as well as development
of our once-weekly formulation of setmelanotide;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;text-align:justify;"><p align=left style="font-family:times;margin-top:12pt;margin-bottom:-12pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> &#149;</font></p> <p align=justify style="font-family:times;margin-top:0pt;margin-left:10pt;"><font size=2></FONT><FONT SIZE=2> approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million for initiatives to expand the diagnosis of genetic obesity, including genetic sequencing of potential patients from targeted populations, expansion of our GO-ID
study and TEMPO registry, research and scientific exchange related to our ongoing genotyping and genetic epidemiology studies; and</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;text-align:justify;"><p align=left style="font-family:times;margin-top:12pt;margin-bottom:-12pt;margin-left:0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> &#149;</font></p> <p align=justify style="font-family:times;margin-top:0pt;margin-left:10pt;"><font size=2></FONT><FONT SIZE=2>the balance to be used
for other activities, including the preclinical development of RM-853 and general corporate purposes.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Risk factors</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;text-align:justify;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 See "</FONT><FONT SIZE=2><I>Risk Factors</I></FONT><FONT SIZE=2>" beginning on page&nbsp;16 and the other information included in this prospectus for a discussion of factors you should carefully consider before deciding to invest in our common
 stock.</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Nasdaq Global Market Symbol</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 "RYTM"</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>10</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=13,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=69777,FOLIO='10',FILE='DISK109:[18ZBU1.18ZBU44601]CE44601A.;11',USER='CHE105614',CD='10-JUN-2018;18:07' -->
<A NAME="page_ce44601_1_11"> </A>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
number of shares of our common stock to be outstanding after this offering is based on 27,284,140 shares of our common stock outstanding as of March&nbsp;31, 2018 and
excludes:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> 223,544 shares of common stock issued to Takeda for the acquisition of the worldwide rights to develop and commercialize T-3525770, now called
RM-853, on April&nbsp;3, 2018; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> 24,250 shares of common stock issued upon the exercise of stock options after March&nbsp;31, 2018 at a weighted average exercise price of
$4.59 per share; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> 2,682,275 shares of common stock reserved for future issuance under our 2017 equity incentive plan, or the 2017 Plan; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> 272,841 shares of common stock reserved for future issuance under our 2017 employee stock purchase plan; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> 2,427,629 shares of common stock issuable upon the exercise of stock options outstanding as of March&nbsp;31, 2018 under our 2017 equity
incentive plan at a weighted average exercise price of $11.85. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
this prospectus, unless otherwise indicated, the number of shares of common stock outstanding as of March&nbsp;31, 2018 and the other information based thereon assumes no exercise
by the underwriters of their option to purchase&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional shares of common stock and no exercise of the outstanding options described above. </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>11</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=14,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=609628,FOLIO='11',FILE='DISK109:[18ZBU1.18ZBU44601]CE44601A.;11',USER='CHE105614',CD='10-JUN-2018;18:07' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_cg44601_1_12"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->


<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><BR></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="cg44601_summary_financial_data"> </A>
<A NAME="toc_cg44601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  SUMMARY FINANCIAL DATA    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following summary financial data for the years ended December&nbsp;31, 2015, 2016 and 2017 are derived from our audited financial
statements included elsewhere in this prospectus. The summary financial data as of March&nbsp;31, 2018 and for the three months ended March&nbsp;31, 2017 and 2018 have been derived from our
unaudited financial statements included elsewhere in this prospectus. These unaudited financial statements have been prepared on a basis consistent with our audited financial statements and, in our
opinion, contain all adjustments, consisting only of normal and recurring adjustments, necessary for a fair presentation of such financial data. You should read this data together with our audited
financial statements and related notes included elsewhere in this prospectus and the information under the captions "Selected Financial Data" and "Management's Discussion and Analysis of Financial
Condition and Results of Operations." Our historical results are not necessarily indicative of our future results, and our operating results for the three-month period ended March&nbsp;31, 2018 are
not necessarily indicative of the results that may be expected for the fiscal year ending December&nbsp;31, 2018 or any other interim periods or any future year or period. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
financial statements for the periods presented include allocations of costs from certain shared functions provided to us by the Relamorelin Company. These allocations were made based
on either a specific identification basis or, when a specific identification is not practicable, a proportional cost allocation method which allocates expenses based on the percentage of employee time
and research and development efforts expended on our business as compared to total employee time and research and development efforts, and have been included in our financial statements for the
periods presented. </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>12</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=15,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=312524,FOLIO='12',FILE='DISK109:[18ZBU1.18ZBU44601]CG44601A.;9',USER='CHE105614',CD='10-JUN-2018;18:07' -->
<A NAME="page_cg44601_1_13"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
financial statements included in this prospectus may not necessarily reflect our financial position, results of operations and cash flows as if we had operated as an independent
company during all of the periods presented. See "</FONT><FONT SIZE=2><I>Corporate Background and Distribution</I></FONT><FONT SIZE=2>." </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:57%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"140%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="140%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Three Months Ended<BR>
March&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=14 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(in thousands, except share and per share data)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(unaudited)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Operating expenses:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7,148</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>19,594</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>22,894</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,873</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>12,286</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Selling, general and administrative</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,425</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6,311</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9,518</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,516</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,715 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total operating expenses</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10,573</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>25,905</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>32,412</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6,389</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>17,001 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Loss from operations</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(10,573</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(25,905</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(32,412</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(6,389</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(17,001</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other income (expense):</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Revaluation of Series&nbsp;A Investor Right/Obligation and Investor Instrument</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1,863</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Interest income, net</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>33</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>566</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>29</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>542 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total other income (expense):</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>33</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1,297</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>29</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>542 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss and comprehensive loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(11,073</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(25,872</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(33,709</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(6,360</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(16,459</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss attributable to common stockholders</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(12,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(29,074</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(37,582</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(7,526</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(16,459</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss attributable to common stockholders per common share, basic and diluted<SUP>(1)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1.18</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(2.85</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(2.83</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(0.74</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(0.60</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Weighted average common shares outstanding, basic and diluted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10,196,292</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10,196,292</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>13,267,960</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10,196,292</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>27,284,140 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pro forma net loss attributable to common stockholders per common share, basic and diluted (unaudited)<SUP>(1)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pro forma weighted average common shares outstanding, basic and diluted (unaudited)<SUP>(1)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>13</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=16,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=906188,FOLIO='13',FILE='DISK109:[18ZBU1.18ZBU44601]CG44601A.;9',USER='CHE105614',CD='10-JUN-2018;18:07' -->
<A NAME="page_cg44601_1_14"> </A>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;<BR></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="56pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>As of<BR>
March&nbsp;31,<BR>
2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Actual </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Pro Forma<SUP>(2)</SUP> </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(unaudited in thousands)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Balance Sheet Data:</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash, cash equivalents and short-term investments</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>136,453</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Working capital</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>132,835</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total assets</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>139,443</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accumulated deficit</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(126,711</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total stockholders' equity</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>133,658</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>See
Note&nbsp;2 within the notes to our financial statements appearing elsewhere in this prospectus for a description of the methods used to calculate basic and
diluted net loss per share and pro forma basic and diluted net loss per share.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Pro
forma to reflect the issuance and sale of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock in this offering, at an assumed offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per
share, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.  </FONT></DD></DL>
 </DIV>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>14</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=17,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=376791,FOLIO='14',FILE='DISK109:[18ZBU1.18ZBU44601]CG44601A.;9',USER='CHE105614',CD='10-JUN-2018;18:07' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_ci44601_1_15"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->


<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><BR></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ci44601_corporate_background_and_distribution"> </A>
<A NAME="toc_ci44601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  CORPORATE BACKGROUND AND DISTRIBUTION    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are a Delaware corporation organized in February 2013 under the name Rhythm Metabolic,&nbsp;Inc. and as of October 2015, under the name
Rhythm Pharmaceuticals,&nbsp;Inc. Prior to our organization and the Corporate Reorganization referred to below, we were part of Rhythm Pharmaceuticals,&nbsp;Inc., a Delaware corporation which was
organized in November 2008 and which commenced active operations in 2010. We refer to this corporation as the Predecessor Company. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
March 2013, the Predecessor Company underwent a corporate reorganization, which we refer to as the Corporate Reorganization, pursuant to which all of the outstanding equity securities
of the Predecessor Company were exchanged for units of Rhythm Holding Company,&nbsp;LLC, a newly-organized limited liability company, which we refer to as the&nbsp;LLC entity. After the
consummation of this exchange and as part of the Corporate Reorganization, the Predecessor Company contributed setmelanotide and the MC4R agonist program to us and distributed to the&nbsp;LLC entity
all of the then issued and outstanding shares of our stock. The result of the Corporate Reorganization was that we and the Predecessor Company became wholly-owned subsidiaries of the&nbsp;LLC entity
and the two product candidates and related programs that were originally held by the Predecessor Company were separated, with relamorelin and the ghrelin agonist program being retained by the
Predecessor Company and setmelanotide and the MC4R agonist program being held by us. We refer to the Predecessor Company after consummation of the Corporate Reorganization as the Relamorelin Company.
The Predecessor Company filed the IND for setmelanotide in October 2011 and conducted the setmelanotide clinical trials up until the Corporate Reorganization, after which all clinical trials have been
conducted by us. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
October 2014, the&nbsp;LLC entity granted to Actavis&nbsp;plc, now owned by Allergan,&nbsp;Inc., or Allergan, an exclusive option to acquire the Relamorelin Company. The
transaction was limited to the acquisition of the Relamorelin Company and did not include our company. In October 2016, the option to acquire the Relamorelin Company was exercised and the sale to
Allergan closed on December&nbsp;15, 2016. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
August 2015, December 2015, January 2017 and August 2017, we sold 25,000,000 shares, 15,000,000 shares, 20,475,001 shares and 20,474,998 shares, respectively, of our series&nbsp;A
convertible preferred stock to certain investors. Following the closing of our series&nbsp;A convertible preferred stock financings, the&nbsp;LLC entity remained our largest stockholder, with the
balance of our stock being owned by our series&nbsp;A investors. In August 2017, the&nbsp;LLC entity exchanged 8,578,646 of its shares of our common stock for 78,666,209 newly-issued shares of our
series&nbsp;A-1 junior preferred stock and the&nbsp;LLC entity distributed all of its shares of our series&nbsp;A-1 junior preferred stock to the holders of its preferred units and the remaining
1,617,646 shares of our common stock to the holders of its common units. We refer to the exchange and distribution as the Distribution. The series&nbsp;A-1 junior preferred stock converted into
shares of our common stock on a 9.17-for-1 basis upon the closing of our IPO. Following the
Distribution, the&nbsp;LLC entity did not own any of our common stock. In connection with our IPO, we effected a 1-for-9.17 reverse stock split on September&nbsp;29, 2017. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
October&nbsp;13, 2015, the Relamorelin Company changed its name to Motus Therapeutics,&nbsp;Inc. and we changed our name to Rhythm Pharmaceuticals,&nbsp;Inc. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
shared certain costs with the Relamorelin Company and effective December 2016 in connection with the sale of the Relamorelin Company we no longer share those costs. </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>15</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=18,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=938379,FOLIO='15',FILE='DISK109:[18ZBU1.18ZBU44601]CI44601A.;5',USER='CHE105614',CD='10-JUN-2018;18:07' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_ck44601_1_16"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ck44601_risk_factors"> </A>
<A NAME="toc_ck44601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  RISK FACTORS    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>Investing in our common stock involves a high degree of risk. You should carefully consider the following risks and
uncertainties, together with all other information in this prospectus, including our financial statements and related notes, before investing in our common stock. Any of the risk factors we describe
below could adversely affect our business, financial condition or results of operations. The market price of our common stock could decline if one or more of these risks or uncertainties actually
occur, causing you to lose all or part of the money you paid to buy our common stock. Additional risks that we currently do not know about or that we currently believe to be immaterial may also impair
our business. Certain statements below are forward-looking statements. See "Cautionary Note Regarding Forward-Looking Statements" in this prospectus.</I></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks Related to Our Financial Position and Need for Capital  </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We are a clinical-stage biopharmaceutical company with a limited operating history and have not generated any
revenue from product sales. We have incurred significant operating losses since our inception, anticipate that we will incur continued losses for the foreseeable future and may never achieve
profitability.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are a clinical-stage biopharmaceutical company with a limited operating history on which to base your investment decision. Biopharmaceutical
product development is a highly speculative undertaking and involves a substantial degree of risk. We were incorporated in February 2013 in connection with the Corporate Reorganization. Our operations
to date have been limited primarily to acquiring rights to intellectual property, business planning, raising capital, developing our technology, identifying potential product candidates, undertaking
preclinical studies and conducting research and development activities, including clinical trials, for setmelanotide. We have never generated any revenue from product sales. We have not obtained any
regulatory approvals for setmelanotide. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Since
our inception, we have focused substantially all of our efforts and financial resources on the research and development of setmelanotide, which is currently in Phase&nbsp;3
clinical development for two indications, POMC deficiency obesity and LepR deficiency obesity, and in various phases of development for other indications. We have funded our operations to date
primarily through capital contributions from the Predecessor Company, the Relamorelin Company and the&nbsp;LLC entity and proceeds from sales of preferred stock and have incurred losses in each year
since our inception. See "</FONT><FONT SIZE=2><I>Corporate Background and Distribution.</I></FONT><FONT SIZE=2>" </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
net loss and comprehensive losses were $16.5&nbsp;million and $6.4&nbsp;million for the three months ended March&nbsp;31, 2018 and 2017, respectively. As of March&nbsp;31,
2018, we had an accumulated deficit of $126.7&nbsp;million. Substantially all of our operating losses have resulted from costs incurred in connection with our development program and from general
and administrative costs associated with our operations. Our prior losses, combined with expected future losses, have had and will continue to have an adverse effect on our stockholders' deficit and
working capital. We expect our research and development expenses to significantly increase in connection with our additional clinical trials of
setmelanotide and development of any other product candidates we may choose to pursue. In addition, if we obtain marketing approval for setmelanotide, we will incur significant sales, marketing and
outsourced manufacturing expenses. We also will incur additional costs associated with operating as a public company. As a result, we expect to continue to incur significant and increasing operating
losses for the foreseeable future. Because of the numerous risks and uncertainties associated with developing pharmaceutical products, we are unable to predict the extent of any future losses or when
we will become profitable, if at all. Even if we do become profitable, we may not be able to sustain or increase our profitability on a quarterly or annual basis. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
ability to become profitable depends upon our ability to generate revenue. To date, we have not generated any revenue from setmelanotide, and we do not know when, or if, we will
generate any revenue. We do not expect to generate significant revenue unless and until we obtain marketing approval for, and </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>16</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=19,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=949461,FOLIO='16',FILE='DISK109:[18ZBU1.18ZBU44601]CK44601A.;11',USER='CHE105614',CD='10-JUN-2018;18:07' -->
<A NAME="page_ck44601_1_17"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>begin
to sell, setmelanotide. Our ability to generate revenue depends on a number of factors, including, but not limited to, our ability to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> initiate and successfully complete later-stage clinical trials that meet their clinical endpoints; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> initiate and successfully complete all safety studies required to obtain U.S. and foreign marketing approval for setmelanotide as a treatment
for obesity caused by genetic deficiencies affecting the MC4 pathway; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> successfully manufacture or contract with others to manufacture setmelanotide; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> commercialize setmelanotide, if approved, by building an internal sales force or entering into collaborations with third parties; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> achieve market acceptance of setmelanotide in the medical community and with third-party payors. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Absent
our entering into collaboration or partnership agreements, we expect to incur significant sales and marketing costs as we prepare to commercialize setmelanotide. Even if we
initiate and successfully complete our pivotal clinical trials and setmelanotide is approved for commercial sale, and we incur the costs associated with these activities, setmelanotide may not be a
commercially successful drug. We may not achieve profitability soon after generating product sales, if ever. If we are unable to generate product revenue, we will not become profitable and will be
unable to continue operations without continued funding. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Even if this offering is successful, we will need to raise additional funding, which may not be available on
acceptable terms, or at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate our product development efforts or other operations.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are currently advancing setmelanotide through clinical development. Developing peptide therapeutic products is expensive, and we expect our
research and development expenses to increase substantially in connection with our ongoing activities, particularly as we advance setmelanotide in clinical trials. We intend to use the remaining
proceeds from our IPO and from this offering primarily for the clinical development and regulatory approval of setmelanotide. Depending on the status of regulatory approval and, if approved,
commercialization of setmelanotide, as well as the progress we make in the sale of setmelanotide, we may still require significant additional capital to fund the continued development of setmelanotide
and our operating needs thereafter. We may also need to raise additional funds if we choose to pursue additional indications and/or geographies for setmelanotide or otherwise expand more rapidly than
we presently anticipate. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Through
August 2015, we received capital contributions from the Predecessor Company, the Relamorelin Company and the&nbsp;LLC entity. In August 2015, December 2015, January 2017 and
August 2017, we raised aggregate gross proceeds of $25.0&nbsp;million, $15.0&nbsp;million, $20.5&nbsp;million and $20.5&nbsp;million, respectively, through our issuance of series&nbsp;A
preferred stock. In October 2017 we completed our initial public offering, or IPO of 8,107,500 shares of common stock at an offering price of $17.00 per share, which included the exercise in full by
the underwriters of their option to purchase up to 1,057,500 additional shares of common stock. We received gross proceeds of approximately $137.8&nbsp;million, before deducting underwriting
discounts, commissions and offering related transaction costs. As of March&nbsp;31, 2018, our cash and cash equivalents and short-term investments were approximately $136.5&nbsp;million. We expect
our existing cash and cash equivalents and the proceeds from this offering will enable us to fund
our operating expenses into&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. However, our operating plan may change as a result of many factors currently unknown to us, and we may need to seek additional funds sooner than
planned,
through public or private equity or debt financings, government or other third-party funding, marketing and distribution arrangements and other collaborations, strategic alliances and licensing
arrangements, or a combination of these approaches. We will also require additional capital to obtain regulatory approval for, and to commercialize, setmelanotide. Raising funds in the current
economic environment may present additional </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>17</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=20,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=864927,FOLIO='17',FILE='DISK109:[18ZBU1.18ZBU44601]CK44601A.;11',USER='CHE105614',CD='10-JUN-2018;18:07' -->
<A NAME="page_ck44601_1_18"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>challenges.
Even if we believe we have sufficient funds for our current or future operating plans, we may seek additional capital if market conditions are favorable or if we have specific strategic
considerations. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize setmelanotide. In
addition, we cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. Moreover, the terms of any financing may adversely affect the
holdings or the rights of our stockholders and the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our shares to
decline. The sale of additional equity or convertible securities would dilute all of our stockholders. The incurrence of indebtedness would result in increased fixed payment obligations and we may be
required to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights,
and other operating restrictions that could adversely impact our ability to conduct our business. We could also be required to seek funds through arrangements with collaborative partners or other
third parties at an earlier stage than otherwise would be desirable and we may be required to relinquish rights to setmelanotide or technologies or otherwise agree to terms unfavorable to us, any of
which may have a material adverse effect on our business, operating results and prospects. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we are unable to obtain funding on a timely basis, we may be required to significantly curtail, delay or discontinue one or more of our research or development programs or the
commercialization of setmelanotide or be unable to expand our operations or otherwise capitalize on our business opportunities, as desired, which could materially adversely affect our business,
financial condition and results of operations. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our very limited operating history may make it difficult for you to evaluate the success of our business to
date and to assess our future viability.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are an early-stage company. The Predecessor Company commenced active operations in February 2010, and we were incorporated as a separate
company in February 2013. Our operations to date have been limited primarily to acquiring rights to intellectual property, business planning, raising capital, developing our technology, identifying
potential product candidates, undertaking preclinical studies and, beginning in November 2010, conducting clinical trials. We have not yet demonstrated our ability to successfully complete a pivotal
Phase&nbsp;3 clinical trial, obtain marketing approvals, manufacture at commercial scale, or arrange for a third party to do so on our behalf or conduct sales, marketing and distribution activities
necessary for successful product commercialization. Consequently, any predictions made about our future success or viability may not be as accurate as they could be if we had a longer operating
history. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, as a new business, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors. We will need to transition at some point
from a company with a research and development focus to a company capable of supporting commercial activities and we may not be successful in such a transition. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
expect our financial condition and operating results to continue to fluctuate significantly from quarter-to-quarter and year-to-year due to a variety of factors, many of which are
beyond our control. Accordingly, you should not rely upon the results of any quarterly or annual periods as indications of future operating performance. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>18</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=21,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=53149,FOLIO='18',FILE='DISK109:[18ZBU1.18ZBU44601]CK44601A.;11',USER='CHE105614',CD='10-JUN-2018;18:07' -->
<A NAME="page_ck44601_1_19"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our historical financial information is not necessarily representative of the results we would have achieved
as an independent company, and may not be a reliable indicator of our future results.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The historical financial information we have included in this prospectus may not reflect what our results of operations, financial position and
cash flows would have been had we been an independent company during the periods presented. This is primarily because:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> our historical financial information reflects allocations for services historically provided to us by the Predecessor Company and the
Relamorelin Company, which allocations may not reflect the costs we now and in the future will incur for similar services as an independent company; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> our historical financial information does not reflect changes that we have incurred and expect to continue to incur as a result of operating as
an independent company and from reduced economies of scale, including changes in cost structure, personnel needs, financing and operations of our business. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks Related to the Development of Setmelanotide  </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Positive results from early clinical trials of setmelanotide may not be predictive of the results of later
clinical trials of setmelanotide. If we cannot generate positive results in our later clinical trials of setmelanotide, we may be unable to successfully develop, obtain regulatory approval for, and
commercialize setmelanotide.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Positive results from any of our Phase&nbsp;1 and Phase&nbsp;2 clinical trials of setmelanotide may not be predictive of the results of
later clinical trials. The duration of effect of setmelanotide tested in our Phase&nbsp;1 and Phase&nbsp;2 clinical trials was often for shorter periods than in our current pivotal Phase&nbsp;3
clinical trials. The duration of effect of setmelanotide has only been studied in long-term durations for a small number of patients in our Phase&nbsp;2 clinical trials and safety or efficacy issues
may arise when more patients are studied in longer trials. It is possible that the effects seen in short-term clinical trials will not be replicated in long-term or larger clinical trials. In
addition, not all of our trials demonstrated statistically significant weight loss and there can be no guarantee that future trials will do so. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Positive
results for one indication are not necessarily predictive of positive results for other indications. We have demonstrated proof of concept in Phase&nbsp;2 clinical trials in
POMC deficiency obesity, LepR deficiency obesity, and Bardet-Biedl syndrome, three genetic disorders of extreme and unrelenting appetite and obesity, in which setmelanotide dramatically reduced both
weight and hunger. We believe we have also demonstrated preliminary proof of concept in Phase&nbsp;2 for Alstr&ouml;m syndrome. We
hypothesize that patients with other upstream genetic defects in the MC4 pathway may also respond with reductions in weight and hunger after treatment with setmelanotide, however patients with other
upstream genetic defects may not have a similar response to setmelanotide, and until we obtain more clinical data in other genetic defects, we will not be sure that we can achieve proof of concept in
such indications. In addition, while we believe that proof of concept in Bardet-Biedl syndrome and Alstr&ouml;m syndrome has been demonstrated by improvements in hunger and weight reduction,
supporting that this is a setmelanotide-responsive, MC4 pathway disorder, the results of this trial are still at a preliminary stage. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have and will continue to have multiple clinical trials of setmelanotide ongoing, which are designed to include multiple genetically and clinically defined populations under one
investigational protocol, although each population is enrolled and analyzed separately. A "basket" trial design could potentially decrease the time to study new populations by decreasing
administrative burden, however, these trials may not provide opportunities for acceleration, and do not overcome limitations to extrapolating data from the experience in one disease to other diseases,
because safety and efficacy results in each indication are analyzed separately. Accordingly, clinical success in a basket trial, or any trial in one indication, may not predict success in another
indication. In contrast, in the event of an adverse safety issue, clinical hold, or other adverse finding in one or more indications being tested, such event could adversely affect our trials in the
other indications and may delay or prevent completion of the clinical trials. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>19</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=22,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=892172,FOLIO='19',FILE='DISK109:[18ZBU1.18ZBU44601]CK44601A.;11',USER='CHE105614',CD='10-JUN-2018;18:07' -->
<A NAME="page_ck44601_1_20"> </A>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Many
companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in later stage clinical trials after achieving positive results in early stage
development, and we cannot be certain that we will not face similar setbacks. These setbacks have been caused by, among other things, pre-clinical findings made while clinical trials were underway.
However, we have completed the key toxicology studies that the U.S. Food and Drug Administration, or the FDA, will require for our first approval, and which we believe the European Medicines Agency,
or EMA, will require for authorization, which include, among others, chronic toxicity studies, reproductive and developmental toxicity studies, and juvenile toxicology studies. Based on the totality
of animal testing results to date, including the lack of any observed genotoxicity or tissue proliferative activity of setmelanotide in chronic toxicity studies, the FDA has agreed to permit us to
defer carcinogenicity studies until after approval of a new drug application, or NDA, for setmelanotide. Accordingly, we believe that we will be able to defer the submission of all carcinogenicity
studies until after we receive regulatory approval to market setmelanotide in the U.S. While we believe this also to be true for the EMA, the EMA has not yet provided firm guidance on the need for
carcinogenicity studies and accordingly, there can be no guarantee that we will be able to achieve this deferral which could impact the timing of any potential European Union, or EU, approval. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition to the foregoing issue, the FDA has requested that in our chronic rat and monkey studies we re-assess certain cells in brain, renal and liver tissues for the presence of
vacuoles, which are common membrane-bound compartments. The recommendation was based on the FDA's review of a
summary of a monkey study that noted the presence of macrophage aggregates, which are groupings of specific white blood cells, in the choroid plexus, a network of blood vessels and epithelial tissue
in the membrane lining outside the brain and spinal cord. The FDA noted that the existence of macrophage aggregates appears to be related to the polyethylene glycol, or PEG, vehicle in the product,
rather than setmelanotide itself. A similar question was raised by the competent authorities in France, in connection with the use of PEG in products for younger pediatric indications, and in
discussion of our Pediatric Investigational Plan, or PIP. Based on this, we performed this re-assessment, which confirmed that no additional findings were present in any monkey tissues, but which did
find a very small number of rats with vacuolated epithelial cells, or brain surface lining cells, in the choroid plexus of minimal severity that also appeared to be related to the PEG vehicle. We do
not believe these findings raise any important safety concerns, in part because of the minimal severity, the localization of these aggregates, the lack of any adverse histopathological changes, and
the lack of findings in other tissues. However, neither the FDA nor regulatory agencies in the EU has indicated that they agree with our position. In addition, we anticipate the EMA may request
additional mechanistic studies to better understand these findings. It is also possible the FDA may require us to reflect these findings in the toxicological portion of the product labeling, and this
may delay study in the youngest pediatric patients in some EU member states, such as France. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additionally,
setbacks may be caused by new safety or efficacy observations made in clinical trials, including previously unreported adverse events. Moreover, preclinical and clinical
data are often susceptible to varying interpretations and analyses, and many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials
nonetheless failed to obtain FDA approval or European Commission authorization. If we fail to obtain positive results in our Phase&nbsp;3 clinical trials of setmelanotide, the development timeline
and regulatory approval and commercialization prospects for setmelanotide and, correspondingly, our business and financial prospects would be materially adversely affected. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The number of patients suffering from each of the MC4 pathway deficiencies we are targeting is small and has
not been established with precision. If the actual number of patients is smaller than we estimate, our revenue and ability to achieve profitability may be materially adversely affected.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Due to the rarity of our target indications, there is no comprehensive patient registry or other method of establishing with precision the
actual number of patients with MC4 pathway deficiencies. As a result, we have had to rely on other available sources to derive clinical prevalence estimates for our target </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>20</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=23,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=969861,FOLIO='20',FILE='DISK109:[18ZBU1.18ZBU44601]CK44601A.;11',USER='CHE105614',CD='10-JUN-2018;18:07' -->
<A NAME="page_ck44601_1_21"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>indications.
Since the published epidemiology studies for these genetic deficiencies are based on relatively small population samples, and are not amenable to robust statistical analyses, it is
possible
that these projections may significantly exceed the addressable population, particularly given the need to genotype patients to definitively confirm a diagnosis. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
on clinical epidemiology, we have estimated the potential addressable patient populations with these MC4 pathway deficiencies based on the following sources and
assumptions: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2><I> POMC Deficiency Obesity.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;There are approximately 50 patients with POMC
deficiency obesity noted in a series of published case reports, each mostly reporting a single or small number of patients. However, we believe our addressable patient population for this deficiency
may be approximately 100 to 500 patients in the United States, and a comparable addressable patient population in Europe, as most of the reported cases are from a small number of academic research
centers, and because genetic testing for POMC deficiency is often unavailable and currently is rarely performed. Based on discussions with experts in rare diseases, we also believe the number of
diagnosed cases could increase several-fold with increased awareness of this deficiency and the availability of new treatments.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2><I> LepR Deficiency Obesity and POMC Heterozygous Deficiency Obesity.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;Our
addressable patient population estimate for LepR deficiency obesity is approximately 500 to 2,000 patients in the United States, and for POMC heterozygous deficiency obesity is approximately 4,000
patients in the United States, with a comparable addressable patient population for both indications in Europe. Our estimates are based on: </FONT> <FONT SIZE=2>
<BR><BR></FONT>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> epidemiology studies on LepR deficiency and POMC heterozygous deficiency in small cohorts of patients comprised of children with
severe obesity and adults with severe obesity who have a history of early onset obesity;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> U.S. Census Bureau figures for adults and children, and Centers for Disease Control and Prevention, or CDC, prevalence numbers for
severe adult obese patients (body mass index, or BMI, greater than 40 kg/ m<SUP>2</SUP>) and for severe early onset obese children (99th&nbsp;percentile at ages two to 17&nbsp;years old); and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> with wider availability of genetic testing expected for LepR deficiency and POMC heterozygous deficiency and increased awareness
of new treatments, our belief that up to 40% of patients with these disorders may eventually be diagnosed. </FONT></DD></DL>
</DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Using
these sources and assumptions, we calculated our estimates for addressable populations by multiplying (x)&nbsp;our estimate of the number of patients comprised of children with
severe obesity and our estimate of a projected number of adults with severe obesity who have a history of early onset obesity, (y)&nbsp;the estimated prevalence from epidemiology studies of
approximately 1% for LepR deficiency and 2% for POMC heterozygous, and (z)&nbsp;our estimated diagnosis rate of up to 40%.  </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2><I> Bardet-Biedl Syndrome.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;Our addressable patient population estimate for
Bardet-Biedl syndrome is approximately 1,500 to 2,500 patients in the United States based on: </FONT> <FONT SIZE=2>
<BR><BR></FONT>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> published prevalence estimates of one in 100,000 in North America, which projects to approximately 3,250 people in the United
States. We believe the majority of these patients are addressable patients; and  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> our belief that with wider availability of genetic testing expected for Bardet-Biedl syndrome and increased awareness of new
treatments, the number of patients diagnosed with this disorder will increase. </FONT></DD></DL>
</DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>21</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=24,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=599733,FOLIO='21',FILE='DISK109:[18ZBU1.18ZBU44601]CK44601A.;11',USER='CHE105614',CD='10-JUN-2018;18:07' -->
<A NAME="page_ck44601_1_22"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2><I> Alstr&ouml;m Syndrome.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;Our addressable patient population
estimate for Alstr&ouml;m syndrome is approximately 500 to 1,000 patients worldwide. This estimate is based on: </FONT> <FONT SIZE=2>
<BR><BR></FONT>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> published prevalence estimates of one in 1,000,000 in North America, which projects to approximately 325 people in the United
States. We believe the majority of these patients are addressable patients; and  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> our belief that with wider availability of genetic testing expected for Alstr&ouml;m syndrome and increased awareness of
new treatments, the number of patients diagnosed with this disorder will increase.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD></DL>
</DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2><I> POMC Epigenetic Disorders.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;There is currently no epidemiology data that
defines the prevalence of POMC epigenetic disorders. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe that the patient populations in the EU are at least as large as those in the United States. However, we do not have comparable epidemiological data from the European Union and
these estimates are therefore based solely on applying relative population percentages to the Company-derived estimates described above. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are conducting additional clinical epidemiology studies to strengthen these prevalence projections. In parallel, we have developed a patient registry for diagnosed patients with POMC
deficiency and LepR deficiency (and other genetic disorders of obesity) which will further inform prevalence projections for these rare genetic orders. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Another
method to estimate the size of these ultra-rare populations by genetic epidemiology is using newly available large genomic databases, containing full genome sequencing or exome
sequencing. Ultra-rare orphan diseases are generally categorized as those that affect fewer than 20 patients per million. We have begun some substantial efforts with a series of such databases and/or
collaborators. Our initial work has been with a database of approximately 140,000 genomes, which is representative of the U.S. population. These efforts generally are based on the prevalence of
heterozygous mutations, as true null mutations are ultra-rare, and then standard scientific methods such as the Hardy-Weinberg equilibrium calculations, are applied to estimate the prevalence in the
U.S. population. These methods make assumptions that may not be sufficiently robust for ultra-rare genetic disorders, and have the inherent variability of estimates for rare events. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, the databases currently available only provide limited clinical data, such as, age, weight and BMI, that would be needed to associate genetic defects with severe obesity.
Our continued investigations support that the genetic epidemiological estimates are larger than the clinical epidemiological estimates, but we will likely need to reconcile the scientific definition
of mutations with the regulatory definition. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe the separate analyses that we have completed using clinical epidemiology and genetic epidemiology provide a robust range of patient population estimates for these rare
disorders. However, to be conservative, we reference the clinical epidemiology figures in our descriptions of our target indications. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, if any approval that we obtain is based on a narrower definition of these patient populations than we had anticipated, then the potential market for setmelanotide for these
indications will be smaller than we originally believed. In either case, a smaller patient population in our target indications would have a materially adverse effect on our ability to achieve
commercialization and generate revenues. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If the actual number of patients suffering from each of the MC4 pathway deficiencies we are targeting is
smaller than we estimate or if any approval that we obtain is based on a narrower definition of these patient populations, including pediatric populations, our ability to recruit patients to our
trials may be materially adversely affected.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If the actual number of patients with any of the MC4 pathway deficiencies we are targeting is lower than we believe, it may be difficult to
recruit patients, and this may affect the timelines for the completion </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>22</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=25,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=445337,FOLIO='22',FILE='DISK109:[18ZBU1.18ZBU44601]CK44601A.;11',USER='CHE105614',CD='10-JUN-2018;18:07' -->
<A NAME="page_ck44601_1_23"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>of
clinical trials. If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could also be delayed or prevented. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
pediatric population is an important patient population for setmelanotide and our addressable patient population estimates include pediatric populations. However, it may be more
challenging to conduct studies in this population, and to locate and enroll pediatric patients. Additionally, it may be challenging to ensure that pediatric or adolescent patients adhere to clinical
trial protocols. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
currently are treating patients 12&nbsp;years of age and older in our trials, and have started treating patients six to 11&nbsp;years of age. Our aim is to gain regulatory
approval and labeling for patients six years of age and older. We have received permission from the FDA and other equivalent competent authorities in the EU member states to enroll these younger
patients, aged six to 11, in our pivotal trials. However, there may be issues that preclude the ultimate approval and labeling including, but not limited to, potential disagreement on dose titration,
or delivery methods for small doses, or the suitability of patient reported outcomes in younger patients, the clinical endpoints in rapidly growing patients, as well as avoiding over-suppression of
normal appetite in adolescents. In addition, the competent authorities in the EU member states may consider the polyethylene glycol vehicle in the product to carry additional risks in pediatric
patients, and may look to new formulations, such as our once-weekly formulation, as being more suitable to younger pediatric patients. We also may not have one-year clinical data in six to
11&nbsp;year old patients at the time of the POMC NDA filing, if we begin
recruiting six to 11&nbsp;year old patients into our pivotal trials, though we can provide one-year clinical data when it becomes available. We cannot predict if the FDA or other equivalent
competent authorities in the EU member states will approve setmelanotide in younger pediatric patients, nor provide an estimate for the timing for approval, if any, for the use of setmelanotide for
such patients. Furthermore, if the FDA or other equivalent competent authorities in the EU member states do not approve the use of setmelanotide in this population, the product candidate will not be
labeled for promotion for these patients, even if they approve an NDA for setmelanotide for patients 12 and older. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;While
we have no knowledge of competitors developing product candidates intended to treat upstream MC4 pathway deficiencies, other than Prader-Willi-Syndrome, competitors may emerge. If
that were to occur and competitors initiated clinical trials for product candidates that treat the same indications as setmelanotide, patients who would otherwise be eligible for our clinical trials
may instead enroll in the clinical trials of our competitors' product candidates, and could impact our commercial success. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Patient
enrollment is also affected by other factors including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the severity of the disease under investigation; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the eligibility criteria for the clinical trial in question; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the perceived risks and benefits of the product candidate under study; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the success of efforts to facilitate timely enrollment in clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the patient referral practices of physicians; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the ability to monitor patients adequately during and after treatment; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the proximity and availability of clinical trial sites for prospective patients. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
inability to enroll a sufficient number of patients for our clinical trials would result in significant delays, could require us to abandon one or more clinical trials altogether and
could delay or prevent our receipt of necessary regulatory approvals. Enrollment delays in our clinical trials may result in increased development costs for setmelanotide, which would cause the value
of our company to decline and limit our ability to obtain additional financing. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>23</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=26,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=199089,FOLIO='23',FILE='DISK109:[18ZBU1.18ZBU44601]CK44601A.;11',USER='CHE105614',CD='10-JUN-2018;18:07' -->
<A NAME="page_ck44601_1_24"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Failures or delays in the commencement or completion of our planned clinical trials of setmelanotide could
result in increased costs to us and could delay, prevent or limit our ability to generate revenue and continue our business.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We completed Phase&nbsp;2 clinical trials for setmelanotide in 2016 for POMC deficiency obesity and are currently advancing an ongoing pivotal
Phase&nbsp;3 clinical trial for setmelanotide for POMC deficiency obesity. We completed Phase&nbsp;2 clinical trials for setmelanotide for LepR deficiency obesity, and are currently advancing an
ongoing pivotal Phase&nbsp;3 clinical trial for setmelanotide in LepR deficiency obesity. These trials are overlapping in timing and duration and we plan to discuss with the FDA and other regulatory
agencies, and will likely file concurrent NDAs for these two indications, which would have an impact on NDA timing and complexity. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe we have demonstrated proof of concept in Bardet-Biedl syndrome and Alstr&ouml;m syndrome, are in ongoing discussions with the FDA to plan a pivotal Phase&nbsp;3
clinical trial in Bardet-Biedl syndrome, likely combined with a pivotal Phase&nbsp;3 clinical trial in Alstr&ouml;m syndrome, that we anticipate we can initiate in 2018. We believe that
the combined Bardet-Biedl syndrome and Alstr&ouml;m syndrome Phase&nbsp;3 pivotal trial may be somewhat different in design that those for POMC and LepR deficiency obesity,
respectively, most likely due to the larger available patient population for inclusion in a clinical study. There may be other changes as well, as our feedback from the FDA is preliminary, and we have
not yet consulted with the European regulatory agencies. We have also initiated Phase&nbsp;2 clinical trials for POMC and other MC4 pathway heterozygous deficiency obesities, and POMC epigenetic
disorders. We anticipate that the Phase&nbsp;2 clinical trials in these indications may be more complex than those for which we have achieved proof of concept. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Successful
completion of such Phase&nbsp;3 clinical trials is a prerequisite to submitting an NDA to the FDA, a marketing authorization application to the EMA, and other applications
for marketing authorization to equivalent competent authorities in foreign jurisdictions, and consequently, the ultimate approval and commercial marketing of setmelanotide. While we believe that a
transition from proof of concept to pivotal trials may be more straight-forward for Alstr&ouml;m syndrome, it is likely that Phase&nbsp;2 clinical trials will be longer and more complex
for POMC heterozygous deficiency obesity and POMC epigenetic disorders, due to the greater variety of clinical presentation in those conditions. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
do not know whether our planned additional Phase&nbsp;2 or Phase&nbsp;3 clinical trials will begin or whether any of our clinical trials will be completed on schedule, if at all,
as the commencement and successful completion of clinical trials can be delayed or prevented for a number of reasons, including but not limited to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the FDA or other equivalent competent authorities in foreign jurisdictions may deny permission to proceed with our planned Phase&nbsp;3
clinical trials or any other clinical trials we may initiate, or may place a clinical trial on hold; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> delays in filing or receiving approvals or additional IND that may be required; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> negative results from our ongoing and planned preclinical studies, or the FDA or other equivalent competent authorities in foreign
jurisdictions requiring additional preclinical studies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> delays in commencing additional necessary preclinical studies, including carcinogenicity and juvenile toxicology studies; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> delays in reaching or failing to reach agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical
trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> since many already diagnosed patients are at academic sites, delays in conducting clinical trials at academic sites due to the particular
challenges and delays typically associated with those sites, as well as the lack of alternatives to these sites which have already-diagnosed patients; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>24</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=27,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=249240,FOLIO='24',FILE='DISK109:[18ZBU1.18ZBU44601]CK44601A.;11',USER='CHE105614',CD='10-JUN-2018;18:07' -->
<A NAME="page_ck44601_1_25"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> inadequate quantity or quality of setmelanotide or other materials necessary to conduct clinical trials, including delays in the manufacturing
of sufficient supply of finished drug product; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> difficulties in obtaining Institutional Review Board, or IRB, and/or ethics committee approval to conduct a clinical trial at a prospective
site or sites; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> challenges in recruiting and enrolling patients to participate in clinical trials, including the size and nature of the patient population, the
proximity of patients to clinical trial sites, eligibility criteria for the clinical trial, the nature of the clinical trial protocol, the availability of approved effective treatments for the
relevant disease and competition from other clinical trial programs for similar indications; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> severe or unexpected drug-related side effects experienced by patients in a clinical trial, including side effects previously identified in our
completed clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> delays in identifying and recruiting patients with any of the genetic causes of obesity in indications that we are targeting; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> disagreement by the FDA, other regulatory agencies or the equivalent competent authorities in foreign jurisdictions with our clinical trial
designs, which may in turn cause delays in initiating our clinical trials, or may lead to rejection of our interpretation of data from clinical trials or to changes in the requirements for approval
even after it has reviewed and commented on the design for our clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the requirement to have a placebo controlled study even though the FDA and EMA did not impose one for POMC deficiency obesity, as we cannot be
certain that this will be true for other indications or that the FDA or EMA, an advisory committee or the equivalent competent authorities in foreign jurisdictions will not change its guidance, as it
has done so in the past for other open control trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> uncertainty related to the length of placebo-controlled intervals in clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the need to perform non-inferiority trials, which can be larger, longer and more costly, if treatment is approved for similar indications; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> potential delays in the enrollment for our clinical trials of Bardet-Biedl syndrome and Alstr&ouml;m syndrome due to the fact that we
have not yet completed our discussions with the FDA regarding clinical trials for these indications, do not know if the FDA will disagree with our proposed Phase&nbsp;3 clinical trial design; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> potential difficulties in defining the indication for Bardet-Biedl syndrome, as there may be discrepancies between the syndromic, or clinical
definition of the syndrome, and the genetic confirmation of the indication; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> lack of ability to predict which patients will have the most consistent responses to setmelanotide in the patients with rare genetic disorders
of obesity that we are studying, as not all patients may show robust responses to treatment; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> POMC heterozygous deficiency may have additional challenges, including that the FDA the EMA, or the equivalent competent authorities in foreign
jurisdictions may require that we show that setmelanotide works better in these patients than in the genetically normal population; other challenges associated with these patients may include
additional delays in initiating clinical trials for this indication due to uncertainty about the subset of these patients who will respond effectively to setmelanotide and the lack of discussion for
this indication with the FDA; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> reports from preclinical or clinical testing of other weight loss therapies may raise safety or efficacy concerns; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>25</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=28,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=241267,FOLIO='25',FILE='DISK109:[18ZBU1.18ZBU44601]CK44601A.;11',USER='CHE105614',CD='10-JUN-2018;18:07' -->
<UL>
<UL>
</UL>
</UL>
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_cm44601_1_26"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A> </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> difficulties retaining patients who have enrolled in a clinical trial but may be prone to withdraw due to rigors of the clinical trial, lack of
efficacy, side-effects, personal issues or loss of interest; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> lack of a complete understanding of the absorption, distribution, metabolism and excretion of setmelanotide, or an incomplete set of clinical
pharmacology studies to support labeling. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Clinical
trials may also be delayed or terminated as a result of ambiguous or negative interim results. In addition, a clinical trial may be suspended or terminated by us, the FDA or
other equivalent competent authorities in foreign jurisdictions, the IRBs or ethics committees at the sites where the IRBs or the ethics committees are overseeing a clinical trial, a data and safety
monitoring board, or DSMB, or Safety Monitoring Committee, or SMC, overseeing the clinical trial at issue or other equivalent competent authorities due to a number of factors, including, among
others:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> failure to conduct the clinical trial in accordance with regulatory requirements or our clinical trial protocols; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> inspection of the clinical trial operations or trial sites by the FDA or other equivalent competent authorities that reveals deficiencies or
violations that require us to undertake corrective action, including the imposition of a clinical hold; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> unforeseen safety issues, adverse side effects or lack of effectiveness; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> changes in government regulations or administrative actions; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> problems with clinical trial supply materials; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> lack of adequate funding to continue the clinical trial. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Changes in regulatory requirements, FDA or EMA guidance or unanticipated events during our clinical trials of
setmelanotide may occur, which may result in changes to clinical trial protocols, changes to instruments for measuring subjective systems or additional clinical trial requirements, which could result
in increased costs to us and could delay our development timeline.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Changes in regulatory requirements, FDA guidance, guidance published by the EMA or the other competent authorities in foreign jurisdictions, or
unanticipated events during our clinical trials may force us to amend clinical trial protocols or the FDA, or the other competent authorities in foreign jurisdictions may impose additional clinical
trial requirements. For instance, the FDA issued draft guidance on developing products for weight management in February 2007. In March 2012, the FDA's Endocrinologic and Metabolic Drugs Advisory
Committee met to discuss possible changes to how the FDA evaluates the cardiovascular safety of weight-management drugs, and the FDA may require additional studies to support registration. In
addition, the FDA is considering broader applicability of requirements for cardiovascular outcomes trials, or CVOTs, presenting the possibility of cardiovascular risk pre-approval, including for
obesity products. While our Phase&nbsp;3 discussions with the FDA have not resulted in a requirement for any of these activities, any future requirement for these activities could result in
additional clinical requirements for setmelanotide, increase our costs and delay approval of setmelanotide. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amendments
to our clinical trial protocols would require resubmission to the FDA and IRBs or other competent authorities and ethics committees in foreign jurisdictions for review and
approval, which may adversely impact the cost, timing or successful completion of a clinical trial. If we experience delays completing, or if we terminate, any of our clinical trials, or if we are
required to conduct additional clinical trials, the commercial prospects for setmelanotide may be harmed and our ability to generate product revenue will be delayed. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, as part of commencing our Phase&nbsp;3 clinical trial for setmelanotide in POMC deficiency obesity, we sought FDA concurrence with, and received substantial input on, the
use of Patient Reported Outcome, or PRO, and Observer Reported Outcome, or ORO, questionnaires for measuring subjective </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>26</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=29,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=129964,FOLIO='26',FILE='DISK109:[18ZBU1.18ZBU44601]CM44601A.;9',USER='CHE105614',CD='10-JUN-2018;18:07' -->
<A NAME="page_cm44601_1_27"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>endpoints
for changes in hunger and/or food-seeking behavior and compulsions. We believe we can apply the same guidance to our future pivotal trials in other indications. A PRO is a measurement
based on a report that comes from the patient about the status of a patient's health condition, without amendment or interpretation of the patient's response by a clinician or anyone else. An ORO is a
measurement based on an observation by someone other than the patient or a health professional, such as a parent, spouse or other non-clinical caregiver who is in a position to regularly observe and
report on a specific aspect of the patient's health. In our Phase&nbsp;3 clinical trials for setmelanotide, based on the FDA feedback, we plan to measure the ability of setmelanotide to mitigate
hunger and/or hyperphagia, the overriding physiological drive to eat, through PRO and ORO questionnaires. The questionnaires are designed to elicit feedback from patients on how well setmelanotide
decreases their hunger, and from their family members or caregivers on the effect of setmelanotide on the patients' food seeking behavior. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
our knowledge, no sponsor of an approved drug has yet used PRO or ORO questionnaires to generate data on hyperphagia or hunger mitigating endpoints. Because we may be relying on
clinical endpoints that have not previously been the subject of prior FDA approvals, there is a risk that the FDA or other equivalent competent authorities in foreign jurisdictions may not consider
the endpoints to provide evidence of clinically meaningful results or that results may be difficult for the FDA to interpret, in particular for the pediatric age group. If we experience delays in our
ongoing validation of our PRO or ORO questionnaires, or do not receive agreement with those proposed questionnaires based on the conceptual framework, content reliability, other measures of validity,
or their ability to detect changes in hyperphagia or hunger, or we experience difficulties in the methods of statistical analysis for hunger and hyperphagia, we may experience delays in our trials or
in product approval as well as be unable to reference data on hyperphagia or hunger in our product labeling. Finally, our Phase&nbsp;3 clinical trials will be assessing hunger using multiple
methods, some of which were previously used in Phase&nbsp;2, but some of which were initiated in Phase&nbsp;3 trials and for which little data is available. Hence it is possible that the effects
on hunger seen in Phase&nbsp;2 trials may differ with some of the new methodologies for assessing hunger being used in Phase&nbsp;3 trials, or may not support language in the proposed product
labeling. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Setmelanotide may cause undesirable side effects that could delay or prevent regulatory approval, limit the
commercial profile of an approved labeling, or result in significant negative consequences following marketing approval, if any.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;First generation MC4R agonists were predominantly small molecules that failed in clinical trials due to significant safety issues, particularly
increases in blood pressure, and had limited efficacy. Undesirable side effects caused by setmelanotide could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could
result in a more restrictive labeling or the delay or denial of regulatory approval by the FDA or other equivalent competent authorities in foreign jurisdictions. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Setmelanotide
is an MC4R agonist. Potential side effects of MC4R agonism, which have been noted either with setmelanotide or with other MC4R agonists in clinical trials and preclinical
studies, may include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> adverse effects on cardiovascular parameters, such as increases in heart rate and blood pressure; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> erections in males and similar effects in women, such as sexual arousal, clitoral swelling and hypersensitivity; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> nausea and vomiting; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> reduced appetite; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> effects on mood, depression, anxiety and other psychiatric manifestations; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> other effects, specifically adverse events noted at somewhat greater rates numerically for setmelanotide compared to placebo across the
clinical program, which include fatigue and related </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>27</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=30,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=795426,FOLIO='27',FILE='DISK109:[18ZBU1.18ZBU44601]CM44601A.;9',USER='CHE105614',CD='10-JUN-2018;18:07' -->
<A NAME="page_cm44601_1_28"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>symptoms,
diarrhea, arthralgia, back pain and headache, though most investigators reported these effects to be unrelated to setmelanotide. </FONT></P>

</UL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Injection
site reactions have been seen in subcutaneous, or SC, injections with setmelanotide. In addition, setmelanotide has likely off-target effects on the closely-related MC1
receptor, which mediates tanning in response to sun exposure. Other MC1 receptor mediated effects include darkening of skin blemishes, such as freckles and moles, and hair color change. The cosmetic
effects are not tolerated by all patients, as a small number of patients have withdrawn from treatment due to tanning. These effects have generally been reversible in clinical trials, but it is still
unknown if they will be reversible with long-term exposure. The MC1 receptor mediated effects may also carry risks. The long-term impact of MC1 receptor activation has not been tested in clinical
trials, and could potentially include increases in skin cancer, excess biopsy procedures and cosmetic blemishes. These skin changes may also result in unblinding, which could make interpretation of
clinical trial results more complex and possibly subject to bias. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
safety data we have disclosed to date represents our interpretation of the data at the time of disclosure and they are subject to our further review and analysis. There has been only
a single serious adverse event possibly attributed to setmelanotide in our clinical trials. In our Phase&nbsp;2 clinical trial with once daily SC injection, one patient was hospitalized for unusual
chest pain, but no evidence of any serious respiratory or cardiac cause was found after careful evaluation, and the event was attributed to musculoskeletal pain. There were no treatment related
changes in physical examination, except as noted below, and few, if any, clinically relevant changes in electrocardiograms, laboratory data and/or anti-drug antibodies. Overall, there have been ten
other serious adverse events in the full development program, in addition to the serious adverse event described above: seven others on setmelanotide, mostly from open label trials, including left arm
numbness, influenza immunization reaction, pancreatitis secondary to pre-existing gallstones, pneumonia, hypoglycemia due to acute adrenal insufficiency, due to non-compliance with hydrocortisone
regimen, a depressive episode with elective admission to a psychiatry ward in a patient with history of depression and who continued on treatment, and rotavirus-related gastroenteritis. There were
also three serious adverse events during treatment with placebo, consisting of biliary dyskinesia, severe groin strain, and pelvic inflammatory disease. None of these serious adverse events was
considered related to setmelanotide treatment. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are also initiating trials of setmelanotide in potential new indications that include patients who might have more serious underlying conditions, such as Alstr&ouml;m
syndrome, lipodystrophy and other indications. It is possible that the underlying conditions in these patients, such as congestive heart failure, pancreatitis, and potentially other conditions may
confound the understanding of the safety profile of setmelanotide. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, our interpretation of the safety data from our clinical trials is contingent upon the review and ultimate approval of the FDA, other regulatory authorities or other
equivalent competent authorities in foreign jurisdictions. The FDA or other equivalent competent authorities in foreign jurisdictions may not agree with our methods of analysis or our interpretation
of the results. In addition, the long-term effects of setmelanotide have only been tested in a limited number of patients. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Further,
if setmelanotide receives marketing approval and we or others identify undesirable side effects caused by the product, or any other similar product, before or after the
approval, a number of potentially significant negative consequences could result, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> regulatory authorities may request that we withdraw the product from the market or may limit their approval of the product through labeling or
other means; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> regulatory authorities may require the addition of labeling statements, such as a "boxed" warning or a contraindication; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the FDA and other equivalent competent authorities in foreign jurisdictions may require the addition of a Risk Evaluation and Mitigation
Strategy, or REMS, or other specific obligations as a </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>28</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=31,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=544014,FOLIO='28',FILE='DISK109:[18ZBU1.18ZBU44601]CM44601A.;9',USER='CHE105614',CD='10-JUN-2018;18:07' -->
<A NAME="page_cm44601_1_29"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>condition
for marketing authorization due to the need to limit treatment to rare patient populations, or to safety concerns; </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> we may be required to change the way the product is distributed or administered, conduct additional clinical trials or change the labeling of
the product; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> we may decide to remove the product from the marketplace; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> we could be sued and held liable for injury caused to individuals exposed to or taking the product; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> our reputation may suffer. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
of these events could prevent us from achieving or maintaining market acceptance of setmelanotide and could substantially increase the costs of commercializing setmelanotide and
significantly impact our ability to successfully commercialize setmelanotide and generate revenues. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Although we have been granted orphan drug designation for setmelanotide in treating POMC deficiency obesity
and LepR deficiency obesity, we may be unable to obtain orphan drug designation for other uses or to obtain exclusivity in any use. Even with exclusivity, competitors may obtain approval for different
drugs that treat the same indications as setmelanotide.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The FDA may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act of 1983, or the Orphan Drug Act,
the FDA may designate a product candidate as an orphan drug if it is intended to treat a rare disease or condition, which is defined under the Federal Food, Drug and Cosmetic Act, or FDCA, as having a
patient population of fewer than 200,000 individuals in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of
developing the drug will be recovered from sales in the United States. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Generally,
if a product candidate with an orphan drug designation receives the first marketing approval for the indication for which it has such designation, the product is entitled to a
period of seven years of marketing exclusivity, which precludes the FDA from approving another marketing application for a product that constitutes the same drug treating the same indication for that
marketing exclusivity period, except in limited circumstances. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
exclusivity period in the United States can be extended by six months if the NDA sponsor submits pediatric data that fairly respond to a written request from the FDA for such data.
Even under these
circumstances, we may not be granted pediatric approval from the FDA for these indications. Orphan drug exclusivity may be revoked if the FDA determines that the request for designation was materially
defective or if the manufacturer is unable to assure sufficient quantity of the product to meet the needs of patients with the rare disease or condition. Other potential benefits of orphan drug
designation and/or approval of a designated drug include eligibility for: exemption from certain prescription drug user fees, tax credits for certain qualified clinical testing expenses, and waivers
from the pediatric assessment requirements of the Pediatric Research Equity Act, or PREA. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Although
we have been granted orphan drug designation for setmelanotide in treating POMC deficiency obesity and LepR deficiency obesity, if we request orphan drug designation for
setmelanotide for other uses, there can be no assurance that the FDA will grant such designation. For example, if the population of patients who would be appropriate candidates for a drug is 200,000
or more individuals, the drug may not qualify for orphan drug designation, even if the population for which the sponsor seeks approval is lower than 200,000. Additionally, the designation of
setmelanotide as an orphan drug does not guarantee that the FDA will accelerate regulatory review of, or ultimately approve, setmelanotide. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Even
if we obtain orphan drug exclusivity for setmelanotide, that exclusivity may not effectively protect setmelanotide from competition because different drugs can be approved for the
same condition. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>29</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=32,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=488763,FOLIO='29',FILE='DISK109:[18ZBU1.18ZBU44601]CM44601A.;9',USER='CHE105614',CD='10-JUN-2018;18:07' -->
<A NAME="page_cm44601_1_30"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>In
the United States, even after an orphan drug is approved, the FDA may subsequently approve another drug for the same condition if the FDA concludes that the latter drug is not the same drug or is
clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
August&nbsp;3, 2017, Congress passed the FDA Reauthorization Act of 2017, or the FDARA. FDARA, among other things, codified the FDA's pre-existing regulatory interpretation, to
require that a drug sponsor demonstrate the clinical superiority of an orphan drug that is otherwise the same as a previously approved drug for the same rare disease in order to receive orphan drug
exclusivity. The new legislation reverses prior precedent holding that the Orphan Drug Act unambiguously requires that the FDA recognize the orphan exclusivity period regardless of a showing of
clinical superiority. The FDA may further reevaluate the Orphan Drug Act and its regulations and policies. We do not know if, when, or how the FDA may change the orphan drug regulations and policies
in the future, and it is uncertain how any changes might affect our business. Depending on what changes the FDA may make to its orphan drug regulations and policies, our business could be adversely
impacted. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Although we have obtained Breakthrough Therapy designation for setmelanotide for the treatment of obesity
associated with genetic defects upstream of the MC4 receptor in the leptin-melanocortin pathway, which includes POMC deficiency obesity, LepR deficiency obesity, Bardet-Biedl syndrome and
Alstr&ouml;m syndrome, the FDA may rescind the Breakthrough Therapy Designation and we may be unable to obtain Breakthrough Therapy designation for other uses. In addition, Breakthrough
Therapy designation by the FDA may not lead to a faster development, regulatory review or approval process, and it does not increase the likelihood that setmelanotide will receive marketing approval
in the United States.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under the Food and Drug Administration Safety and Innovation Act, or FDASIA, the FDA is authorized to give certain products "Breakthrough
Therapy designation." A Breakthrough Therapy product candidate is defined as a product candidate that is intended, alone or in combination with one or more other drugs, to treat a serious or
life-threatening disease or condition and preliminary clinical evidence indicates that such product candidate may demonstrate substantial improvement on one or more clinically significant endpoints
over existing therapies. The FDA will seek to ensure the sponsor of Breakthrough Therapy product candidate receives intensive guidance on an efficient drug development program, intensive involvement
of senior managers and experienced staff on a proactive, collaborative and cross-disciplinary review and a rolling review process whereby the FDA may consider reviewing portions of an NDA before the
sponsor submits the complete application. Product candidates designated as breakthrough therapies by the FDA may be eligible for other expedited programs, such as priority review, if supported by
clinical data. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Designation
as Breakthrough Therapy is within the discretion of the FDA. Accordingly, even if we believe setmelanotide meets the criteria for designation as Breakthrough Therapy for
other uses, the FDA may disagree. In any event, the receipt of Breakthrough Therapy designation for a product candidate, or acceptance for one or more of the FDA's other expedited programs, may not
result in a faster development process, review or approval compared to products considered for approval under conventional FDA procedures and does not guarantee ultimate approval by the FDA.
Additionally, the FDA may later decide that the product candidate no longer meets the conditions for designation and may withdraw designation at any time or decide that the time period for FDA review
or approval will not be shortened. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may not be able to translate the current formulations of setmelanotide for methods of delivery that would
be acceptable to the FDA or other equivalent competent authorities in foreign jurisdictions or commercially successful.  </I></B></FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Setmelanotide is currently administered by SC injection using small insulin-type needles. SC injection is generally less well-received by
patients than other methods of administration, such as oral administration. Considerable additional resources and efforts, including potential studies, may be necessary in order to translate the
current formulations of setmelanotide into forms that will be well-received by patients. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>30</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=33,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=574654,FOLIO='30',FILE='DISK109:[18ZBU1.18ZBU44601]CM44601A.;9',USER='CHE105614',CD='10-JUN-2018;18:07' -->
<A NAME="page_cm44601_1_31"> </A>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have entered into a license agreement with Camurus AB, or Camurus, for the use of Camurus' drug delivery technology, FluidCrystal, to formulate setmelanotide. This formulation, if
successfully developed for setmelanotide, will be delivered subcutaneously, similar to our current formulation, except that we anticipate it will be injected once weekly. The initial Phase&nbsp;1
pharmacokinetic data from healthy obese volunteers supports once-weekly dosing, but has only been administered for short durations. It is possible that the tolerability profile and/or pharmacokinetics
in patients will not be similar to that of healthy obese volunteers, making development of this product more complex. In addition, we have not consulted with regulatory agencies about the path for
approval of the once-weekly formulation, and, accordingly, we cannot estimate the time, cost, and probability of success for approval. The Camurus formulations have also not been approved for any
product at this time, which further complicates our understanding for the path to approval. While we plan to utilize the current formulation, or to develop new and useful formulations and delivery
technology for setmelanotide, we cannot estimate the probability of success, nor the resources and time needed to succeed. If we are unable to utilize this formulation, or to develop new formulations,
setmelanotide may not achieve significant market acceptance and our business, financial condition and results of operations may be materially harmed. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our approach to treating patients with MC4 pathway deficiencies requires the identification of patients with
unique genetic subtypes, for example, POMC genetic deficiency. The FDA or other equivalent competent authorities in foreign jurisdictions could require the approval or CE mark of an in vitro companion
diagnostic device to ensure appropriate selection of patients as a condition of approving setmelanotide. The development and approval or CE mark of an in vitro companion diagnostic device would
require substantial financial resources and could delay regulatory approval of setmelanotide.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We intend to focus our development of setmelanotide as a treatment for obesity caused by certain genetic deficiencies affecting the MC4 pathway.
In order to assist in identifying this subset of patients, we employ a genetic diagnostic test, which is a test or measurement that evaluates the presence of genetic variants in a patient. The FDA has
previously advised that for our clinical trial of setmelanotide to treat POMC deficiency obesity, it will be sufficient to use genetic diagnostic testing known as Sanger bi-directional nucleotide
sequencing, as long as that testing is performed by laboratories meeting the standards of the Clinical Laboratory Improvement Amendments, or CLIA, for Laboratory Developed Tests, or LDTs. Currently
the Centers for Medicare and Medicaid Services, or CMS, regulates LDTs and the laboratories that develop them, and enforces CLIA. CMS evaluates whether there is clinical utility for each specific
test, and also performs postmarket oversight of laboratory operational processes. CMS coverage determinations of clinical utility measure the ability of the test to impact clinically meaningful health
outcomes, such as mortality or morbidity, through the adoption of efficacious treatments. CMS's oversight through the CLIA program is designed to confirm that a lab assesses analytical validity, but
does not confirm whether it had results from an analytical validity assessment that were sufficient to support the claimed intended use of the test. The FDA has issued guidance indicating, however,
that in the future it intends to assert jurisdiction over LDTs and to
increase regulatory requirements for LDTs. If the FDA does so, the burdens and costs of using LDTs to select patients for setmelanotide could increase, the availability of those LDTs could be
negatively affected, and our development program for setmelanotide could be delayed, which in turn could delay or impair our ability to proceed to commercialization. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Although
the FDA had previously advised us that an LDT is sufficient for identifying patients in our clinical trials, the agency also previously indicated that approval of an </FONT> <FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2> companion diagnostic device
may be necessary should clinical results reveal that genetic testing is needed for the safe use of setmelanotide,
such as to avoid significant toxicities in certain patients or because the drug might provide only marginal benefits except in a very clearly defined eligible population. More recent communications
from the FDA have increased the potential for a need for a companion diagnostic device. </FONT><FONT SIZE=2><I>In vitro</I></FONT><FONT SIZE=2> companion diagnostic devices provide information that
is essential for the safe and effective use of a corresponding therapeutic product. These companion diagnostic devices may be co-developed with a device manufacturer or with a laboratory, and
generally require FDA approval as well. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>31</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=34,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=118758,FOLIO='31',FILE='DISK109:[18ZBU1.18ZBU44601]CM44601A.;9',USER='CHE105614',CD='10-JUN-2018;18:07' -->
<A NAME="page_cm44601_1_32"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Should
the FDA or other equivalent competent authorities in foreign jurisdictions require the use of a companion diagnostic device, we may face significant delays or obstacles in
obtaining approval of an NDA, or of comparable foreign marketing authorization for setmelanotide as the FDA or other equivalent competent authorities in foreign jurisdictions may take the position
that a companion diagnostic device is required prior to granting approval of setmelanotide. In addition, we may be dependent on the sustained cooperation and effort of third-party collaborators with
whom we may partner in the future to develop </FONT><FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2> companion diagnostic devices. We and our potential future collaborators may encounter difficulties
in developing such tests, including issues relating to the selectivity and/or specificity of the diagnostic, analytical validation, reproducibility or clinical validation. Any delay or failure by us
or our potential future collaborators to develop or obtain regulatory clearance or approval of, or to CE mark, such tests, if necessary, could delay or prevent approval of setmelanotide. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the FDA deems setmelanotide to require an </FONT><FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2> companion diagnostic device to accurately identify the patients who belong to the
target subset, the FDA will require product labeling that limits use to only those patients who express the genetic variants identified by the device. Moreover, even if setmelanotide and an </FONT> <FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2>
companion diagnostic device are approved together, the device itself may be subject to reimbursement limitations that could limit access to
treatment and therefore adversely affect our business and financial results. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
also are discussing with the FDA the specific mutations, or variants, that will define each indication for which we intend to seek approval. Our efforts have focused on
loss-of-function variants that effectively inactivate the genes in the MC4 pathway, and we have proposed rules to define these
variants for approval, and which can be used to categorize new variants as they are identified. The FDA has asked us to consider an alternative approach for categorizing and validating these variants
that has been used for other diagnostics, and we are likely to agree. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, we intend to apply genetic tests to address goals beyond seeking FDA approval of setmelanotide, including supporting efforts to explore and expand the diagnosis of patients
with genetic causes of obesity, and to assist in building awareness of these illnesses. As such, we may develop or work with partners to develop additional genetic tests in the area of genetic
obesity, including panels that may study a larger number of genes. There are many factors that might influence the success of these efforts, which could be impactful on our commercial efforts,
including the cost, analytical methods, and the ability to provide clinical and diagnostic information to patients and doctors. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We have only one product candidate in clinical development and we may not be successful in any future efforts
to identify and develop additional product candidates.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have only one product candidate in clinical development and may seek to identify and develop additional product candidates for clinical
development, both within and outside of our current area of expertise. If so, the success of our business may depend primarily on our ability to identify, develop and commercialize these products.
Research programs to identify new product candidates require substantial technical, financial and human resources. We may fail to identify other potential product candidates for clinical development
for a number of reasons. Our research methodology may be unsuccessful in identifying potential product candidates or our potential product candidates may be shown to have harmful side effects or may
have other characteristics that may make the products unmarketable or unlikely to receive marketing approval. We may focus our efforts and resources on potential programs or product candidates that
ultimately prove to be unsuccessful. In addition, any such efforts could adversely impact our continued development and commercialization of setmelanotide. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
any of these events occur, we may be forced to abandon some or all of our development efforts for a program or programs, which would have a material adverse effect on our business and
could potentially cause us to cease operations. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>32</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=35,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=661847,FOLIO='32',FILE='DISK109:[18ZBU1.18ZBU44601]CM44601A.;9',USER='CHE105614',CD='10-JUN-2018;18:07' -->
<A NAME="page_cm44601_1_33"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Prader-Willi syndrome, or PWS, is a complex disease, and companies have had difficulties in developing new
therapies for PWS.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Although we have been granted orphan drug designation for setmelanotide in treating PWS, we are not moving directly towards a Phase&nbsp;3
trial in PWS at this time, but instead will be continuing to evaluate setmelanotide in another Phase&nbsp;2 trial. We do not know the probability that we will be able to succeed in this additional
Phase&nbsp;2 trial and/or to proceed to Phase&nbsp;3 and/or approval, even when these efforts are completed. In addition, the experience by others suggests that PWS patients are high risk for
adverse experiences and for this, and many other reasons, clinical trials in that population are extremely challenging. It may be both difficult to determine if adverse effects in this population are
due to the disease, setmelanotide or some combination of both. PWS is a complex multigenic disease, and the hypothesis that PWS is an upstream MC4 pathway disorder is supported primarily on the role
of only one of those genes, MAGEL2, in animal models of obesity. Our results may support that PWS is not an upstream MC4 pathway disorder. Alternatively, other design factors may have influenced the
outcome of this trial, and we will be reassessing in 2018 the possibility of future Phase&nbsp;2 trials in PWS that address the following potential factors: duration of treatment, younger age of
population, improved setmelanotide pharmacokinetics, consideration of higher doses, and operational limitations of the completed Phase&nbsp;2 trial. There can be no assurances that some of the
factors that affected the results of the PWS trials will not also adversely impact the results of our trials for other indications. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, we have begun a program for a new mechanism that may have therapeutic effects in PWS, but this program is in preclinical development, and our candidate, RM-853, may not
succeed in completing the pre-IND studies needed to proceed to clinical trials, or may fail in early Phase&nbsp;1 studies due to unfavorable safety, pharmacokinetics or for other reasons. The
hypothesis supporting the therapeutic effects of this mechanism is also based on limited clinical and preclinical information, and even if RM-853 were to progress to a Phase&nbsp;2 proof of concept
study, it is unclear if there will be safety and efficacy to support proceeding further in development. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks Related to the Commercialization of Setmelanotide  </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Even if approved, reimbursement policies could limit our ability to sell setmelanotide.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Market acceptance and sales of setmelanotide will depend on reimbursement policies and may be affected by healthcare reform measures. Government
authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels for those
medications. Cost containment is a primary concern in the U.S. healthcare industry and in foreign jurisdictions. Government authorities and these third-party payors have attempted to control costs by
limiting coverage and the amount of reimbursement for particular medications. We cannot be sure that reimbursement will be available for setmelanotide and, if reimbursement is available, the level of
such reimbursement. Reimbursement may impact the demand for, or the price of setmelanotide. If reimbursement is not available or is available only at limited levels, we may not be able to successfully
commercialize setmelanotide. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
some foreign countries, particularly in Canada and in the EU member states, the pricing of prescription pharmaceuticals is subject to strict governmental control. In these countries,
pricing negotiations with governmental authorities can take six to 12&nbsp;months or longer after the receipt of regulatory approval and product launch. To obtain favorable reimbursement for the
indications sought or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of setmelanotide with other available therapies. If
reimbursement for setmelanotide is unavailable in any country in which we seek reimbursement, if it is limited in scope or amount, if it is conditioned upon our completion of additional clinical
trials or if pricing is set at unsatisfactory levels, our operating results could be materially adversely affected. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>33</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=36,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=314202,FOLIO='33',FILE='DISK109:[18ZBU1.18ZBU44601]CM44601A.;9',USER='CHE105614',CD='10-JUN-2018;18:07' -->
<A NAME="page_cm44601_1_34"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the EU, in particular, each EU member state can restrict the range of medicinal products for which its national health insurance system provides reimbursement and can control the
prices of medicinal products for human use marketed in its territory. As a result, following receipt of marketing authorization in an EU member state, through any application route, an applicant is
required to engage in pricing discussions and negotiations with the competent pricing authority in the individual EU member states. Some EU member states operate positive and negative list systems
under which products may only be marketed once a reimbursement price has been agreed upon. Other EU member states approve a specific price for the medicinal product or may instead adopt a system of
direct or indirect controls on the profitability of the company placing the medicinal product on the market. The downward pressure on healthcare costs in general, particularly prescription drugs, has
become more intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, we may face competition for setmelanotide from lower priced products in
foreign countries that have placed price controls on pharmaceutical products. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Health
Technology Assessment, or HTA, of medicinal products, however, is becoming an increasingly common part of the pricing and reimbursement procedures in some EU member states,
including the United Kingdom, France, Germany, Ireland, Italy, Spain, and Sweden. HTA is the procedure according to which the assessment of the public health impact, therapeutic impact and the
economic and societal impact of use of a given medicinal product in the national healthcare systems of the individual country is conducted. HTA generally focuses on the clinical efficacy and
effectiveness, safety, cost, and cost-effectiveness of individual medicinal products as well as their potential implications for the healthcare system. Those elements of medicinal products are
compared with other treatment options available on the market. The outcome of HTA regarding specific medicinal products will often influence the pricing and reimbursement status granted to these
medicinal products by the competent authorities of individual EU member states. The extent to which pricing and reimbursement decisions are influenced by the HTA of the specific medicinal product
varies between EU member states. In addition, pursuant to Directive 2011/24/EU on the application of patients' rights in cross-border healthcare, a voluntary network of national authorities or bodies
responsible for HTA in the individual EU member states was established. The purpose of the network is to facilitate and support the exchange of scientific information concerning HTAs. This may lead to
harmonization of the criteria taken into account in the conduct of HTAs between EU member states and in pricing and reimbursement decisions and may negatively affect price in at least some EU member
states. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to
market and sell setmelanotide, if approved, we may not be able to generate any revenue.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We do not currently have infrastructure in place for the sale, marketing or distribution of pharmaceutical products. In order to market
setmelanotide, if approved by the FDA or other equivalent competent authorities in foreign jurisdictions, we must build our sales, marketing, managerial and other non-technical capabilities or make
arrangements with third parties to perform these services. If we are unable to establish adequate sales, marketing and distribution capabilities, whether independently or with third parties, or if we
are unable to do so on commercially reasonable terms, our business, results of operations, financial condition and prospects would be materially adversely affected. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Even if we receive marketing approval for setmelanotide in the United States, we may never receive regulatory
approval to market setmelanotide outside of the United States.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We intend to pursue marketing approval for setmelanotide in the EU and in other countries worldwide. In order to market any product outside of
the United States, we must establish and comply with the numerous and varying safety, efficacy and other regulatory requirements of other countries. Approval procedures vary among countries and can
involve additional setmelanotide testing and additional administrative review periods. The time required to obtain approvals in other countries might differ from </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>34</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=37,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=912526,FOLIO='34',FILE='DISK109:[18ZBU1.18ZBU44601]CM44601A.;9',USER='CHE105614',CD='10-JUN-2018;18:07' -->
<A NAME="page_cm44601_1_35"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>that
required to obtain FDA approval. The marketing approval processes in other countries may implicate all of the risks detailed above regarding FDA approval in the United States as well as other
risks. In particular, in many countries outside of the United States, products must receive pricing and reimbursement approval before the product can be commercialized. Obtaining this approval can
result in substantial delays in bringing products to market in such countries. Marketing approval in one country does not ensure marketing approval in another, but a failure or delay in obtaining
marketing approval in one country may have a negative effect on the regulatory process or commercial activities in others. Failure to obtain marketing approval in other countries or any delay or other
setback in obtaining such approval would impair our ability to market setmelanotide in such foreign markets. Any such impairment would reduce the size of our potential market share and could have a
material adverse impact on our business, results of operations and prospects. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Even if we receive marketing approval for setmelanotide, we may not achieve market acceptance, which would
limit the revenue that we generate from the sale of setmelanotide.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The commercial success of setmelanotide, if approved by the FDA or other equivalent competent authorities in foreign jurisdictions, will also
depend upon the awareness and acceptance of setmelanotide within the medical community, including physicians, patients and third-party payors. If setmelanotide is approved but does not achieve an
adequate level of acceptance by patients, physicians and third-party payors, we may not generate sufficient revenue to become or remain profitable. Before granting reimbursement approval, third-party
payors may require us to demonstrate that, in addition to treating obesity caused by certain genetic deficiencies affecting the MC4 pathway, setmelanotide also provides incremental health benefits to
patients. Our efforts to educate the medical community and third-party payors about the benefits of setmelanotide may require significant resources and may never be successful. All of these challenges
may impact our ability to ever successfully market and sell setmelanotide. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Market
acceptance of setmelanotide, if approved, will depend on a number of factors, including, among others:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the ability of setmelanotide to treat obesity caused by certain genetic deficiencies affecting the MC4 pathway and, if required by any
competent authority in connection with the approval for these indications, to provide patients with incremental health benefits, as compared with other available treatments, therapies, devices or
surgeries; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the relative convenience and ease of SC injections as the necessary method of administration of setmelanotide, including as compared with other
treatments for obese patients; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the prevalence and severity of any adverse side effects associated with setmelanotide; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> limitations or warnings contained in the labeling approved, as well as the existence of a REMS, for setmelanotide by the FDA or the specific
obligations imposed as a condition for marketing authorization imposed by other equivalent competent authorities in foreign jurisdictions, particularly by the European Commission; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> availability of alternative treatments, including a number of obesity therapies already approved or expected to be commercially launched in the
near future; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the size of the target patient population, and the willingness of the target patient population to try new therapies and of physicians to
prescribe these therapies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the ability of setmelanotide to treat the maximum range of pediatric patients, and any limitations on its indications for use, such as if the
labeling limits the approved population to patients ages 12 and above; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the strength of marketing and distribution support and timing of market introduction of competitive products; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>35</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=38,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=291246,FOLIO='35',FILE='DISK109:[18ZBU1.18ZBU44601]CM44601A.;9',USER='CHE105614',CD='10-JUN-2018;18:07' -->
<UL>
<UL>
</UL>
</UL>
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_co44601_1_36"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A> </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> publicity concerning setmelanotide or competing products and treatments; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> pricing and cost effectiveness; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the effectiveness of our sales and marketing strategies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> our ability to increase awareness of setmelanotide through marketing efforts; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> our ability to obtain sufficient third-party coverage or reimbursement; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the willingness of patients to pay out-of-pocket in the absence of third-party coverage; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the likelihood that the FDA or other equivalent competent authorities in foreign jurisdictions may require development of a REMS as a condition
of approval or post-approval, may not agree with our proposed REMS or may impose additional requirements that limit the promotion, advertising, distribution or sales of setmelanotide. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our industry is intensely competitive. If we are not able to compete effectively against current and future
competitors, we may not be able to generate revenue from the sale of setmelanotide, our business will not grow and our financial condition and operations will suffer.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant technological change. We have
competitors in a number of jurisdictions, many of which have substantially greater name recognition, commercial infrastructures and financial, technical and personnel resources than we have.
Established competitors may invest heavily to quickly discover and develop compounds that could make setmelanotide obsolete or uneconomical. Any new product that competes with an approved product may
need to demonstrate compelling advantages in
efficacy, convenience, tolerability and safety to be commercially successful. Other competitive factors, including generic competition, could force us to lower prices or could result in reduced sales.
In addition, new products developed by others could emerge as competitors to setmelanotide. If we are not able to compete effectively against our current and future competitors, our business will not
grow and our financial condition and operations will suffer. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Currently,
there are no approved or effective current treatments for regulating hunger and hyperphagia related behaviors of patients with POMC deficiency obesity, LepR deficiency
obesity, Bardet-Biedl syndrome, Alstr&ouml;m syndrome, POMC heterozygous deficiency obesity, or POMC epigenetic disorders. Bariatric surgery is not a treatment option for these genetic
disorders of obesity because the severe obesity and hyperphagia associated with these disorders are considered to be risk factors for bariatric surgery. While we are unaware of any competitive
products in development for the obesity and hyperphagia caused by upstream MC4 pathway deficiencies specifically, new competitors may emerge which could limit our business opportunity in the future. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We face potential product liability exposure, and, if claims are brought against us, we may incur substantial
liability.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The use of setmelanotide in clinical trials and the sale of setmelanotide, if approved, exposes us to the risk of product liability claims.
Product liability claims might be brought against us by patients, healthcare providers or others selling or otherwise coming into contact with setmelanotide. For example, we may be sued if any product
we develop allegedly causes injury or is found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects
in manufacturing, defects in design or a failure to warn of dangers inherent in the product, including as a result of interactions with alcohol or other drugs, negligence, strict liability and a
breach of warranties. Claims could also be asserted under state consumer protection laws and any equivalent laws in foreign countries. If we become subject to product liability claims and cannot </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>36</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=39,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=994989,FOLIO='36',FILE='DISK109:[18ZBU1.18ZBU44601]CO44601A.;7',USER='CHE105614',CD='10-JUN-2018;18:08' -->
<A NAME="page_co44601_1_37"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>successfully
defend ourselves against them, we could incur substantial liabilities. In addition, regardless of merit or eventual outcome, product liability claims may result in, among other
things:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> withdrawal of patients from our clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> substantial monetary awards to patients or other claimants; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> decreased demand for setmelanotide or any future product candidates following marketing approval, if obtained; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> damage to our reputation and exposure to adverse publicity; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> litigation costs; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> distraction of management's attention from our primary business; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> loss of revenue; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the inability to successfully commercialize setmelanotide or any future product candidates, if approved. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
maintain product liability insurance coverage for our clinical trials with a $10.0&nbsp;million annual aggregate coverage limit. Our insurance coverage may be insufficient to
reimburse us for any expenses or losses we may suffer. Moreover, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against
losses, including if insurance coverage becomes increasingly expensive. If and when we obtain marketing approval for setmelanotide, we intend to expand our insurance coverage to include the sale of
commercial products. However, we may not be able to obtain this product liability insurance on commercially reasonable terms. Large judgments have been awarded in class action lawsuits based on drugs
that had unanticipated side effects. The cost of any product liability litigation or other proceedings, even if resolved in our favor, could be substantial, particularly in light of the size of our
business and financial resources. A product liability claim or series of claims brought against us could cause our stock price to decline and, if we are unsuccessful in defending such a claim or
claims and the resulting judgments exceed our insurance coverage, our financial condition, business and prospects could be materially adversely affected. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks Related to Our Dependence on Third Parties  </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We rely, and expect that we will continue to rely, on third parties to conduct clinical trials for
setmelanotide. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize
setmelanotide and our business could be substantially harmed.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We enter into agreements with third-party CROs to provide monitors for and to manage data for our ongoing clinical trials. We rely heavily on
these parties for the execution of clinical trials for setmelanotide and control only certain aspects of their activities. As a result, we have less direct control over the conduct, timing and
completion of these clinical trials and the management of data developed through the clinical trials than would be the case if we were relying entirely upon our own staff. Communicating with outside
parties can also be challenging, potentially leading to mistakes as well as difficulties in coordinating activities. However, we remain responsible for the conduct of these trials and are subject to
enforcement which may include civil and criminal liabilities for any violations of FDA rules and regulations and the comparable foreign regulatory provisions during the conduct of our clinical trials.
Outside parties may:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> have staffing difficulties; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> fail to comply with contractual obligations; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> devote inadequate resources to our clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> experience regulatory compliance issues; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>37</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=40,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=423721,FOLIO='37',FILE='DISK109:[18ZBU1.18ZBU44601]CO44601A.;7',USER='CHE105614',CD='10-JUN-2018;18:08' -->
<A NAME="page_co44601_1_38"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> undergo changes in priorities or become financially distressed; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> form more favorable relationships with other entities, some of which may be our competitors. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;These
factors may materially adversely affect the willingness or ability of third parties to conduct our clinical trials and may subject us to unexpected cost increases that are beyond
our control. Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our
reliance on CROs does not relieve us of our regulatory responsibilities. We and our CROs are required to comply with current Good Clinical Practices, or cGCPs, which are guidelines enforced by the
FDA, the Competent Authorities of the EU member states and equivalent competent authorities in foreign jurisdictions for any products in clinical development. The FDA enforces these regulations and
cGCP guidelines through periodic inspections of clinical trial sponsors, principal investigators, and trial sites, and IRBs. If we or our CROs fail to comply with applicable cGCPs, the clinical data
generated in our clinical trials may be deemed unreliable and the FDA or other equivalent competent authorities in foreign
jurisdictions may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that, upon inspection, the FDA will determine that any of our
clinical trials comply with cGCPs. In addition, our clinical trials must be conducted with products produced under current Good Manufacturing Practices, or cGMPs. Our failure or the failure of our
CROs to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process and could also subject us to enforcement action up to and including
civil and criminal penalties. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
any of our relationships with these third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs. If CROs do not successfully carry out their
contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain are compromised due to the failure to adhere to
our clinical protocols, regulatory requirements or for other reasons, any such clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for, or
successfully commercialize, setmelanotide. As a result, our financial results and the commercial prospects for setmelanotide in the subject indication would be harmed, our costs could increase and our
ability to generate revenue could be delayed. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We rely completely on third-party suppliers to manufacture our clinical drug supplies of setmelanotide, and
we intend to rely on third parties to produce commercial supplies of setmelanotide and preclinical, clinical and commercial supplies of any future product candidate.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We do not currently have, nor do we plan to acquire, the infrastructure or capability to internally manufacture our clinical drug supply of
setmelanotide, or any future product candidates, for use in the conduct of our preclinical studies and clinical trials, and we lack the internal resources and the capability to manufacture any product
candidate on a clinical or commercial scale. The facilities used by our contract manufacturing organizations, or CMOs, to manufacture the active pharmaceutical ingredient, or API, and final drug
product must pass inspection by the FDA and other equivalent competent authorities in foreign jurisdictions pursuant to inspections that would be conducted after we submit our NDAs or relevant foreign
regulatory submission to the other equivalent competent authorities in foreign jurisdictions. In addition, our clinical trials must be conducted with products produced under cGMP regulations. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
failure or the failure of our CROs or CMOs to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process and could also
subject us to enforcement action, including civil and criminal penalties. If we import any drugs or drug substances, we would be subject to FDA and U.S. Bureau of Customs and Border Patrol, or CBP,
import regulation requirements. Such enforcement for our failure or our CROs or CMOs' failure to comply with these regulations could result in import delays, detention of products, and, depending on
criteria such as the history of violative activities, the FDA could place a foreign firm or certain drug substances or products on Import Alert and require that all such drug substances or products be
subject to detention without physical </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>38</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=41,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=382222,FOLIO='38',FILE='DISK109:[18ZBU1.18ZBU44601]CO44601A.;7',USER='CHE105614',CD='10-JUN-2018;18:08' -->
<A NAME="page_co44601_1_39"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>examination,
or DWPE, which could significantly impact the global supply chain for setmelanotide. FDARA provides that prescription drug products, with the exception of those on the FDA's drug shortage
list or properly imported by individuals, may not be imported for commercial use if they were manufactured in a foreign country, unless they have been approved or are otherwise authorized to be
marketed in the United States and are labeled accordingly. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
currently contract with a third party for the manufacture of setmelanotide and intend to continue to do so in the future. We have entered into a process development and manufacturing
services agreement with Corden Pharma Brussels S.A, or Corden, formerly Peptisyntha&nbsp;SA prior to its acquisition by Corden, under which Corden will provide certain process development and
manufacturing services in connection with the manufacture of setmelanotide. We have also entered into a process development and manufacturing services agreement with Recipharm Monts&nbsp;S.A.S, or
Recipharm, under which Recipharm will provide certain process development and manufacturing services in connection with the manufacture of setmelanotide. Under our agreements, we pay both Corden and
Recipharm for services in accordance with the terms of mutually agreed upon work orders, which we, Corden and Recipharm may enter into from time to time. The agreement with Corden also provides that,
subject to certain conditions, for a period following each product launch date, we will source from Corden a portion of our requirements for that product being sourced from non-affiliate third
parties. We may need to engage additional third-party suppliers to manufacture our clinical drug supplies. In the future, if we approach commercialization of setmelanotide or any future product
candidate, we will need to engage other third parties to assist in, among other things, labeling, packaging, distribution, post-approval safety reporting, and pharmacovigilance activities. We cannot
be certain that we can engage third-party suppliers on terms as favorable as those that are currently in place. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
do not perform the manufacturing of any drug products, and are completely dependent on, our CMOs to comply with cGMPs for manufacture of both API and finished drug product. We
recognize that we are ultimately responsible for ensuring that our drug substances and finished product are manufactured in accordance with cGMPs, and, therefore, the company's management practices
and oversight, including routine auditing, are critical. If our CMOs cannot successfully manufacture material that conform to our specifications and the strict regulatory requirements of the FDA or
other equivalent competent authorities in foreign jurisdictions, they may be subject to administrative and judicial enforcement for non-compliance and the drug products would be deemed misbranded or
adulterated and prohibited from distribution into interstate commerce. Furthermore, all of our CMOs are engaged with other companies to supply and/or manufacture materials or products for such
companies, which exposes our manufacturers to regulatory risks for the production of such materials and products. As a result, failure to satisfy the regulatory requirements for the production of
those materials and products may affect the regulatory clearance of our CMOs' facilities generally. If the FDA or another equivalent competent foreign regulatory agency does not approve these
facilities for the manufacture of setmelanotide or if it withdraws its approval in the future, we may need to find alternative manufacturing facilities, which would adversely impact our ability to
develop, obtain regulatory approval for or market setmelanotide. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are currently in the process of manufacturing finished drug product for use in our upcoming clinical trials. We believe we currently have a sufficient amount of finished
setmelanotide, diluent and placebo to complete our planned clinical trials. However, these projections could change based on delays encountered with manufacturing activities, equipment scheduling and
material lead times. Any such delays in the manufacturing of finished drug product could delay our planned clinical trials of setmelanotide, which could delay, prevent or limit our ability to generate
revenue and continue our business. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
do not have long-term supply agreements in place with our contractors, and each batch of setmelanotide is individually contracted under a quality and supply agreement. If we engage
new contractors, such contractors must be approved by the FDA and other equivalent competent authorities in foreign jurisdictions. We will need to submit information to the FDA and other equivalent
competent authorities in foreign jurisdictions describing the manufacturing changes. If manufacturing changes occur </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>39</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=42,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=1032557,FOLIO='39',FILE='DISK109:[18ZBU1.18ZBU44601]CO44601A.;7',USER='CHE105614',CD='10-JUN-2018;18:08' -->
<A NAME="page_co44601_1_40"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>post-approval,
the FDA may have to approve these changes. We plan to continue to rely upon CMOs and, potentially, collaboration partners to manufacture commercial quantities of setmelanotide, if
approved. Our current scale of manufacturing appears adequate to support all of our current needs for clinical trial supplies for setmelanotide. If setmelanotide is approved, we will need to identify
CMOs or partners to produce setmelanotide on a larger scale. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks Related to Our Intellectual Property Rights  </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we are unable to adequately protect our proprietary technology or maintain issued patents that are
sufficient to protect setmelanotide, others could compete against us more directly, which would have a material adverse impact on our business, results of operations, financial condition and
prospects.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our commercial success will depend in part on our success in obtaining and maintaining issued patents and other intellectual property rights in
the United States and elsewhere
and protecting our proprietary technology. If we do not adequately protect our intellectual property and proprietary technology, competitors may be able to use our technologies and erode or negate any
competitive advantage we may have, which could harm our business and ability to achieve profitability. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
cannot provide any assurances that any of our patents have, or that any of our pending patent applications that mature into issued patents will include, claims with a scope sufficient
to protect setmelanotide. Other parties have developed technologies that may be related or competitive to our approach, and may have filed or may file patent applications and may have received or may
receive patents that may overlap with our patent applications, either by claiming the same methods or formulations or by claiming subject matter that could dominate our patent position. The patent
positions of biotechnology and pharmaceutical companies, including our patent position, involve complex legal and factual questions, and, therefore, the issuance, scope, validity and enforceability of
any patent claims that we may obtain cannot be predicted with certainty. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Although
an issued patent is presumed valid and enforceable, its issuance is not conclusive as to its validity or its enforceability and such patent may not provide us with adequate
proprietary protection or competitive advantages against competitors with similar products. Patents, if issued, may be challenged, deemed unenforceable, invalidated or circumvented. U.S. patents and
patent applications or the patents and patent application obtained or submitted pursuant to comparable foreign laws, may also be subject to interference proceedings, </FONT><FONT SIZE=2><I>ex
parte</I></FONT><FONT SIZE=2> reexamination, </FONT><FONT SIZE=2><I>inter partes</I></FONT><FONT SIZE=2> review proceedings, post-grant review proceedings, supplemental examination and challenges in
district court. Patents may be subjected to opposition or comparable proceedings lodged in various foreign, both national and regional, patent offices. These proceedings could result in either loss of
the patent or denial of the patent application or loss or reduction in the scope of one or more of the claims of the patent or patent application. In addition, such proceedings may be costly. Thus,
any patents that we may own or exclusively license may not provide any protection against competitors. Furthermore, an adverse decision in an interference proceeding can result in a third party
receiving the patent right sought by us, which in turn could affect our ability to develop, market or otherwise commercialize setmelanotide. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Competitors
may also be able to design around our patents. Other parties may develop and obtain patent protection for more effective technologies, designs or methods. The laws of some
foreign countries do not protect our proprietary rights to the same extent as the laws of the United States, and we may encounter significant problems in protecting our proprietary rights in these
countries. If these developments were to occur, they could have a material adverse effect on our sales. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, proceedings to enforce or defend our patents could put our patents at risk of being invalidated, held unenforceable or interpreted narrowly. Such proceedings could also
provoke third parties to assert claims against us, including that some or all of the claims in one or more of our patents are invalid or otherwise unenforceable. If any of our patents covering
setmelanotide are invalidated or found unenforceable, our financial position and results of operations would be materially and adversely </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>40</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=43,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=754916,FOLIO='40',FILE='DISK109:[18ZBU1.18ZBU44601]CO44601A.;7',USER='CHE105614',CD='10-JUN-2018;18:08' -->
<A NAME="page_co44601_1_41"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>impacted.
In addition, if a court found that valid, enforceable patents held by third parties covered setmelanotide, our financial position and results of operations would also be materially and
adversely impacted. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
degree of future protection for our proprietary rights is uncertain, and we cannot ensure that:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> any of our patents, or any of our pending patent applications, if issued, will include claims having a scope sufficient to protect
setmelanotide; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> any of our pending patent applications will issue as patents; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> we will be able to successfully commercialize setmelanotide, if approved, before our relevant patents expire; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> we were the first to make the inventions covered by each of our patents and pending patent applications; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> we were the first to file patent applications for these inventions; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> others will not develop similar or alternative technologies that do not infringe our patents; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> any of our patents will be found to ultimately be valid and enforceable; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> any patents issued to us will provide a basis for an exclusive market for our commercially viable products, will provide us with any
competitive advantages or will not be challenged by third parties; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> we will develop additional proprietary technologies or product candidates that are separately patentable; or </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> our commercial activities or products will not infringe upon the patents of others. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
rely upon unpatented trade secrets, unpatented know-how and continuing technological innovation to develop and maintain our competitive position, which we seek to protect, in part, by
confidentiality agreements with employees, consultants, collaborators and vendors. We also have agreements with employees and selected consultants that obligate them to assign their inventions to us.
It is possible that technology relevant to our business will be independently developed by a person who is not a party to such an agreement. We may not be able to prevent the unauthorized disclosure
or use of our technical knowledge or trade secrets by consultants, collaborators, vendors, former employees and current employees. Furthermore, if the parties to our confidentiality agreements breach
or violate the terms of these agreements, we may not have adequate remedies for any such breach or violation, and we could lose our trade secrets through such breaches or violations. Further, our
trade secrets could otherwise become known or be independently discovered by our competitors. </FONT></P>


<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could
be expensive, time-consuming and unsuccessful.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Competitors may infringe our patents or the patents of our licensors. To counter infringement or unauthorized use, we may be required to file
infringement claims, which can be expensive and time-consuming and divert the attention of our management and key personnel from our business operations. Even if we prevail in any lawsuits that we
initiate, the damages or other remedies awarded may not be commercially meaningful. In addition, in an infringement proceeding, a court may decide that a patent of ours or our licensors is not valid,
is unenforceable and/or is not infringed, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse
result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowly and could put our patent applications at risk of not issuing. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>41</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=44,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=478426,FOLIO='41',FILE='DISK109:[18ZBU1.18ZBU44601]CO44601A.;7',USER='CHE105614',CD='10-JUN-2018;18:08' -->
<A NAME="page_co44601_1_42"> </A>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interference
proceedings provoked by third parties or brought by us may be necessary to determine the priority of inventions with respect to our patents or patent applications or those
of our licensors. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the
prevailing party does not offer us a license on commercially reasonable terms. Our defense of litigation or interference proceedings may fail and, even if successful, may result in substantial costs
and distract our management and other employees. We may not be able to prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in countries where the
laws may not protect those rights as fully as in the United States. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Furthermore,
because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could
be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities
analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may infringe the intellectual property rights of others, which may prevent or delay our product
development efforts and stop us from commercializing or increase the costs of commercializing setmelanotide, if approved.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our success will depend in part on our ability to operate without infringing the intellectual property and proprietary rights of third parties.
We cannot assure you that our business, products and methods do not or will not infringe the patents or other intellectual property rights of third parties. For example, numerous third-party U.S. and
non-U.S. patents and pending applications exist that cover melanocortin receptor analogs and methods of using these analogs. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
pharmaceutical industry is characterized by extensive litigation regarding patents and other intellectual property rights. Other parties may allege that setmelanotide or the use of
our technologies infringes patent claims or other intellectual property rights held by them or that we are employing their proprietary technology without authorization. For example, we received a
letter in January 2013 from a third party bringing to our attention several patents and patent applications, both U.S. and non-U.S. We responded in April 2013 and have not received any further
correspondence since then. All but a few of the patents and patent applications mentioned in the letter were abandoned or not in force at the time the letter was sent to us. Although subsequent to our
response the third party has allowed all the remaining patents to lapse for non-payment of patent maintenance fees, we cannot assure you that the holder of these third-party patents will not attempt
to assert these patents against us. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Patent
and other types of intellectual property litigation can involve complex factual and legal questions, and their outcome is uncertain. Any claim relating to intellectual property
infringement that is successfully asserted against us may require us to pay substantial damages, including treble damages and attorney's fees if we are found to be willfully infringing another party's
patents, for past use of the asserted intellectual property and royalties and other consideration going forward if we are forced or choose to take a license. In addition, if any such claim were
successfully asserted against us and we could not obtain such a license, we may be forced to stop or delay developing, manufacturing, selling or otherwise commercializing setmelanotide. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we are unable to avoid infringing the patent rights of others, we may be required to seek a license, defend an infringement action or challenge the validity of the patents in court,
or redesign our products. Patent litigation is costly and time consuming. We may not have sufficient resources to bring these actions to a successful conclusion. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, in order to avoid infringing the intellectual property rights of third parties and any resulting intellectual property litigation or claims, we could be forced to do one or
more of the following, which may not be possible and, even if possible, could be costly and time-consuming:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> cease development and commercialization of setmelanotide; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>42</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=45,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=145818,FOLIO='42',FILE='DISK109:[18ZBU1.18ZBU44601]CO44601A.;7',USER='CHE105614',CD='10-JUN-2018;18:08' -->
<A NAME="page_co44601_1_43"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> pay substantial damages for past use of the asserted intellectual property; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> obtain a license from the holder of the asserted intellectual property, which license may not be available on reasonable terms, if at all; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> in the case of trademark claims, rename setmelanotide. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
of these risks coming to fruition could have a material adverse effect on our business, results of operations, financial condition and prospects. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual
property.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may also be subject to claims that former employees, collaborators or other third parties have an ownership interest in our patents or other
intellectual property. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying
monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, such intellectual property. Such an outcome could have a material adverse effect
on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Obtaining and maintaining our patent protection depends on compliance with various procedural, document
submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The U.S. Patent and Trademark Office, or U.S. PTO, and various foreign governmental patent agencies require compliance with a number of
procedural, documentary, fee payment and other provisions during the patent process. There are situations in which noncompliance can result in abandonment or lapse of a patent or patent application,
resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case. </FONT></P>


<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Issued patents covering setmelanotide could be found invalid or unenforceable if challenged in court.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If we or one of our licensing partners threatened or initiated legal proceedings against a third party to enforce a patent covering
setmelanotide, the defendant could claim that the patent covering setmelanotide is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity
and/or unenforceability are commonplace. Grounds for a validity challenge include alleged failures to meet any one of several statutory requirements, including novelty, non-obviousness and enablement.
Grounds for unenforceability assertions include allegations that someone connected with prosecution of the patent withheld material information from the U.S. PTO, or made a misleading statement,
during patent prosecution. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include
re-examination, </FONT><FONT SIZE=2><I>inter partes</I></FONT><FONT SIZE=2> review, post grant review and equivalent proceedings in foreign jurisdictions, for example, opposition proceedings. Such
proceedings could result in revocation or amendment of our patents in such a way that they no longer cover setmelanotide or competitive products. The outcome following legal assertions of invalidity
and/or unenforceability is unpredictable. With respect to validity, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during
prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on setmelanotide. Such a
loss of patent protection would have a material adverse impact on our business. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>43</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=46,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=790607,FOLIO='43',FILE='DISK109:[18ZBU1.18ZBU44601]CO44601A.;7',USER='CHE105614',CD='10-JUN-2018;18:08' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_cq44601_1_44"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We do not seek to protect our intellectual property rights in all jurisdictions throughout the world and we
may not be able to adequately enforce our intellectual property rights even in the jurisdictions where we seek protection.  </I></B></FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Filing, prosecuting and defending patents on setmelanotide in all countries and jurisdictions throughout the world would be prohibitively
expensive, and our intellectual property rights in some countries outside the United States could be less extensive than those in the United States. In addition, the laws of some foreign countries do
not protect intellectual property rights to the same
extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from
selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent
protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United
States. These products may compete with our product and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Many
companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries,
particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biopharmaceuticals, which could make it
difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. For example, an April 2017 report from the Office of the
United States Trade Representative identified a number of countries, including India and China, where challenges to the procurement and enforcement of patent rights have been reported. Several
countries, including India and China, have been listed in the report every year since 1989. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and
divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not
issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially
meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we
develop or license. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We are dependent on licensed intellectual property. If we were to lose our rights to licensed intellectual
property, we may not be able to continue developing or commercializing setmelanotide, if approved.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have licensed our rights to setmelanotide from Ipsen Pharma SAS, or Ipsen. Our license with Ipsen imposes various obligations on us, and
provides Ipsen the right to terminate the license in the event of our material breach of the license agreement, our failure to initiate or complete development of a licensed product, or our
commencement of an action seeking to have an Ipsen licensed patent right declared invalid. Termination of our license from Ipsen would result in our loss of the right to use the licensed intellectual
property, which would materially adversely affect our ability to develop and commercialize setmelanotide, as well as harm our competitive business position and our business prospects. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
also have licensed from Camurus its drug delivery technology, FluidCrystal, to formulate setmelanotide. Our license with Camurus imposes various obligations on us, and provides
Camurus the right to terminate the license in the event of our material breach of the license agreement. Termination of our license from Camurus would result in our inability to use the licensed
intellectual property. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have licensed our rights to RM-853 from Takeda Pharmaceutical Company Limited, or Takeda. Our license with Takeda imposes various obligations on us, and provides Takeda the right to
terminate the license in the event of our material breach of the license agreement, if we voluntarily or involuntarily file for bankruptcy, or for our bringing an action seeking to have a Takeda
license patent right declared invalid. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>44</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=47,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=839946,FOLIO='44',FILE='DISK109:[18ZBU1.18ZBU44601]CQ44601A.;14',USER='CHE105614',CD='10-JUN-2018;18:08' -->
<A NAME="page_cq44601_1_45"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>Termination
of our license from Takeda would result in our inability to use the licensed intellectual property. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Among
other obligations under our agreement with Takeda, Takeda has a right of first negotiation under certain circumstances to sublicense the assets we acquired from Takeda in the
territory of Japan. This right of first negotiation remains in effect until the earlier of five years from the date of the agreement, consummation of a change in control, or sublicense to a third
party. This may delay or limit our ability to enter into certain transactions with respect to this product candidate. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may enter into additional licenses to third-party intellectual property that are necessary or useful to our business. Future licensors may also allege that we have breached our
license agreement and may accordingly seek to terminate our license with them. In addition, future licensors may have the right to terminate our license at will. Any termination could result in our
loss of the right to use the licensed intellectual property, which could materially adversely affect our ability to develop and commercialize setmelanotide, if approved, as well as harm our
competitive business position and our business prospects. </FONT></P>


<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We have not yet registered trademarks for a commercial trade name for setmelanotide and failure to secure
such registrations could adversely affect our business.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have not yet registered trademarks for a commercial trade name for setmelanotide. Any future trademark applications may be rejected during
trademark registration proceedings. Although we would be given an opportunity to respond to those rejections, we may be unable to overcome them. In addition, in the U.S. PTO and in comparable agencies
in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may
be filed against our trademarks, and our trademarks may not survive those proceedings. Moreover, any name we propose to use for setmelanotide in the United States must be approved by the FDA,
regardless of whether we have registered it, or applied to register it, as a trademark. The FDA typically conducts a review of
proposed product names, including an evaluation of potential for confusion with other product names. If the FDA objects to any of our proposed product names, we may be required to expend significant
additional resources in an effort to identify a suitable substitute name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the
FDA. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we do not obtain additional protection under the Hatch-Waxman Amendments and similar foreign legislation
by extending the patent terms and obtaining product exclusivity for setmelanotide, our business may be materially harmed.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depending upon the timing, duration and specifics of FDA marketing approval for setmelanotide, one or more of the U.S. patents we license may be
eligible for limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a
patent term restoration of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. However, we may not be granted an extension because
of, for example, failure to apply within applicable deadlines, failure to apply prior to expiration of relevant patents or otherwise failure to satisfy applicable requirements. Moreover, the
applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or restoration or the term of any such extension is
less than we request, our competitors may obtain approval of competing products following our patent expiration, and our ability to generate revenues could be materially adversely affected. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;While
we believe that setmelanotide contains active ingredients that would be treated by the FDA as a new chemical entity, or a new drug product, and, therefore, if approved, should be
afforded five years of marketing exclusivity, the FDA may disagree with that conclusion and may approve generic products within a period that is less than five years. Manufacturers may seek to launch
these generic products </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>45</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=48,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=608977,FOLIO='45',FILE='DISK109:[18ZBU1.18ZBU44601]CQ44601A.;14',USER='CHE105614',CD='10-JUN-2018;18:08' -->
<A NAME="page_cq44601_1_46"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>following
the expiration of the applicable marketing exclusivity period, even if we still have patent protection for setmelanotide. Competition that setmelanotide may face from generic versions could
materially and adversely impact our future revenue, profitability and cash flows and substantially limit our ability to obtain a return on the investments we have made in setmelanotide. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we fail to obtain an extension of patent protection under similar foreign legislation, where applicable, our competitors may obtain approval of competing products following our patent
expiration, and our ability to generate revenues could be materially adversely affected in the foreign countries concerned. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to
protect our product.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The United States has enacted and is currently implementing the America Invents Act of 2011, wide-ranging patent reform legislation. Further,
the U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in
certain situations. In addition to increasing uncertainty with regard to our ability to obtain future patents, this combination of events has created uncertainty with respect to the value of patents,
once obtained. Depending on decisions by the U.S. Congress, the federal courts and the U.S. PTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our
ability to obtain new patents or to enforce our existing patents or future patents. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may be subject to damages resulting from claims that we or our employees have wrongfully used or disclosed
alleged trade secrets of their former employers.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our employees have been previously employed at other biotechnology or pharmaceutical companies, including our competitors or potential
competitors. We may be subject to claims that these employees or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of the former employers of our
employees. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to
management. If we fail in defending such claims, in addition to paying money damages, we may lose valuable intellectual property rights or personnel. A loss of key personnel or their work product
could hamper or prevent our ability to commercialize setmelanotide, which would materially adversely affect our commercial development efforts. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks Related to Regulatory Approval and Marketing of Setmelanotide and Other Legal Compliance Matters  </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Even if we complete the necessary clinical trials, the regulatory and marketing approval process is
expensive, time consuming and uncertain and may prevent us from obtaining approvals for the commercialization of setmelanotide. We depend entirely on the success of setmelanotide, which is in
Phase&nbsp;3 clinical development for treatment of POMC deficiency obesity and LepR deficiency obesity. We cannot be certain that we will be able to obtain regulatory approval for, or successfully
commercialize, setmelanotide. If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals, we will not be able to commercialize setmelanotide, and our ability to
generate revenue will be materially impaired.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We currently have only one product candidate, setmelanotide, in clinical development, and our business depends entirely on its successful
clinical development, regulatory approval and commercialization. We currently have no drug products for sale and may never be able to develop marketable drug products. Setmelanotide, which is
currently in Phase&nbsp;3 clinical development as a treatment for genetic deficiencies affecting the MC4 pathway, including POMC deficiency obesity and LepR deficiency obesity, and which expect to
initiate Phase&nbsp;3 clinical development in Bardet-Biedl syndrome and Alstr&ouml;m syndrome in 2018, will require substantial additional clinical development, testing and regulatory
approval before we are permitted to commence commercialization. The clinical trials of </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>46</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=49,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=1043044,FOLIO='46',FILE='DISK109:[18ZBU1.18ZBU44601]CQ44601A.;14',USER='CHE105614',CD='10-JUN-2018;18:08' -->
<A NAME="page_cq44601_1_47"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>setmelanotide
are, and the manufacturing and marketing of setmelanotide will be, subject to extensive and rigorous review and regulation by numerous government authorities in the United States and in
other countries where we intend to test and, if approved, market setmelanotide. Before obtaining regulatory approvals for the commercial sale of any product candidate, we must demonstrate through
non-clinical testing and clinical trials that the product candidate is safe and effective for use in each target indication. This process can take many years and approval, if any, may be conditional
on post-marketing studies and surveillance, and will require the expenditure of substantial resources beyond our existing cash and the proceeds we raise from this offering. When a sponsor relies
exclusively or predominantly on foreign clinical data, the FDA may require a showing that those data are applicable to the U.S. population and U.S. medical practice, which in some cases may require
bridging studies or other evidence. Of the large number of drugs in development in the United States and in other countries, only a small percentage will successfully complete the FDA regulatory
approval process or the equivalent process in foreign jurisdictions and will be commercialized. In addition, we have not discussed all of our proposed development programs with the FDA of the
competent authorities of foreign jurisdictions. Accordingly, even if we are able to obtain the requisite financing to continue to fund our development and clinical trials, we cannot assure you that
setmelanotide will be successfully developed or commercialized. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are not permitted to market setmelanotide in the United States until we receive approval of an NDA from the FDA, or in any foreign jurisdictions until we receive the requisite
approval from the competent authorities in such countries. We have two Phase&nbsp;3 clinical trials underway, one each for the treatment of POMC deficiency obesity and LepR deficiency obesity, and
plan to initiate a third combined Phase&nbsp;3 trial for Bardet-Biedl syndrome and Alstr&ouml;m syndrome by the end of 2018. Under our
current development program, we plan to conduct a single Phase&nbsp;3 clinical trial for POMC deficiency obesity. To date, in our ongoing discussions with the FDA, the agency has not asked for
additional Phase&nbsp;3 trials in POMC deficiency obesity, but the agency could still require us to conduct additional Phase&nbsp;3 clinical trials for this indication. Moreover, for POMC
deficiency obesity, the FDA has provided clear advice in the past, but could at any time alter its previous advice on many aspects of the trial&#151;the small size, the primary and key
secondary endpoints, the open label design, the amount of past medical history available on individual patients, the statistical analysis plan, the definition of clinically-relevant success for the
protocol, entry of patients ages six or over&#151;all of which may impact the timing and ability to obtain FDA approval. For example, the FDA asked us in December 2017 to switch the order of
our primary and key secondary endpoints for weight in our POMC deficiency Phase&nbsp;3 protocol. While this might be favorable as the new primary endpoint has increased statistical
power&#151;the ability to produce a positive study result&#151;this change occurred after the Phase&nbsp;3 trial had started and may result in additional complexities such as more
attention to compliance and retention. There are other aspects of the trial for which we have not received advice from the FDA, such as the number of U.S. versus non-U.S. patients and the number of
patients with POMC gene defects versus the number of patients with PCSK1 defects, which could also impact the timing of and our ability to obtain FDA approval. We have received FDA comments that
indicate the Phase&nbsp;3 program for LepR deficiency can be similar to POMC deficiency, but we have not yet discussed with the FDA the protocol for a Phase&nbsp;3 program for LepR deficiency
obesity in detail. Therefore, the timeline for enrollment, availability of data, and cost of conducting such trials are less certain, and could be less favorable than those applicable to the POMC
deficiency obesity program. Similarly, the preliminary FDA advice on the design of the Bardet-Biedl syndrome and Alstr&ouml;m syndrome combined clinical Phase&nbsp;3 study could, at any
time, be altered by the FDA, including for example, the size of the trial, the type and importance of endpoints, the length of the trial, the ability to combine the two indications, the inclusion of
pediatric patients and pediatric efficacy endpoints, and the design for any placebo-controlled aspect of the trial. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, the FDA and other equivalent competent authorities in foreign jurisdictions will expect for there to be little or no introduction of bias in the open-label Phase&nbsp;3
trials. Accordingly, we proposed to the FDA that little, if any, efficacy data will be available to us in any form until the Phase&nbsp;3 trials are complete. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>47</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=50,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=130149,FOLIO='47',FILE='DISK109:[18ZBU1.18ZBU44601]CQ44601A.;14',USER='CHE105614',CD='10-JUN-2018;18:08' -->
<A NAME="page_cq44601_1_48"> </A>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
FDA or other regulatory authorities and other equivalent competent authorities in foreign jurisdictions will also require that we conduct one or more pivotal trials for each other
indication sought. In addition, we are not sure if one or more Phase&nbsp;3 trials would be required for approval in each other indications. The need and length of placebo-controlled data in these
pivotal trials and the number of patients required for these approvals is also unclear. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
will determine in our own judgment if a non-pivotal trial meets "proof of concept" in each of these indications. There is no certainty that the FDA, other competent authorities, or
outside investors will agree with our determination, which might have an impact on the ability to transition to Phase&nbsp;3 studies. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the EU we are currently conducting the Phase&nbsp;3 clinical trial RM-493-012 in Germany, France, Belgium, and the United Kingdom for POMC deficiency obesity. We are also conducting
this trial in Canada. On March&nbsp;23, 2017, we received EMA scientific advice on the appropriateness and sufficiency of the non-clinical and clinical development programs to support an initial
marketing authorization application in POMC deficiency obesity. The EMA scientific advice included preliminary advice on the clinical trial RM-493-012. The EMA expressed general support for the
ongoing Phase&nbsp;3 program in POMC deficiency obesity. The EMA advised that the regulatory strategy for a rare disorder is supported and that the EMA may have to rely on scarce data. The EMA also
advised, however, that we need to consider whether full approval or approval under conditional or exceptional circumstances would be the most appropriate pathway for application for POMC deficiency
obesity. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the EU we are currently conducting the Phase&nbsp;3 clinical trial RM-493-015 in Germany, France, Netherlands, and the United Kingdom, for LepR deficiency obesity. We are also
conducting this study in the United States. We have not obtained EMA scientific advice for the LepR deficiency indication, nor have we obtained EMA scientific advice for the Bardet-Biedl syndrome or
Alstr&ouml;m syndrome indications. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Given
the orphan status of setmelanotide for the treatment of POMC deficiency in the EU the marketing authorization application for a POMC deficiency obesity indication will likely be
submitted via the centralized procedure. We will also have to obtain orphan status in the EU for LepR deficiency obesity. In addition, we have submitted a pediatric investigation plan, or PIP, for
setmelanotide to the EMA Pediatric Committee, or PDCO, in 2017. On April&nbsp;27, 2018, the PDCO adopted an opinion accepting the PIPs for Setmelanotide in the treatment of appetite and general
nutritional disorders, including the deferral and the waiver requested by us. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
cannot assure you that the clinical trials we are conducting in the EU will be completed within this timeline. Similar to the United States, we are subject to comprehensive regulatory
oversight by the EMA and the competent authorities of the individual EU member states where we are conducting our clinical trials. Failure by us or by any of our third party partners to comply with EU
laws and the related national laws of individual EU member states governing the conduct of clinical trials may result in the suspension of clinical trials or in other administrative, civil or criminal
penalties. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
plan is to expand our internal clinical development operations and capabilities so that we can continue to enroll and manage our Phase&nbsp;2 and Phase&nbsp;3 clinical trials
such that if the clinical trials are successful, we can file NDAs for POMC deficiency obesity and LepR deficiency obesity in the United States by 2019 or early 2020. We believe we have finalized the
design, timing and size of our Phase&nbsp;3 trial for POMC deficiency obesity with the FDA but we cannot assure you that the trial will not be subject to further modification or that it will be
completed on time. In addition, obtaining approval of an NDA and the approval of a marketing authorization application from the European Commission is a complex, lengthy, expensive and uncertain
process, and the FDA, EMA or equivalent competent authorities in foreign jurisdictions may delay, limit or deny approval of setmelanotide for many reasons, including, among
others:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the FDA, the EMA, or other equivalent competent authorities in foreign jurisdictions may disagree with our interpretation of data from clinical
trials, or may change the requirements for approval even after it has reviewed and commented on the design for our clinical trials; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>48</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=51,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=217363,FOLIO='48',FILE='DISK109:[18ZBU1.18ZBU44601]CQ44601A.;14',USER='CHE105614',CD='10-JUN-2018;18:08' -->
<A NAME="page_cq44601_1_49"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> we may not be able to demonstrate to the satisfaction of the FDA, the EMA, or other equivalent competent authorities in foreign jurisdictions
that setmelanotide is safe and effective in treating obesity caused by certain genetic deficiencies affecting the MC4 pathway; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the results of our clinical trials may not be interpretable or meet the level of statistical or clinical significance required by the FDA, the
EMA, or other equivalent competent authorities in foreign jurisdictions for marketing approval. For example, the potential unblinding of setmelanotide studies due to easily identifiable adverse events
may raise the concern that potential bias has affected the clinical trial results; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the FDA, the EMA, or other equivalent competent authorities in foreign jurisdictions may disagree with the number, size, conduct or
implementation of our clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the FDA, the EMA, or other equivalent competent authorities in foreign jurisdictions may require that we conduct additional clinical trials or
pre-clinical studies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the FDA, the EMA, or other equivalent competent authorities in foreign jurisdictions or the applicable foreign regulatory agency may identify
deficiencies in our chemistry, manufacturing or controls of setmelanotide; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the CROs that we retain to conduct our clinical trials may take actions outside of our control that materially adversely impact our clinical
trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the FDA, the EMA, or other equivalent competent authorities in foreign jurisdictions may find the data from preclinical studies and clinical
trials insufficient to demonstrate that clinical and other benefits of setmelanotide outweigh its safety risks; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the FDA, the EMA, or other equivalent competent authorities in foreign jurisdictions may disagree with our interpretation of data from our
preclinical studies and clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the FDA, the EMA, or other equivalent competent authorities in foreign jurisdictions may not approve the formulation, labeling or
specifications of setmelanotide; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the FDA, the EMA, or other equivalent competent authorities in foreign jurisdictions may not accept data generated at our clinical trial sites; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> if and when our NDA or our marketing authorization application is submitted and reviewed by an advisory committee, the FDA, the EMA, or the
equivalent competent authorities in foreign jurisdictions may have difficulties scheduling an advisory committee meeting in a timely manner or the advisory committee may recommend against approval of
our application or may recommend that the FDA, the EMA, or the equivalent competent authorities in foreign jurisdictions may require, as a condition of approval, additional preclinical studies or
clinical trials, limitations on approved labeling or distribution and use restrictions; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the FDA may require development of a REMS as a condition of approval or post-approval, or may not agree with our proposed REMS or may impose
additional requirements that limit the promotion, advertising, distribution, or sales of setmelanotide. In addition, the European Commission may grant only conditional approval marketing authorization
or impose specific obligations as a condition for marketing authorization, or may require us to conduct post authorization safety studies as a condition of grant of marketing authorization; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the FDA or other equivalent competent foreign regulatory agency may deem our manufacturing processes or our facilities or the facilities of our
CMOs inadequate to preserve the identity, strength, quality, purity, or potency of our product; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the FDA, the European Commission, or the equivalent competent authorities in foreign jurisdictions may change its approval policies or adopt
new regulations and guidance. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>49</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=52,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=938452,FOLIO='49',FILE='DISK109:[18ZBU1.18ZBU44601]CQ44601A.;14',USER='CHE105614',CD='10-JUN-2018;18:08' -->
<A NAME="page_cq44601_1_50"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
of these factors, many of which are beyond our control, could jeopardize our ability to obtain regulatory approval for and successfully market setmelanotide. Moreover, because our
business is entirely dependent upon setmelanotide, any such setback in our pursuit of regulatory approval would have a material adverse effect on our business and prospects. </FONT></P>


<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our failure to obtain marketing approval in foreign jurisdictions would prevent setmelanotide from being
marketed abroad, and any approval we are granted for setmelanotide in the United States would not assure approval of setmelanotide in foreign jurisdictions.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In order to market and sell setmelanotide and any other product candidate that we may develop in the EU and many other jurisdictions, we or our
third-party collaborators must
obtain separate marketing authorizations and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time
required to obtain approval may differ substantially from that required to obtain FDA approval. The regulatory approval process outside the United States generally includes all of the risks associated
with obtaining FDA approval. In addition, in many countries outside the United States, it is required that the product be approved for reimbursement before the product can be sold in that country. We
or these third parties may not obtain approvals from competent authorities outside the United States on a timely basis, if at all. Approval by the FDA does not ensure approval by competent authorities
in other countries or jurisdictions, and approval by one competent authority outside the United States does not ensure approval by competent authorities in other countries or jurisdictions or by the
FDA. We may not be able to file for marketing approvals and may not receive necessary approvals to commercialize setmelanotide in any market. Additionally, on June&nbsp;23, 2016, the electorate in
the United Kingdom voted in favor of leaving the EU, commonly referred to as Brexit. On March&nbsp;29, 2017, the country formally notified the EU of its intention to withdraw pursuant to
Article&nbsp;50 of the Lisbon Treaty. Since a significant proportion of the regulatory framework in the United Kingdom is derived from EU directives and regulations, the withdrawal of the United
Kingdom from the EU could materially impact the regulatory regime with respect to the approval of setmelanotide in the United Kingdom or the EU. Any delay in obtaining, or an inability to obtain, any
marketing approvals, as a result of Brexit or otherwise, would prevent us from commercializing setmelanotide in the United Kingdom and/or the EU and restrict our ability to generate revenue and
achieve and sustain profitability. If any of these outcomes occur, we may be forced to restrict or delay efforts to seek regulatory approval in the United Kingdom and/or EU for setmelanotide, which
could significantly and materially harm our business. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Even if we obtain marketing approval for setmelanotide, the terms of approval and ongoing regulation may
limit how we manufacture and market setmelanotide and compliance with such requirements may involve substantial resources, which could materially impair our ability to generate revenue.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Even if we receive marketing approval for setmelanotide, regulatory authorities may impose significant restrictions on setmelanotide's indicated
uses or marketing or impose ongoing requirements for potentially costly post approval studies. Setmelanotide will also be subject to ongoing requirements by the FDA, the EMA, and the competent
authorities in the EU member states, governing labeling, packaging, storage, advertising, promotion, marketing, distribution, importation, exportation, post-approval changes, manufacturing,
recordkeeping, and submission of safety and other post market information. The FDA and the other competent foreign authorities have significant post market authority, including, for example, the
authority to require labeling changes based on new safety information and to require post market studies or clinical trials to evaluate serious safety risks related to the use of a drug. The FDA also
has the authority to require, as part of an NDA or post approval, the submission of a REMS, which may include Elements to Assure Safe Use, or ETASU. Any REMS required by the FDA may lead to increased
costs to assure compliance with new post approval regulatory requirements and potential requirements or restrictions on the sale of approved products, all of which could lead to lower sales volume and
revenue. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>50</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=53,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=1030582,FOLIO='50',FILE='DISK109:[18ZBU1.18ZBU44601]CQ44601A.;14',USER='CHE105614',CD='10-JUN-2018;18:08' -->
<A NAME="page_cq44601_1_51"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Manufacturers
of drug products and their facilities are subject to continual review and periodic inspections by the FDA and other equivalent competent authorities for compliance with
cGMPs and other regulations. If we or a regulatory agency discover problems with setmelanotide, such as adverse events of unanticipated severity or frequency, or problems with the facility where
setmelanotide is manufactured, a regulatory agency may impose restrictions on setmelanotide, the manufacturer or us, including requiring withdrawal of setmelanotide from the market or suspension of
manufacturing. If we or the manufacturing facilities for setmelanotide fail to comply with applicable regulatory requirements, a regulatory agency may, among other
things:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> issue warning letters or untitled letters; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> seek an injunction or impose civil or criminal penalties or monetary fines; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> suspend or withdraw marketing approval; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> suspend any ongoing clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> refuse to approve pending applications or supplements to applications submitted by us; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> suspend or impose restrictions on operations, including costly new manufacturing requirements; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> seize or detain setmelanotide, refuse to permit the import or export of setmelanotide, or request that we initiate a product recall. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accordingly,
assuming we receive marketing approval for setmelanotide, we and our CMOs will continue to expend time, money and effort in all areas of regulatory compliance, including
manufacturing, production, product surveillance and quality control. If we are not able to comply with post-approval regulatory requirements, we could have the marketing approvals for setmelanotide
withdrawn by regulatory authorities and our ability to market any future products could be limited, which could adversely affect our ability to achieve or sustain profitability. Thus, the cost of
compliance with post-approval regulations may have a negative effect on our operating results and financial condition. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Similar
to the United States, both marketing authorization holders and manufacturers of medicinal products are subject to comprehensive regulatory oversight by the EMA and the competent
authorities of the individual EU member states, both before and after grant of the manufacturing and marketing authorizations. This oversight includes control of compliance with cGMP rules, which
govern quality control of the manufacturing process and require documentation policies and procedures. We and our third party manufacturers would be required to ensure that all of our processes,
methods, and equipment are compliant with cGMP. Failure by us or by any of our third party partners, including suppliers, manufacturers, and distributors to comply with EU laws and the related
national laws of individual EU member states governing the conduct of clinical trials, manufacturing approval, marketing authorization of medicinal products, both before and after grant of marketing
authorization, and marketing of such products following grant of authorization may result in administrative, civil, or criminal penalties. These penalties could include delays in or refusal to
authorize the conduct of clinical trials or to grant marketing authorization, product withdrawals and recalls, product seizures, suspension, or variation of the marketing authorization, total or
partial suspension of production, distribution, manufacturing, or clinical trials, operating restrictions, injunctions, suspension of licenses, fines, and criminal penalties. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, EU legislation related to pharmacovigilance, or the assessment and monitoring of the safety of medicinal products, provides that the EMA and the competent authorities of the
EU member states have the authority to require companies to conduct additional post-approval clinical efficacy and safety studies. The legislation also governs the obligations of marketing
authorization holders with respect to additional monitoring, adverse event management and reporting. Under the pharmacovigilance legislation and its related regulations and guidelines, we may be
required to conduct a labor intensive collection of data regarding the risks and benefits of marketed products and may be required to engage in ongoing assessments of those risks and benefits,
including the possible requirement to conduct additional clinical studies, which may be time-consuming and expensive and could impact our profitability. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>51</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=54,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=844176,FOLIO='51',FILE='DISK109:[18ZBU1.18ZBU44601]CQ44601A.;14',USER='CHE105614',CD='10-JUN-2018;18:08' -->
<A NAME="page_cq44601_1_52"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>Non-compliance
with such obligations can lead to the variation, suspension or withdrawal of marketing authorization or imposition of financial penalties or other enforcement measures. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Current and future healthcare reform legislation or regulation may increase the difficulty and cost for us
and any future collaborators to obtain marketing approval of and commercialize setmelanotide and may adversely affect the prices we, or they, may obtain and may have a negative impact on our business
and results of operations.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes
regarding the healthcare system that could, among other things, prevent or delay marketing approval of setmelanotide, restrict or regulate post-approval activities and affect our ability, or the
ability of any future collaborators, to profitably sell any products for which we, or they, obtain marketing approval. Among policy makers and payors in the United States and elsewhere, there is
significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the United States, the
pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. We expect that current laws, as well as other healthcare
reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we, or any future collaborators, may receive for
any approved products. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
March 2010, President Obama signed into law the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act of 2010, or
collectively the ACA. Among the provisions of the ACA of importance to our business, including, without limitation, our ability to commercialize and the prices we may obtain for any product candidates
and that are approved for sale, are the following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents, apportioned
among these entities according to their market share in certain government healthcare programs, although this fee does not apply to sales of certain products approved exclusively for orphan
indications; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to certain
individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer's Medicaid rebate liability; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> expansion of manufacturers' rebate liability under the Medicaid Drug Rebate Program by increasing the minimum rebate for both branded and
generic drugs and revising the definition of "average manufacturer price," or AMP, for calculating and reporting Medicaid drug rebates on outpatient prescription drug prices and extending rebate
liability to prescriptions for individuals enrolled in Medicare Advantage plans; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> introduction of a price reporting requirement for drugs that are inhaled, instilled, implanted, injected, or infused and not generally
dispensed through retail community pharmacies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> addition of more entity types eligible for participation in the Public Health Service the 340B drug pricing program, or the 340B program; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> established the Medicare Part&nbsp;D coverage gap discount program by requiring manufacturers to provide a 50% point-of-sale-discount off the
negotiated price of applicable brand drugs to eligible beneficiaries during their coverage gap period as a condition for the manufacturers' outpatient drugs to be covered under Medicare Part&nbsp;D; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research,
along with funding for such research; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the Independent Payment Advisory Board, or IPAB, which has authority to recommend certain changes to the Medicare program to reduce
expenditures by the program that could result in reduced payments for prescription drugs. However, the IPAB implementation has been not been </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>52</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=55,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=915237,FOLIO='52',FILE='DISK109:[18ZBU1.18ZBU44601]CQ44601A.;14',USER='CHE105614',CD='10-JUN-2018;18:08' -->
<A NAME="page_cq44601_1_53"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>clearly
defined. ACA provided that under certain circumstances, IPAB recommendations or recommendations of the Secretary of Health and Human Services will become law unless Congress enacts legislation
that will achieve the same or greater Medicare cost savings; and </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> established the Center for Medicare and Medicaid Innovation within CMS to test innovative payment and service delivery models to lower Medicare
and Medicaid spending, potentially including prescription drug spending. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, other legislative changes have been proposed and adopted since the ACA was enacted. For example, beginning April&nbsp;1, 2013, Medicare payments for all items and
services, including drugs and biologics, were reduced by 2% under the sequestration (i.e.,&nbsp;automatic spending reductions) required by the Budget Control Act of 2011, as amended by the American
Taxpayer Relief Act of 2012. Subsequent legislation extended the 2% reduction, on average, to 2025. Sequestration may result in additional reductions in Medicare and other healthcare funding and, if
we obtain regulatory approvals, may otherwise affect the prices we may obtain for setmelanotide or the frequency with which setmelanotide is prescribed or used if approved. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Legislative
changes to or regulatory changes under the ACA have occurred in the 115th&nbsp;U.S. Congress and under the Trump administration. For example, the Tax Cuts and Jobs Act
enacted on December&nbsp;22, 2017, eliminated the shared responsibility payment for individuals who fail to maintain minimum essential coverage under section&nbsp;5000A of the Internal Revenue
Code of 1986, as amended, or the Code, commonly referred to as the individual mandate, beginning in 2019. Further, in the Bipartisan Budget Act of 2018, the Medicare Part&nbsp;D coverage gap
discount program was revised to increase drug manufacturers' discount levels under the program. Additional legislative changes to and regulatory changes under the ACA remain possible, but the nature
and extent of such potential additional changes are uncertain at this time. We expect that the ACA, as currently enacted or as it may be amended in the future, and other healthcare reform measures
that may be adopted in the future, could have a
material adverse effect on our industry generally and on our ability to successfully commercialize our product candidates, if approved. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additional
changes that may affect our business include the expansion of new programs such as Medicare payment for performance initiatives for physicians under the Medicare Access and
CHIP Reauthorization Act of 2015, or MACRA, which will be fully implemented in 2019. At this time, it is unclear how the introduction of the Medicare quality payment program will impact overall
physician reimbursement. The costs of prescription pharmaceuticals in the United States has also been the subject of considerable discussion in the United States, and members of Congress and the
Administration have stated that they will address such costs through new legislative and administrative measures. This focus has resulted in several Congressional inquiries and proposed bills designed
to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies
for drug products. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
expect that these and other healthcare reform measures that may be adopted in the future may result in more rigorous coverage criteria and in additional downward pressure on the price
that we receive for any approved drug. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation
of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our drugs. We expect that additional state and
federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could
result in reduced demand for our drug candidates or additional pricing pressures. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
pricing of prescription pharmaceuticals is also subject to governmental control outside the United States. In these countries, pricing negotiations with governmental authorities can
take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that
compares the cost effectiveness of setmelanotide to other available therapies. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory
levels, our ability to generate revenues and become profitable could be impaired. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>53</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=56,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=94334,FOLIO='53',FILE='DISK109:[18ZBU1.18ZBU44601]CQ44601A.;14',USER='CHE105614',CD='10-JUN-2018;18:08' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_cs44601_1_54"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we participate in the Medicaid Drug Rebate Program and fail to comply with our reporting and payment
obligations under that program or other governmental pricing programs that we participate in, we could be subject to additional reimbursement requirements, penalties, sanctions and fines, which could
have a material adverse effect on our business, financial condition, results of operations and growth prospects.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We expect to participate in and have certain price reporting obligations to the Medicaid Drug Rebate program. Under the Medicaid Drug Rebate
program, if we successfully
commercialize setmelanotide, we would be required to pay a rebate to each state Medicaid program for our covered outpatient drugs that are dispensed to Medicaid beneficiaries and paid for by a state
Medicaid program as a condition of having federal funds being made available to the states for our drugs under Medicaid and Medicare Part&nbsp;B. Those rebates are based on pricing data we would
have to report on a monthly and quarterly basis to the Centers for Medicare and Medicaid Services, or CMS, the federal agency that administers the Medicaid Drug Rebate program. These data include the
average manufacturer price and, in the case of innovator products, the best price for each drug which, in general, represents the lowest price available from the manufacturer to any entity in the U.S.
in any pricing structure, calculated to include all sales and associated rebates, discounts and other price concessions. Our failure to comply with these price reporting and rebate payment obligations
if we participate in the program could negatively impact our financial results. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Federal
law requires that any company that participates in the Medicaid Drug Rebate program also participate in the 340B program in order for federal funds to be available for the
manufacturer's drugs under Medicaid and Medicare Part&nbsp;B. The 340B program requires participating manufacturers to agree to charge statutorily defined covered entities no more than the 340B
"ceiling price" for the manufacturer's covered outpatient drugs. These 340B covered entities include a variety of community health clinics and other entities that receive health services grants from
the Public Health Service, as well as hospitals that serve a disproportionate share of low-income patients. The ACA expanded the list of covered entities to include certain free-standing cancer
hospitals, critical access hospitals, rural referral centers and sole community hospitals, but exempts "orphan drugs" from the ceiling price requirements for these covered entities. The 340B ceiling
price is calculated using a statutory formula based on the average manufacturer price and rebate amount for the covered outpatient drug as calculated under the Medicaid Drug Rebate program, and in
general, products subject to Medicaid price reporting and rebate liability are also subject to the 340B ceiling price calculation and discount requirement. Any additional future changes to the
definition of average manufacturer price and the Medicaid rebate amount under the ACA or other legislation or regulation could affect our 340B ceiling price calculations and negatively impact our
results of operations if we successfully commercialize setmelanotide. In addition, legislation may be introduced that, if passed, would further expand the 340B program to additional covered entities
or would require participating manufacturers to agree to provide 340B discounted pricing on drugs used in an inpatient setting. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
order to be eligible to have our products that we successfully commercialize paid for with federal funds under the Medicaid program and purchased by certain federal agencies and
grantees, we also would have to participate in the U.S. Department of Veterans Affairs, or VA, Federal Supply Schedule, or FSS, pricing program. As part of this program, we would be obligated to make
our products available for procurement on an FSS contract under which we must comply with standard government terms and conditions and charge a price that is no higher than the statutory Federal
Ceiling Price, or FCP, to four federal agencies (VA, U.S. Department of Defense, or DOD, Public Health Service, and U.S. Coast Guard). </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Civil
monetary penalties can be applied if we participate in these programs and if we are found to have knowingly submitted any false price information to the government or if we fail to
submit the required price data on a timely basis. Such conduct also could be grounds for CMS to terminate the Medicaid drug rebate agreement pursuant to which we would participate in the Medicaid drug
rebate program, in which case federal payments may not be available under Medicaid for our covered outpatient </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>54</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=57,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=863,FOLIO='54',FILE='DISK109:[18ZBU1.18ZBU44601]CS44601A.;9',USER='CHE105614',CD='10-JUN-2018;18:08' -->
<A NAME="page_cs44601_1_55"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>drugs.
We cannot assure you that our submissions will not be found by CMS or another government agency to be incomplete or incorrect. </FONT></P>


<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we obtain marketing approval for setmelanotide, we will be subject to strict enforcement of post-marketing
requirements and we could be subject to substantial penalties, including withdrawal of our product from the market, if we fail to comply with all regulatory requirements.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If we obtain marketing approval for setmelanotide, we will be subject to continual requirements of and review by the FDA and equivalent
competent authorities in foreign jurisdictions. These requirements may include, but are not limited to, post-approval studies to be conducted which may include carcinogenicity studies, a QT interval
prolongation study in one form or another, other Phase&nbsp;1 trials, and ongoing natural history studies with patient registries. Other requirements may also include, among other things,
restrictions governing promotion of an approved product, submissions of safety and other post-marketing information and reports, registration and listing requirements, cGMP requirements relating to
manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, and requirements regarding the distribution of samples to physicians and recordkeeping. The
FDA and other federal and state agencies, including the Department of Justice and other equivalent competent authorities in foreign jurisdictions, closely regulate compliance with all requirements
governing prescription drug products, including requirements pertaining to marketing and promotion of drugs in accordance with the provisions of the approved labeling and manufacturing of products in
accordance with cGMP requirements. Violations of such requirements may lead to investigations alleging violations of the FDCA, and other statutes, including the False Claims Act and other federal and
state health care fraud and abuse laws as well as state consumer protection laws. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
example, the FDA and other equivalent competent authorities in foreign jurisdictions strictly regulate the promotional claims that may be made about prescription products, such as
setmelanotide, if approved. In particular, a product may not be promoted for uses that are not approved by the FDA or such other regulatory agencies as reflected in the product's approved labeling. If
we receive marketing approval for setmelanotide as a treatment for obesity caused by certain genetic deficiencies affecting the MC4 pathway, physicians may nevertheless prescribe setmelanotide to
their patients in a manner that is inconsistent with the approved labeling. If we are found to have promoted such off-label uses, we may become subject to significant liability. The federal government
has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off-label promotion. The FDA has also requested that
companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. Oversight and management of promotional practices may require
operational changes and additions, if setmelanotide is approved and commercialized. If we cannot successfully manage the promotion of
setmelanotide, if approved, we could become subject to significant liability, which would materially adversely affect our business and financial condition. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the EU, the advertising and promotion of our products are subject to EU laws governing promotion of medicinal products, interactions with physicians, misleading and comparative
advertising and unfair commercial practices. In addition, other legislation adopted by individual EU member states may apply to the advertising and promotion of medicinal products. These laws require
that promotional materials and advertising in relation to medicinal products comply with the product's Summary of Product Characteristics, or SmPC, as approved by the competent authorities. The SmPC
is the document that provides information to physicians concerning the safe and effective use of the medicinal product. It forms an intrinsic and integral part of the marketing authorization granted
for the medicinal product. Promotion of a medicinal product that does not comply with the SmPC is considered to constitute off-label promotion. The off-label promotion of medicinal products is
prohibited in the EU. The applicable laws at EU level and in the individual EU member states also prohibit the direct-to-consumer advertising of prescription-only medicinal products. Violations of the
rules governing the promotion of medicinal </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>55</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=58,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=378375,FOLIO='55',FILE='DISK109:[18ZBU1.18ZBU44601]CS44601A.;9',USER='CHE105614',CD='10-JUN-2018;18:08' -->
<A NAME="page_cs44601_1_56"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>products
in the EU could be penalized by administrative measures, fines and imprisonment. These laws may further limit or restrict the advertising and promotion of our products to the general public
and may also impose limitations on our promotional activities with health care professionals. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may be subject to federal and state healthcare laws and regulations. If we are unable to comply or have
not fully complied with such laws and regulations, we could face criminal sanctions, damages, civil penalties, reputational harm and diminished profits and future earnings.  </I></B></FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Healthcare providers, physicians and others will play a primary role in the recommendation and prescription of setmelanotide, if approved. Our
arrangements and interactions with healthcare professionals, third-party payors, patients and others will expose us to broadly applicable fraud and abuse, anti-kickback, false claims and other
healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute setmelanotide, if we obtain marketing approval.
The U.S. federal and state healthcare laws and regulations that may affect our ability to operate include, but are not limited to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> The United States federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully
soliciting, offering, paying, or receiving remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, lease order or
arranging for or recommending of the purchase, lease or order of any good or service for which payment may be made, in whole or in part, by federal healthcare programs such as Medicare and Medicaid.
This statute has been interpreted to apply to arrangements between pharmaceutical companies on one hand and prescribers, purchasers and formulary managers on the other. Liability under the
Anti-Kickback Statute may be established without proving actual knowledge of the statute or specific intent to violate it. In addition, the government may assert that a claim including items or
services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act. Although there are a number of
statutory exemptions and regulatory safe harbors to the federal Anti-Kickback Statute protecting certain common business arrangements and activities from prosecution or regulatory sanctions, the
exemptions and safe harbors are drawn narrowly. Practices that involve remuneration to those who prescribe, purchase, or recommend pharmaceutical and biological products, including certain discounts,
or engaging such individuals as consultants, advisors, or speakers, may be subject to scrutiny if they do not fit squarely within an exemption or safe harbor. Our practices may not in all cases meet
all of the criteria for safe harbor protection from anti-kickback liability. Moreover, there are no safe harbors for many common practices, such as educational and research grants, charitable
donations, product support and patient assistance programs. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> The federal civil False Claims Act prohibits individuals or entities from, among other things, knowingly presenting, or causing to be presented
a false or fraudulent claim for payment of government funds, or knowingly making, using or causing to made or used a false record or statement material to an obligation to pay money to the government
or knowingly concealing or knowingly and improperly avoiding, decreasing or concealing an obligation to pay money to the federal government. Actions under the False Claims Act may be brought by the
Attorney General or as a qui tam action by a private individual in the name of the government. Many pharmaceutical manufacturers have been investigated and have reached substantial financial
settlements with the federal government under the civil False Claims Act for a variety of alleged improper activities including causing false claims to be submitted as a result of the marketing of
their products for unapproved and thus non-reimbursable uses, inflating prices reported to private price publication services which are used to set drug payment rates under government healthcare
programs, and other interactions with prescribers and other customers including those that may have affected their billing or coding practices and submission to the federal government. The government
may assert </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>56</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=59,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=435490,FOLIO='56',FILE='DISK109:[18ZBU1.18ZBU44601]CS44601A.;9',USER='CHE105614',CD='10-JUN-2018;18:08' -->
<A NAME="page_cs44601_1_57"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>that
a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act.
Pharmaceutical
and other healthcare companies also are subject to other federal false claims laws, including, among others, federal criminal healthcare fraud and false statement statutes that extend to
non-government health benefit programs. </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> The federal Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and
Clinical Health Act, or HIPAA, imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program and also imposes obligations, with respect to safeguarding the
privacy, security and transmission of individually identifiable health information. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> HIPAA and the federal false statements statute prohibits knowingly and willfully falsifying, concealing or covering up a material fact or
making any materially false, fictitious or fraudulent statement or representation, or making or using any false writing or document knowing the same to contain any materially false, fictitious or
fraudulent statement or entry in connection with the delivery of or payment for healthcare benefits, items or services. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Numerous federal and state laws and regulations that address privacy and data security, including state data breach notification laws, state
health information privacy laws, and federal and state consumer protection laws (e.g.,&nbsp;Section&nbsp;5 of the FTC Act), govern the collection, use, disclosure and protection of health-related
and other personal information. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> The federal Physician Payments Sunshine Act, being implemented as the Open Payments Program, requires certain manufacturers of drugs, devices,
biologics and medical supplies to report payments and other transfers of value to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their
immediate family members. Pharmaceutical and biological manufacturers with products for which payment is available under Medicare, Medicaid or the State Children's Health Insurance Program are
required to submit a report to the Centers for Medicare and Medicaid Services within the U.S. Department of Health and Human Services on or before the 90th&nbsp;day of each calendar year disclosing
reportable payments made in the previous calendar year. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Analogous state laws and regulations, such as state anti-kickback and false claims laws, which may apply to items or services reimbursed under
Medicaid and other state programs or, in several states, regardless of the payer. Some state laws require pharmaceutical companies to report expenses relating to the marketing and promotion of
pharmaceutical products and to report gifts and payments to certain health care providers in those states. Some of these states also prohibit certain marketing-related activities including the
provision of gifts, meals, or other items to certain health care providers. Some states restrict the ability of manufacturers to offer co-pay support to patients for certain prescription drugs. Other
states and cities require identification or licensing of sales representatives. In addition, California, Connecticut, Nevada, and Massachusetts require pharmaceutical companies to implement compliance
programs or marketing codes of conduct. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ensuring
that our business arrangements and interactions with healthcare professionals, third-party payors, patients and others comply with applicable healthcare laws and regulations
will require substantial resources. Various state and federal regulatory and enforcement agencies continue actively to investigate violations of health care laws and regulations, and the United States
Congress continues to strengthen the arsenal of enforcement tools. Most recently, the Bipartisan Budget Act of 2018 increased the criminal and civil penalties that can be imposed for violating certain
federal health care laws, including the Anti-Kickback Statute. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes,
regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations, including anticipated activities to be conducted by our sales and marketing
team, were found to be in violation of any of these laws or any other </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>57</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=60,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=300470,FOLIO='57',FILE='DISK109:[18ZBU1.18ZBU44601]CS44601A.;9',USER='CHE105614',CD='10-JUN-2018;18:08' -->
<A NAME="page_cs44601_1_58"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>governmental
regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, imprisonment, damages, fines, exclusion from government funded healthcare
programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations, any of which could substantially disrupt our operations. Although compliance programs can mitigate the
risk of investigation and prosecution for violations of these laws, the risks cannot be entirely eliminated. Any action against us for violation of these laws or regulations, even if we successfully
defend against it, could cause us to incur significant legal expenses and divert our management's attention from the operation of our business. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our employees may engage in misconduct or other improper activities, including violating applicable
regulatory standards and requirements or engaging in insider trading, which could significantly harm our business.  </I></B></FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with the
regulations of the FDA and applicable
non-U.S. regulators, provide accurate information to the FDA and applicable non-U.S. regulators, comply with healthcare fraud and abuse laws and regulations in the United States and abroad, report
financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws
and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations restrict or prohibit a wide range of pricing, discounting,
marketing and promotion, sales commission, customer incentive programs and other business arrangements. Employee misconduct could also involve the improper use of, including trading on, information
obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter employee misconduct, and any
precautions we take to detect and prevent this activity may be ineffective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or
lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights,
those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions. Some of these laws and related risks are described under the risk
factor "</FONT><FONT SIZE=2><I>We may be subject to federal and state healthcare laws and regulations. If we are unable to comply or have not fully complied with such laws and regulations, we could
face criminal sanctions, damages, civil penalties, reputational harm and diminished profits and future earnings"</I></FONT><FONT SIZE=2> of this prospectus. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our failure to comply with data protection laws and regulations could lead to government enforcement actions
and significant penalties against us, and adversely impact our operating results.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are subject to U.S. data protection laws and regulations (i.e.,&nbsp;laws and regulations that address privacy and data security) at both
the federal and state levels. The legislative and regulatory landscape for data protection continues to evolve, and in recent years there has been an increasing focus on privacy and data security
issues. Numerous federal and state laws, including state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws
(e.g.,&nbsp;Section&nbsp;5 of the FTC Act), govern the collection, use, and disclosure and protection of health-related and other personal information. Failure to comply with data protection laws
and regulations could result in government enforcement actions and create liability for us, which could include civil and/or criminal penalties, private litigation and/or adverse publicity that could
negatively affect our operating results and business. In addition, we may obtain health information from third parties, such as research institutions with which we collaborate, that are subject to
privacy and security requirements under HIPAA. Although we are not directly subject to HIPAA, other than potentially with respect to providing certain employee benefits, we could be subject to
criminal penalties if we knowingly obtain or disclose individually identifiable health information maintained by a HIPAA covered entity in a manner that is not authorized or permitted by HIPAA. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>58</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=61,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=469058,FOLIO='58',FILE='DISK109:[18ZBU1.18ZBU44601]CS44601A.;9',USER='CHE105614',CD='10-JUN-2018;18:08' -->
<A NAME="page_cs44601_1_59"> </A>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;EU
member states, Switzerland and other countries have also adopted data protection laws and regulations, which impose significant compliance obligations. In the EU, the collection and
use of personal health data is governed by the provisions of the General Data Protection Regulation, or GDPR. The GDPR became effective on May&nbsp;25, 2018, repealing the Data Protection Directive
and increasing our responsibility and liability in relation to the processing of personal data of EU subjects. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
GDPR, together with the national legislation of the EU member states governing the processing of personal data, impose strict obligations and restrictions on the ability to collect,
analyze and transfer personal data, including health data from clinical trials and adverse event reporting. In particular, these obligations and restrictions concern the consent of the individuals to
whom the personal data relates, the information provided to the individuals, the transfer of personal data out of the EU, security breach notifications, security and confidentiality of the personal
data, and imposition of substantial potential fines for breaches of the data protection obligations. Data protection authorities from the different EU member states may interpret the GDPR and national
laws differently and impose additional requirements, which add to the complexity of processing personal data in the EU. Guidance on implementation and compliance practices are often updated or
otherwise revised. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With
respect to the transfer of personal data out of the EU, the GDPR provides that the transfer of personal data to countries that are not considered by the European Commission to
provide an adequate level of data protection, including the United States, is permitted only on the basis of complying with specific legal steps. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
judgment by the Court of Justice of the European Union in Case C-362/14 Maximillian Schrems&nbsp;v. Data Protection Commissioner, or the Schrems case, held that the Safe Harbor
Framework, which was relied upon by many United States entities as a basis for transfer of personal data from the EU to the United States, was invalid. United States entities therefore, had only the
possibility to rely on the alternate procedures for such data transfer provided in the EU Data Protection Directive. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
February&nbsp;29, 2016, however, the European Commission announced an agreement with the United States Department of Commerce, or the DOC, to replace the invalidated Safe Harbor
framework with a new "Privacy Shield." On July&nbsp;12, 2016, the European Commission adopted a decision on the adequacy of the protection provided by the Privacy Shield. The Privacy Shield is
intended to address the requirements set out by the Court of Justice of the European Union in the Schrems case. The Privacy Shield imposes more stringent obligations on companies, provides stronger
monitoring and enforcement by the DOC and the Federal Trade Commission, and makes commitments on the part of public authorities regarding access to information. United States entities have been able
to certify to the DOC their compliance with the privacy principles of the Privacy Shield since August&nbsp;1, 2016 and rely on the Privacy Shield certification to transfer of personal data from the
EU to the United States. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;However,
in October 2016, three French digital rights advocacy group, La Quadrature du Net, French Data Network and the F&eacute;d&eacute;ration FDN, brought an action
for annulment of the European Commission decision on the adequacy of the Privacy Shield before the Court of Justice of the EU (Case T-738/16). The case is currently pending before the European Court
of Justice. If the Court of Justice of the European Union invalidates the Privacy Shield, it will no longer be possible to rely on the Privacy
Shield certification to transfer personal data from the EU to entities in the United States. Adherence to the Privacy Shield is not, however, mandatory. Entities based in the United States are
permitted to rely either on their adherence to the Privacy Shield or on the other authorized means and procedures to transfer personal data provided by the GDPR. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
failure to comply with these laws, or changes in the way in which these laws are implemented, could lead to government enforcement actions and significant penalties against us, and
adversely impact our operating results. In particular, our failure to comply with our obligations under the GDPR, including any failure to adopt measures to ensure that we can continue to conduct the
data processing activities that </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>59</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=62,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=41390,FOLIO='59',FILE='DISK109:[18ZBU1.18ZBU44601]CS44601A.;9',USER='CHE105614',CD='10-JUN-2018;18:08' -->
<A NAME="page_cs44601_1_60"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>we
have initiated in the EU before the GDPR entered into application could adversely impact the validity of data generated in our studies. </FONT></P>


<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our future growth depends, in part, on our ability to penetrate foreign markets, where we will be subject to
additional regulatory burdens and other risks and uncertainties.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our future profitability will depend, in part, on our ability to commercialize setmelanotide in foreign markets for which we intend to rely on
collaborations with third parties. If we commercialize setmelanotide in foreign markets, we will be subject to additional risks and uncertainties, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> our customers' ability to obtain reimbursement for setmelanotide in foreign markets; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> our inability to directly control commercial activities because we are relying on third parties; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> different medical practices and customs in foreign countries affecting acceptance in the marketplace; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> import or export licensing requirements; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> longer accounts receivable collection times; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> longer lead times for shipping; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> language barriers for technical training; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> reduced protection of intellectual property rights in some foreign countries; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> foreign currency exchange rate fluctuations; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the interpretation of contractual provisions governed by foreign laws in the event of a contract dispute. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Foreign
sales of setmelanotide could also be adversely affected by the imposition of governmental controls, political and economic instability, trade restrictions and changes in tariffs. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Laws and regulations governing any international operations we may have in the future may preclude us from
developing, manufacturing and selling setmelanotide outside of the United States and require us to develop and implement costly compliance programs.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If we expand our operations outside of the United States, we must dedicate additional resources to comply with numerous laws and regulations in
each jurisdiction in which we plan to operate. The Foreign Corrupt Practices Act of 1977, or the FCPA, prohibits any U.S. individual or business from paying, offering, authorizing payment or offering
anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of such third party in order to assist the
individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with certain accounting provisions requiring the
company to maintain books and records that accurately and fairly reflect all transactions of the company, including international subsidiaries, and to devise and maintain an adequate system of
internal accounting controls for international operations. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Compliance
with the FCPA is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the
pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals
in connection with clinical trials </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>60</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=63,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=255394,FOLIO='60',FILE='DISK109:[18ZBU1.18ZBU44601]CS44601A.;9',USER='CHE105614',CD='10-JUN-2018;18:08' -->
<A NAME="page_cs44601_1_61"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>and
other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Various
laws, regulations and executive orders also restrict the use and dissemination outside of the United States, or the sharing with certain non-U.S. nationals, of information
classified for national security purposes, as well as certain products and technical data relating to those products. If we
expand our presence outside of the United States, it will require us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing or
selling certain product candidates and products outside of the United States, which could limit our growth potential and increase our development costs. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
failure to comply with laws governing international business practices may result in substantial civil and criminal penalties and suspension or debarment from government contracting.
The Securities and Exchange Commission, or SEC, also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA's accounting provisions. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The results of the United Kingdom's referendum on withdrawal from the EU may have a negative effect on global
economic conditions, financial markets and our business.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On March&nbsp;29, 2017, the Government of the United Kingdom initiated the formal procedure of withdrawal from the EU. The procedure involves
a two-year negotiation period in which the United Kingdom and the EU must conclude an agreement setting out the terms of the United Kingdom's withdrawal and the arrangements for the United Kingdom's
future relationship with the EU. This negotiation period could be extended by a unanimous decision of the European Council, in agreement with the United Kingdom. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
referendum has created significant uncertainty concerning the future relationship between the United Kingdom and the EU. This includes the laws and regulations that will apply as the
United Kingdom determines which EU laws to replace or replicate in the event of a withdrawal. From a regulatory perspective, the United Kingdom's withdrawal could result in significant complexity and
risks. A basic requirement related to the grant of a marketing authorization for a medicinal product in the EU is the requirement that the applicant is established in the EU. Following withdrawal of
the United Kingdom from the EU, marketing authorizations previously granted to applicants established in the United Kingdom may no longer be valid. Moreover, depending upon the exact terms of the
United Kingdom's withdrawal, there is an arguable risk that the scope of a marketing authorization for a medicinal product granted by the European Commission pursuant to the centralized procedure
would not, in the future, include the United Kingdom. In these circumstances, an authorization granted by the United Kingdom's competent authorities would always be required to place medicinal
products on the United Kingdom market. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, the laws and regulations that will apply after the United Kingdom withdraws from the EU may have implications for manufacturing sites that hold certification issued by the
United Kingdom competent authorities. Our capability to rely on these manufacturing sites for products intended for the EU market would also depend upon the exact terms of the United Kingdom's
withdrawal. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
United Kingdom referendum has also given rise to calls for the governments of other EU member states to consider withdrawal from the EU. These developments, or the perception that
they could occur, have had and may continue to have a material adverse effect on global economic conditions and the stability of global financial markets. They may significantly reduce global market
liquidity and restrict the ability of key market participants to operate in certain financial markets. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>61</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=64,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=219810,FOLIO='61',FILE='DISK109:[18ZBU1.18ZBU44601]CS44601A.;9',USER='CHE105614',CD='10-JUN-2018;18:08' -->
<A NAME="page_cs44601_1_62"> </A>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks Related to Preclinical Development and Clinical Development of RM-853  </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We have assumed sole responsibility for the global product development and commercialization of RM-853, which
may distract our management team from pursuing regulatory approval of setmelanotide, and we may never complete preclinical development of RM-853 or file an IND with the FDA. Many of the risks we have
faced in preclinical development and in clinical development of setmelanotide will also exist in preclinical development of RM-853 and clinical development, should we ever enter into clinical
development of RM-853  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In March 2018 we entered into a license agreement with Takeda Pharmaceutical Company Limited, which we refer to as Takeda, to develop and
commercialize T-3525770, now known as RM-853. RM-853 is a potent, orally available ghrelin o-acyltransferase, or GOAT, inhibitor currently in preclinical development for PWS. Under the terms of the
license agreement, we assumed sole responsibility for the global product development and commercialization of RM-853. This relationship may distract our management team from clinical development of
setmelanotide and may require us to expend financial and other resources. PWS is a complex disease and companies have had difficulties in developing new therapies for PWS. In addition, many of the
risks we have faced in preclinical development and in clinical development of setmelanotide will also exist in preclinical development of RM-853 and clinical development, should we ever enter into
clinical development of RM-853, including, but not limited to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> RM-853 may not succeed in preclinical toxicology studies or may not be accepted by the FDA under an IND; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> results from preclinical studies may not be predictive of later clinical trials of RM-853; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Phase&nbsp;1 studies may show that RM-853 has a significant toxicities or pharmacokinetics not supportive of proceeding in development; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> failures or delays in the commencement or completion of preclinical studies or clinical trials could result in increased costs to us and could
delay, prevent or limit our ability to generate revenue and continue our business; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> RM-853 could cause undesirable side effects that could result in significant negative consequences, including the inability to enter clinical
development or receive regulatory approval; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> experience by others suggest that PWS patients are high risk for adverse experiences and for this, and many other reasons, clinical trials in
that population are extremely challenging; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> other risks related to regulatory approval, and if ever received, marketing and commercialization of RM-853; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> potential product liability exposure; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> an inability to protect our intellectual property related to RM-853; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> risks related to our dependence on third parties, including in manufacturing RM-853 and conducting preclinical studies and clinical trials of
RM-853; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> competition from other therapies in development for the treatment of PWS may result in reduced availability of patients for our clinical
studies, the possible requirement to achieve clinical meaningful efficacy above any treatment that is approved prior to RM-853, and the potential for increased scrutiny from payers related to the
relative benefit of RM-853 versus other therapies should they be approved prior to RM-853. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>62</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=65,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=601095,FOLIO='62',FILE='DISK109:[18ZBU1.18ZBU44601]CS44601A.;9',USER='CHE105614',CD='10-JUN-2018;18:08' -->
<A NAME="page_cs44601_1_63"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks Related to Employee Matters and Managing Growth  </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our future success depends on our ability to retain our key employees and consultants, and to attract, retain
and motivate qualified personnel.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are highly dependent on Keith M. Gottesdiener, M.D., our Chief Executive Officer and President, Hunter C. Smith, our Chief Financial Officer
and Treasurer, Nithya Desikan, our Chief Commercial Officer, Lex H.T. Van der Ploeg, Ph.D., our Chief Scientific Officer, and Fred T. Fiedorek, M.D., our Chief Medical Officer. We have employment
agreements with these individuals but any individual may terminate his or her employment with us at any time. The loss of their services might impede the achievement of our research, development and
commercialization objectives. We also do not have any key-person life insurance on any of these key employees. We rely on consultants and advisors, including scientific and clinical advisors, to
assist us in formulating our development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory
contracts with other entities that may limit their availability to us and may not be subject to non-compete agreements. Recruiting and retaining qualified scientific personnel and sales and marketing
personnel will also be critical to our success. We may not be able to attract and retain these personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology
companies for similar personnel. We also experience competition for the hiring of scientific personnel from universities and research institutions. Failure to succeed in clinical trials may make it
more challenging to recruit and retain qualified scientific personnel. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We will need to develop and expand our company, and we may encounter difficulties in managing this
development and expansion, which could disrupt our operations.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We expect to increase our number of employees and the scope of our operations. In particular, we will need to transition from a research and
development company to a commercial company. To manage our anticipated development and expansion, we must continue to implement and improve our managerial, operational and financial systems, expand
our facilities and continue to recruit and train additional qualified personnel. Also, our management may need to divert a disproportionate amount of its attention away from their day-to-day
activities and devote a substantial amount of time to managing these development activities. Due to our limited resources, we may not be able to effectively manage the expansion of our operations or
recruit and train additional qualified personnel. This may result in weaknesses in our infrastructure, and give rise to operational mistakes, loss of business and commercial opportunities, loss of
employees and reduced productivity among remaining employees. The physical expansion of our operations may lead to significant costs and may divert financial resources from other projects, such as the
development of setmelanotide. If our management is unable to effectively manage our expected development and expansion, our expenses may increase more than expected, our ability to generate or
increase our revenue could be reduced and we may not be able to implement our business strategy. Our future financial performance and our ability to commercialize setmelanotide, if approved, and
compete effectively will depend, in part, on our ability to effectively manage the future development and expansion of our company. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


In order to satisfy our obligations as a public company, we will need to hire additional qualified accounting
and financial personnel with appropriate public company experience.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As a newly public company, we must establish and maintain effective disclosure and financial controls. We will need to continue to hire
additional accounting and financial personnel with appropriate public company experience and technical accounting knowledge, and it may be difficult to recruit and retain such personnel. Even if we
are able to hire appropriate personnel, our existing operating expenses and operations will be impacted by the direct costs of their employment and the indirect consequences related to the diversion
of management resources from product development efforts. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>63</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=66,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=105001,FOLIO='63',FILE='DISK109:[18ZBU1.18ZBU44601]CS44601A.;9',USER='CHE105614',CD='10-JUN-2018;18:08' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_cu44601_1_64"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our internal computer systems, or those of our third-party CROs, CMOs or other contractors or consultants,
may fail or suffer security breaches, which could result in a material disruption of setmelanotide development programs.  </I></B></FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our internal computer systems and those of our third-party CROs, CMOs, and other contractors and consultants are vulnerable to damage from
computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. If such an event
were to occur and cause interruptions in our operations, it could result in a material disruption of our programs. For example, the loss of clinical trial data for setmelanotide could result in delays
in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach results in a loss of or damage to our
data or applications or other data or applications relating to our technology or product candidate, or inappropriate disclosure of confidential or proprietary information, we could incur liabilities
and the further development of setmelanotide could be delayed. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may acquire businesses or products, form strategic alliances or create joint ventures in the future, and
we may not realize their benefits.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may acquire additional businesses or products, form strategic alliances or create joint ventures with third parties that we believe will
complement or augment our existing business. If we acquire businesses with promising markets or technologies, we may not be able to realize the benefit of acquiring such businesses if we are unable to
successfully integrate them with our existing operations and company culture. We may encounter numerous difficulties in developing, manufacturing and marketing any new products resulting from a
strategic alliance, joint venture or acquisition that delay or prevent us from realizing their expected benefits or enhancing our business. We cannot assure you that, following any such acquisition,
we will achieve the expected synergies to justify the transaction. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks Related to Our Common Stock and This Offering  </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The price of our common stock may be volatile and fluctuate substantially, which could result in substantial
losses for purchasers of our common stock in this offering.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you purchase shares in this offering, you may not be able to resell those shares at or above the public offering price. The trading price of
the shares has fluctuated, and is likely to continue to fluctuate substantially. The trading price of our securities depends on a number of factors, including those described in this "Risk Factors"
section, many of which are beyond our control and may not be related to our operating performance. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Since
the shares were sold at our initial public offering in October 2017 at a price of $17.00 per share, the price per share has ranged as low as $16.80 and as high as $34.33 through
May&nbsp;31, 2018. The market price of shares of our common stock could be subject to wide fluctuations in response to many risk factors listed in this section, and others beyond our control,
including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> results of preclinical and clinical trials of our products and product candidates, including setmelanotide and RM-853; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> results of clinical trials of our competitors' products; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> regulatory actions with respect to our products or our competitors' products; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> actual or anticipated fluctuations in our financial condition and operating results; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> publication of research reports by securities analysts about us or our competitors or our industry; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> our failure or the failure of our competitors to meet analysts' projections or guidance that we or our competitors may give to the market; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> developments or disputes concerning patent applications, issued patents or other proprietary rights; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>64</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=67,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=1005167,FOLIO='64',FILE='DISK109:[18ZBU1.18ZBU44601]CU44601A.;12',USER='CHE105614',CD='10-JUN-2018;18:08' -->
<A NAME="page_cu44601_1_65"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> additions and departures of key personnel; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> strategic decisions by us or our competitors, such as acquisitions, collaborations, divestitures, spin-offs, joint ventures, strategic
investments or changes in business strategy; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the passage of legislation or other regulatory developments in the United States and other countries affecting us or our industry; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> fluctuations in the valuation of companies perceived by investors to be comparable to us; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> sales of our common stock by us, our insiders or our other stockholders; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> speculation in the press or investment community; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> announcement or expectation of additional financing efforts; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> changes in accounting principles; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> changes in the structure of healthcare payment systems; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> terrorist acts, acts of war or periods of widespread civil unrest; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> natural disasters and other calamities; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> changes in market conditions for pharmaceutical and biopharmaceutical stocks; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> changes in general market, industry and economic conditions; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the other factors described in this "Risk Factors" section. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, the stock market has experienced significant volatility, particularly with respect to pharmaceutical, biotechnology and other life sciences company stocks. The volatility of
pharmaceutical,
biotechnology and other life sciences company stocks often does not relate to the operating performance of the companies represented by the stock. In the past, securities class action litigation has
often been initiated against companies following periods of volatility in their stock price. This type of litigation could result in substantial costs and divert our management's attention and
resources, and could also require us to make substantial payments to satisfy judgments or to settle litigation </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our principal stockholders and management own a significant percentage of our stock and will be able to exert
significant control over matters subject to stockholder approval.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based on the number of shares outstanding as of March&nbsp;31, 2018, our executive officers, directors, holders of 5% or more of our capital
stock and their respective affiliates beneficially owned approximately 74% of our voting stock. These stockholders will have the ability to influence us through this ownership position. These
stockholders may be able to determine all matters requiring stockholder approval. For example, these stockholders may be able to control elections of directors, amendments of our organizational
documents, or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may
feel are in your best interest as one of our stockholders. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us,
even one that may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.  </I></B></FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are a Delaware corporation. Provisions in our amended and restated certificate of incorporation and amended and restated bylaws may delay or
prevent an acquisition of us or a change in our management. In addition, because we are incorporated in Delaware, we are governed by the provisions of Section&nbsp;203 of the Delaware General
Corporation Law, which limits the ability of stockholders owning in excess of 15% of our outstanding voting stock to merge or combine with us. Although we believe these </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>65</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=68,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=351340,FOLIO='65',FILE='DISK109:[18ZBU1.18ZBU44601]CU44601A.;12',USER='CHE105614',CD='10-JUN-2018;18:08' -->
<A NAME="page_cu44601_1_66"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>provisions
collectively will provide for an opportunity to obtain greater value for stockholders by requiring potential acquirers to negotiate with our board of directors, they would apply even if an
offer rejected by our board were considered beneficial by some stockholders. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current
management by making it more difficult for stockholders to replace members of our board of directors,
which is responsible for appointing the members of our management. Any provision in our amended and restated certificate of incorporation and amended and restated bylaws or Delaware law that has the
effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock, and could also affect the price that
some investors are willing to pay for our common stock. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


An active market for our common stock may not be maintained.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our stock only recently began trading on the Nasdaq Global Market and we can provide no assurance that we will be able to maintain an active
trading market on the Nasdaq Global Market or any other exchange in the future. If an active market for our common is not maintained, it may be difficult for our stockholders to sell shares without
depressing the market price for the shares or at all. An inactive market may also impair our ability to raise capital by selling shares and may impair our ability to acquire other businesses,
applications or technologies using our shares as consideration. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Market volatility may affect our stock price and the value of your investment.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The market price for our common stock has been volatile and may continue to fluctuate significantly in response to a number of factors, most of
which we cannot control, including, among others:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> plans for, progress of, or results from preclinical studies and clinical trials of setmelanotide; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the failure of the FDA to approve setmelanotide; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> announcements of new products, technologies, commercial relationships, acquisitions or other events by us or our competitors; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the success or failure of other weight loss therapies and companies targeting rare diseases and orphan drug treatment; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> regulatory or legal developments in the United States and other countries; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> failure of setmelanotide, if approved, to achieve commercial success; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> fluctuations in stock market prices and trading volumes of similar companies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> general market conditions and overall fluctuations in U.S. equity markets; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> variations in our quarterly operating results; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> changes in our financial guidance or securities analysts' estimates of our financial performance; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> changes in accounting principles; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> our ability to raise additional capital and the terms on which we can raise it; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> sales of large blocks of our common stock, including sales by our executive officers, directors and significant stockholders; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> additions or departures of key personnel; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> discussion of us or our stock price by the press and by online investor communities; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> other risks and uncertainties described in these risk factors. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>66</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=69,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=724377,FOLIO='66',FILE='DISK109:[18ZBU1.18ZBU44601]CU44601A.;12',USER='CHE105614',CD='10-JUN-2018;18:08' -->
<A NAME="page_cu44601_1_67"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our quarterly operating results may fluctuate significantly.  </I></B></FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We expect our operating results to be subject to quarterly fluctuations. Our net loss and other operating results will be affected by numerous
factors, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> variations in the level of expenses related to our development programs; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> addition or termination of clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> any intellectual property infringement lawsuit in which we may become involved; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> regulatory developments affecting setmelanotide; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> our execution of any collaborative, licensing or similar arrangements, and the timing of payments we may make or receive under these
arrangements; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the achievement and timing of milestone payments under our existing collaboration and license agreements; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> if setmelanotide receives regulatory approval, the level of underlying demand for that product and customers' buying patterns. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
our quarterly operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. Furthermore, any quarterly
fluctuations in our operating results may, in turn, cause the price of our stock to fluctuate substantially. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We will have broad discretion in how we use the proceeds from this offering. We may not use these proceeds
effectively, which could affect our results of operations and cause our stock price to decline.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have considerable discretion in the application of the net proceeds from this offering. We intend to continue to use the net proceeds to fund
development and manufacturing of setmelanotide through completion of our Phase&nbsp;3 clinical trials and subsequent NDA submissions with the FDA for the treatment of POMC deficiency obesity and
LepR deficiency obesity, the development of setmelanotide through our Phase&nbsp;2 proof of concept clinical trials for Bardet-Biedl syndrome, Alstr&ouml;m syndrome, POMC heterozygous
deficiency obesity and POMC epigenetic disorders, as well as the initiation of our Phase&nbsp;3 clinical trials for Bardet-Biedl syndrome and Alstr&ouml;m syndrome, the preparation for
commercialization of setmelanotide, initiatives to expand the diagnosis of genetic obesity, including research and scientific exchange related to our ongoing genotyping and genetic epidemiology
studies and for working capital and administrative expenses, additional research and development expenses, and other general corporate purposes. As a result, investors will be relying upon
management's judgment with only limited information about our specific intentions for the use of the net proceeds. We may use the net proceeds for purposes that do not yield a significant return or
any return at all for our stockholders. In addition, pending their use, we may invest the net proceeds in a manner that does not produce income or that loses value. </FONT></P>


<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our ability to use certain net operating loss carryovers and other tax attributes may be limited.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have incurred substantial losses during our history and we do not expect to become profitable in the near future and may never achieve
profitability. Under the Code, a corporation is generally allowed a deduction for net operating losses, or NOLs, carried over from a prior taxable year. Under the Code, we can carry forward certain
NOLs of our subsidiaries to offset future taxable income, if any, until such losses are used or, for NOLs arising in taxable years ending on or before December&nbsp;31, 2017, until such NOLs expire.
NOLs arising in taxable years ending after December&nbsp;31, 2017 are not subject to expiration. NOLs arising in taxable years beginning after December&nbsp;31, 2017 may only be used to offset up
to 80% of the corporation's taxable income computed without taking into account NOL deductions. Other unused tax attributes, such as research tax credits may also be carried forward to offset future
taxable income, if any, until such credits are used or expire. As of December&nbsp;31, 2017, we had approximately $73.1&nbsp;million and </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>67</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=70,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=920236,FOLIO='67',FILE='DISK109:[18ZBU1.18ZBU44601]CU44601A.;12',USER='CHE105614',CD='10-JUN-2018;18:08' -->
<A NAME="page_cu44601_1_68"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>$3.8&nbsp;million
of unused federal and state carryforwards of NOLs, respectively, and approximately $1.9&nbsp;million and $0.5&nbsp;million of unused federal and state carryforwards of tax
credits, respectively.
Additionally, as of December&nbsp;31, 2017, we had federal orphan drug credits related to qualifying research of $2.3&nbsp;million. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
a corporation undergoes an "ownership change," generally defined as a greater than 50% change by value in its equity ownership over a three-year period, Sections&nbsp;382 and 383 of
the Code limit the corporation's ability to use carryovers of its pre-change NOLs, credits and certain other tax attributes to reduce its tax liability for periods after the ownership change. Our
issuance of common stock pursuant to our IPO may result in a limitation under Code Sections&nbsp;382 and 383, either separately or in combination with certain prior or subsequent shifts in the
ownership of our common stock. As a result, our ability to use carryovers of pre-change NOLs and credits to reduce our future U.S. federal income tax liability may be subject to limitations. This
could result in increased U.S. federal income tax liability for us if we generate taxable income in a future period. Limitations on the use of NOLs and other tax attributes could also increase our
state tax liability. Any such limitation could have a material adverse effect on our results of operations in future years. We have not completed a study to assess whether an ownership change for
purposes of Section&nbsp;382 or 383 has occurred, or whether there have been multiple ownership changes since our inception, due to the significant costs and complexities associated with such study. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
use of our tax attributes will also be limited to the extent that we do not generate positive taxable income in future tax periods. We do not expect to generate positive taxable
income in the near future and we may never achieve tax profitability. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Raising additional capital may cause dilution to our existing stockholders, restrict our operations or
require us to relinquish rights.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may seek additional capital through a combination of private and public equity offerings, debt financings, collaborations and strategic and
licensing arrangements. To the extent that we raise additional capital through the sale of common stock or securities convertible or exchangeable into common stock, a stockholder's ownership interest
in our company will be diluted. In addition, the terms of any such securities may include liquidation or other preferences that materially adversely affect the rights of our stockholders. Debt
financing, if available, would increase our fixed payment obligations and may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring
additional debt, making capital expenditures or declaring dividends. If we raise additional funds through collaboration, strategic partnerships and licensing arrangements with third parties, we may
have to relinquish valuable rights to setmelanotide, our intellectual property or future revenue streams, or grant licenses on terms that are not favorable to us. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Substantial future sales or perceived potential sales of our common stock in the public market could cause
the price of our common stock to decline significantly.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sales of our common stock in the public market, or the perception that these sales could occur, could cause the market price of our common stock
to decline significantly. Upon completion of this offering, we will have&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock outstanding, assuming the underwriters do not exercise their option to
purchase
additional shares. Upon completion of this offering approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock beneficially owned by our executive officers, directors and certain shareholders
will be subject to lock-up agreements that prohibit, subject to certain exceptions, the disposal of any shares of our common stock or securities convertible into or exchangeable for shares of our
common stock for a period of 90&nbsp;days after the date of this prospectus. Any or all of these shares may be released prior to the expiration of the lock-up period at the discretion of the
designated representatives. To the extent shares are released before the expiration of the lock-up period and sold into the market, the market price of our common stock could decline significantly. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>68</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=71,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=849969,FOLIO='68',FILE='DISK109:[18ZBU1.18ZBU44601]CU44601A.;12',USER='CHE105614',CD='10-JUN-2018;18:08' -->
<A NAME="page_cu44601_1_69"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
of the shares sold in this offering and the remaining shares not subject to the lock-up period will be freely tradeable. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
holders of approximately 18.9&nbsp;million shares of our common stock, or approximately 69% of our total outstanding common stock as of March&nbsp;31, 2018, are entitled to
rights with respect to the registration of their shares under the Securities Act, subject to vesting schedules. Registration of these shares under the Securities Act would result in the shares
becoming freely tradable without restriction under the Securities Act, except for shares purchased by affiliates. Any sales of securities by these stockholders could have a material adverse effect on
the trading price of our common stock. </FONT></P>


<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We are an "emerging growth company," and as a result of the reduced disclosure and governance requirements
applicable to emerging growth companies, our common stock may be less attractive to investors.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are an "emerging growth company" as defined in the JOBS Act, and we intend to take advantage of certain exemptions from various reporting
requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements
of Section&nbsp;404 of the Sarbanes-Oxley
Act of 2002, as amended, or Section&nbsp;404, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of
holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. If we choose not to comply with the auditor attestation
requirements of Section&nbsp;404, our auditors will not be required to attest to the effectiveness of our internal control over financial reporting. As a result, investors may become less
comfortable with the effectiveness of our internal controls and the risk that material weaknesses or other deficiencies in our internal controls go undetected or may increase. If we choose to provide
reduced disclosures in our periodic reports and proxy statements while we are an emerging growth company, investors would have access to less information and analysis about our executive compensation,
which may make it difficult for investors to evaluate our executive compensation practices. We cannot predict if investors will find our common stock less attractive because we will rely on these
exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. We may take
advantage of these reporting exemptions until we are no longer an "emerging growth company." We will remain an "emerging growth company" until the earlier of (1)&nbsp;December&nbsp;31, 2022,
(2)&nbsp;the last day of the fiscal year (a)&nbsp;in which we have total annual gross revenue of at least $1.07&nbsp;billion, or (b)&nbsp;in which we are deemed to be a large accelerated
filer, which means the market value of our common stock that is held by non-affiliates exceeds $700&nbsp;million as of the prior June&nbsp;30<SUP>th</SUP>, and (3)&nbsp;the date on which we
have issued more than $1.0&nbsp;billion in non-convertible debt during the prior three-year period. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
as long as we remain an emerging growth company, we may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that
are not applicable to emerging growth companies as described in the preceding risk factor. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to Section&nbsp;404 of Sarbanes-Oxley, we will be required to furnish a report by our management on our internal control over financial reporting. However, while we remain an
emerging growth company, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve
compliance with Section&nbsp;404 within the prescribed period, we will be engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and
challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of
internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous
reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude, within the prescribed timeframe or at all,
that our internal control over financial reporting is effective as required by Section&nbsp;404. If we identify </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>69</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=72,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=225303,FOLIO='69',FILE='DISK109:[18ZBU1.18ZBU44601]CU44601A.;12',USER='CHE105614',CD='10-JUN-2018;18:08' -->
<A NAME="page_cu44601_1_70"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>one
or more material weaknesses in our internal control over financial reporting, it could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our
financial statements. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may be at an increased risk of securities class action litigation.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Historically, securities class action litigation has often been brought against a company following a decline in the market price of its
securities. This risk is especially relevant for us because biotechnology and pharmaceutical companies have experienced significant stock price volatility in recent years. If we were to be sued, it
could result in substantial costs and a diversion of management's attention and resources, which could harm our business. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We do not intend to pay dividends on our common stock and, consequently, your ability to achieve a return on
your investment will depend on appreciation in the price of our common stock.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have never declared or paid any cash dividends on our common stock and do not currently intend to do so in the foreseeable future. We
currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends in the foreseeable
future. Therefore, the success of an investment in shares of our common stock will depend upon any future appreciation in their value. There is no guarantee that shares of our common stock will
appreciate in value or even maintain the price at which you purchased them. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If you purchase our common stock in this offering, you will incur immediate and substantial dilution in the
net tangible book value of your shares.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The public offering price of our common stock will be substantially higher than the net tangible book value per share of common stock.
Therefore, if you purchase shares of our common stock in this offering, you will pay a price per share that substantially exceeds our net tangible book value per share after this offering. Based on
the assumed public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per shares, which is the last reported sale price of our common stock on the Nasdaq Global Market
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018, you will experience
immediate dilution of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;share, representing the difference between our as adjusted net tangible book value per share after giving effect to this
offering and the
assumed public offering price. Furthermore, if the underwriters exercise their option to purchase shares or our previously issued options to acquire common stock at prices below the assumed public
offering price are exercised, you will experience further dilution. See "</FONT><FONT SIZE=2><I>Dilution</I></FONT><FONT SIZE=2>" for a more detailed description of the dilution to new investors in
the offering. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If securities or industry analysts do not publish research or reports or publish unfavorable research or
reports about our business, our stock price and trading volume could decline.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us,
our business, our market or our competitors. We do not control these analysts. We do not currently have and may never obtain research coverage by securities and industry analysts. If no securities or
industry analysts commence coverage of our company, the trading price for our stock would be negatively impacted. In the event we obtain securities or industry analyst coverage, if one or more of the
analysts who covers us downgrades our stock, our stock price would likely decline. If one or more of these analysts issues unfavorable commentary or ceases to cover us or fails to regularly publish
reports on us, interest in our stock could decrease, which could cause our stock price or trading volume to decline. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>70</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=73,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=234256,FOLIO='70',FILE='DISK109:[18ZBU1.18ZBU44601]CU44601A.;12',USER='CHE105614',CD='10-JUN-2018;18:08' -->
<A NAME="page_cu44601_1_71"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Unfavorable global economic conditions could adversely affect our business, financial condition or results of
operations.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. The
global financial crisis caused extreme volatility and disruptions in the capital and credit markets. A severe or prolonged economic downturn, such as the global financial crisis, could result in a
variety of risks to our business, including weakened demand for setmelanotide and our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could
also strain our suppliers, possibly resulting in supply disruption, or cause our customers to delay making payments for our services. Any of the foregoing could harm our business and we cannot
anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We will continue to incur substantial costs as a result of operating as a public company, and our management
will continue to devote substantial time to new compliance initiatives and corporation governance policies.  </I></B></FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As a public company, and particularly after we are no longer an emerging growth company, we will continue to incur significant legal, accounting
and other expenses. The Sarbanes-Oxley Act of 2002, or Sarbanes-Oxley, the Dodd-Frank Wall Street Reform and Consumer
Protection Act, the listing requirements of the Nasdaq Global Market and other applicable securities rules and regulations impose various requirements on public companies, including establishment and
maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel will continue to devote a substantial amount of time to these
compliance initiatives. Moreover, these rules and regulations will continue to increase our legal and financial compliance costs and make some activities more time-consuming and costly. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
cannot predict or estimate the amount of additional costs we may incur or the timing of such costs. These rules and regulations are often subject to varying interpretations, in many
cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in
continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
as long as we remain an emerging growth company, we may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that
are not applicable to emerging growth companies as described in the preceding risk factor. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to Section&nbsp;404 of Sarbanes-Oxley, we will be required to furnish a report by our management on our internal control over financial reporting. However, while we remain an
emerging growth company, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve
compliance with Section&nbsp;404 within the prescribed period, we will be engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and
challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of
internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous
reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude, within the prescribed timeframe or at all,
that our internal control over financial reporting is effective as required by Section&nbsp;404. If we identify one or more material weaknesses in our internal control over financial reporting, it
could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>71</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=74,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=649661,FOLIO='71',FILE='DISK109:[18ZBU1.18ZBU44601]CU44601A.;12',USER='CHE105614',CD='10-JUN-2018;18:08' -->
<A NAME="page_cu44601_1_72"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may be at an increased risk of securities class action litigation.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Historically, securities class action litigation has often been brought against a company following a decline in the market price of its
securities. This risk is especially relevant for us because biotechnology and pharmaceutical companies have experienced significant stock price volatility in recent years. If we were to be sued, it
could result in substantial costs and a diversion of management's attention and resources, which could harm our business. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We do not intend to pay dividends on our common stock and, consequently, your ability to achieve a return on
your investment will depend on appreciation in the price of our common stock.  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have never declared or paid any cash dividends on our common stock and do not currently intend to do so in the foreseeable future. We
currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends in the foreseeable
future. Therefore, the success of an investment in shares of our common stock will depend upon any future appreciation in their value. There is no guarantee that shares of our common stock will
appreciate in value or even maintain the price at which you purchased them. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>72</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=75,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=924372,FOLIO='72',FILE='DISK109:[18ZBU1.18ZBU44601]CU44601A.;12',USER='CHE105614',CD='10-JUN-2018;18:08' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_cw44601_1_73"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="cw44601_special_note_regarding_forward-looking_statements"> </A>
<A NAME="toc_cw44601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus contains forward-looking statements, which reflect our current views with respect to, among other things, our operations and
financial performance. You can identify these forward-looking statements by the use of words such as "outlook," "believes," "expects," "potential," "continues," "may," "will," "should," "seeks,"
"approximately," "predicts," "intends," "plans," "estimates," "anticipates" or the negative version of these words or other comparable words.
Such forward-looking statements are subject to various risks and uncertainties. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially
from those indicated in these statements. We believe these factors include but are not limited to those described under "</FONT><FONT SIZE=2><I>Risk Factors</I></FONT><FONT SIZE=2>" and include,
among other things:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the success, cost and timing of our product development activities and clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> our ability to obtain and maintain regulatory approval for setmelanotide and our future product candidates, if any, and any related
restrictions, limitations, and/or warnings in the label of an approved product candidate; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> our ability to obtain funding for our operations; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the commercialization of setmelanotide, if approved; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the number of people in our target patient population; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> our plans to research, develop and commercialize setmelanotide; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> our ability to operate, and the implementation of our business strategy, as an independent company; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> our ability to attract collaborators with development, regulatory and commercialization expertise; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> our expectations regarding our ability to obtain and maintain intellectual property protection for setmelanotide; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> future agreements with third parties in connection with the commercialization of setmelanotide or our future product candidates, if any; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the size and growth potential of the markets for setmelanotide, and our ability to serve those markets; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> our expectations for the pricing of setmelanotide; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the rate and degree of market acceptance of setmelanotide, as well as the reimbursement coverage for setmelanotide; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> regulatory developments in the United&nbsp;States, the European Union and other jurisdictions; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the performance of our third-party suppliers and manufacturers; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the extent and success of competing therapies that are or may become available; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> our ability to attract and retain key scientific or management personnel; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the accuracy of our estimates regarding our target patient populations, expenses, future revenues, capital requirements and needs for
additional financing; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> our expectations regarding the period during which we qualify as an emerging growth company under the JOBS Act; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> our use of the proceeds from this offering. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;These
factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this prospectus. We undertake no
obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>73</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=76,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=325552,FOLIO='73',FILE='DISK109:[18ZBU1.18ZBU44601]CW44601A.;13',USER='CHE105614',CD='10-JUN-2018;18:08' -->
<A NAME="page_cw44601_1_74"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="cw44601_market,_industry_and_other_data"> </A>
<A NAME="toc_cw44601_2"> </A>
<BR></FONT><FONT SIZE=2><B>  MARKET, INDUSTRY AND OTHER DATA    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus includes market, industry and other data and forecasts that we have derived from independent consultant reports, publicly
available information, various industry publications, other published industry sources and our internal data and estimates. Independent consultant reports, industry publications and other published
industry sources generally indicate that the information contained therein was obtained from sources believed to be reliable. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Due
to the rarity of our target indications, there is no comprehensive patient registry or other method of establishing with precision the actual number of patients with MC4 pathway
deficiencies. As a result, we have had to rely on other available sources to derive prevalence estimates for our target indications. Since the published epidemiology studies for these genetic
deficiencies are based on relatively small population samples, and are not amenable to robust statistical analyses, it is possible that these projections may significantly exceed the addressable
population, particularly given the need to genotype patients to definitively confirm a diagnosis. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have estimated the potential addressable patient populations with these disorders based on the following sources and assumptions: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2><I> POMC Deficiency Obesity.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;There are approximately 50 patients with POMC
deficiency obesity noted in a series of published case reports, each mostly reporting a single or small number of patients. However, we believe our addressable patient population for this deficiency
may be approximately 100 to 500 patients in the United&nbsp;States, and a comparable addressable patient population in Europe, as most of the reported cases are from a small number of academic
research centers, and because genetic testing for POMC deficiency is often unavailable and currently is rarely performed. Based on discussions with experts in rare diseases, we also believe the number
of diagnosed cases could increase several-fold with increased awareness of this deficiency and the availability of new treatments.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2><I> LepR Deficiency Obesity and POMC Heterozygous Deficiency Obesity.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;Our
addressable patient population estimate for LepR deficiency obesity is approximately 500 to 2,000 patients in the United&nbsp;States, and for POMC heterozygous deficiency obesity is approximately
4,000 patients in the United&nbsp;States, with a comparable addressable patient population for both indications in Europe. Our estimates are based on: </FONT> <FONT SIZE=2>
<BR><BR></FONT>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> epidemiology studies on LepR deficiency and POMC heterozygous deficiency in small cohorts of patients comprised of children with
severe obesity and adults with severe obesity who have a history of early onset obesity;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> U.S. Census Bureau figures for adults and children, and Centers for Disease Control and Prevention, or CDC, prevalence numbers for
severe adult obese patients (body mass index, or BMI, greater than 40 kg/ m<SUP>2</SUP>) and for severe early onset obese children (99th&nbsp;percentile at ages two to 17&nbsp;years old); and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> with wider availability of genetic testing expected for LepR deficiency and POMC heterozygous deficiency and increased awareness
of new treatments, our belief that up to 40% of patients with these disorders may eventually be diagnosed. </FONT></DD></DL>
</DD></DL>
</UL>
<UL>
<UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>Using
these sources and assumptions, we calculated our estimates for addressable populations by multiplying (x)&nbsp;our estimate of the number of patients comprised of children with severe obesity
and our estimate of a projected number of adults with severe obesity who have a history of early onset obesity, (y)&nbsp;the estimated prevalence from epidemiology studies of approximately 1% for
LepR deficiency and 2% for POMC heterozygous, and (z)&nbsp;our estimated diagnosis rate of up to 40%. </FONT></P>

</UL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>74</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=77,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=182200,FOLIO='74',FILE='DISK109:[18ZBU1.18ZBU44601]CW44601A.;13',USER='CHE105614',CD='10-JUN-2018;18:08' -->
<A NAME="page_cw44601_1_75"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2><I> Bardet-Biedl Syndrome.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;Our addressable patient population estimate for
Bardet-Biedl syndrome is approximately 1,500 to 2,500 patients in the United&nbsp;States based on: </FONT> <FONT SIZE=2>
<BR><BR></FONT>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> published prevalence estimates of one in 100,000 in North&nbsp;America, which projects to approximately 3,250 people in the
United&nbsp;States. We believe the majority of these patients are addressable patients; and  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> we believe that with wider availability of genetic testing expected for Bardet-Biedl syndrome and increased awareness of new
treatments, the number of patients diagnosed with this disorder will increase.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD></DL>
</DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2><I> Alstr&ouml;m Syndrome.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;Our addressable patient population
estimate for Alstr&ouml;m syndrome is approximately 500 to 1,000 patients worldwide. This estimate is based on: </FONT> <FONT SIZE=2>
<BR><BR></FONT>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> published prevalence estimates of one in 1,000,000 in North&nbsp;America, which projects to approximately 325 people in the
United&nbsp;States. We believe the majority of these patients are addressable patients; and  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> we believe that with wider availability of genetic testing expected for Alstr&ouml;m syndrome and increased awareness of
new treatments, the number of patients diagnosed with this disorder will increase.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD></DL>
</DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2><I> POMC Epigenetic Disorders.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;There is currently no epidemiology data that
defines the prevalence of POMC epigenetic disorders. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe that the patient populations in the European Union are at least as large as those in the United&nbsp;States. However, we do not have comparable epidemiological data from the
European Union and these estimates are therefore based solely on applying relative population percentages to the Company-derived estimates described above. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are conducting additional clinical epidemiology studies to strengthen these prevalence projections. In parallel, we have developed a patient registry for diagnosed patients with POMC
deficiency and LepR deficiency (and other genetic disorders of obesity) which will further inform prevalence projections for these rare genetic orders. See
"</FONT><FONT SIZE=2><I>Business&#151;Other Clinical and Scientific Initiatives in Genetic Obesity&#151;Genotyping Study.</I></FONT><FONT SIZE=2>" for additional information. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Another
method to estimate the size of these ultra-rare populations by genetic epidemiology is using newly available large genomic databases, containing full genome sequencing or exome
sequencing. Ultra-rare orphan diseases are generally categorized as those that affect fewer than 20 patients per million. We have begun some substantial efforts with a series of such databases and/or
collaborators. Much of our preliminary work has been with a database of approximately 140,000 genomes, which is representative of the U.S. population. These efforts generally are based on the
prevalence of heterozygous mutations, as true null mutations are ultra-rare, and then standard scientific methods such as the Hardy-Weinberg equilibrium calculations, are applied to estimate the
prevalence in the U.S. population. These methods make assumptions that may not be sufficiently robust for ultra-rare genetic disorders, and have the inherent variability of estimates for rare events.
In addition, the databases currently available only provide limited clinical data, such as, age, weight and BMI, that would be needed to associate genetic defects with severe obesity. Our continued
investigations support that the genetic epidemiological estimates are larger than the clinical epidemiological estimates, but we will likely need to reconcile the scientific definition of mutations
with the regulatory definition. However, until these data are confirmed, we must continue to base our patient population estimates on clinical epidemiological information. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;See
"</FONT><FONT SIZE=2><I>Risk Factors</I></FONT><FONT SIZE=2>&#151;</FONT><FONT SIZE=2><I>Risks Related to the Development of Setmelanotide&#151;The number of patients
suffering from each of the MC4 pathway deficiencies we are targeting is small and has not been established with precision. If the actual number of patients is smaller than we estimate, our revenue and
ability to achieve profitability may be materially adversely affected."</I></FONT><FONT SIZE=2> for additional information. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>75</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=78,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=1043764,FOLIO='75',FILE='DISK109:[18ZBU1.18ZBU44601]CW44601A.;13',USER='CHE105614',CD='10-JUN-2018;18:08' -->
<A NAME="page_cw44601_1_76"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="cw44601_use_of_proceeds"> </A>
<A NAME="toc_cw44601_3"> </A>
<BR></FONT><FONT SIZE=2><B>  USE OF PROCEEDS    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We estimate that the net proceeds to us from the sale of the shares of our common stock offered by us will be approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming a public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the last reported sale price of
our common stock on the Nasdaq Global Market in
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018, after deducting underwriting discounts and commissions. If the underwriters' option to purchase additional shares in this
offering is exercised in full, we estimate that our net
proceeds will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, after deducting underwriting discounts and commissions. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
$1.00 increase or decrease in the assumed public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which was the last reported sale price of our common stock on the Nasdaq Global Market on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018, would increase or decrease our net proceeds from this offering by approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming that the number of shares offered by us, as set forth
on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions. An increase or decrease of 1,000,000 in
the number of shares offered by us, as set forth on the cover page of this prospectus, would increase or decrease our net proceeds from this offering by approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million,
assuming no change in the assumed public offering price per share, and after deducting estimated underwriting discounts and commissions. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of March&nbsp;31, 2018, we had cash and cash equivalents and short-term investments of approximately $136.5&nbsp;million. We intend to use the net proceeds from this offering,
together with our existing cash resources, as follows:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million for the development of setmelanotide through the completion of our Phase&nbsp;3 studies in POMC
deficiency obesity and LepR deficiency obesity, as well as preparation for regulatory filing for these indications and initial preparation for the commercialization of setmelanotide in the United
States; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million for the development of setmelanotide through the completion of our
Phase&nbsp;3 studies in
Bardet-Biedl syndrome and Alstr&ouml;m syndrome, as well as preparation for regulatory filing for these indications; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million to expand the clinical development of setmelanotide in new indications,
including POMC
heterozygous deficiency obesity and POMC epigenetics, as well as development of our once-weekly formulation of setmelanotide; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million for initiatives to expand the diagnosis of genetic obesity, including
genetic sequencing of
potential patients from targeted populations, expansion of our GO-ID study and TEMPO registry, research and scientific exchange related to our ongoing genotyping and genetic epidemiology studies; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the balance to be used for other activities, including the preclinical development of RM-853 and general corporate purposes. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
expected use of net proceeds from this offering represents our current intentions based upon our present plans and business condition. As of the date of this prospectus, we cannot
predict with certainty all of the particular uses for the net proceeds to be received upon the closing of this offering, or the amounts that we will actually spend on the uses set forth above. The
amounts and timing of our actual use of the net proceeds will vary depending on numerous factors, including the progress of our clinical trials and other development efforts for setmelanotide and
other factors described in "Risk Factors" beginning on page&nbsp;16, as well as the amount of cash we use in our operations. As a result, our management will have broad discretion in the application
of the net proceeds, and investors will be relying on our judgment regarding the application of the net proceeds of this offering. In addition, we might decide to postpone or not pursue clinical
trials or preclinical activities if the net proceeds from this offering and the other sources of cash are less than expected. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>76</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=79,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=931362,FOLIO='76',FILE='DISK109:[18ZBU1.18ZBU44601]CW44601A.;13',USER='CHE105614',CD='10-JUN-2018;18:08' -->
<A NAME="page_cw44601_1_77"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pending
application of the net proceeds, we intend to invest the net proceeds from this offering in short- and intermediate-term, interest-bearing obligations, investment-grade
instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government. We may still require significant additional capital to fund the continued development of setmelanotide
and our operating needs thereafter. We expect to finance our additional cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing
arrangements. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>77</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=80,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=115058,FOLIO='77',FILE='DISK109:[18ZBU1.18ZBU44601]CW44601A.;13',USER='CHE105614',CD='10-JUN-2018;18:08' -->
<A NAME="page_cw44601_1_78"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> <A NAME="CW1"></A>MARKET PRICE OF COMMON STOCK  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our common stock has been listed on the Nasdaq Global Market under the symbol "RYTM" since October&nbsp;5, 2017. Prior to that date, there was
no public trading market for our common stock. The following table sets forth for the period indicated the high and low intraday sale price per share of our common stock as reported on the Nasdaq
Global Market: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Year Ended December&nbsp;31, 2017:

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>High </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Low </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Fourth Quarter (from October&nbsp;5, 2017)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>33.81</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>21.38</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;<BR></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Year Ended December&nbsp;31, 2018:

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>High </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Low </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>First Quarter</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>32.35</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>19.25</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
last reported sale price of our common stock on the Nasdaq Global Market on May&nbsp;31, 2018 was $32.13 per share. As of May&nbsp;31, 2018, there were 28 holders of record of
our common stock. This number does not reflect beneficial owners whose shares are held in street name. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="cw44601_dividend_policy"> </A>
<A NAME="toc_cw44601_4"> </A>
<BR></FONT><FONT SIZE=2><B>  DIVIDEND POLICY    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We currently intend to retain all available funds and any future earnings for use in the operation of our business and do not anticipate paying
any dividends on our common stock in the foreseeable future. Any future determination to declare dividends will be made at the discretion of our board of directors and will depend on our financial
condition, operating results, capital requirements, general business conditions and other factors that our board of directors may deem relevant. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>78</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=81,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=488914,FOLIO='78',FILE='DISK109:[18ZBU1.18ZBU44601]CW44601A.;13',USER='CHE105614',CD='10-JUN-2018;18:08' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_cy44601_1_79"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="cy44601_capitalization"> </A>
<A NAME="toc_cy44601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  CAPITALIZATION    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth our cash and cash equivalents and short-term investments and capitalization as of March&nbsp;31, 2018, as
follows:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> on an actual basis; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> on a pro forma basis to give effect to the issuance and sale
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock in this offering at an assumed
offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which was the last reported sale price of our common stock on the Nasdaq Global Market
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018, after deducting the estimated
underwriting discounts and commissions and estimated offering expenses payable by us. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
capitalization following the closing of this offering will be adjusted based on the actual offering price and other terms of the offering determined at pricing. You should read this
information in conjunction with our financial statements and the related notes appearing at the end of this prospectus, the "</FONT><FONT SIZE=2><I>Management's Discussion and Analysis of Financial
Condition and Results of Operations</I></FONT><FONT SIZE=2>" section and other financial information contained in this prospectus. You should also read this table together with the information
contained in this prospectus, including "</FONT><FONT SIZE=2><I>Use of Proceeds</I></FONT><FONT SIZE=2>," and the historical financial statements and related notes included elsewhere in this
prospectus. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="56pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>As of March&nbsp;31, 2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Actual </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Pro Forma </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(unaudited)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(in thousands)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash and cash equivalents and short-term investments</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>136,453</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Stockholders' equity (deficit):</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Common stock, $0.001 par value; 120,000,000 shares authorized, 27,284,140 shares issued and outstanding actual; shares issued and outstanding pro
forma</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>27</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Additional paid-in capital</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>260,342</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accumulated deficit</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(126,711</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total stockholders' equity</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>133,658</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total capitalization</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>133,658</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
information above is illustrative only and our capitalization following the completion of this offering will be adjusted based on the actual offering price and other terms of this
offering determined at pricing. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
$1.00 increase (decrease) in the assumed offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, would increase (decrease) the amount of cash and cash equivalents, additional paid-in capital,
total stockholders' equity (deficit) and total capitalization on a pro forma basis by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming the number of shares offered by us, as set forth on
the
cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each increase (decrease)
of one million shares offered by us would increase (decrease) cash and cash equivalents, total stockholders' equity (deficit) and total capitalization on a pro forma basis by approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming the assumed offering price remains the same, and after deducting
estimated underwriting discounts and commissions and estimated offering expenses payable by us. A one million share increase in the number of shares offered by us together with a concomitant $1.00
increase in the assumed offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, would increase each of cash and cash equivalents and total stockholders' (deficit) equity by approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million after deducting underwriting discounts and commissions and estimated offering expenses payable by us. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>79</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=82,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=310850,FOLIO='79',FILE='DISK109:[18ZBU1.18ZBU44601]CY44601A.;15',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_cy44601_1_80"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>Conversely,
a one million share decrease in the number of shares offered by us together with a concomitant $1.00 decrease in the assumed offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, would decrease
each of cash and cash equivalents and total stockholders' (deficit) equity by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million after deducting underwriting discounts and commissions and estimated
offering expenses payable by us. The pro forma information discussed above is illustrative only and will be adjusted based on the actual offering price and other terms of this offering determined at
pricing. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
number of shares of our common stock to be outstanding after this offering excludes:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> 223,544 shares of common stock issued to Takeda, for the acquisition of the worldwide rights to develop and commercialize RM-853 on
April&nbsp;3, 2018; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> 24,250 shares of common stock issued upon the exercise of stock options after March&nbsp;31, 2018 at a weighted average exercise price of
$4.59 per share; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> 2,682,275 shares of common stock reserved for future issuance under our 2017 equity incentive plan, or the 2017 Plan; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> 272,841 shares of common stock reserved for future issuance under our 2017 employee stock purchase plan; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> 2,427,629 shares of common stock issuable upon the exercise of stock options outstanding as of March&nbsp;31, 2018 under our 2017 equity
incentive plan at a weighted average exercise price of $11.85. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>80</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=83,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=544933,FOLIO='80',FILE='DISK109:[18ZBU1.18ZBU44601]CY44601A.;15',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_cy44601_1_81"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="cy44601_dilution"> </A>
<A NAME="toc_cy44601_2"> </A>
<BR></FONT><FONT SIZE=2><B>  DILUTION    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you invest in our common stock in this offering, your ownership interest will be immediately diluted to the extent of the difference between
the initial public offering price per share and the pro forma as adjusted net tangible book value per share of our common stock after this offering. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
historical net tangible book value as of March&nbsp;31, 2018 was approximately $133.7&nbsp;million, or $4.90 per share of our common share. Our historical net tangible book value
represents our total tangible assets less our total liabilities. Net historical tangible book value per common share is our historical net tangible book value divided by the number of common shares
outstanding as of March&nbsp;31, 2018. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
pro forma net tangible book value represents our pro forma net tangible book value, plus the effect of the issuance and sale of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock
in this
offering at an assumed public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the last reported sale price of our common stock on the Nasdaq Global Market
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018, after deducting
underwriting discounts and commissions and estimating offering expenses payable by us. Pro forma net tangible book value per share represents pro forma net tangible book value divided by the total
number of common shares outstanding as of March&nbsp;31, 2018, after giving effect to the pro forma adjustments and the offering described above. Our pro forma net tangible book value as of
March&nbsp;31, 2018 was approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share of our common stock. This amount
represents an immediate increase in the pro forma adjusted net
tangible book value of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share to existing shareholders and an immediate dilution of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share to new
investors purchasing shares at an assumed public offering
price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table illustrates this dilution on a per share basis: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="32pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="36pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Assumed public offering price per share</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Historical net tangible book value per share as of March&nbsp;31, 2018</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4.90</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Increase per share attributable to new investors</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pro forma net tangible book value per share at March&nbsp;31, 2018 after giving effect to the offering</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Dilution per share to new investors</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
$1.00 increase (decrease) in the assumed public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the last reported sale price of our common stock on the Nasdaq Global Market on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018, would increase (decrease) the pro forma net tangible book value per share after this offering by approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share and the dilution per share to investors
participating in this offering by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, assuming that
the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the estimated underwriting discounts and commissions and estimated offering
costs payable by us. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table summarizes, on a pro forma basis as of March&nbsp;31, 2018, the total number of shares purchased from us, the total consideration paid, or to be paid, and the
average price per share paid, or to be paid, by existing stockholders and by new investors in this offering at an assumed public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, the last report
sale
price of our common stock on the Nasdaq Global Market on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018, before deducting estimated underwriting discounts and commissions
and estimated </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>81</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=84,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=750438,FOLIO='81',FILE='DISK109:[18ZBU1.18ZBU44601]CY44601A.;15',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_cy44601_1_82"> </A>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>offering
expenses payable by us. As the table below shows, new investors purchasing shares in this offering will pay an average price per share substantially higher than our existing stockholders
paid. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:73%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"110%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="110%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="40pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="69pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="47pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Shares Purchased </B></FONT></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total Consideration </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Average<BR>
Price<BR>
Per Share </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Percentage </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Amount </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Percentage </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=14 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(in thousands)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Existing stockholders</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>New investors</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as otherwise indicated, the discussion and tables above assume no exercise of the underwriters' option to purchase additional shares of our common stock in this offering. If the
underwriters' option to purchase additional shares is exercised in full:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the percentage of outstanding common stock held by existing stockholders will be reduced to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the total number of shares of
common stock to be outstanding upon completion of this offering; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the number of shares of common stock held by investors participating in this offering will be increased to shares, or&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the
total number of shares of common stock to be outstanding upon completion of this offering. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of March&nbsp;31, 2018, an aggregate of 5,109,904 shares of our common stock was reserved for issuance under our amended and restated 2017 equity incentive plan, or the Plan, and an
aggregate of 272,841 shares of our common stock was reserved for issuance under our 2017 employee stock purchase plan. Furthermore, we may choose to raise additional capital through the sale of equity
or convertible debt securities due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. To the extent that any new
options are issued under our equity incentive plans or we issue additional shares of common stock or other equity or convertible debt securities in the future, there will be further dilution to
investors participating in this offering. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>82</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=85,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=869820,FOLIO='82',FILE='DISK109:[18ZBU1.18ZBU44601]CY44601A.;15',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_cy44601_1_83"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="cy44601_selected_financial_data"> </A>
<A NAME="toc_cy44601_3"> </A>
<BR></FONT><FONT SIZE=2><B>  SELECTED FINANCIAL DATA    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following selected statements of operations data for the years ended December&nbsp;31, 2015, 2016 and 2017 and the balance sheet data as
of December&nbsp;31, 2015, 2016 and 2017 are derived from our audited financial statements appearing elsewhere in this prospectus. The selected statements of operations data for the three months
ended March&nbsp;31, 2017 and 2018 and the balance sheet data as of March&nbsp;31, 2018 have been derived from our unaudited financial statements included elsewhere in this prospectus. In our
opinion, these unaudited financial statements have been prepared on a basis consistent with our audited financial statements and contain all adjustments, consisting only of normal and recurring
adjustments, necessary for a fair presentation of such financial data. In our opinion, you should read this data together with our audited financial statements and related notes appearing elsewhere in
this prospectus and the information under the caption "</FONT><FONT SIZE=2><I>Management's Discussion and Analysis of Financial Condition and Results of Operations</I></FONT><FONT SIZE=2>." </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
financial statements for the periods presented include allocations of costs from certain shared functions provided to us by the Relamorelin Company. These allocations were made based
on either a specific identification basis or, when specific identification is not practicable, a proportional cost allocation method which allocates expenses based on the percentage of employee time
and research and development effort expended on our business as compared to total employee time and research and development effort, and have been included in our financial statements for the periods
presented. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
financial statements included in this prospectus may not necessarily reflect our financial position, results of operations and cash flows as if we had operated as an independent
company during all of the periods presented. See "</FONT><FONT SIZE=2><I>Prospectus Summary&#151;Corporate Background and Distribution</I></FONT><FONT SIZE=2>." </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
historical results are not necessarily indicative of our future results, and our operating results for the three-month period ended March&nbsp;31, 2018 are not necessarily
indicative of the results that may be expected for the fiscal year ending December&nbsp;31, 2018 or any other interim periods or any future year or period. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:62%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"130%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="130%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Three Months Ended<BR>
March&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended<BR>
December&nbsp;31,<BR>
2015 </B></FONT></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended<BR>
December&nbsp;31,<BR>
2016 </B></FONT></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended<BR>
December&nbsp;31,<BR>
2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=14 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(in thousands, except share and per share data)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(unaudited)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Operating expenses:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7,148</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>19,594</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>22,894</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,873</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>12,286</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Selling, general and administrative</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,425</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6,311</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9,518</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,516</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,715 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total operating expenses</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10,573</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>25,905</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>32,412</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6,389</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>17,001 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Loss from operations</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(10,573</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(25,905</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(32,412</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(6,389</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(17,001</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other income (expense):</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Revaluation of Series&nbsp;A Investor Right/Obligation and Investor Instrument</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1,863</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Interest income, net</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>33</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>566</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>29</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>542 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total other income (expense):</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>33</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1,297</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>29</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>542 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss and comprehensive loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(11,073</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(25,872</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(33,709</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(6,360</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(16,459</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss attributable to common stockholders</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(12,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(29,074</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(37,582</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(7,526</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(16,459</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss attributable to common stockholders per common share, basic and diluted<SUP>(1)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1.18</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(2.85</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(2.83</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(0.74</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(0.60</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Weighted average common shares outstanding, basic and diluted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10,196,292</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10,196,292</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>13,267,960</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10,196,292</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>27,284,140 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>83</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=86,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=134742,FOLIO='83',FILE='DISK109:[18ZBU1.18ZBU44601]CY44601A.;15',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_cy44601_1_84"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><BR></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31,<BR>
2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31,<BR>
2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31,<BR>
2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>March&nbsp;31,<BR>
2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Balance Sheet Data:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash, cash equivalents and short-term investments</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>34,869</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10,537</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>148,082</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>136,453</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Working capital</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>30,218</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6,444</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>143,951</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>132,835</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>37,275</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>12,339</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>151,736</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>139,443</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Convertible preferred stock</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>40,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>40,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accumulated deficit</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(50,671</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(76,543</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(110,252</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(126,711</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total stockholders' equity (deficit)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(7,999</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(32,703</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>144,788</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>133,658</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>See
Note&nbsp;2 within the notes to our financial statements appearing elsewhere in this prospectus for a description of the methods used to calculate basic and
diluted net loss per share and pro forma basic and diluted net loss per share. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>84</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=87,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=885988,FOLIO='84',FILE='DISK109:[18ZBU1.18ZBU44601]CY44601A.;15',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_da44601_1_85"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="da44601_management_s_discussion_and_an__man03466"> </A>
<A NAME="toc_da44601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  MANAGEMENT'S DISCUSSION AND ANALYSIS<BR>  OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>You should read the following discussion and analysis of our financial condition and results of operations together with
our financial statements and the related notes and other financial information included elsewhere in this prospectus. Some of the information contained in this discussion and analysis or set forth
elsewhere in this prospectus, including information with respect to our plans and
strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those set forth in the "Risk Factors"
section of this prospectus, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and
analysis.</I></FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Overview  </B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic disorders
that result in severe, life-threatening metabolic disorders. Our lead product candidate is setmelanotide, a potent, first-in-class melanocortin-4 receptor, or MC4R, agonist peptide for the treatment
of rare genetic disorders of obesity. We believe setmelanotide, for which we have exclusive worldwide rights, has the potential to serve as replacement therapy for the treatment of melanocortin-4, or
MC4, pathway deficiencies. MC4 pathway deficiencies result in the disruption of satiety signals and energy homeostasis in the body, which, in turn, leads to intense feelings of hunger and to obesity.
Our development efforts are initially focused on obesity related to six single gene-related, or monogenic, MC4 pathway deficiencies&#151;pro-opiomelanocortin, or POMC, leptin receptor, or LepR,
Bardet-Biedl syndrome, Alstr&ouml;m syndrome, POMC heterozygous, and POMC epigenetic disorders&#151;for which there are currently no effective or approved treatments. We believe that
the MC4 pathway is a compelling target for treating these genetic disorders because of its critical role in regulating appetite and weight by promoting satiety and weight control, and that peptide
therapeutics are uniquely suited for activating this target. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have demonstrated proof of concept in Phase&nbsp;2 clinical trials in POMC deficiency obesity, LepR deficiency obesity, Bardet-Biedl syndrome, and Alstr&ouml;m syndrome,
four genetic disorders of extreme and unrelenting appetite and obesity, in which setmelanotide dramatically reduced both weight and hunger. The U.S. Food and Drug Administration, or the FDA, has
acknowledged the importance of these results by giving setmelanotide Breakthrough Therapy designation for the treatment of obesity associated with genetic defects upstream of the MC4 receptor in the
leptin-melanocortin pathway. The Breakthrough Therapy designation currently covers indications for: POMC deficiency obesity, LepR deficiency obesity, Bardet-Biedl syndrome, and Alstr&ouml;m
syndrome. Setmelanotide is currently in Phase&nbsp;3 development for POMC deficiency obesity and LepR deficiency obesity, and we are initiating a combined Phase&nbsp;3 trial for Bardet-Biedl
syndrome and Alstr&ouml;m syndrome. We are close to completing enrollment in the pivotal cohorts for both our POMC deficiency obesity Phase&nbsp;3 clinical trial and our LepR deficiency
obesity Phase&nbsp;3 clinical trial. We expect to report initial Phase&nbsp;3 data from these trials in the third quarter of 2019, and subsequently plan to file for regulatory approval for these
two indications concurrently. We believe that we have demonstrated proof of concept in our Phase&nbsp;2 clinical trial in Bardet-Biedl syndrome and in Alstr&ouml;m syndrome, and met with
the FDA in May 2018, to discuss a combined pivotal Phase&nbsp;3 clinical trial in these indications. Based on these preliminary discussions with the FDA, we currently plan to initiate this trial and
enroll patients in 2018. We have an ongoing Phase&nbsp;2 clinical trial in POMC heterozygous deficiency obesity and POMC epigenetic disorders, expect to report initial, preliminary results in these
additional Phase&nbsp;2 indications in the second quarter of 2018, and plan to provide a further update for these indications early in 2019. In total, approximately 300 obese subjects and patients
have been treated with setmelanotide in previous and ongoing clinical trials in which setmelanotide demonstrated statistically significant weight loss with good tolerability. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>85</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=88,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=211088,FOLIO='85',FILE='DISK109:[18ZBU1.18ZBU44601]DA44601A.;17',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_da44601_1_86"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have leveraged skilled experts, consultants, contract research organizations, or CROs, and contractors to manage our clinical operations under the leadership and direction of our
management. We expect to expand our infrastructure to manage our clinical, finance and commercial operations with a higher proportion of full-time employees. We have 36 employees. Of these employees,
23 are engaged in development activities, four are engaged in commercialization activities and nine are engaged in support administration, including business development and finance. In the near-term,
we expect to significantly expand our clinical, commercial and finance personnel, in particular, and will incur increased expenses as a result. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
March 2018 we acquired exclusive, worldwide rights from Takeda Pharmaceutical Company Limited, or Takeda, to develop and commercialize T-3525770 (now "RM-853"). RM-853 is a potent,
orally available ghrelin o-acyltransferase, or GOAT, inhibitor currently in preclinical development for Prader-Willi Syndrome, or PWS. PWS is a rare genetic disorder that results in hyperphagia and
early-onset, life-threatening obesity, for which there are no approved therapeutic options. We will assume sole responsibility for the global product development and commercialization of RM-853.
Takeda received an upfront fee of $4.4&nbsp;million which we settled in April 2018 with shares of our common stock, and will receive back-end development milestones, and single-digit royalties on
future RM-853 sales. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
operations to date have been limited primarily to conducting research and development activities for setmelanotide. To date, we have not generated any product revenue and have
financed our operations primarily through capital contributions from the Predecessor Company, the Relamorelin Company and the&nbsp;LLC entity and the private placement of equity securities to
outside investors. On October&nbsp;10, 2017 we completed our initial public offering, or IPO, of 8,107,500 shares of common stock at an offering price of $17.00 per share, which included the
exercise in full by the underwriters of their option to purchase up to 1,057,500 additional shares of common stock. We received gross proceeds of approximately $137.8&nbsp;million, before deducting
underwriting discounts, commissions and offering related transaction costs. In connection with the IPO, our outstanding shares of convertible preferred stock were automatically converted into
17,406,338 shares of common stock. We will not generate revenue from product sales until we successfully complete development and obtain regulatory approval for setmelanotide, which we expect will
take a number of years and is subject to significant uncertainty. We expect to continue to fund our operations through the sale of equity, debt financings or other sources. We intend to build our own
marketing and commercial sales infrastructure and we may enter into collaborations with other parties for certain markets outside the United States. However, we may be unable to raise additional funds
or enter into such other arrangements when needed on favorable terms, or at all. If we fail to raise capital or enter into such other arrangements as, and when, needed, we may have to significantly
delay, scale back or discontinue the development or commercialization of setmelanotide. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of March&nbsp;31, 2018, we had an accumulated deficit of $126.7&nbsp;million. Our net losses were $16.5&nbsp;million and $6.4&nbsp;million for the three months ended
March&nbsp;31, 2018 and 2017, respectively. We expect to continue to incur significant expenses and increasing operating losses over the foreseeable future. We expect our expenses will increase
substantially in connection with our ongoing activities, as we:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> continue to conduct clinical trials for setmelanotide; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> engage contract manufacturing organizations, or CMOs, for the manufacture of setmelanotide for clinical trials; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> seek regulatory approval for setmelanotide; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> expand our clinical and financial operations and build a marketing and commercialization infrastructure; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> operate as a public company. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of March&nbsp;31, 2018, our existing cash and cash equivalents and short-term investments were approximately $136.5&nbsp;million. We expect that our existing cash and cash
equivalents and short-term </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>86</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=89,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=257690,FOLIO='86',FILE='DISK109:[18ZBU1.18ZBU44601]DA44601A.;17',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_da44601_1_87"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>investments,
combined with the proceeds of this offering, will enable us to fund our operating expenses into&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.
</FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Corporate Background and Distribution  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are a Delaware corporation organized in February 2013 under the name Rhythm Metabolic,&nbsp;Inc., and as of October 2015, under the name
Rhythm Pharmaceuticals,&nbsp;Inc. Prior to our organization and the Corporate Reorganization referred to below, we were part of Rhythm Pharmaceuticals,&nbsp;Inc., a Delaware corporation which was
organized in November 2008 and which commenced active operations in 2010. We refer to this corporation as the Predecessor Company. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
March 2013, the Predecessor Company underwent a corporate reorganization, which we refer to as the Corporate Reorganization, pursuant to which all of the outstanding equity securities
of the Predecessor Company were exchanged for units of Rhythm Holding Company,&nbsp;LLC, a newly-organized limited liability company, which we refer to as the&nbsp;LLC entity. After the
consummation of this exchange and as part of the Corporate Reorganization, the Predecessor Company contributed setmelanotide and the MC4R agonist program to us and distributed to the&nbsp;LLC entity
all of the then issued and outstanding shares of our stock. The result of the Corporate Reorganization was that we and the Predecessor Company became wholly-owned subsidiaries of the&nbsp;LLC entity
and the two product candidates and related programs that were originally held by the Predecessor Company were separated, with relamorelin and the ghrelin agonist program being retained by the
Predecessor Company and setmelanotide and the MC4R agonist program being held by us. We refer to the Predecessor Company after consummation of the Corporate Reorganization as the Relamorelin Company.
The Predecessor Company filed the Investigational New Drug Application, or IND, for setmelanotide in October 2011 and conducted the setmelanotide clinical trials up until the Corporate Reorganization,
after which all clinical trials have been conducted by us. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
October 2014, the&nbsp;LLC entity granted to Actavis&nbsp;plc, now owned by Allergan,&nbsp;Inc., or Allergan, an exclusive option to acquire the Relamorelin Company. The
transaction was limited to the acquisition of the Relamorelin Company and did not include our company. In October 2016, the option to acquire the Relamorelin Company was exercised and the sale to
Allergan closed on December&nbsp;15, 2016. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
January 2017 and August 2017, we sold 20,475,001 shares and 20,474,998 shares, respectively, of our series&nbsp;A convertible preferred stock to certain investors. Following the
closing of our series&nbsp;A convertible preferred stock financings, the&nbsp;LLC entity remained our largest stockholder, with the balance of our stock being owned by our series&nbsp;A
investors. In August 2017, the&nbsp;LLC entity exchanged 8,578,646 of its
shares of our common stock for 78,666,209 newly-issued shares of our series&nbsp;A-1 junior preferred stock and the&nbsp;LLC entity distributed all of its shares of our series&nbsp;A-1 junior
preferred stock to the holders of its preferred units and the remaining 1,617,646 shares of our common stock to the holders of its common units. We refer to the exchange and distribution as the
Distribution. The series&nbsp;A-1 junior preferred stock converted into shares of our common stock on a 9.17-for-1 basis upon the closing of our IPO. Following the Distribution, the&nbsp;LLC
entity did not own any of our common stock. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
connection with our IPO, we effected a 1-for-9.17 reverse stock split of our outstanding common stock on September&nbsp;29, 2017. All share and per share amounts in the financial
statements have been retrospectively adjusted for all periods presented to give effect of the reverse stock split. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Financial Operations Overview  </B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Revenue  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To date, we have not generated any revenue from product sales and do not expect to generate any revenue from the sale of setmelanotide for at
least several years. We cannot predict if, when, or to what extent we will generate revenues from the commercialization and sale of setmelanotide. Setmelanotide is currently our only product
candidate, and we may never succeed in achieving regulatory approval for setmelanotide or any other product candidate that we decide to pursue in the future. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>87</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=90,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=990932,FOLIO='87',FILE='DISK109:[18ZBU1.18ZBU44601]DA44601A.;17',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_da44601_1_88"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Research and development expenses  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research and development expenses consist primarily of costs incurred for our research activities, including our drug discovery efforts, and the
development of setmelanotide, which include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> expenses incurred under agreements with third parties, including CROs that conduct research and development and preclinical activities on our
behalf, and the cost of consultants and CMOs that manufacture drug products for use in our preclinical studies and clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> employee-related expenses including salaries, benefits, and stock-based compensation expense; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the cost of lab supplies and acquiring, developing, and manufacturing preclinical study materials; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> facilities, depreciation, and other expenses, which include rent and maintenance of facilities, insurance and other operating costs. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
expense research and development costs to operations as incurred. Nonrefundable advance payments for goods or services to be received in the future for use in research and development
activities are recorded as prepaid expenses. The capitalized amounts are expensed as the related goods are delivered or the services are performed. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table summarizes our current research and development expenses. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:73%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"110%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="110%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Three Months<BR>
Ended March&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Research and development summary

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(in thousands)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(unaudited)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development expense</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7,148</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>19,594</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>22,894</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,873</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12,286 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are unable to predict the duration and costs of the current or future clinical trials of setmelanotide. The duration, costs, and timing of clinical trials and development of
setmelanotide will depend on a variety of factors, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the scope, rate of progress, and expense of our ongoing, as well as any additional, clinical trials and other research and development
activities; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the rate of enrollment in clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the safety and efficacy demonstrated by setmelanotide in future clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> changes in regulatory requirements; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> changes in clinical trial design; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the timing and receipt of any regulatory approvals. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
change in the outcome of any of these variables with respect to the development of setmelanotide would significantly change the costs and timing associated with its development and
potential commercialization. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research
and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in
earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect research and development costs to increase significantly for the
foreseeable future as our setmelanotide development program progresses. However, we do not believe that it is possible at this time to accurately project total program-specific expenses to
commercialization and there can be no guarantee that we can meet the funding needs associated with these expenses. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>88</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=91,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=794101,FOLIO='88',FILE='DISK109:[18ZBU1.18ZBU44601]DA44601A.;17',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_da44601_1_89"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Selling, general and administrative expenses  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Selling expenses consist of professional fees related to preparation for the eventual commercialization of setmelanotide, if approved, as well
as salaries and related benefits for commercial employees, including stock-based compensation. As we accelerate our preparation for commercialization and, if it is approved, start to market
setmelanotide and as we explore new collaborations to develop and commercialize setmelanotide, we anticipate that these expenses will materially increase. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;General
and administrative expenses consist primarily of salaries and other related costs, including stock-based compensation, relating to our full-time employees. Other significant
costs include rent, legal fees relating to patent and corporate matters and fees for accounting and consulting services. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table summarizes our current selling, general and administrative expenses. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Three Months<BR>
Ended March&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Selling, general and administrative summary

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(in thousands)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(unaudited)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Selling, general and administrative expense</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,425</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6,311</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9,518</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,516</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,715 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
anticipate that our selling, general and administrative expenses will increase in the future to support continued and expanding development efforts, potential commercialization of
setmelanotide and increased costs of operating as a public company. These increases will likely include increased costs related to the hiring of additional personnel and fees to outside consultants,
lawyers and accountants, compliance with exchange listing and SEC expenses, insurance and investor relations costs, among other expenses. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Critical Accounting Policies and Estimates  </B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our discussion and analysis of our financial condition and results of operations are based on our financial statements, which we have prepared
in accordance with United States generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts
of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting
periods. On an ongoing basis, we evaluate our estimates and judgments, including those described in greater detail below. We base our estimates on historical experience and on various other factors
that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from
other sources. Actual results may differ from these estimates under different assumptions or conditions. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;While
our significant accounting policies are described in more detail in the notes to our financial statements included elsewhere in this prospectus, we believe that the following
accounting policies are the most critical to aid in fully understanding and evaluating our financial condition and results of operations. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Basis of Presentation  </I></B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Presentation  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have historically existed and functioned as part of the consolidated businesses of the Predecessor Company. Our MC4 business was contributed
to us from the Predecessor Company on March&nbsp;21, 2013 as part of the Corporate Reorganization. At that time, we also entered into the Payroll Services Agreement. In December 2016, the shared
employees terminated their existing employment agreements and entered into new agreements with us. Until December 2016, we shared costs with the Relamorelin Company, including finance, accounting,
research and development and operations. These shared costs were allocated to us from the Relamorelin Company for the purposes of preparing the financial statements </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>89</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=92,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=514643,FOLIO='89',FILE='DISK109:[18ZBU1.18ZBU44601]DA44601A.;17',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_da44601_1_90"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>based
on a specific identification basis or, when specific identification is not practicable, a proportional cost allocation method which allocates expenses based upon the percentage of employee time
and research and development effort expended on our business as compared to total employee time and research and development effort. The proportional use basis adopted to allocate shared costs is in
accordance with the guidance of Staff Accounting Bulletin Topic 1B. Our management has determined that the proportional use method of allocating costs to us from the Relamorelin Company is reasonable. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Accrued research and development expenses  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As part of the process of preparing our financial statements, we are required to estimate the value associated with goods and services received
in the period in connection with research and development activities. This process involves reviewing quotations and contracts, identifying services that have been performed on our behalf and
estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost, or alternatively, the deferral
of amounts paid for goods or services to be incurred in the future. The majority of our service providers invoice us monthly in arrears for services performed or when contractual milestones are met.
We make estimates of our accrued expenses or prepaid expenses as of each balance sheet date in our financial statements based on facts and circumstances known to us at the time those financial
statements are prepared. We periodically confirm the accuracy of our estimates with the service providers and make adjustments if necessary. The significant estimates in our accrued research and
development expenses include fees paid to CROs and CMOs in connection with research and development activities. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
accrue our expenses related to CROs and CMOs based on our estimates of the services received and efforts expended pursuant to quotes and contracts with CROs and CMOs that conduct
research and development and manufacturing on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. The
allocation of CRO upfront expenses for both clinical trials and preclinical studies generally tracks actual work activity. However, there may be instances in which payments made to our vendors will
exceed the level of services provided and result in a prepayment of the research and development expense. In accruing service fees delivered over a period of time, we estimate the time period over
which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust
accrued or prepaid expense accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, if our estimates of the status and timing of services
performed differ from the actual status and timing of services performed, it could result in us reporting amounts that are too high or too low in any particular period. To date, there have been no
material differences between our estimates of such expenses and the amounts actually incurred. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


2017 Series&nbsp;A Investor Instrument  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the 2017 series&nbsp;A preferred stock purchase agreement, by and among us and certain purchasers, and as part of an initial
tranche closing, we issued 20,475,001 shares of series&nbsp;A preferred stock at a purchase price of $1.00 per share in January 2017. The series&nbsp;A preferred stock purchase agreement provided
for the delayed issuance by us of up to an additional 20,474,998 shares of series&nbsp;A preferred stock as part of a second tranche closing at a purchase price of $1.00 per share. The
series&nbsp;A investors had the obligation, upon notification by us, or the 2017 Series&nbsp;A Investor
Right/Obligation, to purchase 20,474,998 additional shares of series&nbsp;A preferred stock as part of a second tranche of financing at such time as: (1)&nbsp;our cash, cash equivalents and
short-term investments balance, net of accounts payable and accrued liabilities, falling below $5.0&nbsp;million and (2)&nbsp;our satisfaction of contractual and customary representations and
warranties, or the 2017 Second Tranche Milestone. On August&nbsp;18, 2017, the series&nbsp;A investors waived the $5.0&nbsp;million cash balance requirement of the 2017 second tranche milestone
and such second tranche financing was consummated. As a result of these two tranches, we issued 40.95&nbsp;million shares of our series&nbsp;A preferred stock, resulting in aggregate gross
proceeds of $40.95&nbsp;million. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>90</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=93,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=572337,FOLIO='90',FILE='DISK109:[18ZBU1.18ZBU44601]DA44601A.;17',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_da44601_1_91"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have classified our 2017 Series&nbsp;A Investor Instrument (See Note&nbsp;4 to our financial statements included elsewhere in this prospectus) as a liability as it is a
free-standing financial instrument. The 2017 Series&nbsp;A Investor Instrument was recorded at fair value upon the issuance of our series&nbsp;A preferred stock in January 2017, and subsequently
remeasured to fair value at each reporting period. Changes in fair value of this financial instrument is recognized as a component of other income (expense), net in the statement of operations and
comprehensive loss. We estimated the fair value of the 2017 Series&nbsp;A Investor Right/Obligations as the probability-weighted present value of the expected benefit of the investment. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
used the Black-Scholes option-pricing model, which incorporates assumptions and estimates, to value the 2017 Series&nbsp;A Investor Call Option and assessed these assumptions and
estimates on a quarterly basis as additional information impacting the assumptions was obtained. Estimates and assumptions impacting the fair value measurement include the fair value per share of the
underlying series&nbsp;A preferred stock, the expected term of the 2017 Series&nbsp;A Investor Call Option, risk-free interest rate, expected dividend yield and expected volatility of the price of
the underlying preferred stock. We determined the fair value per share of the underlying preferred stock by taking into consideration the most recent sale of our convertible preferred stock and the
investors' right to invest in a subsequent tranche. As we were a private company and lacked company-specific historical and implied volatility information of our stock, we estimated our expected stock
volatility based on the historical volatility of publicly traded peer companies for a term comparable to the estimated term of the 2017 Series&nbsp;A Investor Call Option. The risk-free interest
rate was determined by reference to the U.S. Treasury yield curve for time periods approximately equal to the estimated term of the 2017 Series&nbsp;A Investor Call Option. A dividend yield of zero
was assumed. The fair value of the Series&nbsp;A Investor Instrument is determined to be the sum of the fair values of the 2017 Series&nbsp;A Investor Right/Obligation and the 2017 Investor Call
Option. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Stock-based compensation  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In August 2015, our Board of Directors and our stockholders approved and we adopted the 2015 equity incentive plan, as amended and in effect
prior to the closing of our IPO, or the 2015 Plan, which we terminated upon consummation of our IPO and replaced with the 2017 equity incentive plan, or the 2017 Plan. The 2017 Plan provides for the
grant of incentive and non-qualified stock options and restricted stock and stock grants to employees, consultants, advisors and directors, as determined by the Board of Directors. We have reserved
5,109,904 shares of common stock under the 2017 Plan. The first option grants issued by us under the 2015 Plan were issued in the fourth quarter of 2015. Shares of common stock issued upon exercise of
stock options are generally issued from authorized but unissued shares. The 2017 Plan provides that the exercise price of incentive stock options cannot be less than 100% of the fair market value of
the common stock on the date of the award for participants who own less than 10% of the total combined voting power of stock, and not less than 110% for participants who own more than 10% of the
voting power. Options and restricted stock granted under the 2017 Plan will vest over periods as determined by our Compensation Committee and approved by our Board of Directors. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
estimate the fair value of our stock-based awards to employees and non-employees using the Black-Scholes option-pricing model, which requires the input of highly subjective
assumptions, including (a)&nbsp;the expected volatility of our stock, (b)&nbsp;the expected term of the award, (c)&nbsp;the risk-free interest rate, and (d)&nbsp;expected dividends. Previously
due to the lack of a public market for the trading of our common stock and a lack of company-specific historical and implied volatility data, we have based our estimate of expected volatility on the
historical volatility of a group of companies in the pharmaceutical and biotechnology industries in a similar stage of development as us and that are publicly traded. For these analyses, we have
selected companies with comparable characteristics to ours including enterprise value, risk profiles and with historical share price information sufficient to meet the expected life of the stock-based
awards. We compute the historical volatility data using the daily closing prices for the selected companies' shares during the equivalent period of the calculated expected term of our stock-based
awards. We will continue to apply this process until a sufficient amount of historical information regarding the volatility of our own stock price becomes available. We have estimated the expected
life of our employee </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>91</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=94,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=195677,FOLIO='91',FILE='DISK109:[18ZBU1.18ZBU44601]DA44601A.;17',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_da44601_1_92"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>stock
options using the "simplified" method, whereby, the expected life equals the average of the vesting term and the original contractual term of the option. The risk-free interest rates for periods
within the expected life of the option are based on the U.S. Treasury yield curve in effect during the period the options were granted. Upon adopting ASU 2016-09, </FONT><FONT SIZE=2><I>Improvements
to Employee Share-Based Payment Accounting (Topic 718)</I></FONT><FONT SIZE=2> on January&nbsp;1, 2017, we have elected to account for forfeitures as they occur. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Income taxes  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income taxes have been calculated on a separate tax return basis. Certain of our activities and costs have been included in the tax returns
filed by the Relamorelin Company and the&nbsp;LLC entity. Prior to the Corporate Reorganization, our operations were included in the tax returns filed by the Predecessor Company. We have filed tax
returns on our own behalf since the Corporate Reorganization. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
account for uncertain tax positions in accordance with the provisions of Accounting Standards Codification, or ASC, Topic 740, </FONT><FONT SIZE=2><I>Accounting for Income
Taxes</I></FONT><FONT SIZE=2>, or ASC 740. When uncertain tax positions exist, we recognize the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The
determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and
circumstances. As of December&nbsp;31, 2017, we do not have any uncertain tax positions. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income
taxes are recorded in accordance with ASC 740, which provides for deferred taxes using an asset and liability approach. We recognize deferred tax assets and liabilities for the
expected future tax consequences of events that have been included in the financial statements or tax returns. We determine our deferred tax assets and liabilities based on differences between
financial reporting and tax bases of assets and liabilities, which are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation
allowances are provided, if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of December&nbsp;31, 2017, we had net operating loss carryforwards to reduce federal and state incomes taxes of approximately $73.1&nbsp;million and $3.8&nbsp;million,
respectively. If not utilized, these carryforwards begin to expire in 2033. At December&nbsp;31, 2017, we also had available research and development tax credits for federal and state income tax
purposes of approximately $1.9&nbsp;million and $0.5&nbsp;million, respectively. The federal and state credits begin to expire in 2033 and 2028, respectively. Additionally, as of
December&nbsp;31, 2017, we had a federal orphan drug credits related to qualifying research of $2.3&nbsp;million. These tax credit carryforwards begin to expire in 2033 for federal purposes and
2028 for state purposes. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Utilization
of the net operating loss and tax credit carryforwards may be subject to a substantial annual limitation due to ownership change limitations that have occurred previously or
that could occur in the future, as provided by Section&nbsp;382 of the Code, or Section&nbsp;382, as well as similar state provisions and other provisions of the Code. Ownership changes may limit
the amount of net operating losses and tax credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. In general, an ownership change, as defined by
Section&nbsp;382, results from transactions that increase the
ownership of 5.0% stockholders in the stock of a corporation by more than 50% in the aggregate over a three-year period. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>92</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=95,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=1010943,FOLIO='92',FILE='DISK109:[18ZBU1.18ZBU44601]DA44601A.;17',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_dc44601_1_93"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A> </FONT></P>


<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Results of Operations  </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Comparison of three months ended March&nbsp;31, 2018 and 2017  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table summarizes our results of operations for the three months ended March&nbsp;31, 2018 and 2017, together with the changes in
those items in dollars and as a percentage: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="26pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Three Months Ended<BR>
March&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Change </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>$ </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>% </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(in thousands)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(unaudited)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Statement of Operations Data:</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Operating Expenses:</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12,286</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,873</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7,413</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>152</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Selling, general, and administrative</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,715</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,516</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,199</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>211</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>% </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total operating expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>17,001</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6,389</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10,612</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>166</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>% </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Loss from operations</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(17,001</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(6,389</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(10,612</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>166</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>% </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other (expense) income, net</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>542</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>29</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>513</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>NM</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>% </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss and comprehensive loss</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(16,459</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(6,360</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(10,099</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>159</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>% </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research and development expense.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Research and development expense increased by $7.4&nbsp;million to $12.3&nbsp;million in 2018 from
$4.9&nbsp;million in 2017, an increase of 152%. The increase was primarily due to the non-cash expense related to the license acquired from Takeda for RM-853, a $1.0&nbsp;million milestone expense
associated with the license agreement with Ipsen and the hiring of additional clinical and development personnel during the second half of 2017. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Selling, general and administrative expense.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Selling, general and administrative expense increased by $3.2&nbsp;million to
$4.7&nbsp;million in
2018 from $1.5&nbsp;million in 2017, an increase of 211%. The increase was primarily due to increased headcount, the development and building of our commercial organization to drive patient
identification, as well as increased professional and consulting fees associated with being a public company. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Comparison of years ended December&nbsp;31, 2017 and 2016  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table summarizes our results of operations for the years ended December&nbsp;31, 2017 and 2016, together with the changes in
those items in dollars and as a percentage: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="26pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Change </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>$ </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>% </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(in thousands)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Statement of Operations Data:</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Operating Expenses:</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>22,894</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>19,594</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,300</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>17</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Selling, general, and administrative</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9,518</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6,311</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,207</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>51</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>% </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total operating expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>32,412</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>25,905</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6,507</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>25</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>% </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Loss from operations</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(32,412</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(25,905</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(6,507</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>25</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other income (loss)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(1,297</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>33</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(1,330</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>NM</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>% </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss and comprehensive loss</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(33,709</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(25,872</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(7,837</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>30</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>% </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>93</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=96,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=739455,FOLIO='93',FILE='DISK109:[18ZBU1.18ZBU44601]DC44601A.;13',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_dc44601_1_94"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research and development expense.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Research and development expense increased by $3.3&nbsp;million to $22.9&nbsp;million in 2017 from
$19.6&nbsp;million in 2016, an increase of 17%. The increase was primarily due to the increased enrollment for our Phase&nbsp;3 POMC deficiency obesity trial and preparing for our Phase&nbsp;3
LepR deficiency obesity trial, as well as the initiation of additional new clinical trials in 2017 and other development activities associated with setmelanotide. We hired additional personnel in the
clinical operations department at the end of 2016 and throughout 2017. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Selling, General and administrative expense.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Selling, general and administrative expense increased by $3.2&nbsp;million to
$9.5&nbsp;million in
2017 from $6.3&nbsp;million in 2016, an increase of 51%. The increase was primarily due to an increase in headcount in both the commercial department and general and administrative departments as
well as increased professional and consulting fees associated with being a public company. In 2017, we began the initiation of pre-commercial activities related to setmelanotide. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Comparison of years ended December&nbsp;31, 2016 and December&nbsp;31, 2015  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table summarizes our results of operations for the years ended December&nbsp;31, 2016 and 2015, together with the changes in
those items in dollars and as a percentage: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="27pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Change </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>$ </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>% </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(in thousands)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Statement of Operations Data:</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Operating Expenses:</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>19,594</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7,148</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12,446</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>174</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>General, and administrative</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6,311</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,425</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,886</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>84</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>% </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total operating expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>25,905</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10,573</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>15,332</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>145</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>% </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Loss from operations</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(25,905</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(10,573</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(15,332</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2> (145</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other income (loss)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>33</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>533</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>107</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>% </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss and comprehensive loss</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(25,872</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(11,073</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(14,799</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2> (134</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)% </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research and development expense.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Research and development expense increased by $12.4&nbsp;million to $19.6&nbsp;million in 2016 from
$7.1&nbsp;million in 2015, an increase of 174%. The increase was partially due to non-cash expenses in 2016 of $0.5&nbsp;million in stock compensation. Our research and development costs increased
subsequent to the initial series&nbsp;A financing at the end of fiscal year 2015 due to the initiation of additional new clinical trials and additional development activities for setmelanotide and
the hiring of additional personnel in the clinical operations department in the fourth quarter of 2015 and in 2016, as well as an increase in the overall proportion of research and development
expenses allocated to us in 2016. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;General and administrative expense.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;General and administrative expense increased by $2.9&nbsp;million to $6.3&nbsp;million in 2016 from
$3.4&nbsp;million in 2015, an increase of 84%. The increase in general and administrative expense was primarily attributable to the write down of capitalized deferred issuance cost of
$1.8&nbsp;million in 2016, as well as an increase in the overall proportion of general and administrative expenses allocated to us in 2016. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Liquidity and Capital Resources  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of March&nbsp;31, 2018, our existing cash and cash equivalents and short-term investments were approximately $136.5&nbsp;million. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>94</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=97,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=361826,FOLIO='94',FILE='DISK109:[18ZBU1.18ZBU44601]DC44601A.;13',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_dc44601_1_95"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Cash flows  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table provides information regarding our cash flows for the years ended December&nbsp;31, 2017, 2016, and 2015 and the three
months ended March&nbsp;31, 2018 and 2017: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="56pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Three Months<BR>
Ended<BR>
March&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=14 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(in thousands)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(unaudited)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net cash provided by (used in):</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Operating activities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
(29,460</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
(23,219</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
(6,752</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
(11,651</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
(7,016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Investing activities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(110,044</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(5,110</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(17</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>20,607</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(8,019</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Financing activities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>167,200</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>41,711</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>20,377 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net increase (decrease) in cash, cash equivalents and restricted cash</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>27,696</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(28,329</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>34,942</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8,956</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,342 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Net cash used in operating activities  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The use of cash in all periods resulted primarily from our net losses adjusted for non-cash charges and changes in components of working
capital. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net
cash used in operating activities was $29.5&nbsp;million for the year ended December&nbsp;31, 2017, and consisted primarily of a net loss of $29.3&nbsp;million adjusted for
non-cash items, which were comprised of stock-based compensation, depreciation and amortization and the mark to market revaluation of the 2017 Series&nbsp;A Investor Instrument. The significant
items in the change in operating assets and liabilities include an increase in accounts payable, accrued expenses and other current liabilities of $1.9&nbsp;million offset by an increase of
approximately $1.9&nbsp;million in prepaid expenses and other current assets. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net
cash used in operating activities was $23.2&nbsp;million for the year ended December&nbsp;31, 2016, and consisted primarily of a net loss of $24.5&nbsp;million adjusted for
non-cash items, which consisted of stock-based compensation, depreciation and amortization and deferred rent expense. The significant items in the change in operating assets and liabilities include a
decrease of $1.5&nbsp;million in deferred issuance costs offset by a decrease in deferred grant income of approximately $0.3&nbsp;million. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net
cash used in operating activities was $7.0&nbsp;million for the year ended December&nbsp;31, 2015, and consisted primarily of a net loss of $9.4&nbsp;million adjusted for
non-cash items, which were comprised of stock-based compensation, warrant amendment expense and mark to market revaluation of the 2015 Series&nbsp;A Investor Right/Obligation. The significant items
in the change in operating assets and liabilities include an increase in accounts payable, accrued expenses and other current liabilities of $4.7&nbsp;million offset by an increase of approximately
$2.1&nbsp;million in deferred issuance costs and prepaid expenses and other current assets. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net
cash used in operating activities was $11.7&nbsp;million for the three months ended March&nbsp;31, 2018 and consisted primarily of a net loss of $11.0&nbsp;million adjusted for
non-cash items, which consisted of the non-cash research and development license expense for RM-853, stock-based compensation, depreciation and amortization and deferred rent expense. The change in
operating assets and liabilities reflected a total use of cash of approximately $0.7&nbsp;million mainly for a decrease in accrued expenses and prepaid expenses. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net
cash used in operating activities was $7.0&nbsp;million for the three months ended March&nbsp;31, 2017, and consisted primarily of a net loss of $6.1&nbsp;million adjusted for
non-cash items, which consisted of stock-based compensation, depreciation and amortization and deferred rent expense. The significant items in the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>95</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=98,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=188700,FOLIO='95',FILE='DISK109:[18ZBU1.18ZBU44601]DC44601A.;13',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_dc44601_1_96"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>change
in operating assets and liabilities include a decrease in accounts payable of $0.5&nbsp;million and an increase in prepaid clinical trial expenses of approximately $0.3&nbsp;million. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Net cash used in investing activities  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in investing activities for the year ended December&nbsp;31, 2017 relates to the net purchases of short-term investments of
$110.0&nbsp;million. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net
cash used in investing activities for the year ended December&nbsp;31, 2016 relates to the net purchases of short-term investments of $4.1&nbsp;million and the buildout of our
offices and furniture and equipment of $1.1&nbsp;million. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net
cash used in investing activities for the year ended December&nbsp;31, 2015 relates to our design costs incurred related to our new facility lease. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net
cash provided by investing activities for the three months ended March&nbsp;31, 2018 relates to the net maturities of short-term investments of $20.6&nbsp;million. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net
cash used in investing activities for the three months ended March&nbsp;31, 2017 relates to the net purchases of short-term investments of $8.0&nbsp;million. </FONT></P>


<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Net cash provided by financing activities  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by financing activities was $167.2&nbsp;million for the year ended December&nbsp;31, 2017, which represents the net
proceeds of $40.8&nbsp;million from the 2017 issuance of series&nbsp;A preferred stock and the net proceeds of $125.7&nbsp;million from our IPO in October 2017. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net
cash provided by financing activities was $41.7&nbsp;million for the year ended December&nbsp;31, 2015, consisting of $39.6&nbsp;million of net proceeds from the issuance of
series&nbsp;A preferred stock and an equity contribution of $2.1&nbsp;million from the&nbsp;LLC entity. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net
cash provided by financing activities was $20.4&nbsp;million for the three months ended March&nbsp;31, 2017, which represents the net proceeds from the first tranche of our
issuance of series&nbsp;A preferred stock in January 2017. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Funding requirements  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We expect our expenses to increase in connection with our ongoing activities, particularly as we continue the clinical development of and seek
marketing approval for setmelanotide. In addition, if we obtain marketing approval for setmelanotide, we expect to incur significant commercialization expenses related to product sales, marketing,
manufacturing and distribution to the extent that such sales, marketing and distribution are not the responsibility of potential collaborators. We also expect to incur additional costs associated with
operating as a public company. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
expect that our existing cash and cash equivalents and the proceeds of this offering will enable us to fund our operating expenses
into&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We may need to obtain
substantial additional funding in connection with our research and development activities and any continuing operations thereafter. If we are unable to raise capital when needed or on favorable terms,
we would be forced to delay, reduce or eliminate our research and development programs or future commercialization efforts. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
future capital requirements will depend on many factors, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the scope, progress, results and costs of clinical trials for our setmelanotide program; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the costs, timing and outcome of regulatory review of our setmelanotide program; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>96</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=99,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=875223,FOLIO='96',FILE='DISK109:[18ZBU1.18ZBU44601]DC44601A.;13',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_dc44601_1_97"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the obligations owed to Ipsen Pharma&nbsp;S.A.S., or Ipsen, Camurus AB, or Camurus, and Takeda, pursuant to our license agreements; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the extent to which we acquire or in-license other product candidates and technologies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending
intellectual property-related claims; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> our ability to establish and maintain additional collaborations on favorable terms, if at all. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Developing
our setmelanotide program is a time-consuming, expensive and uncertain process that may take years to complete, and we may never generate the necessary data or results
required to obtain marketing approval and achieve product sales. In addition, setmelanotide, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from
sales of setmelanotide that we do not expect to be commercially available for several years, if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business
objectives. Adequate additional financing may not be available to us on acceptable terms, or at all. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Until
such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations,
strategic alliances and licensing arrangements. In August 2015, December 2015, January 2017 and August 2017, respectively, we issued 25,000,000, 15,000,000, 20,475,001 and 20,474,998, shares of
series&nbsp;A preferred stock, respectively, at a price of $1.00 per share, resulting in gross proceeds of $81.0&nbsp;million. In October 2017 we completed our IPO in which we received net
proceeds of $125.7&nbsp;million. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be diluted, and the terms of
these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing, if available, involves agreements that include covenants
limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we raise funds through additional collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our setmelanotide
program on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our
product development or future commercialization efforts or grant rights to develop and market our setmelanotide program that we would otherwise prefer to develop and market ourselves. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Contractual obligations  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We enter into agreements in the normal course of business with CROs and CMOs for clinical trials and clinical supply manufacturing and with
vendors for clinical research studies and other services and products for operating purposes. We do not classify these as contractual obligations where the contracts are cancelable at any time by us,
generally upon 30&nbsp;days' prior written notice to the vendor. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Milestone
and royalty payments associated with our license agreements with Ipsen, Camurus and Takeda, have not been included as contractual obligations as we cannot reasonably estimate
if or when they will occur. Under the terms of the Ipsen license agreement, assuming that setmelanotide is successfully developed, receives regulatory approval and is commercialized, Ipsen may receive
aggregate payments of up to $40.0&nbsp;million upon the achievement of certain development and commercial milestones under the license agreement and royalties on future product sales. The majority
of the aggregate payments under the Ipsen license agreement are for milestones that may be achieved no earlier than first commercial sale of setmelanotide. In the event that we enter into a sublicense
agreement, we will make payments to Ipsen, depending on the date of the sublicense agreement, ranging from 10% to 20% of all revenues actually received under the sublicense agreement. Under the terms
of the Camurus license agreement, assuming </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>97</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=100,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=31337,FOLIO='97',FILE='DISK109:[18ZBU1.18ZBU44601]DC44601A.;13',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_dc44601_1_98"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>that
setmelanotide is successfully developed, receives regulatory approval and is commercialized, Camurus may receive aggregate payments of up to $64.75&nbsp;million upon the achievement of certain
development and commercial milestones under the license agreement and royalties on future product sales. The majority of the aggregate payments under the Camurus license agreement are for milestones
that may be achieved no earlier than first commercial sale of this formulation of setmelanotide. Under the terms of the Takeda license agreement, assuming that RM-853, is successfully developed,
receives regulatory approval and is commercialized, Takeda may receive aggregate payments of up to $140.0&nbsp;million upon the achievement of certain development and commercial milestones under the
license agreement and royalties on future product sales. The majority of the aggregate payments under the Takeda license agreement are for milestones that may be achieved no earlier than first
commercial sale of the RM-853. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
November 2015, we entered into a Lease Agreement for an office facility at 500 Boylston Street, Boston, Massachusetts. The lease term commenced in May 2016 and has a term of five
years with a five-year renewal option to extend the lease. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Future
minimum payments under the Lease Agreement as of December&nbsp;31 2017, are as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="77pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Operating Lease </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2018</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>298</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2019</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>305</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2020</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>311</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2021</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>131 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,045 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Off-balance Sheet Arrangements  </B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We did not have, during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under applicable SEC
rules. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Quantitative and Qualitative Disclosures about Market Risk  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are exposed to market risk related to changes in interest rates. Our primary exposure to market risk is interest rate sensitivity, which is
affected by changes in the general level of U.S. interest rates, particularly because our investments, including cash equivalents, are in the form, or may be in the form of, money market funds or
marketable securities and are or may be invested in U.S. Treasury and U.S.&nbsp;government agency obligations. Due to the short-term maturities and low risk profiles of our investments, an immediate
100 basis point change in interest rates would not have a material effect on the fair market value of our investments. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are not materially exposed to market risk related to changes in foreign currency exchange rates. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


JOBS Act  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In April 2012, the JOBS Act was enacted. Section&nbsp;107 of the JOBS Act provides that an "emerging growth company," or EGC, can take
advantage of the extended transition period provided in Section&nbsp;7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. Thus, an EGC can delay the adoption of
certain newly implemented accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this extended transition period
and, as a result, we will adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are in the process of evaluating the benefits of relying on other exemptions and reduced reporting requirements under the JOBS Act. Subject to certain conditions, as an EGC, we intend
to rely on certain </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>98</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=101,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=450495,FOLIO='98',FILE='DISK109:[18ZBU1.18ZBU44601]DC44601A.;13',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_dc44601_1_99"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>of
these exemptions, including without limitation, (i)&nbsp;providing an auditor's attestation report on our system of internal controls over financial reporting pursuant to Section&nbsp;404(b) of
the Sarbanes-Oxley Act and (ii)&nbsp;complying with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to
the auditor's report providing additional information about the audit and the financial statements, known as the auditor discussion and analysis. We will remain an emerging growth company until the
earlier of (1)&nbsp;December&nbsp;31, 2022, and (2)&nbsp;the last day of the fiscal year (a)&nbsp;in which we have total annual gross revenue of at least $1.07&nbsp;billion, or (b)&nbsp;in
which we are deemed to be a large accelerated filer, which means the market value of our common stock that is held by non-affiliates exceeds $700&nbsp;million as of the prior June&nbsp;30th, and
(3)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in non-convertible debt during the prior three year period. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>99</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=102,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=424392,FOLIO='99',FILE='DISK109:[18ZBU1.18ZBU44601]DC44601A.;13',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_de44601_1_100"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="de44601_business"> </A>
<A NAME="toc_de44601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  BUSINESS    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Overview  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic disorders
that result in severe, life-threatening metabolic disorders. Our lead product candidate is setmelanotide, a potent, first-in-class melanocortin-4 receptor, or MC4R, agonist peptide for the treatment
of rare genetic disorders of obesity. We believe setmelanotide, for which we have exclusive worldwide rights, has the potential to serve as replacement therapy for the treatment of melanocortin-4, or
MC4, pathway deficiencies. MC4 pathway deficiencies result in the disruption of satiety signals and energy homeostasis in the body, which, in turn, leads to intense feelings of hunger and to obesity.
Our development efforts are initially focused on obesity related to six single gene-related, or monogenic, MC4 pathway deficiencies&#151;pro-opiomelanocortin, or POMC, leptin receptor, or LepR,
Bardet-Biedl syndrome, Alstr&ouml;m syndrome, POMC heterozygous, and POMC epigenetic disorders&#151;for which there are currently no effective or approved treatments. We believe that
the MC4 pathway is a compelling target for treating these genetic disorders because of its critical role in regulating appetite and weight by promoting satiety and weight control, and that peptide
therapeutics are uniquely suited for activating this target. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have demonstrated proof of concept in Phase&nbsp;2 clinical trials in POMC deficiency obesity, LepR deficiency obesity, Bardet-Biedl syndrome, and Alstr&ouml;m syndrome,
four genetic disorders of extreme and unrelenting appetite and obesity, in which setmelanotide dramatically reduced both weight and hunger. The U.S. Food and Drug Administration, or the FDA, has
acknowledged the importance of these results by giving setmelanotide Breakthrough Therapy designation for the treatment of obesity associated with genetic defects upstream of the MC4 receptor in the
leptin-melanocortin pathway. The Breakthrough Therapy designation currently covers indications for: POMC deficiency obesity, LepR deficiency obesity, Bardet-Biedl syndrome, and Alstr&ouml;m
syndrome. Setmelanotide is currently in Phase&nbsp;3 development for POMC deficiency obesity and LepR deficiency obesity, and we are initiating a combined Phase&nbsp;3 trial for Bardet-Biedl
syndrome and Alstr&ouml;m syndrome. We are close to completing enrollment in the pivotal cohorts for both our POMC deficiency obesity Phase&nbsp;3 clinical trial and our LepR deficiency
obesity Phase&nbsp;3 clinical trial. We expect to report initial Phase&nbsp;3 data from these trials in the third quarter of 2019, and subsequently plan to file for regulatory approval for these
two indications concurrently. We believe that we have demonstrated proof of concept in our Phase&nbsp;2 clinical trial in Bardet-Biedl syndrome and in Alstr&ouml;m syndrome, and met with
the FDA in May 2018, to discuss a combined pivotal Phase&nbsp;3 clinical trial in these indications. Based on these preliminary discussions with the FDA, we currently plan to initiate this trial and
enroll patients in 2018. We have an ongoing Phase&nbsp;2 clinical trial in POMC heterozygous deficiency obesity and POMC epigenetic disorders, expect to report initial, preliminary results in these
additional Phase&nbsp;2 indications in the second quarter of 2018, and plan to provide a further update for these indications early in 2019. In total, approximately 300 obese subjects and patients
have been treated with setmelanotide in previous and ongoing clinical trials in which setmelanotide demonstrated statistically significant weight loss with good tolerability. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Obesity
is epidemic in the United States and current treatment approaches have demonstrated limited long-term success for most obese patients. We are taking a different approach to
obesity drug development by leveraging new understanding of the genetic causes of severe obesity to develop innovative therapies that we believe have the potential for compelling efficacy.
Setmelanotide's unique mechanism of action at MC4R enables a targeted approach to treating very severe obesity in patients
with specific, monogenic defects in the MC4 signaling pathway. By restoring impaired function in this pathway, setmelanotide can serve as replacement therapy for genetic deficiencies, with the
potential for dramatic improvements in weight and appetite. We believe we are at the forefront of developing a therapeutic option to improve treatment outcomes in subtypes of severe obesity caused by
genetically-defined defects in the MC4 pathway. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>100</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=103,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=496290,FOLIO='100',FILE='DISK109:[18ZBU1.18ZBU44601]DE44601A.;14',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_de44601_1_101"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Setmelanotide
activates MC4R, which is part of the key pathway that can independently regulate energy homeostasis, which refers to the body's energy balance, and appetite. The critical
role of the MC4 pathway in weight regulation was validated with the discovery that single genetic defects along this pathway result in early onset and severe obesity. An expanding set of severe
obesity genetic defects are now identified that involve genes in the pathway which are either upstream of MC4R&#151;for example POMC deficiency obesity and LepR deficiency
obesity&#151;or genes that are downstream of MC4R or affect MC4R itself. We are focusing setmelanotide clinical development on patients with monogenic upstream genetic defects in which obesity
is life-threatening but the downstream MC4 pathway is fully functional. We believe setmelanotide has the potential to restore lost activity in the MC4 pathway by bypassing the defects upstream of
MC4R, and activating the MC4 pathway below such defects. In this way, setmelanotide may serve as replacement therapy to reestablish weight and appetite control in patients with these genetic
disorders. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
first generation of MC4R agonists were predominantly small molecules that failed in clinical trials due to safety issues, particularly increases in blood pressure, in addition to
having limited efficacy. In contrast, setmelanotide, a novel eight amino acid peptide, retains the specificity and functionality of the naturally occurring hormone that activates MC4R, and has
exhibited preliminary evidence of efficacy without adversely affecting blood pressure in our Phase&nbsp;1 and ongoing Phase&nbsp;2 clinical trials. We are currently evaluating setmelanotide, which
is administered by subcutaneous, or SC, injection, for the treatment of six genetic disorders of obesity: POMC deficiency obesity, LepR deficiency obesity, Bardet-Biedl syndrome,
Alstr&ouml;m syndrome, POMC heterozygous deficiency obesity, and POMC epigenetic disorders. We have positive Phase&nbsp;2, proof of concept results for four of these indications thus
far&#151;POMC deficiency obesity, LepR deficiency obesity, both of which are currently in Phase&nbsp;3 development&#151;and Bardet-Biedl syndrome and Alstr&ouml;m syndrome,
for which we currently plan to initiate a combined Phase&nbsp;3 clinical trial, and enroll patients, in 2018. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;POMC
deficiency obesity is a life-threatening, ultra-rare orphan disease, with approximately 50 patients reported to date. Ultra-rare orphan diseases are generally categorized as those
that affect fewer than 20 patients per million. We estimate that our addressable patient population for this disorder is approximately 100 to 500 patients in the United States. Patients with POMC
deficiency have unrelenting hunger, or hyperphagia, that begins in infancy and they develop severe, early onset obesity. POMC deficiency obesity results from two different homozygous genetic defects,
both upstream of MC4R, that result in loss of function in the MC4 pathway. Currently, there is no approved treatment for the obesity and hyperphagia associated with this genetic disorder. We are close
to completing
enrollment of the pivotal cohort in our Phase&nbsp;3 open label, single arm, multinational trial to evaluate the safety and efficacy of setmelanotide for POMC deficiency obesity, with setmelanotide
administered once daily by subcutaneous, or SC, injection for 12&nbsp;months, and we plan to report initial Phase&nbsp;3 data in the third quarter of 2019. Previously, we completed a positive
Phase&nbsp;2 clinical trial in which two patients were enrolled and received treatment. These results were published in the New England Journal of Medicine in July 2016. The first patient in this
trial lost 146.6 lbs. over 118&nbsp;weeks, from a baseline weight of 341.7 lbs., and the second patient lost 89.3 lbs. over 64&nbsp;weeks, from a baseline weight of 336.9 lbs. Both patients
experienced substantial reductions in hunger, with hunger scores falling to one to two from baseline scores of nine to 10. Hunger scores were measured using a Likert score of zero to 10, where zero
represents no hunger and 10 represents extreme hunger. Setmelanotide was generally well tolerated in this Phase&nbsp;2 trial. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;LepR
deficiency obesity is an ultra-rare orphan disease that results in hyperphagia and severe early-onset obesity, with an estimated prevalence of 1% of subjects with severe,
early-onset obesity. We estimate that our addressable patient population for this disorder is approximately 500 to 2,000 patients in the United States. Like other deficiencies upstream in the MC4
pathway, LepR deficiency results in loss of function in the MC4 pathway. Therefore, patients with this indication also manifest hyperphagia and severe obesity from early childhood. Currently, there is
no approved treatment for the obesity and hyperphagia associated with LepR deficiency obesity. We are close to completing enrollment of the pivotal </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>101</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=104,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=181653,FOLIO='101',FILE='DISK109:[18ZBU1.18ZBU44601]DE44601A.;14',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_de44601_1_102"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>cohort
in our Phase&nbsp;3 open label, single arm, multinational trial to evaluate the safety and efficacy of setmelanotide for LepR deficiency obesity, with setmelanotide administered once daily by
SC injection for 12&nbsp;months, and we plan to report initial Phase&nbsp;3 data in the third quarter of 2019. Previously, we completed a positive Phase&nbsp;2 clinical trial in which three
patients were enrolled and received treatment in this trial each experiencing significant weight loss and substantial reductions in hunger. These results were published in Nature Medicine in May 2018.
Setmelanotide was generally well tolerated in this Phase&nbsp;2 trial. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
on our POMC deficiency obesity and LepR deficiency obesity Phase&nbsp;2 results, the FDA granted setmelanotide Breakthrough Therapy designation for the treatment of obesity
associated with genetic defects upstream of the MC4 receptor in the leptin-melanocortin pathway, which includes both POMC deficiency obesity and LepR deficiency obesity, enabling an expedited path to
approval of setmelanotide for these two indications. The FDA has granted orphan drug designation for setmelanotide for the treatment of POMC deficiency obesity and LepR deficiency obesity. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Bardet-Biedl
syndrome is a life-threatening, ultra-rare orphan disease with a prevalence of approximately one in 100,000 in North America. We estimate that our addressable patient
population for Bardet-Biedl syndrome obesity is approximately 1,500 to 2,500 patients in the United States. Bardet-Biedl syndrome is a monogenic disorder that causes severe obesity and hyperphagia as
well as
vision loss, polydactyly, kidney abnormalities, and other signs and symptoms. Currently there are no approved or effective therapies for Bardet-Biedl syndrome. We have demonstrated proof of concept
based on data from five patients in our Phase&nbsp;2 clinical trial in Bardet-Biedl syndrome, indicating that this is also a setmelanotide-responsive, upstream MC4 pathway disorder. Four of these
five patients showed early, but significant weight loss and all five patients showed clear improvements in every hunger assessment. We reported preliminary Phase&nbsp;2 results in the fourth quarter
of 2017, and expect to provide an update on these patients in the second quarter of 2018. Based on these results, the FDA recently included Bardet-Biedl syndrome under our existing Breakthrough
Therapy designation for setmelanotide. Setmelanotide has been generally well tolerated in this trial. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Alstr&ouml;m
syndrome is a life-threatening, ultra-rare orphan disease with a prevalence of approximately one in one million in North America. We estimate that our addressable
patient population for Alstr&ouml;m syndrome is approximately 500 to 1,000 patients worldwide. Alstr&ouml;m syndrome is a monogenic disorder, closely related to Bardet-Biedl
syndrome, that causes childhood obesity and hyperphagia as well as progressive vision loss, deafness, cardiomegaly, insulin resistance and other signs and symptoms. Currently there are no approved or
effective therapies for Alstr&ouml;m syndrome. We have recently demonstrated proof of concept in our Phase&nbsp;2 clinical trial in Alstr&ouml;m syndrome, indicating that this is
also a setmelanotide responsive, upstream MC4 pathway disorder. Based on these results, the FDA recently included Alstr&ouml;m syndrome under our existing Breakthrough Therapy designation
for setmelanotide. Setmelanotide has so far been generally well tolerated in this trial. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
met with the FDA in May 2018 to discuss a combined pivotal Phase&nbsp;3 clinical trial in both Bardet-Biedl syndrome and Alstr&ouml;m syndrome. Based on these preliminary
discussions with the FDA, we currently plan to initiate this trial and enroll patients in 2018. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are also focusing on additional monogenic, upstream MC4 pathway deficiencies for which setmelanotide can function as replacement therapy and provide activation of the pathway
downstream of the defect, promoting satiety and weight control. We have enrolled patients in Phase&nbsp;2 proof of concept trials for POMC epigenetic disorders, and for POMC heterozygous deficiency
obesity, for which we estimate our addressable population is approximately 4,000 patients in the United States. For all of these patients, hyperphagia and obesity can have significant health
consequences for which there is currently no approved treatment. We expect to report initial, preliminary results from these trials by the end of the second quarter of 2018, and plan to provide a
further update for these indications early in 2019. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition to our development of setmelanotide, in April 2018, we announced that we had acquired exclusive, worldwide rights from Takeda Pharmaceutical Company Limited, or Takeda, to
develop and </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>102</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=105,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=94173,FOLIO='102',FILE='DISK109:[18ZBU1.18ZBU44601]DE44601A.;14',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_de44601_1_103"> </A>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>commercialize
T-3525770, now called RM-853. RM-853 is a potent, orally available ghrelin o-acyltransferase, or GOAT, inhibitor currently in preclinical development for Prader-Willi Syndrome, or PWS.
PWS is a rare genetic disorder that results in hyperphagia and early-onset, life-threatening obesity, for which there are no approved therapeutic options. RM-853 is currently in pre-clinical
development. We anticipate filing an Investigational New Drug application, or IND, for RM-853 with the FDA in 2020. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
company was founded in November 2008 by former biopharmaceutical executives who have successfully developed, commercialized and in-licensed innovative pharmaceutical products, and we
have subsequently expanded our senior management team to further broaden our team's experience in developing, registering and commercializing new drugs. In addition, our scientific advisory board, or
SAB, members have extensive clinical expertise in obesity, endocrinology and metabolic diseases. We intend to leverage the experience of our senior management team and SAB to develop and commercialize
setmelanotide. Through our senior management team's network of industry contacts, we will continue to evaluate additional product candidate licensing and acquisition opportunities. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
setmelanotide patent portfolio includes composition of matter patents for setmelanotide that expire in the United States in 2027, with possible patent term extension to 2032 under
the Hatch-Waxman Act. Additional patent coverage may be provided due to pending formulation patent applications, if such pending formulation applications were issued. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Our Strategy  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our goal is to be a leader in developing and commercializing targeted therapies for genetic deficiencies that result in life-threatening
metabolic disorders. The key components of our strategy are: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2><B>Rapidly develop setmelanotide for rare genetic disorders of obesity caused by MC4 pathway
deficiencies.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;We are aiming to dramatically improve patient outcomes in severe obesity by targeting setmelanotide's mechanism of action to the
treatment of patients with genetically-defined defects in the MC4 pathway. We are focusing setmelanotide clinical development on monogenic upstream genetic defects in which obesity is life-threatening
but where the downstream MC4 pathway is fully functional. We believe that focusing on these rare life-threatening conditions enables us to rapidly develop and commercialize setmelanotide using
relatively small clinical trials.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2><B>Advance setmelanotide for POMC deficiency obesity and LepR deficiency obesity as our first indications in
upstream MC4 pathway deficiencies.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;We are currently evaluating setmelanotide for the treatment of six genetic disorders of obesity: POMC
deficiency obesity, LepR deficiency obesity, Bardet-Biedl syndrome, Alstr&ouml;m syndrome, POMC heterozygous deficiency obesity, and POMC epigenetic disorders. We are close to completing
enrollment of the pivotal cohorts in our Phase&nbsp;3 trials in POMC deficiency obesity and LepR deficiency obesity, and plan to report initial data from these trials in the third quarter of 2019.
We are working with the FDA, based on our Breakthrough Therapy designation, to prepare concurrent New Drug Application, or NDA, filings for these two indications as part of an expedited path to
approval for POMC deficiency obesity and LepR deficiency obesity.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2><B>Advance setmelanotide for Bardet-Biedl syndrome and Alstr&ouml;m syndrome as our second set of
indications in upstream MC4 pathway deficiencies.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;We have demonstrated proof of concept in Bardet-Biedl syndrome and Alstr&ouml;m
syndrome, indicating that these are also setmelanotide responsive, upstream MC4 pathway disorders. Based on these results, the FDA recently included these disorders under our existing Breakthrough
Therapy designation for setmelanotide. In May 2018, we met with the FDA to discuss a combined pivotal Phase&nbsp;3 clinical trial in both Bardet-Biedl syndrome and Alstr&ouml;m syndrome.
Based on these preliminary discussions with the FDA, we currently plan to initiate this trial and enroll patients in 2018. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>103</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=106,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=245374,FOLIO='103',FILE='DISK109:[18ZBU1.18ZBU44601]DE44601A.;14',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_de44601_1_104"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2><B>Expand setmelanotide development to additional upstream MC4 pathway deficiencies, including POMC
heterozygous deficiency obesity and POMC epigenetic disorders.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;We believe we can leverage our experience with and mechanistic understanding of
the MC4 pathway to advance development of setmelanotide for other upstream MC4 pathway deficiencies. We have an ongoing Phase&nbsp;2 clinical trial that includes patients with these rare genetic
disorders, and expect to report initial, preliminary results in these indications in the second quarter of 2018. We continue to investigate other potential indications that may result from MC4 pathway
deficiencies, in which we may study treatment with setmelanotide in the future.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2><B>Commercialize setmelanotide for rare disease indications in core strategic
markets.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;We intend to establish our own commercial sales and marketing organization in the United States and other core strategic markets. We
expect this sales organization will target physicians treating these rare genetic disorders of obesity, including pediatric and adult endocrinologists. We believe that building our own commercial
operations will deliver a greater return on our product investment than if we license the rights to commercialize these products to third parties. We may also selectively establish partnerships in
markets outside the United States for sales, marketing, and distribution.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2><B>Leverage the broad experience of our team in clinical and commercial drug development, and product
acquisitions.</B></FONT><FONT SIZE=2>&nbsp;&nbsp;We will apply our team's extensive experience in developing and commercializing innovative medicines to the development and launch
of setmelanotide. We will apply similar expertise to advance our second product candidate, RM-853, from pre-clinical to clinical development. In addition, we intend to identify and acquire new
pipeline product candidates in related diseases. Our team is complemented by highly experienced external consultants and collaborators in the areas of drug discovery, development, manufacturing and
regulatory approval. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>104</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=107,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=152097,FOLIO='104',FILE='DISK109:[18ZBU1.18ZBU44601]DE44601A.;14',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_de44601_1_105"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Our Product Pipeline  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following chart depicts key information regarding the development of setmelanotide, including the indications we are pursuing within MC4
pathway deficiencies, the current state of development and our expected upcoming milestones: </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g473593.jpg" ALT="GRAPHIC" WIDTH="684" HEIGHT="418">
  </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Market Overview  </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Recent Advances in the Understanding of Obesity  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diet and lifestyle modifications remain the cornerstones of weight loss therapy, but they are limited by a lack of long-term success for most
obese patients. The long-term efficacy of these interventions and for existing drug therapies is often limited by the counter-regulatory mechanisms of the human body. For example, with diet induced
weight loss, typically there is a large decrease in energy expenditure that offsets that weight loss. Accordingly, the discovery that the MC4 pathway can regulate both appetite and energy homeostasis
separately&#151;helping maintain the balance between food intake and energy burn&#151;has defined an important target for therapeutics. In addition to POMC deficiency obesity and LepR
deficiency obesity, recent advances in genetic studies have identified several diseases that are the result of genetic defects affecting the MC4 pathway, including Bardet-Biedl syndrome,
Alstr&ouml;m syndrome, POMC heterozygous deficiency obesity, and POMC epigenetic disorders. With a deeper understanding of this critical signaling pathway, we are taking a different approach
to drug development by focusing on specific genetic deficiencies affecting the MC4 pathway. We believe that this approach has the potential to provide dramatic improvements in weight and appetite by
restoring lost function in the MC4 pathway. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Obesity Caused by Rare Genetic Deficiencies Affecting the MC4 Pathway  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The MC4 pathway serves a critical role in the control of food intake and energy balance. Its activity decreases appetite and caloric intake, and
increases energy expenditure, with MC4R acting as the final step in the signaling pathway. This important hypothalamic, or lower brainstem, pathway has been the focus of </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>105</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=108,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=473016,FOLIO='105',FILE='DISK109:[18ZBU1.18ZBU44601]DE44601A.;14',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_de44601_1_106"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>extensive
investigation for many years, and we have a deep understanding of this mechanism, which is unlike the targets of most other anti-obesity therapies. As a result, we believe we can better
predict the efficacy and safety profile expected from modulating this target. The critical role of the MC4 pathway in weight regulation was also validated with the discovery that single genetic
defects at many points in this pathway result in early onset, severe obesity. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
MC4 pathway is illustrated in the figure below, from the activation of the pathway to the resulting decrease in appetite and weight. Under normal conditions, POMC neurons are
activated by brain satiety signals, including those resulting from the hormone leptin acting through LepR. POMC neurons produce a protein, which is specifically processed by the proprotein convertase
subtilisin/kexin 1, or PCSK, enzyme, into melanocyte stimulating hormone, or MSH, the natural ligand, or activator, for MC4R. When genetic mutations disrupt this pathway, the result is hyperphagia and
severe obesity. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are focused on developing setmelanotide for genetic disorders that result in defects in this pathway that are upstream of MC4R. Setmelanotide has the potential to restore lost
function in this pathway by activating the intact MC4 pathway below the genetic defect. In this way, we believe setmelanotide acts as replacement therapy. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
figure below also illustrates some of the upstream MC4 pathway deficiencies that are the targets of our development activities. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="de44601_setmelanotide_development_targ__set03270"> </A>
<A NAME="toc_de44601_2"> </A>
<BR></FONT><FONT SIZE=2><B>  Setmelanotide Development Targets: Upstream Deficiencies Affecting the MC4 Pathway    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g419997.jpg" ALT="GRAPHIC" WIDTH="681" HEIGHT="381">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>106</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=109,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=893436,FOLIO='106',FILE='DISK109:[18ZBU1.18ZBU44601]DE44601A.;14',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_de44601_1_107"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Epidemiology of Rare Genetic Disorders of the MC4 Pathway  </I></B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


<U>Clinical Epidemiology</U> </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
figure below summarizes the indications on which we are focusing for the development of setmelanotide, including our clinical epidemiology estimates for the
addressable patient populations within these indications. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g250777.jpg" ALT="GRAPHIC" WIDTH="654" HEIGHT="397">
  </B></FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" >


<DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>*</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>The patient numbers above are based on Company estimates from clinical publications.  </FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>&#134;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Epidemiological
estimates are not yet available for POMC epigenetic disorders. </FONT></DD></DL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We believe that the patient populations in the European Union are at least as large as those in the United States. However, we do not have
comparable epidemiological data from the European Union and these estimates are therefore based solely on applying relative population percentages to the Company-derived estimates described above. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


<U>Genetic Epidemiology Studies</U> </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have estimated the patient populations for our rare genetic disorders of obesity primarily by identifying patients or by estimating from clinical epidemiology
information. Another method to estimate the size of these ultra-rare populations is by genetic epidemiology using newly available large genomic databases of either full genome or exome sequences. We
have begun some substantial efforts, both directly and with collaborators, with a series of such databases. Much of our preliminary work has utilized a database of approximately 140,000 genomes,
representative of the U.S. population. The results of this analysis were published in May 2018 in the Journal of Clinical Endocrinology and Metabolism, a leading journal in this field, which we
believe validates the scientific and epidemiological importance of our findings. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
results from this effort have been supportive of our clinical epidemiological estimates, even when using conservative genetic epidemiology assumptions. The results support estimates
of the number of patients in the United States who are homozygous deficient in the POMC gene, which is one of the two </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>107</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=110,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=64322,FOLIO='107',FILE='DISK109:[18ZBU1.18ZBU44601]DE44601A.;14',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_de44601_1_108"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>genetic
defects causing POMC deficiency obesity, and who are homozygous deficient in the LepR gene, are at least as large, or larger than, our clinical epidemiology assumptions, as provided above. In
addition, the estimates of patients who are homozygous deficient in the PCSK1 gene, which is the other genetic defect causing POMC deficiency obesity, may be substantially larger than our clinical
epidemiology assumptions. Overall, our clinical epidemiology based estimates for POMC deficiency obesity (up to 500 U.S. patients including both POMC and PCSK1 gene disorders) and LepR deficiency
obesity (up to 2,000 U.S. patients) support up to 2,500 U.S. patients combined. Our preliminary genetic epidemiology estimates suggest a total of approximately 13,000 U.S. patients with these
disorders, representing a 5-fold increase in our clinical epidemiology based estimates. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have already begun to expand our genetic epidemiology analysis into other genomic databases that contain patients with different demographics, and are actively working with a series
of academic and industry collaborators. Our published data support that while individual mutations may cluster in specific demographic groups, these rare genetic disorders are seen widely across the
demographic spectrum. The ongoing expansion of genomic data available in other forums also has the effect of supporting this effort. An important improvement in this effort will be working with data
linked to phenotypic information to better characterize the genetic information we are analyzing. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe the separate analyses that we have completed using clinical epidemiology and genetic epidemiology provide a robust range of patient population estimates for these rare
disorders. However, to be conservative, we reference the clinical epidemiology figures in our descriptions of our target indications. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Obesity Caused by Upstream Genetic Deficiencies Affecting the MC4 Pathway  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have completed four positive Phase&nbsp;2 trials of setmelanotide that provide proof of concept for four upstream MC4 pathway genetic
defects in which obesity is life-threatening but the downstream MC4 pathway is fully functional. For POMC deficiency obesity, LepR deficiency obesity, and Bardet-Biedl syndrome, we estimate an
aggregate addressable population of up to 5,000 people in the United States. In addition, we estimate that Alstr&ouml;m syndrome has an addressable patient population of up to 1,000 people
worldwide. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


POMC Deficiency Obesity  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;POMC deficiency obesity is an ultra-rare genetic disorder, with severe, early onset obesity, defined here as a body mass index, or BMI, of
greater than 40 kg/m<SUP>2</SUP>, and hyperphagia as hallmark clinical features. Patients with POMC deficiency obesity are extremely rare. There are approximately 50 patients with POMC deficiency
obesity noted in a series of published case reports, each mostly reporting a single or small number of patients. However, we estimate that our addressable patient population for this disorder is
approximately 100 to 500 patients in the United States, as most of the reported cases are from a small number of academic research centers, and because genetic testing for POMC deficiency is often
unavailable and rarely performed. However, our genetic epidemiological estimates are several times higher. Most patients are not currently diagnosed and based on discussions with experts in rare
diseases, we believe the number of diagnosed cases will markedly increase with increased awareness of this disorder and the availability of new treatments. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;POMC
deficiency obesity is caused by the loss of both genetic copies of either the gene for POMC or the gene for PCSK. This results either in loss of POMC neuropeptide synthesis, in the
case of homozygous deficiency in the POMC gene, or in disruption of the required processing of the POMC neuropeptide product to MSH by the PCSK enzyme, in the case of homozygous deficiency in the PCSK
gene. The end result of both of these two homozygous genetic defects is lack of MSH to bind and activate MC4R, ultimately leading to the lack of stimulation of downstream MC4 neurons and causing
severe, early onset obesity and hyperphagia. POMC homozygous deficiency may also be associated with hormonal deficiencies, such as hypoadrenalism, as well as red hair and fair skin. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>108</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=111,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=463744,FOLIO='108',FILE='DISK109:[18ZBU1.18ZBU44601]DE44601A.;14',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_dg44601_1_109"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;POMC deficiency is characterized by voracious infant feeding, rapid weight gain and severe obesity, often in early infancy, with patients demonstrating remarkable
weight increases many standard deviations from the normal weight growth curves. These patients and their caregivers have attempted to stabilize body weight with the help of psychologists,
nutritionists and pediatric endocrinologists, all without significant success. We are close to completing enrollment in the pivotal cohorts for our POMC deficiency obesity Phase&nbsp;3 clinical
trial, and expect to report initial Phase&nbsp;3 data in the third quarter of 2019. Currently there are no approved or effective therapies for POMC deficiency obesity. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Leptin Receptor Deficiency Obesity  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;LepR deficiency obesity is an ultra-rare genetic disorder that causes hyperphagia and severe, early onset obesity. LepR deficiency accounts for
an estimated 1% of cases of severe, early onset obesity. Based on clinical epidemiology studies in small cohorts of patients with severe, early onset obesity, we estimate that our addressable patient
population for this disorder is approximately 500 to 2,000 patients in the United States, though our genetic epidemiological estimates suggest the number may be moderately higher. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Leptin's
role in obesity has been elucidated by characterization of severely obese people with homozygous mutations that impair the activity of leptin, including disruption of signaling
at the LepR, known as LepR deficiency obesity. Under normal conditions, leptin can activate POMC neurons and the downstream MC4, but like other deficiencies upstream in the MC4 pathway, lack of
signaling at LepR results in loss of function in the MC4 pathway. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Like
POMC deficiency obesity, patients with LepR deficiency obesity exhibit hyperphagia and severe obesity from early childhood. LepR deficiency is also associated with hypogonadism and
reduced immune function. We have completed enrollment of the pivotal cohort for our LepR deficiency obesity Phase&nbsp;3 clinical trial, and expect to report initial Phase&nbsp;3 data in the third
quarter of 2019. It is our intention, pending discussions with the FDA, to file our NDA for LepR deficiency obesity concurrently with our NDA for POMC deficiency obesity, as enrollment of our pivotal
cohort completed almost simultaneously. Currently there are no approved or effective therapies for LepR deficiency obesity. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Bardet-Biedl Syndrome  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Bardet-Biedl syndrome is a life-threatening, ultra-rare orphan disease with a prevalence of approximately one in 100,000 in North America. We
estimate that our addressable patient population for Bardet-Biedl syndrome obesity is approximately 1,500 to 2,500 patients in the United States. Bardet-Biedl syndrome is a monogenic disorder that
causes severe obesity and hyperphagia as well as vision loss, polydactyly, kidney abnormalities, and other signs and symptoms. For Bardet-Biedl syndrome patients, hyperphagia and obesity can have
significant health consequences. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Bardet-Biedl
syndrome is part of a class of disorders called ciliopathies, or disorders associated with the impairment of cilia function in cells. Cilia are hair-like cellular
projections that play a fundamental role in the regulation of several biological processes, including satiety signaling. Cilia dysfunction is thought to contribute to hyperphagia and obesity in
Bardet-Biedl syndrome. Bardet-Biedl syndrome is a
genetically heterogeneous disease that is caused by as many as 21 separate Bardet-Biedl loci defects that result in a similar syndrome, though each Bardet-Biedl syndrome patient only has one of these
defects. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Recent
scientific studies identify deficiencies affecting the MC4 pathway as a potential cause of the obesity and hyperphagia associated with Bardet-Biedl syndrome and demonstrate that
an MC4R agonist can directly impact these symptoms. Studies in mouse models of Bardet-Biedl syndrome show that deficiencies in the MC4 pathway contribute to the obesity and hyperphagia in Bardet-Biedl
syndrome, with animals developing hyperphagic tendencies as early as 10&nbsp;weeks of age. Notably, these mice have decreased leptin receptor signaling, with the essential hallmarks of failure to
activate POMC neurons. The potential utility of MC4 agonists is also supported by studies in Bardet-Biedl syndrome rodent models, </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>109</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=112,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=666756,FOLIO='109',FILE='DISK109:[18ZBU1.18ZBU44601]DG44601A.;22',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_dg44601_1_110"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>where
mice have responded to an MC4 agonist resulting in reduced food intake and body weight. We have demonstrated proof of concept in Bardet-Biedl syndrome indicating that this is also a
setmelanotide-responsive, upstream MC4 pathway disorder. We reported preliminary Phase&nbsp;2 results for Bardet-Biedl syndrome in the fourth quarter of 2017 and updated the clinical status of these
patients in the second quarter of 2018. We have had discussions with the FDA on Phase&nbsp;3 design and we are in the process of submitting a draft Phase&nbsp;3 protocol for FDA review. The FDA
has preliminarily indicated that this Phase 3 trial will include both Bardet-Biedl syndrome and Alstr&ouml;m syndrome patients. We expect to enroll patients in this Phase&nbsp;3 trial
before the end of 2018. Currently there are no approved or effective therapies for Bardet-Biedl syndrome. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Alstr&ouml;m Syndrome  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Alstr&ouml;m syndrome is a life-threatening, ultra-rare orphan disease with a prevalence of approximately one in 1,000,000 in
North&nbsp;America. We estimate that our addressable patient population for Alstr&ouml;m syndrome is approximately 500 to 1,000 patients worldwide. Alstr&ouml;m syndrome is a
monogenic disorder that causes childhood obesity and hyperphagia as well as progressive vision loss, deafness, cardiomegaly, insulin resistance and other signs and symptoms. Variable features include
short stature, cardiomyopathy, and progressive lung, liver, and kidney dysfunction. Symptoms of Alstr&ouml;m syndrome first appear in infancy, and progressive development of multi-organ
pathology leads to a reduced life expectancy, with survival rare beyond the age of 50. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Alstr&ouml;m
syndrome is a ciliopathy caused by mutations in the ALMS1 gene, which has been shown to be important for cilia function. Like Bardet-Biedl syndrome, recent
scientific studies identify genetic deficiencies affecting the MC4 signaling pathway as a potential cause of the obesity and hyperphagia associated with Alstr&ouml;m syndrome. Studies in a
mouse model of Alstr&ouml;m syndrome show a reduction in the number of cilia in specific neurons in the hypothalamus that are critical for MC4 pathway signaling. While Alstr&ouml;m
syndrome is less well studied than Bardet-Biedl syndrome, the similar pathophysiology of cilial dysfunction and clinical presentation support that deficiencies in the MC4 pathway are implicated in the
obesity and hyperphagia observed in Alstr&ouml;m syndrome. We believe we have demonstrated proof of concept in our Phase&nbsp;2 clinical trial in Alstr&ouml;m syndrome and met
with the FDA in May 2018 to discuss a combined pivotal Phase&nbsp;3 clinical trial in both Bardet-Biedl syndrome and Alstr&ouml;m syndrome. Based on these preliminary discussions with the
FDA, we currently plan to initiate this trial and enroll patients in 2018. Currently there are no approved or effective therapies for Alstr&ouml;m syndrome. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Other Upstream Genetic Defects in the MC4 Pathway  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition to POMC deficiency obesity, LepR deficiency obesity, Bardet-Biedl syndrome, and Alstr&ouml;m syndrome, there are other
upstream, MC4 pathway deficiencies for which we believe setmelanotide may function as replacement therapy, including defects that partially modulate POMC activity, such as POMC heterozygous deficiency
obesity and POMC epigenetic disorders. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


POMC Heterozygous Deficiency Obesity  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;POMC heterozygous deficiency results in a strong predisposition to obesity, though the epidemiology and clinical characterization of these
patients is less well known. POMC heterozygous deficiency obesity is caused by the loss of one of the two genetic copies of either the gene for POMC or the gene for PCSK. An estimated 2% of severe,
early onset obesity patients have POMC heterozygous deficiency obesity, which is much more common than the ultra-rare POMC deficiency obesity in which both copies of either the POMC or PCSK genes are
impaired. We believe that the most severe POMC heterozygous deficiency obesity patients may be suitable for treatment with setmelanotide. We estimate that our addressable patient population within
severe POMC heterozygous deficiency obesity is approximately 4,000 patients in the United&nbsp;States, based on epidemiology studies in small cohorts of patients with severe early onset obesity and
adult obesity. Animal models support that such heterozygous deficiency in the critical </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>110</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=113,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=582626,FOLIO='110',FILE='DISK109:[18ZBU1.18ZBU44601]DG44601A.;22',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_dg44601_1_111"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>MC4&nbsp;pathway
can result in a strong predisposition to severe obesity. The effect of heterozygous deficiency was first demonstrated in MC4R heterozygous deficiency obesity. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;It
is thought that the obesity of patients with POMC heterozygous deficiency may have a broader spectrum of severity than POMC deficiency obesity. Therefore, our focus will be on the
most severe of the POMC heterozygous deficiency obesity patients, with our estimate that only a small percentage of these patients will benefit from targeted therapy with substantial efficacy. As a
result, we have initiated a Phase&nbsp;2 proof of concept trial to confirm our hypothesis that the subset of patients with very severe POMC heterozygous deficiency obesity may be highly responsive
to setmelanotide therapy. We have an ongoing Phase&nbsp;2 clinical trial in POMC heterozygous deficiency obesity and expect to report initial, preliminary results in the second quarter of 2018.
There are currently no approved or effective therapies for POMC heterozygous deficiency obesity. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


POMC Epigenetic Disorders  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Recent scientific studies have identified patients with obesity due to a partial lack of MSH that is caused by epigenetic POMC variant. Given
the recent discovery of these epigenetic disorders, there is currently no epidemiology data that defines the prevalence of POMC epigenetic disorders. However, we believe that these are rare disorders.
Epigenetics implies DNA modifications, which can change gene expression without altering the DNA sequence itself. The most stable epigenetic modification is called DNA methylation. Recently, our
academic collaborators in Berlin have described a POMC hypermethylation variant, which correlates with increased body weight in children and adults. Therefore, the presence of the POMC epigenetic
variant leads to an increased risk of obesity based on reduced POMC gene activity. We expect that these patients under-express the POMC gene product and as a result have a partial MSH deficiency. We
have initiated a Phase&nbsp;2 proof of concept trial to confirm our hypothesis that the subset of patients with very severe POMC epigenetic disorders may be highly responsive to setmelanotide
therapy. We have an ongoing Phase&nbsp;2 clinical trial in POMC epigenetic disorders and expect to report initial, preliminary results in the second quarter of 2018, and plan to provide a further
update for these indications early in 2019. There are currently no approved or effective therapies for these disorders. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Obesity Caused by Downstream Genetic Deficiencies Affecting the MC4 Pathway  </I></B></FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


MC4 Heterozygous Deficiency Obesity  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;MC4 heterozygous deficiency is caused by the absence or loss of function of one genetic copy of the gene for MC4R. Consistent with POMC
heterozygous deficiency, MC4 heterozygous deficiency results in a strong predisposition to early onset and severe obesity. MC4 heterozygous deficiency is the most common genetic cause of obesity. An
epidemiological study performed in Europe in 2006 reported a prevalence of 2.6% of genetic defects in the MC4 gene in the obese population with a BMI of greater than 30 kg/m<SUP>2</SUP>, and
studies performed in both Europe and the United&nbsp;States in 2000 and 2003, respectively, reported a prevalence of up to 4% of these genetic defects in more severely obese populations with a BMI
of greater than 35 kg/m<SUP>2</SUP>. These prevalence rates suggest that there are approximately one million people in the United&nbsp;States with obesity caused by a mutation of the MC4R gene. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;These
patients have a higher risk than the general population for early onset obesity and complications such as diabetes. Furthermore, MC4 deficiency may offset the beneficial effects of
diet and exercise for sustained weight loss, limiting treatment options for these individuals. There are currently no approved or effective therapies for MC4 heterozygous deficiency obesity. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;While
setmelanotide appears to show strong efficacy in a Phase&nbsp;1b trial for the treatment of MC4&nbsp;heterozygous deficiency obesity patients, we are currently focusing instead
on genetic defects that are upstream of the MC4 receptor. This is because we believe that many of these upstream genetic disorders cause even more severe, often life-threatening obesity, and because
setmelanotide has the potential to restore lost function in these upstream disorders, delivering more compelling efficacy. We have conducted </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>111</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=114,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=446332,FOLIO='111',FILE='DISK109:[18ZBU1.18ZBU44601]DG44601A.;22',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_dg44601_1_112"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>additional
research that was published in Nature Medicine in May 2018, which suggests that a sizable number of individuals with obesity who carry MC4R mutations, and were previously assessed
functionally normal, may respond to setmelanotide treatment. This may open the possibility of new indications for setmelanotide in the future. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Expanding Attention to the Diagnosis of Genetic Obesity  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Endocrine Society issued new Pediatric Obesity Guidelines in January 2017 that, for the first time, recommend genotyping patients with
severe pediatric obesity and hyperphagia. These guidelines estimate that up to 7% of patients with extreme pediatric obesity have a genetic mutation, including genetic MC4 pathway deficiencies, that
drives their obesity. The guidelines also suggest that this percentage of severe pediatric obesity patients will increase, with newer methods and wider awareness of the need for genetic testing. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are supporting several initiatives to expand the diagnosis of genetic obesity, including The Genetic Obesity Project. The Genetic Obesity Project has initiated a genotyping study,
called GO-ID, and a patient registry, called TEMPO, both focusing initially on identifying people with POMC deficiency obesity and LepR deficiency obesity and which we intend to expand to include
other MC4 pathway deficiencies. We will be expanding our panel of obesity-related genes used in our GO-ID study in the second half of 2018. The preliminary results, in 560 patients, from the GO-ID
study suggest that patients with these disorders can be successfully identified. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are also conducting genetic obesity epidemiology analysis of MC4 pathway genetic defects in a large representative sample of the U.S. population, and we expect to expand the genetic
databases in our research efforts on an ongoing basis. The first results of this research were published in May 2018 in the Journal of Clinical Endocrinology and Metabolism, a leading journal in this
field. An important improvement in this effort will be working with data linked to phenotypic information to better characterize the genetic information we are analyzing. In addition, we tested
associations between BMI and loss of function mutation burden in various populations to further define the MC4 pathway and its potential impact on obesity, showing that the cumulative allele burden,
or number of mutations along the MC4 pathway in a single individual, predisposes to more obesity. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Limitations of Current Therapies  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Although drugs approved for general obesity can potentially be used in obese patients with MC4&nbsp;pathway deficiencies, all have limited
efficacy and aim to treat symptoms rather than addressing the underlying biology. There are currently no treatments approved specifically for obesity and hyperphagia in POMC deficiency obesity, LepR
deficiency obesity, Bardet-Biedl syndrome, Alstr&ouml;m
syndrome, POMC heterozygous deficiency obesity, or POMC epigenetic disorders. Bariatric surgery is not an option in patients with upstream defects in the MC4 pathway who have severe obesity and
hyperphagia. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Setmelanotide: A First-in-Class MC4R Agonist in Two Phase&nbsp;3 Programs  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Setmelanotide is a potent, first-in-class, MC4R agonist peptide administered by daily SC injection. Setmelanotide is in Phase&nbsp;3 for the
treatment of two rare genetic disorders of obesity caused by MC4&nbsp;pathway deficiencies, and we are initiating a combined Phase&nbsp;3 clinical trial in two additional rare genetic disorders.
We also have an ongoing Phase&nbsp;2 clinical trial in two other MC4 pathway disorders. MC4R&nbsp;modulates a key pathway in humans that regulates energy homeostasis and food intake. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
critical role of the MC4 pathway in weight regulation was validated with the discovery that single genetic defects in this pathway result in severe, early onset obesity. The first
generation MC4R agonists were small molecules that failed in clinical trials primarily due to safety issues, particularly increases in blood pressure, as well as limited efficacy. In contrast,
setmelanotide is a peptide that retains the specificity and functionality of the naturally occurring hormone that activates MC4R. In total, approximately </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>112</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=115,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=426241,FOLIO='112',FILE='DISK109:[18ZBU1.18ZBU44601]DG44601A.;22',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_dg44601_1_113"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>300&nbsp;obese
subjects and patients have been treated with setmelanotide in previous and ongoing clinical trials in which setmelanotide demonstrated significant weight loss with good tolerability. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Clinical Development in Rare Genetic Disorders of Obesity Caused by MC4 Pathway Deficiencies  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Setmelanotide is currently in Phase&nbsp;3 development for POMC deficiency obesity and LepR deficiency obesity, and we are initiating a
combined Phase&nbsp;3 trial for Bardet-Biedl syndrome and Alstr&ouml;m syndrome. We are close to completing enrollment in the pivotal cohorts for both our POMC deficiency obesity
Phase&nbsp;3 clinical trial and our LepR deficiency obesity Phase&nbsp;3 clinical trial. We expect to report initial Phase&nbsp;3 data from these trials in the third quarter of 2019, and
subsequently plan
to file for regulatory approval for these two indications concurrently. We believe that we have demonstrated proof of concept in our Phase&nbsp;2 clinical trial in Bardet-Biedl syndrome and in
Alstr&ouml;m syndrome, and met with the FDA in May 2018 to discuss a combined pivotal Phase&nbsp;3 clinical trial in both Bardet-Biedl syndrome and Alstr&ouml;m syndrome. Based
on these preliminary discussions with the FDA, we currently plan to initiate this trial and enroll patients in 2018. We continue to study setmelanotide in these indications in Phase&nbsp;2
development in long-term extensions. We are also enrolling patients for the treatment of other rare monogenic disorders of obesity, including POMC and other heterozygous deficiency obesity, and POMC
epigenetic disorders. We hypothesize that all of these disorders are genetically defined deficiencies upstream in the MC4 pathway. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are enrolling patients in two very similar Phase&nbsp;2 clinical trials, each of which is designed to capture a broad range of indications under one investigational protocol, or a
basket study. We believe that we have demonstrated proof of concept both in Bardet-Biedl syndrome and in Alstr&ouml;m syndrome, indicating that these closely related syndromes are also
setmelanotide-responsive, upstream MC4 pathway disorders. We expect to report initial, preliminary results for POMC heterozygous deficiency obesity and POMC epigenetic patients in the second quarter
of 2018, and plan to provide a further update for these indications early in 2019. We have also completed a Phase&nbsp;2 trial in PWS. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
on FDA consultations to date, and the FDA granting Breakthrough Therapy designation for POMC deficiency obesity and LepR deficiency obesity, and including Bardet-Biedl syndrome and
Alstr&ouml;m syndrome under the existing Breakthrough Therapy designation for setmelanotide, we believe we can seek indications for obesity caused by upstream defects in the MC4 pathway with
rapid paths to approval, as compared to typical obesity drug candidates, because of the high unmet need and rare prevalence of these disorders. We expect to use the results of our Phase&nbsp;3
clinical trials of setmelanotide in POMC deficiency obesity and LepR deficiency obesity, which will run concurrently, as the foundation for proceeding directly to approval for these indications. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe our data in POMC deficiency obesity, LepR deficiency obesity, Bardet-Biedl syndrome, and Alstr&ouml;m syndrome provide strong proof of concept that setmelanotide,
when targeted for deficiencies affecting the upstream portion of the MC4 pathway, can provide compelling efficacy for weight loss and decrease in hunger. Proof of concept for substantial weight loss
in patients with downstream, heterozygous mutations of the MC4R gene itself has also been achieved in a small, four-week, Phase&nbsp;1b clinical trial. While these downstream defects are not our
current area of focus, based on new scientific research, we believe there is evidence supporting the potential for substantial weight loss efficacy in a setting of a partially defective, downstream
defect in the MC4 pathway, which impacts a significantly larger population. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Initial
setmelanotide clinical trials were in patients with general obesity, which provided preliminary evidence of the safety and efficacy of the drug, and were the foundation for the
Phase&nbsp;2 trials in rare genetic disorders of obesity. In these trials, setmelanotide has generally achieved weight loss without adversely increasing blood pressure. These trials in the general
obese population are described below. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>113</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=116,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=840909,FOLIO='113',FILE='DISK109:[18ZBU1.18ZBU44601]DG44601A.;22',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_dg44601_1_114"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table outlines our ongoing and planned setmelanotide trials in rare monogenic disorders of obesity. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Setmelanotide: Key Clinical Programs in Monogenic MC4 Pathway Disorders of Defined Obesity  </I></B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="18%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="18%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="18%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="18%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="18%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>POMC Deficiency<BR>
Pivotal </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>LepR Deficiency Pivotal </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>POMC/LepR Deficiency<BR>
Proof of Concept </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Other Populations Proof<BR>
of Concept Basket<BR>
Protocols<SUP>(6)</SUP> </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=1><B>Clinical trial phase</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Phase&nbsp;3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Phase&nbsp;3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Phase&nbsp;2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Phase&nbsp;2</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=1><B>Status</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Enrollment completing 2Q2018</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Enrollment completing 2Q2018</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Initiated 2014, Completed 4Q 2016 for these indications<SUP>(5)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Initiated 2016<SUP>(7)(8)</SUP></FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=1><B>Treatment groups<SUP>(1)</SUP></B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Setmelanotide<SUP>(2)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Setmelanotide<SUP>(2)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Setmelanotide</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Setmelanotide</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=1><B>Number of patients</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>10<SUP>(3)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>10<SUP>(3)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>2 POMC, 3 LepR</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>20-100<SUP>(9)</SUP></FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=1><B>Patient demographics</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Adult/pediatric POMC deficient<SUP>(4)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Adult/pediatric LepR deficient<SUP>(4)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Adults/Adolescents</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Adult/pediatric<SUP>(4)</SUP><BR>
Multiple indications: Bardet-Biedl syndrome; Alstr&ouml;m syndrome; POMC heterozygous deficiency obesity; POMC epigenetic disorders, and others</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=1><B>Duration of treatment</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>52&nbsp;weeks&nbsp;+&nbsp;Extensions</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>52&nbsp;weeks&nbsp;+&nbsp;Extensions</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>12&nbsp;weeks&nbsp;+&nbsp;Extensions</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>12&nbsp;weeks&nbsp;+&nbsp;Extensions</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=1><B>Location</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>United&nbsp;States, Germany, Canada, United&nbsp;Kingdom, France, Belgium</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>United&nbsp;States, Germany, United&nbsp;Kingdom, France<SUP>(10)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Germany</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>United&nbsp;States, Germany, United&nbsp;Kingdom, France</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;<BR></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="19%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="19%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="19%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="106pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="19%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Extension to ongoing<BR>
Protocols </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>TEMPO Registry Study </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>BBS/Alstr&ouml;m Syndrome<BR>
Pivotal<SUP>(16)</SUP> </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Natural History Study </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=1><B>Clinical trial phase</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Extension</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Prospective Registry cohort</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Phase&nbsp;3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Natural History observational cohort</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=1><B>Status</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Initiating 2H2018</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Initiating 2H2018</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Initiating, first patients to be enrolled in 2018</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Initiated 4Q2017</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=1><B>Treatment groups<SUP>(1)</SUP></B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Setmelanotide<SUP>(11)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>No treatment<SUP>(14)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Setmelanotide<SUP>(17)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>No treatment<SUP>(14)</SUP></FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=1><B>Number of patients</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Up to 100 patients<SUP>(12)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Up to 1000 patients</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>At least 20 BBS<BR>
At least 6 Alstr&ouml;m's</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>10-20</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=1><B>Patient demographics</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Any patient completing another setmelanotide clinical protocol<SUP>(13)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Various<SUP>(15)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Adult/Pediatric</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Adult/pediatric<SUP>(19)</SUP><BR>
Patients with POMC or LepR deficiency obesity</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=1><B>Duration of treatment</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Multi-year Extensions</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Open ended</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>52&nbsp;weeks&nbsp;+&nbsp;Extensions<SUP>(18)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Up to 5&nbsp;years</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=1><B>Location</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Initiating in multiple countries</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>Initiating in multiple countries</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>To be determined</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>To be determined</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:0%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Setmelanotide,
administered as once daily SC injection, except for TEMPO Registry study and Natural History study.  </FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(2)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>These
trials include a placebo controlled, double-blind withdrawal period.  </FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(3)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Approximately
10 POMC deficiency obesity and 10 LepR deficiency obesity patients will be included in the pivotal cohort for each trial, but in agreement with the
FDA, additional patients can be recruited who will not have reached one year of treatment at the time of NDA.  </FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(4)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>POMC
deficiency includes homozygous deficiency in either the POMC or PCSK genes; pediatric patients <FONT FACE="SYMBOL">&#179;</FONT> six years are
currently being studied, though it is likely that the lower age pediatric patients will have less than one year of treatment at the time of NDA filing. We expect to enroll pediatric patients in our
LepR deficiency obesity pivotal trial starting in 2018, and similarly for basket protocols.  </FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(5)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>This
trial will continue as a basket protocol and study additional indications.  </FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(6)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Basket
protocols study a variety of different indications or patient populations administratively in one protocol, though each population is enrolled and analyzed
separately.  </FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(7)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>One
of our proof of concept basket protocols was originally the Phase&nbsp;2 trial for POMC deficiency obesity and LepR deficiency obesity initiated in Germany in
2016 and provided proof of concept in these indications. This trial was later amended in 2016 to include other MC4 pathway disorders. Our second basket protocol is open, or is being opened in other
geographical locations (United&nbsp;States 2016; United&nbsp;Kingdom, France in 2017). </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>114</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=117,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=736547,FOLIO='114',FILE='DISK109:[18ZBU1.18ZBU44601]DG44601A.;22',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_dg44601_1_115"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:0%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(8)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>We
have enrolled patients with Bardet-Biedl syndrome, Alstr&ouml;m syndrome, and POMC epigenetic disorders, and POMC heterozygous deficiency obesity, and
anticipate additional indications for study possibly later in 2018 or early 2019.  </FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(9)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>We
are studying, or plan to study less than 10 patients with Bardet-Biedl syndrome, less than five with Alstr&ouml;m syndrome, but are studying, or plan to
study a larger number of patients with other MC4 pathway indications, such as heterozygous and epigenetic patients, indications with potentially more complexity.  </FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(10)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>We
have ongoing trials approved in the United&nbsp;States, Germany, United&nbsp;Kingdom, France and the Netherlands, and other countries may be included. </FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(11)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>All
patients will receive open label setmelanotide in the extension protocol.  </FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(12)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>It
is anticipated that all patients in any setmelanotide treatment protocol will be transferred over to the extension protocol for long-term follow-up after
completing a minimum one year of treatment in another setmelanotide treatment protocol.  </FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(13)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Only
patients who have been in another setmelanotide treatment protocol can enter an extension.  </FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(14)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Patients
in the TEMPO registry and Natural History study will not receive treatment.  </FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(15)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Individual
subjects enrolled in this registry will need to meet both (1)&nbsp;phenotypic, or BMI, and (2)&nbsp;genotypic entry criteria that fit a working
definition of extreme obesity associated with confirmed or putative MC4R pathway genetic variants.  </FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(16)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>All
protocol details for the Bardet-Biedl syndrome/Alstr&ouml;m syndrome pivotal trial are preliminary, pending final discussions with the FDA. </FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(17)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>This
trial may include a short randomized, placebo-controlled period for study validation, which is not anticipated to be a primary endpoint.  </FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(18)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Primary
endpoint will be one year of treatment, anticipated to be similar to the endpoint for POMC deficiency obesity and LepR deficiency obesity pivotal trials. </FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(19)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Patients
two years or older may be enrolled. </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Setmelanotide: Clinical Development Program in Genetically Defined Obesity  </I></B></FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Phase&nbsp;2 Clinical Development in POMC Deficiency Obesity  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have completed a Phase&nbsp;2 proof of concept, open label clinical trial, Study RM-493-011, in two patients with POMC deficiency obesity
in which these patients have been treated with setmelanotide for more than 2&nbsp;years, resulting in profound reductions of hyperphagia and body weight, with good tolerability. The patients in this
trial have provided proof of concept for the compelling effect of setmelanotide in this disorder. We are close to completing enrollment in the pivotal cohort of patients in our Phase&nbsp;3 trial
for this indication. The results of the Phase&nbsp;2 trial were published in July 2016 in the New England Journal of Medicine, which we believe validates the scientific and clinical importance of
our Phase&nbsp;2 findings, and the accompanying editorial described the trial as demonstrating impressive hunger reduction and weight loss as well as improved insulin sensitivity. A brief update on
these patients was also included in a publication in Nature Medicine in May 2018. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
first setmelanotide-treated patient was a 20-year-old woman, who at three months of age experienced the onset of obesity and hyperphagia. In spite of enormous efforts, the patient
was never able to stabilize her body weight, except for brief periods, and she has remained hyperphagic. Ahead of our trial, the patient's self-reported trial hunger score was eight to nine out of 10
points, representing extreme hunger. She was entered into the trial at adulthood because of her severe obesity, with a baseline weight of 155 kg, or 341.7 lbs., and a BMI of 49.8 kg/m<SUP>2</SUP>,
and significant risk of comorbidities and a reduced life expectancy. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
trial, initially a 13-week, open label, ascending dose Phase&nbsp;2 trial, was approved by the German Federal Institute for Drugs and Medical Devices, with open-label one-year
extensions, and was planned
to include approximately four to six patients with genetically confirmed POMC deficiency obesity. After efficacy-gated dose escalation, aiming for weekly weight loss of approximately two kg, or 4.4
lbs., the primary endpoint was weight loss, with other key endpoints including hunger score, body composition, insulin and glucose parameters, metabolic and cardiovascular risk factors, energy
expenditure and general safety and tolerability. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;After
13&nbsp;weeks of therapy, with approximately the first four weeks at sub-therapeutic doses, our initial patient demonstrated weight loss of 25.8 kg, or 56.9 lbs., representing
16.7% of her initial body weight, with approximately two to three kilograms per week of weight loss demonstrated at the highest 1.5 mg/day dose. Hunger scores, measured using a Likert score of zero to
10, where zero represents no hunger and </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>115</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=118,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=594099,FOLIO='115',FILE='DISK109:[18ZBU1.18ZBU44601]DG44601A.;22',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_dg44601_1_116"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>10&nbsp;represents
extreme hunger, mirrored the rate of weight loss, moving from scores of eight to nine prior to our trial to zero to one, as the patient was treated with increasing doses of
setmelanotide. After termination of the 13-week main trial, the patient underwent a three-week withdrawal period off drug and regained 4.8 kg, or 10.6 lbs., with a return to moderate to severe hunger.
Following approval to restart setmelanotide treatment, there was an immediate reduction of hunger and subsequently a continuation of body weight loss. This patient was on continuous treatment for
106&nbsp;weeks, with a total weight loss of 65.6&nbsp;kg, or 144.6 lbs., representing 42.3% of her initial body weight. There was no apparent difference in the rate of weight loss during the
initial extension phase versus the main trial, however over time, the rate of weight loss has slowed, though this patient has continued to lose weight. The patient's need for continued therapy was
supported by a short period of withdrawal after the patient had been treated for over one year. Reducing her daily dose from 1.5 mg/day to 1.0 mg/day resulted in an increase in her hunger scores from
one to two points to four to five points, resulting in the patient requesting to be returned to her 1.5 mg/day dose, after which her hunger scores returned to one to two points. This data supports the
physiological prediction that pharmacological treatment for this condition to suppress hunger will be required chronically. After approximately 106&nbsp;weeks of treatment, her dose was reduced to 1
mg/day, and while her weight remained stable from week 106 to approximately week 130, her hunger scores increased to three to four points on the lower dose before returning to two points. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
results for this patient are shown in the figure below. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dg44601_the_clinical_course_of_the_ini__the04458"> </A>
<A NAME="toc_dg44601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  The Clinical Course of the Initial Patient in the Setmelanotide POMC Deficiency Obesity Phase&nbsp;2 Trial through Week 118<SUP>(1)</SUP>    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g851047.jpg" ALT="GRAPHIC" WIDTH="666" HEIGHT="433">
  </B></FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" >


<DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>*</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Figures represent cumulative weight lost in kgs through approximately 118&nbsp;weeks of treatment. See text for additional
details.  </FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Daily
setmelanotide dose adjustments over time are indicated at the top of the panel. </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>116</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=119,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=671904,FOLIO='116',FILE='DISK109:[18ZBU1.18ZBU44601]DG44601A.;22',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_di44601_1_117"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In general, diet induced weight loss in patients with general obesity is accompanied by significant counter-regulatory effects, including reductions in energy
expenditure and increases in hunger. These lead to weight regain in the majority of patients. In contrast, the initial patient in our trial did not manifest these counter-regulatory responses, even
after six months of therapy and a tremendous reduction of body weight. This data supports an effect of setmelanotide on energy expenditure independent from the profound effects on hyperphagia,
corroborating results from previous trials of setmelanotide in patients with general obesity. Also of note, the reduction in body weight was mainly due to a loss of body fat mass, and lean body mass
was not greatly altered. In this initial patient,
setmelanotide was also associated with excellent tolerability, additional favorable changes in cardiovascular risk parameters, or lipids, and improvements in blood pressure and heart rate. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;MC4R
activation also causes improvements in glucose and insulin parameters in animal models, independent of weight loss. As shown in the figure below, for the initial patient in our POMC
deficiency proof of concept trial, setmelanotide demonstrated a marked improvement in insulin resistance during treatment. While weight loss likely played an important role in this improvement, we
believe the independent effect of MC4R agonism may also have contributed. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="di44601_setmelanotide_treatment_effect__set09334"> </A>
<A NAME="toc_di44601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Setmelanotide Treatment Effects on Insulin Resistance (Insulin Response in Oral Glucose Tolerance Test) at Baseline, After 13 Weeks of Treatment (Phase&nbsp;1), and at  Approximately 26 Weeks During the Long-term
Extension for our POMC Initial Patient    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g984706.jpg" ALT="GRAPHIC" WIDTH="400" HEIGHT="316">
  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Results
are also available for treatment with setmelanotide of a second patient with POMC deficiency obesity. The second patient is a 26-year-old woman who also experienced early onset
of obesity and hyperphagia. Like the first patient, in spite of significant efforts, she was never able to stabilize her body weight, and she has remained hyperphagic. Ahead of our trial, the
patient's self-reported trial hunger score was nine out of 10 points, representing extreme hunger, and her weight and BMI at trial entry were 152.8&nbsp;kg, or 336.9 lbs., and 54.1
kg/m<SUP>2</SUP>, respectively. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;After
42&nbsp;weeks of therapy at the 1.5 mg/day dose, our second patient demonstrated weight loss of 40.6&nbsp;kg, or 89.5 lbs., representing 26.6% of her initial body weight, with
approximately two to three kilograms per week of weight loss demonstrated initially. Hunger scores, measured using a Likert score of zero to 10, where zero represents no hunger and
10&nbsp;represents extreme hunger, mirrored the rate of weight loss, with scores moving from nine prior to the trial to one on most weeks during the trial, as the patient was treated with increasing
doses of setmelanotide. Similar to the initial patient, setmelanotide </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>117</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=120,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=976025,FOLIO='117',FILE='DISK109:[18ZBU1.18ZBU44601]DI44601A.;35',USER='CHE108055',CD='11-JUN-2018;03:41' -->
<A NAME="page_di44601_1_118"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>demonstrated
an improvement in insulin resistance during treatment in our second POMC deficiency obesity patient. This patient continued on active treatment for 64&nbsp;weeks on therapy and her
weight stabilized at a weight loss of 40.5 kg, or 89.3 lbs. However, a non-serious febrile infection made an increase of the hydrocortisone treatment necessary. Due to a misunderstanding, this planned
temporary elevated dosage of hydrocortisone was not returned to her basal dose of hydrocortisone after a few days as planned; as a result, her hunger feelings started to increase, with an associated
increase in hunger score to 7 points, followed by weight gain. After adaptation of the hydrocortisone dosage during her next visit, the hunger feeling and weight decreased again and she has continued
on treatment for 100&nbsp;weeks in total. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="di44601_the_clinical_course_of_our_sec__the04451"> </A>
<A NAME="toc_di44601_2"> </A>
<BR></FONT><FONT SIZE=2><B>  The Clinical Course of our Second Patient in the Setmelanotide POMC Deficiency Obesity Phase&nbsp;2 Trial through Week 64<SUP>(1)</SUP>    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g545825.jpg" ALT="GRAPHIC" WIDTH="661" HEIGHT="427">
  </B></FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" >


<DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>*</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Figures represent cumulative weight lost in kgs through approximately 64&nbsp;weeks of treatment. See text for additional
details.  </FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Daily
setmelanotide dose adjustments over time are indicated at the top of the panel. </FONT></DD></DL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Setmelanotide was generally well tolerated in the POMC deficiency obesity Phase&nbsp;2 trial, with few adverse events, all mild and infrequent,
and all previously reported in other clinical trials. These included reduced appetite and tanning of skin and nevi, or moles, intermittent and mild injection site reactions, and in rare instances
tiredness, dry mouth, and gastrointestinal symptoms. The single serious adverse event was an influenza immunization reaction, which resulted in an overnight hospitalization and was considered
unrelated to trial drug. A similar immunization reaction had occurred in this patient in a previous influenza immunization prior to treatment, and the patient has continued on setmelanotide since that
event. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
results from the initial patients in our POMC deficiency obesity proof of concept trial are compelling, but these data have limitations due to open label treatment. However, the
strong treatment effect is supported by these patients' long histories of weight gain and hyperphagia prior to treatment, and a strong dose response in the dose escalation phase. More importantly, the
biology of this disorder has </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>118</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=121,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=87335,FOLIO='118',FILE='DISK109:[18ZBU1.18ZBU44601]DI44601A.;35',USER='CHE108055',CD='11-JUN-2018;03:41' -->
<A NAME="page_di44601_1_119"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>been
well studied, and the clinical responses in these patients were strongly predicted by the deep understanding of the role of the MC4 pathway in appetite and weight regulation. The interruption of
treatment effectively allowed the first patient to serve as her own control, demonstrating an immediate and rapid increase in hunger and weight after a short-term treatment withdrawal, and a rapid
response to re-treatment, thereby further demonstrating the strong effect of setmelanotide. The greater than two years of treatment of our first patient, and the greater than one year of treatment for
our second patient also support the ability of setmelanotide to be effective for longer treatment periods. Finally, our data supports that this indication will require chronic treatment. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Most
importantly, this initial proof of concept data provides support for the belief that setmelanotide will restore activity in patients with upstream defects in the MC4 pathway, by
helping patients lose weight and reduce hyperphagia. This was further supported by our other proof of concept results in MC4 pathway rare genetic obesities, such as LepR deficiency obesity,
Bardet-Biedl syndrome, and Alstr&ouml;m syndrome. Similarly, we would expect efficacy in other upstream MC4 pathway genetic disorders, others of which are under study in Phase&nbsp;2 proof
of concept trials. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Phase&nbsp;3 Clinical Development in POMC Deficiency Obesity  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;After discussions with the FDA as part of our Breakthrough Therapy designation, we initiated our Phase&nbsp;3 trial in POMC deficiency obesity
in January 2017, Study RM-493-012. This is an open label, one-year trial, including a double-blind placebo-controlled withdrawal period, of setmelanotide in POMC deficiency obesity. This pivotal trial
is assessing long-term efficacy of setmelanotide given once daily by SC injection. The trial begins with an initial period of dose titration lasting between two and 12&nbsp;weeks where the
individual patient's therapeutic dose will be established by upwards dose titration in two-week intervals. Thereafter, patients will continue on active treatment at their individually titrated optimal
therapeutic dose for an additional 10&nbsp;weeks, for a total combined dosing duration of 12&nbsp;weeks at the individual patient's therapeutic dose. Patients who demonstrate at least five
kilograms weight loss at the end of the open label treatment period will continue onto the double-blind, variably-timed, placebo-controlled, withdrawal period lasting eight weeks inclusive of a
four-week period of placebo treatment. Following the withdrawal period, all patients will complete an additional period of setmelanotide treatment to bring the total therapeutic dosing period to
approximately one year. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
on discussions with the FDA, we plan to file an NDA with the FDA based on approximately one-year data from a pivotal cohort of 10 patients in this trial. We also plan to enroll
supplemental patients who may not complete one year of treatment at the time of NDA filing, including patients between six and eleven years of age under the implementation of a pediatric amendment, to
provide additional important data regarding the use of setmelanotide in people living with POMC deficiency obesity. The primary endpoint of the trial will be a categorical analysis of responders for
weight, defined as patients achieving a 10% change from baseline, with mean percentage change in weight from baseline as the key secondary endpoint. Hunger-related endpoints are also key secondary
endpoints in the study. Other secondary endpoints are safety and tolerability, change in body fat mass and glucose parameters, and the effect of withdrawal of setmelanotide in the double-blind,
placebo controlled period. We have also obtained Scientific Advice from the European Medicines Agency, or EMA, in relation to the protocol for this trial, which is currently enrolling in the
United&nbsp;States, United&nbsp;Kingdom, Germany, France, and Belgium. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are close to completing enrollment of the 10 patients in the pivotal cohort in the second quarter of 2018 and we expect to report initial Phase&nbsp;3 data from this pivotal trial
in the third quarter of 2019. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Phase&nbsp;2 Clinical Development in LepR Deficiency Obesity  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Leptin's role in obesity has been elucidated by characterization of severely obese people with homozygous mutations that impair the activity of
leptin, including disruption of signaling at
the LepR, known as LepR deficiency obesity. To study setmelanotide in this indication we initially amended our Phase&nbsp;2 clinical trial in POMC deficiency obesity, Study RM-493-011, to also
include this new and related </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>119</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=122,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=670771,FOLIO='119',FILE='DISK109:[18ZBU1.18ZBU44601]DI44601A.;35',USER='CHE108055',CD='11-JUN-2018;03:41' -->
<A NAME="page_di44601_1_120"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>genetically
defined population of severely obese patients. We then completed this part of the Phase&nbsp;2 proof of concept, open label clinical trial in patients with LepR deficiency obesity by
treating three patients in this trial, who demonstrated weight loss and hunger reduction as outlined below. The results of this trial were published in May 2018 in Nature Medicine, which we believe
validates the scientific and clinical importance of our Phase&nbsp;2 findings. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Results
from treatment with setmelanotide in these three LepR deficiency obesity patients are available. The first LepR deficiency obesity patient was a 23-year-old male, who experienced
early onset of obesity and hyperphagia. After little success in controlling his weight, he underwent, and failed, a gastric banding procedure, and had regained over 20&nbsp;kg in the last year since
his procedure. Ahead of our trial, the patient's self-reported trial hunger score was nine out of 10&nbsp;points, representing extreme hunger, and his weight and BMI at trial entry were
130.6&nbsp;kg, or 287.9&nbsp;lbs., and 39.9&nbsp;kg/m<SUP>2</SUP>, respectively. After initiation and upwards dose titration over 13&nbsp;weeks of setmelanotide treatment, the patient
demonstrated prompt and striking reductions in appetite and body weight with a total loss of 17.5&nbsp;kg body weight, representing 13.4% of his initial body weight. Hunger scores decreased from
nine&nbsp;points at baseline to one to two&nbsp;points at 13&nbsp;weeks. With continued treatment for 26&nbsp;weeks, the patient lost 28.2&nbsp;kg, or 62.2&nbsp;lbs., representing 21.6% of
his initial body weight, and during that interval, he had a hunger score of one to two. Subsequently, on this dose, his weight has remained stable over an additional 35&nbsp;weeks, with total weight
loss of 25.1&nbsp;kg or 55.3&nbsp;lbs., representing 19.2% of his initial body weight over the 61&nbsp;weeks of treatment. The weight loss was predominantly caused by a reduction in body fat and
resting energy expenditure stayed stable during this period. This patient also had pre-trial insulin levels that were elevated as examined by an oral glucose tolerance test, as were glucose values,
demonstrating insulin resistance. These values improved with setmelanotide treatment. Notably, there was also an improvement in the patient's lipid profile over 13&nbsp;weeks of setmelanotide
treatment. Setmelanotide was generally well tolerated in this LepR deficiency obesity trial. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="di44601_the_clinical_course_of_our_ini__the04503"> </A>
<A NAME="toc_di44601_3"> </A>
<BR></FONT><FONT SIZE=2><B>  The Clinical Course of our Initial Patient in the Setmelanotide LepR Deficiency Obesity Phase&nbsp;2 Trial through Week 49<SUP>(1)</SUP>    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g291910.jpg" ALT="GRAPHIC" WIDTH="684" HEIGHT="382">
  </B></FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" >


<DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>*</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Figures represent cumulative weight loss in kgs through approximately 49&nbsp;weeks of treatment. See text for additional
details.  </FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Daily
setmelanotide dose adjustments over time are indicated at the top of the panel. </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>120</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=123,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=212562,FOLIO='120',FILE='DISK109:[18ZBU1.18ZBU44601]DI44601A.;35',USER='CHE108055',CD='11-JUN-2018;03:41' -->
<A NAME="page_di44601_1_121"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The second LepR deficiency obesity patient is a 22-year-old male who also experienced early onset of obesity and hyperphagia. His growth curve
since infancy demonstrated early onset, severe obesity that had continued through his whole life, with little ability to control his weight gain. Ahead of our trial, the patient's self-reported trial
hunger score was nine to 10 out of 10&nbsp;points, and his weight and BMI at trial entry were 122.1&nbsp;kg, or 269.2&nbsp;lbs., and 40.7&nbsp;kg/m<SUP>2</SUP>, respectively. He was treated
with setmelanotide and his dose was escalated up to 1.5 mg once daily with only modest effects on weight and hunger scores. However, when he was advanced to 2 mg once daily, he demonstrated prompt and
striking reductions in appetite and body weight. After 17&nbsp;weeks, including 11&nbsp;weeks on his therapeutic dose of 2 mg/day, he had lost 9.6&nbsp;kg, or 21.2&nbsp;lbs., representing 7.9%
of his body weight, and his hunger score dropped to two to three&nbsp;points. By 36&nbsp;weeks of total treatment, he had lost 13.9&nbsp;kg, or 30.6&nbsp;lbs., representing 11.4% of his body
weight. Despite good tolerance of treatment and this marked weight loss, the patient still felt dissatisfaction at the rate of weight loss and independently discontinued his setmelanotide
administration for approximately 2&nbsp;weeks. During this time, he regained 5.2&nbsp;kg or 11.5&nbsp;lbs., and his hunger score increased to nine out of 10&nbsp;points, or severe hunger. The
patient reported that he felt hungry every hour, and was struggling to control his appetite. As a result, treatment was re-initiated at the 2 mg dose, and was then increased to 2.5&nbsp;mg per day
with the goal of accelerating his weight loss. As a result, he demonstrated a significant reduction in hunger, with his hunger score decreasing from
nine to two out of ten&nbsp;points, and in body weight. The patient remains on treatment with good tolerability. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
patient had few metabolic abnormalities at baseline, but he was hyperinsulinemic as examined by an oral glucose tolerance test. After 13&nbsp;weeks of treatment, the
hyperinsulinemia started to improve and the blood glucose levels during the oral glucose tolerance test normalized. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="di44601_our_second_and_third_patients___our03436"> </A>
<A NAME="toc_di44601_4"> </A>
<BR></FONT><FONT SIZE=2><B>  Our Second and Third Patients in the Setmelanotide LepR Deficiency Obesity Phase&nbsp;2 Trial<SUP>(1)</SUP>    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g908649.jpg" ALT="GRAPHIC" WIDTH="684" HEIGHT="393">
  </B></FONT></P>


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" >


<DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>*</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Figures represent cumulative weight loss in kgs; further details are in the text.  </FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>*</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Figures
show patient data only during weeks in which patients were in compliance with the trial protocol.  </FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Daily
setmelanotide dose adjustments over time are indicated at the top of the panel. </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>121</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=124,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=1011601,FOLIO='121',FILE='DISK109:[18ZBU1.18ZBU44601]DI44601A.;35',USER='CHE108055',CD='11-JUN-2018;03:41' -->
<A NAME="page_di44601_1_122"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The third LepR deficiency obesity patient is a 14-year-old female adolescent, and the first adolescent patient treated with setmelanotide. Her
growth curve since infancy demonstrated early onset, severe obesity her whole life, with little ability to control her weight gain. Ahead of our trial, the patient's self-reported trial hunger score
was nine out of 10&nbsp;points, and her weight and BMI at trial entry were 120.4&nbsp;kg, or 265.4&nbsp;lbs., and 44.2&nbsp;kg/m<SUP>2</SUP>, respectively. The patient lost 10&nbsp;kg, or
22&nbsp;lbs., representing 8.3% of her body weight, and her hunger score reduced to five out of 10&nbsp;points in the first 13&nbsp;weeks on a dose of 1.5 mg per day. Before and during
treatment, the patient exhibited behavior that compromised compliance with the treatment regimen. This manifested as a misunderstanding that led her to perform the injections late in the afternoon and
at an incorrect, lower dosage of 1.0 mg setmelanotide. Considering that we have noted a dose threshold for therapeutic benefit and SC setmelanotide injections have a 10- to 12-hour half-life, we
concluded that the combination of a lower dose and the occurrence of the highest drug concentration at night most likely precipitated an interval of weight regain. In support of this explanation, her
feeling of hunger was reduced during the night but started to increase during the day. Eventually, these errors were reported and corrected. Following such correction, careful monitoring was
instituted to ensure that the patient performed the injections in the morning as instructed, leading again to reduced hunger. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
trial provides the second proof of concept for the effectiveness of setmelanotide in patients with upstream defects in the MC4 pathway, showing marked weight reduction and decreases
in hunger in patients with LepR deficiency obesity. In addition, the efficacy of the drug correlates well with periods of setmelanotide treatment and withdrawal, as in POMC deficiency obesity. Based
on this proof of concept for the compelling efficacy of setmelanotide in this disorder, and the FDA granting of Breakthrough Therapy designation, we transitioned the LepR development program to
Phase&nbsp;3. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Phase&nbsp;3 Clinical Development in LepR Deficiency Obesity  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our LepR deficiency obesity development program is now in Phase&nbsp;3. We are close to completing enrollment of the 10 patients in the
pivotal cohort in the second quarter of 2018 and we expect to report initial Phase&nbsp;3 data from this pivotal trial in the third quarter of 2019. This is an open label, one-year trial, including
a double-blind placebo-controlled withdrawal period, of setmelanotide in LepR deficiency obesity. This pivotal trial will assess long-term efficacy of setmelanotide given once daily by SC injection in
LepR deficiency obesity, and is planned to be of very similar design to the Phase&nbsp;3 ongoing trial in POMC deficiency obesity. The trial begins with an initial period of dose titration lasting
between two and 12&nbsp;weeks where the individual patient's therapeutic dose will be established by upwards dose titration in two-week intervals. Thereafter, patients continue on active treatment
at their individually titrated optimal therapeutic dose for an additional 10&nbsp;weeks, for a total combined dosing duration of 12&nbsp;weeks at the individual patient's therapeutic dose.
Patients who demonstrate at least five kilograms weight loss at the end of the open label treatment period will
continue onto the double-blind, variably-timed, placebo-controlled, withdrawal period. Following the withdrawal period, all patients will complete an additional period of setmelanotide treatment to
bring the total therapeutic dosing period to approximately one year. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are close to completing enrollment of the pivotal cohort of 10 patients in this trial, aged 12&nbsp;years and older. We also plan to enroll supplemental patients, who may not
complete one year of treatment at the time of NDA filing, including patients between six and eleven years of age under the implementation of a pediatric amendment, to provide additional important data
regarding the use of setmelanotide in people living with LepR deficiency obesity. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
anticipate that completion of enrollment for the pivotal cohort in this Phase&nbsp;3 trial will be contemporaneous with completion of enrollment for our POMC deficiency obesity
pivotal trial, and so we are planning to file an NDA for each of these indications concurrently. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
primary and key secondary endpoints will be identical to those for our POMC deficiency obesity pivotal trial. This trial is currently being conducted in the United&nbsp;States, the
United&nbsp;Kingdom, France, Netherlands, and Germany. Based on the FDA granting Breakthrough Therapy designation for the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>122</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=125,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=287105,FOLIO='122',FILE='DISK109:[18ZBU1.18ZBU44601]DI44601A.;35',USER='CHE108055',CD='11-JUN-2018;03:41' -->
<A NAME="page_di44601_1_123"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>treatment
of obesity associated with genetic defects upstream of the MC4 receptor in the leptin-melanocortin pathway, which includes the LepR deficiency obesity indication, we believe we can seek
indications for this type of obesity with a faster path to approval, as compared to typical obesity drug candidates, because of the high unmet need and rare prevalence of this disorder. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Phase&nbsp;2 Clinical Development in Bardet-Biedl Syndrome  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Bardet-Biedl syndrome is a life-threatening, orphan disease with prevalence of approximately one in 100,000 in North&nbsp;America. We estimate
that the addressable patient population for Bardet-Biedl syndrome is approximately 1,500 to 2,500 patients in the United&nbsp;States. It is a rare monogenic disorder that causes severe obesity and
hyperphagia as well as vision loss, polydactyly, kidney abnormalities, and other signs and symptoms. Bardet-Biedl syndrome is part of a class of disorders called ciliopathies, or disorders associated
with the impairment of cilia function in cells. Cilia are hair-like cellular projections that play a fundamental role in the regulation of several biological processes, including satiety signaling.
Cilia dysfunction is thought to contribute to hyperphagia and
obesity in Bardet-Biedl syndrome. Bardet-Biedl syndrome is a genetically heterogeneous disease that is caused by as many as 21 separate Bardet-Biedl loci defects resulting in a similar syndrome,
though each Bardet-Biedl syndrome patient only has one of these defects. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
role of abnormal cilia development and function in obesity has been elucidated in animal models, most strongly for Bardet-Biedl syndrome. Studies in mouse models of Bardet-Biedl
syndrome show that deficiencies in the MC4 pathway contribute to the obesity and hyperphagia in Bardet-Biedl syndrome, with animals developing hyperphagic tendencies early in life. Notably, these mice
have decreased leptin receptor signaling, with the essential hallmarks of failure to activate POMC neurons. This is supported in Bardet-Biedl syndrome rodent models, where the mice respond to an MC4
agonist resulting in reduced food intake and body weight. The relation of Bardet-Biedl syndrome gene mutations to the MC4 pathway is supported by clinical data. Patients with Bardet-Biedl syndrome
have higher leptin than expected for their degree of adiposity, or leptin resistance, which is consistent with the notion that ciliopathy-induced leptin signaling dysfunction is associated with leptin
resistance. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Overall,
these data support that the phenotypes of these ciliopathies, while complex with additional clinically important features along with obesity and hyperphagia, may be responsive
to setmelanotide treatment, and will be investigated in our proof of concept Phase&nbsp;2 trial. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are studying Bardet-Biedl syndrome patients who are severely obese, and have provided proof of concept that Bardet-Biedl syndrome patients will also demonstrate decreased hunger and
significant weight loss, similar to that seen in patients with POMC deficiency obesity, or LepR deficiency obesity. We have enrolled the first five patients in this trial, have reported preliminary
results for these patients in the fourth quarter of 2017, and are updating the clinical status of these patients in the second quarter of 2018. In the second quarter of 2018, the FDA agreed to include
Bardet-Biedl syndrome under our existing Breakthrough Therapy designation for setmelanotide. We are having ongoing discussions with the FDA regarding a Phase&nbsp;3 trial and plan to initiate this
trial and to enroll patients before the end of 2018. The FDA has preliminarily indicated that this Phase&nbsp;3 trial will include both Bardet-Biedl syndrome and Alstr&ouml;m syndrome
patients. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
the Phase&nbsp;2 trial, additional assessments of hunger using daily hunger scores and questionnaires were also obtained. We are using these new assessments in all our ongoing
Phase&nbsp;2 and Phase&nbsp;3 trials and for future trials. These new assessments are as follows: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Daily Hunger Scores.&nbsp;&nbsp;In addition to our morning assessment of hunger, as
performed in the Phase&nbsp;2 trials in POMC deficiency obesity and LepR deficiency obesity, we are also obtaining a daily hunger score rating in response to the question: "In the last
24&nbsp;hours, how hungry did you feel when you were the </FONT><FONT SIZE=2><I>most</I></FONT><FONT SIZE=2> hungry?" Patients are asked to give a response that is measured on a scale of 0-10,
whereby 0&nbsp;points signifies "not hungry at all" and 10&nbsp;points indicates the patient feels his or her "hungriest possible." </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>123</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=126,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=1044479,FOLIO='123',FILE='DISK109:[18ZBU1.18ZBU44601]DI44601A.;35',USER='CHE108055',CD='11-JUN-2018;03:41' -->
<A NAME="page_di44601_1_124"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Questionnaires.&nbsp;&nbsp;For patients 16&nbsp;years of age and younger, we are
using two observer related questionnaires as exploratory endpoints. These questionnaires are completed by the patient's parent or other caregiver.  </FONT> <FONT SIZE=2>
<BR><BR></FONT>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> The Food Problem Diary, or FPD, is based on food-related behaviors. This questionnaire was adapted from a similar questionnaire
that was used with patients with Prader-Willi syndrome. The questionnaire is rated on a 30-point scale where 30&nbsp;points is strong evidence of hyperphagia and 0&nbsp;points is evidence of no
hyperphagia. The best possible response therefore is 0&nbsp;points.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> The Significant Event Questionnaire, or SEQ, counts events not typically seen in this population, such as a patient leaving food
on his or her plate at a meal. This questionnaire consists of eight "yes" or "no" questions. The best possible response is 8&nbsp;points, since this questionnaire tracks events and behavior not
typically seen in patients with MC4 pathway disorders. In contrast with other score scales, a higher score in this hunger assessment category represents improvement, and thus, the results are plotted
in reverse scale and downward trends indicate improvement. </FONT></DD></DL>
</DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe that proof of concept in Bardet-Biedl syndrome has been demonstrated by improvements in hunger and weight reduction, supporting that this is a setmelanotide-responsive, MC4
pathway disorder. The age of the patients ranged from 12 to 61&nbsp;years of age. The starting weights of the patients ranged from 98.3 to 147.5&nbsp;kg and BMI ranged from 42 to 49. The starting
hunger scores for the adult patients ranged from 6 to 9&nbsp;points on the 10-point scale, with higher scores indicating more hunger and the SEQ scores for the two adolescent patients were both 1. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="di44601_description_of_the_five_bardet__des03238"> </A>
<A NAME="toc_di44601_5"> </A>
<BR></FONT><FONT SIZE=2><B>  Description of the Five Bardet-Biedl patients in the Phase&nbsp;2 Proof of Concept study    <BR>    </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="25pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="60pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="40pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="133pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Patient Number

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Age<BR>
(yrs) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Bardet-Biedl<BR>
Type </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Starting<BR>
Weight&nbsp;(kg) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Starting<BR>
BMI </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Starting Hunger Score </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>1</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>25</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>147.5</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>44</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Most hungry score&nbsp;= 9</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>61</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>99.4</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>44</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Most hungry score&nbsp;= 7</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>3</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>16</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>121.6</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>44</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>FPD&nbsp;= 6/SEQ&nbsp;= 1</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>4</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>17</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>98.3</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>42</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Most hungry score&nbsp;= 6</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>5</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>119.3</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>49</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>FDP&nbsp;= 15/SEQ&nbsp;= 1</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Two
patients with Bardet-Biedl syndrome type&nbsp;1 mutations and one each with Bardet-Biedl syndrome types&nbsp;2, 10 and 12 mutations were enrolled. Results for weight and hunger
endpoints are depicted for four Bardet-Biedl patients demonstrating therapeutic responses to setmelanotide. Total treatment durations now lasting between 45 and 58&nbsp;weeks, with up to
14&nbsp;weeks, and in one case up to 42&nbsp;weeks, representing time spent in the dose titration period designed to define an individualized therapeutic dose. Four of the five patients showed
clinically important, marked weight loss of 27.0&nbsp;kg, 14.1&nbsp;kg, 24.2&nbsp;kg, and 21.2&nbsp;kg, or 59.5&nbsp;lbs., 31.1&nbsp;lbs., 53.4&nbsp;lbs., and 46.7&nbsp;lbs.
respectively, and a decrease of 18.3%, 14.2%, 19.9%, and 21.6%, respectively. Hunger scores were reduced by 44.4%, 85.7%, 100.0%, and 66.7%, respectively, in these four patients. This data is
summarized below. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="di44601_summary_of_the_phase_2_data_fo__sum06187"> </A>
<A NAME="toc_di44601_6"> </A>
<BR></FONT><FONT SIZE=2><B>  Summary of the Phase&nbsp;2 data for Our Four Patients in the Setmelanotide Bardet-Biedl Syndrome Phase&nbsp;2 Trial who showed improvements in both weight and hunger    <BR>    </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="54pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="54pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="54pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Bardet-Biedl Patient Number

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Weight loss<BR>
(kg) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Weight loss<BR>
(lbs) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Weight loss<BR>
(%) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Decrease in<BR>
hunger score<BR>
(%) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>1</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>27.0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>59.5</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>18.3</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>44.4</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>14.1</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>31.1</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>14.2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>85.7</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>3</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>24.2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>53.4</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>19.9</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100.0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>4</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>21.2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>46.7</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>21.6</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>66.7</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>% </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:9pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Mean</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B><BR>
21.6</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B><BR>&nbsp;kg</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B><BR>
47.7</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B><BR>&nbsp;lbs</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B><BR>
18.5</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B><BR>%</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B><BR>
74.2</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><B><BR>%</B></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
these four Bardet-Biedl syndrome patients who responded to treatment with setmelanotide, there was a mean weight loss of 18.5% of body weight, and a mean hunger decrease of 74.2%.
The time course of response for the individual patient weight loss and hunger scores are shown below. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>124</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=127,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=399989,FOLIO='124',FILE='DISK109:[18ZBU1.18ZBU44601]DI44601A.;35',USER='CHE108055',CD='11-JUN-2018;03:41' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_dk44601_1_125"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dk44601_our_four_patients_in_the_setme__our04778"> </A>
<A NAME="toc_dk44601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Our Four Patients in the Setmelanotide Bardet-Biedl syndrome Phase&nbsp;2 Trial who showed improvements in both weight and hunger<SUP>(1)(2)(3)</SUP>    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g484696.jpg" ALT="GRAPHIC" WIDTH="651" HEIGHT="403">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g773914.jpg" ALT="GRAPHIC" WIDTH="651" HEIGHT="403">
  </B></FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" >


<DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>*</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Figures represent cumulative weight lost in kgs </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>125</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=128,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=428887,FOLIO='125',FILE='DISK109:[18ZBU1.18ZBU44601]DK44601A.;19',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_dk44601_1_126"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=1>FPD: Food Problem Diary; Score Range 0 to 30, higher score means worse result </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=1>SEQ: Significant Event Questionnaire, which counts significant food behavior events rarely seen in this population (Y/N
for 8&nbsp;behaviors), so maximum score of 8 points means greatest improvement. Shown in reverse scale so downward movement equals improvement for clarity.  </FONT></P>

<DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Daily setmelanotide dose adjustments over time are indicated at the top of the panel.  </FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(2)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>In some cases, dates for entry of weight and hunger
assessment data may differ within a single patient.  </FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(3)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>For Bardet-Biedl syndrome and Alstr&ouml;m syndrome patients, data as of May&nbsp;27,
2018.</FONT></DD></DL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
fifth patient, a patient with a Bardet-Biedl syndrome type&nbsp;1 mutation, showed marked improvement in hunger scores with a 53.3% decrease, but did not demonstrate any body
weight change after 33&nbsp;weeks on treatment, including a final 12-week test period on 3.0 mg daily. However, the weight curve for this patient indicated a slowing of prior childhood weight gain
upon treatment with setmelanotide, as indicated with an arrow in her pediatric growth chart, below. This patient was a 12-year-old with Type&nbsp;1 diabetes who entered the trial with extremely poor
glucose control, with an average blood sugar level, or HbA1c, of 10.1%. We have investigating the reason for the inconsistency between her improvement in hunger and lack of weight loss. During her
treatment, her HbA1c showed an improvement to 7.6%. Setmelanotide was generally well tolerated in all patients in this Bardet-Biedl syndrome Phase&nbsp;2 proof of concept study. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g172986.jpg" ALT="GRAPHIC" WIDTH="547" HEIGHT="336">
  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Four
additional Bardet-Biedl patients (3 adolescents, 1 adult) have been enrolled in this Phase&nbsp;2 study, all of whom have been treated for short duration and/or are still in the
titration phase, including patients with two additional Bardet-Biedl syndrome types. In addition, one of these patients, an adolescent who had syndromic Bardet-Biedl syndrome, was diagnosed by
clinical presentation but had no genetic abnormalities in any Bardet-Biedl syndrome gene. Two of these patients are showing promising responses in weight loss and hunger. The third patient, diagnosed
by clinical presentation only, is too early to determine. The fourth patient did not show improvements in either weight or hunger and was discontinued. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Phase&nbsp;2 Proof of Concept Study of Patients with Alstr&ouml;m Syndrome  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are conducting a Phase&nbsp;2, proof of concept trial in Alstr&ouml;m syndrome, which is a life-threatening, ultra-rare orphan
disease with a prevalence of approximately one in 1,000,000 in North America and we estimate that the addressable patient population for Alstr&ouml;m syndrome obesity is approximately 500 to
1,000 patients worldwide. Alstr&ouml;m syndrome shares many clinical features with Bardet-Biedl syndrome, </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>126</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=129,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=223986,FOLIO='126',FILE='DISK109:[18ZBU1.18ZBU44601]DK44601A.;19',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_dk44601_1_127"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>including
obesity and hyperphagia, and is also characterized by progressive vision loss, deafness, congestive heart failure, hyperinsulinemia and type&nbsp;2 diabetes mellitus. Similarly,
Alstr&ouml;m syndrome is a ciliopathy caused by mutations in the ALMS1 gene, which has also been shown to be important for cilia function. Like Bardet-Biedl syndrome, recent scientific
studies identify genetic deficiencies affecting the MC4 signaling pathway as a potential cause of the obesity and hyperphagia associated with Alstr&ouml;m syndrome. Studies in a mouse model
of Alstr&ouml;m syndrome show a reduction in the number of cilia in specific neurons in the hypothalamus that are critical for MC4 pathway signaling. While Alstr&ouml;m syndrome is
less well studied than Bardet-Biedl syndrome, the similar pathophysiology of cilial dysfunction and clinical presentation support that deficiencies in the MC4 pathway are implicated in the obesity and
hyperphagia observed in Alstr&ouml;m syndrome. Therefore, we hypothesize that setmelanotide treatment can be applied to treat Alstr&ouml;m syndrome. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are studying Alstr&ouml;m syndrome patients who are severely obese. We believe, our initial proof of concept data, shown below, demonstrates that Alstr&ouml;m
syndrome patients may also experience decreased hunger and significant weight loss similar to that seen in patients with POMC deficiency obesity, LepR deficiency obesity, or Bardet-Biedl syndrome. We
have enrolled patients in this trial and are updating the clinical status of these patients in the second quarter of 2018. The FDA has also recently included Alstr&ouml;m syndrome under our
existing Breakthrough Therapy designation. As mentioned for Bardet-Biedl syndrome, we are having ongoing discussions with the FDA regarding a Phase&nbsp;3 trial and plan to initiate this trial and
to enroll patients before the end of 2018. The FDA has preliminarily indicated that this Phase&nbsp;3 trial will include both Bardet-Biedl syndrome and Alstr&ouml;m syndrome patients. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
initial Alstr&ouml;m syndrome patient in our Phase 2 clinical trial was a 12-year-old male, starting weight of 78.6 kg, or 173.2 lbs., with a BMI of 28.2
kg/m<SUP>2</SUP> (above the 98<SUP>th</SUP>&nbsp;percentile for his age). At baseline, his initial "worst hunger" score was 3 points, and his morning hunger score was 5 points. This patient
has been treated for 38&nbsp;weeks including titration, most of that time on a dose of 2 mg/day. During the course of treatment, he demonstrated weight loss of 18.2 kg, or 40.1 lbs., which
represented a 23.2% weight loss. Because his body weight was approaching ideal body weight, and he is a growing child, his dose </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>127</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=130,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=983653,FOLIO='127',FILE='DISK109:[18ZBU1.18ZBU44601]DK44601A.;19',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_dk44601_1_128"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>was
reduced to 1.5 mg/day, with stabilization of his weight. Despite the marked weight loss, there was little change in his hunger scores. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g395251.jpg" ALT="GRAPHIC" WIDTH="652" HEIGHT="496">
  </B></FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Three
additional Alstr&ouml;m patients (2 adolescents, 1 adult) have been enrolled in this Phase&nbsp;2 study, all of whom have been treated for short duration and/or are
still in the titration phase. One of these patients is showing promising responses in weight loss and hunger, one is too early to determine, but one patient, the adult, did not show improvements in
either weight or hunger and was discontinued. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Phase&nbsp;3 Clinical Development in Bardet-Biedl and Alstr&ouml;m Syndrome  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Since the FDA agreed to include Bardet-Biedl syndrome and Alstr&ouml;m syndrome under our Breakthrough Therapy designation, we have
begun in May 2018 an ongoing discussion about Phase&nbsp;3 trial design with the FDA, and have received preliminary guidance on many aspects of the Phase&nbsp;3 development programs in
Bardet-Biedl syndrome and Alstr&ouml;m syndrome. Based on these discussions, we are planning a combined Phase&nbsp;3 study to include both Bardet-Biedl and Alstr&ouml;m patients
in a single Phase&nbsp;3 trial, including at least 20 Bardet-Biedl syndrome patients and at least 6 Alstr&ouml;m syndrome patients, aged 6&nbsp;years and older. The combined trial is
likely to lead to a more rapid path for approval of these two indications than two separate trials. Like previous setmelanotide Phase&nbsp;3 trials in POMC and LepR deficiency obesities, we are
planning an open label, approximately one-year trial, assessing long term efficacy of setmelanotide given once daily by SC injection. We may also plan to enroll supplemental patients who may not
complete one year of treatment at the time of NDA filing. We expect to discuss with the FDA the primary endpoint of the trial. Potential endpoints will likely include a categorical analysis of </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>128</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=131,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=603240,FOLIO='128',FILE='DISK109:[18ZBU1.18ZBU44601]DK44601A.;19',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_dk44601_1_129"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>responders
for weight, with mean percentage change in weight from baseline as a key secondary endpoint. Hunger-related endpoints are also likely to be key secondary endpoints in the study. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are planning the trial to begin with an initial period of dose titration, using a simplified titration scheme over 2&nbsp;weeks for adults, and possibly slightly longer for
pediatric patients. This trial may include a short, 12-week, randomized, placebo-controlled period. Following the 12-week, double-blind, placebo controlled period, all patients will complete an
additional period of active setmelanotide treatment to
complete the approximately one-year trial. We are also discussing with the FDA a potential alternative primary endpoint for growing pediatric patients that will capture the therapeutic benefits of
setmelanotide in the pediatric population. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
plan to continue ongoing discussion with the FDA, complete the Phase&nbsp;3 protocol, initiate the Phase&nbsp;3 study and enroll our first patients by the end of 2018. It is
anticipated that this study will be conducted in both the United States and Europe. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Phase&nbsp;2 Proof of Concept Studies Focused on Patients with Monogenic Disorders of the MC4
Pathway: Heterozygous Mutations in the MC4 Pathway and Epigenetic Disorders of the MC4 Pathway  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are conducting Phase&nbsp;2, proof of concept trials in a variety of monogenic, upstream disorders of the MC4 pathway, including POMC and
other MC4 pathway gene heterozygous mutations, and epigenetic disorders of the MC4 pathway. These trials are Phase&nbsp;2 open label, single arm, proof of concept trials assessing the effect of
setmelanotide on the rare genetic disorders of obesity described below. We hypothesize that these disorders may be genetically-defined deficiencies upstream in the MC4 pathway. Each trial includes a
three-month proof of concept phase at which weight loss, hunger and other metabolic parameters will be evaluated. If patients demonstrate significant weight loss and acceptable safety and
tolerability, they will continue treatment for evaluation of setmelanotide's effects for a total of one year. Similar to our previous trials, this trial will begin with an initial period of dose
titration where the individual patient's therapeutic dose will be established by upwards dose titration in two week intervals. We plan to enroll from 20 up to 100 patients between these two rare
genetic populations. We are conducting these trials, as we did for the ongoing Bardet-Biedl syndrome and Alstr&ouml;m syndrome Phase&nbsp;2 trial described above, under basket protocols,
which are designed to capture a broad range of patient populations to be treated under one investigational protocol. We believe this approach is efficient for studying many potential indications, and
we intend to add additional populations to these basket protocols over the next one to two years. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
genetic disorders we are studying in our additional Phase&nbsp;2 proof of concept trials are outlined below, and initial, preliminary Phase&nbsp;2 data for each indication is
summarized.  </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>a.</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Clinical
Development in MC4 Pathway Heterozygous Deficiency Obesity </FONT></DD></DL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;MC4
pathway heterozygous deficiency obesity is caused by the loss of one of the two genetic copies of either the genes for POMC, PCSK, or LepR. Animal models support that such
heterozygous deficiency in the critical leptin-melanocortin pathway can result in a strong predisposition to severe obesity. The effect of genetic heterozygous deficiency obesity was first
demonstrated for another gene in the MC4
pathway: MC4R heterozygous deficiency obesity. Later data also supported that POMC heterozygous deficiency obesity also results in a strong predisposition to obesity, though the epidemiology and
clinical characterization of these patients is less well known. An estimated 2% of severe, early onset obesity patients have POMC heterozygous deficiency obesity, which is much more common than the
ultra-rare POMC deficiency obesity in which both copies of either the POMC or PCSK genes are impaired. Our initial clinical focus is on the most severely obese MC4 pathway heterozygous patients to
test the hypothesis that severely obese heterozygous POMC patients might also respond substantially to setmelanotide treatment. </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>129</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=132,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=274931,FOLIO='129',FILE='DISK109:[18ZBU1.18ZBU44601]DK44601A.;19',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_dk44601_1_130"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are studying patients who are severely obese, or whose BMI is equal to or greater than 40kg/m<SUP>2</SUP>, and who are heterozygous deficient for POMC, LepR, or other genes in the
MC4 pathway. These patients have a heterozygous genetic mutation resulting in full or partial loss of MC4 pathway signaling to the downstream MC4R. The purpose of studying these patients in this trial
is to provide proof of concept that severely impaired MC4 pathway heterozygous deficiency obesity patients will also demonstrate significant weight loss, similar to though possibly of less magnitude,
as that seen in patients with POMC deficiency obesity or LepR deficiency obesity. We are enrolling this trial at sites in the United States and Europe, and expect to report the initial, preliminary
results in the second quarter of 2018. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Five
heterozygous patients have been enrolled, mostly for short durations, in this Phase&nbsp;2 trial. The longest treated patient, on treatment for 34&nbsp;weeks including
titration, is showing promising responses in weight loss of 23.1 kg, or 50.9 lbs., and an 80% decrease in hunger score. A second patient has shown 9.5 kg, or 21.0 lbs. of weight loss, but only a
moderate 20% decrease in hunger score. One patient did not show improvements in either weight or hunger and was discontinued due to lack of efficacy, and two patients discontinued early due to
tolerability issues related to muscle cramps or tanning, respectively. Four of the five patients treated to date were enrolled at a single site. We are currently opening a number of additional sites
with relevant pre-identified heterozygous patients in their databases. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;POMC
heterozygous deficiency obesity is complex in many ways, in that there appears to be variable penetrance, or manifestation of heterozygous mutations. As a result, we intend to study
a larger number of heterozygous patients in Phase&nbsp;2, to more carefully delineate those patients most debilitated and those who will have the best response to setmelanotide, before we discuss
the design for a Phase&nbsp;3 study with the FDA. We intend to provide an update on a larger number of heterozygous patients in the first quarter of 2019. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mutations
that are of particular interest include mutations to the section of the POMC gene that are translated into the protein, beta-melanocyte stimulating hormone, or
<FONT FACE="SYMBOL">b</FONT>-MSH. These mutations have been implicated in human and canine obesity. In 2002, researchers identified one specific heterozygote mutation of
<FONT FACE="SYMBOL">b</FONT>-MSH, called the R236G mutation, in two children with extreme childhood obesity. This R236G mutation results in an abnormal
<FONT FACE="SYMBOL">b</FONT>-MSH protein with a markedly reduced ability to activate the MC4R itself, and may also prevent other natural MC4R ligands from activating the MC4R. These
combined effects may result in more significant obesity than other heterozygous mutations. The overall prevalence of this mutation is rare, 0.7% of the obese population is estimated to carry this
mutation, but our genotyping study of 560 patients with early onset, childhood obesity has identified five heterozygote patients with the R236G mutation, all with severe obesity. Because, in our
genotyping study and possibly in the scientific literature, this mutation is associated with severe obesity and has a relatively-high observed prevalence, this mutation will be a focus when enrolling
our Phase&nbsp;2 trial in POMC heterozygous obesity. We are studying patients who are heterozygous deficient for other genes in the MC4 pathway, though less is known about the epidemiology and
clinical impact of these other heterozygous deficiency obesities. We have also hypothesized that patients who carry high allelic burden in this pathway, or who have genetic disorders in two or more of
the genes of the MC4 pathway, and who therefore might have some impairment at more than one location in the MC4 pathway, might also be responsive to setmelanotide.  </FONT></P>

<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>b.</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Clinical
Development in Patients with Epigenetic Changes at the POMC receptor </FONT></DD></DL>
</UL>
<UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
our proof of concept Phase&nbsp;2 trials, we are studying patients suffering from obesity due to a partial lack of MSH due to an epigenetic POMC variant. Epigenetics changes are DNA
modifications that can change gene expression without altering the DNA sequence itself. The most stable epigenetic modification is called DNA methylation. Recently, our academic collaborators in
Berlin have described a POMC hypermethylation variant, which correlates with increased body weight in children </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>130</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=133,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=458740,FOLIO='130',FILE='DISK109:[18ZBU1.18ZBU44601]DK44601A.;19',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_dk44601_1_131"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>and
adults. Therefore, the presence of the POMC genetic/epigenetic variant leads to an increased risk for obesity based on reduced POMC gene activity. We expect that these patients under express the
POMC gene product and as a result have a partial MSH deficiency. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
is convincing evidence that such epigenetic variants are potentially major factors for an increased individual risk to develop obesity later in life, and we hypothesize that the
most obese patients in their populations may benefit from treatment with setmelanotide. However, epigenetic variation is likely not the only reason for the development of obesity in this patient
group, because these variants are also
observed in normal weight individuals, although to a lesser extent. At this point, no epidemiology data is available to estimate the size of the POMC epigenetic deficiency obese population. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are studying patients who are severely obese, or whose BMI is equal to or greater than 40kg/m<SUP>2</SUP>, and who have hypermethylation at the POMC gene. The purpose of studying
these patients in this trial is to provide proof of concept that severely impaired, epigenetic POMC variant obesity patients will also demonstrate significant weight loss similar to, though possibly
of less magnitude, as that seen in patients with POMC deficiency obesity or LepR deficiency obesity. We are enrolling this trial at sites in the United States and Europe, and expect to report the
initial, preliminary results in the second quarter of 2018. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Two
epigenetic patients have been enrolled, one of whom is just starting titration. The longer treated patient, on treatment for 27&nbsp;weeks including titration, is a 20-year-old
female, with a starting weight of 182.2 kg, or 401.7 lbs., and a BMI of 55.0 kg/m<SUP>2</SUP>. Her starting hunger score was 7.5 points. As she was titrated, her hunger score decreased 60% to three
points and she began to lose weight. Due to a vacation, she withdrew from treatment for approximately four weeks and her hunger score returned to baseline but she did not regain weight over that
period. With resumption of treatment, her hunger score decreased to 3.5 points, and at week 27, she had lost 16.8 kg, or 37.0 lbs., which represented a loss of 9.2% of body weight. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Phase&nbsp;1b Clinical Development in Patients with Heterozygous MC4R Gene Mutations  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Early studies in downstream MC4 pathway defects demonstrated good efficacy and tolerability, and served as a foundation for potentially greater
efficacy in upstream MC4 pathway deficiencies. We established proof of concept for efficacy of setmelanotide in patients with an MC4R heterozygous genetic mutation in one cohort of patients in our
Phase&nbsp;1b clinical trial. This clinical trial was a double-blind, placebo-controlled, randomized Phase&nbsp;1b clinical trial designed to evaluate the effect of setmelanotide on weight loss
and safety in obese patients with a heterozygous mutation of the MC4R gene. The initial cohort of eight patients was treated for four weeks with setmelanotide or placebo. The setmelanotide group
showed weight loss of 3.48 kg, or 7.67 lbs., approximately 2.62 kg, or 5.78 lbs., more weight loss than the placebo group, which showed weight loss of 0.85 kg, or 1.87 lbs. Other parameters supporting
weight loss were also positively impacted by setmelanotide. We believe that these results support the hypothesis that setmelanotide can be effective in weight loss in MC4R deficient patients, and
provide evidence of the minimum expected treatment effect of setmelanotide, approximately 0.9 kg/week, or 1.98 lbs./week, of weight loss over four weeks, even in a situation where setmelanotide's
action is on a downstream MC4 pathway that is no longer fully functional due to heterozygous MC4R mutations. However, our focus is on upstream disorders of the MC4 pathway where we hypothesize that
setmelanotide can serve as replacement therapy and provide more compelling efficacy. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>131</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=134,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=45837,FOLIO='131',FILE='DISK109:[18ZBU1.18ZBU44601]DK44601A.;19',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_dk44601_1_132"> </A>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following figure depicts preliminary data relating to our setmelanotide Phase&nbsp;1b clinical trial in MC4 heterozygous deficiency obesity patients: </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dk44601_setmelanotide_phase_1b_trial_m__set03254"> </A>
<A NAME="toc_dk44601_2"> </A>
<BR></FONT><FONT SIZE=2><B>  Setmelanotide Phase&nbsp;1b Trial MC4 Heterozygous Patients: Placebo Subtracted Differences<SUP>(1)(2)</SUP>    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g264539.jpg" ALT="GRAPHIC" WIDTH="433" HEIGHT="402">
  </B></FONT></P>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" >


<DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Over four weeks of treatment with setmelanotide 0.01 mg/kg/day by continuous SC infusion.  </FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(2)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Preliminary data.</FONT></DD></DL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
general, we consider a p-value of 0.05 to be significant. P-values are an indication of statistical significance reflecting the probability of an observation occurring due to chance
alone. However, it is not possible to determine a p-value for very small sample sizes, such as one- or two-patient trials. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Other Clinical and Scientific Initiatives in Genetic Obesity  </I></FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>Genotyping
Study </FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Leveraging
new understanding of severe obesity caused by specific genetic defects has the potential to improve both diagnosis and treatment for specific types of life-threatening
obesity. Therefore, we are sponsoring the Genetic Obesity Project, which is dedicated to improving the understanding of severe obesity that is caused by specific genetic
defects&#151;particularly rare genetic disorders that result in life-threatening obesity. As part of that initiative, we have initiated a genotyping study&#151;the Genetic Obesity ID
&#124; Genotyping Study&#151;in which eligible patients are genotyped for rare genetic disorders of obesity. The goal is to develop a screening algorithm for selecting patients to be
genotyped and diagnosed with POMC deficiency obesity and LepR deficiency obesity, and to guide further genotyping efforts; in addition, it is our expectation that patients who can participate in our
clinical trials will be genetically identified. We are currently including other MC4 pathway deficiencies in the study. Key entry criteria for the study include a history of severe, early onset
obesity, along with hyperphagia and are consistent with the recently published Pediatric Obesity guidelines published by the Endocrine Society. Study investigators, who are academic experts in
childhood obesity, are located in both the United States and </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>132</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=135,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=444705,FOLIO='132',FILE='DISK109:[18ZBU1.18ZBU44601]DK44601A.;19',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_dk44601_1_133"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>Europe.
We plan to work with these investigators to publish the results of this study and guidance on the use of the algorithm for screening, to enable more systematic diagnoses of these rare genetic
disorders of obesity. Our preliminary results in 560 genotyped patients, described below, suggest we can successfully identify these patients using our algorithms. We have now genotyped a few thousand
patients and our preliminary results from these additional patients remain consistent. We are continuing our efforts to genotype patients. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="37pt" style="font-family:times;"></TD>
<TD WIDTH="24pt" style="font-family:times;"></TD>
<TD WIDTH="197pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Number of Patients

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Percent </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Genetic Defect </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.36</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>POMC deficiency obesity (PCSK1)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>3</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.54</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>LepR deficiency obesity</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>59</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10.5</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Heterozygous deficiency</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>5</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.89</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>R236G Heterozygous deficiency</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>Unique
Mechanism of Action of Setmelanotide at the MC4R </FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
recently published new molecular evidence of setmelanotide action on MC4R in Nature Medicine in May 2018, which demonstrates a unique mechanism of action compared to the endogenous
activator, MSH, and first generation MC4R agonists. With agonism of the MC4R, setmelanotide appears to use different signaling pathways inside the MC4R cell, and to better compete away the natural
antagonist at MC4R (AgRP). This may explain the remarkable efficacy of setmelanotide for appetite control in individuals with severe hyperphagia, and may also suggest why setmelanotide does not
clinically increase blood pressure or heart rate, compared to former MC4R agonists. Further research in this area is planned as well. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Setmelanotide: Clinical Development Program in Prader-Willi Syndrome  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;PWS is a life threatening, orphan multigenic disease with prevalence estimates ranging from approximately one in 8,000 to one in 52,000, with at
least 8,000 diagnosed patients in the United States. A hallmark of PWS is hyperphagia, leading to severe obesity and other complications. For PWS patients, hyperphagia and obesity are the greatest
threats to their health, and these patients are likely to die prematurely as a result of choking, stomach rupture, or from complications caused by morbid obesity. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
genetics of PWS are complex, involving many genes on chromosome 15 that are not properly expressed. Recent discoveries highlight that a defect in one of these, the melanoma antigen
family L2, or MAGEL2, gene, in rodent models impairs the function of POMC neurons, which are key components of the MC4 pathway. Studies have suggested a link between defects in MAGEL2 in some humans
with obesity, hyperphagia, autism spectrum disorders, reduced intellectual ability and most other aspects of behavior and metabolism associated with PWS. However, the connection of PWS with the MC4
pathway is complex. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have completed a Phase&nbsp;2 proof of concept, double-blind, placebo-controlled, randomized clinical trial in PWS, Study RM-493-010, which enrolled 40 patients for four weeks of
active setmelanotide treatment, administered once daily by SC injection. This trial was intended to assess the effects of setmelanotide on weight reduction, and PWS-specific hyperphagia-related
behaviors, as PWS patients do not respond to hunger questionnaires, as well as determine its safety profile. Based on the data from this Phase&nbsp;2 clinical trial, we do not believe we will be
positioned to proceed directly into a Phase&nbsp;3 clinical trial. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
trial included a two-week run-in period, a four-week double blind, randomized, placebo-controlled parallel group main trial, a two-week double-blind, randomized, placebo-controlled
withdrawal period during which half of the trial patients were randomized to either continue to receive their therapy or be switched to the alternative therapy, from active to placebo, or vice versa,
and a two-week active-treatment extension. There were four treatment arms in the trial: placebo (N=14); 0.5 mg of </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>133</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=136,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=477709,FOLIO='133',FILE='DISK109:[18ZBU1.18ZBU44601]DK44601A.;19',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_dk44601_1_134"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>setmelanotide
SC injection daily (N=4), 1.5 mg of setmelanotide SC injection daily (N=12), and 2.5 mg of setmelanotide SC injection daily (N=10). Patients were 17 to 54&nbsp;years of age, with a
mean BMI of 39.4&nbsp;kg/m<SUP>2</SUP>, and with a genetically confirmed diagnosis of PWS. Primary endpoints for the trial included safety and tolerability, weight loss and hyperphagia, with
hyperphagia to be measured by a PWS
hyperphagia observer reported outcome, or ORO, questionnaire. Secondary endpoints included dual-energy x-ray absorptiometry measurements, pharmacokinetics, effects during the randomized withdrawal
stage, and effects on quality of life and food-related and other behaviors. Primary evaluations were assessed at the end of the four-week double blind parallel group stage, as well as after the
withdrawal stage and open label extension. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
results of the trial showed modest effects on hyperphagia, which did not approach statistical significance, and no effect on weight, though there may have been some small evidence of
clinically-important weight loss in the very small group of patients who were randomized to the highest dose of setmelanotide over the longest interval of treatment (N=4 patients, post-hoc evaluation,
non-significant). There was good safety and tolerability, providing support for the 2.5 mg daily dose, with only injection site reactions common in both active and placebo groups. There were no
serious adverse events, no significant safety issues or changes in labs or other safety parameters, and the one discontinuation was due to injection site reactions. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;PWS
is a complex multigenic disease, and the hypothesis that PWS is an upstream MC4 pathway disorder is supported primarily on the role of only one of those genes, MAGEL2, in animal
models of obesity. Our results may support that PWS is not an upstream MC4 pathway disorder. Alternatively, other design factors may have influenced the outcome of this trial, and we have started
initial planning for future Phase&nbsp;2 trials in PWS that address these potential factors: longer duration of treatment, younger patient population, improved setmelanotide pharmacokinetics,
consideration of higher doses, and operational limitations of the completed Phase&nbsp;2 trial. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition to our plans to further evaluate setmelanotide in PWS, we also plan to pursue the development of of RM-853, our preclinical candidate GOAT inhibitor for PWS. Additionally,
given setmelanotide and RM-853's distinct mechanisms of action, we plan to explore opportunities to evaluate the two compounds in combination, as we believe there may be complementary effects. </FONT></P>


<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Setmelanotide Clinical Development in General Obesity Patients  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Initial studies in general obesity provided preliminary evidence of efficacy and of good tolerability, and served as a foundation for the
clinical development of setmelanotide. The general obese population is defined as having a BMI of equal to or greater than 30 kg/m<SUP>2</SUP>. In our initial clinical trials, we delivered
setmelanotide with continuous SC infusion using an insulin pump. More recently, our administration has been converted to a once daily SC injectable formulation. In addition, we have an ongoing trial
to assess the pharmacokinetics of a new, long-acting formulation of setmelanotide. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
table below summarizes the setmelanotide studies that we conducted in general obese patients under IND # 112595 submitted to the Division of Metabolism and Endocrinology Products,
Center for Drug Evaluation and Research, FDA. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>134</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=137,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=92015,FOLIO='134',FILE='DISK109:[18ZBU1.18ZBU44601]DK44601A.;19',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_dm44601_1_135"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dm44601_completed_and_ongoing_setmelan__com03343"> </A>
<A NAME="toc_dm44601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Completed and Ongoing Setmelanotide Clinical Trials in the General Obese Population    <BR>    </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:73%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"110%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="110%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="92pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="87pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="84pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Short Study Title

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Population </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Route of<BR>
Administration<BR>
Formulation </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Subjects/<BR>
Patients </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Status </B></FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 RM-493-001</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Obesity</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Continuous</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>36 healthy</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Completed</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Single Ascending Dose Trial in</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>infusion</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>obese subjects</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Healthy Obese Subjects</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>RM-493-002</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Obesity</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Continuous</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>54 healthy</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Completed</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Multiple Ascending Dose Trial in</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>infusion SC</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>obese subjects</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Healthy Obese Subjects</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>injection</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 RM-493-003</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Obesity</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Continuous</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>74 healthy</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Completed</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 A Phase&nbsp;2a Weight Loss Trial in</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>infusion</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>obese subjects</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Obese Patients using Continuous</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Infusion</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>RM-493-005</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>N/A Genetic</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>N/A</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>N/A</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Completed</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pre-screening Genetic Testing of</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Screening Study</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Healthy Obese Subjects</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 RM-493-006</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Energy</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Continuous</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>12 healthy</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Completed</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 A Phase&nbsp;1b 2-Period Crossover Trial</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Expenditure In</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>infusion</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>obese subjects</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 on Energy Expenditure in Obese</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Obesity</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Subjects</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>RM-493-008</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>PK/Obesity</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>SC injection</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>12 healthy</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Completed</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>A Phase&nbsp;1 Pharmacokinetic Trial of</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>obese subjects</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>New Once-daily Injectable</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Formulations</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 RM-493-009</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Obesity</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>SC injection</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>97 healthy</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Completed</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 A Staged, Phase&nbsp;1b/Phase&nbsp;2a</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>obese subjects</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Pharmacokinetic/Weight Loss Trial</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 in Obese Patients using</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Sub-Cutaneous Injection</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>RM 493&nbsp;018</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Obesity</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>SC injection of</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>30 healthy</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>Parts&nbsp;A</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>A Long-Acting Formulation PK</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>long-acting</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>obese subjects</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>and B</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Study of RM-493</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>formulation</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>completed</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <P style="font-family:times;text-align:justify"><FONT SIZE=1>SC=subcutaneous.</FONT></P>
 </DIV>
 <UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Phase&nbsp;2 Clinical Development in the General Obese Population  </I></FONT></P>

<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>a.</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Phase&nbsp;2
Clinical Trial Results with Continuous Infusion </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
conducted our first Phase&nbsp;2 clinical trial of setmelanotide using continuous SC infusion. This was a 12-week, Phase&nbsp;2 proof of concept clinical trial in general obese
patients using the SC continuous infusion formulation of setmelanotide delivered by an insulin pump. We treated approximately 74 obese patients with either placebo or setmelanotide at a dose of 1.0 mg
over 24&nbsp;hours, with no serious adverse events or other safety indications from laboratory tests, electrocardiograms or vital signs noted in the setmelanotide treatment group. Evaluation of the
pharmacokinetics, or blood levels, of setmelanotide from this clinical trial demonstrated that the SC continuous infusion method of drug administration was not optimal. A large number of patients did
not meet the target pharmacokinetic exposures of setmelanotide that our Phase&nbsp;1 clinical trials suggested would have to be achieved in order for setmelanotide to show efficacy. This clinical
trial did not demonstrate statistically significant weight loss compared to the placebo. We believe patients in this clinical trial lacked adequate exposure to setmelanotide, and concluded that all
future efficacy clinical trials in obese patients should be conducted using the SC injection method. This belief is </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>135</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=138,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=736323,FOLIO='135',FILE='DISK109:[18ZBU1.18ZBU44601]DM44601A.;21',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_dm44601_1_136"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>based
on a prior Phase&nbsp;1 pharmacokinetic trial, which used the SC injection formulation and demonstrated higher pharmacokinetic exposures in obese patients.  </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>b.</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Phase&nbsp;2
Clinical Trial with Once Daily SC Injection </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
conducted a three-stage, randomized, placebo-controlled, Phase&nbsp;2 12-week general obesity trial, with approximately 100 obese patients, using our SC injection formulation,
primarily with once daily dosing. We designed this Phase&nbsp;2 clinical trial to bridge between the earlier clinical trials that used continuous infusion and all future clinical trials that use the
formulation for once daily SC injection. Therefore, the primary purpose of the staged approach in this trial was to assess if appropriate pharmacokinetic targets could be reached with the new SC
injection, first in an in-patient setting similar to the setting where robust weight loss was demonstrated in the Phase&nbsp;1 general obesity trial, and then in an outpatient setting. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Overall,
setmelanotide demonstrated significant weight loss over 12-weeks in all stages, with placebo subtracted weight loss, or the difference in the amount of weight gained or lost in
the active treatment group as compared to the placebo treatment group, from baseline of &#150;2.78% to &#150;4.69% and p-values ranging from 0.005 to &#60;0.001.
However, weight loss was more pronounced and consistent in the cohort treated with an initial four-week, observed dosing, inpatient period, for which overall placebo subtracted weight loss from
baseline at week 12 ranged from &#150;3.87% to &#150;4.69%, all with p-values of less than 0.005, with the most pronounced weight loss during the in-patient period. The once
daily SC injection formulation also showed consistent and predictable pharmacokinetic measurements during the four-week inpatient interval in the first stage, validating the characteristics of the SC
injection formulation. However, this trial demonstrated challenges in drug administration and compliance when administered in an outpatient setting in the general obese population. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dm44601_setmelanotide_phase_2_sc_injec__set06634"> </A>
<A NAME="toc_dm44601_2"> </A>
<BR></FONT><FONT SIZE=2><B>  Setmelanotide Phase&nbsp;2 SC Injection Trial 4-week In-Patient Dosing Period: Percent Weight Loss for Setmelanotide 1.5 mg/day SC injection vs Placebo over 26&nbsp;days of  Observed Dosing    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g57159.jpg" ALT="GRAPHIC" WIDTH="438" HEIGHT="319">
  </B></FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Phase&nbsp;1 Clinical Development in the General Obese Population  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have completed a Phase&nbsp;1 single-ascending dose, or SAD, clinical trial of setmelanotide, as well as five cohorts in a Phase&nbsp;1
multiple-ascending dose, or MAD, clinical trial of setmelanotide. Both clinical trials were in healthy obese subjects, and included a double-blind, placebo-controlled randomized </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>136</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=139,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=274971,FOLIO='136',FILE='DISK109:[18ZBU1.18ZBU44601]DM44601A.;21',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_dm44601_1_137"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>escalating
dose design. Subjects received treatment in these Phase&nbsp;1 clinical trials for one day at doses up to 0.1 mg/kg/day, which is a total daily dose of approximately 10 mg/day, and for up
to 28&nbsp;days at doses up to 0.015 mg/kg/day, which is a total daily dose of approximately 1.5 mg/day. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the SAD clinical trial, our extensive monitoring of heart rate and blood pressure did not demonstrate any clinically meaningful changes with setmelanotide treatment compared with
placebo. Similarly, in the MAD clinical trial, there was no evidence of any notable changes in cardiovascular parameters compared to placebo when assessed by 24-hour ambulatory blood pressure
monitoring, or ABPM. We determined that the terminal half-life of setmelanotide is approximately nine to ten hours, making it suitable for once daily dosing. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Four
cohorts of the Phase&nbsp;1 MAD clinical trial that included doses of greater than 0.01 mg/kg/day, which is approximately 1 mg/day, for two to four weeks, demonstrated placebo
subtracted weight loss differences. Most panels showed statistically significant, placebo subtracted weight reduction that ranged from 0.6 to 1.4 kg/week, with a mean of approximately 0.9 kg/week over
the two to four weeks of treatment in Phase&nbsp;1. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dm44601_setmelanotide__phase_1b_genera__set03009"> </A>
<A NAME="toc_dm44601_3"> </A>
<BR></FONT><FONT SIZE=2><B>  Setmelanotide: Phase&nbsp;1b General Obesity Patients: Placebo Subtracted Differences<SUP>(1)(2)</SUP>    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g29192.jpg" ALT="GRAPHIC" WIDTH="682" HEIGHT="405">
  </B></FONT></P>


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" >


<DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Over two to four weeks of treatment with setmelanotide by continuous SC infusion. Placebo subtracted differences are the FDA's
primary weight loss analysis approach, assessing the weight difference between active and placebo treatment groups for changes from baseline for weight.  </FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(2)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Preliminary
data. </FONT></DD></DL>

<P style="font-family:times;text-align:justify"><FONT SIZE=1><FONT FACE="SYMBOL">D</FONT>&nbsp;= Placebo subtracted weight loss from baseline. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=1>BID&nbsp;= Two times per day. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>137</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=140,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=991064,FOLIO='137',FILE='DISK109:[18ZBU1.18ZBU44601]DM44601A.;21',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_dm44601_1_138"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Phase&nbsp;1 Energy Expenditure Clinical Trial  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In collaboration with the National Institute of Diabetes, Digestive and Kidney Diseases, we investigated setmelanotide in a Phase&nbsp;1
clinical trial to determine the effects of setmelanotide on energy expenditure, a mechanism for weight loss, in addition to the well-known effects of MC4R agonists on appetite and food intake. Twelve
obese adults were randomized to receive setmelanotide or placebo by continuous SC infusion over 72&nbsp;hours, followed immediately by crossover to the other treatment. Setmelanotide showed
statistically significant 6.85% increases in resting energy expenditure, supporting a role for setmelanotide in weight regulation. This trial provided the first clinical demonstration that MC4R
activation with setmelanotide increases resting energy expenditure in obese humans. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Long-Acting Setmelanotide Pharmacokinetic Trial  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition to developing the once daily SC injectable formulation of setmelanotide that we are using in our ongoing clinical trials, in
collaboration with Camurus AB, or Camurus, we have developed a once weekly, long-acting formulation using FluidCrystal&reg; technology. When injected subcutaneously, aqueous body fluid is
absorbed by the excipient lipid phase which forms&nbsp;a gel-like depot consisting of liquid crystals formed in situ leading to slow diffusion of setmelanotide from the depot. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have compelling preclinical data with the long-acting formulation: in monkeys, the terminal half-life of the long-acting formulation is approximately 105&nbsp;hours, and in rats,
approximately 92&nbsp;hours. Two-week toxicology studies in rats have been completed, and the long-acting formulation was well tolerated. During the two-week dosing period, animals given
setmelanotide had dose-related, statistically significant lower body weights, from &#150;9.8% to &#150;11.7%, compared to those given placebo controls. Food consumption for
animals given setmelanotide was also lower compared to controls, which decreased by approximately &#150;20.5%. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Two
parts of this clinical pharmacokinetic trial are completed, defining the single-dose and multiple-dose pharmacokinetics of this formulation. The first part, Part&nbsp;A, is an
ascending-dose,
placebo-controlled, up to three sequential panel PK trial, and PK and safety/tolerability will be collected for approximately 14&nbsp;days. Dose for the three panels will range from 2.5 mg up to 30
mg given as a single SC injection. The second part, Part&nbsp;B, is a placebo-controlled, single panel of 12 normal healthy obese patients who received four once-weekly injections of 10 mg
setmelanotide long-acting formulation. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
results from Part&nbsp;A demonstrate that a 10 mg single subcutaneous dose showed a profile that was consistent with once weekly dosing with a mean pharmacokinetic half-life of
123&nbsp;hours. Following the completion of the single-dose part, we completed Part&nbsp;B, with multiple dosing in order to evaluate the extended-release, once-weekly formulation of
setmelanotide. Multiple dosing of the formulation demonstrated tolerability and pharmacokinetics that support further clinical development. While this data is preliminary, and this formulation is
anticipated to be only ready for submission in 2021, or later, this simpler dosing regimen may provide improvements in patient convenience, and may provide additional advantages in the pediatric
population. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>138</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=141,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=223941,FOLIO='138',FILE='DISK109:[18ZBU1.18ZBU44601]DM44601A.;21',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_dm44601_1_139"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dm44601_mean_setmelanotide_concentrati__mea05484"> </A>
<A NAME="toc_dm44601_4"> </A>
<BR></FONT><FONT SIZE=2><B>  Mean setmelanotide concentrations (ng/mL) in plasma during weeks 1 and 4 following 10 mg subcutaneous weekly injections of a Camurus formulation    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g1025011.jpg" ALT="GRAPHIC" WIDTH="610" HEIGHT="447">
  </B></FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Safety and Tolerability  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Historically, clinical data with other MC4R therapies suggested that MC4R-mediated side effects may include changes in blood pressure and heart
rate, increased erections in males, changes in libido and sexual function in females and nausea and vomiting. As a result, primarily due to concerns about blood pressure and heart rate changes, none
of these therapies have proceeded to commercialization and no other MC4R agonists are currently in the clinic for the treatment of obesity and/or hyperphagia. It is noteworthy that the pattern of
effects differed among each of the other MC4R therapies, underscoring the complex physiology of MC4R. With setmelanotide, there has been little, if any, evidence of blood pressure or heart rate
changes, preliminarily supporting an important differentiation of setmelanotide from previous MC4R therapies. Careful monitoring for blood pressure and heart rate changes, as well as other potential
adverse events, is included in all setmelanotide clinical trials. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Because
of these first generation MC4 therapy failures, the setmelanotide program employed an intensive preclinical screening program to assess clinical candidates for blood pressure and
heart rate effects, along with efficacy. The cornerstone of this preclinical screening program was a significant investment in obese primate studies which validated setmelanotide as a promising
compound for clinical development. More recently, new research supporting a unique mechanism of action of setmelanotide, compared to earlier MC4R agonists and the endogenous ligand MSH, was published
in May 2018 in Nature Medicine. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Setmelanotide
was generally well tolerated in our Phase&nbsp;1 and Phase&nbsp;2 clinical trials, and in very preliminary data from our ongoing Phase&nbsp;3 trials. Overall, except
as outlined below, the number and patterns of adverse events was generally low, and the intensity of the adverse events was generally mild, and infrequently led to clinical trial discontinuation. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>139</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=142,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=948855,FOLIO='139',FILE='DISK109:[18ZBU1.18ZBU44601]DM44601A.;21',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_do44601_1_140"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There has been only a single serious adverse event possibly attributed to setmelanotide in our clinical trials. In our Phase&nbsp;2 clinical trial with once
daily SC injection, one patient was hospitalized for unusual chest pain, but no evidence of any serious respiratory or cardiac cause was found after careful evaluation, and the event was attributed to
musculoskeletal pain. There were no treatment-related changes in physical examination, except as noted below, and few, if any, clinically relevant changes in electrocardiograms, laboratory data and/or
anti-drug antibodies. Overall, there have been ten other serious adverse events in the full development program, in addition to the serious adverse event described above: seven others on
setmelanotide, mostly from open label trials, including left arm numbness, influenza immunization reaction, pancreatitis secondary to pre-existing gallstones, pneumonia, hypoglycemia due to acute
adrenal insufficiency, due to non-compliance with hydrocortisone regimen, a depressive episode with elective admission to a psychiatry ward in a patient
with history of depression and who continued on treatment, and rotavirus-related gastroenteritis. There were also three serious adverse events during treatment with placebo, consisting of biliary
dyskinesia, severe groin strain, and pelvic inflammatory disease. None of these serious adverse events was considered related to setmelanotide treatment. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
demonstrate that setmelanotide has the potential to provide a safe cardiovascular profile, we extensively validated setmelanotide in obese primate preclinical studies, with special
attention to cardiovascular effects. The results of these studies supported testing in clinical trials. In the clinical trials, we monitored blood pressure and heart rate extensively, primarily by
24-hour ABPM. In most clinical trials, there were multiple 24-hour ABPM periods, both on a pre-treatment and post-treatment basis. Trial-by-trial review of the 24-hour ABPM data shows little, if any,
evidence of changes in heart rate and/or blood pressure even at the highest doses tested in Phase&nbsp;1 and Phase&nbsp;2 clinical trials. We have also conducted an analysis of 24-hour
ABPMs&nbsp;that were obtained pre-dose and post-dose across completed studies, which was presented at the Obesity Society in 2015. This included 128 patients, of which 79 were active and 49 were on
a placebo. Overall, there was little, if any, evidence of blood pressure or heart rate changes evident from baseline versus placebo in any trial, preliminarily supporting an important differentiation
of setmelanotide from previous MC4 therapies. While the preliminary data are encouraging, there will be continued focus on potential cardiovascular risk until addressed in larger and longer clinical
trials. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="do44601_setmelanotide_phase_2_sc_injec__set05682"> </A>
<A NAME="toc_do44601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Setmelanotide Phase&nbsp;2 SC Injection Trial: 24-hr ABPM (All Studied Patients), Showing No Adverse Effect of Setmelanotide on Blood Pressure or Heart Rate    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g686660.jpg" ALT="GRAPHIC" WIDTH="556" HEIGHT="339">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>140</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=143,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=201846,FOLIO='140',FILE='DISK109:[18ZBU1.18ZBU44601]DO44601A.;17',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_do44601_1_141"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the majority of our trials, there was a small increase in penile erections in male patients, as well as signs of sexual arousal in a small number of female patients. These symptoms
were infrequent,
generally mild, not painful, and short-lived. Most often these symptoms were reported in the first week of treatment. There was a small incidence of nausea and vomiting, as well as injection site
reactions, both of which usually were reported as mild, early in treatment, and short-lived. A small number of patients had dose reductions and/or discontinued treatment due to nausea and vomiting. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
also noted darkening of skin and skin lesions, such as moles and freckles, in most patients who received setmelanotide. This was likely caused by activation of the closely related MC1
receptor, the receptor that mediates skin darkening in response to sun exposure. This was observed generally after one to two weeks of treatment, most often plateaued by two to four weeks of
treatment, and like sun-related tanning, generally returned to baseline after cessation of exposure. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additional
adverse events noted at somewhat greater rates numerically for setmelanotide compared to placebo across the clinical program include fatigue and related symptoms, diarrhea,
arthralgia, back pain and headache, but most investigators reported these effects to be unrelated to setmelanotide. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;While
general obese patients are not currently the focus of setmelanotide studies, the FDA and EMA consider the risk and benefit information observed to date with setmelanotide in
general obese patients to be supportive of the continued development of this therapy. These data from general obese patients do not raise any new safety concerns and suggest that substantial benefit,
as evidenced by weight loss, is possible. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Preclinical Development  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Preclinical studies demonstrated the efficacy of setmelanotide in suppressing food intake and body weight gain in diet-induced obese mice, rats,
dogs, and rhesus macaques, as well as in genetic models of obesity, including leptin-deficient ob/ob mice and obese Zucker, or fa/fa (leptin-receptor deficient), rats. Furthermore, setmelanotide is
associated with restoring insulin sensitivity in nonclinical models of obesity in rodents and lowering of plasma triglycerides, cholesterol, and free fatty acids. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
particular, we demonstrated activity in obese non-human primates, where approximately 13% weight loss was demonstrated with eight weeks of treatment, without evidence of
cardiovascular toxicity. We also studied obese primates in crossover studies to confirm the lack of cardiovascular toxicity by setmelanotide in obese primates. These preclinical studies also confirmed
the cardiovascular effects of previous MC4 therapies that had produced cardiovascular toxicity in humans. In contrast, setmelanotide was without cardiovascular effects in head-to-head studies. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Lastly,
the toxicology program to support the NDA filing of setmelanotide for POMC deficiency obesity is completed. We completed three-month toxicology studies in rats and monkeys, with
doses and exposures that are more than 300-fold greater than those at the anticipated clinical doses without evidence of clinically relevant toxicological findings. Similarly, we have also completed
chronic toxicity studies (6-month rat, 9-month monkey), which in rats provided 219- (maximum concentration) and 106-times (area under the curve), respectively, and in monkeys 282- and 82-times,
respectively, the exposures at the anticipated clinical doses compared to the No-Observed-Adverse-Effect-Level(s) in animals. We have evaluated the potential reproductive and development effects of
setmelanotide in rats and rabbits with administration by SC injection, to support the administration of setmelanotide in women of child-bearing potential. In addition, a juvenile toxicology study has
been completed that will support dosing in pediatric patients less than 12&nbsp;years of age. In addition, we are planning carcinogenicity studies, the longest of which is expected to be two years.
The FDA has allowed us to defer carcinogenicity studies until after approval of an NDA for setmelanotide. We believe this also to be true for the EMA, however, the EMA has not yet provided firm
guidance on the need for one or more carcinogenicity studies at time of filing. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


RM-853, a Preclinical Ghrelin O-Acyltransferase Inhibitor  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition to our development of setmelanotide, in April 2018, we announced that we had acquired exclusive, worldwide rights from Takeda
Pharmaceutical Company Limited, or Takeda, to develop and </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>141</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=144,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=48586,FOLIO='141',FILE='DISK109:[18ZBU1.18ZBU44601]DO44601A.;17',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_do44601_1_142"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>commercialize
RM-853. RM-853 is a potent, orally available GOAT inhibitor currently in preclinical development for PWS. PWS is a rare genetic disorder that results in hyperphagia and early-onset,
life-threatening obesity, for which there are no approved therapeutic options. RM-853 is currently in pre-clinical development. We anticipate filing an IND for RM-853 with the FDA in 2020. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ghrelin
is an orexigenic peptide, secreted by the stomach and proximal small intestine in response to a negative energy balance. Ghrelin can play a key physiological role in stimulating
appetite and promoting food intake, thereby maintaining overall energy balance. In people living with PWS, levels of active ghrelin are elevated, contributing to hyperphagia, which leads to severe
obesity. RM-853 is designed to block GOAT, the key enzyme involved in the production of the active form of ghrelin, with the expected effect of lowering active ghrelin levels. This blockage also
increases the levels of des-acyl-ghrelin, or DAG, a ghrelin precursor; high levels of DAG are believed to have independent beneficial effects on the control of appetite and tissue homeostasis, which
might add to the potential efficacy of RM-853 in PWS. In preclinical research, RM-853 prevented body weight gain and reduced fat mass in high fat-fed mice, with a favorable pharmacokinetic,
pharmacodynamic, and safety profile.
We plan to complete preclinical studies of RM-853 and file an IND with the FDA in approximately the first quarter of 2020. Under the terms of the agreement, we will assume sole responsibility for the
global product development and commercialization of RM-853. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Competition  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant technological change. We have
competitors in a number of jurisdictions, many of which have substantially greater name recognition, commercial infrastructures and financial, technical and personnel resources than we have.
Established competitors may invest heavily to quickly discover and develop compounds that could make setmelanotide obsolete or uneconomical. Any new product that competes with an approved product may
need to demonstrate compelling advantages in efficacy, convenience, tolerability and safety to be commercially successful. Other competitive factors, including generic competition, could force us to
lower prices or could result in reduced sales. In addition, new products developed by others could emerge as competitors to setmelanotide. If we are not able to compete effectively against our current
and future competitors, our business will not grow and our financial condition and operations will suffer. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
are no current pharmacological treatments for regulating hunger and hyperphagia-related behaviors of patients with PWS. In contrast with the absence of companies who have disclosed
efforts to study upstream disorders of the MC4 pathway, there are several companies investigating or developing therapies intended to treat hunger and hyperphagia associated with PWS. The different
companies and compounds in development involve multiple mechanisms of action. The companies and their compounds include; Millendo Therapeutics&nbsp;Inc. (AZP-531), Soleno Therapeutics (Diazoxide
Choline Controlled Release), Zafgen (ZGN-1258), GLWL Research&nbsp;Inc. (GLWL-01), Insys Therapeutics&nbsp;Inc. (Oral Cannabidiol Solution) and Calm Therapeutics. </FONT></P>


<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Licensing Agreements  </B></FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Ipsen Pharma&nbsp;S.A.S.  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In February 2010, the Predecessor Company entered into a license agreement with Ipsen&nbsp;S.A.S., or Ipsen, pursuant to which Ipsen granted
to it an exclusive, sublicensable, worldwide license to certain patents and other intellectual property rights to research, develop, and commercialize compounds that were discovered or researched by
Ipsen in the course of conducting its MC4 program or that otherwise were covered by the licensed patents. Rights under the license included the right to research, develop and commercialize
setmelanotide. Pursuant to the license, Ipsen also granted to the Predecessor Company a non-exclusive, sublicensable, worldwide license to certain patents and other intellectual property rights that
were licensed by Ipsen from a third party or that Ipsen may develop in the future to research, develop, and </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>142</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=145,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=288355,FOLIO='142',FILE='DISK109:[18ZBU1.18ZBU44601]DO44601A.;17',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_do44601_1_143"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>commercialize
any of the compounds exclusively licensed by Ipsen pursuant to the license. See "</FONT><FONT SIZE=2><I>Management's Discussion and Analysis of Financial Condition and Results of
Operations&#151;Corporate Background and Distribution.</I></FONT><FONT SIZE=2>" </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
March&nbsp;21, 2013, the&nbsp;LLC entity completed the Corporate Reorganization pursuant to which, among other things, the existing license with Ipsen with respect to the MC4
program is now held separately by us. As a result, we hold the rights to the MC4 program, including the rights to develop and commercialize setmelanotide. See "</FONT><FONT SIZE=2><I>Management's
Discussion and Analysis of Financial Condition and Results of Operations&#151;Corporate Background and Distribution.</I></FONT><FONT SIZE=2>" </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
the terms of the Ipsen license agreement, Ipsen will receive payments of up to $40.0&nbsp;million upon the achievement of certain development and commercial milestones in
connection with the development, regulatory approval and commercialization of applicable licensed products, and royalties on future sales of the licensed products. Substantially all of the aggregate
payments under the Ipsen license agreement are for milestones that may be achieved no earlier than first commercial sale of the applicable licensed product. Royalties in the mid-single digits on
future sales of the applicable licensed products will be due under the Ipsen license agreement on a licensed product-by-licensed product and country-by-country basis until the later of the date when
sales of a licensed product in a particular country are no longer covered by patent rights licensed pursuant to the Ipsen license agreement and the tenth anniversary of the date of the first
commercial sale of the applicable licensed product in the applicable country. The term of the Ipsen license agreement continues until the expiration of the applicable royalty term on a
country-by-country and product-by-product basis. Upon expiration of the term of the agreement, the licensed rights granted to us under the agreement, to the extent they remain in effect at the time of
expiration, will thereafter become irrevocable, perpetual and fully paid-up licenses that survive the expiration of the term. We have a right to terminate the license
agreement at any time during the term for any reason on 180&nbsp;days' written notice to Ipsen. Ipsen has a right to terminate the agreement prior to expiration of its term for our material breach
of the agreement, our failure to initiate or complete development of a licensed product or our bringing an action seeking to have an Ipsen license patent right declared invalid. Upon any early
termination of the license agreement not due to Ipsen's material breach, all licensed rights granted under the license agreement will terminate. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Camurus  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In January 2016, we entered into a license agreement for the use of Camurus' drug delivery technology, FluidCrystal, to formulate setmelanotide
with Camurus. Under the terms of the agreement, Camurus granted us a worldwide license to the FluidCrystal technology to formulate setmelanotide and to develop, manufacture, and commercialize this new
formulation for once-weekly dosing, administered as a SC injection. The license granted to us is specific to the FluidCrystal technology incorporating setmelanotide. Under the terms of the license
agreement, we are responsible for manufacturing, development, and commercialization of the setmelanotide FluidCrystal formulation worldwide. Camurus received a non-refundable and non-creditable
upfront payment of $0.5&nbsp;million in January 2016, and is eligible to receive progressive payments of approximately $65.0&nbsp;million, of which the majority are sales milestones. In addition,
Camurus is eligible to receive tiered, mid to mid-high, single digit royalties on future sales of the product. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
term of the agreement continues until the expiration of the applicable royalty term on a country-by-country and product-by-product basis. Upon expiration of the term of the
agreement, the licensed rights granted to us under the agreement, to the extent they remain in effect at the time of expiration, will thereafter become irrevocable, perpetual and fully paid-up
licenses that survive the expiration of the term. We have a right to terminate the license agreement at any time during the term for any reason upon 90&nbsp;days' written notice to Camurus. Camurus
has a right to terminate the agreement prior to expiration of its term for our material breach of the agreement, if we voluntarily or involuntarily file for bankruptcy, or for our bringing an action
seeking to have a Camurus license patent right declared invalid. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>143</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=146,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=900091,FOLIO='143',FILE='DISK109:[18ZBU1.18ZBU44601]DO44601A.;17',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_do44601_1_144"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>Upon
any early termination of the license agreement not due to Camurus' material breach, all licensed rights granted under the license agreement will terminate. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Takeda  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In March 2018, we acquired exclusive, worldwide rights from Takeda to develop and commercialize RM-853. RM-853 is a potent, orally available
GOAT inhibitor currently in preclinical development for PWS. PWS is a rare genetic disorder that results in hyperphagia and early-onset, life-threatening obesity, for which there are no approved
therapeutic options. We will assume sole responsibility for the global product development and commercialization of RM-853. Takeda received an upfront fee of $4.4&nbsp;million which we settled in
April 2018 with shares of our common stock, and is eligible to receive milestone payments of approximately $140.0&nbsp;million, most of which are payable upon regulatory approval or are sales
milestones. In addition, Takeda is eligible to receive back-end development milestones, and single-digit royalties on future RM-853 sales. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Among
other obligations under our agreement with Takeda, Takeda has a right of first negotiation under certain circumstances to sublicense the assets we acquired from Takeda in the
territory of Japan. This right of first negotiation remains in effect until the earlier of five years from the date of the agreement, consummation of a change in control, or sublicense to a third
party. This may delay or limit our ability to enter into certain transactions with respect to this product candidate. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
term of the agreement continues until the expiration of the applicable royalty term on a country-by-country and product-by-product basis. Upon expiration of the term of the
agreement, the licensed rights granted to us under the agreement, to the extent they remain in effect at the time of expiration, will thereafter become irrevocable, perpetual and fully paid-up
licenses that survive the expiration of the term. We have a right to terminate the license agreement at any time during the term for any reason upon 90&nbsp;days' written notice to Takeda. Takeda
has a right to terminate the agreement prior to expiration of its term for our material breach of the agreement, if we voluntarily or involuntarily file for bankruptcy, or for our bringing an action
seeking to have a Takeda license patent right declared invalid. Upon any early termination of the license agreement not due to Takeda's material breach, all licensed rights granted under the license
agreement will terminate. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Commercial Operations  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our commercial strategies center around creating a well-informed, supportive genetic obesity community of institutions, healthcare providers,
patients, caregivers, and payers to support our ongoing research and development efforts to transform the care of patients with MC4 pathway deficiencies. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
commercial priorities for the launch of setmelanotide include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Improving methods of evaluation and diagnosis of rare genetic obesity patients through enhanced diagnostic capabilities and partnership with
key opinion leaders and pediatric endocrinologists in order to more clearly articulate the clinical presentation of these patients to referring physicians; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Facilitating an integrated genetic obesity community through services that support patient awareness, education, advocacy, and treatment; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Communicating the burden of rare genetic obesity syndromes to promote advocacy for patient sequencing and support for pricing and reimbursement
of setmelanotide; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Building a global commercial organization to drive patient identification and enable a successful launch of setmelanotide. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
management team understands the complexity of rare diseases and we believe has the necessary expertise to be a true partner to patients, caregivers, advocacy, and healthcare teams
leading to shared success. We intend to establish a specialty sales force and develop an organizational infrastructure that will support an extensive network of endocrinologists and other physicians
treating severe childhood obesity </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>144</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=147,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=813643,FOLIO='144',FILE='DISK109:[18ZBU1.18ZBU44601]DO44601A.;17',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_do44601_1_145"> </A>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>and
rare genetic disorders of obesity which in turn we believe will help establish genetic obesity centers of excellence. Our goal is for our field personnel to work directly with patients, caregivers
and healthcare providers to facilitate therapy initiation and adherence. We also expect to partner with existing and new advocacy organizations to further educate our patient population on genetic
obesity
and support coverage for setmelanotide. In addition, we intend to establish our own commercial sales and marketing organization in the United States and core strategic markets and to selectively
establish partnerships in markets outside the United States for sales, marketing, and distribution. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Patents and Proprietary Rights  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have in-licensed a large patent portfolio from Ipsen for our melanocortin programs. The portfolio includes multiple patent families, and all
of these in-licensed patent families are being prosecuted or maintained by Ipsen in consultation with us. We have also filed patent applications in five families which are exclusively owned and
maintained by us that relate to the melanocortin program. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
MC4 portfolio of licensed and exclusively owned patent families, which includes setmelanotide, consists of 12 patent families currently being prosecuted or maintained, which include
applications and patents directed to compositions of matter, formulations and methods of treatment using setmelanotide. As of June&nbsp;8, 2018, the portfolio for the MC-4 program consists of 14
issued United States patents and 54 issued non-United States patents across eight of the 12 families. We are actively pursuing eight United States patent applications and 43 non-United States
applications in 12 jurisdictions. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the patent family directed to selected MC4 receptor agonists, including the composition of matter for setmelanotide, we have three issued United States patents and 26 issued
non-United States patents, including Australia, Canada, China, Europe, Hong Kong, India, Israel, Japan, Korea, New Zealand, Russia and Singapore. The standard 20-year term for patents in this family
would expire in 2026, but two of the United States patents are expected to expire in 2027 due to patent term adjustments. Patent term extensions for delays in marketing approval may also extend the
terms of patents in this family. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition to the patents and patent applications discussed above, we co-own one patent family with Charit&eacute;-Universit&auml;tsmedizin Berlin, which has been
filed in 21 jurisdictions. We have also filed one application in the United States co-owned with the University of Strasbourg and the French National Institute of Health and Medical Research. These
applications relate to the melanocortin program and, have not yet entered active prosecution. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have also in-licensed a patent family from Takeda directed to the composition of matter and methods of use of ghrelin O-acetyltransferase inhibitors, including RM-853. This patent
family includes one issued United States patent, nine issued non-United States patents including China, Europe, and Japan, and one pending application in Canada. The standard 20-year term for the
patents in this family will expire in 2033, though patent term extensions for delays in marketing approval may also extend the terms of patents in this family. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Intellectual Property Protection Strategy  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We currently seek, and intend to continue seeking, patent protection whenever commercially reasonable for any patentable aspects of
setmelanotide and related technology or any new products or product candidates we acquire in the future. Where our intellectual property is not protected by patents, we may seek to protect it through
other means, including maintenance of trade secrets and careful protection of our proprietary information. Our license from Ipsen for the melanocortin program require Ipsen, subject to certain
exceptions and upon consultation with us, to prosecute and maintain its patent rights as they relate to the licensed compounds and methods. If Ipsen decides to cease prosecution or maintenance of any
of the licensed patent rights, we have the option to take over prosecution and maintenance of those patents and Ipsen will assign to us all of its rights in such patents. For those patent rights that
we own exclusively, we control all prosecution and maintenance activities. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>145</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=148,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=795969,FOLIO='145',FILE='DISK109:[18ZBU1.18ZBU44601]DO44601A.;17',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_do44601_1_146"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
patent positions of biopharmaceutical companies are generally uncertain and involve complex legal, scientific and factual questions. In addition, the coverage claimed in a patent
application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Consequently, we do not know whether the product candidate we in-license will
be protectable or remain protected by enforceable patents. We cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction, and
furthermore, we cannot determine whether the claims of any issued patents will provide sufficient proprietary protection to protect us from competitors, or will be challenged, circumvented or
invalidated by third parties. Because patent applications in the United States and certain other jurisdictions are maintained in secrecy for 18&nbsp;months, and since publication of discoveries in
the scientific or patent literature often lags behind actual discoveries, we cannot be certain of the priority of inventions covered by pending patent applications. This potential issue is exacerbated
by the fact that, prior to March&nbsp;16, 2013, in the United States, the first to make the claimed invention may be entitled to the patent. On March&nbsp;16, 2013, the United States transitioned
to a "first to file" system in which the first inventor to file&nbsp;a patent application may be entitled to the patent. Therefore, we may have to participate in interference proceedings declared by
the United States Patent and Trademark Office, or PTO, or a foreign patent office to determine priority of invention. Moreover, we may have to participate in other proceedings declared by the United
States PTO or a foreign patent office, such as post-grant proceedings and oppositions, that challenge the validity of a granted patent. Such proceedings could result in substantial cost, even if the
eventual outcome is favorable to us. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Although
we currently have issued patents directed to a number of different attributes of our products, and pending applications on others, there can be no assurance that any issued
patents would be held
valid by a court of competent jurisdiction. An adverse outcome could subject us to significant liabilities to third parties, require disputed rights to be licensed from third parties or require us to
cease using specific compounds or technology. To the extent prudent, we intend to bring litigation against third parties that we believe are infringing our patents. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In most countries in which we file, the patent term is
20&nbsp;years from the earliest date of filing a non-provisional patent application. In the United States, a patent's term may be lengthened by patent term adjustment, which compensates a patentee
for administrative delays by the United States PTO in granting a patent, or may be shortened if a patent is terminally disclaimed over another patent with an earlier expiration date. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
mentioned above, in the United States, the patent term of a patent that covers an FDA-approved drug may also be eligible for patent term extension, which permits patent term
restoration as compensation for the patent term lost during the FDA regulatory review process. In the future, if and when our pharmaceutical products receive FDA approval, we expect to apply for
patent term extensions on patents covering those products. We intend to seek patent term adjustments and extensions to any of our issued patents in any jurisdiction where these are available, however
there is no guarantee that the applicable authorities, including the FDA in the United States, will agree with our assessment of whether such extensions should be granted, and even if granted, the
length of such adjustments or extensions. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
protect our rights to any of our issued patents and proprietary information, we may need to litigate against infringing third parties, or avail ourselves of the courts or participate
in hearings to determine the scope and validity of those patents or other proprietary rights. These types of proceedings are often costly and could be very time-consuming to us, and we cannot be
certain that the deciding authorities will rule in our favor. An unfavorable decision could result in the invalidation or a limitation in the scope of our patents or forfeiture of the rights
associated with our patents or pending patent applications. Any such decision could result in our key technologies not being protectable, allowing third parties to use our technology without being
required to pay us licensing fees or may compel us to license needed technologies from third parties to avoid infringing third-party patent and proprietary rights. Such a decision could even </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>146</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=149,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=393483,FOLIO='146',FILE='DISK109:[18ZBU1.18ZBU44601]DO44601A.;17',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_do44601_1_147"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>result
in the invalidation or a limitation in the scope of our patents or could cause us to lose our rights under existing issued patents or not to have rights granted under our pending patent
applications. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, we intend to seek orphan drug exclusivity in jurisdictions in which it is available. A prerequisite to orphan drug exclusivity in the United States and in the European Union
is orphan drug
designation. An orphan drug designation may be granted where a drug is developed specifically to treat a rare or uncommon medical treatment. If a product which has an orphan drug designation
subsequently receives the first regulatory approval for the indication for which it has such designation, the product is entitled to orphan exclusivity, meaning that the applicable regulatory
authority may not approve any other applications to market the same drug for the same indication, except in certain very limited circumstances, for a period of seven years in the United States and
10&nbsp;years in the European Union. Orphan drug exclusivity does not prevent competitors from developing or marketing different drugs for an indication. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
also rely on trade secret protection for our confidential and proprietary information. Although we take steps to protect our proprietary information and trade secrets, including
through contractual means with our employees and consultants, no assurance can be given that others will not independently develop substantially equivalent proprietary information and techniques or
otherwise gain access to our trade secrets or disclose such technology, or that we can meaningfully protect our trade secrets. It is our policy to require our employees, consultants, outside
scientific collaborators, sponsored researchers and other advisors to execute confidentiality agreements upon the commencement of employment or consulting relationships with us. These agreements
provide that all confidential information developed or made known to the individual during the course of the individual's relationship with us is to be kept confidential and not disclosed to third
parties except in specific circumstances. In the case of employees, the agreements provide that all inventions conceived by the individual will be our exclusive property. There can be no assurance,
however, that these agreements will provide meaningful protection or adequate remedies for our trade secrets in the event of unauthorized use or disclosure of such information. </FONT></P>


<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Manufacturing  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We currently contract with a third party for the manufacture of setmelanotide and intend to continue to do so in the future. We have entered
into a process development and manufacturing services agreement with CordenPharma International, formerly Peptisyntha&nbsp;SA prior to its acquisition by CordenPharma International, or Peptisyntha,
under which Peptisyntha will provide certain process development and manufacturing services in connection with the manufacture of setmelanotide. Under the agreement, we pay Peptisyntha for services in
accordance with the terms of mutually agreed upon work orders, which we and Peptisyntha may enter into from time to time. The agreement also provides that, subject to certain conditions, for a period
following each product launch date, we will source from Peptisyntha a portion of our requirements for that product being sourced from non-affiliate third parties. Under the agreement, each party is
subject to customary indemnification provisions. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Peptisyntha agreement will continue, unless earlier terminated pursuant to its terms, until the later of six years from the July&nbsp;17, 2013 effective date or the completion of
all services under all work plans executed in accordance with the terms of the agreement prior to the sixth anniversary of its effective date. The agreement may be extended by us continuously for
additional two-year periods upon written notice to Peptisyntha. We also may terminate the agreement or any work order thereunder upon at least 30&nbsp;days' prior written notice to Peptisyntha. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have also entered into a process development and manufacturing services agreement with Recipharm Monts&nbsp;S.A.S., or Recipharm, under which Recipharm will provide certain process
development and manufacturing services in connection with the manufacture of setmelanotide. Under the agreement, we pay Recipharm for services in accordance with the terms of mutually agreed upon work
orders, which we and Recipharm may enter into from time to time. Under the agreement, each party is subject to customary indemnification provisions. The Recipharm agreement will continue, unless
earlier terminated pursuant to its terms, until the later of three years from the December&nbsp;21, 2016 effective date or the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>147</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=150,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=1036302,FOLIO='147',FILE='DISK109:[18ZBU1.18ZBU44601]DO44601A.;17',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_do44601_1_148"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>completion
of all services under all work plans executed in accordance with the terms of the agreement prior to the third anniversary of its effective date. The agreement may be extended by us
continuously for additional two-year periods upon written notice to Recipharm. We also may terminate the agreement or any work order thereunder upon at least 60&nbsp;days' prior written notice to
Recipharm. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
contract manufacturing agreements give us visibility into the expected future cost of producing setmelanotide at commercial scale. Based upon a range of prices of currently-marketed
therapies indicated for orphan diseases, we believe that our cost of goods for setmelanotide will be highly competitive. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
currently have no plans to build our own clinical or commercial scale manufacturing capabilities. To meet our projected needs for clinical supplies to support our activities through
regulatory approval and commercial manufacturing, the contract manufacturing organizations, or CMOs, with whom we currently work will need to increase scale of production or we expect that we will
need to secure alternate suppliers. We have not currently identified alternate suppliers in the event the current CMOs we utilize are unable to scale production. Because we rely on these CMOs, we have
personnel with pharmaceutical development and manufacturing experience who are responsible for maintaining our CMO relationships. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Regulatory Matters  </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Government Regulation and Product Approvals  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Government authorities in the United States, at the federal, state and local level, and in other countries and jurisdictions, including the
European Union, extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, packaging, storage, recordkeeping, labeling, advertising,
promotion, distribution, marketing, post-approval monitoring and reporting, and import and export of pharmaceutical products. The processes for obtaining marketing approvals in the United States and
in foreign countries and jurisdictions, along with subsequent compliance with applicable statutes and regulations and other competent authorities, require the expenditure of substantial time and
financial resources. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Review and Approval of Drugs in the United States  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the United States, the FDA approves drug products under the Federal Food, Drug, and Cosmetic Act, or FDCA, and associated implementing
regulations. Biological products, on the other hand, are licensed by the FDA under the Public Health Service Act, or PHSA. With passage of the Biologics Price Competition and Innovation Act of 2009,
Congress amended the definition of "biological product" in the PHSA so as to exclude a chemically synthesized polypeptide from licensure under the PHSA. Rather, the Act provided that such products
would be treated as drugs under the FDCA. Subsequently, through final guidance issued in April 2015, the FDA indicated that a "chemically synthesized polypeptide" is any alpha amino acid polymer that
is made entirely by chemical synthesis and is less than 100 amino acids in size. Accordingly, based on this FDA guidance, we believe that our products will not be treated as biologics subject to
approval of a biologics license application, or BLA, by the FDA, and rather will be treated as drug products subject to approval of a new drug application, or NDA, by the FDA pursuant to the FDCA. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
failure to comply with applicable requirements under the FDCA and other applicable laws at any time during the product development process, approval process or after approval may
subject an applicant and/or sponsor to a variety of administrative or judicial sanctions, including refusal by the FDA to approve pending applications, withdrawal of an approval, imposition of a
clinical hold, issuance of warning letters and other types of letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of
government contracts, restitution, disgorgement of profits, or civil or criminal investigations and penalties brought by the FDA and the Department of Justice or other governmental entities. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>148</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=151,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=549113,FOLIO='148',FILE='DISK109:[18ZBU1.18ZBU44601]DO44601A.;17',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_do44601_1_149"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;An
applicant seeking approval to market and distribute a new drug product in the United States must typically undertake the following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> completion of preclinical laboratory tests, animal studies and formulation studies in compliance with the FDA's good laboratory practice, or
GLP, regulations; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> submission to the FDA of an IND, which must take effect before human clinical trials may begin; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> approval by an independent institutional review board, or IRB, representing each clinical site before each clinical trial may be initiated; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> performance of adequate and well-controlled human clinical trials in accordance with current Good Clinical Practices, or cGCPs, to establish
the safety and efficacy of the proposed drug product for each proposed indication; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> preparation and submission to the FDA of an NDA requesting marketing for one or more proposed indications; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> review by an FDA advisory committee, where appropriate or if applicable, as may be requested by the FDA to assist with its review; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities at which the product, or components thereof,
are produced to assess compliance with current Good Manufacturing Practices, or cGMP, requirements and to assure that the facilities, methods and controls are adequate to preserve the product's
identity, strength, quality and purity; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> satisfactory completion of FDA audits of clinical trial sites to assure compliance with cGCPs and the integrity of the clinical data; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> payment of user fees, per published Prescription Drug User Fee Act, or PDUFA, guidelines for the relevant year, and securing FDA approval of
the NDA; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> compliance with any post-approval requirements, including the potential requirement to implement a Risk Evaluation and Mitigation Strategy, or
REMS, and the potential requirement to conduct post-approval studies. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Preclinical Studies  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Before an applicant begins testing a compound with potential therapeutic value in humans, the drug candidate enters the preclinical testing
stage. Preclinical studies include laboratory evaluation of product chemistry, toxicity and formulation, as well as </FONT><FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2> and animal studies to
assess the potential safety and activity of the drug for initial testing in humans and to establish a rationale for therapeutic use. The conduct of preclinical studies is subject to federal
regulations and requirements, including GLP regulations. The results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and
plans for clinical trials, among other things, are submitted to the FDA as part of an IND. Some long-term preclinical testing, such as animal tests of reproductive adverse events and carcinogenicity,
may continue after the IND is submitted. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


The IND and IRB Processes  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;An IND is an exemption from the FDCA that allows an unapproved drug to be shipped in interstate commerce for use in an investigational clinical
trial and a request for FDA authorization to administer an investigational drug to humans. Such authorization must be secured prior to interstate shipment and administration of any new drug that is
not the subject of an approved NDA. In support of a request for an IND, applicants must submit a protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as
part of the IND. In addition, the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical trials,
among other things, are submitted to the FDA as part of an IND. The FDA requires a 30-day waiting period after the filing of each IND before clinical trials may begin. This waiting period is designed </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>149</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=152,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=430644,FOLIO='149',FILE='DISK109:[18ZBU1.18ZBU44601]DO44601A.;17',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_do44601_1_150"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>to
allow the FDA to review the IND to determine whether human research subjects will be exposed to unreasonable health risks. At any time during this 30-day period, the FDA may raise concerns or
questions about the conduct of the trials as outlined in the IND and impose a clinical hold. In this case, the IND sponsor and the FDA must resolve any outstanding concerns before clinical trials can
begin. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Following
commencement of a clinical trial under an IND, the FDA may also place a clinical hold or partial clinical hold on that trial. A clinical hold is an order issued by the FDA to
the sponsor to delay a proposed clinical investigation or to suspend an ongoing investigation. A partial clinical hold is a delay or suspension of only part of the clinical work requested under the
IND. For example, a specific protocol or part of a protocol is not allowed to proceed, while other protocols may do so. No more than 30&nbsp;days after imposition of a clinical hold or partial
clinical hold, the FDA will provide the sponsor a written explanation of the basis for the hold. Following issuance of a clinical hold or partial clinical hold, an investigation may only resume after
the FDA has notified the sponsor that the investigation may proceed. The FDA will base that determination on information provided by the sponsor correcting the deficiencies previously cited or
otherwise satisfying the FDA that the investigation can proceed. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
sponsor may choose, but is not required, to conduct a foreign clinical study under an IND. When a foreign clinical study is conducted under an IND, all FDA IND requirements must be met
unless waived. When the foreign clinical study is not conducted under an IND, the sponsor must ensure that the study complies with certain regulatory requirements in order to use the study as support
for an IND or application for marketing approval. Specifically, on April&nbsp;28, 2008, the FDA amended its regulations governing the acceptance of foreign clinical studies not conducted under an
IND or a NDA.
The final rule provides that such studies must be conducted in accordance with good clinical practice, or GCP, including review and approval by an independent ethics committee, or IEC, and informed
consent from subjects. The GCP requirements in the final rule encompass both ethical and data integrity standards for clinical studies. The FDA's regulations are intended to help ensure the protection
of human subjects enrolled in non-IND foreign clinical studies, as well as the quality and integrity of the resulting data. They further help ensure that non-IND foreign studies are conducted in a
manner comparable to that required for IND studies. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition to the foregoing IND requirements, an IRB representing each institution participating in the clinical trial must review and approve the plan for any clinical trial before it
commences at that institution, and the IRB must conduct continuing review and reapprove the study at least annually. The IRB must review and approve, among other things, the study protocol and
informed consent information to be provided to study subjects. An IRB must operate in compliance with FDA regulations. An IRB can suspend or terminate approval of a clinical trial at its institution,
or an institution it represents, if the clinical trial is not being conducted in accordance with the IRB's requirements or if the product candidate has been associated with unexpected serious harm to
patients. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additionally,
some trials are overseen by an independent group of qualified experts organized by the trial sponsor, known as a data safety monitoring board or committee. This group
provides authorization for whether or not a trial may move forward at designated check points based on access that only the group maintains to available data from the study. Suspension or termination
of development during any phase of clinical trials can occur if it is determined that the participants or patients are being exposed to an unacceptable health risk. Other reasons for suspension or
termination may be made by us based on evolving business objectives and/or competitive climate. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Information
about certain clinical trials must be submitted within specific timeframes to the National Institutes of Health, or NIH, for public dissemination on its ClinicalTrials.gov
website. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Human Clinical Studies in Support of an NDA  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in
accordance with GCP requirements, which include, among other things, the requirement that all research subjects provide their informed consent in writing before their participation in any clinical
trial. Clinical trials are conducted under written study protocols detailing, among other things, the inclusion and exclusion criteria, the objectives of the study, the parameters to be used in
monitoring safety and the effectiveness criteria to be evaluated. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>150</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=153,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=861934,FOLIO='150',FILE='DISK109:[18ZBU1.18ZBU44601]DO44601A.;17',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_dq44601_1_151"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Human clinical trials are typically conducted in the following sequential phases, which may overlap or be combined:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Phase&nbsp;1: The drug is initially introduced into healthy human subjects or, in certain indications such as cancer, patients with the
target disease or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early indication of its effectiveness and to determine
optimal dosage. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Phase&nbsp;2: The drug is administered to a limited patient population to identify possible adverse effects and safety risks, to
preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Phase&nbsp;3: The drug is administered to an expanded patient population, generally at geographically dispersed clinical trial sites, in
well-controlled clinical trials to generate enough data to statistically evaluate the efficacy and safety of the product for approval, to establish the overall risk-benefit profile of the product, and
to provide adequate information for the labeling of the product. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Phase&nbsp;4: Post-approval studies, when applicable, are conducted following initial approval, typically to gain additional experience and
data from treatment of patients in the intended therapeutic indication. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Progress
reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently if serious adverse events occur. In addition, IND safety
reports must be submitted to the FDA for any of the following: serious and unexpected suspected adverse reactions; findings from other studies or animal or </FONT><FONT SIZE=2><I>in
vitro</I></FONT><FONT SIZE=2> testing that suggest a significant risk in humans exposed to the drug; and any clinically important increase in the case of a serious suspected adverse reaction over that
listed in the protocol or investigator brochure. Phase&nbsp;1, Phase&nbsp;2 and Phase&nbsp;3 clinical trials may not be completed successfully within any specified period, or at all.
Furthermore, the FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health
risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution, or an institution it represents, if the clinical trial is not being conducted in accordance with the
IRB's requirements or if the drug has been associated with unexpected serious harm to patients. The FDA will typically inspect one or more clinical sites to assure compliance with GCP and the
integrity of the clinical data submitted. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
the course of clinical development, the sponsor often refines the indication and endpoints on which the NDA will be based. For endpoints based on PROs and OROs, the process
typically is an iterative one. The FDA has issued guidance on the framework it uses to evaluate PRO instruments, and it may offer advice on optimizing PRO and ORO instruments during the clinical
development process, but the FDA usually reserves final judgment until it reviews the NDA. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Concurrent
with clinical trials, companies often complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the
drug as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing
quality batches of the drug candidate and, among other things, must develop methods for testing the identity, strength, quality, purity and potency of the final drug. Additionally, appropriate
packaging must be selected and tested and stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable deterioration over its shelf life. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
a general guidance meeting with FDA review staff in 2013, following the opening of our independent new drug application for the development of setmelanotide, the FDA provided us with
general principles to follow in designing clinical studies for drugs intended for use in an indication targeted to a specific obese population. In 2015, we received further guidance from FDA review
staff in a meeting to discuss clinical endpoints and trial design strategies for the study of setmelanotide in patients with rare </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>151</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=154,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=578524,FOLIO='151',FILE='DISK109:[18ZBU1.18ZBU44601]DQ44601A.;8',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_dq44601_1_152"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>genetic
forms of obesity. At that meeting, the FDA noted its experience in applying regulatory flexibility for drugs intended to treat rare diseases. It indicated that it would take into account
factors related to particular patient populations, such as the prevalence and severity of the disease, but also noted that the requirements for a phase&nbsp;3 program would depend on the effect
observed and the robustness of the results. The FDA also indicated that it would exercise flexibility regarding the timing and requirements for certain preclinical toxicology testing. Additional
meetings occurred in 2017 and 2018. We intend to continue to take advantage of our Breakthrough Therapy designation by continuing to meet regularly with FDA review staff to discuss methods to shorten
the development timeline for indication in POMC deficiency obesity, LEPR deficiency obesity, Bardet-Biedl syndrome, and Alstr&ouml;m syndrome, and to use the knowledge gained to do likewise
for other closely-related indications in rare genetic forms of obesity. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Submission and Review of an NDA by the FDA  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Assuming successful completion of required clinical testing and other requirements, the results of the preclinical studies and clinical trials,
together with detailed information relating to the product's chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an NDA requesting approval
to market the drug product for one or more indications. Under the Prescription Drug User Fee Amendments of 2017 (PDUFA VI), the submission of most NDAs is additionally subject to a human drug
application fee, which is collected at the time of submission. PDUFA VI eliminated user fees for supplements and establishments. In
addition, the sponsor of an approved NDA is also subject to annual program fee rather than product fees under the previous iteration of PDUFA. For federal fiscal year 2018, the submission of an NDA
for which clinical data (other than bioavailability or bioequivalence studies) with respect to safety or effectiveness are required for approval is subject to an application user fee of $2,421,495.
The annual program user fee for fiscal year 2018 is $304,162. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certain
exceptions and waivers are available for some of these fees, such as an exception from the application fee for drugs with orphan designation and a waiver for certain small
businesses. Orphan designated drugs are also exempt from program fees if the drug meets certain public health and revenue criteria. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
FDA conducts a preliminary review of an NDA generally within 60 calendar days of its receipt and strives to inform the sponsor by the 74th&nbsp;day after the FDA's receipt of the
submission to determine whether the application is sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event,
the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for
filing, the FDA begins an in-depth substantive review. The FDA has agreed to specified performance goals in the review process of NDAs. Under that agreement, 90% of applications seeking approval of
New Molecular Entities, or NMEs, are meant to be reviewed within ten months from the date on which the FDA accepts the NDA for filing, and 90% of applications for NMEs that have been designated for
"priority review" are meant to be reviewed within six months of the filing date. For applications seeking approval of drugs that are not NMEs, the ten-month and six-month review periods run from the
date the FDA receives the application. The review process and the Prescription Drug User Fee Act goal date may be extended by the FDA for three additional months to consider new information or
clarification provided by the applicant to address an outstanding deficiency identified by the FDA following the original submission. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Before
approving an NDA, the FDA typically will inspect the facility or facilities where the product is or will be manufactured. These pre-approval inspections may cover all facilities
associated with an NDA submission, including drug component manufacturing, e.g.,&nbsp;active pharmaceutical ingredients, finished drug product manufacturing, and control testing laboratories. The
FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the
product within required specifications. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>152</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=155,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=93624,FOLIO='152',FILE='DISK109:[18ZBU1.18ZBU44601]DQ44601A.;8',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_dq44601_1_153"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>Additionally,
before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with cGCP. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, as a condition of approval, the FDA may require an applicant to develop a REMS. REMS use risk minimization strategies beyond the professional labeling to ensure that the
benefits of the product outweigh the potential risks. To determine whether a REMS is needed, the FDA will consider the size of the population likely to use the product, seriousness of the disease,
expected benefit of the product, expected duration of treatment, seriousness of known or potential adverse events, and whether the product is a new molecular entity. REMS can include medication
guides, physician communication plans for healthcare professionals, and elements to assure safe use, or ETASU. ETASU may include, but are not limited to, special training or certification for
prescribing or dispensing, dispensing only under certain circumstances, special monitoring, and the use of patient registries. The FDA may require a REMS before approval or post-approval if it becomes
aware of a serious risk associated with use of the product. The requirement for a REMS can materially affect the potential market and profitability of a product. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
FDA is required to refer an application for a novel drug to an advisory committee or explain why such referral was not made. Typically, an advisory committee is a panel of
independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what
conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Expedited Programs for Serious Conditions: Fast Track, Breakthrough Therapy, Priority Review and
Accelerated Approval  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The FDA is authorized to designate certain products for beneficial treatment if they are intended to address an unmet medical need in the
treatment of a serious or life-threatening disease or condition. These expedited programs are referred to as Fast Track designation, Breakthrough Therapy designation, priority review designation, and
accelerated approval. The 21st&nbsp;Century Cures Act, or the Cures Act, signed into law in December 2016, authorized $500&nbsp;million in new funding over 9&nbsp;years to help the FDA
accelerate review and approval of products and bring new innovations and advances to patients faster and more efficiently. The Cures Act enhances the Agency's ability to modernize clinical trial
designs and clinical outcome assessments to speed the development and review of novel medical products. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Fast Track  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The FDA may designate a product for Fast Track review if it is intended, whether alone or in combination with one or more other products, for
the treatment of a serious or life-threatening disease or condition, and it demonstrates the potential to address unmet medical needs
for such a disease or condition. For Fast Track products, sponsors may have greater interactions with the FDA and the FDA may initiate review of sections of a Fast Track product's application before
the application is complete. This rolling review may be available if the FDA determines, after preliminary evaluation of clinical data submitted by the sponsor, that a Fast Track product may be
effective. The sponsor must also provide, and the FDA must approve, a schedule for the submission of the remaining information and the sponsor must pay applicable user fees. However, the FDA's time
period goal for reviewing a Fast Track application does not begin until the last section of the application is submitted. In addition, the Fast Track designation may be withdrawn by the FDA if the FDA
believes that the designation is no longer supported by data emerging in the clinical trial process. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Breakthrough Therapy  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A product may be designated as Breakthrough Therapy if it is intended, either alone or in combination with one or more other products, to treat
a serious or life-threatening disease or condition </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>153</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=156,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=320624,FOLIO='153',FILE='DISK109:[18ZBU1.18ZBU44601]DQ44601A.;8',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_dq44601_1_154"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>and
preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial
treatment effects observed early in clinical development. The FDA may take certain actions with respect to Breakthrough Therapies, including holding meetings with the sponsor throughout the
development process; providing timely advice to the product sponsor regarding development and approval; involving more senior staff in the review process; assigning a cross-disciplinary project lead
for the review team; and taking other steps to design the clinical trials in an efficient manner. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Priority Review  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The FDA may designate a product for priority review if it is a product that treats a serious condition and, if approved, would provide a
significant improvement in safety or effectiveness. The FDA determines, on a case- by-case basis, whether the proposed product represents a significant improvement when compared with other available
therapies. Significant improvement may be illustrated by evidence of increased effectiveness in the treatment of a condition, elimination or substantial reduction of a treatment-limiting product
reaction, documented enhancement of patient compliance
that may lead to improvement in serious outcomes, and evidence of safety and effectiveness in a new subpopulation. A priority designation is intended to direct overall attention and resources to the
evaluation of such applications, and to shorten the FDA's goal for taking action on a marketing application from ten months to six months. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Accelerated Approval Pathway  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The FDA may grant accelerated approval to a drug for a serious or life-threatening condition that provides meaningful therapeutic advantage to
patients over existing treatments based upon a determination that the drug has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit. The FDA may also grant
accelerated approval for such a condition when the product has an effect on an intermediate clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality, or
IMM, and that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and
the availability or lack of alternative treatments. Drugs granted accelerated approval must meet the same statutory standards for safety and effectiveness as those granted traditional approval. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign or other measure that is thought to
predict clinical benefit, but is not itself a measure of clinical benefit. Surrogate endpoints can often be measured more easily or more rapidly than clinical endpoints. An intermediate clinical
endpoint is a measurement of a therapeutic effect that is considered reasonably likely to predict the clinical benefit of a drug, such as an effect on IMM. The FDA has limited experience with
accelerated approvals based on intermediate clinical endpoints, but has indicated that such endpoints generally may support accelerated approval where the therapeutic effect measured by the endpoint
is not itself a clinical benefit and basis for traditional approval, if there is a basis for concluding that the therapeutic effect is reasonably likely to predict the ultimate clinical benefit of a
drug. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accelerated
approval is most often used in settings in which the course of a disease is long and an extended period of time is required to measure the intended clinical benefit of a
drug, even if the effect on the surrogate or intermediate clinical endpoint occurs rapidly. Thus, accelerated approval has been used extensively in the development and approval of drugs for treatment
of a variety of cancers in which the goal of therapy is generally to improve survival or decrease morbidity and the duration of the typical disease course requires lengthy and sometimes large trials
to demonstrate a clinical or survival benefit. Thus, the benefit of accelerated approval derives from the potential to receive approval based on surrogate endpoints sooner than possible for trials
with clinical or survival endpoints, rather than deriving from any explicit shortening of the FDA approval timeline, as is the case with priority review. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>154</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=157,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=660099,FOLIO='154',FILE='DISK109:[18ZBU1.18ZBU44601]DQ44601A.;8',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_dq44601_1_155"> </A>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accelerated
approval is usually contingent on a sponsor's agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the drug's
clinical benefit. As a result, a drug candidate approved on this basis is subject to rigorous post-marketing compliance requirements, including the completion of Phase&nbsp;4 or post-approval
clinical trials to confirm the effect on the clinical endpoint. Failure to conduct required post-approval studies, or confirm a clinical benefit during post-marketing studies, would allow the FDA to
initiate expedited proceedings to withdraw approval of the drug. All promotional materials for drug candidates approved under accelerated regulations are subject to prior review by the FDA. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


The FDA's Decision on an NDA  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On the basis of the FDA's evaluation of the NDA and accompanying information, including the results of the inspection of the manufacturing
facilities, the FDA may issue an approval letter or a complete response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific
indications. A complete response letter generally outlines the deficiencies in the submission and may require substantial additional testing or information in order for the FDA to reconsider the
application. If and when those deficiencies have been addressed to the FDA's satisfaction in a resubmission of the NDA, the FDA will issue an approval letter. The FDA has committed to reviewing such
resubmissions in two or six months depending on the type of information included. Even with submission of this additional information, the FDA ultimately may decide that the application does not
satisfy the regulatory criteria for approval. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the FDA approves a product, it may limit the approved indications for use for the product, require that contraindications, warnings or precautions be included in the product labeling,
require that post-approval studies, including Phase&nbsp;4 clinical trials, be conducted to further assess the drug's safety after approval, require testing and surveillance programs to monitor the
product after commercialization, or impose other conditions, including distribution restrictions or other risk management mechanisms, including REMS, which can materially affect the potential market
and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-market studies or surveillance programs. After approval, many types of
changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Post-Approval Requirements  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among
other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences with the product. After
approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing, annual program user
fee requirements for any marketed products. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and state
agencies, and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and
often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements
upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality
control to maintain cGMP compliance. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>155</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=158,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=1046111,FOLIO='155',FILE='DISK109:[18ZBU1.18ZBU44601]DQ44601A.;8',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_dq44601_1_156"> </A>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Once
an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches
the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with
regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition
of distribution or other restrictions under a REMS program. Other potential consequences include, among other things:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> restrictions on the marketing or manufacturing of the product, suspension of the approval, or complete withdrawal of the product from the
market or product recalls; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> fines, warning letters or holds on post-approval clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> refusal of the FDA to approve pending NDAs or supplements to approved NDAs; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> product seizure or detention, or refusal to permit the import or export of products; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> injunctions or the imposition of civil or criminal penalties. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
FDA strictly regulates the marketing, labeling, advertising and promotion of prescription drug products placed on the market. This regulation includes, among other things, standards
and regulations for direct-to-consumer advertising, communications regarding unapproved uses, industry-sponsored scientific and educational activities, and promotional activities involving the
Internet and social media. Promotional claims about a drug's safety or effectiveness are prohibited before the drug is approved. After approval, a drug product generally may not be promoted for uses
that are not approved by the FDA, as reflected in the product's prescribing information. In the United States, healthcare professionals are generally permitted to prescribe drugs for such uses not
described in the drug's labeling, known as off-label uses, because the FDA does not regulate the practice of medicine. However, FDA regulations impose rigorous restrictions on manufacturers'
communications, prohibiting the promotion of off-label uses. It may be permissible, under very specific, narrow conditions, for a manufacturer to engage in non-promotional, non-misleading
communication regarding off-label information, such as distributing scientific or medical journal information. If a company is found to have promoted off-label uses, it may become subject to adverse
public relations and administrative and judicial enforcement by the FDA, the Department of Justice, or the Office of the Inspector General of the Department of Health and Human Services, as well as
state authorities. This could subject a company to a range of penalties that could have a significant commercial impact, including civil and criminal fines and agreements that materially restrict the
manner in which a company promotes or distributes drug products. The federal government has levied large civil and criminal fines against companies for alleged improper promotion, and has also
requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act, or PDMA, and its implementation regulations, as well as the Drug
Supply Chain
Security Act, or DSCSA, which regulate the distribution and tracing of prescription drugs and prescription drug samples at the federal level, and set minimum standards for the regulation of drug
distributors by the states. The PDMA, its implementing regulations and state laws limit the distribution of prescription pharmaceutical product samples, and the DSCSA imposes requirements to ensure
accountability in distribution and to identify and remove counterfeit and other illegitimate products from the market. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Abbreviated New Drug Applications for Generic Drugs  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In 1984, with passage of the Hatch-Waxman Amendments to the FDCA, Congress established an abbreviated regulatory scheme allowing the FDA to
approve generic drugs that are shown to contain the same active ingredients as, and to be bioequivalent to, drugs previously approved by the FDA pursuant to NDAs. To obtain approval of a generic drug,
an applicant must submit an abbreviated new drug </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>156</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=159,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=509338,FOLIO='156',FILE='DISK109:[18ZBU1.18ZBU44601]DQ44601A.;8',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_dq44601_1_157"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>application,
or ANDA, to the agency. An ANDA is a comprehensive submission that contains, among other things, data and information pertaining to the active pharmaceutical ingredient, bioequivalence,
drug product formulation, specifications and stability of the generic drug, as well as analytical methods, manufacturing process validation data and quality control procedures. ANDAs are "abbreviated"
because they generally do not include preclinical and clinical data to demonstrate safety and effectiveness. Instead, in support of such applications, a generic manufacturer may rely on the
preclinical and clinical testing previously conducted for a drug product previously approved under an NDA, known as the reference-listed drug, or RLD. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Specifically,
in order for an ANDA to be approved, the FDA must find that the generic version is identical to the RLD with respect to the active ingredients, the route of administration,
the dosage form, the strength and the conditions of use of the drug. At the same time, the FDA must also determine that the generic drug is "bioequivalent" to the innovator drug. Under the statute, a
generic drug is bioequivalent to a RLD if "the rate and extent of absorption of the drug do not show a significant difference from the rate and extent of absorption of the listed drug..." </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
approval of an ANDA, the FDA indicates whether the generic product is "therapeutically equivalent" to the RLD in its publication "Approved Drug Products with Therapeutic Equivalence
Evaluations," also referred to as the "Orange Book." Physicians and pharmacists consider a therapeutic equivalent generic drug to be fully substitutable for the RLD. In addition, by operation of
certain state
laws and numerous health insurance programs, the FDA's designation of therapeutic equivalence often results in substitution of the generic drug without the knowledge or consent of either the
prescribing physician or patient. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
the Hatch-Waxman Amendments, the FDA may not approve an ANDA until any applicable period of non-patent exclusivity for the RLD has expired. The FDCA provides a period of five years
of non-patent data exclusivity for a new drug containing a new chemical entity. For the purposes of this provision, a new chemical entity, or NCE, is a drug that contains no active moiety that has
previously been approved by the FDA in any other NDA. An active moiety is the molecule or ion responsible for the physiological or pharmacological action of the drug substance. In cases where such NCE
exclusivity has been granted, an ANDA may not be filed with the FDA until the expiration of five years unless the submission is accompanied by a Paragraph&nbsp;IV certification, in which case the
applicant may submit its application four years following the original product approval. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
FDCA also provides for a period of three years of exclusivity if the NDA includes reports of one or more new clinical investigations, other than bioavailability or bioequivalence
studies, that were conducted by or for the applicant and are essential to the approval of the application. This three-year exclusivity period often protects changes to a previously approved drug
product, such as a new dosage form, route of administration, combination or indication. Three-year exclusivity would be available for a drug product that contains a previously approved active moiety,
provided the statutory requirement for a new clinical investigation is satisfied. Unlike five-year NCE exclusivity, an award of three-year exclusivity does not block the FDA from accepting ANDAs
seeking approval for generic versions of the drug as of the date of approval of the original drug product. The FDA typically makes decisions about granting data exclusivity shortly before a product is
approved. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


505(b)(2) NDAs  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As an alternative path to FDA approval for modifications to formulations or uses of products previously approved by the FDA pursuant to an NDA,
an applicant may submit an NDA under Section&nbsp;505(b)(2) of the FDCA. Section&nbsp;505(b)(2) was enacted as part of the Hatch-Waxman Amendments and permits the filing of an NDA where at least
some of the information required for approval comes from studies not conducted by, or for, the applicant. If the 505(b)(2) applicant can establish that reliance on FDA's previous findings of safety
and effectiveness is scientifically and legally appropriate, it may eliminate </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>157</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=160,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=628705,FOLIO='157',FILE='DISK109:[18ZBU1.18ZBU44601]DQ44601A.;8',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_dq44601_1_158"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>the
need to conduct certain preclinical or clinical studies of the new product. The FDA may also require companies to perform additional studies or measurements, including clinical trials, to support
the change from the previously approved reference drug. The FDA may then approve the new product candidate for all, or some, of the label indications for which the reference drug has been approved, as
well as for any new indication sought by the 505(b)(2) applicant. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Hatch-Waxman Patent Certification and the 30-Month Stay  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon approval of an NDA or a supplement thereto, NDA sponsors are required to list with the FDA each patent with claims that cover the
applicant's product or an approved method of using the product. Each of the patents listed by the NDA sponsor is published in the Orange Book. When an ANDA applicant files its application with the
FDA, the applicant is required to certify to the FDA concerning any patents listed for the reference product in the Orange Book, except for patents covering methods of use for which the ANDA applicant
is not seeking approval. To the extent that the Section&nbsp;505(b)(2) applicant is relying on studies conducted for an already approved product, the applicant is required to certify to the FDA
concerning any patents listed for the approved product in the Orange Book to the same extent that an ANDA applicant would. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Specifically,
the applicant must certify with respect to each patent that:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the required patent information has not been filed; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the listed patent has expired; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the listed patent has not expired, but will expire on a particular date and approval is sought after patent expiration; or </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the listed patent is invalid, unenforceable or will not be infringed by the new product. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
certification that the new product will not infringe the already approved product's listed patents or that such patents are invalid or unenforceable is called a Paragraph&nbsp;IV
certification. If the applicant does not challenge the listed patents or indicates that it is not seeking approval of a patented method of use, the application will not be approved until all the
listed patents claiming the referenced product have expired, other than method of use patents involving indications for which the applicant is not seeking approval. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the ANDA or 505(b)(2) applicant has provided a Paragraph&nbsp;IV certification to the FDA, the applicant must also send notice of the Paragraph&nbsp;IV certification to the NDA
and patent holders once the ANDA or 505(b)(2) application has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice
of the Paragraph&nbsp;IV certification. The filing of a patent infringement lawsuit within 45&nbsp;days after the receipt of a Paragraph&nbsp;IV certification automatically prevents the FDA from
approving the application until the earlier of 30&nbsp;months after the receipt of the Paragraph&nbsp;IV notice, expiration of the patent, or a decision in the infringement case that is favorable
to the applicant. The ANDA or 505(b)(2) application also will not be approved until any applicable non-patent exclusivity listed in the Orange Book for the branded reference drug has expired. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Pediatric Studies and Exclusivity  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under the Pediatric Research Equity Act, an NDA or supplement thereto must contain data that are adequate to assess the safety and effectiveness
of the drug product for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and
effective. With enactment of the FDA Safety and Innovation Act of 2012 (FDASIA) , sponsors must also submit pediatric study plans prior to the assessment data. Those plans must contain an outline of
the proposed pediatric study or studies the applicant plans to conduct, including study objectives and design, any deferral or waiver requests, and any other information required by regulation. The
applicant, the FDA, and the FDA's internal review </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>158</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=161,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=726703,FOLIO='158',FILE='DISK109:[18ZBU1.18ZBU44601]DQ44601A.;8',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_dq44601_1_159"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>committee
must then review the information submitted, consult with each other, and agree upon a final plan. The FDA or the applicant may request an amendment to the plan at any time. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, the FDA Reauthorization Act of 2017 (FDARA) requires the FDA to meet early in the development process to discuss pediatric study plans with drug sponsors. The legislation
requires the FDA to meet with drug sponsors by no later than the end-of-phase&nbsp;1 meeting for serious or life-threatening diseases and by no later than 90&nbsp;days after the FDA's receipt of
the study plan. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults,
or full or partial waivers from the pediatric data requirements. Additional requirements and procedures relating to deferral requests and requests for extension of deferrals are contained in FDASIA.
Unless and until the FDA promulgates a regulation stating otherwise, the pediatric data requirements do not apply to products with orphan designation. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pediatric
exclusivity is another type of non-patent marketing exclusivity in the United States and, if granted, provides for the attachment of an additional six months of marketing
protection to the term of any existing regulatory exclusivity, including the non-patent and orphan exclusivity. This six-month exclusivity may be granted if an NDA sponsor submits pediatric data that
fairly respond to a written request from the FDA for such data. The data do not need to show the product to be effective in the pediatric population studied; rather, if the clinical trial is deemed to
fairly respond to the FDA's request, the additional protection is granted. If reports of requested pediatric studies are submitted to and accepted by the FDA within the statutory time limits, whatever
statutory or regulatory periods of exclusivity or patent protection cover the product are extended by six months. This is not a patent term extension, but it effectively extends the regulatory period
during which the FDA cannot approve another application. With regard to patents, the six-month pediatric exclusivity period will not attach to any patents for which a generic (ANDA or 505(b)(2) NDA)
applicant submitted a paragraph&nbsp;IV patent certification, unless the NDA sponsor or patent owner first obtains a court determination that the patent is valid and infringed by a proposed generic
product. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Orphan Drug Designation and Exclusivity  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under the Orphan Drug Act, the FDA may designate a drug product as an "orphan drug" if it is intended to treat a rare disease or condition,
generally meaning that it affects fewer than 200,000 individuals in the United States, or more in cases in which there is no reasonable expectation that the cost of developing and making a drug
product available in the United States for
treatment of the disease or condition will be recovered from sales of the product. A company must request orphan drug designation before submitting an NDA for that drug for that rare disease or
condition. If the request is granted, the FDA will disclose the identity of the therapeutic agent and its potential use. orphan drug designation does not shorten the PDUFA goal dates for the
regulatory review and approval process, although it does convey certain advantages, such as tax benefits and exemptions from the PDUFA application and program fees. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
a product with orphan designation receives the first FDA approval for the disease or condition for which it has such designation or for a select indication or use within the rare
disease or condition for which it was designated, the product generally will receive orphan drug exclusivity. Orphan drug exclusivity means that the FDA may not approve another sponsor's marketing
application for the same drug for the same indication for seven years, except in certain limited circumstances. Orphan drug exclusivity does not block the approval of a different drug for the same
rare disease or condition, nor does it block the approval of the same drug for different indications. If a drug or drug product designated as an orphan product ultimately receives marketing approval
for an indication broader than what was designated on its orphan product application, it may not be entitled to exclusivity. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
FDARA, orphan exclusivity will not bar approval of another orphan drug under certain circumstances, including if a subsequent product with the same drug for the same indication is
shown to be </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>159</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=162,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=70458,FOLIO='159',FILE='DISK109:[18ZBU1.18ZBU44601]DQ44601A.;8',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_dq44601_1_160"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>clinically
superior to the approved product on the basis of greater efficacy or safety, or providing a major contribution to patient care, or if the company with orphan drug exclusivity is not able to
meet market demand. The new legislation reverses prior precedent holding that the Orphan Drug Act unambiguously required the FDA to recognize orphan exclusivity regardless of a showing of clinical
superiority. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Patent Term Restoration and Extension  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A patent claiming a new drug product may be eligible for a limited patent term extension, also known as patent term restriction, under the
Hatch-Waxman Act, which permits a patent restoration of up to five years for patent term lost during product development and the FDA regulatory review. Patent term extension is generally available
only for drug products whose active ingredient has not previously been approved by the FDA. The restoration period granted is typically one-half the time between the effective date of an IND and the
submission date of an NDA, plus the time between the
submission date of an NDA and the ultimate approval date. Patent term extension cannot be used to extend the remaining term of a patent past a total of 14&nbsp;years from the product's approval
date. Only one patent applicable to an approved drug product is eligible for the extension, and the application for the extension must be submitted prior to the expiration of the patent in question. A
patent that covers multiple drugs for which approval is sought can only be extended in connection with one of the approvals. The United States PTO reviews and approves the application for any patent
term extension in consultation with the FDA. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


FDA Approval and Regulation of Companion Diagnostics  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If safe and effective use of a therapeutic product depends on an </FONT><FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2> diagnostic medical
device, then the FDA generally will require approval or clearance of that diagnostic, known as an </FONT><FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2> companion diagnostic device, at the same time
that the FDA approves the therapeutic product. In August 2014, the FDA issued final guidance clarifying the requirements that will apply to approval of therapeutic products and </FONT> <FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2> companion
diagnostic devices. According to the guidance, for novel drugs, an </FONT><FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2> companion
diagnostic device and its corresponding therapeutic should be approved or cleared contemporaneously by the FDA for the use indicated in the therapeutic product's labeling. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the FDA determines that an </FONT><FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2> companion diagnostic device is essential to the safe and effective use of a novel therapeutic
product or indication, the FDA generally will not approve the therapeutic product or new therapeutic product indication if the </FONT><FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2> companion
diagnostic device is not approved or cleared for that indication. Approval or clearance of the </FONT><FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2> companion diagnostic device will ensure that the
device has been adequately evaluated and has adequate performance characteristics in the intended population. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
the FDCA, </FONT><FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2> diagnostics, including </FONT><FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2> companion diagnostic devices, are
generally regulated as medical devices. In the United States, the FDCA and its implementing regulations, and other federal and state statutes and regulations govern, among other things, medical device
design and development, preclinical and clinical testing, premarket clearance or approval, registration and listing, manufacturing, labeling, storage, advertising and promotion, sales and
distribution, export and import, and post-market surveillance. Unless an exemption applies, diagnostic tests require marketing clearance or approval from the FDA prior to commercial distribution. The
two primary types of FDA marketing authorization applicable to a medical device are premarket notification, also called 510(k) clearance, and premarket approval, or PMA approval. The FDA has generally
required </FONT><FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2> companion diagnostic devices intended to select the patients who will respond to a drug to obtain a PMA for that diagnostic
simultaneously with approval of the drug. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
PMA process, including the gathering of clinical and preclinical data and the submission to and review by the FDA, can take several years or longer. It involves a rigorous premarket
review during which the applicant must prepare and provide the FDA with reasonable assurance of the device's safety
and effectiveness and information about the device and its components regarding, among other things, device </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>160</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=163,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=907854,FOLIO='160',FILE='DISK109:[18ZBU1.18ZBU44601]DQ44601A.;8',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_dq44601_1_161"> </A>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>design,
manufacturing and labeling. PMA applications are subject to an application fee, which exceeds $250,000 for most PMAs. In addition, PMAs for certain devices must generally include the results
from extensive preclinical and adequate and well-controlled clinical trials to establish the safety and effectiveness of the device for each indication for which FDA approval is sought. In particular,
for a diagnostic, a PMA application typically requires data regarding analytical and clinical validation studies. As part of the PMA review, the FDA will typically inspect the manufacturer's
facilities for compliance with the Quality System Regulation, or QSR, which imposes elaborate testing, control, documentation and other quality assurance requirements. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;PMA
approval is not guaranteed, and the FDA may ultimately respond to a PMA submission with a not approvable determination based on deficiencies in the application and require additional
clinical trial or other data that may be expensive and time-consuming to generate and that can substantially delay approval. If the FDA's evaluation of the PMA application is favorable, the FDA
typically issues an approvable letter requiring the applicant's agreement to specific conditions, such as changes in labeling, or specific additional information, such as submission of final labeling,
in order to secure final approval of the PMA. If the FDA's evaluation of the PMA or manufacturing facilities is not favorable, the FDA will deny approval of the PMA or issue a not approvable letter. A
not approvable letter will outline the deficiencies in the application and, where practical, will identify what is necessary to make the PMA approvable. The FDA may also determine that additional
clinical trials are necessary, in which case the PMA approval may be delayed for several months or years while the trials are conducted and then the data submitted in an amendment to the PMA. If the
FDA concludes that the applicable criteria have been met, the FDA will issue a PMA for the approved indications, which can be more limited than those originally sought by the applicant. The PMA can
include post-approval conditions that the FDA believes necessary to ensure the safety and effectiveness of the device, including, among other things, restrictions on labeling, promotion, sale and
distribution. Once granted, PMA approval may be withdrawn by the FDA if compliance with post approval requirements, conditions of approval or other regulatory standards are not maintained or problems
are identified following initial marketing. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;After
a device is placed on the market, it remains subject to significant regulatory requirements. Medical devices may be marketed only for the uses and indications for which they are
cleared or approved. Device manufacturers must also establish registration and device listings with the FDA. A medical device manufacturer's manufacturing processes and those of its suppliers are
required to comply with the applicable portions of the QSR, which cover the methods and documentation of the design, testing, production, processes, controls, quality assurance, labeling, packaging
and shipping of medical devices. Domestic facility records and manufacturing processes are subject to periodic unscheduled inspections by the FDA. The FDA also may inspect foreign facilities that
export products to the United States. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


The 21st&nbsp;Century Cures Act  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On December&nbsp;13, 2016, President Obama signed the 21<SUP>st</SUP>&nbsp;Century Cures Act, or the Cures Act, into law. The Cures Act
is designed to modernize and personalize healthcare, spur innovation and research, and streamline the discovery and development of new therapies through increased federal funding of particular
programs. It authorizes increased funding for the FDA to spend on innovation projects. The new law also amends the Public Health Service Act to reauthorize and expand funding for the National
Institutes of Health. The Act establishes the NIH Innovation Fund to pay for the cost of development and implementation of a strategic plan, early stage investigators and research. It also charges NIH
with leading and coordinating expanded pediatric research. Further, the Cures Act directs the Centers for Disease Control and Prevention to expand surveillance of neurological diseases. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With
amendments to the FDCA and the Public Health Service Act, or PHSA, Title III of the Cures Act seeks to accelerate the discovery, development, and delivery of new medicines and
medical technologies. To that end, and among other provisions, the Cures Act reauthorizes the existing priority review voucher program for certain drugs intended to treat rare pediatric diseases until
2020, and requires the FDA to evaluate the potential use of "real world evidence" to help support approval of new indications for approved drugs. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>161</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=164,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=191279,FOLIO='161',FILE='DISK109:[18ZBU1.18ZBU44601]DQ44601A.;8',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_ds44601_1_162"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


The FDA Reauthorization Act of 2017  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On August&nbsp;18, 2017, President Trump signed the FDA Reauthorization Act of 2017 (FDARA) into law. FDARA reauthorizes the various user fees
to facilitate the agency's review and oversight relating to prescription drugs, generic drugs, medical devices, and biosimilars. The legislation also includes several policy riders that will impact an
array of issues within the FDA's authority
including, among others, pediatric study requirements, orphan drug exclusivity, and the approval process for generic drugs. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Regulation and Procedures Governing Approval of Medicinal Products in the European Union  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition to regulations in the United States, we will be subject to a variety of foreign regulations governing clinical trials and commercial
sales and distribution of setmelanotide to the extent we choose to sell any setmelanotide outside of the United States. Whether or not we obtain FDA approval for a product, we must obtain approval of
a product by equivalent competent authorities in foreign jurisdictions before we can commence clinical trials or marketing of the product in those countries. The approval process varies from country
to country and the time may be longer or shorter than that required for FDA approval. The requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary
greatly from country to country. As in the United States, post-approval regulatory requirements, such as those regarding product manufacture, marketing, or distribution would apply to any product that
is approved outside the United States. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
process governing the marketing authorization of medicinal products in the European Union entails satisfactory completion of preclinical studies and adequate and well-controlled
clinical trials to establish the safety, quality and efficacy of the medicinal product for each proposed therapeutic indication. It also requires the submission to the relevant competent authorities
of a marketing authorization application, or MAA, and granting of a marketing authorization by these authorities before the product can be marketed and sold in the European Union. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Clinical Trial Approval  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Clinical Trials Directive 2001/20/EC, the Directive 2005/28/EC on Good Clinical Practice, or GCP, and the related national implementing
provisions of the individual EU member states govern the system for the approval of clinical trials in the European Union. Under this system, an applicant must obtain prior approval from the competent
national authority of the EU member states in which the clinical trial is to be conducted. Furthermore, the applicant may only start a clinical trial at a specific study site after the competent
ethics committee has issued a favorable opinion. The clinical trial application must be accompanied by, among other documents, an investigational medicinal product dossier (the Common Technical
Document) with supporting information prescribed by Directive 2001/20/EC, Directive&nbsp;2005/28/EC, where relevant the implementing national provisions of the individual EU member states and
further detailed in applicable guidance documents. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
April 2014, the new Clinical Trials Regulation, (EU) No 536/2014 (Clinical Trials Regulation) was adopted. The Regulation was anticipated to enter into force in 2019, but it is
expected to be delayed. The Clinical Trials Regulation will be directly applicable in all the EU member states, repealing the current Clinical Trials Directive 2001/20/EC. Conduct of all clinical
trials performed in the European Union will continue to be bound by currently applicable provisions until the new Clinical Trials Regulation becomes applicable. The extent to which on-going clinical
trials will be governed by the Clinical Trials Regulation will depend on when the Clinical Trials Regulation becomes applicable and on the duration of the individual clinical trial. If a clinical
trial continues for more than three years from the day on which the Clinical Trials Regulation becomes applicable the Clinical Trials Regulation will at that time begin to apply to the clinical trial. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
new Clinical Trials Regulation aims to simplify and streamline the approval of clinical trials in the European Union. The main characteristics of the regulation include: a
streamlined application procedure </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>162</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=165,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=1047229,FOLIO='162',FILE='DISK109:[18ZBU1.18ZBU44601]DS44601A.;12',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_ds44601_1_163"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>via
a single entry point, the "EU portal"; a single set of documents to be prepared and submitted for the application as well as simplified reporting procedures for clinical trial sponsors; and a
harmonized procedure for the assessment of applications for clinical trials, which is divided in two parts. Part&nbsp;I is assessed by the competent authorities of all EU member states in which an
application for authorization of a clinical trial has been submitted (member states concerned). Part&nbsp;II is assessed separately by each member state concerned. Strict deadlines have been
established for the assessment of clinical trial applications. The role of the relevant ethics committees in the assessment procedure will continue to be governed by the national law of the concerned
EU member state. However, overall related timelines will be defined by the Clinical Trials Regulation. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Marketing Authorization  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To obtain a marketing authorization for a product under European Union regulatory systems, an applicant must submit an MAA either under a
centralized procedure administered by the EMA or one of the procedures administered by competent authorities in the EU member states (decentralized procedure, national procedure or mutual recognition
procedure). A marketing authorization may be granted only to an applicant established in the European Union. Regulation (EC) No 1901/2006 provides that prior to obtaining a marketing authorization in
the European Union, applicants have to demonstrate compliance with all measures included in an EMA-approved Pediatric Investigation Plan, or PIP, covering all subsets of the pediatric population,
unless the EMA has granted (1)&nbsp;a product-specific waiver, (2)&nbsp;a class waiver or (3)&nbsp;a deferral for one or
more of the measures included in the PIP. On April&nbsp;27, 2018, the EMA adopted a positive opinion concerning the PIPs for setmelanotide in the treatment of appetite and general nutritional
disorders. This included the deferral and the waiver requested by us </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
centralized procedure provides for the grant of a single marketing authorization by the European Commission that is valid for all EU member states and three of the four European Free
Trade Association, or EFTA, States, Iceland, Liechtenstein and Norway. Pursuant to Regulation (EC) No 726/2004, the centralized procedure is compulsory for specific products, including for medicines
produced by certain biotechnological processes, products designated as orphan medicinal products, advanced therapy products and products with a new active substance indicated for the treatment of
certain diseases, including products for the treatment of cancer. For products with a new active substance indicated for the treatment of other diseases and products that are highly innovative or for
which a centralized process is in the interest of patients, the centralized procedure may be optional. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
the centralized procedure, the Committee for Medicinal Products for Human Use, or the CHMP, established at the EMA is responsible for conducting the initial assessment of a
product. The CHMP is also responsible for several post-authorization and maintenance activities, such as the assessment of modifications or extensions to an existing marketing authorization. Under the
centralized procedure in the European Union, the maximum timeframe for the evaluation of an MAA is 210&nbsp;days, excluding clock stops, when additional information or written or oral explanation is
to be provided by the applicant in response to questions of the CHMP. Accelerated evaluation might be granted by the CHMP in exceptional cases, when a medicinal product is of major interest from the
point of view of public health and in particular from the viewpoint of therapeutic innovation. If the CHMP accepts such request, the time limit of 210&nbsp;days will be reduced to 150&nbsp;days
but it is possible that the CHMP can revert to the standard time limit for the centralized procedure if it considers that it is no longer appropriate to conduct an accelerated assessment. At the end
of this period, the CHMP provides a scientific opinion on whether or not a marketing authorization should be granted in relation to a medicinal product. Within 15 calendar days of receipt of a final
opinion from the CHMP, the European Commission must prepare a draft decision concerning an application for marketing authorization. This draft decision must take the opinion and any relevant
provisions of EU law into account. Before arriving at a final decision on an application for centralized authorization of a medicinal product the European Commission must consult the Standing
Committee on Medicinal Products for Human Use. The Standing Committee is composed of </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>163</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=166,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=413363,FOLIO='163',FILE='DISK109:[18ZBU1.18ZBU44601]DS44601A.;12',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_ds44601_1_164"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>representatives
of the EU member states and chaired by a non-voting European Commission representative. The European Parliament also has a related "droit de regard." The European Parliament's role is
to ensure that the European Commission has not exceeded its powers in deciding to grant or refuse to grant a marketing authorization. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
EMA offers the possibility to medicinal products developers to participate in a voluntary scheme of enhanced interaction and early dialogue with the Agency, to enhance support for
the development of medicinal products that target an unmet medical need. This voluntary scheme is called Priority Medicine support scheme, or PRIME. PRIME is intended to enable accelerated assessment
of applications for marketing authorizations of medicinal products. Rhythm submitted an applicable to EMA for eligibility for inclusion in the PRIME scheme for Setmelanotide in treatment of obesity
and the control of hunger associated with deficiency disorders of the MC4R receptor pathway. The decision of the EMA is expected to be adopted at the end of June 2018. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unlike
the centralized authorization procedure, the decentralized marketing authorization procedure requires a separate application to, and leads to separate approval by, the competent
authorities of each EU&nbsp;member state in which the product is to be marketed. This application is identical to the application that would be submitted to the EMA for authorization through the
centralized procedure. The reference EU&nbsp;member state prepares a draft assessment and drafts of the related materials within 120&nbsp;days after receipt of a valid application. The resulting
assessment report is submitted to the concerned EU member states who, within 90&nbsp;days of receipt, must decide whether to approve the assessment report and related materials. If a concerned EU
member state cannot approve the assessment report and related materials due to concerns relating to a potential serious risk to public health, disputed elements may be referred to the European
Commission, whose decision is binding on all EU member states. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
mutual recognition procedure similarly is based on the acceptance by the competent authorities of the EU member states of the marketing authorization of a medicinal product by the
competent authorities of other EU member states. The holder of a national marketing authorization may submit an application to the competent authority of an EU member state requesting that this
authority recognize the marketing authorization delivered by the competent authority of another EU member state. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Regulatory Data Protection in the European Union  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the European Union, innovative medicinal products approved on the basis of a complete independent data package qualify for eight years of
data exclusivity upon marketing authorization and an additional two years of market exclusivity pursuant to Directive 2001/83/EC. Regulation (EC) No 726/2004 repeats this entitlement for medicinal
products authorized in accordance the centralized authorization procedure. Data exclusivity prevents applicants for authorization of generics of these innovative products from referencing the
innovator's data to assess a generic (abbreviated) application for a period of eight years. During an additional two-year period of market exclusivity, a generic marketing authorization application
can be submitted and authorized, and the innovator's data may be referenced, but no generic medicinal product can be placed on the European Union market until the expiration of the market exclusivity.
The overall ten-year period will be extended to a maximum of 11&nbsp;years if, during the first eight years of those ten years, the marketing authorization holder obtains an authorization for one or
more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical
benefit in comparison with existing therapies. Even if a compound is considered to be a new chemical entity so that the innovator gains the prescribed period of data exclusivity, another company
nevertheless could also market another version of the product if such company obtained marketing authorization based on an MAA with a complete independent data package of pharmaceutical tests,
preclinical tests and clinical trials. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>164</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=167,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=757877,FOLIO='164',FILE='DISK109:[18ZBU1.18ZBU44601]DS44601A.;12',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_ds44601_1_165"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Periods of Authorization and Renewals  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A marketing authorization has an initial validity for five years in principle. The marketing authorization may be renewed after five years on
the basis of a re-evaluation of the risk-benefit balance by the EMA or by the competent authority of the EU member state. To this end, the marketing authorization holder must provide the EMA or the
competent authority with a consolidated version of the file in respect of quality, safety and efficacy, including all variations introduced since the marketing authorization was granted, at least six
months before the marketing authorization ceases to be valid. The European Commission or the competent authorities of the EU member states may decide, on justified grounds relating to
pharmacovigilance, to proceed with one further five-year period of marketing authorization. Once subsequently definitively renewed, the marketing authorization shall be valid for an unlimited period.
Any authorization which is not followed by the actual placing of the medicinal product on the European Union market (in case of centralized procedure) or on the market of the authorizing EU member
state within three years after authorization ceases to be valid (the so-called sunset clause). </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Orphan Drug Designation and Exclusivity  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Regulation (EC) No.&nbsp;141/2000, as implemented by Regulation (EC) No.&nbsp;847/2000 provides that a medicinal product can be designated
as an orphan drug by the European Commission if its sponsor can establish: that the product is intended for the diagnosis, prevention or treatment of (1)&nbsp;a life-threatening or chronically
debilitating condition affecting not more than five in ten thousand persons in the European Union when the application is made, or (2)&nbsp;a life-threatening, seriously debilitating or serious and
chronic condition in the European Union and that without incentives it is unlikely that the marketing of the medicinal product in the European Union would generate sufficient return to justify the
necessary investment. For either of these conditions, the applicant must demonstrate that there exists no satisfactory method of diagnosis, prevention or treatment of the
condition in question that has been authorized in the European Union or, if such method exists, the medicinal product will be of significant benefit to those affected by that condition. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Once
authorized, orphan medicinal products are entitled to 10&nbsp;years of market exclusivity in all EU&nbsp;member states and in addition a range of other benefits during the
development and regulatory review process including scientific assistance for study protocols, authorization through the centralized marketing authorization procedure covering all member countries and
a reduction or elimination of registration and marketing authorization fees. However, marketing authorization may be granted to a similar medicinal product with the same orphan indication during the
10-year period with the consent of the marketing authorization holder for the original orphan medicinal product or if the manufacturer of the original orphan medicinal product is unable to supply
sufficient quantities. Marketing authorization may also be granted to a similar medicinal product with the same orphan indication if this product is safer, more effective or otherwise clinically
superior to the original orphan medicinal product. The period of market exclusivity may, in addition, be reduced to six years if it can be demonstrated on the basis of available evidence that the
original orphan medicinal product is sufficiently profitable not to justify maintenance of market exclusivity </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Regulatory Requirements after a Marketing Authorization has been Obtained  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In case an authorization for a medicinal product in the European Union is obtained, the holder of the marketing authorization is required to
comply with a range of requirements applicable to the manufacturing, marketing, promotion and sale of medicinal products. These include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Compliance with the European Union's stringent pharmacovigilance or safety reporting rules must be ensured. These rules can impose
post-authorization studies and additional monitoring obligations. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>165</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=168,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=301496,FOLIO='165',FILE='DISK109:[18ZBU1.18ZBU44601]DS44601A.;12',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_ds44601_1_166"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> The manufacturing of authorized medicinal products, for which a separate manufacturer's license is mandatory, must also be conducted in strict
compliance with the applicable European Union laws, regulations and guidance, including Directive 2001/83/EC, Directive 2003/94/EC, Regulation (EC) No 726/2004 and the European Commission Guidelines
for Good Manufacturing Practice. These requirements include compliance with European Union cGMP standards when manufacturing medicinal products and active pharmaceutical ingredients, including the
manufacture of active pharmaceutical ingredients outside of the European Union with the intention to import the active pharmaceutical ingredients into the European Union. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> The marketing and promotion of authorized medicinal products, including industry-sponsored continuing medical education and advertising
directed toward the prescribers of medicinal products and/or the general public, are strictly regulated in the European Union notably under Directive&nbsp;2001/83EC, as amended, and EU member state
laws. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Regulatory Procedure Governing CE marking Companion Diagnostics in the European Union  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the European Union, </FONT><FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2> medical devices are required to conform with the essential
requirements of the European Union Directive on </FONT><FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2> diagnostic medical devices (Directive No&nbsp;98/79/EC, as amended). To demonstrate
compliance with the essential requirements, the manufacturer must undergo a conformity assessment procedure. The conformity assessment varies according to the type of </FONT><FONT SIZE=2><I>in
vitro</I></FONT><FONT SIZE=2> diagnostic medical device. The conformity assessment of </FONT><FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2> diagnostic medical devices can require the intervention
of a Notified Body, which is an organization designated by the competent authorities of an EU member state to conduct conformity assessments. The Notified Body will issue a CE&nbsp;Certificate of
Conformity following successful completion of a conformity assessment procedure conducted in relation to the </FONT><FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2> diagnostic medical device and its
manufacturer and their conformity with the requirements of the Directive. This Certificate entitles the manufacturer to affix the CE mark to its medical device after having prepared and signed a
related EC Declaration of Conformity. For </FONT><FONT SIZE=2><I>in vitro</I></FONT><FONT SIZE=2> diagnostic medical devices which do not require the intervention of a notified body, the manufacturer
can issue an EC Declaration of Conformity based on a self-assessment of the conformity of its products with the Essential Requirements laid down in the </FONT><FONT SIZE=2><I>in
vitro</I></FONT><FONT SIZE=2> diagnostic medical device Directive. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Brexit and the Regulatory Framework in the United Kingdom  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On June&nbsp;23, 2016, the electorate in the United Kingdom voted in favor of leaving the European Union, commonly referred to as Brexit.
Thereafter, on March&nbsp;29, 2017, the country formally notified the European Union of its intention to withdraw pursuant to Article&nbsp;50 of the Lisbon Treaty. The withdrawal of the United
Kingdom from the European Union will take effect either on the effective date of the withdrawal agreement or, in the absence of agreement, two years after the United Kingdom provides a notice of
withdrawal pursuant to the E.U. Treaty. Since the regulatory framework for pharmaceutical products in the United Kingdom. covering quality, safety and efficacy of pharmaceutical products, clinical
trials, marketing authorization, commercial sales and distribution of pharmaceutical products is derived from European Union directives and regulations, Brexit could materially impact the future
regulatory regime which applies to products and the approval of product candidates in the United Kingdom. It remains to be seen how, if at all, Brexit will impact regulatory requirements for product
candidates and products in the United Kingdom. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Pharmaceutical Coverage and Reimbursement  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the United States and markets in other countries, patients who are prescribed treatments for their conditions and providers performing the
prescribed services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Patients are unlikely to use setmelanotide unless coverage is provided and
reimbursement is adequate to cover a significant portion of the cost of our products. Significant uncertainty exists as to the coverage and reimbursement status of products approved </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>166</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=169,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=472528,FOLIO='166',FILE='DISK109:[18ZBU1.18ZBU44601]DS44601A.;12',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_ds44601_1_167"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>by
the FDA and other government authorities. Even if setmelanotide is approved, sales will depend, in part, on the extent to which third-party payors, including government health programs in the
United States such as Medicare and Medicaid, commercial health insurers and managed care organizations, provide coverage, and establish adequate reimbursement levels for, such products. The process
for determining whether a payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product once coverage
is approved. Third-party payors are increasingly challenging the prices charged, examining the medical necessity, and reviewing the cost-effectiveness of medical products and services and imposing
controls to manage costs. Third-party payors may limit coverage to specific products on an approved list, also known as a formulary, which might not include all of the approved products for a
particular indication. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
order to secure coverage and reimbursement for any product that might be approved for sale, a company may need to conduct expensive pharmacoeconomic studies in order to demonstrate
the medical necessity and cost-effectiveness of the product, in addition to the costs required to obtain FDA or other comparable marketing approvals. Nonetheless, setmelanotide may not be considered
medically necessary or cost effective. A decision by a third-party payor not to cover setmelanotide could reduce physician utilization of our products once approved and have a material adverse effect
on our sales, results of operations and financial condition. Additionally, a payor's decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved.
Further, one payor's determination to provide coverage for a product does not assure that other payors will also provide coverage and reimbursement for the product, and the level of coverage and
reimbursement can differ significantly from payor to payor. Third-party reimbursement and coverage may not be available to enable us to maintain price levels sufficient to realize an appropriate
return on our investment in product development. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
containment of healthcare costs also has become a priority of federal, state and foreign governments and the prices of products have been a focus in this effort. Governments have
shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic products. Adoption of price
controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit a company's revenue generated from the sale
of any approved products. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for
which a company or its collaborators receive marketing approval, less favorable coverage policies and reimbursement rates may be implemented in the future. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Outside
the United States, ensuring adequate coverage and payment for setmelanotide will face challenges. Pricing of prescription pharmaceuticals is subject to governmental control in
many countries. Pricing negotiations with governmental authorities can extend well beyond the receipt of regulatory marketing approval for a product and may require us to conduct a clinical trial that
compares the cost effectiveness of setmelanotide or products to other available therapies. The conduct of such a clinical trial could be expensive and result in delays in our commercialization
efforts. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the European Union, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has
been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness of a particular medicinal product candidate to currently available therapies or so
called Health Technology Assessments, in order to obtain reimbursement or pricing approval. For example, the European Union provides options for its member states to restrict the range of products for
which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. EU member states may approve a specific price for a product or it may
instead adopt a system of direct or indirect controls on the profitability of the company placing the product on the market. Other EU member states allow companies to fix their own prices for
products, but monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>167</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=170,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=939593,FOLIO='167',FILE='DISK109:[18ZBU1.18ZBU44601]DS44601A.;12',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_ds44601_1_168"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Healthcare Law and Regulation  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Healthcare providers and third-party payors play a primary role in the recommendation and prescription of drug products that are granted
marketing approval. Arrangements and interactions with healthcare professionals, third-party payors, and patients, among others, are subject to broadly applicable fraud and abuse, anti-kickback, false
claims laws, patient privacy laws and regulations and other healthcare laws and regulations that may constrain our business and/or financial arrangements, particularly once third-party reimbursement,
including under Medicare, Medicaid or other federally-funded health care programs, becomes available for one or more of our products. The federal and state healthcare laws and regulations that may
affect our ability to operate include, but are not limited to the following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the United States federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully
soliciting, offering, paying, or receiving remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, lease, order or
arranging for or recommending the purchase, lease, or order of any good or service, for which payment may be made, in whole or in part, by federal healthcare programs such as Medicare and Medicaid.
This statute has been interpreted to apply to arrangements between pharmaceutical companies on one hand and prescribers, purchasers and formulary managers on the other. Liability under the
Anti-Kickback Statute may be established without proving actual knowledge of the statute or specific intent to violate it. In addition, the government may assert that a claim including items or
services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act. Although there are a number of
statutory exemptions and regulatory safe harbors to the federal Anti-Kickback Statute protecting certain common business arrangements and activities from prosecution or regulatory sanctions, the
exemptions and safe harbors are drawn narrowly. Practices that involve remuneration to those who prescribe, purchase, or recommend pharmaceutical and biological products, including certain discounts,
or engaging such individuals as consultants, advisors and speakers, may be subject to scrutiny if they do not fit squarely within an exemption or safe harbor. Our practices may not in all cases meet
all of the criteria for safe harbor protection from anti-kickback liability. Moreover, there are no safe harbors for many common practices, such as educational and research grants, charitable
donations, product support and patient assistance programs; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the federal civil False Claims Act prohibits individuals or entities from, among other things, knowingly presenting, or causing to be
presented, a false or fraudulent claim for payment of government funds, or knowingly making, using or causing to made or used a false record or statement material to an obligation to pay money to the
government or knowingly concealing or knowingly and improperly avoiding, decreasing, or concealing an obligation to pay money to the federal government. Actions under the False Claims Act may be
brought by the Attorney General or as a qui tam action by a private individual in the name of the government. Many pharmaceutical manufacturers have been investigated and have reached substantial
financial settlements with the federal government under the civil False Claims Act for a variety of alleged improper activities including causing false claims to be submitted as a result of the
marketing of their products for unapproved and thus non-reimbursable uses, inflating prices reported to private price publication services which are used to set drug payment rates under government
healthcare programs, and other interactions with prescribers and other customers including those that may have affected their billing or coding practices and submission to the federal government. The
government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil
False Claims Act. Pharmaceutical and other healthcare companies also are subject to other federal false claims laws, including, among others, federal criminal healthcare fraud and false statement
statutes that extend to non-government health benefit programs; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>168</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=171,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=525488,FOLIO='168',FILE='DISK109:[18ZBU1.18ZBU44601]DS44601A.;12',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_ds44601_1_169"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the federal Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and
Clinical Health Act, or HIPAA, which imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare
benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement or representation, or making or
using any false writing or document knowing the same to contain any materially false, fictitious or fraudulent statement or entry, in connection with the delivery of or payment for healthcare
benefits, items or services; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> HIPAA and its implementing regulations, which impose obligations with respect to safeguarding the privacy, security and transmission of
individually identifiable health information; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the federal Physician Payments Sunshine Act, being implemented as the Open Payments Program requires certain manufacturers of drugs, devices,
biologics and medical supplies report payments and other transfers of value to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate
family members. Pharmaceutical and biological manufacturers with products for which payment is available under Medicare, Medicaid or the State Children's Health Insurance Program are required to
submit a report to the Centers for Medicare and Medicaid Services within the U.S. Department of Health and Human Services on or before the 90th&nbsp;day of each calendar year disclosing reportable
payments made in the previous calendar year; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> analogous state laws and regulations, such as state anti-kickback and false claims laws, which may apply to healthcare items or services that
are reimbursed by non-governmental third-party payors, including private insurers. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition to the foregoing requirements, several states now require prescription drug companies to report expenses relating to the marketing and promotion of drug products and to
report gifts and payments to individual physicians in these states. Other states prohibit various other marketing-related activities, including the ability of manufacturers to offer co-pay support to
patients for certain prescription drugs. Still other states require the posting of information relating to clinical studies and their outcomes and other states and cities require identification or
licensing of sales representatives. In addition, California, Connecticut, Nevada, and Massachusetts require pharmaceutical companies to implement compliance programs and/or marketing codes. Several
additional states are considering similar proposals. Numerous federal, state and foreign laws and regulations also govern the privacy and security of health information and the collection, use,
disclosure, and protection of health-related and other personal information, including state data breach notification laws, state health information privacy laws, and federal and state consumer
protection laws, such as Section&nbsp;5 of the FTC Act, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.
Compliance with these laws is difficult and time consuming, and companies that do not comply with these state laws may face civil penalties. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Compliance
with these federal and state laws and regulations will require substantial resources. If our operations are found to be in violation of any of the laws described above or any
other governmental regulations that apply to us, we may be subject to significant civil, criminal and administrative penalties, imprisonment, damages, fines, imprisonment, exclusion from
government-funded healthcare programs like Medicare and Medicaid, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and
our financial results. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
additional information regarding obligations under federal health care programs, refer to the risk factor entitled "</FONT><FONT SIZE=2><I>If we participate in the Medicaid Drug
Rebate Program and fail to comply with our reporting and payment obligations under that program or other governmental pricing programs that we participate in, we could be subject to additional
reimbursement requirements, penalties, sanctions and fines, which could have a material adverse effect on our business, financial condition, results of operations and growth
prospects</I></FONT><FONT SIZE=2>." </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>169</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=172,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=867860,FOLIO='169',FILE='DISK109:[18ZBU1.18ZBU44601]DS44601A.;12',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_ds44601_1_170"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the EU, once a marketing authorization is granted for a medicinal product the applicant is required to engage in pricing and reimbursement discussions and negotiate with a separate
pricing authority in each of the EU member states. The EU member states governments influence the price of pharmaceutical products through their pricing and reimbursement rules and control of national
healthcare systems that fund a large part of the cost of those products to consumers. Some jurisdictions operate positive and negative list systems under which products may only be marketed once a
reimbursement price has been agreed upon. To obtain reimbursement or pricing approval, some of the EU member states may require the completion of clinical trials that compare the cost-effectiveness of
a particular product candidate to currently available therapies. Other EU member states allow companies to fix their own prices for medicinal products, but monitor and control company profits. The
downward pressure on healthcare costs in general, particularly pharmaceuticals, has become more intense. As a result, increasingly high barriers are being erected to the entry of new products.
Furthermore, an increasing number of EU member states and other foreign countries use prices for medicinal products established in other countries as "reference prices" to help determine the price of
the product in their own territory. Consequently, a downward trend in prices of medicinal products in some countries could contribute to similar downward trends elsewhere. The EU member states have
discretion to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. An EU
member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on
the market. Health Technology Assessment, or HTA, of medicinal products is becoming an increasingly common part of the pricing and reimbursement procedures in some E.U. Member States. These EU member
states include the United Kingdom, France, Germany, Ireland, Italy and Sweden. The HTA process in European Economic Area, or EEA, countries is governed by the national laws of these countries. HTA is
the procedure according to which the assessment of the public health impact, therapeutic impact and the economic and societal impact of use of a given medicinal product in the national healthcare
systems of the individual country is conducted. HTA generally focuses on the clinical efficacy and effectiveness, safety, cost, and cost-effectiveness of individual medicinal products as well as their
potential implications for the healthcare system. Those elements of medicinal products are compared with other treatment options available on the market. </FONT></P>


<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Healthcare Reform  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A primary trend in the United States healthcare industry and elsewhere is cost containment. There have been a number of federal and state
proposals during the last few years regarding the pricing of pharmaceutical and biopharmaceutical products, limiting coverage and reimbursement for drugs and other medical products, government control
and other changes to the healthcare system in the United States. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;By
way of example, the United States and state governments continue to propose and pass legislation designed to reduce the cost of healthcare. In March 2010, President Obama signed into
law the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act of 2010, or collectively the ACA, which, among other things, includes
changes to the coverage and payment for products under government health care programs. Among the provisions of the ACA of importance to our potential drug candidates
are:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents, apportioned
among these entities according to their market share in certain government healthcare programs, although this fee does not apply to sales of certain products approved exclusively for orphan
indications; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to certain
individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer's Medicaid rebate liability; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>170</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=173,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=239811,FOLIO='170',FILE='DISK109:[18ZBU1.18ZBU44601]DS44601A.;12',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_ds44601_1_171"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> expansion of manufacturers' rebate liability under the Medicaid Drug Rebate Program by increasing the minimum rebate for both branded and
generic drugs and revising the definition of "average manufacturer price," or AMP, for calculating and reporting Medicaid drug rebates on outpatient prescription drug prices and extending rebate
liability to prescriptions for individuals enrolled in Medicare Advantage plans; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> introduction of a price reporting requirement for drugs that are inhaled, instilled, implanted, injected, or infused and not generally
dispensed through retail community pharmacies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> addition of more entity types eligible for participation in the Public Health Service 340B drug pricing program, or the 340B program; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> established the Medicare Part&nbsp;D coverage gap discount program by requiring manufacturers to provide a 50% point-of-sale-discount off the
negotiated price of applicable brand drugs to eligible beneficiaries during their coverage gap period as a condition for the manufacturers' outpatient drugs to be covered under Medicare Part&nbsp;D; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research,
along with funding for such research; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the Independent Payment Advisory Board, or IPAB, which has authority to recommend certain changes to the Medicare program to reduce
expenditures by the program that could result in reduced payments for prescription drugs. However, the IPAB implementation has been not been clearly defined. ACA provided that under certain
circumstances, IPAB recommendations or recommendations of the Secretary of Health and Human Services will become law unless Congress enacts legislation that will achieve the same or greater Medicare
cost savings; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> established the Center for Medicare and Medicaid Innovation within CMS to test innovative payment and service delivery models to lower Medicare
and Medicaid spending, potentially including prescription drug spending. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other
legislative changes have been proposed and adopted in the United States since the ACA was enacted. For example, beginning April&nbsp;1, 2013, Medicare payments for all items and
services, including drugs and biologics, were reduced by 2% under the sequestration (i.e.,&nbsp;automatic spending reductions) required by the Budget Control Act of 2011, as amended by the American
Taxpayer Relief Act of 2012. Subsequent legislation extended the 2% reduction, on average, to 2025. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Legislative
changes to or regulatory changes under the ACA have occurred in the 115th&nbsp;U.S. Congress and under the Trump administration. For example, the Tax Cuts and Jobs Act
enacted on December&nbsp;22, 2017, eliminated the shared responsibility payment for individuals who fail to maintain minimum essential coverage under section&nbsp;5000A of the Internal Revenue
Code of 1986, commonly referred to as the individual mandate, beginning in 2019. Additional legislative changes to and regulatory changes under the ACA remain possible, but the nature and extent of
such potential additional changes are uncertain at this time. We expect that the ACA, as currently enacted or as it may be amended in the future, and other healthcare reform measures that may be
adopted in the future, could have a material adverse effect on our industry generally and on our ability to successfully commercialize our product candidates, if approved. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Employees  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have leveraged skilled experts, consultants, CROs, and contractors to manage our clinical operations, under the leadership and direction of
our management. We will expand our infrastructure to manage our clinical, finance and commercial operations with additional full-time employees. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have 36 employees who are directly employed by us. Of these employees, 23 are engaged in development activities, four are engaged in commercialization activities and nine are engaged
in support administration, including business development and finance. None of these employees are represented by </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>171</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=174,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=364396,FOLIO='171',FILE='DISK109:[18ZBU1.18ZBU44601]DS44601A.;12',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_ds44601_1_172"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>labor
unions or covered by collective bargaining agreements. We consider our relationships with these employees to be good. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Facilities  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our offices are located at a 6,830 square foot facility in Boston, Massachusetts used primarily for corporate functions. The lease for this
space expires in May 2021. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Legal Proceedings  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are not currently a party to any material legal proceedings. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
additional information regarding healthcare reform, refer to the risk factor entitled </FONT><FONT SIZE=2><I>"Current and future healthcare reform legislation or regulation may
increase the difficulty and cost for us and any future collaborators to obtain marketing approval of and commercialize setmelanotide and may adversely affect the prices we, or they, may obtain and may
have a negative impact on our business and results of operations."</I></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>172</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=175,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=573398,FOLIO='172',FILE='DISK109:[18ZBU1.18ZBU44601]DS44601A.;12',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_du44601_1_173"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="du44601_management"> </A>
<A NAME="toc_du44601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  MANAGEMENT    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Executive Officers and Directors  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth the names, ages and positions of our directors and executive officers as
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018. Each executive
officer is employed by us pursuant to a letter agreement entered into as of November 2016 except for Hunter C. Smith and Nithya Desikan, who entered into letter agreements as of July 2017. Prior to
November 2016, each executive officer other than Hunter C. Smith and Nithya Desikan provided services to us pursuant to the Payroll Services Agreement, which was terminated in November 2016. Each
executive officer will be elected annually and will serve until his re-election, or earlier resignation or removal. The executive officers, other than Hunter C. Smith and Nithya Desikan and directors
have served as executive officers and directors of us, the&nbsp;LLC entity, the Predecessor Company and/or the Relamorelin Company during the periods set forth below. We refer to each of these
persons as our executive officers. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="268pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Age </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Position(s) </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Keith M. Gottesdiener, M.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>64</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Chief Executive Officer, President and Director</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Hunter C. Smith</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>50</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Chief Financial Officer and Treasurer</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Nithya Desikan</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>39</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Chief Commercial Officer</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Lex H.T. Van der Ploeg, Ph.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>63</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Chief Scientific Officer</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Fred T. Fiedorek, M.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>63</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Chief Medical Officer</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Simon D. Kelner</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>45</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Chief Human Resources Officer</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Todd Foley<SUP>(1)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>46</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Ed Mathers<SUP>(3)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>58</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Neil Exter<SUP>(1)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>59</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Christophe R. Jean<SUP>(2)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>62</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>David P. Meeker<SUP>(2)(3)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>62</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Director and Chairman</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>David W.J. McGirr<SUP>(2)(3)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>64</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Member
of Compensation Committee.  </FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(2)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Member
of Audit Committee.  </FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(3)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Member
of Governance and Nominating Committee. </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Keith M. Gottesdiener, M.D.</I></B></FONT><FONT SIZE=2> &#124; </FONT><FONT SIZE=2><I>Chief Executive Officer and President</I></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dr.&nbsp;Gottesdiener
has been Chief Executive Officer and a member of the Board since October 2011 and was chairman of the Board from that date until April 2017. He has been President
since August 2017. He joined Rhythm after 16&nbsp;years at Merck Research Laboratories, or Merck. Dr.&nbsp;Gottesdiener joined Merck in 1995 and held positions of increasing responsibility,
eventually leading Merck's early clinical development across all therapeutic areas from 2001 through early 2006. From 2006 to 2011, he was a leader of Merck's late clinical development organization,
first overseeing the development of Merck's infectious diseases and vaccine products through pivotal trials, registration, and life cycle management, including Gardasil&#153; (HPV Vaccine),
Rotateq&#153; (rotavirus vaccine), Zostavax&#153; (zoster vaccine) and Isentress&#153; (HIV integrase inhibitor), among others. In 2008, Dr.&nbsp;Gottesdiener was appointed Late
Stage Therapeutic Group Leader, and in that role led Merck's late stage clinical development efforts (from Phase&nbsp;2 thru patent expiry) across all therapeutic areas. After Merck's merger with
Schering Plough in 2009, he continued as co-head of late development. Dr.&nbsp;Gottesdiener received his B.A. from Harvard College and his M.D. from the University of Pennsylvania. He completed his
residency and fellowship at the Brigham and Women's
Hospital Beth Israel Medical Center Dana Farber Cancer Institute Children's Hospital programs. After his fellowship, Dr.&nbsp;Gottesdiener did postdoctoral research in the laboratory of
Dr.&nbsp;Jack Strominger at Dana Farber Cancer Institute working on the molecular immunology of the T cell receptor. In 1986, he joined the faculty as an assistant professor at Columbia University,
started an independent research laboratory with NIH RO 1 funding, focusing on gene transcription, and was Associate Clinical </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>173</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=176,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=216289,FOLIO='173',FILE='DISK109:[18ZBU1.18ZBU44601]DU44601A.;15',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_du44601_1_174"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>Professor
of Medicine at the time he left to join Merck in 1995. Dr.&nbsp;Gottesdiener was a director and the chief executive officer of Motus Therapeutics,&nbsp;Inc., with which the Company was
previously affiliated ("Motus") until December 2016. Dr.&nbsp;Gottesdiener is currently a director of Intercept Pharmaceuticals and Rhythm Holding Company,&nbsp;LLC. We believe that
Dr.&nbsp;Gottesdiener's detailed knowledge of our company, his extensive experience in the pharmaceutical industry as a senior executive, and his research work for both medical and academic
institutions provide him with the qualifications to serve as director of our company. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Hunter C. Smith</I></B></FONT><FONT SIZE=2> &#124; </FONT><FONT SIZE=2><I>Chief Financial Officer and Treasurer</I></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Smith
has been Chief Financial Officer since July 2017 and Treasurer since August 2017. He has more than 25&nbsp;years of global finance and management experience across
multiple industries and financial disciplines, including expertise in business analysis and planning, mergers and acquisitions, capital raising and investor relations. Previously, he was Vice
President, Finance and Chief Financial Officer of the Inflammation and Immunology Business Unit at Celgene Corporation from 2013 to July 2017. In this role, Mr.&nbsp;Smith provided finance
leadership for the global launch of Otezla&reg;, co led the integration of Receptos,&nbsp;Inc. following its acquisition by Celgene, and led global business planning and analysis for
commercial affiliates and clinical study activities in over 16 countries. Before joining Celgene, Mr.&nbsp;Smith worked in roles of increasing responsibility at Bunge Limited from 1999 to 2013,
including Director of Investor Relations, Chief Financial Officer&#151;Asia, Corporate Treasurer, and Chief Financial Officer of Bunge's Sugar and Bioenergy Segment. Mr.&nbsp;Smith also
serves as an independent director of Genessee&nbsp;&amp; Wyoming&nbsp;Inc. and is a member of its compensation and governance committees. Mr.&nbsp;Smith holds an MBA in Finance from New York
University's Stern School of Business and a B.A. in History, with honors, from Northwestern University. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Nithya Desikan</I></B></FONT><FONT SIZE=2> &#124; </FONT><FONT SIZE=2><I>Chief Commercial Officer</I></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ms.&nbsp;Desikan
has been Chief Commercial Officer since July 2017. She has over 15&nbsp;years of experience commercializing new therapies in domestic and global markets. Previously,
Ms.&nbsp;Desikan worked at Biogen&nbsp;Inc., where she served most recently as Vice President and Asset Executive, from September 2016 to July 2017, overseeing global profit and loss account for
TECFIDERA&reg; and supporting the product's position as the #1 prescribed oral therapy in multiple sclerosis and from November 2015 to September 2016, building a team to support the Biogen
pipeline for the clinical development of inflammatory bowel disease. Prior to that, Ms.&nbsp;Desikan held the role of Vice President and Program Executive from September 2014 to November 2015, where
she led Biogen's Hematology business, now the Biogen spin off, Bioverativ, to drive the growth of ALPROLIX&reg; and ELOCTATE&reg; and the development of multiple preclinical assets.
Before that, from February 2012 to September 2014, Ms.&nbsp;Desikan built the strategy to support the U.S. launch of ALPROLIX, Biogen's first entrant into the orphan hemophilia market. Before
joining Biogen&nbsp;Inc., Ms.&nbsp;Desikan spent 12&nbsp;years at Johnson&nbsp;&amp; Johnson in the United States and China, supporting brands including: XARELTO&reg;,
LEVAQUIN&reg;, TOPAMAX&reg;, ULTRACET&reg;, NUCYNTA&reg;, NUCYNTA&reg;ER and VELCADE&reg;. Ms.&nbsp;Desikan holds a B.S. in Material Science
Engineering, with honors, from the University of Florida. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Lex H.T. Van der Ploeg, Ph.D.</I></B></FONT><FONT SIZE=2> &#124; </FONT><FONT SIZE=2><I>Chief Scientific Officer</I></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dr.&nbsp;Van
der Ploeg has been Chief Scientific Officer since October 2011. He has more than 25&nbsp;years of drug development experience focused on obesity, metabolic disorders,
oncology, and neurodegenerative diseases. Before joining Rhythm, he was Senior Vice President of Integrative Medicine and Translational Science at Abraxis Bioscience and Head of R&amp;D at Abraxis Health;
both companies were acquired by Celgene Corporation. Prior to that, he held R&amp;D leadership roles at Merck directing drug development programs in metabolism, oncology, and neurodegenerative diseases as
Vice President, Basic Research and Site Head, Merck Boston; Site Head, Merck San Diego; and Head, Obesity Research for Merck Rahway </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>174</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=177,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=10188,FOLIO='174',FILE='DISK109:[18ZBU1.18ZBU44601]DU44601A.;15',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_du44601_1_175"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>and
Banyu, Japan. Previously, Dr.&nbsp;Van der Ploeg was an associate professor in the Department of Genetics and Development at Columbia University. He has received numerous awards and grants for
his research and has published more than 200 peer reviewed research papers. Dr.&nbsp;Van der Ploeg is a named inventor on more than 50 patents and patent applications. Dr.&nbsp;Van der Ploeg was
the Chief Scientific Officer of Motus until December 2016. He received an M.S. in Biochemistry from the University of Amsterdam and a Ph.D.&nbsp;in Biochemistry/Enzymology/Genetics from the
University of Amsterdam/Netherlands Cancer Institute. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Fred T. Fiedorek, M.D.</I></B></FONT><FONT SIZE=2> &#124; </FONT><FONT SIZE=2><I>Chief Medical Officer</I></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dr.&nbsp;Fiedorek
has been Chief Medical Officer since October 2014, joining us after nearly 14&nbsp;years at Bristol Myers Squibb, or BMS. He has extensive drug development
experience across many therapeutic areas, ranging from early development through Phase&nbsp;4 and commercial launch. Dr.&nbsp;Fiedorek has particular expertise in diabetes, metabolic disorders and
cardiovascular disease, most recently serving as Senior Vice President, Head of Cardiovascular and Metabolic Development at BMS, where he led Phase&nbsp;2 through Phase&nbsp;4 global development
for these therapeutic areas. Under his leadership, several new medicines achieved successful marketing authorization, including Onglyza&reg; (saxagliptin), Farxiga&#153;
(dapagliflozin), Eliquis&reg; (apixaban), Myalept&#153; (metreleptin), Bydureon&reg; Dual Chamber Pen, and Glucovance&reg; (metformin/glyburide). While at BMS,
Dr.&nbsp;Fiedorek also co led exploratory development, helping to transition compounds from discovery stage to proof of concept patient trials. In addition, Dr.&nbsp;Fiedorek co-directed the
Clinical Science Committee charged with providing scientific, regulatory, and biostatistical review of Phase&nbsp;1 through Phase&nbsp;4 clinical trials; he was a member of the Medical Review
Group charged with oversight of potential emerging safety signals from marketed medicines or compounds in development; and he participated in joint development committees for BMS alliances with Astra
Zeneca, Pfizer, Otsuka, KAI Pharmaceuticals, Solvay, and Merck. Prior to joining BMS, Dr.&nbsp;Fiedorek held positions of increasing responsibility at Glaxo Wellcome in Research Triangle Park, or
RTP, and was International Project Leader for a Phase&nbsp;3 metabolic drug development program prior to his move to BMS. Dr.&nbsp;Fiedorek was the Chief Medical Officer of Motus until December
2016. Dr.&nbsp;Fiedorek received his B.A. from Yale University and his M.D. from Harvard Medical School. He completed residency and fellowship training in Internal Medicine and
Endocrinology&nbsp;&amp; Metabolism at Washington University in St.&nbsp;Louis, including post-doctoral research on the genetics of animal models of diabetes and obesity. He also served on the
faculties at Washington University School of Medicine in St.&nbsp;Louis and the University of North Carolina in Chapel Hill School of Medicine, including an adjunct clinical appointment while at
Glaxo Wellcome in RTP. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>Simon D. Kelner</I></B></FONT><FONT SIZE=2> &#124; </FONT><FONT SIZE=2><I>Chief Human Resources Officer</I></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Kelner
has been Chief Human Resources Officer since June 2018. He has over 20&nbsp;years of experience serving in various human resources leadership roles across multiple
industries, including with pharmaceutical companies and in the United States, Switzerland, Israel, and the United Kingdom. Previously, Mr.&nbsp;Kelner worked at Teva Pharmaceuticals from 2016
through 2018, where he served as Vice President, Human Resources&#151;Global Talent Acquisition and Mobility, and developed hiring and talent engagement models. Prior to that, Mr.&nbsp;Kelner
held roles of increasing responsibility at Merck from 2003 to 2016, and served most recently as Global Head Talent Development / Future Employment Models and Executive Director, HR Business
Partner&#151;R&amp;D, Technology, Finance and Strategy. Mr.&nbsp;Kelner holds an International Executive MBA from Northwestern's Kellogg School of Management, a B.Sc. with Honors in Management
Sciences from the University of Manchester Institute of Science and Technology, and a certification in Professional Human Resources Qualifications from the Chartered Institute of Personnel and
Development. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>175</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=178,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=877057,FOLIO='175',FILE='DISK109:[18ZBU1.18ZBU44601]DU44601A.;15',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_du44601_1_176"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Todd Foley  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Foley has served as a member of our Board since July 2014. Mr.&nbsp;Foley is a managing director with MPM Capital, a venture
capital firm, which he joined in 1999. Prior to joining MPM, Mr.&nbsp;Foley worked in business development at Genentech and in management consulting with Arthur D. Little. Mr.&nbsp;Foley currently
serves as a member of the board of directors of Chiasma,&nbsp;Inc., Clinical Ink,&nbsp;Inc., Iconic Therapeutics,&nbsp;Inc., Repare Therapeutics&nbsp;Inc., Semma Therapeutics,&nbsp;Inc.,
Switch Bio,&nbsp;Inc. and Tetherex Pharmaceuticals,&nbsp;Inc. Mr.&nbsp;Foley received a B.S. in chemistry from the Massachusetts Institute of Technology and an MBA from Harvard Business School.
We believe that Mr.&nbsp;Foley's broad experience in the life sciences industry as a venture capitalist, as well as his service on the boards of directors of numerous companies provide him with the
qualifications to serve as a director of our company. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Ed Mathers  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Mathers has served as a member of our Board since March 2013. He has been a Partner at New Enterprise Associates, or NEA, a venture
capital firm, since August 2008. Mr.&nbsp;Mathers currently serves on the boards of directors of Amplyx Pharmaceuticals,&nbsp;Inc., Envisia Therapeutics&nbsp;Inc., Intarcia
Therapeutics,&nbsp;Inc., Inozyme Pharma,&nbsp;Inc., Liquidia Technologies,&nbsp;Inc., Lumos Pharma,&nbsp;Inc., Lumena Pharmaceuticals,&nbsp;Inc., Mirna Therapeutics,&nbsp;Inc.,
ObsEva&nbsp;SA, Ra Pharmaceuticals,&nbsp;Inc., Satori Pharmaceuticals Incorporated, Senti Biosciences and Synlogic,&nbsp;LLC, all of which are biotechnology companies. In addition,
Mr.&nbsp;Mathers is a member of the Biotechnology Industry Organization board, the Southeast BIO board and the North Carolina State Physical and Mathematical Sciences Foundation board. Prior to
joining NEA, Mr.&nbsp;Mathers served in various corporate development roles at MedImmune,&nbsp;Inc., a biotechnology company that was acquired by AstraZeneca&nbsp;PLC in 2007, culminating in the
position of Executive Vice President, Corporate Development and Venture. In this role, he also led the company's venture capital subsidiary, MedImmune Ventures,&nbsp;Inc., from 2002 to 2008.
Mr.&nbsp;Mathers was a director of MedImmune,&nbsp;LLC, from 2007 to 2008. From 2000 to 2002, Mr.&nbsp;Mathers was Vice President, Marketing and Corporate Licensing and Acquisitions at Inhale
Therapeutic Systems,&nbsp;Inc., a biopharmaceutical company, which is now known as Nektar Therapeutics,&nbsp;Inc. Previously, for 15&nbsp;years, Mr.&nbsp;Mathers was at Glaxo
Wellcome,&nbsp;Inc., where he held sales and marketing positions of increasing responsibility. Mr.&nbsp;Mathers received a B.S. in chemistry from North Carolina State University. We believe that
Mr.&nbsp;Mather's extensive experience in the life sciences industry as a venture capitalist
and senior executive, as well as his service on the boards of directors of numerous biotechnology companies provide him with the qualifications to serve as a director of our company. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Neil Exter  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Exter has served as a member of our Board since April 2014. He is a partner at Third Rock Ventures, where he plays an integral role
in the formation, development, business strategy, and business development efforts of portfolio companies. He has more than 20&nbsp;years of business development and strategic experience,
facilitating the successful development and implementation of operations and collaborations across the spectrum of newly emerging and established biotech companies. Mr.&nbsp;Exeter is currently the
interim chief operating officer of Goldfinch Bio. Prior to joining Third Rock Ventures, Mr.&nbsp;Exter was CBO of Alantos Pharmaceuticals and led the sale of that company to Amgen. Previously, he
served as Vice President of Business Development for Millennium Pharmaceuticals. Mr.&nbsp;Exter is a board member of CytomX Therapeutics, Cibiem, Lotus Tissue Repair, Coridea NC1, Coridea NC2,
Element Science, Goldfinch Bio, Pliant Therapeutics, Revolution Medicine, and Seventh Sense. He is a member of the Research Committee of Children's Hospital Boston, the investment committee of the
Innovation Research Fund at Partners Healthcare, the board of directors of the New England Venture Capital Association, the Advisory Council of the Electrical and Computer Engineering Department at
Cornell University, and the Board of Visitors of Columbia College. He holds an MBA as a Baker Scholar from Harvard Business School, an M.S. from Stanford University, and a B.S. from Cornell
University. We </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>176</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=179,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=893096,FOLIO='176',FILE='DISK109:[18ZBU1.18ZBU44601]DU44601A.;15',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_du44601_1_177"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>believe
that Mr.&nbsp;Exter's extensive experience in the life sciences industry as a venture capitalist and senior executive, as well as his service on the boards of directors of numerous
biotechnology companies provide him with the qualifications to serve as a director of our company. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Christophe R. Jean  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Jean has served as a member of our Board since April 2015. He is Executive Vice President of Corporate Strategy, Business
Development, Alliances and M&amp;A for the Ipsen Group, a position he assumed in 2013 after serving for 11&nbsp;years in the position of Executive Vice President, Chief Operating Officer, with
responsibility for all commercial operations and medical affairs worldwide
as well as Ipsen's therapeutic area franchises. Prior to joining Ipsen, Mr.&nbsp;Jean was President and CEO for the pharmaceutical activities of the Pierre Fabre Group and President of Europe,
Middle East, and Africa for Novartis' Pharmaceutical Division. Prior to the merger of Ciba Geigy and Sandoz that formed Novartis, he held a number of marketing and management positions in Europe and
Latin America for Ciba Geigy, culminating as Head of Finance and IT Worldwide and Member of the Pharma Executive Committee. Mr.&nbsp;Jean is a member of the Ipsen Executive Leadership Team, the
Supervisory Board of Keosys, and the European Biopharmaceutical Enterprises Board. He holds an MBA from Harvard Business School. We believe that Mr.&nbsp;Jean's extensive experience in the life
sciences industry as a senior executive provides him with the qualifications to serve as a director of our company. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


David P. Meeker  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dr.&nbsp;Meeker has served as a member of our Board since November 2015 and became Chairman of the Board in April 2017. Mr.&nbsp;Meeker
currently serves as CEO of KSQ Therapeutics,&nbsp;Inc., a position he has held since October 2017. From October 2011 until June 2017, Dr.&nbsp;Meeker served as President and Chief Executive
officer of Genzyme, a unit of Sanofi, a global biotechnology company. Dr.&nbsp;Meeker oversaw the company's two business units&#151;Rare Diseases and Multiple Sclerosis. As an Executive Vice
President of Sanofi, he was a member of Sanofi's Executive Committee. Dr.&nbsp;Meeker joined Genzyme in 1994 as Medical Director to work on the Cystic Fibrosis Gene Therapy program. Subsequently, as
Vice President, Medical Affairs, he was responsible for the development of rare disease therapies that today represent transformative and life-saving advancements in medicine for patients. Prior to
Genzyme's merger with Sanofi in 2011, Dr.&nbsp;Meeker was Genzyme's Chief Operating Officer, responsible for its commercial organization, overseeing its business units, country management
organization and global market access functions. He played an important role in the integration with Sanofi. Prior to joining Genzyme, Dr.&nbsp;Meeker was the director of the Pulmonary Critical Care
Fellowship at the Cleveland Clinic and an assistant professor of medicine at Ohio State University. Dr.&nbsp;Meeker is currently a member of the board of directors of MyoKardia,&nbsp;Inc. He has
authored more than 40 articles and multiple book chapters. Dr.&nbsp;Meeker received his M.D. from the University of Vermont Medical School. He completed the Advanced Management Program at Harvard
Business School in 2000. We believe that Dr.&nbsp;Meeker's deep experience as a senior executive at global pharmaceutical companies and involvement in the development and commercialization of
pharmaceutical product candidates for the treatment of rare and ultra-rare diseases provide him with the qualifications to serve as a director of our company. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


David W.J. McGirr  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;McGirr has served as a member of our Board since November 2015. Mr.&nbsp;McGirr serves as a director of Arsanis,&nbsp;Inc., a
clinical-stage biopharmaceutical company focused on applying monoclonal antibody immunotherapies to address serious infectious diseases, Menlo
Therapeutics,&nbsp;Inc., a late-stage biopharmaceutical company focused on an NK-1 receptor antagonist for the treatment of pruritus and for refractory chronic cough, and Insmed Incorporated, a
pharmaceutical company devoted to the treatment of rare diseases. From March 2013 until June 2014, Mr.&nbsp;McGirr was Senior Advisor to the chief executive officer of Cubist Pharmaceuticals and
from November 2002 to March 2013, Mr.&nbsp;McGirr was Senior Vice </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>177</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=180,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=718249,FOLIO='177',FILE='DISK109:[18ZBU1.18ZBU44601]DU44601A.;15',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_du44601_1_178"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>President
and Chief Financial Officer of Cubist. Prior to joining Cubist in 2002, Mr.&nbsp;McGirr was the President and Chief Operating Officer of hippo&nbsp;inc., an internet technology,
venture-financed company. Mr.&nbsp;McGirr served as a member of hippo's board of directors from 1999 to 2003. From 1996 to 1999, he was the President of GAB Robins North America,&nbsp;Inc., a risk
management company, serving also as Chief Executive Officer from 1997 to 1999. Mr.&nbsp;McGirr was a private equity investor from 1995 to 1996. From 1978 to 1995, Mr.&nbsp;McGirr served in various
positions within the S.G. Warburg Group, ultimately as Chief Financial Officer, Chief Administrative Officer and Managing Director of S.G. Warburg&nbsp;&amp;&nbsp;Co.,&nbsp;Inc., a position he held
from 1992 to 1995. Mr.&nbsp;McGirr received a B.Sc. in Civil Engineering from the University of Glasgow and received an M.B.A. from The Wharton School at the University of Pennsylvania.
Mr.&nbsp;McGirr has been designated an audit committee financial expert as defined in applicable SEC rules. We believe that Mr.&nbsp;McGirr's senior-level executive experience in a variety of
industries, including in the life sciences industry, provides him with the qualifications to serve as a director of our company. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Director Independence  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under Nasdaq rules, a majority of a listed company's board of directors must be comprised of independent directors. In addition, Nasdaq rules
require that, subject to specified exceptions, each member of a listed company's audit committee and compensation committee be independent and satisfy additional independence criteria set forth in
Rules&nbsp;10A-3 and 10C-1, respectively, under the Securities Exchange Act of 1934, as amended, or the Exchange Act. Under Nasdaq rules, a director will only qualify as an "independent director"
if, in the opinion of that company's board of directors, that person does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of
a director. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
upon information requested from and provided by each director concerning their background, employment and affiliations, including family relationships, our Board has determined,
upon the recommendation of our Governance and Nominating Committee, that each of our directors other than Keith M. Gottesdiener, our President and Chief Executive Officer, has no relationship that
would interfere with the exercise of independent judgment in carrying out the responsibilities of a director and is independent within the meaning of the director independence standards of the Nasdaq
rules and
the SEC. Our Board has also determined that each of the current members of our Audit Committee and our Compensation Committee as set forth in the "Board Committees" section below satisfies the
independence standards for such committee. In making such determination, our Board considered the relationships that each such non-employee director has with Rhythm and all other facts and
circumstances deemed relevant in determining their independence, including Christophe R. Jean's role as executive vice president at Ipsen Pharma SAS, an entity with which we have an ongoing
contractual relationship. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certain
members of our Board were elected in compliance with the provisions of a voting agreement among us and our major stockholders. The voting agreement terminated upon the closing of
our IPO, and at present we do not have any contractual obligations regarding the election of our directors. See "</FONT><FONT SIZE=2><I>Transactions with Related Persons</I></FONT><FONT SIZE=2>."
There are no family relationships among any of our directors or executive officers. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Board Meetings, Attendance and Executive Sessions  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Board held six meetings and took action by written consent twice during the year ended December&nbsp;31, 2017. With the exception of
Christophe R. Jean, all board members attended at least 75% of the meetings of the Board and the committees of the Board on which he served (in each case, which were held during the period for which
he was a director and/or a member of the applicable committee). Christophe R. Jean attended 70% of the meetings of the Board and the committees of the Board on which he served (which were held during
the period for which he was a director and/or a member of the applicable committee). </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>178</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=181,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=303766,FOLIO='178',FILE='DISK109:[18ZBU1.18ZBU44601]DU44601A.;15',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_du44601_1_179"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Executive
sessions, or meetings of the outside (non-management) directors without management present, are held regularly. The non-management directors met in executive session during
each of the regularly scheduled Board meetings during the year ended December&nbsp;31, 2017. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Rhythm
encourages its directors to attend the Annual Meeting of Stockholders. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Board Composition and Structure  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our certificate of incorporation and bylaws, each as currently amended and in effect, state that our Board shall consist of a number of
directors that shall be fixed exclusively by the Board from time to time in accordance with the bylaws of the Company. Each director holds office until his or her successor is duly elected and
qualified or until his or her death, incapacity, resignation or removal. Our certificate of incorporation provides that our directors may be removed only for cause by the affirmative vote of the
holders of at least 75% of the voting power of the outstanding shares of capital stock of Rhythm entitled to vote in the election of directors, voting together as a single class, at a meeting of the
stockholders called for that purpose. Any vacancy in the Board, including a vacancy that results from an increase in the number of directors, may be filled only by the vote of a majority of the
remaining directors then in office, although less than a quorum, or by the sole remaining director. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
certificate of incorporation, as currently amended and in effect, provides that our Board is divided into three classes of directors, with the classes as nearly equal in number as
possible. Each of our directors identified below serves in the class indicated. Subject to any earlier resignation or removal in accordance with the terms of our certificate of incorporation and
bylaws, our current Class&nbsp;I directors will serve until the 2021 annual meeting of stockholders; our current Class&nbsp;II directors will serve until the 2019 annual meeting of stockholders;
and our current Class&nbsp;III directors will serve until the 2020 annual meeting of stockholders. Any additional directorships resulting from an increase in the number of directors will be
apportioned by our Board among the three classes as equally as possible. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Board is currently comprised of seven members. In consultation with the Governance and Nominating Committee, the Board has determined that the classified board structure is
appropriate for the Company, particularly following its initial public offering. A classified board provides for stability, continuity and experience among our Board. Further, the Board believes that
building a cohesive Board is an important goal. In our industry in particular, long-term focus is critical. The time horizon required for successful development of pharmaceuticals makes it vital that
we have a board that understands the implications of this process and has the ability to develop and implement long-term strategies while benefiting from an in-depth knowledge of Rhythm's business and
operations. A classified board structure helps to ensure that there will be the continuity and stability of leadership required to navigate a challenging economic environment while resisting the
pressure to focus on short-term results at the expense of the long-term value and success of the Company. The future success of Rhythm depends in significant part on the ability to attract and retain
capable and experienced directors. In this regard, we believe that longer terms for our directors will enhance director independence from both management and stockholder special interest groups. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Board Leadership Structure  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The positions of chairman of the board and chief executive officer are presently separated. Our Board recognizes the time, effort and energy
that the chief executive officer is required to devote to his position in the current business environment, as well as the commitment required to serve as our chairman, particularly as the board of
directors' oversight responsibilities continue to grow. Our Board believes that having separate positions is the appropriate leadership structure for us at this time and demonstrates our commitment to
good corporate governance. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>179</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=182,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=615664,FOLIO='179',FILE='DISK109:[18ZBU1.18ZBU44601]DU44601A.;15',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_du44601_1_180"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Board Committees  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Board has established the following committees: an Audit Committee, a Compensation Committee, and a Governance and Nominating Committee. The
composition and responsibilities of each committee are described below. Members will serve on these committees until their resignation or until otherwise determined by our Board. Each of the Audit
Committee, Compensation Committee, and Governance and Nominating Committee operates pursuant to a written charter and each committee reviews and assesses the adequacy of its charter annually and
submits its charter to the Board for approval. The charters for the Audit Committee, Compensation Committee, and Governance and Nominating Committee are all available on our website at
www.rhythmtx.com under "Investors&nbsp;&amp; Media" at "Corporate Governance." </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table describes which directors serve on each of the Board committees and includes the class for each director. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="107pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="67pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="27pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name:


<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Governance and<BR>
Nominating Committee </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Compensation<BR>
Committee </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Audit<BR>
Committee </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Class </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Neil Exter</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>X</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>II</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Todd Foley</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>X</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>II</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Keith M. Gottesdiener</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>I</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Christophe R. Jean</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>X</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>I</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Ed Mathers</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>X</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>II</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>David W. J. McGirr</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>X</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>X</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>III</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>David P. Meeker</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>X</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>X</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>III</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Audit Committee  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Audit Committee provides oversight of our accounting and financial reporting process, the audit of our financial statements and our internal
control function. Among other matters, the Audit Committee is responsible for the following: assisting the Board in oversight of the independent auditors' qualifications, independence and performance;
the engagement, retention and compensation of the independent auditors; reviewing the scope of the annual audit; reviewing and discussing with management and the independent auditors the results of
the annual audit and the review of our quarterly financial statements, including the disclosures in our annual and quarterly reports filed with the SEC; reviewing our risk assessment and risk
management processes; establishing procedures for receiving, retaining and investigating complaints received by us regarding accounting, internal accounting controls or audit matters; and approving
audit and permissible non-audit services provided by our independent auditor. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
current members of our Audit Committee are David W.J. McGirr, who is the chair of the Audit Committee, Christophe R. Jean, and David P. Meeker. All members of our Audit Committee
meet the requirements for financial literacy under the applicable rules and regulations of the SEC and Nasdaq. Our Board has determined that David W.J. McGirr is an audit committee financial expert as
defined under the applicable rules of the SEC and has the requisite financial sophistication as defined under the applicable rules and regulations of Nasdaq. All of the members of our Audit Committee
are independent directors as defined under the applicable rules and regulations of the SEC and Nasdaq. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
the year ended December&nbsp;31, 2017, the Audit Committee met four times. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Compensation Committee  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Compensation Committee adopts and administers the compensation policies, plans and benefit programs for our executive officers and all other
members of our executive team. Our Compensation Committee is also responsible for making recommendations regarding
non-employee director compensation to the full Board. In addition, among other things, our Compensation Committee evaluates </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>180</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=183,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=53513,FOLIO='180',FILE='DISK109:[18ZBU1.18ZBU44601]DU44601A.;15',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_du44601_1_181"> </A>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>annually,
in consultation with the Board, the performance of our chief executive officer, reviews and approves corporate goals and objectives relevant to compensation of our chief executive officer
and other executives and evaluates the performance of these executives in light of those goals and objectives. Our Compensation Committee also adopts and administer our equity compensation plans. The
current members of our Compensation Committee are Neil Exter, who is the chair of the Compensation Committee, and Todd Foley. All of the members of our Compensation Committee are independent under the
applicable rules and regulations of the SEC and Nasdaq. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
the year ended December&nbsp;31, 2017, the Compensation Committee met two times. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Governance and Nominating Committee  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Governance and Nominating committee is responsible for, among other things, making recommendations regarding corporate governance, the
composition of our Board, the identification, evaluation and nomination of director candidates and the structure and composition of committees of our Board. In addition, our Governance and Nominating
committee oversees our corporate governance guidelines, approves our committee charters, oversees compliance with our code of business conduct and ethics, contributes to succession planning, reviews
policies and procedures with respect to our related party transactions policy and oversees our board self-evaluation process. The current members of our Governance and Nominating committee are David
P. Meeker, who is the chair of the Governance and Nominating Committee, Ed Mathers, and David W.J. McGirr. All of the members of our Governance and Nominating committee are independent under the
applicable rules and regulations of Nasdaq. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
the year ended December&nbsp;31, 2017, the Governance and Nominating committee did not meet. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Compensation Committee Interlocks and Insider Participation  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During the last completed fiscal year Neil Exter and Todd Foley served on the Compensation Committee. None of the members of our Compensation
Committee has at any time during the prior fiscal year been one of our officers or employees. None of the members of the Compensation Committee during the prior fiscal year were formerly one of our
officers. None of our executive officers currently serves, or in the past fiscal year has served, as a member of the Board or Compensation Committee of any entity that has one or more executive
officers serving on our Board or Compensation Committee. For a description of transactions between us and members of our Compensation Committee and affiliates of such members, please see
"</FONT><FONT SIZE=2><I>Transactions with Related Pers</I></FONT><FONT SIZE=2>ons." </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Board Observer Rights  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with our initial public offering, the Board invited Sara Brownstein of Baker Bros. Advisors&nbsp;LP to continue to attend all
meetings of the Board in a nonvoting observer capacity. The Board may terminate the board observer rights in its sole discretion. See "</FONT><FONT SIZE=2><I>Transactions with Related
Persons&#151;Transactions with Baker Bros. Advisors&nbsp;LP</I></FONT><FONT SIZE=2>." </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


The Board of Directors' Role in Risk Oversight  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The audit committee of the Board, or the Audit Committee, is primarily responsible for overseeing our risk management processes on behalf of the
Board. The Audit Committee receives reports from management regarding our assessment of risks. In addition, the Audit Committee reports regularly to the Board, which also considers our risk profile.
The Audit Committee and the Board focus on the most significant risks we face and our general risk management strategies. While the Board oversees our risk management, management is responsible for
day-to-day risk management processes. Our Board expects management to consider risk and risk management in each business decision, to proactively develop and monitor risk management strategies and
processes for day-to-day activities and to effectively implement risk management strategies adopted by the Audit Committee and the Board. We believe this division of </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>181</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=184,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=139464,FOLIO='181',FILE='DISK109:[18ZBU1.18ZBU44601]DU44601A.;15',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_du44601_1_182"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>responsibilities
is the most effective approach for addressing the risks we face and that the leadership structure of our Board, which also emphasizes the independence of the Board in its oversight of
its business and affairs, supports this approach. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Scientific Advisory Board  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our management team is supported by a scientific advisory board composed of leading academic and industry scientists. This group generally meets
quarterly with our management team either as a group or individually to provide advice and guidance on our development programs. Our scientific advisory board consists of: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="187pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>John Amatruda, M.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 Dr.&nbsp;Amatruda has broad clinical development expertise in metabolic disease. Most recently, he was Senior Vice President and Franchise Head for Diabetes and Obesity at Merck&nbsp;&amp;&nbsp;Co.,&nbsp;Inc.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Michael Camilleri, M.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 Dr.&nbsp;Camilleri is a Professor of Medicine and Physiology in the Mayo Clinic College of Medicine. He is a leading expert in gastroenterology, with a research focus on enteric neurosciences and the physiology, pathophysiology, and treatment of
 diseases that affect gastrointestinal motility, including gastroparesis, diabetes, obesity, and irritable bowel syndrome.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>William Chin, M.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 Dr.&nbsp;Chin is Chief Medical Officer and Executive Vice President at PhRMA. Formerly, he was Executive Dean for Research at Harvard Medical School, following a 10-year career at Eli Lilly and Company, where he was most recently Senior Vice
 President for Discovery Research and Clinical Investigation.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;text-align:left;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


 Lee Kaplan, M.D., Ph.D.&nbsp;</font> <p align=left style="font-family:times;margin-top:0pt;margin-left:10pt;"> <font size=2> </FONT><FONT SIZE=2><I>Chairman</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 Dr.&nbsp;Kaplan is Director of the Obesity, Metabolism,&nbsp;&amp; Nutrition Institute and was Founding Director of the Weight Center at the Massachusetts General Hospital. He is an Associate Professor of Medicine at Harvard Medical
 School.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Elizabeth Stoner, M.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 Dr.&nbsp;Stoner is a founder of the&nbsp;LLC entity and served as our Chief Development Officer from 2010 through 2014. Dr.&nbsp;Stoner previously served in various roles at Merck, most recently as Senior Vice President of Global Clinical
 Development Operations, and is a Managing Director at MPM Ventures.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Code of Business Conduct and Ethics and Corporate Governance Guidelines  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have adopted a code of business conduct and ethics that applies to all of our employees, including our executive officers, and directors, and
those employees responsible for financial reporting. The code of business conduct and ethics is available on our website. We expect that, to the
extent required by law, any amendments to the code, or any waivers of its requirements, will be disclosed on our website at www.rhythmtx.com under "Investors&nbsp;&amp; Media" at "Corporate Governance"
or by requesting a copy, free of charge, in writing from our Secretary at Rhythm Pharmaceuticals,&nbsp;Inc., 500 Boylston Street, 11th&nbsp;Floor, Boston, MA 02116. We intend to post on our
website any amendment to, or waiver under, a provision of the code of business conduct and ethics that applies to certain of our executive officers within four business days following the date of such
amendment or waiver. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
copy of our corporate governance guidelines may also be accessed free of charge by visiting the website at www.rhythmtx.com under "Investors&nbsp;&amp; Media" at "Corporate Governance"
or by requesting a copy from our Secretary at our principal executive offices above. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>182</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=185,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=672462,FOLIO='182',FILE='DISK109:[18ZBU1.18ZBU44601]DU44601A.;15',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_dw44601_1_183"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dw44601_executive_and_director_compensation"> </A>
<A NAME="toc_dw44601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  EXECUTIVE AND DIRECTOR COMPENSATION    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This section discusses the material elements of compensation for our named executive officers and the most important factors relevant to an
analysis of these policies. It provides qualitative information regarding the manner and context in which compensation is awarded to and earned by our executive officers named in the "Summary
Compensation Table" below, or our named
executive officers, and is intended to place in perspective the data presented in the following tables and the corresponding narrative. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Summary Compensation Table  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth information about compensation awarded or paid to our named executive officers for the 2016 and 2017 fiscal
years. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="30pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="81pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="67pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name and Principal Position

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Base<BR>
Salary<SUP>(1)</SUP><BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Bonus<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
Awards<SUP>(2)</SUP><BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Non-Equity<BR>
Incentive Plan<BR>
Compensation<SUP>(3)</SUP><BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>All Other<BR>
Compensation<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Keith M. Gottesdiener, M.D.,</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>490,795</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>799,994</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>245,398</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,536,187</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><I>President and Chief</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>476,500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>85,770</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>562,270</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><I> Executive Officer, Director</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Hunter C. Smith<SUP>(4)</SUP>,</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>159,795</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>832,497</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>70,490</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>27,495</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,090,277</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>Chief Financial Officer</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Nithya Desikan<SUP>(5)</SUP>,</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>158,100</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>100,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>832,497</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>66,780</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,157,377</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><I>Chief Commercial Officer</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Salaries include amounts contributed by the named executive officer to our 401(k) plan.  </FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(2)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Amounts shown reflect the grant date fair value of
options awarded during each of fiscal year 2016 and 2017, determined in
accordance with the Financial Accounting Standards Board, Accounting Standards Codification Topic 718, </FONT><FONT SIZE=1><I>Compensation&#151;Stock Compensation</I></FONT><FONT SIZE=1>. These
amounts exclude the value of estimated forfeitures. Note that the amounts reported in this column reflect the accounting cost for these stock options, and do not correspond to the actual economic
value that may be received by the named executive officers from the options.  </FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(3)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Amounts shown reflect the cash performance bonus amount paid to the named executive officer for fiscal years
2016 and 2017
that was earned based on Rhythm's performance. Annual cash incentive compensation earned during the year is typically paid in the following year.  </FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(4)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Mr.&nbsp;Smith's first day of employment
was July&nbsp;31, 2017.  </FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(5)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Ms.&nbsp;Desikan's first day of employment was July&nbsp;24,
2017.</FONT></DD></DL>
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
executive compensation program is based on a pay-for-performance philosophy. The Compensation Committee designed our executive compensation program to achieve the following primary
objectives: provide compensation and benefit levels that will attract, retain, motivate and reward a highly talented executive team within the context of responsible cost management; establish a
direct link between our individual/team performance and results and our executives' compensation; and align the interests and objectives of our executives with those of our stockholders by linking
executive equity awards to stockholder value creation. The compensation program for our executive officers is composed primarily of the following three main components: base salary, annual cash
incentives and long-term equity incentives. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Base Salary  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The 2017 base salaries, effective January&nbsp;1, 2017 for Mr.&nbsp;Gottesdiener, July&nbsp;31, 2017 for Mr.&nbsp;Smith, and
July&nbsp;24, 2017 for Ms.&nbsp;Desikan, were determined for each named executive officer by the Compensation </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>183</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=186,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=805086,FOLIO='183',FILE='DISK109:[18ZBU1.18ZBU44601]DW44601A.;16',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_dw44601_1_184"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>Committee,
which gives consideration to each officer's experience, expertise and performance, as well as market compensation levels for similar positions. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="73pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017<BR>
Base Salary ($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Keith M. Gottesdiener, M.D., </FONT><FONT SIZE=2><I>President and Chief Executive Officer</I></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>490,795</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Hunter C. Smith, </FONT><FONT SIZE=2><I>Chief Financial Officer</I></FONT><FONT SIZE=2><SUP>(1)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>380,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Nithya Desikan, </FONT><FONT SIZE=2><I>Chief Commercial Officer</I></FONT><FONT SIZE=2><SUP>(2)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>360,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Mr.&nbsp;Smith was hired on July&nbsp;31, 2017 and his base salary was prorated to $159,795.  </FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(2)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Ms.&nbsp;Desikan was hired on July&nbsp;24,
2017 and her base salary was prorated to
$158,100.</FONT></DD></DL>
 </DIV>
 <P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Annual Performance-Based Incentive Opportunity  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In addition to base salaries, our named executive officers are eligible to receive annual performance-based cash incentives, which are designed
to motivate our executives to achieve defined annual corporate goals and to reward our executives for their contributions towards achievement of these goals. The annual performance-based incentive
each named executive officer was eligible to receive in 2017 was generally based on the extent to which the officer contributed to the achievement of the corporate goals that the Compensation
Committee established at the beginning of 2017. After the end of 2017, the Compensation Committee reviewed performance against each goal and determined the extent to which each goal was achieved. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Compensation Committee generally considered each named executive officer's individual contributions towards reaching the annual corporate goals but did not establish specific
individual goals for each of them. Pursuant to the terms of their respective agreements governing their employment relationship, described below under "Employment Agreements," Dr.&nbsp;Gottesdiener
was eligible to receive a target bonus of up to 50% of his base salary, Mr.&nbsp;Smith was eligible to receive a target bonus of up to 35% of his base salary, and Ms.&nbsp;Desikan was eligible to
receive a target bonus of up to 35% of her base salary. However, there is no minimum bonus percentage or amount established for the named executive officers and, as a result, the bonus amounts have
varied from year to year based on corporate and individual performance. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
December 2017, the Compensation Committee reviewed the 2017 corporate goals and based on the Compensation Committee's determination of achievement of the goals, the Compensation
Committee awarded each of our named executive officers eligible for performance bonuses 100% of their target bonus opportunity for 2017. For 2017, Dr.&nbsp;Gottesdiener received a bonus of $245,398,
Mr.&nbsp;Smith received a prorated bonus of $70,490, and Ms.&nbsp;Desikan received a prorated bonus of $66,780. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>184</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=187,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=484833,FOLIO='184',FILE='DISK109:[18ZBU1.18ZBU44601]DW44601A.;16',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_dw44601_1_185"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Outstanding Equity Awards at End of 2017  </B></FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table provides information about outstanding equity awards held by each of our named executive officers at December&nbsp;31,
2017. All options were granted under our 2015 equity incentive plan. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:62%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"130%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="130%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="112pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="124pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="42pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option Awards<SUP>(1)</SUP> </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of Securities<BR>
Underlying Unexercised<BR>
Options (#) Exercisable </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of Securities<BR>
Underlying Unexercised<BR>
Options (#) Unexercisable </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
Exercise<BR>
Price ($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
Expiration<BR>
Date </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Keith M. Gottesdiener, M.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>25,391</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><SUP>(2)(3)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>102,389</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4.59</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11/16/2025</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>34,597</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><SUP>(2)(3)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>22,655</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7.52</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12/30/2025</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>40,896</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><SUP>(3)(4)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>122,680</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6.14</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4/4/2027</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>13,632</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><SUP>(3)(4)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>40,893</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6.14</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4/4/2027</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Hunter C. Smith</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><SUP>(5)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>201,744</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6.88</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8/8/2027</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Nithya Desikan</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>32,715</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><SUP>(6)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>169,029</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6.88</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8/8/2027</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Upon an option holder's termination of employment on account of the option holder's death or disability, these options expire
on the first anniversary of the option holder's termination. If an option holder's employment terminates for any other reason, these options expire three months after the option holder's termination. </FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(2)
</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>These options vest in 48 equal monthly installments, starting on August&nbsp;3, 2015, except that the last installment, if
necessary, may be smaller.  </FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(3)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>If the option holder's employment is terminated within the three months preceding or the 12&nbsp;months immediately
following a change of control of us, 100% of the option holder's equity awards will become immediately exercisable.  </FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(4)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>These options vest in 48 equal monthly installments, starting on
January&nbsp;6, 2017, except that the last installment, if
necessary, may be smaller.  </FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(5)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>50,436 of these options vest on July&nbsp;31, 2018, and the remaining options vest in 36&nbsp;monthly installments,
starting on August&nbsp;31, 2018, except that the last installment, if necessary, may be smaller.  </FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(6)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>42,257 of these options vest on July&nbsp;24, 2018, and the remaining options vest in
36&nbsp;monthly installments,
starting on August&nbsp;24, 2018, except that the last installment, if necessary, may be smaller.</FONT></DD></DL>
 </DIV>
 <P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Pension Benefits  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our named executive officers did not participate in, or otherwise receive any benefits under, any pension or retirement plan during 2017, other
than pursuant to the 401(k) plan described under "401(k)&nbsp;Plan." </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Nonqualified Deferred Compensation  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our named executive officers did not participate in, or earn any benefits under, a nonqualified deferred compensation plan during 2017. </FONT></P>


<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Employment Agreements and Potential Payments Upon Termination or Change of Control  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Below are written descriptions of our employment agreements with each of our named executive officers. Regardless of the manner in which a named
executive officer's employment terminates, each named executive officer is entitled to receive amounts earned during his term of employment, including salary and unused vacation pay. In addition, each
of our named executive officers is eligible to receive certain benefits pursuant to his letter agreement as described below. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Agreement with Dr.&nbsp;Gottesdiener.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Under Dr.&nbsp;Gottesdiener's letter agreement, he is entitled to a base salary of $490,795,
subject to
adjustment in the Compensation Committee's sole discretion, is eligible to receive an annual target performance bonus of up to 50% of his base salary, as determined by the Compensation Committee, and
is entitled to certain severance benefits as described below. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
Termination without "cause" or for "good reason" within the three months immediately preceding or the 12&nbsp;months immediately following a "change of control" as defined in the
letter </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>185</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=188,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=836306,FOLIO='185',FILE='DISK109:[18ZBU1.18ZBU44601]DW44601A.;16',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_dw44601_1_186"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>agreement,
subject to customary conditions, including his execution and nonrevocation of an acceptable release, Dr.&nbsp;Gottesdiener, in lieu of the above benefits, will be entitled to receive a
severance payment in an aggregate amount equal to 18&nbsp;months of his base salary then in effect, paid in substantially equal installments over a period of 18&nbsp;months, as applicable, in
accordance with ordinary payroll practices, a payment equal to 100% of his annual target bonus for the year in which the termination occurs, and reimbursement of his COBRA premiums for up to
18&nbsp;months. In addition, each unvested equity award held by Dr.&nbsp;Gottesdiener granted by both us or the&nbsp;LLC entity will immediately become fully vested. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
Termination without "cause" or for "good reason" unrelated to a "change of control" as defined in the letter agreement, subject to customary conditions, including his execution and
nonrevocation of an acceptable release, Dr.&nbsp;Gottesdiener, in lieu of the above benefits, will be entitled to receive a severance payment in an aggregate amount equal to 12&nbsp;months of his
base salary then in effect, paid in substantially equal installments over a period of 12&nbsp;months, as applicable, in accordance with ordinary payroll practices. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Agreement with Mr.&nbsp;Smith.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Under Mr.&nbsp;Smith's letter agreement, he is entitled to a base salary of $380,000, prorated for
Mr.&nbsp;Smith's hire date of July&nbsp;31, 2017 and subject to adjustment in the Compensation Committee's sole discretion, is eligible to receive an annual target performance bonus of up to 35%
of his base salary, prorated for Mr.&nbsp;Smith's hire date of July&nbsp;31, 2017, as determined by the Compensation Committee, and is entitled to certain severance benefits as described below. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
Termination without "cause" or for "good reason" within the three months immediately preceding or the 12&nbsp;months immediately following a "change of control" as defined in the
letter agreement, subject to customary conditions, including his execution and nonrevocation of an acceptable release, Mr.&nbsp;Smith, in lieu of the above benefits, will be entitled to receive a
severance payment in an aggregate amount equal to 12&nbsp;months of his base salary then in effect, paid in substantially equal installments over a period of 12&nbsp;months, as applicable, in
accordance with ordinary payroll practices, a payment equal to 100% of his annual target bonus for the year in which the termination occurs, and reimbursement of his COBRA premiums for up to
18&nbsp;months. In addition, each unvested equity award held by Mr.&nbsp;Smith granted by us will immediately become fully vested. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
Termination without "cause" or for "good reason" unrelated to a "change of control" as defined in the letter agreement, subject to customary conditions, including his execution and
nonrevocation of an acceptable release, Mr.&nbsp;Smith, in lieu of the above benefits, will be entitled to receive a severance payment in an aggregate amount equal to (i)&nbsp;9&nbsp;months of
his base salary then in effect, paid in substantially equal installments over a period of 9&nbsp;months, or (ii)&nbsp;12&nbsp;months of his base salary then in
effect, paid in substantially equal installments over a period of 12&nbsp;months, if such termination occurs prior to July&nbsp;31, 2018, in each case as applicable, in accordance with ordinary
payroll practices. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Agreement with Ms.&nbsp;Desikan.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Under Ms.&nbsp;Desikan's letter agreement, she is entitled to a base salary of $360,000, subject to
adjustment
in the Compensation Committee's sole discretion, is eligible to receive an annual target performance bonus of up to 35% of her base salary, as determined by the Compensation Committee, and is entitled
to certain severance benefits as described below. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
Termination without "cause" or for "good reason", within the three months immediately preceding or the 12&nbsp;months immediately following a "change of control" as defined in the
letter agreement, subject to customary conditions, including her execution and nonrevocation of an acceptable release, Ms.&nbsp;Desikan, in lieu of the above benefits, will be entitled to receive a
severance payment in an aggregate amount equal to 12&nbsp;months of her base salary then in effect, paid in substantially equal installments over a period of 12&nbsp;months in accordance with
ordinary payroll practices, and a payment equal to 100% of her annual target bonus for the year in which the termination occurs. In addition, each unvested equity award held by Ms.&nbsp;Desikan
granted by us will immediately become fully vested. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>186</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=189,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=20666,FOLIO='186',FILE='DISK109:[18ZBU1.18ZBU44601]DW44601A.;16',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_dw44601_1_187"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
Termination without "cause" or for "good reason" unrelated to a "change of control" as defined in the letter agreement, subject to customary conditions, including her execution and
nonrevocation of an acceptable release, Ms.&nbsp;Desikan, in lieu of the above benefits, will be entitled to receive a severance payment in an aggregate amount equal to (i)&nbsp;9&nbsp;months of
her base salary then in effect, paid in substantially equal installments over a period of 9&nbsp;months, or (ii)&nbsp;12&nbsp;months of her base salary then in effect, paid in substantially
equal installments over a period of 12&nbsp;months, if such termination occurs prior to July&nbsp;24, 2018, in each case as applicable, in accordance with ordinary payroll practices. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
purposes of these letter agreements, "cause" generally means the occurrence of any of the following events by the individual: (i)&nbsp;commission of any crime involving fraud,
breach of trust, or physical or emotional harm to any person, moral turpitude or dishonesty; (ii)&nbsp;any unauthorized use or disclosure of proprietary information (other than any such use or
disclosure that is not intentional and is not material); (iii)&nbsp;any intentional misconduct or gross negligence that has a material adverse effect on business or reputation; (iv)&nbsp;any
material breach by the executive of any agreement that is not cured within 30&nbsp;days after receipt of notice; or (v)&nbsp;repeated and willful failure to perform the duties, functions and
responsibilities of his position after a written warning from us. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
purposes of the letter agreements, "good reason" generally means resignation by the executive from all positions if, without the executive's written consent, there is a
(i)&nbsp;material diminution of duties or authority; (ii)&nbsp;material reduction of the executive's base salary not pursuant to a program affecting all or substantially all employees unless the
executive is affected to a greater extent than other similarly situated employees pursuant to such a program; or (iii)&nbsp;requirement to relocate the primary work location to a location that would
increase the one way commute distance by more than 35 miles from the executive's primary work location as of immediately prior to such change, in each case, provided that the executive provides
written notice within 30&nbsp;days following such event, and failure to remedy the event within 30&nbsp;days following receipt of such notice and the executive's resignation is effective no more
than 30&nbsp;days following the expiration of a cure period. Good reason may also occur if the executive resigns from all positions on the one-year anniversary of a change in control if the
executive has not entered into a written letter or agreement providing for the executive's continued employment with us or our successor. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Compensation Consultant  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with our executive compensation review, in 2017 our Compensation Committee engaged Radford, an Aon Hewitt company, or Radford, an
independent executive compensation consultant, to provide our Compensation Committee guidance with respect to the development and implementation of our compensation programs. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Compensation Committee charter requires that its compensation consultant be independent of Rhythm management. During 2017, Radford did not provide services to us other than the
services described in this registration statement. Our Compensation Committee has determined that Radford is independent and that its work has not raised any conflict of interest. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Employee Benefit and Stock Plans  </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


2017 Equity Incentive Plan  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following summary of the material terms of the 2017 Plan does not purport to be complete and is qualified by reference to the full text of
the 2017 Plan. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
2017 Plan provides for the grant of incentive stock options and nonstatutory stock options, stock appreciation rights, restricted stock and restricted stock unit awards, performance
units, stock grants and qualified performance-based awards (that is, any of the foregoing that are intended to constitute performance-based compensation under Section&nbsp;162(m) of the Code), which
we collectively refer to as "awards" in connection with the 2017 Plan. Our directors, officers and other employees, as well as others </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>187</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=190,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=486350,FOLIO='187',FILE='DISK109:[18ZBU1.18ZBU44601]DW44601A.;16',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_dw44601_1_188"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>performing
consulting or advisory services for us, are eligible for grants under the Plan. The purpose of the Plan is to provide incentives that will attract, retain and motivate highly competent
officers, directors, employees and consultants and advisors to promote the success of our business and align employees' interests with stockholders' interests. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Administration  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under its terms, the 2017 Plan is administered by the compensation committee of our board of directors which is made up of independent outside
non-employee directors for purposes of applicable securities and tax laws. The board of directors itself may also exercise any of the powers and responsibilities under the 2017 Plan. The compensation
committee may delegate to an executive officer or officers the authority to grant awards under the 2017 Plan subject to applicable law and to guidelines specified by the compensation committee.
Subject to the terms of the Plan, the compensation committee will select the recipients of awards and determine, among other things, the:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> number of shares of common stock covered by awards and the dates upon which such awards become exercisable or any restrictions to which they
are subject lapse, as applicable; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> type of award and the exercise or purchase price and method of payment for each such award; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> vesting period for awards, risks of forfeiture and any potential acceleration of vesting or lapses in risks of forfeiture; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> duration of awards. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
decisions, determinations and interpretations made in good faith by the compensation committee with respect to the 2017 Plan and the terms and conditions of or operation of any award
are final and binding on all participants, beneficiaries, heirs, assigns or other persons holding or claiming rights under the 2017 Plan or any award. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Available Shares  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject to the following sentence, the aggregate number of shares of our common stock which may be issued under the 2017 Plan or with respect to
which awards may be granted may not exceed&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares (including pursuant to incentive stock options), which may be either authorized and unissued shares of our common stock or shares
of
common stock held in or acquired for our treasury. The number of shares authorized under the 2017 Plan will be increased each January&nbsp;1, commencing on January&nbsp;1, 2018, by an amount equal
to 4% of outstanding shares of stock as of the end of the immediately preceding fiscal year. Notwithstanding the foregoing, our board of directors may act prior to January&nbsp;1 of a given year to
provide that there will be no such January&nbsp;1 increase in the number of shares of stock authorized under the 2017 Plan for such year or that the increase in the number of shares of stock
authorized under the 2017 Plan for such year will be a lesser number than would otherwise occur pursuant to the preceding sentence. Notwithstanding the preceding sentences, in no event shall the
number of shares available for issuance pursuant to incentive options over the term of the 2017 Plan exceed 4,018,538 shares of stock. In general, if awards under the 2017 Plan are for any
reason cancelled, or expire or terminate unexercised, the number of shares covered by such awards will again be available for the grant of awards under the 2017 Plan. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Eligibility for Participation  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Members of our board of directors, as well as employees of, and consultants and advisors to, us or any of our subsidiaries and affiliates are
eligible to receive awards under the 2017 Plan. The selection of participants is within the sole discretion of the compensation committee. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>188</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=191,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=255439,FOLIO='188',FILE='DISK109:[18ZBU1.18ZBU44601]DW44601A.;16',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_dw44601_1_189"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Individual Limitations  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The maximum number of shares of common stock that may be subject to options or stock appreciation rights or any combination thereof granted to
any one person during any single calendar year shall be 1,200,000. The maximum number of shares of common stock that may be subject to all other awards granted to any one person during any single
calendar year that are intended to be qualified performance-based awards shall be 1,200,000. The maximum value of awards denominated in cash granted to any one person other than a non-employee member
of our board of directors during any single calendar year and that are intended to be qualified performance-based awards shall be $30,000,000. Each of the foregoing limitations shall be doubled with
respect to awards granted to an individual during the first calendar year in which he or she commences employment. The maximum value of awards denominated in cash granted to any non-employee member of
our board of directors during any single calendar year shall be $1,000,000. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Incentive Stock Options  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Incentive stock options are options that are intended to qualify as incentive stock options under Section&nbsp;422 of the Code, and will be
granted pursuant to incentive stock option agreements. Only our employees or employees of our parent or subsidiary corporations, as contemplated by the Code, are eligible to receive incentive stock
options. The compensation committee will determine the exercise price for an incentive stock option, which may not be less than 100% of the fair market value of the stock underlying the option on the
date of grant. In addition, incentive options granted to employees who own, or are deemed to own, more than 10% of our voting stock, must have an exercise price not less than 110% of the fair market
value of the stock underlying the option on the date of grant. No incentive stock option may be exercised on or after the tenth anniversary of the date of grant, or after the fifth anniversary of the
date of grant for employees who own, or are deemed to own, more than 10% of our voting stock. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Nonstatutory Stock Options  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Nonstatutory stock options are not intended to qualify as incentive stock options under Section&nbsp;422 of the Code and will be granted
pursuant to nonstatutory stock option agreements. The compensation committee will determine the exercise price which may not be less than 100% of the fair market value of the stock underlying the
option on the date of grant and term of a nonstatutory stock option. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Stock Appreciation Rights  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A stock appreciation right, or a SAR, entitles a participant to receive a payment equal in value to the difference between the fair market value
of a share of stock on the date of exercise of the SAR over a specified exercise price of the SAR. SARs may be granted in tandem with a stock option, such that the recipient has the opportunity to
exercise either the stock option or the SAR, but not both. The exercise price (above which any appreciation is measured) will not be less than 100% of the fair market value of the common stock on the
date of grant of the SAR or, in the case of an SAR granted in tandem with a stock option, the exercise price will be the same as the exercise price of the related stock option. The compensation
committee may settle a SAR amount in cash, in shares of our common stock, or a combination of cash and shares of our common stock as determined by the compensation committee at or after grant but
subject to the terms of the applicable aware agreement. The terms, methods of exercise, and any other terms and conditions of any SAR will be determined by
the compensation committee at the time of the grant of the award and will be reflected in the award agreement. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Restricted Stock and Restricted Stock Units  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A restricted stock award or restricted stock unit award is the grant of shares of our common stock either currently (in the case of restricted
stock) or at a future date (in the case of restricted stock units) at a </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>189</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=192,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=863209,FOLIO='189',FILE='DISK109:[18ZBU1.18ZBU44601]DW44601A.;16',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_dw44601_1_190"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>price
determined by the compensation committee (including zero), based on satisfaction of certain vesting conditions, including continuing employment or other service, or achievement of performance
goals. During the vesting period, participants holding shares of restricted stock shall, except as otherwise provided in the Plan or an individual award agreement, have full voting and dividend rights
with respect to such shares but any stock dividends or other distributions payable in shares of stock or other securities of ours will be subject to the same vesting conditions that apply to the
shares of restricted stock in respect of which the dividend was made. The receipt of cash dividends may also be deferred or required to be invested in additional shares of restricted stock.
Participants holding restricted stock units may be entitled to receive payments equivalent to any dividends declared with respect to the common stock referenced in the grant of the restricted stock
units, but only following the close of the applicable restriction period and then only if the employment or other service and/or performance goals have been met. The restrictions will lapse in
accordance with a schedule or other conditions determined by the compensation committee. The compensation committee may settle restricted stock units in cash, in shares of our common stock, or a
combination of cash and shares of our common stock as determined by the compensation committee at or after grant but subject to the terms of the applicable award agreement. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Performance Units  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A performance unit award is a contingent right to receive the value of a specified number of shares of our common stock over an initial value
for such number of shares (which may be zero) established by the compensation committee at the time of grant if certain performance goals or other business objectives are met with the specified
performance period. The value of performance
units will depend on the degree to which the specified performance goals are achieved. The compensation committee may, in its discretion, pay earned performance units in cash, in shares of our common
stock, or a combination of both cash and shares of our common stock as determined by the compensation committee at or after grant but subject to the terms of the applicable award agreement. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
compensation committee has discretion to select the length of any applicable restriction or performance period, the kind and/or level of the applicable performance goal and whether
the performance goal is to apply to us, to one of our subsidiaries or any division or business unit or to the recipient. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Stock Grants  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A stock grant is an award of shares of common stock without restriction. Stock grants may only be made in limited circumstances, such as in lieu
of other earned compensation or as an inducement to employment. Stock grants are made without any forfeiture conditions. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Qualified Performance-Based Awards  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Qualified performance-based awards are earned based on the achievement of certain performance criteria intended to satisfy Section&nbsp;162(m)
of the Code. Section&nbsp;162(m) of the Code limits our federal income tax deduction for compensation to certain of our executive officers to $1.0&nbsp;million dollars, but excludes from that
limit "performance-based compensation." Any form of award permitted under the 2017 Plan other than a stock grant may be granted as a qualified performance-based award, but, in the case of awards other
than stock options and SARs, will be subject to satisfaction of pre-established, objective performance goals. Qualified performance-based awards include any of the foregoing awards that are granted
subject to vesting and/or payment based on the attainment of specified performance goals. Performance criteria upon which performance goals are established by the plan administrator may include but
are not limited to: (i)&nbsp;net earnings (either before or after one or more of (A)&nbsp;interest, (B)&nbsp;taxes, (C)&nbsp;depreciation and (D)&nbsp;amortization); (ii)&nbsp;gross or net
sales or revenue; (iii)&nbsp;net income (either before or after taxes); (iv)&nbsp;adjusted net income; (v)&nbsp;operating earnings or profit; (vi)&nbsp;cash flow (including, but not limited
to, operating cash flow and free cash flow); (vii)&nbsp;return on assets; (viii)&nbsp;return on capital; (ix)&nbsp;return </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>190</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=193,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=143262,FOLIO='190',FILE='DISK109:[18ZBU1.18ZBU44601]DW44601A.;16',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_dw44601_1_191"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>on
stockholders' equity; (x)&nbsp;total stockholder return; (xi)&nbsp;return on sales; (xii)&nbsp;gross or net profit or operating margin; (xiii)&nbsp;costs; (xiv)&nbsp;expenses;
(xv)&nbsp;working capital; (xvi)&nbsp;earnings per share; (xvii)&nbsp;adjusted earnings per share; (xviii)&nbsp;price per share; (xix)&nbsp;regulatory body approval for commercialization of
a product; (xx)&nbsp;implementation, completion or attainment of objectives relating to research, development, regulatory, commercial or strategic milestones or developments; (xxi)&nbsp;market
share; (xxii)&nbsp;economic value; (xxiii)&nbsp;revenue; (xxiv)&nbsp;revenue growth; and (xxv)&nbsp;operational and organizational metrics. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Transferability  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Awards, other than stock grants, granted under the 2017 Plan are generally nontransferable (other than by will or the laws of descent and
distribution), except that the compensation committee may, at the time of grant or thereafter, provide for the transferability of nonstatutory stock options or restricted stock to certain family
members and/or certain trusts, foundations or other entities owned or controlled by such family members. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Adjustment for Corporate Actions  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the event of any change in the outstanding shares of common stock as a result of a reorganization, recapitalization, reclassification, stock
dividend, stock split, reverse stock split or other similar distribution with respect to the shares of common stock, an equitable adjustment will be made in (i)&nbsp;the maximum numbers and kinds of
shares subject to the 2017 Plan, (ii)&nbsp;the numbers and kinds of shares or other securities subject to then outstanding awards, (iii)&nbsp;the exercise price for each share or unit of any other
securities subject to then outstanding stock options or SARs (without change in the aggregate purchase price as to which such stock options or SARs remain exercisable), and (iv)&nbsp;the repurchase
price of each share of restricted stock then subject to a risk of forfeiture in the form of a company repurchase right. Any such adjustment in awards will be determined and made by the compensation
committee in its sole discretion. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Transactions  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the event of a transaction, including (i)&nbsp;any merger or consolidation of our company with or into another entity as a result of which
our stock is converted into or exchanged for the right to receive cash, securities or other property or is cancelled, (ii)&nbsp;any sale or exchange of all or substantially all of our common stock
for cash, securities, or other property, (iii)&nbsp;any sale, transfer or other disposition of all or substantially all of our assets to one or more other persons in a single transaction or series
of related transactions, or (iv)&nbsp;any liquidation or dissolution of our company, the compensation committee may, (1)&nbsp;provide that awards will be assumed, or substantially equivalent
rights shall be provided in substitution therefor by the acquiring or succeeding entity (or an affiliate thereof), (2)&nbsp;upon written notice to the recipient, provide that the recipient's
unexercised outstanding stock options and SARs will terminate immediately prior to the consummation of such transaction unless exercised within a specified period following the date of such written
notice, (3)&nbsp;provide that all or any unvested restricted stock or restricted stock unit awards will terminate immediately prior to the consummation of such transaction, (4)&nbsp;provide that
all or any outstanding stock options and SARs shall become exercisable in whole or in part prior to or upon the transaction, (5)&nbsp;provide that the vesting of all or any unrestricted stock or
restricted stock unit awards shall accelerate and any restrictions applicable to such awards shall lapse prior to or upon such transaction, (6)&nbsp;provide for cash payments, net of applicable tax
withholdings, to be made to the recipients, (7)&nbsp;provide that, in connection with our liquidation or dissolution, awards other than awards of restricted stock or stock grants shall convert into
the right to receive liquidation proceeds net of the exercise price of the awards and any applicable tax withholdings, or (8)&nbsp;any combination of the foregoing. With respect to outstanding
awards other than stock options or SARs, that are not terminated prior to or upon the transaction, upon the occurrence of a transaction other than our liquidation or dissolution which is not part of
another form of transaction, our repurchase and other rights under each such award will transfer to </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>191</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=194,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=917591,FOLIO='191',FILE='DISK109:[18ZBU1.18ZBU44601]DW44601A.;16',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_dw44601_1_192"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>our
successor and inure to the benefit of our successor, and shall, unless the compensation committee determines otherwise, apply to the cash, securities or other property which the stock was
converted into or exchanged for pursuant to such transaction in the same manner and to the same extent as they applied to the award. In taking any of the actions described in the event of a
transaction, the compensation committee is not obligated to treat all awards, all awards held by a participant or all awards of the same type identically. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Change of Control  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as otherwise provided in the 2017 Plan or in the applicable award agreement, in the event of a change of control, to the extent that the
surviving entity declines to continue, convert, assume or replace outstanding awards, then all such awards shall become fully vested and exercisable and any restrictions applicable to any such awards
shall lapse in connection with the transaction. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
change of control is defined as the occurrence of any of the following: (1)&nbsp;a transaction, as described above, unless securities possessing more than 50% of the total combined
voting power of the resulting entity or acquiror's outstanding securities (or the securities of any parent thereof) are held by a person or persons who held securities possessing more than 50% of the
total combined voting power of our outstanding securities immediately prior to the transaction; (2)&nbsp;any person or group of persons, excluding our company and certain other related entities or
any of its affiliates, directly or indirectly acquires, including but not limited to by means of a merger or consolidation, beneficial ownership of securities possessing more than 50% of the total
combined voting power of our outstanding securities, unless pursuant to a tender or exchange offer made directly to our stockholders that our board of directors recommends such stockholders accept; or
(3)&nbsp;over a period of no more than 36 consecutive months there is a change in the composition of our board such that a majority of the board members ceases to be composed of individuals who
either (i)&nbsp;have been board members continuously since the beginning of that period, or (ii)&nbsp;have been elected or nominated for election as board members during such period by at least a
majority of the remaining board members who have been board members continuously since the beginning of that period; or (4)&nbsp;a majority of the board of directors votes in favor of a decision
that a change of control has occurred. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Amendment and Termination  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors may at any time amend any or all of the provisions of the 2017 Plan, or suspend or terminate it entirely, retroactively
or otherwise. However, except as set forth in the Plan, we must obtain stockholder approval to increase the number of shares available under the Plan, or to change the description of persons eligible
for awards, or as otherwise required by law or applicable stock exchange rules. Unless otherwise required by law or specifically provided in the Plan, the rights of a participant under awards granted
prior to any amendment, suspension or termination may not be adversely affected without the consent of the participant. Unless the 2017 Plan is earlier terminated by our board of directors, the Plan
terminates immediately prior to the tenth anniversary of the effective date. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Allocation of Awards; Plan Benefits.  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;It is not presently possible to determine the dollar value of award payments that may be made or the number of options, shares of restricted
stock, restricted stock units, or other awards that may be granted under the 2017 Plan in the future, or the individuals who may be selected to receive such awards because awards under the 2017 Plan
are granted at the discretion of the compensation committee. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


2015 Equity Incentive Plan  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The 2015 Equity Incentive Plan, or the 2015 Plan was adopted on August&nbsp;3, 2015, and was amended on January&nbsp;5, 2017 to increase the
number of shares issuable under the 2015 Plan. The following summary </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>192</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=195,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=994197,FOLIO='192',FILE='DISK109:[18ZBU1.18ZBU44601]DW44601A.;16',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_dw44601_1_193"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>of
the 2015 Plan does not purport to be complete and is qualified by reference to the full text of the 2015 Plan. The 2015 Plan was terminated and no further awards are granted under the 2015 Plan.
All awards outstanding under the 2015 Plan were transferred to the 2017 Plan and are treated as outstanding under the 2017 Plan. However, each such transferred award continues to be governed by its
existing terms. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
2015 Plan provides for the grant of incentive stock options and nonstatutory stock options, restricted stock awards and stock grants, which we collectively refer to as "awards" in
connection with the 2017 Plan. Our directors, officers and other employees, as well as consultants were eligible to receive grants under the 2015 Plan. The purpose of the 2015 Plan was to encourage
ownership of our common stock by employees, consultants, officers and directors and to provide additional incentive to them to promote the success of our business. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Administration  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under its terms, the 2015 Plan is administered by the compensation committee of our board of directors which is made up of independent outside
non-employee directors for purposes of applicable securities and tax laws. The board of directors itself may also exercise any of the powers and responsibilities under the 2015 Plan. The compensation
committee may delegate to an executive officer or officers the authority to grant awards under the 2015 Plan subject to applicable law and to guidelines specified by the compensation committee.
Subject to the terms of the 2015 Plan, the compensation committee will select the recipients of awards and determine, among other things, the:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> recipient of an award; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> form of award and the exercise or purchase price and method of payment for each such award; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> vesting period for awards, risks of forfeiture and any potential acceleration of vesting or lapses in risks of forfeiture; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> duration of awards. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
determinations made in good faith by the compensation committee with respect to the 2015 Plan and the terms and conditions of or operation of any award are final and binding on all
participants, beneficiaries, heirs, assigns or other persons holding or claiming rights under the 2015 Plan or any award. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Available Shares  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The aggregate number of shares of our common stock which may be issued under the 2015 Plan or with respect to which awards may be granted may
not exceed 2,317,339 shares (including pursuant to incentive stock options), which may be either authorized and unissued shares of our common stock or shares of common stock held in or acquired for
our treasury. In general, if awards under the 2015 Plan are for any reason cancelled, or expire or terminate unexercised, the number of shares covered by such awards will again be available for the
grant of awards under the 2015 Plan. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Eligibility for Participation  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Members of our board of directors, as well as employees of, and consultants to, us or any of our subsidiaries and affiliates are eligible to
receive awards under the 2015 Plan. The selection of participants is within the sole discretion of the compensation committee. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Stock Options  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The 2015 Plan provides for the grant of nonstatutory stock options and incentive stock options. Incentive stock options may only be granted to
employees. The exercise price of an incentive stock option must be at least 100% of the fair market value of the common stock on the grant date, or 110% for employees who own or are deemed to own more
than 10% of our voting stock. No incentive stock option may be exercised on or after the tenth anniversary or the grant date or after the fifth anniversary of the grant date for employees who own or
are deemed to own more than 10% of our voting stock. Stock options generally are not transferable except by will or the laws of descent and distribution </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>193</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=196,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=588539,FOLIO='193',FILE='DISK109:[18ZBU1.18ZBU44601]DW44601A.;16',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_dy44601_1_194"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A> </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Restricted Stock  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A restricted stock award is the grant of shares of our common stock at a price determined by the compensation committee (including zero), based
on satisfaction of certain vesting conditions, including continuing employment or other service, or achievement of performance goals. During the vesting period, participants holding shares of
restricted stock shall, except as otherwise
provided in the 2015 Plan or an individual award agreement, have full voting rights with respect to such shares. In general, restricted stock may not be sold, transferred, pledged, assigned or
otherwise alienated or hypothecated until the restrictions have lapsed or are removed. The restrictions lapse in accordance with a schedule or other conditions determined by the compensation
committee. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Stock Grants  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A stock grant is an award of shares of common stock without restriction for such consideration, in cash, other property or services or any
combination thereof, as is determined by the committee. Stock grants may be awarded in such circumstances as the committee deems appropriate, including in recognition of significant contributions to
our success or in lieu of compensation already due. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Adjustment for Corporate Actions  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the event of any change in the outstanding shares of common stock as a result of a reorganization, recapitalization, reclassification, stock
dividend, stock split, reverse stock split or other similar distribution with respect to the shares of common stock, an appropriate and proportionate adjustment will be made in (i)&nbsp;the maximum
numbers and kinds of shares subject to the 2015 Plan, (ii)&nbsp;the numbers and kinds of shares or other securities subject to then outstanding awards, (iii)&nbsp;the exercise price for each share
subject to then outstanding stock options, and (iv)&nbsp;the repurchase price of each share of restricted stock then subject to a risk of forfeiture in the form of a company repurchase right. Any
such adjustment in awards will be determined and made by the compensation committee in its sole discretion. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Change of Control  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as otherwise provided in the 2015 Plan or in the applicable award agreement, in the event of a change of control, the committee has the
discretion to determine the treatment of each outstanding award and may provide that the awards will be assumed or substituted, that the awards will terminate or accelerate in full immediately prior
to the change in control, or that awards will terminate in exchange for cash or other property. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


2017 Employee Stock Purchase Plan  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors have adopted and our stockholders have approved the 2017 employee stock purchase plan, or the ESPP, which will become
effective immediately prior to the completion of this offering. The following summary of the material terms of the ESPP does not purport to be complete and is qualified by reference to the full text
of the ESPP, which is filed as an exhibit to our registration statement of which this prospectus is a part. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
ESPP provides an incentive to, and encourages stock ownership by, all of our eligible employees and those of our participating subsidiaries so that they may share in our growth by
acquiring or increasing their share ownership in us. It is intended that the ESPP constitute an "employee stock purchase plan" within the meaning of Section&nbsp;423 of the Code. Under the ESPP,
eligible employees may purchase shares of our common stock at a discount through payroll deductions. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>194</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=197,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=708148,FOLIO='194',FILE='DISK109:[18ZBU1.18ZBU44601]DY44601A.;13',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_dy44601_1_195"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Administration  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The ESPP is administered by the compensation committee of our board of directors. The board of directors itself may exercise any of the powers
and responsibilities under the ESPP. The compensation committee may delegate its duties in order to facilitate the purchase and transfer of shares of our common stock and for the day-to-day
administration of the ESPP. The compensation committee, has the discretion, subject to the provisions of the ESPP, to make or to select the manner of making all determinations with respect to options
granted under the ESPP. Further, the compensation committee has complete authority to interpret the ESPP, to prescribe, amend and rescind rules and regulations relating to it, and to make all other
determinations necessary or advisable for the administration of the ESPP. All decisions, determinations and interpretations made in good faith by the compensation committee with respect to the ESPP
are final and binding on all persons having or claiming any interest in the ESPP or any option granted under the ESPP. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Shares Subject to the Plan  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The shares issued or to be issued under the ESPP are authorized but unissued shares of our common stock or are shares held by us in our
treasury. Subject to the following sentence, the ESPP authorizes the issuance of up to 272,841 shares of common stock. The number of shares authorized under the ESPP will be increased each
January&nbsp;1, commencing on January&nbsp;1, 2019 and ending on (and including) January&nbsp;1, 2027, by an amount equal to the lesser of 1% of outstanding shares as of the end of the
immediately preceding fiscal year and 655,666. Notwithstanding the foregoing, our board of directors may act prior to January&nbsp;1 of a given year to provide that there will be no such
January&nbsp;1 increase in the number of shares authorized under the ESPP for such year, or that the increase in the number of shares authorized under the ESPP for such year will be a lesser number
than would otherwise occur pursuant to the preceding sentence. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Terms of Participation  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The ESPP will be implemented through a series of purchase periods called "plan periods." The initial plan period shall commence on
September&nbsp;1, 2018 and will continue for six months. After the initial plan period, there will be two consecutive six-month plan periods, during each twelve-month period thereafter, with the
first six-month Plan Period beginning on March&nbsp;1 and ending on the immediately following August&nbsp;31, and the second six-month Plan Period beginning on September&nbsp;1 and ending on the
immediately following February&nbsp;28 unless otherwise determined by the compensation committee. Notwithstanding the foregoing, the Chief Executive Officer and/or Chief Financial Officer of the
Company shall have the authority, in their sole discretion, to select different dates for the start date of the initial plan period and the subsequent plan periods. An eligible employee will be
granted an option at the beginning of the plan period, and can accumulate money to pay the exercise price for the option by electing to have payroll deductions taken from each payroll during a plan
period of an amount, in whole percentages, between 1% and 15% of his or her compensation, but will not exceed $25,000 on an annual basis. At the end of each plan period, unless the participating
employee has withdrawn from the ESPP, the option will be exercised by applying the employee's accumulated payroll deductions to the purchase of shares of our common stock. The exercise price paid by
the employee will be the lower of 85% of the fair market value of our common stock at (i)&nbsp;the commencement of the plan period and (ii)&nbsp;the end of the plan period. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Withdrawal  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;An employee may withdraw from participation in an offering up to two weeks prior to the plan period termination date and permanently draw out
the balance accumulated in his or her account. In such case, the employee's option for the plan period he or she is withdrawing from will be automatically terminated. A participant's withdrawal from a
plan period will not have any effect upon his or her eligibility to participate in a succeeding plan period or in any similar plan which we may adopt. If a participant's </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>195</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=198,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=941822,FOLIO='195',FILE='DISK109:[18ZBU1.18ZBU44601]DY44601A.;13',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_dy44601_1_196"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>employment
ends prior to a plan period termination date for any reason, including retirement or death, the contributions credited to his or her account will be returned to him or her or, in the case
of his or her death, to his or her designated beneficiaries, and his or her option will be automatically terminated. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Eligibility  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our employees and those of a participating subsidiary are eligible to participate in the ESPP if we customarily employ them for at least
20&nbsp;hours per week and more than five months per year, provided that the compensation committee may waive one or both requirements prior to the start of a plan period. However, no employee shall
be granted an option under the ESPP if, immediately after the grant, the employee would own stock, including any outstanding options to purchase stock, equaling 5% or more of the total voting power or
value of all classes of our stock. In addition, the ESPP provides that no employee may be granted an option if the option would permit the employee to purchase stock under all of our employee stock
purchase plans in an amount that exceeds $25,000 of the fair market value of such stock, determined as of the date(s) of grant, for each calendar year in which the option is outstanding. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Adjustment for Corporate Actions  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the event of any change in the outstanding shares of common stock as a result of a reorganization, recapitalization, reclassification, stock
dividend, stock split, reverse stock split, or other similar distribution with respect to the shares of common stock, an appropriate and proportionate adjustment will be made in (i)&nbsp;the maximum
numbers and kinds of shares subject to the ESPP, (ii)&nbsp;the numbers and kinds of shares or other securities subject to the then outstanding options, and (iii)&nbsp;the exercise price for each
share or other unit of any other securities subject to then outstanding options. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Corporate Transactions  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the event of our dissolution or liquidation, the plan period then in progress will terminate unless otherwise provided by the compensation
committee. In the event of another significant corporate transaction such as a merger or consolidation of us with and into another person or entity or the sale or transfer of all or substantially all
of our assets, each right to purchase stock under the ESPP may be assumed, or an equivalent right substituted by, the successor corporation or a parent or subsidiary of the successor corporation. In
the event that the successor corporation refuses to assume each purchase right or to substitute an equivalent right, any ongoing offering period will be shortened so that employees' rights to purchase
stock under the ESPP are exercised prior to the transaction, unless the employee has withdrawn. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Amendment and Termination  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors has the power to amend or terminate the ESPP and to change or terminate plan periods as long as any such action does not
adversely affect any outstanding rights to purchase stock; provided, however, that the board of directors may amend or terminate the ESPP or a plan period even if it would adversely affect outstanding
options in order to avoid our incurring adverse accounting charges or if the board of directors determines that termination of the ESPP and/or plan period is in our best interest and the best interest
of our stockholders. The ESPP will continue in effect until the tenth anniversary of the closing of the offering described in this prospectus, unless earlier terminated by the board of directors. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Amount of Benefits  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The dollar value of benefits that will be received by any employee or group of employees in the ESPP is not determinable due to the voluntary
nature of the ESPP and the variables involved in the calculation of any such benefits (including our stock price). </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>196</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=199,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=611517,FOLIO='196',FILE='DISK109:[18ZBU1.18ZBU44601]DY44601A.;13',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_dy44601_1_197"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


401(k) Plan  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We maintain a tax qualified retirement plan that provides eligible U.S. employees with an opportunity to save for retirement on a tax advantaged
basis. Eligible employees are able to defer eligible compensation up to certain Code limits, which are updated annually. We have the ability to make matching and discretionary contributions to the
401(k) plan but have not done so to date. Employee contributions are allocated to each participant's individual account and are then invested in selected investment alternatives according to the
participants' directions. Employees are immediately and fully vested in their own contributions. The 401(k) plan is intended to be qualified under Section&nbsp;401(a) of the Code, with the related
trust intended to be tax exempt under Section&nbsp;501(a) of the Code. As a tax qualified retirement plan, contributions to the 401(k) plan are deductible by us when made, and contributions and
earnings on those amounts are not taxable to the employees until withdrawn or distributed from the 401(k) plan. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Non-Employee Director Compensation  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under our director compensation program, we pay our non-employee directors retainers in cash. We do not pay any compensation to our President
and Chief Executive Officer in connection with his service on our Board and, consequently, he is not included in the table. The compensation that we pay to our President and Chief Executive Officer is
discussed in the "Executive
Compensation" section of this prospectus. Each non-employee director receives an annual retainer fee of $35,000 paid in arrears. In addition, non-employee directors receive the following, as
applicable: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="54pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Non-Employee Director

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Annual Fee </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Lead Director</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>25,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Non-Executive Chair</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>30,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Chairman of the Audit Committee</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Member of the Audit Committee (other than chairman)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7,500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Chairman of the Compensation Committee</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Member of the Compensation Committee (other than chairman)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Chairman of the Governance and Nominating committee</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Member of the Governance and Nominating committee (other than chairman)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
also reimburse our non-employee directors for reasonable travel and out-of-pocket expenses incurred in connection with attending Board and committee meetings. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
the non-employee director compensation policy, each individual who is initially appointed or elected to the Board is also eligible to receive an option to purchase up to 20,000
shares of our common stock under our 2017 Equity Incentive Plan, or the Plan, on the date he or she first becomes a nonemployee director. These option grants vest annually over a three-year period
from the date of
grant, subject to continued service as a non-employee director through that vesting date. In addition, on the date of the annual meeting of stockholders, each continuing non-employee director who has
served on the Board for a minimum of six months is eligible to receive an option grant to purchase 10,000 shares of our common stock, which will vest in full upon the earlier of the first anniversary
of the date of grant or the date of the next annual meeting of stockholders. The exercise price for each of these option grants will be equal to the fair market value of our common stock on the date
of grant. These new director grants and annual grants will be subject to approval by our Board at the time of grant. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
policy is intended to provide a total compensation package that enables us to attract and retain qualified and experienced individuals to serve as directors and to align our
directors' interests with those of our stockholders. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
current director compensation arrangements have been in effect since the time of our initial public offering in October 2017. Prior to that time, we did not have a formal
non-employee director </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>197</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=200,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=829862,FOLIO='197',FILE='DISK109:[18ZBU1.18ZBU44601]DY44601A.;13',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_dy44601_1_198"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>compensation
policy. We reimbursed our non-employee directors for reasonable travel and out-of-pocket expenses incurred in connection with attending board of director and committee meetings. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table sets forth information regarding compensation earned by our non-employee directors during fiscal year 2017. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="69pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="78pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Fees earned in<BR>
cash ($)<SUP>(1)</SUP> </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
Awards ($)<SUP>(2)(3)</SUP> </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total ($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Neil Exter</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11,250</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11,250</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Todd Foley</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Christophe R. Jean</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10,625</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10,625</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Ed Mathers</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9,750</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9,750</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>David W. J. McGirr</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>28,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>80,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>108,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>David P. Meeker</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>27,625</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>240,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>267,625</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jonathan T. Silverstein, J.D.<SUP>(4)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Amounts represent annual cash compensation earned for services rendered by each member of the Board.  </FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(2)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>The options granted to our Board
during fiscal year 2017 vest annually over 3&nbsp;years. These grants have a weighted
average exercise price of $6.05 per option.  </FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(3)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Amounts shown reflect the grant date fair value of options awarded during fiscal year 2017 determined in accordance with the
Financial Accounting Standards Board, Accounting Standards Codification Topic 718, </FONT><FONT SIZE=1><I>Compensation&#151;Stock Compensation</I></FONT><FONT SIZE=1>. These amounts exclude the
value of estimated forfeitures.  </FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(4)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Mr.&nbsp;Silverstein resigned from the Board in October 2017 concurrently with our initial public
offering.</FONT></DD></DL>
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table sets forth, as of December&nbsp;31, 2017, the aggregate number of exercisable and unexercisable option awards outstanding held by our non-employee directors at that
time. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="54pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="65pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option Awards </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Exercisable </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Unexercisable </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Neil Exter</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Todd Foley</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Christophe R. Jean</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Ed Mathers</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>David W. J. McGirr</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>43,621</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>43,620</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>David P. Meeker</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>21,811</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>87,240</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jonathan T. Silverstein, J.D.<SUP>(1)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Mr.&nbsp;Silverstein resigned from the Board in October 2017 concurrently with our initial public
offering.</FONT></DD></DL>
 </DIV>
 <P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Limitation on Liability and Indemnification Matters  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;145 of the Delaware General Corporation Law authorizes a corporation's board of directors to grant, and authorizes a court to
award, indemnity to officers, directors and other corporate agents. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
permitted by Delaware law, our amended and restated certificate of incorporation provides that, to the fullest extent permitted by Delaware law, no director will be personally liable
to us or our stockholders for monetary damages for breach of fiduciary duty as a director. Pursuant to Delaware law, such protection would be not available for
liability:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> for any breach of a duty of loyalty to us or our stockholders; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> for acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> for any transaction from which the director derived an improper benefit; or </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>198</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=201,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=524990,FOLIO='198',FILE='DISK109:[18ZBU1.18ZBU44601]DY44601A.;13',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_dy44601_1_199"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> for an act or omission for which the liability of a director is expressly provided by an applicable statute, including unlawful payments of
dividends or unlawful stock repurchases or redemptions as provided in Section&nbsp;174 of the Delaware General Corporation Law. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
amended and restated certificate of incorporation also provides that if Delaware law is amended after the approval by our stockholders of the amended and restated certificate of
incorporation to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of our directors will be eliminated or limited to the fullest extent
permitted by Delaware law. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
amended and restated bylaws further provide that we must indemnify our directors and officers to the fullest extent permitted by Delaware law. Our amended and restated bylaws also
authorize us to indemnify any of our employees or agents and permit us to secure insurance on behalf of any officer, director, employee or agent for any liability arising out of his or her action in
that capacity, whether or not Delaware law would otherwise permit indemnification. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, our amended and restated bylaws provide that we are required to advance expenses to our directors and officers as incurred in connection with legal proceedings against them
for which they may be indemnified and that the rights conferred in the amended and restated bylaws are not exclusive. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have entered into indemnification agreements with each of our directors and executive officers. These agreements, among other things, require us to indemnify each director and officer
to the fullest extent permitted by Delaware law, the amended and restated certificate of incorporation and amended and restated bylaws, for expenses such as, among other things, attorneys' fees,
judgments, fines and settlement amounts incurred by the director or executive officer in any action or proceeding, including any action by or in our right, arising out of the person's services as our
director or executive officer or as the director or executive officer of any subsidiary of ours or any other company or enterprise to which the person provides services at our request. We maintain
directors' and officers' liability insurance. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
SEC has taken the position that personal liability of directors for violation of the federal securities laws cannot be limited and that indemnification by us for any such violation
is unenforceable. The limitation of liability and indemnification provisions in our amended and restated certificate of incorporation and amended and restated bylaws may discourage stockholders from
bringing a lawsuit against our directors and officers for breach of their fiduciary duty. They may also reduce the likelihood of derivative litigation against our directors and officers, even though
an action, if successful, might benefit us and other stockholders. Further, a stockholder's investment may be adversely affected to the extent that we pay the costs of settlement and damage awards
against directors and officers as required by these indemnification provisions. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Rule&nbsp;10b5-1 Sales Plans  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our directors and executive officers may adopt written plans, known as Rule&nbsp;10b5-1 plans, pursuant to which, if adopted, they would
contract with a broker to buy or sell shares of our common stock on a periodic basis. Under a Rule&nbsp;10b5-1 plan, a broker executes trades pursuant to parameters established by the director or
officer when entering into the plan, without further direction from them. The director or officer may amend a Rule&nbsp;10b5-1 plan in some circumstances and may terminate a plan at any time. Our
directors and executive officers also may buy or sell additional shares outside of a Rule&nbsp;10b5-1 plan when they are not in possession of material nonpublic information subject to compliance
with the terms of our insider trading policy. Prior to 90&nbsp;days after the date of this offering (subject to early termination), the sale of any shares under such plan would be subject to the
lock-up agreement that the director or officer has entered into with the underwriters. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>199</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=202,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=127815,FOLIO='199',FILE='DISK109:[18ZBU1.18ZBU44601]DY44601A.;13',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_dy44601_1_200"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dy44601_transactions_with_related_persons"> </A>
<A NAME="toc_dy44601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  TRANSACTIONS WITH RELATED PERSONS    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We describe below transactions and series of similar transactions, during our last three fiscal years, to which we were a party or will be a
party, in which:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the amounts involved exceeded or will exceed $120,000; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> any of the directors, executive officers or holders of more than 5% of our voting equity, or any member of the immediate family of the
foregoing persons, had or will have a direct or indirect material interest. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Compensation
arrangements for our directors and named executive officers are described elsewhere in this prospectus. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Series&nbsp;A Preferred Stock Financing  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In January 2017 and August 2017, pursuant to the series&nbsp;A preferred stock purchase agreement we issued an aggregate of 40,949,999 shares
of series&nbsp;A preferred stock, par value $0.001 per share, at a purchase price of $1.00 per share, resulting in aggregate gross proceeds of $40.9&nbsp;million to us. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Holders
of our series&nbsp;A preferred stock are entitled to certain registration rights with respect to the resale of such shares under the Securities Act, pursuant to the investors'
rights agreement entered into between us and certain of our stockholders. See "</FONT><FONT SIZE=2><I>Description of Capital Stock&#151;Registration Rights."</I></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table summarizes the participation in the series&nbsp;A preferred stock financing by our directors, executive officers, holders of more than 5% of our voting securities,
or any member of the immediate family of the foregoing persons. For further information on the ownership of securities of our directors, executive officers and holders of more than 5% of our voting
securities, see "</FONT><FONT SIZE=2><I>Principal Stockholders."</I></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="74pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="97pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Shares of<BR>
Series&nbsp;A<BR>
Preferred Stock </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Date(s) Purchased </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>New Enterprise Associates 13,&nbsp;L.P.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,067,162</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>January&nbsp;6, 2017</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Third Rock Ventures,&nbsp;L.P.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,624,751</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>January&nbsp;6, 2017</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>MPM BioVentures V,&nbsp;L.P. and MPM Asset Management Investors BV5&nbsp;LLC</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,015,916</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>January&nbsp;6, 2017</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>OrbiMed Private Investments V,&nbsp;LP</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,924,766</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>January&nbsp;6, 2017</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pfizer&nbsp;Inc.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,611,852</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>January&nbsp;6, 2017</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>667&nbsp;L.P. and Baker Brothers Life Sciences,&nbsp;L.P.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,337,036</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>January&nbsp;6, 2017</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>David P. Meeker</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>250,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>January&nbsp;6, 2017</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Keith M. Gottesdiener, M.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>125,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>January&nbsp;6, 2017</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Bart Henderson</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>100,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>January&nbsp;6, 2017</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>New Enterprise Associates 13,&nbsp;L.P.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,067,162</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>August&nbsp;18, 2017</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Third Rock Ventures,&nbsp;L.P.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,624,751</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>August&nbsp;18, 2017</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>MPM BioVentures V,&nbsp;L.P. and MPM Asset Management Investors BV5&nbsp;LLC</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,015,915</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>August&nbsp;18, 2017</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>OrbiMed Private Investments V,&nbsp;LP</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,924,765</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>August&nbsp;18, 2017</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pfizer&nbsp;Inc.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,611,852</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>August&nbsp;18, 2017</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>667&nbsp;L.P. and Baker Brothers Life Sciences,&nbsp;L.P.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,337,035</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>August&nbsp;18, 2017</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>David P. Meeker</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>250,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>August&nbsp;18, 2017</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Keith M. Gottesdiener, M.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>125,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>August&nbsp;18, 2017</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Bart Henderson</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>100,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>August&nbsp;18, 2017</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>200</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=203,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=827002,FOLIO='200',FILE='DISK109:[18ZBU1.18ZBU44601]DY44601A.;13',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_dy44601_1_201"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Indemnification Agreements  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We currently have indemnification agreements with each of our directors and executive officers. These agreements, among other things, require us
to indemnify each director and officer to the fullest extent permitted by Delaware law, our amended and restated certificate of incorporation and amended and restated bylaws, for expenses such as,
among other things, attorneys' fees, judgments, fines, and settlement amounts incurred by the director or executive officer in any action or proceeding, including any action by or in our right,
arising out of the person's services as our director or executive officer or as the director or executive officer of any subsidiary of ours or any other company or enterprise to which the person
provides services at our request. We maintain directors' and officers' liability insurance. See "</FONT><FONT SIZE=2><I>Executive and Director Compensation&#151;Limitation on Liability and
Indemnification Matters.</I></FONT><FONT SIZE=2>" </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Employment and Board Arrangements  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our executive officers have employment letters with us for their services. For information about the employment letters with our named executive
officers, refer to "</FONT><FONT SIZE=2><I>Executive and Director Compensation&#151;Agreements with our Executive Officers</I></FONT><FONT SIZE=2>." </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Transactions with Baker Bros. Advisors&nbsp;LP  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The board of directors has invited Sara Brownstein of Baker Bros. Advisors&nbsp;LP to participate in meetings of the board of directors in a
non-voting observer capacity. See "</FONT><FONT SIZE=2><I>Management&#151;Board Observer Rights</I></FONT><FONT SIZE=2>." </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Consulting Agreement with Mr.&nbsp;Henderson  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Henderson resigned from employment with us as President in June 2017 and thereafter entered into a consulting agreement with us.
Under the terms of Mr.&nbsp;Henderson's consulting agreement, he was entitled to a consulting fee on an hourly basis, subject to adjustment by us. In consideration of Mr.&nbsp;Henderson's prior
service to us as a founder and former officer and employee, under the terms of Mr.&nbsp;Henderson's consulting agreement with us, Mr.&nbsp;Henderson continued to vest in any unvested equity awards
held by him, through and including December&nbsp;31, 2017, with a right to exercise any vested equity through and including October&nbsp;1, 2018. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Related Party Transactions Policy  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Board has adopted a policy that our executive officers, directors, nominees for election as a director, beneficial owners of more than 5% of
any class of our common stock and any members of the immediate family of any of the foregoing persons are not permitted to enter into a related person transaction with us without the prior review and
approval of our Governance and Nominating committee. Any request for us to enter into a transaction with an executive officer, director, nominee for election as a director, beneficial owner of more
than 5% of any class of our common stock or any member of the immediate family of any of the foregoing persons in which the amount involved exceeds $120,000 and such person would have a direct or
indirect material interest must first be presented to our Governance and Nominating committee for review, consideration and approval. In approving or rejecting any such proposal, our Governance and
Nominating committee is to consider the material facts of the transaction, including, but not limited to, whether the transaction is on terms no less favorable than terms generally available to an
unaffiliated third party under the same or similar circumstances and the extent of the related person's interest in the transaction. We did not have a formal review and approval policy for related
party transactions at the time of any of the transactions described above. However, the transactions described under "</FONT><FONT SIZE=2><I>Transactions with Related Persons"</I></FONT><FONT SIZE=2>
were entered into after presentation, consideration and approval by our Board. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>201</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=204,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=575596,FOLIO='201',FILE='DISK109:[18ZBU1.18ZBU44601]DY44601A.;13',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_ea44601_1_202"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ea44601_principal_stockholders"> </A>
<A NAME="toc_ea44601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PRINCIPAL STOCKHOLDERS    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth certain information as of May&nbsp;31, 2018 (unless otherwise specified), with respect to the beneficial
ownership of our common stock by each person who is known to own beneficially more than 5% of the outstanding shares of common stock, each person currently serving as a director, each nominee for
director, each named executive officer (as set forth in the Summary Compensation Table below), and all directors and executive officers as a group). </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares
of common stock subject to options or other rights to purchase which are now exercisable or are exercisable within 60&nbsp;days after May&nbsp;31, 2018, are to be considered
outstanding for purposes of computing the number of shares beneficially owned and the percentage ownership of the persons holding these options or other rights, but are not to be considered
outstanding for the purpose of computing the number of shares beneficially owned or the percentage ownership of any other person. As of May&nbsp;31, 2018, there were 27,284,140 shares of common
stock outstanding. Unless otherwise indicated, the address for each beneficial owner is c/o Rhythm Pharmaceuticals,&nbsp;Inc., 500 Boylston Street, 11th&nbsp;Floor, Boston, MA&nbsp;02116. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Beneficial
ownership is determined according to the rules of the SEC and generally means that a person has beneficial ownership of a security if he, she or it possesses sole or shared
voting or investment power of that security, and of convertible securities that are currently exercisable or exercisable within 60&nbsp;days after May&nbsp;31, 2018. Shares of our common stock
issuable pursuant to options or warrants, if any, are deemed outstanding for computing the percentage of the person holding such options or warrants and the percentage of any group of which the person
is a member but are not deemed outstanding for computing the percentage of any other person. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
calculation of the percentage of beneficial ownership after this offering is based on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock outstanding immediately after the closing of this
offering (assuming no exercise of the underwriters' option to purchase additional shares of our common stock). Except as indicated by the footnotes below, we believe, based on the information
furnished to us, that the persons named in the table below have sole voting and investment power with respect to all shares of common stock shown that they beneficially own, subject to community
property laws where applicable. The information does not necessarily indicate beneficial ownership for any other purpose, including for purposes of Section&nbsp;13(d) and 13(g) of the Securities
Act. If any shares are purchased by our existing principal stockholders, directors or their affiliated entities, the number and percentage of shares of our common stock beneficially owned by them
after this offering will differ from those set forth in the following table. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>202</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=205,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=896135,FOLIO='202',FILE='DISK109:[18ZBU1.18ZBU44601]EA44601A.;17',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_ea44601_1_203"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
as otherwise noted below, the address for persons listed in the table is c/o Rhythm Pharmaceuticals,&nbsp;Inc., 500 Boylston Street, Eleventh Floor, Boston, MA 02116. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="49pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="49pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Prior to the Offering </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>After the Offering </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name and Address of Beneficial Owner


<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
shares of<BR>
common<BR>
stock </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Percent of<BR>
class </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
shares of<BR>
common<BR>
stock </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Percent of<BR>
class </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><B>5% Stockholders:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>New Enterprise Associates 13,&nbsp;L.P. and NEA Ventures 2009 Limited Partnership<SUP>(1)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,912,306</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>17.84</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2855 Sand Hill Road</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Menlo Park, CA 94025</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Third Rock Ventures,&nbsp;L.P.<SUP>(2)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,981,437</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>14.46</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 29 Newbury Street</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Boston, MA 02116</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>MPM BioVentures V,&nbsp;L.P. and MPM Asset Management Investors BV5&nbsp;LLC<SUP>(3)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,696,392</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9.79</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>450 Kendall Street</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cambridge, MA 02142</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 OrbiMed Private Investments V,&nbsp;LP<SUP>(4)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,375,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8.63</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 601 Lexington Avenue, 54th&nbsp;Floor</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 New York NY 10022-4629</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>667,&nbsp;L.P. and Baker Brothers Life Sciences,&nbsp;L.P.<SUP>(5)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,049,020</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7.44</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>667 Madison avenue, 21st&nbsp;Floor</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>New York, NY 10065</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Pfizer&nbsp;Inc.<SUP>(6)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,427,639</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5.19</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 235 East 42nd&nbsp;Street</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 New York, NY 10017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Directors and Named Executive Officers:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Keith M. Gottesdiener<SUP>(7)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>788,867</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2.84</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Hunter C. Smith<SUP>(8)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,812</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Nithya Desikan<SUP>(9)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>78,784</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Todd Foley</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Ed Mathers</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Neil Exter</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Christophe R. Jean</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>David Meeker<SUP>(10)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>144,956</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 David McGirr<SUP>(11)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>50,891</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>All executive officers and directors as a group (11&nbsp;persons)<SUP>(12)</SUP></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,444,233</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5.14</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>*</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Represents
beneficial ownership of less than 1%.  </FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>The
shares held directly by NEA Ventures 2009,&nbsp;L.P., or NEA 2009, are indirectly held by Karen P. Welsh, the general partner of NEA 2009 and the shares held
by New Enterprise Associates 13,&nbsp;L.P., or NEA 13, are indirectly held by NEA Partners 13,&nbsp;L.P., or Partners 13, which is the sole general partner of NEA 13; NEA 13&nbsp;GP,&nbsp;LTD,
or NEA 13&nbsp;LTD, which is the sole general partner of Partners 13; and each of the individual directors of NEA 13&nbsp;LTD. The individual Directors of NEA 13&nbsp;LTD, or the NEA 13
Directors, are M. James Barrett, Peter J. Barris, Forest Baskett, Patrick J. Kerins, David M. Mott, Scott D. Sandell and Ravi Viswanathan. Karen P. Welsh holds voting and dispositive power with regard
to the shares held by NEA 2009. NEA Partners 13, NEA 13&nbsp;LTD, and the NEA 13 Directors share voting and dispositive power with regard to the shares owned directly by NEA 13. All indirect holders
of the above referenced shares disclaim beneficial ownership of all applicable shares except to the extent of their actual pecuniary interest therein.  </FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(2)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Based
solely on a Schedule&nbsp;13G filed on February&nbsp;13, 2018, each of Third Rock Ventures&nbsp;GP,&nbsp;LP, or TRV&nbsp;GP, the general partner of
Third Rock Ventures,&nbsp;L.P., or TRV&nbsp;LP, and Third Rock Ventures&nbsp;GP,&nbsp;LLC, TRV&nbsp;LLC, the general partner of TRV&nbsp;GP, and Mark Levin, Kevin Starr and Robert Tepper,
the managers of TRV&nbsp;LLC, may be deemed to share voting and investment power over the shares held by TRV&nbsp;LP. Each of the reporting persons disclaims beneficial ownership of such shares,
except to the extent of their proportionate pecuniary interest therein, if any.  </FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(3)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Based
solely on a Schedule&nbsp;13D filed on October&nbsp;24, 2017, MPM BioVentures V&nbsp;LLC is the Managing Member of MPM BioVentures
V&nbsp;GP&nbsp;LLC, which is the General Partner of MPM BioVentures V,&nbsp;L.P. MPM BioVentures V&nbsp;LLC is the Manager of MPM Asset Management Investors BV5&nbsp;LLC. Todd Foley, one of
our directors, is a Member of MPM BioVentures V&nbsp;LLC </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>203</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=206,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=1021653,FOLIO='203',FILE='DISK109:[18ZBU1.18ZBU44601]EA44601A.;17',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_ea44601_1_204"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
<UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=1>and
shares the power to vote, hold and dispose of the shares held by MPM BioVentures V,&nbsp;L.P., and MPM Asset Management Investors BV5&nbsp;LLC. Mr.&nbsp;Foley and each such other Member of
MPM BioVentures V&nbsp;LLC disclaims beneficial ownership of the securities reported herein except to the extent of his respective pecuniary interest therein.  </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(4)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Based
solely on Amendment No.&nbsp;1 to Schedule&nbsp;13D filed on February&nbsp;7, 2018, OrbiMed Capital&nbsp;GP&nbsp;V&nbsp;LLC, or&nbsp;GP V, is the
sole general partner of OrbiMed Private Investments V,&nbsp;LP, or OPI&nbsp;V, and OrbiMed Advisors&nbsp;LLC, or Advisors, a registered adviser under the Investment Advisers Act of 1940, as
amended, is the sole managing member of&nbsp;GP V. By virtue of such relationships,&nbsp;GP V and Advisors may be deemed to have voting and investment power with respect to the shares held by
OPI&nbsp;V noted above and as a result may be deemed to have beneficial ownership over such shares. Advisors exercises this investment and voting power through a management committee comprised of
Carl&nbsp;L. Gordon, Sven H. Borho and Jonathan T. Silverstein. Each of&nbsp;GP V, Advisors, Mr.&nbsp;Gordon, Mr.&nbsp;Borho, and Mr.&nbsp;Silverstein disclaims beneficial ownership of the
shares held by OPI V, except to the extent of its or his pecuniary interest therein if any.  </FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(5)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Based
solely on a Schedule&nbsp;13G filed on February&nbsp;13, 2018, Baker Bros. Advisors&nbsp;LP, or Baker Bros. Advisors, is the investment adviser to
667,&nbsp;L.P., or 667&nbsp;LP, and Baker Brothers Life Sciences,&nbsp;L.P., or Baker Brothers Life Sciences, and, pursuant to amended and restated management agreements between Baker Bros.
Advisors, 667&nbsp;LP and Baker Brothers Life Sciences and the respective general partners of 667&nbsp;LP and Baker Brother Life Sciences, Baker Bros. Advisors has complete and unlimited
discretion and authority with respect to the investments and voting power over investments of 667&nbsp;LP and Baker Brothers Life Sciences. Baker Bros. Advisors disclaims beneficial ownership of all
shares held by 667&nbsp;LP and Baker Brothers Life Sciences except to the extent of any pecuniary interest therein.  </FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(6)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>As
of May&nbsp;31, 2018, the board of directors of Pfizer&nbsp;Inc. is comprised of the following individuals: Dennis A. Ausiello, Ronald E. Blaylock, Albert
Bourla, W. Don Cornwell, Joseph J. Echevarria, Helen&nbsp;H. Hobbs, James M. Kilts, Dan R. Littman, Shantanu Narayen, Suzanne Nora Johnson, Ian C. Read, and James C. Smith. Pfizer&nbsp;Inc. is a
publicly traded company.  </FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(7)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Consists
of (i)&nbsp;588,539 shares of common stock and (ii)&nbsp;includes 200,328 shares of common stock underlying options that are exercisable within
60&nbsp;days of May&nbsp;31, 2018.  </FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(8)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Includes
3,812 shares of common stock underlying options that are exercisable within 60&nbsp;days of May&nbsp;31, 2018.  </FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(9)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Includes
of 73,087 shares of common stock underlying options that are exercisable within 60&nbsp;days of May&nbsp;31, 2018.  </FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(10)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Consists
of (i)&nbsp;101,335 shares of common stock and (ii)&nbsp;includes 43,621 shares of common stock underlying options that are exercisable within
60&nbsp;days of May&nbsp;31, 2018.  </FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(11)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Includes
50,891 shares of common stock underlying options that are exercisable within 60&nbsp;days of May&nbsp;31, 2018.  </FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(12)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Consists
of (i)&nbsp;886,112 shares of common stock and (ii)&nbsp;includes 558,121 shares of common stock underlying options that are exercisable within
60&nbsp;days of May&nbsp;31, 2018. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>204</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=207,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=496843,FOLIO='204',FILE='DISK109:[18ZBU1.18ZBU44601]EA44601A.;17',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_ea44601_1_205"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ea44601_description_of_capital_stock"> </A>
<A NAME="toc_ea44601_2"> </A>
<BR></FONT><FONT SIZE=2><B>  DESCRIPTION OF CAPITAL STOCK    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following is a description of certain provisions of our amended and restated certificate of incorporation and restated bylaws, both of which
were adopted in connection with our initial public offering in October 2017, and certain provisions of our outstanding options and the Delaware General Corporation Law, or DGCL. The following
description does not purport to be complete and is subject to, and qualified in its entirety by reference to, the forms of our amended and restated certificate of incorporation and restated bylaws,
the forms of stock option agreements filed as exhibits to the registration statement, of which this prospectus forms&nbsp;a part, and the terms and provisions of the DGCL. For more complete
information, you should carefully review the forms of our amended and restated certificate of incorporation and amended and restated bylaws and stock option agreements, which have been filed with the
SEC as exhibits to our registration statement of which this prospectus forms&nbsp;a part and which may be obtained as described below under "Where You Can Find More Information." </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
authorized capital stock consists of 120,000,000 shares of common stock, par value $0.001 per share, our "common stock," and 10,000,000 shares of preferred stock, par value $0.001
per share, our "preferred stock." </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of March&nbsp;31, 2018, there were 27,284,140 shares of our common stock outstanding, held by approximately 28 stockholders of record, and 2,427,629 shares of our common stock
issuable upon the exercise of outstanding stock options. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Common Stock  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Holders of shares of our common stock are entitled to one vote for each share held of record on all matters submitted to a vote of stockholders.
The holders of a plurality of the shares of our common stock entitled to vote in any election of directors can elect all of the directors standing for election. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Holders
of shares of our common stock are entitled to receive dividends when and if declared by our board of directors out of funds legally available therefor, subject to any statutory
or contractual restrictions on the payment of dividends and to any restrictions on the payment of dividends imposed by the terms of any outstanding preferred stock. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
our dissolution or liquidation or the sale of all or substantially all of our assets, after payment in full of all amounts required to be paid to creditors and to the holders of
preferred stock having liquidation preferences, if any, the holders of shares of our common stock will be entitled to receive pro rata our remaining assets available for distribution. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Holders
of shares of our common stock do not have preemptive, subscription, redemption or conversion rights. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Preferred Stock  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our amended and restated certificate of incorporation authorizes our board of directors to establish one or more series of preferred stock
(including convertible preferred stock). Unless required by law or by any stock exchange, the authorized shares of preferred stock will be available for issuance without further action by our
stockholders. Our board of directors is able to determine, with respect to any series of preferred stock, the terms and rights of that series, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the designation of the series; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the number of shares of the series, which our board may, except where otherwise provided in the preferred stock designation, increase or
decrease, but not below the number of shares then outstanding; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the voting rights, if any, of the holders of the series; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>205</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=208,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=357787,FOLIO='205',FILE='DISK109:[18ZBU1.18ZBU44601]EA44601A.;17',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_ea44601_1_206"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> whether dividends, if any, will be cumulative or non-cumulative and the dividend rate of the series; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the dates at which dividends, if any, will be payable; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the rights of priority and amounts payable, if any, on shares of the series in the event of any voluntary or involuntary liquidation,
dissolution or winding-up of the affairs of our company; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the redemption rights and price or prices, if any, for shares of the series; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the terms of any purchase, retirement or sinking fund, if any, provided for shares of the series; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the terms, if any, upon which the shares of the series will be convertible into or exchangeable for shares of any other class, classes or
series or other securities, whether or not issued by our company or any other entity; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> restrictions, if any, upon issuance of indebtedness of our company so long as any shares of the series are outstanding; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> restrictions, if any, on the issuance of shares of the same series or of any other class or series. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
could issue a series of preferred stock that could, depending on the terms of the series, impede or discourage an acquisition attempt or other transaction that some, or a majority, of
our stockholders might believe to be in their best interests or in which our stockholders might receive a premium for their shares of common stock over the market price of the shares of common stock. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Options  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of March&nbsp;31, 2018 we had 2,427,629 options to purchase our common stock outstanding. See "</FONT><FONT SIZE=2><I>Executive and
Director Compensation</I></FONT><FONT SIZE=2>&#151;</FONT><FONT SIZE=2><I>Employee Benefit and Stock Plans</I></FONT><FONT SIZE=2>" for a discussion of the terms of the Plan. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Authorized but Unissued Capital Stock  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The DGCL does not require stockholder approval for any issuance of authorized shares. However, the listing requirements of Nasdaq, which apply
so long as our common stock remains listed on Nasdaq, require stockholder approval of certain issuances equal to or exceeding 20% of the then outstanding voting power or then outstanding number of
shares of common stock. These additional shares may be used for a variety of corporate purposes, including future public offerings, to raise additional capital or to facilitate acquisitions. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;One
of the effects of the existence of unissued and unreserved common stock or preferred stock may be to enable our board of directors to issue shares to persons friendly to current
management, which issuance could render more difficult or discourage an attempt to obtain control of our company by means of a merger, tender offer, proxy contest or otherwise, and thereby protect the
continuity of our management and possibly deprive our stockholders of opportunities to sell their shares of common stock at prices higher than prevailing market prices. </FONT></P>


<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Anti-Takeover Effects of Provisions of Delaware Law and Our Amended and Restated Certificate of
Incorporation and Amended and Restated Bylaws  </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Undesignated Preferred Stock  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The ability to authorize undesignated preferred stock will make it possible for our board of directors to issue preferred stock with super
voting, special approval, dividend or other rights or preferences on a discriminatory basis that could impede the success of any attempt to acquire us or otherwise effect a change in control of us.
These and other provisions may have the effect of deferring, delaying or discouraging hostile takeovers, or changes in control or management of our company. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>206</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=209,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=760081,FOLIO='206',FILE='DISK109:[18ZBU1.18ZBU44601]EA44601A.;17',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_ea44601_1_207"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Requirements for Advance Notification of Stockholder Meetings, Nominations and Proposals  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our amended and restated certificate of incorporation provides that special meetings of the stockholders may be called only by or at the
direction of our board of directors. Our amended and restated bylaws prohibit the conduct of any business at a special meeting other than as specified in the notice for such meeting. These provisions
may have the effect of deferring, delaying or discouraging hostile takeovers, or changes in control or management of our company. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
amended and restated bylaws establish advance notice procedures with respect to stockholder proposals and the nomination of candidates for election as directors, other than
nominations made by or at the direction of the board of directors or a committee of the board of directors. In order for any matter to be "properly brought" before a meeting, a stockholder will have
to comply with advance notice requirements and provide us with certain information. Additionally, vacancies and newly created directorships may be filled only by a vote of a majority of the directors
then in office, even though less than a quorum, and not by the stockholders. Our amended and restated bylaws allow the presiding officer at a meeting of the stockholders to adopt rules and regulations
for the conduct of meetings which may have the effect of precluding the conduct of certain business at a meeting if the rules and regulations are not followed. These provisions may also defer, delay
or discourage a potential acquirer from conducting a solicitation of proxies to elect the acquirer's own slate of directors or otherwise attempting to obtain control of our company. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
amended and restated certificate of incorporation provides that the board of directors is expressly authorized to adopt, amend or repeal our amended and restated bylaws. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


No Cumulative Voting  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The DGCL provides that stockholders are not entitled to cumulate votes in the election of directors unless our amended and restated certificate
of incorporation provides otherwise. Our amended and restated certificate of incorporation does not expressly provide for cumulative voting. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Removal of Directors  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In accordance with the terms of our amended and restated certificate of incorporation and amended and restated bylaws, our board of directors
are divided into three staggered classes of directors of the same or nearly the same number. At each annual meeting of the stockholders, a class of directors will be elected for a three-year term to
succeed the directors of the same class whose terms are then expiring. </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Our Class&nbsp;I directors are Keith Gottesdiener and Christophe Jean, whose terms expire in 2021; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Our Class&nbsp;II directors are Ed Mathers, Todd Foley, and Neil Exter, whose terms expire in 2019; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Our Class&nbsp;III directors are David Meeker and David McGirr, whose terms expire in 2020. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
amended and restated certificate of incorporation and amended and restated bylaws provide that the number of our directors shall be fixed from time to time by a resolution of the
majority of our board of directors. Any additional directorships resulting from an increase in the number of directors will be distributed among the three classes so that, as nearly as possible, each
class shall consist of one third of the board of directors. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
division of our board of directors into three classes with staggered three-year terms may delay or prevent stockholder efforts to effect a change of our management or a change in
control. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
amended and restated certificate of incorporation and amended and restated bylaws provide that our directors may be removed only for cause by the affirmative vote of the holders of
at least 75% of the outstanding shares of capital stock entitled to vote in the election of directors or class of directors,
voting together as a single class, at a meeting of the stockholders called for that purpose. This requirement of a </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>207</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=210,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=970447,FOLIO='207',FILE='DISK109:[18ZBU1.18ZBU44601]EA44601A.;17',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_ea44601_1_208"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>supermajority
vote to remove directors could enable a minority of our stockholders to prevent a change in the composition of our board. Any vacancy on our board of directors, including a vacancy
resulting from an enlargement of our board of directors, may be filled only by the vote of a majority of the remaining directors then in office, although less than a quorum, or by the sole remaining
director. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Amendments to Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The DGCL provides that, unless a corporation's certificate of incorporation provides otherwise, the affirmative vote of holders of shares
constituting a majority of the votes of all shares entitled to vote may approve amendments to the certificate of incorporation. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
amended and rested certificate of incorporation and amended and restated bylaws provide that the affirmative vote of holders of at least 75% of the outstanding shares of capital
stock, voting together as a single class, and entitled to vote in the election of directors will be required to amend, alter, change or repeal the amended and restated certificate of incorporation and
the amended and restated bylaws. This requirement of a supermajority vote to approve amendments to our amended and restated certificate of incorporation and amended and restated bylaws could enable a
minority of our stockholders to exercise veto power over such amendments. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Stockholder Action by Written Consent  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to Section&nbsp;228 of the DGCL, any action required to be taken at any annual or special meeting of the stockholders may be taken
without a meeting, without prior notice and without a vote if a consent or consents in writing, setting forth the action so taken, is signed by the holders of outstanding stock having not less than
the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares of our stock entitled to vote thereon were present and voted, unless the
corporation's certificate of incorporation provides
otherwise. Our amended and restated certificate of incorporation prohibits the taking of any action of our stockholders by written consent without a meeting. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Delaware Anti-Takeover Statute  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have not opted out of, and therefore are subject to, Section&nbsp;203 of the DGCL. Section&nbsp;203 provides that, subject to certain
exceptions specified in the law, a publicly-held Delaware corporation shall not engage in certain "business combinations" with any "interested stockholder" for a three-year period after the date of
the transaction in which the person became an interested stockholder unless:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction
that resulted in the stockholder becoming an interested stockholder; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the stockholder owned at least 85% of
the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the number of shares outstanding (1)&nbsp;shares owned by persons who are
directors and also officers and (2)&nbsp;shares owned under employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the
plan will be tendered in a tender or exchange offer; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> on or subsequent to the date of the transaction, the business combination is approved by the board and authorized at an annual or special
meeting of stockholders, and not by written consent, by the affirmative vote of at least 66<SUP>2</SUP>/<SMALL>3</SMALL>% of the outstanding voting stock which is not owned by the interested stockholder. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Generally,
a business combination includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. An interested stockholder
is a person who, together </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>208</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=211,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=778193,FOLIO='208',FILE='DISK109:[18ZBU1.18ZBU44601]EA44601A.;17',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_ea44601_1_209"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>with
affiliates and associates, owns or, within three years prior to the determination of interested stockholder status, did own 15% or more of a corporation's outstanding voting stock. Since
Section&nbsp;203 will apply to us, we expect that it would have an anti-takeover effect with respect to transactions our board of directors does not approve in advance. In such event, we would also
anticipate that Section&nbsp;203 could discourage attempts that might result in a premium over the market price for the shares of common stock held by stockholders. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
certain circumstances, Section&nbsp;203 makes it more difficult for a person who would be an "interested stockholder" to effect various business combinations with a corporation
for a three-year period. The provisions of Section&nbsp;203 may encourage companies interested in acquiring our company to negotiate in advance with our board of directors because the stockholder
approval requirement would be avoided if our board of directors approves either the business combination or the transaction that results in the stockholder becoming an interested stockholder. These
provisions also may make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interests. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Registration Rights  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of March&nbsp;31, 2018, the holders of approximately 18.9&nbsp;million shares of our common stock, or their transferees, are entitled to
the registration rights set forth below with respect to registration of the resale of such shares under the Securities Act pursuant to the investors' rights agreement, by and among us and certain of
our stockholders. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Demand Registration Rights  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon the written request of at least a majority of the holders of the registrable securities then outstanding that we file&nbsp;a registration
statement under the Securities Act covering the registration of registrable securities owned by such holder(s) having an anticipated aggregate offering price, net of selling expenses, of at least
$15.0&nbsp;million, we will be obligated to notify all holders of registrable securities of such request. As soon as practicable thereafter, and in any event within 60&nbsp;days after the date
such request is received, we will be required to register the sale on a registration statement on Form&nbsp;S-1 of all registrable securities that holders may request to be registered, subject to
specified exceptions, conditions and limitations. We may postpone the filing of a registration statement for up to 120&nbsp;days once in any 12-month period if in the good faith judgment of our
board of directors such registration would be materially detrimental to us, and we are not required to effect the filing of a registration statement during the period starting with the date that is
60&nbsp;days prior to our good faith estimate of the date of filing of a registration statement initiated by us and ending on a date 180&nbsp;days after the effective date of a registration
statement initiated by us. The underwriters of any underwritten offering will have the right to limit the number of shares having registration rights to be included in the registration statement. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


"Piggyback" Registration Rights  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If we register any securities for public sale, holders of registration rights will have the right to include their shares in the registration
statement. The underwriters of any underwritten offering will have the right to limit the number of registrable securities to be included in the registration statement, but such number may not be
below 30% of the total number of shares included in such registration statement. The holders of registration rights have waived any and all rights to which they would otherwise be entitled to have
their shares included in this offering. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Form&nbsp;S-3 Registration Rights  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If we are eligible to file&nbsp;a registration statement on Form&nbsp;S-3, holders of at least 10% of our registrable securities then
outstanding have the right to request that we file&nbsp;a registration statement on Form&nbsp;S-3, so long as the aggregate price to the public of the securities to be sold under the registration </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>209</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=212,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=916947,FOLIO='209',FILE='DISK109:[18ZBU1.18ZBU44601]EA44601A.;17',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_ea44601_1_210"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>statement
on Form&nbsp;S-3 is at least $10.0&nbsp;million or consists of all the remaining registrable securities, and subject to specified exceptions, conditions and limitations. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Expenses of Registration  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the investors' rights agreement, we are generally required to bear all registration expenses, including the fees and expenses of one
counsel, not to exceed $50,000, representing the selling holders, incurred in connection with the demand, piggyback and Form&nbsp;S-3 registrations described above. We are not required to bear
selling expenses, which include all underwriting discounts, selling commissions, stock transfer taxes applicable to the sale of registrable securities and fees and disbursements of any additional
counsel for any selling holder. We are not required to pay registration expenses if the registration request under the investors' rights agreement is withdrawn at the request of the holders of a
majority of the registrable securities unless (i)&nbsp;the holders of a majority of the registrable securities then outstanding agree to forfeit their right to one registration under the investors'
rights agreement or (ii)&nbsp;the withdrawal is due to the discovery of a material adverse change in our business. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Termination of Registration Rights  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The demand, piggyback and Form&nbsp;S-3 registration rights discussed above will terminate as to a given holder of registrable securities upon
the earlier of (i)&nbsp;five years following the closing of our initial public offering or (ii)&nbsp;such time as SEC Rule&nbsp;144 or another similar exemption under the Securities Act is
available for the sale of all shares held by the holder during a three-month period without registration and without the requirement for us to be in compliance with the current public information
required under SEC Rule&nbsp;144(c)(1). </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Limitations of Liability and Indemnification  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;See "</FONT><FONT SIZE=2><I>Executive and Director Compensation</I></FONT><FONT SIZE=2>&#151;</FONT><FONT SIZE=2><I>Limitation on
Liability and Indemnification Matters</I></FONT><FONT SIZE=2>." </FONT></P>


<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Market Listing  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our common stock is listed on the Nasdaq Global Market under the symbol "RYTM." </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Transfer Agent and Registrar  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The transfer agent and registrar for our common stock is Computershare Trust Company, Inc. The transfer agent and registrar's address is
250&nbsp;Royall Street, Canton, MA&nbsp;02021. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>210</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=213,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=395030,FOLIO='210',FILE='DISK109:[18ZBU1.18ZBU44601]EA44601A.;17',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_ec44601_1_211"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ec44601_material_united_states_federal__mat04124"> </A>
<A NAME="toc_ec44601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  MATERIAL UNITED STATES FEDERAL INCOME AND ESTATE TAX CONSEQUENCES TO<BR>  NON-U.S. HOLDERS OF OUR COMMON STOCK    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following is a discussion of the material U.S. federal income and estate tax consequences of the acquisition, ownership, and disposition of
our common stock to a non-U.S. holder that purchases shares of our common stock for cash in this offering. For purposes of this discussion, a "non-U.S. holder" means a beneficial owner (other than a
partnership or other pass-through entity) of our common stock that is not, for U.S. federal income tax purposes:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> an individual who is a citizen or resident alien of the United States; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> a corporation or any other organization taxable as a corporation for U.S. federal income tax purposes, created or organized in the United
States or under the laws of the United States or of any state thereof or the District of Columbia; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> an estate, the income of which is subject to U.S. federal income tax regardless of its source; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> a trust if (i)&nbsp;the trust is subject to the primary supervision of a U.S. court and all substantial decisions of the trust are controlled
by one or more U.S. persons or (ii)&nbsp;the trust has a valid election in effect under applicable U.S. Treasury regulations to be treated as a U.S. person. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
discussion does not address the tax treatment of partnerships (or other entities that are treated as partnerships, grantor trusts, or other pass-through entities for U.S. federal
income tax purposes) or persons that hold their common stock through partnerships, grantor trusts or such other pass-through entities. The tax treatment of a partner in a partnership or a holder of an
interest in another pass-through entity that will hold our common stock generally will depend upon the status of the
partner or interest holder and the activities of the partner or interest holder and the partnership or other pass-through entity, as applicable. Such a partner or interest holder should consult his,
her, or its own tax advisor regarding the tax consequences of the acquisition, ownership and disposition of our common stock through a partnership or other pass-through entity, as applicable. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
discussion is based upon the provisions of the Code, the U.S. Treasury regulations promulgated thereunder, judicial decisions, and published rulings, administrative procedures and
other guidance of the Internal Revenue Service, which we refer to as the IRS, all as in effect as of the date hereof. These authorities are subject to change and to differing interpretations, possibly
with retroactive effect, which could result in U.S. federal income or estate tax consequences different from those summarized below. No ruling has been or will be sought from the IRS with respect to
the matters summarized below, and there can be no assurance that the IRS will not take a contrary position regarding the U.S. federal income or estate tax consequences of the acquisition, ownership,
or disposition of our common stock, or that any such contrary position would not be sustained by a court. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
discussion is not a complete analysis of all of the potential U.S. federal income and estate tax consequences relating to the acquisition, ownership, and disposition of our common
stock by non-U.S. holders, nor does it address any U.S. federal gift tax or generation-skipping transfer tax consequences, any tax consequences arising under any state, local, or non-U.S. tax laws,
the impact of any applicable tax treaty, any consequences under the Medicare contribution tax on net investment income, the alternative minimum tax, or any consequences under other U.S. federal tax
laws. In addition, this discussion does not address tax consequences resulting from a non-U.S. holder's particular circumstances or to non-U.S. holders that may be subject to special tax rules,
including, without limitation:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> non-U.S. governments, agencies or instrumentalities thereof, or entities they control; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> "controlled foreign corporations" and their shareholders; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> "passive foreign investment companies" and their shareholders; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>211</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=214,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=603494,FOLIO='211',FILE='DISK109:[18ZBU1.18ZBU44601]EC44601A.;19',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_ec44601_1_212"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> partnerships, grantor trusts or other entities that are treated as pass-through entities for U.S. federal income tax purposes, and their
owners; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> corporations that accumulate earnings to avoid U.S. federal income tax; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> former citizens or former long-term residents of the United States; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> banks, insurance companies or other financial institutions; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> tax-exempt pension funds or other tax-exempt organizations; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> persons who acquired our common stock pursuant to the exercise of employee stock options or otherwise as compensation; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> tax-qualified retirement plans; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> traders, brokers or dealers in securities, commodities or currencies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> persons who hold our common stock as a position in a hedging transaction, wash sale, "straddle," "conversion transaction" or other risk
reduction transaction or synthetic security; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> persons who do not hold our common stock as a capital asset within the meaning of Section&nbsp;1221 of the Code (generally, for investment
purposes); </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> persons who own or have owned, or are deemed to own or to have owned, more than 5% of our common stock (except to the extent specifically set
forth below); or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> persons deemed to sell our common stock under the constructive sale provisions of the Code. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prospective
investors should consult their tax advisors regarding the particular U.S. federal income, estate, gift, and generation-skipping transfer tax consequences to them of
acquiring, owning and disposing of our common stock, as well as any tax consequences arising under any state, local or foreign tax laws and any other U.S. federal tax laws. Prospective investors
should also consult their tax advisors regarding the potential impact of any applicable income or estate tax treaty between the United States and such prospective investor's country of residence and
of the rules described below under the heading "Foreign Account Tax Compliance Act." </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Distributions on Common Stock  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As described in the section entitled "Dividend Policy," we currently intend to retain all available funds and any future earnings for use in the
operation of our business and do not anticipate paying any dividends on our common stock in the foreseeable future. The disclosure in this section addresses the consequences should our board of
directors, in the future, determine to make a distribution of cash or property with respect to our common stock (other than certain distributions of stock which may be made free of tax), or to effect
a redemption that is treated for tax purposes as a distribution. Any such distribution will generally constitute a dividend for U.S. federal tax purposes to the extent paid from our current or
accumulated earnings and profits, as determined under U.S. federal income tax principles. To the extent such a distribution exceeds both our current and our accumulated earnings and profits, such
excess will be allocated ratably among the shares of common stock with respect to which the distribution is made, will constitute a return of capital, and will first be applied against and reduce the
non-U.S. holder's adjusted tax basis in those shares of common stock, but not below zero. Distributions in excess of our current and accumulated earnings and profits and in excess of a non-U.S.
holder's tax basis in that non-U.S. holder's shares of common stock then will be treated as gain from the sale of that common stock, subject to the tax treatment described below under "Gain on
Disposition of Common Stock." A non-U.S. holder's adjusted tax basis in a share of common stock is generally the purchase price of the share, reduced by the amount of any distributions constituting a
return of capital with respect to that share. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
dividend paid to a non-U.S. holder of our common stock generally will be subject to U.S. federal withholding tax at a rate of 30% of the gross amount of the dividend, or such lower
rate as may be </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>212</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=215,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=545851,FOLIO='212',FILE='DISK109:[18ZBU1.18ZBU44601]EC44601A.;19',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_ec44601_1_213"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>specified
by an applicable income tax treaty between the United States and such non-U.S. holder's country of residence. If a non-U.S. holder is eligible for benefits under an income tax treaty and
wishes to claim a reduced rate of withholding, the non-U.S. holder generally will be required to provide us or our paying agent with a properly completed IRS Form&nbsp;W-8BEN, Form&nbsp;W-8BEN-E,
or other applicable form, certifying under penalties of perjury the non-U.S. holder's qualification for the reduced rate. This certification must be provided to us or our paying agent prior to the
payment of the dividend and may be required to be updated periodically. Special certification requirements apply to non-U.S. holders that hold common stock through certain foreign intermediaries.
Non-U.S. holders that do not timely provide the required certifications, but that qualify for a reduced treaty rate, may obtain a refund of any excess amounts withheld by timely filing an appropriate
claim for refund with the IRS. If we are not able to determine whether or not a distribution will exceed current and accumulated earnings and profits at the time the distribution is made, we may
withhold tax on the entire amount of any distribution at the same rate as we would withhold on a dividend. However, a non-U.S. holder may obtain a refund of amounts that we withhold to the extent
attributable to the portion of the distribution in excess of our current and accumulated earnings and profits. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
a non-U.S. holder holds our common stock in connection with the conduct of a trade or business in the U.S., and dividends paid on the common stock are effectively connected with the
non-U.S. holder's U.S. trade or business (and, if required by an applicable income tax treaty between the United States and such non-U.S. holder's country of residence, are attributable to a permanent
establishment or fixed base maintained by the non-U.S. holder in the U.S., as defined under the applicable treaty), the non-U.S. holder will be exempt from U.S. federal withholding tax on the
dividends. To claim the exemption, the non-U.S. holder must furnish a properly executed IRS Form&nbsp;W-8ECI (or other applicable form) prior to the payment of the dividends. Any dividends paid on
our common stock that are effectively connected with a non-U.S. holder's U.S. trade or business (and satisfy any other applicable treaty requirements) generally will be subject to U.S. federal income
tax on a net income basis at the regular graduated U.S. federal income tax rates generally applicable to U.S. persons (as defined in the Code). A non-U.S. holder that is treated as a corporation for
U.S. federal income tax purposes also may be subject to an additional branch profits tax equal to 30% (or such lower rate as is specified by an applicable income tax treaty between the United States
and such non-U.S. holder's country of residence) of a portion of its earnings and profits for the taxable year that are effectively connected with a U.S. trade or business, as adjusted for certain
items. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Gain on Disposition of Common Stock  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject to the discussion below regarding backup withholding and foreign accounts, a non-U.S. holder generally will not be subject to U.S.
federal income tax on any gain realized upon the sale, exchange, or other taxable disposition of our common stock unless:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the gain is effectively connected with the non-U.S. holder's conduct of a U.S. trade or business (and, if required by an applicable income tax
treaty between the United States and such non-U.S. holder's country of residence, the gain is attributable to a permanent establishment or fixed base maintained by the non-U.S. holder in the United
States), in which case the non-U.S. holder will generally be required to pay tax on the gain derived from the sale, exchange, or other taxable disposition (net of certain deductions or credits) under
regular graduated U.S. federal income tax rates generally applicable to U.S. persons, and in the case of a non-U.S. holder that is treated as a corporation for U.S. federal income tax purposes, such
non-U.S. holder may be subject to a branch profits tax at a 30% rate or such lower rate as may be specified by an applicable income tax treaty between the United States and such non-U.S. holder's
country of residence; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the non-U.S. holder is an individual who is present in the U.S. for a period or periods aggregating 183&nbsp;days or more during the taxable
year in which the sale, exchange, or other taxable disposition occurs and certain other conditions are met, in which case the non-U.S. holder will be subject to U.S. federal income tax at a flat 30%
rate (or such lower rate as is specified by an applicable income </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>213</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=216,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=258910,FOLIO='213',FILE='DISK109:[18ZBU1.18ZBU44601]EC44601A.;19',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_ec44601_1_214"> </A>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>tax
treaty between the United States and such non-U.S. holder's country of residence) on the net gain derived from the sale, exchange, or other taxable disposition, which gain may be offset by U.S.
source capital losses (even though the non-U.S. holder is not considered a resident of the United States) provided that the non-U.S. holder has timely filed U.S. federal income tax returns reporting
those losses; or </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> our common stock is a "United States real property interest" by reason of our status as a "United States real property holding corporation," or
USRPHC, for U.S. federal income tax purposes during the five-year period preceding such sale, exchange or other taxable disposition (or the non-U.S. holder's holding period, if shorter). Generally, a
corporation is a USRPHC only if the fair market value of its U.S. real property interests equals or exceeds 50% of the sum of the fair market value of its worldwide real property interests plus its
other assets used or held for use in a trade or business. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe we are not now and we do not anticipate becoming a USRPHC. However, there can be no assurance that we are not now a USRPHC or will not become one in the future. Even if we are
or become a USRPHC, for so long as our common stock is "regularly traded," as defined by applicable U.S. Treasury regulations, on an established securities market, sales of our common stock generally
will not be subject to tax for non-U.S. holders that have not held more than 5% of our common stock, actually or constructively, during the five-year period preceding such non-U.S. holder's sale,
exchange or other taxable disposition of our common stock (or the non-U.S. holder's holding period, if shorter). If we are determined to be a USRPHC and the foregoing exception does not apply, then
the non-U.S. holder generally will be taxed on its net gain derived from the disposition at the graduated U.S. federal income tax rates applicable to U.S. persons. No assurance can be provided that
our common stock will be regularly traded on an established securities market for purposes of the rule described above. </FONT></P>


<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


U.S. Federal Estate Tax  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares of our common stock that are owned or treated as owned at the time of death by an individual who is not a citizen or resident of the
United States, as specifically defined for U.S. federal estate tax purposes, are considered U.S. situs assets and will be included in the individual's gross estate for U.S. federal estate tax
purposes. Such shares, therefore, may be subject to U.S. federal estate tax, unless an applicable estate tax or other treaty between the United States and such individual's country of residence
provides otherwise. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Information Reporting and Backup Withholding  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Generally, we or certain financial middlemen must report annually to the IRS and to each non-U.S. holder the gross amount of dividends and other
distributions on our common stock paid to the non-U.S. holder and the amount of tax withheld, if any, with respect to those distributions. Pursuant to applicable income tax treaties or other
agreements, the IRS may make these reports available to tax authorities in the non-U.S. holder's country of residence or incorporation. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
non-U.S. holder may be subject to backup withholding with respect to dividends paid on shares of our common stock, unless, generally, the non-U.S. holder certifies under penalties of
perjury (usually on IRS Form&nbsp;W-8BEN or W-8BEN-E) that the non-U.S. holder is not a U.S. person or otherwise establishes an exemption. The backup withholding rate is currently 24%. Dividends
that are paid to non-U.S. holders subject to the withholding of U.S. federal income tax, as described above under the heading "Distributions on Common Stock" generally will be exempt from U.S. backup
withholding. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additional
rules relating to information reporting requirements and backup withholding with respect to payments of the proceeds from the disposition of shares of our common stock are as
follows:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> If the proceeds are paid to or through the U.S. office of a broker, the proceeds generally will be subject to backup withholding and
information reporting, unless the non-U.S. holder certifies under </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>214</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=217,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=989041,FOLIO='214',FILE='DISK109:[18ZBU1.18ZBU44601]EC44601A.;19',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_ec44601_1_215"> </A>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>penalties
of perjury (usually on IRS Form&nbsp;W-8BEN or W-8BEN-E) that the non-U.S. holder is not a U.S. person and satisfies certain other requirements or otherwise establishes an exemption. </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> If the proceeds are paid to or through a non-U.S. office of a broker that is not a U.S. person and is not a foreign person with certain
specified U.S. connections, which we refer to below as a "U.S.-related person," information reporting and backup withholding generally will not apply. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> If the proceeds are paid to or through a non-U.S. office of a broker that is a U.S. person or a U.S.-related person, the proceeds generally
will be subject to information reporting (but not to backup withholding), unless the non-U.S. holder certifies under penalties of perjury (usually on IRS Form&nbsp;W-8BEN or W-8BEN-E) that the
non-U.S. holder is not a U.S. person. A "U.S.-related person" includes (i)&nbsp;an entity classified as a "controlled foreign corporation" for U.S. federal income tax purposes, (ii)&nbsp;a foreign
person, 50% or more of whose gross income from certain periods is effectively connected with a U.S. trade or business, or (iii)&nbsp;a foreign partnership if at any time during its tax year
(a)&nbsp;one or more of its partners are U.S. persons who, in the aggregate, hold more than 50% of the income or capital interests of the partnership or (b)&nbsp;the foreign partnership is engaged
in a U.S. trade or business. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Backup
withholding is not an additional tax. Any amounts withheld from a non-U.S. holder under the backup withholding rules may be allowed as a refund or a credit against the non-U.S.
holder's U.S. federal income tax liability, if any, provided that the non-U.S. holder timely furnishes the required information to the IRS. Non-U.S. holders should consult their own tax advisors
regarding the application of the information reporting and backup withholding rules to them. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Foreign Account Tax Compliance Act  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sections&nbsp;1471 to 1474 of the Code (commonly referred to as the Foreign Account Tax Compliance Act, or FATCA) generally impose withholding
tax on certain types of payments made to "foreign financial institutions" (as defined in the Code) and other non-U.S. entities unless those institutions and entities meet additional certification,
information reporting and other requirements. FATCA generally imposes a 30% withholding tax on dividends on, or gross proceeds from the sale or other disposition of, our common stock paid to a foreign
financial institution unless the foreign financial institution enters into an agreement with the U.S. Treasury to, among other things, (i)&nbsp;undertake to identify accounts held by certain U.S.
persons (including certain equity and debt holders of such institution) or by U.S.-owned foreign entities, (ii)&nbsp;annually report certain information about such accounts, and
(iii)&nbsp;withhold 30% on payments to account holders whose actions prevent it from complying with these reporting and other requirements. In addition, subject to certain exceptions, FATCA imposes
a 30% withholding tax on the same types of payments to a "non-financial foreign entity" (as defined in the Code) unless the entity certifies that it does not have any substantial U.S. owners (which
generally include any U.S. persons who directly or indirectly own more than 10% of the entity) or furnishes identifying information regarding each such substantial U.S. owner or agrees to report that
information to the IRS. These withholding taxes will be imposed on dividends paid on our common stock, and, after December&nbsp;31, 2018, on gross proceeds from sales or other dispositions of our
common stock. Withholding under FATCA generally will not be reduced or limited by bilateral income tax treaties. However, intergovernmental agreements between the U.S. and other countries with respect
to the implementation of FATCA and non-U.S. laws, regulations and other authorities enacted or issued with respect to those intergovernmental agreements may modify the FATCA requirements described
above. Non-U.S. holders should consult their own tax advisors regarding the possible implications of FATCA on their investment in our common stock and the entities through which they hold our common
stock, including, without limitation, the process and deadlines for meeting the applicable requirements to prevent the imposition of the 30% withholding tax under FATCA. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>215</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=218,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=917924,FOLIO='215',FILE='DISK109:[18ZBU1.18ZBU44601]EC44601A.;19',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_ec44601_1_216"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ec44601_shares_eligible_for_future_sale"> </A>
<A NAME="toc_ec44601_2"> </A>
<BR></FONT><FONT SIZE=2><B>  SHARES ELIGIBLE FOR FUTURE SALE    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We cannot predict the effect, if any, that future sales of shares of common stock, or the availability for future sales of shares of common
stock, will have on the market price of shares of our common stock prevailing from time to time. The sale of substantial amounts of shares of our
common stock in the public market, or the perception that such sales could occur, could harm the prevailing market price of shares of our common stock. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
completion of this offering, we will have a total of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock outstanding (or&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of
common stock if the underwriters exercise
in full their option to purchase additional shares of common stock), based upon the 27,284,140 shares of our common stock that were outstanding at March&nbsp;31, 2018. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Of
those shares, we expect that&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares, including the shares sold in this offering, will be freely tradeable without restriction under the Securities Act by persons other
than our "affiliates." Under the Securities Act, an "affiliate" of an issuer is a person who directly or indirectly controls, is controlled by or is under common control with that issuer. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, 5,109,904 shares of common stock may be granted under the 2017 Plan, which amount includes 2,427,629 shares subject to options outstanding as of March&nbsp;31, 2018. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
remaining&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock will be "restricted securities" under Rule&nbsp;144. Of these shares,
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares will be subject to the 90-day
lockup period under the lock-up agreements entered into in connection with this offering, as further described below. Upon expiration of the lock-up period, these restricted securities may be sold in
the public market only if registered or pursuant to an exemption from registration, such as Rule&nbsp;144 or Rule&nbsp;701 under the Securities Act. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
amended and restated certificate of incorporation authorizes us to issue additional shares of common stock and options, rights, warrants and appreciation rights relating to common
stock for the consideration and on the terms and conditions established by our board of directors in its sole discretion. In accordance with the Delaware General Corporation Law and the provisions of
our amended and restated certificate of incorporation, we may also issue preferred stock that has designations, preferences, rights, powers and duties that are different from, and may be senior to,
those applicable to shares of common stock. See "</FONT><FONT SIZE=2><I>Description of Capital Stock.</I></FONT><FONT SIZE=2>" </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Lock-Up Agreements  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We, along with our directors, executive officers and certain of our other stockholders, have agreed with the underwriters that for a period of
90&nbsp;days (the restricted period) after the date of this prospectus, subject to specified exceptions, we or they will not offer, pledge, sell, contract to sell, sell any option or contract to
purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly,
any shares of common stock or any securities convertible into or exercisable or exchangeable for shares of common stock, or enter into any swap or other arrangement that transfers to another, in whole
or in part, any of the economic consequences of ownership of the common stock. Certain of our stockholders have the right to require us to register their shares under the Securities Act. See
"&#151;</FONT><FONT SIZE=2><I>Registration Rights"</I></FONT><FONT SIZE=2> below and </FONT><FONT SIZE=2><I>"Description of Capital Stock&#151;Registration
Rights."</I></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;After
this offering, our executive officers and/or directors may enter into written trading plans that are intended to comply with Rule&nbsp;10b5-1 under the Securities Exchange Act of
1934, as amended, or the Exchange Act. Sales under these trading plans would not be permitted until the expiration of the lock-up agreements relating to the offering described above. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>216</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=219,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=68339,FOLIO='216',FILE='DISK109:[18ZBU1.18ZBU44601]EC44601A.;19',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_ec44601_1_217"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Registration Rights  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The holders of approximately 18.9&nbsp;million shares of our common stock are entitled to rights with respect to the registration of their
shares under the Securities Act. Registration of these shares under the Securities Act would result in the shares becoming freely tradable without restriction under the Securities Act, except for
shares purchased by affiliates. Any sales of securities by these stockholders could have a material adverse effect on the trading price of our common stock. See "</FONT><FONT SIZE=2><I>Description of
Capital Stock</I></FONT><FONT SIZE=2>&#151;</FONT><FONT SIZE=2><I>Registration Rights</I></FONT><FONT SIZE=2>." </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Rule&nbsp;144  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In general, under Rule&nbsp;144 a person (or persons whose shares are aggregated) who may be deemed our affiliate is entitled to sell within
any three-month period a number of restricted securities that does not exceed the greater of 1% of the then outstanding shares of common stock and the average weekly trading volume during the four
calendar weeks preceding each such sale, provided that at least six months has elapsed since such shares of common stock were acquired from us or any affiliate of ours and certain manner of sale,
notice requirements and requirements as to availability of current public information about us are satisfied. Any person who is deemed to be our affiliate must also comply with such provisions of
Rule&nbsp;144 (other than the six-month holding period requirement) in order to sell shares of common stock which are not restricted securities (such as shares of common
stock acquired by affiliates through purchases in the open market following this offering). As of May&nbsp;31, 2018, 19,419,684 shares of our common stock are "restricted securities" as such term is
defined in Rule&nbsp;144. A person who is not our affiliate, and who has not been our affiliate at any time during the 90&nbsp;days preceding any sale, is entitled to sell shares of common stock
(i)&nbsp;subject only to the requirements as to availability of current public information about us, provided that a period of at least six months has elapsed since the shares of common stock were
acquired from us or any affiliate of ours, and (ii)&nbsp;without regard to the requirements as to availability of current public information about us or any other requirement of Rule&nbsp;144,
provided that at least one year has elapsed since the shares of common stock were acquired from us or any affiliate of ours. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Rule&nbsp;701  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In general, under Rule&nbsp;701 of the Securities Act, any of our employees, consultants or advisors, other than our affiliates, who purchased
shares from us in connection with a qualified compensatory stock plan or other written agreement before our initial public offering is eligible to resell these shares in reliance on Rule&nbsp;144,
but without compliance with the holding period requirements of Rule&nbsp;144 and without regard to the volume of such sales or the availability of public information about us. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>217</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=220,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=841302,FOLIO='217',FILE='DISK109:[18ZBU1.18ZBU44601]EC44601A.;19',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_ee44601_1_218"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ee44601_underwriting"> </A>
<A NAME="toc_ee44601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  UNDERWRITING    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under the terms and subject to the conditions in an underwriting agreement dated the date of this prospectus, the underwriters named below, for
whom Morgan Stanley&nbsp;&amp;&nbsp;Co.&nbsp;LLC, Merrill Lynch, Pierce, Fenner&nbsp;&amp; Smith Incorporated and Cowen and Company,&nbsp;LLC are acting as
representatives, have severally agreed to purchase, and we have agreed to sell to them, severally, the number of shares indicated below: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Underwriter

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Shares </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Morgan Stanley&nbsp;&amp;&nbsp;Co.&nbsp;LLC</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Merrill Lynch, Pierce, Fenner&nbsp;&amp; Smith<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Incorporated</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cowen and Company,&nbsp;LLC</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Needham&nbsp;&amp; Company,&nbsp;LLC</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
underwriters and the representatives are collectively referred to as the "underwriters" and the "representatives," respectively. The underwriters are offering the shares of common
stock subject to their acceptance of the shares from us and subject to prior sale. The underwriting agreement provides that the obligations of the several underwriters to pay for and accept delivery
of the shares of common stock offered by this prospectus are subject to the approval of certain legal matters by their counsel and to certain other conditions. The underwriters are obligated to take
and pay for all of the shares of common stock offered by this prospectus if any such shares are taken. However, the underwriters are not required to take or pay for the shares covered by the
underwriters' option to purchase additional shares described below. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
underwriters initially propose to offer part of the shares of common stock directly to the public at the offering price listed on the cover page of this prospectus and part to
certain dealers. After the initial offering of the shares of common stock, the offering price and other selling terms may from time to time be varied by the representatives. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have granted to the underwriters an option, exercisable for 30&nbsp;days from the date of this prospectus, to purchase up
to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional shares of common stock at the
public offering price listed on the cover page of this prospectus, less underwriting discounts and commissions. To the extent the option is exercised, each underwriter will become obligated, subject
to certain conditions, to purchase about the same percentage of the additional shares of common stock as the number listed next to the underwriter's name in the preceding table bears to the total
number of shares of common stock listed next to the names of all underwriters in the preceding table. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table shows the per share and total public offering price, underwriting discounts and commissions, and proceeds before expenses to us. These amounts are shown assuming both
no exercise and full exercise of the underwriters' option to purchase up to an additional&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common
stock. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="49pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="56pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Per Share </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>No Exercise </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Full Exercise </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Public offering price</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Underwriting discounts and commissions to be paid by us</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proceeds, before expenses, to us</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
estimated offering expenses payable by us, exclusive of the underwriting discounts and commissions, are approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We have agreed to reimburse the underwriters
for expenses relating to clearance of this offering with the Financial Industry Regulatory Authority up to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>218</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=221,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=421903,FOLIO='218',FILE='DISK109:[18ZBU1.18ZBU44601]EE44601A.;14',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_ee44601_1_219"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
underwriters have informed us that they do not intend sales to discretionary accounts to exceed 5% of the total number of shares of common stock offered by them. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
common stock is listed on the Nasdaq Global Market under the trading symbol "RYTM." </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
and all directors, executive officers and certain stockholders have agreed that, without the prior written consent of Morgan Stanley&nbsp;&amp;&nbsp;Co.&nbsp;LLC, Merrill Lynch,
Pierce, Fenner&nbsp;&amp; Smith Incorporated and Cowen and Company,&nbsp;LLC on behalf of the underwriters, we and they will not, during the period ending 90&nbsp;days after the date of this
prospectus, the restricted period:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> offer, sell, contract to sell, pledge or otherwise dispose of, (or enter into any transaction which is designed to, or might reasonably be
expected to, result in the disposition (whether by actual disposition or effective economic disposition due to cash settlement or otherwise), directly or indirectly) any capital stock or any
securities convertible into, or exercisable or exchangeable for such capital stock; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> file any registration statement with the SEC (other than a registration statement on Form&nbsp;S-8) relating to the offering of any shares of
capital stock or any securities convertible into or exercisable or exchangeable for capital stock; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> establish or increase a put equivalent position or liquidate or decrease a call equivalent position within the meaning of Section&nbsp;16 of
the Exchange Act and the rules and regulations of the SEC promulgated thereunder with respect to any shares of capital stock or any securities convertible into or exercisable or exchangeable for
capital stock; </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>whether
any such transaction described above is to be settled by delivery of common stock or such other securities, in cash or otherwise. In addition, we and each such person agrees that, without the
prior written consent of Morgan Stanley&nbsp;&amp;&nbsp;Co.&nbsp;LLC, Merrill Lynch, Pierce, Fenner&nbsp;&amp; Smith Incorporated and Cowen and Company,&nbsp;LLC on behalf of the underwriters, we or
such other person will not, during the restricted period, make any demand for, or exercise any right with respect to, the registration of any shares of common stock or any security convertible into or
exercisable or exchangeable for common stock. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
restrictions described in the immediately preceding paragraph do not apply to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the sale of shares to the underwriters; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the issuance by us of shares of common stock upon the exercise of an option or a warrant or the conversion of a security outstanding on the
date of this prospectus of which the underwriters have been advised in writing; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> transactions by any person other than us relating to shares of common stock or other securities acquired in open market transactions after the
completion of the offering of the shares; provided that no filing under Section&nbsp;16(a) of the Exchange Act is required or voluntarily made in connection with subsequent sales of the common stock
or other securities acquired in such open market transactions; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the establishment of a trading plan pursuant to Rule&nbsp;10b5-1 under the Exchange Act for the transfer of shares of common stock, provided
that (i)&nbsp;such plan does not provide for the transfer of common stock during the restricted period and (ii)&nbsp;to the extent a public announcement or filing under the Exchange Act, if any,
is required or voluntarily made regarding the establishment of such plan, such announcement or filing shall include a statement to the effect that no transfer of common stock may be made under such
plan during the restricted period. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Morgan
Stanley&nbsp;&amp;&nbsp;Co.&nbsp;LLC, Merrill Lynch, Pierce, Fenner&nbsp;&amp; Smith Incorporated and Cowen and Company,&nbsp;LLC, in their sole discretion, may release the
common stock and other securities subject to the lock-up agreements described above in whole or in part at any time. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>219</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=222,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=403315,FOLIO='219',FILE='DISK109:[18ZBU1.18ZBU44601]EE44601A.;14',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_ee44601_1_220"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
order to facilitate the offering of the common stock, the underwriters may engage in transactions that stabilize, maintain or otherwise affect the price of the common stock.
Specifically, the underwriters may sell more shares than they are obligated to purchase under the underwriting agreement, creating a short position. A short sale is covered if the short position is no
greater than the number of shares available for purchase by the underwriters under the option. The underwriters can close out a covered short sale by exercising the option or purchasing shares in the
open market. In determining the source of shares to close out a covered short sale, the underwriters will consider, among other things, the open market price of shares compared to the price available
under the option. The underwriters may also sell shares in excess of the option, creating a naked short position. The underwriters must close out any naked short position by purchasing shares in the
open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the common stock in the open market after pricing
that could adversely affect investors who purchase in this offering. As an additional means of facilitating this offering, the underwriters may bid for, and
purchase, shares of common stock in the open market to stabilize the price of the common stock. These activities may raise or maintain the market price of the common stock above independent market
levels or prevent or retard a decline in the market price of the common stock. The underwriters are not required to engage in these activities and may end any of these activities at any time. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
and the underwriters have agreed to indemnify each other against certain liabilities, including liabilities under the Securities Act. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
prospectus in electronic format may be made available on websites maintained by one or more underwriters, or selling group members, if any, participating in this offering. The
representatives may agree to allocate a number of shares of common stock to underwriters for sale to their online brokerage account holders. Internet distributions will be allocated by the
representatives to underwriters that may make Internet distributions on the same basis as other allocations. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
underwriters and their respective affiliates are full service financial institutions engaged in various activities, which may include securities trading, commercial and investment
banking, financial advisory, investment management, investment research, principal investment, hedging. financing and brokerage activities. Certain of the underwriters and their respective affiliates
have, from time to time, performed, and may in the future perform, various financial advisory and investment banking services for us, for which they received or will receive customary fees and
expenses. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, in the ordinary course of their various business activities, the underwriters and their respective affiliates may make or hold a broad array of investments and actively
trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers and may at any time
hold long and short positions in such securities and instruments. Such investment and securities activities may involve our securities and instruments. The underwriters and their respective affiliates
may also make investment recommendations or publish or express independent research views in respect of such securities or instruments and may at any time hold, or recommend to clients that they
acquire, long or short positions in such securities and instruments. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Pricing of the Offering  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The public offering price was determined by negotiations between us and the representatives. Among the factors considered in determining the
public offering price were our future prospects and those of our industry in general, our sales, earnings and certain other financial and operating information in recent periods, and the
price-earnings ratios, price-sales ratios, market prices of securities, and certain financial and operating information of companies engaged in activities similar to ours. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>220</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=223,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=379550,FOLIO='220',FILE='DISK109:[18ZBU1.18ZBU44601]EE44601A.;14',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_ee44601_1_221"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Selling Restrictions  </B></FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


European Economic Area  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In relation to each Country of the European Economic Area which has implemented the Prospectus Directive, each, a Relevant Country, an offer to
the public of any shares of our common stock may not be made in that Relevant Country, except that an offer to the public in that Relevant Country of any shares of our common stock may be made at any
time under the following exemptions under the Prospectus Directive, if they have been implemented in that Relevant Country: </FONT></P>

<UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;to
any legal entity which is a qualified investor as defined in the Prospectus Directive; </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;to
fewer than 100 or, if the Relevant Country has implemented the relevant provision of the 2010 PD Amending Directive, 150, natural or legal persons (other than
qualified investors as defined in the Prospectus Directive), as permitted under the Prospectus Directive, subject to obtaining the prior consent of the representatives for any such offer; or </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;in
any other circumstances falling within Article&nbsp;3(2) of the Prospectus Directive, provided that no such offer of shares of our common stock shall result in a
requirement for the publication by us or any underwriter of a prospectus pursuant to Article&nbsp;3 of the Prospectus Directive. </FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
the purposes of this provision, the expression an "offer to the public" in relation to any shares of our common stock in any Relevant Country means the communication in any form and
by any means
of sufficient information on the terms of the offer and any shares of our common stock to be offered so as to enable an investor to decide to purchase any shares of our common stock, as the same may
be varied in that Relevant Country by any measure implementing the Prospectus Directive in that Relevant Country, the expression "Prospectus Directive" means Directive 2003/71/EC (and amendments
thereto, including the 2010 PD Amending Directive, to the extent implemented in the Relevant Country), and includes any relevant implementing measure in the Relevant Country, and the expression "2010
PD Amending Directive" means Directive 2010/73/EU. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


United Kingdom  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each underwriter has represented and agreed that: </FONT></P>

<UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;it
has only communicated or caused to be communicated and will only communicate or cause to be communicated an invitation or inducement to engage in investment activity
(within the meaning of Section&nbsp;21 of the Financial Services and Markets Act 2000, or FSMA, received by it in connection with the issue or sale of the shares of our common stock in circumstances
in which Section&nbsp;21(1) of the FSMA does not apply to us; and </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;it
has complied and will comply with all applicable provisions of the FSMA with respect to anything done by it in relation to the shares of our common stock in, from or
otherwise involving the United Kingdom. </FONT></P>


<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Canada  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The shares may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in
National Instrument&nbsp;45-106 Prospectus Exemptions or subsection&nbsp;73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument&nbsp;31-103
Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the shares must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus
requirements of applicable securities laws. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Securities
legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto)
contains a </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>221</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=224,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=35158,FOLIO='221',FILE='DISK109:[18ZBU1.18ZBU44601]EE44601A.;14',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_ee44601_1_222"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>misrepresentation,
provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser's province or
territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser's province or territory for particulars of these rights or consult with a legal
advisor. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to section&nbsp;3A.3 (or, in the case of securities issued or guaranteed by the government of a non-Canadian jurisdiction, section&nbsp;3A.4) of National
Instrument&nbsp;33-105 Underwriting Conflicts (NI&nbsp;33-105), the underwriters are not required to comply with the disclosure requirements of NI&nbsp;33-105 regarding underwriter conflicts of
interest in connection with this offering. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Notice to Prospective Investors in Switzerland  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The shares may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange, or SIX, or on any other stock exchange
or regulated trading facility in Switzerland. This document has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of
Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in
Switzerland. Neither this document nor any other offering or marketing material relating to the shares or the offering may be publicly distributed or otherwise made publicly available in Switzerland. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Neither
this document nor any other offering or marketing material relating to the offering, the Company or the shares have been or will be filed with or approved by any Swiss regulatory
authority. In particular, this document will not be filed with, and the offer of shares will not be supervised by, the Swiss Financial Market Supervisory Authority, or FINMA, and the offer of shares
has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes, or CISA. The investor protection afforded to acquirers of interests in collective investment
schemes under the CISA does not extend to acquirers of shares. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Notice to Prospective Investors in the Dubai International Financial Centre  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus relates to an Exempt Offer in accordance with the Offered Securities Rules of the Dubai Financial Services Authority, or DFSA.
This prospectus is intended for distribution only to persons of a type specified in the Offered Securities Rules of the DFSA. It must not be delivered to, or relied on by, any other person. The DFSA
has no responsibility for reviewing or verifying any documents in connection with Exempt Offers. The DFSA has not approved this prospectus nor taken steps to verify the information set forth herein
and has no responsibility for the prospectus. The shares to which this prospectus relates may be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the shares offered
should conduct their own due diligence on the shares. If you do not understand the contents of this prospectus you should consult an authorized financial advisor. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Notice to Prospective Investors in Singapore  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other
document or material in connection with the offer or sale, or invitation for subscription or purchase, of Non-CIS Securities may not be circulated or distributed, nor may the Non-CIS Securities be
offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i)&nbsp;to an institutional investor under
Section&nbsp;274 of the Securities and Futures Act, Chapter&nbsp;289 of Singapore, or SFA, (ii)&nbsp;to a relevant person pursuant to Section&nbsp;275(1), or any person pursuant to
Section&nbsp;275(1A), and in accordance with the conditions specified in Section&nbsp;275, of the SFA, or (iii)&nbsp;otherwise pursuant to, and in accordance with the conditions of, any other
applicable provision of the SFA. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>222</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=225,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=436999,FOLIO='222',FILE='DISK109:[18ZBU1.18ZBU44601]EE44601A.;14',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_ee44601_1_223"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Where
the Non-CIS Securities are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person which is: </FONT></P>

<UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;a
corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole business of which is to hold investments and the entire share
capital of which is owned by one or more individuals, each of whom is an accredited investor; or </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;a
trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual who is an
accredited investor, </FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>securities
(as defined in Section&nbsp;239(1) of the SFA) of that corporation or the beneficiaries' rights and interest (howsoever described) in that trust shall not be transferred within six months
after that corporation or that trust has acquired the Non-CIS Securities pursuant to an offer made under Section&nbsp;275 of the SFA except: </FONT></P>

<UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;to
an institutional investor or to a relevant person defined in Section&nbsp;275(2) of the SFA, or to any person arising from an offer referred to in
Section&nbsp;275(1A) or Section&nbsp;276(4)(i)(B) of the SFA; </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;where
no consideration is or will be given for the transfer; </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;where
the transfer is by operation of law; </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;as
specified in Section&nbsp;276(7) of the SFA; or </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;&nbsp;&nbsp;as
specified in Regulation&nbsp;32 of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations&nbsp;2005 of Singapore. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Notice to Prospective Investors in Hong Kong  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The securities have not been offered or sold and will not be offered or sold in Hong Kong, by means of any document, other than (a)&nbsp;to
"professional investors" as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong and any rules made under that Ordinance; or (b)&nbsp;in other circumstances which do not result in
the document being a "prospectus" as defined in the Companies Ordinance (Cap. 32)&nbsp;of Hong Kong or which do not constitute an offer to the public within the meaning of that Ordinance. No
advertisement, invitation or document relating to the securities has been or may be issued or has been or may be in the possession of any person for the
purposes of issue, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under
the securities laws of Hong Kong) other than with respect to securities which are or are intended to be disposed of only to persons outside Hong Kong or only to "professional investors" as defined in
the Securities and Futures Ordinance and any rules made under that Ordinance. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Notice to Prospective Investors in Japan  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The securities have not been and will not be registered under the Financial Instruments and Exchange Law of Japan (Law No.&nbsp;25 of 1948, as
amended) and, accordingly, will not be offered or sold, directly or indirectly, in Japan, or for the benefit of any Japanese Person or to others for re-offering or resale, directly or indirectly, in
Japan or to any Japanese Person, except in compliance with all applicable laws, regulations and ministerial guidelines promulgated by relevant Japanese governmental or regulatory authorities in effect
at the relevant time. For the purposes of this paragraph, "Japanese Person" shall mean any person resident in Japan, including any corporation or other entity organized under the laws of Japan. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Notice to Prospective Investors in Australia  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No placement document, prospectus, product disclosure statement or other disclosure document has been lodged with the Australian Securities and
Investments Commission, in relation to the offering. This </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>223</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=226,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=47292,FOLIO='223',FILE='DISK109:[18ZBU1.18ZBU44601]EE44601A.;14',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_ee44601_1_224"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>prospectus
does not constitute a prospectus, product disclosure statement or other disclosure document under the Corporations Act 2001, or Corporations Act, and does not purport to include the
information required for a prospectus, product disclosure statement or other disclosure document under the Corporations Act. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
offer in Australia of the shares may only be made to persons, or Exempt Investors, who are "sophisticated investors" (within the meaning of section&nbsp;708(8) of the Corporations
Act), "professional
investors" (within the meaning of section&nbsp;708(11) of the Corporations Act) or otherwise pursuant to one or more exemptions contained in section&nbsp;708 of the Corporations Act so that it is
lawful to offer the shares without disclosure to investors under Chapter&nbsp;6D of the Corporations Act. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
shares applied for by Exempt Investors in Australia must not be offered for sale in Australia in the period of 12&nbsp;months after the date of allotment under the offering, except
in circumstances where disclosure to investors under Chapter&nbsp;6D of the Corporations Act would not be required pursuant to an exemption under section&nbsp;708 of the Corporations Act or
otherwise or where the offer is pursuant to a disclosure document which complies with Chapter&nbsp;6D of the Corporations Act. Any person acquiring shares must observe such Australian on-sale
restrictions. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
prospectus contains general information only and does not take account of the investment objectives, financial situation or particular needs of any particular person. It does not
contain any securities recommendations or financial product advice. Before making an investment decision, investors need to consider whether the information in this prospectus is appropriate to their
needs, objectives and circumstances, and, if necessary, seek expert advice on those matters. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>224</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=227,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=611054,FOLIO='224',FILE='DISK109:[18ZBU1.18ZBU44601]EE44601A.;14',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<A NAME="page_ee44601_1_225"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ee44601_legal_matters"> </A>
<A NAME="toc_ee44601_2"> </A>
<BR></FONT><FONT SIZE=2><B>  LEGAL MATTERS    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The validity of the shares of common stock offered hereby has been passed upon for us by Morgan, Lewis&nbsp;&amp; Bockius&nbsp;LLP, Boston,
Massachusetts. Certain legal matters in connection with this offering will be passed upon for the underwriters by Ropes and Gray&nbsp;LLP, Boston, Massachusetts. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ee44601_experts"> </A>
<A NAME="toc_ee44601_3"> </A>
<BR></FONT><FONT SIZE=2><B>  EXPERTS    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The consolidated financial statements of Rhythm Pharmaceuticals,&nbsp;Inc. at December&nbsp;31, 2016 and 2017, and for each of the three
years in the period ended December&nbsp;31, 2017 appearing in this prospectus and the registration statement have been audited by Ernst&nbsp;&amp; Young&nbsp;LLP, independent registered public
accounting firm, as set forth in their report thereon appearing elsewhere
herein, and are included in reliance upon such report given on the authority of such firm as experts in accounting and auditing. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ee44601_where_you_can_find_more_information"> </A>
<A NAME="toc_ee44601_4"> </A>
<BR></FONT><FONT SIZE=2><B>  WHERE YOU CAN FIND MORE INFORMATION    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have filed with the SEC a registration statement on Form&nbsp;S-1 (including exhibits, schedules, and amendments) under the Securities Act
with respect to the shares of common stock offered by this prospectus. This prospectus does not contain all the information set forth in the registration statement. For further information about us
and the shares of common stock to be sold in this offering, you should refer to the registration statement. Statements contained in this prospectus relating to the contents of any contract, agreement
or other document are not necessarily complete and are qualified in all respects by the complete text of the applicable contract, agreement or other document, a copy of which has been filed as an
exhibit to the registration statement. Whenever this prospectus refers to any contract, agreement, or other document, you should refer to the exhibits that are a part of the registration statement for
a copy of the contract, agreement, or document. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are subject to the reporting and information requirements of the Exchange Act and, as a result, file, or will file, periodic reports, proxy statements and other information with the
SEC. These periodic reports and other information are available for inspection and copying at the SEC's public reference room and the website of the SEC, in each case, referred to below. We also
maintain a website at http://&nbsp;http://www.rhythmtx.com and make available free of charge through this website our annual report on Form&nbsp;10-K, quarterly reports on Form&nbsp;10-Q,
current reports on Form&nbsp;8-K and amendments to those reports filed or furnished pursuant to Sections&nbsp;13(a) and 15(d) of the Exchange Act. We make these reports available through our
website as soon as reasonably practicable after we electronically file such reports with, or furnish such reports to, the SEC. The information contained on, or that can be accessed through, our
website is not a part of this prospectus. The reference to our web address does not constitute incorporation by reference of the information contained in, or that can be accessed through, our website. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
may read and copy this information at the SEC's Public Reference Room at 100&nbsp;F Street, N.E., Washington D.C. 20549, on official business days during the hours of 10:00 am to
3:00 pm. You may obtain information regarding the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC also maintains a website (http://www.sec.gov) that contains
reports, proxy and information statements and other information regarding issuers that file electronically with the SEC. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>225</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=228,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=854411,FOLIO='225',FILE='DISK109:[18ZBU1.18ZBU44601]EE44601A.;14',USER='CHE108055',CD='11-JUN-2018;03:28' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_fa44601_1_1"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->



<!-- PARA=JUSTIFY -->
</FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> <A NAME="FA1"></A>RHYTHM PHARMACEUTICALS,&nbsp;INC.<BR>
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>
<A NAME="FA44601_TOC"></A> </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- COMMAND=ADD_START_LINKTABLE -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="28pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Page </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#fc44601_report_of_independent___fc402279"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Report of Independent Registered Public Accounting Firm</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#fc44601_report_of_independent___fc402279"><FONT SIZE=2>F-2</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Audited Consolidated Financial Statements</B></FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#page_fe44601_1_3"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Consolidated Balance Sheets as of December&nbsp;31, 2017 and 2016</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#page_fe44601_1_3"><FONT SIZE=2>F-3</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#page_fg44601_1_4"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Consolidated Statements of Operations and Comprehensive Loss for the Years Ended December&nbsp;31, 2017, 2016,
and 2015</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#page_fg44601_1_4"><FONT SIZE=2>F-4</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#page_fi44601_1_5"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) for the Years Ended
December&nbsp;31, 2017, 2016, and 2015</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#page_fi44601_1_5"><FONT SIZE=2>F-5</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#page_fk44601_1_6"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Consolidated Statements of Cash Flows for the Years Ended December&nbsp;31, 2017, 2016, and 2015</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#page_fk44601_1_6"><FONT SIZE=2>F-6</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#fm44601_rhythm_pharmaceuticals,_inc._n__rhy04839"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Notes to Consolidated Financial Statements</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#fm44601_rhythm_pharmaceuticals,_inc._n__rhy04839"><FONT SIZE=2>F-7</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Condensed Consolidated (Unaudited) Financial Statements</B></FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#page_fs44601_1_36"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Condensed Consolidated Balance Sheets as of March&nbsp;31, 2018 and December&nbsp;31, 2017</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#page_fs44601_1_36"><FONT SIZE=2>F-36</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#page_fu44601_1_37"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three Months Ended March&nbsp;31,
 2018 and 2017</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#page_fu44601_1_37"><FONT SIZE=2>F-37</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#page_fw44601_1_38"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Condensed Consolidated Statements of Cash Flows for the Three Months Ended March&nbsp;31, 2018 and
2017</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#page_fw44601_1_38"><FONT SIZE=2>F-38</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#fy44601_rhythm_pharmaceuticals,_inc._n__rhy05639"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Notes to Unaudited Condensed Consolidated Financial Statements</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#fy44601_rhythm_pharmaceuticals,_inc._n__rhy05639"><FONT SIZE=2>F-39</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
<!-- COMMAND=ADD_END_LINKTABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-1</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=229,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=769924,FOLIO='F-1',FILE='DISK109:[18ZBU1.18ZBU44601]FA44601A.;8',USER='CHE105614',CD='10-JUN-2018;18:09' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_fc44601_1_2"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="fc44601_report_of_independent___fc402279"> </A>
<A NAME="toc_fc44601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>To
the Stockholders and the Board of Directors of Rhythm Pharmaceuticals,&nbsp;Inc. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Opinion on the Financial Statements  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have audited the accompanying consolidated balance sheets of Rhythm Pharmaceuticals,&nbsp;Inc. (the Company) as of December&nbsp;31, 2017
and 2016, the related consolidated statements of operations and comprehensive loss, convertible preferred stock and stockholders' equity (deficit) and cash flows for each of the three years in the
period ended December&nbsp;31, 2017, and the related notes (collectively referred to as the "consolidated financial statements"). In our opinion, the consolidated financial statements present
fairly, in all material respects, the financial position of the Company at December&nbsp;31, 2017 and 2016, and the results of its operations and its cash flows for each of the three years in the
period ended December&nbsp;31, 2017, in conformity with U.S. generally accepted accounting principles. </FONT></P>


<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Basis for Opinion  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's
financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with
respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the
financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over
financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness
of the Company's internal control over financial reporting. Accordingly, we express no such opinion. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond
to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting
principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our
opinion. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="50%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="50%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>/s/ Ernst&nbsp;&amp; Young&nbsp;LLP<BR></FONT>
</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>We
have served as the Company's auditor since 2015.<BR>
Boston, Massachusetts<BR>
March&nbsp;12, 2018, except for Note&nbsp;12, as to which the date is June&nbsp;11, 2018 </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=230,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=408573,FOLIO='F-2',FILE='DISK109:[18ZBU1.18ZBU44601]FC44601A.;7',USER='CHE105614',CD='10-JUN-2018;18:09' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_fe44601_1_3"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="fe44601_rhythm_pharmaceuticals,_inc._c__rhy03852"> </A>
<A NAME="toc_fe44601_1"> </A></FONT> <FONT SIZE=2><B><BR>  RHYTHM PHARMACEUTICALS,&nbsp;INC.    <BR>    <BR>    CONSOLIDATED BALANCE SHEETS    <BR>    <BR>    (in thousands, except share and per share data)    <BR>    </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31,<BR>
2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31,<BR>
2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Assets</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Current assets:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash and cash equivalents</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>34,236</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6,540</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Short-term investments</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>113,846</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,997</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Prepaid expenses and other current assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,589</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>638 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total current assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>150,671</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>11,175</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Property, plant and equipment, net</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>840</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>930</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deferred issuance costs</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Restricted cash</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>225</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>225 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>151,736</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>12,339 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Liabilities, convertible preferred stock and stockholders' equity (deficit)</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Current liabilities:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accounts payable</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,427</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,895</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Due to related party</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>105</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deferred rent</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>83</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>76</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued expenses and other current liabilities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,210</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,655 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total current liabilities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6,720</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,731</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Long-term liabilities:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deferred rent</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>228</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>311 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total liabilities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6,948</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,042</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Commitments and contingencies</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Preferred stock:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Series&nbsp;A Convertible Preferred Stock, $0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding at December&nbsp;31, 2017 and
40,000,000 shares issued and outstanding at December&nbsp;31, 2016; (aggregate liquidation preference of $0 and $44,129 at December&nbsp;31, 2017 and December&nbsp;31, 2016 respectively)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>40,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Stockholders' equity (deficit):</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Common stock, $0.001 par value: 120,000,000 shares authorized; 27,284,140 and 10,196,292 shares issued and outstanding and December&nbsp;31, 2017 and
December&nbsp;31, 2016, respectively</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>27</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Additional paid-in capital</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>255,013</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>43,830</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accumulated deficit</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(110,252</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(76,543</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total stockholders' equity (deficit)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>144,788</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(32,703</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total liabilities, convertible preferred stock and stockholders' equity (deficit)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>151,736</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>12,339 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p><p align=center style="font-family:times;"><font> </FONT> <FONT SIZE=2>
The accompanying notes are an integral part of these financial statements </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=231,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=803940,FOLIO='F-3',FILE='DISK109:[18ZBU1.18ZBU44601]FE44601A.;4',USER='CHE105614',CD='10-JUN-2018;18:09' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_fg44601_1_4"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="fg44601_rhythm_pharmaceuticals,_inc._c__rhy05282"> </A>
<A NAME="toc_fg44601_1"> </A></FONT> <FONT SIZE=2><B><BR>  RHYTHM PHARMACEUTICALS,&nbsp;INC.    <BR>    <BR>    CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS    <BR>    <BR>    (in thousands, except share and per share data)    <BR>
</B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended<BR>
December&nbsp;31,<BR>
2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended<BR>
December&nbsp;31,<BR>
2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended<BR>
December&nbsp;31,<BR>
2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Operating expenses:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>22,894</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>19,594</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7,148</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Selling, general, and administrative</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9,518</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6,311</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,425 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total operating expenses</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>32,412</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>25,905</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10,573 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Loss from operations</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(32,412</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(25,905</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(10,573</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other income (expense):</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Revaluation of Series&nbsp;A Investor Instrument and Series&nbsp;A Investor Right/Obligation</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1,863</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Interest income, net</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>566</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>33</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total other income (expense):</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1,297</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>33</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss and comprehensive loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(33,709</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(25,872</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(11,073</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss attributable to common stockholders</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(37,582</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(29,074</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(12,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss attributable to common stockholders per common share, basic and diluted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(2.83</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(2.85</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1.18</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Weighted average common shares outstanding, basic and diluted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>13,267,960</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10,196,292</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10,196,292 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p><p align=center style="font-family:times;"><font> </FONT> <FONT SIZE=2>
The accompanying notes are an integral part of these financial statements </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-4</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=232,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=179440,FOLIO='F-4',FILE='DISK109:[18ZBU1.18ZBU44601]FG44601A.;4',USER='CHE105614',CD='10-JUN-2018;18:09' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_fi44601_1_5"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="fi44601_rhythm_pharmaceuticals,_inc._c__rhy06307"> </A>
<A NAME="toc_fi44601_1"> </A></FONT> <FONT SIZE=2><B><BR>  RHYTHM PHARMACEUTICALS,&nbsp;INC.    <BR>    <BR>    CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND<BR>  STOCKHOLDERS' EQUITY (DEFICIT)    <BR>    <BR>    (in thousands, except
share and per share data)    <BR>    </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="47pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="36pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="35pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="47pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="35pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="54pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="56pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=3 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=3 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Series&nbsp;A Convertible<BR>
Preferred Stock </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=3 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=3 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Series&nbsp;A-1&nbsp;Junior<BR>
Preferred Stock </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Common Stock </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=3 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=3 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total<BR>
Stockholders'<BR>
Equity<BR>
(Deficit) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Additional<BR>
Paid-In<BR>
Capital </B></FONT></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Accumulated<BR>
Deficit </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Shares </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Amount </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1><B>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Shares </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Amount </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Shares </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Amount </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Balance at December&nbsp;31, 2014</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="TOP" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>



<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>10,196,292</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>10</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>39,230</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(39,598</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(358</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Equity contribution</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="TOP" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2,094</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2,094</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Modification of warrant in connection with a license agreement</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="TOP" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>



<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>923</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>923</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Stock compensation expense</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="TOP" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>298</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>298</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Dividend to Rhythm Holding Company&nbsp;LLC (associated with common stock options granted to employees of Motus Therapeutics,&nbsp;Inc.)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="TOP" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2,695</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2,695</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Dividend to Rhythm Holding Company&nbsp;LLC (associated with common stock options granted to employees of Motus Therapeutics,&nbsp;Inc.)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="TOP" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(2,695</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(2,695</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Reclassification of Series&nbsp;A Investor Right/Obligation liability upon Series&nbsp;A second tranche closing</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>883</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="TOP" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>117</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>117</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Issuance of Series&nbsp;A Convertible Preferred Stock</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>40,000,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>39,117</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="TOP" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Net loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="TOP" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(11,073</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(11,073</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="TOP" style="line-height:0pt;font-size:1.5pt;font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="TOP" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Balance at December&nbsp;31, 2015</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>40,000,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>40,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="TOP" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>10,196,292</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>10</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>42,662</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(50,671</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(7,999</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Stock compensation expense</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="TOP" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,168</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,168</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Net loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="TOP" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>



<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(25,872</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(25,872</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="TOP" style="line-height:0pt;font-size:1.5pt;font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="TOP" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Balance at December&nbsp;31, 2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>40,000,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>40,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="TOP" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>10,196,292</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>10</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>43,830</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(76,543</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(32,703</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Stock compensation expense</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="TOP" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2,278</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2,278</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Issuance of common stock in connection with exercise of stock options</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="TOP" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>152,671</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>700</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>700</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Change in unrealized loss on marketable securities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="TOP" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(141</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(141</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Issuance of Series&nbsp;A Convertible Preferred Stock</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>40,949,999</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>40,622</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="TOP" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(108</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(108</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Settlement of Series&nbsp;A investor instrument</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>328</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="TOP" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,863</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,863</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Exchange of common stock held by&nbsp;LLC entity for Series&nbsp;A-1&nbsp;Junior Preferred Stock</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="TOP" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(8,578,661</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(8</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>78,666,209</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>79</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(71</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Issuance of common stock upon completion of initial public offering, net of offering costs</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="TOP" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>8,107,500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>8</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>125,650</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>125,658</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Conversion of Series&nbsp;A Convertible Preferred Stock and Series&nbsp;A-1&nbsp;Junior Preferred Stock into common stock on a 9.17 to 1 basis</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(80,949,999</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(80,950</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD ALIGN="CENTER" VALIGN="TOP" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>17,406,338</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>17</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(78,666,209</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(79</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>81,012</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>80,950</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Net loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="TOP" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>



<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(33,709</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(33,709</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="TOP" style="line-height:0pt;font-size:1.5pt;font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="TOP" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Balance at December&nbsp;31, 2017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="TOP" style="font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=1>


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>27,284,140</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>27</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>255,013</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>(110,252</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>144,788 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="TOP" style="line-height:0pt;font-size:1.5pt;font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="TOP" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="TOP" style="line-height:0.75pt;font-size:0.75pt;font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="TOP" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="CENTER" VALIGN="TOP" style="line-height:0pt;font-size:1.5pt;font-family:times;border-right:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-right:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="TOP" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p><p align=center style="font-family:times;"><font> </FONT> <FONT SIZE=2>
The accompanying notes are an integral part of these financial statements </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=233,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=562549,FOLIO='F-5',FILE='DISK109:[18ZBU1.18ZBU44601]FI44601A.;6',USER='CHE105614',CD='10-JUN-2018;18:09' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_fk44601_1_6"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="fk44601_rhythm_pharmaceuticals,_inc._c__rhy04309"> </A>
<A NAME="toc_fk44601_1"> </A></FONT> <FONT SIZE=2><B><BR>  RHYTHM PHARMACEUTICALS,&nbsp;INC.    <BR>    <BR>    CONSOLIDATED STATEMENTS OF CASH FLOWS    <BR>    <BR>    (in thousands, except share and per share data)    <BR>    </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="56pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Fiscal Year Ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Operating activities</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(33,709</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(25,872</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(11,073</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Adjustments to reconcile net loss to cash used in operating activities:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Stock-based compensation expense</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,278</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,168</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>298</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Depreciation and amortization</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>223</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>144</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Non-cash rent expense</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(76</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>11</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Modification of warrant in connection with license agreement&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>923</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Mark to market revaluation of Series&nbsp;A Investor Instrument and Series&nbsp;A Investor Right/Obligation</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,863</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Changes in operating assets and liabilities:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Prepaid expenses and other current assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1,889</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>41</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(581</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deferred issuance costs</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,472</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1,481</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Tenant improvement allowance</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>376</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accounts payable, accrued expenses and other current liabilities&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,946</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>160</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,838</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deferred grant income</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(249</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>249</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Due to related parties</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(105</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(470</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>575 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:40pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net cash used in operating activities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(29,460</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(23,219</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(6,752</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Investing activities</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Purchases of short-term investments</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(126,917</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(15,222</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Maturities of short-term investments</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>17,006</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>11,169</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Purchases of property, plant and equipment</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(133</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1,057</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(17</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:40pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net cash used in investing activities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(110,044</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(5,110</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(17</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Financing activities</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net proceeds from issuance of common stock</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>125,658</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net proceeds from issuance of Series&nbsp;A Convertible Preferred Stock</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>40,842</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>39,617</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Equity Contribution</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,094</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proceeds from the exercise of stock options</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>700</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:40pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net cash provided by financing activities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>167,200</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>41,711 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net increase (decrease) in cash, cash equivalents and restricted cash</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>27,696</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(28,329</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>34,942</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash, cash equivalents and restricted cash at beginning of year</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6,765</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>35,094</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>152 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash, cash equivalents and restricted cash at end of year</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>34,461</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6,765</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>35,094 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p><p align=center style="font-family:times;"><font> </FONT> <FONT SIZE=2>
The accompanying notes are an integral part of these financial statements </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-6</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=234,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=683622,FOLIO='F-6',FILE='DISK109:[18ZBU1.18ZBU44601]FK44601A.;5',USER='CHE105614',CD='10-JUN-2018;18:09' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_fm44601_1_7"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="fm44601_rhythm_pharmaceuticals,_inc._n__rhy04839"> </A>
<A NAME="toc_fm44601_1"> </A></FONT> <FONT SIZE=2><B><BR>  Rhythm Pharmaceuticals,&nbsp;Inc.    <BR>    <BR>    Notes to Consolidated Financial Statements    <BR>    <BR>    (In thousands, except share and per share information)    <BR>
</B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


1. Nature of Business  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Rhythm Pharmaceuticals,&nbsp;Inc. (the "Company"), is a biopharmaceutical company focused on the development and commercialization of peptide therapeutics for the treatment of genetic
deficiencies that result in life-threatening metabolic disorders. The Company's lead product candidate is setmelanotide (RM-493), which is a potent, first-in-class, melanocortin-4, or MC4, receptor
agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. The Company is currently evaluating setmelanotide for the treatment of six genetic disorders of
obesity: pro-opiomelanocortin, or POMC, leptin receptor, or LepR, Bardet-Biedl syndrome, Alstr&ouml;m syndrome, POMC heterozygous, and POMC epigenetic disorders. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Corporate Reorganization  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company is a Delaware corporation organized in February 2013 under the name Rhythm Metabolic,&nbsp;Inc. Prior to the Company's
organization and the Corporate Reorganization referred to below, the Company was part of Rhythm Pharmaceuticals,&nbsp;Inc. (the "Predecessor Company"), a Delaware corporation which was organized in
November 2008 and which commenced active operations in 2010. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
March 2013, the Predecessor Company underwent a corporate reorganization, (the "Corporate Reorganization"), pursuant to which all of the outstanding equity securities of the
Predecessor Company were exchanged for units of Rhythm Holding Company,&nbsp;LLC, a newly-organized limited liability company (the "LLC entity"). After the consummation of this exchange and as part
of the Corporate Reorganization, the Predecessor Company contributed setmelanotide and the MC4R agonist program to the Company and distributed to the&nbsp;LLC entity all of the then issued and
outstanding shares of the Company's stock. The result of the Corporate Reorganization was that the Company and the Predecessor Company became wholly-owned subsidiaries of the&nbsp;LLC entity and the
two product candidates and related programs that were originally held by the Predecessor Company were separated,
with relamorelin and the ghrelin agonist program being retained by the Predecessor Company and setmelanotide and the MC4R agonist program being held by the Company. The Predecessor Company, after
consummation of the Corporate Reorganization, is referred to within these Notes to Financial Statements as the Relamorelin Company and/or Motus. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
October&nbsp;13, 2015, the Relamorelin Company changed its name to Motus Therapeutics, Inc ("Motus") and the Company changed its name to Rhythm Pharmaceuticals,&nbsp;Inc. On
December&nbsp;15, 2016, Motus was sold to a large pharmaceutical company. On August&nbsp;21, 2017, the&nbsp;LLC entity distributed to its members all of its shares of the Company (see
Note&nbsp;5 for further discussion). </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Liquidity  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has incurred operating losses and negative cash flows from operations since inception, incurred a net loss of $33,709, $25,872 and
$11,073 during the years ended December&nbsp;31, 2017, 2016 and 2015, respectively, and has an accumulated deficit of $110,252 as of December&nbsp;31, 2017. The Company has primarily funded these
losses through capital contributions received from the&nbsp;LLC entity and the sale of preferred and common stock to outside investors. To date, the Company has no product revenue and management
expects operating losses to continue for the foreseeable future. The Company has devoted substantially all of its resources to its drug development efforts, comprising research and development,
manufacturing, conducting clinical trials for its product candidates, protecting its intellectual property and general and administrative functions relating to these operations. The future success of
the Company is </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-7</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=235,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=755986,FOLIO='F-7',FILE='DISK109:[18ZBU1.18ZBU44601]FM44601A.;10',USER='CHE105614',CD='10-JUN-2018;18:09' -->
<A NAME="page_fm44601_1_8"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Rhythm Pharmaceuticals,&nbsp;Inc. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes to Consolidated Financial Statements (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> (In thousands, except share and per share information) </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


1. Nature of Business (Continued) </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>dependent
on its ability to develop its product candidates and ultimately upon its ability to attain profitable operations. At December&nbsp;31, 2017, the Company had $148,082 of cash and cash
equivalents and short-term investments on hand. In the future, the Company will be dependent on obtaining funding from third parties, such as proceeds from the issuance of debt, sale of equity, and
funded research and development programs, to maintain the Company's operations and meet the Company's obligations. There is no guarantee that additional equity or other financings will be available to
the Company on acceptable terms, or at all. If the Company fails to obtain additional funding when needed, the Company would be forced to scale back, terminate its operations or seek to merge with or
be acquired by another company. Management believes that the Company's existing cash resources will be sufficient to fund the Company's operating plan into the second half of 2019. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. Summary of Significant Accounting Policies  </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Basis of Presentation  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company's consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United
States ("GAAP"). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards
Codification ("ASC") and Accounting Standards Updates ("ASU") of the Financial Accounting Standards Board ("FASB"). </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company has historically existed and functioned as part of the consolidated businesses of the Predecessor Company. As noted above, the Predecessor Company's setmelanotide and the
MC4R agonist program were transferred to the Company as part of the Corporate Reorganization on March&nbsp;21, 2013. These financial statements include the results of operations of setmelanotide and
the MC4R agonist program from its inception. As part of the Corporate Reorganization, the Company also entered into a formal payroll services intercompany agreement with the Relamorelin Company. On
November&nbsp;16, 2016, the employees of the Relamorelin Company that were providing services to the Company, terminated their employment contracts with the Relamorelin Company and entered into new
employment agreements with the Company. On December&nbsp;15, 2016, the Relamorelin Company closed on its sale to a large pharmaceutical company. During 2016 and 2015, costs have been allocated to
the Company for the purposes of preparing the financial statements based on a specific identification basis or, when specific identification is not practicable, a proportional cost allocation method
which allocates expenses based upon the percentage of employee time and research and development effort expended on the Company's business as compared to total employee time and research and
development effort of the combined Motus and Rhythm. The proportional use basis adopted to allocate shared costs is in accordance with the guidance of SEC Staff Accounting Bulletin ("SAB") Topic 1B, </FONT> <FONT SIZE=2><I>Allocation Of Expenses And
Related Disclosure In Financial Statements Of Subsidiaries, Divisions Or Lesser Business Components Of Another Entity</I></FONT><FONT SIZE=2>.
Management has determined that the method of allocating costs to the
Company is reasonable. Cost allocation was no longer required subsequent to the 2016 sale of the Relamorelin Company. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Management
believes that the statements of operations include a reasonable allocation of costs and expenses incurred by the Relamorelin Company, which benefited the Company. However,
such amounts may not be indicative of the actual level of costs and expenses that would have been incurred by the Company if it had operated as an independent company or of the costs and expenses
expected to be incurred in the future. Management has not presented an estimate of what the expenses of the Company </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-8</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=236,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=820217,FOLIO='F-8',FILE='DISK109:[18ZBU1.18ZBU44601]FM44601A.;10',USER='CHE105614',CD='10-JUN-2018;18:09' -->
<A NAME="page_fm44601_1_9"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Rhythm Pharmaceuticals,&nbsp;Inc. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes to Consolidated Financial Statements (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> (In thousands, except share and per share information) </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. Summary of Significant Accounting Policies (Continued) </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>would
have been on a standalone basis as it was not practicable to make a reasonable estimate. As such, the financial information herein may not necessarily reflect the financial position, results of
operations and cash flows of the Company expected in the future or what it would have been had it been an independent company during the periods presented. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
described above, Relamorelin Company employee costs are allocated to the Company based on a proportional use method. For those employees who became employees of the Company on
November&nbsp;16, 2016, their full employment cost was $2,727 and $3,155 for the years ended December&nbsp;31, 2016 and 2015, respectively. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
September&nbsp;22, 2017, the Company's board of directors approved a 1-for-9.17 reverse stock split of the Company's issued and outstanding shares of common stock. All share and per
share amounts in the financial statements have been retrospectively adjusted for all periods presented to give effect of the reverse stock split. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
October&nbsp;5, 2017, the Company filed an amended and restated certificate of incorporation with the Secretary of State of the State of Delaware to increase its authorized number
of shares of common stock to 120,000,000 shares of common stock, $0.001 par value per share and 10,000,000 shares of preferred stock, $0.001 par value per share. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
October&nbsp;10, 2017 the Company completed its initial public offering ("IPO") of 8,107,500 shares of common stock at an offering price of $17.00 per share, which included the
exercise in full by the underwriters of their option to purchase up to 1,057,500 additional shares of common stock. The Company received gross proceeds of approximately $137,828 or net proceeds of
$125,658 after deducting underwriting discounts, commissions and estimated offering expenses. In connection with the IPO, the Company's outstanding shares of convertible preferred stock were
automatically converted
into 17,406,338&nbsp;shares of common stock. After the IPO and as of December&nbsp;31, 2017, our outstanding common shares were 27,284,140. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Use of Estimates  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and the disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. The
Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. This process may result in
actual results differing materially from those estimated amounts used in the preparation of the financial statements if these results differ from historical experience, or other assumptions do not
turn out to be substantially accurate, even if such assumptions are reasonable when made. Significant estimates relied upon in preparing these financial statements include the allocation of costs from
the Relamorelin Company in accordance with SAB Topic 1B, accrued expenses, stock-based compensation expense, the valuation allowance on the Company's deferred tax assets, and the fair value of the
Series&nbsp;A Investor Instrument. See Note&nbsp;4. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-9</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=237,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=476277,FOLIO='F-9',FILE='DISK109:[18ZBU1.18ZBU44601]FM44601A.;10',USER='CHE105614',CD='10-JUN-2018;18:09' -->
<A NAME="page_fm44601_1_10"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Rhythm Pharmaceuticals,&nbsp;Inc. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes to Consolidated Financial Statements (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> (In thousands, except share and per share information) </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. Summary of Significant Accounting Policies (Continued) </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Principles of Consolidation  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The consolidated financial statements include the accounts of Rhythm Pharmaceuticals,&nbsp;Inc. and its subsidiaries. All significant
intercompany balances and transactions have been eliminated in consolidation. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Off-Balance Sheet Risk and Concentrations of Credit Risk  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial instruments, which potentially subject the Company to significant concentration of credit risk, consist primarily of cash and cash
equivalents and short-term investments, which are maintained at two federally insured financial institutions. The deposits held at these two institutions are in excess of federally insured limits. The
Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions
in which those deposits are held. The Company has no off-balance sheet risk, such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Segment Information  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating segments are defined as components of an entity about which separate discrete information is available for evaluation by the chief
operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating
segment operating exclusively in the United States. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Cash and Cash Equivalents  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company considers all highly liquid investments with original or remaining maturity from the date of purchase of three months or less to be
cash equivalents. Cash and cash equivalents includes bank demand deposits, U.S. treasury bills and money market funds that invest primarily in U.S. government treasuries. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Short-term Investments  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Short-term investments consist of investments with original maturities greater than 90&nbsp;days, as of the date of purchase. The Company has
classified its investments with maturities beyond one year as short term, based on their highly liquid nature and because such marketable securities represent the investment of cash that is available
for current operations. The Company considers its investment portfolio available-for-sale. Accordingly, these investments are recorded at fair value, which is based on quoted market prices. Unrealized
gains and losses are reported as a component of accumulated other comprehensive income (loss) in stockholders' equity (deficit). Realized gains and losses and declines in value judged to be other than
temporary are included as a component of other income (expense), net based on the specific identification method. When determining whether a decline in value is other than temporary, the Company
considers various factors, including whether the Company has the intent to sell the security, and whether it is more likely than not that the Company will be required to sell the security prior to
recovery of its amortized cost basis. Fair value is determined based on quoted market prices. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-10</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=238,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=513349,FOLIO='F-10',FILE='DISK109:[18ZBU1.18ZBU44601]FM44601A.;10',USER='CHE105614',CD='10-JUN-2018;18:09' -->
<A NAME="page_fm44601_1_11"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Rhythm Pharmaceuticals,&nbsp;Inc. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes to Consolidated Financial Statements (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> (In thousands, except share and per share information) </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. Summary of Significant Accounting Policies (Continued) </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Restricted Cash  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restricted cash consists of a security deposit in the form of a letter of credit placed in a separate restricted bank account as required under
the terms of the Company's new lease arrangement for its corporate office in Boston, Massachusetts. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Deferred Issuance Costs  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred issuance costs, which consist of direct incremental legal and accounting fees relating to the IPO, were capitalized and included in
non-current assets. The deferred issuance costs were to be offset against IPO proceeds upon the consummation of the offering. In the event the offering was terminated, deferred issuance costs would be
expensed. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company had capitalized $1,825 of deferred issuance costs related to a prior registration statement confidentially submitted to the Securities and Exchange Commission in 2015 and
2016. In the fourth quarter of 2016, the Company wrote off these deferred issuance costs to general and administrative expenses because the offering was postponed significantly in excess of
90&nbsp;days. As a result, the costs were not deemed realizable as the Company incurred similar costs in connection with its IPO in October 2017. The Company incurred $9 of deferred issuance costs
as of December&nbsp;31, 2016, which is included in non-current assets. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Prepaid Expenses and Other Current Assets  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets consist primarily of costs incurred in advance of services being received, including services related
to clinical trial programs. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="30pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Prepaid research and development costs</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,533</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>422</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other current assets</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,056</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>216 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Prepaid expenses and other current assets</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,589</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>638 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-11</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=239,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=559455,FOLIO='F-11',FILE='DISK109:[18ZBU1.18ZBU44601]FM44601A.;10',USER='CHE105614',CD='10-JUN-2018;18:09' -->
<A NAME="page_fm44601_1_12"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Rhythm Pharmaceuticals,&nbsp;Inc. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes to Consolidated Financial Statements (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> (In thousands, except share and per share information) </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. Summary of Significant Accounting Policies (Continued) </B></FONT></P>


<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Property, Plant and Equipment  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Property, Plant and Equipment consists of the following: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="42pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Useful<BR>
Life </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Leasehold improvements</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>891</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>891</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Office equipment</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5&nbsp;years</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>70</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>70</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Computers and software</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3&nbsp;years</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>19</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>19</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Furniture and fixtures</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5&nbsp;years</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>227</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>94 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,207</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,074</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Less accumulated depreciation and amortization</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(367</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(144</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Property, Plant and Equipment, net</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>840</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>930 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>*</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Shorter
of asset life or lease term.  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


2017 Series&nbsp;A Investor Instrument, 2015 Series&nbsp;A Investor Right/Obligation and 2015
Series&nbsp;A Investor Call Option  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company classified its 2017 Series&nbsp;A Investor Instrument, 2015 Series&nbsp;A Investor Right/Obligation and its 2015 Series&nbsp;A
Investor Call Option (See Notes&nbsp;4 and 5)&nbsp;as a liability as it is a free-standing financial instrument. The 2017 Series&nbsp;A Investor Instrument, the 2015 Series&nbsp;A Investor
Right/Obligation and the 2015 Series&nbsp;A Investor Call Option were recorded at fair value upon the issuance of the Company's series&nbsp;A preferred stock in January 2017 and August 2015,
respectively, and subsequently remeasured to fair value at each reporting period. Changes in fair value of these financial instruments are recognized as a component of other income (expense), net in
the statement of operations and comprehensive loss. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
fair value of the 2017 Series&nbsp;A Investor Instrument is determined to be the sum of the fair values of the 2017 Series&nbsp;A Investor Right/Obligation and the 2017 Investor
Call Option. The Company estimated the fair value of the 2017 and 2015 Series&nbsp;A Investor Right/Obligations as the probability-weighted present value of the expected benefit of the investment. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company used the Black-Scholes option-pricing model, which incorporates assumptions and estimates, to value the 2017 and 2015 Series&nbsp;A Investor Call Options and assessed these
assumptions and estimates on a quarterly basis as additional information impacting the assumptions was obtained. Estimates and assumptions impacting the fair value measurement include the fair value
per share of the underlying series&nbsp;A preferred stock, the expected term of the Series&nbsp;A Investor Call Options, risk-free interest rate, expected dividend yield and expected volatility of
the price of the underlying preferred stock. The Company determined the fair value per share of the underlying preferred stock by taking into consideration the most recent sale of its convertible
preferred stock and the investors' right to invest in a subsequent tranche. As the Company was a private company and lacked company-specific historical and implied volatility information of its stock,
it estimated its expected stock volatility based on the historical volatility of publicly traded peer companies for a term comparable to the estimated term of the Series&nbsp;A </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-12</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=240,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=709726,FOLIO='F-12',FILE='DISK109:[18ZBU1.18ZBU44601]FM44601A.;10',USER='CHE105614',CD='10-JUN-2018;18:09' -->
<A NAME="page_fm44601_1_13"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Rhythm Pharmaceuticals,&nbsp;Inc. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes to Consolidated Financial Statements (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> (In thousands, except share and per share information) </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. Summary of Significant Accounting Policies (Continued) </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>Investor
Call Options. The risk-free interest rate was determined by reference to the U.S. Treasury yield curve for time periods approximately equal to the estimated term of the Series&nbsp;A
Investor Call Options. A dividend yield of zero was assumed. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Government Grants  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company obtained an Orphan Products Development grant entitled "Phase&nbsp;2 study of the melanocortin 4 receptor agonist RM-493 for the
treatment of Prader-Willi syndrome" in 36 patients. The grant was awarded by the Public Health Service ("PHS") Food and Drug Administration. The PHS grant is for a total of $999 and is effective July
2015 through June 2018 for reimbursement of expenses relating to the Phase&nbsp;2 Prader-Willi Study. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company recognizes government grants upon the determination that it will comply with the conditions attached to the grant arrangement and the grant will be received. Government
grants are recognized in the statements of operations on a systematic basis over the periods in which the Company recognizes the related costs for which the government grant is intended to compensate.
Government grants for research and development efforts are deducted in reporting the related expense in the statement of operations. Government grant income received during the year ended
December&nbsp;31, 2017, 2016 and 2015 of zero, $642 and $147, respectively, and is included as a deduction to research and development expense in the consolidated statements of operations. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Research and Development Expenses  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Costs incurred in the research and development of the Company's products are expensed to operations as incurred. Research and development
expenses consist of costs incurred in performing research and development activities, including salaries and benefits, facilities costs, overhead costs, contract services and other outside costs, both
directly incurred and allocated from the Relamorelin Company. The value of goods and services received from contract research organizations or contract manufacturing organizations in the reporting
period are estimated based on the level of services performed and progress in the period for which the Company has not yet received an invoice from the supplier. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Nonrefundable
advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses, and expensed as the
related goods are delivered or the services are performed. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Income Taxes  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company is taxed as a C corporation for federal income tax purposes. Income taxes for the Company are recorded in accordance with FASB ASC
Topic 740, </FONT><FONT SIZE=2><I>Income Taxes</I></FONT><FONT SIZE=2> ("ASC 740"), which provides for deferred taxes using an asset and liability approach. Income taxes have been calculated on a
separate tax return basis. Certain of the Company's activities and costs have been included in the tax returns filed by the Relamorelin Company and the&nbsp;LLC entity. Prior to the Corporate
Reorganization, the Company's operations were included in the tax returns filed by the Predecessor Company. The Company has filed tax returns on its own behalf since the Corporate Reorganization. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences
of events that </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-13</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=241,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=898107,FOLIO='F-13',FILE='DISK109:[18ZBU1.18ZBU44601]FM44601A.;10',USER='CHE105614',CD='10-JUN-2018;18:09' -->
<A NAME="page_fm44601_1_14"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Rhythm Pharmaceuticals,&nbsp;Inc. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes to Consolidated Financial Statements (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> (In thousands, except share and per share information) </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. Summary of Significant Accounting Policies (Continued) </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>have
been included in the financial statements. Under this method, the Company determined deferred tax assets and liabilities on the basis of the differences between the financial statement and tax
bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and
liabilities is recognized in income in the period that includes the enactment date. The Company recognized deferred tax assets to the extent that it believes that these assets are more likely than not
to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected
future taxable income, tax-planning strategies, and results of recent operations. If the Company determines that it would be able to realize our deferred tax assets in the future in excess of their
net recorded amount, it would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company records uncertain tax positions in accordance with ASC 740 on the basis of a two-step process in which (1)&nbsp;it determines whether it is more likely than not that the
tax positions will be sustained on the basis of the technical merits of the position and (2)&nbsp;for those tax positions that meet the more-likely-than-not recognition threshold, the Company
recognizes the largest amount of tax benefit that is more than 50&nbsp;percent likely to be realized upon ultimate settlement with the related tax authority. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying consolidated statement of operations. As of
December&nbsp;31, 2017, no accrued interest or penalties are included on the related tax liability line in the consolidated balance sheet. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Net Loss Per Share Attributable to Common Shareholders  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic net loss per share attributable to common stockholders is calculated by dividing net loss attributable to common stockholders by the
weighted average shares outstanding during the period, without consideration for Common Stock equivalents. Net loss attributable to common stockholders is calculated by adjusting the net loss of the
Company for cumulative preferred stock dividends. During periods of income, the Company allocates participating securities a proportional share of income determined by dividing total weighted average
participating securities by the sum of the total weighted average common shares and participating securities (the "two class method"). The Company's convertible preferred stock participates in any
dividends declared by the Company and are therefore considered to be participating securities. Participating securities have the effect of diluting both basic and diluted earnings per share during
periods of income. During periods of loss, the Company allocates no loss to participating securities because they have no contractual obligation to share in the losses of the Company. Diluted net loss
per share attributable to common stockholders is calculated by adjusting weighted average shares outstanding for the dilutive effect of Common Stock equivalents outstanding for the period, determined
using the treasury-stock and if-converted methods. For purposes of the diluted net loss per share attributable to common stockholders calculation, convertible preferred stock and stock options are
considered to be Common Stock equivalents but have been excluded from the calculation of diluted net loss per share attributable to common stockholders, as their effect would be anti-dilutive for all
periods presented. Therefore, basic and diluted net loss per share were the same for all periods presented. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-14</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=242,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=959955,FOLIO='F-14',FILE='DISK109:[18ZBU1.18ZBU44601]FM44601A.;10',USER='CHE105614',CD='10-JUN-2018;18:09' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_fo44601_1_15"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Rhythm Pharmaceuticals,&nbsp;Inc.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes to Consolidated Financial Statements (Continued)  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> (In thousands, except share and per share information)  </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. Summary of Significant Accounting Policies (Continued)  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic and diluted earnings per share is calculated as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Numerator:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(33,709</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(25,872</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(11,073</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cumulative dividends on convertible preferred shares</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(3,873</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(3,202</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(927</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Loss attributable to common shares&#151;basic and diluted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(37,582</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(29,074</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(12,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Denominator:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Weighted-average number of common shares&#151;basic and diluted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>13,267,960</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10,196,292</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10,196,292 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Loss per common share&#151;basic and diluted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(2.83</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(2.85</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1.18</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Patent Costs  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Costs to secure and defend patents are expensed as incurred and are classified as general and administrative expenses. Patent costs were $180,
$231 and $280 for the years ended December&nbsp;31, 2017, 2016 and 2015, respectively. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Subsequent Events  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the financial statements to
provide additional evidence for certain estimates or to identify matters that require additional disclosure. Subsequent events have been evaluated as required. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Application of New or Revised Accounting Standards  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From time to time, new accounting pronouncements are issued by the FASB and adopted by the Company as of the specified effective date. Unless
otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations
upon adoption. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
April 2012, the Jump-Start Our Business Startups Act (the "JOBS Act") was signed into law. The JOBS Act contains provisions that, among other things, reduce certain reporting
requirements for an "emerging growth company." As an emerging growth company, the Company elected to not take advantage of the extended transition period afforded by the JOBS Act for the
implementation of new or revised accounting standards, and as a result, will comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for
non-emerging growth companies. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). ASU 2016-02 requires lessees to recognize lease assets and lease liabilities for those leases classified as operating
leases under previous GAAP. A lessee should recognize in the statement of financial position a liability to make lease payments </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-15</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=243,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=546473,FOLIO='F-15',FILE='DISK109:[18ZBU1.18ZBU44601]FO44601A.;14',USER='CHE105614',CD='10-JUN-2018;18:09' -->
<A NAME="page_fo44601_1_16"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Rhythm Pharmaceuticals,&nbsp;Inc. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes to Consolidated Financial Statements (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> (In thousands, except share and per share information) </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. Summary of Significant Accounting Policies (Continued) </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>(the
lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. For leases with a term of 12&nbsp;months or less, a lessee is permitted to make
an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. The
recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee have not significantly changed from previous GAAP. There continues to be a differentiation
between finance leases and operating leases. ASU 2016-02 is effective for fiscal years beginning after December&nbsp;15, 2018, and interim periods within those fiscal years, and early adoption is
permitted. The Company is currently in the process of evaluating the impact of adoption of ASU No.&nbsp;2016-02 on its financial position and results of operations. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
March 2016, the FASB issued ASU 2016-09, </FONT><FONT SIZE=2><I>Improvements to Employee Share-Based Payment Accounting (Topic 718)</I></FONT><FONT SIZE=2> that changes the
accounting for certain aspects of share-based payments to employees. The guidance requires the recognition of the income tax effects of awards in the income statement when the awards vest or are
settled, thus eliminating additional paid in capital pools. The guidance also allows for the employer to repurchase more of an employee's shares for tax withholding purposes without triggering
liability accounting. In addition, the guidance allows for a policy election to account for forfeitures as they occur rather than on an estimated basis. The guidance is effective for annual periods
beginning after December&nbsp;15, 2016, and interim periods within those annual periods with early adoption permitted. Accordingly, the standard is effective for the Company on January&nbsp;1,
2018. The Company adopted the standard as of January&nbsp;1, 2017. The adoption did not have a material impact on the Company's financial position, results of operations or cash flows. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
May 2017, the FASB issued ASU 2017-09, Compensation&#151;Stock Compensation (Topic 718): Scope of Modification Accounting, ("ASU 2017-09"). ASU 2017-09 provides clarity and
reduces both (1)&nbsp;diversity in practice and (2)&nbsp;cost and complexity when applying the guidance in Topic 718, to a change to the terms or conditions of a share-based payment award. The
amendments in ASU 2017-09 should be applied prospectively to an award modified on or after the adoption date. This ASU is effective for fiscal years, and interim periods within those years, beginning
after December&nbsp;15, 2017. The adoption of this ASU is not expected to have a material impact on the Company's financial position or results of operations. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives and Hedging (Topic 815): I. Accounting for
Certain Financial Instruments with Down Round Features; II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain
Mandatorily Redeemable Noncontrolling Interests with a Scope Exception, ('ASU 2017-11'). Part&nbsp;I of this update addresses the complexity of accounting for certain financial instruments with down
round features. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced on the basis of the pricing of future equity
offerings. Current accounting guidance creates cost and complexity for entities that issue financial instruments (such as warrants and convertible instruments) with down round features that require
fair value measurement of the entire instrument or conversion option. Part&nbsp;II of this update addresses the difficulty of navigating Topic 480, Distinguishing Liabilities from Equity, because of
the existence of extensive pending content in the FASB Accounting Standards Codification. This pending content is the result of the indefinite deferral of accounting requirements about mandatorily
redeemable financial instruments of certain nonpublic entities and certain mandatorily redeemable noncontrolling interests. The amendments in Part&nbsp;II of this update do not have an </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-16</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=244,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=857068,FOLIO='F-16',FILE='DISK109:[18ZBU1.18ZBU44601]FO44601A.;14',USER='CHE105614',CD='10-JUN-2018;18:09' -->
<A NAME="page_fo44601_1_17"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Rhythm Pharmaceuticals,&nbsp;Inc. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes to Consolidated Financial Statements (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> (In thousands, except share and per share information) </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. Summary of Significant Accounting Policies (Continued) </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>accounting
effect. This ASU is effective for fiscal years, and interim periods within those years, beginning after December&nbsp;15, 2018. The Company is currently assessing the potential impact of
adopting ASU 2017-11 on its financial statements and related disclosures. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


3. Accrued Expenses  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses consisted of the following: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31,<BR>
2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31,<BR>
2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development costs</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,771</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,049</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Professional fees</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>327</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>182</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Payroll related</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,094</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>344</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>18</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>80 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,210</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,655 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


4. Fair Value of Financial Assets and Liability  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of December&nbsp;31, 2017 and 2016, the carrying amount of cash and cash equivalents and short-term investments was $148,082 and $10,537, respectively, which approximates fair
value. Cash and cash equivalents and short-term investments includes investments in money market funds that invest in U.S. government securities that are valued using quoted market prices.
Accordingly, money market funds and government funds are categorized as Level&nbsp;1 and had a total balance of $34,698 and $7,984 as of December&nbsp;31, 2017 and 2016, respectively. The
financial assets valued based on level&nbsp;2 inputs consist of corporate debt securities, which consist of investments in highly-rated investment-grade corporations. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
financial liability was recognized by the Company during the year ending December&nbsp;31, 2017 related to the 2017 Series&nbsp;A Investor Instrument. The liability was valued
based on significant inputs not observable in the market, which represents a Level&nbsp;3 measurement within the fair value hierarchy. Upon the closing of the second tranche of the 2017
Series&nbsp;A preferred financing in August 2017, this liability was settled. For the year ended December&nbsp;31, 2016, the Company had no financial liability outstanding measured at fair value.
The Company recognized a financial liability during 2015 related to its 2015 Series&nbsp;A Investor Right/Obligation and 2015 Series&nbsp;A Investor Call Option that was exercised or expired,
respectively, in December 2015. The liability was based on significant inputs not observable in the market, which represents a Level&nbsp;3 measurement within the fair value hierarchy. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-17</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=245,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=82927,FOLIO='F-17',FILE='DISK109:[18ZBU1.18ZBU44601]FO44601A.;14',USER='CHE105614',CD='10-JUN-2018;18:09' -->
<A NAME="page_fo44601_1_18"> </A>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Rhythm Pharmaceuticals,&nbsp;Inc. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes to Consolidated Financial Statements (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> (In thousands, except share and per share information) </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


4. Fair Value of Financial Assets and Liability (Continued) </B></FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following tables present information about the Company's financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value
hierarchy utilized to determine such fair values: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="36pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Fair value Measurements as of<BR>
December&nbsp;31, 2017 using: </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Level&nbsp;1 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Level&nbsp;2 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Level&nbsp;3 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Assets:</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash Equivalents:</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Corporate Debt Securities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>15,104</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>15,104</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Money Market Funds</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>17,753</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>17,753</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Marketable Securities:</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Corporate Debt Securities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>96,901</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>96,901</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>U.S. Treasury Securities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>16,945</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>16,945 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>34,698</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>112,005</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>146,703 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Liabilities:</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2017 Series&nbsp;A Investor Instrument</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;<BR></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="36pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="36pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Fair value Measurements as of<BR>
December&nbsp;31, 2016 using: </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Level&nbsp;1 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Level&nbsp;2 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Level&nbsp;3 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Assets:</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash Equivalents:</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Government Funds</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Money Market Funds</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,987</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,987</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Marketable Securities:</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Government Funds</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,997</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,997 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7,984</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7,984 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Marketable Securities  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following tables summarize the Company's marketable securities: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31, 2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Amortized<BR>
Cost </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Gross<BR>
Unrealized<BR>
Gains </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Gross<BR>
Unrealized<BR>
Losses </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Fair Value </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Assets</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Corporate Debt Securities (due within 1&nbsp;year)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>97,029</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(128</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>96,901</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>U.S. Treasury Securities (due within 1&nbsp;year)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>16,958</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(13</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>16,945 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>113,987</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(141</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>113,846 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-18</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=246,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=789844,FOLIO='F-18',FILE='DISK109:[18ZBU1.18ZBU44601]FO44601A.;14',USER='CHE105614',CD='10-JUN-2018;18:09' -->
<A NAME="page_fo44601_1_19"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Rhythm Pharmaceuticals,&nbsp;Inc. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes to Consolidated Financial Statements (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> (In thousands, except share and per share information) </B></FONT></P>


<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


4. Fair Value of Financial Assets and Liability (Continued) </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><BR></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="49pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="49pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31, 2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Amortized<BR>
Cost </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Gross<BR>
Unrealized<BR>
Gains </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Gross<BR>
Unrealized<BR>
Losses </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Fair Value </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Assets</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Government Funds (due within 1&nbsp;year)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,997</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,997 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,997</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,997 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Below
is a roll forward of the fair value of the financial liability, the 2017 Series&nbsp;A Investor Instrument for the year ended December&nbsp;31, 2017: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="93pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 Series&nbsp;A<BR>
Investor Instrument </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Fair value at December&nbsp;31, 2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Fair value upon the January 2017 Initial Closing, net</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>328</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Change in fair value through the date of settlement</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,863</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Reclassification of liability upon August 2017 Second Tranche Closing</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(2,191</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Fair value at December&nbsp;31, 2017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
fair value of the Series&nbsp;A Investor Instrument is the sum of the probability-weighted fair value of the 2017 Investor Right/Obligation and the 2017 Series&nbsp;A Call
Option. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following assumptions and inputs were used in determining the fair value of the 2017 Series&nbsp;A Investor Call Option valued using the Black- Scholes option pricing model: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="111pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>August 2017<BR>
Second Tranche Closing </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Series&nbsp;A Convertible Preferred Stock Exercise Price</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.00</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Series&nbsp;A Convertible Preferred Stock Fair Value</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.33</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected term</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.5&nbsp;months</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected volatility</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>64.0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected interest rate</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.95</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected dividend yield</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company estimated the fair value of the 2017 Series&nbsp;A Investor Right/Obligation as the probability-weighted present value of the expected benefit of the investment. The
expected benefit is the difference between the expected future value of shares issued upon the second tranche closing and the investment price for the second tranche closing. The expected future value
is estimated as a weighted average of IPO and remain private scenarios, and the future value is converted to a present value assuming a closing date of August&nbsp;15, 2017 and a nominal, risk-free
discount rate. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-19</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=247,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=490061,FOLIO='F-19',FILE='DISK109:[18ZBU1.18ZBU44601]FO44601A.;14',USER='CHE105614',CD='10-JUN-2018;18:09' -->
<A NAME="page_fo44601_1_20"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Rhythm Pharmaceuticals,&nbsp;Inc. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes to Consolidated Financial Statements (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> (In thousands, except share and per share information) </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


4. Fair Value of Financial Assets and Liability (Continued) </B></FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Below
is a roll forward of the fair value of financial liabilities for the year ended December&nbsp;31, 2015: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="86pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 Series&nbsp;A<BR>
Investor<BR>
Right/Obligation<BR>
And 2015 Series&nbsp;A<BR>
Investor Call<BR>
Option </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Fair value at December&nbsp;31, 2014</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Fair value upon the August 2015 Initial Closing</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Change in fair value through the date of settlement</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Reclassification of liability upon December 2015 Second Tranche closing</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Fair value at December&nbsp;31, 2015</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following assumptions and inputs were used in determining the fair value of the 2015 Series&nbsp;A Investor Call Option valued using the Black- Scholes option pricing model: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="107pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>August 2015<BR>
Initial Tranche Closing </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Series&nbsp;A Convertible Preferred Stock Exercise Price</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.00</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Series&nbsp;A Convertible Preferred Stock Fair Value</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.81</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected term</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2&nbsp;months</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected volatility</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>24.0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected interest rate</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.08</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected dividend yield</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
2015 Series&nbsp;A Investor Call Option expired upon the Second Tranche Closing in December 2015. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company estimated the fair value of the 2015 Series&nbsp;A Investor Right/Obligation as the probability-weighted present value of the expected benefit of the investment. The
expected benefit is the difference between the expected future value of shares issued upon the second tranche closing and the investment price for the second tranche closing. The expected future value
as of the August 2015 Initial Tranche Closing was estimated through a backsolve calculation which assumes a 70&nbsp;percent probability of closing, a discount rate of 0.08% and a second tranche
closing date of November&nbsp;30, 2015. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company performed a contemporaneous valuation of the 2015 Series&nbsp;A Investor Right/Obligation to invest in the second tranche of our series&nbsp;A preferred stock financing.
This valuation coincided with the 2015 Series&nbsp;A Second Tranche Closing on December&nbsp;1, 2015. The Company valued the 2015 Series&nbsp;A Investor Right/Obligation as the benefit
associated with the second tranche investment. The benefit is a function of the difference between the fair value of the series&nbsp;A shares and the 2015 Series&nbsp;A Investor Right/Obligation
exercise price on the date of closing and the number of shares acquired. The Company estimated the fair value of the 2015 Series&nbsp;A Investor Right/Obligation as the probability weighted average
of two scenarios: an IPO and a remain-private scenario. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-20</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=248,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=125887,FOLIO='F-20',FILE='DISK109:[18ZBU1.18ZBU44601]FO44601A.;14',USER='CHE105614',CD='10-JUN-2018;18:09' -->
<A NAME="page_fo44601_1_21"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Rhythm Pharmaceuticals,&nbsp;Inc. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes to Consolidated Financial Statements (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> (In thousands, except share and per share information) </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


5. Preferred Stock  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In August 2015, pursuant to the Series&nbsp;A Preferred Stock Purchase Agreement, by and among the Company and certain purchasers, and as part of an initial tranche closing, the
Company issued 25,000,000 shares of Series&nbsp;A Convertible Preferred Stock, par value $0.001 per share, at a purchase price of $1.00 per share, resulting in net proceeds of $24,976 to the Company
(the "August 2015 Initial Tranche Closing"). The Series&nbsp;A Preferred Stock Purchase Agreement provided for the delayed issuance of up to an additional 15,000,000 shares of Series&nbsp;A
Convertible Preferred Stock as part of a Second Tranche Closing. The delayed issuance was to be automatically settled upon the achievement of a specific milestone, resulting in the issuance of shares
of Series&nbsp;A Convertible Preferred Stock (the "2015 Series&nbsp;A Investor Right/Obligation"). The 2015 Series&nbsp;A Investor Call Option would become exercisable in the event that a Second
Tranche Closing was not been consummated. Both the 2015 Series&nbsp;A Investor Right/Obligation and the 2015 Series&nbsp;A Investor Call Option were evaluated and determined to be free standing
instruments and were being accounted as liabilities (see Note&nbsp;2). In December 2015, the specific milestones were met and 15,000,000 shares of Series&nbsp;A Convertible Preferred Stock were
issued at a purchase price of $1.00 per share for net proceeds of $14,641. The 2015 Series&nbsp;A Investor Call Option expired unexercised at that time. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
January 2017, pursuant to the Series&nbsp;A preferred stock purchase agreement, by and among the Company and certain purchasers, and as part of an initial tranche closing, the
Company issued 20,475,001 shares of Series&nbsp;A convertible preferred stock, par value $0.001 per share, at a purchase price of $1.00 per share, resulting in net proceeds of $20,377 to the Company
(the "January 2017 Initial Tranche Closing"). The Series&nbsp;A preferred stock purchase agreement provided for the delayed issuance by the Company of up to an additional 20,474,998 shares of
Series&nbsp;A convertible preferred stock as part of a second tranche closing at a purchase price of $1.00 per share (the "2017 Series&nbsp;A Investor Right/Obligation"). The second tranche is
contingent upon: (1)&nbsp;the Company's cash, cash equivalents and short-term investments balance, net of accounts payable and accrued liabilities, falling below $5.0&nbsp;million and
(2)&nbsp;the Company's satisfaction of contractual and customary representations and warranties. Unless otherwise mutually agreed upon in writing, the rights and obligations underlying the second
tranche (if not previously executed) will terminate on the first to occur of the following dates: (1)&nbsp;the date (the "Roadshow Acceleration Date") on which the Company files with the U.S.
Securities and Exchange Commission, or SEC, the last pre-effective amendment to the registration statement prior to the start of the Company's roadshow in connection with the IPO, provided, that such
termination shall be contingent upon the consummation of the IPO pursuant to the same registration statement that was on file with the SEC on the Roadshow Acceleration Date, without withdrawal
thereof or filing of a subsequent registration statement in replacement thereof; and (2)&nbsp;the date of the consummation of a Deemed Liquidation Event (as defined below). To the extent the closing
of the second tranche has not already taken place, the investors in the first tranche also have a call right on the shares underlying the second tranche whereby such shares can be purchased for the
same price as the second tranche (the "2017 Series&nbsp;A Investor Call Option"). The 2017 Series&nbsp;A Investor Call Option terminates upon the Roadshow Acceleration Date. The 2017
Series&nbsp;A Investor Right/Obligation and the 2017 Series&nbsp;A Investor Call Option have been evaluated and determined to be a free standing instrument, the 2017 Series&nbsp;A Investor
Instrument. The 2017 Series&nbsp;A Investor Instrument was accounted for as a liability (see Note&nbsp;2). </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
August 2017, the Series&nbsp;A Investors waived the $5.0&nbsp;million cash balance requirement of the Series&nbsp;A Investor Right/Obligation and closed the second tranche of
the series&nbsp;A preferred stock financing. The Company issued 20,474,998 shares of Series&nbsp;A convertible preferred stock, par value $0.001 per share, </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-21</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=249,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=463361,FOLIO='F-21',FILE='DISK109:[18ZBU1.18ZBU44601]FO44601A.;14',USER='CHE105614',CD='10-JUN-2018;18:09' -->
<A NAME="page_fo44601_1_22"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Rhythm Pharmaceuticals,&nbsp;Inc. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes to Consolidated Financial Statements (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> (In thousands, except share and per share information) </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


5. Preferred Stock (Continued) </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>at
a purchase price of $1.00 per share, resulting in gross proceeds of $20,475 to the Company. The 2017 Series&nbsp;A Investor Call Option expired unexercised at that time. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
the closing of the IPO, the Series&nbsp;A convertible preferred stock automatically converted into shares of common stock on a 9.17-for-1 basis. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
holders of the Series&nbsp;A convertible preferred stock had the following rights and preferences: </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Voting Rights  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The holders of Series&nbsp;A convertible preferred stock are entitled to vote, together with the holders of common stock, on all matters
submitted to stockholders for a vote. Each preferred stockholder is entitled to the number of votes equal to the number of shares of common stock into which each preferred share is convertible at the
time of such vote. In addition, pursuant to the Company's charter, the holders of record of the outstanding shares of Series&nbsp;A convertible preferred stock are entitled to elect one director to
serve as the Series&nbsp;A preferred director on the board of directors of the Company. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Dividends  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The holders of Series&nbsp;A convertible preferred stock are entitled to receive dividends in preference to any dividend on common stock at
the rate of 8.0% per year of the original issue price. Dividends shall accrue annually, whether or not declared, and shall be cumulative. The Company may not declare, pay or set aside any dividends on
shares of any other class or series of capital stock of the Company unless the holders of Series&nbsp;A convertible preferred stock then outstanding shall first receive, or simultaneously receive,
dividends on each outstanding share of Series&nbsp;A convertible preferred stock. Through December&nbsp;31, 2017, no dividends had been declared or paid by the Company. Accrued dividends, whether
or not declared, shall also be payable upon any liquidation event. At December&nbsp;31, 2017 and December&nbsp;31, 2016, cumulative preference dividends amounted to zero, or $0.00 per share and
$4,129, or $0.10 per share, respectively. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Liquidation  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the event of any liquidation, dissolution or winding-up of the Company or a Deemed Liquidation Event (as defined below), the holders of
Series&nbsp;A convertible preferred stock then outstanding shall be entitled to be paid out of the assets of the Company available for distribution to stockholders, and before any payment shall be
made to holders of common stock, an amount per share equal to greater of (i)&nbsp;the original issue price per share, plus any accrued but unpaid dividends thereon, whether or not declared, plus any
declared but unpaid dividends thereon, if any, or (ii)&nbsp;such amount per share as would have been payable had all shares of Series&nbsp;A convertible preferred stock been converted to common
stock prior to such liquidation. If upon such event, the assets of the Company available for distribution are insufficient to permit payment in full to the holders of Series&nbsp;A convertible
preferred stock, the proceeds will be ratably distributed among the holders of Series&nbsp;A convertible preferred stock in proportion to the respective amounts that they would have received if they
were paid in full. After payments have been made in full to the holders of Series&nbsp;A convertible preferred stock, the remaining assets of the Company available for distribution will be
distributed among the holders of Series&nbsp;A convertible preferred stock, the holders of the Series&nbsp;A-1 convertible junior preferred stock, and the holders of common stock as if the shares
of </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-22</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=250,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=76191,FOLIO='F-22',FILE='DISK109:[18ZBU1.18ZBU44601]FO44601A.;14',USER='CHE105614',CD='10-JUN-2018;18:09' -->
<A NAME="page_fo44601_1_23"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Rhythm Pharmaceuticals,&nbsp;Inc. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes to Consolidated Financial Statements (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> (In thousands, except share and per share information) </B></FONT></P>


<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


5. Preferred Stock (Continued) </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>Series&nbsp;A
convertible preferred stock and Series&nbsp;A-1 convertible junior preferred stock were converted to common stock immediately prior to the liquidation event. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
merger, acquisition, sale of voting control or other transaction of the Company in which the stockholders of the Company do not own a majority of the outstanding shares of the
surviving company shall be considered a Deemed Liquidation Event. A sale, exclusive license, transfer or other disposition of all or substantially all of the assets of the Company shall also be
considered a Deemed Liquidation Event. Each share of Series&nbsp;A convertible preferred stock may be redeemed at the option of the holder upon the occurrence of a deemed liquidation event. As of
December&nbsp;31, 2017 and December&nbsp;31, 2016, the liquidation preference of the outstanding shares of Series&nbsp;A convertible preferred stock was approximately zero and $44,129,
respectively. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Conversion  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each share of Series&nbsp;A convertible preferred stock is convertible into common stock at the option of the stockholder at any time after
the date of issuance. In addition, each share of Series&nbsp;A convertible preferred stock will be automatically converted into shares of common stock, at the applicable conversion ratio then in
effect, upon the earlier of (i)&nbsp;a qualified public offering with gross proceeds of at least $50,000 and a price of not less than $1.00 per share, subject to appropriate adjustment for any stock
dividend, stock split, combination or other similar recapitalization, and (ii)&nbsp;the date specified by vote or written consent of the holders of at least two-thirds of the then outstanding shares
of series&nbsp;A preferred stock. The shares of Series&nbsp;A convertible preferred stock will be converted to common stock, at par value, with the remainder recorded to additional paid-in
capital. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
conversion ratio of the Series&nbsp;A convertible preferred stock is determined by dividing the original issue price per share by the conversion price of $9.17 per share, subject
to appropriate adjustment in the event of any stock dividend, stock split, combination or recapitalization affecting the Series&nbsp;A convertible preferred stock. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
October&nbsp;10, 2017 the Company completed its IPO and in connection with the IPO, the Company's outstanding shares of Series&nbsp;A convertible preferred stock and
Series&nbsp;A-1 convertible junior preferred stock were automatically converted into 17,406,338 shares of common stock. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


6. Common Stock  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In March 2013, the Company issued 10,196,292 shares of common stock at a purchase price of $0.001 per share. As of December&nbsp;31, 2016, the&nbsp;LLC entity owned all of these
shares. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
August&nbsp;21, 2017, the&nbsp;LLC entity exchanged 8,578,646 of its shares of the Company's common stock for 78,666,209 shares of the Company's series&nbsp;A-1 junior preferred
stock and the&nbsp;LLC entity distributed all of its shares of the Company's series&nbsp;A-1 junior preferred stock to the holders of its preferred units and the remaining 1,617,646 shares of its
common stock to the holders of its common units. Following this distribution, the&nbsp;LLC entity no longer owned any of the Company's shares. The series&nbsp;A-1 junior preferred stock is not
redeemable and does not have a stated dividend or liquidation preference. These shares converted to common stock on a 9.17-to-1 basis upon the closing of the IPO in October 2017. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-23</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=251,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=193537,FOLIO='F-23',FILE='DISK109:[18ZBU1.18ZBU44601]FO44601A.;14',USER='CHE105614',CD='10-JUN-2018;18:09' -->
<A NAME="page_fo44601_1_24"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Rhythm Pharmaceuticals,&nbsp;Inc. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes to Consolidated Financial Statements (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> (In thousands, except share and per share information) </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


6. Common Stock (Continued) </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
September 2017, the Company's board of directors approved a 1-for-9.17 reverse stock split of the Company's issued and outstanding shares of common stock. All shares and per share
amounts in the financial statements have been retrospectively adjusted for all periods presented to give effect of the reverse stock split. </FONT></P>


<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


7. Stock-based Compensation  </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


2017 Stock Incentive Plan  </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


2017 Plan Overview  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior to August 2015, we did not have our own equity compensation plan. In August 2015, our Board of Directors and our stockholders approved and
we adopted the 2015 equity incentive plan, as amended and in effect prior to the closing of our IPO, or the 2015 Plan, which we terminated upon consummation of our IPO and replaced with the 2017
equity incentive plan, or the 2017 Plan. The 2017 Plan provides for the grant of incentive and non-qualified stock options and restricted stock awards to employees, consultants, advisors and
directors, as determined by the board of directors. The Company reserved 4,018,538 shares of common stock to be issued under the Plan. The number of shares authorized under the 2017 Plan will be
increased each January&nbsp;1, commencing on January&nbsp;1, 2018 and ending on (and including) January&nbsp;1, 2027, by an amount equal to 4% of the outstanding shares of stock outstanding as
of the end of the immediately precedeing fiscal year. Notwithstanding the foregoing, our board of directors may act prior to January&nbsp;1 for a given year to provide that there will be no such
January&nbsp;1 increase in the number of shares authorized under the 2017 Plan for such year, or that the increase in the number of shares authorized under the 2017 Plan for such year will be a
lesser number than would otherwise occur pursuant to the preceding sentence. Shares of common stock issued upon exercise of stock options are generally issued from new shares of the Company. The Plan
provides that the exercise price of incentive stock options cannot be less than
100% of the fair market value of the common stock on the date of the award for participants who own less than 10% of the total combined voting power of stock of the Company, and not less than 110% for
participants who own more than 10% of the Company's voting power. Options and restricted stock granted under the Plan will vest over periods as determined by the Company's board of directors. For
options granted to date, the exercise price equaled the fair value of the common stock as determined by the board of directors on the date of grant. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company estimates the fair value of stock-based awards to employees and non-employees using the Black-Scholes option-pricing model, which requires the input of highly subjective
assumptions, including (a)&nbsp;the expected volatility of the underlying common stock, (b)&nbsp;the expected term of the award, (c)&nbsp;the risk-free interest rate, and (d)&nbsp;expected
dividends. Due to the lack of a public market for the trading of its common stock and a lack of company-specific historical and implied volatility data, the Company based its estimate of expected
volatility on the historical volatility of a group of companies in the pharmaceutical and biotechnology industries in a similar stage of development as the Company that are publicly traded. For these
analyses, the Company selected companies with comparable characteristics to its own including enterprise value, risk profiles and with historical share price information sufficient to meet the
expected life of the stock-based awards. The Company computes the historical volatility data using the daily closing prices for the selected companies' shares during the equivalent period of the
calculated expected term of its stock-based awards. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price
becomes available. The </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-24</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=252,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=988335,FOLIO='F-24',FILE='DISK109:[18ZBU1.18ZBU44601]FO44601A.;14',USER='CHE105614',CD='10-JUN-2018;18:09' -->
<A NAME="page_fo44601_1_25"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Rhythm Pharmaceuticals,&nbsp;Inc. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes to Consolidated Financial Statements (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> (In thousands, except share and per share information) </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


7. Stock-based Compensation (Continued) </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>Company
estimated the expected life of its employee stock options using the "simplified" method, whereby, the expected life equals the average of the vesting term and the original contractual term of
the option. The risk-free interest rates for periods within the expected life of the option are based on the U.S. Treasury yield curve in effect during the period the options were granted. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company was historically required to estimate forfeitures at the time of grant, and revise those estimates in subsequent periods if actual forfeitures differ from estimates. The
Company used historical data to estimate pre-vesting option forfeitures and record stock-based compensation expense only for those awards that are expected to vest. To the extent that actual
forfeitures differ from its estimates, the difference was recorded as a cumulative adjustment in the period the estimates were revised. Stock-based compensation expense recognized in the financial
statements is based on awards that are ultimately expected to vest. Upon adopting ASU 2016-09 on January&nbsp;1, 2017, the Company elected to account for forfeitures as they occur. The adoption did
not have a material impact on the Company's financial position, results of operations or cash flows. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
grant date fair value of awards subject to service-based vesting, net of estimated forfeitures, is recognized ratably over the requisite service period, which is generally the
vesting period of the respective awards. The Company's stock option awards typically vest over a service period that ranges
from three to four years and includes awards with one year cliff vesting followed by ratable monthly and quarterly vesting thereafter and ratable monthly vesting beginning on the grant date. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
unvested portion of stock options granted to non-employees are subject to remeasurement at subsequent reporting periods. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
the years ended December&nbsp;31, 2017, 2016 and 2015, the Company granted 1,112,717, 164,229 and 900,167 common stock option awards to certain directors, employees and
non-employees, respectively. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Using
the Black-Scholes option pricing model, the weighted average grant date fair value of options granted to employees and directors during the year ended December&nbsp;31, 2017 was
$4.98. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
fair value of share options granted to employees and directors was estimated at the date of grant using the Black-Scholes option pricing model with the following weighted-average
assumptions: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="32pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="32pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="32pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year ended<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Risk- free interest rate</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.97</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.39</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.84</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected term (in years)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5.95</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6.25</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5.93</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected volatility</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>66.18</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>74.20</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>66.50</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected dividend yield</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Using
the Black-Scholes option pricing model, the weighted average grant date fair value of options granted to non-employees during the year ended December&nbsp;31, 2017 was $5.25. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-25</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=253,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=295071,FOLIO='F-25',FILE='DISK109:[18ZBU1.18ZBU44601]FO44601A.;14',USER='CHE105614',CD='10-JUN-2018;18:09' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_fq44601_1_26"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Rhythm Pharmaceuticals,&nbsp;Inc.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes to Consolidated Financial Statements (Continued)  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> (In thousands, except share and per share information)  </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


7. Stock-based Compensation (Continued)  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The fair value of share options granted to non-employees was estimated at the date of grant using the Black-Scholes option pricing model with the following weighted-average assumptions: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="32pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="32pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="32pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year ended<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Risk- free interest rate</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2.27</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.58</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2.25</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected term (in years)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10.00</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10.00</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>10.00</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected volatility</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>74.91</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>71.18</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>75.70</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected dividend yield</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
summary of the Company's common stock option activity for the year ended December&nbsp;31, 2017 is as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="56pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="47pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Options </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Weighted<BR>
Average<BR>
Exercise<BR>
Price </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Weighted-<BR>
Average<BR>
Remaining<BR>
Contractual<BR>
Term </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Aggregate<BR>
Intrinsic<BR>
Value </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Outstanding as of December&nbsp;31, 2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,064,396</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5.32</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9.02</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Granted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,112,717</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8.22</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Exercised</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(152,671</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4.59</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>588</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cancelled</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(191,803</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6.27</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Outstanding as of December&nbsp;31, 2017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,832,639</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7.04</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8.48</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>40,382 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Options vested and expected to vest as of December&nbsp;31, 2017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,832,639</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>7.04</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8.48</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>40,382 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Options exercisable at December&nbsp;31, 2017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>535,416</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5.53</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6.98</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>12,598 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following summarizes information about stock options at December&nbsp;31, 2017 by range of exercise prices: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:73%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"110%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="110%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="59pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="56pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="54pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Range of Exercise Prices

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number<BR>
Oustanding </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Weighted<BR>
Average<BR>
Remaining<BR>
Contractual<BR>
Term </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Weighted<BR>
Average<BR>
Exercise<BR>
Price </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number<BR>
Exercisable </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Weighted<BR>
Average<BR>
Exercise<BR>
Price </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>$4.59 $6.05</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>650,851</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7.26</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4.79</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>309,174</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4.59</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>$6.14 $6.88</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>930,958</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9.34</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6.59</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>143,650</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6.41</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>$7.52 $30.51</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>250,830</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8.44</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>14.54</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>82,592</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7.52 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,832,639</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8.48</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7.04</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>535,416</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5.53</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
the Plan, the Company recorded stock-based compensation of $2,084, $993 and $192 during the year ended December&nbsp;31, 2017, 2016 and 2015, respectively, that consists of
stock-based compensation expense for stock options granted to (or modified for) employees and directors of $1,859, $277 and $39, respectively, and stock options granted to non-employees and employees
of the Motus entity that are allocated to the Company of $225, $716 and $153, respectively. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-26</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=254,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=541275,FOLIO='F-26',FILE='DISK109:[18ZBU1.18ZBU44601]FQ44601A.;13',USER='CHE105614',CD='10-JUN-2018;18:09' -->
<A NAME="page_fq44601_1_27"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Rhythm Pharmaceuticals,&nbsp;Inc. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes to Consolidated Financial Statements (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> (In thousands, except share and per share information) </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


7. Stock-based Compensation (Continued) </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
2017, there were three awards subject to modification accounting under ASC 718-20-35-3 through 35-4. Per terms of separation with a former employee, three months of accelerated
vesting was granted for the former employee's three stock option awards. As a result, the Company recognized incremental expense for the stock option awards of $254. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of December&nbsp;31, 2017, the Company has unrecognized compensation cost of $6,599 related to non-vested employee, non-employee and director awards that is expected to be
recognized over a weighted-average period of 2.79&nbsp;years. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table summarizes the classification of the Company's stock-based compensation expenses related to the Plan recognized in the Company's statements of operations and
comprehensive loss. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="30pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="30pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>775</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>343</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>68</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Selling, general, and administrative</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,309</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>650</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>124 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,084</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>993</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>192 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


LLC Incentive Plan  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company was allocated stock compensation expense from the&nbsp;LLC entity's plan using the same proportional use basis for other shared
costs (see Note&nbsp;2). The following table summarizes the classification of the Company's stock-based compensation expenses related to the costs allocated from the&nbsp;LLC's Plan recognized in
the Company's statements of operations and comprehensive loss. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="30pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="30pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="30pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year Ended<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>152</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>163</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>76</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>General and administrative</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>42</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>30 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>194</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>175</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>106 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
remainder of this Note discloses the stock-based compensation activity of the Predecessor Company and the&nbsp;LLC entity. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Original Plan  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Predecessor Company had one stock based compensation plan&#151;the 2010 equity incentive plan, as amended (the "Original Plan"). The
Original Plan previously provided for the grant of incentive and non-qualified stock options and restricted stock grants to employees, consultants, advisors and directors, as determined by the board
of directors of the Predecessor Company. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-27</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=255,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=327754,FOLIO='F-27',FILE='DISK109:[18ZBU1.18ZBU44601]FQ44601A.;13',USER='CHE105614',CD='10-JUN-2018;18:09' -->
<A NAME="page_fq44601_1_28"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Rhythm Pharmaceuticals,&nbsp;Inc. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes to Consolidated Financial Statements (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> (In thousands, except share and per share information) </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


7. Stock-based Compensation (Continued) </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
a result of the Corporate Reorganization, all outstanding option grants under the Original Plan were cancelled. Each holder of a stock option that was cancelled was issued a
restricted common unit of the&nbsp;LLC entity in its place on a one-for-one basis. Restricted common unit vesting agreements were contracted between the&nbsp;LLC entity and the restricted common
unit holder granting the holder the same vesting terms as originally granted in the respective option agreement. Any unvested portion of the stock option at the Corporate Reorganization would continue
to vest under those original time frames and conditions. Exercise prices were eliminated as they are not applicable to common unit instruments, and all equity incentive grants after the Corporate
Reorganization were of restricted common units. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
holder of a restricted common unit is entitled to one vote per unit. After the payment of all preferential amounts to the holders of the convertible preferred units, the holder of a
restricted
common unit is entitled to his pro rata share of the remaining consideration, if any, based on the number of restricted common units held by the holder. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Restricted Common Units  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon the Corporate Reorganization, all 615,685 common stock options of the Predecessor Company under the Original Plan outstanding as of
March&nbsp;21, 2013 were exchanged on a one-for-one basis for 615,685 restricted common units of the&nbsp;LLC entity. Vesting continued on the same schedule as originally granted per the
respective option agreement. At the time of the exchange, the&nbsp;LLC entity determined the fair value of a restricted common unit to be $1.21 per unit, equivalent to the fair value of a common
unit. The fair value of stock options immediately prior to the Corporate Reorganization was determined using a Black-Scholes option pricing model and ranged in value from $0.48 to $0.64. The exchange
was accounted for by the&nbsp;LLC entity as a modification in accordance with ASC 718, with the incremental fair value determined to be $255, of which $99 was recognized immediately upon the
Corporate Reorganization for the portion related to the vested awards, and the remaining $156 will be recognized over the remaining service period of the restricted common units, net of estimated
forfeitures. No common stock options were issued by the Relamorelin Company under the Original Plan subsequent to the Corporate Reorganization. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
restricted common units granted subsequent to the Corporate Reorganization were valued at the fair value of the&nbsp;LLC entity's common unit on the date of grant and will be
expensed over their respective service period. Forfeitures are required to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those
estimates. The term "forfeitures" is distinct from "cancellations" and represents only the unvested portion of the surrendered unit. Ultimately, the actual expense recognized over the vesting period
will only be for those options that vest. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-28</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=256,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=372616,FOLIO='F-28',FILE='DISK109:[18ZBU1.18ZBU44601]FQ44601A.;13',USER='CHE105614',CD='10-JUN-2018;18:09' -->
<A NAME="page_fq44601_1_29"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Rhythm Pharmaceuticals,&nbsp;Inc. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes to Consolidated Financial Statements (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> (In thousands, except share and per share information) </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


7. Stock-based Compensation (Continued) </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
summary of the&nbsp;LLC entity's restricted common unit activity for the year ended December&nbsp;31, 2017 is as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="54pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Units </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Weighted-<BR>
Average<BR>
Grant Date<BR>
Fair Value<BR>
Per Unit </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Outstanding unvested as of December&nbsp;31, 2016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>94,617</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3.31</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Granted</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Vested</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(71,048</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2.73</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cancelled</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Outstanding unvested as of December&nbsp;31, 2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>23,569</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5.06 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The&nbsp;LLC
entity recorded total stock-based compensation expense for restricted common units granted to employees, directors and non-employees of $194, $221 and $337 during the
years ended December&nbsp;31, 2017, 2016 and 2015, respectively. The total fair value of restricted common units vested during the years ended December&nbsp;31, 2017, 2016 and 2015 was $194, $208
and $309, respectively. As of December&nbsp;31, 2017, we have unrecognized compensation expense related to the unvested portion of these awards of $119, and we expect to recognize this amount over a
weighted-average period of approximately 0.8&nbsp;years. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


2017 Employee Stock Purchase Plan  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company's board of directors has adopted and the Company's stockholders have approved the 2017 Employee Stock Purchase Plan (the "2017
ESPP"), which became effective in connection with the completion of the Company's IPO in October 2017. A total of 272,841 shares of common stock were reserved for issuance under this plan. In
addition, The number of shares authorized under the ESPP will be increased each January&nbsp;1, commencing on January&nbsp;1, 2019 and ending on (and including) January&nbsp;1, 2027, by an
amount equal to the lesser of 1% of outstanding shares as of the end of the immediately preceding fiscal year and 682,102. Notwithstanding the foregoing, our board of directors may act prior to
January&nbsp;1 of a given year to provide that there will be no such January&nbsp;1 increase in the number of shares authorized under the ESPP for such year, or that the increase in the number of
shares authorized under the ESPP for such year will be a lesser number than would otherwise occur pursuant to the preceeding sentence. No shares were issued under this plan during the year ended
December&nbsp;31, 2017. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


8. Significant Agreements  </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


License Agreements  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Predecessor Company entered into a license agreement on February&nbsp;26, 2010 with Ipsen Pharma,&nbsp;S.A.S. ("Ipsen") that granted
full worldwide right for two programs that include the clinical candidates setmelanotide, which is in Phase&nbsp;3 clinical trials, and relamorelin, which has completed a Phase&nbsp;2 clinical
trial. As a result of the Corporate Reorganization described in Note&nbsp;1, the Ipsen license was converted to separate license agreements for the setmelanotide program held by the Company and the
relamorelin program held by the Relamorelin Company, respectively. Under the terms of the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-29</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=257,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=446463,FOLIO='F-29',FILE='DISK109:[18ZBU1.18ZBU44601]FQ44601A.;13',USER='CHE105614',CD='10-JUN-2018;18:09' -->
<A NAME="page_fq44601_1_30"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Rhythm Pharmaceuticals,&nbsp;Inc. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes to Consolidated Financial Statements (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> (In thousands, except share and per share information) </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


8. Significant Agreements (Continued) </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>setmelanotide
Ipsen license agreement, assuming that setmelanotide is successfully developed, receives regulatory approval and is commercialized, Ipsen may receive aggregate payments of up to $40,000
upon the achievement of certain development and commercial milestones and royalties on future product sales in the mid-single digits. Substantially all of such aggregate payments of up to $40,000 are
for milestones that may be achieved no earlier than first commercial sale of setmelanotide. In the event that the Company executes a sublicense agreement, it shall make payments to Ipsen, depending on
the date of such sublicense agreement, ranging from 10% to 20% of all revenues actually received under such sublicense agreement. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
connection with this license agreement, the&nbsp;LLC entity issued two warrants in March 2010 to an affiliate of Ipsen to purchase a total of 489,500 common units. These warrants
were vested in full in 2010 and 2011, respectively. In July 2015, the warrant agreement was amended to extend the expiration date to July&nbsp;31, 2015 as the original warrant agreement expired in
March 2015. In July 2015, an affiliate of Ipsen elected to exercise these warrants in full for a total of 489,500 common units of the&nbsp;LLC entity. In July 2015, upon exercise, warrant expense of
$923 was allocated to the Company relating to the modification of these warrants and is included within research and development expense. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
January 2016, the Company entered into a licensing agreement with Camurus AB, or Camurus, for the use of Camurus' drug delivery technology. The contract includes a non-refundable and
non-creditable signing fee of $500, which was paid during January 2016. The Camurus Agreement also includes up to $7,750 in one-time, non-refundable development milestones achievable upon certain
regulatory successes. The Company is also required to pay to Camurus royalties, mid to mid-high single digit, on a product-by-product and country-by-country basis of annual net sales, until the later
of (i)&nbsp;10&nbsp;years after the date of first commercial sale of such product in such country; or (ii)&nbsp;the expiration of the last to expire valid claim of all licensed patent rights in
such country covering such product. The Company is also required to pay one-time, non-refundable, non-creditable sales milestones upon the achievement of certain sales levels for such product and
cannot be in excess of $57,000. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
March 2017, the Company achieved the first milestone event associated with this license agreement. The Company completed the first manufactured batch using the Camurus drug delivery
technology and filed an investigational new drug application with the FDA. The fee associated with this first milestone was $250 and was recorded as research and development expense. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
December 2017, the Company achieved the second milestone event associated with this license agreement. The Company completed the Phase&nbsp;I proof of concept study using the
Camurus drug delivery technology. The fee associated with this second milestone was $1,000 and was recorded as research and development expense. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


9. Commitments and Contingencies  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company is not a party to the lease for the facility it previously shared with the Relamorelin Company. In November 2015, the Company entered into a Lease Agreement for an office
facility at 500&nbsp;Boylston Street, Boston, Massachusetts. The lease term commenced in May 2016 and has a term of 5&nbsp;years with a five -year renewal option to extend the lease. Rent expense
for the years ended December&nbsp;31, 2017 and 2016 was $215 and $179, respectively. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-30</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=258,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=600277,FOLIO='F-30',FILE='DISK109:[18ZBU1.18ZBU44601]FQ44601A.;13',USER='CHE105614',CD='10-JUN-2018;18:09' -->
<A NAME="page_fq44601_1_31"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Rhythm Pharmaceuticals,&nbsp;Inc. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes to Consolidated Financial Statements (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> (In thousands, except share and per share information) </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


9. Commitments and Contingencies (Continued) </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Future
minimum payments under the Lease Agreement as of December&nbsp;31, 2017, are as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2018</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>298</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2019</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>305</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2020</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>311</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>2021</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>131 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,045 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


10. Related-Party Transactions  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company shared costs with the Relamorelin Company, its affiliate, including payroll, facilities, information technology and other research and development and general and
administrative overhead costs. Additionally, the Relamorelin Company had paid certain Company expenses directly on behalf of the Company. Shared costs incurred by the Relamorelin Company and Company
expenses paid by the Relamorelin Company on behalf of the Company are allocated from the Relamorelin Company to the Company as described in Note&nbsp;1 and Note&nbsp;2. These net costs totaled
$1,570 and $2,149 for the years ended December&nbsp;31, 2016 and 2015, respectively. The Relamorelin Company was sold to a large pharmaceutical company on December&nbsp;15, 2016. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The&nbsp;LLC
made payments on behalf of the Company totaling $105 related to allocated 2016 employee bonuses. Those costs are recorded as a payable due to the&nbsp;LLC entity from
the Company at December&nbsp;31, 2016 on the balance sheet. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Expenses
paid directly by the Company to consultants considered to be related parties amounted to $2,400, $619 and $153 for the years ended December&nbsp;31, 2017, 2016 and 2015,
respectively. Outstanding payments due to these related parties as of December&nbsp;31, 2017 and 2016 were $90 and $50, respectively and were included within Accounts payable on the balance sheet.
Expenses paid by the Relamorelin Company to these related parties amounted to zero, $966 and $1,357 for the years ended December&nbsp;31, 2017, 2016 and 2015, respectively. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Employees
of certain holders of series&nbsp;A and series&nbsp;B convertible preferred units of the&nbsp;LLC entity, have been retained as consultants supporting development
activities of the Company and the Relamorelin Company for which the holders are paid cash compensation pursuant to consulting arrangements. Compensation payments related to these consultants totaled
$97, $78 and $125 for the years ended December&nbsp;31, 2017, 2016 and 2015, respectively. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


11. Income Tax  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the Company's financial statements, income taxes, including deferred tax balances, have been calculated on a separate tax return basis. Certain of the Company's activities and costs
have been included in the tax returns filed by the Relamorelin Company and the&nbsp;LLC entity. Prior to the Corporate Reorganization, the Company's operations were included in the tax returns filed
by the Predecessor Company. The Company has filed tax returns on its own behalf since the Corporate Reorganization. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-31</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=259,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=972471,FOLIO='F-31',FILE='DISK109:[18ZBU1.18ZBU44601]FQ44601A.;13',USER='CHE105614',CD='10-JUN-2018;18:09' -->
<A NAME="page_fq44601_1_32"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Rhythm Pharmaceuticals,&nbsp;Inc. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes to Consolidated Financial Statements (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> (In thousands, except share and per share information) </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


11. Income Tax (Continued) </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
the years ended December&nbsp;31, 2017 and 2016, the Company did not have a current or deferred income tax expense or benefit as the entity has incurred losses since inception and
has provided a full valuation allowance against its deferred tax assets. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
reconciliation of the income tax benefit at the federal statutory tax rate to the Company's effective income tax rate follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="37pt" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="37pt" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="37pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>As of December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Statutory tax rate</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>34.00</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>34.00</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>34.00</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>State tax, net of federal benefit</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4.08</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2.63</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4.33</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development credit</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.87</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.34</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.85</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Orphan drug credit</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2.29</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2.15</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.91</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Non deductible deferred issuance costs</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2> (2.40</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Tax law change</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2> (27.98</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Stock compensation</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2> (1.84</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Investor instrument revaluation</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2> (1.88</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Non deductible warrant expense</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2> (2.82</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2> (0.07</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2> (1.32</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2> (2.23</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Change in valuation allowance</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2> (10.47</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2> (36.40</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2> (36.04</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)% </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Effective tax rate</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>% </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
principal components of the Company's deferred tax assets are as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>As of December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deferred tax assets:</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net operating loss carryforwards</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>18,325</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>17,248</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development credits</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,317</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,214</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Orphan drug credit</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,333</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,164</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Capitalized license fee</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>600</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>599</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>262 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total gross deferred tax assets</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>24,074</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>20,488</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Valuation allowance</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(24,074</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(20,488</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net deferred tax assets</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
December&nbsp;22, 2017, the Tax Cuts and Jobs Act ("The Act"), was signed into law. The Act includes a number of provisions, including the lowering of the U.S. corporate tax rate
from 34% to 21%, effective January&nbsp;1, 2018 and the establishment of a territorial-style system for taxing foreign source income of domestic multinational corporations. The Company is in the
process of quantifying the tax impacts of The Act. As a result of The Act, the Company expects there will be one-time adjustments for the re-measurement of deferred tax assets (liabilities). Given the
Company's full valuation allowance as of December&nbsp;31, 2017, the Company does not expect the adjustment to materially impact the Company's </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-32</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=260,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=698003,FOLIO='F-32',FILE='DISK109:[18ZBU1.18ZBU44601]FQ44601A.;13',USER='CHE105614',CD='10-JUN-2018;18:09' -->
<A NAME="page_fq44601_1_33"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Rhythm Pharmaceuticals,&nbsp;Inc. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes to Consolidated Financial Statements (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> (In thousands, except share and per share information) </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


11. Income Tax (Continued) </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>income
tax provision or balance sheet. On December&nbsp;22, 2017, the SEC staff issued Staff Accounting Bulletin No.&nbsp;118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act, or
SAB&nbsp;118, which allows the recording of provisional amounts during a measurement period not to extend beyond one year of the enactment date. In accordance with SAB&nbsp;118, we have determined
that our deferred tax asset value and associated valuation allowance reduction of $9,432 is a provisional amount and a reasonable estimate at December&nbsp;31, 2017. The final impact may differ from
this provisional amount due to, among other things, changes in interpretations and assumptions we have made thus far and the issuance of additional regulatory or other guidance. We expect to complete
the final impact within the
measurement period. The Company has quantified the impact of the rate reduction from 34% to 21% in its balance sheet. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ASC
740 requires a valuation allowance to reduce the deferred tax assets reported if, based on the weight of available evidence, it is more likely than not that some portion or all of
the deferred tax assets will not be realized. After consideration of all the evidence, both positive and negative, the Company has recorded a full valuation allowance against its deferred tax assets
at December&nbsp;31, 2017 and 2016, because the Company's management has determined that is it more likely than not that these assets will not be realized. The increase in the valuation allowance of
$3,586 in 2017 and $9,417 in 2016 primarily relates to the net loss incurred by the Company during each period, partially offset by the federal rate reduction from 34% to 21% as a result of The Act in
2017. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of December&nbsp;31, 2017, the Company had federal and state net operating loss carryforwards of approximately $73,109 and $3,763, respectively, which are available to reduce future
taxable income. The net operating loss carryforwards expire at various times beginning in 2033 for federal and state purposes. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of December&nbsp;31, 2017, the Company had federal and state research tax credits of approximately $1,925 and $496, respectively, which may be used to offset future tax liabilities.
Additionally, as of December&nbsp;31, 2017, the Company had a federal orphan drug credit related to qualifying research of $2,333. These tax credit carryforwards will begin to expire at various
times beginning in 2033 for federal purposes and 2028 for state purposes. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
net operating loss and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. Net operating loss and tax
credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of
50%, as defined under Sections&nbsp;382 and 383 of the Internal Revenue Code, respectively, as well as similar state provisions and other provisions within the Internal Revenue Code. This could
limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company
immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company has not recorded any reserves for uncertain tax positions as of December&nbsp;31, 2017 and 2016. The Company has not, as yet, conducted a study of research and development
credit carryforwards. This study may result in an adjustment to the Company's research and development credit carryforwards; however, until a study is completed and any adjustment is known, no amounts
are being presented as an uncertain tax position. A full valuation allowance has been provided against the Company's research and development credits and, if an adjustment is required, this adjustment
would be offset by an adjustment to </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-33</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=261,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=504804,FOLIO='F-33',FILE='DISK109:[18ZBU1.18ZBU44601]FQ44601A.;13',USER='CHE105614',CD='10-JUN-2018;18:09' -->
<A NAME="page_fq44601_1_34"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Rhythm Pharmaceuticals,&nbsp;Inc. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes to Consolidated Financial Statements (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> (In thousands, except share and per share information) </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


11. Income Tax (Continued) </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>the
valuation allowance. Thus, there would be no impact to the balance sheets or statements of operations and comprehensive loss if an adjustment were required. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Interest
and penalty charges, if any, related to unrecognized tax benefits will be classified as income tax expense in the accompanying statements of operations and comprehensive loss.
As of December&nbsp;31, 2017 and 2016, the Company had no accrued interest or penalties related to uncertain tax positions. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company is subject to examination by the U.S. federal, state and local income tax authorities for tax years 2013 forward. The Company is not currently under examination by the
Internal Revenue Service or any other jurisdictions for any tax years. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


12. Retrospective Adoption of New Accounting Standard  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In November 2016, the FASB issued ASU No.&nbsp;2016-18, Statement of Cash Flows (Topic 230): Restricted Cash ("ASU 2016-18") that changes the presentation of restricted cash and cash
equivalents on the statement of cash flows. ASU 2016-18 requires that restricted cash and restricted cash equivalents be included with cash and cash equivalents when reconciling the
beginning-of-period and end-of-period total amounts shown on the statement of cash flows. This amendment is effective for fiscal years beginning after December&nbsp;15, 2017, including interim
periods within those fiscal years, and is applied using retrospective transition method. We adopted ASU on January&nbsp;1, 2018 and have applied its content to the statement of cash flows for the
years ended December&nbsp;31, 2015, 2016 and 2017 presented herein. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


13. Selected Quarterly Financial Data (unaudited)  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table contains selected quarterly financial information from 2017 and 2016. The Company believes that the following information reflects all normal recurring adjustments
necessary for a fair statement of the information for the periods presented. The operating results for any quarter are not necessarily indicative of results for any future period. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="49pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="67pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Three months ended </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>March&nbsp;31,<BR>
2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>June&nbsp;30,<BR>
2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>September&nbsp;30,<BR>
2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31,<BR>
2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total revenue</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total operating expenses</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6,389</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6,754</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8,286</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10,983</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other income (expense), net:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>29</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(48</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1,730</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>452 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss and comprehensive loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(6,360</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(6,802</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(10,016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(10,531</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss attributable to common stockholders</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(7,526</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(8,008</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(11,429</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(10,619</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss attributable to common stockholders per common share, basic and diluted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(0.74</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(0.78</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1.78</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(0.41</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-34</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=262,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=142456,FOLIO='F-34',FILE='DISK109:[18ZBU1.18ZBU44601]FQ44601A.;13',USER='CHE105614',CD='10-JUN-2018;18:09' -->
<A NAME="page_fq44601_1_35"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Rhythm Pharmaceuticals,&nbsp;Inc. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes to Consolidated Financial Statements (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> (In thousands, except share and per share information) </B></FONT></P>


<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


13. Selected Quarterly Financial Data (unaudited) (Continued) </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><BR></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="49pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="67pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Three months ended </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>March&nbsp;31,<BR>
2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>June&nbsp;30,<BR>
2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>September&nbsp;30,<BR>
2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31,<BR>
2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total revenue</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total operating expenses</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,391</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,738</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6,401</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8,375</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other income (expense), net:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>9 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss and comprehensive loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(5,385</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(5,730</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(6,391</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(8,366</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss attributable to common stockholders</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(6,183</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(6,528</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(7,191</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(9,172</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss attributable to common stockholders per common share, basic and diluted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(0.61</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(0.64</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(0.71</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(0.90</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>*
* * * * * </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-35</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=263,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=617384,FOLIO='F-35',FILE='DISK109:[18ZBU1.18ZBU44601]FQ44601A.;13',USER='CHE105614',CD='10-JUN-2018;18:09' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_fs44601_1_36"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="fs44601_rhythm_pharmaceuticals,_inc._c__rhy04244"> </A>
<A NAME="toc_fs44601_1"> </A></FONT> <FONT SIZE=2><B><BR>  Rhythm Pharmaceuticals,&nbsp;Inc.    <BR>    <BR>    Condensed Consolidated Balance Sheets    <BR>    <BR>    (in thousands, except share and per share data)    <BR>    </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="58pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>(Unaudited)<BR>
March&nbsp;31,<BR>
2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31,<BR>
2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Assets</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Current assets:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash and cash equivalents</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>43,167</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>34,236</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Short-term investments</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>93,286</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>113,846</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Prepaid expenses and other current assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,961</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,589 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total current assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>138,414</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>150,671</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Property, plant and equipment, net</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>779</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>840</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Restricted cash</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>250</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>225 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>139,443</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>151,736 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Liabilities, convertible preferred stock and stockholders' equity</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Current liabilities:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accounts payable</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,456</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2,427</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deferred rent</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>85</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>83</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued expenses and other current liabilities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,038</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,210 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total current liabilities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,579</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6,720</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Long-term liabilities:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deferred rent</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>206</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>228 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total liabilities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,785</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6,948</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Commitments and contingencies</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-top:9pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Preferred stock:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Convertible Preferred Stock, $0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding at March&nbsp;31, 2018 and December&nbsp;31,
 2017, respectively</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Stockholders' equity:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Common stock, $0.001 par value: 120,000,000 shares authorized; 27,284,140 shares issued and outstanding March&nbsp;31, 2018 and December&nbsp;31, 2017,
respectively</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>27</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>27</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Additional paid-in capital</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>260,342</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>255,013</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accumulated deficit</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(126,711</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(110,252</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total stockholders' equity</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>133,658</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>144,788 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total liabilities, convertible preferred stock and stockholders' equity</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>139,443</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>151,736 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p><p align=center style="font-family:times;"><font> </FONT> <FONT SIZE=2>
The accompanying notes are an integral part of these financial statements </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-36</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=264,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=271802,FOLIO='F-36',FILE='DISK109:[18ZBU1.18ZBU44601]FS44601A.;5',USER='CHE105614',CD='10-JUN-2018;18:09' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_fu44601_1_37"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="fu44601_rhythm_pharmaceuticals,_inc._c__rhy06033"> </A>
<A NAME="toc_fu44601_1"> </A></FONT> <FONT SIZE=2><B><BR>  Rhythm Pharmaceuticals,&nbsp;Inc.    <BR>    <BR>    Condensed Consolidated Statements of Operations and Comprehensive Loss    <BR>    <BR>    (in thousands, except share and per share data)
  <BR>    <BR>    (Unaudited)    <BR>    </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Three months ended March&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Operating expenses:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>12,286</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,873</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Selling, general, and administrative</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4,715</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1,516 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total operating expenses</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>17,001</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>6,389 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Loss from operations</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(17,001</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(6,389</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other income (expense):</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Interest income, net</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>542</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>29 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total other income (expense):</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>542</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>29 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss and comprehensive loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(16,459</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(6,360</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss attributable to common stockholders</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(16,459</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(7,526</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss attributable to common stockholders per common share, basic and diluted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(0.60</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(0.74</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Weighted average common shares outstanding, basic and diluted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>27,284,140</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10,196,292 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p><p align=center style="font-family:times;"><font> </FONT> <FONT SIZE=2>
The accompanying notes are an integral part of these financial statements </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-37</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=265,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=140188,FOLIO='F-37',FILE='DISK109:[18ZBU1.18ZBU44601]FU44601A.;4',USER='CHE105614',CD='10-JUN-2018;18:09' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_fw44601_1_38"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="fw44601_rhythm_pharmaceuticals,_inc._c__rhy05060"> </A>
<A NAME="toc_fw44601_1"> </A></FONT> <FONT SIZE=2><B><BR>  Rhythm Pharmaceuticals,&nbsp;Inc.    <BR>    <BR>    Condensed Consolidated Statements of Cash Flows    <BR>    <BR>    (in thousands, except share and per share data)    <BR>    <BR>
(Unaudited)    <BR>    </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Three months ended<BR>
March&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Operating activities</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(16,459</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(6,360</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Adjustments to reconcile net loss to cash used in operating activities:</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Non-cash research and development license expense</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,448</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Stock-based compensation expense</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>958</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>264</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Depreciation and amortization</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>61</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>54</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Non-cash rent expense</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(20</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(18</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Changes in operating assets and liabilities:</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Prepaid expenses and other current assets</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>581</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(305</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Deferred issuance costs</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(82</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accounts payable, accrued expenses and other current liabilities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(1,220</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(464</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:30pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Due to related parties</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(105</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:40pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net cash used in operating activities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(11,651</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(7,016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Investing activities</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Purchases of short-term investments</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(2,023</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(12,009</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Maturities of short-term investments</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>22,630</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,990</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Purchases of property, plant and equipment</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:40pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net cash provided by (used in) investing activities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>20,607</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(8,019</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Financing activities</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net proceeds from issuance of Series&nbsp;A Convertible Preferred Stock</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>20,377 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:40pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net cash provided by financing activities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>20,377 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net increase (decrease) in cash, cash equivalents and restricted cash</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8,956</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,342</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash, cash equivalents and restricted cash at beginning of year</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>34,461</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6,765 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash, cash equivalents and restricted cash at end of year</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>43,417</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12,107 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p><p align=center style="font-family:times;"><font> </FONT> <FONT SIZE=2>
The accompanying notes are an integral part of these financial statements </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-38</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=266,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=879769,FOLIO='F-38',FILE='DISK109:[18ZBU1.18ZBU44601]FW44601A.;5',USER='CHE105614',CD='10-JUN-2018;18:09' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_fy44601_1_39"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="fy44601_rhythm_pharmaceuticals,_inc._n__rhy05639"> </A>
<A NAME="toc_fy44601_1"> </A></FONT> <FONT SIZE=2><B><BR>  Rhythm Pharmaceuticals,&nbsp;Inc.    <BR>    <BR>    Notes to Unaudited Condensed Consolidated Financial Statements    <BR>    <BR>    (In thousands, except share and per share information)
 <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


1. Nature of Business  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Rhythm Pharmaceuticals,&nbsp;Inc. (the "Company"), is a biopharmaceutical company focused on the development and commercialization of peptide therapeutics for the treatment of genetic
deficiencies that result in life-threatening metabolic disorders. The Company's lead product candidate is setmelanotide ("RM-493"), which is a potent, first-in-class, melanocortin-4, or MC4, receptor,
agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. The Company is currently evaluating setmelanotide for the treatment of six genetic disorders of
obesity: pro-opiomelanocortin, or POMC, leptin receptor, or LepR, Bardet-Biedl syndrome, Alstr&ouml;m syndrome, POMC heterozygous, and POMC epigenetic disorders. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
March 2018 the Company acquired exclusive, worldwide rights from Takeda Pharmaceutical Company Limited ("Takeda") to develop and commercialize T-3525770 (now "RM-853"). RM-853 is a
potent, orally available ghrelin o-acyltransferase ("GOAT") inhibitor currently in preclinical development for Prader-Willi Syndrome ("PWS"). PWS is a rare genetic disorder that results in hyperphagia
and early-onset, life-threatening obesity, for which there are no approved therapeutic options. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Corporate Reorganization  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company is a Delaware corporation organized in February 2013 under the name Rhythm Metabolic,&nbsp;Inc. Prior to the Company's
organization and the Corporate Reorganization referred to below, the Company was part of Rhythm Pharmaceuticals,&nbsp;Inc. (the "Predecessor Company"), a Delaware corporation which was organized in
November 2008 and which commenced active operations in 2010. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
March 2013, the Predecessor Company underwent a corporate reorganization, (the "Corporate Reorganization"), pursuant to which all of the outstanding equity securities of the
Predecessor Company were exchanged for units of Rhythm Holding Company,&nbsp;LLC, a newly-organized limited liability company (the "LLC entity"). After the consummation of this exchange and as part
of the Corporate Reorganization, the Predecessor Company contributed setmelanotide and the MC4R agonist program to the Company and distributed to the&nbsp;LLC entity all of the then issued and
outstanding shares of the Company's stock. The result of the Corporate Reorganization was that the Company and the Predecessor Company became wholly-owned subsidiaries of the&nbsp;LLC entity and the
two product candidates and related programs that were originally held by the Predecessor Company were separated, with relamorelin and the ghrelin agonist program being retained by the Predecessor
Company and setmelanotide and the MC4R agonist program being held by the Company. The Predecessor Company, after consummation of the Corporate Reorganization, is referred to within these Notes to
Financial Statements as the Relamorelin Company and/or Motus. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
October&nbsp;13, 2015, the Relamorelin Company changed its name to Motus Therapeutics,&nbsp;Inc. ("Motus") and the Company changed its name to Rhythm Pharmaceuticals,&nbsp;Inc.
On December&nbsp;15, 2016, Motus was sold to a large pharmaceutical company. On August&nbsp;21, 2017, the&nbsp;LLC entity distributed to its members all of its shares of the Company (see
Note&nbsp;5 for further discussion). </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Liquidity  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has incurred operating losses and negative cash flows from operations since inception. As of March&nbsp;31, 2018, the Company had
an accumulated deficit of $126,711. The Company has primarily funded these losses through capital contributions received from the&nbsp;LLC entity and the sale of preferred </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-39</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=267,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=311945,FOLIO='F-39',FILE='DISK109:[18ZBU1.18ZBU44601]FY44601A.;7',USER='CHE105614',CD='10-JUN-2018;18:09' -->
<A NAME="page_fy44601_1_40"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Rhythm Pharmaceuticals,&nbsp;Inc. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes to Unaudited Condensed Consolidated Financial Statements (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> (In thousands, except share and per share information) </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


1. Nature of Business (Continued) </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>and
common stock to outside investors. To date, the Company has no product revenue and management expects operating losses to continue for the foreseeable future. The Company has devoted substantially
all of its resources to its drug development efforts, comprising research and development, manufacturing, conducting clinical trials for its product candidates, protecting its intellectual property
and general and administrative functions relating to these operations. The future success of the Company is dependent on its ability to develop its product candidates and ultimately upon its ability
to attain profitable operations. At March&nbsp;31, 2018, the Company had $136,453 of cash and cash equivalents and short-term investments on hand. In the future, the Company will be dependent on
obtaining funding from third parties, such as proceeds from the issuance of debt, sale of equity, and funded research and development programs, to maintain the Company's operations and meet the
Company's obligations. There is no guarantee that additional equity or other financings will be available to the Company on acceptable terms, or at all. If the Company fails to obtain additional
funding when
needed, the Company would be forced to scale back, terminate its operations or seek to merge with or be acquired by another company. Management believes that the Company's existing cash resources will
be sufficient to fund the Company's operating plan into the second half of 2019. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. Summary of Significant Accounting Policies  </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Basis of Presentation  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company's unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally
accepted in the United States ("GAAP") and the applicable rules and regulations of the Securities and Exchange Commission ("SEC") regarding interim financial reporting. Any reference in these notes to
applicable guidance is meant to refer to the authoritative United States generally accepted accounting principles as found in the Accounting Standards Codification ("ASC") and Accounting Standards
Updates ("ASU") of the Financial Accounting Standards Board ("FASB"). As permitted under these rules, certain footnotes or other financial information that are normally required by GAAP have been
condensed or omitted. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
accompanying interim balance sheet as of March&nbsp;31, 2018, the statements of operations and comprehensive loss for the three months ended March&nbsp;31, 2018 and 2017, the
statement of cash flows for the three months ended March&nbsp;31, 2018 and 2017 and the related footnote disclosures are unaudited. In management's opinion, the unaudited interim financial
statements have been prepared on the same basis as the audited financial statements and include all adjustments, which include all normal recurring adjustments necessary for the fair presentation of
the interim financial statements. The results for the three months ended March&nbsp;31, 2018 are not necessarily indicative of the results expected for the full fiscal year. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company has historically existed and functioned as part of the consolidated businesses of the Predecessor Company. As noted above, the Predecessor Company's setmelanotide and the
MC4R agonist program were transferred to the Company as part of the Corporate Reorganization on March&nbsp;21, 2013. These financial statements include the results of operations of setmelanotide and
the MC4R agonist program from its inception. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
September&nbsp;22, 2017, the Company's board of directors approved a 1-for-9.17 reverse stock split of the Company's issued and outstanding shares of common stock. All share and per
share amounts in the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-40</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=268,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=513737,FOLIO='F-40',FILE='DISK109:[18ZBU1.18ZBU44601]FY44601A.;7',USER='CHE105614',CD='10-JUN-2018;18:09' -->
<A NAME="page_fy44601_1_41"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Rhythm Pharmaceuticals,&nbsp;Inc. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes to Unaudited Condensed Consolidated Financial Statements (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> (In thousands, except share and per share information) </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. Summary of Significant Accounting Policies (Continued) </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>financial
statements have been retrospectively adjusted for all periods presented to give effect of the reverse stock split. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
October&nbsp;5, 2017, the Company filed an amended and restated certificate of incorporation with the Secretary of State of the State of Delaware to increase its authorized number
of shares of common stock to 120,000,000 shares of common stock, $0.001 par value per share and 10,000,000 shares of preferred stock, $0.001 par value per share. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
October&nbsp;10, 2017 the Company completed its initial public offering ("IPO") of 8,107,500 shares of common stock at an offering price of $17.00 per share, which included the
exercise in full by the underwriters of their option to purchase up to 1,057,500 additional shares of common stock. The Company received gross proceeds of approximately $137,828 or net proceeds of
$125,658 after deducting underwriting discounts, commissions and estimated offering expenses. In connection with the IPO, the Company's outstanding shares of convertible preferred stock were
automatically converted into 17,406,338&nbsp;shares of common stock. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Use of Estimates  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and the disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. The
Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it
believes to be reasonable under the circumstances. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements if
these results differ from historical experience, or other assumptions do not turn out to be substantially accurate, even if such assumptions are reasonable when made. Significant estimates relied upon
in preparing these financial statements include accrued expenses, stock-based compensation expense, the valuation allowance on the Company's deferred tax assets, and the fair value of the
Series&nbsp;A Investor Instrument (see Note&nbsp;4). </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Principles of Consolidation  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The consolidated financial statements include the accounts of Rhythm Pharmaceuticals,&nbsp;Inc. and its subsidiaries. All significant
intercompany balances and transactions have been eliminated in consolidation. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Off-Balance Sheet Risk and Concentrations of Credit Risk  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial instruments, which potentially subject the Company to significant concentration of credit risk, consist primarily of cash and cash
equivalents and short-term investments, which are maintained at two federally insured financial institutions. The deposits held at these two institutions are in excess of federally insured limits. The
Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions
in which those deposits are held. The Company has no off-balance sheet risk, such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-41</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=269,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=554640,FOLIO='F-41',FILE='DISK109:[18ZBU1.18ZBU44601]FY44601A.;7',USER='CHE105614',CD='10-JUN-2018;18:09' -->
<A NAME="page_fy44601_1_42"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Rhythm Pharmaceuticals,&nbsp;Inc. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes to Unaudited Condensed Consolidated Financial Statements (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> (In thousands, except share and per share information) </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. Summary of Significant Accounting Policies (Continued) </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Segment Information  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating segments are defined as components of an entity about which separate discrete information is available for evaluation by the chief
operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating
segment operating exclusively in the United States. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


2017 Series&nbsp;A Investor Instrument  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has classified its 2017 Series&nbsp;A Investor Instrument (See Note&nbsp;4) as a liability as it is a free-standing financial
instrument. The 2017 Series&nbsp;A Investor Instrument was recorded at fair value upon the issuance of the Company's series&nbsp;A preferred stock in January 2017, and subsequently remeasured to
fair value at each reporting period. Changes in fair value of the financial instrument is recognized as a component of other income (expense), net in the statement of operations and comprehensive
loss. The Company estimated the fair value of the 2017 Series&nbsp;A Investor Right/Obligation as the probability-weighted present value of the expected benefit of the investment. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company used the Black-Scholes option-pricing model, which incorporates assumptions and estimates, to value the 2017 Series&nbsp;A Investor Call Option and assessed these
assumptions and estimates on a quarterly basis as additional information impacting the assumptions was obtained. Estimates and assumptions impacting the fair value measurement include the fair value
per share of the underlying series&nbsp;A preferred stock, the expected term of the Series&nbsp;A Investor Call Option, risk-free interest rate, expected dividend yield and expected volatility of
the price of the underlying preferred stock. The Company determined the fair value per share of the underlying preferred stock by taking into consideration the most recent sale of our convertible
preferred stock and the investors' right to invest in a subsequent tranche. As the Company was a private company and lacked company-specific historical and implied volatility information of its stock,
it estimated its expected stock volatility based on the historical volatility of publicly traded peer companies for a term comparable to the estimated term of the Series&nbsp;A Investor Call Option.
The risk-free interest rate was determined by reference to the U.S. Treasury yield curve for time periods approximately equal to the estimated term of the Series&nbsp;A Investor Call Option. A
dividend yield of zero was assumed. The fair value of the Series&nbsp;A Investor Instrument is determined to be the sum of the fair values of the 2017 Series&nbsp;A Investor Right/Obligation and
the 2017 Investor Call Option. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Net Loss Per Share Attributable to Common Shareholders  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic net loss per share attributable to common stockholders is calculated by dividing net loss attributable to common stockholders by the
weighted average shares outstanding during the period, without consideration for Common Stock equivalents. Net loss attributable to common stockholders is calculated by adjusting the net loss of the
Company for cumulative preferred stock dividends. During periods of income, the Company allocates participating securities a proportional share of income determined by dividing total weighted average
participating securities by the sum of the total weighted average common shares and participating securities (the "two class method"). The Company's convertible preferred stock participates in any
dividends declared by the Company and are therefore considered to be participating securities. Participating securities have the effect of diluting both basic and diluted earnings per share during
periods of income. During periods of loss, the Company allocates no loss to participating </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-42</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=270,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=862890,FOLIO='F-42',FILE='DISK109:[18ZBU1.18ZBU44601]FY44601A.;7',USER='CHE105614',CD='10-JUN-2018;18:09' -->
<A NAME="page_fy44601_1_43"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Rhythm Pharmaceuticals,&nbsp;Inc. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes to Unaudited Condensed Consolidated Financial Statements (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> (In thousands, except share and per share information) </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. Summary of Significant Accounting Policies (Continued) </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>securities
because they have no contractual obligation to share in the losses of the Company. Diluted net loss per share attributable to common stockholders is calculated by adjusting weighted average
shares outstanding for the dilutive effect of Common Stock equivalents outstanding for the period, determined using the treasury-stock and if-converted methods. For purposes of the diluted net loss
per share attributable to common stockholders calculation, convertible preferred stock and stock options are considered to be Common Stock equivalents but have been excluded from the calculation of
diluted net loss per share attributable to common stockholders, as their effect would be anti-dilutive for all periods presented. Therefore, basic and diluted net loss per share were the same for all
periods presented. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table includes the potential common shares, presented based on amounts outstanding at each period end, that were excluded from the computation of diluted net loss per share
attributable to common stockholders for the periods indicated: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Three Months Ended<BR>
March&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Stock options</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,427,629</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,037,131</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Series&nbsp;A convertible preferred shares</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6,594,870 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,427,629</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7,632,001 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic
and diluted earnings per share is calculated as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Three Months Ended<BR>
March&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Numerator:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net loss</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(16,459</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(6,360</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cumulative dividends on convertible preferred shares</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(1,166</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Loss attributable to common shares&#151;basic and diluted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(16,459</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(7,526</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Denominator:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Weighted-average number of common shares&#151;basic and diluted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>27,284,140</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10,196,292 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Loss per common share&#151;basic and diluted</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(0.60</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(0.74</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>) </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Subsequent Events  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the financial statements to
provide additional evidence for certain estimates or to identify matters that require additional disclosure. Subsequent events have been evaluated as required. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Application of New or Revised Accounting Standards  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From time to time, new accounting pronouncements are issued by the FASB and adopted by the Company as of the specified effective date. Unless
otherwise discussed, the Company believes that the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-43</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=271,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=67420,FOLIO='F-43',FILE='DISK109:[18ZBU1.18ZBU44601]FY44601A.;7',USER='CHE105614',CD='10-JUN-2018;18:09' -->
<A NAME="page_fy44601_1_44"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Rhythm Pharmaceuticals,&nbsp;Inc. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes to Unaudited Condensed Consolidated Financial Statements (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> (In thousands, except share and per share information) </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


2. Summary of Significant Accounting Policies (Continued) </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>impact
of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
April 2012, the Jump-Start Our Business Startups Act (the "JOBS Act") was signed into law. The JOBS Act contains provisions that, among other things, reduce certain reporting
requirements for an "emerging growth company." As an emerging growth company, the Company elected to not take advantage of the extended transition period afforded by the JOBS Act for the
implementation of new or revised accounting standards, and as a result, will comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for
non-emerging growth companies. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). ASU 2016-02 requires lessees to recognize lease assets and lease liabilities for those leases classified as operating
leases under previous GAAP. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to
use the underlying asset for the lease term. For leases with a term of 12&nbsp;months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to
recognize lease assets and lease liabilities. The recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee have not significantly changed from previous
GAAP. There continues to be a differentiation between finance leases and operating leases. ASU 2016-02 is effective for fiscal years beginning after December&nbsp;15, 2018, and interim periods
within those fiscal years, and early adoption is permitted. The Company is currently in the process of evaluating the impact of adoption of ASU No.&nbsp;2016-02 on its financial position and results
of operations. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
November 2016, the FASB issued ASU No.&nbsp;2016-18, Statement of Cash Flows (Topic 230): Restricted Cash ("ASU 2016-18") that changes the presentation of restricted cash and cash
equivalents on the statement of cash flows. Restricted cash and restricted cash equivalents will be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period
total amounts shown on the statement of cash flows. This amendment is effective for fiscal years beginning after December&nbsp;15, 2017, including interim periods within those fiscal years. Early
adoption is permitted, including adoption in an interim period. The adoption of this ASU did not have a material impact on the Company's statements of cash flows. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
May 2017, the FASB issued ASU 2017-09, Compensation&#151;Stock Compensation (Topic 718): Scope of Modification Accounting, ("ASU 2017-09"). ASU 2017-09 provides clarity and
reduces both (1)&nbsp;diversity in practice and (2)&nbsp;cost and complexity when applying the guidance in Topic 718, to a change to the terms or conditions of a share-based payment award. The
amendments in ASU 2017-09 should be applied prospectively to an award modified on or after the adoption date. This ASU is effective for fiscal years, and interim periods within those years, beginning
after December&nbsp;15, 2017. The adoption of this ASU did not have a material impact on the Company's financial position or results of operations. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-44</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=272,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=40554,FOLIO='F-44',FILE='DISK109:[18ZBU1.18ZBU44601]FY44601A.;7',USER='CHE105614',CD='10-JUN-2018;18:09' -->
<A NAME="page_fy44601_1_45"> </A>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Rhythm Pharmaceuticals,&nbsp;Inc. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes to Unaudited Condensed Consolidated Financial Statements (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> (In thousands, except share and per share information) </B></FONT></P>


<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


3. Accrued Expenses  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses consisted of the following: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="49pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>March&nbsp;31,<BR>
2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31,<BR>
2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Research and development costs</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,426</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,771</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Professional fees</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,137</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>327</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Payroll related</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>462</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,094</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>13</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>18 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accrued expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,038</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,210 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


4. Fair Value of Financial Assets and Liability  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of March&nbsp;31, 2018 and December&nbsp;31, 2017, the carrying amount of cash and cash equivalents and short-term investments was $136,453 and $148,082, respectively, which
approximates fair value. Cash and cash equivalents and short-term investments includes investments in money market funds that invest in U.S. government securities that are valued using quoted market
prices. Accordingly, money market funds and government funds are categorized as Level&nbsp;1 and had a total balance of $51,742 and $34,698 as of March&nbsp;31, 2018 and December&nbsp;31, 2017,
respectively. The financial assets valued based on level&nbsp;2 inputs consist of corporate debt securities and commercial paper, which consist of investments in highly-rated investment-grade
corporations. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
financial liability was recognized by the Company during the three months ended March&nbsp;31, 2017 related to the 2017 Series&nbsp;A Investor Instrument. The liability was valued
based on significant inputs not observable in the market, which represents a Level&nbsp;3 measurement within the fair value hierarchy. Upon the closing of the second tranche of the 2017
Series&nbsp;A preferred financing in August 2017, this liability was settled. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following tables present information about the Company's financial assets measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to
determine such fair values: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="36pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Fair value Measurements as of March&nbsp;31,<BR>
2018 using: </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Level&nbsp;1 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Level&nbsp;2 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Level&nbsp;3 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Assets:</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash Equivalents:</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Corporate Debt Securities and Commercial Paper</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6,989</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6,989</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Money Market Funds</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>36,779</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>36,779</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Marketable Securities:</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Corporate Debt Securities and Commercial Paper</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>78,323</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>78,323</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>U.S. Treasury Securities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>14,963</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>14,963 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>51,742</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>85,312</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>137,054 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-45</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=273,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=932430,FOLIO='F-45',FILE='DISK109:[18ZBU1.18ZBU44601]FY44601A.;7',USER='CHE105614',CD='10-JUN-2018;18:09' -->
<A NAME="page_fy44601_1_46"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Rhythm Pharmaceuticals,&nbsp;Inc. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes to Unaudited Condensed Consolidated Financial Statements (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> (In thousands, except share and per share information) </B></FONT></P>


<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


4. Fair Value of Financial Assets and Liability (Continued) </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><BR></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="36pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Fair value Measurements as of December&nbsp;31,<BR>
2017 using: </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Level&nbsp;1 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Level&nbsp;2 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Level&nbsp;3 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Assets:</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cash Equivalents:</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Corporate Debt Securities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>15,104</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>15,104</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Money Market Funds</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>17,753</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>17,753</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Marketable Securities:</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Corporate Debt Securities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>96,901</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>96,901</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>U.S. Treasury Securities</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>16,945</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>16,945 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>34,698</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>112,005</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>146,703 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Marketable Securities  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following tables summarize the Company's marketable securities: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="49pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>March&nbsp;31, 2018 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Amortized<BR>
Cost </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Gross<BR>
Unrealized<BR>
Gains </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Gross<BR>
Unrealized<BR>
Losses </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Fair<BR>
Value </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Assets</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Corporate Debt Securities and Commercial Paper (due within 1&nbsp;year)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>78,528</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(205</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>78,323</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>U.S. Treasury Securities (due within 1&nbsp;year)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>14,979</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(16</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>14,963 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>93,507</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>(221</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>93,286 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;<BR></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31, 2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Amortized<BR>
Cost </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Gross<BR>
Unrealized<BR>
Gains </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Gross<BR>
Unrealized<BR>
Losses </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Fair<BR>
Value </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Assets</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Corporate Debt Securities (due within 1&nbsp;year)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>97,029</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(128</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>96,901</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>U.S. Treasury Securities (due within 1&nbsp;year)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>16,958</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(13</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>16,945 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>113,987</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(141</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>113,846 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-46</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=274,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=738840,FOLIO='F-46',FILE='DISK109:[18ZBU1.18ZBU44601]FY44601A.;7',USER='CHE105614',CD='10-JUN-2018;18:09' -->
<A NAME="page_fy44601_1_47"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Rhythm Pharmaceuticals,&nbsp;Inc. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes to Unaudited Condensed Consolidated Financial Statements (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> (In thousands, except share and per share information) </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


4. Fair Value of Financial Assets and Liability (Continued) </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Below
is a roll forward of the fair value of the 2017 Series&nbsp;A Investor Instrument for the three months ended March&nbsp;31, 2017: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="64pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2017 Series&nbsp;A<BR>
Investor<BR>
Instrument </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Fair value at December&nbsp;31, 2016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Fair value upon the January 2017 Initial Closing, net</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>328</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Change in fair value</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Fair value at March&nbsp;31, 2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>328 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
fair value of the Series&nbsp;A Investor Instrument is the sum of the probability-weighted fair value of the 2017 Investor Right/Obligation and the 2017 Series&nbsp;A Call
Option. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following assumptions and inputs were used in determining the fair value of the 2017 Series&nbsp;A Investor Call Option valued using the Black- Scholes option pricing model: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="73pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>March&nbsp;31, 2017 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Series&nbsp;A Convertible Preferred Stock Exercise Price</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.00</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Series&nbsp;A Convertible Preferred Stock Fair Value</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.39</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected term</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3.5&nbsp;months</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected volatility</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>82.0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected interest rate</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0.76</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Expected dividend yield</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
August 2017, upon the closing of the second tranche of the series&nbsp;A preferred stock financing, the 2017 Series&nbsp;A Investor Call Option expired unexercised. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company estimated the fair value of the 2017 Series&nbsp;A Investor Right/Obligation as the probability-weighted present value of the expected benefit of the investment. The
expected benefit is the difference between the expected future value of shares issued upon the second tranche closing and the investment price for the second tranche closing. The expected future value
is estimated as a weighted average of IPO and remain private scenarios, and the future value is converted to a present value assuming a closing date of October&nbsp;15, 2017 and a nominal, risk-free
discount rate. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


5. Preferred and Common Stock  </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Preferred Stock  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon the closing of the IPO, the series&nbsp;A convertible preferred stock automatically converted into shares of common stock on a 9.17-for-1
basis. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Common Stock  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In March 2013, the Company issued 10,196,292 shares of common stock at a purchase price of $0.001&nbsp;per share. Prior to August, 2017,
the&nbsp;LLC entity owned all of these shares. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-47</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=275,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=272192,FOLIO='F-47',FILE='DISK109:[18ZBU1.18ZBU44601]FY44601A.;7',USER='CHE105614',CD='10-JUN-2018;18:09' -->
<A NAME="page_fy44601_1_48"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Rhythm Pharmaceuticals,&nbsp;Inc. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes to Unaudited Condensed Consolidated Financial Statements (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> (In thousands, except share and per share information) </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


5. Preferred and Common Stock (Continued) </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
August&nbsp;21, 2017, the&nbsp;LLC entity exchanged 8,578,646 of its shares of the Company's common stock for 78,666,209 shares of the Company's series&nbsp;A-1 junior preferred
stock and the&nbsp;LLC entity distributed
all of its shares of the Company's series&nbsp;A-1 junior preferred stock to the holders of its preferred units and the remaining 1,617,646 shares of its common stock to the holders of its common
units. Following this distribution, the&nbsp;LLC entity no longer owns any of the Company's shares. The series&nbsp;A-1 junior preferred stock is not redeemable and does not have a stated dividend
or liquidation preference. These shares converted to common stock on a 9.17-to-1 basis upon the closing of the IPO in October 2017. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
September 2017, the Company's board of directors approved a 1-for-9.17 reverse stock split of the Company's issued and outstanding shares of common stock. All shares and per share
amounts in the financial statements have been retrospectively adjusted for all periods presented to give effect of the reverse stock split. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
October&nbsp;10, 2017 the Company completed its IPO of 8,107,500 shares of common stock at an offering price of $17.00 per share, which included the exercise in full by the
underwriters of their option to purchase up to 1,057,500 additional shares of common stock. The Company received gross proceeds of approximately $137,828 or net proceeds of $125,658 after deducting
underwriting discounts, commissions and estimated offering expenses. In connection with the IPO, the Company's outstanding shares of convertible preferred stock were automatically converted into
17,406,338&nbsp;shares of common stock. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
April&nbsp;3, 2018, in association with the Takeda license agreement, the Company issued 223,544&nbsp;shares of common stock. See Note&nbsp;6 for further discussion. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


6. Significant Agreements  </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


License Agreements  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Predecessor Company entered into a license agreement on February&nbsp;26, 2010 with Ipsen Pharma,&nbsp;S.A.S. ("Ipsen") that granted
full worldwide right for two programs that include the clinical candidates setmelanotide, which is in Phase&nbsp;3 clinical trials, and relamorelin. As a result of the Corporate Reorganization
described in Note&nbsp;1, the Ipsen license was converted to separate license agreements for the setmelanotide program held by the Company and the relamorelin program held by the Relamorelin
Company, respectively. Under the terms of the setmelanotide Ipsen license agreement, assuming that setmelanotide is successfully developed, receives regulatory approval and is commercialized, Ipsen
may receive aggregate payments of up to $40,000 upon the achievement of certain development and commercial milestones and royalties on future product sales in the mid-single digits. Substantially all
of such aggregate payments of up to $40,000 are for milestones that may be achieved no earlier than first commercial sale of setmelanotide. In the event that the Company executes a sublicense
agreement, it shall make payments to Ipsen, depending on the date of such sublicense agreement, ranging from 10% to 20% of all revenues actually received under such sublicense agreement. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
July 2017, the Company made a prepayment on the first milestone event associated with this license agreement. The first milestone relates to the initiation of a Phase&nbsp;3 study
for setmelanotide in a pivotal multi-center human clinical trial in a large number of patients. The prepayment associated with this milestone was $1,000 and was recorded as research and development
expenses during the three months ended March&nbsp;31, 2018 when the milestone criteria was met in full. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-48</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=276,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=961794,FOLIO='F-48',FILE='DISK109:[18ZBU1.18ZBU44601]FY44601A.;7',USER='CHE105614',CD='10-JUN-2018;18:09' -->
<A NAME="page_fy44601_1_49"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Rhythm Pharmaceuticals,&nbsp;Inc. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes to Unaudited Condensed Consolidated Financial Statements (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> (In thousands, except share and per share information) </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


6. Significant Agreements (Continued) </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
January 2016, the Company entered into a license agreement with Camurus AB, or Camurus, for the use of Camurus' drug delivery technology. The contract includes a non-refundable and
non-creditable signing fee of $500, which was paid during January 2016. The Camurus agreement also includes up to $7,750 in one-time, non-refundable development milestones achievable upon certain
regulatory successes. The Company is also required to pay to Camurus, mid to mid-high single digit royalties, on a product-by-product and country-by-country basis of annual net sales, until the later
of (i)&nbsp;10&nbsp;years after the date of first commercial sale of such product in such country; or (ii)&nbsp;the expiration of the last to expire valid claim of all licensed patent rights in
such country covering such product. The Company is also required to pay one-time, non-refundable, non-creditable sales milestones upon the achievement of certain sales levels for such product that
cannot be in excess of $57,000. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
March 2017, the Company achieved the first milestone event associated with this license agreement. The Company completed the first manufactured batch using the Camurus drug delivery
technology and
filed an investigational new drug application with the FDA. The fee associated with this milestone was $250. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
December 2017, the Company achieved the second milestone event associated with this license agreement. The Company completed the Phase&nbsp;I proof of concept study using the
Camurus drug delivery technology. The fee associated with this second milestone was $1,000 and was recorded as research and development expense. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
March 2018, the Company entered into a license agreement with Takeda, for the rights of a program that includes the clinical candidate RM-853, which is a GOAT inhibitor, which is
currently in preclinical development for PWS. Pursuant to the license agreement the Company was required to pay a non-refundable and non-creditable signing fee, which the Company settled by issuing on
April&nbsp;3, 2018, 223,544 shares of common stock valued at $4,448. Under the terms of the license agreement, assuming that RM-853 is successfully developed, receives regulatory approval and is
commercialized, the Company is also required to pay up to $70,000 in one-time, non-refundable development milestone payments upon the achievement of certain clinical and regulatory milestones. The
Company is also required to pay up to $70,000 in one-time, non-refundable, non-creditable sales milestone payments upon the achievement of certain sales levels. The Company is also required to pay to
Takeda, mid to mid-high single digit royalties (subject to certain potential reductions over time), on a product-by-product and country-by-country basis of annual net sales, of each product in such
country, beginning on the first commercial sale of a product in such country, and continuing until the latest of (i)&nbsp;10&nbsp;years after the date of first commercial sale of such product in
such country; or (ii)&nbsp;the expiration of the last to expire valid claim of a Takeda patents covering the composition or use of such product in such country; or (iii)&nbsp;the expiration of all
regulatory exclusivity for such product in such country. The Company recorded the fair value of the common stock to be issued to the licensors as research and development expense, as the license does
not have a future alternative use, in accordance with ASC Topic 730, </FONT><FONT SIZE=2><I>Research and Development.</I></FONT><FONT SIZE=2> As the shares were not issued prior to the end of the
period, the Company evaluated the forward contract and concluded that it met the criteria for equity classification and such amounts have been recorded within additional paid-in capital as of
March&nbsp;31, 2018. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-49</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=277,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=865270,FOLIO='F-49',FILE='DISK109:[18ZBU1.18ZBU44601]FY44601A.;7',USER='CHE105614',CD='10-JUN-2018;18:09' -->
<A NAME="page_fy44601_1_50"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B><BR>
Rhythm Pharmaceuticals,&nbsp;Inc. </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Notes to Unaudited Condensed Consolidated Financial Statements (Continued) </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> (In thousands, except share and per share information) </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


7. Related-Party Transactions  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Expenses paid directly to consultants considered to be related parties amounted to $472 and $229 for the three months ended March&nbsp;31, 2018 and 2017, respectively. Outstanding
payments due to these related parties as of March&nbsp;31, 2018 and December&nbsp;31, 2017 were $102 and $112, respectively, and were included within accounts payable on the balance sheet. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


8. Income Taxes  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For the year ended December&nbsp;31, 2017, the Company did not have a current or deferred income tax expense or benefit as the entity has incurred losses since inception and has
provided a full valuation allowance against its deferred tax assets. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>*
* * * * * </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>F-50</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=12,SEQ=278,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=341362,FOLIO='F-50',FILE='DISK109:[18ZBU1.18ZBU44601]FY44601A.;7',USER='CHE105614',CD='10-JUN-2018;18:09' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=5><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares  </I></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=5><B>
<IMG SRC="g460244.jpg" ALT="LOGO" WIDTH="204" HEIGHT="94">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=3><I>Common Stock  </I></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=3><I>PROSPECTUS  </I></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="199pt" style="font-family:times;"></TD>
<TD WIDTH="7%" style="font-family:times;"></TD>
<TD WIDTH="229pt" style="font-family:times;"></TD>
<TD WIDTH="7%" style="font-family:times;"></TD>
<TD WIDTH="81pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=4><I>MORGAN&nbsp;STANLEY</I></FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="TOP" style="font-family:times;"><FONT SIZE=4><I> BofA&nbsp;MERRILL&nbsp;LYNCH</I></FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=4><I> COWEN</I></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><I>NEEDHAM&nbsp;&amp;&nbsp;COMPANY  </I></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="21%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="21%" ALIGN="CENTER" >


 </FONT> <FONT SIZE=4><I>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </I></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018  </I></FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=279,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=540395,FOLIO='blank',FILE='DISK109:[18ZBU1.18ZBU44601]HO44601A.;27',USER='CHE105614',CD='10-JUN-2018;18:09' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_ja44601_1_1"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ja44601_part_ii_information_not_required_in_prospectus"> </A>
<A NAME="toc_ja44601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PART II<BR>  INFORMATION NOT REQUIRED IN PROSPECTUS    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="ja44601_item_13._other_expense__ja401988"> </A>
<A NAME="toc_ja44601_2"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;13.&nbsp;&nbsp;&nbsp;&nbsp;Other Expenses of Issuance and Distribution.    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth the fees and expenses in connection with the issuance and distribution of the securities being registered
(excluding the underwriting discount). Except for the SEC registration fee, the Nasdaq listing fee and the FINRA filing fee, all amounts are estimates. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Amount Paid<BR>
or to be<BR>
Paid </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>SEC registration fee</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>FINRA filing fee</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Nasdaq listing fee</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Legal fees and expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Accounting fees and expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Printing expenses</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Transfer and registrar fee</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Miscellaneous</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="ja44601_item_14._indemnification_of_directors_and_officers."> </A>
<A NAME="toc_ja44601_3"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;14.&nbsp;&nbsp;&nbsp;&nbsp;Indemnification of Directors and Officers.    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;145 of the Delaware General Corporation Law authorizes a corporation's board of directors to grant, and authorizes a court to
award, indemnity to officers, directors, and other corporate agents. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
permitted by Delaware law, our amended and restated certificate of incorporation provides that, to the fullest extent permitted by Delaware law, no director will be personally liable
to us or our stockholders for monetary damages for breach of fiduciary duty as a director. Pursuant to Delaware law such protection would be not available for
liability:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> for any breach of a duty of loyalty to us or our stockholders; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> for acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> for any transaction from which the director derived an improper benefit; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> for an act or omission for which the liability of a director is expressly provided by an applicable statute, including unlawful payments of
dividends or unlawful stock repurchases or redemptions as provided in Section&nbsp;174 of the Delaware General Corporation Law. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
amended and restated certificate of incorporation also provides that if Delaware law is amended after the approval by our stockholders of the amended and restated certificate of
incorporation to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of our directors will be eliminated or limited to the fullest extent
permitted by Delaware law. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
amended and restated bylaws further provide that we must indemnify our directors and officers to the fullest extent permitted by Delaware law. Our amended and restated bylaws also
authorize us to indemnify any of our employees or agents and permit us to secure insurance on behalf of any officer, director, employee or agent for any liability arising out of his or her action in
that capacity, whether or not Delaware law would otherwise permit indemnification. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>II-1</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=280,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=533509,FOLIO='II-1',FILE='DISK109:[18ZBU1.18ZBU44601]JA44601A.;11',USER='JVANGB',CD='11-JUN-2018;07:27' -->
<A NAME="page_ja44601_1_2"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, our amended and restated bylaws also provide that we are required to advance expenses to our directors and officers as incurred in connection with legal proceedings against
them for which they may be indemnified and that the rights conferred in the amended and restated bylaws are not exclusive. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have entered into indemnification agreements with each of our directors and executive officers. These agreements, among other things, require us to indemnify each director and officer
to the fullest extent permitted by Delaware law, the amended and restated certificate of incorporation and amended and restated bylaws, for expenses such as, among other things, attorneys' fees,
judgments, fines, and settlement amounts incurred by the director or executive officer in any action or proceeding, including
any action by or in our right, arising out of the person's services as our director or executive officer or as the director or executive officer of any subsidiary of ours or any other company or
enterprise to which the person provides services at our request. We also have directors' and officers' liability insurance. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
SEC has taken the position that personal liability of directors for violation of the federal securities laws cannot be limited and that indemnification by us for any such violation
is unenforceable. The limitation of liability and indemnification provisions in our amended and restated certificate of incorporation and amended and restated bylaws may discourage stockholders from
bringing a lawsuit against our directors and officers for breach of their fiduciary duty. They may also reduce the likelihood of derivative litigation against our directors and officers, even though
an action, if successful, might benefit us and other stockholders. Further, a stockholder's investment may be adversely affected to the extent that we pay the costs of settlement and damage awards
against directors and officers as required by these indemnification provisions.  </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="ja44601_item_15._recent_sales_of_unregistered_securities"> </A>
<A NAME="toc_ja44601_4"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;15.&nbsp;&nbsp;&nbsp;&nbsp;Recent Sales of Unregistered Securities    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Set forth below is information regarding securities we have issued within the past three years that were not registered under the Securities
Act: </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
January&nbsp;6, 2017 and August&nbsp;18, 2017 we issued 20,475,001 shares and 20,474,998 shares, respectively, of series&nbsp;A preferred stock, $0.001 par value per share, to a
number of accredited investors for $1.00 per share. These shares were issued in reliance on Regulation&nbsp;D, Rule&nbsp;506 and/or Section&nbsp;4(a)(2) under the Securities Act. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;From
January&nbsp;1, 2014 through September&nbsp;22, 2017, we granted options under the 2015 Plan to purchase an aggregate of 2,088,769 shares of our common stock to employees,
consultants and directors, having exercise prices ranging from $4.59 to $8.44 per share. During this period, 152,671 stock options were exercised and 114,503 were forfeited. These options and their
exercises were granted or issued in reliance on Rule&nbsp;701 and/or Section&nbsp;4(a)(2) under the Securities Act. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
April&nbsp;3, 2018, we issued 223,544 shares of our common stock to Takeda Pharmaceutical Company Limited at a price per share of $17.96. These shares were issued in reliance on
Section&nbsp;4(a)(2) under the Securities Act.  </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="ja44601_item_16._exhibits_and_financial_statement_schedules."> </A>
<A NAME="toc_ja44601_5"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;16.&nbsp;&nbsp;&nbsp;&nbsp;Exhibits and Financial Statement Schedules.    <BR>    </B></FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><B>(a)&nbsp;&nbsp;&nbsp;Exhibits  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The exhibits to the registration statement are listed in the Exhibit Index attached hereto and incorporated by reference herein. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><B>(b)&nbsp;&nbsp;&nbsp;Financial Statement Schedules  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All financial statement schedules have been omitted because they are not required or because the required information is given in the financial statements or
notes to those statements. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>II-2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=281,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=947325,FOLIO='II-2',FILE='DISK109:[18ZBU1.18ZBU44601]JA44601A.;11',USER='JVANGB',CD='11-JUN-2018;07:27' -->
<A NAME="page_ja44601_1_3"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="ja44601_item_17._undertakings."> </A>
<A NAME="toc_ja44601_6"> </A></FONT> <FONT SIZE=2><B>  Item&nbsp;17.&nbsp;&nbsp;&nbsp;&nbsp;Undertakings.    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of
the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public
policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred
or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in
connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to
a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
undersigned Registrant hereby undertakes that: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>For
purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement
in reliance upon Rule&nbsp;430A and contained in a form of prospectus filed by the Registrant pursuant to Rule&nbsp;424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be
part of this registration statement as of the time it was declared effective.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>For
the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new
registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial </FONT><FONT SIZE=2><I>bona
fide</I></FONT><FONT SIZE=2> offering thereof. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>II-3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=282,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=876291,FOLIO='II-3',FILE='DISK109:[18ZBU1.18ZBU44601]JA44601A.;11',USER='JVANGB',CD='11-JUN-2018;07:27' -->
<UL>
<UL>
</UL>
</UL>
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_jc44601_1_4"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="jc44601_exhibit_index"> </A>
<A NAME="toc_jc44601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  EXHIBIT INDEX    <BR>    </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="53pt" style="font-family:times;"></TD>
<TD WIDTH="18pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="35pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="40pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=6 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Incorporated by Reference </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Exhibit<BR>
Number </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Exhibit Description </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Form </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Date </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form of Underwriting Agreement</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Amended and Restated Certificate of Incorporation.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>S-1/A</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>9/25/2017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>3.3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Amended and Restated Bylaws.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>S-1/A</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>9/25/2017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>3.5</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form of Common Stock Certificate.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>S-1/A</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>9/25/2017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>4.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Amended and Restated Investors' Rights Agreement, dated August&nbsp;21, 2017.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>S-1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>9/5/2017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>4.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Form of Indemnification Agreement.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>S-1/A</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>9/25/2017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>10.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>2017 Equity Incentive Plan and Form of Option Agreement and Notice of Exercise.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>10-Q</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>11/14/2017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>10.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.3</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&#135;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>License Agreement, dated March&nbsp;21, 2013, by and between the Registrant (f/k/a Rhythm Metabolic,&nbsp;Inc.) and Ipsen Pharma&nbsp;S.A.S.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>S-1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>9/5/2017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>10.6</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.4</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&#135;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Development and Manufacturing Services Agreement, dated July&nbsp;17, 2013, by and between the Registrant (f/k/a Rhythm Metabolic,&nbsp;Inc.) and Peptisyntha&nbsp;Inc. (n/k/a Corden Pharma International).</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>S-1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>9/5/2017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>10.7</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.5</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&#135;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>License Agreement dated January&nbsp;4, 2016, by and between the Registrant and Camurus AB.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>S-1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>9/5/2017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>10.8</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.6</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Amended and Restated Payroll Services Agreement, dated March&nbsp;21, 2013, by and between the Registrant (f/k/a&nbsp;Rhythm Metabolic,&nbsp;Inc.) and Rhythm Pharmaceuticals,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>S-1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>9/5/2017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>10.9</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.7</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Rhythm Pharmaceuticals,&nbsp;Inc. 2017 Employee Stock Purchase Plan.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>10-Q</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>11/14/2017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>10.10</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.8</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Lease, dated November&nbsp;25, 2015, by and between 500&nbsp;Boylston&nbsp;&amp; 222 Berkeley Owner (DE)&nbsp;LLC and the Registrant.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>S-1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>9/5/2017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>10.11</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.9</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Consulting Agreement, dated June&nbsp;12, 2017, by and between the Registrant and Bart Henderson.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>S-1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>9/5/2017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>10.12</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.10</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Offer Letter, dated September&nbsp;13, 2017, by and between the Registrant and Keith M. Gottesdiener.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>S-1/A</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>9/25/2017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>10.13</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.11</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Development and Manufacturing Services Agreement, dated as of December&nbsp;21, 2016, by and between Registrant and Recipharm Monts&nbsp;S.A.S.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>S-1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>9/5/2017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>10.15</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.12</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Offer Letter, dated September&nbsp;13, 2017, by and between the Registrant and Hunter Smith.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>S-1/A</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>9/25/2017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>10.18</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.13</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Offer Letter, dated September&nbsp;13, 2017, by and between the Registrant and Nithya Desikan.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>S-1/A</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>9/25/2017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>10.19</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><BR></FONT>
</TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>II-4</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=283,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=763830,FOLIO='II-4',FILE='DISK109:[18ZBU1.18ZBU44601]JC44601A.;9',USER='CHE105614',CD='10-JUN-2018;18:09' -->
<A NAME="page_jc44601_1_5"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="53pt" style="font-family:times;"></TD>
<TD WIDTH="18pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="35pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="40pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=6 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Incorporated by Reference </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Exhibit<BR>
Number </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Exhibit Description </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Form </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Date </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.14</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Summary of Non-Employee Director Compensation Policy.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>10-Q</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>5/14/18</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>10.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.15</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&#134;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>2015 Equity Incentive Plan and Form of Option Agreement and Notice of Exercise.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>S-1/A</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>9/25/2017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>10.21</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.16</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&#135;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>License Agreement, dated March&nbsp;30, 2018, by and between Registrant and Takeda Pharmaceutical Company Limited</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>10-Q</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>5/14/18</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>10.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10.17</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>*&#134;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>First Amendment to the 2017 Employee Stock Purchase Plan</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>21.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>List of Subsidiaries</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>23.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Consent of Ernst&nbsp;&amp; Young&nbsp;LLP, Independent Registered Public Accounting Firm.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>31.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Certification of the Chief Executive Officer, as required by Section&nbsp;302 of the Sarbanes-Oxley Act of 2002 (18&nbsp;U.S.C.&nbsp;1350).</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>31.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Certification of the Chief Financial Officer, as required by Section&nbsp;302 of the Sarbanes-Oxley Act of 2002 (18&nbsp;U.S.C.&nbsp;1350).</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>32.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>**</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Certification of the Chief Executive Officer, as required by Section&nbsp;906 of the Sarbanes-Oxley Act of 2002 (18&nbsp;U.S.C.&nbsp;1350).</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>32.2</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>**</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Certification of the Chief Financial Officer, as required by Section&nbsp;906 of the Sarbanes-Oxley Act of 2002 (18&nbsp;U.S.C.&nbsp;1350).</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>101.INS</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>XBRL Instance Document.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>101.SCH</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>XBRL Taxonomy Extension Schema Document.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>101.CAL</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>XBRL Taxonomy Extension Calculation Linkbase Document.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>101.DEF</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>XBRL Taxonomy Extension Definition Linkbase Document.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>101.LAB</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>XBRL Taxonomy Extension Label Linkbase Document.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>101.PRE</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>XBRL Taxonomy Extension Presentation Linkbase Document.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>*</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>To
be filed by amendment.  </FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>**</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Furnished
and not filed herewith  </FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>&#134;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Indicates
management contract or compensatory plan.  </FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>&#135;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Indicates
confidential treatment has been granted with respect to specific portions of this exhibit. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>II-5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=284,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=836248,FOLIO='II-5',FILE='DISK109:[18ZBU1.18ZBU44601]JC44601A.;9',USER='CHE105614',CD='10-JUN-2018;18:09' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_je44601_1_6"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->





<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="je44601_signatures"> </A>
<A NAME="toc_je44601_1"> </A>
<BR></FONT><FONT SIZE=2><B>  SIGNATURES    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant has duly caused this Registration Statement to be signed
on its behalf by the undersigned, thereunto duly authorized, in the city of Boston, Commonwealth of Massachusetts
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="49%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="22pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="46%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2><B> RHYTHM PHARMACEUTICALS,&nbsp;INC.</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2> By:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;&nbsp;<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Keith M. Gottesdiener<BR></FONT> <FONT SIZE=2><I>Chief Executive Officer, President and Director</I></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;KNOW
ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Keith M. Gottesdiener and Hunter C. Smith his true and lawful attorney-in-fact
and agent with full power of substitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this
registration statement, and to sign any registration statement for the same offerings covered by the registration statement that is to be effective upon filing pursuant to Rule&nbsp;462(b)
promulgated under the Securities Act, and all post-effective amendments thereto, and to file the same, with all exhibits thereto and all documents in connection therewith, with the Securities and
Exchange Commission, granting unto said attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the
premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming that all said attorneys-in-fact and agents or any of them, or his or their substitute
or substitutes, may lawfully do or cause to be done by virtue hereof </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="37%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="37%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="114pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH NOWRAP  ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Title

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH NOWRAP  COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Date

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>&nbsp;<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Keith M. Gottesdiener</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>Chief Executive Officer, President and Director (Principal Executive Officer)</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>, 2018</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;&nbsp;<BR>



<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Hunter C. Smith</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>Chief Financial Officer and Treasurer (Principal Financial and Accounting Officer)</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>, 2018</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;&nbsp;<BR>



<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Neil Exter</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>, 2018</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;&nbsp;<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Todd Foley</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>, 2018</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;&nbsp;<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Christophe R. Jean</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>, 2018</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>II-6</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=285,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=593928,FOLIO='II-6',FILE='DISK109:[18ZBU1.18ZBU44601]JE44601A.;8',USER='CHE105614',CD='10-JUN-2018;18:09' -->
<A NAME="page_je44601_1_7"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A HREF="#bg44601a_main_toc">Table of Contents</A></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="37%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="37%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="114pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH NOWRAP  ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Title

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH NOWRAP  COLSPAN=2 ALIGN="CENTER" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Date

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> Ed Mathers</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>, 2018</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> David W. J. McGirr</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>Director</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>, 2018</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD ALIGN="CENTER" VALIGN="TOP" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> David P. Meeker</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>Director, Chairman of the Board</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="MIDDLE" style="font-family:times;"><BR><FONT SIZE=2>, 2018</FONT></TD>
<TD VALIGN="MIDDLE" style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>II-7</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=286,EFW="2235972",CP="RHYTHM PHARMACEUTICALS, INC.",DN="1",CHK=342724,FOLIO='II-7',FILE='DISK109:[18ZBU1.18ZBU44601]JE44601A.;8',USER='CHE105614',CD='10-JUN-2018;18:09' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g29192.jpg
<TEXT>
begin 644 g29192.jpg
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MT+SN3S_9Z?FFMXM',^.-LM,?X^97..RSE&C^JN!OUN=VB5AG&/(B8E[13Z3
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MGOFOKN V;SC.*JY4KI 0MHW6%<L'R:E(B7EXJN 7_J83(_4-&*M<XVAXL<)
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M#_!E6?F6C]3[V0_8I8#_  95GYEHBECUR6W;W^L+_A3HOZ>T>N2V[>_UA?\
M"G1?T]J)_P!3[V0_8I8#_!E6?F6C]3[V0_8I8#_!E6?F6B*6/7);=O?ZPO\
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MK-R#<G2)UA6BP($ZKDIR=,J0)$ZGH&*<G)02Z!@,!>B( "W<%(14S9P5)42
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MZ7=:Q.4.+?WS*$GC F.]R%/5CE[,@;(60,#.JQBN0]33PS,ZT;=/5R_%XWL
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M%XGV^6L#+TN;L,-&P4[/2:5%C#7J2+9I2-8P3@KQB+J.ZIT\C&_7#VWII9@
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M.1ZOFL2HNO.KWK#2,2'5E[;]"RD=$HAP(!P'@' <!\6CHE$  2@(!X!P' ?
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MDA)&48DBBI3<K H#*2#!+M'9E%G2.4 "$ ! "E ![A "@ "'N#P'?XCX^[H
MI0 0 I0 ?$    ?A  [_ (]/<S@W-7><5'VJ;U'R?2[K6+:C&N%TH^1[H[P3
MN+HCO'T>F_8T6[T*CLKMD@ZC!X]&/QVRB,JS,3(OTSM"L%$YR9@$0?/&B95S
M(G472_12$K=<L?9#O;O".X.CO:$@JLRQ[=*)2V5^R(*48,B"&/V$5E*7A9!=
M50/-:19J<@B&DA!,QRM_UQK*"!"  @!2@ ^( 4  ?A#COT 0@ ( 4H /B %
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MDH5[9[_B.^)VR5456(I76*./[=(KQ+I!---8\E+E2C3E7(1-0QR*=')[P >
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M:W31(K@>UJ&*R#K!R>\![@?)HX#W ^33W,X-S5WG%1]JF]1\GTNZUBZJE7W
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M;]?(NM"9IP189#<1=-KF1L%9<P?GA#(N"CY'RE!4N7QW*,K5.J(5ZZ5*L9D
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M)T+<1M4B#;4=R9DZ9M?P">.QAA;$"UY''ZE$CCR532'-ED;H2;%G)V=BWB)
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MLZJX"9BHF$@R+8XV(^5>R/N5W.O]GNY[9E9=FV=I7;-![Q,7PZF:*/GFMWS
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M   #@.?C$3#\IA$?QZKHT:(C5!*4>>0 >?'D/'X?=X]KGGCVM5T:(J< //(
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ML7#N @'<7$OEHZ-5>M'!XYD*#^Z-&B)=\>XF=53<'N&RLK8(60:Y8A,)1S6
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M=6"[.U[(1>H,8!PW6Z@GG%LJC*=)7MO6G871$:^?5%]U3]V5_AZ^FC1%0 X
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M$B876*[?%OOR1MJR)(UK'].IT["8IVZ/]U66"6QM8G<S>*,PS-3L3AC+%SB
MF(QO6;V];3%EL;>U6*,ND620C*Q52TUP2TO[)6<J.H2RAMPP;FFSX\N64\8U
M2[V?%<L$U0YF=8&</()X64AIXJ13)K(IR462QUJL6@D',IR4&2U5:K6@L:%@
MK4%)1Y%CZW>>40R%MORQE9&$HE8L>(=M,%M6E<Q1+IE87&5,AJ[LK]DVB02>
M(Y&/FVU:@#8S"@L[!,MK/7;,-[3EY&':NJ($ G-S,O[$MV64]PKR^53,%?H+
M&TUO&.V3-L;,XR:V:/JPU+=%CJ;N\/1'C6U3%A?/K=C:0JTW#3-H:RC"/NL.
M^K5J0IM&5DG%;:3^KL]VQK7JC9*6PG0E;OC<\XI3; K$"HZB%K!8;3;7C@R*
MBYF,HX:6B\W6PP#B::22]5F;A:I*KJ0SNQ2ZKRZL([=,([;X"7K&#L:U?&L%
M.S'GV6CZTR4;IO7Z4>SAH\JBCA=TX+'04#&QE;K$*DLG"U2L1<76:U'Q,#&L
M8YN1)?D_RI6',79%NV-Y6B9#D92C621K$B^8*TQ-BZ?1:A47*S,CZS-W@-A5
M$P)"Y;H*F*4#&23Z0%"Q?U8;!OO<9._?%"_C9K*&\QY0I!VX?/Z347KUXL=P
M[=NZS!N73EPH/*B[APNP46764'O.JJ<YSCWF,(Z_-Z,,;_6!2?O2KWZ-T18Q
MB^6$P><0*3&N4#F'N I%J(<PC[@%+;!,/N]P#W=_AK[?JOF&/>LRS]S2?XT:
MFGRAE'I4#LEW,RL-4:Q$R+7%,\9N_C:_$,'J F49@8R+IFR1<)&$.X3)J%'@
M1UI$GE'72,':W7<(AW.7(>W_ &>IGN9W'OW24U34-KVT@IYVPECJ8SEUXP_,
M")XK6O:UCJO=5[WA<!TA;AOZKYACWK,L_<TG^-&C]5\PN'>.+<L@'MB(4D #
M[8B-IX /MCK3P\Z.OVTZ_?3G_2:DG#4@NKF#$J2CA=1-7*>.$U$U%UU"*)J7
M6#(<AR',8ATSD,8AR' 2'*82F*8HB&I#-V,9(899>[+';U&^3+V@X9LC2ZU^
MVS:]B+V-M&CB=YRQXO\ -;7_ .K#8-][C)W[XH7\;-'ZL-@WWN,G?OBA?QLU
MDZ]&..#"8PT"E")C',(C4Z^(B)C"(B(C'"(B(B(B(B(C[8Z/1AC?ZP*3]Z5>
M_1NM5JBC?;5N(J^YS':^1ZE#3D%%(667K!F4^>*.^,[AT6"RZY30[^1:=G4+
M() D N 6 Q%.L3('1$UY9OG:[5\,9<LMPK:=RJ5=QA?YVT5%4C51*TUV(J<O
M(3=<43??K(Y)R,;NHLY'?ZU,5V)7'T$3ZOZ)AHB!:!'PD7'0[$JBBQ6<6Q:1
MS0%5C=)50&S-%!$%%3 !E#@GTCCWF$1U'N=9^!JN$LPV>U5EM=*Q7,69"GK'
M3GAFY&EK@8>H3$C,5IR=VBX:D;ST<V<Q2YG+== J3LXK(JI <AB*%[A>KVVI
M&T>5PA67T55[SD_#\9<X*,K2$\E5\+3^/['*OVSPS5NX;5V,AUVU7C5;"W[.
MA'G*@U1<$3>E*=NB"(E*)OIA* CW<=_'?W>UW^UI0K9?+^A1=HDMA2KNXBN7
MO)F'8V[P$17D;&VJN&;!CVQ2TDT<K(,S(0,3"N6U8C361%)DDR$K=NDHB1\5
M(S>D$1*43?3"4!'NX[^._N]KO]K1$EF[W/V3<4S& <98:9T-+)&X*_WRJ1%J
MRE&6&<Q_3XO&>#,F9QGGLU!U2QU.>EWL\UQZA48E-M88IO#JSSFU.QETZ\2L
MSRDY7\HUEA/!^VW*N(\<TB%E<M;#LO>4+N,)E+U5R[-ACW"- PE<)[#%><5I
MU6'K2[W)]FR/BX;(TLVDH6K1]>>3#O'MK7E&T2SR6YKP)A_<73TJ%FN@P.0Z
MHVF&E@9Q4ZDY_6$RT:/XTLC&OH]TQDXUTXAI:9K\B=@];>=JW.3M;E >0,W+
M1SRP;SLRVL9);QC2[X(QQ8&D/:XZY1S-W7T4F3>9C*?5,?))"S9':M5J^ZH]
M%I=2EZ>NDK3YVO52NQ4Y 2+2&8)($2D;.-^&2MR.5*BPL=*JD'C#.^/=T.3<
M-LHN/LS+(V/(3:QN0JFWF9A<R.9&8EJ[.3F1CW.-N42>N1E/0I+J-FJ.Z;W,
MZ*-L-->YG?GCK:_>XJ@VZH7.?DI:JL[8B\KIZT5DFR>2DM%)MU0F)N.<]I*M
M$+J'$B!D.J42Z*IC],I)ZH.V_!F+LB9#RQC_ !A4JID3*KI5[?+7$QPHRDZN
M[E',])CTCJJMXM*=LCU[:K(V@V\6VLUM>O+78$9.QNEY127'D-$2*I5G\7'/
M5BD!,JKMBU<J%3 QC F51=%0X$ QC& @"!0,8P@'(B(D6)_]6#PA[VF4OW6B
M_P :]'ZL'A$?#&>4OW6B_P :]95?4O6_K?A/[DQWS;5O6VM5U.JV4Y(&%*8M
M?FQ*8(F/ 0'S6[[P$&W^WM]V@TD#C18T/U7S#'O699^YI/\ &C1^J^88]ZS+
M/W-)_C1K3Z&1==(WZ\=A[(_'ZY6#NZ0^ "KW<_\ =KCYQ<_MQWW>'ZY5[O\
M]IK:X[%LI /=J/3_ *@[9_K?M;HO]A@Y0\71MVCQK<'_ %7S#'O699^YI/\
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M<.WCA3@.FNX645/P'3.80YTXGH+PG[S^+?P>U']#ZUE4PFFJ)Z<N#S!-+"7
M6#C$]S"X DD EMP"3:]KJB7?!F_W!6X3(+7&M"0O*=B>1$O-)&GJZRCH[L<(
MFW4>@=TA./U"K"5REU).SB"@](!.3@.7<U8D!B[&E5D23%8QY1JY+)HK-TY2
M!J-?AY$C=P!0<($?1T<V=%17 A 62*J!%0*4#E,!0XOO7BB7#'6-HRM[BMQN
M1VUTK\U)9(@\&,)*F,"-PGZ6G1("Y1[!U8#IR+AP9&U)S2[N%[1'1Q2H1KL$
M#OBB=1%C3"(!W>/2('ASW"8 -_>\]_M>.E[Q]C6"K>X+<)D=C>(F;G,D0N$V
M$Y26B3(DM2$:)!6^/B'<LJC*.GJJ=M1FG3R-![&194THMP#120(951!A#<\>
MQ\>D3Y.D'2_O>?@T1+YM8LV5+AA"KV#-+&0CLC/)G(2$RSE*YZDWR;",R5<(
MFJG5@NSM>R$7J#&!<-UNH)YQ;*HR?25[;UIV#,/ <]WTQ0[_ .N,!?E[^[[?
M&E\VL3&6I_"%7E,XMI9IDM>9R$G-MYR%95Z3)',\E7!C4C+Q,>V9M&Z:E,;5
MY5HJFW(9ZS.W?K&57=*JG871%A$VH^43S7?HF]W/)T-4[7%V'9<[WM8_IE*K
M[NL3..5$\@9>IK#;M8Y5Q/V5>Y6288XW3-%60T'7Y=S9X#)*)8$S%BQB8-5A
M\IYO#!,U &WX-"SI[8G.]U?,@XMD/1\C6FNUICN)5VS*5WTJ=$D\F]D&SI7(
M:MG2FB8?<-I@*X>;7]4Y-@& V[X#JTK/SE;PGB:!FK5?6>5+)+1..ZC'R,[D
MR.*\+'Y"E7K6'2<OKJQ\Y21F=G74/,M5)*150>)K2#U1Q:Y=H&U,E/;X])MK
MP02AM,@#E=K3"8EH9:LVR:/1 <@-X ('S4C<!3(1 ;"FU+)BT*5D+@610;@1
M6[>]R$]3=L-9W!M<4S\[-S]7QI85\8)+O6\]%KW]O!+/(ITLRA)AT#JLFF%4
MWW$2;IG8+%4[, F.1'_U4S(GV'5__NQ:/]5NLQ@@ AQX>WW"(?;\0X'O]OW=
M4Z(>Z;[L_P#"T18=/U4S(GV'5_\ [L6C_5;JWISRO4O6#-B6;;++5H[TJIV9
M+'?G5?.\(@8I5CM"3./F)G1$3'(58S<%"I&.0J@E$Y0'-9T0]TWW9_X6M9/^
M2"G -[3M? >\#0.5> ,/(!Q(TGD?9#[?(<C[8  #W '&9W/X4W&\7I,,=,ZG
M%3O]YFQB4LWFGEG%F%\8=F,64W>+ WTVL:$@:2;#1<].CA(]::+]6DC?>,C_
M ,,$=_$W1^K21OO&1_X8([^)NM3+S@G]23PY\">'N^/AH\X)_4D\.? GA[OC
MX:V5_HKA_P"^IO\ A[-G^N>WS%,\?*]+-GA=/MKVYX3RO\E9EUFM:VU2-D=-
MD0<.&M=R$O/N6[<5 2!PX;0U ?+H-Q5,5(%UDR)"H()@<3B!1N7]5,R)]AU?
M_P"[%H_U6ZQK>0%<D<;BLXD  #HX3C3#T>"\_P#EY&=$?8B CQW\=X\=_''?
MSM:=$/=-]V?^%K7&Z+!Q@6+5&&-G=4B%E.\3.C$1=O\ !'-IC#Y W*7Y??F]
MKZ+V5;@Z0;CYOY$CTK#J'E2\B"(!ZSJ_]X\?^F+1_JMUDRP7DM_F'$],R3*5
M)]17]KCW3US4Y)9RN^A3MY1_'%;N%7<9#N3F5(R*Z**L:T,!%R@"9B@"AY8Z
M(>Z;[L_\+7( X[ORB(_C'OU@T5!'CY0#Y1 /]O<\=*[MWNN0\X[6J?;\@,6L
M!D.]4J?"89DAY6L-(^4</)^':<Q,BHZE8Q(J"+)=0BRBJ_!C.$^2J)ETT0\^
MU[H>USW<AS^+V_:\=*]MWL>3LO[6Z?.Y59C!Y-N=*GT;&U?5Y]4^PRCIY/Q+
M47%?=%[=%$*S(Q7.B<G6F3,*Y"B"I T17YMTH4_BS &$,9VJ18S%GQ[B3'=(
ML4M&/'LC'2<Y5JG%0DJ_8/Y)!M(/6;Q\R7<-G;YN@\<(J$6<HIK'.0)FU#>W
M;'<MB+ 6$L53LE'3,WC7$N/*%+R\09T>*E).HU.*@7\A&F?)I/3,'CEBHX:&
M=IIN1043%<A5>D 3)HBQ/>4-WBYIV\68\1B96EPK3'&TS<'O)M:MVJCRT!E5
MM@>ZX:IS' U:70M543J<E>5,I."K6] ;!+1DL:HM(Z#6)(.TGML;Q=]69,+9
MCMR&-D*I)T/ N/=I=_MV.7=57GK[G^0W3[I;[MMDL?46QM+=&HTNQ8Q3H+J0
M:&8U^X.9J\R[6NS3!JP9&;/LH-]P]BC*;VF262\:T/($CCJR-KC07]SJ4#9G
ME*MC(R9FEDJKF98/%H"<;F11,E)Q9VSLAT$#@KTT$3)].[V^X)?6>F75YAG%
MCFX8ZF;;8Z#:%L?U0]@I=@OTL^G[Q.5:7&)[?!2]QGI.1G;/)1J[=[.S;]Y+
MR:SF2=+NE")'/)X[J<RY_?6"'R_+T.TK2NVO:!NNK\SCVI.JG&U!ENV@<HSB
MV%9-)U<;<K.O,=(X[82$3;7!XJ4LD!;&CN5B&ZB39=U^#*7E&;SCO)-ZH3':
MQ=K2RIUHE:ZULC*4L23.=0C5^I)*-DVV.9%NFBZ#V9"(OWB90^E<*!WZR$XW
MP[B?#C.?CL38TH6,X^TV.0N%D8T&HP-09SUJE2I%D[',-H!@P1D9M^5!$CJ2
M=D5=*D233,IT"%*$C"4![^3?$8P?B >-$6'3]5,R)]AU?_[L6C_5;K\C_P J
MW=8IDYDI3:3<8N.9(F</9&3LL]'1[- @@!UWC]]C-NS:(%$Q0,LX622*(@!C
MAR&LRW1#W3?=G_A:2KRC/!-C>Z$W(]V(;/SR8P]W0;\AWB(=X=P^Z B ]PB&
MO>EA%354U.79!//#"7@9BT2R-9FM<7RYKVN+VM<(D+_5HH_WBV'X7X_^)FC]
M6BC_ 'BV'X7X_P#B9K5%.L7I&[B?3#_2![OP#\O.N/7![A/N _-K;7^BV'_O
MN7_A[?\ WG3['17O>,^(?6VCQK; 2\LZS75200P.T677531011RVR66665."
M:2***5+.HJLJH8J:229#J**&*0A3', #?7ZJ7D0!$!V=7\! 1 0\\6CD!#N$
M!_\ -;X@/<.M4K#ZP>EW%'<4!]*&.N."\#_/I!^ AP(#[G'@/?[6O0_ H=_>
M;Q-_3&#VQ]P=0K=5N:9N;FHXF5CJSMJ*60N= (,F]N:VP EES7S7O<:M2:+:
M#?3_ "!''QK#K^JF9$^PZO\ _=BT?ZK=,-MDWN6W<#DE6A36WRU8R9)UB7L(
M669D)MRS,O%NXELG& G(4BOM^N=EDCK$/V\5"E:' K=4#&,GD%Z(>Z;[L_\
M"U4"@'?W_&8P_B$1#435$O6ZW*+;"VWW)N3G=2A[TVJ,(UD%:G/KD;0\T5:<
MB(X&SY=2/E")I)F? Y*)F#D!5;IEZ "('(P0F#D?8@/>/N?FTOFZ[++K!NWS
M)N5F=?AK4ZID&UDD8"PJJ(0TF9><B(P4'ZJ**ZA$BE?BN42)''K44PX !$08
M(3F 1  +W"(>(_FT1?71HT:(J&\!^ ?R:TUMM7]$073^V*W1_P";>_:W*3>
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MD?E%Y:\0R^WVF3-&VQTQABF:<TX7DOF?$N+I*K;ALZF;4*Q6BON2Y=M#VN,
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M6,[OMBJU$E$+"[R19*GMZQY6[#4*ZUR/6ZZOB2$CF-+K:"S*T2"JV;X0 ?$
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M3,")Q 1#N[A'W?SZ(OIHT:-$5#> _ /Y-::VVK^B(+I_;%;H_P#-O?M;E)O
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M=7U:9EDBG, G* R+K'+[2X8ZJ^/XO<7N-L\!>_/E]M$'@MO?Z-U;8OJ%95Z
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M!7'V*)M,$(J<CP/=R/'L>>[Y=$7UT:-&B*AO ?@'\FM-;;5_1$%T_MBMT?\
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ME//O;6_3]6/GKS3YOZ*W:NAYB_7O;.GU'9^?H'1Z[K>_H:(KMU;5S_G0M/\
MS<G?\E.]1%_NH_\ D%_PDZZ>P^N3\P3GG7T(^:_,TKYQ\W^D+M_8?-[GM?8N
MU_K;M?4=9V;M'T'KNAUGL>=5&L=(]:+S(E7'T0_> _1%._N#_P!H?[7^WX@^
M?:!]T/E#\VND6=#UJO!C<=:MT>?'H]<IQSP''/''/'=SSQW:^7:A^J'\?\'7
M;K6C*WWNH?H]'3M]M<:WP\9\?ZO@<'_3XNY=N![&\[_!F['NZ(^#=3[6O40V
MPCSMKV]C[N#L3#__  !7M>6<\=&[&]X,/^\W?N_M=3^MUZ8V !W!C@7!@U7T
M.^IP<+8E&&]4'J[\]]B''=:Z/G/S9_*_M76];TNR?0NKZO\ I^GK2_9D%J;<
M_J_'XEJ%O@Z*_MZUD<.<7&6_$SA_6\%NK4G=T:7W_=1_\@O^$G5\4;TN]L?^
MD?T<]@[*CYL]17JJ[9VSKC=H[=ZH/H'9NHZ'4]G^B]=TNG[#C6B5E%)(\<=_
MNE^4!#CY1X#6/E]2Y$NQ3.U2V:7BQVV[RR.Z8<96EC*,:M86^8;%E/)$E-Q,
M7-/VU>81"]3R4_G*U&2;L&Z"*,0@Y6D'8=*0<9!AXX[_ '2_* AQ\H\!I ):
M@&E-C.=J'LSNM@GK58FNZ!MCBTDLHU6=99ALN3<B/;*Q86D65<\PFJ^4'U@@
M8N4%-#S>VBVRGG%_U?G)R1//74Y%&!A49<RAI5*(C$Y(RRI%E3/R,6Y'IE5B
M&,15070+"=0IC%4,(G*82F 1[@3 4.1'CVOA$?  #Q$1]H Y$1[@#73UU"0:
MP,*VE3G4DV\1&(2)U%^TJ'?(L6Z;PQW'2-UYS.2JF,MTC=:814Y'I<Z1'?/C
MC<1ES NZFBU10T;"N<0*R.$E\.7J]5;-]BR9%1KB05K%C,T91<&C5)F50;1I
M8Z&L:RUBC5UXV<3:MG"H"19!3& H<B!A]KV)3&'Y"@(A\(]VJ@8!$0#GD/=*
M8 ^(1  'CV^!'@>X>!UA4\K#0[5F^!ID+!8ZSW;&V(K=D23C:E5L(63)>/,N
M90D<(HOL20=I4IV4:':8S'LK.V.5I[C)3=OZE:-<FTH-PM>,O-T%<7/1[(L<
M[F8O=RXMN3L?9)H=R,QWB.MU=EFG]LF<.7UI>,T8SF]D--Q):I>3]2]]:8AP
MZQM%9A']1@6;C'<#'3M<N2=;G[@$;.$6<C1JVK=ZK_,;GU#>ISU1=:U[)ZJ_
M.OF7J>T)]M[1YE_EAUO9.M[+U7L.T=7UWT+I:B+_ '4?_(+_ (2=$3 &\ _L
MB?XY=>2#N:=@7<IN*+W^QS[FH/ /:R=:@\0 ?<]W7JA(>N;Z]MVKT%=E[2V[
M3U'I&Z_LW:$^T=1UOT+KNIZ?4];]#ZWH=9[#I:\I'="]$NYO<@4O2$"[@\W@
M')N\ #*5L .>[CP]SD/Q:WIV#F9L0Q_91T7#;X>;3QZ/;@4;W1R;W%2GCD>.
M#B9Q^CV"CSM@?;^0/S:Y$>@!R^/TQ?: ?;#W0U9?;C>X?N_KO^[O^/7,CXW3
M)W&^F#Q-]OV^X>?QZZ-WK9Z3LV^UNA13MK9Q<#?!V^VC9?U/_)!FZ?DR-D1_
MJMOE&'VO;;+\>'=K(_K#SY*0V=S^3;V2GI/HF]39MNF/!8^JGU:^>^F,<IVG
MM8PW$>)>T=9U'5 !NIZ'6!T^=9!/]U'_ ,@O^$G7"6."V-8P.+%,0'BJYELF
MG-Z> \<,1\;&I@M&HIIGIL\\&]7_ *+O,/8G'1]1_JQ\[><.FAV7I>??UCV/
MJNT]?Q]'ZSJ.J]CUFI6UBU[)<L=Q6*FNXC<7*5:RS,EE*5@\&IY3K;Q)8D/6
MXZ.@;BGCI>&5/#LTEE9Z-7GG$H5*7F!359-@42BQ,5)PQ9@$0[O'I$'X@, C
M^(!^'PTO>/HW$C;<%N$D:G.RS[+$C"X3)EJ#=]M\TP<:Q@K>GC56)Z^,:LNL
MEXM:P+20,I.3/UK5N+M.//U2:["& 1#N\>D0?B P"/X@'X?#1$O>U:DY(QW@
M^K5++4@M*WR.F<ANI9\XL3NU*JL9O)EQGJV0TX^$SET#>KR<*V(B<>C'$1+&
M)<(LDP!AM+SM6I.2,=X/JU2RU(+2M\CIG(;J6?.+$[M2JK&;R9<9ZMD-./A,
MY= WJ\G"MB(G'HQQ$2QB7"+), D+)ZN54:TF?#K+'[ZW>>H4%$,E25FBJX$
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M@B 1HF8I(PI53++ HNJ1,-HT:-$5.B'N!W?]G>'R"(B'N"/(:   \  /]O\
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M(^9Y1P_E;*S-A.257;+4E7']D6M4.5GUJCB99^?)^( E8DE54W)&R2KHRB[
MIQ;L@"!2@/B!0 ?;[P#O[_ATI=K@,MY?I&TVU0,F6N2\/DG$.5LLLTY2:J9)
M"IEH-A&W5XD:W(X6D"*SU@C#%JTRH5FH#(!?..T1Z/3;0@"!2@/B!0 ?;[P#
MO[_AT1<M4$ 'V@^W]OPYY]T!X#D![AX#W-5T:(J<  \\!S[OQ\_C'O'W1[_'
M5=&C1$:MFZ?SGVK_ )MSO^2GFKFU;-T_G/M7_-N=_P E/-5;K'2/6B\G-5P;
MK5.#\<J*^T'AUI^[Z77S[0?ZL?#CP#P]SP\-=6JL7K5.\O\ -%>?9!^RGYYU
M\^N+[I?#GZ8/#W?@UW(UHRMT#4-8T^H*(V/+;P?H,V7_ $^GV(MV#QR<&;WV
M?_S)WX@'AV97N[PUZI&UP>=L^W<?=P7B,?EQ]7=>5 \6+V-[WE_WB\'Z8/VL
MK[G'RZ]5[:U_ZLNW7_\  5B+_-]7=:4[,X IMSUA;[_B?\.A66PL$.F[X'O6
M: UHX[ZB?;YE.^C1HUH59A4'CCO]TOR](./E'C6/I_1C3>Q7.U(V97&T2]JL
M2.Z5EC>S+3RM,L3/,-@RED=S96C"R+,:T>!)6\H/+!"PDQU2!&T?',W2<E()
M=&4=9!1XX[_=+\O(<?CXUC_E\=1]SV,9WQQL[M<V[F+>UW00]"LDC89:IRK#
M+MCR;D4]O21LWFZ'E()O Y3>62,BI5LT#L4>Q:+,';]N5!^Y(GHKJ$@U@85M
M+'.I)H1$8C(G47[2H=\BQ;IO#'<=(W7G,Y*J8RW2-UIA%3D>ESKN1 ! 0$.0
M'N$!\!#W!UTU=:OF,!",Y(XJ2#2(C&SY0RQG(G>-V+=%T<7!^3+B9P10PK&'
MI*B(J&[S#KN=$7$2E'Q*4>>\>0 >1XXY[P]SN^#NU7@ $1   1\1X#D?A'V_
M -5T:(C1HT:(N)O /[(G^.77CO[J) "[H=RQ>F(<;B,Z!]('M95MH<?S0/#X
MO@#7L0&\ _LB?XY=>-3NQ>"3=1N<+P ]'<9G4/I0'_ZUK</B(A[OQ>&N@>P%
M%ON);HK@FU%0?XB;BTC3;9KXEKSL@UG:=+AKB2 ^HG;H<6_!L/!KMI-BH\\X
MA^R#]P'^DUR)(ATR?1##[(.X"!SX_P#O!U8/;Q^I#[@/X6N1'X],GL0#V1>_
MH![H>X;73?:HXCP<KP/\O;7JWNVWEG@UR.V;-I\17K2>1L/UGDM-B9^>>GMQ
MH!N>..>6:W?QR/C\(\^/.LF.L8WD8#=+R5>PPWN[;<?#_P#N2VLG.OSYQX6Q
MW&AQ8MB(\59,%T50'-0T3C^E24QX]<+#K1HT:-8E7:7''33$R6XG<8[JDG8'
M.5G<'@TN6(U^1V6 C(YM 7$N-SP!U8]NU.L_C%)]29!J_?F(NBT!P1D<4R+,
M88!$.[QZ1!^(# (_B ?A\-+SCU'$1-P>X9:I.II7+*T)A(N6VKP)3S,UC4H*
MX!C0T,+I D8*KB+/8#2OFQ==0%DVWG $5>H*=AC (AW>/2(/Q 8!'\0#\/AH
MB7O:OCF]8HP?5J+DF21E[C%3.0WLE(-YN1L22S2QY+N-G@B%EI5%N^<"VK\U
M%-3I*I%(R.@9@W$[5JBH=AM+SM7QS>L48/JU%R3)(R]QBIG(;V2D&\W(V))9
MI8\EW&SP1"RTJBW?.!;5^:BFITE4BD9'0,P;B=JU14.PVB*G >/ <\@// >(
M=P#\(!W .J= G''1+QX\=$..>..>./<[O@[O#7+1HB-&C1HB-:37\ES82S3F
M&U[&/1#B+).4_4_ ;@?/_H^I-DN(0?G.1Q3YL&6]3\<_&/\ .(L7O8NU=5VD
M6;H$>GU"O1W91$ \1X\ [_=$> #XQ[@^WI;JWN0VEY:R$]QA4,ZX"R+E.%:V
M1:0Q]7,G4&SWR+95"<<5VV+/*I&S;N?9-JW8VSJ%GE%V":<3+MUV+X4'"9RA
M(MRN,UFYS&J7'J.B%=)AHJ'NB?OHA#:BEJ*5SI9(071AK)G/:38%S+'O;K&X
MM108E12X?43;RVJ,;0X.:'DQS1R@,:X@/)+&BVFP*\@OUDN]'[$?<CX<_P#
MGDC^+WC]KQT>LEWH_8C[D?#G_@3R1_%[Q^UXZ]=O<AF_!FU['!,C7Z >3A92
MW4['5*I./ZPA;LAY)R5D*92K]&QW0JRW7:^>;59Y10R3-%T^C8MBS:R$S-RD
M7"Q<C(-K$PWNVVR9FVQ2.[)E#3M%QE7)'(L)>([(= >Q5ZH%BQ/>9K'5_KMI
MJ5?):7@3%=M4#(,%T(!:>1=%(FNQ7<IJ>QW&WLW;IWT[*INY:A=3OJ&TK)6U
M%<YKZA[<S866!+GN =E#0;D #3H4,.X7"6R&-V)SM>V/?7-+6#+&"T%[B7V
M&DZ3JTG025J+_P B8X$SKB#=INEDLMX6REBZ.F=N=;80\CD"AVFH,I9^VR@P
M=.&,<YL$8P0>NV[40<KMFRBJR2!BJJ$*F8IAWS=8S5?*7[-*KL93\HVJI98'
M <LPMR]-%6CBPR;D5&MV6U0#5G1Z$9X26E7=Q3I,Q::RS=K1JGJ+;GM=F"MQ
M,=,KQ60BC6UE?J54;S&L96,C[E5Z_:V,;.M4F,W'L['#LIIJQF&2+EXBTE6C
M=\FWD6J+MTDW>)K(IN5R$!4VIMV.*XINAQFKQW$L-[FR3S##Y(6B4Q1U6&P0
M4\\ ?, \RQ ,,S#IC+P#:X4OP>EI:"CAH::H[8;'&V=KS;,Z*<ET;R 7=Z^Q
MRF_? 7 &I75HT:-1-994'GVO=#Y.0Y_%SI7=O=0R/6-K52J&?IJ0-D%C2;!'
MWZ<E;$6W2"2KEW8#G?.;"9=X65.UAG+50%C+K%*1$C<P\(]$&B'GVO=#Y.0Y
M_%SI7]O-1R+6-KE0J&X&9DE+^QI<^PR!-R=D+;))-1R\GU%7KBQG6?DDU6T*
MY:G*X.JX*0B)$# 8$1)HBO;;; U"K;><%UK'UL]7M$K^(,;PE,O'003]6%5B
MZA$,J_9^K;)I-B>?HM%K)]!!)-$O:>BF0I  H37J&MNL'2:S@'"-<QK:%+MC
MN!Q+CN&HER64;*K6NGQE3BF=;L:JC-JR:J*3<0BTD3G;,VC<QG BBV03Z*99
MET1' #XAS[?Q^[JG1+X]$O//// >(B(B/PB(B/PB(^.JZ-$5   \  /@  _)
MJNC1HB-8XO*\FZ'DR=[YN0#H[=[^/(^ <,$^\?M?[#K([K&WY8,W1\F#OF-]
M3MRR$/R1Y-93 _SW@_\ M3#_ /%PKQJ#:GG/%#*>+]!W#P+RZSO#=,_LR?3#
M]3W=_P /M_;YUP[8;ZM/\7=^/\O.K9.Z#IF[@^F-[ONC]K7'M0>X'X_S:[OW
MH;/)'7[6Z+ZSW]W*;P?"2;/ V^DVX$RNVEV8VY#;R43D]EGK# =W'/ Y,JP=
MP<]X^YKUS"^ _P!D?_'-KR#=LCGG<KMT#@._/V% _I@\<GU4/M:]?(O@/]D?
M_'-KG'LY-#<0W/@<-'6G4!\/!Q'VVJ6[FWE\-5<@VDCU.+M;#PN XNCB7+1H
MT:T4I*EYW63&6X#;]DR8P4VEGF6&,(U5I;:"A65BEE9,TY$)+E90TBU>,WZ@
M1BC\QDEVRQ"I%46 H'2*8K!")^1XYXY'CN_[M+]NLF<MU_;]DR8P4VEGF6&,
M(U5I;:"A65BEE9,TY$)+E90TBU>LGZ@1BC\QDG#98A4BJ+ 7IIE,5@1$_(\<
M\<CQW?\ =HB^FC1HT14-X#\ _DUIK;:OZ(@NG]L5NC_S;W[6Y2;P'X!_)K36
MVU?T1!=/[8K='_FWOVH+NT_*MR']J,/_ 'UU-]S9^8?NB/[B]UW\(+<I+X!\
M ?DU75"^ ? 'Y-5U.ERRN)@ 0#D> Z1!^,#@(!\8\!\>EUVGP.-*S@FJ0V(;
MD]O]!;361EHBU2*14';]\_R=<Y&RME$B1L0!2PUJ=S<&B/8$NFA&I'$[D3"Z
M78HP (=X\!TB#\8& 2A\9N _-XZ7S:S"8KKN$*O$86M4A=<<MYC(2L-8Y4_6
M/GK]]DJX/[4W5-YJA.215O=3\0W_ )6H<-F")>L=\=L<$3"Z47<GO,QQM=>Q
MJ5ZJ64)Z'+5Y"^WFUTFK1TG5\4X\B[75J6\NMZD9NPUQ9RT\_6V/1952@L[U
MDB69-)J5B:2^C(9\Z3;H0Y\?M#\@\A^/6.7)GD[:E9KSC&TXUO[[$]:QI;+%
MDAIBM.@4+(^-93+=GM,'8WV9'5>R)'S $RG'(0@0E4M2JKTU(9RDQ)4QG 6)
M\I, 121FC?C@W V45<9WXMO0;5^.QM)Y2R5'1$4YQEA)OFB?ME4P[Z4YIQ/L
MIR,])%DI-BB8A6MUJTMH 6K.2O:]2A9J$DY"Z=L>[S'&Z=K934^ R!3)JL16
M.[4[JF2X"-@;&\Q[F"K&N>)<C,6\)/V>/]3&0J\WDG,4S?R3"WP4C"S=<O%6
MJEEBGD.DNF6?)JUG.&09>T9.S#=[-4<EM,=L=P>/5*S1(^/S.RP3D#)5_P
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M3S&ZVRIPJ;"@P$] HO(B)G9>PVB8G8>-HD7: ?)NBW/@S?YAS<%DUC0:+%7
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MBW<JG'=ANB$3$Y'<AG@1$0$1'_SL6_O$>F'(CXB/'>(\ZZ$^Y_<!B>Z.]C^
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M!"-8"&I#?9-];AM]#O#".* 'VA"@5<!#[8"$9R _;#1ZW#;Z/>.$<4"/MB-
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M:"C@IGODA:YKI&11ON][@6PM+8[-<X@$--B0!?AX;S!VUG^VVW[NE_#U^@!
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MK8NO\YUK_P";4]_DEYJY]6Q=?YSK7_S:GO\ )+S56ZQTCUHO(,57^BJ^S/\
MS9;Q#VNN4^'_ &]WQ'Y]<'U9_'W/:_/]O\6NG6<GZY7V0!]&7[N[]F4]SC\F
MOEVD_P!6'R_]^N^FL-AHOH''X.W:?8BVNC*VYTR:^,^#MZ/Y?HKM7J_ZQ?\
MLS_[Q>^ =_'95OQ_[<:]:K:F/.U[;>/NX%P\/?X_\'=<\=>1P\<J=A?\'#_>
M#WPX_:JOP_!KUQ=J \[7-MH^[@/#@_+CJMZT5V<&D4NYR_#48G_"H.OV"D&
M/#GU(!=H;#[X\>?5I/%I]&BRG[1HT:YY4E5#<<=_NE^7I!Q^/C6/=]CN#RWL
M3SOC+:?)3,.ZOB6Z>J4Z5MLU.UQ]'Y4FLIY(97)VK/-T7$U$1*&3U;(>&D8]
M!8[6%!@K')F1*@ Y"!XX[_=+\O(<?CXUC_E<9U+.FQC.V)MKKM>L-\DMMT-(
MK4C<G]FC"1N3IO)V18N]R3^1*25L+.'])Y[,[8N8Y%P*,0=J:':E9@U0(1/1
M763N-@(2/?J J]8Q$8S=J%5.N"CIJQ;MW!P64 JBH'63.8%#E Z@"!S !C"
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M=)BT0D05Y4:CZM947K= T1ZH(VM=!FH585WOG&526;&[.8B1>S 3K5NNZ1!
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M[2_F&F"T:(E]](F<_L>_\+M+^8:/2)G/['O_  NTOYAI@M&B)??2)G/['O\
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M.' Z!/-<:T1=K]H5 J'334 J/3ZP_)0UF;UB_P#+4 /ZE%O]_M8LEA\8QA.
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M.$P;M:I^-G=DB<BP%*I4^S>V"M-DVL78XTSR?E7PQK=&3>IIE.W>+L0*244
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MQZ!/J2_<A^;1T"?4E^Y#\VN6C1%QZ!/J2_<A^;1T"?4E^Y#\VN6C1%0  /
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MQS]S?<M0&/[)%'I1I&044-*/)Q5]89([F/44D'IXE5R@<Z9US"W9  "E !Y
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M.=/H.4DR+EZLYR=%0.@8Q>!'N=$7P6;-W )E7136*DJFNF"I"J@FNB8#I+$
MX& BJ1P Z:I>%$SATR&*;OU4C=!-55<B29%EP3!94I"@HJ"0&!(%#@ &."8&
M,"8'$03*8Q2=$#" _;1HBH( /<( (>X(<ZIT"?4E^Y#\VN6C1%QZ!/J2_<A^
M;1T"?4E^Y#\VN6C1%QZ!/J2_<A^;1T"?4E^Y#\VN6C1%QZ!/J2_<A^;1T"?4
ME^Y#\VN6C1%0"E#O H /N@ !JNC1HB7G'V2H*R;@MPF.&-'B82<QO"X3?3EV
M:+,CRUW2O<%;Y"(:2R2,6U>I)U)&%=,XT7LG*%42E' M$X\A54UV$, "'>/
M=(@_&!@$ ^,0 /CTN6.LDQEDW%;C<<-J77X62QO!X,?25RCSMQG[HG>X"Y2#
M!K8")QS=P5&JIPJ[.%[1(R(&0DG@HD8E Z:S&F !#O'@.D0?C P" ?&( 'QZ
M(E[VK4ZBT+!]6JV-KXCDNG,)G(;F-N+=6.62DG<SDRXS<ZT*I%<L1&!L$E*U
MTX)>S*I$F*X_715M,,( /</?_P!P\@/P@/> ^T/?I<=IM7H%-P35*[C"]^DF
ME,YO([B,N/5MDO.+R4RA=):?:=!HDB@'F*QOI>O<D3 3>:>FH)E3'.9CM$4)
MUC;7MXI4A.RU0P7B"LRMGN[/)5BDH+&U.BWTUD..-)J1UYDW3.&26=VV/4FY
MM9A8%CFE&2TU,+-7**LK('<VPUV;;26-,:XY9[9,!-: QO3?)[.E-\0T%*JM
M,C,T4VK2\MH D $6C:VC))*/;3J;4L@A&I)1B2Y(Y,C4&3T:(C_;Y?'7$2E'
MO$I1'W1 /S:Y:-$7'H$^I+]R'YM'0)]27[D/S:Y:-$7'H$^I+]R'YM'0)]27
M[D/S:Y:-$7'H$^I+]R'YM'0)]27[D/S:Y:-$7'H$^I+]R'YM<M&C1%00Y^4!
M^00'\>E?V\X]JF%MKE0H4?;8K*U1IM+GVX6B 1CT8NV1@/)^4?&8HL9>5CRD
M4(Z=1HE2EG*0K(G$ZY#"<J;0"'/R@/R" _CTJVW&D4[$6U.FTR"N,+F"F5*C
MV%)"V5XC!&&N$8#VPR3TS K"5F&!$E>T.HLW4RCI/KD%1.J4W333(I%VZSE)
MLV <(V/&M74I..Y[$N.YFB4U9-LDM5*?)U.*>5NN*ILW3UJFI"1"S2..1L\=
MMRF;B"+E=/HJ&F74*;;9ZH6G;S@NRX^J?J"HE@Q!C>;IE'Z:"GJ/JLI4(A[7
MZQUC915L?S#%K-8SIH*J(F[-TDSF((&&:]$489#PGAW+<A3);*6*\>9&E,<S
MI;/0)&\4RO6I]2[$51FL6;JSJ;CWJT%* O'1SCMD:=NL+B.CW!C"NP9J(]*^
MVX;?9*WU#(#_  ?B-Y><?RMCG:-<'&.JBI9JA-W"P2=LM<S6YLT1YQAI6R6J
M:F;/.2+%PB\D['+2<Z[65EI!X\6FG1HBC?&^'<3X<9S\=B;&E"QG'VJQR%PL
MK&@U&!J+.>M4J5(LG8YAM ,&",C-ORH(D=23LBKI4B2:9E.@0I0D<0 ?$ 'X
M0 ?RZKHT1<>@3ZDOW(?FT= GU)?N0_-KEHT1<>@3ZDOW(?FT= GU)?N0_-KE
MHT1<>@3ZDOW(?FT= GU)?N0_-KEHT1<>@3ZDOW(?FU4  /  #X  /R:KHT1+
MQNOQ=:LT[?,G8QI,O&P-HMT&UCX>6F)&1BHUDY1G(B1.J[D(EL\D6R9FS%=(
M#M6RIQ44(F)>K.<Q6#$@B(CW=XC[OYM+]NLQ).9UV_9,Q/6IB)@)RZ0C6,CY
M>=,])$L5D)R(DS*O31R2ST$S(L%4B]G2.?K5$P$.ATA!@1((B(]W>(^[^;1%
M]-&C1HB-&C1HB-&C1HBXF$ #O#D.D0/C$P  _$(@/Q:7O:O<*+?<'U:TXVH:
M.-*<_F<AMHVG-THY%*-=P^2[C"3KLJ<4 ,0&>L$;*V(XI>S,>6,=Q^NC+:80
MP@ !R'/LB!\8G  'XA$!^+2Z;3KG3,@8)JEKH% 8XPJK^:R,V84J-49*LXQS
M"Y/N<%,NTSQ[5DT$T_.QDG8UP3;$,5Q+JE6,JN"JRA$QNNBL%HK53:-']IL,
M'6V+^9@ZZR>S\LPAFCRP6>6:0-;@VKF1<-D7$Q89Q^QAH.,1.=]+2SUI'1Z#
MAXY11/WH_#QX?E\/C\-8=MZ&P/=-N(+@N0AMTE6M2F&=R6(LS156RGA>*0AH
MYS5MS.*LBJW.)=8[N%)9+6W&.)*K;Z32T)ZOS;NQM;99V:L_5YNS(6VOD65&
M9R=C>NW*JXZL&0*1!Y!O:,HYI%%F+9 1EQN+>#1%Q-+U6L/9!"<L2,.W 5Y1
M6(8/"1Z/T5T9(@"8*T+)F.,J1<A.8QO])R-"Q,[)5>5F*):X"WQ<9984R1)B
MNR$A7I"1:,IV).LB23B'*R4@P.JD5TW2%0G.&C=1LEW1;DLP9'D&D)4:'#;A
MHK:]&.,K-,F%E[9M?+L^S+G2[-WU.CO4K&S%F?YG@+[57T(G5WE>)5)N8O<9
M:7J"$5%SEK8GR<&V/,6"S9"M.7ZG3\;/IS%NU'!\/C^D6II;X55#:MBB3QO(
M90\YQ\%7VC4<C.Y@K2OQ*S,TU'X^IM*)8DH684<U> (LHNC5A7.GV"SJQZD+
MDVZ4 C--R1PA5&5$=I29ESHF35>C<*;:52*- 2.1 &"K),Q7"HN$US@B9*RO
M1->_LC\P?W&PE_JBT13EHU!OHFO?V1^8/[C82_U1:/1->_LC\P?W&PE_JBT1
M3EHU!OHFO?V1^8/[C82_U1:/1->_LC\P?W&PE_JBT13EHU!OHFO?V1^8/[C8
M2_U1:/1->_LC\P?W&PE_JBT13EJ+\WU^UVW"^7*K1'2C*[V7&%_K].>I2J\&
MJTM4S4Y>-KKI.:;"#B(4;S#EFJ240$%H\Q >)""B)=7#3JW,5EBZ:3-[M%]7
M<.^TI2-I:U)H[9(]0DEV%L2H5BKLC-NL3.YZ3IHY=]<LH7M/4 DBG;V;Z_:[
M;A?+E5HCI1E=[+C"_P!?ISU*57@U6EJF:G+QM==)S380<1"C>8<LU22B @M'
MF(#Q(041+HB@J\T&O+TK9_#YCR$:I6RA98PY)PIE'2<N>_9:KV/+/$%IAY)\
MFJN\/.BXL,F:1(*;UR,4*_6E%94#.&0  I0 >0 H  ^Z !W#\8:4.Y42JJ4G
M:-#YKOCFKVVB90P_(5TY9)!^>\9BK^/K)$HU)Q(R+)ZO)DFP7LLBJY2,T?O3
MQI7(/4NFL15O"@ $* #R %  'W0X[A]S[>B+JYZ>@ZM!S-FL\S%5VMUV*D)R
MP6"=D6<1"0<+$M%G\K,3$M(+-V$9%QC%NN]D)!\X09LFB"SERLDBD<Y;6M^5
M\78_CZU+7S)%!I45<YN)K50D[;<:Y6X^U6.>3,K!5^MO9J28MIR;FDB&4B(J
M+5=/Y),ICLVZQ"B(8\O*-[)MPN\'"&>,84;<9#Q5;R'4; TA\+W[%4'*X]F7
MA,4VZN0=1L%OK4[4KL6!D\ERM9R)(24XYM\?&RM4AV2]1GZP25KLQ"NZ7:%N
MHRM5<9PS.D8LR%*UG:/N!V13#N7O9*Q!B^W,8FVW1CK=.U@Y>L6I2':8YN>.
M,AU>1QTRDK%=Y*IO8B9KU@DS3<I 1I%E^KV3L;VVT7&D57(%(LMTQXO'-;_4
M:_;("9M%&<RZ"CF);W"OQL@YEJRO*-DE7,<C-LV*CU!,ZK8JA"&$+XUAVV-[
M+<Y8'SA!R61V]>5JV$*!NWQY$98:VU":N>YUUNGW55K<7$WRZ018-&4K,ACV
M"K PL^ULD[*/7]^M=C<5U=_7&Y)V8RPVV E;'%%CXBY6*C.RNT'(S59;5EU(
MG12*J51B9*UUZRQ?97(J$,L8L<5V4R*?4.40%0%"*Z-6K>?YS+;_ ,V;!_D=
M[J-_1->_LC\P?W&PE_JBU^9[ANYOV;MBZW%9>6;/6KAHX2/#83Z*J#I$[=9,
M>CB,I@ Z2ARB)3D.'/)3%, &"HT$'B(1>*LZ46[0O[(_\W7]W]G4U\.L6^J/
M^/7JRF_D>SR:X\F-A6I&$>1,8<;8@$QA$1$1_P"#\1$3"(B/B(B/MB.J!_(]
MGDU3!R&$ZD ?UV-,0E$/A V/@$/C#[>NH6]GO PT#W/XKH 'XVBX!_YBU:>Q
M]5$D]OTFDW_%2[-G!_T]"\I1THMV1YP8_/8GGN_M977M1[.N?6D;7.?'UNF$
M.>?'GT85;QUC$-_(]GDTSD.4V$JF)#%,F<HXRQ& F*<HE,7H^CX#& Q1$!Z(
M>'/?W#K)S5\"3U-K5=J%8S]EB&KE7@XFNUZ'9P>%B-8J#A&*$7$QS9-3$BBJ
M;5@P:MV: *J',1)$A3J&,'(ZS[)/9!H-V\.$QT6'5="<.DK'R&I? X2BI;3M
M8&;RYQ&0PN+LUO?"W"I3N;W/2X%VSOD\,QJ-[MO3',RY+Z\P%]=A;BZ$R.C4
M&^B:]_9'Y@_N-A+_ %1:O&FTRQ5EV]<364KO?D73=)!!E:F-!:-H]1-4RAW3
M0U0I57='77(8$%2O'#MN"92BD@DKTE#:I4I4@"/ >'/>4/E$ Y^+GG6/BPR>
M,]RVQ#/K*Q.:YMMQK;&&Z/'%LLB PKN!I,?5LEY%Q[:\BO2F;UR(4/*O(&0N
MTPD\!L!'TJ[1D)%XX*O(N,@XCP'ASWE#Y1 .?BYYUCW?2N--R6Q/.[6[.*WM
MWQG:4=T^.;G8H->')"4R&JV4\D8^LV05EWL?%PZ;Z4/!/+G."_:]2G+RC\KU
MR^."KUP1/?6VK5E7X-FR>$D&;6'BVS5\0" 1ZV08-T4'9 3,<@%<HD(N4"&,
M7A0.B82\"-O9.R?C_#&/;OE?*=MAJ-CG&]7FKI>+=/N@:0];J]>8+2<Q,2*P
M%44*W9LFZBG0126<N%.K;-4%W2R**EQ5ULT90$(T8.P?LFL1&-VCXHD$'C5!
MBW2;N@%/Z&(.$2$6 2>P$% $OL>-([O"V'1F[*J9"AG&=L[4!Y<(MMYNB86X
M1L[BZ-GH.FVFMUIT[Q3=*U:*FYBTI:QM[;.-F+2.E9.S5ZNSS28C9F#BW[4B
MF?)>[[;IB&AT3)>0,DM(2G9+BQGZ5(-Z_;Y]_,5E"HGO\O;C5VMUZ8LL73*I
M2"'MM[N4S#QU7Q_7"&F+O+0#$.NUV="W38#R?D^T8=H>18ZQY J+>:=2<6SC
M+"E%/T:O(0<1<!J=N>0[:FWQ2B3-FKD)D%"C6"Q+X_G)^$A;DG!RDJQ:+8\<
ME^3PS_8<8X#I=6S;C9U9,#[>KQM+B+;>*+95U)[$F;L!XLQ1E6[6)A69Z+:/
M,HUZXXU;W>@M(UO 5*4KB_J'LI8^665OR=[[2_)USVVG*M'77O\  S^%-O$-
MN9B-NL0VB["CDMRCNTR11\E7KTO3CV76K4HI07%(+6:>M6HE ;,SFUY^>2@Y
M*+182!%E8T:MZT0TC/P[B,BK3.4UZLHV.G/5U"ON95L5!<BJB2*5FA+#$&3=
MID,V7%>+64*BH<S=1!<"+$B[T37O[(_,']QL)?ZHM$4Y:-0;Z)KW]D?F#^XV
M$O\ 5%H]$U[^R/S!_<;"7^J+1%.6C4&^B:]_9'Y@_N-A+_5%H]$U[^R/S!_<
M;"7^J+1%.6C4&^B:]_9'Y@_N-A+_ %1:/1->_LC\P?W&PE_JBT13EHU&E2HE
MGKDJ:0E\OY O#06B[8(6RQ^-VL:594Z)B/@5JM!K<IVEN5(Z:)1D1:&(X5%=
MLL<$3)27HB7?'N4VMHW![AL8)5.%B76+H3"4@ZM;-PFI,VPN0H*X23=M,MRL
M$%&Z5;+!*-8H5'[\%D7[HQ",P()%F&, " <CP'2(/Q@<! /C'@/CTN6.LH#9
M]Q6XS&7J7K\6&,(/!D@%G8<^J"T>D" N<B+>?_6Z8=37O,8-X7A=?Z ^><@C
M]*=C3  AWCP'2(/Q@8!*'QFX#\WCHB77:? XTK.":I#8AN3V_P!!;361EHBU
M2*14';]\_P G7.1LK91(D;$ 4L-:G<W!HCV!+IH1J1Q.Y$PNEV,TO6UF$Q77
M<(5>(PM:I"ZXY;S&0E8:QRI^L?/7[[)5P?VINJ;S5"<DBK>ZGXAO_*U#ALP1
M+UCOCMCB0\EUBZ6RO(1=$R.^Q=-)SL%(K6./J]7MR[F(CI!-S+U\T5;6;V+3
M0L#,IXY>221+)1R:@N8U9%T4AP(KC8VNKR<].U6-L<$_L]7;PKRRUQE+QSN>
MKS2R)OE:\ZG(=NY4D8EM/)1<FI"KR#9NE*DCGQV!W!6C@4XP]<QMQ]2WJX]/
MV%/47ZNO1?ZK_2M0_4OZ2^LZGT=^J#S_ .:/5UUWT'U(]L]4'6^P\W]+NUBW
MP[L(W6X>ROOQL$WE''F4V>]FD8FILCEF*@I?%F3X2U-8G<1"VS+,_&A:KK&3
M#O',)D+'U7I-0KSZKLI2L5V%C(%Q0VE*196--P\FCO',T;WWT5XC),GVRN-D
MA\%'RM%FI;5 ^T]AMK0W5*3Q:-YJ<E*_3D(E:HI0OJ_' PL$$426@[W&29%L
M_?[?)XZ-6)B^GNL>XVQ_0WTZ]M#VE4BI5%W99'D)"P.JU7HV$<3CX#'5$'DN
MLP/(N0,HH/7N5.D<P\F&V9C&ERDI61D&>><HP+1Z[6<MH6+BL1JQL4BJ;I$8
ML59?&$G**-6X>Q2/(2+YV)?YLY5-WZ(IAT:@WT37O[(_,']QL)?ZHM'HFO?V
M1^8/[C82_P!46B*<M&H-]$U[^R/S!_<;"7^J+1Z)KW]D?F#^XV$O]46B*<M&
MH-]$U[^R/S!_<;"7^J+1Z)KW]D?F#^XV$O\ 5%HBG+1J#1Q->Q 0]<?F$.0$
M.0AL(\AR'B'.(1#D/$.0$.?$!#NU,[!NLS8LVCAZYDUVK1NW6D7A6I'C]5!$
MB2CUT1BV9LB.79RF77*S:-6I55#@W;H(@1(A%^H>\.\>.\/Q" @'QCW?D[]*
MMMNJU Q?M4I=:IUS89CQ_5Z38 C[='I1Q&%RBDWUAD7HH),W3V.!-115Y%&*
MFZ61$R!^L, B<I6I'X>.\/RAW?'X?'I7-O-9QUC':Q4:[0K>VR_CJL4BP!$V
MI-6+5:W"*2>6"0>?18TJD6*:RRKZ+.9 IT0!$P*%,8% $BO_ &ZV6IW/ .$;
M=0ZDG0J1:,2X[L-0HZ*;))&G5B8J<5(05723C?Y7IIP,8X;19",?UF4K4 ;?
M00)J9=0KMML]9NNWK!=PI=/:8^I]JQ!C>QU:AL#M5&5+KLU4(F1A:HS48MVC
M([6OQSAO%(':-6[8R34HH())"4@34/P\>'Y?#X_#1%T5CM%:I\6:<MMA@ZO"
ME?P\6:7L4M'PD663L,NQK\#'FD)-PU:%?3<]*1L)$-!6!Q)R\BQC&2:[UXW0
M4Z.PY.QO4K13Z1:L@4BM73(:\BUH%1L%L@(:SWEU$(D<RS:GP$E(-I:S.(ML
MJFXD481F^49(*$5<E2(<HCBJW\[ ]U&Y^E56.J>Y^KSKFCYPJ.6:W2LJ8>BD
M:RQ>PN>,.WBN3#>6Q[:Z8HK-88H=.OL92U+)"V=S9WEUE1D'T'8!KEMJW1[L
M]G&Y/</FJX3416ZA58'.%6VW8P7R>VR.@O;-M,=M"WBY,SRPRC4HI6IMY*?G
MLX46Q51S$5ZKR<0ZH^18M*(MDX[A(AG=%2++E1\G8WR<A.NL;Y I&0&U7L,A
M4;*XI%L@+8A7K9$=7YVK$ZM 2$@G$6&+%9()&%D#-Y)D*J?:6R?3+S?&L5GD
MW=K.9,!N+%,Y=J-*QZM%[;]H.U:'KE%MC2V1MT7VH0648J;SFZ<,ZU7RQA,F
MN<D-F==A)0JMICJU568VA*.?.48MGD@N57FK.W8HPN0+70%&CA59=W56E/=K
MR*:B(I%:NRW"JVEN1!$X]H3,R0:.!5  4741Y2$BO/1J#?1->_LC\P?W&PE_
MJBT>B:]_9'Y@_N-A+_5%HBG+1J#?1->_LC\P?W&PE_JBT>B:]_9'Y@_N-A+_
M %1:(IRT:@WT37O[(_,']QL)?ZHM'HFO?V1^8/[C82_U1:(IRT:@WT37O[(_
M,']QL)?ZHM7S3*E/5?SCY[R1<,@=M[+V;U5LZ0T\U=GZ_K>P^HZH57K.V]<G
MVGSCV[H]F1[+V;I+]<11;NSQ9*YKV\Y/Q=!ST'6)6X0;6.9SMD7=-X2.41G8
M>1,M(+,B*.DT3),5$2BB0QA652 0Z(F$&'$@B(CW=XC[OYM+YNNQ,ZSEM\R;
MBEE8(:JNKG!M8U&?L*2B\-&F0G(B3%=^DDL@H=(Q6 H% JI!ZU9,1$0 0%@A
M(81$0$O>(CX#^?1%]=&C1HB-&C1HB-&C1HBXF$ #O#GV1 ^,3  #\0B _%I?
M-K-^J>3<(5>YTBA1^,JW)S&0FC*F101A6,8X@,E7"N2SM((AE',.G/S,1(6)
MP*+1,XN9987)UW77N%6$$.?: >\![_M" \_"'B'V^-*%B2*W55:_A5YS&6U&
MC;=F<G=%HM/%EQR(K>FS60?RLM N J;W&U;I:4C,RCWSC;Q0EB)I/7TDZ9'D
M5C =8B;[1I8Z#(;PULJ2;;)U4VXQV%RKV<(>7HU]R9,9,5;)O#!3C2-?GZ)#
MU=!=W']%2R$;3ZZ;!YTDHP[]$ 5T4&0WAK94DVV3JIMQCL+E7LX0\O1K[DR8
MR8JV3>&"G&D:_/T2'JZ"[N/Z*ED(VGUTV#SI)1AWZ( KHB9S1I8\72&\-QD.
M60S+5-N,3BLJ$^,))XUON3)^_+.22B!:P64A;/1(&O-T',,+E:<.UFG"C.2*
M@W8$>-CJ."&+I#>&XR'+(9EJFW&)Q65"?&$D\:WW)D_?EG))1 M8+*0MGHD#
M7FZ#F&%RM.':S3A1G)%0;L"/&QU'!")G-&EEP](;P75SF$L\U3;E"8_+&2)H
M%]B:^9+LUN7F"RK0L4E+1=OHE:AFT:K""^6D%V<HY=(2A&K9L@NT46<I\<12
M&\1S<)M+.M4VX0M#)%29J\]Q3?<F66V.)LLHT+#HS$9;J)6X=I%JPPO5I%PR
MDW3I"2(U;MFZ[515PF1,YHTLN%I#>"ZL,X3<'5-N4%5B0ISUQSA^^9+M,\XL
M /T2IH3+.Z42KQ[2'&,%=0[ID\=O0? DB#44#'6#XX?D-Y+J9L9,\5/;9"0"
M=?<'J:^)[_D^RR[JT \3!JVL#:WT*M,V,$9@*IUWL<Y?2!'8$239G1$RH$30
M:-*WB21WFN1M_ISJ6VF&*E6NLHHXKR!E"QB]MW+C]:VH+;0:YYMKO -/U]$>
M<9+D[@.P^P3%3]&(9#>&Z9W,<[U3;C"/DH)L?'Y,4WW)EE:OK(*4D+QO;U;=
M1*VK%PA%BQ(-GD,G)OCI*R!E&B9D6Q5B)G-&E<Q7([S7,3?#YIJ6VF(FT:T1
M3&B.,L@90L,7(6[LTH*C6[N+30:^ZB*Z#LL,0CZ";R\D+=624,Q!1!JFO^G%
M<AO!<5[(!\U53;E$6E"%1/B]MC*^9+L,#)6#L$N9="]O+31*_(0T.63+!IHN
MJ^SF'IV*TJL=J1=LT1<$3-:B_-]5L5ZPQERDT]VFPMMPQA?ZM5WRL@ZB4F5B
ML-3EXB$=J2K%-5[&D;2;QJL>0:)*.F12"Y;IG62(48LQM(;S%ZKD=3+=2VU1
M=T0@4SXF9X\O^4)VLR=E[!+&5;Y!D+)08.5@X,),L&FF\KD?-OS,5I5<S,KA
MLT0<VJ%?W@9(P5N#H^6HS =*R!;\<6NIXED<37_)LO#-IJRTR?ATY.W3%AI-
M>FX$L9./(I=HYK;*5=E:$=.B%2>(MTE"+]-WHM-:4G:!7LSWIW6[-1,KX</5
M%(]9642NV8*[CVS0[2JN7SN*?.5X^:3/99!206"+<+FCD557[8ZQT5W"(  0
MH /( 4  ?=#@.!^,-+98,$GLF-L&Q%AD'DK<\!2E%R#7S,YLS"+LV1L?T27K
M+!K8962AYB1/69=],O59%PDS3EQ*9!X"G6I+-U^NQ3:]WLK$7M3,&&L(4R9C
M:RFYQPRH^;K3>6-FM799,RD1:7TKB>I*U>&*[1B$2S+!G8')D7CU88LIF223
MHB:;1I9,5VG=G+U[(+G,.(,+TNS1T*BOC2+HV:+/>8FT3QH^647C[9+2N+:D
MXJD<G)(PK5.1CXVQ+*-7S]T9B12/1;O?SXVMF[R4JN1W>5<-X1J5PC(%-QBV
M%IV;K3<8.V6(8^645C;A.2>**P[I\6221AFI)2-B+,X.T>OW8QY5&"+=X1-'
MHTLF-[3NSDZ9D=]E/$&%ZG>HR,%7%L!3\T6>X5VV2_FJ06!G<+%)8MK+VGLA
MF4XQD+V-A+,J#%T[? U%5HFT<_FHELW?2%$R3(9%PUA"M9$BXY)7%5;J^;K5
M:*O;906#Q15I<K0_Q17W].:$DB,6Q'<9 6=0[5PX="V*HW(W7(FB,/!1[^!'
M@H#QSP)A H#Q[?>(=WMZU6J!Y3_>!E7<RD? .7Z?N325WO[QL>CL(I&-,>L+
MU&;/]O\ 4KM$U[*]TS9(246YQ\[MV3:;7H[&%DMRL53[=(Y'3K@2]I=PSMG$
M;!-(M&[21QSD:0R%B#"U;R='-UAQ?5JQFJT66I6ER$6*J*=MM[[%D#)4\AI?
MAF9:-K5F,DSX?E3.L --0?M3Q1F;;=MADL4TW;MA7'TIC&(&$P=1(_<+>LAP
MUH8N9&4LS[TBY7LV+(^W,'2UJL=B?JO5(*V.'*\BY?J&*X=K$#,X77T%#!7&
MIP^.OJ9V,AIFSMB,$4;X:IL\CW/CDF;(V5U(Z,TQIYR&29*N @9[*KIZB=\&
M]5#J>-A<^4L+M\>0^(L:T!S6$%HE#C+OC!<7ADO=N [<3Y2K=!G&!JE)SIE6
MK>3[KEJW'[<<0;H-LBV,\UXUSYA;;CF7(2T-=LGY"WB957QK1V=-?,:TXHS7
M(6 JNE4FRMY()LH(.4F@+WO0]UKS;'Y)K?>YPUDFTUB_S[_<;N6V?TFYSE]L
M^2,(['LN;C$-O&$,TMG%[7E[$SI\:#*SYCI(V.35%O'KMGJB:D0@X=ZV&X*4
MW06#$F0W>1<'8';95;'5;X_H+++U@M6/+8Q*VBW* 6ZWRN*(U_60/*%>$.V9
M4^PI$38L7H&,NN9)M6!L&[.1Q)D"2M^$L$L<OMW)&-#HD=FBRSM M<&L2,!V
M-NNSW$T=*5TX=HG$RQS2H6%LNFT9@=4@2"Y6F9.Z;#]XIZ:/ F14T.(4M<^E
M951;S*VG<QY@?>@,DHDL^(3U,E14LIR(732ETSY;$854YY93B#G2O@EA;*Z)
MY?&9&EH>W\)R,RZ'Y(VLB,EWAC+-#=34UYPMBS*LQ37F=<H0ODE<U[NK6T5O
M<MN RW)1V?8_9#L2]4.0V-!R\\O:T_/5[=#NGLK)LU;8_MZA<SVK#CF"I19=
MI,N8YT\&U[&NXAO?O(%X9ROE?<(WLL%@//6Z3.^&YZ^20P$16<?UYXEAEADM
M%VQ"\62^UJP;DZ'C^20N%NDH4&F-3ME:HE-(+R1<\\$]W,O,*6%Y9\$X#CLQ
MUR9;&QGC:,RQ.2^,G<?&A"EBY&1O#K$\?)5&29$5F^R-HFD2A67FZ-[.\+YQ
M7[#^F'LV[9;$-JL$YAC![#.S*929TVD1^:K/(T&9K1G$'U[Z=R*MBAE.04B1
M)>?6)$M*;+ME5HZ,*9\3SDNHPK5;KM_A;$V@(=VO-#+)/4LG?+*[#Z_#8*YQ
M[5817""MC?5S@YJJ:BI'M, CRI#@YC>7&I-M\C>QL<;HPQC:BGJ9*<??7 TY
MD@>V&,@B".HF8,P=H:4H=$ +[@ '?X]P<=^JZ62+M.[-7"UAG)?$&%V>>6TU
MU%9Q^QS19WV.)2![?$I^<);(RN+6DW$R/FY::<^;F]'D4>U,6#7MW5OUG#/\
MS.V;O3X9EIM]AO"+?.R-D3:PM ;YNM+C'3ZJB\C2*RS_ "(?%"$TQF2,599<
MD,E27;8[AFS;C*%(\56:PQ9M-&(\!X<]Y0^40#GXN>=8][!9\<;D=A^?5LCO
MX? .,["QW28YN]F@U&;^/IM>I>3,C8YL%\'KHQHS4>ODJZXMLJ@X8*$2DY!X
M@NJ^$AW:\VH6K=H;"KN<<X?PLGGHD\#=ECU+--G5QNO7?.[9$9)?)!L6$FV\
MH$(9T_",)1EF_G!)%AV_J53/$^O?X@M>>=J=SPSG6"J>)[%EJGY"J5VB\(S0
MV&#K;>XR,VB$A6IRQU:$+)S3F,>-Y>5>257105L3N1,=LY2X55(F2K;=FUK\
M&VCW?;V+>'BT&;W@ [8T18-TVSK@H 4.T(%36X*  '6<  !KNM*E7YC=?%97
M84U3$6&B[?8Q\6';9&]-5E7R<M68ZO G'2J^."XI;0)9AU,((,W<8G=@;(,E
M%7Z;Y14A61NR@[3NS<9I=0=AQ!A>-P,2:GT&>0(S-%GD\CK0+=@[4K<@OCE?
M%K"$0D9.1(R;2L<2\+(Q35=PZ;OI!1N1NN1,WHTLD':=V;C-+J#L.(,+1V!B
M34^@SR!&9HL\GD=:!;L7:E;D%\<KXM80B$E)R!&3:5CB7A9"+:KN'3=](*-R
M-UBI6G=F\S#(0MTQ!A:$P>G)VA*-OD#FBSSV0G42T!UZD7CO'SO%L/#-'LR)
M&@3;).Z.4H3KE^RNI;J"=<1,WHTME,L^ZI]EZ;AKUB7#D!A-!W9R0%ZKN8[+
M8K_(,VKH"5)>2H#W&,)#QJ\PSY6FVZ%R?$A%P!!JM*D^C:_+0+5NUD<J2<3D
MC#^%:SAY)>SEB+G5<TVBU7AXV:/!)457M'D,65Z*9*S##HN)M)*V.BPKD1;M
M5)4@=>)$SNC2QXNM6[26R)+1N7L/X5IN,44)\T-::1FFT7:W/7+>402K:3^I
M2F+*I',4I.(,X>2JJ5D=FBGJ23)N2125,Z3,76K=I+9$EHW+V'\*TW&**$^:
M&M-(S3:+M;GKEO*()5M)_4I3%E4CF*4G$&</)55*R.S13U))DW)(I*F=)D3.
M:-+)AZT[LYJYS#'.&(,+T.BH1DBK!S^/<T6?(-B?RZ4JT1C&<A79G%M+91S)
MU#'>O7;U&;>JLWR#=BFU<I.#NT..(;5NVF;A-LLVX?PK1:0A$R:T!.X_S3:+
M_8)"92E&J44RDJ],8LIK.-8.X@[QX]?(33Y5D]108I-'22YW:)$SNC2R86M.
M[.<L,XVSSB#"^/ZRA"G7K\ICC-%GR/+2,\$@DFG'R<3-XMH[>,CC1IEW1I%"
M2?K%=)IM08BFH9P3XX?M>[J:F;&AF_#F$J)!-J^X<U>0Q]FRTY!D96RE>)D:
MQ<Q'S&*:8C#Q*K$57"LLV>R;A)P0C<L<H0XK%(FAT:6/#%JW:3CNRDSOA_"M
M 9-8)%Q5%\=9IM&17$O8C*K@O&S*$UBRDDAHM-$K<Z<HU6E%U#J*$-'I@F4Q
M_P ^([9N^F1M_IJPUA"C@SK7:J2-!S=:;\,[:^7/\J+ $OBBG>8(;@K4?/+,
M9ESRJM_*OZ"7K"+O,>Y9=6O<'N&Q2I7H6/:XGA,(R+6?9K*&F; ;)$%<)-PA
M,I&1(FDE"F@$T(L4U5A41=N14!(2E S#&XX#D> Z1/EZ8=$/ ?$W #]KVP\=
M+E@"3W+3*UUDMQ>-L+8W654K2-19XFOUCR,^D4$(][ZH%[9/S]+HQ>&S]1HC
M76C*).*+,[T73@YS):8X0 0X'W0'XRB!@_&&B)==J,5BN%P758["UEF;=CE&
M:R,I#3T^DJA*NY!WDZYO+4@X27AX%0J4;;W$_%,Q-%H =BR;'(J\(8KUPQ>D
M9=87W+X;@J=CG:/;\%0^,H)M9GTFCGZHY'O=S<62V7RQW.56CYFC7&EQ:,,4
M;"N@S:.XI=X@<A ,[51(4II,S3'[P75A@S[?+7MR@JL2%(2QMLP4/)=IGG%@
M!^L91>&>4N]U>/:0XQ@H)D:O6;MZ#X%5A="@8B($3-:-+'EZ/WB.;A"*X*M>
MW"%H9(J,+8665J%DRRVQQ-EE'9IA:'DZC>ZW#M(M6&%DC'-WL8Z=(21'3ARX
M7:J)-TS*,?O#<9#BE\-6O;C$XK*A !-QF2J%DR?ORSDDHN:SFBYJL7N!KS=!
MS#"V1@R.H5PHSDBKN'YWC8Z;<A$SFC2QY1C]X;C(<4OAJU[<8G%94( )N,R5
M0LF3]^6<DE%S6<T7-5B]P->;H.886R,&1U"N%&<D5=P_.\;'3;D+]'[PULJ1
MCG&-KVXQV%RKU@9B(O-"R9,9,5;)O"C<2QU@@+W#U=!=W']).MG<P"Z;!YT5
M9,C]$!2T1,YHTL=^C]X:V5(QSC&U[<8["Y5ZP,Q$7FA9,F,F*MDWA1N)8ZP0
M%[AZN@N[C^DG6SN8!=-@\Z*LF1^B I:Y6V/W@JYACW5'M>W)E@8).KFE(2TT
M/)<EEE2'3[+ZLDF%FB;W'4]&2=\//4TNXK2S6/Z3;SHA(=!7ID3-:-++;8_>
M"KF&/=4>U[<F>!BR=7-*0EIH>2Y'+*L.GV7U9),+-$WN.J"$D[X>>IIPXK2S
M:/Z3;SHA(=!7IDY'[P3YH:NZY:]N3?;X$U G>P4U0\EN\P'KY&#0+,@VM+&]
MM*8G,.)('RD&Z5JZC)FQ.U1?M7CA-990B9K1I99R/W@GS2U=URU[<F^WP)J!
M.]@IJAY+=Y@/7R,&@69!M:6-[:4Q.8<28/E(-TK5U&3-B=JB_:O'":RRG%U'
M[PQS4F[9VO;B3;T$ZT.I!.:%DQ3,(UL(A(KUN2TI7LE+";/.]<LU>#5Q8IQ0
MI-E6BCLIW(D3.:-+&ZC]X8YJ3=L[7MQ)MZ"=:'4@G-"R8IF$:V$0D5ZW):4K
MV2EA-GG>N6:O!JXL4XH4FRK11V4[D1K'[PPS4H[>6O;B?;T,Z[.G!-J%DQ/,
M(5L8A4K)N>TJWL]+&;).]2LZ>!5P8J10*MDFB;LQ'($3-CX>/'>'Y0X#X_#X
M]*MMMA,;XZVITJ(QU;D\NXWK=(L"D):E$V225OBD'U@D'@J)HMRLB$5<'?1A
MP!N*711$5$S\G W[FT?O#]-1W3VU[<3[>O/SI1.";4+)B>80K?FE4K%N>TJW
MM2EC-DG>I6=/"U<&*D4"K=%HF[,1R6^L(X8@,(8?J&&HA_(6.OU&'=0B+VR)
ML%7\FS>R$B_<ED4F+5I'J=8,FNW$B35-(R $*<AA$XF(N.W:WU[(& L)7JI5
M%E0*M<\2X\M5;HL<#$(^FP4_4XJ4B:LQ",:L8X&D Q=(1;8&#)HR!%J0&K9!
M'H)EF32GX2J>ZFH6D(+(4KM>;8*@H61A:14,.8UR)3;- ,(]TS:T>,!S.7>9
MJ:$1#UM!1A(,(N 9)G=$:&B@8,DC-C=IBZ/WAM\ARR^9;7MQEL5F0GPA(S&M
M"R9 7Y%R>40-6#2DU9[W/5YP@VA@<HSA&L*W4>21D'# [-L11N<B9S1I9</1
M^\%K<YA7/-KVY3>/S1DB6!8XFH>2ZS;D)@TJT-%*RTI;[W989S&I0@/D9!!G
M%MG2\H=JY;+H-$UFRG'$4?O$;7";5SK:]N$U0SQ4F6O,L4T+)E:MC>;-*-#0
MZTQ)VZ]V2'=Q:4,#U&1;LHQJZ7DCM7#9P@U35;J$3.:-++A:/W@M;#.'W!VO
M;E.U8\*<E<;8?H>2ZM/-[ +]$R:\R\NE[M$>[APC 73.U9,VCT7PI+ Z! IT
M1^.'X_>2UF;&?/%LVV3< I7W!*FAB>@9/K4NUM O$Q:N; YM]]LK-]!%8 J1
M=E'-F,@=V)%4WA$0,D)$T&C2QX9C]X;5Y91W 6O;C.,5()$E0)B&A9,J[II9
M 56%PXL2MRO=G2?PAD1;@BSC4V+XJI5C'=F*<A2?GQ)';S6PV_TYVW;3,E5K
M75T4,5X_RA7!96[EQ^NK4-MOUC\Y5W@6GZQB/-TER1P/;O9I@F1-)HTL>(8_
M>&U9W,,[VO;C-OE8)L3'Y\4T+)E::L;("4D#QQ;TK=>[(K*0AUC1(MF<,I&/
MB))2!5':AEFQD?ABN.WFMHF^$S3;=M,O-K5HB>-%L98_RA7HN/MW9I0%'5W;
MVF_6!U+UT79H8Y&,$XB)(&Z4DF9\*B[51 B:/1I9<5Q^\%O7L@$S5:]N4O:5
MX5$F+W.,J'DNO0,;8.P2Y5U[VSM-[L$A,PYI,T&HBUK[R'>D8HRJ)W1UW+19
MO^;&T?O,0JN1T\MVW;5*71>!3)B9YCR@90@JS&67L$L55QD&/LE^G)6<@QDS
M0:B;.N2$(_*Q1E4#/#.'+1=L1-'HTK=$CMYJ-$R2CDJV[:9')*\>F7$<A2<?
MY0B*3%RH,'A55,AQ$[?I>=G& R8L%$T:W+0;@K$CM$RQEU$5D_T4:/WAHX\R
M*AD>U[<9#*BZ"H8IDZ70LF1-"C'(Q8E0-?X6;O<K89M )GA94E=FH50T;RW(
M<KGAQHB_=NWQ@.9MNV4<9!:*_2QML$TCPL]IY\P1'4SL/(]HD^%VH]0?L/9R
M_1T_HRZ7>/THL0)1Y'V1/$?'GGQ]OOTBESPAN>SIMPS3AW/%WP,-HOJ,5&4Z
M=Q=1;_"UV(B6[^(DY#U3Q5MM]ED)5^H[CE>QGC'D>W3042(LD=0IEA>L4Q$1
M'V'>(CW@//>.B+[:-&C1$:-&C1$:-&C1$:-&C1$:-&C1$KN];<83:1M0S_N0
M"#1L[W$&,+/<(.M.G:D>RL=H:- :5*OOY%$BJT;'35H>P\;(R**#A9@Q<N':
M+=95$B9H3VQ9XW !N/S;M&W03.(+EDC&>$MONX:#R#A>D7+'%6E:CFR>S!1I
M^K2E2N-WR.Y9R-'O>&)XT+/-[<H-HJ%AA%)&"AIF)DE9%O,WX<HVX3#^3,&Y
M,CW,G0,M4>RX^M[-B]5C9%2!M,4YB7ZD7*-P[3%2S5-SVR*E&W#F-DF[5\@/
M6MR:5C$.QJ3QE.3M_G-UVX_)N8[;9,)'N>7K8.&&-EMF*MO[FSN*)@:1A*SB
M2'ID=CB56NEPE+_(5VNPN0K=9+;89XETAU5HMK$$2:;<_*'[D\A3FSR[W2O8
M?GL:>49H6YF[[<<:5"&M=0O6+'.)*VME+#]>R!E&:M]QK6029/Q#'R3B\V!K
MC['"-"OHL&,)%V:"66%)Z]B&XC*^Y+$MZN&:Z+3<;9"INX[<=A:7I-#L4E<J
M_ H8:R[8L=QK9.Y2D= KVU\HRAD7,G8DJS56<D\65595N);@1MJQ=OODY,?;
M?\E4^XL<K9<OM)PK#Y5KNU_#5X<412A[;X#-<VQF\@1M,D:[28"]W#HH,$*=
M2'F4K9<WM QV9U3X!<$7SY^Y:C".":E@6'OL+49"P2#7(>:<P9TF5+ Z8.EV
MULS5?I;(EHCXTT?&QI$H!C-3#EM!M7*;I^VC2(HOI&0<E.Z.18V7WE?F3V6B
M8R@;*=UE_1O">Y8N)Y5D]V\UV-R*ML[R/(8\W$NDE;/FZ.6IM=JJS-"4JECO
M"$(UR*6281%8;JRSA) _9S7ED,*EIJ.7,?X3W"9;P7#X]VU7G)V5Z/"8\2C\
M4N]W,'CZV81J%EJMIR+7KE,SSFFY.IEOR([IL/8J_C&OV&)>V26,*S].,8^H
M>3WPW3/17YLL>15_1%"[R(*N=NE:ZKVUIO=R(UR7E129ZBKM^T.(*<:)M:*9
MGV%.-BS'1G4["Z$'9<5N3?)1Y9J[5AM:VWH9 KFW:S1/D^ZO<<AK9[Q<E6KA
M ;-V>,ZA)WC.&-Y# WI55S GC/#-/J\-$X0O$1BC,BS>K#E)C2H^%L[>R$61
MVV;ILLMMO_E*<]UIK6Q@]N".X>'V[)2%??*$GIO;7A<XWF8M9@ED#3T<?<5"
MWVF(L8\8CHPU+.D#PSE\=RC85%\JQCO(N'*9D;%.,\D9X=Y-R37,!X&7QT./
MH:L[I<T-L<S]^RT7",]=+["QY,7X=;TC(+:[Y7O*M6I*S^E6&-HDG>E6\<K+
M-XCM'QLAM-N6STDK<CX[OV,\K8TM%F<RL:ZR'*I9H;V[TAW-Y-*PPP[B\V"7
MO%CL[V3/7QC%;"_4=&AQ:#V(48S=Y.AMCA*&R%M8B\C.+A$;@<19M9UVF9*Q
M'C68QE;ZI@RU;;LBY<P>VR1AZ[8ID+MEW%4S"UO,^,LE,X[&F1&D:\NL+(4C
M*15)NQD3][6MS%;W5XWE\B5NE9#QV-=R?E;$%EIN48J$AKE W?#5ZF,=W1C(
M,:]8;1%]F3L<&_"*>-9ARE)QO9I)'AL[0,=D=(AY.7;OD/;7MK2J67)!=_E&
M]9?S_G2\D=7%#(3Z,FLZYEN>3TH26O+2JTF/M=AAXFQ1;"T34/58*N.K.C,!
M5(UK5DX5$CWZ(C1HT:(C1HT:(C1HT:(L4N[K..Y24W+K[;=N>2ZMA9?&VS3)
M.[ZV7&S8Q:Y/"[SS&[$Q]BC&?8IAY%1D11U9.%N,[E%]!/POKA@6L15;E*@9
M\M-K]9;]XN8,O[;_ "8DUAU[%X7R1Y2:8PX=Y:I>GJW8F&Z;8=K=\W6Y(5@(
M2;*:OR%R-!8[<T&D^K4CN%;/K"6ROXFP>9#0SYG-S^QG%NZ6Q5ZXV"X9@Q=<
MX>C7?$DQ;L'7\^.[#><+9*<1#R^8?NK\L1,^<J;/OX*,DFCZ.2B+S399)S+8
M^N-2DI*4=/>LO^P'#UYK;>LM+;F:@-:C:\/7;!;C'^2'<1ZV&S80Q^IB^G/=
MOD/*QL[5Z3'/J0\F8"[5:4K]FJ%_CK%8F-O@99C,.VIB)#TM\>\4FWNG6.):
M89L,]BKRG,;L.W,9,L,=9ZA(6NF1^]V@[<(V_8>Q9&,+)6S6B^T^WM5[<2>O
M<)7:18$IN0J3"=3&,AHO)-NVW-.]L=2QK+Q&,YG+-JRUG/&F Z94(:Q0=4%6
MV91>R;&'E):>L!%6$;7(<\:J^L+LB#R0;1*;IS&1LM((MXI[^.O[)L(U[ M3
MV\HHV^3I]9RS3<[O9Z<MK^7O]VS'4<ZQ&Y%;(M]N#I,7UEL=NS!$$M%Q662;
MM91-V[AF32*A@9L64N9:PC1<TCC0;NA)KCB?+=+S74?-LDK&]3>*":4-7EW_
M %29^WQB8R[SM4:IT$G7*?34+U8<D6(^'\M,A5D6EIW([7[-@_%BT1O7C%+S
M&98J&37R^4O)^QMOE=P]:B*NR@*F9]0':5 M\=B'(DA-PLU?9Z(3CIO&M&;2
MT-(O[]MGE#\]+QV6L*SFW-QMQW/GQCMTF,/K3&2:-F"DOY_>-FNQ[?\ $2Z;
MR&CH;ML]CFPP,K9\K5J2ABQ$06NRZ$++72HH(VZ3G++GDT< WS'?J;8UE.<E
MJP??#9:-#9"LMM<8_D;GOM@LGL,Q,LBM*@_K]JE:/-.\IV%%./KD_ S]<BUT
MS5J::2D>P>$7C:'Y-J]5W<');G-U<D[G;O7:U@2L8PKBNX_(VXT[=WA.$SXP
M9VJX7.\8SQ$S?MHM7<#/M,>U6,H;9U&/(4V3;S:KCDBTOGD411AMQ\L="OL.
M;AY[(4;8<MO=G,AFJ,W"9(KZ5*IB*607>[/)^&-KV :C3'"D(O:<D9)J\!6R
M/[6S:0V)ZU(*(QT[?G=U4LM?KV1G:YNOON:\HYWP9E[ $E@3+6WV"PO/VR.3
MR/7<ITNR1V;F%_DZZ_HEPA(>M/92-C$:%(1<RM/U6L2"=A3D6+6)<13%C.S4
M#9C\E=@R:Q-<8+%E69&R ZP_GS&,.C?[K>XVG7B-S;F:1W''KN3IJ@.(R[M6
M-.S?)/[MB>[U%PWO&$YN4D)>EJO4GT[!V#O]@6T'*^!,A;H<X9MG D,A;C)#
M#,:I&N,PVO/DVQJ^$J5-5Z&D;+D^RX^Q%'O)N<E;;8UB5NDXKIM0K<&RA4TT
MYFR2%DFGA%DVT:-&B(T:-&B(T:-&B*AC=$IC>/1*)N/=X#G6##)6]7<Q"Y%S
MSGBO7*L--O&W#RAFVG8:^V_+8K\Y6+(D#E:<VZT+)V5'60G4C'6>*NL1==RD
M=)XXCH!(**-3QTNE/QUG=7=*8K>= 0 0$!#D![A ? 0]P=(E9O)Z8.M.X!SG
MI[.979H363L>9UNF$HJ_+L,!9 SWB6%B(#&F:[?0"1AWKN]5)A6::JDE%V2(
MJ%@FJ-1[1<:K8[/4(&79$4(;M\Y;E)7<LOMNVYY+JV%G&-MFN2]WEMN-EQBU
MR<%XGX^\%QYBK&?89A[%QD11U92$N,[E!]!/POKA@6L1-;E:@=\M-KVIBO?!
MN1RSE[R7,N>GXJI>W??/M<L&:)QLG*6J8R\TR & *5EUO6%H>4KD77*I2ZZO
M:'2*,LVLUGL5F519I/&$ S17,^GW+/DX,49?1KSF9RSN8K]OAH?--&E\DU+-
M$C&Y(O.&<^W=2^9!P/=;9(0TN[D\6)R98YA0VL>E$W'%$-#1K+&-RJ:H/7;U
MBS;9<1)6K;Q:XJOJU]?:W 6FK8:AH!X>-K=:KMLH\5CMY#FAB$40>,(^J0L;
M'0J"IREC0;%4)UAA$-$6,#;+NOW&3>\_U$[F;3G3$-2RWDC=/4]N.)\D;2*1
M0<8Y$:XKMEN<5""IF<VUMD<K2%T:86J"F74V^0Z#1(C(T$:S25"?V:&K9G)Y
M6W(^4VM6#LLY7Q]3]J5PS! 81N6U6@Y ML1E*BU%\\M6\>5:U##L)C^JV%DJ
MI9I!M>9BM,+V>?G*7#5RK31K1&3%C?1SBKFGG&/D^,1XRS#6<NDON>;V7&DU
MDRQ8.QMDS*TC<L9X'G<P(2K'(,KC:*=QS>RKO):(L%CKL*?(=NOQ:#5;%.53
M'1:G79-Q&C?EPV6X1O-HR=;YYC9%)C+>1-L>3[@=K8W+9NM:=I%HKUOP^K'M
MRH&*P8LIFL1:D^Q3$Z<^W(NW<'1*N80(D:I?E6[KD2>DL.4C:7)VK=+C:U;A
MV&>\+Q&<::A7Z'3=M,SC2%N%KH^3[#5H!+)LA>'^8*'&8EK3RF8_3L,T>TL[
MG8,>1]75F'\$[@O*PV&-I&W#<]4[*AA7;87'.P3-FXUE9:O'7NS1U5WTYQI;
M6"IKPD1$3\PC/5#!]1RO(23.C1[F?D9BZ4H\.B[<KPI%9AW-^33M9+M/Y(VC
MQ$0RN>5IC<W8<K6"<W+Y@P);#SFXR+P\SF(5&R8]Q]DQE9,)RCO$,#)6;'7J
M<JF0:Y/1L9:L29?IS]Y:8^=9' ODTL(8?P-B7#TH>9LLKCN<V@7N4MK:4?QB
MDWD#9GCS$E#Q4LP:N%9%U$46,2Q#!NFU'._>MR _FNT/UW<N_=JD4%S'E6K:
MI3(ZU4/:#=+K(Q^U:3WT9)HYLR8HB;?1]J4M*71EARQ,5&"]EIMQRWF6+H=B
MM,'BV+MS.!KD!$2R-@R@G9TXBN3>5'%%_996QACG)\:R7C8[(U#IU\81[E5-
M=PQ9W&MQEC:LUUTB)IK+-4)--!55-,A%%$S'(0I3 4,(^Y[R2ML5B;#C[9^R
MK]2QYD; N;,"3H3&X_,^(W=+J>8,@VN^-Z"[@J-1;RPR?MVH4YD2ZV:@8IBY
M3$5\HJ[Z:QM5<N-,37V3KE;S?8PHK'%^-Z!C:,=+/HW'])J=(CWCA,B*[MC4
MJ_'5YHY623$R:2SAO&IK*IIF$B9SF(01*4!$BOG1HT:(C1HT:(C1HT:(C7$P
M]$.?=$I0]O@3& H#Q]H1Y'7+5! !#@?]A#O ?A >\/<'OT18,,(;U=S%GR#M
M7S=:[G5YC .]C>ANGVHU?!#'%0Q,[A^KX?C=RZ^)<@DR I(M;5,VV;<;6YAS
MEAA:X]6N)-\D,V-3AZTO23O+/\-Y6]C<WC^X[]LCXBN%4J^+_)H8HP/D"SXK
MFL9DMK_<A/9!A9'*^1H62N+MY&RU.A8[$Z,+6,<N<?B9VEDJ2E9NUOYR(A?4
M6X=ZE^3GP;0\QN,NP=ES'V2.MN8LD8UQ&[R0Z5PWA+*NX%M,M<QY0Q'4$8QM
M(5NWW4MHN:Q0DK%/5NFN;S>G./*[45;G8S2%LW;R8.!<@SE;F+1=\^R#8<>8
M:QCFN 6RR\<0N[.L8"D59C&!MT0/8=W+9(G8B4=2"L_98N6J4[D"*DY"HY#?
M6FDKEK29%V=.SWN)=>4?O^W&^1&+8C!J.U:*S3B@]3DK).Y!F9%7+_J$F)+)
M*\Y7*Y&59RDUZIK%5&KGM#(I>UR<E9E72K>.9QANM\I=8]N&2,M5"M[7+?F.
MM8"B=K4WEFUP>3*14Y!)ONWR):<48S@L=U2Q-%%KI<DKM7V83<;,S-'K+.M2
MIYCU9#)LD*_(OX&#Z*&=O7% A*>DGT3#A?M/G-7S.-)&[#?Q1\S]7U/G,;$(
MJ^<04ZSLGZT!,">RU%N2-E^$LJ3>8)^V,;&M(9P+MJ)>S,;&Y8I."[4<C2&4
M<2!&))H'",[':Y-TM/=4*GGUB8C%?J4R <2)*ZEY4:]72RC@2 VJJ/\ >1$Y
MTS%A^W8,0SM54Z+"0N",;82R[D')$?FN1I4=Y\@C4W<7AZ&K$6;&L5(2V2K8
M:K2JM=K4)-WQDL6X3RL]YF]OV(]R6'5I# M'B\5UC/NX:(R#5ZU<;!2:9=-Y
MN*=KE4JEA69(V&/:/W\<CN-L\@:J)R;\5\9IL8)W)G4(HNU6Y+R>TX3(".:]
MK4(R#*-HSME+->2)N4W%Y-P!=DI7*6#\386L$;0,C4O'>68B.H]F@L&XW8WJ
M@67&<T=9>,89!Q_;Z-D*K1;N1NG;)Y+3$F'=J%3V_7UY)6FPK4G:_#Y'LE>L
M=E:,'<SM?OA<O4..I:UA<REAC*=#9/>S\TBC+/'DY8 G9J2L3Q29G)%?1%;%
M=\J3-93C,5JX%VP6?)]CS#0<J;D*=3I#+>.*5..=G&,[-5J?&9J='7+.QT;>
M\NV&W1C/$^"Y=W'3Q2D?)9?M>()>)G(>*R$[:LV1>Y3;Q@S<-!P<G6(;.>(L
M=Y<B:W-K-7$S 1V1*I%VME"RZS(19JR<8WE4V3\[0QFQG:*O4&,GT3#C!W*>
M35MC&<1L6SJ)BH9S8?73&L3>4W-9DP&^J2FZ&9I-VN]2JDM0:%E%B_P'=<GU
MR:R?>\5-J_4KC7,CSKR[X3RKC]Q-VN$FLFFUO"C?;9MIV^;>6LHE-ML%82Q9
MA]&:0:KL$)<F-Z/!U#SHBQ=.Y!RQ1D#Q!G:+-=\]5:)+$;J.W!TS+'(IWT:-
M&B(T:-&B(T:-&B*AAX#[?( '<(]XB !R <<AR/?WA\(>.L&-*WJ;EW.2\,YT
MGKC697;QN)\I)GG8%7=OS'%GFZ?H].QC)[@\<4O+Y\C.GZ%M6OLIDG;I)62\
MP\W'.J4G0+NG"P$/$3-7)9YW*'FS=OMLVZS5=K6;,R4C'5BML)/V2MP%@DU4
MIN9KM5=13*RS["+9-GC]6%@7DY#-9:5Z@K*/<RL>BX735=H%.BE0Q/Y/&!R#
M#[P(#<P,KC.989XW[XVHYL[Q,UM>K<L[@6]<W$;OL>UQNW4%)PV99-?*6V6=
M6J6H=(L^3;/9H"J5FZ7*;EW9%'&]3>!N?J%YWSV'!=XIU'H_DV]H6-]S5HH]
MGQAZL5]Q=ONK3,61):ARUD?2$2]J-(88PPT>O0LICU=&Q^D"[&F)687BZ<K4
M9NS8S?+N<F;G5]P*%TK[;;SDKRELGY.^N8!'%"*5HK]1\Z67#D7FR0OLBZ0M
M!,E-LUUT]OF*^^8.,>%Q2JI7&\/Y_33NRE\5/;_Y.G>K9_4;C_=QD;*MNJ>$
ML<XHW)46!W%/'=RW+X(IMED+#0XS=?#3,5ZN+S7B3MDLC)2^0OJ.G+%$W.SX
M_GK;)5"SR%8==GFJL^30VF[L83(>==RDEC&P6'(LCNMC-O-PR8]';]6,R6.*
M<8PD=U4]2FU<>IX^>2Y7$RV3L]]N4%AXEX5LE_BX)OD9*9M*!%#%GRMY2*@*
M[T!QSN"EMV3+;EC>J8M32JVT.AEMB^[3+4[C20:-<?U?'<F]4NK7;UB*UIW[
M*D%/.F4*_E;S689S(PK&H75^V?+R?.?+1DRBYIK65\DY&N6;\+9/<U[)U(S%
MA#'VW_)N+4)>DUVWTJ!F*GB^U7FBV*!M-8>I76J9$K%LGXFPL)MQ& [0DJY)
M1C")-P5B\F]MEQG=-L^8=QJ^&W6?KQ=MU$M-P>4;9&YCA[-=LP&RJ&=BW"B,
MI"8Q_4:YD!DQ;56U6I"/QFW@*FE29$\Y58F<B%&CP;A[ ^V&HV*U)Y4LF1)G
M<[D&E2]PSWE>[15PNF:KM<H&LXSQ>D6PUN&@*@C%J5EA6*OCZN4.MURELF1B
M.8B+(ZEY.1D"+&B\\MEDAOC=3+1-AUL)1@V7(>40[8_W"8\:RC+:7#IK^KB8
MF8UK4I%)IE]$Q$'N-L71CZ;B+U"JJN[-D3&4LT7@09Z4\J"8<E-6U.V\VB[;
M=UMV^+MC[G<!&9"J#%>,SYD*7JD/*JO,5OVA9TV+Z7*V^/I\G<6U@6L3_(;:
M0@6U";U9 E\4ON^["MG%*P)::M>W-BK>(H?83);#++,2MX?-$XO;"HR.Q?(N
MI<&9E$;,DW7$#V\J9GJ9A*;LW2#C2DW+R8&5+;N9AGT>^KE(VXP^[S'N[)1Y
M5<_YB2=25DQS0(F+;2)MN;JFJ5".S78K;!Q:5BR,US0?&?FM@KD>(PK&Y@EI
M&9,11LW\K-?Z;NP@J=/NB93KFZN(R.39+@BKQE2ITE=I*N[I?0#39AWE2S(1
M\5#5F7HU(MF:9JP6V>%NXKUN@J]2(6UWQ[4J5+NI7/*6R%GRQC>&B]NMA>[>
M\Q;KL@[-L:[AV&3*8\1D\M8A89?3R3*S^,P:)V"!QR%NPA?J9CVSM9J<E;C)
M0CJ1GJS0HEY6W%BOK(/D\]G+B@P=3N3>1JM6BMO^(]G5.?!D-W35X""J.4J?
M;,'OJG/E68NH_,L/F>%I$WCVXLG2EC7OS6$&/;/I5PF@Y3#$FQ2^7;=/C#,\
M9::2MMDQ!O'W';H*D:F[@LMVJ$L&0;7$9HQM/$BMO4U08JFXSOLOD;(]VG\T
MSP93O-$;VV$M:V&,<XT2RQ8V%<(L\Q1Z12F\.D #Q\(<ZKKB E*!2 (]P  =
MPB'< <<CQP'/M<CWCW!R.N6B(T:-&B(T:-&B(T:-&B(T:-&B(T:-6$_R'#1[
MUVP6;2)EF:ZC=0R:3<4S'3'HF$@F<E,)1'P$2E'CQ -6U35TU(UKZF9D+7NR
M-+R0'.L386!TV%U<4]+453G,IXGS.:W,X,%R&W N;D:+D!7[HU&_I/@?VI*?
MN+;YWH])\#^U)3]Q;?.]6G=K"N?0>4=FS:%==Q\3YE-XAUJ2-&HW])\#^U)3
M]Q;?.]'I/@?VI*?N+;YWIW:PKGT'E'9LVA.X^)\RF\0ZU)&C4;^D^!_:DI^X
MMOG>CTGP/[4E/W%M\[T[M85SZ#RCLV;0G<?$^93>(=:DC1J-_2? _M24_<6W
MSO1Z3X']J2G[BV^=Z=VL*Y]!Y1V;-H3N/B?,IO$.M21HU&_I/@?VI*?N+;YW
MH])\#^U)3]Q;?.].[6%<^@\H[-FT)W'Q/F4WB'6I(T:C?TGP/[4E/W%M\[T>
MD^!_:DI^XMOG>G=K"N?0>4=FS:$[CXGS*;Q#K4D:-1OZ3X']J2G[BV^=Z/2?
M _M24_<6WSO3NUA7/H/*.S9M"=Q\3YE-XAUJ2-&HW])\#^U)3]Q;?.]'I/@?
MVI*?N+;YWIW:PKGT'E'9LVA.X^)\RF\0ZU)&C4;^D^!_:DI^XMOG>CTGP/[4
ME/W%M\[T[M85SZ#RCLV;0G<?$^93>(=:DC1J-_2? _M24_<6WSO1Z3X']J2G
M[BV^=Z=VL*Y]!Y1V;-H3N/B?,IO$.M21HU&_I/@?VI*?N+;YWH])\#^U)3]Q
M;?.].[6%<^@\H[-FT)W'Q/F4WB'6I(T:C?TGP/[4E/W%M\[T>D^!_:DI^XMO
MG>G=K"N?0>4=FS:$[CXGS*;Q#K4D:-1OZ3X']J2G[BV^=Z/2? _M24_<6WSO
M3NUA7/H/*.S9M"=Q\3YE-XAUJ2-&HW])\#^U)3]Q;?.]'I/@?VI*?N+;YWIW
M:PKGT'E'9LVA.X^)\RF\0ZU)&C4;^D^!_:DI^XMOG>CTGP/[4E/W%M\[T[M8
M5SZ#RCLV;0G<?$^93>(=:DC1J-_2? _M24_<6WSO1Z3X']J2G[BV^=Z=VL*Y
M]!Y1V;-H3N/B?,IO$.M21HU&_I/@?VI*?N+;YWH])\#^U)3]Q;?.].[6%<^@
M\H[-FT)W'Q/F4WB'6I(T:C?TGP/[4E/W%M\[T>D^!_:DI^XMOG>G=K"N?0>4
M=FS:$[CXGS*;Q#K4D:-1OZ3X']J2G[BV^=Z/2? _M24_<6WSO3NUA7/H/*.S
M9M"=Q\3YE-XAUJ2-&HW])\#^U)3]Q;?.]'I/@?VI*?N+;YWIW:PKGT'E'9LV
MA.X^)\RF\0ZU)&C4;^D^!_:DI^XMOG>CTGP/[4E/W%M\[T[M85SZ#RCLV;0G
M<?$^93>(=:DC1J-_2? _M24_<6WSO1Z3X']J2G[BV^=Z=VL*Y]!Y1V;-H3N/
MB?,IO$.M21HU8T7?XB6D&L<W;2!%W9S$3,JD@5,HE3.J(G$CDY@#HIB "!3=
MX@ \!R(7SJ\IZJGJV&2FF9,QKLA<PD@. :XC2!I <TGI"M*BFGI7AE1$Z)[F
MYPU]@2TDM#M!.B[2/F*-&HZL-^\PRJ\9YK[3U*:!^N[9U72ZY(JO'5]F4XZ/
M2Z//3'GCGNYXUTGI6_XD_P"D/_!ZL)<=PN"62&6JRR1/=&]N\5#LKVG*X7;$
M6FQOI!(-M!.B]]%@N)S1LECILT<C6O8[?H!F8\ M=9TH(N' V(!&FXT*8-&H
M?]*W_$G_ $A_X/1Z5O\ B3_I#_P>O/W18/SL^;U/V/M8[+_?<#%N:_MJ?9\K
MM]!XE,&C4/\ I6_XD_Z0_P#!Z/2M_P 2?](?^#T]T6#\[/F]3]C[6.R[N!BW
M-?VU/L^5V^@\2F#1J'_2M_Q)_P!(?^#T>E;_ (D_Z0_\'I[HL'YV?-ZG['VL
M=EW<#%N:_MJ?9\KM]!XE,&C4/^E;_B3_ *0_\'H]*W_$G_2'_@]/=%@_.SYO
M4_8^UCLN[@8MS7]M3[/E=OH/$I@T:A_TK?\ $G_2'_@]'I6_XD_Z0_\ !Z>Z
M+!^=GS>I^Q]K'9=W Q;FO[:GV?*[?0>)3!HU#_I6_P")/^D/_!Z/2M_Q)_TA
M_P"#T]T6#\[/F]3]C[6.R[N!BW-?VU/L^5V^@\2F#1J'_2M_Q)_TA_X/1Z5O
M^)/^D/\ P>GNBP?G9\WJ?L?:QV7=P,6YK^VI]GRNWT'B4P:-0_Z5O^)/^D/_
M  >CTK?\2?\ 2'_@]/=%@_.SYO4_8^UCLN[@8MS7]M3[/E=OH/$L1._<UUH_
ME(]KF7VM@W6XOQ\PV3[ML;R^7]L.UJP[GWT=<K9FW:I8JU1;+"1F MPL97D+
M!$U"Q65B_>U./=.%*@9LVERME7K!^@J.W?<"GLR4K*>$,R.':7DP_+Q4BLJR
MN*K-!9+R+(9KW!X(NN%;3DK'K,)=:D[A=T$8E9<HR6)6R43(C8G5A9UZATY!
M@M1JSLX#E7G_ .A!_N@(?D::H&50 . @^ [^X)#CQ\?!GX_;\=/=%@_.SYO4
M_8^UCLN[@8MS7]M3[/E=OH/$L8<):'F[S?CLJRCA_&6?*=1-JF,-QCG,N4<S
M;?<P[>8Z>;YEHU.HE/P164,VTJA6^^/'ULA&^6+*6NPTC3*RGCBNN)J93L<O
M LCKIOV)+8]W*[G+=2)'<Y@?)64<$8NJ4+&06TZ2WW[3_*$1E:K&26\+B^_X
MWA<+6R6QW=*A,V6Q8OM5;CLS8A<VVAW>"M3AW)1IW3N#SC^E4 'GS'W^'/G#
MD>/<Y%GSQ]K5!RH ]XP?R2(AS]HW#0.D'VAY#Q[N_3W18/SL^;U/V/M8[+NX
M&+<U_;4^SY7;Z#Q+"S@W*TKLMS'N>N.Z_;-EZM3>[#&NSW(F+JMM\V]9)SW3
MR+8]VD4/$5TV7UMWABIW6.K,[C#,->R \I]0OKJKT^4K&44[/!3L@V"]OHIO
ML@PV8ZSM%V*PF*,,S^V^=CL^; FE[P#A"9DIR*PMBD<M4,V5L4O9FDQ<)'R6
M-*+2U)2LWA="+9T=6N1\B19$:X4ASO0.5"C_ /0?AP'=("'(!SP \- Y+WC[
M$>0[Q[N_7+TJ^UYCX#[4AQX?_B>GNBP?G9\WJ?L?:QV7=P,6YK^VI]GRNWT'
MB6L!:*3NGVX;*L>YZ->MZD!EO(WDQ=X<WNHN>0\O[@)A_7,T5>Q;?;#@IU(L
M+C8W41AK(%73G,E5S'GJ7C:9-O:N>PP[H)L&:[EO*2;;?>XWJ9*>4NQ9;C-S
M+7/F[Y6#@[!2=W$KAB6VR,Z;N 2VKQ%ML%EOK#85 8ADR&P-(0-AQ_59_-#+
M+B2S"<KCV9=Y>=,<\6666,<ZT]3'V7L80N0*.XFZS8'M4LCI9[ 2<E4)]A9Z
M^:7C"I)-9ADRG(M@^4B90CR(D#-R(2;!ZT,HW/)(93* B(07'(B/'G >.1$1
M$>.R<<B(CR/'(\CR.GNBP?G9\WJ?L?:QV7=P,6YK^VI]GRNWT'B6MHAC"!R/
MMECAC:AY3JRR];MODJLE;O&>6%MVWFP^=*;O,Q9-[E)>C5"T@EF>8S'4J*&0
M;+EU3;H5[M_B*='T63JT02WUBDRL/^2Z+;@UX)5MNQ;>4)>P9<$;NG6T'T-'
MW6EOCS>:3>INH+2FUK?86XL25C3P.CML';9Z>'!<-%HRMO6:%+#H3)R[*_I4
M /\ Z#_Z0'VO  _6G< >T < 'M!J@Y4*(\C!]_\ ^D![P]P?UIWA_6CR'VM/
M=%@_.SYO4_8^UCLN[@8MS7]M3[/E=OH/$L&#?!^\![,7/<#E"=W0/]R^-=\'
MDR*[6XRF9&S(UPFGC:=Q)L#JN]=:B8>@9EOBJT8?L5CM^Y1;(\\M6)N$C7D'
M-S#63@W-45=-=C .X.._NY#OY$> 'N[Q[Q[O;'O'QU$'I5_XC_Z0_P#!_BT>
ME;_B3_I#_P 'I[HL'YV?-ZG['VL=EW<#%N:_MJ?9\KM]!XE,&C4/^E;_ (D_
MZ0_\'KN$<@]:BDKYJZ/6)D4Z/;>>CTR@;CGLH<\<\<\!SKTCQW"I20RJN0+D
M&&=NC0/THA?7P<71?SDP;$H0#)390XV'WV Z; \$AX_0>)21HT:-9=8M&C1H
MT1&C1HT1&D4O69,10USM$5+Y1Q]%RD=./V<A&R%O@F;YB[15Z*S5VU7?)K-W
M"1AX415(50@]QB@.GK\=8M\H;,MO=RR/>;98*G,.YRQV>5F9=RC<;$S2<2#U
M<5'"J;5N[*@W(<W>"*)2ID\"% -1K=,*8TU-VR^9K=_.7>&,>XG(Z]P][ !:
M^D$F]A:VE2/<T9Q4U&\-B<>UQFWUSF@-WUFD90XDWT6T:.%7EZ=\(^^_C/[]
MZY^D='IWPC[[^,_OWKGZ1U"7K#=L?UESOW]6CY[H]8;MC^LN=^_JT?/=0W+A
M/QM?]#!L^6Z?1M4QS5_Q5)]+-L\#I]M4V^G?"/OOXS^_>N?I'1Z=\(^^_C/[
M]ZY^D=0EZPW;']9<[]_5H^>Z/6&[8_K+G?OZM'SW3+A/QM?]#!L^6Z?1M3-7
M_%4GTLVSP.GVU3;Z=\(^^_C/[]ZY^D='IWPC[[^,_OWKGZ1U"7K#=L?UESOW
M]6CY[H]8;MC^LN=^_JT?/=,N$_&U_P!#!L^6Z?1M3-7_ !5)]+-L\#I]M4V^
MG?"/OOXS^_>N?I'1Z=\(^^_C/[]ZY^D=0EZPW;']9<[]_5H^>Z/6&[8_K+G?
MOZM'SW3+A/QM?]#!L^6Z?1M3-7_%4GTLVSP.GVU3;Z=\(^^_C/[]ZY^D='IW
MPC[[^,_OWKGZ1U"7K#=L?UESOW]6CY[H]8;MC^LN=^_JT?/=,N$_&U_T,&SY
M;I]&U,U?\52?2S;/ Z?;5-OIWPC[[^,_OWKGZ1T>G?"/OOXS^_>N?I'4)>L-
MVQ_67._?U:/GNCUANV/ZRYW[^K1\]TRX3\;7_0P;/ENGT;4S5_Q5)]+-L\#I
M]M4V^G?"/OOXS^_>N?I'1Z=\(^^_C/[]ZY^D=0EZPW;']9<[]_5H^>Z/6&[8
M_K+G?OZM'SW3+A/QM?\ 0P;/ENGT;4S5_P 52?2S;/ Z?;5-OIWPC[[^,_OW
MKGZ1T>G?"/OOXS^_>N?I'4)>L-VQ_67._?U:/GNCUANV/ZRYW[^K1\]TRX3\
M;7_0P;/ENGT;4S5_Q5)]+-L\#I]M4V^G?"/OOXS^_>N?I'7Z&F;,-OW39BQR
MOCIX]>N$&C-HVN5?7<NG;I4B#9LW13?F467<+*$1123*8ZBIRD(43& !@KUA
MNV/ZRYW[^K1\]UV,/LBVXP,O%3L94)I"3A9./EXY92Z61P1%_%O$7S)4Z"KL
MR2Q$W+=(YDE %-0"B0X"4PAJA;A5C:6NO;1>&"U]&NTI-KWX.)5#J^XO%26N
M+VEEO;1>W>:]?MJ;(>[GGNXY >>[@0\0'GPX]OGPTH=QW'S3/<IB#"]+@8R5
MI\U=K+0\LWA^=T8(2ZM<1VG)\'CZHD;+)MWEDC(N"8S>0'CL'+:ML9^N0 M1
MFYAT>);\#F!0%0XZ8*@L'( )1.!P4]D4>X2B8.\HAT1#DHAP/&D??;)JLQO^
M&+91[WE2O0^-LN77*T[7'^7,B2K.2D+E7[@G(C6&JLBHS@I"5MMH&0L[E8#$
MGJLK-5=T=5G)BB6TBWOO]\-CD<&Z"1F+38Z"#<&V46L3KM971OHM\_\ (\/#
MH.CAO?1I:2R9$J]2G\>UN<=.&[[)MBEZI6':+;M$0$]#5.9NJS"9DDU>JAC/
M8"O32\4=R0Q'[F.<,R"FJ!1-!\!O/V_V.D5;(K.T2S2H6N$S%9&TI*UJ28FA
MX#!(MR9$EK*RY6=P[5JN_B&D"7JG;FS/9V!:1""RTLV*-EY*V0XU6Q-=J7MX
M@ZC@.[V>W5B_LKI$1<N\;-KC77,FS&7D6/G-=RN9S5;/<X A62B!4PGS**)J
M))=$+5?["X206W'PA;@2*H&7<5Q>.<:0+"(46>8I=NXZGJWRP+E6=(L)XMKM
M>,\=3JD6W,R!1M$2C)RZ24D@6)]M;3D7<]_BL2 0";#.!?."-.J-]]+FA4)=
MP#3<:#Q$@$\6C2; DD:+@D99S9[J<<(,KBZOD)DS#CBDX_1RM(PV7*&[J\]*
M8W<R!(=K;*W&1SZP'F@5GEV5=5K":J-VC[%)P\+)UID]EX]->.\E[L5HBGS0
M5^G7;'.4(*T;?%'='S?11KTLYQOF'-E5QDO;XUFSGI&,?,5$)&>BBJ$FR2M3
ML[5!O9H5DN5)JYL)WLJF;W5\I0]X:8+QU(W+&C*@U]SA^L6Z?%M.,KG 7]2[
MV*<R Y8V(862L52KB2^*(-="&3C&[U9[:)B9/'/X_P#).[)IK(59O<9<(7;W
M25K@.((8\#CBOWB:B7E8HF8:WE*^!8+A;S-+DZ)?V\"6!BZ2P;MZQ60(E(OI
M">D7+I\GZ!M*' YCH<RX/? "[,UA;O@07DB^BP&;3I^6E]VY@=.:_>@:K9;V
MD=;AX#?ARV%WCH&2ZIE)C-3M'5DY.K1EEEZW&VI>,695ZWJ0BXM)&8H\DN8/
M555F\@1Q$HVID@G"2TBQ?^8W4HP0!^I=,W.0]:B)&?L,HQA8.(;&>2DM)N"-
M6$>T*<B9G+MP?V"*)3J$*)S=P&.4/;#40X.Q-(X4CK=0HZ9CGV)6MK>R^%:Z
M1L^2F<:4Z=Z<G)8Q=.ESJLY*K5:Q+OQQVJU.FYAZH_0J[Q$4(..74E&V56!O
M%:FJA:&/G.O6%B>-F&':'33M;)11-4Z/:62S=VARHBF;K&ZZ2@='@#@ B VU
MHQ( 2[>LS;EH!?O=QF(#LHSY;V!(;FT7MI7T<V4Y;9['*'ZLUC;-EOHO:]KF
MVK2HT]<GM\#QS5C7[Z&6CUR>WSWZL:_?0RU'X[(]L@B(CC<>1'D?_*NY>(__
M .?U3UD>V/WMQ^^RY?I_5]EPGXW$>#X*F\&_PGZWM96M\0Y-'Y<VSY/I]&U2
M#ZY/;Y[]6-?OH9:/7)[?/?JQK]]#+4?>LCVQ^]N/WV7+]/Z/61[8_>W'[[+E
M^G],N$_&XCP?!4W@W^$_6]K)?$.31_23[/D^GT;5(/KD]OGOU8U^^AEH]<GM
M\]^K&OWT,M1]ZR/;'[VX_?9<OT_H]9'MC][<?OLN7Z?TRX3\;B/!\%3>#?X3
M];VLE\0Y-'])/L^3Z?1M4@^N3V^>_5C7[Z&6CUR>WSWZL:_?0RU'WK(]L?O;
MC]]ER_3^CUD>V/WMQ^^RY?I_3+A/QN(\'P5-X-_A/UO:R7Q#DT?TD^SY/I]&
MU2#ZY/;Y[]6-?OH9:/7)[?/?JQK]]#+4?>LCVQ^]N/WV7+]/Z/61[8_>W'[[
M+E^G],N$_&XCP?!4W@W^$_6]K)?$.31_23[/D^GT;5(/KD]OGOU8U^^AEH]<
MGM\]^K&OWT,M1]ZR/;'[VX_?9<OT_H]9'MC][<?OLN7Z?TRX3\;B/!\%3>#?
MX3];VLE\0Y-'])/L^3Z?1M4@^N3V^>_5C7[Z&6CUR>WSWZL:_?0RU'WK(]L?
MO;C]]ER_3^CUD>V/WMQ^^RY?I_3+A/QN(\'P5-X-_A/UO:R7Q#DT?TD^SY/I
M]&U2#ZY/;Y[]6-?OH9:/7)[?/?JQK]]#+4?>LCVQ^]N/WV7+]/Z/61[8_>W'
M[[+E^G],N$_&XCP?!4W@W^$_6]K)?$.31_23[/D^GT;5(/KD]OGOU8U^^AEH
M]<GM\]^K&OWT,M1]ZR/;'[VX_?9<OT_H]9'MC][<?OLN7Z?TRX3\;B/!\%3>
M#?X3];VLE\0Y-'])/L^3Z?1M3,X:RGC7(-S:,Z+?*M;W<847D@VKTLA)+,FC
MA)RV1<N2(]Z2*K@.I(<W<93V(=^G4T@^WW >)\/7@DGCNK#7WLV@6-DUAF)R
M3[2R:%=/6Z/5RTB^31Z#D14ZQ B:AOI#G,3@H/QJ9;F1"*6H[7,KH^V76,P8
MU]]XILUPPN;[[-:QU6X;J&[I-][<I]^$8D[4;<1EQ9^/GM8N#7:M=QH/&DTS
MCE?&5 O"D9>;_4ZC(/HUC(,F5@F&\<Y=L>@+87:"2OLE&X.$54!4#NZU,Y/$
M-0]ZY/;Y[]6-?OH9:OO<;M]Q'E_(!)S(=4&?E(J&91#!SYZGHSJ(X1,^%OU,
M3),45/UTX55ZU5,ZOLQ)T^@!2A ?K(]L?O;C]]ER_3^HSB PTU]9OSZYLO;5
M1G$<<#H[[\?>ET@<1EOK -[[%)Z UO:-'O;:7)VK3Y<[Y0^V]1ZPUA%]>H\6
MT*0?7)[?/?JQK]]#+1ZY/;Y[]6-?OH9:C[UD>V/WMQ^^RY?I_1ZR/;'[VX_?
M9<OT_JSRX3\;B/!\%3>#?X3];VLKN^(<FC^DGV?)]/HVJ0?7)[?/?JQK]]#+
M1ZY/;Y[]6-?OH9:C[UD>V/WMQ^^RY?I_1ZR/;'[VX_?9<OT_IEPGXW$>#X*F
M\&_PGZWM9+XAR:/Z2?9\GT^C:I!]<GM\]^K&OWT,M'KD]OGOU8U^^AEJ/O61
M[8_>W'[[+E^G]'K(]L?O;C]]ER_3^F7"?C<1X/@J;P;_  GZWM9+XAR:/Z2?
M9\GT^C:I!]<GM\]^K&OWT,M'KD]OGOU8U^^AEJ/O61[8_>W'[[+E^G]'K(]L
M?O;C]]ER_3^F7"?C<1X/@J;P;_"?K>UDOB')H_I)]GR?3Z-JD'UR>WSWZL:_
M?0RU)56MU6N\02?IUAB+1!J.73).6@WJ;]@=VR,4CML5PE[ 5FQSE(L3Q3,8
M 'QTNGK(]L?O;C]]ER_3^IWQ]CJG8MK:51HL1YDKZ+Y_))L.W2$AT7LFH15Z
MMVF3=/'8]<=,ANK%<4T^.$B$ 1 ?&<4 8.UGU;I<PN)V0M9EMWVF-[G9LVK1
M:U[\"](C59OOS:<,L?Q3I'.S:+:'L:+>^N;WU:-:O8? >[G[7N_:T@>X7->X
MW$:.3,G(>BZMX[HETIM,Q9BRU5J1F\@;I'DNVK1IE"F6R(NC5:K6*:EK!(UO
M&]:CJ58GYWU4D)BW-B03XKAF_8\\#QW#P/ CW@ ^UR&DH?X!S:AG6Z9MBK7M
M]LTQ)RA4,;/\JXYRA9;-B"ADB(R.]1-&7A<CQ%<KQ7[QK)SECL4!"QT_:9.8
M5"<D'3!E'L6M*0Q-D<9M[+0SWLC2<YSLNQIL0PN;<&2Q<UI<8QGRD4J1(6-$
M8?F+@"YA R"Q[\BX+@TV(:#9S@ [O;@LC=\K4ZA&K?GAXHY)9<D4K%Q/,RL7
M+JP%DR#-&K=95M:+62!:&B%K$9G /)$4G MI:18( U436451AJN[S,(V=NH[
MCI"P(MF^;;[@EXO(PR+%!A/XUIT_D&W7)ZLI)&31QA'TNMR5B3N0&.5RP!L9
M*-ZQR4@&0-H.(9VH9J;8VI5#Q'E+,L:5U*Y:K-0:IV U^B+0SR%4+I/&;*M7
M5A4K^1XR-MIVBSI)1ZY07+UY%%S'U&-5V(5J#MP2<G;UY*FNML@8/F*FSC#Q
MSE]D"8IYL;7C,Z$N9VN5M,63'AE(!&.,T56:+JJ/%WK@INJUZ1MH#&XODF#]
M.4%MKV:T^]:'BQ<YP%WBX9<AN:P^)'5H> QD1:1KS:C>VDNRG4 ;!AL7:,V4
MJ1H/>1C9VV:R]SJV3<156>QI;\QT2X90K,;#P>0,:4.+8SUJL4(C"S]@FH5_
M&UR3B[,C4;K%5FVR5>DFLC'1+@P.FK:/,M[Q'\/AO-$M!4#(V(\L5O;W:<[8
MLBLRU"!*A;ZM"N8F-&QLXZ#L]B:@K"2<[!H6:BVA>!M\*6<B5)"'(DY.="SZ
M]L'.]JTCC_(+O"+*L)84N>%V5DQ'AUO6LEV\UMK3.H(Y(NM@LCJ72KMCAH=B
M+I6K8^5;5ZSSLG*N+#)+P8LJ^A]76QZS6>B9:JMDD-O%.DKS@BT8/A97#^%G
M,!VES;58D9O)%SD9F3=6E!Z_;PK9H&/*9,Q]4;E=/G;Z2GG:,(>(N&MPULC7
M9P6A["YIWQS<H>#HNTDW9^-:X.%[Y<E\K? OKRVV0W+7BX#&G,&B]SOG>Z;[
MV6Z>$AU@2Z..,MU7*KJW$I82DQ!TR9+5WEY29(DHUCM+-,Q+/#T><!X<UK"F
MR"9H6TRT:R]3K&P X@6$Q*2<9+H1]]3]@@JK#O[#99>/@8*+2(O)2\JY(SCV
M**BR3<BKIRI[!(AW"Z*)3&[A45(7Q,&H2PQ@AO@JQ7^/H<C$1.%;<M"V:LXF
M8PJC%MC2^=B)&7E>GNT'0Q[6BWDC*,L2M2*P1&"N?GZ4CW)V=B<M4)>N5/KE
M_K$Q3K;'^=:Y/-TVLK']J=L^U((NF[U,G:F"[9VCT7+5!3I(+IF'H= 1$AC%
M&P>(!. US^UR8R2 #(&$-+Q9UFF1MW B^3,+!Q;8J^89=Z[X-$P#@ 3WA<"<
MND9CD.C3[ZVMH=H4<^N3V^>_5C7[Z&6CUR>WSWZL:_?0RU'WK(]L@_\ U;C]
M]=R_3^CUD>V/WMQ^^RY?I_5UEPGXW$>#X*F\&_PGZWM9>%\0Y-'])/L^3Z?1
MM4@^N3V^>_5C7[Z&6CUR>WSWZL:_?0RU'WK(]L?O;C]]ER_3^CUD>V/WMQ^^
MRY?I_3+A/QN(\'P5-X-_A/UO:R7Q#DT?TD^SY/I]&U2#ZY/;Y[]6-?OH9:/7
M)[?/?JQK]]#+4?>LCVQ^]N/WV7+]/Z/61[8_>W'[[+E^G],N$_&XCP?!4W@W
M^$_6]K)?$.31_23[/D^GT;5(/KD]OGOU8U^^AEH]<GM\]^K&OWT,M1]ZR/;'
M[VX_?9<OT_H]9'MC][<?OLN7Z?TRX3\;B/!\%3>#?X3];VLE\0Y-'])/L^3Z
M?1M4@^N3V^>_5C7[Z&6CUR>WSWZL:_?0RU'WK(]L?O;C]]ER_3^CUD>V/WMQ
M^^RY?I_3+A/QN(\'P5-X-_A/UO:R7Q#DT?TD^SY/I]&U3!6<U8AN<PWK]1R9
M2K+.NDG*[:(A9UL^D%T6:)G+M5)LG[,Y&S<AUEC!W$3*8X]P:GUI_O1K_P#F
MZ/\ U9=*G0ML.#\96=G<:32QAK''H/FS20&?LC_J4))JHR>D[+)2SMH?KFRI
MTNDH@8R?2Z:9B' # UC3_>C7_P#-T?\ JRZ^H!3B=W:QF='O0N9VL:_/F[ZP
MC<YN6UK&][WT6LK:LW[>8]_$8?OAMO1<YN7*.%[6F][Z+6M;3>Z9#1HT:VJM
M:(T:-&B(T:-&B(TKEH_GCG/_ -)NO^L'1HU$]UOY)2_UAW\-RE.Y7\JJOZL/
MXT:Z+1HT:@:FZ-&C1HB-&C1HB-&C1HB-&C1HB-&C1HB-&C1HB-&C1HB-&C1H
MB-&C1HB-&C1HB-&C1HB-&C1HB-&C1HB-&C1HB-&C1HB-&C1HB-&C1HB-&C1H
MB-&C1HB-&C1HB-&C1HBNFD_SU0W_ +]?_P#TW.F7T:-3[<G^13_UI_\ !@4$
MW4_ET']49_&G4&7:.1<6-XJ=18IC(LP$""F!0Z+<@!QTDS#W\=_)A^UQJU/,
M[;]E<?=)?Z'1HU',2:TXA6W:T_A,W .6[8I%0.<*&C <ZW:T'"?BV[4>9VW[
M*X^Z2_T.CS.V_97'W27^AT:-661G);Y(ZE=YW\IWE'K1YG;?LKC[I+_0Z/,[
M;]E<?=)?Z'1HTR,Y+?)'4F=_*=Y1ZT>9VW[*X^Z2_P!#H\SMOV5Q]TE_H=&C
M3(SDM\D=29W\IWE'K1YG;?LKC[I+_0Z/,[;]E<?=)?Z'1HTR,Y+?)'4F=_*=
MY1ZT>9VW[*X^Z2_T.CS.V_97'W27^AT:-,C.2WR1U)G?RG>4>M'F=M^RN/ND
MO]#H\SMOV5Q]TE_H=&C3(SDM\D=29W\IWE'K1YG;?LKC[I+_ $.CS.V_97'W
M27^AT:-,C.2WR1U)G?RG>4>M'F=M^RN/NDO]#H\SMOV5Q]TE_H=&C3(SDM\D
M=29W\IWE'K1YG;?LKC[I+_0Z/,[;]E<?=)?Z'1HTR,Y+?)'4F=_*=Y1ZT>9V
MW[*X^Z2_T.CS.V_97'W27^AT:-,C.2WR1U)G?RG>4>M'F=M^RN/NDO\ 0Z/,
M[;]E<?=)?Z'1HTR,Y+?)'4F=_*=Y1ZT>9VW[*X^Z2_T.CS.V_97'W27^AT:-
M,C.2WR1U)G?RG>4>M'F=M^RN/NDO]#H\SMOV5Q]TE_H=&C3(SDM\D=29W\IW
ME'K1YG;?LKC[I+_0Z/,[;]E<?=)?Z'1HTR,Y+?)'4F=_*=Y1ZT>9VW[*X^Z2
M_P!#JYVL8B5LW*"BX@""(=YD^>Y,H=_T+QT:-7=(UH>^S0.]&H <(5A7N=DC
)[YWO^,[-J__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g57159.jpg
<TEXT>
begin 644 g57159.jpg
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M^T=4?^7D<S>^29=*X^5D4*2RTWVU*6UV*H[*"V@!L@#>@!OT ])BAS;33:0
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MTB:#J<1%'IU#/X&:=HSRA:<UE4F-?=1^H O/2'@SIKO#\KO8N]:]C-2BGST
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MHOI\7PQ;3;67900@>LJ6^L W79;1*[UK8]9ZF=;UK6^N]:\1>O?3X=X[X/\
M\@_[VOSRD?CO0/:CZI> HM<FH_4#6F8@I&>"3:O$<SGL;9!*E>T**2O3HTJ5
MA3FE2#*\P;#W)<>S-WF#4I-3*$(TI&ZM</>=SIO>WWM'Y6DV0'0$OL=J"/(-
M&:,WO9NUFBW=%HT0>Z7Y$6]&"!H1NM"!H7C7#D@$(WF/CU'R^9^W_P \]2E0
M#KNO[.Q_<I'YRT_KKX^O\/'^77..]KXA?[@__P#.58Z[/B_5H@^G>T=Y0KBR
M@[$2!J/)8QEGBV#OC&:5(%6CB=A#O021EZ$ 6]"";KH,(_DOLMVEP" $NY<\
MPI,5W=G'$F6J%"28XBUO0EQ0-MZ[9.M[&=T)V(W>@F[#L[?=ZBSMO[GXL/LW
MZ;_\'PF-+_?_ /B?_P EIPS2RP]\P80!ZZUWA[T .M[]6MB'L.M;W\&NO7KF
M/N,QB;1I0)UDT>; I.[YT)P?&I$%-WN[H/G&U*PK1/>V,&@^4[O78P].O>UU
MK6+[(KC0>+0W^9\A96,>Q&+-/]OKS0+U.^NPJU0434D'M0 6]# ,HP&N_K6Q
MZ'K8M"[UN[(_A$C$28OKN22$TLT1IQK]9,W4B6ZWO?=*6!2.R$LTLL.] !H(
M"Q]T .^,6];WO&W_ +J_M8_9_P OW_AO[#G2?WF/W*/]VDU'*_J+9O+:=[FJ
MEK$G*T>>!PL2'I#"B-AV()QA9SR$82Q!UO81[#T%K6]AZYKYVYI<2V00@./(
M^ERQ!3[5;"384=6BV2'RG780H%BK8Q[\F/020=XX6]:T$O>Q T+4[=V8?!-L
MT7Y'CQ%E BCM'@&Y/,Q=1=_6PBT SS^2'!-(UL.NJ<T(R1:V((@;",6MY\V\
M#.&[2 1:/C;47=&=H_?G<00N(]&!T$.MA,<=JC  Z #U* ()6]]1;!L0A;V]
M_P#Y!^TG_8?;]WVQ[GS<_L _W,Q5?VDO!QMV7I3R/@(]FA$('F.WYSUK0-ZT
M+1FVYD5:)%^UKN@.V 0]==@UO01;U@CAVL7!1%HK9-RG.FS1#"(+5 ; 5"(T
M#0=Z&?H4<([@!][>B]Z[^Q;"+7373765B'C-QR;?*^84)3*3R_<V=Y"L(4#R
MG<[_ '.__H7?7N]\?=UX:UWM_'F=H*VKUJ$,37!8:VB,+"48)!%F!&(90-]0
M%CVG;B]B+!OQ" 6]A#OQUK6\>_\ -/P)^7VC[?R'VS'N?)C^T#_ZG[?W?;*Y
MU7:^\3=%&B9DMQR8\(3AEIV:JGK>S22@#'I7Y9<H2$@1"[H-;4"%O903BS3"
MM "9W*V:![5&0H.4\FL&T(Q"H]7%UKX+'9FH0"?_ #FOF"')']JB;ZD<!*G#
M3SYB7(3CI< QHT)X#U4L93-I*!&I]-!*!&G  I.E3D%EEZ) 62022 !6M:#H
MH("P "$O0=:#HO6NYW==.[T\,JXJ#B#QF)Y><GRA4M!5B&.QZFUS"SNC5MWC
MS,JLICGZN;&MD<=#E;$C]-J&I"/0"6\(&P!9I#.%O(4J2S;-%.795FM3<J5T
MXJ692^\OBT'.PJEK  8.1DV46E6*+JLG9("F*RS&1\9;:BSV7,E#>3=+1CWN
M7)/7KNI;$VH8[<#KHDBQ: VC7-IM!;]7$YBDY:!@+'M=%'YN?22?*ZZA+4Z0
M*#C4AW3P$0K*(/!OJ$981:WK6=ZWK?JWK?P>&^OC\65IS_LL..#RY#E%1J9U
MQPG(-;,22.G)2Y,R0"K0]#+,4,"M0H2!( (.M[3M"IET+IKH8'?CK!A0KM1N
M/ =[AEAUMS&AB,(PDLEAHMPFS IP!T,6R7G2Y&0O4Z#K8 &N,H=SC!;\$@M[
MT'=;LP^LN_M3S_(Z/[Y-U4_5;]C#1_'S'YB6S8RK!B[4:(1)P2QOE92=P<7Y
M&=L!?G\HC#G)(.I%K7=&<AD+6WIW(XDPS6^X(IC5D!#O756+^MN?M9W;4ERM
M@7BK+&A\\0[*"<;N-/J%Q5I #WT"%Q;"S=.C:;U\!$N"),:'?@(&M]<R&4^0
M(W\O0_@?.8*LOJ"/M^'XCRFTLUK<W[HK2^CF<_A5VS9.MZWZM^KU_-_'XOKS
M6US?NBM+Z.9S^%7;+.+^DX_^/3_$65\C^@N_PW_Z3,2XN>]IX]_0=4?^7D;S
M>^:(XN>]IX]_0=4?^7D;S>^3<E_6&=^MY'\5YKB?HF+^KT_PUC&,92EB,8QB
M(QC&(E8':$<RYYQFGO%ZMX=9/$JC4E^.MP%/=U<QGYV05M'_ &KX>Q/[5"F1
ME9K J]0[S.>*7X\UO7+YFWLS.U19Y+-2NCRZL: Z4?$BSY!;M0)9A)KLXR7\
MZ&R.2-H["XDG+CZ@/(;5H""&=*8XV3:RGV1LP-^;20.Y::#2T0.XWMVOZ'<)
M^U7:>6#VRUHW<9C9VUC%#N1;B8^5[2="W.O46]'*]9I31\!FI=[PNP&F#5E9
M!['/F%PEK)'42PVR2ZJC+C+(ZWOVP.>P^S"6SI/0=H.UC'7>*."Y#W([UE-N
M2];MM"V3,*;.$PN$7DS]22.MZ:;J?;F?8GJ'IF4%905-(2(>?:!;$A2SLO6T
M2S'&5J\CN>RF+P&@[5XF-51\HZALWD[1M$63=$/NV&/L$JYIM&^ZOIMQ7MZ:
M'N#RKL.6^7GJA$WL3(Z($T<=$Q3K*U V\G;2X9MS\Y'6UQWA%-&4NSLZ^86W
M?D>J=2\OM*7UR#:H9'%$"LB>O<E/JSCB7JRI&K,# T<9:@)%[4U(G22I7%X7
M:0I#"#D2:LK_ +,2+^XGC_#56:LXQ>]OH+Z&:R_!C-D=J_YE5A(N*]6VE/[B
MKZ6K;:A$KVDF%7U[:L9A,AD<;4N$>EJ%KA,M+E$^@"R-OY1D<D,/L5>3+(Q)
M&]W8WXE*ZMJY$CD5QCUO7'"@P[\-AIJM [U\6PPUFUO7U;U\'AB)O'&,8B,8
MQB(QC&(C&,8B,C+REXD4OR]K\R!V['0JQH_.%,4E[7HE%,H.['@!H3I&7H1)
MIB?RHB4^W%I5 5,CT!.04[-ZK2=,,B36,@RL7'S<>[$RZ*LG&O0UW47('KL0
M^JLK @^>B#ZJP# @@$17T4Y-5E&14EU-JE+*K%#HZGX,I!!\]$?$$ C1 ,HI
M@_)7D/V:\L9:1YO*'>U^-3HO)8JCY;-3>O<U[ G%K0&Z-V@D+VM<S-I$P0Z&
M!::MDC>60I-9G"<L975BN\CDD8)>Q-,HBKTUR../R!,Z,CZR+TSHT.S:L+"<
ME7MS@C,.2K$B@H01DGD&C+&'?AOKK>M=9.H'#;-B;[!)_&F>7P^3-YS6_1U^
M1$N#6YHCM>)2A,<'>N^6/03TR@K9:I&I+*5(SR%)11P-+T#Q]I_AA4;W"X J
M>F6NFIYF%AN*B82=>_ 8B7'8W5U"2M<1=UM8&5N1A+(3$%%Z\@E-<W(UP>EK
MFZ+>+QF!R7$Y#8GTM<W@A2[XSYMUAY+C60KUQ#<RN,[#Z%C3;>]>3C*GAV69
M*E&7G86+F8%K4>.,GBQ6S4MDV.<W#92NL<VD,,K&Z]C79:RWTA>CO<O4K(9U
M<TC,V.+NO,$4A:T*QQ6& +&<,M*A3&JU(PE%Z$88(!!)@@E@#L8]ZT$.MBWK
M6_S1U^;92P,DF9C1J&B0M#8^-9YA)J8PYN=T)#BA-,3GA >0,Q*I*&,DX #2
MA"V68$(P[UJ.<,Y&TSR<H>:V#2<Y:YO&]QB6H59B,"E&YM*\MA<M^8OC&XDI
M7=F5FDZ"J2E.*,CSY":0O0B4(SRCQ;0HS]RM0^O]U]?>O6]?_2#-\?\ UK.I
M1F59-E38UM.1BWXIR*KZ76VNT&Q55J[49JW0J=@KO9^/PEVO(2YZS397;1;0
M;DMK8.KCNH5D=2592"=$;W\YM3&,9=EF,8QB(QC&(C&,8B,BGS.UK=()>NO_
M +Z\3/X^'+"D]Z\?7X;UK>OGR5F14YG?N02_3KQ-_P#5?2F=+AOZWXK_ #+!
M_P!55*F?^@YOZID_P7DJM>KZQ?SWG.<:]7UB_GO.<YLMQC&,1&,8Q$8QC$1C
M&,1&0^J;WWW+G_93C%^&[/R8.0^J;WWW+G_93C%^&[/SIX'Z+S7^65?]YXF4
M<O\ I^-_7'_T.9)@X]?KQC.9+TZ=\CS#)VQ2RR-E:G]F6@\FL:'MN1NS6K+]
M6RU+>X$J$AP-_"$PD6O^.5_V7V77%>:KA2*%,,AHF; $:<DEE+2!9$3B%0][
M$ S;)L2MB"4 S?>$6WHFPT0?V J"]:#L-C&,P55O4 _>)D,1Z$C[C*F 5!VF
MG'D.AU7>D'Y5Q!%O?D89=C:9'YL,G0>Z E)+-.'E%9Y980AT:X3 @G8_$*+I
MONYJ.[>TXL&"5=+8/>'$&S*RLV4,3Q%&;TB[I@UP\#=&Q6V.[NW2\YM$<K"T
M%+"UY30TI'S:T.RR!O"$H6UH;P\B-S5X]UOR!HR4-=@(%PC(0UO\\B;NS+=-
MSPR2%DCCJ84:F4[(4DG(EY/?0NS<K3'I%J0SKL!:HA(I3YK2WQ*Q0Y6PN@K[
M':ARP"G;!M:.C\1]FMS#O7T<W*&3JQ?6P2NO/R4@'R^X_([FGNS.Y/,O(.A&
MV+IHXNC4AHEE@=:/I!RXMS0/"5MB") R25M6@2(1$@>2F5<-6SGIA'M"L@9&
MEC@E,3+3K&L@]V?E UU2''.!N4(0+@.]L0Z!63.'AU6[7N+K('^%LZ_9 #-%
M)R4;,T>?*$C(V)B %I$QAIAYBM<J5K%$X<FR!>M]ZY+!L@76"]AK36AV#D=0
M%\VWY@ 'X 32LU&NLT@K2:T-0.]BOJ.@\R3]77J2?F28QC&0S>,8QB(QC&_5
MOX?F^/$3S;]MM;/'VS#T5+E7IQ6EMD4JR66GG/&.Z+[#59D,L*VJXCAM#<AE
M>Q,LGC!D\HXX1LL@46L-O9D3DVSMPET5D[-+XY'=KK">RG5-\MXX6!-F^5U=
M(89:_(F\+"BU<5%8YUR5=1;%,'A I=:7CD]4,["VR$"*3^R:;21&P,:"&Q^4
M6"_12'%*8HSM2Q56]VE=W17W6$CKJ(=F=RA-M6+-4;TN[1F#TWS4BK,+3K%F
MES1-E;61V?\ !WR^+S)C"%P(87F.OLTKZ$-<@;G".JW8TE$H 9:_V9SS8+SQ
M6C8[-N*_;SE"*4S-M'/.2/&:5\4+*-;$;J'32RGU=.FELFA[$PHC"VYAFLM.
M>9%-$A8W=W?G5;L\T")N^=\4:;F=7,=/-,:05A!(];M.W2WLM4LD7A2'4OI:
MXH3=L?T-L0,(F?2![E<#:$DI\BW%.+BSGKR4K@@7F)W!-C%P\99Y9#NYRF'\
MN.1U.R<F9LDS@NX2JJ]PAT%"AKQ?7<AAPZ_E-;O$=L:"38IQ.FKTR6P":KF&
MR$C1+Z^>88I:4B74N<8B1RJ&AXIQLX_BJ2(.DED*%I2V3)7F5S-P2.DPFLXL
M>1RNQ[%G,J7MS>T-AT@F<\EDBDKF4T-#0QH5#GMN8FAJ9T:%O3=WQB][?07T
M,UE^#&;-IRO^S$B_N)X_PU5FK.,7O;Z"^AFLOP8S8B;RQC&(C&,8B,8QB(QC
M&(C&,8B,;\=;U\>,8B>5#MJN*U3\=W&O[JILE?6KC<LND,?GL2C+H:Q0QS<6
M]C,?R9(WLZ Q&6UN:H9BQ,ZH$@MLRWSG:\EO0KAKSG'MNP=OJ 16;W56M@68
MB;)=97M8)JR8Y/(%8M2%3']S1,Z,S H<E)C<6[!V[-):5B*/3N#H$80-J19Y
MH: GT;WE 8+.J\DP)O"XE,0,L:E3BS@E4;9I"%I<-QUP*VO;0NZ)9I"LV5K1
M>U*711VP:[FQ[#X9IVD>-''HR"<?I^&DJL33:(PV#RB.RI!!HXVOS9(5D&0(
MU+P4Y-[>E4G+C25B@6SE0U&PJ#-*R^XK+*/!\O;V*OQ?;>KV@XG(P<6A1](;
MC6Q[EI*VTC"SF4TV*B6VBZ[)KU6$.05-@(+F>(/LU;1[2IRV!=BT5#^>.&U5
M@K(>L8^20:W"K8_B67)I.OBD%P029,3&0FYG<G+2XLL\%GD1X]2B[ZT"Z.WM
MS.L.<DX9%7T:3HB-MSPVL 2U2MXV<J-4J%JE2G2L3<C;1DNCNU#<4RTC9?&_
MEA1/*Z'@F-*SINDA!)9.WN/GB"W3"*J3M>".3QE09Z1:A['H0$ZWN'M#CH C
MFIR7I^Z=OWZ\MQ[<C;Q)R%KY"M%M&-<KTO=4R*_BXIM5$RZT[=;7QFM%5@9+
M>C#4]6,_$.6^!XP7+10XHL5JVLK*AO$H+JJY"+OJ[4EQ6X*/U8$21V,8SHRY
M&,8Q$8QC$1D6>9!)RBE$I:<DY09[>7%$SR:<DT\SR9/*NECCS=ED@&/R1!)9
MAYYG=[A)!9AQH@%%C&&4V,L8>0<3+Q<H+W.-D49 0GJ'--JV!2VFZ]NNMZ.M
M[T?217U>/1=26Z^-595VUOKXB,G;6QO6]ZV-^FQ.->KZQ?SWG.,97DL8QC$1
MC&,1&,8Q$8QC$1D/JF]]]RY_V4XQ?ANS\F#FKXU5C3&;.LRT4KDYJ':SVVOF
MQV;E/F?HQO*KQ!(6]M,;?(IBUGE%Q<B4F.'G:A0#RA"?S4) ?*A,NXE]=5')
M5N2&RL*NBK0)!L7D>/R2"?[(\+'M.SY; 7U(E7(J>RW"=0.M.2UEFSK2'%R:
M@0/B>]B#0\_/?H#-H8QC*4M1C&,1&:UN;]T5I?1S.?PJ[9LK-:W-^Z*TOHYG
M/X5=LGQ?TG'_ ,>G^(LAR/Z"[_#?_I,Q+BY[VGCW]!U1_P"7D;S>^:(XN>]I
MX]_0=4?^7D;S>^3<E_6&=^MY'\5YKB?HF+^KT_PUC&,92EB,8QB(QC&(D!N3
MO%V&2%V=;>0\O>1?"Y_?1LK/*IK4=SP^-0^2+1@;X[&@O< OF)VG2A,D,T6A
M9D#^R0IBF#Q_V)L6.[J E$F*S_C?Q@AM2K%EB"NB[N2=@/S:J9!6Y>EJ:L%R
M*CYBQ$<L8H?'HJVQ&H((TJ7)H2GNY5>5['%#VM0)MR%:Z&-R0*:LWMSHU#WR
M)43Z5EE,*IT[)>0U?UC3]UP^ZYPWO\AG]8-Z-7>==M="U!?\X9;9XWHFD#U%
MYB94;LS,[-.90U'2N"NTA9WH<O.RM:""^/\ 8$X(5L2/VX^2%V6\IKJ$P6XH
M#6M/.,Q>F[TK7=<-UZUE3-A/C&)T;EDZD,U757!&R;V1.)U)F.-MC:X$IPHE
MF&0%OSE6M6M#DT\4K>XK+7&N[(717E3<5C6-$)C6_"Z'Q^*3*0/TGN:!QJV:
M]DRB3+7Z+H8"RPEQF,'VW.CTMD\H=4+%%'-,KGUD!^379ZU-R+)B F>0OE .
ML8NE#?SL[4W!*$4%V59+,QR1HCCQ;D8MFG[/@]F#BR^4KYE&#Y=%W1>Q3Y&R
MS%N6D/C*W*B$3#Z*YP-\[X>UE;_(K3)74QMEGM9(RZBL=L<^%V SPN82>(1J
MU8$C>F)3+6>O[@B:*,6K!D4Q 6Z)HK-FD@3B^%$:>5DM^,>MZXX4&'?AL--5
MH'>OBV&&LVMZ^K>O@\,_=%(5(J]IPV(2NTYS=+\T,,HTNLJR$4 ;9G(_/1.R
M]/MY1U?"J[@Y6VM*J)9T6V6'M/?;T"4U?I:YC6."K\'&+WM]!?0S67X,9L1-
MY8QC$1C&,1&,8Q$8QC$1C&,1&,8Q$ZYW:TKVU.;,NT8)$[-ZUL5Z*,$2;M*O
M2FHU&BS0]1%F;).'H!@?$ N@M>.L_+&H^W1..L$7: G!:HVRM3 V!4G"4J M
M[,@3MJ()Z@?09YVDR4K1IP]:$:9H1@O$6\[O&:]%[]^H[]2G;7O=202N_EL
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M3P^L<2GSN\W8RA-5*:D;/8<YM!<;46TH6K65R]".14]^S=CC-%N,[:U,5?\
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MU[<DAB,7AIR]Z0H)$%YESS#V3::21%6J*D<1##SI[$'"S#Y&WMY58L3\WO\
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MQB)4GVKW-FS.&L'@CO Y73E4H)"SW'*7:V;V879^A:MYJ*'M<QB?'J,EIY=
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M/YA2]F6)E#PI.<%)1JD8A[V;87%6SG-(E*ICEC:U$ AD@B#E3L:CD5K:0UO
M(Q'ZQ65F^5F_PIVCZ0^UX'*MK0SP1-@21?*(A/VIA=8+*8\T(%+"X39QB)&B
ME:#8.-''@521^02.7Z;BK2E\CFDN$U;D\WG]IRR86C94T?"V%L9F-(OE<^F,
MC?1-C*U-S,S$K26EG1)6Y"F*#DO&+WM]!?0S67X,9LVG*_[,2+^XGC_#56:L
MXQ>]OH+Z&:R_!C-B)O+&,8B,8QB(QC&(C&,8B,8QB(QC&(C&,8B,8QB(QC&(
MC&,8B,8QB(QC&(C&,8B,8QB(QC&(C&,8B,8QB(QC&(C&,8B,8QB(QC&(D>.5
M'[DI)_?M<?YHPK)"A]6_]8?_ #BR/7*C]R4D_OVN/\T85DA0^K?^L/\ YQ93
M3^L,K]3P?X_(R!?TF[_ Q_XF5/K&,9<D\8QC$1C&,1&,8Q$947SD[1U73>Z4
M:^-<CH^=BLIXO$$JL%Y:[LN^"P9LHB!LDME+<O:.)L9L25D2$!DI8U#CMX"V
M-L=CB9W=G+8A!2ECMT_Z^SU9!&=<)$[,GCXN&=FF\#U*!RG*R5,E#U-4 JPL
M<VQ]18,BD\WJ=WBQ42=K2:/8>U&P>T=E@D$?$H>&]X(E4<>5["8B9TZ<G*L;
MJ,K6:S.QX8Y:N.JT4DC,FK9-)Y97\U&Z1%K<5#U!'5M;7A0HB+D:]I%<:6NQ
MQ2E:T+41HQFGZ4=S7]!<IZ"BU%TU&9!9#0U/T>JV!,CTUJT+^!4VNK7%VM"X
M(5( LX]!/2*B#2#@Z%O03 "UK>]:UO<F:%I2$\<J6JRAJY*<BH-4,#C-?1<3
MRNTXO2EHB[6G;$ZYZ<0$)2U[RX[(&X.RPI*D)4N*I2<2D2DC G+VUTU\_P!N
M_P \1(BO7.7C<S.,7;PSPIUU)GDYG$N:V]Q&B8=%-+@Z^DWT2Q*C/);#-H M
MQ9C>G<5.W!:D )*%-M0J3Y%[L7C7\J[!]SD'Z+F\'Z&1>3.<3>7YI(<7.#OA
MTCBBLXY2 QF>U#.Y,!R].$D\HLTTQG=W)#LM4!03HM48,)6C0EF RCNZU\?^
M]O\ /$2,_NQ>-?RL,'W.0?HN/=B\:_E88/N<@_1<DQTU\_V[_/'37S_;O\\1
M(S^[%XU_*PP?<Y!^BX]V+QK^5A@^YR#]%R3'37S_ &[_ #QTU\_V[_/$2,_N
MQ>-?RL,'W.0?HN/=B\:_E88/N<@_1<DQTU\_V[_/'37S_;O\\1(S^[%XU_*P
MP?<Y!^BX]V+QK^5A@^YR#]%R3'37S_;O\\=-?/\ ;O\ /$2,_NQ>-?RL,'W.
M0?HN-<Q>->]ZUJUV#KO>M?\ =)!KU_/MEUK7UY)CIKY_MW^>-ZUZ]]>FO'Q%
MOIX>/CXXB1$B7.;C=*H\WOXYV5&Q.&E>]LLB;W$EX1^:KE2'7GA38E=$0/./
M-O.T_D5Q_>2GD",\F:(PDO(_=B\:_E88/N<@_1<W?"H9%J_C3;$86U)V2--'
MGFFYK2'*3B$OGZ]6Z+- ,5*%*@6SUZY4I%Y0X>]#.$$'=+T  <IZ:^?[=_GB
M)&?W8O&OY6&#[G(/T7'NQ>-?RL,'W.0?HN28Z:^?[=_GCIKY_MW^>(D9_=B\
M:_E88/N<@_1<>[%XU_*PP?<Y!^BY)CIKY_MW^>.FOG^W?YXB1G]V+QK^5A@^
MYR#]%Q[L7C7\K#!]SD'Z+DF.FOG^W?YXZ:^?[=_GB)&?W8O&OY6&#[G(/T7'
MNQ>-?RL,'W.0?HN28Z:^?[=_GCIKY_MW^>(D9_=B\:_E88/N<@_1<QR5\YN-
ML79#GD$\*D0B5C2CTU1]O<370W3J[(FK:DLMR2MB3:9NTLVXN(A+ F@;TJH:
M8I4I"2E.EWTU\_V[_/,7F$,B\^8CXQ+VDA[8U*UF<CFY2:J*+,6Q]X0O[.HV
M-(>G/T)"\-B%<7H)N@#-3@ <$PH0RQ(FC]\Q>->M[UNUV#6];WK?_9'_ 'ZM
M[UX;TS;UO6^G76];\=>./=B\:_E88/N<@_1<DL'98NO<%H73?7?='UZ;WO>_
M'IOPZ[Z_\<^NFOG^W?YXB1G]V+QK^5A@^YR#]%Q[L7C7\K#!]SD'Z+DF.FOG
M^W?YXZ:^?[=_GB)&?W8O&OY6&#[G(/T7'NQ>-?RL,'W.0?HN28Z:^?[=_GCI
MKY_MW^>(D9_=B\:_E88/N<@_1<>[%XU_*PP?<Y!^BY)CIKY_MW^>.FOG^W?Y
MXB1G]V+QK^5A@^YR#]%Q[L7C7\K#!]SD'Z+DF.FOG^W?YXZ:^?[=_GB)&?W8
MO&OY6&#[G(/T7,=0<Y>-RZ2R"."GA2,+"B8EH7U6@< LCUZ< X#VE9S2$IZ\
MQ4T>8:"[ 6MZ$HH2U'I(:L[Q^R)<[[NM;WO?36O7O8MZUK^.][S%VZ'15HE$
MDFS>UIDLGEZ%@;)&\ /4[.=444 Y 84YQ9B@:4L+8%V<M%"3$$F#\Y,\X$;L
M(-@1-(>[%XU_*PP?<Y!^BX]V+QK^5A@^YR#]%R3'37S_ .]O\\=-?/\ ;O\
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MBF9MU6=HU?;KVG=75M>/)&:P[C!($U,4,;#;K=6.4S^<<D;:J'DMR?A3C*;
MF4-ADV>^)S QO/'*),_MF0@C5=SF45S!K>JU6YD/B#U-I[\IA79%BU"GLN'&
M6144)C%C6A$M/24+G7\)F>W[<8D<OV,04C WO!$9?%J43DJ3G:;4(W0XDEM/
M2*U&F>/W: <+>4Y\^3\?>2M2VF=6;67()P"-RI.+T'%3A*P)YJ/;F!O N@2H
M:!:!)/&G:^&*C$J@"=\,&6+6(F'=F7".1];\)Z7@_*YM5-%TQTF:HWQM<[!>
MK.>T4?-L&4K8$D?96_SFTW$3LD@ZE@2J6(=KVD1%"R2(PFL.6$M(74Z>F1!X
MU\^N&W,%[E,:XT<BZPN*0PQO3/3^R0]]VH=2(XM7&M:&6($"Y,@5/D-7.)(T
M"&9,)3I%EBON)T[N8::2 R0%DVC7U/QCV9V;+&>%1?<@AT4"]OJG:5".26!+
MF2!PMD+,T P1KE)9A(V./M*4L S5+BY)BM:T$0A@1,^QG4OCZSQID=Y'(')$
MSL+ V.+T].[B>!*WM;2T)#U[FXKE)N]%IT:%$F4*E1YF] )(),,%O00[WD5.
M.O: \*.7$H>X5QEY14E>DLC<>#*WZ/5C/6:6.S1&QN*-I"]KT;:<8:F;=N2]
M$ATJ'K1?G*H@KKWC0]428.,XV+6O7_+>_P"6M^&OAWZM>O?36<:$'?7IOPUK
MKU\=:WKX];WX;UKX=ZWO6OAQ$^L9QK>M^&M^K_K_ (_!\?P9$SD[SBXR</CX
M*VWM82UDE-GJW=)7->0N V1<-K3GV.I"U\D716J*=B,\L5Z98RC.(4R60)(T
M-ACY:E)Z6<DABM*6<B2TQD<.-7+?CYR[BCY,*!L-/,D43D2F(3=B<6&506?U
M[+490%!\6LBL;"8HK8M=R/20TI>4RS.+LB]4VGIW)&2H0'E*1R.[VNG7KZOC
MUO7P]->&^F^F]^K?JW\'7$3G&?/>#TZ]>GP=-ZWK?7?JUW=ZUOKOX-=.N_#I
MUZZQW@]W8NO@'6]B]?77377?77KUO6O'>MZZ_-B)]8RLZQNV%[.FI;(GU4V'
MR(!&9;5<O.@EEJ%=47HIA$"E"1,U+7!OE]HMU8+:QCY#2B>VI:].SG,$[,RH
MUQ*IU<$:?8C V/,[VSR)H:I!'W5N?&)];D+PR/3,M3.C2\-#FF*6MKJUN*$U
M0C<&UP1GD*T*](<<D5I3BE"<XPDT Q(G9XR.-P\MN/5!*YBCMVQDD*-@%)2?
MD7,#5S!+5R)CIJ&OS=&9+-%+DS1]R;C26Q[=4",;*D5*)*H"?YVC95*(H]25
M(HLTLTL!I8N^68  P"UK?[0# A&#?3>M;UW@B#OIO6M^/CK6\1/Z8QC$1C&,
M1&,8Q$8QC$1C&,1&,8Q$8QC$1C&,1&,8Q$BOR6NVZ*>]AWM1\:91R&U(/3WI
M_<;E"".>Q+T7IJVV;6:6MKAYYZ;\^6^0T5Y'R'HLW0^_Y8/<\_W);M(.;#5>
MR\K9KUQT%$#6KS6E5R!C>@)RU"),J+,F"I>S:43'V0^6\J2<@$B;](CB$K&
MA>2:O.]5&]:WZ]:W_'6M_P \P5_JZM95(&:62>OX5(I1'>YZ D3[%F-V?&3R
M1NSBO1+LO0J%S?Y(\0CRM)CR]$G;V:5H!F]BW&Z,WHY7S!UH?O&C]OF=?=ZS
M=&5?5 WD?,[_ &>1V/L\AO\ /<-*%Y4<GK,G<-BUB\)9M5,6?4"DY[LQQF:!
M:RM!J:.J71,?MA$SD.19#TYD$-R1&H6[5MXG D"PPXU,=L>]^8?=]R9R=V9H
M6P>YXN[OA +01[#[5\K[V@C%H00BZ==:%L.]:WTWO6]:Z9([00ZWUT'6M^/C
MTUU\?7OKZ^N_AW\.?G6HD;DC5-[@E3+D"Y,>C6HEA!2I(L2*BAD*4JI,> PA
M0G4$&&$GD'%C*.*&,LP @"$'>X!'J2?M( _<!-203Y  ?($G]Y,\[/#/A]S3
MY+\3.S!UR%Y*<=DG&&FXGP*Y-16M*4XU3F.W!,'*C(17U@TU#IW;]A<@[!C2
M-J9Y0V1A[G+Q!ZP8W6:&LZQH;=0]B>E:$J"D+L>/.E2\6>-[LNL \Z4WOVT-
MZ2.*J^=$I[.GC:]0: =I/:D2<I7;_(6L6QPN>22.M7*2$O$.J6M?+-8FIWDL
M]L%$>1&8OH/L,;&QN9FUO9VA B:VEI1)&UK:VU(G0MS<W(""TJ% @0I2R4J-
M&C3$E)TJ5,440F(*+))+ 6 (=:IF'':@+";8XSSZCZ?F[3#Y.NF\2:Y?64(D
MK=%YFYN"EV<9='4+TQ+DK))U[FL5N*U_;"4KLK7*E*Q2K-4GF&BS,3RH<1>0
MQG+*#]G+4W.OEI.HMQYD'%WFQ.G::MO*FP:.6WIR+HWEF@JZ$PF=<G8C+:KL
M6:**>X]N0+$;(LXR..2"P JT5JV"Q/9S" INPQ]O^>6E/DD,6\E;.MSC5479
M_P!2W#QIO>V.T0FO9D3*=MD@L&_&B9\Q9$HB==*W#D5)*U2P6!PQ&\SPM=!4
M<?0,UD/\+FBF^ OZOUKR7C-QRFD9<X5,*"I25PY[G"NSGF)R6J8$_1EWLE<H
M\[6V"YL+K'U;4OG"M5T5*I:K2'2!0HUY8YQ,,_:SM)]05&6L1#TUH4U5-CIZ
M\7$.<!(GM<PV8DP=S2A3 2N4/*D;(Y%QE>F B1@3JV0*$\D"5,$L80IR= 1/
M*C7H:;M7DM8[QV@?-]_J*P5/8U=FY;3U/*AY2V3Q(8[%GC4FY2.DMY#MZJ/.
M--2:1JZY4+6261Z)S&/$1EF6SQP5OM6GA,0I&W):(N!1RG9&DWM5.4MM\9GN
MI^RGX5\CJQ!&>2M@\/5R^86=#[<<K]Y:.!5>R6MC+.L.+/T5KQE6QN1M\I@5
M4N2X;$=7FEDT5*'OU"V%Q]H>VEB)PM2E:ELM>VN3&\MRVP*VA<T6('F,>D?8
MV[HE4E8W0]*Z1_TP[>A%Y)@%33Z3</,#4_GJKROZ+*HBD;E4157;U/59:BN"
MNGIN$JK(KV(3I1#GKOIS/3$5.E3,[&1YU[Z1*/T@T"1J]C3)Q[-V(DK8430W
M9SV%<5L<"N'-F<@2EQ=USWC534MLXQT:-1]V6S%^@K,XN[H\,.@$A97AX-/"
M[.S2!*@ WN*Y2F VMH"PH4\T,>K&(GP;LS19FRM!V;H ]EZ'UT'8^[ON:%O7
MJ#L730OFZYY?^TKL?M-D/'M(=R'B]'5C7OMH10M))J*G4U1S@U_VDD?H5K/-
M!)QZVQ+4VEIKJ7L.MB/3H^[T"$77U!YA4\K>OK29 1JRX/$; CI:],ZEL4TC
MK3)V<#FB >6D< -KRE6) K4H%*@"=5HK1Q(3S@EC#HP?7SOM+P=W.\=?B4<E
ME\?8^/?4G@6*N-<UP0+],3PGMMKKZ>ZM5E3 .X[>8(Y'-<9;RF';CU9F1B.U
M5M:^$ZK38; NOI"^&SNB=3H5O6=,P).QKQO]F7:/-==>\J)XWN#!:4W#5;R8
MZ,%]V'-EL021@,GBFE;LW%BD@.[(2'(36E2CUO?1O5N(=Z[HM[SUA<77?E(\
MP)V5<M(M5D2L,$K7$LS=4CDYND=/AP6MH&WK%I[HX.1X'DQV,>B5!0#PDZ1D
M(AA*",8Q#S2 \?J*JIX4R&LJ:JVO'Y8W&M"MYA,"C$7=5+4>H3*SFU0O96U&
MJ.0&JD:128D,-$0,]*G.$#9A)8@[?SE^Q_LIE^S>)75E<SF9MB/D$XZ6 <<1
M<0584V5&_P 5=;[>/U[$D+KRE'V>X&_AL=*[^1R,EU:TFI7 Q"+""&\-ZS;X
MBZ]?%Z[]%UL2B[M26ZSW;GKV*S?34MA4%LI1R+Y>^QJ56+!7FS(8U;*X-6R<
M[;>H-'I]5[R^Z6,9;FWH-(IVP[;G)6C=#QKTR(YJ75"]IDTW!$ ]N*=R=FM:
M63R!3=E-Q%?ZEGM019WJ*&H:"#R)N<*N)+J>DDTLU_U+VNY6)Z?7:<J[-EB%
MS8WJ,-"!NB.DZEM6^S%PC<>=G1A>W1B9G)YBRE<MC3LO:T"QSCRQR;CVAQ5,
M:]2G-5M"E>U*5+:M/;CDQJI H.1*!F)C3"A=#(*RKB6+71RE$!A4C<7N,ZA;
MRO?HG'WE:[1 +CZ8#%7-4Y-RI0OC>G;6G/3$K,.:M.&M+=)-*OZ7/;3TL\7G
M,'<H*X[<PNRA !:7#NSBK?M%N;1KV=MP$E5\8F7CO(;,[.N)%+E!0FQU+:K9
MY)!8$S66,9K87Q"4%GIDY.B!AOGKFU>T6@M!,6Z6XFT?;]5Q#A%63Q02HOD2
ML8;BM2WR:!KLR-PF2UW)X1&J_A\6/GJQX0N\C.N4P_4-9=.Z0CTXZ)V0NV9P
M@$%=5,C6.<,BCBKF$=*B$L4KXXS+%$FBB<+@ B,R$Y2A-,>X^2!U= $LKH)6
MV%!<5X0)0Z6J=&Y*C1I&](E0($J9$A1)R$B-&D(*3)$B5,4 A,F3)B %DD)T
MY)8"B22@ ***  LL 0!"'2)XS8M5;HDMOM2:1OBMN45'.-Z=C,PR3E]RQL-/
M1,NE@)\\R[FT[S_DC+J^H*][5DCS")(6,5>513=4I)<_QBNZN;JO.CD4BJ%A
M?W/8LQMI[MWDM34RY,Q[BC->,%"=CQS/6\DXWP$L>S[S3R_B]<+'0T?TJD)J
M>N:@<8=%+/\ 8FJ=J2I=@6.<G0QB#6O(]S560S%ED^MX,>80O*R1 96D+^XM
M*)A7O@6U$%X6LC<I7K&]G5NFB-+E+6A5NKFJ1MQZ@Q&E4."X\@@LU8I&;@-:
M4325+I)$@IZGZMJE#+W0Q]EB*M:^B$$22=[-*$0:\R%-%69I)>W4TD8B3'%S
M J5C*$(O9W<$(.T2C2J)W')#VQ?&]TA]_<?^5E6R/A#R=9^/47X[MS(PN7#J
MG29CQUD"=3:JZ(SNQT=H1ZTB&V)0*!RUZW6*-G<HNK2QZ$.2US?G1/N?MNN.
M=+3>CZGY$2F!-;U<U)<L>!#954Z6K'?TA"4<VY]<;V25A9D1;F4R!4O;.YKF
MQ4M4MBE=YBJ/2$J"RS.[JUJJ^/="T89(CJ4I.HZ@-F"PIQEIE75K"J^'*'$D
M1XBG"1CB#&SB?%I8E*@1:ISVJ.+$><( P[-,V+93TPLDC0^C) SM;ZV^>-CC
MY@\-R-T1>D&5R2O#0N\T7D*$_GC4[(43FVJO)^70N"1*N2&$JDY)H$2#O:#V
M11X>+/+&E;$OZ-TV^2WA_?L@?5Z9F56985?TXM85-;36^4U*18\<]F,'K9PF
M3:9(G!I1%M:-2<F2.#LV[/T>"#'">V;!K/F=6/$:-<W(GV@M)33A8_W"J?V:
M#T"P/'&H58RBJ('5&FR4<;F-BB3E4=^,,NDR>"1N=IWZ9IE=5KG=EG<A:MO1
M9=WZF)Q=:^!DRN.,*J1@8E\7 _J&=M/>P1MT5IE[E'P.QJ4;@%D<%R-(L7-.
ME.FY6J2IU"A,:<04,&$U91%(T:G?DE*T]5E0I)4YA>Y.EJ^O(?7Z:1O02Q%:
M>'XB(LS.4\.FBAC+TX.(%*H)8Q@":$(Q:VB4&=I QS.?\I.T1T=?')&$1CC'
MV,T+Y)5/!*BY VE3L0:^02.?\TW9AMEV;:WD\:.?I P#J>+)"6UY4+(B^H2O
M-IA'I(!L8=,\5[8GG([AI"UMC4AR Y&SFS[Q["ZZ^6MH.UHV;-;P2;Y#0*S^
M'R ?(.#5G,UTBA=</$$@=[VHX$PRK8O&JTVQL,;0K8,M1QE, SUG+X?$W14]
M+7*,1YP622/ B,A5KF1K5J7V*E#<S"XT\GJ$AAKHP%C>G<8&5>-0V $ZN0@I
M="7J]G8-95/LL]@TFBK&ZNM521UK:2UE%;4K1+'F:R*P:9$C2D@65Z\N+([(
MF<]G7-C*\(&M4VKXTH<&-KTZLC@E2@3Z1*.>)TMIV,]K55U,<8.;]N\F:B>.
MS0N.U+ ADLY>SKE9$TD^3WSQG88#;:IZE,TFJ-HF5A1-UEBG;.@<$#0W-P5#
MC%8K%VZ1N'IG;ZBPZZX^]M;>,MY32^)UVBO'@KQXB/#>Q;(>&N'Q)<WU?9MT
M//)^GHA-90N;6,5@'/\ )ZILB10EL7@?7N($-$@,;UC=&SE*.0W#CLY5/&VX
M7J_++N=ON:S=UN\5!"=0Z@*CXU5_"H'*IBPSN<K0U_4R02&0V58TAB$(/GD]
M='$LM>FAK&WL$<C: "M.IGM:-.U+=\:]A=SU?7=N0[:U,Y"B=G0F,3^,B<4?
M>VC7B89:UN[5M:EV,>TROS3S@CO"\D:#O"ZHGENYFV<HL+D;V@O(;A5;#U"J
M[413L>>']D\EJ"E28A)*^2[IVD,>0S1MALZ:D[I$I?-:GXTVJWP.<KREDA2,
MA4R;*^DR$T1"QF#W_(M_G?#BS^;W&NO>1_(F%<85\][&]79-E6'R!M&SYMQH
MJGEU>7(.J.6]AP>[K8E<MG-2MLT9:OAA;M,3I-MHJV0R^03R*#B2T:16U^G>
M/U)5D4@[/647K: QNN(\8VG,%?L,,C3/"6,UG=B'YI&S1-N;$T?:QM;VE3/#
M<-"W$#1.J<AQ3"*6E%GA[ES@T+>MR;;Q$HPZ[FC&GC$PVY,#0NW*XVD+<RDT
M?DNU2,W;\R)RGIX*(:7;SQO)+=7(!:8 5ZO1R)Y2^3MHQRD67V@N$7+.W[5X
MY2OG]QQJ"_44MYC6+'8G0S7-^.UF6*;1D"[1N5^V_9\.9;]G\8JY+.PM<Z?7
MJM'F5DUW&W6O'&[&I6EM*[(J16>O9^741DL^CTNJRMK^;H?4<2;>3TZYH/5'
M>3J2$N-BTH^<FIQ"(JX6"3&9@LV_LC0K>Y_(*\1RL^"266!6LI#&TV:,_'RA
MH]5JNC6"DZC8Z57I%B!=4#/6L*;*N6('$W1[@A55\B8R(BI1KCPZ.6)CV<PI
M4;K1AX#!A"+6802OH'5T39X'6<*B5>0>/$&)6"&P:-LL1BC&E-/-4FIF>.1]
M$W,[8G,4GG*#"42(@L9YIIPPB,,&+:)0UQ*YD\+..CMVMS!RAY&<?:U&G[2'
MD[)WZO+0LN!M<H?8(LIJAR3]I:U?'@$DER*1ITCDT-32VL#J9)UNS69L2+UA
MWFPZMZG5R^$\:.STX?W<.XXE/*S[/64\DI'7=F\_ISV:5'596LYOQ]04E(IE
M.*?9G>^K*O*GHDU1Z%D5"),I@U4MJ@D4I1"ED@8]9Z^U?'JA5\T]L=;2E2*[
M!]*DOGLZ55I"%$R]-)] "0[^R@YB&^^E" E%A)</2'GA6BP:+.#W ].RG=)T
MW:+W"I+9=3UI8<CK9U$_5V_SF!Q27/<"?!FI3QO4+=I"TN*^+.PSD*(T;DQ*
M$"P1B1*8([8TY(@(GC'M+DU>5Z=GCM585T36?)K _P#9B[AL^P$KA+%2Q@D]
MWM%QUE"GN?R)C3*0,2NR4!)CU&WB0*V\,B2B4/#4XG$'*%Z;=EECV?R%;N8L
MP[+1LM&V$CKR4YI41S!K:P"IM,$TQ@O9XK(RHN;DY!HQ-DBS2^+QJ.7GQ\D_
M'A@;$+BF(9XGR-B$=;2"FO6D!'H);Z/IEH:EK$T5+634S.+?*&E>TMT B*-L
M6MDVD!\MF3>L;T[.6C5(99*E*B329&H),3/\@//>78I8Y&F*1:(@7$?3%R[L
MOF%8%G/=G3A]KLJE*;CZZ+16+QZA:54R=/.Y3"XX8P)].LL=IQ-4#&ZR>82I
M8<XGMT5BC&WHT"9M6GNJ),<.MZUKKUZ[Z[WK>^O38M[WTZ_#H/7IKYM:SZQC
M$1C&,1&,8Q$@>Z]HGQ[A"N>I[F,G=%%0RV)E4K.KM. R9J*LU=7L09IM.)E5
MY#&@D*V8UK$F%V-7R.P4"7449D#,^NK@[$-;*[*T&=W]SDXN\;8D;*+(MV':
M6*8>=-XI!XZ_LTAL.PF3:/2EJ/@</0. W1_2R!0>W-;,]Z FC!SD\-)*M^1E
MKB3MZMYD<3K2Y'650K_7=KFTVW5_'>1,?E\N;66.2F0[;;E@<<@P6YGC4M:'
M)D5&F(B'E<F=3E"0<??D$><#T4C9O3$;=--F]CGQKC=>3*IZ5E=K4=6UG15M
MC-IPN*/<=E;)/%L;C3:R0F=*AV;&)F]QF>0MSC4.D[4XPA\C<;='2-%)93$W
MYJ<G%&:B2"2<]*_*I6UK7E-=6G"913-OLG'V<4<^HX2MM(B[9F\5RRUI7S.H
MC<W?*Y?%%GG6_5ZV&R-#/11,35,T+@_/3&6VOH&O2S)VL=/2"XJBH%#5UCI+
M>LB22^(2N#R6?\6X2^U!(X'<+A2\H:9.VS3D-'W&Q5J9_:'.1-:3CZCN%=(H
M.2ADC$D7 ?6)(X92?V>:IZJBPH1*^0\[>)O;-A$WU8EF(X16[8K=>2D/D]"R
M2D+9:(V>S.Z!@;*3*X\PR-1NMR'!7%Y+&US\3-S7UW/;'AKP@_LMT#BE;6IZ
MY"SUWC\QGK=:G)5F40.KBQ798C??0.1@Y!'I"6P>RZE"7&:)66*+VN%R!Q3I
MZQB<19X\8P3IH/LIP1)C6?RFA5>5E';59(G9]N,,EM!BJI$W5% 7N7R1.\.D
M[65^ZO+BPB*;G!!%H@\-CNHE<A4D@;6AK;%+J>>%JZ.&M7I>=T8-D[9'%E%<
MF6A.OY%V;QY42=UI]U21-F,JJ+&2F17 ]O@UGFS;1:LD&FZ/V<=KV/R%S\HC
M9%#@I 40HE563-.V*(D-UDS!-.I7I]F2X^0HV=$PD"97::2!WB+*%O;DJ)*(
M<4B"YABI[CI,4>]'LACRL!YXO/$+]%E1Y=*Z[G<8:M)MN<CALK8V[2TXTA'M
M>\Q]Q;$FE9Q(3#24VU"HK1YA0!F%%=\98!##K6T32-9\VN*5NP:7V7!KVKY;
M 8$D8'282U[=APMB8&"6M('V(RM>OG*:-$@A<O9A"<XC-B]F1*4HB%1\?>G$
M"-5Y'4<&[1ZC++MN,U] VN:2F 3&R3Z0C7(II+B)U*N]Z$4V._@52D5&RXF?
MF.BZJRS'MKENH'NO'1V!N*(I:=(S$Z ^,52]CU7YT2K*2<E;$FUE\BJPJ_C]
M7M8VK&E3)!7*BVRAX&[QV,MT'3QQE3Q29N*9YF]@N3S)K(A\A02DQY1AW#V5
M UH6\O<;'V<;DTV0IL!7R@LU\$.:NM^I$+C *7(.)Y=N5 K.,Y7(Q6<UPE"S
M+E*&M#DCH15WL:2UYJRDIDP+0$M:@N))43[L#M5J$K66SMCDL,MH,7B\DM"L
MH?9:%BBJN&W!?%/+XLR3:@ZY(]F94NW8Q<FE1<78#YA&(G"I*]QR9DM,M-2Q
ME6L-S6-]HQ4SPXT]%GNO+JAUA6OR8G/$EQ@[S"4;H*J;GK^(OT]>&>T9W$GV
M158S-[Q#&='*(,L:9R]JK 8I"T.42;G,A/(=L6DYWV2L$L=[L,R3W78QD/?9
M79-QU=$4##!4NJ9Y)V\OBLCG=XL3P<SJSI4Y^S:*FS")1&5H54;C2^;6"U'!
M>H\[QUJB6\X=P'B[,TU>JEMD2Z8V+#.7;IS9FL^TV1Y@W9=TO5>36L%9*^.)
M$RU!&X,WP^7(V*.QYE5F.34U1"-)54A=E '5<Y(DB)GR9H6NW.3,TZM.(Q)S
MARBM4TG1R!P$V&,H[@6O;?6YJT2DD!0$<J5QF2EH7 LPQO)#''\]P5(T[*YF
MI=,3?GU0[#Q*NKF'"'%UM.NJ0BDCDTB:H\V+HO)U9C QMLD(:B6NQT<0.:S)
M P/;%(HVZOI3>QOD5?666M3BMC3LWNBG]5V<(*ZN^^*_Y .\KG$9ED"K2>UT
M%NC0HH>P2(V3,4IC\%FLB:I9&).A<I;2":Q[95U4-6D4L+<OM&6'/[&_$F(D
MZ?2$'[,2$1[B#R(X@R*T)6\PSD<C7M+_ +C;"P0J*0!D50N,P4;34-6%BD$'
MKMK=&^+E223L+*F!$G:<OTH>VF-1IG<T<9:T3$VCM@*"99,^0^\HY(Z5>8G+
MI/%)4X">XE<$0:]L%2QFZT[RFE%)N<Y*<VM1 ) J>7_12%.NKY#&WQZGB-AC
M'HM^<9A%\W>*Q\OFD&1W1%7&1P&&/<_D*=J*>W9N'&(PP-$KE*F.R!L:%<=F
MCC%(S(8]()7'84[2&21AFD+ Y/S.WI'IL-5:LOO@1%[%00@%&S<?%!SA*>WV
MM.9458U8?'W9GO:+L\,L73I$'J.;93'T;(S(ET;D!(2U#;)4#2X/:63LB19&
M733<&[+IHH]0 =#W+)XBP5:U7/(.*4#>X[%WQ@HV[KMK<RNI'9SJ^JVY9(+*
M0-*10[+HO"9*5IC:C9;+4[F&1I!0\B&HEL !A, $8!:$ 80C"+7J$$6M"#O7
MS;UO6]?-O/K/Y$ - 24 \W1YP"BPFGZ+T5HXP( A,-T4'8@EZ,'H0_)Z$+0.
M]W-"WK6M[_KB(QC&(C&,8B,8QB(QC&(C&,8B,8QB(QC&(C&,8B,8QB(QC&(C
E&,8B,8QB(QC&(C&,8B,8QB(QC&(C&,8B,8QB(QC&(C&,8B?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g172986.jpg
<TEXT>
begin 644 g172986.jpg
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M-D5(IK+A.$-55UAF<G-W>'F"AI2EMK?_Q  8 0$! 0$!
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M+K\H]NWWQOGL;-NT[>[E7T#55Z&SD8N(<0[E644,<QT]#5IY:?XQZMXLJ<?
MN@^!X\3;Q:0[>O\ +#D!X[>O>J_K^/SUI^ MA.__ #F_BT]P#_YX3_MQZ_\
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M.-#5IY:<H^W1DPB_@+H/_2:^+3_MAR/_ (6_^S0? N@O4?$U\6G_ &PY$/\
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M0]/@(ZX@[6<3F*)3(W$>1 W(Y"N74!B^@@8)<! ??Z\"/KK4-KF*@$!Z+H/
M@/?(=R'D0'D!'F7_ -W ?$-!RC8PS$)U3%W$S92G()2$^KZFB"1Q_).41)R/
M'/<INH!X#D0'1/&692=77N(EU0,''VL=TTH@/Q#I)V'Y=P]VA=L^,2\=);B'
M'_Y_6X>?ASS*CZ>[_CK[#;9C3D!$+>80'D!-?;:/OY__  I_<-!\%QEF8G/_
M )1,N?D?_OF.Z:(\<]@#I*4 _3P(_/7R.,LU"3H+N+E"@)N3*#C>FF5  $#
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M"ADE"B8WO 2_9].P]P#1:@9U*9<4<]G#K$@D <9UM4$^W!@*/M!>KD0Y$1
M ..WQWS;9\9F!0 -=$_-.1104\@6XIC&(("7D?I0> $0^T4. 'T$-?9]MN.C
MGZS.;SSVX*&0;8!"\!Q]DH20  ^O(]Q$1$??H.$3'^?_ "^/K_;\_P"2*F+J
MX"OY7^5PZ$O/'8.W/'<0'D.-_P"\+/!5""?/:)DB\=1"XPKXB?X@)RN1$ ^
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MHVX?[(ESO"?]H!Q7#<<?$H@_YY^0\A^G7T.VBAF#@T[DPP<\]\EVSY]N0?\
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M::::!IIIH&FFF@:A=93G/OWQJGP8"-]M60%1,40 !,O>8!,"J /(GX!/J3
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M=F"#JQUQ%S.0B*H*B0\G&M7;EH ^:#-V0IVRH5JA:*RX9P\@VL$$NPL+A-I
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M> G_ $5VWG^O&['^V1N!_3IHFC".D*P\($>G+_C3F 1 1\6?//;W#QBW'P@
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M0=!G MMQJ=#@WMFNMD@ZI7HY/SGTU89-G$1C1,!#@R[QZLBB3DW   GZC"(
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MUJ%R!;UG6/FMAG2&93EOC*[+ :/6M<.R47?U1L^=DC6LR<BX$ "% ,W.F@P
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M5ME:]/'! #[UK6N8>1YZC?;#N'  'V>.>1T&-GP%/Z*[;S_7C=E_;(W Z:>
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MFKUQU4:LYIY&:=2<5R#7JR<>D"$>2NK1;52$(Q0*!2HLRQAFI6R12E!-$"$
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M!V& 521E(]R9N8R"Q"BN@LU<)#T+MEDU."B(E++#0---- TTTT#3330----
MTTTT#3330---- TTTT#333G^_P#?X>_0--6EON=<18S;JK77(-9@UDBE-]'J
MR";R7/UKD;%\J%CO:Y5;E=1-(?*:& ISE*<2]0#JUZFY67LB)38CPAD_(A'!
M5BLYJ0C4,?U914I3@D)I>UJMG0MS*E #K)1I^$S@<A3\\:"56G/K\O743"M]
MX%O1;'.\Q+A@BSKJ<(MVTMD^?29"GR)?/<GB()-[YAN Z2+MBE)U<GYZ==TV
MP)<Y9N@7(>X7*]E7(B=-PG5UX7&\8X,<ADQ/[/5XY-\0P ;D!"2'I,!3$Z3
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MJ .=?9\YY)=A(!![9\J/#MQ<%8?2\E3*VE)'143(GTJR,R<6B3@ASJ)+.2
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M!)+LBDF(HE3\O[.I,::"/<;M1VY1:$LW;8=HZR4^]3D9L)*(),?2S]/@2NI
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M@::::!IKJ9>=AJ^P<RDY*QT-&M"@=S(RSUO',$ -STBJ\=J)($Y$...L3<B
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MH[J#@TB'*C+/9F,6=.'*:QR"4(MH995-LHD4BJ+@ZW)NOH.FF)1YK4$R ?S
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M]M6,ZI8AO4HQ>Y R0H!/-R)D)V-GLR9BEXZ(@7:?T=7&Q#";R&T"R8D2(($
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MRLCD>QF%<GT1C:)=V\45&YP25(]E(XIH5B9-00*JFYD2*IAR<2=(#KI6>V&
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M::::!IIIH&FFF@::::!IIIH&FFME1NDJ=%0X&$R!Q.F('.4 ,(<"(E*8 ,'
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MZ'0+R(  ?9*F!0  ^R =(B(@(Z#&UX"G]%=MY_KQNR_MD;@=-/ 4_HKMO/\
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MN7Q''MMS;F#C,DV_!F;8#;5$)1\;1;[?,4U9RUP6Y<2\A6RS59Z8)E](1V/
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M-SRB8%"=0#H+J3E<DP@48>AR4?2547#,J2S:&:NF32-26 [QJRB0%NR15<)
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M"60B >OOUU\E+1D.T6?RL@RC&2!#J+.I%T@Q;)D3*)CG.NZ.DD4A" )C&$P
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M"%8%6SUNB/HN?GT*HZNUC@EFS27LM/B(V286Y:LH%-*1J4^B$=&F34==:2H
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M+>()%+M_+*(BZ3?&;\\%!03" #4.X]2JL,1VJ>NEL4I=>KC,9U[84HZ'E'#
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M.WC;?+-$Y=U04[""$J\(:0R*]L<^L64:.#D<*@2XR+DH]3D3E161;D17*'*
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M\\0;8(TWVT!M4ULU9+Q6^BBQQXE"O/&,E0EI%A98BPMK!9*+),E6<_8(@\6
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M,41[G>_M<9;SML.4MM[^XRM":Y(C(YBI9H=$7+EF,9,L)E-!9J"[874=('8
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M/DNKRX6RC6RH6&-K-8DF#W($G8\DR-^9W.VN)E^\;P4I!H/AA&T+3TF<*Z3
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MB 2AW%A:3\" ?8\ZZV54Q"]N2](CTCW'G@>1'UT&+;P%/Z*[;S_7C=E_;(W
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IB1"ONK+7H"=69,&ET;1YC242T7!PU6*'GI@1RLTP<XHJT1^;HWP__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g250777.jpg
<TEXT>
begin 644 g250777.jpg
M_]C_X  02D9)1@ ! 0$!FP&;  #__@ _1$E32S$P.3I;,3A:0E4Q+C$X6D)5
M-#0V,#$N3U544%5473$T.30V7S%?4%E204U)1%\T0U]&3$]7+D504__; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
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M%R,R0E)59).QU$-$4\'A!R0S-45TDI:RXB4V=;0T<X*4HJ3Q<L+_V@ , P$
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M7\:Y=- <-E#D*Z0%;QFPF+XY$^\7K&%VX[-AVZNO9O40=W8ZE]V>U#_?T/\
MZZ/_ -TF8/TSR#U=OC5%?W319:684&SO)]A%.]BUN9U5->9K=REJ%(%?5F_M
MH*:CTE[/#.V4*Z=-2-K @K'OH95XUDV1ULXH@(.$0, E,#A(!*8!*8H@J4!
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M&8OWB2)'+[R:!C(,_-JK>40,9%MX21C$'Z\ZBI:7/<QP: 6@C6<RYK6N.1!
M,2 #E.LKW2_,$#5OXPN6_LZN ?*#2G)?AG)V/BK+Z,V/QU#F<3M!N<*VP]=2
M\)VD!-R*6-75I(]:K769V?MD\W>9&M;A</-ST^L.-'+U@:M"B1=T1LKEC97$
MKEV/:?/=J:&TSR6U-)[%YS<=MQ[)Y3PO,1E(\-]A\/Z#JB*U]MO7M_XSC8X-
M\&V[7 U^(H4'1I75-X<HRR$1<:_MZN5=@O&.]Z]\]I)5N+&_^5$/O-2#9<>>
M-_'3B)M-^_H=-V'<=ZFN_*/>%MTS%-'4"S$*I9*<O)Q4(A!Q]4 ]X:R"\BI(
M-))LK'-<^9QVOW&AKK24N[K67*U#8<9RAC^&Q.+JVA7"7*66WW,5!#8\35(?
M6I[5Z%=1DCK!TEL<ME6N[:$854XGEW$?+AZ*-EQ5W.T@IM.-@IB,AX<.$^$#
M/A YY $9[3))F8G(#H)S$]?1JSD*,OEUK_F/S&:S/*34'#>RV)3FUV4_*CLU
M'6O8W;&II)WQROUMY+S:U0W%?+K8)ZEPMHT;;:JR?6IQ;M9M;.[23B*WY:+G
MF<K%RA_#?L[.743OF(XX$U;)2&H5>T[T+VASOFNG8:..NH_6FJN%<#HN=UB>
MI+V]#;A-OK;*K@1D+#HU1Q /:=.N)]2P,6I%VYMH="=LDKM*]ISNR(/7&F>/
M59C>U)MNQ).X0&X(_;D'K;@'LG6E.JEQ& >LU&%9EI&$NKI?:>N[+%$M;"P(
MLH2F-"+MW+%SG>&[9KC5.4F:L372O-1OL&,M&K*W&\?)/C++QV];5'[KJ$YL
M#6%Z@(9S9RZ_;ZXL]+K%DGE+;:]E5=O6S0RT#:FL+:'T1"2,XJ[8#:38:TL$
M20)=A;))&;<,9Y9R=D2<1 R!\$MU@;AN&J-G6M/>RBX>\M=7[RX]36^] N="
MUGA)V8\EV?BL](6[7]GCN1.SICD) 7YQLK5(T:R34F?4K6E4")L"<U?8BH6)
M:UWR1@2USQHB0DW&!>9W#'G/8JOVOG#/5_%2T;-KG:?\I-2[MU+RBB-AZG@M
M*:HJ3L--H[*:[Q866YQVS:_.Z^'5[L\?&56BVSY<(R:"L.Y;B1!%YM==^W5I
MDZNJ[XZ:DM-GUM9^R\Y+=H-1=[[#IMSCZ1"3FAY!U"GIVRJO6UCV%&E0D_&2
MM5V=.5M\YGHF]EKM2JB4ZWMC"Q-]E$^U_P".50F*93-JQNS?2<;7.,;'D7OC
M7FH[3*\1^.^V.3]*J%CUY2MC[6G9!G/5-&V2%RKZ<4HO69XM2CK34QV1*5QU
M(KG1DFTX\9I ES6' )RP'&TZY!!G*9DZIA/"F2 9 R!(U&9W:SVS6&>T0U-O
M;DDXH$E*<'.0;Z(XR\C+U6J'MWB5RZJFIN;2>K+9IZ C&W)+B\Y;W"BU&/B;
M+9TY#7.U](;CL"D\O78N*LT,U?%.L:-RMV:\=SMTKK;5NJ.1VE;Y;(G9.V>6
M%SD=N;!V1H,VX>/VI&+N"D^.,!RF8:R91\3O#D#N+OV EVO&LSRX5U\G''O<
MM(..^9G>]=[7?B79-YO-&#$[\@A8[>Y#<?W6XK1I.;B= _ERXNP=HMFV]5M]
MDDE'II"SQ5-I=DMD8NPK[F!DXR+58FF&EB$8,F2^%?:-:,YVNIAOJ*G;XJ;5
MG2ZMLZISFX-4K4>L;/U3<Y1Y#5O8^NK-&SUKA)&$?/V1TW,!8'M9V#$)+-W,
MO3&38RRK?$[2BD6.HM#&@.G,P'8@"/#)F9.X$21!,U).'-HC+;T1MD=N*Y].
MT*XY6GE%VB7:CZMUEPXE>1N]+%Q5[..LZ WPPM>O::VX1[2ES[.F8C>$C9;5
M<:W<ZC'LTJVO85;CJF*L]O%6C$U^XBRPU_>'/^*/V8_,"V]H\WW+N'BNU5ID
MYO;GW"<B[HK%Z,=:QVUJ#>''"Z:UTO8W^P;/MV\\F=^U6[V1O2)JW:VNL'5-
M1\?9=1.+U[J&(33>/F4U,EVQ? .LW!U 6*UV:IW,\SS(J]H2F=:*,)2!D>S\
M@9&Q;O8721:O%UFB;.#;/W6K2.G3U.Z%44:PQ(UPX,BIA'6O;?ZJL/(;9.KK
MSIO===U@CLKA-1]7;C@]36B5K\$AS?T5KC9FI%.2[U64,SU9/6F[;"94* AJ
M^WLCR/ &DA:V<8T=%E3YL=HPN:VC %.))SCP6$M(+0<P8@9:]@5I= $?-W]$
MY#;NSG\%#DQ[*3M 7?#.T:FIO&5[HNQ(=EGP^XX6:A-]BZ0[NYMO:.YX7S<'
M)*LLE*9L%]67+WD!J:02LC:5MLE%1%\^4*%%V%.1:\M86[':+CYV5FQ[E:N'
MT=N;B5)L^*D'VAG*??NR=!;N@>-%1JE U/=^&[.@4]P3C+I2Y6[6.NJ-==]1
M3>1#2-.L.PV?I961NUBCHR'M4@U"5-QVT/"QC;]M5V3'=<76-7QG)IQ$[B?Z
MC>HZ8W9-\.*X_M?)6D:&NWILRE^N.L8*(G'SB/?P]8BK2E!32E,F[ C'+*Y:
MDSVY'#>$K%2MBE$Y<.HJQZ\MV]YALUXSV=M8-;<6:?88NM.>7&RJK,3$58:_
MQSL#^5*XI=PC8Z>G[;$Q\O+1-159QRASQI+5!&B$N)(.8^4W5\K/(2).3I&N
M0DOW">G+HUYG*=>2AWU'V37*NGU+CFC=.(2MFO;?LE^>O"^S7*O[KTO0K]I_
M:UKW7:Y_C8FON"0D+K881N\X_K.-,4.ZTNL[+1HD+>QI]FCX>DC94VLD'8.<
M4>0O%1'E"VW'H(NBZ)<[%QY<ZX4GM?Z8TCL>Y2=$H$K6=@/KCHWC'M?97'F'
M;5Y4(.*B=M5**U_>-Y+FD[3L*M+/6D:9C/3%2D9.1<9-PK]I*PTS&Q\Q#RC!
M8KAA)Q,LS0D8R28N"_FKLY!@Z;O&JQ0 %6ZZ9^@=[H'W@ !Z@  #V]   ]?O
M]68'VJH]KFN:T$ELQB$878H@DYR,_:JEYU$9R/49U?Q7'Q2.QVY$7O36H:3R
M3XQ5Z^OM8=DCVDNG*_#WBU:VMK:K\R=N\H[1?N.*4<;Y7OF86E6CSAK!5KTF
M=:!H<@HV=+V"NV>.8G:=27$VLWRE<8N+],VHF]2VA3^/VAZILI*2E4)V12V#
M6M85"#NJ4A-M7D@UF7R5E82B3N6;/WS:27(H\;O72*Q%U,Z] ]P>[V?H]V>Y
M#_?T/_KH_P#W292K7?6 #@T09&$$;(VN.7[U!<3D8URHU.Q)_P 4_87_ %HM
MW_\ FJ[DPV0\]B3_ (I^PO\ K1;O_P#-5W)ALQ\C/^5;A_Z;9_\ 2O-Y/_U)
M=?\ <Z/^E,8QG3+V$QC&$3&,81,8QA$QC&$3&,81,8QA$QC&$3+2O-N84:JS
M-FD1*9*-:&,@W$X$,]?JB"+!BF/7KWW;HZ:7>* ^&03JF#NIF$+MS72UN:=N
M*Z.M5O4K"H2FKM)Y](Q;E L(L\0,1!["RJ2@&,(@DY!HDH0AE <+/2MUFZC5
M43D5U:FC6$LP#9[FJ-JU:[PP06EP;O';HCINFJ<S9ZDFZ*3R02:947:B"9.\
M9(K/S"BRB8'#,.?A---%,B21")I)D*FFF0I2$(0A0*0A"% "E(0H 4I0  *4
M   Z!G[PB8QC"+ ^^G5T@:]&7"G2;EL2K2[:3L$4W*D5&7C ,DF)GQP)YE5J
MS.4".FY5/!,S=+.%4S'9HF)EFK6./MM>B+)%'$["88HO$.H@8Z0G 2K-E1+^
M;X[1P15JN "(%61.'4>G7*PZ:MWK9PS=H).FCM!5LY;+D*H@X;KIF26063.!
MBJ)*IG,FH0P"4Q#"40$!$,P!5KU,P6VYS5]G1CF,0[:H/-=%CF*$:P3C$$E3
M$CDRE$1457;IK@83'$"/HQVBB1)%9NF!%L-C&,(F,8PB8QC")C&,(F,8PB8Q
MC")C&,(F,8PB8QC")C&,(F,8PB8QC")C&,(F,8PB8QC")C&,(F,8PB8QC"*"
MCL3?\3&1_P"G79G_ *;2\EWSF[XM[UV-QF[%CE'OC4*FKD=G:TMVTYRC*[HL
M,95M9IV%T\U?!-%+-,S<U6H-/N$EUC04?.66MPD[9@A(&7GX>/DW#Y'4I+MA
MN>3RL:ZT*PG"DWS<>:U^T';-H37$#6D)MG5-'J/&N)WW7*S:=#RW*.-XHV'9
MNR))\_+4;)5.3SBO.]4PCR3]"EV X:Q1OG?(R@ZKR7N-P+0.86<&3J 8"YW0
M 1TRN>Y--)N&Z<Q_X*C_ *>VU=?70>G7H/3KTZ]!Z=?=U]G7IZ^G7KT]>>,X
MWG?:9<Y&MZF^6LYMO4U8EFO8(;4Y1Q'&:'6B]AZ-G=V:KY#V;7KRRUAS4]UV
M*K6B0EI:JK;&<SM>=6"6KNM'Z^G7<PNUB%[8;9ASV@G:4ZYW/M*O7C<?&J]4
MSCMRI[+NEW2&A.,DE3Y?:NO.TU:4QM)T^-F_RP38Z\/H%U-/W-+M*+*S6+8"
MZZ2]T<MF3%*#==0;%4B<3/D@Q.<G8-A@D"9VS&4+W,!R@^S9MSW\-2E1Y0=F
M)1.4EYY#76>VA<ZL[Y$T+A/09>.@J_"2*==;\*>1COD75)"(6>NTEG[N]3CO
MY-3[9TDDG%128/8P[MZ<$26KMSLLVETN.T=NZSY%7;3F][/SDJ'/#66Q4=?U
M2\Q.J=D5S0,1QLG*3(T*;E(ICLF@736S28;3K23EZO,-9*83<Q[Y).-,C(P6
M37:S\Z-]:3YI.;8C 476>U>)O:\)4.OP\1K;4.S^,]FX?TK8#+7,EKN[1W(>
M;W[NJS.RP1D-QN9W1&M5=8VV1K=CJT@E6E457.P]:[5#EM7^6?$75E5L-3NG
M&V6Y#\'."6PF,CJB),<]TVUQDIEWVA)3^]+7MZ%V_.[\K5AF&T\Q@=9:1M6D
MFM+7;NKMLU>T/5&<GD;2M AK:C)@0W(@EK6@"3M!:&&>G45;PAD")\^P-[<9
MZM]Z?V(NJ&,#:J]LS?NV-M);%UOVA.OMFS4A7:12['<5^T5NNO;[M&XD=5A$
MT+7[#4;#047M5;QE?-!.CRBJ4A%HL&9(]S0;EV-VTMO5>B,.07:%;*Y%V#76
MS:+:ZY6MP\?-8VWBXI1Z%JR>U7&U*>X?N+0&L;/='3:?5OSO:4_)R'?V?&0E
MB4HRT9'$@S:':O[7SGY7=1:GY,[9<:&V[6>1'!KM0N1M*T=0],S>O7NO+=V?
M%G2CZ89[L%#8-HFKPSV;&O!<;&C/0,*RK;..46JAP617?NL2\W.??.J-XK<J
M]4)\RM([#LL3PWX=\ZX?E;Q:U^YUF;5L/N#DU2M76?CI(.*IM>08QQ)1*387
M_7^SG%DC+=-:PB+E7K957#*R)3<19K+3,"HR21J;.IWA'-N0#I!&MP'@C4D.
M$B01ET\?4=\[H4G\#V$M"J.I=<ZAK/)K:D17JAP;YB\ I]ZKK36SIUL'2'+B
MZ6783Q\[36\-K6+=KNZS,5+1DE31CV%A2J[*$<LJ_#R<TQ=7E?.QEC[;+W&I
ML>5VU:MQ@WN_XOV?E3QQ;ZYH#X=V6WBS5-8U.J3%:VX\60M^GX38T;IS7@;5
M@("+LA9Q.$41K<O7$G[KOZ22G+'?6M=V<E-?ZFV]J/7UTY']KWQ[XH2O*J_0
M%CV#JNFUMUV>=)W"YOE:U1:-INM?1TYL^<BW->H%9B+'7ZFOZ>:$=.)R8;H6
M0L?E [5/GQK6+N^LM3;&I-ZG0VKVKG*:;W?,5&G;-U-M%OI+DDRI]1U+1IC>
MG)K4L!IOC,@R4<6&:ME<V/L2YZYU_8ZJM5*VYAHR3DWH,KDR*K9R )&\!TDY
M@008@R,(.L2 #CG.>6P:B!.[?.6Z#.SI)@.RXHT%.T6P,]N[#*]H7/WEGV@3
M5Q'PL$R>_+3EE6-I5FQ4QH^*J\"%AJ*&U'TI4[.+>0D59*'BQE(LR:JY!L?L
M[>R5KG ';>U-NQ^[5]A2>Q]:5W4WR<JVD-;\>*B\@JS;GMM9;#VG6=6O5:[M
MCD*_4=$A9K<:D+3EG\+Y] E:07EWRYL8=HIM3?MYUMV-=FTM>&&@MG<B>>7&
M1*8< ^?[%HL"UV7Q7W;<+%7;%%TZVUB.W/4:\[.=["P:UI;U*XS<#6)5Y(GB
MP\T:.C<G:]\[:_Q9U\I2+KJMQR,H,#VDUQW3-5OCQ7IQ.^4C@7N>9TU4MC2%
M>VCNW6NH]*:KN\O&)DVZ\AK[?-L,9A[&L=.ZQG/-&9KXPVM48)>V*A--V0D!
MA/SM9&6P[1TJ '1KW@[8V9=4>OB-]N2W^#]\:.2VR.8>RIK:NTJ=)<P=C::V
M-.1M890@,-;OZ''24-MN-I!S/&BQF/).(EGK/:(OO".8% [Q)MN'E!VMO'99
M:^O-FY'6./V)=(!/D)RCX-<G7,/#U>&?1M!DN"T5JJ'H=$KX&<$.]KUKC]3P
MZ$R_D/+OHDCUT6-:NR-T0-$W)=K]S!_A8\>49:8T[2>.5X'LWHBVPE:U=";;
M@6DUS6U#3;U<8+=%ZA]SDY%\>-DKV:X!%\<XQGHJZ:YL4"UB)F_6DC-Y-NV6
MPG:Q06RM@]H+PKT_4=2[ZY#0<SQ)YF6Z8TCI'F=/\*';^PU/8NC(J V%,["B
M-B4"-E#TM.=?1[:(?O9<3EL"CQ&)DFL>X0&0*^.FQU4#P"0=<!H82!) S#6F
M9&<DJ1,P2-7$_1RSWY'SG>%6F_\ @^^I$;AR//#;?)%ZRW?7^8<?7:I"\5>/
MZNX]=RG,RIVNI70TURB=PLCN39%,UR6\V]WJNENW-,6C@DF\':;59H)D>.=Y
M1Y:]B9K?E#==*W^(V='4V[ZRXN5OAW;9"]\8]+<H&URT[47[&2B9RI5;<[23
MKVH=T1$AZ?",V9"Q5C2;1]E=P\K699FU3*YT.U3IJVV_D7H+@_VP7(^X3#72
MG9GZ_P!G5*NGY,;#T]2MS[LG-W;+B]O7JQ[?I%VU=,;PV1QMU/#:SI!I61F'
MZ48!9G9YX@ZDN:<D-7=2[1'DS:.S[XW<T>5.VB=GK9;!VH".H]KV/?\ :M,J
M<T(_COO9*D\36NUN0]=M%*LMO2B-2K2,Y57:MPCSWQW%,9=^XL<DJB]R\5):
M=,71F8IRUPP.(PR(>Z&G?F0=D)!D$&=IRB1&6[,QGGNRC)=EU<K[&IUZ JL6
MFHE&5>"A:U&I+(M&ZR<=7HIG#,"+(,&4:P16*S8H JDQCH]BFIWB,V#)J"35
M*M=TW= _</W!,)0/W#>&)P !$@'Z=P3@40,) 'O 40,(=! <A3TWR&I?'+LD
MN3O('BKOG87.RA<9:SRWLVB[SN1M;'[B89ZC7FEH;63:_P JR9V7=.KM6S+-
MU 1.W&KN13NE6AWC6'L0L(MLY81.R7._ESIK?&^+9*\R-)\C-K67L\^SUA]1
MRVJ=63,EJ1CMOE5RULR#&OQW'VN;7D*=8=Y_)2QNX[7TU.VG5=:NE93U8\VK
M+5R(-)J26LVS.>7^$):[#F""XF-A@M^4)G?E,*N&9,[1PUD3(V:]6WJGL.Z#
MT$0 1 /:( (@'7V=1]@=?T=>G7]&>Q#_ ']#_P"NC_\ =)G&KK;M+.8]\W_P
MEOV^.1=1U13--<C.UUT;N. ?46.J%>W'&<0M$5+8T9([CK6EMU[-U\O>9"&G
MRU=A7-42.U8W7MU@Y2VZ[<WN9D3QJDBO8]]HCRXY4\A]CZDY+.JQ/P;OB5QZ
MY?ZYG8S3=4TJ]8,=V76;A$H:O056W1M^8E]22M=0A;-KB8W.AKO>CZ+73E+?
M0X-A+1HOI?9'L:78@<+<1Z).HSGX/A<) .93 =XG<MZNQ)_Q3]A?]:+=_P#Y
MJNY,-D//8D_XI^PO^M%N_P#\U7<F&S7Y&?\ *MP_]-L_^E>9R?\ ZDNO^YT?
M]*8QC.F7L)C&,(F,8PB8QU ?8/7&$3&,=0]^$3&,81,8QA$QC&$5EWNZP%$A
M/2U@D%8ULZ=(QC9PW:&?.".W@* FLDS*4YERLTR*/5P BG=0;J#X:@B5,]K:
MFUTRUU"2CA25/.R=@?KS4G/KM5FCEZW."BS$JK95155$Z:"JKAR0PB8SYTZ.
M)2]XJ9+.FZPCMS8U;G$+%!3=!I"SU-]#,G*IWJ=J9.1[Z$BV$IDCI+KH-Q*J
M(D*+-@JBF15)Z*QMC1#U"'O ?QPBB;8]M!PKE=3\VMXQ$KLF1U?P6G*-5-BV
M,->2\4[V!;]C5^OR=/JVHJI8CPEQL,M/V&T0=!AC6. J4=-VF0:NH9^_J#IK
M:%[5>]M5H5O08:19Z"Y8S._I3?\ LKC4ZX6Q.OJ MRBA=G:=U@7=NSDG\*XV
MHUU8[K55T\ZB-BC:8/:LM$3L'881E7%I6P.U8=MASDWV5>\=WPO:_HUR^ZUK
MTWS;W'PMWIQO=R+JQ/F<%:^'U"T$I'0FWVR=< \/#6K9.E#1R[BJK6IPTJ$P
M28!+TF@>## :/9M=H1";,C.T%A(CC6ZYC..9O)SD#(\:)#<%Q;Z5A]6<@>(E
M(XBP%/;[Y0TTO.SUZH#76-/V5)2YM40,%:P>353;I0JZ"$L\(ID[#V@7'.#X
M(K=HLUFK!9^-X:28;Z82%;@A7M\Q3I1@S>,(N/K$H]B3)W!P[>HP)JY)/X]9
MK8 5BWKANHBHH77FS]K/2JAK.F7.>XA<VXS8.U=V?D(TGQR?ZVU4UWONNTM*
M'(;*L,]KV'#=J]%5I%0J$)8'MGLUGO\ 6D8Y_!/8,C9>9<1C-_IE'=B#9=>\
M!(#15/W+-[<W+7>(U&X_/M,\@=N[UD>SKO<]"+UZ3N*TWQVHUEKBM>">?,)@
ME;V!7S)6VL3J\5>7L9-22$G&/\/ZQ[*#E_I&1JO*C2VK.)>K-L:[YYW'E3K'
M@!3-IVV$XLZ_UIL3B$[XF7^EUK;T=I5LI"WZW.5FVWY=]!:4B*::505@4&29
ME6KR/(MXK?V\W":M0NFKC#Q.\MA:VV;H_7W)"_[-HVNXU[4>,>EMG[5#2-4N
MW(@)FV0D_7DS[3;6"JS<%18385DK@4^U6"9B&M8C"3#J5;:,4Q2B!V TJT?9
M[71V;N2KI'BJR1$3=]%9PY$K<!%Z+%)$TBU;F#OF42,#-5NX7!7.5^7["3F;
M2^/\3QEUML'15IJ7)?@[I#AWR^OUHL5JK4WJ"<HG*?8_(V^[/TK6&E!FV^UX
M:<@-T;$UU5Z?89C6TE'S3&K6^1F%F"SZ!:==R*2:;<B ?G)II%1Z*=!$4R$*
M0H* ( '44P#O@)0 >H^KNCTPBL[7%V9[!J$39F@)IJ.T?!D6I#]_R,HWZ)OF
M@B)C&[I%?XU QQ[RC19NMZP4 1OG-<HAU3M*WIC0V3"8;M-D/WDRG+OGR/H-
MA('55;,86-:$)U2 IO 8J'.5)4@+Q95UW13$!OL;A$QC&$3&,81,8QA$QC&$
M3&,81,8QA$QC&$3&,81,8QA$QC&$3&,81,8QA$QC&$3&,81,8QA$QC&$3&,8
M10(=C=7H"V\%+75K5!PUGK%DW!MR"L5;L44PG("?@Y:$J#*5A9N%E&[N-EHF
M39++-)".?M7#-XV540<(J)G,4=[B\(.%Q-.J\>"\1.,9=!+6%.W+:3+HC6!=
M4JVU(PG2M2M""L!6U+,F81!.PGCS3!$Q% CTK811S2GL3?\ $QD?^G79G_IM
M+R7?/FO(]SAR8N,!Q [GV<P"1F&Y'+;Q7.<FR>X-TY_J5'_3_ +#$KQOXZSS
M6N,9W0&CIME3Z'*:KJ+.8U#KN4:U35\Y'!#S>M:TW?5M=*!U],Q(!%R]*BB-
M*S*1W5D_BW#<QDS5]]IK3\HO,.I/4^L))S8I*AS-@<R&OJ>]<3TQJLS<VKY:
M:6<PRJLM*:U,T:FU[(R!W#RD&;-QJZT4*"7<R1C.DQ.^D[K.^=^_/IS7N2=Y
MZU@%GQ0XM1UUVALEAQJT SV)N^&EJYNB]M]-ZZ3M^W*]/E(2?@MF6(*YZ4O,
M-8"))%L$797,BQG@3)Z90?"0H@-Q0XM'V".VC\:N/Y]J"2EI_E*4TUKE2^D+
MK9-DCKOP+:>N&G6JE#1C8U&GKM'R#BN(QT>C$K-4F#,B&?L8QOUXW3$3B.K=
MKU<$D[SUK'$1IS4-?"J%@=4:Q@RT.-MD-1BP^OJA%EI<-?G)'E[B*B1C#(%K
M43=WB9'5RC(0K%C:G)"KS[>05 #98-,XC\4M<TN_:VU]QBX\4;76U7*[S:%
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ME'4U0[W1K+L&DWRER4BS]'2JM?M$!$-G[=K-1O\ ^GS<4Z\Y$3+0J:4BP<^
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MAUH$WL?6M?7*QG;) Q[B19M)4&[LP 9VS= 86;PY? ."I%01,*1U.IOS/T=
MS&4E4H[<VP(>RC8H&RZZJB+^/5K[91=18+&DIW7+>3:J%,@JW=G\%91013*N
MR8-T")+-W1G!LORNNJ-.KHNIBIP$FY;M&[!%=[&-W"B3-J!P;-DS'*(E01 Y
MP23#\TG>-T#UX14Q+8&M$(,+<C/U]*"+(C$!,I%(FV"1,GWQ9 L1N50%A3]8
MD .@E]H_HS\0EZUA9EWC>#FZY*N&+%Q*/$VJ2*AT&+<Q <.U0,U+T23,J0#F
M]8]3AZAZCE9_)[2/0OR=^2D#Z"\_Z3]$^C6_D/2'=[GG?+=WP_,]W\WQNG?[
MOJZ],1&OJ1 +.5X6JP,6L\9K1[I5C&MVYW#)P)#+-5C)E 3H*BF05$A_-,)2
M]?9A%:9-NZ=D'""9;=5W3ER=!LW*82J**G6.5)ND03M1$>^=0I$RB/3J8 #H
M Y]TQLK5D"^<P$S9*XP?1RQ0<QKD"%.U751(L'>1!L9,BAT5B'ZE_.$J@=1]
M?3/K1U+K-NJBLA1:LDJW426043AFA3I*H'*HBHF8"=2F2.0AR"'K*8H"'K ,
M^R4UK0)I^YE9:GUV1D7ARJ.GKR+;+N7"A$TT2G56.43G,5))-,!$>H$(4OL
M,(J<ZV'K*(C(N8=6&O,8NR(N_13TP$3;RB#10J3L$3$;]54T5#E(J4Y0+WC!
MZA]N?F/V!J]]'2TY'3U<7CJZ5HM+2"!$@2C =JF3:*+J V*9/QE4S%2,4!'O
M%'V=.N5=WKJBOX^+BGM2@'4;"D<)Q+%>,;J-8XCM0JKDK-$Q1(@"ZA"G5 @!
MWS% 1]88::ZHK"/E(IE4H!K&S1&Z<LQ0C&Z;61(T4,JV*\1*4"+@@H<QT@.
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M^P #](CD:_/;A/O#E:K&J:6Y<#QV2?ZFV]HS959L^BZ;OVEVS7>Z(E&%L<S
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M8PB8QC")C&,(F,8PB8QC")C&,(F,8PB8QC")C&,(F,8PB8QC")G@P]"B(?H
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M[I $!,( .$5>QEKEN],.)2EMM9,8XE*4"S\0(F,80 I2@#P1,)A$ * =1$1
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MM1:>=7*KUWY/2-/E ZA4;#1GY$X=O.55X1X86Z<8C*0[@KHZYC"*!&*;@Y7
MK',8PH@B<53B)A*8P]<]ZMNI[)15HM9ZXU6:G,V6;*SD6@JW41$4SHJ(G=E.
MBHD)1(9,Q2G3$O<$"]WH!%RE[4VI=]-[*Y@U&"YD2U*=37:=[2E[OKZ]<C8[
MC/-S%0D>#^F[SKZ#IO)27TW>=<:8.WEIF6O=)H&RU:%"[^A-4&KL'=7K"D;
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MLY%(I'"9FS^5.!2KI 7NG%(#@'0R9B]>HT=/C/J%)8C@E>=@JFL1P0WIV7$
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MS!%P4YD_'01,#1)!3PUA<R9W9$SIL@5#8I)PD@DFBBB5-)(A$DDR"4"IIIE
MA"% #  %(0H%*'3U  !F M.14U 4MNI89&3?2\^Z6L+Q%^Z<+ECQDOX])JBB
MLH)6JJA#B]?II%*0SUTH E 4NHY5\W_SO]O^]FA4M;0\AIR!B1.>K/*-^7FW
MK&7P<HA79YT/H?B7^UCSH?0_$O\ :RT_-_\ ._V_[V/-_P#._P!O^]E.>#?Z
MSPX\?PWY1C.X>OVJ[/.A]#\2_P!K'G0^A^)?[66GYO\ YW^W_>QYO_G?[?\
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M/^;L/>4NQ=73'%K9MZTS5M.: XN=HAH#BEM&JV2T66\;2G.<6[83;58L^ZJ
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M @(" ^X0$P" _P! @ X\W_SO]O\ O8YWQ_'AQX_AOR8SN'K]JNSSH?0_$O\
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MYXGO_J^&.<C>.O\ W<!U)C.\^KV=/89W/Y\?I!]H_#'GQ^D'VC\,MCSQ/?\
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MBH=)$Z[8Q#%]:+I3NG2[O?"2:JV2.M]>B;)%'[[*79).TRB8#'0.8.ZX:+=
M  <,W!56S@H?R54CA[.F1,BZ(8!*;O"4P"4P"H @("'00$.GL$!Z9MOQNV/6
M8Q..UL#>4;R<FK+202#UXBM&+R8G*HE'1J ""C3S$<@=<Y# 4AWR"X%,LLZ
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MV;.CV>HQL0/=EX0V;_)]OKSVJY?-C[P^P/CCS8^\/L#XY;7FS?YWVACS9O\
M.^T,:<[SLV='L]1C8@>[+PALW^3[?7GM5R^;'WA]@?''FQ]X?8'QRVO-F_SO
MM#'FS?YWVAC3G>=FSH]GJ,;$#W9>$-F_R?;Z\]JNM%VJF<C@A!.#=5%83"F)
MDBB14!3\4Q1Z%*=0G<#J8HG$!*4>\'JT>8<5$]2:OI5#U7M>^4>GP?+.T<HM
MC6.6M[>NGLM/NE[O.S]Q:TG'\' QC.6U[-+V=>%3B73VN>B(QI&V.=MSUS6E
M6LY&OOVR7F5Y1\O&]$MO*!WR,HNU.%L7PSK%5F=U.M!QDG:M;ZLEMPQ]K@:J
M1;31*E,0+N;E=[EVYX#=C1'#2?JIF4^Y4D%L4W.5W'M.P[[JKRJ[J9Q>W>/7
M:6TBTU$[GEO,6Z4V3!,G4YQMJ&SY^4KE(T)$6=>(K\U^1JL:"AF<$ZUFNG3;
M1<[^2RD2LW6V.Z[2QE-[;<*5*M3LUJJM?9VNB;$RU,J!CZPTM)E&TUJ-.O I
MNMK*MF>QK0VJ=^G1J@-.F#6N;3J.!:<OBVU 8+AB ;4<T.R!J!S7  8COG#]
MFMH#8R>VZ!LWD?R%Y2$C=+RO&*!A-G;$K=DLO'#6^UI:O;S1BJY8X:J1\[9;
MQ*N6%!N-<V%LUS<K 6L5ZJL$CK1*9B+7D3LS:D:!4G0Y$<@3\E2;X/R1-S&(
MCJP=R)7\NL TEX*M?"A&U5\BT]2B6F*5DU1(U$3!/"[3ES%-FC%AD=TE;U=*
M)4VPAQ&?7OC^E8E[A)<NZU&%U\S[/?7_ ,FV4S/:HB)+D[7Z"/(5&P(WQ:O,
M6_<VFS@8?9#EFT6<-G'O=TSE79M.[4NMHG>44WLW6G!K0]QX_F;R6X*7('WF
MAO3D/)-9QQ26\BS=W/<\?J5KJRN7J,OK":EY^N/DW>PJ>A+V1PW:[C^Z+13<
MZ^A3IU7V4!CZ%$X7VK14GTWL#64F_&D5+QLI&'1.H5J_.ZA+FY":XAQM( <6
M""T&"\L:YI$-:/",U6:H+7.%0YJ2R.X(<?$.*RW$[6AY&CQ$+JM_H0VYM=I4
M1;D5 P9E#J7I(^TW%6F9.*M%G"8G4;HW7;-RMV=PF62,7%H/6@(X^HO$X>,M
M7XVZDJW+W<:>NJ]OG7["L4F]V#5](B)JG0>N=IHO^/%1@-,ZBUTC:&6R2N5+
M7,1<V_0D2S-,)L ; ]DX1U$6&-#;-8D*#;^0<' GWE#L6G+[G!='%/E_X<[3
M7]]6N%8U-)Z9GJ9NG1*EOLU;W2E!?*F1X_/7M*V-INQR[NP!;$T[Q48"-"4?
MD#)V3\GW##;LY4-C),-2[[T9N#<<,I$.+YLJBU9?3.RZ9:92SP-#C'4C:YBF
M6G8<,78BM(K[U5 J5AL<=!!$QSANVU*QMM$4&F\7VBE>-2T5\-:STM(ZU.H$
MTG,=5=5>]]=SFM::3A3BJQH<7U74VXW&LW"--C;6+WD%HG'@!:1BQ%Q=(S;E
MX0 ))(6*H[LUN/\ ?%=N:TVOR2Y"<G7,7HQYQPA:WM78E;G[;QMU7N*R,=P1
M[2!G8BJ1U@L%TG9NK5BQ5?8.TE[?8_0=+@HE+Q8QFJFKCFJ\;N)%VMCW7E3Y
MW[%L'.%KO^U<AD^2S%YK4F\Y'9='UR&A;M%UJ.>:T;Z*N]:H^L>M"NE*I43/
MGJ[E-Q,SYXN9;.3-]E=#["05WKR0W-'5K9"^O]Y;.XNZQU-9%]97R-0L<WK;
M2L]#6BW/XJ:@(VQ574D79#FKRFUK7"PU/<R3=4&3YTS58O7FDW':2MU:O7%3
M4NNX[=L_3*+MN;?WGB1R:XWO73S@C#FKFTW%COVG^8["AT* L;.JV*>4K%#0
M=2^T'6X:CL3R<'*D*=5PQO2M5XN;;!4MUH:ZA9K/:&M+*%.DVK5L#J]KI56"
MRU&M8VU4A9[10J-L]GK59%NM'.VT65K-?7.D)JN\%C'9!H;+J..HTC X :08
M',<&->1\8[&&ATKV@:UH?C)3-7<.-:6R$9N=9:W;A6J3,V>*>[#DZXA(JK2U
MQFVA3-7+^5L5CEY&PR[A-DU.\<2;V381R<(W,LVV2\V/O#[ ^.:P52B:8V'=
M*5RR9ZR5CMK26M$ZQ W2XU&=I6SX?7\RHX>J4^P5FPIL)>NG*Y<+.'D'.12$
MPP=>%XHHBDB0F>O-F_SOM#.7M5H#JN,U*[Z[Y?;#:&M#^>.J.-?"6N)<W%!Q
M/#7EV/$T$-6B^HXNG$XN/])B&>DQ#''#/;!DD$:YN7S8^\/L#XX\V/O#[ ^.
M6UYLW^=]H8\V;_.^T,UM.=YV;.CV>HQL5 ]V7A#9O\GV^O/:KE\V/O#[ ^./
M-C[P^P/CEM>;-_G?:&/-F_SOM#&G.\[-G1[/48V('NR\(;-_D^WUY[5<OFQ]
MX?8'QQYL?>'V!\<MKS9O\[[0QYLW^=]H8TYWG9LZ/9ZC&Q ]V7A#9O\ )]OK
MSVJY?-C[P^P/CCS8^\/L#XY;7FS?YWVACS9O\[[0QISO.S9T>SU&-B![LO"&
MS?Y/M]>>U7+YL?>'V!\<J]>?H(6""<NI-S#(-I>.75EV2)7#N,(D[2.+]NW$
MY074:=WQ@2$?SRD,7NJ=?"/8?FS?YWVACS9O>;[0S=N^];1=MLL]NLSRRM9Z
M@>TP(<" U[' AP+:C"YC@6D%I.7R5DHVBI1J,JL=#F$$:X/R00<LP02#.^=<
MJ:FF7*"O4&E/5YTH[8F<NF9S+(F;.$W+)8452KMCB)T#*!W'*1#]#&;+H*=T
MO?[H77D>?%"Y,HB0GVLQ9XF*CI%6'8MX5^H=-[(3SU<S>/>QPB3P1(*)%6+\
M0/WN^9B94$R$344D,S]/7=;[->EBLUOLCP^A::8J,,@EIU/IO F*E)X=3J-^
M:]KAL7<4:S*])E:F98]H(X'46G<6F6N&P@A,8QFZLJ8QC")C&,(F,8PB8QC"
M)C&,(F,8PB8QC")C&,(F,8PB8QC")C&,(F,8PB9A#<Z\$W0KYYG0T_O#Q%I%
M-!"!JVN[,I7 !-J=1=T6_P!GK2;-*2$$TDABU'BBRC00=IHD30.?-^! !]H
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MBH)W+&/,LK"W;K-V2J(C'M/]Q]TSE114JJ#< !/OIF4 O?* Y(18>2.OJXG
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M.N2)6WDCKZH3CF!=)S$JLU2:JF>P@1+V.5!V@5<I47)IA RAT@,!%BBF'AJ
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MLII'=G-X<>WG*K0*=T.A>X4/<4J90^P"@&/$#J)@\,##ZA,!$P,(?H 1Z=1
M/T=?9E%\8?I'^T?CCQA^D?[1^.-,WZ>K5F<DTARX>4WAQ[><JM"IU$!'PQ$!
MZ@(D3$0'WAU*/0?Z0Z#GD5.H=!$@@/M 2D$!_H$!#H(?T#E$\8?I'^T?CCQA
M^D?[1^.-,W]IZRFD=V<WAQ[><JM@J(!T 2  >H  I   #V   '0 #] ![,\
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M>$,?!FSYPX>S/S[PJKYD?>/LZ^W]'O\ Y7LQYD?>/LZ^W]'O_E>S*5XI_?\
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M$.\/K#I_*#XY>LCJF_QJ:*BD H]!=RDU*G#+IS:R1UN]W5W*,6#I5JQ3[O\
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M4O\ G;6OO#$?W['RXI?\[:U]X8C^_9%?\TMV?OU -OO_ ++_ 'MQ\TMV?OU
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MG%]>(W7Z4M?NA2>ISNLT45VZ,O1DF[H" Y03D:VFBX!,1,F"Z1%P36 AA$Q
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M/89N<7UXC=?I2U^Z%)L64U40Q3$?T AB&*8ABNZN4Q#$$#%,405 2F*( )1
M0$! ! 0$,]J\WK!TLHX<RE%<+JB!E5UW]:664,  4!4557.H<0*4"@)C"(
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M\G]ZZOAVO%H88.2"\A:F;=/1PV*.)+P(;,$P=:P,Q&*$?1Q78"9RV,!R!ZA
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MUY?8]C8'UEG3KM*#1D26!@V<QLSLJ8;.(.DOW,0YB9F6;.6;-=RNV723ARY
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M'MYQ^^;QQ\TAVA7!O^#D7ET/+#18<:32GR?#<QKW'%IWRH\7P1IPG,4)GY;
MH/KI/H?Y6@E_NH84&?\ NG(U.U?T-R)M7.[LG^4>G^'\[S%UMQ%D^6=FW)0H
M68UA&/V"%YHM&AJ4]A&NT):/KTS?(]_'R%HU]#G2%O*6NK,8STO7'SV,ED(8
MK=V87/:WUP>95<XM[1TC&O\ M:[[S4;<#-.6+1#7D%0M+636]8H\3M*EP.R8
M"Y:#-NYC,PKZPGUU8:M*G3;/ 508E(X*9E#*-%].F2\-<?E>$/".-PPP3+26
M@9@1M@ZE :T@$GS;\R!VX>=='V^^U9TC0]<\*MN\?'U$Y6ZSYD<X]-\+8VZZ
M\V6U;P=+D=J*3R4G;5UFD#.N)&:I2L*FG(Z]EFU8E5C/D1=R$644#.+ZI':-
M:A8:ZY1;<Y.7/C]QSUIQPY7['XS%NA.1M1V="SYJ6>+)!O+4> BH]YK[;-E,
M^=#(:!5:6&[U<C(%G2[U!8ZK> "E=FIRI7UAQSN59XT\C*?+6;M\N,_.?9]'
MWWM/CK9]HP.E]>U>PP5XY"WBH:.UMI35NI7]F6?L'%EU?5$+Q8P5C&,D+DJ2
MK:/)C7;G9<\^2L[]N&&T]N)VEK/M\>87-5EJS4MCT@GNC9''3<E:UK"T+?&D
M&.W(_86HYJX5!Y5)9W U+8=7=2KAO+.Q2A&YBN%D+:&A(;B S,N+A/RA#9!C
M/Y(,':84AK8\X$[]6XQM(_?DNK+7_.GAIM5CI>1UOR?TG=F?(J<M%6T:K7KU
M&OS;1M=(:-']SJ=30+W7+JUU-D_8NK#67J+">BD'K-5U'D([;BI\-\Y^<)M8
M4S9NP]@<J-(5.E::V<KI/:%BEKPP(RI>XT&QGJ^J91-N5P]<;$;LDU7KJH1#
M23FVC%!R]=-$6K9=9/F^KG9F\GX[A1M/D+J;CSOFF\QZ#VE>L^T;XUZ5Y%[5
MT#/;4V78=?*UNKWI:W0N@]6Z8U/I-]OVD/I@;9K!@O8P<NJ7!O9671[\0Q1M
M+:O90\S*!QG[+7=$)2-N77>.G.1_)/E]SQUAQSE-(DY!_EAYB*QEAE+UJ]IO
M*'V#I:]WC1:4)":]4CYN%LBSUHP!W7UD?,.;%#5T%"1\9K>6X2YNL#%!(V&0
MS$-3B#O !K<L]?$=._,[,MXZ5TNV+M$^"E4X^5[E;/\ +70T?QSMTL%>JFWS
M7^-=4^R68#NB+U6$58 [E9*UL18OS2U7;12E@A4H]\YF(U@V:+K$QYV?_:"5
M3G^[Y=N]?5^O)4?C7RFGN/%*OU1V"TV)7MW5N.J<#:X7:T*^CX6+CXB/LK6<
M2!A#L7]D;%;%1=$GEC+F;H\WM$[.CE9H93AMS0B^#G(S;,%JSM!^5')#;O"#
M9NU.-FR]]2$%O_5-'U]5>1,72]?Z\TOHBF7R,LU-3O#K2M?B[ O5IKT'*&L,
M6R</CU28KL3./^_-*L>T7MN]>+[[B,/)+G_?N06KM/NYFA3(0VN+E38#T<FW
M=:XD7U83-'R!74:_18E9-T99!Z1FW%H1)4\5*5%E)[FD.=EAE[26^&T%H#3F
M0W,G<X(6M .^-IU&-662S1QI[9/A1R+4YI/1VSKC652X4;4EZ1=;S==HU(M9
MM- 8NXR%B=YPKY/R2<?KNU6Z2"F5L'"LC(2=F1"*9F<OG3=H;='C=R^XO<PJ
MO,W/BYOK6.]ZY7))*&LC_75D1F%JW*N457#-A8XE9)G.0#B0;(+.HWTM&,TY
M-LBLO'*.DD%C)\M^[>S;YH2KGM!86N<.GMUAV';+:K[3O6E=7LVH(W6?-7CS
M55_1$WQNC79["K(Q=K!E)N[B-5OT PK"IXYY&)H/+(JTC9*3OL\=+;XN_:+\
MQ.T(NW$6Q<#M2;>X_P"G]!4_2%^<4)EM':USHEG-9[#O*_5'6CQ[7ZRI&LDR
M4> 6DG"\M-QZH.FA_*)/A":M&C@>]CH@-+1B:1J;X)$DESB2<CE!UD.4%H@D
M'4/7#8'GUR-ZS%(=LUQ:UGS"YH\6N4-UU9QAA^*D]QPK51V?LK:;=L&[YC?N
MLW>QWS>)IYJZW>UU#7C9%HSG))*2L,4FUD6DK-OZZBNW17V^WQV@_!SC ?7:
M?(+ECH?4IMM1;6P:V^5VP(E$MRK#X$A97"&/&FDR'I+OQTO*W9T9K4W(F$&\
MTKX:OA\_7)+CYRUUKSF[:G:T=V65IYK:SYX:9T9I30]VAY;2:X1MBB^/2=%E
MRR\->)?Y616JEK@\3=7>U0C=D\@;%0*LH[C'T?(1]@@])[#V3G/+C78*.>PZ
MBY2<H*OL?LN]%<0K PX=6_B2[?TO9%(KR<3;]![3<\J=8;5;P.B91=90S7:N
ML&46=FJV]))*O#IE8HV%"@X4SB@EC26AX\)VC870<\)#B9!SG* %(:W+C&V-
MV7XG(;=8R7;Z[N-185!SL%[:JVTH3.LK75W>'$[%)4]M36\0:P+VY:SF=A")
MU=*!(:</8!?>B0AP&3!V++HL,;]H[8WL\4./?)OD)JSE#IC><1Q9UU)WZ]5:
M@[ CFT\]."OHBGU^,/.LVA#.-B7)>)H=1FV[61@'EKG(>-,\%9^U37M9QQJW
MMJ3L57'%33^MJ_==_P!.X.+:KI6FMU6.B[XKKZW_ "7,BEJRUV.;IU$U?M5&
M"9/753BEIFD5W75C?P\,SD(8*NHIYCG\T=V='.S8.RN4EQLW'#E'$P>[>POW
M-PSI,GRR-Q,J#I+DL92"<P>O:QK?01:[3M&ZC+--'K+2[*Q0AI4&$:E;;%.0
MZDTP;LL5.E2(>YSQ#7  X@) ()!!F<0F"#E$YJ  9W3 USK&S+7,$\1J75'H
MCFQK3DCP@@>;^I@96&H3VCK!MOY+MK(PDG4%8JG27]GM6J;#8(MJLQ;VVH3D
M<[I5J4;,54XR;:NQ*T5!$$#:[:I[7KB.\X:\3>6W*G:^HN( \L:$C<ZEKS8&
MRTY=\DN22?1LK'PSQ& C)NQQ4(9LT/*6@]4B8=@>29MY!5FLL@5;W\+-:[>B
MNR'U?H:]Z(MFE-UTKA=,<?IC5%J<44\Z_OM1TU(ZV2GF[RDSLQ6%8_9$\W3G
M(%TZERRRC*4;K68K*2%T1/FR8]F?SYT>GV?^Y)GC_P L;I%5?LLS<+]GZOXH
MS'$R6W9I[:J.T+_:W->MM;Y-4O;VN7>IMH0EL:-;5:*3$>GH989,SZ729-_0
MEKO3I47Z0$@.%1P9\8T$M D 9AIDY @$J0&R1MG+/9EVC7LV2NLG=G:-\#>.
M4+K6Q[OY=Z#US![C@F]JU3)S-_C7K7851=%2,VN-4-72S9Y6G+>.B1.VI$+7
M3*JE0+)BN51,GT;R[1#@MQHC=93&^>6>B=7Q>YX9G9=4OK'>F"C>_5203;*L
M[C6CPI)<7U*73>-3$N1BHU?_ '0F7TMW^^4G*9L'LX^T UYK70W':C<5N1B&
MNUNS(V5I.K*Z2NG"S9FY:CO?9NU]CWV2X[<O.:&S=:4Z>A>,U/@K2W<DA]%5
MNOQ4F\=*U2J*V&<<RME+=FP."',"D:H[/VQQ7%CGI3MU:R[+"L<1+)M/AK;>
M/VP+2RN[&;G59KC7RBXQ[MDF5%GM$R+MW\I1V+6;J[;S#*2]%S\%*&C&*;&S
M;-2.'PP029\-LD?-.J-A^27#([H+ W?ETZ]7[\LM^M=#=O[5SBO4^='''@R6
MZT^=M')?42FU*5L.&V/4WE2*M.G9JZBIS=JU%VI8)G>,4\)-:T=Q,L5K.1HH
MKLD'Q'**@[+<F>:W$KAI%U>8Y4<A]6:'9W=U(,Z<78=C+&2%J6B"M#3!J_"L
MVTA-RK6'"0CPF'[2.4CXLT@P3?NFZCUJ16"?0/$CG)K+E1V+V\-S\3:E-N-2
M\)]I\9N22W'F.T54J1QWO%[N(.J/.2U*BINMPK*O4^I.VSRS'TS%RT!'69O:
MFE$C2-56,:\RQVO&E>8FS>5?'64TUHW<=YTJ?C;OG7$ML3B76>*#7D;";JOS
MX[2N4*];JY+PDT_TEQDLD#Y1S>++K@K>05.:P'73D9I"";)4-&D:E)H>W"6$
MO(>V"6DY8AD"=N4P"1E$,(D:HC/.9CMZCJA2D;<[2+@-HBD:IV1MWE_H*C43
M>D66>TW:)2_,'D9LVNB#05++3?02<N[EZRS%^Q3DK$FU)"Q3AV@TDWS1X<6X
M9_G=PU,FC;#ONAR]>V9266I[/MRI353L4?*5>]UZ$ILK<8MU 6J)&5C7<186
ML<1)G-, ?MRI.?,D2<"D9 W&C6>SWYFZ>XS]FZO*<4>>]#W;H[B#OG0EKVMP
MCO6@KIMFF6>V\A-G6R/TMNOC;MV:0UOL#0-YK5FC;>GL*KW])R;SKJO6F(<#
M'QS9#HTX3Z:Y.U'LC*-H[D1KG6U(Y,H\7MO4F=UAIRNT&E4V&G;'#;%:T>LL
MZ[KI.-U?"6AY&S-?+<V](28TLMV?S2\85!L=8X*E&DP4R'X@:@:XES<Q,$B#
MDT1\H'408$R(+0(Z8,[NP)UY+Y-6=L+P_<\.N)W*[E5MO4/$%SRPUR%^J6M;
M[LCTW*) WE'D5,-(1PUKL?.V6*A%D&025E&IQ,8T6DV;5V9NX52(KM%L;G_P
M@U%%T*:V9RRT'2XK:E'9[*U>_FMCP96VR:#)247#QMKH)V:KL;?$R4K-14?'
M'@2OW+YT]23;-E>ZN*/*I*<&^TCJNE.SUTT'%C=J,'5^RVV/QWMLQQI@^';+
M?M<Y-V_8=S=%U)OOD!N]C99G4O%5W2WT3,V1UJR4!]+2+^7;,DY&>6228;9<
M"^S7WQ#;O[$VP\E.*YUJ;Q)[/O?>L]M([&C=?VIEJ_?;S8TT\UXP/$+S$XV=
M6)\P>^EZA-1+62;M$GC9YYV.?D$&V1UGL\%VD $N(:U[22!,-$G7D0,R29F(
M5L+<CJWZ^K//7^_S3E6OM/>SLHFS+YINZ\V.-E5VCK"1;0U_I,[L^%8357G'
M,VSK?H&0!0PL5I]G8)%C#2\%'/7TO R3M)K.,HU3Q/#NJU=H)P?H_(2.XH7#
ME=HFM<CY5_%Q#/3DSL")97+T[.D24@JV\04-Z+B[3.)N6AX:K2THPL<H5]'@
MQBUS2#$KGASY&5N^:I[.O<?&IYQ?T1O&!I_:LL+5&=I!KG?^@]CEV5<;SR#A
M95E4H^NU]]-[H=\CG,%,*TB]TB0;1:]4U\PEW5B3259-6LMN1L[LI>9P[QYJ
M<>;CH/F9N2G\H>T8D>4=%W/IG<G#W5_&A2B6*_1]KC=C[9VMLS1FW>3&MML:
M8237;&J-.EDVUH39O(*O0J;5^O)6\;+1 !TAS!'RF#,8)<).R2["3.R0,Q&%
MN7K@C/5O/'9OZ)[*-Y;]TGQEUU+[<Y";4H^F=:03EDQE+KL.=;5Z#;R4FJHA
M&1*2SCO.'\U)KI*HQL+&MGDJ_426*U9J@BL*>$&':)<%9/CK(\MV/+/1:_&N
M(G#5:4W(%X9ITZ/MH&1*2G/#K))S"%Q<>9:G9U(\0%C?(.FSME&.&:Z3@VH/
M;2Z[Y+[ T-H!OQQU5-[B)3^7.IKON=37FL-%[;Y'TS4E<96$);97&>I<CF$C
MK)#=#"4<LT&,^]9C-PS657.P<,(UQ/OF\$U/[-OE\RXB\J(':O#GF+9;%.]K
MO2>:VOE:QR)T7#<U:E0$=;BRB^0^M[36VCG1NV=]4645=,[CJU=C4ZZYF)5R
MO4Y!FI#1\JWQ4J%-],.<\ XX@N:) ($0=1(,C/60(S!4-:" 3OW]':-<].77
MMQ_Y):#Y6:^;;5XV;?H&\->NI)S"%M6N; VGXYK/,TFRSNORJ28(R,'/M4'K
M)=S!SC&.E46SUFZ.T!L[;JJPM7__  A;CK'Z1YJ[9U!4X':TIPSY/ZYT%*5,
M^Y*_#H[*HNP-D5;6R/(:LS476Y]2*ULG+V!^WBQ?1C\DC*P3F-=S$8#@CE++
M78LZJY?:ZJ_+J<Y0TJWUF!VAOZ-NVD;%OC66AM8<R=EUP:<$=:+MRI9<>G\M
M5)JV'ETHR*JTY:9J7OSI@SF5I*0&#6@6S>)SDAV=',FU:6[9_CU6^'-DG!Y+
M]ICJ+E?HZXQ,CJ%>B[8TFMMK6SF=K$>D%N:SD=)U.NPLY:+!7;5$1<:@P.]:
M-?$F#JM7MZ=*B*M1CR"&NIX27Y07#&"1$D @& (@R0)D )<#&S*9UGS'APG.
M5TTZ:YX\*N1$+MFS:,Y4Z*VC6-%B\6V]8JML*$6A=<Q3,DFN:QVV2>K,6454
MUFL-+.FEP%=6IOD(Q^HPFW1&JA@^#0':"<(.5)KV3CKRLT9N!76,6ZG]@H4Z
M]1ZSJHUIEXGF[9,M90L6Y0IS<4E 7N"22]81$O1:63[Q._!)S_[*_D=R$WKV
MP,1Q^UA"ZYHG)?@#Q'UOHJUQZM2H](O^S=([6K5\M&J2DBWD<K!C/5NGITAW
M*3+&)@VK&39(N),D2V,"5OH\6^3?,WD=%;J+V6[SA5KO1?9G\FN)EMU/LV_:
MXU8[Y<WG=&MU:+7M!5ZQZ?\ 2$A!Z<I9!<J5O<$RQ(VAU';-VC'-7)4D4V@H
M%I=I(D @8F>!(:0'9D^$21LB-1UD&@C4=FW; .W?,1GGM"GMT3VBW _DX^OT
M9H#EUH+:K_5T))VC8#6K["BP5JU0A1 )B[2 3'HDJE%BQ,3TE=V)GE38 JB9
MY,H$<(&4K_&WG9PVYA2%OB>+G)G3F]Y>A DI<(?7-O;3$O LG+H6+28=12R3
M*17K[QZ46;.R,&KRONG0IMD),ZRR!%.0&K]F?VE.X==;%X[:TU3R@U5JUOV>
MNQN/1#=HO&\5)2WZJNK>2J-EIG&SA]R9U0[#:UET7<)&M.*9.2-CBZAK<:6Y
M7=6>NE=KQ2[21_LE>&W(&!YC:VY [DXW<T](+Z)X5K<:9.X<F]F<.(NMS$L[
M7K;8^G-5:LXQ<?J98]DZLJ[J+6M=3VQL'8*"T65FS8KQ]ADEVZI8J4*+6O(J
M9M @8@2V0#)$"<4Y '+7)4EK1.>S?MV'S]N$VUTYD0^N>6UJT#?2:AIVK:-P
MZF>6URV]8=]U:-O57B:]>EZM.IS>@E8KY5,=51$*U<3TAO!2;^33:314JYXS
MSI1<95](]H-P=Y*;)E-/\?\ ECH?<FSH>M(7%[2=>7^+L<V:K+-6+U2<CTVH
M@UF6+!M*1RDSZ$=2+BOB]02GD(Q83IDB-[0/A;RBW!SQYI;;UIJ2>M.N]G?X
M/_OSB!0;2PDZTV:6'DI;MG6.>K6K&;>1G&4@A.2<4]:/4))ZS:5Y(BI2N)I%
M4#)EI'&S@%N_5')#L#+RCQ[;4BO\6>SQW7J7E;/0K*BQ7R!V[;]'UF(CJ[<#
MPK]-[8IJ;OZUI.>1BR6!HK-OYJ6<R *2CQ\YIHJ6CQ%T.T<@!P@N#2\R"29)
M&&! SD"4#1&>T2#NRXG/?UZLE)7R7[3_ (Y\6.:G#OA-LR9BF%YY=?*X[2QO
M+E 0L9JM",1(SUXO=8:13&3>)[JN)'^O];FCG#8LA;(QZS4,<$Q ,)\ >VJX
ME\TZ]KN MNQ=/:&Y-[,O6UJ;7.+DGMYC:[^[+KS8ECH\&NDX6@*P 3=Z95Y2
MPPM5?L8^9=MUQ1@4K"@F1\M0.T&X][OLO:5]CWRSUEQ\F=ZZUXT7;DO7-\#4
M7NN&UDI,3N^BU2E46[2#"]SD"M-56FRPS%IE%(924DX5"(=GAV))R2C2NXI-
M/=EUREI7"+LKJ<MQ>-$[TT;VXD%RHWZ+)OKE"YU_C_';EV3*NMES]E1F2+3,
M2-+4I)RQ[69DYM:,:P#$T48L0W09793L[J323#RV)Q"0[%4&;21E :3EJC.)
M*!K2 =^7GU;X\RZ1D>T#X/N.1A^(R/*[12O)@DD,$.E27Z*-=QLI41<'J)&P
M#Z,5NB:)3'5I24H>V)"4R"D*5R4R 8O[17GH;@/6>+UB)JTFU!Y(\Q]+\3?*
M'N1Z8%/+MWTZ)[Z#@E:LPSQJ^2$,)*T*,425,X IIR/*F)S<P>H>R@YFU79D
M'Q@VMH;F->H^M]I.OROBN1U(W!PYH'$0E3+L-O;XKD>ML&>X_;%Y8*;A:1R9
MHZ;TXC:4'EC,!8YH[K2G<61GV[<;BMOWE%QPTC8N,U*:[3VQQ5YHZ+Y?Q6GU
MIR,JLAM>&U:\L9)VDUZ=F7",1&V%=K8$I"/1?.B@\;L'S-D9U*C'LGT&E195
MHC$'-=\HEP@ZH=((P@DZB8$:R)40V1&H\=D"..?FW"-:V/F.=AHGM4('LT?R
M7D<$FN'%@Y9&W+\L#I*-30FQY'7Y*&6@_)M0BY'01QY8UE&W(F0%0K(L&N "
MZ#!'+?M(-Y:[YFUW@-PYXM4KD?R$5T$ER2NRNWN0\#QTHD#0I2TNZ=6(&IO9
M&#GIF_WF=EVBBCEA&H,F$"Q5:K/%'*7I1U":IZ2J7,/D%VJ&U.U1M_"'<''"
M@ZA[.FT<:M4:,W7:-=1^Z.06W7UTFMH&CX%C69RPQ-*KAW"YZDSLEF5\FN_>
MPCU(KDB\RS@L3=H+I?:G*K8NCMH\P>Q1D^46DK+QGK"[-CQUV$SB.?O#[D*>
M:],V?5EUV#$[7UK$[%U8D=X[?5J1J\6C%Q4ZXE7KA-%P9=G,2RE3%5C7!A 8
M [PP9J$;L0DC7AD"3!$@A2 W++9G.J2 1KU^;5NW3J<+.2%SY4:%@MI[)XX[
M>XG[)).V2F[!T9NF&?QUEJ5MJ3U-E)KP,P]B8-*]:^FRKMY.E7Z-BV4?8XU9
M3N-TG+%R [7Y WV556[07B3QUT]J3?&B-R['B=M<NMPA 1VQM_T[8.Q^!O#J
M4BV$GJ9CN:Y*$E1VO)L)9E)LSUJKR#-S7B3J2)311&XUEC/& B( (AT$0 1#
MV]!$/6'7]/3V9KUF!CR&EI:3+2UP<(_Q.(@Y>$9RVJCA!X?O $^M><8QF)0F
M,8PB9 MVI?\ C5\?O^KAM;_\MTG)Z<@6[4O_ !J^/W_5PVM_^6Z3G+\L/ZDJ
M?WR[O^]H+G^4_P#5%7^\6+_O*"SEV)O^)C(_].NS/_3:7DN^1$=B;_B8R/\
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M+EC6J_<9;??(:&:<>X>SUB.LL)![MUQ%/+76;X_7?R;$M16K15W)8.VE0?\
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M,_M>X05G:[>TE-7.J-W$6VEK!<G%*5;3#25L!D';M\A#/)V26,)G3G(J>8_
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M>$7AQ=,S\F6D"!JPD;09R@M$9",QF3OC/<1YQ'6MP-#<DZSO'4\5MB8I5ZT
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MFXMW%S&G> N<N?E;=MBNNP62K0MSJEGLU*D]U.E0+"YH ):76EKBV7""6M/
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MW!. >H#B F /5US]>,OWS*>.OXAB]TZHKJBJ<@] $AU._P!\Y!   2F,)1
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M.I=G1EUSF*=1PY443_WM15PLHHGZP'^+4.H8Z?K !_,,7\X 'V@ Y^>^?O\
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MF,('4Z>KQ# )^GJ[W3/(K+&(5,ZZYTB=WN(J+*J(%[@@) *@<YD0 O0 * $
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M[7Q'5P"[.2JK$*<J:ZZ9%/\ ?")+JID4]7='Q")G*53J7\T>^!NI?S?9ZL\
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C'S*ST;8RK6KV4M=6IT6TP*=>E5=)9:*CI+6P(:9.L@9K_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g264539.jpg
<TEXT>
begin 644 g264539.jpg
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M=<&+(0Q8\(;;O2#WP[.8B-MP 'VQ$  //R$>?+M[J!> \@^J[?/9> ?"(V@
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MS1/J0G2B]Y"8I5%>TP(9-K8EIFO=PM5.3D]Z/G$R\*HL+I- S*N))Q%+3EH
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M-:"7Z8V21C4F8PIF$^G-LRPU]LJ>%,5[4=,RKJ<:/&B:X<)%U!6Q'%'&!NK
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MS2V_PAK,427"G8)!,%O!G0/93J,?3""=;86.XL2H8RXPM9 ;>C^F"X+>^X1
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MYOY_OQY*V=>>;_D!YKN8PLNIX.I9,YCRJJG<MN+%C HE)11,0TU+2R6;:4'
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M;*?#KS>'UE0,OMG0\OP+%P?Z*G14!N&MD'+JLV<@]]SH>WEY]R[EM[_@J?-
MI2E I2E K!4PP6@RJK,1Y&5B1$YX1,?/N1@DVO-TT1<R%1QW7II\@6E%IQ:]
M6PA2BUQ4T1,QFT!_H[J2\:7F6215.#"LJ> YG6E!0I&&AN[5S,G;UP;$T#FF
M=YMB(6\^YXF-VSELB3D]R)3P1G@GQ LPL]X@8#*B/5-9RVN%-)1G$BI@38]/
M7-I\F6K*[S3%=279(ZN:K;(0G(,^S:68NJ42KNS,R:_FWA $7.%]*T2L")(K
M:IIGOM\(KN*Q?&E[ZV,D0@IY,AD\<BQDM2](:L?MA<5%06_G73%K5*#7?/\
M"0V#DZ#&3IS*CYAEO:_:NP=LQ$VM3]91EY.207^MRTU%F-X2>DN1TL-9K-N/
M\<%1\JY"[A;[6D"1<<J.S**V04(_32>%+SV1:QPAL5;/4L;4[688<;LFO6(8
M:@!K1[!+I>KY9" RHE7I+?2X\SSO?;+CM9.N&2Y E5:-X6M:T?%6"TVVVT87
M6\%4XL*EL_J4'X+H;*(\VZMM-R$@44!Q)AM'6" F#A0#B<>Q78#1?QI/,%#N
M#PN*ZZWPI4S@SV<^ECRV7  U&3UBNK8__9?9_#.1_P"F=2YI01&]8KJW^Q?9
M_#.1_P"F=5O[XQ<PH95XR;,=(8-Q%/)3J63)(%-;5@RJ6<^D%,QGQA<4E4YC
MZ1<F6Q^!L,VE[?!].S%;??DNNO9JE/BI&?%WM$7;RZ36<_E\RPG_ $_[=E!6
MKXX/M_P7?13QP?;_ (+OHKJ/67[;\-.LOVWX:#.L.F0RRW&&*Z[G;D?[1QW!
MRN#G;>ND;1#GY.8"(<P$!#O 0'MJ]>[1C5S)?DR71A8-V3)DON$7G(W,;K[[
MKKA'D\K0[1$1[  /, !V50'"!_PLS1/CZ7/IR,S;>_SN @%;68=WPW?.-!$?
MUBNK?[%]G\,Y'_IG67(L@F+(5Z\]35KVMOTQBGBL\EIR*_C@I0' (\_3 LJ_
MB_@ /FO_ &3Q?PGA?T;PO0Q=#+M*!2E*!2E*"DK>LY,*>[]9Y$W#9D)D=-(8
MWX:;\<2NP5.3)-O(Q[9"6Q39BR3-AT1?CILH#$0(_GEP0HO*B@FFWXT&TMYR
M+K6U5#3&C8O#BN%5YHDM MQHQQF)+8;$V?4>*'+NI2)'\(OMZN=*U76G2>PW
M/J,HJ2TAK76EU!2DPU*<21)F4VFZ7\VG@EW,-//8KS%Y#8($ $.0\_(/8(@/
M9[X" _;[>T.8#V"(5QT0[NWN$/TUW;SY<Q'M[1[.P1YB'D$.8T&G^D'6"GG&
MP4:#L9NRO#<@'9GA\2]-D^M34UH1*A%E4LU-B6JOQ^^\4.,)CM&4V#K])!'6
M2;W6LJS17UF"<;JSHDIK9NYNFU1"O"X6!(IDC;99ZLM(.(D"RONM/TI:S%,B
M8:048]#;JM9GC#M9S>-IR3E1V-(LM$)4D9HCC3L!)=1G7@=:;>937 5-F+/N
M@'(0^J[>7;T[Q'L\P]+F'P"'/F//O'GR   <@_"(B/PB/,1^$:#HTA)\CJ2#
MC+Q<Z&>T7*"B5RY%5[LI7?J-<E669P.$[$1%>[!.6'L]]Q>XN?%<OP%K<6:S
M(GFASV7X,)^E+<O]G/77[V:0O_,[4IJ4$6?2EN7^SGKK][-(7_F=JFWBJX)+
M0UJ$\$INMEN]PY4A]Y"JFQV,LL!)PI/6+=MP$LZ,MOR031@_C,@:RY5'&LE<
M&;!FP8+$S#>7R&36QQ6N]QNSGBCU@#M$.FUWYW<OUJPW_/\ ;&@I^ZT_O?B_
MUTZT_O?B_P!=8TZX'VP_@IUP/MA_!09+ZT_O?B_UU;[PJ<$EKETX8(K=;+9[
MAQ6L#(;4GPQEA_I.9)Z3CMSDBZ,B/N/3990R&A*9L2CD631?%@P&,%R9EO,X
MS)6C?K@?;#^"KXN"&;\;6=@QY\_!I[ #MY=G2SKX^3[0?@H+9?2EN7^SGKK]
M[-(7_F=IZ4MR_P!G/77[V:0O_,[4IJ4'18]3Y'34'(7E%T,]W.45$UEQJK(9
M2NPD:U*OLP 3)WHBT]W\<O/8+[3%Q@^"Y9@,VY<-F-/*C@OOS]ZI2@4I2@X$
M0 .8B  '>(CR#XQJ)KVW:U[8>UD+Z5JSOR'=B)T17FZ&FQ48E<?S)+28S06W
MBJ.MX&QRX"Z B*!5!.I3?R#<;.K2T%Q8H1$F35#Y#-<MQ^HRC'Z^QDF3)'A]
M06[4\"\B1*>:Z:_V]X@J$E+)<@G7FTGRV\-RCB)WI2AUBUU,+TL\=QE@*F[\
M!TO#"6]79-<&T/#*D5$7#CW:&IJCL';*SW?BZC6OY?PO[659BAM.,\52$9#2
MW"XUUU&\!IR7(:.A)Y83!H^63290+"F,,L[-;F,+65>8+*/,"99DDF1D60'B
MA1A K'*OQ\%XXB@JAF9+DM7(*+@:Z80:30RNEJI.3$"OG=+H<;F0VNQ&TZW$
M>L3+<&K?%?U63E]M8$$)/?L;*3,U_?[XGUDL+*HPG"S6VFO)^H HRXY5-61E
M] "1"RDF*UUB$U'1<Q&ZIIKIE#TDML^45,O1)E;&XB'LNQ-R(TU@1Y*<2#%&
MT.IZI#>/85HM\X+4<$R1Z_H%GDHX72FHS/P(3GLC+PDM,O%;DD!DHKM3;$##
M)*HTLJ*?@ @<,S;6&8%D_1!ILUFR1&NVT3Z=LR0]D\,B(J0CP6O1%$\>PYL-
MF,QBZ29=W.)&5V_&A=QZ^$6"CG\/IC<]R,^\+")(>1SJ@;-(" AS#SB'P@(@
M(? (" _:IS .\0#X:XM 0#M[Q&X?M -PB =X]H ( /;RY\^796&)+A!(D]73
MUA0?DSM3*G)HIEA*-9A?D=))G&)K*;\:/I345T\D?40NRCA!0,XKS0%;,18,
MG@<5EMH9HYAYP^,*XN$.0]H=P^4/-44?6C-C]F7:S[Z*9/Z35Q=J,V.C<'JR
M[6=MHA_RHIDY]H#_ /W-W^8?)04 <0 [=AV[F3&%W+HJJ'V<P_7-A''R]ODJ
M&_663VWX;:D)OT4PMO:^4F_@/JA_"B^E!,PGUU4.+2V=Q$F8AE[#:NLJ.;.H
M*RD8MQAE.J)[-F-G3-V0P8RWY<EUPPZZP#ZX'QA]-!D'K+)[;\-M.LLGMOPV
MUC[K /K@?&'TTZP#ZX'QA]-!M8<,+,.74EIY+A#G<Z7UW\NWDXC 581S#SA\
M853WP]X01I2U58+@/R!-;6S%55\I5I"-YE?\>(F?%@=ZH8M-FD9JK)!/-*=U
MQF_%E4LV&XYE+XBQ?)ENQ%\-MDU?6C-C]F7:S[Z*9/Z34$K^8></C"N:B?ZT
M9L=O_IEVL[0$/^5%,GE\W_";O\P^2I-(*1B;Z&CH6 ZK*.%&3"*7B4%Y5.KB
MV>QD"V,K8;5UE1RYU!64S%N(,IY2.YLILZ9OR&3&2_+DNN$/UJ4I0*4I0*4I
M0*4I0*4I0*HXXM>8<3UAKD CTFN[/+YEA+]_WZO'JB#C &/ /:$PYB'2:[P\
MWD6$CSB'GH*H_'!\P_&/TT\<'S#\8_374?'Q]L/X/QJ>/C[8?P?C4$AX%-#?
M.$/6\A^JDYD!W^=P$O?K;A#N^&[YQK3XU[.C?/$,6=(?JI28UOD\K@)![:MP
M<.[X;OG&@YI2E I2E I2E I2E I2E I2E K6XX[ID"SUUUYCRZ;7D+_)6&U[
MX>VK9'K63X_QP2KVUJY?\XUY(#Y*NUA\X?Z:"C'K.WS_ #_CTZSM\_S_ (]8
MWZVN_P!A#\:G6UW^PA^-09(ZSM\_S_CUL%<" R!A6V/$!Y] E'0?'E<7OCYJ
MUK>MKO\ 80_&K8QX !H32GLS</\ S96- \GZZ]S#W\Q\W=[]!LHTI2@4I2@4
MI2@4I2@4I2@4I2@5Q=W#]H?FKFN+NX?M#\U!IW\2\^!?=F;L7,>=I]KW?*:"
M+=Y_?J"/6P><?P?34O\ BC'0P[T3GC$>7(XTA[[/*S$0?+VU7_UE;[;\..@R
M#UL'G'\'TTZV#SC^#Z:Q]UE;[;\..G65OMOPXZ#<6X2^7P^E;%R]_2=$A<O@
M=A\/]%6556+P@\OAM'(^R //I.B1O-Y'BI6^3L\E6=4"E*4"E*4"O\QTQD*E
M3)C"5SGLV$OGS82)6\M89.9<6*_)85+7'#!4K;G,7VVX,-QDS@+VY<E@Y\^'
M%T\EO^FL)RA!R1*CLBYWJ+_FEH&HJ<%[A34:,9C?L;-1W9[SJ,>%-D]K--73
MT62T"V]%Q8+$%WE5),M)GE@D& "ZN>LRA!-9XIA9B+TFMV8M,=KH@4(HUL>.
MT#IM<2GJJ[_ ,=N*EK;;2!?AB79>0S:6]99=]BDU8H2G"71D]U*#;=ZA<K$&
M\TU]:(S:U\FQQ3@UE=S.&#I%@VY-<&9#(H\ANV!'H:<&$N6*WF5I'5]>YCFE
MI@GE5',:0S153<*<N%U1-.AF2;"0E3AF&*CII+2I".^1=W(.M<SS7MI,[Q=Q
M9J36DNMT0,OPNTU5O-'7Z$9#M2B".Y"B.G0JSB!=<,)*2M)33E9Y.YX%D%_D
MA/I[GZYIWJ_L/ 3QGN7$.$-88')[)S) 9M5U?C*2'#DC2+8ZCQI&&;*DOIR^
MV89:39<^P<E8#6 UG;B-'#,:BJDLUAIKD?V57+*2QB#^B1Q@(+ @M/U^QI,$
M8P(J1UL=*L%3TYRK"4&CL4RM5,)DY+)V/FLUWRM24A*1Y&)G79%2-(30:IZ5
MF:2,KS;MLOMQI^63^L.X'K@'7(,7OB#I5UIFF-VO'$B+<2S"<CA1<1J,)?O=
MV"/'TE*D8/A]MLX3/*K#>+6<B1<J85MGN]M*2,KDQ+9D=55JDE/A1[-RQK^P
M]*I+58=9<*ZF03LS%>OLL-=XNIWNJ9'+*3)6HR@%UR)&YQA-?U*T^)&(K9C$
MGI";(,A7R&\,W0;65(0\%IRZR[5V(=D%+8.7=K]J&Q%4;/QX0[#6O30B^'I#
M7Y4;:4UHG=4K/YROU4?#BC^-#AE0D-[2J;QH36M;5XM)HM1'RJ2T?77$JIR(
M%A8B !S$0  [Q'L /AKX\)C^N6?*M^FOQ'0A"YVZMMX%A=;PK28;307&PH]4
M.%*\;Q78O'T54\ 9\04BW2\(4-> S>!RA;?X.[ERJ,GK3<GNE=L_NTW?T7H)
M;>$Q_7+/E6_35!/&5,VX7K!@@-HA>UWIR'F'(>BL(O/D//D/:-6@>M-R>Z5V
MS^[3=_1>J8^+ Q?4N5X.0KGQ(3]$XEO]3ZXDMS>FM=+^$/M<OU>541(IXXDO
M%XN&?"4\ /@S)@UD\)=X7E:%7'6 >>WX[?IIU@'GM^.WZ:Z=UB'G#\%.L0\X
M?@H),ZX'0OV!A&SG;]5*[#M[[?*XB/=R'X:W, R6!S ;[ $!N 0&X.8#TA[!
M[:TI=9SH9=BH*Q!=R\)+;"Q\[1Y7!TW"2MYVCY+@$>=H\AY7  \AY<JVIKM3
M[[[\EX;*;8VA?DR7!;;,XVVVA=?==T;;?2P/1MMY\K;>8]$  .8\N=!+7PF/
MZY9\JWZ:^@NMNY]&ZV[EW\A >7V^51']:;D]TKMG]VF[^B]9<BR)KHOZ\Z4E
MRU(?78IXAZJ+U%W]4]7@<#_>3FEIO5X'?&^:A_Z[QD2I3_U?@/JPR[2E*!2E
M*"/NTFPJ-JQ TESTO,:3)'2HT;*DXSC.B1DK3\>ZSC3RA@SX%-0T8MGS8BEO
M@!O55X[X!#;B:!A<73I)))&C6/H%VY+$1=$D[?-Z(:RAL#)K @;.J[31LI9S
MN4JBK<9ITC8V>AYK;4@DX7'FZR+MM'OY)1-75\Q6ZX4\N8&[#_5P:>QV38FU
M2+&ESD0'?M.S7PBNY9=\F2S(B#@7W.VG<C$%)(;#W>KG1&2EDCKM.&C2+':4
MUT\T6MPE;B5^,BFXRD?G9HW(SST-C?A_JCWCK!'!71X-;9(?-S8<2J\,$KLZ
M.8U:$3R''Z9G5B+?N:*(OMQRN=T-UT8;EM5NL:9-'5T8<"QGS!CU2XG\BLR]
M7BB4=/W SMPE%>UO2(HUY3)G:+L;LC$]I#<F$V*NFYC*-=-*M!,8&:$YAMG6
M_.PUL6*#"-YFB,DE%YK&EF;VJ&RF+9=BO!64V0H1C(\42L^X-F6-5!;(.D&3
M*$>F2(JQ!*=J643R#L;"X@K3:>;.<F),1S*LU'.C&%5"0%GK%$3ZY79H/N)+
M;\P[=R>]M9TW<:,W5K.=@]L,]/E!1@# UM?!GBQW);N<"^2*R E*FP.#9J5<
M*D?06HK#$!=-CHH0OE($-Q&'//K3+7Y\P2RY-599<;;<DR[ 3@_-AI;RLC&L
MV,!"=KV)-MNIK,8=[CLPN \UF,Q62SFF37%HHF*3G-I)YS&4-O7*]J$G!,'G
MR_\ D(_-7',/?^(?HKH<C1='LN-_&U9+:*(]6[B4BBQC1U\H!TC8ID;,^,F=
M#"-UG]4%[#1BW%?S^I#-?V=M8,]8OJ)[GN,?X/6?S]!*_F'O_$/T5JU^B(CH
M%'MJ[V\O"-B4.\!_6JS1_&J^7UB^HGN>XQ_@]9_/UK9\?V-(YA99U:;,9,Y"
M9""?2I=6324WB@$"6=4SGV&5SG\N*VZ[IF<I8J4PWY!N$1QE\=O8%H!044=<
M![8/PTZX#VP?AK&/6H><?EC3K4/./RQH,G=<![8/PULN>AW#GC9_:4>?/P>&
M+@[.?9TA=(]WP>3W^=:JO6H><?EC6R)P 8SCF:4[:=MR:SD)[H*>HQ$LE4IP
ME /DBZMA*O8K@/X\5UUO1,XRIPU@LR /.W'GR!^NH-MSF'O_ !#]%.8>_P#$
M/T5%#UB^HGN>XQ_@]9_/T]8OJ)[GN,?X/6?S]!+#GS_^0A\]*Z%',71[$3?R
M-6-&BB,INY5(VKY$= * 2(WJ9ZS!C.'1PA=>'C!BPJ7MRW\_J@PV=@<J[[0*
M4I0*4KY&ZT!Y"/X!$ \W,0#E;S\G,0Y^2@^J5P(@'?Y?, C\/8 ]@>4>X/*-
M<=*WF <^_MY]HAV]W,0[ Y^3F(<_)SH/JE*4"N+NX?M#\U<UQ=W#]H?FH-)'
MBNG;L.^T[XP$0 #3-'LY^5DH0U79UE?[:[XQJ<7%U/VE^(//N+I<NCF8X\NW
M]<Q$&[\//YJK9ZUM]O\ /09$ZRO]M=\8TZRO]M=\8UCOK6WV_P ].M;?;_/0
M;O?!MRCFT-C;)</,;G/)/:/?V/55#_15I=51\%?+X?A^Q?E >?2<\G=O]Z^E
MBW_15KE I2E I2E I2E I2E I2E I2E K72XXQCP#VU][>07-=^^;R+#=\X#
M6Q;6MSQW<X87KKKS$ Z37D+O#GW+#:^F@H_ZP#VWX+?HIU@'MOP6_173/'0]
ML'Q!]-/'0]L'Q!]-!*S5D\&39: +.E^FF./;?)Y7(1\P<ZWC [OAN^<:T2-3
MS87[/Z\6=(!Z4SQT'+EW\W*1]^M[<.[X;OG&@YI2E I2E I2E I2E I2E I2
ME K49]$UF_%7MJ+^E^K;$O=X@'<K,;SC[];<U:>7HHXZ!1[:=<[PM\(UYF^'
MH*K!_&H-9?K<?-9\H/IIUN/FL^4'TUB_KD/KH?@^BG7(?70_!]%!E#K<?-9\
MH/IK:R]#)&_&C&WH_4_4#$(=@@/Z;$\1[>0^]6G[UR'UT/P?16VYZ%N.>-Y-
MR1"[I>#RPX'9Y.E@>@^;R\OP4&W32E*!2E*!2E*#&\MR HQ='Z^^4F,Y'F!0
M0[4^XO'<3$&NI/\ <'CZH23<@())YNUC-O,*;B.7JRAUBZ$L+$LB=R%A-&[,
M!(Q1A/S=?.Q&SI_)!3UV<Q;38')J:]2IA7D=PQ!!/#%C($YB/AXQ;-;59\L'
MXDV FZ<D'$]5):B#"TY4=*TD2$V";N4&5$B2S'Z9V%A +@$+@"X![P$ $!^V
M ]@U%)[:):4R3))J9)"U*UO?$M'5=#7SDFNV%X^<+]-KC9PI1=NK!EVJJ :7
M,ZFA%T-%+HY[(=N,IV!(3,)3)BQD"MN((3;=):3L)N]"&O,G2A(; UY(ZF;8
M3E8<BJ<7I"F9RSC&<G09'V$^L.Z-74UEY3,:_LUZ.5WE&OD6+T9.<*]A<KC2
M#9EL)EY&G1CS;.\OZFSGN?)\XRZG;2ZJZ^\,I7UK+(TCO]JM1;4)8BB(Y!,.
MYS0BTW,BLB1#.ZDFO5RQJ[\,CMAU6&$LEA:;;ZFSM[);AV=)'TIU#EYL8&7)
MVLL%/EIEI"=DLX6\Y(N9ZDDV28_EA07Y ?0$\R3X(71("PKJY]^J]P7&GKF5
MU7TTWJV-2.V9_P!UV:I:T/J4(YFMXP+$CFEN(RI(E&<CK3 ;2@\6.32LILPB
ME6XNYT^XZFEV^;/J!YN8<60<;;/GSQ]!M33IPR8RAG^P>8#V\_JKPY_:ON#E
M\'+E\%87DR0Y/9ZNGD&/ 3NEE.-)HFSBVWGO%;7*IAT#67""5G)OQWMY2,&!
M+V6' ,DBN<B&/-;B$QXQ;DQV9JI01.]7#8/W%\F_=<US_.;7%TX;"=&[^LOD
MW]*/9ZKNN?;V#V?\9OE[OGJ65<7=P_:'YJ#08XN2VH'-_)J.JR08;:H>3XT.
MJ+>/&TX^<0CQJ.&WF-)!H\D&SJ4<,)^:^\KF-)IPV0SY,=V0H9SX+K,EU;/6
M?_66_P"W_P 56#\:90N+\2;8?%TPM"WU/!Y" <_JH];UW/M$._G5676UWUVW
M\'TT&1NL_P#K+?\ ;_XJ=9_]9;_M_P#%6.>MKOKMOX/IIUM=]=M_!]-!N\<(
MJ2I1:VA$.$F1K^[Y82S*K)QTPX6\^8H;!(F>ND=QX+TC(1?;Q0%;,9PX<&$U
M>:+$LA"[&;QXL9F_/CSX\5E?JX;!^XODW[KFN?YS:AAP*LWA^&]$&41"X;G/
M*_,0_:R*OV_, 5<!01.]7#83M_K+Y-[A[/5=US[?>_XS?+W?/4FT$\HJ:&CJ
M*NBFFVJGTL@<4F\=.)J@<0SQDMCS&T@T?1S1U).F4[/?>4S&DPX:3S&3%=E)
MF<V"ZS)=^M2@4I2@4K@;K;0YW"%H><1  ^,:B9@W<UU.;=*FD*<]K%.?VU#;
MDG5[H!(L-R1'[$;JQ'B/;>]%XQE+DTE:7O5*0U9!1\0'<^=!*J:NHWI96U-%
M3"6E*JV:_%OUO<#><;U5&1L$Q(_QZ_R-M'$C]?468T=M[*09%QM *NE[P2!-
MS*BVKY/!O)B*:(TW\C1T]7&@OEL.!%;IQ%.&CQ&9FO\ /0SVVUQQ70W/,+BB
M+X(/44^QR,;N)6$4XBH=;HB8*TM@H(72.]7=9 8Q6]9E#Q3P7]3CDN#/M*K)
M;?%FU26C#P5%SU4(]BU"8T^R4R9V?K S)<03@QM7<^;#/#AAE<2U5;<+D+L2
MPL94"Y)=:K657Z@%3;JC(B\VN4,J^+/VLNXK'V:47LUB<?3)#,DQ^CL)V.2*
M)Z9)1BO_  ,*5":V<C:0"I!*<+K13S7> MAT)Q<2R]>NMYPMEP-1Z(;9<Z2<
M2,82XI01 .T1Y!YQKYZ=GMK?E!]-!]5K/\?0QX!ZZV]O+I->1_UW1[E=K^^'
M/\(^]RK9>Z=GMK?E!]-:PWH@LP&%ZZRCTNR]L27R$!#D/15VK\W.@H.ZP_;_
M .7_ /RIUA^W_P O_P#E73/'P]L/QA]%/'P]L/QA]%!+S40[X3:K6^SI?IYN
MC>W]/S[W,1#NZ7;6_$'=\-WSC7GY:<G0OVTUHLZ0CTISC0.7,/*YR->@6%UH
M<^=UO?=Y0\X^_0?=*^>G9[:WY0?37(" ]P@/VA ?FH.:4I0*4I0*XYARY\PY
M<N?/GV<N_GS[N7+RU7ALKL4\GMKIN86U<<[KAZ9H 8#W.W/^;=5)MP,K"H(3
M:=RGG,QQ<^KH7;,KYLN)LG<2*\&*\7DTFRI&$-Q+B0Z4<R40%W^$927-[NX3
ML<2XS3YYV;)NWA[LJ0&BI*ZBVBJBYYS<NN"2NMXXJ*SI/MIHX#RU(2B2,&SB
M\I(:&)DSDR'C)$D.6[&%BO3L$!$+[>0=X](.0?;'GR#X:Y 0$ $! 0'M 0'F
M AYP$.^M8LA,NUK-6&3HO)\L[E1C/\YSQJ B2!),G29K1*:RT]<I49&QC@7'
M' 3]AN+F:@L%YOQ]:W/&%G*1=K9<3@9:PK)KICM354_*D.7';;P\'_(SC:FR
M,82._EB6,^LNW4O:],^473>G&7H]X^;:*P7NT\KY4D9&;R2MO%G%)#S1HX%\
MFD%\ZZ=9(JJWD-N,TL'#(6$4K'TE/X8X;V-P6LM_OP<BF43>I(W;0NIP6>-V
M&+_'\B8!Y/Z*:6\7Z)LUX<? WYB]O@[O"<[<#^NRR>YJVS^XM=_2B@ES6F)Z
M*X.@3>^EG,0_1&O-W8-P6\^@JQWW<Q#G^FK:"]=ED]S5MG]Q:[^E%:A'HIB3
MKW\L:3+OI)D1@#B2Y^3!1Y);'I573'BQV+<_6!9-$\H>$3,WC88<!OPX>$,%
MS./P=O@N=P:QO75G[7]\#\:G75G[7]\#\:L/]<Y/;7?)M^BG7.3VUWR;?HH,
MP==6?M?WP/QJW#_0HIP#?KUA#E]08A,.RX+OTQ5\#Y!'EW=E:2'7.3VUWR;?
MHK;]]"SR=>P6[NTO>DB1'^.9PP*E CQJV/36NEO&$B1C76!I. \G^"2\7B?@
M,QOP]W@S1DIB\'=X;I6AO"TJ(WKLLGN:ML_N+7?THIZ[+)[FK;/[BUW]**"7
M-*Q]&K^&1V]D<%S+?[#'&IFTWJ22&T+5<%_BEA>_Q_&F">4.DFF?&.B4->'#
MPU^$Q;X.WP?.[(- I2E I2E I2E I2E KB[N'[0_-7-<7=P_:'YJ#SQ>."=M
MP\3?8S&-UH"%D:]@B'/MCAN#_IJISK*SVUOQA5E?';4KB_%(V2P\A$+<$7B'
M;R_31HVQ'R#50_7 ^U'Y0_BT&3>LK/;6_&% 4K!$ Z5O:/+O"L9=<#[4?E#^
M+7-JP/,/J1[P_7#Y_P"]H/18X"64,W#-AC( @(7.>6^[N[)*<5O^BKDJI9]#
M]9O&.%Y"&7ERZ3GF#W^Z4','O>:KIJ!2E*!2E*##<YQ,L3,RK&@AS5,<#';%
MI/5Q?$'*C'2'IDPD<)S%D0[S<@,&2$$451$W9F4,5K>M/WYB1,2R@5LLSV&(
MP/;7^3\W$!AK99'34QT,"-]$]GH*506'"0(+RY(\C2YK&]V:0SE/$!PB074F
M)W2"VOXRMA%,.7E;+R%UAS'BLL#I0:X+2U9W(EQDS>?VZTE;<NSG($ *[%P9
M)!V^;+>UX1&D;>+!<SHU+UZ8D$HJ8Y(&C=[DF[CP8I24!<\AO)<8C",3B[UY
M!)IZ4W9:Z30EL#KZY)\?#7U82X,B*>IQ@O T-2 G9J&<<(-5);)EMSUL3?Z3
MA>D7I+G?)TRD*N2'HO7LY=QX60F.10<24\G6O%R=Q-*#6+6N&=M_-.N$7Z2/
M%D,V,FGIGK[M3&,73UGE$@XTK8AZR''KAB37]2)H+>P')*8C5+M)6N<D_P"-
M[%4U3M<N3$V6D4D1%N..*VU35F/]@7OLW,>X&PD.D==U1TP1!FN+.B3'([1E
M)=RE(N>,P2:]Y!6W2Q\69N6H2^[9>M;L=)=JG<X/2RU#+D=:&U%=T V4NR"E
M!^$YT7.XF^LH19?76L85DTVGX7&V<R>7<")D,XAQV*:-F5DU83,2B4$?"E;S
MR6H%;<MH#F*9[.=@QM];&ZO==;6_PCAS\R-2OI010];&ZO==;6_PCAS\R-:Z
M_'<9RA&ZSK*BJ4CR#)F<TERNHVKTCG6T=72V+(?8^"U++9FLUFBG@F8+L%YG
M!9F3<QNTP:,C><R8APXL.VO6J;Z(]S#B>VJO*X+>DV)4[_+R5F;]-!KM]8?]
M9=\JG6'_ %EWRJZ1XV/UP/PT\;'ZX'X:"9^EYWPNWFL./PEX#DG>,[ &V[M
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M:(=H>3L[.5; ]8V:6SI;/*NW"VXXVS2W'&V=+9+9\N")_K%]0QYAZWN,>T!
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M^J!UOUQXWFY=7^E+^H>K?$? <_&OZK\:\+R_0>A09QKB[N'[0_-41/Z^O_\
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M1L;\B4$BNLT[^[B?^-E_YVO/C]'"YL6=Y\.G)ARX\M@M?9<.GBOLR6\P5X;
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M%(@*JG);V>[=;"@>3 ,Y28J!0FL*!3.8) ;PY2PF<5EV'P^+)BZ?3LNM#+0
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M_N7!4Y;5SA(Q+7F4=B$J$8:8L?F93C3&DZSQO(25(N=#?%KHCV/5N9'.ZL+
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MT=]D6E,I2^V'//IE6*[LRUJLZ9Q@MB:ON+86(GD4G-,6WLW#6*<7$M(+V9[
MEI#UE9;MR-C.E/B66@3,(*G=(-J4:4V$2;-V*X7HV]OU-O:'(>P.T/,/9W5S
MT0\P=X#YQ$0[A$1[1$/(/DH-0-V:M['31IO!6ES$@&9FO.^G6JF_C#G1U.I@
M+;#8<BNJ1XV=,:)#"CF37$22(QFK'N$Z%.R1+U5BK+G2$%&PV*DCF62Y#),C
M5UNI!U4FO<_8':AK1/,$.0RKZP:MP E)\T16\H.=#TDJ-GOL#(;NN+1D^D]
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MU5Q)KD::J75TDYF355WG4H_CQ&2UMWBJD4,D\P\O"X<@6@%;%@!R^,1^,>=
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M1P\@;MB?,\B1BWDAO'S[X1C;P5FHV4@Z4"?;0V\U<?[_ )0BME;"0XYY&A;
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MEV*G$SB1FSK-F9VXGP=-1+'*N71%%TF63@0E]'M$VW2#>F>P<[FM5BWC;13
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>V%_G\_2E!M*8N^W_ -QB^>ZO[TI0*4I0*4I0?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g291910.jpg
<TEXT>
begin 644 g291910.jpg
M_]C_X  02D9)1@ ! 0$!FP&;  #__@ _1$E32S$P.3I;,3A:0E4Q+C$X6D)5
M-#0V,#$N3U544%5473$T.30V7S%?3$504E\P,5\T0U],24Y%+D504__; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
M !$( 7X"K ,!(@ "$0$#$0'_Q  >   " 04! 0$             !@@! P0'
M"04* O_$ &X0   & 0$"!P41"P8*!@D!"0$" P0%!@< "!$2$S9U=K2U"10A
M,705%C,T-3=14U:!DY:QLK/2U!<8&2(R06%RE=/6(U57<7.1)"4X.494>+?$
MT29$=Y?5\"="0T5'4F>AP6)FABAD986DIL;_Q  = 0$  @(# 0$
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MZP_J,):*6Q-4(6&JR,S7XR(-9K2^=X\B+?&8X"\2,C;9*A'M*[I^M.T
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M4C"<E@V;JV'J]4VZ3563V>*Y:*WC5"4O![45:PQ48TLS@A'=XIEUR)#Q/?\
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MD$I6VM! 4A0&,5>[,E#KBKO;$ML(;<>6J?%"&4.LM2&ENJ+H2VAQB0P^VI9
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MA!/CJSR  T!R#+;I\?'R;=^S.2W$+^T+_ J_4T<0O[0O\"K]36B_O-<.CO\
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M%_:%_@5?J:.(7]H7^!5^IJ--CV2,3Q2$8=J[R8!GD_"QJPGRSD X=[/WI4'
M% TX(%.*8CP#@'"*/A 0$/"Q?>:X=#_K>3_&'_Q<R#^<=W\^Z9.YD:",QO\
M"'CW?=_78T6_35EQ=X.;/S^+/GX^;/>G$+^T+_ J_4T<0O[0O\"K]349*ALE
MXHFX<7SUYDP5PDYAIO3RS?TR\2QDW+1#\4DX <($D2\(V[>8V\PB(CJDWLF8
MHCYBJ,6[S)@(3$H\:/.'EF_G,**$8X=DXLPSF],W&I%WB02B)=X".X=P/"Y
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M_M"_P*OU-1ZA]C[$3Z)BWJSO)W'/(UBZ6X.6\@E+QKAJDJIP2A.;BEX9S;@
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M&V-</ 4P]]Y/\!1$/_2YD'Q@ [O_ '[[.@#IS 0C-)R/A#R!7H<AIDWZ:O\
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M**3Q5=)F8J@M"(\:;7<C-%W,N'5ML-ZQ2D#6*(S0R $$MC,J="B2L9)!V$Y
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MG.75%\FM746>F&R<G9_F65ZBOI>G.75%\FM746>F&R<G9_F65ZBOJ!][UO\
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MB6]<&J<Q6;YT7JH\FC^7\2:MQ^K_ ,E/9_R#?JF^0=)^/N1M?YO)],MIP/\
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MJR_+2H\VVGZ.*U4>31_+^)-3YRO6[#3D?\@WZIOD'21C7D1 ?V#KK[O3N?\
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MGX=O#:?$/"'W%MG+KF2]=^(I2$25))2I,49'C![HC#C]FV@.6>6\#YBIL-4
M:-F[8%5UP;H)( LY4%9RL"*94P476-N,JNH!>&JH.X5%#&./A'4::E"6='.&
MT-D^<JLRL5A!4BBXS*J1J0\W6("O/+5.$KRHN#$*2;NTRX9K"Y*W SJ,9BL
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M5LDQOFTG'/V+-^ 244WIZKEDNBD\;@\3,/!;+'XL5A 2&/TFVD  :/FD!#A
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M:)<XGBH--A+0E.@*@D^7L+2;;MG22BJ1463QXZ9@,Z8[)5CRKF?*VS=>L(R
MXD9U!5J-TD"2P1ED:N6<2D)5%CLVT6+6="0>!#&AI5649JQ"ZRP$5(<[)RKN
MSUA2)[ZQBAC:KO:+!LH"?C:_., L+9&<6DYY=>946G#R#MQ*.#F,19\X<*KJ
MH"#50YFI01UN%O?M=@ANPKY;ES7[O_#7R8[D!TLV=Z')>2N++"WU1;@MYYA:
MFG&BD(:3K AU#:AYM>8U_P 87*)=,)WMJUQ,.&]0@F:S=XXE8EC7&#'4W/MY
M;BMS[.U%C3&D/LOI4IR0M+:GH[KR#N*VOFDGC^=D6*Y'+)_67+UFX3 W 7:N
MF'?#=8G" I@*JBH10H&*4W!,&\ '> ,L1ZEQOD#+JJ.HA;1N$<A72\43)%8R
MO)U"GX[B'A[%168RQ&EA30=*/5@208R36*6/+1YO,)Z279.DD&"::C8IC<8D
M.3'[4R4=G2>PA-8\L,17J;CXUQD<GN%5309(Z+K#&?>R"S(L:)4H$457$<TE
M4Y-PX<2[-5GYG)B)S)8)%G7*2ERV/HGN(MKUQGQD LNVYIF46-6M3^J1+<4E
M;+@3#UBCK-$-YI.>V.8G;MS[C-_BN6=ER]1+):)SBDR(]ZD2X"98?:1$,ERW
M,(<1*86NXEEM!CE:W@%I%2(JW*6_\^QO83+4?]KO9?Q7M$TI(;K%JM+1!J-6
M57N\,9-M8X!.7EF+=VW(H<IFTK$K&."[B%E4UV*BI./0[T>"5V5CP1FVC98L
M=_)6O/&P>&)5[:VC+769:JR3^J6")!O!V:-:2Z""K^"E5&+@&DB@44E-Q!$"
ME52,?<]_Y,.><8#MZ-UKE_P]'G0IMAQ):D/QY#13+MUQCYI6A63S2E-N *2H
M>#>8>1HN-J"'F5I6E*QNN$,8S+9.MN+,%8@=B38;RG+=>K+, 6VZV5QI"$/,
MJ*%H.3L:5'<"VGFR['D-K:6M"OE<VGMA7-&S0N]E96."[XS!90C3(E;9KJQR
M#<Q^"BG<(<>^'E3=& 2$45=G>0"JQ@3:3:R@\03=>S'MY2FS78*A6Y.Z3^8\
M.SE:K*UT:3-??1ULQE/*HN$9.&I;^0DWSBSQ%3_D.+076",GH]0R, E#NT2)
MK_3(NW0=MUVKI%)PW<I+-W""R9%45T%BF351624*9-5%4AC$424*9-0AA*<I
MBB(#\X6WKL*J8_FKWE["L( 8WAWC1[=J?'D.8]%&49D?N)^$;E >%2Q7.H:0
M8I?CU4RG'-TAKQ3C%?(.-N"B^\%#S^.^"N7,,:.M#UPMCCDB1+MT)E1?>#:4
M/H:O%G6D%$V+<(TJ5$82F2V\LH=E1_T6X,N'["G#\Q#X*N'N!;TS9K;L6S7U
MEJ%$@7FYR6T1XVO4Y#=D8<Q&A>3MLGV:; @SY*UP'XS:7&(4SO98[/7[GBY&
MUU6783]=GT*]*PTS&+E<L9&/=RT<JW<MEB#N,0Y1W&*8"J)*%.BL1-9-0A=L
M:^4/9 VR;%@59;'5J>N9/"MHDV;B48'XYTXHTB,BV=K6JMHD!106JQD>%8X%
M$O%2*8GE&)$I=)7S1^J:"G8:SPT98:]*,9J#FF+:3B9:,<I/(^1CWB15VKUF
MZ0,=)=NX2.51)5,PE, [O 8! /?."_A,M'"59S.BZ,.[PVV&KS:%+"G(CYUF
M3S!.2GH$@YJC/Y9@A3+H2\VH'Y+X<N!#$7 IB8VRX:RXX=N*WWL-XB0T4,7*
M*@ITHTD)S1%NL,*0F;$*B.^;D,*<C/-KKP:9_I7TTG?^%U9O?H%7Z;5OK*FK
MU,_TKZ:3O_"ZLWOT"K]-JWUE37I?W?UZ5>(IWCI';3UI%I/H]UZ;2W5H_3UI
M%I/H]UZ;2W5H_5CXR?6[*#<KH^8J]=O2L%TNK':9-.8^+WR_*&DR[>E8+I=6
M.TR:<Q\7OE^4-!XRO5[*<0Z3V)I$QQR;-SY8^W'^J6GE+0.?9+L)[JN..39N
M?+'VX_U2T\I:!S[)=A/=5'DT?R_B35_O/KT:?=)E$]1G?2.T=OR&G/291/49
MWTCM';\AJQ\=/55VHKCK&N/JK0NEA.R9/3FZ])N/)EOHC:3+CZJT+I83LF3T
MYNO2;CR9;Z(VB=Z^L/@34\0Z3V)I3QUR(K7-2'SE-5E^6E1YMM/T<5JF.N1%
M:YJ0^<IJLORTJ/-MI^CBM5'DT?R_B34^<KUNPTY'_(-^J;Y!TD8UY$0']@ZZ
M^[T[G_(-^J;Y!TD8UY$0']@ZZ^[U)\HGJ.?$W5:_,YRZHODUJZBSTPV3D[/\
MRRO45]+TYRZHODUJZBSTPV3D[/\ ,LKU%?4#[WK?])%2G>.D=M%;Y.P',L5U
M%#2^IZY3;H2Z[<;:8*WR=@.98KJ*&E]3URFW0EUVXVU'F-]+?RJ*8K#Z@3G,
M\GU)?6+4.2E:YAB>H(:RK#Z@3G,\GU)?6+4.2E:YAB>H(:M]X.H?B32O-5]<
M%CT1E.V8W5,B\B++S4O\Y/55?7!8]$93MF-U3(O(BR\U+_.3U!\5W\_Z::MY
MR?5[!3:T]*-?)T?HRZ2HGUP;7S%6?G2FG5IZ4:^3H_1ETE1/K@VOF*L_.E-#
MN;ZR?A-0-RNCYBO2O7(VS\R2/5CZ8VGI1KY.C]&72Y>N1MGYDD>K'TQM/2C7
MR='Z,NI^\/4'Q*IQ#I/8FDIIZY$WT4A.TY+5<C\FR\^5SMQAJC3UR)OHI"=I
MR6JY'Y-EY\KG;C#5#Y-SK+^*I\Y/J]@I[#Q>^;Y1TF5_E/>><H7L!IIS#Q>^
M;Y1TF5_E/>><H7L!IKD5O1UC\"J@;E='S%6,E<CI+RF'[:C]/>D3)7(Z2\IA
M^VH_3WJ!Y174;^)RG$.D]B:1*YRQR#Y36^Q2ZK>_0*OTVK?65-4KG+'(/E-;
M[%+JM[] J_3:M]94U4>35UW/ZJJGSD^KV"GK2+2?1[KTVENK1^GK2+2?1[KT
MVENK1^KGQD^MV5 W*Z/F*+WZ!5^FU;ZRIIY-XA_J'Y-(U[] J_3:M]94T\F\
M0_U#\F@\97J]E.(=)[$TFU'TW<^E[WLR)UBVGE+0.?9+L)[K*J/INY]+WO9D
M3K%M/*6@<^R783W5?,3UD_U!5D^..@?#3X/B]\ORAI$QQR;-SY8^W'^GL?%[
MY?E#2)CCDV;GRQ]N/]6/CIZJNU%0/%5ZO;639_5FC=(W'8$QISTF6?U9HW2-
MQV!,:<]$[U]8? FJTA8]]2Y;I7:>UEM$MZX-4YBLWSHO1CWU+ENE=I[66T2W
MK@U3F*S?.B]5'DT?R_B35N/U?^2GL_Y!OU3?(.D_'W(VO\WD^F6TX'_(-^J;
MY!TGX^Y&U_F\GTRVK'QT]57:BHXCTCL56-.<NJ+Y-:NHL]/)_P @WZIOD'2-
M.<NJ+Y-:NHL]/)_R#?JF^0=0GQG.N/Z;=121C7D1 ?V#KK[O5%/7*;="77;C
M;5<:\B(#^P==?=ZHIZY3;H2Z[<;:H/),_P KY4IBL/J!.<SR?4E]8M0Y*5KF
M&)Z@AK*L/J!.<SR?4E]8M0Y*5KF&)Z@AJ_W@ZA^)-*U5EFIO+ZE?:-'.6S-_
M<L(7.KL7;T%19M7<Z8\:V<.P0*HMWLDJY*=?B4U%>+ PID.8 */.[+UVSWLG
MT.NI6W"NS/98*S1<70)FRP439I%W,*UZ':)1C2]N7[*)"0<2K2/5=,0<%>ME
M5V#H@$0.F@0_4Y3URFW0EUVXVU'K;(MF*$\:/\9Y(:62:7R!$33V(B*97)*S
M6-DVII&LU*6U)*+:NU8AE6@[W7<3*Y2(MQ6X!N,2,X*7;<)7(M3F+=(M8O%N
M?GZ^3";;?5+*$LIU[L94=UEPK9::3(T%*+9,=.D4#24/..$2R"1:;A>X=^.&
M[U$MIB0+F^]%1;@ZY(!BQIR9C$AH-RGWE0BXA(=2F8K1#J@ALZ0Q!<=JS-U.
M4RU6<6;,-4"],G\,$U.$O,9<)V%8B>,2>K/HQC)+.8DZR2Q8DKU\<%"- <$;
MD;G;J*8NQW0)3%>T3E''$T[8OY>D[,FR[7I)Y&"N,>X>LWN43K*,C.DD'!VP
M"L!$U%T45% ()S(I<("!T)Q^M5W%%IJ])[R\YRU6@%:MYG%XM@%?4BVIH@&B
M8@!DVX,10!,ARE4( <%0H' P:B?C,?\ ^/#:@_1A;9Q_,(^-YDO=\@ZK<;P9
MB;K$8M\>V0M:E]N*VAW7MB,^(\1F0Z^ZXXI49A]QL@: *U*.B,D@9;"^&1;&
MX5REWF;?;K_"#%=N#[L?N1XSW(,RX28D>*PRTA$Z7#8?2I1=6&TI&L45+4N;
M^C<'L!H$=P"/L!OU'.J[0GGRRM8<;06,+\[B*K:)FH3F2B^=KSEL)J#B4Y)V
M@L4)WSP< 7"R$4FJ2'.GYHK$3.8A 4,G@8\.3*1)<8;"D1&3(D+4XTTEMH$)
MSS=6@+45$!#2-)U9V(0H@UL,ZZ0;<Y!9EO%MVY2DPX3:67WUO2%)*]'18:=+
M;:$I*W'W=!AE(TG7$#(U(O<'@\ >#P!X/$'L!JNHPV[:BK-1RXTQ>XJUH?L4
M)FDU>V7UF$66L4VUY)(X4HT%*IN7J,HY6F2H)&7=1[5=K&%>LA=GWK&*G)[4
MR8,N&B,Y)94TB6RF1'42DZQI82I*LDJ44%2%MN!#@0YJG6G='5NMJ76!=[;<
MW9S$&4B0[;92X<U"4N)+,AM2D+2"M"0ZA+K;S!=9+C(D,2(^LUT=YMLT:-&N
MI62HT#O_ ##N\(?W;_"'OAX/T>/1HTI7/G/>$LV2FS)M*UZQ797:!N]J@;"3
M%C!CCRM5*:J\=*B@DI4HE:.<B,JH[0(DFXD';AJLZ2:@1<#%'<&GML+$%CNS
MV,C(C9IF[GD2=P_2JGB?.E?G'*RF++]$6M"173M<>[DH^,H,?7DEEK"VO$:F
M^D)DJCRNJ&$A2-QZSB #X!#>'L#HW![ :T&[\'EJNS$Z.J7.;1/@0+<\J2IF
M\OAJ#*N\D/)E7UJY23,4+S(;9EJ>4_"#$/N1;2&-6OU?#_"[?K!+M4QN!:G7
MK1=KK>(Z(;<C#D5<BZ0<.PE1W(.%Y%EA?PY/^S4-V3;T1D1;D95Q_B#<AR5K
MF\2/2=(,6:+UP#IXDU;ING12 F#ERFBF1PX!,-P$!=8IU0(  !0. ;@W:A@]
M_P XG _[&MD_WTP>IM:A*]_SB<#_ +&MD_WTP>O1H@T0\D9D)BN@$DDG)(&T
MG:3RD[2=IKRHDJ*U'+-69.0"1F5 G(   <@   V 95,*P^H$YS/)]27UX\)&
M1TS0XB(F&+24BI2K,(^2C7[=)VQ?L7D6DW=-';5<IT7#9PBH=)9%4ADU$S&*
M8H@(AKV+#Z@3G,\GU)?7GUGOCSF0'>G$]]>=N-[W[XX?$<?YFI<3QW%_RG%<
M;P.-X'X_ X7!_&W:ZH)#R2DE*@G,*!(*2%)(((V@@[01M&^N-:4J0I*TA:%)
M4E2"D*"TD$*24G,*"@2"D["#D=E0_P!E_->%[7,9BB<:5=3'--Q,W9LW[1W$
M1U>A&[1F^LWFE-$08+JIQQ5%HU\[?-Y4K6633 KAXB!A.5+R\^'D]J;$\+:]
MFS/"$)7JM9Y ]J=Q"DXT;SA6C5F'F>Z,U2:20.X<ZZ$BUB7[<(F72?)+.C<4
M1HN&E=GF>S#]WA_BG+E1R'-)Y)QQ9AS<C;*[56U,CK&61F!82]/E:FP;MWE%
MG(!3SN$2F'Z\V\?2"1Q PLU.#.:.Q#C["F(;13\;0):_!*EDIAPW%](R:[F2
M> U25=.7THZ>/%C@V:M6J)3KB1!LV112*4I/#O=Z1#P[<GYL4E=P5W).M><B
M+?K8ZP\Q(8N+TUZ9';=??>E(4_%"HP0&W YF? N5Y'A9VZ8UL$>V7!"6K*V+
ME:[_ *,.X81OL>;%E0IEEBVN+;9;S$2+&@/-Q;AHSM87V51]%.4EH[TCR'(Q
M9E45%90K1L4ZPD*F*IRH$*904R?R:8J& 3B0GXI=_!#P%#2PQY>V#HY7>NSF
MFMIZ4:^3H_1ETJ,>7M@Z.5WKLYK0E'/5D[RL$\6])XAL'Y5Z\D9 @9Y!(&TD
MG81O)))/*223O)SJ_>^1EHYCD>K*:RO,B-GJL:$F&:,A%3-?\R91BX QD'L;
M(QG>CUFN4IBB9%RV7614*!@$2J&W" ^$,6]\C+1S'(]64U[<1ZEQOD#+JJ.K
M))2[I))2I*4E*@2""%$@@C:"#M!&T';4+0AQLH6E*T+"TK0M(4E25 !25)((
M4D@D$$$$'(BN?-?^X'L2VFSS%LNUW6-=):MXYJ065W+7-Q7JC68TDFVA&"B#
M=5XRJM9&=*!W;]5<[9JHR;) L=-4RLX[Z8IJNN8H@8II"OF*8! 0,49V-$!
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M>^9#PR0(L7#,WG;;-DYR="1>1X$BW2)FQS&$3#[L\ZVH VEZTUA6%:-LVC
M-C>K>8_FJ$F,9,&<[C*.O/&$B25+#DCTF308<[%1<STPJ\8=/MM627H)>?>@
MPVI5ODW6*N5-81W2Q%)94RTE"G%B8ZZRXB/&=2VXZ4[,AMK&NXIMX??C1(UV
MN3\.^0;#/;M]KEN]PR9[3+Z)4A;J&&U6R.P^T],GQUOLQT*&D2HA)W7C4?\
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M3BBW/VU,A]YU;Y;4AAGK!LXYHQ9ERG"]QW>("T"22F7;R.8O2DG(M)Y*N'*
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MPQ@BV,7#$MU8M[3FB(S)"WYLQ: DJ;APF$N29"DYI"U(;+36FE3SC:#I5ON
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M>^XYR8!'B%MRL>^(4Z\<]>-RBKK<,'\*.#\;.285IGNQ;PR'52+#=XZK;>6
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MOE8>9FNQ9JV5NP&(DJW_ ,2B7+N^6U'BW5U$UU$>/?(#,-J'.MUUDH^F\&X
MX/)%LL"L02\.W%4VYRFQ=X6+I%L9G6QN2RQ=I5P@W@66X68VJWOS)U@CNVN.
M[+FX8NLFXO7*U7JPPG.T91 P (" @/A 0'> A^80'\X"'A ?S@(#J$SW_.)P
M/^QK9/\ ?3!ZFLBGQ22:>_?P"$)OW;MX$*! '=O'=O N_=O'=OW>'=J%+W_.
M)P/^QK9/]],'KW>+GX;,9'N5W,<AT1F*^9?2Z/F*F%8?4"<YGD^I+ZQ:AR4K
M7,,3U!#658?4"<YGD^I+ZQ:AR4K7,,3U!#74^\'4/Q)J*\2)]<&U\Q5GYTIK
M(R+R(LO-2_SD]8\3ZX-KYBK/SI361D7D19>:E_G)ZKYCG2Y\ZMYR?5[!3:T]
M*-?)T?HRZ5&/+VP='*[UV<TUM/2C7R='Z,NE1CR]L'1RN]=G-2=S?63\)J!N
M5T?,5?O?(RT<QR/5E->W$>I<;Y RZJCKQ+WR,M',<CU937MQ'J7&^0,NJHZG
M[P]0?$JG$.D]B:4ZMREO_/L;V$RUE7_DPYYQ@.WHW6+5N4M_Y]C>PF6LJ_\
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MDOVV;D!DDRHKJD9YMJ0K)0^4#.6Q5M$8",[=72A.Y>J-3F,%YIA5K54A2(8
M(Y>+M6Q)2 #>.\//#%1?!,4PD54* *#[6!]N_:+P$FTCJW<"VVFH'X1:7>RK
M6*$*F8>$<D5)]\)6"$ PB)BECI;O$IQX9H]41$#?7 8A#@8IR@8I@$IBF !
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MB6]<&J<Q6;YT7JH\FC^7\2:MQ^K_ ,E/9_R#?JF^0=)^/N1M?YO)],MIP/\
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M>E&ODZ/T9=*C'E[8.CE=Z[.::VGI1KY.C]&72HQY>V#HY7>NSFI.YOK)^$U
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M+>N#5.8K-\Z+T8]]2Y;I7:>UEM$MZX-4YBLWSHO51Y-'\OXDU;C]7_DI[/\
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M)<<,ER*TVW%$6&\)KZ53H1?CPR^_%1+C.R6VFWVE+W2T<'N+;[!B7*V6V.[
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M%RX\QC>L=66-M57EV=L%I)QJHF*18C!CQ[%\V5*F[C91H8P)OHN00;OV2O\
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M'76BT%%L)"4H*TJYF,+P.Z43;@],O,J)>I]]M3]T>2ZNS/SV#$7$MH8;CI1
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M"?@3('L$+\T-0CQG_EX;4'_8MLY=<R7J;*!N$BD;?O 4TQ 0W" @*91W[P\
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M^,^VV:-&C73K)T:-&C2E&C1HTI1J$KW_ #B<#_L:V3_?3!ZFUJ$KW_.)P/\
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M<L>0_$?:DQ7WHTEAQ+K$AAQ;+[+J#I(<:=;4EQMQ"@%)6A25)(!201G7+#:
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M/"$ W>$-_IFSW@PAC$/F?%!#D,8ARGR-3BF(<AA*<IBC,@)3%, E,40W@8!
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MLB$V4=F2>B6,PTQ&#-N_0*X2:S87N E4"&,8O%OH>8E&4G'K@)1X3=XU06*
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M15+[I+8>-3W><EUX>&7=ZN-_T_H'^[46*?AC8LODB2+JM'C9-9>$+86"X&R
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M!9%0"&,4I0,)0#> %]@NY2R7BO$[JO%.XQSCIVH$[ F [FG59P8IG$PT2<'
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M;(=G@GEF@:-7Y& 8/['&N95&7MH,B.ZG*R$)8 (LI-$*LA'R44_;F=H<:T<
MW,LT67;F35.G5[$VQ=:)6#A(/&3YU*SR<DNFQ/ 999N(AO%JI)+.K4F]%L:I
M-W1G#8T6O9 C"2Z+IJO&F<I+IG-AY'V?."E\@C"R6,]Y8O\ B!.>Q(&B%3U(
M&61W)VE1)VG,;%$^U[]H"+EGCSNI*?-E85PDYRY@J39FW#O.6:\QHI (2"FN
M4%C[DEG2!39*(Y)P_)A(3+.';E!U;H\Y3/CJ$;N5Q4@79"% 2%XY%,53$X8\
M ZH$$3+4GW*#:J8<?WFOBB7!)?BD^\[X\:F<I[Q#CTR2=99E3('Y0IK*E6 !
MW 0P[P#LY;,&;&M(E&<39Z"QC5W<>ZE>^C!D)S$L6C1O(.2#*331ZXB8EU(D
MBI-.$92#QL]G7+!VTB&[QTD*(^G![.FR5/U56YM<9I,H-LA*.'IIY+(=<DXT
MD,9P63+)P<Z^CYJ/5:]ZK',DZ8)**(@1= JJ*R*BF(?^S1P:.Z0:B7:*3NU%
M\?7HG(9G_>HTG/?GD<QF!LR)%;'$^VUPY1RDOW##EP ()$K#$1L+VI.2NX)$
M'9D"!H:*LCGGGM'!%3N;6U^*DF1A0J_,#%/C1[@8S(U/WJN2)(*G*V))2$8H
MH5--PF)SK%;^(X%*82!PDR<V"MKR!<(M)#"<^NLY.8C4D;.4N9*[5*@+DZ34
M6-E7X]8B(&.H0A0$O!.4.$8HAKOA$XMV+9J6J\(RQ;,%?7%](1<0#VJYACFZ
M<S%-Y=[(PDVZ?D;-Z[-,V$%(2+B+G5(]XE'E:O3) W?L5''K6_"6Q=190L5:
MJ"PBE_,5[/K/%"9"7B&<>Q92\@)7TXU>+Q#&1?,J_.KQ$0Y>I2DP2'D C&;H
M[<2CAW_LL8#<!U%UQ.PKBRN5L=0"<SXJ[%I9[4C:O<D;,U9C8XGV\N%MDI$B
MPX"E)&1.=GOS#AR"!XS6*0@9Z*CGJMA5LV )'SGN=CK:BAG22[_9NR,[!H=N
M_51&FC-,7"3=8JYD'7F4NZ!PBN5$R+IHDL#I1 YR% AE$SZ\ZRX%SK=+%.VF
M.V8;A6VDW*O'J=>I.)K2SJ<&8QP35BH%DNUD5F4>T5(<J;-1ZX,W.91/AE*!
M4R?2K&[/>Q_)TI7(+/';$M8;-)9XZ<+FOK.29&@73R/F6#N"<2"4ZVFHN2CG
ML6]A5(XLLC*M58X68O"@B/DUO#>QG:I./AH;'Y#2$BFN!&[QODJ)%G)MDY!=
MW6I<TD[9IPUO:-HJ3>NZG*&:6!!DP=/%8\K9+C1QJ_LJ8>U:F&<4WEN.XZV^
MI#K%L>6IQI#B&U!Y,-A82$O.@H T%E25$:2$D9EK[?&->Z$3). \+.RVF'8K
M;L>9?HS26'W([KZ%1UW&4VI2W(K"@ZHEQM*"A"@EQP'YMD]DK:043:*%V><H
M%+(*&19 K0GS=1TH0BBATDD7""*PJ%(BJH*9TRFX"9C@ EW".>&QWM0>  V<
M<K>P'_05S]77TEVW FQK2GS6-LU)@V$F]@YZQLV(R%T=O'416CQ3>6=(HM)9
MPH<R3J<B(]JAN[YD9&1:1T<DZ>*@B'LPFS)LF6"O)6F.QW#!"*)/E57;Z2ML
M8+$8MPZ:2R$FWD9EJXC'40\8O6<JU?)(+QSIFZ0=$2404 M1]D["^P'$M]*@
M!GDFVIS.0S(28"B 3F0"3D" 2=I/(K_\@./R24X)PB$YG1TW+XL@9@@%0NB
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M+.[).HNF<D5\S9LDH\8Q<73E?<FC4$ [ZD$C=7YX(<'@CN$-P%$!#> ANW"
MA^<!#P"'B]G>&EJGUL*G"$ABN^_2IR,\_*N" -@ LU8)6<! $@56  :!)@T
MP'W*@@"O 3XSBB,^C4_7U[*BM16*@VB=RM2KJ:RPRE.J$>\!M3)"!E5W*-DD
M491D]MC"796>/C1EO,EVVA8WS9KTP2$CU+",<*;JQ+.&FQ; SEG\)*,H&7+
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M!@72DA:[C(W>=3C"+&E>](I>3E7D>FP>GDN,A#C'R"KSCG"BFX-&F0VG+?\
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M&L_<IU2=/+GL963!@W*281;QL1'35GG4" TDK!,Q[-XY>6ET,@A5F58K2JZ
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MY(V9:9CJVZ=24@D7<'X,G;M>VJJY'GV5QD+UBFN]PD9XM?--I)XP;1$OLZ6
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E.0.9/,>GC%04* S(R'2.;GYQ6]=&C1J]5HT:-&E*-&C1I2O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g395251.jpg
<TEXT>
begin 644 g395251.jpg
M_]C_X  02D9)1@ ! 0$!F@&:  #__@ _1$E32S$P.3I;,3A:0E4Q+C$X6D)5
M-#0V,#$N3U544%5473$T.30V7S%?04Q35%)/35\T0U],24Y%+D504__; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
M !$( ? "C ,!(@ "$0$#$0'_Q  ?  $  00# 0$!            !08'" D#
M! H" 0O_Q !U$   !@(! 0$("@D-"0L%#0D! @,$!08 !P@1$@D3%!4A,76U
M%A<T-395=K&SM#(S05%Q=)>RU1@B)#=687)W@9&5MM(*(SA3<Y.4EM0E0E)E
MH:31T];C\!DF*$5B*3E#6&AY@H6FN,'$X41&5'B2I;G%\?_$ !P! 0 !!0$!
M               ' 0,$!08""/_$ $<1  (" @(! P$$!@<"# <!  (# 00
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M%J/2MV)W1XT93P,[@6K7P@R K"V0$_>B,9! (E$#%$2F >H" B @(?= 0Z"
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M<$IVQ4:Q:&<G'F;A;*S,.X5VO$NVR35C-CGL^7_<C8/\[#?I/'L^7_<C8/\
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M>Y-A4W)$GSEDS90,S992-*]%_P"DUJ8Q[-83G$3'4:PBAS"  )CJ$?'.80
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M/E'J/E'RCY<NL>Q5]&)\?*3<0G" '7QPI)L21?3OXMA$9$S@&?D<%,@(]_\
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M<++\4;?0DR%L?G@OE'%?.YR:8>X67XHV^A)D+8_/!?*.*^=SG?9%&5(7S!^
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MDX;,D 3(B"1,O\  !Y #H'W@QE-C?;L[K[SQ &/(9D%1,+ %@*EK#RDBF 6
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M(?WIC/1['ZHCG._]PO?Q1S]"?."']Z8ST>Q^J(XQG5G?L(OTY%?6 R;+Y@_
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M7#9/Q7'3(MG+CP7T>"'7R?\ C_Q^_E.PJ"/:G4^])]A6;>]\(!"@10#-F93
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M -F?&'=!^0>B==;=7AB5][;HAPK)Q"2RCALSEHF3?0<J5BNL4JJD>L_C5W+
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M$P$%A/,9!N4O4>J)43^0#@&7]'S?RE^<,U6]R%DC.^,EDCS?^I]PVQNGT 0
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M=$Q!\W8[V("/D .N:8:W/K<0]FTT&HDOO#03K;&R\(GJ86^XVU6\SB/AA(2
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M^3V"<W7I]D-_L0#TZ>< Z '4W0W4!\@!TS7-JU]A_2,5-Q0VHU'ID%_6B_\
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M49!Z[8-UW3VK2#EV#E]77:QSN(9VX#OR\<HW44$QS"89$_=.^U*MG?ZC+F(
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M@*RJB8]]8]]#O380*'>'/A*G?U.VEWE+L=L^5^E>@_\ G_R\O^2W?P@O'O\
MY/\ O^/_ %_#,V.?\1F>OM:>_*!Z^@V<?>(/.(^:7_1^9_*/PGJ?C-I#GW_B
M/1LW]/"Y-9J$5[J6913QO^HTY9 >-;S[<B?L##P8_978=D[AYT 6O>?!BED
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M\A02Z"[=2NXW:_84MA"J%#5V[;P%X)NI0.S)59$V:+;%>S<!R;2:C'DAGN=
M=>4BI56M!-GKE:K]?,ZF'J+HT'"QD09RDU<* U3<#'-6PKD; JJ"!51."0**
M=CIVS=9.X0$#88!\SL,'#V%DB@Y>)L)R-9RS('2+-R1-8&S]%PB54I%54RK%
M("I4U5"E.4#F >W7S%.C)'(8IR'FY0Y#E$!*<AU^T0Q3!U Q3$$!*8!$# (&
M 1 0'.Y,>],GZ/??5%LU7MK@)7"PA?S$K\!@.IGYB1ZZ^9_&.OQS?0I/M^U"
MEPJ8F/;@ ]N8GYF/"(\)B9GN?CJ9^<U-\+72_%?DSN'A%/KK$I=O47WOQP?/
M!.4CRNS:0*6FIM3'(('<1 M53]X2$B8.*[87H@87R9C[4;'YX+Y1Q7SN<UT=
MT?UC9%-7:_Y0:O;&#;W%6=C-B1*S9+M+RE&*+3V<0;LB:8G>1Z;)%*7<MU%
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MFK5:M90)V&!$>Y8L,ZF*NNJ00LNW61X)"8 (98:E+.9TZOW=3[ZI&1BEAH/
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M2/0/+Y ZB(] \G41^_DJJ =Z5\H_:S_='_@C^_D5$^ZK!Z:#U/$9++?:E?\
M)G_-'&,C8+RP<,(B81&*CAZB(]1_8:/E'RCY1\X^4?+]T<IF[U"IV5&-5L=8
MKM@5;2D4V;*3D)%S!V[=W+,BND4#2+1R9%)P %[\1(2%5$I1. B4.E30'O%"
M^B8[ZFCG'.^Y6?IJ!]<,L\D &,B8B8SUV)#!#/4]QW$Q,3U/S'\<\F ,&08
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M7JIGE#<@_P!H7=O\46ROZES>5S2_@?5?DW!>JF>7)_LA_P 0O](97\H_G/\
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M+Q5/'-D*YNU:TOFUJ) :[];-UU^1C8^Y[%.W$:MRX";#+)0ZNIU3MT7HGCE
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MNRE3C["U6\5O3/B(2R,BDS>(+"]CVX*J!'@[:J*"190JIP:+(FXXC3$0YWC
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MQC&,8QC&,8QC&,8QC&,8QC&:_P#?VV-1[9JE[J<UL_8VJ*AIR\P;C=#Q"G[
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M>A%O6+;)POF#\ ?-D&?X2)>A%O6+;&,G<@H7[;->FWGT#+)W(*%^VS7IMY]
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M&C?JB6,9RV#WN#TE">NX_)K(6P>]P>DH3UW'Y-8QD*Y]_P"(#[GBV;^GAO\
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M$4B\==.*@FF"GL$B0[8$(!^AN_','; H&Z"81,(=>@F$3#U$1',A52"HFHF
M]!.0Y $0Z@ F*)>HAY.O3KUZ=0S)(P"U+/;%@@_R)39(@9 L[(#]N5EX'UT4
M"0EXS,0<3\Y:L+)R7*!K4$U;%B]$A#DR8R,-3+08N&K[\URQ; \ACS H[&;
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ML9=JVH^)&$M-=D#2HM)"I&D5F[ ML(L6M&>.FC8)45G2!%,J2F*<I3D,!BF
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MBT#5J5NCU'T2]DO9[/9+V?+^MZ!V?*/4?)TZ>4?*/[^?HE*(  @ @'E ! !
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M7324,5C('VQ(CXDOOY.;Q^@<>V)$?$E]_)S>/T#E=]HO:[/:+VO^#U#M??\
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M5LUNH BRK4@-L]G>B=$Z-XX(;-C]4K(0<#M'<E[WI)UES96TC7ZW?-G"P>[
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MZZ;.(P]G3@))0S)O&R,FT2DDHMR?P0J1UR$3.S5.DNA?3V00/QS$_P!),?\
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M,#\=1/\ 23'_ &C&,F,9#^R&!^.HG^DF/^T9SI3$2L43(RD<J4#=D3)OFJ@
78  >R(D5, #T, ]!'KT$!Z=!#&,__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g419997.jpg
<TEXT>
begin 644 g419997.jpg
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M3XL:2^T;/W5HF(KKSRO HDP($\A#HU) N:/K!>",KJ/.$RTA,ZMJ //M-.N
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M6678S U@6QL.OOL.WUB1*4#F2&,38B:?FN-HHMN2W0N:'(<;;56FS=(B!I!
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MW_S3._W&:\)_4]ZG"<7A,X%\/];[]N^N>=@;U_[(FO\ !G\0]4OJ7$" <?P
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M>3?.20?PTY_Z5CWSR;YR2#^&G/\ TK'.T[B^/KCZ3>V"]Y/!:LDQE;(Y/)O
M9_VR2#^ECW_5MS]N@;[;_P!]?%EB3(,9C,U#,&(8QMJ 8QC%L8QB$C)$(0A"
MWL0A"%O8A"WO>][WO>][WO,S3VU54TY9(B]/;5AMJ&6:HN>?1PR_C7:8QC,U
M8Z8QC%*91IUJG0]Z7=.^FU^S#(39/-0$HFC6$X84LC^ 6A;@NB"L;TCWH29S
M8D]EQB(RM0@5 &4-SBK.?K7B3ZWJ\O*(>LI_\\G2U_\ .JNG_P!C.]\UMY,@
MM%S,"42&!+423<J*C#F2HO4J=2]*+O2M7?"(+)># E$AM5P(2%<E$DB/*BHJ
M;T5%WHM8%[[WO>Q"$,0M[$(8M[$(8A;WL0Q"WO>Q"$+>Q"%O>]B%O>][WO>=
M\SH=GF:%L/?O[.^OBU\G^'?[F8D66K5C=-4-:N-GUNW6.YA3C;J]7SZ(HIXX
M 5@T8D$AABIY)DRO2HO>C$OJ[69M27O0R-& WK>Y$QA($0BPZUK8O+L'7;8M
M[WO7AUH.N^^_GK6M:[[WWUV[[SP1&SU A"HH2(:*0JFI,T1%'--XJN>],TW<
M*^9H\<U=;U@0BJ(8ZA44-"72)"JHB$*JO2F[=NKWS S:WH =AUK?</Q;U_@U
MV_C[[U]K,Q,S%H6@:]'KV:UW\/;??Y>__!U[?\'GYZSR,)4-#TC)<&AR;'9O
M$H6)0KVI>C<D(U#:M/;7),6M0G'IAJ$#DD5MRXD!NS$BY*I1*0EJDYQ0)#QY
ML /0.WAWVT'>^VP[\OEWY^7EV^UYZ^3-_!B*2HBBO3O[47J3)>OM1>CHX5WM
MK@(6E%%<]VY<\\TRS147IR5,ES3<N>[HKJ$<;UL.M>CUKR]GAW]S[O\ 'Y^7
MMU[/N.C78/\ 0>?GY^'?W-Z[;UKV^SO\7W\R*X.<.B"5F53"4Q>))9!(V6',
M*F42!GCR=[E\E4[11R)LQ[PM1%NLGD*P DC%'T U#N\*0"3MJ-4<$0,]RKCP
M @%KPZ\0>^A:[^SP[\];UO>]ZV'>M]];UY?'O6=&-K^1GIW9)U>S?GTY;^KH
M^JNM"U)L\]*)N[JY=75I7HZUS_?E%)TCWA"/^9ZUKMOXOM?N=]^7GOMW\_BU
MF)WUET'0_P!9V[?%VU]O[7R;^WY^6_+)>OK26'1G;0=]M"WO6MZ\M:[[WO6^
M_P"M^W[?B^UO(_3=0S,+>M=WMT:V5I0A )8Z/#BB:FQ&$\XM,2)6X.!Z=&GT
M:I/(3D^F/!Z52<0G*\9YI98M+-A(WNRX?2N2)EV[\TZ^FM!<K<(HOR?H1-ZJ
MN62(F:YK]?%<TJ*TA:M!V/?A_KM_;U[/X_+[>M;UK>8Y&'8!B!OVAWV_]_[N
M9F>7N,.;W)XRVR./N,EAPVHN7QQN>FM8_P 3,?D9S@Q@E#*F5FN<>&]H"#U[
M.!X2HA.B(HU6ATH3E#,U@PJ0QM\6OI+!(6%].C;XKC,D)97EM=C8])4)*94M
MCK\6WJ5 V9_1IEJ-0K97(*5R3)U24XY* I02(?-/-D!+\DD1$%5S1=R$B*)+
MT9(2*FE>O=EGG7GEQC$V:EH5$'+4J"J(@DB*"KP5%322[BS3)5KP+0H,A_/3
MIK6*R!*2R1TO^RZ"=UH0"":Z5A;?'.VI7)8PL,+&6(YN#,*H@TK1IC-C)3OK
M&G6@!HP1NS+_ *QW^%(N0M%M;S1$AFTN=44C][=P-\63.+-6A8$QVUA#D^F;
M]*V[7!"/?;N':<M4 ]/Z0U2:#6OTY?\ ?<=,K_SYD_\ [+'*#-C29EW^*V*H
M' E$$!3.B7KX627LI6*5C'I-O;/MA&7KT>@C,V4$OT>]>%0$\2[Q)=DZSUO!
MI$5A:15)4"4^(HB(60[03R1%Z$0B)<TZ,U5-]>X<G!D6'&4(E5 D30!"-101
M4]>D53H13,BT]"D2Y]*UG/7LUY=O+7EORWK[7;.<:[]M=^W?MY]O9W^/M]K&
M=?7:TQC&*4QC&*4QC&*4QC&*4QC&*4QC&*4QC&*4QC&*4QC&*4QC&*4QC&*4
MQC&*4QC&*4QC&*4QC&*4QC&*4QC&*4QC&*4QC&*4QC&*4QC&*4QC&*4QC&*4
MQC&*4QC&*4QC&*4QC&*4QC&*4QC&*56.L_WXL_YXK_R@S*N>9W.NU*4N&(T#
MQMJ>K;ALHROU-IVF?:MC2VOXC6L4=7P$;K=K.60B(3)W6S*QEZ&6NK.U'(B$
MQ$8A[DZJ# @5(S-V%6]9L(I: V7;]E/!;!7U81N5SR9NXQ!")%'(PE6.KGM*
M'?F>XJB4_J+2D!H1JYU5(D1(!FJ !WI&RWE;?T6Y*R^0R^T.(U%V!R5K(7,"
M?/\ RM!+"4J)2Y2A9!JGXX11PCTU8=E:J6H&F,,!+42D=3"WE+-'5,0=MQ$3
MJ1AVVQY\LG)XNK;HJ(LE6E02(W4(8[*&1 (*X:*1*I(J-@>2YY5.141 15R1
M=.:[O#?N3/M7JSRWHE7\M'-+J=/6@[2<5N"(=#[;UL[D]R(#[?\ R*!,^/RW
MGL0<G.JB8#TFN+? 30?;Y\HN1_?^+CSO7[O?ME=E \T^0/)*/\.ZZX\5Y3L(
MY#<D./4PY+SAWO$,^>*GJ6LH/-C*X)<T,;A:AOF<Q6V++PIM1-()\0D-+*K"
MO<5+AW ;DB^4/+SF3Q4I+C6X7E4- \9I9:D]MN%6YR,GC=>%]<4ZH15XE;5%
M:R(YFHU IL=LWR2*6JU,(:9<YI!PI,RNADD/4F $6@WLV%AI@_N4>0K:H!"1
M//9+K1LT',EW$@F.I"R3>J(N8EE<NCIU'EDF],LLURR3HR1>A5SR1,UWY9Y9
MH=.8'5":0B$IXL<#!:#K>]^AY/\ (H6_+OW[:%Q^!\GLWVW]K/Z4SU'^0H;]
MJ6J.65%T+5L)NZ2+ZRA=CTY<%CSX#3;ZII/>8!$YHWSVNH2C:VJRAMKM%HR[
M(5RI0*::9V8U+V>"!;K2NWJRNE+L_#^=WDS4.&NKMK3EK)I\Z4#.-70T35_H
MWW,;ZJ!1<R;'L+>SEVD].2=(ZQ*P&]9(H:J/4H)(I:-M:@XSMT4>L_D_Q="\
MWD=7D0D%TM*"PZY)J$]<Y$T\W..VZ94R[#G"AY=DTRL2#/":/2IRE<=):8\-
MU1;;VE -.6H-.V,'#U@O#$F/!:?;N'-R-@R><5MMS9MFTKHFJ"@/$2-Y;RWF
M2)]S5:JB"JJ(J2DB(JHO5N%4S7+=GFB>U5[-VU8/^EF?\F9]K_@"^7++&'^H
MC1_:MN_R(C*&.#?))PY4<:H=9<J;R&&UV@^05C?,4($7H,7O.M5@HW8Z1,2'
M0#"F-^<R"9O$3#22/7(A*F)427Z$81;OG8?ZB-']JV[_ "(C//F -IUYMP5
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MCKE5!R*G)5NWPPIWTI0*3*$>TI>FH+ ,)9A81 ,T/P^A&09I5O0E@S4?\RU
M7@ITYIE3=G+.5G+&>0ZTN4*N$KJWA4>K)J>6VA>.-?O3BC<Y9':A(E^S9I*9
M=82YJ93K)MZ9:;7R2(61EC<?C$,BZ ]J<9E7"S5PMN[CTYRNZI' Y<V/3]N#
MURV2C36T6:K.3$!5(WAE]$9MQ EUZ,L A#)"I"=M $0S!A#KTVP6UZU6EF*^
M0J_M"><0#R$"=-%T(?02B*(A99B19H*JBH2^PX1L[UDL\>#*("D:GWWD!-H
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M/3&,8I3&,8I3&,8I3&,8I3&,8I7X,_I9G_D"_P 7>::O3L_\+AZOO_FS)?\
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MO^8V?5M;V5$FEAK:4T)2\/=3X7"2':NGE>P*F6R-2=EG07!6\C=5J17M-MM
M,O0(<)^4?,.S;LKZLR[TY02-F4V]U;$*]CJ"^Z(H:5KV>@.5%8P6J"ETYNIG
M!#E## 8L_.3&E8B-EOBLER J)]9*;UP@SX_)W,>1M#ND&,Z,9^1-8E ^P<%8
MKM]C/LO..@$=76Y6';DPJH]LLT9/::'%4<!7]I%/1&==';-,LFTNTV^U9AR
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MO^9&X?Z_KSW>U.S?LY>^Z*?.>/?PTV_Z3CWW13YSQ[^&FW_2<UC=R;JW:_\
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M5_';CY/UT2Y(66!/LI=J21YT4HG.H:U,6I1(W>RG4Q >!2>,LUK@S(9[YI
M1IS$ROBE?Z:O#;J745U *Y?;3XKV ^3V#QYX+C+T^/53SJODJ22&-X7(]A2J
M)Q&F1$_.+:C.3F/(8PM>TK,-8B(<51!ZQ.69JK<<N4L;X^_5>G.!GF+PVL6^
M2\<-H&-/#D,M,A)G:ZM:%GD*9Q&' $FTIECE7X(>U /-)]8>GEM(T:(X\!9N
MW535+U;QUJ:$TC2D*9Z[JNMH^5'(9#F(!@4#0VD[,.-&8H4#-6NCLYK3E#H_
M/KF>I=GYX5K'1S5'JU(QYHMW5TX8YU.?J@+J\T@KG[M4]@PJN(O;=+66VZ6*
M4D2LV-(>-C6UG2%J;U"1>Y1UQ;7US;UYC4J3OC*><CD+*)2O:2V]=3H3ZO%<
MD_G3K1.C-%^K+^/7]*]=;\#_ ,GXA%+&@%0RBT(5'+1M9ODKI6,"?5S6TR6P
M4D.,;BY2&'-Z[T&Y"O8O=9O,7L[:8H>0IU'K9+><E(5G)\D>_P!DV_\ ]M(]
MN];_ -Q)_+>M[UO6_P!9Y;UO6];UOSUO6];\\_RENN \=6^L9-Q)J/J4.<=>
M9A13/8JSCKR+K]^0+'ZVH\KD$/+7RISET<7M[DOD,3=8XRD(7M]BL-L HU8(
MZ1Z<G+1:\N^KZG@ZNO5 Y+/S90UT4#8W+ZDV?2=I-Y<:VW161U"2G,3I_0V?
M8TJ,:H9;C>B3'$; U;7_  S;+#H:53+ B);RGM]?QSZOLSIZ]>LJW?\ W^R?
M]F$?O)-_(R.=O.K(\VEQ^>);;CQ"I)'Y:Z*(-#VQR$V-EC.9Z5( ]I>$! ?1
M+22/"G+T-3L)1I:PUM!_-%VMZRW\>^WGKOOMOV=]?+VWYZ[^WMOMOY=:WF#K
M0=8NWS^E$KY4[Q/7=SE:Y-&9@W,I+BCK%?HA'HU\<UQFMC;B5 # "T+6P!]&
MA/5!%LY(4'=KGS>KI'ISRW$B_>[\^SJSRSW9U>&>K=GT%T:<_FKWMV2]?7EG
MI^5E5<=K/[XNZBO-AT<ERD+FS<&N+0H>HT(1'J+4 7*-Y7J6KMOPDC!,P>LJ
MAD=M 6D(Q#[#++T'64XL<[>>CD;TQZ+E-^WPX.*3E=Q'NF_[9=9:]!5VIQUY
MMR[C-%ZFJB3OQBLQ1)HV@?I-?*$]K<U"M$)'%BRCT0?YAM/M4\[T0Z3M^FN8
MJA%LVJM1ARXP<HUW@].EB%<S64)9+3UN/Z;:<POWG5[:"Q]BM@.9XPDLL2M+
M;RN -I9EXR,R0BJ:*0>XPTE,T\F&QI(&A91I:S@17N2AJ]>H=ZQ1M!B=BT%
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M*S@^WI5=4+7W:PXY_P"TWGR&=2"PRM;V9TL>I^#M[>]8<=/\&N37?X\:27H
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M;T?8&OKH/E#QQY41PR6<;+TJN\V!/WTN65C-&>4J6H>BRS!E/C*C4:D$?/*
M<5Z8E\:6XPD0P@,"$>_#F==;T+7<.];UWWKOK>MZ[Z]NO+X]?'BE<ZUVWWUY
M;[^+OKV^+OW\6]^W8N_GO?M[^??OG0QV*QB'HUK=$XXPQ=O<G^02IQ0QUH0,
MJ-?*)8Z'/<IDBU,W)TY*M^DCPH/='YX4 ,<'9>:-4N4'F[T+7?8UO6_/6^^O
MEUBE?@S^EF?^0+_%WFIUP/\ _"HNKS_^0*#_ !N*N;8IG]+,_P#(%_B[S4ZX
M'_\ A475Y_\ R!0?XW%7*+T?2/VI5.M/8OVC5S/,[I.\2.H#>M&77RI9)18J
M*@8?(HO%*E+?11^N9$JDDL02M2]3T3.4GE4A)3#;RFTF-(GUD9U:4TXQU$O[
MZ3:L(A<)AM;Q*/P&O(G&H'!8DWD-,6A<-8VR,Q2.-B8O11*%DC[*F1-3:G 6
M'0=A2I2Q&[[C.$88(0]^GQC)$]>NRJTS&,Y!<(I/6PJX.BI</!(5&[9 _E&#
M<S8SZ).)-[WQ UV"IT8%6$6B]@/VH&B,WO:0M5K>3LP';S)!'2;T>OEMH.4#
M>62;*%L,CJ)[+:TU@O R418V1<F&$6U8"M:3E:'K8.Q2\Y#XO$X UE#^;NSZ
M1Z"T_?)UK]:=?1UU<&6K>F:9%]ZI_>KOTIET=.?WN6I=R5FEZ96>2,SO'9"U
M-S['Y U.+$_,;RC(<6A[9'A$>VN[.[-ZD!B9>V.C>I4(7!$> 9*I*>:28'81
M[RI]1QJY+<05"9KXSL^^37&)*$)#%1<GGC;&N0]&MP-#$7'JHLF?+$L.N&KV
MPH.DL9@=E/L9GL01>K,C+.)&SIDZ1';G[/;Y?N=OW.WQ?<_<RO\ NSG26P3B
M04AQEK!7R:O*+*0ML^ FDI$'HFD'0Y-I02V7;<YK<^)T$NT2:G5[J: L<PLS
M2$T"IU:HX0:G4']+AUZ[;9Z+;XS,Z,Z(NS8DU4"W(#68-RI,DGXJ0":)S9MS
M EQ7,W5C(Z02#9=Y7%<'#TNVJYB)QN/'8+-F9M-E)8=/=E%-!,S,T%,V4;=%
MQ!12:+0BI'5SYZPV&' :K%J#F+7+^(D!@X_)N&_(5T6%C%K01%$.E?PB=1AP
M\ ]>C I;G]4E4:UHU.<84,(]]LGNSDA=P4+5QIXGVVL-?3429/:7*!C<>,5-
MQPAR4>K!?%J"8 %=$]*;]#TM,CD$KH*YP++]4$]LPSBU8/3$2'J02+0EZWD7
MQ[J31VBQEQ*K>,CS8;2AV(O6S"CY?;%M('IX- 9O8!*"HZRD&AUZ0M*G\6B@
M<$7GU!Z>7(WJ2Q>@N7D30.:=8]((.V/W&:]S&DDPHU0;&$#_ "BPJ6EKT1X!
MC3,3J]0'3KVTG+?DJDPG6==L(R(*PHMC?G;LX\N]SEBJ6Y<AVMLL\9-/5M+V
M\T2Y:E>%50O'8T? 924"3?;^<34B"KL-6&"3--SDAIDG=!9IF2,1U%-ZJBY+
M5??"QH>9ZPR/DG<#N1/>0\XF5N57*9P!#MM862&4W=\^K=C@E5189AY4 KHT
MZ' E2MC)4+'A_D+@:[R][?'(A(<FB*Q]7N.JW7J),LAI Z.N'!MOGKG$"]SL
M*S7(0F"6.KJ58E9M"B*4R*N1T\4Q)G4)$P98)$.6).VU!I "U4O>G])T3M2#
MS'E:1UC$[BEW\AUL_K.7(O<*QJU4V)R#M&S8HS3Z*FFFJF%U=(9*69W2;"8K
M:G$A08:S.KFF(,4:JYD?2)NR6WC";!<9#!4<1<NH'?\ ;UUL:.3FC,F?$VQ;
MMI>]X9&-DBCX35<Q3S&KCCG:,@5)DZ(9J(8'A46,_P &JN3UX)QI98.C-%IM
MM]DV 9V*(RT#38," -QV6D)"9:9 &1: 1;#9J.>UAL6!9MR:<-EN #Y?!QMO
M'LTCMR''4%E1/)U'X[:1Q(U+)7A<1=>15-:KNJ@_V90_$R5UKQ7<9IR:Y@O]
MU--?<;BK698VS1AIH&32!@LB:6#<$CBB=%'HNS%L8.QPHD8K5OB[3 F*V<1I
M0HG-!N<JF&\:KOOOE]QUL'B>[\?) Y125P9Z7MU@M=BO8_4D\*!Q[G[(@:FR
MX4MBOCHUQ&.":FQ$H!+%1C8>2:F)&X;K1I;I[<M:)KGA?9-6NE)N_*'BK).7
M33):^FTODJ"H+6I_E+:TQFRMA#/X_&%;Y&Y5'D[NRO2%=[@&(1.@5K2K&80E
M+&MEFNX*\UN5<4B4EY3<PT5+V? N2CSR#J:!\<:X@-H594:5%$BXG6\0,<K@
MCC>;9[K#E!CY,FZ6S)@=3H_)9(H.CX2E+8W.*;1N')RS-#)Q0#=I! 74VUJ(
MB72J&CBGF"+ET(@HGRZZ6,S:4<5&%C@PC[WR]L^<A$&6\C3;0(KB$PL5&=+R
MMDN9*2ND:*W5AW#3EH1R@X)0+FH*N"X3J9U-8EHCK;4EU(=M>X"LG2,3!N5B
M8&42L;D*%;V-P%'DFT8G 0-HCO5=;/@W077FJR^>'M#<E8?280V!8O-^@>$]
MMT4NL39+G3#W?[N^ BUB)9)[Q]'SB+KHJU)Y'&@ZC4=(D*K;VP&.38J8#U*C
M/_3*X97IQ0Z;+3Q+N*R6NP+,3U];\;:TJ';1J$5X"=(I<F8H+&).U,C2Y26+
M$.3T*5+I-)FTZ1%.LG?6W^;M+.TDY6L5T$.0#-%NDS,JRF%;1.WN-<EXQ)>>
M4,(FRU!75S1OC7;J^QZZG48<DD9.)DUDP%E>)!#VP]R;6I0\,CPWHP.9!+0H
M"KUCI.Y"JHJ*J?*14R^4J#X9+GN3)$3//):ZZ"U#4G111T(\NR5"7+9IJ5$W
M[R'H34N>9(GRB1?E;%$;YD<+I]=T_P"-4#Y+4Q,+XK$N5'3FK&"4$KI;'BH-
ML7OR]8( FTVKE41#K8I2VLSDZ.4>\)P75(E$G4>A\F#EAQ8DB6B%C#=T =4W
M*!@FLKX]')#W7M;\;KAE5R*=O,/">SDF'(HHQH%CH[B= -9I25./T)2@W6B]
MU"\-NC7R'X\\E:T5V7*HS-Z)H*V>6MGU?9H^3=POKVK%R*;INT-(V#B2;"F>
MNZVFPVR>+T5LR!?8LL:9DF;RAH$P' PM6=X&@>FGU 8),NF'&[<2<6TE0]->
M#\O*J;)77MKSA\GMML=Z51-X9#)DZ1%^@+2SQ0]&XN[ C<XPB?G=4G+->7PY
M<40D0-)UK1GJ3-%7-41=RY;U%%5>O+)55-^29=>]:S2X\547)P4015=ZCO5
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MR=R.2<>[9D,YJ]4J;6^Y8L^\9QQ"3-TI7.K>L0*UY+<K3;$WUC4I_P#&?/\
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MR,AEZ<#IFV5O8::PKU@$Y>0,/&FX8A%3Y+,[5>%PP@9:,L)BCR<*=NY#I@B
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M7)L6D$J4JI YD*4JHHH](?HPH)@:>.Y<OL7UV;^BE?Z4HM:&#>M;\A!WKO\
M=UVS4II%T0\</JLSEE&9\I*1;YM<8FYSJ)8<8!(G<G,V$U1-$[*4)4('KJQ5
MNFITQ)2D>QFJ'M"4B)+,&(0=;&7#6'\J*[X^0>#<S+5K.[KSBB8;*]6S6;7)
M61%/&=$626RODL;Y,WM9FY\,G1J>4.C2@1M#^H)(>PHDCDN<P&5\=9+I/_JB
ML&KJSJ2G!5+\XN,[D&3<<[@ [+V!(?M.Z%2 < E3XT$J7-F;QOZ<F0PV7(DZ
ME7!Y7ZPK&0H8WQ^(V]?SWY='K?2KG!O#06ZHV(QU; /CBWK79O9#'%$6\N#4
MV&$%.;F@:AGA<%S<VF*DP'%<D3')6\2E/I8:1Z<KQ]C[?9G^7IUB>='5D2V3
MPR:>:]4R;BIROXCHK,507D!7"IPAF[F!)W:(%[L.*NL64J(8:N;Q1H*20NE=
M/YL8?A/GHUT9CWI#6Y9?YT+?JAR_N8LZC_$WE+0]@V[9 DR4IMY(4%7@W1,D
M1^D"FT[\CH8S ;X["6<&PBVLM2/FM+2(WPEND.,6&#<U#/Z?95<OW?3GV;O7
M4O16X?F";<?8RSR^EDS]4KI8K@\S@Q!&Y&WLJ5T*K=TV0E%N0*U"@H8T(32]
MZ,#X!DA$2VJ56S?2HB0"SIXP?UX/;O7?0M;UOMOMWUOX];]NM_'KSS&%@%W"
M:]UV*KU<2(CI4G\=I@D19QJP^(> C7HV390!^%1H>E6Q^C$2IVIVA$$[28"L
M Z%\WZ4Z$0NM.I?2=/55S>6M,\LLBZ24$^:OWR;T]G7T+N6HM<]+GGT-C%:T
M-2CTHC-Y\J)2]P**SM*3ZP;4%;Q-D*DEWW6F 8482)_A<05(F2O@*0^@%9<R
MB"HP!Q3>>G,_C0]%0.H8+':ZKB.D1V(QXDX+>@"88L7*UBX\2QXD$A=E0C5\
MBETE<3#WF5RAW.4O$B>U2QR<5)QYVM!PIR/7*!\\W1Q]-L:BLNG4]R"%!.['
M%-SQ-KTF@Y*X$IA]TQAZTNKH0C7;& 6CTJ!,F,ULG>@BUW>,764YQS(GIPU%
M))K%%%U6AR[I/7**0I:JA*5N<.)7)5[XT--))D" N/D,T=>9$ONJ7,PWR-)&
MIY,,@C@<6Z[,1G;4=H]("V6>UP6D(%F,)<Y9"G^D2GG#&/K5<E((L$F6V6R0
MA9=.>XWI62ZA^*X@@W#%6*)\='&DM]@*+%!APC'[I*BK+>DZ4 A)2(-AK54)
M,V $5U$J;FR"%:&5K>BM=NVO+0.^_9W]OW?/?W^VO+.F?(=HHL?B*U[!=]^'
MRUOMOVZ[=MZ]O^#MW]M:/$2^N97(DZ)\QGGEUQEIKC;)^:]N<<B.'UIU9%XT
M VN*SLZ=4^D:V7D2H>@V,[<II.K@ZB>,$7&D)A[FG5B9PL29O2;$=5K>G7*M
MBTW?GS).,UR5$VU=#J8XQRWARV0=OK"W[;5M\FYKM_&ZV;"ET%=25KB;8,OC
MPELNB]+2;?IHC Y54;P]M,=?)<-4IT23LCZ3W=7:B(G:71EVKV=%;%[ P%$%
M!V.HD 5555-)F0!I7(2)=*DBD2"2:4544LDSL>YNTXZ1(@7+FH6+9MW4>P*'
M"1M+8,2(=[42S:/=9]3,F]'H)+PN0L@'.5U Y. 35,-GS8E+;3BFQ]=T2K&<
M8NWD7-(W'9E$.FUS=D43ES$SRB+2!M%Q:/;GV.2!N3.[$\H3M<D@^D2.;6L2
M+2!;  >BSPA,++,",L/S]//D%R"ONTN6L8LZP9A;E24U+ZSKF-R>Y^/%=<5[
M\CUQJ$SNON"L9[2L#>EBENC[(R'P]TCDEE+"Q*7P]U<B&4]Y:TIYZ>P/I.N:
MISZ?/'<EP."IU&4UJP!I-&$&M[B]<7K:,$B)(>VM:$4BB\>:&\D7;N(I& 0M
M[WO>=-+N$A_#;,Q"3:6VXQK<!N#K<.+<(\]]IA555391';8^3&6]$FN"JZ0;
M$-%A7#T0[Y=K!<LW^:Q69L<XSS@@VADUM6US "52YPT2"0BH$+B(BHJJL0VV
MX>4Z/P^DZ7W.\7;MW\!7%C?GK[8N2X=]OW/9Y9[UNY%<F$?AT9TN>?0NWEO8
M".*>_+?G\?)O7GY>W?G\7MRY'L1\A7W@8[$?(5]X&<D=QDG\Y0^@$3[*]/9P
MK:6,MF#^:=KYKV9^.7\<\JJG;^67(M)X=#Z6G4#WV[>84O%#?LUV[^?)[7M^
M/_W^7KTO-/D&0'7?I8]0OOK7GX4?$[MO?VM[Y0ZW\>_;K[WGWLI[$?(5]X&.
MQ'R%?>!D<GW"Z51?]U/I\?\ #*MFU;(K29 A]6]3)5W9="Y^WTF^N WFUR!,
M#L.NEAU#->WVH^)O[G_VH?M^WRW[>_EOMGG%W,+D.JUO0.EEU!@Z\^VA)>)_
MMW\>^W)_??>ONZ^U\F[0NQ'R%?>!CL1\A7W@907C'H5/^%/X?7TU<=NCN)D2
M&J?[9?Q7CE[>%5#.')ODFLT+T?2WY_!V+OVV-/Q2UVUY_)R<WY[^UW^WY;SP
M;E>7*%9XO1=+WGF'8M_\,KBMKM\G?P\F-]_C^7??+MM *WYZ 7O7RZ"'?_1G
M/HR_[&#^Y#_FS.$^0'S5'_@3A_#V5KWL-6Q__. ]]#Q)TY9]OK+CG0FHLWE8
M<9L>NF#SKUK?L[@XM=_W?YY3?\7QY\AMC\O=E[TT]+?FRN<][!I C>7OBG%V
ME0JV,.B2G22*>1#B0Q-PA]O778;>OT@3:-4!1JAEA3F7[^C+_L8/[D/^;'HR
M]>?@!KM\?A#KM^[VS/\ "\W++4'_ "QX>OI]F6O7!%A4M2M25WYJG.7$1>C=
MN5%1%RRW*B[^G/-5AOT]>-]@\;^-D9K&RG*//=M2JQ;CN>QRX8:J50]FGM]V
MA)+1?H?%'%<G1K'F.PD4A(BZ21K$2 Q_]R%+]M"B(7%IRK6V-C)86GU,OPC/
M$6(U8?K6^YZD1?80M>7?T8.V@%![=] #K>]>+8M[\S XUZ@G"\+2]Z6JR_\
M<Q8]=A)DH^V]"WK?GHY1KL(7LV KP \A",UF1LUJJJJJJN:JN:KVJO2M=: "
M B )I !$!%.A!%$04W[]R(B5I9V-R]XL4-='U15QXY!MTKEED\G;.):Z.I!E
MH>T[6=+K>'7A['X-'FB-"C,"D43*7G3=S;4*-0_/C.%"K\#@6>4 D!^XF\F)
MESNXOH>,W'&XKVY!\:C:]Z1?$R*<=SHC9/,B+,Q_+UM;S6VT34C!Q8J6SF'D
MC<<$>$4:@RVGKG>F:'JXD:4:A,\+IMV3[_FPZW[=B\_D&/7^ 6NW[F-AUO\
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M',12R+:.9./U?;>ZYX\V#QNBDC5T_P AF^^VV7GR-<L.A[N)Y>V=ZD3Z;#B
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M*P$F!\::BC\(*4)2@2*9JR2GZSIN?V 88LFEA.!&W]X\9VO2DM!!S?&&S?A
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MT4/]8\5*<4/K&]'5!74A5HFQ3.9;*7Q&@DEX7*J:FDZQ9*V,C/'VIF@$/C2
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M=8.QA100RU<>< >T10-# <$(A$)S2VU0L-4%J&Q& RT\M._+I'ISR^<G9O\
MW=N[.LC>>M,L\\BZ-.?S5[V[Q^C?E5>/4YC">IKJXT\K%;: NJ'5JF?#SD8\
M:-4%-T9B=U/#"\4G+W\M.6$E#&&JX6Q3 G=Y-.( T;MU,M-& DHP\G$%>\">
M%3"MAZY!0$60N4 ;Z 9(LI]W)WM:PH>*LD42JA499ILM,,.,K62*#'!$>O\
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M!QJL@X>[15*5,M3*$:Q.0K2*B34RE*I*+/3J$YY8BCR#R#0C*.).*&,LTHP
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MPWRP9YPKM%VBHF\V6Q19,YEL\=>2TP\EM>]L2=XDK&,A44WC+9 %HU,9N'_
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MNW+;3YD3>?QUA;U+Q':0,NFHK>D$!8GYZ;?6FED21F5N\6:$[@>J(;"Y!HM
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MJF"VW.W>[(7'[*32&?,\;7.CG!J7<6DB0V;'X(7)6PV<R%I7-!!)FW<38D4
M:S=;DOXML3&:2Y#L9DV6#0I4*:RIC)*X#D4=Z,,@&P;MLEUQUUH649%'%/9D
MA+J[?R)\HT]16R6V)=)[,VXQR:LV(</SP9<M3>%W%)BZP;L];)$IV3BRSPXL
M*'->GN7!PHC<=9+9MA<DD1I$"5.B0I4Z)$D()2I$B0@I,E2I4Q0"$Z9.G)"
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M0LS^(.M>+8M=M^S??7;?[OLS4^IWG9RJ3<=KW@,EN:7R2]K[>:W/XG2AY.;
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MLKG M=X:N)1'%=B*]%NL*;%'FA+E%1IEM([:"TR@-"()2RY].">7%R?YP/\
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MB7E'((I'8U E<LHYYO1.HM2((FQE96(A].BSP<:IVBF1Q)Y)^B2FH0!$A%L
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M;HNY(%9QL<]!M^1Q5](6N+04JWL*52O;#0IW).C4C",I.N&DTC.. 826>(T
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MB2BCMN&)O#&D*VA(RYIJJ^%/KR_M0>FE^6=?_P#LT8^%/KR_M0>FE^6=?_\
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MV_:LU>)"-I;AH]K3C!&FK-I1)MI]JC31",,4^C].,8A#&8(6][S4_P!7[C+
MQ(E[>".T#R1U?B@;[12CLQRLRC.1&7 =*T*X0.1R1UZ9(<E)*U&+O;E_29C7
M">]>+YR?6^1<YTBW.71+==Y,>WS&;.SCQBU(#-UBWN?%?ALXW"(R_%N;+L*!
M8;9%LQVA6HSL/7,89=&K+Y0]'>^+(G%XP8FPZ2L>,-[O94_,9I!)I_%Y-'$D
M*8'5PBS3&HV^G7,X+=^[I#:RLR2WHE[US7IIT62 O?DHK-+K:>"I/(]RY(\A
MS S[EF[T9<\O/FSQ,VFEN-2'DG*V253&'QQ<A?$4?D38WMJ1F5V">G7NS"QN
MAJ5*:D1(4($&S<H:FQ5M")2WH5 FTX"AN$>D3';0GEA\!9R+9I0]I#0 _6 ,
M3^B&$/8(1:#K6M<)VEK2(S&Y*W($R W:@1B).C3$)#!*QC,5;,2E% ('M288
M,P_8R]^F&,0S?&(0M[E)@M[5),KN6TD1Y";5N.\R93I%MLD ICR-SA1S);5(
M=0!V;@I<7@;?;-L72T+G+U 5FT1@P2WS2UW*UD,*5=(4Z..'K9BO'^)0L4)9
MF'WBBHX&,K;#.0ZDN.ZYAB%)DV^0Q)<@M:R\LN^R"ZNN^.T7R;MZ8\>V#G!P
MEK^B.17ON4N4O<-62_H4=Y05HLQ0D+':$8C#BI:M)W9\]WTB]6[JV=Q.>4J4
M:4KKK:D5WU8DY[.D=Y7\EE)'#7D_QA8J>;7ZV%;RG$CN-RKI5.T=BJEJ0;E8
M;4X$216@9XY)UA[%'R-F"9V\@Y4:/6SG[@LFD*=L]R&OW.2'$J4J#W.1^I)E
M"<WTZ<].D]!ZN0<0=_-B32B@&%F_S0 @C_79P='V)1I>%0S-1^G4],I<]'-J
M(W3@H1^C]4/7:&0+2PY-Z(KU<U3Z4PCT8/1"!X ]K7<$R70R6]/"XC3S;9-A
M+$&-HW>=D# +<"(68DFY0GHP&X9@-HB KBD+;C.>)R_6J&^*M\G]O>BK,M\F
M4U*=LK\FY<TEX!YZ_<)*89;;<N%[M>%,1PKK(8C1V'GL<WIX(C;)R8LZN?JK
MMU5N'&5G,N!PM*+Q9JNJK7M)9U7Q9GFQE/29L=EQT<LZ>1=\](A>:UCS@()$
MJ2#1.)G@7HQD)-G!+.+JYJMTM>_%W/IBI&SZNN"VFVA*YFL-YS\9H1(Z2<Y9
M/X+(CI%%Z,G@X\[^]&2.KFC9STYVF0T2/3,Z*FYZV> 6DK;LX'D$J2C"%!19
MQ)P!%&E&@ 84:6/6PC+,+,"(!A8P[V$8!A$$6M[T+6]9C&QZF9[!K>2UFBD,
MQJ]!)B""#9+4#T5 IFT:*7)%IQK"^H4"@+:>N+2[;UQND9PE#:J5I>X?3:,!
M.O.%W+E<CN3<H6Q6(3+D9H'FI,A1B7",V(RDE\T:)%FJ3,H[>[+BJABS(%MU
M1#G,"\KD7"^%6<+2+0<IX;VS/BW68_ EVJV-G?<,7>2\Y9_@(KW-:),.@W.L
MS.)XMBO"%&=G6EZ5!!U_7FFG):]+QX9<[>>3'8EFUI'G-#0%24-'VF72"-H8
M<?!Y%7F[FFC4QIG I*A>I)8S^]Q,UUT$"U5'V)6S*#CD*HTK?M+FM'DUQU<^
MI96=07/<MCKH%QJXX7#$'"=/F[&FD&>;#ECHS6]+H=ZPW#&VIT4/3.4B;HXW
MH0,+(K;"E+,UD%(_5C+UZ>HBLZ,I^'T9 F ">NX2T%M#4U/!NWTY4'2PYR5.
M#PK<@&B=75R=%"EU<5RD&QJ'!0:>$)?ZP ,IA:VX*I2N @1 6K$Y216L"E3A
M5*4I'C]"F4*0EZ./()](/T1)I@RB_&/P UXA=X(80N3K#+K]\D,7(X2!+D1U
M?71-D-7U;@['5)#(HV4F\L%&16A)EJUQ@1=X*ST+_+=A6'<9T2V<G=LN&%8^
M(EEV6VW1( *_8+5.Y,QPY!NHK;)CA20M& +BQ=G&Y9C.EXRN[YHJ)(&X:ICE
M8D98)?U#IYQXY*6;;K9&.EPPN41NE]L1YD4N;9&U3!X6N:1ALH04#PN P.2K
M1VU92]6IC3PXN<>"X)QM>FUNE;9CLYU'(.),&OOF'R)K/C;<=.32XK(O=9:K
MQ'WE_P"0HHW 36*N2[(2(Q"KV$)F@Q[E\9KAD&V-;V\;4H]A<]"$C.OW#&(X
M$DQ,%A9=)SD FHTC32W:),;!G#/$W&%:3:+&A$>88<)&(.TVS3!F;*V,0A;^
MU6TM:]&!O7-R!8@+]%X$2I&F4I >@UK1&PICRC" [)T'6BMZ+UZ+6M:!X>V7
M,X+>:!]?A,$<<<!QMMN/+"&"?";D^0R<?X35YQB2T8PG$YT+FR#)7":,V%MG
M<O<"9)MY+A&0L>*P_&DR9%ULLB_/HF#X.&+9/9N182&''N5JFQ'<01G/@ER-
MSZ1FD<);#-Q'7&J6;\B>1,FZ>T#M>];\AB2TZ1YP.3^]0V3.-23:U8-7LXCJ
M.EIY)D#<G3#9Y"_P\;6]#>$+:VOGJRLT] I;T[^MVJQK15X\H6%AZ<%Q-U^W
M!;5@<F&'E_#)' 9I*"WR"R4--0*7GU.V-D.3IT: 4H+?V)K-<9;XS95)ERDT
M#PYJ 'Z)#M##;6\Q4E7&(49BU$2<G1K!IB!JDI"G0-*"4Z@1>SB"3]%EZ.**
M& LW0 :,"+0 ]OD)CS$G"VA(9FD@+.-08TZ);4)6FPQ5H6E(V_1:<.D(U&A"
MT>-)Z$1VA"])L7?>7)@R2ALNK?IA/LK#57UYQM36(F'1U%G,42(PL]Q',Q/_
M ,:D*>T475DVN<O-I-B?#'DWL+5NFI?1&V@EKYI'"])RI.*RUIL(/ Q'DXXP
MJ\(1W(V:<G]K!CFHNP_@G5JX>\I^24N4.IR+D')EKW(>(MYS>^E,DLQ\Y#OM
M76<R-(S(G9#50L8J\EPHEZB<MV<P*J63+E1CY'CDJQM87EQ:3E*F5G2FY"2V
M67E):ODMC3:X#7*CFV?*Y?&.32SDU2H'%%(&YO-?'<N9Q%HL6D+&E87(0P5L
ML>2F8A&B7D!BC>>A+4EWX)&AK0'K%2%N0HU+@9Z5<H2HTR8]:;Y]C%9Q!19J
MDS7B%V&>,P>N^]]^^][WPW,S2T^L;:VQO;O6S=GJO4$25%ZR?OOW.4:2DDZ/
M-WWW_-#?&/SWV%Y[[K;A"X0'[4^YB%^5\'NNN/"Y'<_M0.---DVB',<!C639
M.NN "NN.NN$Z;N>58\6<MV%\26_&4&-R86^S_&>'"8@N1;LTBVB1#ERI34HR
M8LL5^X\W"2W"AQ9#XPHD*%%9AQHBAKKLL8QG>5\YTQC&*4QC&*4QC&*4QC&*
M4QC&*4QC&*4QC&*4QC&*4QC&*4QC&*4QC&*4QC&*4QC&*4QC&*4QC&*4QC&*
M4QC&*4QC&*4QC&*4QC&*4QC&*4QC&*4QC&*4QC&*4QC(M6-.K39YB[-T<D$/
M0LZ?2+U1,Z0IP=UQ>S4)!I_IG B9M)1_C/&,9>@H"/1E["7O9FP^D%89H&2J
MBJB]F6[H[53=[-_"KA'4N6:)NSWY_N1:E+C(1_";=_SLK_\ %NZ_I$Q\)MW_
M #LK_P#%NZ_I$S'MQ[I^ ^;UDO#.[9KWA][RU-S&0C^$V[_G97_XMW7](F/A
M-N_YV5_^+=U_2)C;CW3\!\WK)>&;9KWA][RU-S&0C^$V[_G97_XMW7](F/A-
MN_YV5_\ BW=?TB8VX]T_ ?-ZR7AFV:]X?>\M3<QD(_A-N_YV5_\ BW=?TB8^
M$V[_ )V5_P#BW=?TB8VX]T_ ?-ZR7AFV:]X?>\M3<QD(_A-N_P"=E?\ XMW7
M](F/A-N_YV5_^+=U_2)C;CW3\!\WK)>&;9KWA][RU-S&0C^$V[_G97_XMW7]
M(F/A-N_YV5_^+=U_2)C;CW3\!\WK)>&;9KWA][RU-S&0C^$V[_G97_XMW7](
MF/A-N_YV5_\ BW=?TB8VX]T_ ?-ZR7AFV:]X?>\M3<QD(_A-N_YV5_\ BW=?
MTB8^$V[_ )V5_P#BW=?TB8VX]T_ ?-ZR7AFV:]X?>\M3<QD(_A-N_P"=E?\
MXMW7](F/A-N_YV5_^+=U_2)C;CW3\!\WK)>&;9KWA][RU-S&0C^$V[_G97_X
MMW7](F/A-N_YV5_^+=U_2)C;CW3\!\WK)>&;9KWA][RU-S&0C^$V[_G97_XM
MW7](F/A-N_YV5_\ BW=?TB8VX]T_ ?-ZR7AFV:]X?>\M3<QD(_A-N_YV5_\
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MR7AFV:]X?>\M3<QD(_A-N_YV5_\ BW=?TB8^$V[_ )V5_P#BW=?TB8VX]T_
M?-ZR7AFV:]X?>\M3<QD(_A-N_P"=E?\ XMW7](F>HA<_MMRE; @>I)"E32J<
M2R7!,@@CDW+3D^RCA; F7&SAP+2F^,(-Z.&A5!T'0@^BWL6A!JCPJJ(@EFJH
BGWO7E^5Q^I>&;9KWA7_B_>-2TQG&O/6M_+K6<YFK'7__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g460244.jpg
<TEXT>
begin 644 g460244.jpg
M_]C_X  02D9)1@ ! 0$ K0"M  #__@ ^35),3%]'4D%02$E#4SI;4DA95$A-
M7TA/3$1)3D=?0T]-4$%.65],3$-=4DA95$A-7S1#7TQ/1T\N15!3_]L 0P !
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
M$0@ 7@#, P$B  (1 0,1 ?_$ !\  0 !! ,! 0$            *!P@)"P$"
M!@0#!?_$ $<0   & 0,# P$#!P8,!P    $" P0%!@< "!$)$B$*$S$4%4%1
M%R(D,G&!D18C-V&AT1@H,S0V.4)(=X*V\%5D<GBRP>'_Q  < 0$  @,! 0$
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MD!$/U>>!U1ZR[>,/6H%ADZ6Q156-WG6B7+^&/\B)@ L:Z;H@!N1 P CP(#P
M!X'5:]<#Y 0_'Q_'QK(@MVJK=ZUF>NP.^T$TD1W_ +HRYB6J%*ZO2Y3JVDUK
MK8@BF&OX$BMK_K(V>]G'F.Z9F=_3L<PZK!I7H:,3GG3I^M)N7L_+)?:RJ17"
MY?<3;Q\:XC4"H^X?EPHY.H(G*4"6-/X<4^XW:(%*!A'QR!0* B(_FAR/''(!
MP//W /SK)UF*BV',.XK($=5(I>8FI^\332.;I' ""VB#EBOK'3I4009Q[9M'
M LY=KF*@T1X+W"/M)GK#@;8Z]AL\LT<G,&=D@*4@^G7:;)L^&N*S;-6"/44G
M[UZT1:RS:3.\E)1.#1_24D(%%>?0;-GZ#!S:+C_,*/C_  %$<C>>>[!P\5N2
M"28R7+3K"C2'M(25]6PS11&5A'O4:=NI7*/\S].^4\K\JY)^(XU*W'6_(9:$
M5B*MZ/'TXFG9(OMC50WHU$$\PA5I H,LO4OV-VG3\P4[PE@&+&>8BQN.0WQK
MU8FRI1*ZCT7[1LVKD,Y+WCV+QT"W:*.T!(0Z$B^?I*% Y#:OCTTU6;EN3L\S
MR=[E+9!L7K,EB0#?5.[?;&F]D1Q)UBC!_"(H^,NGX_PE/QSA.,X+CU(J<73A
MJ1%M=Y/24"2>4@ &:Q(7GF8 !I9';0WC3334=DQC3333&----,8TTTTQC333
M3&----,8TUP(@7Y_KX  $1'@.1X .1$>//  (ZIE=\U8>QHY:L\BY4QO0G;Y
M)59DUNM[JE4<NTD! %U&S>P2\<LNFB)B@L=(ARI"8 4$HCQIC*G:L<WV=1C:
M7TV\>T_*.[S(DECBE7NZEQ[692,HMWOJKZU&@96RECU(ZBP4_(LTAB(61<?7
M.VR+(#HE0%<%U4B'JC";R=HUF>IQM;W2;<[!(JN&S1-A!YQQ;+/3NGCE-FT;
M$:L+6X7.NZ=JI-6Z)4Q57<J)H)$.J<I!BJ^M>'_$.VHB _[X2'D/^">30'^X
M=,9+"VP[E\/;P\$8[W)X!LCJWXARG&2$O2K&]@)ZKNI1C%STM67JJT#9H^*G
M8XR4Q!R38$I!@W44*@5PF4[=9%0]>M8(O3PVFMT[H;;%K!;9^%K$#&XVOSB0
MF[%+1\'#L6Y,X91 RSR4E7+1@V2)R'<==P0I>2]PAW%YRC&WH;0"21(4^ZG;
M>294*!DX@V=<5%DU"F("A3$8#;0=&*9,04 2I" D$# / \Z8RY?37FJM<JE>
M(9K8J99J_;:^^ QF<[6)J,L,,Z*0QB&,WE89T]8+% Y#$$R;@P 8IB\]Q1 /
M2B(!\CQ\!Y_$1X /WCX#^O3&-?#*/21L;(2*@"*<>Q=OE #D1$C1NHX-P >1
M$03XX#R.J&TS=CM:R->?R8X^W*8!O62?>FV_Y/J;F3'-HN_U%:!P-B0_DG!V
M5_/^]  T=C-)?9_?% V<?7E;^RIVUBM+<[NM6!J0O>=Q#22(% !$3>ZT5)P
M!Y$1 1  #SS]P_&OW& TB*QTK.H8_L"P!/\ YGSF9EBE9?=EC=E_Y!21^/Y
MRU':12$63:Z7UZBFK,3TN,6D[. F<I-$0)*R12G,(B!7\D_(=?[U!9(]PCV!
MJ\SC[_\ O_\ -4WQ37U*Y36;14ADU'+I](BF8G88I7:XBCW@( (B9 B9P$0
M>TX (!QKP]_W9;6<4V\,?Y1W*8!QO?#(13D*5?<R8XIUM%M.G,G". K=BLL;
M-"A,*%,G%J@R]N0.4Q&AEC (!(<S;:[R=NP6[@R>G&=[ BA411JOP%"(-:T/
MR?G(KQZBO'<-0K!.C"'U901IC+.S32,_R6+.=D^X  _ &5_$0#R(@ ?B(\:
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M*8 ^>P>\?W%)R81_   1'[@UJ:/489PH6;^N]>G..K##VJ#QI+[=</R$[!/
M?QJ]MHS*OA=(TKM,!05=UJT2TG5I,K915%"3A'C<5!616*1C)C7JZ?\ 4[7/
M_P!P6!/^HYO4/[I$^FPNW5?VIO\ =!7MV53PLR89;N>*CTZ:P[,7IVHO4(>H
M2YYHLVPOU<2*B_+:RH$8&C.]L+$R@NEP<=B$RKU9%,L5JZ,V9)."CU7[2AY9
MP/<[*9'DQV-=1R&A67$A[8 )E$VTG:(@KCM /:;JJN3B":)QU:3Z,3,N/;#T
MZLQX386.-')^-MT-SMUFIPO$!G&M.R'2,<DJMJ^SP/\ 4_8DG*5JR0J;[VQ0
M+)PCMLHH10R)#L9Z#H[^F5O?2VWG0VZV>W<U',<=$8WR/1CTN&PU-TAZNM>(
MQBQ1D2S;Z_6)N1..%H911N,>)W ' A%4O)M0XO4!3-[KW7IWD3>+Y.UPN1XO
M,V*7E%EJ([EV%TC[:EA_$W\GW54>0"B4VVL2<H9K]C+1"A),L@9O]"8'(IZW
M ISD$BA0.43=AOS0, C^J/W /.M6MO7A8RQ>KUAH:8:)OHQ_U%]E:3QFL &1
M<I$C<!K^RL0P&*=(ZB)/<3,42G* E-X$=,963 /HZNH9GJ!B<F;G=QF(<%3M
MTC4[!)5J=3N^<<MPC^01(Z"-O(-CP%61G2J*F)+)QN0;(#)?O24<N'1%DDZQ
MW7T1NY&.@UG..-]&$+59B&$6L5<L0WW'T.H!2B8#'L<'/Y%>ME?< "E *XL4
M 'O]T!#MUL9B_'[S?VF$1_MUSIC-4MMVWK]3_P!-?OOA=M.Z&>L]HP@V<5R2
MR'A"0NTM?\27?#]H>'9?E:P#)2/>-;G&K>/DW,-*0<? N'4Y77E)R%7%#M7T
M4SV:.XG<]1L![2,P[O%SA:J!BO!%QSNV+%K&0&V5^N4EW=(AI%KKI<HJ6=NF
MP:,5ED@]D\BD=0H"00U K];BP:)[D]CDH1$I7SS!.6V#A<"E[U&D;D6'<,D3
M& H'$J"TJ_.0IC&*47!Q(4HF.)Y"O40E'S'TN-F?H+&^K<]-S;*S764$RAU4
M)JJX3C)'O,)@.91=F]<D$YC"/<?N,!_)18R$#M^P%U._4[[OLM66Q9GB%4*,
MR;6^XV/)L]966&,(UFSS$@UI>-\:X_KC&=.S.Z!C*H5Z&CHM!:41@9BQ7*T*
M2RSN5D,O]@]$/GEM!/G-6W[8?FK*FV T;$3^"KK6H)V\'M[D'MBC;I;)"/;%
M$3]KMO6)-4P%*(L@[Q ET'H?_P"C+J)_\1-N7_3&7_[QU.VTQFE\S-E3JF](
M.\[ENF](;C\LX@8'6BH#)--QUD2?4H5G@W[%A9X&VXUFG;=C*UR'O5;D&"CR
M:IR=-G+'77*E3N2!DFSZ#;YN=KWHX=Y^?,5U7+F>MS>*< S^1*Y"W1I07%,N
M&7;[#(V1HE*IQV1782E*AH:SH-72"DC'Q$U;B-7:BK)S(E<MUBEH+ZI^/:2O
M7-0C'R(+,I+&>U9B\1[C$]YL\*LU<)B=,2G+[B"AT^XI@,4! 2B @ AM/T$D
MT44T4B@1)$H))D#G@B:0>VF4.1$>"D*4H<B(CQR(B/(Z8S57=13TV&^7I,8C
ME=[&+-R-3RA1L.R%:D+-;\4#>L,9GQV$O-1\*QN3&)3?/RJP<38I&(9.Y2NW
MU2>C3/VTJ>#)&-9-]'R4^B1ZB*LY3V,P+??==73[/N+[S/8L>W<B4664R;4H
M2 J<[5KQ9TQ69)#:U6=F5K4^^0;E^W']:4L3L324N^'6;SK:))+=)#J+D63(
MJ0NT+-BH%4(4Y050J+Q=!0"F 0 Z*R::J1P#N35(10@E.4HAJ&MOMPM$!3I9
MG"S\M%M5;2]<J-V+U9LB=P>)A$3+&(F8"BH9)!%,3CY$B9 'P4-,9+NVB=+;
MJ"T;U+*F[:V[4LKP6V\V]/<W?@S _BXTE/&F6^ R\C6K%]6G*J.@CIAQ.Q*+
M-06G<<[]N!RD.8Q"[#Q,! A 'P($* A^ @ :X!,@#W 0@&^>X"ASS^//'.N^
MF,:BO>J]V9[H=ZNSS;A0]J^%+MF^WU7<^E;[% 4=FT>OXBLEQ-D"&&:>$>/6
M*1&02LDP8=X*B;WW:1>T>[4J'74Q2F#@Q2F /( 8 $.?Q\@.F,Q*]"G"65]N
M72>V;85SC19W&F5:)1[@PN%'LR"3:=K[V0RSD*<9MI!!!9PDFJO$RL>^3*58
MX^PZ2$W:<3$+ELUP  4  H  !\    !^P \:YTQF,3K.8AR7GOI=[UL/X=IL
MUD+)M_PG,0%,I==03<S=BFE9B#<HQL:@JJ@FJY41;+J%(94G)4S<<FX*.#;T
ME&Q7=QLCH.^&*W7X$OV#'V0[Q@U_2FM[8LF2ME8UVNY+;3CF-!F_?%52C7$S
M&HNA,8G:=XB4O<(G DP,0 0$! ! ?D!#D!_: ZX*0A.>TI2\_/:4 Y_;P :8
MR'AUZ?3)ONH!EB;WD[-;E3:!N*L[".3RYC3(3A["X^RT]K\2WB8NXP5HBXZ6
M4I>0E(>-C8.7:R42O4K:#2/EWLC5YE"8DK#@-9;1O5X[3FL?3*9,[W9&JQC8
M8>NMJ)N.I^;ZFRBVQ$V[5")CW&0[<:!CD&S%%.,2<1D3]$V[$&R+4%SHJ3F^
MNEDK*^'^E!O*R3@_(-FQ7E2J4.J/JA?Z=.2%;LM;=KY5H$>^=1,W%"$A'N',
M0\D8\ZK4Q5#H/%D1.0BIS!K&%.J!UE@.< ZD^Z$  Y@ /R_9%\  C_Y?3&93
MGFUWU?.Z)!]2[3,;YXRO/FI8R<2M^X6GX-K3J.7$XK)2/T^0*8,TT52753?D
M;MI(ZS8!:N2*I$(@$?BO;4+M4>H/C+:"QMM"RIDU3<+B'%3N8P[8#7^F*Y L
M=OJK*6K\+9RMHIE97%1FY)U7K!+1IAKJLY"S Q,U)1"*,RYNMALC=53?U<V&
M'KGOSS-=PMRL973Q&4MQV;%J,X2G'[:(31E(2,9R\>NS.L9$[XIH%T*J2?>9
M-PJ $--LZ&7ICJAT_LD57=_NHR-4LZ[C(.("0Q55*+'2Y,18BDYN-5:.[>A)
MVAC$3^0+PC%O5V-=D9&LU6&J/UCZ190<E8"0L[",9*9S;A?&^XO#^2<%9@K#
M*X8QRS3[#0[O6W_<5*4KUB:+L'I$7"?#B/D$"*$>Q4JR.E(0\HW92D>NB]9H
M*DUTNXCTL'5;V39TD<J=+O,4CDNN).9/^0EIHN9VVW/<C5:^]52.>O6US(S=
M)J\T((&28.Y:J7(6%I*Q5D9"HUSZA.)2V6     !X  X /P --,9"/Z%]>]1
M%5=^D)7>I"ONX=[:([%^6F\NOF*S5RZ4I6ZFCXU:H":SQLK.+RKS[0.Y+#N4
MI5V@4 50;J V342+:5N9Z7V_ZW^IV@MW]:VK95F=M#;?1M5R(XS(RC(TU-3H
M]+B</)VFRF>*2J;K[,A%8*73?*@S$Q#1[@"%4.4I#;"($R%'DI"%'\0* #Y^
M?(!SH*9!-W"0@FY >X2AW<A\#SQSR'W#IC.P?_8_VB.N=--,9!P]6?T[=[6]
MG-FT"P;4]MN2LY0M$Q-E>(MTE18YB^;0,K,7.NOXM@_,[D61B.'S-LX<($3(
MH)TTCB4#"4P%S-;Z=M.>,B>GAF]KE'Q?:;-N"6V-;<L=(XHBVS=6V*W>IQ6'
MT;%6R-3.2-QDHA6"ER.TBNA*4T>X!(ZH@4#Y\S$(;]8A3<?'<4!X_B ZY$I1
M#M$H"7CCM$ $. ^ X^. TQD/WTE&Q7=SLBH.^"+W78$OV#'^0KS@R0I+6],6
M3)6R,JY7<EMYMS&@S?OBJI1KB9C47)C&)VG=HE+W")P),#UU*0A.>TI2\_/:
M4 Y_;P :[:8S7A>H4Z7'4$W0]8./SIM_VI98RKB-&E;:X]2_56*CG5?*]J[@
MX6-L+AS*-515A@ #/0! ?: 0,80()3CL.RAP'_,8?XF$0_LUP*9##R8A##^(
ME 1\?'D0YUWTQF/CJOXPO^:>FMODQ-BNJRMXR/D3;#EVH4BGP:1%YBRV:;JK
MQG$PT:BJHBFJ]?NE"(-R'5(4QS  F#6L8Q/T,>K9"U^0:RNP_/+%PI.N7":2
M\)"%.= \?&$*J !8!#M%1)4@" B'*9@$0$! -O:( (" @ @/@0$.0$/P$!^=
/=?:3#X3('_(7^[3&?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g473593.jpg
<TEXT>
begin 644 g473593.jpg
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MFC;& .RI$EBD)"21N0%8A'5B%<9HQ )(##:I.QAM&8K?UXV/^[&?_<[;+?\
MI]L3_P"U0=KV3Z\;'_=C/_N=MEO_ $^V)_\ :H.U[;J8_P"W>CO]JG_[&ZKB
M:4_[/XK_ &8_]1*\!VC1HU^W*_/U8$0Q#+(1 ,<<<LLA'O &.(#EED(^P&.(
M"(C[ !J7LLV [WH+5J"[YCM-O^.4ZZ(8FZ(;.=*U?RH2>USLQN)ACH+\40<D
M3MDG/>&DAE<E8IT*Q0YMY&*@#EB<LR'YP#D0HQQ 1RS3*,,0#IRRS(,QQQ#R
MY9" !Y1UZ,]R?*7[>X?+E#+M[K!CE,_N;8ELOVI7%ND47M.GZ'H8&V5?2)%P
M0]IH'&.ML*:IM#ET&")&RQ?(7DUE<6IQ>D39BY*3BA\YCF(8Q9W&'0X3AZ7W
M7'7$ET9%\I##;R6:G.4W-NL):.XF<,$NYF,(6*SES=D[.&6=A<0W4M[<& QZ
MB0@, 6>19-7)=5B_EE52"44 EFD7+;4M:_)Y[ZJ+9&>2W)M$W"5E'9!+6*!L
MS[,JT?FAI<)I*%.2*-1<E?F28F+>I MPR1LR)48GS<E@ D2":HRQ*'0N[81O
M6VU0PNQ-P.U>\J9@ASZWQ<J76+ W*-,!DB=2EQS:R8."L>I9.2XEL<#$R8 Y
MYN")0(?H8Z] EU[]=C\YG?*C'54775-O=A[W]F<_(MM#=-CV$GWIU'!]XC=.
M9Z[LD(L 5L0KSU&)6UIMPU762=I<!:DBMA3=58E"U(J83E&IGLEGEYVQ>SVU
M\G7;=-2C=-8M@+T^QG<G?\9WZV]%)\Z3XR,.DQ-MMNL&C([B#H\L$XMP(K"T
M>!*]!V,B>:%M59EZ\QA^EFD4UQ90W^#O;;J2TR)ATNZRAK/"KN*" OBO6T$D
MC7\UNDDEQ< M &GAM)%N((.W=8!AJ1326MVDNJ0 QNTU8E$L\3RN%@9W4;D&
M*Y*=K!2P52_F_P!&E1.%<.7S26KJ\9'Z-0%9)7M5"8[*7U+*),Q10]P4&,#/
M(9*A;&5%('MN;,DR1S>DC.U)G-84<L(;D19V*<M+Z^D(Q9%8JR%E5BCZNNA(
M!*MJLRZRYY-JLRY@Y,1D3XQ@%9E#!@"0&7/5;(Y9C, Y'A&8%&C1HUM6*-&C
M3T[<:+E>YV_*<V[05RC[/,[ML6,5G%G65J'%)&F]\E:_%O;U;\J:6UX<T[42
M=D&2PU U."O OB)*,_/A@,4TT5O#-<3N(X8(I)II&SU8XHD+R.V0)R5%+'($
MY#@K>.-YI$BC4O)(P1%'"S,<@!V33+:-6P8\D;;$A;4,IJ'<7M4OVO#1W'L[
MY8M3RNTU+##+#VQ4N]7Y-:LEC/-*DALQ13&1UVP."^"JT$=<HD\JR@3KY&T$
M#BJSC/$=C=U3J%;,IG%AC;KW=%WV#0--1DE2]829%-JXE-<1-[4S%,:R8(&U
MB5+K.9%;<N:E[TH[&MSVJ<$:$4B<M7RX=(<%G76CQ" @,58-ND;(RQ7LY61)
M$1XF$.'WLI615(2W=B,BFM>DPC$8CJO:2 ^5RRR((=H$4J02&!:XA7,$@%P"
M1MJ&^C5I4FY)'<7#=W5S[2)7.*/CZF@*5'<A9]]N,JEAM!,]!BPQ=[(M1M?&
MB#.\\DS$O43!ECK8WQV .3ZND1BI&6W8)$2E>7OMW)/38_MPR-YW<;*6"EZ@
MK>B;7/W$E6-9<XJ*:0W<7+Y+ JW-C&5:5%,;!;'_ #ET3=V.2Q*=0*(R*,JR
MR,W- 6D4%JAB.D^ A8W&)0NLT%K<1&-)I=TCO6B2T";G$Y::=IX=SMUSN")%
M;<M4YUOO-B>;@VKJ8Y)(G#LB%&B#F0L&8%441N3(<D\J?+;*JFT:?E[H)U.O
M<B@J@GE=;BWUW=F=CA\RJAU>62 39U=V=.["E9'BZ6*IG!LP:S#%34ZK9@U1
MAO3N+:NS+5G-H)G!3^]T.VZR-H=\6%MRMX(]A9-8+&)OE9<5>1D+ 2M?XE'Y
MDE(;WKK-!@X@G:Y(@(5J"$P)!7EJL$1ZU'@0N4].._LY9H;=)TZYN+0WT5LV
MM'<-:*\2-.8) LJ(KS1H=T12';4(UE8"FUK<)'),T9W&.;K=Y00T8E(8A RD
MALPK$%25(!R-,'HT:-6ZKT:-&G7HBGI-N%N^GJ$A2MF03&[;/@E31-=(E"M(
MP(Y)84E;HLR*7M4@1.*Y,TDN+FGS<#T;>N5%)<3,R$B@S'$K*.66."*2:5PD
M4,;RR.WG4CC4N[G+,Y*H)/0*V1&D=(T!9W9451M+,Q  '220*:C1JX%)R-%T
M2MU;4U/[C=I=[L(6-=5.S:7U?,;4R:JKMFCZ3L:_7N 3]HFU0PV6IW*5P2JI
MMC"'B.,$BC+J^-.;>N>6PG+%;J%D6V<6[-*HVT6Q%P8GA+NMW&2K;!5D-2F/
M037.R(J56.9AKRA-9L&HAA=S;6CR5H5-SNYK\ST;R*YM1$ITAJWDP:18+<C.
M'$(3D5#!A)$Z%TO)%$B2HCQ%H["[D D53N<+/YUD+7Y,(Q&(E7M9 1R:K9[8
M1L*D@[9X@<B<F< [=E11T:M6G/) [F*]WFS;9A(YC221[KJCW'<O,[Q&62D:
M"9Z!8XX7()#:1<@(A*F</3(RGB=&3VZ/P%T?UDI2J6QN:U)!6:[ :>2CF;DJ
MLU[.W<[*T=*5G1]:;A%.Y%%85GS"H)!7MJ6?E3D<*;TT%I^26E'Y>BL7$8[(
M8;.JXBSXRFY%*CR,T1Y:C4?DGP$K$ZXE"ZSV]O<PF)9I=TBNW6.UU!'&Y,L[
M.HBMP.N'&;"(J"1OO-B8U]:U=-SDDB?79$*M$"TA(=@=10K$OYP9'RVPY54Z
M-2R8]HDLL?=-$=IVWVR*FW'S">.C.T1*>5H[RYAJYT4KH^?)GP]0^6U#*YD+
M.VP=G0.ZN8.3O%4B=&2S.)S5V8+Q2BJT]T&T>P=JRRLU$FE]26E KIA*ZP*B
MN*B)X%CU18L<9I0Z0F391^1&L\=<RW.)3%F<HU)6AX8&M:W.:?$,,%"8XI1E
M>7%</>XM[074:W5W +FWMI \4[PLLC*QBD5'1F6&9ECD5)&6"<A"()2E8V%V
M(IKC<&:""3<I9D*O&K[,P'1B& UES9=95+*"06&<6=&C1KH54HT:-.O1%/2;
M<+=]/4)"E;,@F-VV?!*FB:Z1*%:1@1R2PI*W19D4O:I B<5R9I)<7-/FX'HV
M]<J*2XF9D)%!F.)64<LL<$4DTKA(H8WED=O.I'&I=W.69R502>@5LB-(Z1H"
MSNRHJC:69B  .DD@4U&C5P#=R--S3&602.4[N.VE7JURV^)_MED<RK*96H+'
M4UWU_5D]N%3![+:IK4,.EZ/.1PVLYGG%GR+QV41]Q=&<Y"H<D>.6"C*$#'M'
MM>2[?JGW#L&#,Z,%T[H'/:3!88FS>/5^NM-NAT$F9&9C68T8-/J?>$MAL+2U
M*DSRI<CGG!:0>UITI9"M1RK?2'!;K\1B$#$&)65MTB=&FZZW(21RHCQ%Q973
M 2*OE(6?SA1FOR81B,)RDM)0<F89 ,"$$1;(J2#ENT>8!SS8#+/947M&K8+,
MY'/=-5.],O9'))-2^<OPIIYW"NMNHY9)<J,8J8B3+(G:P)XODN4,&6*T%?J8
ME(XY)&YBA+P]YR=J.:F=N<L3"U.N<R<E7+GUVF"Y'N[V6FTO$-O*/<R=N3:Y
M_:4GJ-?7I]GQ^GEK<8UQ:GG>X(Q.66?21M9W>(3.KX^O(PSS6)\U2<,APA&E
M& %(95Q.!TN+>&ZA:-9I1)#<.4@*;G&Q,DS*XC@RW=]1RL9",1OO-B8+JUI(
MICD:)PY1"'0!GV,P.JH(+.!J#/:PVY58:-2R3;2'Z8;F85M>HNW*4W$2:?J6
M=%'K!KJ02V,50"M<VN3R]8/$DN6%5B\,:6%,S2X.LM<G&.%H$J),9DTG/)XE
MIL]'=/M)L#::^UP@ETOJ6RXM<-;)+9JBTZ-G?;#K&P8.ID+[$E+HP/Q[/'70
ML]IE$:>V)U;GA@:UB=:A$PDM2C.(4YWTQ7#WN+>S%TBW=W;]=6]M('BN)(/+
MG7W&54D3,1R$*ZJ["*4A2(I"M9K"[6&6XW%C!!((I)D9'C5SED Z,P8>67RR
MDJ"P!() J+>O17_W+5_[[9!_^@*__P#[#QG7G4UZ*_\ N6K_ -]L@_\ T!7_
M /\ V'C.N%IY_L9I/_P:^_Z+5TM&?R_A7]K3O-7].W3*69N3V[4L\-4>N*^J
M7JA_?4>+@R,=E6G!((\/"#)68@Q6M39*G]I6N"3)<2<BQ4I"#B!5E&)@,ZL7
ME@#UZ\_6_3D]+IWF<HL>M87-BK&F7GDWGRFY1;\SV[UIN'8ED@D.X!R7.->Q
M9IL=W2-\1G^$4<LI.W2K%J=RT:4D,,T:GGY$Z_%.#VEC>7;1XC>BPM8[>:9Y
MR&8YQ@:J*J1RNS.3L5(I&)&04#-E^[WLUQ!"&MH.N)FDCC6/, 9,=K$L\:@*
M!F274=).0-_Y*@A024H(.+.(/*+.).*SQ,*-*.QQS*-+,P'+ PLW#+'(O/#+
M+$S$0RP'(! =?7G!X0]SV>]PX][I[W$./@]G7EX?]G>^ZFZZWHLE"2K>DY1*
MK[IVFT50-?M-\JV^3R/D_H#5.V!NW!*]M!#_ "!GA3)>\H+B<V:6FP%'J?D+
M4Z)):WUPIB;O*7$]Y;!;7/*4X-L=/FD6Y4)ZV)*;=W2+*XJ>LK[;&GE&8:S/
M4 K-+MR579/\;;;)O(JU9;*PNY;$XX\VM)GIA1.4!5W/B_,"! U(NQ'HS:S
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M&?P)O]#1U7'P&?P)O]#75PW&;_"1*+*58A-+;S.2BL3):B=8B"1FH N90P!
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M.OU,S[GG_FY?-KT4_P#<MF.6'*UP@<L,P#M!;@/U&7L,\9'V X^YX1X '?$
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MK V-."G-6H>5\VF.-Z)J0);;=[%*K,8:A37R->$F;<C)[+MOJ7=!#&?&S2)
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M3";C?8I?EI2BR-P;Q:UF-EBN31!R(FYU7/8J]JV)S;F8A@/CQA*!I@+3$&Y
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M\0L9+]#+8I>6SWL:YZTEHLZ-<(NJ5;-X0ZC)@<SL(.VH;D3-;W"V[!;AH91
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M)0I$4D1FQ#$XC-%+!-+&D86&7*\DDMWM8[24Q$3[D)I8$FMY)8>O[5CY71P
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M:IUK/SE>]SP[P"H$]U;RD_X,NNOYPJK?0SK'=6\I-QX_F9==<?#^:%5;Q_\
MM,ZGOHTWQL^8,)[MCOVU3K6?G*][GAW@%0)[JWE)_P &777?Z?\ ]855O?\
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M\;/F#">[8[]M4ZUGYRO>YX=X!4">ZNY2?\&97?\ .%5=Z&='=7<I/^#,KO\
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M[P<1[W0'A'P!Y1[W1X=-\;/F#">[8[]M4ZUGYRO>YX=X!4">ZNY2?\&97?\
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M_-E8NP3JM 2P8LU&*A"[*^>VY*$B\Q"4L\U!W0/N!\NM3+UH]/2 ]X1#OAD
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MTD:,2L)79<$M#)O3MR2N/3,>&.)Y^.'-ZGB>?B7S<ASQZGB;F& 89CWS, Q
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MCN$O1^STBF6-]G]Z/Y=<-6'' OO$#]O*_1QX!TCWR_"<'Z@/9[_>'3\F4!>
M\>%26 /V/#O1Q9[/'A['?Z=)]SH>ZDA2;)754T38GKDR4G)='U1>!JD[,<22
M$_.$.>K,R 0(P#B.0@/>X!J,X+C&P[TXG\GW8_.7VFJLEI=EMEK<\)/H>7@.
M1'"FVF?,Z,O=_+KGG=(^Z'R:?,S;Q>_V7]Y^Q.GH]32WCT^#AK2-VZWT/'A3
MMBCWPZ(RM\'N:JO@F-<SXKP\W7GJ5]IJ&2SO"JY6ET?^7FY3^QTBF$.];_;P
MAK2SZ ]W\@Z?4W;C?V0< IFR!_[,+/"&M3/;?N $ X4O9(]_C^E=;Y0U&V!X
MUY7\#XIYX'\GW?!W'I%1-97I?/K2ZRR/I>;]D>HIA\N@?<'Y-:6?KA_%\@:?
MD=MFX/@/]Y6RN@?\%UNM3+;3N%'(>%)V7['^"RWR!X/[=/1J$8)C7,^*\#?T
M=><G^YZ?'(U +&]!'F.[X1Z7F[/J/'9RTPIOL_OA_+K2RZ1]T?ET_IFV;<0/
M12-FC]D(_I57='?\FM3+;'N*XC_>0LWI'_!5</L^YY?[<!U$V!8WDHWFQ78-
MOX.O.,#VFH38WQ<$65WM(]+3] ]13 Y] >[^0=<U5['Z'Z['U_3T?K?[OP>3
MCJ0V>V'<8(!PHZSQ[_M57>7R:Y#CMIW")A3@II6Q4XJE121*"F,+"Q4*3,1$
MM.FYPASU.?-'F88\1$ '\>N\6-\S8K\G7GU-5=[[\^D;SE]"S]'M?2*8//UH
M_B^4-:IGL?C_ ":D)EM9W)\!#M$VGQ_^B3AX?<UKY[5]RH\.%#VF/3_@BX>3
M]SJ)L"QPA/P+BW!E^3;S9P<(W'9[]1[WWY9LK&\VKEZ%GZ!ZWRFHZY^M'\7R
MAK0RZ!]P?DU(W/:IN7YH\*%M4>CO!$'#CT^YY/[=[6D.U'<UP$.T':W0/^"#
MA\W'_1J-L QW5/X%Q;WL-O#Q_P"YJ!,.Q >D+WC]*7'[/M?CMY#4<\^D/<_*
M.M;/UP_B^0-2+SVG[G![_:!MCO=[O0]P'V?_ +NM?+:;N>$1$* MD?\ L>X>
M#R@']O!J/>''=7\BXOY[FV]XP/:-G"*A.&XCG^3[WSZGT)/R#CW/*HY:TS?T
M3+\7^J&I(=R7N@]C;];7P.< ^?6J9M)W1"8(AM\ML0'AWPAKCPZ ]GAPUIO#
MCO,N+_)M[T>T=/CD:V&&XCD/P?>\ ]*3_5U&LWV?WP_EU\#O6X>M]CUW3['K
M?+X?)J2!FT7=(/1M[MT?LA'O0QP'PZT%FT_<VG%*6HH*U2#%9V*=(6?$EI6:
ME0./. A-CF(":?S0'+J9899<T.C6AP#'?*C>3%_.D?DV]X2 /6.GQR-4QA>)
M^6_!]]L'L2XY0=GWO:.D9CCJ.F?0'N_D'6B=TC[H?)J3.6T+=.(?^YXM_I]B
M%N(_D#6H;L_W4CT;=K@'OAT0IQ\&H]X<=YDQCY,OOJ*KOA>)EAEAU^?*GTG<
M\H]KZ?'(U&7/I#W/RCK5RZ1]T?EU)K/9YNM$0'';G<67>]B%./X_#X0UK#LZ
MW7<1X[<[C#B(_P"!+E_;^P^#6=X,=U0=Y,8RS/\ 1E[R+[14#X7BF8_!N(<'
M%97)_P#:Z1VZC,=T#[@?+K4S]:/XOE#4GC=G&Z_(.]MRN,>\'1"'+V![_>U(
M+;1R;=VVQ8"=#;D-F5/5NS"G7R=YD;7FROKVF$P>9'88E6!GD>ZN'4\RU;P:
M3DWQU&.2TT%2[- @46K'1323$;RWLK;!,4W:YE6*,S6-S;PJ6.UY9YHDBBB1
M<WDD=@JH"2>*IK3 <9O)TMH<-O=TG.YH9;::*,%OSI))$5$11FSNQ 503Q4W
MFR?9++-ULLR<G+)PC%,QIP+*F4R)+ZDL=%90EJ!AT,,-PR*42-05EADX.88F
MI(HC,P6J@-<C6Y H]7[6W)6=L;FA""@$34WHFQ&"M:L<E8)&]*4C3 J<7 Y2
MO<%($$E@H7+E!ZQ6;SU"DXT\S//+B0F$Q2N8HPP:#,+?&8E&4!;8QL;84):1
M"D+$<LOLLAR.5*U)V1BIP<%1ARUQ7''K5IYR@XS,53K]B:!Z#6.A6&-"C"YQ
M2\$3XG?9,%ED0'4@MT8_>[6 NXCS DE9FEER++''^@-%-%[;1FQ,2-N][<!&
MO;K:!(ZYE8H5/G((BS!,QKN27?+-40TG7H [)1D1P8,N#L;P%W'FN. BA-#C
M'>^'.<QZ#<> \4HB/#['B"BTG7KAV1C/'U/_ /A8WAV8X]D>/69OZ7.'>[)\
MWG=5X_\ %N=P[^O=UZFE$'0'Y.C\6C0'0'1T>QT?B\FC2E&J:.4.V4W)-+;K
MG<)LY3GQZ[)67(*BMI[;7=,PI\H7)8JL:$LVD+FO.'!$WM31@OC#X<W$'.9I
M:J,JVQ+D^-B)5A<OH_)T:Y.-8-:8[8M8WAE1-UAGBGMW$5U;3P2+(D]M-JL8
M9@ T>Z*,]SDD7@8U0Q'#H,3MC:W!=5UXY4EB;4GAEB<.LD,F1,;C(KK 9ZK,
MO 33';;J&B&V>E(%2\*))%MA[,02YNN";!,IE$H588'R:6.../'+)<^NG53P
M W//-(WEM[9AEUN@(PQ?'1HUT+>WAM+>"UMHUAM[:*."")!DL<42A(T4<BJH
M SV[-I)JW##%;Q1P0HL<4*)'&BC)41%"JH'(% 'O4:-&C4U24T&X6N7&XJ!O
M6HF=<WM;O:U,6I6;4YNPJP:FYSG\"D$20+W,4!"E<#>C5/!2E:*),H6 E+-%
M*0:>!9>46G[D\Z.;X0VQ^LJ]A;)(7&S=I\HL2131=,;"73"#;<;HAUKG050[
MS]TG+R8QYF,3PIB\6R-2Q0J3N>+NXI$ZHU2Y%V":-*50ON0Y-#<M.76U$56/
MM,%0RQI';DP;&[*8+J?5,SM+=R [@F1BGSA'=O\ 8,RLJ&/9R-E3&PQHG4$A
M<)GR9XGKPRV88_&"CQ9_)F;D[#D&X'*/R*JJTBLUG4RMF',A,^76 W2.:2;=
MI5VZDUK:AF6WMSGVVALF[C %[7>*5HLF^*IFD^7LMBQJCV5M9$$<:KZ1[P"/
M@U5Y<&]JUJSGNX:3)4&W=31>VN:.%4/M?2::R6.;C[4G;5M&5;KE[C6SL"A9
M!$AAS8L96.*U8XPIYD4OBK)8UE!-F B/-T9<%*7^W#;UN&I#;E<;03)8 3N,
MM"WK(O)N.D#^_6?!6R32A7$@;(]-)B$)KT^2*9&SPTLFP)M$:HB"--))4\2M
MBA;R[-YR^3<>F-G<PC^VK>'3CYZDZ65;K9'?+TPQBNIO.;I:*/RN>HV>MG!T
M+LJP$$0F%CR)UE2!UME]ZJVQYH9W!^QA44 EF9TRXUGVC>)N[<[3@FVU.7L^
M=K8M-+3TRC]K1<NVI!4,+@]OT)N3MHMED<$33P)9*9I''O;H>CCSDAL:(,-I
M5W.&J=DM<#5M9S$X-@U<HQNKSA=.GOD3VMMTVW*J^3^45FKQSME/!*V;=[LQ
MO> JFN=8N$J+?+)?X*[4PE<XT='EM9)9\NEJ>"J$$;/2)9BO4I1[6>3BMZ%V
MM5%K;@5U7/AU6S&H#2(PEESE:I:Z.4KMGW$TK&I"UJE%+4Q%61U(DE[8G0.,
M>H<QTKZO6(]J7V3(UYS*QL'1C_)ERB*5++6)&=1K[8HPK8O'HOB\LCSA#I,V
M;-KHD%T*JCG+@5&Q>FRIK#<5Z-E2$-;0_)6!2H4O[A#G8EL)9G-B$'*8WJGE
M\HS6L#*XSI3858[,<$,-C=DV=2J6UHONAWXP">W]6M5L<E:[ FS;/8M032TL
M<$)GS,Z^JW!##'RR5#?#5+NY+*#;T=Q]QV'4S[)SXG%ZH>DNV=,Y06!N<UB,
MJ,M-3RF+[M*?YAV=*=7!8-<2]HC9SL_4A,SEQV#"L+KF9G*7]N>WUP4IWX7L
M#M\RRW*Y96KI> /$YO*,7;):MKIRE3W$(.:Q;M]LUZ+H_&I"JAD6QE3Q(X=M
M]<7>62K.+P]$_P!S3]W68,J5BZYD2K58>3(<X] :[C2 VETS]"=JFV"B#W5%
M&U20M3+:.W3L^XF5/Z-<5%L7(IBDW8TW-M.,+P=S)@<6[.C>FR#)TQ;E-RBF
M[<J(4HK<X+MG)EV[^#;<W^@BR0M<N'TX]WO?C%3PDWJ[JY?U]93(UL,F:9,U
M'0?"J'!YGF:6J\,<BGQKFNK%MEM\3K<)4TLDUEM%?M$YK_<%N(H"1Y58Y/SK
M 'MPH"TGJL5$IC2B39G/B9')CV,YWS:'!2L/8#E&;)FX.1C?FXJU*JZCW)07
MB=ZMX3/IQ7DJKQ#'+DAT'=9%,7J1YSUAN[>%66XZ0DRJLF^G(J@@3=A%("J9
MYDQR"?7Z9/+.<$,M;7F*-J9T4O$XVK9W*8KO 9MP+$T5*X1-5?FXFPW5,8*A
M@EL.B=S[:]OE7-SA&R"(2XH'B7$3^D7-9(&DI[C214PS/%^QE"YX1.+&KL9T
M:4H#H\'N='Y/DT:-&E*-&C1I2L\1$  1$0#CS<1$1QQYP\<N;B(\,><( .7
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MQQ4I^^ > />#1P#P![P:9SU47KXEH;\>R/T9Z/51>OB6AOQ[(_1GI2GCX!X
M]X-' / 'O!IG/51>OB6AOQ[(_1GH]5%Z^):&_'LC]&>E*>/@'@#W@T< \ >\
M&F<]5%Z^):&_'LC]&>CU47KXEH;\>R/T9Z4IX^ > />#1P#P![P:9SU47KXE
MH;\>R/T9Z/51>OB6AOQ[(_1GI2GCX!X ]X-)U\''%;&P$R/ECD]XXXXO)89*
MS1%,;QP8,OUMV]G'+O<2N(<0[P9M]ZJ+U\2T-^/9'Z,]<=SE=TXJ6;%54M<)
M#,W( 1$N-SH%BA>JZD( D:S<Z_3"WKA+',P%A9:PP,< *!,.)@Y@I3]\ \ >
M\&C@'@#W@TSGJHO3Q+PWX]D?HTT>JB]?$M#?CV1^C/2E/'P#P![P:. > />#
M3.>JB]?$M#?CV1^C/1ZJ+U\2T-^/9'Z,]*4\? / 'O!H  #H  X]/ .''3.>
MJB]?$M#?CV1^C/1ZJ+U\2T-^/9'Z,]*4\FC3-^JB]?$M#?CV1^C/1ZJ+U\2T
M-^/9'Z,]*4\FDZ\Y8XN48 36 O+-W-QQP=RQS<31ZQ-^PCN0<>IN70)N0\ %
M+Q#C[ M[ZJ+U\2T-^/9'Z,]<=RE=SXK6+%74U<HS\G$P&],NN9 L5N2H$V?.
M2-2C. )LFQ7B2.9V:PHA;GD4'6_4,0,Y^E*?S1IF_51>OB7AOQ[(_1IH]5%Z
M^):&_'LC]&>E*>31IF_51>OB6AOQ[(_1GH]5%Z^):&_'LC]&>E*>31IF_51>
MOB6AOQ[(_1GH]5%Z^):&_'LC]&>E*>31IF_51>OB6AOQ[(_1GH]5%Z^):&_'
MLC]&>E*>31IF_51>OB6AOQ[(_1GH]5%Z^):&_'LC]&>E*>337GTA2ZJT2;P5
M5'62FZ$[$,73VTH@D8/L@F.9(U+:+&7-#6S-_!M[&K5K7BG%<(8-*U:T898M
M:Q2C-Y?JHO7Q+0WX]D?HST>JB]?$M#?CV1^C/2E;%<[?Z'I]-UE4U*5-620)
M,LF@)X#7<1B96$P7L9\86RDH&1H19$OZB,*5,9R="<BU9<;4'QY.82R&YH,D
MA:VU.BKD98-&)G7D1412"RJ"R)/$R8?#C(Q(&JN4$W11.OI.Q+V!:W.-=-)E
M@2)S;XN40E2M+LI[(,V;:H.6YJE/ZJ+U\2T-^/9'Z,]'JHO7Q+0WX]D?HSTI
M7R4;;MO*NO1J571-.*:MRC3!#,JZ-K.&C"\HE%'A9(HO&O4[BS8MN#-&Y$XN
M$BCZ$LC IED3@X/[9UJ\KUBX_<:]O]#L:V$.3+2E2LZ^LXLC@]<+&NNHBW'0
M"&-S^SRINBD,%&T$XQF/-\HCS#)6]J9\$B1!(F9M?$19#HD*5A\/51>OB6AO
MQ[(_1GH]5%Z^):&_'LC]&>E*2MX[6ZKO*IW*HG%J10EE5L;!&6YRAD2KTTYF
MB\<DS-+$4*QC4PA\J@;]6ZUU8T.+_6,HBKO!7Q)@&*IE+6IV]P0]?;;MWK[:
MU4S54%:X+LF!"_3"6N+BZ$,*-P?I=/Y*OEDN?U+9$V2,Q!BP<GEQ.ZPC</C4
M=B<<:B$#(P,J!O0EX9=/U47KXEH;\>R/T9Z/51>OB6AOQ[(_1GI2GDT:9OU4
M7KXEH;\>R/T9Z/51>OB6AOQ[(_1GI2GDT:9OU47KXEH;\>R/T9Z/51>OB6AO
MQ[(_1GI2GDT:9OU47KXEH;\>R/T9Z/51>OB6AOQ[(_1GI2GDT:9OU47KXEH;
M\>R/T9Z/51>OB6AOQ[(_1GI2GDT:9OU47KXEH;\>R/T9Z/51>OB6AOQ[(_1G
MI2GDT:9OU47KXEH;\>R/T9Z/51>OB6AOQ[(_1GI2GDT:9OU47KXEH;\>R/T9
MZ/51>OB6AOQ[(_1GI2GDT:9OU47KXEH;\>R/T9Z/51>OB6AOQ[(_1GI2GDT:
M9OU47KXEH;\>R/T9Z/51>OB6AOQ[(_1GI2M^>VBF@DXHJ$G,Q[D=>,_ET"1N
M)2XM*5'3HG3=BW :YJDV:4_-S*6I:]/8BTA)R+,A0Z$N&1YI2,Q&HB9;V]UX
M@%^S>BH[%MNV2J"12II(M>+TW@LVWES?S;83RM4@11")+J;L(]\1L^,6S2*W
M;LVE%8Z+RD"9MP%.<<,@[ZIB=VJXTO)JRL-EK><TE8[[8+&YR2KE=N1]V*DM
M3V#4;PS.D606!6BTH!:+!5N2%U3R4.M'%O3%'MZQ.H,QPCN^;/+G<+2DMNXW
M/MY7S2=PBHHO/<K V4C.T.3]4B:8H4K[!DSAN3:ET%;'M'+0S4Q98ME1S:YM
MH+TDB-+7&(B%*3*SE$%;1<3;!GFJH/A G;>:.RA$_,NXIC=+IQG*EZSB[;-E
M&WE;6S(H,@N<AQ UZ%ILUU?V"&"=.CFM8TM[DG2:%#<HN\VW,]J[#(Z>K^/,
M6[MIF3C7:VMMRK7=$YA1D4K)UMC'.XZT3U+ UL(854>9E# [2=!(Y$WQ6?.4
M9BKP7EC)&]SU+:G]K=8U#+[ LM-$8>]V-/[EM*W3K,4US&&^<-@6>ZE+%,32
MS7!&LD2AN9T963$2L!X39N#8((CT*=*3@E!A*RY.VK*?<-E\CKSU*Q27;344
MH891-(W4T3C<BW QJ9TU(*N?F&>/; I;G-#BL?7!AM#+)<X3 E5*H@UYKD"Q
M46E>FU2K!]&C1I2C1HT:4HT@;*D[9#HQZH7EP:VQL0O#+UVH=6L]X+RP/7%D
MXD(T27',\7$TS/$$AY>(BF$,SAR+QQ$S%?:CWND- JE9((JD"7GN49P 5Y/5
ML3A%_0CU!*'$.IK<PQ'(D[]1A@:'''G<_&ABMU)8X9B-Y"$,MI8W=S&) 2AD
M@@DE0.%*DJ64!@&4D9Y$';4-S(T-O/*N1:.*1U# D9JI(S ()&8VY$=FOIGN
M?IK$1 9"Z](][U+O@CPX][C_ ','?X=(^R/L  ][YCNDI8.F1.P<.G_>J^^Q
MT_\ %]5=G^Q^+\NN?G^J_P K\NOA[=5'2($CK?"?BUST>[>SX\/DVT@O@2-2
MVV9?HY/K:M/'=520=\9&[_!1]^KZ^0[L*.#IDKO\$W[ZM\FJH\_6C^+Y0US\
M_6C^+Y0U#]U72/,#K;". ^EKKBR]V])K4Z0WP!.I;;!ZW)];T?XGHRMG'=O1
M0#P&3/'P1?\ ZMKYCN\H<./&3O'>_P#-"0>S_P#DNJB,_7#^+Y UH9=.7NX_
M(.JS=5K28>EL'X>.UNN13[.Z3VZA.DN( CREKW.3E4>O=)[=7!Y;OZ&Q 1&3
MO(  <>/J0D ^QQ]A+QU\!WD4  !D,I>@ >C_ 'G2+I[_ 'N'6G3WO9[WEU3V
M=^AY>X/^J.N(9^A8_OOZ6HCU7M)\B1;8-PY#S+=[.//T?XYUIY)\0];M#_\
M;E^:85<UEO-V^8],J>OQ0V1C\B0=<!\WG4(<4@!',#BLBG=O./%VK^3+"\DQ
M1F0G8HL01_:7$0X=:*>\).7.R#+$1YVJ=C?9_>C^77"69<W L>>3AQ/+#[=C
MSPRXB/V& >P9E^HR_4\!'6AZK^E ]+8,<_<MWRJ!Z?Y"<^7HJ!]+,24Y"*SX
M2/Q4W$1R3_3P]BKN\M[6W0.(C+'S@ ^S"I,(]/L\$7?\HAKYY;W]N./$,I<^
MA[D(DP]_AQ#_ (E[/AU2$9T9>[^77/.Z1]T/DU W5DTJ'!:X)PY;;2[Y%/.
MXR?>[=1-I?B:@'<K/;[5+TCU\\G^)Z*O'RWS;:\0XC,'X/\ L-)_J6OP.^O;
M2'?&8/\ PX\/TBRCY.L^/^C5$QWK?[>$-:6?0'N_D'49ZLNE8R\RX)M('H2\
M^T>CO\IJ-M,,5#9".RRR/Z*7H]OZ:OB'?AMF !'U8O\ WO\ S$E/U+7S'?KM
MC#B S*0<0_\ ,.4_4M4)Y= ^X/R:TL_7#^+Y UH.K/I9[%P3@/I2]XAGSCT=
M_E-1#33%B0-RL=I]9F\(J_4=_.V#'IF<@Z>'Z0I5]2\FOP._W:\'^&DAX^#U
M ROO?_P/#_3J@$WV?WP_EUI9=(^Z/RZC;JU:6 *1:X'MV^A+T\G]8]OW^4UH
M=-L7#9;E899C]#-QY>Z:] X\H#M;#IFDA^ ,K^HZXKOO^VR'9-@I9RNP!.ZI
MU"OLE6DN699)"\,^J8MP@@_N5P'G !*KB'4\1SX9!WP&@;/H#W?R#KFJAX!Z
M[ ..6(<,@XCEWNC#P9>R ^ ![_?UC[M>EHS\R8&=FSS)>_:)Y.S4 T[QCUG#
MSV(9_"37H<'E#=J@ (C-Y%WO_D^EP_(WCK\CRB&U( XC-Y'\7LNX^]V/XZ\[
M&?K1_%\H:U3/8_'^36AZMNEP"Y6F!9G:?,E]T?UE_//LYZ>3S&<V&XX?L!/X
MB?H]U5Z+1Y17:>'3.9'WO_D\F _(W:^7YHUM,]O,D^+N8?[.UYR<_6C^+Y0U
MH9= ^X/R:C/5OTN )ZTP'9[DONC^LOY^^<XEZH&-GA@P[C_07'%E[KZ:](0\
MH]M)#IG<D#_ZG4Q'\8<&[OZ_(\I#M'#_  [DGL?\G,Q\ ^!N$?\ 1[.O-GGT
MA[GY1UK9^N'\7R!K7[N.F&KGUI@/#EZ#O>0?UEXYGHRC/5#QL'\1AV6L!^(N
M., ^RO'/L5Z4AY27:('^'DF^+B8C\C?K\#RE.T'$> SV3 />X_WMYEWN(<?8
M;A_T>'W=>:;6F;^B9?B_U0UC[N6F'L3 ?B5[T?UEV>WV*R.J%CA .XX;M /X
MBXZ/=7CF>C+TPY<I;L^QZ9])OBVF?N_M=KD.G*3;2CE#.8EL%SQ*2N(*%O7]
M5314>*4"3,!Q:S ;A!(N'/, !3WN!8CB&7 <L<_-.;[/[X?RZ^!WK<.^ <>'
M2''CX #P#Y>'>\.M#U<],1J^9, V@D^8KWB&?.7+5<=4?'CG]XPS8,Q]XN.4
M</FL?-Q]&7IQ'E,]G0=\; D_Q:S3_9NOGERG&S?'IL"4>Q_R:34>D./[6Z\Q
M&?0'N_D'6B=TC[H?)K7[NNF/L/1_XE??:=0MU2L?# "#"\B,_0]SQ$#V97J"
M'E/=FH=-@RCXLYM_LW7X_-0-F0?\H4H^+*;?[,UY=,^D/<_*.M7+I'W1^73[
MNNF.0/6F <)])7W%E_67CMZ,HVZIND(.0@PK@]C7/3[LKU)Y<J'LQQZ;"E/Q
M8S;W/VLT\%*;SMN>X.2K(;5\[-<Y2D;3';!C>X\]19>XMY&7-6GLI;XE2XO&
M3=CS3W).@S-5(DF>*PXD$@&G%>00[H'W ^76ZPR%^B3XT2B+O#C'Y''W%*[,
M;XTJ3$;FU.:,P#$RU$I+'G%'%9<0$!#,HXK(Q.H*.3G'%9V;+J[Z3)=V[7^'
MX//9"1.NHK6"Z@N'AX'W":2]FC24#-DUXG0L K  EA+;=4_&5F1KNTP^6V4Y
MS)!%/%,T8\]N<CW,B*^6U=9&4G81D<Q[DM&JZMB6^UAW/L1<)FAC?'[UC[?D
M<ZM9(8(VR?-:+#$%$MB2?++FE*2L>:;)HP4.1C,;GDXMP',1P=CK%=?IK!<:
MPW2'#;?%<*N%N;2Y7-6&R2*09;I!/'F6BGB)U9(VV@Y$%D96;[+AF)V6+V4-
M_83":WF7,$;'1QEKQ2IF3'+&?*NAV@[02I5B:3KR=B6YQ<L5;(G$]V/PQ(=$
MW5URT<4)N74&(W@()7#']$-.$<>*?B6 Y#D&&:BTG7E1B4Y1@H7!G2"H=CBP
M3.24%"UQYJ(T>MF4WOBC78"(&&'][BG'(OC]ES#.K5^E%HT:-*4:-&C2E&C4
M;+\W*,%+KH9!66/.-H7I:BLYOJBF(XL(1/4ES3B(.$FDCP>4I1P6MH[CB:ID
M\Z=TQJ1$G3*2&Y(YKRC$Y+V0K&9XQ-@"Q#HN?.<FTHR4Y0E.ZIHD6\'9F'*$
ML>P?5*MX.;$&!A2 A<XFEJG3)-FYYI&X%F+<DJQWMO-=3VD3&26V53<E%)C@
M=PK1P22Y:@N'C82[@I:1(2DDJQI- 98$N(I)I8(V+O"!NQ4$I$S!66-W\Z)6
M1A)N8)=8RKN%5XRZGT:-&K53T:AMN0W0RBEK%KZLX;!*LE3U-ZQM>TU#K;VX
ME!MWC#6SU9(*VC:AI1/:^L+**>GMY6V0B58E&DLJ)I:VE>N5JS\,L<"IE  B
M(!B Y9"( &.(#EED(]X QQQ 1R$1[P  "(CW@#CJ/-F;7ZXMJXH!:UGQ&+3E
M-7]66;6[3"+ KF.S)DS.LB859*UDM3#*T+B2WN;016>#(&"5KSR5H9 K,/7I
ML$>*=6I3+5;RC6UVQHAM\?G6:F5S(]Q%>U#/6"$RMHD"PV'#>!2LFM([8L\C
MC(ZUC!W2>O38[,=:'2^71U-::MOZI P> 5IB<MXKE -O$B9$$HKF8(9E&DTI
MB2&7.#FU61 %J.!3:'6E+(M95:LDMK1,YWFQ2X:K?D,".K<I=&IX2CD+A&YF
MJSC![<XIVW=DLAL6QIXX1RX&J%4U>+[MND-[UL95:)_ESLLVP.C6OAR.J+"+
ME;*TUZU3%%&H@QS@B20&PC6Y#'C5T",CCF^+#$C8T-R;;Q4SBW*GV[FQ8S,%
MIUI9;%!*OKN5UW613G7K5;K4Y2)+6\CN6QX96\[L8JUL<IB713/5]2)@B;8#
M)5))JS%0TJ4]M#;_ "B;U;VA]32-BA++.8&QVC6*>7/QS=+I%!#*8B5R3AQE
ML87L+617SM7[3*L 7,RE]D 2&,(\;!87 Z.K P2N5%]XVVJ:36*5_%;4;GR1
MS=+&#8L:BCDY&*.KC-:\)MR(1'MAGQ4BO$%D2:K%*:Q62JG65(+,7PI2GD),
M2%O/)-,@:X\DFBE]!L%.SJ_WD)&W*-O3>Y3^NJ_(BF;A"*BV[J-HUF0-$S/D
MRE:Y U[BMN+Q*H)-5F3^H41MTDYLC8DR\YD9$9#HX\FRV(=X!^XE#82)+!%5
M\LFY9;5CA#94MD:*S([5#)5[/&X^_'VD35,?K!*;&X_.R"RJ%-M9O?T1[*U6
M6DC2_(DA2MC=-RAJW;3*+Y(RJJ!RN#[;:UJ^T;'<GO<>PUE9K^QV*GDSDH;*
M@JQ]K9Y;["D;.U1A3BU-"VQHF=,Y&L119HR2+SRC\W1AO*#[;'YTL^/2V:IZ
MTD-4R?<NU2-++FN8I&'*.[7)6\,UA2-'/%,/;X(X.S;%FY!8,BKMED3S.8;'
M'M%D[-2C O-9FYJ?:Q5A]]V#N#E,7A<WF,Q::9:X\HE=?11[=ZZRIQNE:1 L
MBDH=TCD[(SW==)^S'.;\6@QF7MQ1J,Y0<I,4%LC9&Q55,X0MC<8O275W),9S
MO9L*.SB/,8EO$<D&\?&PC#A0F(I0TN"3&NE,_4X)W-H=VI^D"),IR;G.%/2Y
M.\MBE+-RY0?:.S1T9*\V<]M"8I_F,;<F)TIB_4%@1Q;7D0CM@SQQF-6*JJ*L
MV$Q*&P*7Q*;26>RZ(,D$9XE*8Y(%DD+;'MN4*'1;MT=!N]L8TDUV,@<+$-<C
MV%,B2,<N/BRZ5I(8GL=7 FVS<(Z-6.=EHZ]5)YVLK)OFJJP$L.,"1J(V6U8&
MJ2ZNU')"S4R/2%K:[QJ-A6R"S7.U4CG'Z)NAJ>*WE\GIF"5#)Y'5-HMF[=)?
MT=E:1-6<;D[.\N=P.#=*U#I+6>W8],V@N"F0E]H#R:">";IT=^!<2B4Q)%<;
MQN)]2TJBTB=+#<;A?JGQK-R/7R_*S,:E00_-V/=[.+&+T$P65ZJWE4P96$$0
M%:C=5*?R?[MWVO;PC=>N^WRP\*A>[:KJ@3MPJ^1PU@9%%RVLUM+G#F.#UF\J
MD\\LZ%)C7]J99C8\3#-LC+P3*>HM+VU0*9.K3**!SN*6;#H_/H,[8OT1E*(Q
MQ87C!"Z-N+@C*6JVXPX$+TA;'5-S%J%60):Y E-R$D3,2\B3"C3(B%[29\&\
M%PW3K[>KZ5)\W%G:H;%I]1#]+Y=3%4EQEJC\PK6CYZ-_-$5KE18:Q,]2.:V
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M"D;S^&78]5AWC<E(\P,BN<6.0\>9G]&KV5*'1HT:4HU5'O&WX6ULKO=@RL.
M162[8YS7DM/A#G%RG;&?96=&&?!8#/*'1<X%-:)(>\&MJ96F;VTP@B(O>,A2
M+53NS+V_.US3=V'4=96UA$R;-@\>G*:#RM'.(JCDB'%R0M,J0(UJ!$\8HC<N
MM59B=.O4<U*X$JV\PX$R@](:>C2&$\C&[3$KRQ,>$W^]N(1S0307#*)(#N<B
M[K%<Q:K&6"2$R QC5)DW,E@%-4,2@N[BV*V%UUI=))%)%*1K1G4<:\<R9'=(
MG0L"@RS;5.8 -0PV%T3-&UJ?=V&X?/LWN@W'(4#\_'K$N)(5?6R@DI5#JIC"
M/(<^P#>G:^L7%\0I0(SZMD@:%O5CVE8<LL3UD1$1$1$1$1$1$1$1$1'B(B(\
M1$1$>(B/?$>^.L:L89A\.%V4-G"7<1@M+/*=:>ZN)"7N+NX<[7GN9F>:5SPN
MY R4 "6RM([&VCMXM9@@)>1R6DFE<ZTL\K',M+-(6D=B?/-D,E  -&C1J_5J
MHT;TE:]!LWW<KFI2I1NB+:YN&5MJM$H4)%B5P34_,CD2A(K298*DJDE3@480
MI2YXJ4YN.!Q @;AAJJ1UVJWM2+#G8T565)MI:[*G7)QUA':PI2:W'=D)QGI>
M[Z .KW?$P;K*:*C08R'.&OIM=F1*/MF*>6L&9ID]E;DWM[.PI;\<L<<@''+'
M'+'(!QRQRQ#+'+$0X#CECD XY8B'>''(! 0X@("&L#CCD !ECCD #CD 98XY
M &6(@..0!D @&6(@&6.0!QQR ,L1#( $%*\X=_\ *0[CZ'*<HJX7+"G":45-
M;*0RU<]5I0]=L%M0R%;IR:M;)--UMB6_&'7#$^N6V0MCW%]J<"=9(V3 I!/Y
M(Z0:-/#!$5_9LWE*MQ-=2_=LD1SF!3,J)S2P([7S?#HK1DRA-55]'-V]4TCE
M9D@D:6[XI8L*E%6U78*U]M2.;PXA6M12R?)T\JKJWNU2RN*1\]!KA'H^['IE
M+LP,+JI1$.B9&I=&1J<E"-,^)NLGM.D/7(U!R5.](O[C>"$^993LD_N5RP5)
M_M>F377;M=C-T*:,<+(I2/WS,(RE=7&N%+I$6F?22+IF!Y7-P/B/,M.H<D81
M%@D;FTLSZJ,4G0]C?G9L;3(TU.*M.I4)*CW +K_V)[A9?>5LRJ#PJ)V/:%4K
M]PM2*(,V3[*I8E((6B?)LI>Z&D=B5A&I4QEO4J@%ASVF):IB\?;HZ_6"PN$(
M=4#BDC.EM!M.607:QOI?88G8;9[G>U-Q+A1L6KFV9_N+J]Y8XM1$(LV%U765
MQ27#.P;!2X2I4X,\Y;<$N!\%M!^F=:P_ YHC;(>9*YKWM['$]9K9DR;D]OA%
M5Q9W*KTU<SS"-DQQM>38RMEB"'-K$WX8&*#76$I'&6L#.QLZI-(X:E<)+'RW
M./)EB\O]1S>ML;10-_DD1W+;<V^MJU<(LPN[I&IU$6Z'QMQG6#HY0=L:\6C-
M,V*3)P8V/F<-*BQ"\N7.S8]H(\+F^-[DD)4JK+;7O?W8[F))7]01"YX&F+LB
M?5(VO%ZX5QM]FTAA!,\VN;A[RF4)CL4I>XK7ITE2C>*H@3I7JNPWI=8$<@\T
M=FFT(>_NF44D[DIV7>QNZ=ZID%KO5BU'#HY#*3V/-,F>5-,J36.-S[=#;J^N
MK=W,352?+%8MM<TW#(ZJG3%7*<YLC2!W<G9;8\T/@3*20FL89-Y>TYN3OKHS
M3^M66HT%:5W>1%Q,[I%TM628N[;-L^L&=$QJV0 5NM@.DUJU\;G-N+;39&[/
M"U$QXIUD@(<F]-\5&^C;&\3R)U' 9] [6E]@Q2I)LW,D5FU=X-;E4ET6AC3K
M9-DKC('YO:Y0B0/*SJJ^"-.*^7R!N5DM,;8GA_<2V,Q2JLVJ^K-M*ZXR0YVZ
MUVZP0:Y*?J6+736R+")PZZ8A'^4TV8(E,J%EBRY3"%+^S#,9K2\\>(4>="9(
M\0>3G-*1I0+W.,MJ@BVZS?0:R5E9TBO"ME;)**#VG;GG^!(-NK UMN!5V;DF
MBCY;5".3'2U7($<010US-DB.0'''3M%.B"W?U1^HSJL"SL_9M[&QQ/$YZ[Q_
M<MMT2P:BH\Q.T\<6><Q%)$J\BCR\YQV-+\CT.13.7'W*5$F19C.C77S<IF.
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ME9*5N!T!W^/>Z?#Y=&C1I2C1HT:4I&M5?Q%DF<VL%L:032ZQ$4+;Y@ZBL7'
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M4JQ4LH#!6!(S (.VH;B1HH)I5 +1Q.Z@YD$JI(S VD9C;EMKZY[H*9PR$,I
MZX]/>"+O@\/)QZV#H\.OCENFI3  $9&[=_\ \U'WZOJKI1Z_+V/L>CP=X=<L
M_HQ]T?DU\./51TB&?F?"=F?I:ZXO^=KR;:07P.6I;;,OT<G0?7:M4RW6TAB/
M#*2.X?\ 9-^'Y$VOAENUHO$> R9X_%$G\?\ 3UMJI\[UW]O &N2?Z[+]]^0=
M5VZJVDHSRM\(V'+T+=<@/L[L]OHK0Z17P*C4MMIV_>Y.CVWQS[%6XCN[H?'C
MQD[P'#I_WH2#R_\ Q7R#KY9[P:$+#CG*'D [W^!\A'I'A["4>@>G5/YWZO\
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M>7XJ7]GV_I-7GY[Z-M6(]^7OP<>(@'J&E ][P<>LOEU\LM]NV?'UTQ?PX_\
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MSQ\>*N<=Z[^W@#7)/]=E^^_(.NH=GASOT0O^$P\ ?NM<D_,OG#]L+]=]TP\
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M\9D$JC"6$2A]CU70-D>I+"T+8A9$,/D3JV1]*O?(JC96QM9TT<=5"MF*:FY
MW8H@1(DI!+MG9@:<>: #B!IYQH8CPXX@:;F8 #P[W$ RX#S>&/$!YH '  ^>
ME*1<)K>NJTB9$"K>OX-7L%2]DNM83!(?'(?#TXO)AIKP),7CK8VL18NYIQQC
MJ.* !<LSC<EHGB9F(_F 5I6]3Q\(E5=>02L8H#@L=@B]<PZ-P6. ZN/4NR#G
MV"BK8TM79%?U CKU>*05:H"",3SC,2"L<%MHTI1HT:-*5CB'A#WPT<X.\'.[
MP"(@'.[P"/>$0#CPXB   CPX\ X:9WM4/WCZOGX10+T::.U0_>/J^?A% O1I
MI2GBXAX0]\-'$/"'OAIG>U0_>/J^?A% O1IH[5#]X^KY^$4"]&FE*>+B'A#W
MPT<0\(>^&F=[5#]X^KY^$4"]&FCM4/WCZOGX10+T::4IXN(>$/?#1Q#PA[X:
M9WM4/WCZOGX10+T::.U0_>/J^?A% O1II2GBXAX0]\-)F5FEX-Z,,U[@AP->
MFDG+-L;"W<U0&:D!ZS4I3"3\<$*GF\U4J$L>ML<<3._ZW)!]JA^\?5\_"*!>
MC36FN@;PP%$JS[MOA=@I5I6S$K)?#W8"\UYH$XJ.MT$!0&D]2[_]V&&G$)AR
M#,Q(I^Q+T(!!!&8.P@\!'(:4\>3>V\X>+>V][(>]U@A$ [_0'$CO@'0 ^R'?
M[_3K'8]L'I;FP?\ JY!]7TU/:G?@$0[?5\CP$0X^J*!#QX=[CQ"M  ?=#O#T
MAWM':H?O'U?/PB@7HTUIN<?K:?!7Z*QJKZD=H4ZO8YK_ &N:_-K?]6UCL:UC
MTMK5YM;_ *MIJ^U0_>/J^?A% O1IH[5#]X^KY^$4"]&FFY1^MI\!?HZ!VJQJ
MKZE>T/'B':IU.QC5^UC5YL;_ *MK'8MI_:MI]C_Q8W>QT?\ %O8]C36=JA^\
M?5\_"*!>C31VJ'[Q]7S\(H%Z--8W*+UN/X"_1T#M4U5]2O:'T4Z78IH'I:F@
M?^JV[ZMH[%,_[5-'FMM^K::WM4/WCZOGX10+T::.U0_>/J^?A% O1IIN47K4
M?P%^BLZJ\@[0IT>Q+-^U+/YJ;?JNDY)$#.F(:\@)P;NJ/K60.;3&6QR,5@8;
MF H%F H3 3-RGH5*QYH$!CB/?'( %(]JA^\?5\_"*!>C36FM@;NQ8IC3[LOA
M<#@M2M&& KX>Z=1,7YCABH M% 4.242N8/!<?FH3IN(B8B4\['$&Y1>MQ_ 7
MZ*QJ(>%5^"/HZ!VJ=[)H9>(_[CLG2(?^"&L0Z>CCUIWP^77Y[#LO[3LGFAK^
MJ::_M3OP=[M]7R/#O<?5% AX\/9X]K3O\=':H?O'U?/PB@7HTUC<8?6H_@+]
M'1W^4TU$]2OP1]%.AV&8_P!IF/S.U?5-8[#,?[2L?F=J^J:;#M4/WCZOGX10
M+T::.U0_>/J^?A% O1IIN,/K4?P%^CH[_*::B>I7X(^BG/["L0]+(Q#_ -3-
M7U36.PC%^TC%YF:OJ>FQ[5#]X^KY^$4"]&FCM4/WCZOGX10+T::;A#ZU'L_8
M7HZ.@4U$]2OP1]%.<+&PCTL;"/NLK3]3UCL&P_M&P^96GZGILNU0_>/J^?A%
M O1IH[5#]X^KY^$4"]&FL[C%ZVGP5Z.CH'B3343U"_!'T4YO8-@_:-A\RM/U
M/2>?FAA),8^")(@ZL^I"<@;8JT+L5P9X&_W$Y"+>9UFW&\.<<LXX=3'''OY"
M(#BD^U0_>/J^?A% O1IK360%X9Q1X'7=?*L7=:2TE#V1AS@*8Q0&>0* R20!
M("#F<S_OY3BK3E!QQR2'<[CAC<8?6H_@+]'1W^4TU$]0OP1]%.QV"C_[1,'F
M1H^IZ.P,>_:"/>8F?ZE_;HTV?:H?O'U?/PB@7HTT=JA^\?5\_"*!>C33<8?6
MH_@+T='0.U343U"_!'T4YG8&/?M!'O,3/]2T=@8]^T$>\Q,WU+39]JA^\?5\
M_"*!>C31VJ'[Q]7S\(H%Z---QA]9B[FGT4U$]0OP1]%.7V COM?COF%F^I:.
MP$=]K\=\PLWU+3:=JA^\?5\_"*!>C31VJ'[Q]7S\(H%Z--9W&'UJ/N:_1T"L
M;FGJ$^"/HZ!VJ<OU/QSVO1SS"S?4=8]3T<]KT<\P,WU'3:]JA^\?5\_"*!>C
M31VJ'[Q]7S\(H%Z---QA]:C^ OT4W./UM/@K]%.5ZGHV/3'8X/\ U R_4=:3
MCBE;38VD1*%3*F,>A+Q0L341V/6B808:8D<L$R?$EO0FYAU8Q7B!0YG@ YY9
M9?9EH+M4/WCZOGX10+T::TE<!>&HU"F-N^^563TL!L)S[(PY=UH8)1AW7'5D
MT 2E-W#FAQ6+"UI   X=:B(Y&896.-#FD:*<LLU55.6S9F #EL&SH%9"(IS5
M54\&84 Y<FP4]_$/"'OAHXAX0]\-,[VJ'[Q]7S\(H%Z--':H?O'U?/PB@7HT
MUO6U/%Q#PA[X:.(>$/?#3.]JA^\?5\_"*!>C31VJ'[Q]7S\(H%Z--*4\7$/"
M'OAHXAX0]\-,[VJ'[Q]7S\(H%Z--':H?O'U?/PB@7HTTI3Q<0\(>^&CB'A#W
MPTSO:H?O'U?/PB@7HTT=JA^\?5\_"*!>C32E/%Q#PA[X:3[PI ERC)0.+JCZ
MX=32Q3MZ(5*-R $1F76CNHYF0(46(\#L#QRPYYV(%@(^N+;WM4/WCZOGX10+
MT::TE, >&T]O0F7??"@Q]4YH"3A<(<N%'F4G-49'8J4T"2$-8CCCS>NUQ#@1
MD( 7BFQS#JQ:E/?Q#PA[X:.(>$/?#3.]JA^\?5\_"*!>C31VJ'[Q]7S\(H%Z
M--*4\7$/"'OAHXAX0]\-,[VJ'[Q]7S\(H%Z--':H?O'U?/PB@7HTTI3Q<0\(
M>^&CB'A#WPTSO:H?O'U?/PB@7HTT=JA^\?5\_"*!>C32E/%Q#PA[X:.(>$/?
M#3.]JA^\?5\_"*!>C31VJ'[Q]7S\(H%Z--*4\7$/"'OAHXAX0]\-,[VJ'[Q]
M7S\(H%Z--':H?O'U?/PB@7HTTI3Q<0\(>^&CB'A#WPTSO:H?O'U?/PB@7HTT
M=JA^\?5\_"*!>C32E/%Q#PA[X:.(>$/?#3.]JA^\?5\_"*!>C31VJ'[Q]7S\
M(H%Z--*4\7$/"'OAHXAX0]\-,[VJ'[Q]7S\(H%Z--':H?O'U?/PB@7HTTI3Q
M<0\(>^&CB'A#WPTSO:H?O'U?/PB@7HTT=JA^\?5\_"*!>C32E/%Q#PA[X:.(
M>$/?#3.]JA^\?5\_"*!>C31VJ'[Q]7S\(H%Z--*4\7$/"'OAHXAX0]\-,[VJ
M'[Q]7S\(H%Z--':H?O'U?/PB@7HTTI3Q<0\(>^&CB'A#WPTSO:H?O'U?/PB@
M7HTT=JA^\?5\_"*!>C32E/%Q#PA[X:.(>$/?#3.]JA^\?5\_"*!>C31VJ'[Q
M]7S\(H%Z--*4\7$/"'OAHXAX0]\-,[VJ'[Q]7S\(H%Z--':H?O'U?/PB@7HT
MTI3Q<0\(>^&CB'A#WPTSO:H?O'U?/PB@7HTT=JA^\?5\_"*!>C32E/%Q#PA[
MX:.(>$/?#3.]JA^\?5\_"*!>C31VJ'[Q]7S\(H%Z--*4\7$/"'OAHXAX0]\-
M,[VJ'[Q]7S\(H%Z--':H?O'U?/PB@7HTTI3Q<0\(>^&CB'A#WPTSO:H?O'U?
M/PB@7HTT=JA^\?5\_"*!>C32E.TL6(V]*H7."M(@0HR3%*Q<O5)T2)(F*QYQ
MJA6L5F$I4J<K$!R-/4'%$EXASL\\0[^OT"I-D;U#%2FR/%,6LZABH(R/ZS-,
M$HI9U'$P312&&XY%%JN9UN8;CD5@;D9B.(5G\I]#[!OBN:CV?P*NLK%:-S-L
MMR:]D#H^26!0LO;+3:3&U+7CLJM9@B4T""96H]-=>U0T@+&M=9"1+G]$TD%%
MI')U:ZOV69;O8=4C MF[Y*J/N6B:)I/9Y<-H.+?/6F,R+"C-YMDP5]7I;R;J
M.M,V"Q>Z:O20&;(MQ2>F)DTQMNF2=P=62-D.RV1Q92O3O^IYP\0Q[_V8@/,$
M0 ,A ,O6B(8B&0@ \0 <1$ #(!'Y@<3D9D5B<3D;@ 99E8FEY&X8CS>&6909
MB9AB//PX998@'V>'?^SPYWG:B4OW13Z>5BL:-P>[B"32^*$V'QAWP>X14[F\
M-M=Y;NMP,$OFTHYB30R>$)I,J@26&/26T%+(PY%-%KLMG+JU82UD>B413,PG
M.X"'6?N"E-*2RTD.[R4O&\%FNRO$^W&,O#+5=5PE:V1/:G<T<D:VM3LY%*):
MPP?;^H97-YFT^9MPQ,EEJI7#$I-=8%UZI7I.#+$>C(![PCWA >\ \!'W 'O#
MY>]K.JIJK9]ST#W/(&Q\OG<M:58H]VENT<#%:#/7J^**:2+V9I;VC$V<WF,U
M'$G5<]-=_JE4+C=BYOY27L,415JK!W4)>?E:SI2C1HT:4HTVUL2U+!H:?*%I
MLC+2-CLR"?A%BTV;DIQ4N!24$AHK!Q3EMYV1H N,,S#@6&.&(9Y9XEYN3J/F
MZ/,<*6DG QS+YSC&L1%L+ S+(!?T \Q9QQRYB#+A]OS#FB!@$8\?LN \[%[F
M6SPK$[N A9K6PO+B)F4,HDAMY)$+*<PP#*"0=A&RH+F1HK>>1<@T<4CJ2,P"
MJD@D<>T4B#-XT%PR'C$YB/?$> &,'  Z> "+CT>P''P=_6OGO.@6  (Q":#Q
M'AWC8]_M#5>RCU^71ZWV.CH'H\G@URS^C'W1^37P-NJ1I4,_-5KLS])6_%_=
MZ._RUX]L<Q $C=(^Y)T='CF?>L5RWK0# > PZ:_B-COD_P 8AX=:V>^"O<!$
M!ALX'@/#]%CG@\KEJN [UW]O &N2?Z[+]]^0=5VZIFE@X+JU&1R] V_(#QKT
M?XFHSCV(@J-TCVG;]Z3HZ*LMRWT5WCQXPN<][_X6-^7_ !EQ]@?8U\3=]]<E
M8\[*$SL>CO ;&O9'@/2YAT?Z=5B'?J_[?\_7/6?H8_Y/^MJJ>JEI>"HZ[M-I
M]@6W1^QX[>6H#I%B@ REC[C'R*>,=-6@9[^JVP$0&#ST>'3P-C/@X_MIX-:^
M?*!UI@( ,%L >/@-B_Y78/R:JN/]?G[@?ZH:Y9_3C[@_+J(]533$9>;+3;[@
MMN51ZCO].?#4,FDN*J,Q+%W"(\&0]3X^^<[71Y0RL0'@,#L'\1L6_P!K>S_[
M>&N$\\H76AQ:("HE:K=U%Q1J<S&PR(CFJ**SR'- JZHZ9AUBI >:I$ X\ QX
M<X.\-5>?2'N?E'7$<!X8%_9'X\32P^T!QR'B.7>,X]!0_JQ\'#4#]5C3-6(%
MY9^_A]J>,CC3H'B3G =*,7U1]^BX<O0\7!FO[-6]Y\H_5> ]^OK'[_$>\=$^
M >3OO'1[_P"/7PSY26J<!X#7MD#QZ! Z)?E> U3T?TX^X/RZYY_3C[@_+J%N
MJSIH."]M.#F^VY0/4=-1/I7C*YY30[,LL[>(\G1_\5<?GREE3X<.-=V4/'P'
M1'R_XX\FOCERF538\>-=67T<?T:(]'GG5,Y_L?B_+K1-]G]Z/Y=1GJMZ:[/-
MMIMS_H^UXM7]CI-0'2[&P/Q\/"!Z&AY0/4]_YS5SX\IS4@#P[7%F#_\ CHA_
MMG7Q'E/ZB > UO9W\-#_ /;6J5L_7#^+Y UH9](>Y^4=1?=>TW]FV?R=:_P5
M ^F6.J%(G@VD^EH>+5R_-\<S5V.?*CU!APXUK: \1$/T:'>Q_P!=^SKX#RIU
M/ /#M:6E[O5H;_MP?RZI#/Z,?='Y-:&?KA_%\@:T/5@TX&MYMLMF67X.M>/^
MYX^^:B;37'P5 G@&9V^98>4<J^.WEJ\7+E5:<QZ:RM0>\(]XZ&='XWT-<9RY
M5&H%62 2H%<C<"1P)5&@@/@X O)+#,,T"T#'O/BC.YP"8& AEQQ 0X]X0I#-
M]G]Z/Y=<H[I#U_KA]9T>SZ_P8\>G6AZL.G !/7UGL'-UKQ?W*A\G&D&L!N\'
M#[%@X@IXU[?'P\NV]X>5BI@.FL+7_$="O]O:^0\K12P<1&KK8X=[]?A/^WO<
M]CR^35#F?2'N?E'6EGZT?Q?*&HONR:=9 ]?67"1^3;3BR/J*B.G>D69\T6^P
M'TI!Q!2/S?'WS5]>?*VTI@'$:LMH0X@'>/A'E_Q]X U\,N5TI+$.(U7;8]/Z
M_!^D!X#_ ./_ .WDU0>?ZP/WP?(.N<;ZS\>7^L&GW9-.O9UE\FVFW@Y4Z._R
MUK)IWI&JYBXM\\QZ4@/^GH[_ "U?Z/*\4@ <>U7;G1QX=7@_'P?M_P .GRZ^
M8\K[1X<.-56[W_\ X>#?U@UY_,_6![G_ *PZU#/8_'^34;=6;3Q3D+^RX./#
M+,_^WT=^J[Z?Z2J 1<VP\JI]!P';GTKT=_E->@?+EA*-Q'@-46^(]_\ 7X+X
M>'MAU\1Y8NBPZ:FN'^'@GE_\X=>>XWUX_C^4=:&?0'N_D'6!U:-/",S?6/ #
M^3+/AS'M=5VZH>DX&8NK;A'I*W_@Z._RUZ'<N6.HO$./:FN$>_P_1X)_6'4I
M=O.\ZI-U($EP9;,(I*&!]QR>8$[)VT7E0RF$Y8I7M;DVJER%;$#S\@3J7!$H
MR-:7+$M*Z)TPJ$)YWDUSZ ]W\@Z4<!L&959+V*?P!_6QF6QI;BN:'=#D YE9
MB'4U"54GSXIW!K<$XYHW5J68&HG)$::F4E98Y ./3P?JW:4V^(6\F,]:XAAN
MOJW=O#:06UQN39 RV\L83[]%Y]4D)BER,;E"PECM8=U2<:BNXWQ$PW=D-D\4
M=O%#+J'(%XG0*-T3SRHYU'.:,5U@Z>WC1J%6S'>=#=V$.R <$49MF-(B,YU!
M,#\APZF.6! 2N)]7SR4.$2<% ACECED:MCBTT&EU'+') O<)JZ_4^%8K88W8
M6V)X9<QW=E=('BEC/O-'(IR:*6-@4EBD"R1NK(ZA@17VZPO[3$[2&]LIEGMI
MT#QR+VF5U.3)(C9K)&P#HP*L 11HT:-="KE&C1HTI1HT:-*4:3[P<)3E&, 5
MO:<#W8XH26M.!R%8'6)N74'XP<1ZV;\>'52C0'B*C$,0[X!E@H-)YY,'!RC.
M(*'TD#78TL2FHD#&]3_<9F74I#F. ]1;L1#G%&!EB/77-#O].*E*'1HT:4HT
M:-?H<,PP SF9\P1YH9\S+F#EQX<T,N'-'+B' ,0$1$>]PX][2E?GHZ=?K+'+
M#(<<\<L,@X<<<\1QR#B "'''( $.(" AQ#O@("'>$-5Y6)?4[ORZW?:MM;D)
M\<30%20.Z/<<UITJT*H0'9FEXU=5AJU.K:EUUR+J*E-V:4IUC;!2TZ]7B4>Y
MMJG-%.&#PUBKR(QZ$1K!RQ8HRW%MC<+T]NTD>3R\335!ZQXD#ZJ6O#TZKUBA
M2O<G-P5&J%BU2></4\,L"B^=:8C'?3W"VR-):VSO ][K 0RW<;A98+89$SK;
MD.EQ."L27"];QF61+@6]2WNUNI)1 I>"%FB:YS C>=&"O%",B95B.LLLH(19
M5W)#(ZRB)5:-&C71JW1KXXJ$^9IQ&*@C(]-B3DI(P/*R/3XJ<<\T^2@G',34
M^*C HS-/D=@6"C LS,D<\2\QQ^VJF+8C5Z.6\691ZN)5:52Q2X[;V7PJP+-K
MR*M2MX&L6';1O D<K2,$JE,6DK'%\L9JRU^R.<P1(\G*.K'=N;DRM"XO:,#5
M*M=Q7(LS%I."Q'F:VEDFN16"M/F:VE*"!4IS7$O$T3&\H]-CDH(-6XD%G)\<
MCRLLR@',/V0J2J2"5294F4I5*<M6G5)E!*A*H2'% <2K3J2<S"#TIQ.6)Q*D
MDS,@TG+$TLS(O+'(?.O'SK[=)]04CMV76S%#4]_T)#9S,R:G@L;>+[-[2._R
MKF--?#HBIDT9RGD1D5J6*+4QA+)&D!MD&XMJ>->J6.*&OAU[N5W&,-Q[3Z_<
M'VR('#FY@VEU%:M,+HN1#8.W0NR]E35DX/,8HV#;6U;:P5\=>TDCD2:KAD^X
M:O\ *'6.SJJ4B]7HF!DP;'92O1>ZR>,L+64^/LDCC(R'"F EZ>G]F:&8X5N
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MACPJRRA[X_X RW_8^M'*H+;YP_WJK,^ $N\'_H;49P[$/+^8;S\WTK/_  5
MUK<YIYGGX?6I.4?LTU9OL_O1_+KDG=(>O#[/]1T?Y?[D>@=.X93MNCQX519P
M_8B'>KZ7CW^_X&;7,-INX!$.%36D/V?ZBO9APX>SS_\ <7UG?[X^'O=.HCAV
M(9'S#><!]*S_ ,%5^M;G6'F>?A/Z&3U(_9IK<^D/<_*.M+/UH_B^4-.MG35P
M\0_O2VAT<.]7DQ'P_P")=:>5,7%P$.U):/'_ */)CX?_ $+J+>W$<AY@O>$G
MT+/P>5V_BZ@-I=9MYFN.!OT,G(O[--2?ZP/WP?(.N<;ZS\>7^L&G;.I>XQQ
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M!(Y-3=3;AJ4V_P!VS7>E<U-5362'<&P6!!;>DA5!M-&FRRNMO\7F#O#W.T)
MT7I>4?IVX2H9MU(DL\=$^XO!!*UX,S,I5J\\V9;1+(N"3QE!?[U%+W33PFV&
M"*1&Q*6=;%J%S4;;(1M^E_J6@TZ@L[<!CD_I5D@2F4);'C\VP1NJ>/V##5<2
M?,T#OFYYNRK;&WQPBAX_,)1#)AD[5/=T&7M5G)EUS1)ZVVPRLZ8AEHQ;.8%2
M98]D,3-&(E'9DNF3!,HM+%\G=6V=(W8N8J6Y36F\U'O4I]YW:SFO&N\'NR+
MSW.6"#ZW,R65'960LV0[*VQF<Z>12+!W8692=93;;C#6$90N:R+NL@@,=A"L
MR2L\/;DNN789VY]N@=@/6T3N[9;7+=$I*SL$MW$QZQ"[F/B>5Y["0MP:QDTT
MA:W=J2@5U69N2=H6AE\>-MLZ5,MC*:.CSDV,U2=9*58\Q\FA5,5FE;6+&;GW
M+,LYKIFF[:$H*M!D7KI>YVK:9EOW/,I4F>X*ZM>$TMZ78M:>?OD10Q$5L0C4
M3@+0G9(9&69E21@CO)>S:)TQ<3NP'U.P[J;=W[*=]F+K&I3.V6+5M)2I*:B8
MXE55F.<,D[G'5+;7[A)3#7B5T1/ZZ=9/9%FM#]23U$IBJQ+9*&0G>O<E3/&+
MK-MX,/A\?JGE")C2J>+RB]8#-W27,;SM^2;5FN3S&R$L>W%SLA ^G7B[U&S7
M8B9)+8,.-3H;)BDVC30S+7;\O+KNYD"?<8M33S?97N[5LBVXZ8XK7ME,C>R*
M*Q"NHY"YEMI1%&R]"AJ),@F^<>9&YU<*=6K+?6O<IO1IN[)'%VDMKCRE2VJ?
MDH8DV4S'87:-M6OZLW]MMQEW!JJQL!0W,=XP:Z=QM@[F9'3M@NTEC"Z4/\39
MYA9\Q8BIW&NUA9<BC\FF:$USCD9F:Z&-[SAR;-4%RJ62I-;>Y1M,=&R_6VO6
M1BM@B-,-##N6FZ*RK5<J>2QR+-2UO=G.>-Z9^:'"<N$]-CZ');!FH"*W<W2'
M+57R=D]M.ZML,4W'VTHD:%XW0.CWN'B%>R/- 8=3M068:F<J3JL@4"1)CUU'
MJH3Q%QE1AV)IJF?/LO5XF];*$Q1,YM*5'W;CMO@VV2'2&)0I:]O)\QGLDLV:
M260IH>VNLHF\J+;$SJ]J&*NXE :]8 S;V5G08-<+A$79N:@!P/;U#VO=W5QX
M^[PD3J,D8 A<%W4W6+&B#>LZSR3!A(6_^ZU(]5+ZND)YW U/]GS\C"\^:'4^
MJ%R:U&3=ZGZXHV1!V/6N'4G:*G<U$M!&*;J<B;_[K4B)A?5TI/.X&)@#,3,S
M"\PQQZEU0OC:1?D#&_\ A&(_]G-TCOCLU6O/0EU_9YO^FWCQ=D<-5*G>N,_'
MP[W#C^+7!4])G[\/D#7>.]=GTCZ[O^'IZ/)^7CK@J>DS]^'R!K\D2_G>]\U?
M-VX#V#WJXJCH_P O\F6N0?ZW+]]^4===1T?Y?Y,M<@_UN7[[\HZHS>=\>456
M/'^\O^FN(?T8^Z/R:XQ_KLOWWY!UV3^C'W1^37&/]=E^^_(.J,G%[_S5SW\Z
M?>[XKA'=.7N#\HZX2GUV7^5\@:[IW3E[@_*.N$I]=E_E?(&J\G#VO\B5 _G/
M?/\ IKA'= ^X'RZXZ[$<L2@ LTS@<4/VK/F#APR'[9D/$.<7CTY8^R'OAV#N
M@?<#Y=<=?CSL2OM9AO-.*RX%Y\P<.:.0]4R'B''#']5CTB ZJ_G'LGQX1WQ5
M1N'BX3P\' O2._7//Z ]T=<L[HR]T?D'74/Z ]T=<L[HR]T?D'4#\(['SFJ\
MG%[_ ,U<8_V?\O7-.];_ &\(:Z1_L_Y>N:=ZW^WA#4+\'O'OK51^+L_ZS7(,
M]?E[NN8H]8'X_DUTS/7Y>[KF*/6!^/Y-1-PK[W^0U2DXO?\ FKE9](>Y^4=:
M!OKQ_'\HZW\^D/<_*.M WUX_C^4=0MPC]U/\BU"WYO[P^>M$[UW]O &N09T]
M CPRX]X>'#AQ[XCQ#O>'77.]=_;P!KD&!Q$>\(_9#[/#AT]\>^'>#V0UK4!\
M^W9;_36KGT![OY!UR3ND?=#Y-=;/H#W?R#KDG=(^Z'R:A;\W]T?/7.EX_P!X
M_/7-SZ ]W\@ZTS^C'W1^36YGT![OY!U\RD:MP5(T"!*J7+ERI.B0H42<Y8M6
MK59V"=(B1)$^!BA6L5J#"TZ5*G+,/4'F%DE89F9XXBR+,  23J@ #,DD   #
M:23L '#48!+@ $DOD -I))V #C)I6U38MC518\5G53.SHT3YH=$Y<?,:4QS@
MH<U"\TI&,>4,Y..8R!OD F%MBR/YE'8NV)Q9!98*@3'%>WVHY!.Y56<'D=G0
MXBO[ >8XW+Y;#4SEB[D1]Z/*#)6@+6X@'. !YIHIL\SSD&1HMYZI6>E,5'5?
M<G1R<J.CT[7=UV-29=<RY*"B,1E2!*M'5:)62.(YYCB)B=7/5:<S(IQ<2LC"
M(Z08:T-!N:C-Q<55PW1T:_7G4AT1QK1O"[B[Q:YN(!BHCFAP-LMSLP ,KNX5
M@6BOIX]5'AC,>YPA%NA).J1VGWS0'1_$L'M+BXOYY8Q?E)(L,)\I;@  3RA@
M2EU*H"M&A75C"B?7E"I :-&C7V*OH5&DE)4PGN$4S!K=W#K9_P #A/;7+K%,
MV "-3B*UU)ZN5U^A#G=3%+S#><9F \W]0:K=)"3(^NG&)&]B'-RZS?\ !1UP
M@<@0D-7]QJ<.OW$@3B^R"/'G=3R2ACGQSS >:/'F&*4K]&C1I2C1HT:4HT:-
M&E*-&C1I2C2-DJ05#S##0:GE?UH]J#A5MKD*)$U +8J+Z\>$W5RP<4F8Y G+
M3#@8.)QG5  . X&K+2.DB,5#S##@9W1RZS>U!PK$#GUBF9N<UJR^O7-+U8OL
MDDS#(4^*;FF<T\S#/FCQYABE+'1HT:4HT:-&E*-&C1I2C1HT:4HT:-&E*0]F
MU]';;K>P:JEY:LZ)V9")97TH)0*\T"XV.S-@<(V]E(EQ>.9B)68V.2K%,KPP
MSS3'#@=CCD.  ,=YEL?HF<Q9[B#\WR8QF?YM>]@.."62JDRG*0[BZPL"HK(,
M)48I\\RDBJ'67)R&=)CB.#0X&H5Y.1IB+##.8&FEOS)LPHRY<GJ&3.QF@*JL
M/LI7]<9O!5A3ENRB#Q@MA\%.CRUM?B)C)TV1K'&CV9Q;W0AY7HST"]&I++4E
M*57]8VU/8E9T#W(65,[T(6U=))%:CC8LT+N:N"Z_I>02^'4Y$+#)320MM.8&
M+K-535>RMPC]G+Y6WHI-DY)7-K/BDD5Q-0Y6T#;KMF1NJW<;2-ZOVXG*4O-C
MJ<[ [8-=S.+92:<,5-0JSP:2JOBD6BK*>O)V_P!:IUD/:D3?'82O8E2**1F+
M(W1P;SJMZ]ILIO0P3<,Z[5Y&0RQ#<#MKF%[;2Z=V@W'4\!KRHZ[K._XM4;U#
M8K9E=0J5;R;9V^6U:<:LJUYY&HJ4]/K174155U5Z%= H6@EDV=J$U+M#<_RA
M-Z,-$7_356/=?4I$U#!-ZRG-:3/<;.J[QOE([;CJPCKFG87T4<QK157591IX
M,+8K+?ET#;4$L88SA&(>I=E*=NPMMFSNTHE*G!!<*&)KJ4W#67?SU;$.L6K'
MEXI&WYVR25CLTN0C/V.P*W9&YRBDOD3,\0^S8>Z-[:WKB7(I&A>FEF>&[79.
M3YVR)G:BY3G9=DRROH,V0I/5,"EEFQZ:01WD+;6S["6::1Z8OD><+5*?Y?$W
MEQ>)*U5_:S#!K&>2QF$CAKXYBN7*:FH32S<OA\4MY;M.FM7Q",3C9AE:&T&"
M;0-QL=11C;)6%F.\H2'V9)9Q62)[WQ;@*WG3K#K!M)1$H\X]81V&O*.#QZ<J
MU#Y.YU+RNMKJIZ@FP:S$=*V3#G&J.4'O^RZU@ZXV<QK&HMMMSV5N?>HRMF%2
ME.J*,Q[$*^E4,!I;IM%C9-4K9(TT*0EQ!8+HRE*5*:C-C^V2 3M0RM]W67=%
MGU83M\(,:;"N.,RF45O$*%CMJL%%Q$Z%Q%CC"2,1AL8KDG0"J<8VFD%@*EQ$
MBETBD[^GR=CNW N34J*#R*AGE99]ZV U;<T->85O$+$DT#?6!N?JJ@RRMX1+
M$RY#6;/,XRY((::V-;Y'Z_ET,KV=K6%MDU@0J4RM2_/;W7UL?IRQH[OP43QU
M@UCM[OA+N41,M.,2/;ZIK"*4TTW#N#9IQ '=EW1Y1-D[K?"T0C34ZQYE-FMC
M$L;!(3GX2(+E7[<RF>AK2E8  Q ,0#@&(  !X  . !W^_P!'AUG1HTI1HT:-
M*4:-&C2E(J.5Y$(G(;!E+ T@A?;2DK1+YRN%:O4]FY"Q0N+5\UN'6ZM4>E;^
MM8E"XVU F;"4:0WL=UZ<08X*EBI1'B:;&=M4W@#77+K"G1"PQQGG;1$U;#-Y
MLRR&)&6):<)NV0/4;D"%^P=4$C*M>N(1-V)\ZN>OCKK'TJ=FS2M9ZYO5R\U7
MQREL5OJ7[=6YKH8) I-+N*H5]N,T13R5QE+_ $0BEA.=GM;*Q0B>55.I6&+=
MDA='R%PBSH/*YG%FQ^B[,Z.*AU]33\I6@HY,';(L3.Z-8Y7\L1R]YE3M8J1;
MN4N]:EM%/8#7#&VQH]9*95,CB93%9V; F!Q?H^MP*0IEW9DJ.!'VJ1/K6O7<
M6VK[6ZCW%-M@-"Q\9+*FRRX99 JU<K8G*JOFN138QJ>+YFM9TTOD1L(89#*S
MUR!TF[RS,>.:92_/*YNP:%$TE1KY1'9]4\H)E4U0IVNO]T:J70B(SJQ:C<6\
MRXW>4M"=)NN?IE&JO41MOWEIX]44UB]!,$141^2;C9GN7EDIKZ5$4*FC2R91
MJ7QF524O;;A?D;C-Q7PLLFSJOEAZSE.[+2WG8MV.*%EI-MSE+$\;-2FWU0RK
M%OK:J%45A,>:WF",B!I;%<;=).S3U!@K=5*<%*MG8]J-"TO/)[?[5([0@1KQ
M,YG>%EX*MQUR-E/KY,],H)Y?,IE7CI8.-7&-Z9C;DN6?9=B["1UO8FK) 2VI
M6)O!)$:QX[R:EG'AO?#=-6I#5+)@<V0JRR=V1V6VQ5N-;JBE%&LDQPAR*QTE
M32FVH]6#DY10Y,M3+%6,=:@6JFPM<TDO:7CU@JO&P^2ZE=X6O1KWN.NC=$RK
M=RZ;:?*9.<ZL,;(MQ\CLDI^B" >CFS!LA=10,B!939D1$IC'AW8IVY)FE4^R
M0Q&JC(-9VO'I(R;FIQMHW![C9G+G+=;'+V8#*<A%8.+C8]O493E<4W**PHQ-
M:<W:8]326!U>X[?G.4RBP97.6<V=KY+9TE4Q12_OC&I4L:WY*W9?"H-7%*.\
M@FKM;T;J>G"*\G#=N%MAJN"NXEMN;$\797';@]&V NFE05DRR&QG?%S8H0X%
MQE7C8Y,6EN3RT&L#4C*SV)\FU>,(/9MOE@/<I@$09D]32\JC=W=G/3<Z.T6M
M"8WM%S+/?(S9+JZ2F>PJU;*F=C1UWE[LN<L7&5*<UV+RP@W($R?JW8>L@S_3
M<@=*B;2K =>28D>TS<7.XA(6M#()5/H\T[:(Y"H(,_6]66'"E11RS<8?*3&E
M2TM(%K'==@!JPI.KZW)D5Y?K5,[3G]NQZ=Q*-)Z'VK;>(2R6%44&HY_%10A=
MOFO?58;!)W/VZ1]@4-A1Z,+[43NK9"[ D3<^J*?B$5K!M8L752I"3#DU-L,W
M7/K@[I+61GRF4VV^2D8S>=LQ 9)&KVES=8-MU*\FQ>5-*A93,TG[>;-%E:B?
M@Q-C^]RH^/@T)I?)DCK/HHHH@LLDDLLDDK# HHHK#$LLHLO$,"RR\, #'###
M#$,<,,0#''$ QQ    U^]&E*-&C1I2HC;F[JL^$R&EZ:HB/0QVN6^)+)T3._
MV;F_C6M;06NXX$JL.PY0UQ4Q)))BK0)E3!&8I F9ZBITGE,K;!<9A&(^VO+L
M1!IVY3BP:5NA%MMOJDG.<VVRRF91Q>1M>A<[L!=;3#E4+)<M86%55;JCECW&
M&U\9";+CT_B\UE;L5#I763BW-$WE1$BBRAUL)W%;;FJ^\:W?T$XF%2VK3,Q4
M3JJ+8@),;4R.+NKG'G2)29C<6B7L,CC,L@LWB[PM89I#GUK-1NB?%M=6Y6RR
MA@CL@:8BN?)B)CWB/6PR;KMPT;W2M%B3BSW7<DD::.=Y')WZ>5>QTLJ87.O)
M)4KO5B&OXA6+"BCM<PMBB[4CC"[$^6K5C_+G20O+ZI3CQ7E-MJDZ>(8$,?9A
M)J^FF==-1-VMD#?<J=8)O;D'(L2N:VE4L58)5S)/))$UC4>:T&,*A%&GM\CT
M+F3I'9M(&>.K$,3RF,"E]80^YJ[@UF8PA[7G/3>VSNI9\V22Z*[=MMMT7U W
MG;ZJCB611F2N,L3U7F>I)D+LWJ8BS(9 US5DC<U.C#$[-U6/(M;8*:L^M)S6
MKU+(^PUSE6[R$8.C52NTCD,VJRNT=;1R4JKK<*X-NF/)W5$V,LPF<3ADTCL9
MD-C,2"5D(6?%QE;5)5Y27)6U)4(N2Q78$RE3RXS%'+USDW0VFJL2O[BWTY>%
M)XOLRC=2UO$(O*K&D,9OZ9.<^M=8T)YQ.'YIA8.B\F/Q=(P&J4ZU!<HA0=\Q
M^K34)DHB=@V9,8=6^-3R**2%/-8]/IAMP0;JBFQU0G-:8T(NEIQ:$GQL3-.F
MAZ\C E,0OP=%:=MRF%/J\@5K0V0UY9T+BMA0&7MIK/*H5-F!KE$4DC2HS*-/
M:WZ//258U.S>?F25D<B7I3TYHEX=4+RYH!JKO:YR=;O3>\U3N"ERU,],-2[/
MJ2VCU$_JGM(MDEL+X<E4C,;^L"#L,1BL)KF?$Q,N+TDTA&\W]6_1&/.C@J5L
M#:XH(^7;KQ#R^\/S:4KXIDR=&G(2)""4J5*24G3)DY19"=.G(+Q*)(()*QP*
M)))*PP+**+PQ+++QQPPQQQQ  ^^L<0\OO#\VCB'E]X?FTI6=-I:\0;9S%<(V
M[QQPD[8M>V,Q8WMKZ9'CR2DJ_!0#CFM*/3YG$(#,,#SD6)G%5B 8@''$,L7*
MXAY?>'YM(Z:H.R3>VE!'U,B$F0LBH$J9WR9<T?6ZL,^RN:D#"A/*;^^<:B 1
M%5B/4^;[..DL4<T<D,R)+%*C1RQR*'22-U*NCJP(964E64@@@D$95AE#*58!
ME8%64C,$$9$$'801L(/"*9O+:3260B(Q]U[XCQ_WT/X=(CX%WO> .][&M?/9
M_1F?'G1UV'B/$?\ ?5(0[_XEVI.@/D'V?8$?9]S_ -G1HXAY?>'YM<4Z+Z-G
MAP'"#V</M>CVKH%5>L+'V';=PC_AJ+6>S:ALPX91MWZ>/>EDC#O_ (E_EU\,
MMEM YAPRC+P(<>/Z;Y*'?_$X:E9Q#R^\/S:.(>7WA^;6AT4T9.6>C^#G+@SP
MZU^JK&]UA["M>(_B(N+@_-J)>6R3;WGZZ,//3Q[TPDP?_P"1U\<MCFW;/UT6
M>A[_ !_3E)P[_P")Q#4NN(>7WA^;1Q#R^\/S:P=$M%SEGH]@QRX,\-M-G![5
MT"M3AF''AL+0]FWBZ/V>@5#S+8CMPRXB,4>^(_\ GI*/D[)</]&M?+8/MIS$
M1RB3X/'CQ_W[2L.GW',-3+XAY?>'YM'$/+[P_-K7R(:+'AT=P4Y<N&V?1[3T
M>.S+7>K#.#>^RRY#;0]'['0*A7ER?NV/+IB#Z/L?IXE@>7V'32??]@&VX@IO
MR0UO)7K,YV0)E!2>QI*A%"C-,R!0Z&YJ';$#R46/#(Q*5Q//#(,2^' <@GIQ
M#R^\/S:2$Q0=D$['AV 42#K:4,BWJ*=U%HR;>MSL\NS)AG/+Z]);N/5#&[B/
M709 '#[ !# T.T4!S\CF"9_\,L^'9MV0\.SQV98WGPKFVQ^*PY]O4Z*B=ER=
MVUK+IAS^/@_W]R[Y.RH_VZ-?'+DY]JV7'C#9!W^/^'LP#I]QV\NIS<0\OO#\
MVCB'E]X?FUCR&Z)\/D;P/Y+LN4'UGE'^)K&\V$\VV/Q6'^"H)9<F]M1R]="Y
M"/\ V^F/Y';W]?++DV-IN73"Y%[@6!,@#_0[?V]G4\N(>7WA^;1Q#R^\/S:>
M0S1([3HU@9V9;<+LMHV</WGHK4X)@YX<+P\]FT@/^BH#CR:&T@1$1A$B$1Z?
M[X4T]_\ \+Z^.7)D[1,PX90>1B'_ $AS4/D> U/[B'E]X?FT<0\OO#\VL>0O
M1#]6,"V;1^"K+9EL]9Y!6IP'!#PX3AQ_Y.W^KJOL>3"V@#P 8-).\'#_ (19
MM_MC^WNZ^67)>;/,AXC!9+^*Q9L'R/&K">(>7WA^;1Q#R^\/S:QY"M#SEGHO
M@)R&0_!5EP#@_0]%-X<$V?@C#=G!YBM\^WN=5Y9<EOLYS'CE!)+\8TW#R>P\
M_P!O=UPW;DO-HB7-LQ0U;*W7%6YD)5V95I2](#8B-Q,$YR- ]ZYRDM...(9)
MB ZL8.8<T>\(#93Q#R^\/S:2DH1=>FQK(&-0] CDK>L',ATR; :.I8'@#P=A
MS\ <B4G/X9(!YW51,#(,1''@./(3H?\ JO@'R59?4]'?Y36IT?P(G,X/AF?+
MUE;]'M?0*@F/)5[,AZ8%)Q_^J3.O]M:^67)2;+<AXC 9/^*RIT'D_;K5CG$/
M+[P_-HXAY?>'YM/(1H=^JV <GY)LN#D_$^.WE-:G1S1\\."X6>S8VQ_]NJWA
MY)[92/37\G^,N>?[;TYU/\GSM6HZ<-]BP.O#RY:T$*2F9RD$FD4HP9SE6(%&
MN#6B?7%8C1NH$=43$.A1'7J4@]26E.)ZX-'*:?$/+[P_-HXAY?>'YM2P:'Z*
M6L\-S;:-X)!<02)+!/%AEFDL4L9!22-UA#(Z$!D92&5@&!!VUO%H_@<$J30X
M/AL4T3K)'*EE;JZ.IS5T81@JRD JP(((!!!%9Z.C1K'$/+[P_-HXAY?>'YM>
MCKKUG1K'$/+[P_-HXAY?>'YM*5G23D:+)4X14W%F6N@(WW%1DI2NW8XIG $B
MC#L@L3]6+[*)\>=U'K+F&<<S SYO>X9JOB'E]X?FTDI*AZ\<(H;V!4/'6+_@
MIZZ)=!;L&3@D/P!S/3\_ ',K$<NHBBYN?'+,#.'>YN2E*[1K'$/+[P_-HXAY
M?>'YM*5G1K'$/+[P_-HXAY?>'YM*5G1K'$/+[P_-HXAY?>'YM*5G1K'$/+[P
M_-HXAY?>'YM*5G2/D:$53Q#SP8USKUB]'GBM2NW8\AC#)O4%]?K4G5B^RI&8
MY GQ2<PT<## .YH<WAFK^(>7WA^;20D2'KMXB"CL"I=@0/1Z@5Y+KDWEL/.;
M5)0."A)U3#LL4;SNM 2<W/F9&@;S> "&2E+ .@/8[W1X-&L (< [PAWNC@/>
M_P!&CB'E]X?FTI6=&L<0\OO#\VCB'E]X?FTI6=&L<0\OO#\VCB'E]X?FTI6=
M&L<0\OO#\VCB'E]X?FTI6=&L<0\OO#\VCB'E]X?FTI6='3TZQQ#R^\/S:.(>
M7WA^;2E' .C@'#O=[@'L#Q#WA[X>70  ''@'3T^7V.(^$>'>$>D0 ./0&CB'
ME]X?FT<0\OO#\VE*. <.'  #O= <.CH][V/!H      #@'0'@T<0\OO#\VCB
M'E]X?FTI1P#CQX=_O_BX]/#P<?9X=/LZSK'$/+[P_-HXAY?>'YM*5G1K'$/+
M[P_-HXAY?>'YM*5G1K'$/+[P_-HXAY?>'YM*5G1K'$/+[P_-HXAY?>'YM*5G
M6! ! 0$ $!Z0$.(#[H#HXAY?>'YM'$/+[P_-I2L#A@/ !PQ$  0#CB'> 0X"
M =[O (=X0#O"&N+(XQ')@QN,9EC R2>..Y'6KJPR%I;WME<TW52SNMW!J=$Z
MMO6D=6**-ZBJ3FE]4++,YO/PQ$.WQ#R^\/S:.(>7WA^;2E' .'-$ $.'#@(<
M0X!Y!UCJ>'#AS,.''CPYH<./AX<.''RZSQ#R^\/S:.(>7WA^;2E9_M_;W@U@
M,<<>]B   CQ$   XB/2/>]D?#HXAY?>'YM'$/+[P_-I2LZ-8XAY?>'YM'$/+
M[P_-I2LZ-8XAY?>'YM'$/+[P_-I2F%':[M[#_DAA'XF?$?DSUKJ-L^W)*4)Z
MJJ8&F)#+# 35#8406&9F>)9>.1AIN&&.1AF6.!899 )F>6.. 999  Q.Y1FN
M7ZV'[93!V.OJHM$''<O+ECE"[S3/*NJ'%$U;3]QZ\M5*4[&Q253FH;%Y2);'
M1.9U*;"0E-V661)P$F! -AH2D-M%G5%37*3OM3/-#MM0W;/:!;K0*%)LB@UN
M6'N LF<694K4EMUR<XN#Q3M'R.K85M\+LPQ,]%UHAM,VJ69@382QC9U*NT#:
M]MZ'A_>BA'?X\/\ <?'V.D!^S[P^0> ]X>]WAX8RVP;>,0YV51P?'$./'+)H
MPQ  #I$1$P #']T(\.(@''B(<?-"%O3_ &SR#;EO8;\[LF- ;9(#O6/BL->T
M5AO4^LC89=6ZIAKN@\%#._H54Q=EL2.[34JJ[*1$&R?"C&=K<W\.N\W$"E?M
M3A$4HJ1UA N4FEK6X5LGMO>K+IY)+L>L\=M;GOFLM!MRM%Z1V,ODQQ%:*L6F
M,SO<"T;>")V&44'-LF(L'5IZ3%LL%*]& ;7=O0AQ"HH1YGQ#WP$SB A[(#WP
M'O#K/<N[>_%%"/-&'TFF_P!BJV%K]LD"/K-)=26K@<["*JS._59BV=KJT*L>
M68P1S;3EJA2^XU:OC0-Y]'%2G/"6$TOE BY&22YXG8!+O2E,)W+NWOQ10CS1
MA])H[EW;WXHH1YHP^DT_>C2E,)W+NWOQ10CS1A])KF.NW&F6DE.HCU+Q96K.
M7(T:K% ;BP&EMBDX,5YYJH#L>NDI16(9*&P1$%^'VK@(@ A([4?MS;NZ1^I7
M1^9D*9:Y,[U&%J0Q6<664@,!]1$"X 2;EB6LS(Q.$O%)D(@;U8<N;EU/FC6O
M+J.QM+J]F#F*TMYKF41@%S'!&TKA S*I8JIU0S*"<@6 VUI+(L4<DK9ZL:,[
M9<.2@DY9D#/(;,R!RD5]NY=V]^*&$!['#L1AT!W@X<#.\'#H#V.C1W+NWOQ1
M0CS1A])J 9F[&\L1R#&4-O .=PXQ=C'R_L?7*/W=WS@.?-E38'-$,0_WJL0^
MP \>^F'P]&OGS=531M<\[?%MGN:UZ/=HY?\ #L9\4Z0V(S\I<;/:TZ/;>SVJ
ML1[EW;WXHH1YHP^DT=R[M[\44(\T8?2:K;.WB7_@''&6-?KN'?B; /A_^*^3
M7.-WF;@\<1X2UI[V7#OQ&/CQ#C[/]RZA;JM:,H,S;8QMY+6U\.][LUH=),/]
M1=<('XN/C_\ N\68S_PSJS7N7=O?BBA'FC#Z31W+NWOQ10CS1A])JK4W>IN(
MP !QE[1WQ]I\='_^TUSC=[NX[ 1#&8,X<!X?I-C@^QY4FHSU8-%ERSML9V^Y
M+7P^H3I7AH&>YW?<HOKZM;[EW;WXHH1YHP^DT=R[M[\44(\T8?2:J/,WS;E,
M1$ F;-W@$?TEQKV!'_XGY-<D_?AN;P'(,9JR@ <>'&$1D1[P?_@8?)K0]6/1
M4'(VV-;<O2EIQ@'G#9P^.S/4Z786!F8[S+_=1='M_35PW<N[>_%%"/-&'TFN
M8Z;<:8:BTF;#2T56'*W!(@<,4)F#%F2T*<Q!<H/-ZMCV02%88XBH:>(@OQ$,
M!Q'FZIW,W];HL>/";LG0'3!HOX?_ ,"TFW[?1N5=RT!;A*F!=@A=$+HEQSA<
M;)!.M1YYY)U0"6FP$P21R$0)SYY9G'AEAD'>U']V?1//+K;&_BEGWSB '\NQ
MG&=,L)'#'>\.7XF+H]T=-7?]RYM[#HJ&$>:,/I-'<N[>_%%"/-&'TFJ2#>4(
MW58@ A.F/OC[0XJ/RHOGUH&\H?NOQ >;/&(. C_@%%!Z./A0ZU/5IT2&PVN.
M?%+/[1\<C6ATVP@99Q7VWVF'PCQXJO&[EW;WXHH1YHP^DT=R[M[\44(\T8?2
M:HG-Y1?=ICZV>L(<.=_@!$QZ/=0^'^P>QIF<H]NWQ[X3Y@ .'1VOHD/?[W_Q
M$/#X?Q=_O:GJUZ(C/.VQS8,_0=GR@;/PCM.T5&=.L&'#%B'<(.7+V3RU?)W+
MNWOQ10CS1A])H[EW;WXHH1YHP^DU03GRDN[T,A + CX<!\7L1'O?Q#6D=REF
M\' ..-@Q[V?^3R(>#RM_S?CUJ>K=H@,O,N.[?<=GR9\X\E1G3_!!PQ8AW"#P
MKIKT!]R[M[\44(\T8?2:.Y=V]^**$>:,/I->>W/E,]XP"'"PX[T>+J'_ %#W
M?]&M0SE.-Y..0@%BQ[W.UQ#O"/L]8".M#U<=#QZ4Q[@!]!67& 1_27(:U^Z#
M@>S[SB.TY?B+?A]^Z\<C7H=[EW;WXHH1YHP^DUSG#;=2K?DAQ9Z8BBC!>O(1
M.PHQQ: 3M1H&"H4*\ -Q[*I"Q#'JC4/$%(Y8Y" ]3UYZ#>4]WF8CPQL:.AT_
M\F\-'V X?\0]CY^]T:3KGREN[]US;\W">QI5DU.)+F@'.N8C@"9<GQSQ)4@!
M2/ #!+#/+[68&9>0B Y8#P#@^[EH?[$QX_\ )67SXE6AZHF! E=QQ+,>Y[?+
MB]U]/?KTE=R[M[\44(\T8?2:.Y=V]^**$>:,/I->;_+E2-Z@=_MDQOI]FM89
MQZ!]GL=X=:!O*H;V,1^QLJ-@''A_P9PKCT<>]_N=\NM3U=-#AEYDQ_:,_05E
M]I>/:J%NJ7H^O##BGO6]OR9^S/$UZ3^Y=V]^**$>:,/I-'<N[>_%%"/-&'TF
MO-'ERJV]P.^%F1OA_P!&4)Z?-VG1I?E>MPT9L-C778O:K#K108*&2L[+$(_'
M9"WI%.98=GX\K:B48+7-JX"=V&<,Q1NR7)0CP.1+<TBTF6WZM^AD]Q# \>,V
MJS2(C7%S9VPMX Y W28PWTTHC3/-S'%(0 2%.5;1=4K1V6:.)EQ"$.ZH9IK>
M$0QZQ UY#'<R.$7/-BL;$#,Y$"O07W+NWOQ10CS1A])H[EW;WXHH1YHP^DTY
MD"GL/M"'L$]@3^WR>(R=O*<V1[;#>JI5B4WCCD XY!B<F5)CL3$J] J+)6MZ
MTD]$M((5$&E8J_7UZ*6.:..:&1)8I462*6-E>.2-U#(Z.I*NCJ0RLI(8$$$@
MU[Y'215=&5T=5='1@RNC %65@2&5@058$@@@@Y4PG<N[>_%%"/-&'TFCN7=O
M?BBA'FC#Z33]Z-;UM3"=R[M[\44(\T8?2:YR[;?2R$YO(::8BBA*XK<4CT8E
MRQ:BD[:))N8FK4P&AV93=5YN(MF098Y&98G"'V''4C-)*2(15N$4-!A)=P1O
MV"G)6:ZBW9,G!(?B#F2G#/$'0S$1ZD"$0SXAEU7F<<.?@I38]R[M[\44(\T8
M?2:.Y=V]^**$>:,/I-/WHTI3"=R[M[\44(\T8?2:.Y=V]^**$>:,/I-/WHTI
M3"=R[M[\44(\T8?2:.Y=V]^**$>:,/I-/WHTI3"=R[M[\44(\T8?2:.Y=V]^
M**$>:,/I-/WHTI3"=R[M[\44(\T8?2:YJ[;C3*%2VI&FE8HI;W17DF?CDV9;
M62D0%ICC"C5R+JH"^)Q4"&&* 0R# P<5(X_8:D;I'R-!UV\0\_L"2[=8O1ZC
MK\QXR;C&+BW*"P<"489X@[YF"()LD>6)@88F"HY@<SGXJ4VG<N[>QZ:AA''V
M?]R,/I-'<N[>_%%"/-&'TFG[#H#V.]T>#1I2F$[EW;WXHH1YHP^DT=R[M[\4
M4(\T8?2:?O1I2F$[EW;WXHH1YHP^DT=R[M[\44(\T8?2:?O1I2F$[EW;WXHH
M1YHP^DT=R[M[\44(\T8?2:?O1I2F$[EW;WXHH1YHP^DT=R[M[\44(\T8?2:?
MO1I2F$[EW;WXHH1YHP^DT=R[M[\44(\T8?2:=6:S&-5W#I98$S=26*'P:,OT
MQE;VH*5'D,\:C#4K>WUU/(1$*EAQ+<UH5:PPI(F4*3,"<L$Y!IN6!>6O*YU&
M85!Y%8TA6*R(C%8NZ3)Z<&YE?']83'F=K->5ZQ$Q1]M=) \*,&XDPXAK9FIP
M=UN8 E0H%*O/ C)2FR[EW;WXHH1YHP^DT=R[M[\44(\T8?2:6;?;M=.TT(KY
MHDR9WE9J68J#F]H1NCHF:CH";""I:SR%Y0(5#%&9,T]L:&G^I.0N;9)UR-X!
M>V-"U$WNJA!VE\[B;7-8S7:]Y)33.8L$OE$:8LR%@J'5A@:N)():XDGX)LD1
M13*KG43)/+4JB#S\GD@49*G E7DF4ILNY=V]^**$>:,/I-'<N[>_%%"/-&'T
MFGYYP?NN\/#UN7^CO=\/*'>Z X\1#6><'[K_ #<O!Q\'@_T][I[VE*87N7=O
M?BBA'FC#Z31W+NWOQ10CS1A])IQIA8L)@!\43S*0HH]G-Y"KBL9S<,5."=R?
M4$.EM@+D>2HL@Q*@+10V"RV0*USD<C;TZ%D5"<KP.R3E'*%E>VB1M+6_L#FA
M>F-\;D+PS/#4J)7M;JU.B0I>VN3<O2Y&)5B!>B/(5HU:<TPA2G.*.*SS+,PR
MR4IF.Y=V]^**$>:,/I-'<N[>_%%"/-&'TFG[T:4IA.Y=V]^**$>:,/I-'<N[
M>_%%"/-&'TFG[T:4IA.Y=V]^**$>:,/I-'<N[>_%%"/-&'TFG[T:4IA.Y=V]
M^**$>:,/I-'<N[>_%%"/-&'TFD1.-\.V>M[&=:MFL[>F&31^75] I(Z**MMU
M17,6F-JDQL^OH[++A0P)54<6<Y1C,8F6WD2&<-H8JI,PHE>:96[(23I P2P(
MA9D:2R^#O)3_ !Q8M?FY,YD)5Z4LQ=&9"ZQ5]2]0<$B-7@:W2!D=6P[$Q/AS
MSD9F9(FD9%FYJ4VO<N[>_%%"/-&'TFCN7=O?BBA'FC#Z33\\X/!E[/ZG+V!X
M>#R][PAWPX@ ZSS@XB'?#AQ[X@(!WNGOB'#_ $^P/@'@I3"]R[M[\44(\T8?
M2:.Y=V]^**$>:,/I-<Q/NYVW*K].VO)[?B!U[D)CSS*\P5*Q<P5)F8J2*6('
M#K,(_G+4T9.*E"F%%O&<P3Q?+U2',6#(&2_&1O$/+[P^#CWAX<!#RAWN/>Z>
M]I2F%[EW;WXHH1YHP^DT=R[M[\44(\T8?2:?GGX_N@XB =_'(.D> =(>_P#\
MWIRX!I)PF>1*Q6+.2PMY)?F/!_ET7S<$Z=:07B_0.7OD#EK<):U,E/ UEEL:
M?&909U+J!IS>:>D.4(S"%)JE-EW+NWOQ10CS1A])H[EW;WXHH1YHP^DT\#%)
M8])TJM;&WMJ?T:!Z?HXN5,RY.Y)T<@BSPLC\E9%1R,PXLAV8'UO7LSRWFY8J
MFQU0K&]842J3'%8=O2E,)W+NWOQ10CS1A])H[EW;WXHH1YHP^DT_>C2E1 W=
M[HU.V1!3PM[!7+RZ7!:*ZMF]=;=SI*&KV/9MM6V-:"AS?)\KA$_P+/5HZ\4,
M;,T8,//<G9V2 *Y*629SVN'E%=MD78X8BW&V-34'F<P9AFHLM8S>3[C*W8Z\
MSLE763'9TDMB,56PQJ*5]E-D.,:>9_/&V(PB)S$1CB^3"LP*4GN_NIVY/E_X
M4TY1B80F)2.FK.<K%:^V/47;LA3[V8JFQZJ7-+S"L9W79N1I+?8BEY:W8J1
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M;>#@'0Q_Z?\ 1KC+N1SOQ.*4 LZFS.N5A2;[,Z8)NI]5#,0,QZNR8BHRQYO
M$Q'.4&<>)>(ACD.-YO=1;>_&["/.^'T>DW(MQ] N1C!D39%7N?8Y_1.!V;N^
M9E9MI!&)P9N#5U)*;U5T)'/$$Y9@EE9!EGS\N@<7W&]!/8%[\IWGUGCQ5H=
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MHMO?C=A'G?#Z/7TY55%5$4*B*%55 "JJC)54#8    !L &0KV@ 4!5 "@
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MVVF23%))^!N61#-BGJ4L#GC(2^*8A1STYF(9\_$1QQ 9(Z2<I- HV- *B-D
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MI*9M W^)0]Z8)Q&8S(7B*.CND9',Q+M1GE%=G$QB;Q-HK<.,@86@^M4Z06F
MVFM>9ME<BM\056;4\6)@^4INE)8+A%I6W1)=4C+-D;VYQ*7-Z)08LBTA);E*
MHE,>)6?3^$C405"<CQVS))#VMS(X_95V!Z+D<$[HDB0105@FA&4TG2ID9#*#
MAUT4K(*3X+ =,,30]6@='X\OE'2$K.RX+<4&C]DUM(DDJADH3*%#.\HL%J8#
M,D*Y6TNB!<WN29"ZLSTR/#>XLD@8'I WOD??6YQ9'MN;W9 L1D+S2E&D;-U
M)VYMR[(1MNY\B8R@,DZ;KI&>.:W'@E1X=4PZFZG\.#>?W^HFXY9_8<.JEK+2
M-FZH$C:VYBYQYKY\B8B>KR1)UXD-$Q=@ )49?5"P+=5 AS6\\1X$G .?' 0
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MIA/6+1ZS4#ULQ9AD )G0>/.Q/$.\5SL.(\_J9JOTD),H EQB6 N+"B$^08%
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M!:D1Q$5!>!>>99>!O/QP+SRPP#'#++$=G''''$,<0#''$ QQQQ  QQQ .
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M9]L+Z!#OYX![&'A'R:860YE\XP>J%\..7ZYA_P T/W6O0<9!H.;^BPV+&?\
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M>"8<<\^.'>SQ6/$/+[P_-I(3%7DE3L66#NW,XFRAD($QS;,W+!;B8?GQ;DN
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g484696.jpg
<TEXT>
begin 644 g484696.jpg
M_]C_X  02D9)1@ ! 0$!FP&;  #__@!#1$E32S$P.3I;,3A:0E4Q+C$X6D)5
M-#0V,#$N3U544%5473$T.30V7S%?0D)37U!!5%\Q7S)?-$-?3$E.12Y%4%/_
MVP!#  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0'_P  1" &4 HL# 2(  A$! Q$!_\0 '@   @(" P$!              4'
M" 8) P0* 0+_Q !M$  !! ("  $&!0H3!0$+!!,% @,$!@$'  @1"1(3%"%U
M%3$UM+46%S,V5G.1L;/4(B,R-#=!45-587%T=H&2D[+1TT65M\/5) H8&25"
M5(>AML'P)B=#5V*%HJ-$4EAR@Y27UT9'@J36X?'_Q  < 0$  @(# 0
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M'=3;YTWJF;"ZJ=A+EOD:.%WG4FQ>NE4V! DPM3QH@8.Y5D0+=/)5LTT6L ^
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M\)M54>D9F'CU2+UY\I,8EX%1C,9R*R3XQF;6KR]FD-8@GGW=(=H=] -)=?\
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M;6*Y#NNMSUUKCK%7BVP[^U!H] GWR]"]YTO==NO4"NU;6^R6J+J0]FI7V.[
MM6P3R4_D^-G]%NC4SHCO/8^N-PZ[JY_:P/6]EUH OVM+.2U-M4]8;8;A; ER
MK>0E1;RL_<K0S#,4*>#8"@E!8\&4^:'.GI5'^E'D&YG20S<MS:TV+4&^S4+I
M_:-0:6O\PUNZP52E=A-@['['7>Z[7.5&TW8L-L%,=&;+U'7Q].)#S+[\K6I6
MX$7<W6SE; 58S/ND/E >_DCOAKGI'WKJ_6^=>=V],9?;\E6>O8.T@+OU"/Q;
M2/#O:4WI&,;%V0%LX^:/)QHU>V$,( WR5ICR8D<86!S()=/H1YH/\D[Y.;NM
MT(M]@3M^^=)]K!=F_5'9M^;XK6M^PLGNGOO9<EY<JM639NYMG;7LM?*AP[\J
M:RU5QE2"@!$)6,5T2/(SBQ*=OO\ ''[N/PXXQGWASYXX_=Q^''#QQ^[C\..,
M9]X<^>./W<?AQS[QC#APX<8PX<.'&,.'#AQC#APX<8PX<.'&,.'#AQC#APX<
M8PX<.'&,.'#AQC.B3^3I_P#,Y/Y%?*N[7VSKC1>N+EM_<%U!Z[UEKT(]8KG=
M;+*<BA0 AEYB+B3*6PS)EOO29TN&-&CA\684+%9L$4*A324V+%>M$3^39_\
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MG+'29!\<-TK2JLT^?+M5.IUYQU\I.8RQ/8+NMUIZM':[6-X[$)U.P6JEW/9
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MJF_];[+H<73#_7@\(A=8J>0E-WV-'MVXZ^Z3OD,2(<<K[DLG.?RZQFR"E^5
MZ'WVH6Z_ NQ B#4*3JD-O,T;NU"W%K!F9IZQ&HE:K^R:=%V;KBGD=E5$Y9B0
MFL""FM8=O02LQP!7X:'BY\-#G+3'E6/)]UZI,72P=EZ^ %+N-VH4\2;HFY!-
M^K-GUH #VS8\:]:HGZV8VKKL30*G8:]:[I:[Y2ZY4:S5SX2P%ST445A2GM3?
M7SR)6^->:TL]*O93J;+<5Y.^L=*60!NY=M^R6O-QVRK[%UQ?QNPMBBMH3==G
M=!U(0J@E6*Y2NL),)\!62]XN0]QJ5KBFC',P*^2_\H9]:H]J43N/0$_5FT-G
M60CLW4=QWYVJNEN!==Y^LZE3"'5K6_=[8FJ-B=F&=8;OM(27:][>G%@#L.IP
M0&J]<G1H>58C<AC-X][[-:&UG=] :YO&T*^!N7:<^3K'7L4M!8BQM0X(K\"T
MS(5?.!QI&O1D* %1A&!..%A XN@C!8$3)TN4Q'6=?^S6B>T^O7MK=?MEA=FZ
M[CVRY4=RU"(QP6/^JC7Y)L1<!K;-G$@2+[04@\RRLJS"<"SFGV)8LC.A/LR%
MZU/*3^3;W'W##=3B.A[[JO0NPNIM)VG*UO*DIM:JW2MNGP>B86KIE.R)JY.8
MFD4=[5UC!R7IPR(:Q62PA<,/+F*(0HU-9'D3^R>L]4WG5G7?9_7..'O6F?*1
M]9,,;(D[A%,U+47=:?HPI1+H D4RJE7Y^SJ,_ICU*Q!"C#5:_P#E$X8%V T[
M$6->8ST64W:>O-A.WQBDW0#9G=8;%,:CV"D9.\_ZDMFU^&((&*074^AA#9^#
M"/AI"HT=4EJ0D@RF&_)=0^VSA SLKI<[=X>NJY<W;3;9.V[[HF9"JE7N=F'5
MK;>LJ5'V%=:1>+$&KTRNT0B)JLV!+8F6TJ(#FB)$=70)(I8IC(O/FZ[)^0'W
MMLT)NRC:J,],Z73]F;TW=N\*;?%WJMW^%8-L=?M=:TJ,LU/%:6N4-C.F+W6K
M]8@(ZO28A"R-[+F68?==?%H1NO6R?S'D5MP34[:#T39FE^OZ-E]G.Q'8"/M/
M4,>ZQ=HC(G83R?EZZNX"DXT.I5)@F5UAN2YE+N FQ;E'CG*?;+N8B.TR]$,0
M"#&>C3UIC#>'LRH^&5>F\U_,IC#"O5L^$GS7O2^B5F,K]#*QA><QE>"9'H\Y
MQSGSE6,YQGSL9QGPSC/CC.,_N9QGPSC/\N.>;37_ )#FPS+K6C^W@/3L'JC%
MHV$;LG473(+9LSK6)D%.DI7K& N%6KUZKHULG>+YL2<.VAM7X3KH,?"B5:HN
MPY]\OHF3:9^\;J5JBWZ'ZK=:M'; LT2ZWO3>@]1ZKN=P'RR\^!:K1K^B ZJ;
ML$&=8&(IV7"+3Q;TR)(,QHY1V.ZVJ<PS(\]M+&6-A9SZ[#]N?UW&_;S^_M\F
M;D,0OU[#_G<;\NWR9^,8<.'#C&'#APXQAPX<.,8<.'#C&'#APXQAPX<.,8<.
M'#C&'#ASYG.,8\<Y\/BQ_7GV8QC'QYSG]K&.,9]X<^>./'P]OCC'C\6?#\/A
MX>/\7CX_M^'/O&,Z)/Y-G_S.3^17RD?:.[777/7?<5TUH5H 38X.DS5:_);2
M+P0-"9NI.:/!UAFP%BCC(B)B>8*Q!H7X;D1:_(LTT'$L4N(!?)2&KN$_DV?_
M #.3^17RL&U".M1&L[^3W*Y4V]2PJ@>=V5F]Q()"F+I2H+K)^/9QQ*--A$A$
MR$ZN%(%O0IJBBY+0Z-#ES)4>,ZQFH&M=ZM]ZNM>:->&C]N>JNT[+G>=<[=B=
M-];=X:.U*+Z>;E[!C"3EVT,W9>J^S:[:C>D[83JFRA1.JB0 ,-8*=L&0P^X.
MN0:0*MY2_9VP*Y*AU?K$%'[/8+;S'2Q=EV_;Z_2J\)U+UBU3V5'VA\C=>O%&
MV*=6>%[CJU356TZQKC2S42:9&VF92IL.RMV'U2'\GEMVO,:\UWK33.!M7V\X
MK&IK/I@MJRS"]T2-3%".9!/5&T:;2;Q*LYK1CAQZ/(-UJ="LNJ8YJ*PLG51A
M*)#G>E]7^L.E8Y@KK[K]I75L5F ;DV E5=;56K,I'/@< ;)+.3(0R/AQF16!
MZ 9^<3=6Y*!CF!)1]V .CQH[&:VZUY2#>L"A(L1;KZ&V#>54*^[BV/5V-V5[
M7M-U=2]-=1NGN_;W#U[8'M.%;'?WK3([*Q7ZH$N Z*5%F\EA1>[IJ<(/,AVG
MZ_=XI>\]R4BDKTL[4-9[5JG9"]:JV1+VK73UDL-<ZP;FI6E;JBXZJ&5V*0H!
M&PV"VN%:ZTQ;[='A!!R8=CF![=)?K8Z;-6Z@ZN2*O/JNI=1ZR72@0*317X('
M72<UB;4-FZWUU(GAQ9,B'R/N=)O>KQ^L1A":%(V&LGJ_7JY5I9!YRI_ XG!M
M2]$-3ZA[%WOLV!7826P=A0[L$C)(UK6(& $@[1ME<M]OC?#E)UU4;AL"42)5
M*L#@13:UJNY"JU8.R# R6$RB9&:QFE:V^5&[@:[@7F.8*U0^3TC7M\](-A/1
MZ$ C3#_E.[;<-X(Z:D8XZ-!0PU7#U)U/K=XO3A&(U>+$NPU77+&/,QX+J;NV
M_P I380MWO>BTT*Z-RZ3>U=?8^^1(H@N:<V]K@WJ(-LBWSP%@TQ(T('HMDE7
M0K"#1 FRKA< \_,-LWKZG1+-6R(.PB^R7DYYT/;YLJYKN"+JQ&[]O=GG;=H*
M_5L/9K%U;GB@MY[# S5JU:+%[EN6D)E(KD:=>-<2[Q:ZNS7JQ+A/I@L!I2GU
MVM'DZJOL2'L"[A>O*=I;PTG.WVB[RM8#SUNV1HNF%M59E; *64;4B4TC7(98
MUJ+T#I2<R8./1*ZF''*-51W 1C*U6;RC^T+:8H0'6>D1=38VM=:!8=/V4[N*
MJG'[SK"'WYU#U%NU=O\ 48U#*3]/G+9#V!*-P9\.;LARKA%M1<3U;&@EJ^#G
M3K-W&VANO8F]XUZU/3=>:OT[JBM6=XD!V*0O5L^KX5M;L_JW9PA3#](J(LI4
MES.N9DM22_I@A= Y$/)L+ZU9WH]/S75_0#1.IMY[(WPMF5<[]>R).2K%NJ^I
M8L>N$)NW!VZYA;!"CZZJ)^^7&+LVO5LR#V#M U=KE6V*N&B C41_)<F9F:?7
M>N.E[> NDT%J_6EVVN9%:%KAU(\=7C&P#MVM=PV6*UG!1%0VFP$3]P(W^]X@
MKBOOY(S[@?E2F(\PR^ZQF =<>YVFNW V^O:%GF2A"BCA#\Y%R"M5\?B=:(AE
MRM(==$&K%+<@O2@[Z2KC#*946+A2X;,Q]2&L:\=[>49W3U^Z/6.^; FZB']H
MYFW.XVO1)P?6[H[H2HB.L^V+N)+FDXG07BYR9#I82OU6@URSRA9S9.PC\(F6
MR/KPNUNC]NXO8.I&2^TJ^!L-+;.:<@ R6W@U?:@-DJ)#/U&7?*[FVPQ$-+L6
M04I4619Q@]Q+Y!85R/,1$0@C"Q+[M< :WO&MU1ZU6ZZ=U;MT-,NLP3$KR/J7
MOP?;:%VTL=-@78++19-^78)!D]DS S*+SRLU99K)!Z4WAC*FU6];/N'<@D$H
MW8!-PT)6-5P]O;#I\W5FM((2O,;HB3877*@U?9$&,-V'*+SQ]=N&W;*4LCLI
M<>H0:D%G04/W=B2)PC1N]]\%.Z-DUYNAZP#M6;$VAV-I_6N#6A_6ZQZRL-;T
M5)J[4ML];Z!<K+ONM;'BBF+4<)C;_ $"$D%$*@:%5*PBJ^+-W8D5'3UV*;DI
M$RHT>U%;BS4'=]UV778!=^WM%:V@52<;-CO0GD6-<BIUV.."L&US7V (V!%2
MTQ#S!2['F(W6;4&\X9D9KRF4[>/82>Q!(;'J6J,1R]V*SGY[XN'>=I5VNY@L
ME;//IQ%0QFPG6B%H(U9Z3*Q*<#L2V6,H#H'REM\V/&#:RA:<F7O>$_=,W2@A
M5WMHG00>[%Y]A[1VV/>1,:32;+(^LE7]3]=CE:KNT  (\K:VW@INE *XTQ7[
M->$;(.LN[&.R/7O3>_(U8DTIG;M#%7=%0EG1EGDUK)%^9'=#/60*RP&/KAO0
MG$_"XEI(R>G*7X"G8JVGG(YWETJT9O*F#JF]5ZW07Q$V#*#62JZPTU8ID.#$
MM)*].5V97-I:ZOU).U6?=RLJ\2@1>N/LM7E,2XP'H9R.[(E3;IG4M-T+J36V
MD]>1IL2C:JI@2C55@E+1.)8#@XWH67B,QJ-#8DD)CRGYTUR+"@PL2I3K8\>/
M@(C08[&27PX<.,8<.'#C&',^IOZVG?SAO\ECF \SZF_K:=_.&_R6.,9F7#AP
MXQAPX<.,8<.'#C&'#APXQAPX<.,9C$O[<@/]&K7])T[F3\QB7]N0'^C5K^DZ
M=S)^,8<.'#C&'#APXQAPX<.,8<.'#C&85<_L0_[[(_)HYK![M[%["UD_J:HZ
M$F7M39NN;AN&PQ.@0/7J_=G4":A#I0JH6FBZL[,$!M&O.J@-IMN8FW8U4=?V
M@@H7UN,K3+ HQ89:-GUS^Q#_ +[(_)HY0WMD:Z@# U.C]LZE3;U%<D6\K1:X
M<TY:]Y65EL/74)V)8@%-H-(OMRA5P35R,6)L"QLAX]7BC"PH79YWB6$PI3&:
MW!WE9-F5_5MOV++UOJ3>5?B-UDCJ>TTJ\['U>7VY1@'2C77:';6P']/9TKMO
M8-1D-SK:VRR"Q#(U#5J;,-";:V)5A "'=KI*?8+RAF[:Q*L3VL='UR%JNKG=
MHU6T[,L&UQ[>QW%57R=Q;N\LU0=;.:NL]5AEJG$(UP:WF]'S0*TG I $^%C5
M\^Q91]R8?7_HGV/B3KK$TQUFW>-,P-;$21K%%HU\#R1SFK@BM5O2HSL">(A1
M9>F;/6&:U&S!AME-=%*U!>CS03(2-%R?86FNIU=I@.O;$U+J2)2QA8K;:I4I
MU%B3&)UBHFFC%?+2*I41(V45MUB#:$JQNL20(04=*$-: 9584()!X:1N&,IC
M9_*57"CVLA5B?6W)L40VM=^O&GK:SO:L#">TMPT"\:/UBX]=ZS*UM#$:=H=F
MM6YFY.;2S9KP1#1*J9RBBR,%ZK$GYAL?N+LQSIKMKLJ'J@_4EEZR=DR%2W95
MG#X+;@61JOKEV2JU&[/O"[0U7@+2QIG4*;W:019@"&M=6^"XB)T<0>C$X,.U
M^T>L&H=W:QL5+F4P6"&;!'GI2;, H5-?.,.[&D@#MN)-#KQ3+-7B+M^Q7@T>
M_AK562D2XC(CH>S#W%-^=#CD'J3K?TBZHVC7ET;7-T8LA;7]ELVK7L2S-WLO
MV)NZ0UD$RM2:IU^R%EC-@66\0J>,UK0-;,5Y DC!!00#D;,V5)8S53K3RGG8
M5NV'U[2Q (@:%1NTGE';#5JK4JZ./GO)P$=.#SW3.B0"LV)EB!="^R[<BMF;
MJMJ,5.DM<%6)L]X7+(MKL<'\IY:3%M"UYW2I^)L%PDC5XW6J#1RFZSO6R]E;
M"ZJ5;615_8F\-"ZUV_50]7C;[?CW&7C6"([<D8;; U/9R[!K AFW-+W9T3N=
MQU]5*R_J].Q=TU?9'6.FU ]JDS3[[8:?UU!Q[EL3KP?JEWHH&QUNOZ\K-OC6
MM.IKZ-!#IU?LK9VM S PKB2]&8;6OD]>P&O[IUNT+#U#4X;A+<]&)1=/:EHT
M7 LKHS;NHAF^J^\,NVLSFO;8($;0@ZBK^P U@$6&OW!,&OQASA")7(), QD6
MT/RA6W[;L8R2>TF!B:] OZCUC>*2[N0#,,4795G\H3OOHP;M-3MP/6D^)LT0
M7.TFIV#(R=)IL,#5ATY4;$BX3)8A<K4CO\/H_3O079#M^"'Z[L>XY!84L'J5
M^3?0#1*(2M.1K\258\4F;&C$ -=S-?C.(GJA2U>@:FSV7</,V)T3U*T;H'6@
M35]4J08[!%2&R,\_9Z]3EG[ 9C[9L.]8!,A'K=<KE9%QZ]MVTF[U2JW5ZZ!J
MM ,267*>&$YC(<4]J,CK5KZ+L'4M-SJ>K#M)0D[-V718" T81JR!M3-QV$FW
M68?-2Z,J,:X-!KI<?2.N0V_@V(1+XC0A3T5;[&53[5=H-BMZ5T/M+KJ9.5FC
M[>@W*X$=BC-,0-YWT&$ ZK,WF@"(VEE'48?"7.PP?4MC79APQ!UQ6!:W2I.D
MP;%G9%2@CK=WA[&[/[":$'[&#NUFG=@(9>+G6,'4?HZ+1J\.ZC >Q==V.*[(
MY-RUV*\';,HL NNHRF,R:$"/!X9H#5I@ 5<MF[#;]!ZI;YH6DX6SJKJ#<>M-
MP'JK/T0/N=$$7JH6H^?U]8]@U$I3QY8!/@C7RNMQ-E,#R+D<4Q*K^)HF2ZM!
M3 J;EI;KEU]F']@[%-Z)U$_9]DTDA1MIWDAK2IX-7G7CP^(/*U2\6-P.B4=J
ML@4%'#B@TO+>A2Q80:.GI>@!8$>&QE.M.]ZF-P>4+V1UB%E*O U]3-37+%=
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MW,GYC$O[<@/]&K7])T[F3\8PX<.'&,.'#AQC#AS'K;;*W0ZK9;O<30^N5*G
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MNL6&1;*-I6Y5VW5J7/V17[4-K+&>HSX1MGW00_\ <$?\^X?"-M^Z"'_N"/\
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MFXJHH^8\RF'[)#%K>;U\*W+7"E^K,".4LE&&FZ 0NE>&2U1DQ")ZIP\OV$+
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MO-BLY8M4PP. A@22F*,]0/>ZY^4!C=AM:4GJK<[9KK5Q.FZCB7*R@^N%-W3
MQ9-I]FX>I;@?>/7$-/C YVI-0DI6T6Q")21&%B!YVWPGZHT6BE:E>3[[W=Y=
MQ]TM8:?[0D"-05<-';CLUVT:YU]"T.MT\SK+4/4$]4[ *VJ\W+M9*^V6T;<V
MA/VQJ*>83,U.39!U,]6Z@U""LVKT4Q1MME9E(:BU]/JLIV&[A14GC"G&D-+4
MI&,"<XRVI+R4XRK&%9\%84G&/#QCT+UVIM;V=<-UUW3ND .Y-A"AH*_;9#5L
M6,V5=@H;U; D3;+O"JK-DL \=B%!Q%BE",EM&(,'"L+Q!AX8E\KV2.GX\?RX
M_'Q%7?DS_P"V!CZ7G<<PQ=LF,^L-1*]A&'Y3'@X4)85Y\.4]$=SX)$JQYJG&
M%J1GQ\<HRG.<85XIQQCZI<($;U=+-<=QZQ+?\]1,DG/C+EO2LI\,"<X\&\O9
M1C/CXJPG"LXQG.<88SGX<(X>W28[$EN)7<(D,M/HPHH2PK"'4)<3A6,"<XPK
M&%8QG&,YQX^/AG/Q\_,L3;8463,=B5U342._)<P@H2RM3;#2G5X1C(G&,KRE
M&<)QE6,95G'CG&/'.&,_7#G*D%<%)2K$6M^"DX5CQ*D_'P5C&<>/_BCX_;[?
MX_V\\ZTT9;($9<IZ)7E(0II.4ME"65YR\\VPGPPH2E/AA;J<J\58_0X5X>.?
M#&6,Y.<L=*%R(Z'<XPTN0PAW.<^;C#2G4)<SE6?U.,(RK.5>./-Q[?''AX\^
M_ %Q_P#-:WG_ .VI/_WA^=64,MD/$?+L2O9Q(EQX:/,*$LYPY)7YB%*\1./!
MM*O:O./%7A^I2K/&,\M..U?EG]?:S-;/MQ&QV'+NEW#,NO7+I[1Z*-UW9KIU
MGM^W)UH6:8CU-18WI+8%-':\JM(LA&&.V%;;@U1+7')VNQ4\7 W(>3(WKL?L
M/UG-WG:%S-;"L /LIVGU6)N5GU>+TM:S]&U+NBQT:A3K=JT0*!QJ7:WJR+@N
MV(-(#"2D<L[*26$AI^'@PZ^MFUW.NU<.T^Y5:@6^HVD1/ 6>K6C#E@K=C EH
MZXA0*>!EP$P87$DHKKD></(19$64RM2'FEXSQ%0]1C=0U&K:SU=KS5VMJ!6X
MC@BI4:@P&JE3ZT/1F627"#5X%7H(L9&<D.RY+B(D5.7YDE^3(RMY]UY3&9EP
MYS? %Q_\UK?^]2?_ $CG64+MB9C4',2O>F>BR):%8*$O1X;C/1F7$JS\$^=Y
M^52F\IQA.4Y3A?BK&<8QEC/WPYS? %Q_\UK?^]2?_2.=9(NV*F.P<1*]Z9F+
M'EK5DH2]'EN2])9;2G/P3YWGX5%<RK&4X3A.4>"LYSG&&,_?/J?CQ_+C\?.7
MX N/_FM;_P!ZD_\ I'.JP,MCTF7&1$KWI(*HZ7<J*$L)5F0RF0CT><",YSA*
M%82OSL)SA?CYN%)]O&,45OY!%_>'/G+_ !WS@'52X#X,:$EFN.XC(4C#BB9)
M&5^<XMSQRG E6$^U><>&%9^+Q_;\.?N,,MDM4I+<2O8S$ENPW//*$L84XTAI
M:EH\!.?%O.'DX3E7FJ\<*\4XQX9RQGZ7E6$+RG]5A*LI\,>.?.QC/A[/V_;^
MU^WSSQ;GWUY6VH;VV]9-<.V _J>G[FV%]0>HSW5ZJ,TRRZ]J'8OKMIRJ@"N[
M/@\5:!U0MNMMQ;1W*9V0LW&E"A&FVK!&.P:/7=@RB?HE^ +C_P":UO'_ -M2
M?_N#\Z<45:B</TF(5<7&D)DL.,221!Q#C>%O0WVGF5B'&767DI=0MI>%MN,.
M*;=1E*UHXQFH+R0':;>_9VD]B'=\W\[L4SK38&C 04O:-'U[0!T:O8/5?5&W
M+Y7G*37H4)F>""[)N-G%TRV2_7,V6G009865L 67 M-AW!\CO5/7JH:(J[E'
MTAI_2>G*6Z9*6-VHZMKHZ@UIVP&W&G3!QT)5ZL+'.%BBV&,S9ZXZI+Z(\=E3
MF&([#3<B1P]NDQV)+<2NX1(9:?1A10EA6$.H2XG"L8$YQA6,*QC.,9SCQ\?#
M.?CXQAQC3OMALGNZN_XS/%DL3;8463,=B5U342._)<P@H2RM3;#2G5X1C(G&
M,KRE&<)QE6,95G'CG&/'..\'$W$9-GD6XE<>R2BCF<M*+$D8:Q!];4E6%8#K
MRK+GKF<*3X8PCT>/#*O.]C&9!:OLE6_I8-^:$>9'*B1I\.1!FQV9<.9&=BRX
MLEM#T>3&D-*9D1WVG$J0ZR^TM;3K:TJ2MM:DJQG&<XY ^Z+==:52%6Y &L3Y
M82PU- V L^48CS"UBL@RG"VITE%?>=BCVIUD8ESY$>/*DHB1G4QXK[RT)Y*M
M,=N[P5*K_!JPZP^M2T+CT\J8,A\0DN83"<1-.!@4[,IQK&52FLP,,M.>"67W
MT^*^=H$H&&1/4>4Q$P407D,1/<1WW\=Q\Q]IG.)&"B8*(D9[B8F(F)C]8F)^
M)CJ?URI'67IW6>OFQ=GVY,R"3?.D'X&MH^5>EG5C7KJHLZ3#?RZVWG))TJ\@
M/(E1T+1D2&%_IR72,QC%VX\J-+9Q)BR&),=65X2_'=;>95EM2D.82ZTI:%90
MM*D+QA6?-6E25>"DYQC7COZO6 1LK>A:FDKA/M%DZ<;)FC8V"\\BL1-A6,+"
M9A4J$I64@\OLI=E>J"L(D3"B\3&_.F>B5R&XENK8C2O:FK:A)+AUVXC,8TR,
MJ#<W,,O)KFC:*2W1FG+'-.--282W2#YW,-UAQX^HHB+AT]B<C%\M:N_R0D[6
MYM66K5E>L43&UI\%+[I5&>J8NGT_1!YV8F B+":>QM'*I67EIVAR'4<&&QQW
M6\>5K]=2=O;"DIOQ++#_ !V>Q3[<&5HEONFU5T)&725*QL]+05%B'+@=N<:3
M'F,HDQ'V9,=W&<MOQW6WV7,)5E"LH=:4MM>,*2I.<I5G&%)RG/AG&<8Y^4^Z
MBYK^6-V9U[B$G4/UWG<:QP&]'BLY%8H5)Q8,U?T6<L?!.;7\+Y?]1\('PSDK
MZ+&)/KF.7!Y3MC4BC<;5@S.%PHHEB_1:,-2MT+<KS9Z3U>IZ3U^9^#0,?*>N
M\V;H]G.XU=;82M:I=+PF$O\ <USFO8;6EU:QZ2?<5+$I]>J_TE^K78IG@/EU
M!PX<.862V?E2$KQC"TX5C&<*QA6,9QA6,^.,XQGQQXXS[<9^/&?;C.,^W@I"
M%^'GIPKS585CSL8SX*Q\2L>.,^"L?M*QX9Q^UG'CGGZX<=1_#'<_Q^WS']?X
M_P#9'_1ARJ=>K(.Z[8[84^S0&BM<M ;5E?.#'\K2S/$E]=EH,^(XII2'6\/1
MGW$8<96V\TK*76EH<0A6+6<KCK7]G[LC_P"AK_V'(<[>FMR+:F@#5-KRMJV#
M!K8LVJ$P,"B1,#&9$A*)@AF8F)B<]4N;7:#T-8EZ#!R7*,EM4U9B:VK8$P8,
M68P8&,P0E$$,Q,1.:XMT:LM70+9FJ>R] .7[9VG:X&C:DV, OMC<MYRFT<H1
MCI@1ZV3FMQG!M?0XW#P(93Z)J!8QHZ$1DOCK"]F-LVT%O/56\:DZ2U=<(5H9
MK[[(X]&1&GC"P2=*;<F18Y<,6BPB4!4N+XOQ778WJTM"'<Q)$A++BD_>R&EV
M]_:BLFM?AURLSR,@"8!G4PVB<<;8:L<@6,$^1$OK;8+"E$AL=DH->6E,N"X\
MA*T.X;5C7EURV!=-6=X-F4?L<Y77+[V"IM!F4&]52 ]6Z398](@E8L(,/"2'
MWE,D)R'2S"WR$N232:"/"LK]6)"&LZ36%KZ<<RK4:28K<!Y=LM<D8>N75=/R
M&W0VJ#54NQ>A^N3?L:[0UTTK6OM4K%K8NFM?UYK]M8^CFLI?6/Z<WMILGS<^
MJ_T^TVWLD55WM[_(^'T-KH+2K&QUI:LJNXLZFIN>67+.TI;BCLZ>NTU>+NJV
MRFQ=I[9+)\DR/OL'Z1A\>\16/.,B'\X]N,NP?I&'Q[S=6?-F+7_E4=_-27^*
M!QEQ:_\ *H[^:DO\4#C+C&)1GRC8O>43Z$%\=<2C/E&Q>\HGT(+XZXQB6N?(
M ;W;#_((X'?UK#]] ?IB%PKGR &]VP_R".!W]:P_?0'Z8A<8QUQ*[]L4'W*5
M^?!N.N)7?MB@^Y2OSX-QC'7$07[*:]]S/R$+CWB(+]E->^YGY"%QC&4_]8S?
MYI)_(KYP!_DD9[O@_-&><\_]8S?YI)_(KYP!_DD9[O@_-&>,9^2G^SO>D3_F
M<:<5E/\ 9WO2)_S.-.,8B1]LCON1GZ1D\>*^+/\ )G\7$:/MD=]R,_2,GCQ7
MQ9_DS^+C&) 7Z@I[\*_.,\YC_P A&O=)'YF]SA!?J"GOPK\XSSF/_(1KW21^
M9O<8QDS]B:^]H_PXXI)_*-=]Y2_H0IQLS]B:^]H_PXXI)_*-=]Y2_H0IQC'7
M$L;Y?+^[0GY<UQUQ+&^7R_NT)^7-<8QSGXOZT_CQROG5W]AT=_3C<G_&?8/+
M!Y^+^M/X\<KYU=_8='?TXW)_QGV#STC_  C_ -XK_NNQEA.?GS$X5E6$XPI6
M,8RK&/!6<8^+&<_'G&/VOW/'/A\>>8?;]AT2@8#YN]OK=3Q8"*!(3ZH#$$3D
MJ2<RC&(<#$QYK,E['I&_28;QE+6'&\NJ1A:,JY+5?Z31W0;-QME?K#MF*-A:
M^V=+0QBS!5WS,(@CTRW6LR9&<N-IREOQPA3K25J2IUO"^PU[!^GX(<?K^IZ/
MBHR];TOEOI]#/J>GUVSQ[\.OS==9BLO452^&W*JYJ2F+4,L)":TV.HKP_P C
MCT9?Y1"?4\?5[CP\NXS+,)3A65X3C"E8QC*O#'G9QCXL9S\><8_:QGXO'/A\
M>>?KAPYXYE8<.'#C&8Q+^W(#_1JU_2=.YD_,8E_;D!_HU:_I.G<R?C&'#APX
MQASK28<29AE,N-'DXCR&I3&)#+3^&9+.<Y9D-8=0O#3[6<YRT\WYKK><YRA:
M?'/CV>'.)B)CJ8B8G[Q,=Q_T3G,3(S$C,Q,?:8F8F/Z3'SG4D0(4K#>),2-(
MPU);F-8?CLNX;EL_8I+>'$*\R0U_]&^GP>;_ /(<3SM\.'$1$3,Q$1,]=S$1
M$SU]N_X]?IB9F8B)F9B.^HF9F([^_4?IWU'?6:T.T6AZOO6L]H(YF3D+8-?/
MU+8-)M<>,Z_-KQJNZHB$)"$IB>!!T<9@Q7!Q&+#5E_&51"41I9(9 4CK]0>U
M.X[$YH;7F]Z@$S(W)J@C<=:[(KULBF25HCTZ%#?)+OU<:93BOFB(F0R1S-@R
MY,%^?Z6(\U&(.RH8^XU%99D;0WTQ(:;?8>*4!IYEU"7&G6G-=C&W&W&UX4AQ
MMQ"E(6A:5(6E64JQG&<XYK>[2=8V.I96H=N>J=9R#7JXC)<V9KR).*309BC&
MY:LFGQT&?+G*#"FDR7X1H8&Q'&CX,J+8X4**^!D.2-2<_P!?M>.;Q'U#T4-&
MI6I:Q'-:E)D>XV.EI7J+6WF:XZ5I>U=K-.S;@F4V=7L*JS U6;RE#KY^A?I?
MM=%S#C=CZ0<H-)7KUW8V_IK?V2IBIJ.3;31WD)UBMRK:47Z*MO.1)X\=@;%'
M>ZBXU3%OIZMUAFV';J%^RFO?<S\A"X]Y7S0/8#4^^ LTWK>Y@SDEW,4R6KC!
M*&NS5A)6#!6F#9 K;ZYHR7&E)?@/9=:S&7*C.X8?<3E.<V#YM&A?H[2HB_K;
M=:_2LAZB+=1R[%=P=S':VJ(@+J8D2B)[$HD2B"B8C1.TU6STE^SJMSK[FKV5
M-DJMT-A6;4MUV1$3XM0\ 8$R,P0^0Q!#(D,R)1,I:_\ )V?>1OZ;(<=<2U_Y
M.S[R-_39#CKF7D?B\3\E#/=\+YLUSA/_ "$:]TD?F;W.83\E#/=\+YLUSA/_
M "$:]TD?F;W&,9,_8FOO:/\ #CB:R?),C[[!^D8?'+/V)K[VC_#CB:R?),C[
M[!^D8?&,>\1G?U OWX*^<8X\XC._J!?OP5\XQQC':?BQ_)C\7%TS]>B/YU)^
MCY?&*?BQ_)C\7%TS]>B/YU)^CY?&,9<2N_;%!]RE?GP;CKB5W[8H/N4K\^#<
M8QUQ*U]L4[W**^?&>.N)6OMBG>Y17SXSQC'7$0WY6/\ WT9]'-<>\1#?E8_]
M]&?1S7&,>\1!?LIKWW,_(0N/>(@OV4U[[F?D(7&,>\15OY)C_?9WTC,X]XBK
M?R3'^^SOI&9QC'O%XGY*&>[X7S9KC#B\3\E#/=\+YLUQC.$_\A&O=)'YF]QD
MS]B:^]H_PXXM/_(1KW21^9O<9,_8FOO:/\..,97_ +1?L.D?Z<:;_P",^ON6
M#Q\7]:OQYY7SM%^PZ1_IQIO_ (SZ^Y8/'Q?UJ_'GGI/^$'^\;_W4YS^D?UG_
M "'#S4^=YWACSO#S?.\,>=YN<^/AYWQ^'CCQ\/'P\?;\?.O'AQ(K2&(T6/'9
M;RYE#3#+3+2,O*4MW*&VD(0C+JU*4YE*<>>I2E*\5*SG*1NY5%VSR*2U:*\Y
M<HH]!655&S0Y=DC"W/,]&1?")DY),PE^E:\R2Y&2RK#C><+RE:<Y_;%NJLFR
MS:9'LH%^WCA[!8A5V2X]VPP1<E2$QR,L,B0HC'A/J<;PU*>CH9<RMOS5Y](C
MSN?1?$3$J;$>F+YCTSB/1GJ!=/Q_ASY1 L_=GRCJ?GYQ?<U)F)]Q7DO7*H,P
MY??N8_,=:/S=^O'I]DF/VD0$S(_EGIU&C1X;*(T1AF-':QG#;$=IMAEO"E95
MG#;324-HQE2E*SA*<8RK.59]N<YSS\.'/*9F9F9GN9^9F?O,_P 9S(B(B(B(
MB(B(B(C[1$?$1'\HC#APX<9SAG.,?'G&/Y>?/''[O-8_9_;EZLN1[U3 [;HH
M/6CNY#E[ $]EL=<+=L2N46HL3%6+6Y#";&1O%7$>=*(K>ACHL1J>\"P7FAX1
M'$A73[.;4(V&OZ:BT/9=SIU8*:,WQMN03"V=8:WKM>L]/UBXT$3;3$*0I_+X
M]-B59++6IKJXIQ<5&3,.8*](A>O[_P!0M=2_'/"I8L?@YZE:8[*M.R/;6:E,
M#K%92M/H5;-P$VC%K&JE;)) B2)?M?5?2;;[.>,05^I5_M"O?.>706XTR]#2
MO[%B[JZ;W6/=7:6O98HJ)"4V(<D5VC,;8U=HN?\ WX_'[>:6^IE>WQ6O**;]
MJ^P;D?)01E0M-W/1Y>RCEG V0!?[XUC1SH^MS($:,'E4JHP3%?7$>=>4,86I
MJ"ZQ%?;CO[9=46 M;-7ZXM)Y*4'+)0J<?,H0QZLA!8S7!I(BA$;.$YCI3,DO
M82QG&,M8\&_#'F^&-=U4-(&>5WV<)7CV6;J/5D-_H/.SE\'9Q4Y/Z/TB/1X]
M!(D>./,>RYG&,>#:495R7VL!=_LSLU-LJ3&SI,D!.5PQ%]4^D%@([B9BQ[7N
M._B)8KN187>@^9ZUE3;<?ASV@S5<J"C9&L^8KN]2+%:1/\L>J'O4U8 ORR2B
M:N?R/,9VGY^+^M/X\<U=]_->1+10^O%OEA+BD71-OB)=QOVLQ,\SL;7])G1B
M2IA6O01;,R:XARPPJYEZ4V,)J%2F(1%F*IUK"'=HF?B_K3^/'$E;QX@AWWE7
M\6?LKG[>/;CF5RC0(Y1HMAH[)BI5X$],),/ &UK*;:"-/J*)@0Y"_4%;J[_#
MR]"S7=X.#:'!^5VN$<IU'**:S<[6-L3*5V)JL:BY3L4+0*L>E8!32K6G0HW5
MK=:&>/NJ=ROZM9NMKI3V2A;!$;5T_9ME6&WV^C;#+KH'URQSX+:5AU)F>$D!
MRMC@RQPMV>5&R),MHCE45LK"@.CGBL.*R_%4O:#R@/<CJ#$VWZCN;5Y5>O>Q
M="Q"F5*XCGDP&K&] D-)&!+2\EEW"\M9<5%$G'6WE#V9#D JP4K[CPY/SJ1W
M'?VB2F:.WB(<USV9I:'H5BK!.,@9%N*1[2'7CM:;](Y'Q-=AJ02) HC\AGU5
M>3==?(5]WTD*E<:W>PXM=J<'YDP9:TV)XIR>"L1KN1(\B8K5..W8M.H\@IJ+
MT1HV;;_?UDBZG8L,%RQV1S/C.IYSK-A]3?ITHHKUE)?SSA)#4G<</M>"TOWU
M96OIZ^MM.([*Q'KGM*6OJ1J;MDZFQI55%6<V]K_RJ._FI+_% XRXL>SC)0=X
M9QG_ +*2Q[,XS[?.@>SC/FU,T9B49\HV+WE$^A!?'7$HSY1L7O*)]""^.N,8
MEKGR &]VP_R".!W]:P_?0'Z8A<*Y\@!O=L/\@C@=_6L/WT!^F(7&,=<2N_;%
M!]RE?GP;CKB5W[8H/N4K\^#<8QUQ$%^RFO?<S\A"X]XB"_937ON9^0A<8QE/
M_6,W^:2?R*^< ?Y)&>[X/S1GG//_ %C-_FDG\BOG '^21GN^#\T9XQGY*?[.
M]Z1/^9QIQ64_V=[TB?\ ,XR6M+:5+6I*$(3E2E*SA*4I3C.5*4K.<82E.,9S
MG.<XQC&,YSG&,9SQC$B?MD=]R,_2,GG:(&1(M'GDR8\<E7G82J?-BPDYSC&/
M'&,R76L9\,*3GV?M*3GXE8\=8-XWMN?L]LL_JSJ/,;K51KK;8B];SE(=:CLN
M,S7G%1ZY.2W(S'CRU>G8@*@Q5GSR6'" V2##,_"LN'=:=?O)^;.VU;-%%>Z-
M3[ =HJBZ?D['U> WU09FT*Q+KDV&-MCEAUL.,6&_A,!2DZ#!-O6%UQX?*DPH
MTUQAUUIO-2GD=V^YH<=T\[6N@S2S:6KH:W6&]92#%5&RBU8N^F0D!N16FM#(
MD1>4Q,97YW-FTQ@:;73L$J,ULO.M#2HDT"\3779*;#K,K*"$V*1*(.)&&E,%
MUN1KDB/)CD7XS[,EEPV5RAYAQ#S*L8DY_4NM*6C/L\,_JOV_B]G.X?\ D(U[
MI(_,WN:?'^N^EJQN([I[J3W7#TOM)203%N/: G[=J9^Z0:V^F(Y&+6:@!9C-
MR"U^8V0'>84L%5."%M3X2W8KC4UAQRQFBNU-K.%[1U\[& FJ1O0&&)XA2<(C
MPPM^C-#W742!:&G5Q$%Y,7"B$=H6[($FX+<B:*5$=C3!,/VK<A>JY7U^]U;=
M-8N'Z5*Q%E=[5W'=3,5E7E@DE6C@2E=>W6KDV!F$DTORYZ(V[0L*J;6@S6NL
M%X570X+5"RSJ9A*[8"L@L%$3()L(23.IA4LF)C-A+/V)K[VC_#CBDG\HUWWE
M+^A"G&S/V)K[VC_#CBDG\HUWWE+^A"G+/DYCKB6-\OE_=H3\N:XZXEC?+Y?W
M:$_+FN,8YS\7]:?QXY4CJ:)O#-/>*D;@(G4F5;=S-!JBQ3\P2PF7G=5VSB5+
MMV;'+P6;QAJ;CU;%='8SZVSG+WG1,^LVWS\7]:?QXY7SJ[^PZ._IQN3_ (S[
M!YZC,PEGV^35$]Q$_P"RW[=Q/4_SCJ?YXR ^\-:L$^&,(5$?92=BL>MMLZIC
MPQ^MI6PPDYN\QJXXP(<DCR,.51+*6(BXB0MO(QIE8BP8AK!ST+K(U+\5;^&6
MRP-KB?6[V";DN]?-F]; CSM2+3FWMOR#.M9$ W#>PS)3%JMCCP)LD3?YBH0F
M2D%,S*FQ78\9+VU7AG&,_P#Q_P#'L_B^+EDH<G911K$^S4Z=85PE&3/3(_=E
M!2,DM4' KZZB",RGLH@@@HB->[G@"-O:W]G\3?5C?CK0>H$PY:HUP0,&(.?*
MI8[YDI%2QB861"PQDBZ MB3%&CXTQWTTN/!B,27O/6YZ60S';;?<](YC"W/2
M.I6OSUXPI?G><K&,YSSO\.'*O,]S,S]YF9GK[?,]YL 1@!$([Z$8&.Y[GH8Z
MCN?UGJ/F<.'#ASC.V8Q+^W(#_1JU_2=.YD_,8E_;D!_HU:_I.G<R?C&'#APX
MQAPX<.,8<.'#C&0GK_\ 95WM[XU[_P /1?,LVO1<;/UEL#7*B\T F]4VQU/)
MH?G/K@OX?$RAN)S*$K:R[F-F1AQ;'I6L2&L.,9<;PYYZ<3U_^RKO;WQKW_AZ
M+Y-G.MVNFVEU2P'J5[-6*[U]D/FEU85M#R"1(?("(>Q(2CON)B>IS*J6[&ON
M5+]1GHVZ5BO;JM@0.56*S <EG@P367@P!+Q,2 NNB&1F8G1*4A;_ .E5^UCO
MBZZGU38-8:YUZO0%VGZ"8+"9RJ^J6'DQKE;X9B)#4Z8=EPHDN$](2]7F9+D\
M7-(B9I:"1SN=UGLZC[?IH>_:\L$.RU<VTI<,A#\]*FWFE>CE0)\1Y*)0TG ?
MPJ//&SFF)D-]"FWFL8RE2FT.##)Q[*.(Q(TZ!/)$X4Z%,CM2H<R'*AQ6),27
M&?0XQ)BR6'%LR([R%LO-+4VXA2%9QG1;N31I7K#L_>;&K&.U='JULJ .Y=?H
MG7]5@.T9[9$2-)0<#[ CC&R"(HL,2:BJ@##C6&DU:7+;CRY>&AT%.E+:MI])
M#.[K(?R'ANS><W==;:M6TT.S7KIE5NG?76A%G7;)>N50*G>%35[5U**ULO>M
M5'T;KW:/Z_+5KMT5;B'U&TE58:W<4$M?HN5Z1VX6+J&QU3KTV:6ZTSMN_;#L
M=63J[M!6V<W->O\ #4O+>_7_ ).S[R-_39#CKE1.G_9V@]B-:AW@]CAR-A!A
MD=6Q:L^RD6;$'Y"U**3DB%KRIP%.)+D.#R8]4D=X.8AN.QYK#\-FW?CC/Q9\
M>;;U&WUV^UM/;ZFVB]K[R0?7L5V T"$H^0DED8BU1=K<N9\U-$UG$&,Q&@>0
M\>W/%=SL./[_ %]K5[;5V#K7*=M+4-683V)P+0 C2X)%U=T#Z;T&MRB)9B4K
MQ/R4,]WPOFS7.$_\A&O=)'YF]SF$_)0SW?"^;-<X3_R$:]TD?F;W)+(;&3/V
M)K[VC_#CB:R?),C[[!^D8?'+/V)K[VC_  XXFLGR3(^^P?I&'QC'O$9W]0+]
M^"OG&./.(SOZ@7[\%?.,<8QVGXL?R8_%Q=,_7HC^=2?H^7QBGXL?R8_%Q=,_
M7HC^=2?H^7QC&7$KOVQ0?<I7Y\&XZXE=^V*#[E*_/@W&,=<2M?;%.]RBOGQG
MCKB5K[8IWN45\^,\8QUQ$-^5C_WT9]'-<>\1#?E8_P#?1GT<UQC'O$07[*:]
M]S/R$+CWB(+]E->^YGY"%QC'O$5;^28_WV=](S./>(JW\DQ_OL[Z1F<8Q[Q>
M)^2AGN^%\V:XPXO$_)0SW?"^;-<8SA/_ "$:]TD?F;W&3/V)K[VC_#CBT_\
M(1KW21^9O<9,_8FOO:/\..,973MDB:YHX^V,D1HA)RV:E0.E38KDZ'%GKW!0
MDPY,R"S*@O38K$G+3LF(U.A.RF4+8;F15N)?;F>IQ+?$$*8NYNO'SF9DU>2%
M8K1"IB\PG'LYA,($%+1;Y2)##/Z"1(4:=1(7X+0RQC&4YB/M%^PZ1_IQIO\
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M>P?>'R;VA86S:#BC;FZ9L6'=\1X178%PVSV=/]9]7[XC%@66A2, :15HI\D
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M.]O2KMLN]-KB!027IH0LG6+#BC\J:U9(&^S8;()KH W.,%@11)_#FJXYVE[
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M/%8KK\A82T>FI52;KILQ+CEZ*PC:>-B%'=WAPX<J&;-PY')_4NO[1>JALLX
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M*8EDK6N]'0Q/4MB/B2B)V@A?LIKWW,_(0N/>(@OV4U[[F?D(7'O)W+3B6O\
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M]M''M7Z?<SZDU0FUY2SUO4]],3=]7U/S^K[CU(GKH_B,UF5WR6O4^+3I]'E
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MD-'1Y:V+: 8$[*F(A-P(7JR25QE^G5&1F?ZUAV9ZWM.G_K&;_-)/Y%?. /\
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MY]:MY2:U,578?9$IURK]L8P3!Q0-+)[4V!LN+JZJ3S%>K"@Z&:F'.V0+/,C
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M4#XUKV%!ON0(RIS;$"O[*4MZ0XQ/ NHPW CF"GF2)44?#6Z'/,)S,J\MW.9
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MVS@TA>4$OK@SK>#I2R;C>7/3+;LX"0LRE]6$,2)62:&\*987RC6GCQV=W6@
M"E:UNPW.K7 B*EVJ]>9V5 !B( 8:<IOI7]V%8O2,>"?C7=ZR'%9Y'4%:UZZ[
MJ-KO],H1$4JO5:I3N-8L(B &',E&T0J(DFLM;*1'P1U%#M'3,H\G]>=.S!$8
M?:S?<GK4((^B88:+DQNQY&OK0%]-E",8(Y3"#$G8,>>ZN*B*M]O'FJ;4C/JR
M4A+C:D+0E:%86A3:DX4E:,^*<HRG/Z'*5)\4Y3GV9QG.,X\.>;+;U3QK?O9K
M+046(XBM;2V9TBO/H_#S1[LK2^;?0R>7L-8].XJ0H9^E.,9PE,B-E4GS&L8S
MSTH8^+V?M^W\/MYA<#05:-I29/D>H]MHCF8Z\HU]G:.4774=RRO>2V9_663D
M;],JQTXW6O87DS1>SXTR?&!\HU5W=/2?41$3+:NQKNDOL4M_EW.M#R>\AW6A
MSLMU/)JPT[I7;4RW45E:U)P_J?<K:KG5U0F5YS_V0=/>)Q5Y;_2VG)+;6?!>
M<^.QH_\ (1KW21^9O<UN;=1G2G>#JINJ-G$6M;^J)/K#L-;>,--+L"(Z;?JP
MA+4O.&U2'B3,P.TYG/G889PRGPRI.%;(SWM!&<^'A_XH(^S]S_L;WLY9./\
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M8& ;:,3&HA1Y:&F(K[,;NV'KLVL;0G*_#:IFH;SO6TY/"W2V;,)I)^LA&J5
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M$I@[(D)E*CB'1*\U;HN=Z;6\1U;+8[0V:[7UJ+ 7J;Y>LRF 4QD;9)'7P3O
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MZ: ^F*28F^FF-9;<0/0K+C+2O3O>H#LZG;"MD[65Z@?6^A1BLF+3(,S94,K
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MS7C&2'PY'GUU]>_=2._!+_->'UU]>_=2._!+_->,9(?#D>?77U[]U([\$O\
M->'UU]>_=2._!+_->,9(?#D>?77U[]U([\$O\UX?77U[]U([\$O\UXQDA\.1
MY]=?7OW4COP2_P UX?77U[]U([\$O\UXQDA\.1Y]=?7OW4COP2_S7A]=?7OW
M4COP2_S7C&2'PY'GUU]>_=2._!+_ #7A]=?7OW4COP2_S7C&2'PY'GUU]>_=
M2._!+_->'UU]>_=2._!+_->,9(?#D>?77U[]U([\$O\ ->'UU]>_=2._!+_-
M>,9(?#D>?77U[]U([\$O\UX?77U[]U([\$O\UXQDA\.1Y]=?7OW4COP2_P U
MX?77U[]U([\$O\UXQDA\.1Y]=?7OW4COP2_S7A]=?7OW4COP2_S7C&2'PY'G
MUU]>_=2._!+_ #7A]=?7OW4COP2_S7C&2'PY'GUU]>_=2._!+_->'UU]>_=2
M._!+_->,9(?#D>?77U[]U([\$O\ ->'UU]>_=2._!+_->,9(?#D>?77U[]U(
M[\$O\UX?77U[]U([\$O\UXQDA\.1Y]=?7OW4COP2_P UX?77U[]U([\$O\UX
MQF$;VZQZ,[+YU K=U '7S.A]V4CL1JKX0FEH7U*;@UT@HW3[<S@3/@8)+$I,
MD,9#F,3P,_+R%$1DM4>-EG$?^\FZN+M_:J]2-/UR?9.[0"GU;M#))2#!*%MJ
MOT.D3]=5@6:#S23P@;'@4\I.%/9KT(0Z16_\)$7)19IF<W,OUU]>_=2._!+_
M #7A]=?7OW4COP2_S7C&4Y&>3'ZOP*1=Z@05O*W&+Q8]?VN1MR^]F-^7G?M6
M.ZCP81J2;KO>=GV 2V9KOZVK=BL[=68I]A$Q_"VW51QHTN[6Y1IZ)\FUT^@4
M,GKTMK,G=Q%BU/N;3%R*;&V-LJ_W"^T_L+= >Q=R2[S=;5:R=HM-VNUVK0"P
MO[#*$W;L E!A4:IG  T8/A1;4_77U[]U([\$O\UX?77U[]U([\$O\UXQE5JK
MY.CK94-T#MWP&=M$SH:\RML!Z9:]];BN.HA6YB-/DT0KNB#J6SW$K1FMJEJX
M0,-D[FL2X0EF;!8K6O&+6=)FI%[,8QC&,8]F,8\,8_<QCD>?77U[]U([\$O\
MUX?77U[]U([\$O\ ->,9(?#D>?77U[]U([\$O\UX?77U[]U([\$O\UXQDA\.
M1Y]=?7OW4COP2_S7A]=?7OW4COP2_P UXQDA\.1Y]=?7OW4COP2_S7A]=?7O
MW4COP2_S7C&2'PY'GUU]>_=2._!+_->'UU]>_=2._!+_ #7C&2'PY'GUU]>_
M=2._!+_->.@=VJUDE.P@9F(1E,L9E.,L>GPM#"7&VLN9]*RWC*<..MISX9SG
MQ5CV>'MPQF4\.'#C&'#APXQAPX<.,8<.'#C&'/GAC^/\.?\ /GWAQC/GAC^/
M\.?\^'AC^/\ #G_/GWAQC/GAC^/\.?\ /AX8_C_#G_/GWAQC/GAC^/\ #G_/
MG77)BMJRA<AI*D^S*5/MI5C/AX^&4J<QG'LS^WC'.PK'CC./W<9Q^''-(_9G
MR9.Z-U[WV1M.M[&UR'!W,Q!(CAAEVXI)0V8M?#"'&Y:1PF1"PXJ0.?=3ZN\X
MC+3K?G9PYYZ<4_FF^Y#Q_75K?&^)6.8W'70KNUU?9(U9UZI(>PKA/?7L 8@U
M:D^E 04R^#@N@F)V']-N+</Y;N;FOYI]0*OTYUM?6,N5MQ;TEO>KN7@MTT!K
M!JT[51BC97?8M18)A (U"7X23!(=UWKD/_SIC_\ 66O]7F-6Z_4>@@9EHNUN
MKE2KH_S,3#=B.0!(R.IW.4LMN3)DEIK#SZDY0PRE2G7EXRAI"U>SF@#_ ,#O
MV#_^MC4W]]?O^B<R&G^3&[!Z7N51VDJ)J+?C%)L4 U*U0Z:,!\VJ.TE]AQJ/
M.N 7%=:G#\OH)C\$\XC*FQ&//PXG"F7-:Q]2OJD4B+?HOL->HR 6WV<@5M H
MJ(A%EL]9K=7^(; :P23BI4O[U:@)37GU3"9W27T6^A( 9UO])74;>R"V,KZE
M7#[6B9M+ !)IUR]UN=W&HU!W6P-8-ELY]A2)D6;?[!9YO<I^P:+L$!"M5'MU
M<MM;(9<Q".5XW *C)"V580^VW+B2'&_3,+SA#[*LI=97^A<0G.<8SD_KD/\
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M"TN!<*&-8:H+P(RF)G/7MM+;VN=+:]-[4V?9F*C0:XV'=-6.?#+R(T!!\P+
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M:R9'5N'"I QR_)AC'@H:,-FR6\ K\"&><4DLKFN^@&,+\]S/IEON^<ZJOO\
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KXK.6TN85XH3XX\,J=5CP\?C_ $.?ZN'#C&9)PX<.,8<.'#C&'#APXQG_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g545825.jpg
<TEXT>
begin 644 g545825.jpg
M_]C_X  02D9)1@ ! 0$!A &$  #__@!"1$E32S$P.3I;,3A:0E4Q+C$X6D)5
M-#0V,#$N3U544%5473$T.30V7S%?4$]-0U]/0D5315\T0U],24Y%+D504__;
M $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M ?_  !$( :H"E0,!(@ "$0$#$0'_Q  ?  $!  (# 0$! 0$        &  <(
M! 4)"@,! @O_Q !O$   !@(  @,("0P-" <#" L! @,$!08 !P@1$C:U"1,4
M(3%U=K05%C0U-U9TL;,7&"(R06%Q<H&&D:%&1U%7>(66E[?$Q='6&2,D566D
MU.0*)28SD]/P0E*2)RA%@\'2X?$X.4-$5%AF=Y29MO_$ !L! 0$  P$! 0
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MGGC!W!RLG"),Y*2@B/U8Y-DX!(.EI'<3>$JB;4X,-FM65[E9K@JX1K9P?TR
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MHV:H2*6LM?R'#Q0[?39Y25N<SL&95VOM;;\=7W'A-4@% ;N7#V:#9SU.7O\
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MVGMV2MH0W]7=FM+=$ZMK[U)2*IK"#A#U:'E%MB-%W<+.C K2+:<59LSIHR@
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M(5W6H-_MT2F3(95?4\\DF!UE"I)$$YQ H&55.1),HCS.H<I"\S" 8WBCI/\
M*WTIL-U?B/K6Q&6:^_7 H_O-<0GB\0__ "1V'RAY0\GW,_)?B(9M457+G3_$
M W;H)F5776U-/I(HI$#F=150_(B9"AXS',(%*'C$0#&\7K/W-]/SQZC38;J_
M$?6MA\\RN,ONE\)P?;,:ZO\ J [6V_+J4&E7V2EZ1;M652$B4=B3>YJ_281P
M>^VN#DGDK)RFC;BHX78,'$;#LO ';IX"ZQ6A]L@X@D! !#37$&(& # (:DL
M@)1#F @(>(0$! 0$/$(#S#Q8%L]XU9:G:TW<N%K8]E?E8,&CB7M'#HG./0BX
M)6=>Q35:0F(QVX]CX9>RV9W'-E%O!8Y:P3R[5-$\Q)&<T2)TYGX-UCW=7YX4
MV&ZOQ'UK"7!OW3?6'&MM2S:XU_KG8-9C8S6LCM6HW*W3FNW3>X5"$VY+Z2F
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M>?YVJG7X+X"AC'KY8/1RN^NSF,\&,>OM@]'*[Z[.8SR)HW??Q-#K\%\!0O\
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MTXW#:#O)\ZU5]KNGRI[@6Q=<-?\ RJQ=BGQU@6Q=<-?_ "JQ=BGR2<T=^/\
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MZ)-RD]NI6&]E@M3(IE#1R32QK#(%F#JT:D8/*9GCP+$ITE:%K.&.^,BWE_8
M+87$-XXDN<+M[N_$+I R3Q6UM.]S"TEL8W25@?54,"035J^D-@LGK9!XS=SA
M6KMHZ13<-739Q7(I%=NY;JE.DN@ND<Z2R*I3)JIG,0Y1*80QA'NO#F+)Z+5V
MR%XT;NQ9OD@0>M!<HD6%L\1 Z@(ND!/WIPD!S@FL0Y .8"\Q+UCWYO/I&W[
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M7I=6.TR8?FGX>(JKJ.T>--,&7_JPY\XP';T;C/!E_P"K#GSC =O1N'YC=UO
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M*@*:R9@Y" &#F0X%.02G*4P9*P7+]=*CYMM/T<5GYE570HZJZ/LJZ, RLK,
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M>UR^[KX?YV0AX2:NFM)<051F*J_0>1S5V0P'25+*52:;FCGB9RG,4'1H\QQ
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MU[?;SS#&W9ALY9#9$$D"C7(FOG?TOW1#>&KT6$-91C=HU1H4B1&=@YQUE;M
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M8#O&F%U?O#Y%JG1>SS-#+=[KIGI>R[,EL9%\@?@#YL&V[W73/2]EV9+8R+Y
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MC'%;HL$<$$J0QPJ(TB2.WD6-8U0 (J  (% "@ #+*N[BC2)8XHT6..-5CC1
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M]WKPUVBV02<N^\E$B/A3A-,JSGO)!$B7?CJ=[*(E)T0\6<LQRD !,8"@8Q2
M)A  $QA I2@(B'C,(@!0\HB(  "(@&?ZY_A_0.3(9YY#////(9YY;.?;L^KG
MKEPTJ9#J&N?QRRS[<N'9PK^#Y/RE^<,U"X.>K6[_ .%=Q)_TE2.;>CY/RE^<
M,U"X.>K6[_X5W$G_ $E2.9"?X>?OP?\ 5K]#1NSS%;?9I=MYM1&^P==V*U:?
MM>T9R-WK%QM/EJNU?NBZ[D).OUQ96U3I&CMNW/$(+LF*_>Y!)=MWYD=P7O2C
M?DMNCFJFV0N!&D@[J.X:QI?P'<-3<6"P6II&N&$W!'A(Q!2IH'E5T&J#V8=G
M;D1 # L[ AFR:S<!,H;*PARF*6>4ABWGI$!<37=OD+BUF@8&2PCENMEQ(49(
MHWWJL8G4QN]:#E/&),#OLX1<;KT6Z$1M<-O"6L[ZVND=8,7FM\.+QM")(Y;B
M>+T=T6XB<3Q1UM7@N#ZX7G\V>RUL:8+@^N%Y_-GLM;-8VJ=X_(U;\:'L\Q33
M!:7P@OO1&+[9DL:8+2^$%]Z(Q?;,EAO9[P\Z#1NSS%-,%J_""Q]$93MF-PI%
MWR\O]T62@+ZY6::\A:C'2[+9_LZQ70E+&\6;=^K?L&D47;-5!LNNKWUPH500
M8G6%+P=VU.*M7X06/HC*=LQN>US;R6^Z$AC)ECM[A=W-%,!'-LN@<Q.XCDV2
M-N&39EC/JR(K<*Q;.\AO5N&@$X%O<W%G)O[:YM29K67=2F(7,41G@VP=U<PA
M[:=?7@ED3)J:8+5^$%CZ(RG;,;C3!:OP@L?1&4[9C<\6T'>3YUK*&C=GF*:8
M+E^NE1\VVGZ.*QI@N7ZZ5'S;:?HXK#:#O)\ZT&OP;P--,&6?WYHWI&X[ F,9
MX,L_OS1O2-QV!,8;0=Y/G6I3/!=V]RP7I=6.TR8TP7=O<L%Z75CM,F'YI^'B
M*JZCM'C33!E_ZL.?.,!V]&XSP9?^K#GSC =O1N'YC=UO T74=H\:9!Y/RF^<
M<*WKJ;9_,DCZL?%0>3\IOG'"MZZFV?S)(^K'P_,;NMX&BZCM'C2-I[D:_)T?
MHRYUMDZNS_F65]17SLFGN1K\G1^C+G6V3J[/^997U%?'L?P^5%U':/&JM]78
M#S+%>HH9W!_M#?BF^8<Z>M]78#S+%>HH9W!_M#?BF^8<)S%[J^ J4/U]U-K_
M )O)],MC+!NONIM?\WD^F6QEA.8O=7P%5M3VGQH910_ZF=^D=H[?D,[*P5*K
M6QJ+&T5N!LC(Q3$,TGHB/F&XD,'(Q11D6SE, '[H 4/'X\ZVB>\SOTCM';\A
MC//SL))$$D171E4,CJ&5AD.!4@@CW$5^&574JZJRD9%6 92.H@Y@CMK1)UP,
M\,VP M!WFNT*X]1M<TT;OJ7*2=94;MTN\"DDDQ9.30W02,H8Q$SQ9TBB/+H=
M'['->[EW**K.166U_MFPPP\A%&/M\''6-OTN7B(,A$*UQV0O,1^S.V<FY<N9
M1$!$?3VF?LK]-)W^JXTSF+WD3R4Q)2;K [$.V9,EM&;*4G,\6DLV@9C[V+9]
M.=:.[Y+\G[W/?X5:!FU>!#:N3UE[8Q,3[R3GTYU\Y]F[G3Q%P[V9:5QM4;X6
M%6;HN1@K"2*>*BZ9I/DA1865&*3,((*@!B!('-WP#%3[X7D8=;YW4&]]1.0D
M)C7VS*&L@?I$FF45.1[<IR&Y=\3L%>%1D/(W+D<)#D(CS ?'SSZC*_UGO/G*
M%[ :8S$H"'+EXAY\P\@#S\O, \OY<XR[^Q[ I3O<.Q#$L-E#-L9M%=Q1D,0I
M4,L-QF,M3=$GKSKFKK[-\)=MNRO+VR<9%<V2XC0D \ RQS</?.3[Z^7:E\8W
M$C1WAG,/MB=E3]X;LUVUM!C<4CMF9CF0:JGG4'<BD1(5%  47R"Q2G,'?/((
M;;4[NJ>T8P$4;SKBFVI%, *H[@'\K49!3Q_9',BY"RQYC_N%(FV((AXP /%G
MJ;9]':?V+=+&VNVM*78RG@();O\ (5^.%\19=W,D662DFZ"$BBLJ5,@&52=$
M4$2$'I?8%Y:^7+N:'#A8^_JU]&XT%TH!A1]KUC5D8Y(X@/+G&VA&<+WHHCS[
MTBY;\@#HE.4,P%Y'_:/@^9P3E8+V*,D+!=S3 D G@MO>QWUJN>0X;Y1T9@9U
MAGDWRUPPYX9R@%VB@;,=Q+*#ED,@L%TMW;KPX9;Q1PURT!T[NEFC)RTH2]KA
M[O1>^5\8A8742A8V*+GV2!X!_":ZY=/CH"ES#O@Q29@. @) #D8VZ%+XG>'_
M &")$ZIMRC2#E02@G'N9MO#2IQ,',"EBISV,D3&#R"4K8PA]WEGE3<>Y<VMK
M/*0^O]IP4R;V(]F$T;A"/H);O?AAF?@POH12;;G/TNB8%ACFY1 3<TR\N>:R
M7/@0XH:B50[G5ZUJ9)"( ZIDI$6<AR@/VQ(XKAK-^3HCT?8CI?N<^0X'*K[3
M,%S7%>2Z8E$A_636L#N[9 9LTV&R7-O&#P.;6RY=60RI^G^76&\,1P);V-<L
MY+>%F<@  DR64D\*#WF!<NK+*OHPDU$UKA3UD3D51/%V<Y%4S HD<ADHH2F*
MH01(8I@\91*80$/& B&-\^3%I9=TZ7DDB-IG9VKI)J*A4FZ[BS53O?/H%63(
MPD :LU4S]%,BR8-E$52E(10IR]$!V2IO=%.)ZJ@W(^L\!>F*)2E!"W5IBHNJ
M0H^/I2U>/ /CG-XP[\LHY-_[0](<S++[8<'+F+%<*Q+#I=H;8CW5W'&<E!V]
MHVLXRR)X6['J!K*M_M(PUF$=_87ME(.#!-W<(G$\6S,$HZ> A8\*^@E]U]K_
M *.6+UV#QGGBO5>ZDIKSL3*[!U*LD9C'R,<LYI5A2<E4"078*@N2,L+=B9,$
M@9" I^S"PF%0.1^0#FY%/[H?PNVL$R.[E)4MTH( #:ZUZ3BTRF$/(>48)2T*
M0 'Q=,\B0GD\8"(!G8X?R[Y)8B3N,<LXG<@B.\9K!\RJC9 O%@#-GPR1FX\
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M9UY.W"S62HM(F/7>0CQL'><(4^Z6XS82:C[?.R>P=GVCNB#/B)KKNR2<H9M
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MI(;$T2[V/+O)XJV(RHHDY@)3IIIH&Y<PYAR 0^F^?\5GHW+Q<Y*:$>7BY_\
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MWT4XU/1T47R H**IV*Q&.0HF*;F4HM" (\R 'VQ?P_<'M [JYLP  /J1T3Q
M =9+%]P.7_\ !?\ K[_ES:BU=SCX:86O2THTCKQX2R:&61[Y>90Y.F"B9?LB
M&2,40Y&'RE$/O<_&'?AW-#A@$"C['7OQE >O<MY1 .?_ .S_ '?_ ,@\F/T)
M]K^9_P#N+#\\AG^L@TS.7_!^O:Z/B>B_HO[1\A_]9L\LS[<7_+G_ ,-_/NSX
M:5R?=3MD2D;(1JNIJ,FE(,G+)10ECL1CID=(G1.<H"S+S,4IQ$H=(O,0 !$
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MG-W]PLY-S*#0P!R,L)0^R'F  /B\@;N_Y,_A@_U=>_Y=RW_EAAVJ=SCX:9J
MCY-W'7CPASX5WSO=YE"$_P R]<MR<BE2 H?YM(G/D <QYB/,>8C/T)]K^T!_
MXBP_:V6R.\@TS7/_ (/UE?NI^C/M&_\ 6;/H]N'W?^V]OYRRU9_RKNS/WHZ)
M_*2Q?\%G5Q/=1]C1";Q-'4]'5!Y)R$H<3V*Q%$BLBX%PJD7DT-S(F8>B0PB
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M\/UEOKD?_9^K.@PO[1^/_P!9L^ X^O%UK_[;V]7X\-6/\J[LS]Z.B?RDL?\
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MAFQ7*:QD#+E= +8R)5!4!P44>CWP.CF1.D7I"3F'2  ,)>?C HB( 80\O(1
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MR+L6+=,Z;8S,K=HHFW>O0-AVT:GW@AJFQ51QQ"R3J[63;4=,U2_&JD:BXJ$
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MYQPK>NIMG\R2/JQ\P9YYYDREFEE"1+&@DD=PL<2,L2*&8A4B5F6-1DJ*Q"@
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M_P"56+L4^23FCOQ_YBU^:=8$G.O5%^36KU%GCO DYUZHOR:U>HL\2<T=^/\
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MP>1<K%235!]'2<;(-U&CZ/?LG)%&[QD]:K*MG35=-1%P@JHBJ0R9S%'GY9"
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M$TM:$*Y HV5V06[JQ)1$>G.N6_(B7>'$N1N$@LCWI%%/O2C@Q.@DD3H]%,H
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,*LLLL4JRRRQ2O__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g686660.jpg
<TEXT>
begin 644 g686660.jpg
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M"2OV_DVWR1'*7E\=7,55GV+,(N_.2+P28I*9LX-T10+%Q4,]BK#2G!/MIN_
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M^4/9O13D);3=?4%Y \AN*MRFU HX]3>?\=W^$-;C95)*7A4_%0N6MT]@TX:
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MZ-()_+0I'R5.BU8Z ='!P0(\V,K(X/'//YYY_:C.&Q6,K+L)-NT60 *_H">
M&<?2Q*\J[JQ'<K,I!+&,9&:^,MASFT.9%#TD>97&VA5&XT.:2%.Z/K6WGL4/
M*&X%F2MX*6*R3&R-%F-+H6-^6A(:0&-K@ 2O0T2G15S[UUUO7Q],TN\BN+RG
M=Y]HI)HK6%NG1SD?V<<:A4LE%6I$TDF4SG(YMR&9I''JX*L)]*B:NP&:OGYF
M5LL&\TU,2D;BV%^1VH>=A4;_ $_5U]JE$V-@ZP5)LC=B,KLVUKQ=6+UGVA8U
MI4%11F:80JJLSIK[-:156G,4Y9@P+,I4"5'! "-SRZJA!*@!BW)("MM@KJVZ
MJM]J6/E3697UH,C>M"VKWBNYI&YLUH7$:1.O @6.$9<W-(F6C0JTJT*4XX!X
MDBE.IT7LDXL8I"S7QP0>+7<#KY;W]WLF742P3>#-''6<W533=1-JO\?(JF*_
M. W.4'05I31ZB'16=>:8X3(GJL(T\+0$OC/X\A9F!GD+CD2V.]EL5V-,.DLM
MCTEBTMA=BRIL2(84...C"=%I- D#8C.==2=X+>"A-TP/)5&B;FX9RA&2J $G
M1HTX*][7&IM4@K!@@FPX9F(%))7L<M*#+6??V6FT9M*JO-EY4G)UJFT4H1P6
M[@1P%!*NR\J ] 4;M[D8.P92&!X(R?LZ9K<@.6I7$U$D-<$)*I.B7&)B!K$A
M"[9 EA"94(O9Z<E7M*FVI*), 6HVG(V<$>R2^YW,9J9?R1['CW']!'!'](]#
M^6.FOAK'37PU[NG\GP^]C&,8Z:^'U_R_'&]:W[]:W]_&,8QTU\/J_D^&,93'
MM6<A9W5:F_MA(VKU1'4@:G[LG2''%?I8LPH:C[H /W !A8S?V,(P"%H6F,J>
M<=->[IKI\.F6A7CTODD!A$B==:TZ/T0C+RY:TW'L^M+W1D0KUFO9*E0K4-?1
M0H,_4Y0K4G(O[6-4'&%"-%>&,9QTU\-?B^/O_'G/37P]WN^K&,8SCIKX:_%\
M??G.,8QG'37OZ:Z_'IG.,8QC&1VHDKL7:S1$ :U[#65](I&?OV.I'OVJVR:+
MM237M_2S2-/K:-V6;]D#0&*5F]>=*5DE(32#Y$QC'37PUZ^_Z\=-?#&,8QTU
M\/K_ )?CCIKX>_W_ %XQC&.FOA_OKW?BQTU\->GN^K&,8QC&,8QC&,8QC&,8
MQC&,8QC&,8QF,G*WES2_#.MT5H7:\.K<PNTNBL$84# QKI"_/\LF3XWL+(T-
MC>D" DO8U;B6H6N#JM;&AM;R5*Q<X$ *T$S)O,3N<% 23E#QALVCHD\L<?D$
MW##0M[M(]N.F9)N-V)#YBJ\Y[*2+EW0]#'%*5/X"4WJJ/(T;W"-FF 8S]$/*
MYK?>14ZXZ1&G[CF+A5KI &6SK-8R*L3U?!'6QX8;/F%$['R&U6*P',Y-&!-B
M]ZU%J\D.FO4@8-&[&%Q",O*W6^NM;Z;UUUUZ;]^OJWTZZZ_RYI^MO@18%C\T
MH_=K=6W%F+-[9R6I+D(9RKCFI>Q<N@Q"HZU3PQVH%W;28RN:I2SSTY .(N<J
M!:49BFJ=D[O''6IG>6,:&2/>P7D9%TKG5$ZD6W>8,[U"Z\GSRP+(I.9E#O =
M$T86+4JM:3%GUH(>-I%;>F/2%/!:\A.()H2RPEJ50#F,GS/P5)4RU,H1K$Y"
MI(K(-3*DRDDL].I3'EB*/3J"#0C*.).*&(LTHT RS"Q" ,(@BWK=(BQYRF,Q
MY2H-&<>H8V@X\XT6QF&G&MR8PTPP8M[V(9@Q"&,6][V(6][WZ[RO8Q[>V?BG
M3D)2"4J8DHA,G*+((()+ 42222 )9111180EEE%%A" LL 0@+ $( !"$.M:_
M;IKX:]??]>,8QC&,8QG'37PU^+.<8QC&.FNO7IKK\?IR*6=S4&W7/6D3@(Q*
MCK:KUY+7MV<#BTA[A(K3(/7!93"0M: 2\#>G($Y)#S%KIIO F7%$DM: 1LK8
MQCIKX:^G_P ??^/Z<=-?#6,8QCIKX?5_)\,=-?#Z_P"7XXQC&-ZUOWZUO[^,
M8QC&,C"[7$]HIVTW1*O$U*6ZO9@M3N8'1>R#;SDK"N.+6@>&LH]R:A)A@T=I
MQ0$FK$>P:/3%#-  .Y(2BV-,G%O?>V(@K>Q=[8][WLL.][V(6M"%O?7KWA:Z
M[]^_7>,9^_37PUCIKX>_WXQC&,=-?#&,8QCIKX:QC&,8QC&,8QC&,9QTU\->
MNNF_3WZ^'WOJSG&,8UK6O]_?]_XY!K_^^.J[\#]T_E;2.3ED&O\ ^^.J[\#]
MT_E;2.,9.6,8QC&,8QC&,8QC&4&5;#J,R'8]EZ!IB=]BV:,THK0?9RGO;,,)
MZG%EZUU[XRONH ]1%_;ZUE>RAR?8M1Q_V'8]"TRNVP[*,+),T+3>IZ;+..ZD
ME#UOIL!ANME@%T$/[76\8RSZ6V4*G:H$0),,D5:P/9(D:E6M2"*W%6G98DJQ
MPUI>K3;!TV0I6ZTK/*V$U3K1PQZR3,CFGA&BJ6KQ'"4C.%74($:-8J2+E8C=
MQAKV8)4M0:T@6*1#Z[/5(M:2*#=B.3:T2,&LD;&,8QC&,8QC&,8QC&,A1:(C
M[(B-AV-'YG=,3800"6N 7#9&IW -#&6WAU[*-1Z,V7HY::+3@0>(@A/K:90J
MWJ:\AQ8([Y_8\#0UGE]U!,A"+TN0!0;.U-X)H S&P6O:AJS0-F!)7%"T@()$
M>G4:VH4)=ZF/&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,9
M$]]?N'7+^"FQ?R.><EC(GOK]PZY?P4V+^1SSC&7K#_VIQC^+S)_1:3+CRW(?
M^U.,?Q>9/Z+29<>,8QC&,8QC&,8QC&,9$;,([=XV  0U>R-5E58BP#7(#$03
M122U]'"(;B]>T4JD00DZ5JU0MHUA0$I2'6CD2W>Y<R(&4OI>MAF>%O6AU?5
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M"76O)Y(PU<_0%R)0SB!/ED-%A-*)H9MSW)F1N[+35C)&V"R>5IW>L+'(7N+
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MNW*B@_!*?5E8/(#A5R(2E\BI19*&:B=N)4"!%MUR\-$?I2=,8X1+EYSH<8K
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MD3JI3(;37K5!#<S-RU8:0C1*E)H"1 ((--$$&_ZO?AE_\F#_ *H?ZL>&7KW
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MH39]F1OG@D73_BM')0Z22]>+O RD^-;S().97SXK45'*..\>8;N7%N SU2Z
ML<\3)6M5!=K'"2(2)(B:BR?2'GI_C=N[XBW"75R BGLV]C=1""P,YVV>*A$/
MTK/M19@!511Z#F=% ^0GP. 23^[$V;E5^IP .7;W=_4LW))/OFGV>=G3+I=R
M@@5@I&+CBWPN$<@./]]H>1(V23*.<7LZAJO204%,R>?KV5T5VBWSM0TEL\BM
MV86HF?Q5)*I;6SM I.L$@EHL_.34*:)-3=CN#DLDZ=1'*QLA4@ P3.719&H-
M,B+@8(+RWQM[:D4@3:$D*T%$^D.*,)0U)&B/ 6*RS\ALB>^OW#KE_!38OY'/
M.>2SK9>T0WUBD9WOIUW'V3?IK6M>K8E]VM:UK6OAK6M:U[M:Z9<66Y#_ -J<
M8_B\R?T6DRX\8QC&,8QC&,8QC&,8R(V81V[QL  AJ]D:K*JQ%@&N0&(@FBDE
MKZ.$0W%Z]HI5(@A)TK5JA;1K"@)2D.M'(EN]RYD0,I?2];#,\+>M#J^J >-[
M%T1H?AR:VA>'I_[^]N.RN_WO96P!TS^+I5WA>U]Z#+^,8QC&,8QC&,8QC&,9
M%=YB.!2]L"3C5 /#7,R$2-"M1-RP!NH^OV 25P<M";T2G0NFR52X.TA!G=-4
M:V4$628EZ^53]>O7P"?UVPBW^QA]X@^@M]??O7IO?7>O3ID87N#Q:3MLO16S
MMF5O- >#IGU(-F]Z/.&O#TQ[$#3QW^O=]F;&'SW7R_>UXG7)/2>B5-Z=/N!/
MIW.Y_P"Z!_<?W/\ T=?K?UOT8QG8QC&,8QC&,8QC&,8QC&,8S6WSXX$2;F/*
M>/$[@]WQZDIGQZ<[16L[G)^.U:\CFIZ36G&&6+.Z(R+V@N3L#6-*C:-*"7 A
M&K7"4&%;*-2@3CTIV28S;TMW9Z=LSV]1UG>:U16>4;IV7C2%5>.Q.L:+2-:3
M9:38$,?3G@BG8A+9DT;*6FQ0D*[S;F;K1"KS9'4JZ*P*L""/?(1XXU=*:6I2
M UA-9TRV7*(BV+$+O.(]5T0I=FD)ZEY<W(I4@K"!;W$8B40E7$(1H63?EU)R
M4QR-_3:Y1DW8QUU\=>[K_)\?O916KVK2U.TTK1ZN51)J7HQ=NV<U2<U[B>$F
MBHHX5550 +$19HDUY[4547EF8]J@*.6<LS'@#EF8L3ZDDDG&0:__ +XZKOP/
MW3^5M(Y..MZW[MZW][?7_1D'/_[XZKOP/W3^5M(Y7F63EC&,8QC&,8QC&,8Q
ME"D^MBC;^'01"WMD=M:" @"H8M[;U.M!"F,WHM2+>_0) ]Z =OH6+>@BWE=R
M@2KN_)F1=_P^Y[">._XWC>#W?9RGO>+Y?[OX?3KW_ ^[=WKX?V_=QC+7IP R
MZCJTL99I(P5S!P#*/;2&8XL0(PU!$6<T)1"3-1H!:V$QM3B$0A'H24D6RR@[
MR1\C.EO!^9VI_+^4\#YM('X'D//>1\'Y*M/A>3]I_JEY7N=WR_M#]/>#W/-_
MICQ,DS&,8QC&,8QC&,8QC&,AM849OD!'3M$G[+#3TS+V?IF2C3!&*<0,>BA2
M'8O.ISQA (8&8 -I5A8#%QHM&H"=;F3(46>7^R)C?7R'FOF8FW<[WM/VGY?Y
M=U_XGA=W]1O(>)X7C^-^J?F/+>6_2GG,FO&,8QC&,8QC&,8QC&,8QC&,8QC&
M,8QC&,8QC&,91Y"PM,J87J,OR32]DD+2Y,3PAV<I3:6-3NB/;G%+M0C.3JR-
M*4:D\G9R8\E05W_$(.*-" 8:QC)!((()!!!!!X((]001Z@@^H(]L@@$$$ @C
M@@^H(/N"/O!S!/B_V:/"3AC,5D^XTT@EK"5+X<= %+@DGEIR0C<0/<&=T&RD
M-$TG,D94A&EK"TFEJ$C<0M)"C"02I+3FJ"3L[,91)%)8[$6A7()6^L\:86_1
M(E[V_N:)F:$ 5"@E(0-:YN)Z9"D <K4)TI0E!Y83%!Y) -B--+ +8VMS;WK'
M8W=K9W-A@%:^U>NQ9E4<*IK9G<A1Z %N /;*XPCKIXX1E"?)/CC-)IR?<]J!
M5Y/WGCD_?E;R)[Z_<.N7\%-B_D<\Y7EEH5JW6 T5,X6%!T-I2!A62IAK99+8
M^FG[W%VX\Y*XR1HAI[B"1N3 @4ISTRUX1-A[<E/)-)/4@,*,"&@WU^X=<OX*
M;%_(YYS6RW+UA_[4XQ_%YD_HM)EQY;D/_:G&/XO,G]%I,N/&,8QC&,8QC&,8
MQC&,AECT7\_UD;T>0(SYJJBT-,$3AM24#4HN+99QH3 :;-$GBV8 D20P:T8R
M#]+P ) @V.9LB)F&9N]+"+V:?LH-8U4,!(G=,<G ,<DMG0S"F,(=*V\XP("P
MG.9PQ)W4!1"9.$)C2IV*7<8QC&,8QC&,8QC&,8R(>0&@;HNXM&G$)B]UE.-&
M*%(EP$Q -QMQ[QIXFP!CB$HO749@D!8U@0:WM, 1W<UN5DG]J)O76_TN3ZZZ
M]-_<@^NN]Z]/O^OQ]>N1E>HQETK;)A1AQ)@*YF8RS4SJG8E!8PQ]PV$PAZ5A
M&E:30;UH1;DI (A$/6E!H=@+%K).2_VJF]^_TN3[Q:%O]C#[Q:]!;_YVO3?O
MUC&?OC&,8QC&,8QC&,8QC&,8QC&,8R/[+G2JNXP.1HX)/;%."X-R#4<K=G;'
MV2""X'^ )P"@=GV.I-M[?K[NXG;<0FDD?;%$'B^TS4#RKNODU1ML=HV\QRY7
M%Y21'LY8?=U(Q(R)-)$?I&0JK OJ+N<H]CEGKRYF^($\81R1SD4G#Y,U*PHF
MA4W%L;<H+/W>[UH6NF]:WKX;UK>OQ;RWU,2BJUT<GM9&F!4\O,?*B;N[J&9M
M/<W6+$*7%81&G)>:E&K7,!*MW=513,J..;2U#FX'!2Z,6J1&]+I^['3=FKJ2
MV5<(KK14?O5-K5V H\B4\7*P>;-(*[I9T<M,LC:NSKTNH"7>1!)0H6':3*L^
MXA67O]:*X5R5#(K* P## _A@\R=AN;F%09EDSJV:XI&647J 2VR9.YS^8HE-
MG45')W,HVXV$[G*7"3)=NBEOGC80O5JSH\CL$+.U"11$J+L[9-J:025ZY.0U
M,_01VB"5KJNZ4[0XN+U%W4F2I_EM3Q6UR$B/NSDK;R@DITRGP7DA"J[BXHKP
M=GD*@%3#6-1U92L9^1E05S!ZNB6W%8[BC5?Q5DB#$-U<-$A6N0VMA1($9B]6
M!,F*/6&%"4&$IDQ C-DIR"R[0?\ ]\=5WX'[I_*VD<HWKSV=EK20JAGKH2RJ
MKT>.O*-=AU0E5ILTF^Q10S]KU8&E""[9Z\VE)4<@D-0^A+!5>CNDU9@"5DK+
M-20"50>@]A.6,8S4R_&,8QC&,8QC&4*3[V&-O^P[$$6F1VWH0#P)1AWIO4[U
ML"DS6RTXM;]0GCUL!.^A@M;"'>5W*#*?2-2#?KZ,;O[B2U.__P N4^Y.;L)1
M^_@28+19N_M![T$6]XQEK4Z,9E25<,P9II@ZZA S#3W(AY/,&*,-6Q&'.Z4(
M$SJ:/>]B,<4X0D+A[$J*#HLT.M2/D:TSOK4%5[UH6M;K>#;UH:!,U#UK<6:M
M]!M:,9B1M'K^Z0)3!ID>^J<@8BBP;W)6,8QC&,8QC&,8QC&,9#:PPS5_QXKQ
M5&BMT_,C-D:>4H$HC S>"!":./[!M:H/ $0@%O(!Z2HRQFH30[-7DB#,F0PL
MWK[(2.!Z#Z[IN:;Z^RD0RNGRY@6NFWP1GM @S?7[5J+*VC5AT)8<8$]$0$4S
MXQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC?7Z/J]_PZ^O\ X>[Z
M\U"=I)QVN'D+PON2.SZ'1FU+ BUMUW8/'J/TPW60C<D:.-VO!%K.NDS(NDRX
MJ52YD92WIQ<- 2CBA9:<3DF9"%",L\&WO&,9Y\+?IZP5'-N=LJ.FK%=[.LKM
M,N#/)JO+F00>5+($Q\5:0H>N(I9HEMTI&M1#(6;'#XM?U?J*M>Y"Q220K+E*
M&RQ][:K#7.)NXCDRBG*FFK&'%)!&&5M35A8XI*D?XHYR)8Z(]Q%PV6G9UJ"7
MQHED4@* L+$K6(WXK9IZ8[R?<2FD+,ANFNO7IKK\>GP]V_OZ^C?T>O3WY%%]
M?N'7+^"FQ?R.><8R]HAT^2D9Z:WK7R?9.FM[Z[UKV8EZ:WO6M:WOI[]]-=?A
MKW9<66Y#_P!J<8_B\R?T6DRX\8QC&,8QC&,8QC&,8R(F8!FKTL(S91^BA5C5
M0 '":$Q*<8P22V=C+*? BVK<#BPC+$<V' "G:@&D*4XA&.RG09=R'&3P/G\L
M;N^2\S\UE2>+X?M+VAX/RGM_P/,[-_4GRG?\?R?DOT_HW:WVC]PVVY,>,8QC
M&,8QC&,8QC&,9%5Z@&92MLEE%G'&#KF9@+*3-2=]4&#%'W#02R&56("5V-'O
M>@EMJD82%H]Z3FBT P6\DY+_ &JF]^OTN3[PZ#O]C#[PZ] [_P";KTU[M9%=
M^^!\QUP>9\GM/\VDW\?VC[1V@\+Y../B>=TT?JKM+W.OC^S?T]X7>\K]W[F2
MFDZ>53=.G3RY/3IUZ=/##[N]]MT^'>]>GO\ 7&,[&,8QC&,8QC&,8QC&,8QC
M&,8QC&,8QC&0:_\ [XZKOP/W3^5M(Y.60:__ +XZKOP/W3^5M(XQDY8QC&,8
MQC&,8QC&,9095W=QF0][0-A]AN_>T: TTO8?9RGKHPLGH<8#IU[X"M^*,/4)
M?V^]97LH4HWW8W(-][N]&1WWWO,>5[O1N4[[WFMZWY;I[_,=-^#^R=-]W&,M
M"EM%ZIZJ-$Z3A*U6L$T4%(F6(TFB]15I[FDJ1QV)P2I]!Z:)3+A;6$%]TI3O
M9X![R3,C:FA^)4-5F>)XO?KB##\7VG[;\7O1=J%XGMG00>U^_P!>][3[@?/]
M?-]T/B]-23C&,8QC&,8QC&,8QC&0JMT3]D/&]["C\Q\S,VT$6T;B)?HG<[@&
MQA+< B]DEH]CT#9R,X.W$X[1!Z86DR=5K<U9#*PSIR"CA7B[UUIR:&>![;T#
M0N[.8$'Q?DYW.JG8.]W/;??UI#W_ "'<W[0ZAF;&,8QC&,8QC&,8QC&,8QC&
M,8QC&,8QC&,8QC&,8QC&,8QC&,9$]]?N'7+^"FQ?R.><EC(GOK]PZY?P4V+^
M1SSC&41TM5GKJ/5DV+&.721WES.4G96>',(WYQ.TR1M&YN9YQ.E20LA.F2"
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M8QF+&W*R12A'-=\76S4L01Y=$TC^&U(0!Q)C;DZ-KVM9=' ;PZ$@/=FAN</
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M$ 6M>4)QXN2N:55R$506E+BEM7KHKP%B$NHRL^!#AP(8[(05SS'KRRY>RQZ
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MNE:BE8ZE61'4EYV:_4ZVV80.LA2L_(UY6[ICTL>%6DY4IXS))U*H56EE!92
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MU7R4?)63'1&.+D_&IP;K*I1RKE$X'M4DDMK\MY/,9S.K1DA+ZP*:]<6)S;'
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M:*#QA*XN;@YJR5KDN<%I#66I6+'!:G(5KE*DTP]6J()4*!F&E@&%C+C^Q?\
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*C&,8QC&,8QG_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g773914.jpg
<TEXT>
begin 644 g773914.jpg
M_]C_X  02D9)1@ ! 0$!FP&;  #__@!!1$E32S$P.3I;,3A:0E4Q+C$X6D)5
M-#0V,#$N3U544%5473$T.30V7S%?0D)37U!!5%\S7S1#7TQ)3D4N15!3_]L
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M%TDU@0?,UT@53(J!0.0I@Y)CB;;K%UV:J,;B;%,?5+)#UZO6"LL<951I7IR
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M-(IC&R\;4Y""9DDIV$EKB0)Q"X2?VE[,+53,T8[L> ,03E%W%Y 3RKG6I2E
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M&=L2@W5YQ  -,8]A X$*'LE "CX_&7T(\./#JXAU#[(=>OUI#"QPP   [X
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M7;))=*0GU&2>IKT#;_B3&Z.>H.$BQ?,MQ64[_FS+]=LTL6>:2]ER]6H"F6Y
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M;#9#8O4E\2,9<=SR<_HN<3I.BZ?HN>7I>@Z7H.GZ+CTG<_3_ -C]/S>AZ?\
M8.?TOH-?H!YQN87T1QX !"@)CB(CP  *7B81$>H  !$1Z@ 1U4'7L>9#GM\$
M/EPN!\M5^PS.=8?*BN<;7",8B)@]F$WL)2HA=NLS8U)Q\^C9V&W+&*XL&W$&
MRH1&0$W&7BE=$(>T'B9FV;WP9ND-\-(QG:=XTM6F-GY0K&\JC7(:DQN+:]C^
M@8_:_P!;Q";<;!!5AQ=YC.#C,3-E45X-H[EK=+UZ3R:RG(]*)1H$J1C/HN 0
M'B " B'#B " \./6''WPZP]O7NJRMJ=BW4R.ZK.[3)RFX6;P8YC+8YQ])99I
MB&/:S6!B[W L<?0D?!R-':#8;)/T!=_-^&N.,G66,L<=W8^S1C_&64TTH"/L
MUTQAHT:-,8:-&C3&*\!Y88?"G^85T[.FF@/+##X4_P PKIV=,8:-&C3&&C1H
MTQAHT:-,8:-,E+;CL)P4E)0\QD")CI2'=7]G),73>6(NT<XNJ\7=+XF<O>X0
M,%>JTU%32ZB0G2=LWJ(QIWJ@F3+S['=G@&27FD&=Z54+7E#(3#Q2H7MO%,W)
M9Z)K!F8S+FKHQ*S\D_.1D6=@V>KO".G(E,@!&[HZ$.?(N/K82F;W3K:)FLEG
MLZ0,%BUPY@$!/@H,$D+3&8\A64&40,Q.6%?$>5N4#T\8Y"U#%J:MR]+LF*-3
MG%62T&#6D"6VP)5U&)2+'"2AF61(Q(W1J.RN[#;^A,7"$<9$9(/:*VFG4^JM
M#65.,Z*LRS&!LX0DR,-WHM2M8F9-A&65"KO9A>!>.B(RB;8Q5.87+==@.@3;
MRNVJ]&83+"<5K#IDUJEWF3)V)&/C)4T&5:#K4DV6E5(V8CGK=B@LHY=MW J-
M4U@0<=%X/DO'%J8]F_T@(4T4M<>UHBI;C)H HV$^ !AFAP"!3!$26C$3*SB/
M:^&\O<]557%.2-LO25E%=>CVAO=7 $--ZDC5EC$@NU68;0&0$+""(H%JY*1!
MN E, ]8" \0]L.'7XNOQ:^:G,62=@2NX#=N29AM[M6ON09&>Q]-V6I$Q:-(E
MK?7+[8,7+T3#J%HFYID@XR=F''SZW&1R["(8YDK1CAA*V9_6J<!(:;^AVDY,
MH62 GAH]JA[-X,2YX&?+%NR.#Q4L1NBY%F\3#@HF<4E@YIC$ AU$W"!3"LU<
MII5_[KR[=9RZ8,VYSV):9)P6]&VYRQM=K[612I-TJS>J82RIG.:G(R=@8():
M2D++,1\O$S)5I)LA()7.RKR8324K,Q<G+(L(M*%]9RK"3\O!R& U1^)$!>+%
MD0%XF) 74ST0D,]3$QD%9JV:;CK7*[ZMA<!+$65,0X(8 L#S4T1,?-9@P?(8
M\@(2CN)B9BQ.RV-[#N+_ *GMF<.1\_$8EE*QN/7QC$VP_/M$700V 2K:HQUC
M4"0ENEG&,$BQ:RJP2LF"KU)=4)!X!P<*-#N!W:[$<PL=RE0ME9WL51OD:S/9
MRUC2V6+HUCFBU0T/A_;SW@I)+1<)ZME$M(KU>>QR>1F50@F\5*6>PMI1I<',
M&@UD1G:OXUQ5O6Y#['&-TVT-C?%DIO#HM1C4W+YVE#56E[&I^)B6(O7XK/GG
M<46@S3.\=KN'3H_.56667,J;3@;I66UW).=,1;#+9A>DJ8^W78&W/9(N>0:<
MO]3RT037;_;=M[PM:;.JU M'<E$WYQD%)[8CKRZ#8R=,CV[J.ERO$C,LN8,G
M=BTD7=,9XYMU$;+(4>S4"DSM+;R:RY9)M49:K1+^KM9 KM9X[[O:P+B/;O1=
M/'C@SI)4R[QVJ)W*O<A4Y4./!%J''Q\%BAQZ^/7Z#KZ^OK]GKUGJTCCJEUJO
M5"KKLXFMU:#B*Y7XM'ODLC'0D%'-HJ(8)+.B.'*J3..:-FR:KA=9=0B13JJJ
M*&,<R]X;U?[;H?FG?ZMIC.:"IRH#S@1:@(CQ$06* B/'CQX@3CQX]?O]>O?!
M26 >()-@'V^G+Q]G_P GWQ_A'VQUTGAO5_MNA^:=_JVCPWJ_VW0_-._U;3&-
MP3$<,E:UKXG3:8G>G$*G6W%W3@( ES7KJ*Q7*5?7MI(P+&M!)."E73AE9,\8
MFL4BA&H'(40Z/P4E>=SNA:\[]UTY>=[7CYG'Q:Z3PWJ_VW0_-._U;1X;U?[;
MH?FG?ZMIC.9"I2@<>"#0.(<!X*D#B'M#P)UA]X=>A5)4 YH(M0*/'B4%B@ \
M>H>H"<.L.H?;UTOAO5_MNA^:=_JVCPWJ_P!MT/S3O]6TQG->"<KU?L+7J$1#
M]F+U"/C$/0=0C[(AUZ JDJ''@BU#B/.'@L4.)NOK'@3K'K'K\?6.NE\-ZO\
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M^AKH_#>K_;=#\T[_ %;1X;U?[;H?FG?ZMIC.<\%I?W-O_C ?T-'@M+^YM_\
M& _H:Z/PWJ_VW0_-._U;1X;U?[;H?FG?ZMIC.<\%I?W-O_C ?T-'@M+^YM_\
M8#^AKH_#>K_;=#\T[_5M'AO5_MNA^:=_JVF,YXE7ERG(84V_ IR&'^R \13
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M]>O?!:7]S;_XP']#71^&]7^VZ'YIW^K:/#>K_;=#\T[_ %;3&<YX+2_N;?\
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MQ9)MS3!1#P82 ZJ'/"'<  &42YP#T*X@'6;B \[K /'QZPZQUB<*(#4%/V1
M5/!K@ =(F)^=WKX  !SN=SN/4 >/CU<..N6D\U[:X:#NUU+<L33<)7:LSM M
MXF?ICQTY9!&NG;=*/:$>](+V:5%HRCD.811](.FC8A3K*$+I@=OFY*=R/?\
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MNDF:O6D21HI5^$3$\S&IG$D6R+STSK\#IFX(>B3. \#D'B4P=1@$-*X5*K"
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M8 ,/ =.0G1*.,Z\0&F50421,:J5(:[#\PJBCR6(=0I>X^ '.5),IC '$P$(
MB(%#@2=$HZ;B$*G3:H0JTL*2H%KL. *)=ZY17HS@#/@8G2)IGYH\0YY"FX<2
M@.F,XSPLJGW4UC^,<)^OZ/"RJ?=36/XQPGZ_KMIJAT9&&EE4J94TU4HQ^HFH
M2N0Y3IJ$:JF(<A@9@)3%, &*8! 0$ $.O2@E0*(*:8C2:B(B0@B(UN&XB(E
M1$?["]G3&-SX653[J:Q_&.$_7]'A95/NIK'\8X3]?UV<-1*.JV=&5IE44,66
MFDBB>NPYA*FC*.TTDP$68B!$TRE(0OB*0H%    #68M"HPRJZ?@74^C"/:G!
M/P<A^8!S.7A3' O<? #"4I0$P!Q$"@ ]0!P8SAO"RJ?=36/XQPGZ_H\*ZK]U
M-8_C'"?K^NSDZ)1TW,(5.F50A5I84E0+78<H*)]ZY13HS@#/@8G2)IGYH\0Y
MY"FX<2@(9I6A49.,D5$Z74TU",7AR')7(<IR'*V5,4Q3 RXE,4P 8I@'B @
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MCW;P,41 > @(@/ ==!*T*C)QDBHG2ZFFH1B\.0Y*Y#E.0Y6RIBF*8&7$IBF
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MU%0H)Q(V^;@;CMWGYK9GNNE6<=)0%<?!AC*LDZ(TKEQI;=@^3BH]_.2+A-!
MR;5KW/!.WZB:S=1NO49E0LLQBUY?B>C;>^&V]G1[ID(X/O+]U7%;@O2W6:38
M6]E:NU=&^2HU+.H5:JV8K45V[NTIMM4Y53L41<FC'Z1Y.G6?&;B\<IXXJ;?Q
M/XUJM8[G>O*J]&[Y/JJ&EUVLO<HJB&TOTN0/H7:++NV=0UFBV2:.QBSL:NV.
MK:VN6ZH^I)?!D^2&DF"]:O.VI[Z8>ZRPDO%3T3'S$')Q\S$R#5)PPE(IZVD8
MYZW,' J[-\S56:N43"4P%505.01 0 W$! ,4%ZU>=M3WTP]UV@2$Q$P(3 Q@
M@,9@A(2CL2$HF8(2B8F)B9B8GN)ZS\W&!K,UL EL61 Q9C(&!A,B0&)1!"0E
M$P0S$3$Q,3$3&"7UQ/NQ8KSZ9T2WKJO]M#]#R^A+ZXGW8L5Y],Z);UU7^VA^
MAY?7K/.9)_R%-=DR/F:VE)'U)+X,GR0TFS_D*:[)D?,UM*2/J27P9/DAIC$F
M"]:O.VI[Z8>ZV">6''9K/SI]K7@O6KSMJ>^F'NM@GEAQV:S\Z?:8S7EO75?[
M:'Z'E];$QY)D^SWWFBVM>6]=5_MH?H>7UL3'DF3[/?>:+:8S.P]8LOP1M\R3
M6"+]1==I27GJVL[#UBR_!&WS)-8(OU%UVE)>>K:8S72^N)]V+%>?3.OQ->JP
MO;;/YA[K]I?7$^[%BO/IG7XFO587MMG\P]TQF_*>39'\!=^;J:V4_4$_@B_(
M#6M*>39'\!=^;J:V4_4$_@B_(#3&)$%Z24[<E?.!UX3ZY%>Q$?I%SKV"])*=
MN2OG Z\)]<BO8B/TBYTQFW(>K17:1?,GNB8\DR?9[[S1;1(>K17:1?,GNB8\
MDR?9[[S1;3&9F/D]G^!M_F":3X+TDIVY*^<#I08^3V?X&W^8)I/@O22G;DKY
MP.F,\)]<BO8B/TBYT37JL+VVS^8>Z"?7(KV(C](N=$UZK"]ML_F'NF,VYCR3
M)]GOO-%M9F/D]G^!M_F":PS'DF3[/?>:+:S,?)[/\#;_ #!-,8GP7I)3MR5\
MX'3+1_[:JV_X/V//Y2LGZ>F"])*=N2OG ZB]8\CTW'^ZV13MLP$2>R8,Q[&P
MI1CY9]W:]+D_(2 H\8M@^!OP4D&I>D=B@D(J@(*<TBID\JA(O4@8DIE<]1$3
M,ST0S/M'O[1$S/[,^Q^/[O\ ;&2]T::C.-YG,;XHNMXK<8A+3->BB.VC9TW?
MNV3<JC]FS=R\@TBP&1=QL R<N9R1:LA(X<,8YPBDLB8X+$XK;3EU_EVJV]U)
M2M?LCBE9#GZ,E<*JQ<Q4!<X^.91$K&66/B';^46BRO&4RDW6:%E))J==HH\9
M/5FCI'F[8:RTS6NVHB,U$6(K,GN?,63"Y[F/'Q@>W*&((X,Y*96!BIQ+A&[[
M7IWM;CS#,=C;I%?2,B/IDD3</C!27F1S%:P12*R6J%B+F+98K Z1FC1HU'Y-
M8:-&HG[A,V/XN$O..,-2$U);@(B'IL^SKE>IY[),L*S/7>MPLK/Q[:P-F=-F
M%V,+(OW18YW-)BGT?=#SN1LBJZ1CMKM*FGI/O6RF14IQJKJE<V[K4H;8BG12
MQB_F;KP2R*]8"@VE'4=1!%$OH])>Y!LZNLHB(F]]9;[;X:-#6U[%I%,MCM+"
ME.^2UM9ME4V[AA*T 43,$4B)2PT:KU7SS=W&W2J2=/NTV_R+;\_UK 4C:<B4
M*K0%EQ]/3^4TJ78D9FCUP[BHO9JGL^Z4(XK-V_AI186,BNX>H&5(I(3;!D6S
M9+Q2WE[FX:/[5 7+)./YR88,$XIG/.\=7ZPTTE@1C$E%4HXTTTB&T@Z9('[F
M;/5W*;4J;8$2%B-;RW6;78U=96"U#[>D5O5L.*Q5XKM-0_+$VO:?$W%PY9L%
M8LK0)3 638)!%@W/ =WHM/=W=UE*:M#DMCB[4@5U=PK:%/9\X%>U1K2.O=-=
MRTDXE7),()E):B!A-ANENEEQQ:ZQD"FU16]VVDX&W26JLTM!1PDM:IN#B<8/
MX^"3.T1<NP,_61 @E:-UW:A"F2:I'7.F&NMV6Y[M6YK;E0,U7"E-J++7,)YP
MA%1[J1>1,A"L+!)1L%9H968:,94(FS1+1K,L"/VY7!477IE$^C4,HY/9I2&>
M<+,%R&50>XWW#M%DR"8IU$G+7%J"A"&)Z,#'(H8I1)Z(!$!+U@&F=Y+MPFXV
M#;9BI(*-DV%"<0@(JCQ4*-?M-B@SF-Q # *AX\R@%4 %2@<"K "H'U*6&61W
MNM5%DXJ.T>S853Q7Z96*NRH"%CSD/5@X7<)?C#(#KJ?#R[*><L)P[2L$-*$,
MU]PY1XAXRU%FD(MDO'S\O"P0=0?CU'?7>3<9>79OX*(^8>:7=(3+R[-_!1'S
M#S2[J4S?RM'E,*1!6+;#)6IR9RPMV/\ )%<EJ'/LQ2;GAYV=N3"KF%])+'33
MBH19&3(YD)%10$V#J/C9 2G.S3*+L[:,^WFYVW)>#<PDH"V4<4P=.F7-CQI/
MK3-5M]?M,48Q) B3Y%L_CYV.?-Q+86A4.X4S2;!=J5NW<H$5E1(UJOW&N3]7
MM4-&6&NSBLQ'3$),LT)",DF+AVL55L\9N2'172/U#S3E$2G*50@E4(0Q:^,S
M<G/34TXB_;3G*6WK,E+!1Q7'E9</(^KSXB)C*QE@:E,],S5>%,9L,L@@[;N$
M#]Q6"'FH_F)M^4<CTO*-/RMO-^+UE;-#Z.KK<AX^FZ-*[N:^LC<K(JRWU'4[
M6R!>RININ;=UK!'4_9TL:J]Y([QP[DG".0\#1\,N<WGZ6U6VN\N\1Y;8UA;/
M6\<N;PN,L$+KJNPK[*AI6,TFRK[)%?6;I1'R"=P*$6-5XV['H#R%"]DQWF:.
ML%D\DN/A6/TBSU5I@7>WG5Y%XO<Y;Q31D:1.Y=:[9Y2X52Y\+.CD]NY7AB2A
MZ(JW79%KXR+9-I)!'32BJ E<R\>@:*58MSVEV/KB%_A6/^B19\=7+C/+-1RV
MF5S4S=$5C7)J-A0MZZTH;21>@B3;4N36P)* >F6H82VBMI^F77.N:\#Y!P'8
MCK=\.N,V';6BUJ=MK]S1>=&Q-:TL;6OL/%3TL@9;5LQ7MJ6U!NKKAH=KND63
M\HUWM)W]"2FEK2+)^4:[VD[^A)35ERF8M:0C_7(EV(M](MM+ND(_UR)=B+?2
M+;3&+ND6,\HV+M)I]"1>EK2+&>4;%VDT^A(O3&+6D*M^26_PK[Z1>:7=(5;\
MDM_A7WTB\TQF>?\ (4UV3(^9K:4D?4DO@R?)#2;/^0IKLF1\S6TI(^I)?!D^
M2&F,1YWTD7VY%><!I;+X@]X/BTB3OI(OMR*\X#2V7Q![P?%IC$Y?RK'?@LE\
MIAI2TFK^58[\%DOE,-*6F,16WE^7[-A/GYK2R;Q#[P_%I&;>7Y?LV$^?FM+)
MO$/O#\6F,1(+TDIVY*^<#I<TAP7I)3MR5\X'2YIC$^)\E1G9[+S9+6G9?(<C
M\"7YU/6Y$^2HSL]EYLEK3LOD.1^!+\ZGIC%L/%^,WQCI@\P?9!VR_OTS7\A&
M9-/X'B_&;XQU&;<+8F%3LVW*?DT)ERQ89JD070K]>GK7+G[JPEEYHGW) UF.
MEIM]S55R&7[B8+]S-P5=+]&V165)E5$R<Q$3,RML1$>\S,J/J(C\9G&29+X@
M]X/BU[I)A)AM/PT;-QZ,@BUE&*#YJA,14G R2:3A,%$TY"(F6;*6BW( ( NS
MD&+=XV-Q(LW(H42ZKY=9.W,C]4"!A9SZH,K#SF,8^8GL5T"$D65#M$Y;I-/(
M&/:DI:5HV%NR56I3>,=/Y6P.V[JNS#\J=@?M3N 8,-[7:IVRET+?5K^@5>&3
M;8:A@;#QK^I)BI@""C,9;+" IB8%0M9,+F WO(:VA^6FQ3V-OYL;LJ'7I389
M)TJIVY3Z1V$M-KUK,40H&#!"1V"0@2<-CFF/R7EYA7K)$8@K4F@RS5D.M623
MQBE8Z-D*>Q^=] M%UU%[A9*K&I0L0P0,@<ZD;(6F!EI9,O01!E%U4A%DI#,5
MMF,-X(7H5X>J6++^4([&[V_6JEP;&P5X4E;BZLIW5(:\ZMI6.(5J;JLBU#NF
M)!P11^4[HHIK'?3;SD"7RIAFA7JQ)-4YZ8BW"<P+!([9BXE(:6D8)\]:MC*J
MBW;OW,6H^1;"HIW.FX*B!C 0!UYV.CV%6D=DFH4(WYH-B0?+Q\&V080K+Y8E
M>M\E<4EA'ZJ&J]1]7QE8-UZ/)Z&WNKUM*7 ]VK1MP>8(;6*JP-<YJ%NK7#@K
M*Z^UH'ZH>I4GYH#KNMRIZP;G9#>K[DG;)CRXY0GD;-?I)]D1I99MLQ0C&3U]
M Y1NU>)WNCVZ:9648V:139I&-E.E=)1[=L5ZY=O 7=+2OUQ6/<>5#%=3CZ/1
M8D(.L1;J;>L8P'K^0!!S8IZ3LTPIW7)N7CU3NN:F)%[S57!R(=T= W*DV211
M3[74)12ZO1IHL,EKT5:Z7MDS9+7+2 ,9+&=,9)F)%)G$&7?D7WIG+!56Q5:N
MIQRQJT)6UDD1R; 6(F<F71%)%$EY%]XN^Y]YG&\RO]CVT]G!YVUTX0>+\9OC
M'3>Y7^Q[:>S@\[:Z<(/%^,WQCK:S/GNC1HTQAIA]P&<6>":Q7)Y>"2L+JT72
M-I<<P<VNLTEFDZ?Q,W,JR#^QV]XP@F#!DQ@G1USNG28G,=))$3JG(F=^!#B
MA[?5J).6=N!Y09BRXMCZ"ZN-DN;*UVV(S:TL.1*%9.Y:[8*XBG'Q<F\F0QY(
M1I9]23:2-#C8L[\6RT-*)J,9)5=M \D9NEZM\Z)<%<F)B7#*SM5@ZF?6IU'U
MW5[SX*!'T'FD161N"++5+I6+3PY7'&[NK')F%% 3&1KF+0I76^8Q\ML;]:W6
MN:VJ029_,U56#)P*K,*BA[=E3DI49F0L-7@)V4A_!^0EXEC).X7OM&3P1BSQ
M BXM"S,*JO$RA4@.4"/HY95FY*)56ZATS%,/ 1GV>[K^]%C#_;;+NMK!F,0P
MSB#'.+._*UA&B5.(KBDTNB+89%9@AS5G"+055Q9,Q6,<C!CTZW<3$C=KTRG0
M\\=6,^SW=?WHL8?[;9=U*ZP[3-=5.\HD73H53N(-BG&FT0(FPHG5UI0TENDP
M)B5*4<Q)+6 2(Q#[9=%6UVJM98&UK5W[B]?:!#ZP6:(6C&H\*UIUBU7%R(6P
M4V7N>J"@'-8P2.7'EO75?[:'Z'E]0]WG8%G\M-,37.KU7'^097#EZ<6U[CK)
M*A8^LWJNOH5S&R<([FA82:;(S5R#":;-I!BYA7SE@GWS05*BDDK,*6]=5_MH
M?H>7UDG_ "%-=DR/F:VM+>Z6ER'5VM1L8.:MJ4$4K]/U%MJV4W*S@AZGH,D6
M:Z70NPA]=LAZ=A#DD:RWN,<DV7$=Y2Y!J"7%ZC%H %WK>DU%ZG8U]VNPJSJU
MI86:5JQ7)U.U5N(AOK5+5:R"G!6WR8UUBGU%S)CMQ&I4FZ4[-][EYO%*)#-H
MW'<59WY31T%6&JQNG"N,I"-EVGI$R(RB;OFI)(.FQEK((+UJ\[:GOIA[JJ3=
MU S&U+/U#WPT*/=*T^<6CZ%N,@8PH@62B9(&K-E8E&Z8@0SAVBU:(=T'*4@6
M>$K0J&Z29>*J6B4.>A[16F=CK\BUEX.>7?3,/*,52K-)",E'J[YB\04+XTW#
M5PDJ!3 50G/YBA2G 2A2_AS;=KZU_@FSD8W'#F!76R %0[7CUPF-T>Z0H8A8
M"](LHW$H_,U=E1M)6*D^@N.D?&&C7V]W5_%+2P9<>^(RFW6IEAV#T'+M<%='
M*N,V[!D3F'5M,3L];8M3-F]I-KK[+F/L_,ME72^N)]V+%>?3.B6]=5_MH?H>
M7T)?7$^[%BO/IG1+>NJ_VT/T/+ZZ5G&,R3_D*:[)D?,UM*2/J27P9/DAI-G_
M "%-=DR/F:VE)'U)+X,GR0TQB3!>M7G;4]],/=;!/+#CLUGYT^UKP7K5YVU/
M?3#W6P3RPX[-9^=/M,9KRWKJO]M#]#R^MB8\DR?9[[S1;6O+>NJ_VT/T/+ZV
M)CR3)]GOO-%M,9G8>L67X(V^9)K!%^HNNTI+SU;6=AZQ9?@C;YDFL$7ZBZ[2
MDO/5M,9KI?7$^[%BO/IG7XFO587MMG\P]U^TOKB?=BQ7GTSK\37JL+VVS^8>
MZ8S?E/)LC^ N_-U-;*?J"?P1?D!K6E/)LC^ N_-U-;*?J"?P1?D!IC$B"])*
M=N2OG Z\)]<BO8B/TBYU[!>DE.W)7S@=>$^N17L1'Z1<Z8S;D/5HKM(OF3W1
M,>29/L]]YHMHD/5HKM(OF3W1,>29/L]]YHMIC,S'R>S_  -O\P32?!>DE.W)
M7S@=*#'R>S_ V_S!-)\%Z24[<E?.!TQGA/KD5[$1^D7.B:]5A>VV?S#W03ZY
M%>Q$?I%SHFO587MMG\P]TQFW,>29/L]]YHMK,Q\GL_P-O\P36&8\DR?9[[S1
M;69CY/9_@;?Y@FF,3X+TDIVY*^<#IE6 <=U5M\?[7['GB$0__$K)P^P(>U_!
MQ#Q"("]4%Z24[<E?.!TRT?\ MJK;_@_8\_E*R?K(OZ-_R<__ !AGV/H7[O\
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M[ ]LRK<O6+"#V9K-)WS4UA 5LE,8N7S$L\#,8+HR[CW=OVR& _[Q\\_'B?3
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M5N:^P<,UL5U.:B+.OFR6PH-5=K(F:V3<I+)Y'2IN-J#A6QT[*N3I=G5XQ[G
M%ZABR/!Y$JNI:1"Q,.FFIKN<2*HQ<6RBVSZ0*HU6,=)==%BM-W:UFR9SGCJ5
MG+/ 1%>M=.OMPQG:6U<ES3U6>SU*?),G<M5Y90A%W<%(D706:"X**R*G3H&5
M<$2(X5</+N,\?Y3HTM6LC5"!ND"BFI+HQ5A8D?M4)2-;KJ,7[8#B55J[;B8Y
M2.&JJ*W1**HB<4E5"&JK*$SR9N=$U2A(O=EV<9M,#EYSF1+B"XK) /$##TBQ
M6[1L0QNOG+V&I-CAQ?3]2(5]4+-OF?!MMK]QROD4<AX@THUFUV%>C5U8:4K8
MUUT-CL-6FNZ!IIOK8NYMT[;I:]B$6-<NO4^8GH=+7_#?XH:';<>X%Q N(_$&
MNN=UHM3<VE[>GR4->5INVT^IWMBW6D]E8U3%NUO'G\?\GNT[2J;EUW8Q2BXF
M"]:O.VI[Z8>ZV">6''9K/SI]I.JKQI(Q(R$>Z;OF#^0E7S%ZS73<M'K)W).7
M#1VT<HF.BX:NFZB:[==(YTED5"*IF,0Q1%1)Y8<=FL_.GVNS1,%$$,Q(S$3$
MQ,3$Q,=Q,3'M,3'O$Q[3&?G$A(2D2B1(9D2$HF"$HGJ8F)]XF)]IB?>)]IS7
MEO75?[:'Z'E];$QY)D^SWWFBVM>6]=5_MH?H>7UL3'DF3[/?>:+:^Y\S.P]8
MLOP1M\R36"+]1==I27GJVL[#UBR_!&WS)-8(OU%UVE)>>K:8S72^N)]V+%>?
M3.OQ->JPO;;/YA[K]I?7$^[%BO/IG7XFO587MMG\P]TQF_*>39'\!=^;J:V4
M_4$_@B_(#6M*>39'\!=^;J:V4_4$_@B_(#3&)$%Z24[<E?.!UX3ZY%>Q$?I%
MSKV"])*=N2OG Z\)]<BO8B/TBYTQFW(>K17:1?,GNB8\DR?9[[S1;1(>K17:
M1?,GNB8\DR?9[[S1;3&9F/D]G^!M_F":3X+TDIVY*^<#I08^3V?X&W^8)I/@
MO22G;DKYP.F,\)]<BO8B/TBYT37JL+VVS^8>Z"]5D5\?D1'Q (_]XN?:_P"?
M&/B =(LK8Z^L\BVJ4Y#*.D+ U07;$E8\[A%8K=X)DE42N1435 #%$4C%!3T0
M>AX:\D0CUY$(]^T>4Q'<_JCN??\ FST(&7?B)%XQV7B,SU'ZYZB>H_;.=+,>
M29/L]]YHMK,Q\GL_P-O\P36"8$!B9/Q^3WWC 0_^Z+>+B <?Q:SL?)[/\#;_
M #!->L\XGP7I)3MR5\X'3+1_[:JV_P"#]CS^4K)^GI@O22G;DKYP.HUR\S8H
MC=9,! 5!U:BO,$8]1D#-IJ$APB&X9/R(0'BH3#EN+P@IK.%.A9 JL'<HIB3G
MKH\<JH[]2(Z_M<_68B/T@_&9B(_GG/L?C^[_ &QDL-&N"RBVAG./+AX1SEBK
M4"S@WTM,SU3FGU=L,7&0B??AZZC)F-41>L5BMV"A3G04(95 ZK8QN8L?BUVU
M2%G([#D!.6&=MDR^ORJV0&S:X6B4M\E6H.SI-W=:JZ<Q,*JO5RQ->+&=\#G-
MS5YQQ+.DRII+II)[(U +7.O2Z1)=I5442J>FRU9M\Q;Y]=K%9>H/A/CVOLHE
MHQD.S9L#=UM0-86 _76+[+46(@J\5WI1Z;*WI3/3C>OT3]:)9(O\5S%=A9([
M1HT:T<E\X#(]PGZ3!M)6N8[M637SB;C(M: J#FMM9-FR>F5!S..%+1-04>:-
MC 3(+Q-%VH_."R?<C5<0/S*T,NR5_ILSNXB5,J7>3:R=\V<1DE95W[2#>TG'
MF2;P]AK3$0#FMMH5G5HII .UXP+ @@A-F2<*2$I,.I3FR)+;A !\8 /O]>N;
MDZ;49I"PMI>KUV4;VUDWC;2A(PD:]2LD>S260:,9XCALH689M47"Z39M(=T)
M-TUE2(D(50X#4>3\;M[Y4"C:OJ$L+PI7V8(45S1;G4D754D-;)NV5>P96#?*
M1J3%/Y=CF&5^X5S"CQ9Y':T=:^#6:L[#8@#M.#7\IXWOQ"9NC90D0KZ6Y36-
M5-:+![""V$W$UU*"K%7)SI7;XECDF4I-./'=Z7&7?SPY<#?5-L8;G#X["<4M
MAI(MH3@.@X4 <@"\(L8A"L1FAD3BN:9.S2P3=BP9'+2\M)6%O$7K+=5K-AF)
M!S,24U2ZEE&V5VGO7<R[45<S)R0$<R9$E5U5%Y!%FFY<+.%U%%U'G-B7%AX;
MP=/C>AG@?!LM-[S&J%?-%^")'@2)*OW",>+?P>+(%*^+#<SO>5Z .P;@X %=
M=A#PT17HJ/@H&+CH2%B6B#"+B(EDVCHR-8MB DV9L6+1-%LT:H)E!-%!!(B2
M9  I2@ :CN/\4VVJW%+8W=JNRFIQE.B^75%G[[%/2T6?G6$$)6*V0K[LNDFS
MY' P4,E^6<ZT6\X]L=/KM$ZC9O<TL<H^;<5.86A]2Q7-$^@D6S9<;EDZ88-:
M!0,"HCD"6Q=ZZ]QF!@]NBYZ__P!4:CYM:2:QV\7E(8=N@Y2.;*&W^T+*+B(D
M6-8]O=90,* GX*<PKB&<#P O0E*<A$CF,54I)!WGKW&X%#_^A<]?'B?3 X*4
M,RY0'?G&J/D3=]Z+M"M#:/#F@LDF-2R-6G#@0,'2' RD(D0QR""( =$G-!4#
MF-:MMU%OC)?JV=@?I'\;3[[V[F8F.YB/IW,SU[==S'&KOM9U,_\ K[(_#\=9
ML?QGZ>\1]/>?IU[Y.=EY=F_@HCYAYI=TA,O+LW\%$?,/-+NI7)#$V+]1==I2
M7GJVMY;U)7X,_P D=:,7ZBZ[2DO/5M;RWJ2OP9_DCIC$V \A0O9,=YFCK!9/
M)+CX5C](L]9X#R%"]DQWF:.L%D\DN/A6/TBSTQE7^]K;Y=K_ )H9W]/!DIG^
MKN<(2>/:A'5R\QU"E\99,/87\JQNK]VYE8=R_CC(/6YF;ILZ>'C7#5USH[G"
MB=?W;GO=CX):@[?=U+&QXAS31FK&OOK#D8Z:$%?#,X1U#-+ >R*@DU9OII4R
M"@N7JKB$DUE.Z(ZR2"JYDB6MB #XP >'BXAQX:C+NFQEA+(..I%UG.LM)FGU
M2(M5FD99%LX"R5V+@:G-S<G(UR2C0+,-'B#:.,X!HS4.A(*()MW3-XF;H#<L
MV'!]KJ-UL^7\.W::NUOL8_9:C>5*C-'M4E"28BS?I5$[NLU4H\M?>=:V0ZP3
M;613FDTZ^=PUGQ1X[N>,:?@GQ*XZZUQS2UP3J>2<;V%]')>.FKYGJW3U>TV-
MCB]JJX+$QN=96H:,]T:47K6R'9("V4F$U4UB$42.11-0A5"'(8#D.0X 8AR&
M*(E.0Y1 Q#E$2F*("41 >.D4_P!<B78BWTBVU1#MXR+GG%^.$,Q[3)FV[I=I
M*<[/0KW%]_@I.NY:Q\:MO0;R[2)CE$7,@5!D10AT'591D8=PFH99S2&/-4?E
MLJPAO7P!G1!6Q1%TC:A(0M>5-:JM?GT=5YRMJ%DFQ%C.C/G:<8_CTE0%/OK%
MOG30@\Q-V+)V8S0DCQ[XBZG;-1K=PD^,;]U?YE6LVCT%5V*!&#*YQ_<J+[.W
MM*!GSDZC!MI")FY2JS$C$!OOA=L:^J'EG#-E4^(O!7FD5<FXTI[':\[,Q\O4
MY/H3@MKQF^R9$ &\H]?:84#K=E?&8*9HZKF?#WZY5.N-P-SR4'9-=9?F)/PX
M)O+[EZB1:7=,>(&X=,UJJO1+DYIE.B#I!YJ")36&L)!C*LFTC&/6DC'O42.6
M;YBY1>,W;=4.<FNV=-CJH.$5"CSB*HJ'3.'64PZKVQH@K,\IMNBF1(L*5,VQ
M;;J>DJ9H@"*:MGM63;6X12>E'I@%1./:G.@</V82"8>!&R/.M&V*&3IU#,$-
MG<4YB1F)@AK)L;&"B?>)'^!P42/UCZ3UG']C!"=)!"0D>Q4)@4=$)5P=9D2@
MNI&1*O[Q]8F.NLC%"9/5VL[=N4]Q@Q*HUF=OV3<BS>*8Q$X$,C";K(IE<</-
M&"0 !NA+D.[34.T*D %,JQ.@D4IDQ .RO>+D,"47DD*T@FD57$6X;'&*9!<&
M!G2IGUMPKDRE3JPK 8 :]\+")EG"Q^=SUU$U^<)T@ T?]]<?'-.4NVW8]"50
M95#<V.W53-$.HU>KA)*X&S19+-BSIC()]");;.F+5%A-TH(MXXIWHMFO1JC-
MO?\ +][L+8-O"IT"> 6]#;!;UEEG3AHFD1?.#*N/%!,W 3J%[GLJY3I#P*"9
MU%>LR12C3P]T<@$^O#C)(I5H[CI:Z^TG=QX=>\!&NC3)F?P=48/783U7@]U[
M2)F)C32NLJ/P %79V4>/4_HQ4C7+F?;IE<Q_BSU8;.=4!,=CR'F2VE1'U)+X
M,GR0TF3H\8*:[*DP_@:KA_Z:4T?4DO@R?)#72LN&(\[Z2+[<BO. TME\0>\'
MQ:1)WTD7VY%><!I;+X@]X/BTQB<OY5COP62^4PTI:35_*L=^"R7RF&E+3&(K
M;R_+]FPGS\UI9-XA]X?BTC-O+\OV;"?/S6EDWB'WA^+3&(D%Z24[<E?.!TN:
M0X/J3E.W)7S@=,)"[L\/3^Y6U[48Z0GSY;IM;+9YILK6I)&ME9=[*S,JM&MF
M.7O<ZDVT9;X!XNS3X<U-]S"J'5173)@?:KUI1%AZDS9>%:O##$)=88)D"5]S
M'FPQ Y$([F8$IB/;,3')3*X:P%RY@I5!E RQI01"L.YCR,H$I@8]YB)_5DAX
MGR5&=GLO-DM:=E\AR/P)?G4];D3Y*C.SV7FR6M.R^0Y'X$OSJ>L^9<6P\7XS
M?&.HP[BY*?B+%MSD*Q6_"Z<;YJD>XJ]WY90'?#I<)Y=1<?VVD4U6;7N9LHL[
MX*D$5^A[G3X*JD$)/!XOQF^,=,'F#[(.V7]^F:_D(S)K*F>C[F(F(!L]3WU/
MYH_:>IB>I^D]3$_JF)QCQP+R5D(*+?343X/3#N/;+R,-WP:R_>EZJD!EV7?)
MF5-H_P"Y5!%,72!"(+\WGE "CJI-*TJ23MXQJ68[;8,66;+.%,<WZS2>2536
MBX/W5]LR5^OL8VCID)3$])GU2PN/&2L0%9C9XK4JD$R;-.Y9&0N$X 8O 0 0
M$O 0$.(" AP$! >H0$.H0'QZ;TF(<3I,9F,2QCCY*.L35)C/L$J96TF<VR0<
M%=H-)9NE&D2D6R+HA'**+PBR:3@A5TRE5*!PF])MJVLBWZZ&.*P=.5P$*D%0
MA\M8SQ:,G+PCQFM/J>F)P4L63/1<BF\MXY=Y 6O^4M(JA37LH=ZDV88\K=44
M*1Y). BHS\X%V)7\P:B$4N!/S5>W %ED5W:\#[>*E-Y&DBEL.:(RL7Z2:W!S
M%V]YB0]GRI&4>0FK!'R#.?BXZY#382/2LH.F2UA40<HH/U%7#D#R]VIV.P6W
M;WBZ?L\@\EI=[7U2'EI!05GTLQ8R\G'0TL\<& IW;F3AFD>^6>'#G/%%S.C<
M3+"(N@_QKCN4C',+)4.G2$.]B8B!>1;VLPKF/=0=?5.M!0[EHLR.@M%PJRBB
ML2P4(9K&JJ'49)('.8P\YD:ZGQ]5)"+H%?@[=D=O5WZ^-,0)6JLTM]<'<2U!
M%C#Q:DPZ:MXV(;<P@2$@@U7;Q,:W742;+*I(M56YWM"Q0>I5(JL%LW;'N( Y
M6+9M&2$@E4,:QLV5H@ 'R)=&H  PY@5ZVAXWLM-L$['8;8;JZ_'T:<Q +/J6
M65QUZU.,#:V"D(H.>H1AC3M[>_ ^,3$O=C1J)&SC<//[CZ!=[%8XRDH2%$RU
M<<6&L.,[*_M6.KN-2;PRKBS4^2F8^*FRQI'TJZKSIO*,"*EEH*06;++L5VQP
MEOJK5+:+U9-NL4FAX>:RD2"9CN8GL2B)CJ8F.^NIZ\ADAF)FZH>NRE;U3)+:
M/D$S$C,QW,?28B?K$^_TGZQ,Q,3+>97^Q[:>S@\[:Z<(/%^,WQCIO<K_ &/;
M3V<'G;73A!XOQF^,=;.9L]T:-&F,-&C1IC#3/1GV>[K^]%C#_;;+NGATST9]
MGNZA[/U(L8?[;9=U[']%G_8C_6+S['T+]W^V,<>6]=5_MH?H>7UDG_(4UV3(
M^9K:QRWKJO\ ;0_0\OK)/^0IKLF1\S6UXSYBDCZDE\&3Y(:28+UJ\[:GOIA[
MI61]22^#)\D-),%ZU>=M3WTP]TQ@E]<3[L6*\^F=$MZZK_;0_0\OH2^N)]V+
M%>?3.B6]=5_MH?H>7TQF2?\ (4UV3(^9K:Y')F,:=F+'T]CF^19):LV>,!B_
M;\X$W+<X 55G)1SD2G,RE8MV1%_&/2%$[5X@DIP.3GIGZZ?\A379,CYFMI21
M]22^#)\D-8+-:O<KOJ6T*LU;265[-=ZQ:EZ'!*VI:LXD&+8!$!@42)#,Q,3$
MYLT[EO77*NPH67T[U&PFW3MUFFFS5M5F"ZO80Y<BQ3DM &*8!00&(D,Q,1.4
MQ;?\_P AL6N-AVK;EY:1/C:([ZS6#\J)0DO+(O*RE(N4W,(Z80325?@R26(Z
M5 J#=<M4E&TK%/#D@UX-9O;C5;17KJUC;94YF/L%;L5<BI:$FHIRF[CY.->+
M/56SMJX3$2J)*$, ]? Y# 9-0I%"&*$6LS;?;_?[E4,N8?R' T+(M-89,H*W
MAC3PN]7EJA=YXKB4#O:1_'.6,Y'N6)'#!XDLJV=D,9A(("T.ITD,\,9NONP*
M:@MNNZ6"1^I/SUXW%>=*LQ<*UXD:[E9"5.SL;9(BBQ4TWD@]7=I]"G8*^45.
MF8SM?(C.-^,ZG;;+X;7SX_R,;8_#]5EU3CG);:(L)TZ'1KSU.LVVU5L;#AH@
M;]CK*]O9ZO7C1BA04Z_="Z#4?H[?:#3?&?4ARWAY4"^++Z=?8<QX7K[)U;'(
MK=>=JO?[O0:%^GIURVC5U=/N[>OT>]W#-H6VVSZNIUK-:U%FX>6]=5_MH?H>
M7UL3'DF3[/?>:+:1@EXJ?;5&:@Y)C,1$H_0?QLI&.T'\=(,G4)+*MW;)ZU45
M;.FRZ9@.DN@H=-0H@)3#I9F/),GV>^\T6UVL2$Q$P(3 Q@@,9@A(2CL2$HF8
M(2B8F)B9B8GN)ZS\U&!K,UL EL61 8&,B8&,R) 8E$$)"43!#,1,3$Q,1,9G
M8>L67X(V^9)K!%^HNNTI+SU;6=AZQ9?@C;YDFL$7ZBZ[2DO/5M>L\YKI?7$^
M[%BO/IG7XFO587MMG\P]U^TOKB?=BQ7GTSK\37JL+VVS^8>Z8S?E/)LC^ N_
M-U-;*?J"?P1?D!K6E/)LC^ N_-U-;*?J"?P1?D!IC$B"])*=N2OG Z\)]<BO
M8B/TBYU[!>DE.W)7S@=>$^N17L1'Z1<Z8S;D/5HKM(OF3W1,>29/L]]YHMHD
M/5HKM(OF3W1,>29/L]]YHMIC,S'R>S_ V_S)-0+W4[WZ3M7BG4$W8ENF6Y^1
MDW5=HK=P=!-FS</%&[6>M+MNFNO'Q*KDAD8]BW14F)]<HH1J*;<KF0:R?S#E
M:$PAABW93GP!5A3:J:339\_F'E)0Z*+2$A43=8@O,S+EC&)&X#S3.N>(<T@Z
MJIY.C 3S+EEM&]S.P(6*RV*SR[^A)R:8BR:RC)THA,W9)NL4K4B,2JD-;I*0
M"=O#,8QV\13(Y*P70YASKDN['::?@W#C0KE/(4V+K]I95%BMQGC]0P7;W;JQ
M?=LV&..*FKKL_,NN04.*!#Q/MOPNX9QD])R'XH?$5=JQP;B-FIK*FBIO*G<Y
MORZ^LWT.,U[P??HTD5EEL=]=3!6JVN@8JC+70:^3AML._#>6NWO6>,J/<+TZ
M5;F&,J+5*4BWZ,0X5%PB@ECN"DHE!HW$0 4UKW./+"9,0.X;<TX%%P0Y&/&X
M-3<,V7\)4P&,+\*U4@;&6.("94S,"=U&XF$PFXRG2&X]:HF#G&MBB\K8PFJ?
M(Y!ALB465H<0,B$K=8RX5R0J4:,0;F2O?&RLY->$9=[#^@D1=OTNX3^A=BD(
MAI<M=RJ5$@'MJNMHKM0K$:5 TA8K1.1=>@F!7*R;=N9[,3#ME&M2KKJI((F<
M.4P565323YRAR%&.1\#^#.'U^2(VO,-NR(FUNN0[K:ON//J._377N5ZM50S'
MYE5=(^D$"'F7CY3,6/[)SXI53^6X=;TGP]T"2_@/&^(<;T5/6U5Q/W8:VUK[
M=Z^XAZFP^]:=+V2;) ?+QBD>>VQ;^=H31_9,%Y=D,ST-DB[4E*0\"1D7AXL$
MNC6.;'UAD99L\4!MZ$YZ1/-)P 3$S5HH0 3U.?9KOEI&Y^.5JKZ/+1<M5^/%
M67I;EV+AM*LV/1M7DU5'BY$'3UBV7,1.4BWJ"4Q!+JE2=D=M13D59V,WC219
MM7[%RW>L7S=!VS>-%DG+5TU<ID7;.FSE ZB*[==$Y%D%T5#I*IG(HF<Q#%,-
M,'*-;?7^*9V!WL8+)X+W&HV6+>Y#)%IBFU=.72Z;&-NR[1,H(CW2Y53K=V0X
M A.1<LB[=I&72?N'$-M]%M_A*DN3<1O[;:<-H3#N2<*V=QVT^3U4%'S.TXS<
MMDVY4=KER5E]!KV5K2!<9, U*C+%Q[E&@^/MH.%?$'5Z'2?$7;1-?A?Q+TNM
MJ:&=AOB'^!:+F^NUJZ^MV%7<N@*-7;UZ:KVOM'7&%O6]TQ<9!>DE.W)7S@=,
MM'_MJK;_ (/V//Y2LGZ4=M^5X;.&(*ME2$*5!O<$W<@\C@.90\--HNE&4_"*
MG,0ACGB9EL]9$5$A>G1227 .:J Z3H_]M5;?\'['G\I63]=TU]RML*2;]-P6
M*=VDFW5>N>P=6LBIR&A,]3(L48F/M$]3'MGYEV&ON:F_?U>QKLJ;#6V[-"]5
M='BVM<IV"KV:[8[GIB7+-9QW/1#,=X^\G&1TU'/X>88,Y2)E6;F.DXR0;(O&
M$@P>HG;NV3UHX(H@Y:NFZBB+ANL0Z2R1SIJ%,4P@.9HT:L6K9DR;H-&;-!%J
MT:-DB(-VS9NF5%NW;HIE*FBBBD0B22292D33*4A"@4H &QKPIBG #%,!BCXC
M%$! ?>$.H>OJZO9XA[&L_D7CX>1>$%)>/<^,%,1$EU]/*8B(F>NYB(CZ1D?X
M!Y^IX#ZDAX2SQCSD!F2@)/KR\8(I*![ZB9F8CN9SW1HT:\Y[PT:-&F,-&C1I
MC(]7C]L=@3^\;//QXGU'NAD/%\IIN':][@03L^TG;I/B_P"<("\6@LC9B@3"
M! YQ5.:FX3;F4$4S)]QD(4AP.)PD)>/VQV!/[QL\_'B?4?D^B9<J<[ SQ0%)
M_8.Q,1CP."1@K&X1Z4S@>;Q3.HF6Q<T@K 4Z95%00$P*K@6*W7L6A9_>]JCW
M^[[>LO8UOXT3]?7\?N]%,SU$QW.1]_V*@7]SL%>_M_TB7I_']?J=>WO[]9.E
MEY=F_@HCYAYI=TA,O+LW\%$?,/-+NI7)#$V+]1==I27GJVMY;U)7X,_R1UHQ
M?J+KM*2\]6UO+>I*_!G^2.F,38#R%"]DQWF:.L%D\DN/A6/TBSUG@/(4+V3'
M>9HZP63R2X^%8_2+/3&+NFHS.LP;T.QKRC4CZ,1JUZ5D62B"+I-XQ2H5G4=M
M5&SC]@<$<-RJ(F07_85@.*:GH#&TZ^HS[P9?P>VVYPL '73&#PQFB5!1J;F.
MDS,L2W18AVQ^>GS%B'*4R9^D3YI@YP' 0#6O<9"JEII==+KO9/<=QT"B*>X_
M&.H]X_',5@H!#CGZ IA3W].A IGOOV^D9$_D9WT>^Y._!0,F;=JHS4R"P?F0
M8MV0NWS3(EF*9XL9N!>[7*C4[1-:07XNG)D@Z4P]&4=+N[39]"7K(^/,Q8XP
M[C6]7JI3QK#?J%:%V]:B<Q5\Y>X"LI615:/8$L]$/7*4LVD)N*<%E2(@PE'#
MALBDT5;+D5V"U;VEV.@NE.<[Q[G"\P"Q#@N1=,LM 4FZ(D=)KI(=&N5.S\WF
M)(IID(4H&**W2F-:V?ZY$NQ%OI%MJD5./:SE?!='J]U66T5Z_5&MGI57.H[#
M6PF56JWS:+*(>BQ7^]#4.0X/4KV4OK-<EDQ\,>9[_@\:?=Z*VRM;#4%K;M<;
M%VO6V-&U1+7[#779U]JE:*O84;!DZ]JO:K.A5RE9K7:]>RJH3'M8Y0G:9"/4
MZ=B'%&2<62T]/W,F(*E:'RDUC$EDE%I)S4*G(O1BE5XR, Y$FC6+C["R!4RZ
MS1FETZ@"V>V3?;B:&W<;QK;G>+GL#63(TG@JL,J_;H:<='@!QKC=RPD(VQR+
M:.(9@X6E)Y5^R6=1#!(T<X17<BB!B":^(X )3 /L@(>WUB'#596TO'M$R_,[
M]W^0*I7[Q$6#?%DN"*SLS2/LK$&]#Q_C6C)'9 \;*'CED31KI$@MU$EV?,*B
MW5(5$IC5YG#-[QMNEI\2Y9;-*6N90TW*ZM?;Z>H5:C844H=05J]M40:+#:JZ
MR[K*=2; ,KU("NJO/0=[\2.+\VWFDL\^X#KPLLVUZ]M^0\#NW./\BV""TFUJ
M!\TG:OWV@NV57[M*\^\W5HV6PBH:+>Q)UUUP9 V;*.R2Q6_&EWMMSVX3MY24
M_P#97;YZ3H$K9XU19V0@A4YYX9Q)PYS/G/,,#5TR,5V=0! JP*B#-\HZFJ&P
M7,<LUZ?NFIJT>]MSMC($62-1LT5&U'7(HY**28((12JQE X'*0@BGSC<"FCS
MN"V%S^+:_GJ9VPT7%,Q1LEXO[UV2@VZ)F)V]U9W"B]</Y##LH\/(%6>R;)P9
M^G"2SY 4)>.:FB1<JIQK%/L;%D.G[D>2>S>A57!EI&N;8L@U:RP4D=69F(.U
MTJA.WQ$)$#%1<O5'O>UI,14D) %ZV=-W8E!RDY;I>:?)]Y:L\FXIRO4ZW2;F
MQQ[97]=- K1U=N-:+5&VVC=LK6.SA:/LZZ705K=)-X*EFJ1UFOSW\1_AUQ2K
M\/SYM\.]QL^0Z1UEVIWA;&OKZ^QTUN_I4W=6.ZU]%KF:IS7CM=0HV.OTMDW3
ME<I7P5:13&U.663<5N5<)"!DEX5\NF8!*8#$68JJD$#$,8I@$IP$!*82CXRB
M(<!TL(^I)?!D^2&F>QC.A:-OU LP&YX6/#M3G@-T70<X)>CQS\#=!Q'H>/='
M'HN(]'Z3B/#CIX4?4DO@R?)#77DLAJE-CZ,6#(_<8P4?3V^DYR8"@P X^AB)
M1^XHB8_TXCSOI(OMR*\X#2V7Q![P?%I$G?21?;D5YP&ELOB#W@^+63/6)R_E
M6._!9+Y3#2EI-7\JQWX+)?*8:4M,8BMO+\OV;"?/S6EDWB'WA^+2,V\OR_9L
M)\_-:63>(?>'XM,8B07I)3MR5\X'505?LD1&<M_?H4T/&-WMDV90+$LB1HV[
MN?RL5/1DZ9^JZ!KTX.CP:7>A4_3@*\=%,4%E5$FK5LG;[!]2<IVY*^<#JABR
MBWB.67;Y1*Y75!EE?&.W:13.4X(M6^1=G%^N$<@F<Z2ARI+3L&V.5-,$FQW!
MU3@ITPK'+4^5M)/Y.&/C_P#:G5B<SU]U1*MBXH[]_NKDBGQ]^HG\.\@MX<K^
MR"'K_P ]TH+OKV @L"R8_<$S,]>_7?X>V7YQ/DJ,[/9>;):T[+Y#D?@2_.IZ
MVX@>,3%C[<<R'^%LEK4LOD.1^!+\ZGJV9.XMAXOQF^,=,'F#[(.V7]^F:_D(
MS)I_ \7XS?&.F#S!]D';+^_3-?R$9DUD5^E/^3=_JCQC^%\0>\'Q:]UX7Q![
MP?%KW6/&&F0S%@*BYA8/'CUHG5\EMZM/5FCYLK$=$M,MXP)/(F(Y?4"Z+LEY
M:OJG5$#O6C1PDQEVQG,=)HN&3QRDH]^C6)R$V%DIZQ:LOJ)QW'<>\%$_43&>
MB QF" H@AF"B)CPQ8-"5L&# OJ)1W[Q/<3'XP0SU(E$P0S$2,Q,1.1MVW[?%
M<$L<DOYZ\.,D9"S!D9[D[(ES/6HJEL9*>6K\!56+>'J,&X=1L)'1\!6HQ 2@
M[?/I!^9])/WRRKDB:$DM&C7FM6342%>N$@I?EXC)FPIDS)AD;&D;&&9D1L8P
MR,S(B,I*9G/B4K0L5*'Q .^HDB.>R*2(B,Y(S(BF2(B*2(IDBF9F9QO,K_8]
MM/9P>=M=.$'B_&;XQTWN5_L>VGLX/.VNG"#Q?C-\8ZSYDSW1HT:8SPQBE*8Q
MA I2@)C&$0 "E .(B(CU   '$1'J -,A.;DL&UR!?V>8R57&D!&7ASC9W+ L
M[=,BWEE&]]W=:069-'(/9%O'<YPL#('"!.B<(F7!=NNDGUEVK][G)6G*5>YP
M]<KD=*N%K_7Y2EHVA6\5Y9)!(8)A)JS,;X+*B4'15),K*8Z4CD"&9@"/[)6[
M:\,3=+JUM:PN+<T04#";ILIVZ@-]N;R"JTY7(R<Q"TK52GH>LM69Q>U&2FW;
M^$6"&5ACP:SE24DBF@B2:1Z5RG?;S4CY:S5BQ0PX3M6D/MK(H758MR:^M?+H
MKKAME=B;LT2]:O'AU4*;@])X/Q;C&^.!W6\)3CFN:Z%&S6U[A$G7D.JV+>XK
M#6FXV4TG58UP;,/EK9>?E? =<=J$%.1=FA(FQ03U*1AIV,93$0_1!0J+V-DF
MR;MB[2*L1)4J;ANJFJ0%4TS@4P <A3<0"HB@7O<S%\J#,T*_3%C:TNV1.3IB
M&A'C?'HU.5P=4T#ABQ]7UXUN:V%E(NZ34\$X60=)2*BCY+GHJQY79DK0\-HY
M!;XHQNCE==NYR6E2*RG?%FHMS)*6PL2U"<-SV8 R.IW?TI5U&( R4< J=H -
MS)ZK?W7/7% W_P"T#,)5A2B&BT#A:R"8P$;IL\VN,K1<4LX,;@0$RS,"@8>>
M;F@H1(Q2BH4I@V]H5BQJ]/MI=>H%5N:2]=K#)TB-%FW33;KWJ\,=(@@+!FZL
M3FP$J,"8SKSGB_/J)4GJ=4V;QKZ#E6OEK-9?EE/8ZZ-RC7O)EA::\7Z$UG%:
M@Y0A;TC+)2N#\!M0EO75?[:'Z'E]9)_R%-=DR/F:VL4KQ[IK_'Q]^NOW^\\O
MQ_TZRS_D*:[)D?,UM6K)_%)'U)+X,GR0TDP7K5YVU/?3#W2LCZDE\&3Y(:28
M+UJ\[:GOIA[IC!+ZXGW8L5Y],Z);UU7^VA^AY?0E]<3[L6*\^F=$MZZK_;0_
M0\OIC,D_Y"FNR9'S-;2DCZDE\&3Y(:39_P A379,CYFMI21]22^#)\D-,8DP
M7K5YVU/?3#W7*WO'U,RC&SE)O]<B[75IF'9HR$-+(=,V5$KI\9%PB<ADW#)^
MT/\ LS&19+-W[!P!7#-R@L4I]=5!>M7G;4]],/=;!/+#CLUGYT^UB>A%I+:U
ME*K%=ZS2]#U@U+E,&08IJF00,68S(F!C(D,S!1,3,9GJVK-*RBY2L/J6ZKEV
M*MJJYE>S6L).&*>AZB!J7*,1-;5D)@8P0E$Q$Y3;/4+/?)QS);5C!2:S?M+-
M-K2T[CA\J9Q;L;=.W>B[D8IPF@82-$6JSI92:9($B'AD@"WQ3%?_ *T&LPQ3
MGG&.X7&SF\8PL2$U&'CW24DP5 K6=KL@=BJ<\38HDRAUXR0('.,F!A49OD !
M[%NWS%5)R=V9@I3N($I@ Q33)BF*8 $!*:&F"F*(#U"!BB)3 /4)1$! 0$0U
M67GC9+:L>VB3W";*9=#'.1"-GRUNQ@F"*%!R%&*%.X?LFL6L)(F-=NA%54T*
MZ*E NW1RNXMS5I8II%SRPM/O?AV16>*HM<@X;!2RWPWU)=M=$N9[;8X>]Y]V
M:@Q)&?&K+8B)&8U#U$?R9]T#D/%OB^ 4N=VJ/$OB/(BK7_$:4Q7T'*6]>*:G
MQ$K553\EL3F!4OFM%!$4%$\BIV! MFNT1AZQ9?@C;YDFL$7ZBZ[2DO/5M0JV
MI[UZ=G<ZF.;=%.,59XK2)F5DQC8RN&#AVZCDB%>NJJ>2(W=R"*9.#EU#.4R3
M\6B855F[V-*E+N)JQ?J+KM*2\]6UT#1;[4<EUR=KI;JKU)TD'FOR!B7+GIU6
MTA@@^I;07W+%6RM3TG]UBQG.2\HXIR#AFXL:'DNL?J]G7@&>DWP8JQ6</G7O
M4;2295V&OMKZ;4OTW/J6E3#$.,9[S72^N)]V+%>?3.OQ->JPO;;/YA[K]I?7
M$^[%BO/IG7XFO587MMG\P]U,97LWY3R;(_@+OS=36RGZ@G\$7Y :UI3R;(_@
M+OS=36RGZ@G\$7Y :8Q(@O22G;DKYP.O"?7(KV(C](N=>P7I)3MR5\X'7A/K
MD5[$1^D7.F,VY#U:*[2+YD]T3'DF3[/?>:+:)#U:*[2+YD]T3'DF3[/?>:+:
M8RJ?E<K(\B-K-1AFHG(G9<CUI!\<"@)3-H*MV"Q(HF$>LH&DF#!4! .(BAS1
M'FB(#R6YE].XYVEJ81OV+DZOR>#C8?D4^ZW=E2-P36AYDPQ"M<2VMS9V6.,/
MCC:U/[W/61!%D@PGFEKCQ2E+<X(,/(GC^@DW1Y5:@+6[:8VL+1JNX<X\MM4L
MBZC=-14R$-*-7=2F5E2DX\UNV3G6KU=8P<Q!-H*IQ*F4YPE1M1OL%FW;!BJ?
M<)LI9!_1(RLVF/?(MWB'?RMM"5NRL)%FX(H@8AY".75,@X2,FJV714YIDE2"
M/(-60J^-_*UV^HLW."<<;IY/KL]=5V6P7LQ3,Q[B-]M<F@,S/<@11UU,?H3>
M ;_[&7@+M?,S3U_Q3YK6Y$*YGH-S>TNA?I#LC$]>9ZFM<&N91^B+1">X/OX:
MLE8]VU95Y$3E:MS&WZVXVQ72+7;]IN7\=[+-K6<3.*[MTK==@<<8*J26Z6 Q
M8^@<?6',>=ZVG-Y%S%C*5B;)4HN]P\'(R+V<R#7)*7;?09RV>Y_D]:UBS']4
MW+.:=F_(F#,\8'EZCM+O%XJM2PS=\OYNQYE:OX64W9.K_ 2].8;?X:OL,@Y/
ML$[+%6;0G@*D^!K(R)X^"EY<YUWR4S;_ )[Q'@^'VC/[U@S/%SQ?BIWG&FO<
M:,*G8<PY3+E9Q1L<X\HSEDFEFN2J2.))B5S*^:6&$0PW!S]4GY!*4CW<NM"\
M>CRE^)9KD\<_\H7FW;'(X]C\(Y(SACB<P[>'&/IV_EL^$\Z3>WBKQ-TL23=_
M2JK-2UJ49-K(Y:3EKJ>-D96:.VM=JA8M26D^OY^>\KBR#=,E;#>0\Y-9WM/R
M\?>);<7Y_P!K5>KS[;SD*;)4=R/19*O3F8P32;2@X[XV#$CB:0/B>+BYA!1:
M5IE78QTA#DD@)'(HF/N5)SMNISMA+;#/YAVJWC$FX:ORN+[%4(/&5LJF;<CU
MMWR7+W>@TWATA*9R4]0IV%[1F644Q!7JN_I\VYKK[&[^,D+U)6Y6>:1LP\<\
ML]7;?)8BI++:S2CL,@XREKEC,V-\Z4_)].L>3T,D9*H./4L:V:J8T9T1YA^:
MN%%8UFQ97FYNA9,Q;DC(55I]NP/'O26*3BI.;HMJ>VK&<K<>4%/)7Y_D"IT&
MQJ8FJ@9;LS_!]<R5D;%;C ["^XYQF9VI6H*QS="L3RNE4K@-*VJPF[):&]<1
MM=AG+*\A^16*570;RSL9"-?7U&R=>]3KPFHNFXK$%$Q,3$J@XF.I[[ZZGOK+
M!Q.KLKW*N-4M-#)V]O?Z>MJ_1F8;]H.V%==.5S$Q,'%@ER)1,>,Q$]QUWFUR
M.ME?RNW2WP#M/BWK649$6#GI"B!D[#6J]-O&Q4@'GI@A(JNE^<8.:IW;Z$1,
M0X%EE85\B([K9,*#&4N13/@O'I;$-OG)Z&.UCOJGY#YJL*6$KT\#]Z*(OQ,W
M?&CD 4(T '(IJKF1C_R3%$<U+:NG.O$%$5,@7JR61H*@<T5(B-2CJC&K%()0
M,";GP?=.TC&$W2)+D5*/,.4-2VC_ -M5;?\ !^QY_*5D_56^#J;57X9<+7=$
MO6CC5$X!O?D*'"#J@E'W9CPJL2,1^$1$?AG1/[(.U1N_&WXHV-=*RK%R_;+\
ME=2L[->Q%>\8R,S$^=Y5@I*)Z*9DOQSS=<K8$=O.45*VL\;200*)5W+ 7X+M
MX,\Q&$L[@YHLQ),K5&L&EU9 \:<D@1B5T9BH1R"1PY39XY8*8YM3"%8U<E=A
M,IWB*KD]1"RS:A7&)378N2V2F14K/64D+"*/'3N*-'0\P\@1DXJ0>QBQRO%C
M#+ Q2F*8I@ Q3 )3%$ $#%$. @(#U" @/ 0'J$-8F[9NT13;-4$6S=$H$20;
MI$112('B*FDF4J:9>(B/-(4H<1$>'7KJX;.!TS=3*.Y9>^<A\,\8B?24N!)<
M!VR0A10J29Z80]TRJ3D##\\-T!,Y37Y)%SQ%.HG5S3E$',Q\P]_FMY-D4BTG
MC+X77AS)J5H^8%4-4S-HT:-1.6/#2$\M%:C^^X/[!",1@$&+J<!Y+1[489M)
MF5)&N94%W"?>YO('07*Q6>="D[,BJ#<Z@IGX<]D9?)S>#:'Q1'4:3L8S4:1Z
MWR!+ST+#$KYC+=]EVKJO1,R]4ETB@@,>U5:ILEQ%8'+E$"DYU;V4,8UJ$>[W
M(9<+E7:5;)3:S9)^SC59K, HB:R2$S9Y5U$6F4<&F:G&=QHA8XQD\=Q-2KIE
MSH0(Q;7O4K4^2<BM:40FKK8M_<ORUEEY440=?0[G;U158:GY1@,?J8JW&NM5
MET LJ<PB@H&+YP[B-#DAG%_<3KX]35BE=.J.SM2NURKC?'[IOIHL1?6:JV_.
M]KTUZ-QNT92=62 2)%EH#:UUAY"*V1I8H)U7D".%%IUM,1R\,BFT.9-VHK*I
M.3L$R-5"F(X.=P4J!RF*J)# (:5VCMJ_:MWK)P@[9NT4W+5TU63<-G+=8@*(
MKMUT3'16153,51)5(YTU"&*<AA*(#JG1_=D)[;33J9:JR!*Y YMI^1K4I6\2
M2-(IU]VQ5S<>UA%\B3-1AH5"!:EM$>DULUAJ#=$KR0@$UK4:$""6,<)O[)6#
M^/P!#%58.8J">W7+$O0XQVR7C5&.-YG)]LDZ DWC7*2*[",4K+I@YAF:B90;
MPZ[!-(B: ))DC=!S:=YN:>K72 56>,HWK+0NF6)L,<A9U3K0!K%,>O,!8BV?
MFU1@L&+Z=DQROX;1QCCVQW;=DPWT^:V^+)I%6B$V*B*]EZ[Z[I,4TK!?+P3*
MDT%PM#U,8U3NZV=?>/VQV!/[QL\_'B?3 6X7<=RG&%':;9KW)9=FF=X59T;F
MBZ.:O9;Q%,$1)S#E4 B!I(AB"L51+FN7((E(H*IM/_>/VQV!/[QL\_'B?4><
MW)M&'*([&)$Q'1GDWBO=]64A*("U(#>'Q98R&5*/-YIC$8.B\\IE#"842@B!
M.>J2T[^?&IKCC^)M=+'UZ_MN[17G\)_!T^WMW].\XWLO9*"]_N[#6_2>OT[]
M=7ZI[C\Y[Q^/ZXR=S+R[-_!1'S#S2[I"9>79OX*(^8>:7=2N2&)L7ZBZ[2DO
M/5M;RWJ2OP9_DCK1B_477:4EYZMK>6]25^#/\D=,8FP'D*%[)CO,T=8+)Y)<
M?"L?I%GK/ >0H7LF.\S1U@LGDEQ\*Q^D6>F,7=08Y2F3-$;&]S[PAW9%#X1R
M5&I'8B(.@5G*K(P*0)B!R#S3GE"IK 41,9N=8A2*"8$SSGU77RJKCH]DF5V(
M'>IC8W="J &C^MP/A5D2J0IR<T!XG252=*IJI@57I2FZ(45@.*9HG?'(:+='
M'U'4[*8_[44W>/\ W]9H[,O'6[$OQ&C;*/WQ79,?S=Q[_LQ)V%L3U+*N^+'
MG>]%7\SXCLS9%\Y;G6(VNNU_#Z@*F9($3%B99S!..>50A#F.F*!R%6:K<;#3
M_7(EV(M](MM04P87O#R@F^B!$JP$LN.]I%];&,R*BFMT59R'0W:QG@" O%CC
M5VI!.! (44E$0YIFYN?.L_UR)=B+?2+;6+CXPO7$J.^D;+=(B)Z]@5N;X+CV
M_"%P'7[.ISQJX\:A!'T7<V2XC]0AL;0A'X?Q('K]F+9O%_\ W%^4&J[>3.46
ME,*Y9N"Q5^??]W&Z:X%4<-&[15=%WEN<BVRQBMA%)8!;PZ:8+%]"'1BB0131
M((V#2;U&-CWL@X.":#%HY>K',4YP(DT04<J'$B8"H8"D2$PE( G, "!0YPAJ
M ')7L>Y-C>$'@E0*I9X>9O*W<Y7!$SK7BU3]G,IS'0BL0YR2:8F+QY@"'[&)
MB"!C>K$>6^U8^W2]7NG==^\%%G2I&>O^RYD9];'EM*4?@%+8LZ[_ (T.URQF
M8_<TXRPW_G^#Q:HCW5X[L.TNPWW.6/HQP_P-N.JUYQOGBC1INYVT%.VN/L<7
M'V1@4B8HQB#V2?B_BW10(1E+KS-?%5%I9XXK2]S3=25.KF0<>35(M\6VFJS:
MHZ;@YJ,>)E50=L)%V^;K$X& W1JDYQ5FSA/FK-G*2+E Z:R*9RQ/-.+1RC5@
M%6Q]G;W6/^T>/;<1\F:_9+ @B&1U/JT+R391V=0H)=FD]@D$L%1!TO@/,_R0
MV5U>PIQN>*<CUSM!S'CS"\4[C1VR$C].9F(1M=98!6TTE\9!M'9U4,$X43P9
M''8_81L^PC;9+&5264';908Y=1%95=,SF#I3:"=!TB_[*)RN(U4J@&](H4Y
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M86BM2DTV*F\8F,59HZ2;N^Z8V58+%3?1$JR,8"/8V10;NVQA*)T^C434/O\
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MSJ-<8I1E?JYSP$)'(<>B91421-DR;D$PB8PD01)TBAA$ZJHG5.(F.(Z;./\
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MB,.G)OU52<[N5FR=/%"]$W.(3UB2E(^GR$#@0D@S(0.L>!2PD44H (B(B'
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MM8K<M9)EP5I$5^%?SDHZ/P C:-B&"TB^7.(B4 *BU;+*"(B  !>(CPU Z)C
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MX0.X,7B  FW*H<QC%*4HB.J:]PN3.4>J_>LV0GI,2404&41;,A8EI498G2;
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MD4GBK-!J]711EDE>]RJ#]+NV',_8).F2R3MFJZ3=MU"+($,#;;7J7=J'0;!
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MVW6JQF(]Z.ZC$$24&T(.+MD5UK+0HD3($96:O9\)NCIH%<GYO!*C0B:QBMD
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MKUJZ['0S88:X(&C!#YX'\.=5H+_Q3Y!\3],W9:3X0*/7W="%]^L7O^:W-O\
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MW*Q-ZD<'$QE#W>:QM*Q^(&%O?,3TEO=$\H*J+-W]9:S#,\I'N4HP7<HKW/&
M1%X=4Z=^^D$X?]9$@Z_(BWLC[,BV^_\ \AU>+6MLM/?MVW6J6W^SO7UGV<81
M059*"AKFC8%IN60D$.(17$>,3V?EW/48KE"T]['5K_RGJ4_E"'Y4'3W#&&+H
M,F!,$,,*!'KJ)^]WW[8PFR^NP]4VC[9X& C9&(BF."L6]SQ\PU%E+H'=4Z)?
M/#2S0>MO*+OG3ES()#UE=K*@;KXZ?^,\HV+M)I]"1>EK2+&>4;%VDT^A(O4U
M50-6K6K#,2-="4#,# 1(I6*XF B9@8F!]AB9@8]NYZ[R00J$)2F.IA*EJB8'
MQB86$!'0Q,P,=1[#$SU].\6M(5;\DM_A7WTB\TNZ0JWY);_"OOI%YK/F7-N9
M,8D/*G+PYQ(U\<O.]+SB-E3%YWWN(!Q^]JBWDQ*J2'WI;Y8]1G.HP>+IJR4#
M$;:3;*-VU:H5HSYE&YV:%0*=NF4G?2VHHS3(&ZRR*T*:/<\2D61*%YT_Y"FN
MR9'S-;2DCZDE\&3Y(:B+^J&]?T]Z72N=2^R[TH7YQ9&Q6)/I$?F/@(,]*Q'W
M61+4*GQ@A$HT+5&+-K7V99X30:YGAX>7JPU,K\)+R'Q$3]-OZ)]FH/:)&)BN
MS=B)J_O"Y.*[@846Z^3\W8H>J=()"*ER'AU_-1[<X"X2*?GR=$0%,G0KB90"
M\WFG @&EIG[,#' 6%<CYGDH"7M,?CFJ/[2[@(([9.4DF[ $Q40;KO#%:-BE*
MIT[EVY-W.S:)+NE>*:1@U%7E%E2P-/VT9(']C3Q;O6VU61ZXY_1]#$V*VN<;
M2_..+EJ4$E&=W,FKSS'(8@B4Z8D$PEW>4JF))7;$[Q17W*K.T[E,E8LVV5Q=
M X$41/E6[1D39'( (\#$94AI:'B_.X)E00.94>C X#&/LLU_Y6L473Q4G95^
MA$YESM4JE7@0+[IR=C6^(@78F<^,S[S&:;7%5G?&!=,$%W%?=@I]1E$*R8@2
M]BDFT^A&?:2F(GZSCX[:,\QVYK$F.LV1%;E:G&W1K<A:0DN[8R+I%. M3JLB
M[1DHP1CY&.E#PQI.*?M!%!W&NVJY!$#\=2/\7CU7CR9;LX;/L+5IRL==]CA?
M,&*7QU0YJH*XRRQ9J6B"@=$D4#BQB&:@@0G-#I.'.$0'45N47W[9O89BJO)[
M[!H-E:=W>3(<LI;[N\%->O;?:0^1,MX02P*MW4>TL:T2(S2<C.).8VJQ:L4\
M/"V"<LE:B5[GP73[7F"=17KG7^9L:A&RV5^VQ=/7Z^LJHM^QV6P?UZ52G6[(
MVD(E/<@A"VN8I1XW[M&LTE39[ F-8Y%( 375#+=Z_:6$+J4ZP2/JV;#BF 4/
MB(Q!&9+4LS&UR]9)Q9CE:;?96O=!HU?>P\4W5=Y!M%=K$2Z054FT5T5%;&^8
MM7"*Q5#(*)\5"* 8R1BFXF+JK65V[['LOJM6^T+=;2JIF6JR1Y/'9:#N&;7Q
MA65UES/ @HBF(7*0=P-=<O%Q4(G4B-#MEU  R,DTZ6*7C+ <DML-HE_QM_TE
M^ZA+<QNTSO)F84Z&SGG?ZGQ,BV5'HP?5K$&/7%NBKQ=$F+I^W1%DG*2HBHHR
M%O"0O=98[3H;GN26Y&&G1M&K-]3QYL_N>2K.A4\.6V/SS]3&ZVB]G4:]QUZ@
MLLEVN5AKI8CK+LREA6<%*27%VF+<6KIT@N,UR'@'P3Y"H=7R3<[S=/7!J5NZ
M/$Z@T]>UI*([&KLV=_0Y"L <A#8M5U:^U)5TN"O#%K&)SB7Q)^,7#+);3B*Z
M>B6TU-M:>QR)Y_:BT@Y85]SK@U%WC]X"1:M5SIW?M&I*;5E!LE;F^7-;C=XM
M\K.U'=;MCW5T]W7<W/L19"AZG;6#42U+*RDRAWF2<L3Q[0S-I(. =BY0=L$R
M04DJFHS=%K$T(1!KT:[6(A_BR%ILE')J0+NA1=9D(A<IQ24B'%:;13N.6(H)
ME!(9D=1L8J@B?K]&(FXCKY ][53WL<G_ (MDMNFXV7:[K]E=WF8V(PWN;L\8
M\?Y.V_SCF98.5(^6F5G4E+QKA:#8OFSBOS;Z:@[/%HN"5*>BW"+FJ!<G3<M9
MKV%H59*]RKW<7LLM3.(>8\S)72C*3=,@)ML@ZKX.3@X5*K#N8]RV781;Q\M%
MOVBB)Z?--UP\%AY!R/1[_P"#MZO:Y3LSYW\-]W2"KH?B91KP\*=*L]_\!Y@C
MQ"Z%RK-J$;6^VDB:8S2;LT^-LKY=)X\&C^./(=U:X-IJOP\^(NLT^B;L?AC9
MMS71O]V=WD+=I8^'=AO== 371JKNOXX>PL3<.S<5H+!?)*U8UVR>3L@;3*MN
MNV@+1[A=M>)F-CHF1!58%(^'<]$1Y*L0,0BS\;QCQ2 8MS@ %!V4ZI@,)C<Z
M_;:?A0V!=J].I3YF1G9WD06V78H H"AK=9U&\E)H+]*1,_/B43LX(A1* )(Q
M9$B<2$ 1JAY2'&$)F:ML=T^ ;C3IUM X MEMN;F)EXI:4.7$L8%D@70P:KP)
MU:4D&196KN$>\IUX%2'24F&Z*394"7TMIU"SXZC;(U$#-K!6X2<;& 1$#(2[
M)C(I" F32-P$CDHAQ33'AXR$]*',?A%P]VFY=RRQ9L_/:K2UE:;@#Q:E]4.*
M[>_;Y$WY1RI*'B+K=6H5CR*8*NVN!>B  /:/C_\ %?7<GXOPOCE&BW5<IWB4
M<X^+B&UWU+%CFNNJ3P2J-NN_P.JX%\>V>S92],1$=M4N'$V;+3+O \7XS?&.
MF#S!]D';+^_3-?R$9DT_@>+\9OC'3!Y@^R#ME_?IFOY",R:_1ROTI_R;O]4>
M?E''\+X@]X/BU[KPOB#W@^+7NL>,-0BWM;J%=N^+[XE58JV.LIKXMMUIH4DW
MQQ:[+1HR2BC(1J+JRVMI&'I,.^:.GI'T5 VJ>ABV)PW18)J]$Z$^INZ0+55:
M[>*U/TZW0[&PU>TPTE7K#!2B!7,;,0LPT682<:^;'] LV>-%U4%B#UB0XB42
MF I@T[Z;3Z=A-.P-6RU1@JP02?I$0S'D,"82)QW]P^R],NC\&=>$X+0.;7:N
MNV$.,"$&R,EX3,3'E$00S!1_%+[WC/1>)=>,Q&V0W^X6RH94J61K)DN=R#B?
M,,Y1[*RRW'XT3NM<*XK=5ML-%/+%B C?'UQ8.8BQMIN*G(>/C'#1G*DKDDU7
M<P82LE-C36XAPOC?!-45I>,*^I 0;F8D+#(B\FIZS3,S/2A6Z;Z:G[-:9.9L
M<_*+-F;%B#Z8E'KE&.81\<BHFQ8M4$G2UYUJ+%:C61;9ZMA2_%C/5-TE]XI&
M"<P5FXQ"1$VRM4,*),4I&84'FFMJ:R5//S: ^)%YDR9]Y\>V' DPH'J"/P"#
M*)(5K&8 6\RO]CVT]G!YVUTX0>+\9OC'3>Y7^Q[:>S@\[:Z<(/%^,WQCK>S9
MSW1HT:8S&LBBX240<))KHK)J(K(K)D52525()%$U$S@8ATU"&,0Y#E$IRB)3
M ("(:X<^+,9JQSN'5QY1E8E^X8.WT6I4:Z>.>.HM0ZT8Y=L1C1:N'$<LH=5@
MNLD=5FJ<YVQTC',(]YHU@;6KV)B7UTNF!,(]50,Z!@^+ CS$ONL'[IC]"&9B
M8F)F,V47+=6)BM:L5X(ULF$/8KMB2@U,GTR'LU'$$L_T@+W&8GWS\E*4A2D*
M %*4 *4I0   I0    #@       !P  X!U::",^SW=?WHL8?[;9=T\.F>C/L
M]W7]Z+&'^VV7=;0_HL_[$?ZQ>:\?QOW?[8QQY;UU7^VA^AY?62?\A379,CYF
MMK'+>NJ_VT/T/+ZR3_D*:[)D?,UM>,^8R6Y"NQ$QBQ28D,1O,W2=&F:[=:M0
M(V1<1<E(66)?(MV3QFZ;&YQCQK9\\>*MCHNTG;=%5 [183E .5SK@.&W18%G
M*#/D7JUA>/G-KID\50 F<<Y'CG[F2@)IJ\:<\Y'4)**'CY,S0W!W'J2**!R@
MNDH60UK8-Y6FV*,=S;^M-9&MRS)S8HIX6.DX%NZC'"*TS'R!BG*Q>QB1S/6S
MLQ3%;K($5,40(("P^TG(>.[OB:.B\?7J>OJ%(<N:[)2]Q!=.Z.3"Z=/(V3L*
M+I-%PH:9CU4WC"0Z,4'S4/V,XK(.4TI"S3^U..O18KMLTZMIB+/8W6(77VB1
M& ,_4FE4\FU2]/P6JR]K9(FG"%0NI7$ZT]_8UEZ*4KY-HS455AZU-B\6J:8V
M) !4&WND%39!Y,*PVKKUUUDA==UAK&-YLHS]/YCKMCJF4&98'/\ A0T=C7--
M<4 "*'L,2YEB,+@P#CS7,)=6!2S#1VW#N7NLSU)O_8H,U%ID2WKJO]M#]#R^
MJTMY45.;=LLU_?7CAN"J-.B:W2]RM2;G2:FR#B*?GCP[*;2ZTRNK30Y'N!6*
M.KTBZK0S1 !%HP707E=2=TN <N0L-::3E"LN8IK:WL0\+/.5*;*LI*.B7Y'K
M1Y!7!*"FFRC<SIN!C*, 1.*@ DJH)3@2G:O8Q78S2[.TO[1HB,I:]@+9L]<7
M<5M@$%,>HSH"KWO".@N):?B"G(\O6EVORK6\=W%U?VMK0&4.LM6INXU)>0T]
MH E(^H[Q JNRA<=+OUW,@ 0^MY2#G_(4UV3(^9K:4D?4DO@R?)#36S>5\7*0
MLNF3(]!,<\7($(4+G6N)C&:+%* ?VT\8B( 'WQTHI9:Q:"28#DB@\03)Q_ZY
MUKQ\T./_ 'I[&IKYJM_*$?YY?^]EB^<J?RJM_GU?[W[8_ISJX+UJ\[:GOIA[
MK8)Y8<=FL_.GVHQ7K>!MNPI%,WN0<K5]DE/3]J3BTJ^G)7AXN6.<NY-\X584
MAC87K-DT8F*X</GJ#=HF0Q0,MSAX YL-FS$$YW%/1F3:(XBIJO0\G'.3VN#:
MF79/^G>-53MGCYN[;'5;.$510=((.$N?T:Z2:I3IEQ#L=>;6H"]3-Z8 G)&R
MDFJ%D=@3%P<F$''N,E$04>\=YA#:ZMCVU0V5 [-> )]<;E<GI%L>2Y:J&2:X
M9'N$D,04>X]XY$MZZK_;0_0\OK8F/),GV>^\T6TW$IE?%YW,&)<CT$03F.><
M?#.M>A)WJE2<X?[:>+G'*'OF#6>5RQBY2+D2$R/03&,P>E* 7.M<1,+54  /
M[:>,1$ #[X]? .(ZR_-5OY0C_/+_ -[,_P Y4_E5?_/J_P![''8>L67X(V^9
M)K!%^HNNTI+SU;7#,LL8N(R9E-DB@@8K5N AX9UKJ$$2<0ZY0/$/5\75K!'9
M8Q<1)R!LD4$.,C(F#C<JV'$IGBIBB'&3#J$! 0T^:K?RA'^>7_O8^<J?RJO_
M )]7^]G<)?7$^[%BO/IG7XFO587MMG\P]UP:65\7A//51R/0>8:'C" ;PSK7
M 3D>RQC%\J>,"G*(_>$/9ZM,[E_>;MDQ3+U&(NV6H%F]EW1)AL6&:S%N;-XE
MHX&+<R<H^J,;.,89B@_?-6ZB\JY9E 5!. &2(H<N)VQU]99.L7J:%#(P3764
MJ6,D4",$9F(QY%,#'<^\S$1[SFO9VVKII*Q;V5"J@)&"=8N5TJ&3*!""8Q@A
M$D1"(Q,_>(HB.YF,E;*>39'\!=^;J:V4_4$_@B_(#3:R&6<6J1SXI,DT$PG8
MNN9PN=:'G<YNIS>'"4'CSN(<!#J'B \>'7K93RSBWH4P^J10>/1$ZO#.M!U\
MP/;E-9?FJW\H1_GE_P"]F?YRI_*JW^?5_O?MC^G.J@O22G;DKYP.O"?7(KV(
MC](N=<%#96Q>F22Y^1Z$7GS4F<O&Y5L.)#+\2F#C)AU&#K#V>'C ->%RMC +
M JK]4>A=&,,B0#>&5:X"?O@X-S>/?3AQ H@8?8X"'7QZM/FJW\H1_G5_[V??
MG*G\JK_Y]7^]^V/Z<<F0]6BNTB^9/=0]WY8DFLHX*>/ZDF<]SQG-,<CUPK9,
MAWS@8))R669LA,8A@=&BUUW[1)(W/=/HUHU*!A5 HR"?98Q<96,$N2*"/,D2
MF-PN5;'@46;PO$>$F/4 B ?CZN/7KV5RSC T9(E3R10N>9@\ O-N=:YW.%LK
MS0+PE./.$W#A]_AQX!Q'6CLTZ_:Z^YK;-E4)NUV5S('+@P\QF!8N?+V8HO%B
MY_ Q&?PS5N_9]^G8I/M(]*TDTE(O5!#!QU!A/E[&!3!A/X' SE'N]JD;BN49
MVM0]SPKEZP2%"K$]M<LV6MIF):I1ZYG65NF$]S6/,MY&M&*<YW*WQD-%7AUC
MBOOG>'Z7;*^E396T,:Y*/+,P>J*),Z\=G6Q7E/-OFZC">>[MB+)UYEO!.FY'
MO-9+;]K2.+U:)BK;)NEQ_#8AOK112'&,WUSN1[3AEO$95QLDQQH0N1LVV2=O
M3=*V90<3EVN3<+L:?='&;=HN>,;8_N,FV06M&.GUSJ[>GVIRN<5Y!5$JTBXB
MT >K*"Y<0LI'&BRO 5>P[^"=+J'4Y6Q<I=E'#C5BAFC"M.6=/73^+C9NF9#:
MO(J9=0[7NB2.T;0"-\$B1$$5WIC]V$;E;AZ 1Z%8"5E'+?L=/RO*%6%-JP"Y
MW-*JZ_J]@$>(+M>5$+#:3W3UZU6RI< V9A+&!(S$$')T:M,JWYRHJT"!;2NL
M[5"V'W078(JT-.HULR,,38 !AQ>*F,&1G./MFR"T[F,X;R\[;E<*7"CL&&)-
MN=1VCL<1Y'JE4S+&2%7KL=N2SC9*5>Z#**.*EDRX;B'T+A>;L<B\;#9(7#<6
M=J=U29A%[)*&RC:CN:J+?-NU;<3C^EL=II,>8\=8VFH)*N#(GR7+PL0^GW-4
MM:-UG\BV16C.3/:>Y>Y3I=*/5XW'N+XJAR%^@Y*SR3'H#[@-SVZ2.C(^"L>)
M-M.,[7%MI12UNLA0+JW2-:DR$.@HQ$99.P-E7+;K3;H0]3>'*KS%Y5F0QRZ5
M!VW.Z0@S+B[E"9J#5570:G9R]QB7L7SSHK&.OT#2[IHIH <@\U!1DX,'2DYR
MRAD^<;TWDY;-;0I<;N;/5.3*W-NOI:LK2W#,$-:AM&(=802R^\QT5A+RB%0V
M.RCT?(@OK.*NJ;>U[52#&6K%.A-@&CU,(JWF*8U)++[QM] 2@HA<,B9*.RVW
M9*MF KI.;,LV/>F.U8/W&$+HN4Z3.R0+EN\68P"2JJBB94G)$W!H%N*PFC)!
MO)5$YSG0A2.+1&/D]G^!M_F":HISCA[<5?H:);6K<AMWRR6JNG$I7Y3POJE3
MND2H"7/6(QF^];!8$GAD&RBC1>660[M9,7A3HN&I%]6-X!SZZ+BY)+<#.4JJ
MW.H,.@EIY/(5"FXFX13%DHX3M,>:O6&151>&9-Q">BUVS9PE)%,NS;':O4$T
MM;B6VLUSL:2_3V56G4B3T]W8BDYBE[?\GV[=:Q;K$ZEW"Z[RL=VJL#YB#E%!
MXN/[64D_67%V:]:M'GKK5TZY3\IU'\$L6$6+")94[@$M)WE8KP!% L O.5<%
MPYDIPX^7)7CQX>/N@?%P]CVO9]OKTRT?^VJMO^#]CS^4K)^M+;QN6PIN'1N)
M\07,+7X-2C5Y,IG@;- +M6-H[M=5Y^1"RPT.J[8R[>/>J,W;0BZ)P;*<XY>)
M.=LLU4T]U5LZ0Y"<=OV/.'/.4O'_ -I>32=7.$./HCD+_P#,8H>,P -_IV:]
MQ$V:EA-JNQ9>F^NT')9XM@"\&+(@+Q,2 NBGQ(2&>IB8BU4[E2_7&W1M5[E5
ML%Z5FJY=A#/!DK/TW*(UGX, P+Q*?$Q(9ZD9B)$Z-<C>[0XIE1G+,SK<];WL
M6U*HRK-9:@\FIEZX<(,V;)FF8032*HY<I&=O%A!O'LB.7[D0;ME-<UB3)9\F
MP4T]>UYQ5;!5;=/T:U0"LDSFV\=8JZJ@#Q..G&*:#:7CU6[QFNB\*U9JE.JJ
MT=-&[IJLF7<&I8*J=T0B:RVBDSAB_(6%$3':O/UO#[PQ+87*H(A"3@R$9PGL
MJ8;!6K-I#>=7*TI4I?X&D"D2F+/I?+>IV)E")=#R &,%<K69"Z>C1HUK9O9X
M(\ ]GQ@'4 CUB/ ./ !X!Q'K'Q '6.H,V3>[&59*ZK36)KS"EB(=U/T+PED:
MQ6!R/#1F4H/$4J_32EY%%S1T4K18HEY'#=6\:66K3M.=0.DW*J1.5.1L9U'*
ML&TKMS:2CR*93<98$$HBS66JN2R4294S-0\C59:&D5FY>G5Z5@L[.P=<XO=3
M=8$T^;"Q#;-N <S>9;):+5@*YSV0Y"-DHB2MN.K)9E20U4O$59:?BJ496"7D
M:[$XU8Q+1\U/X,U]&Q-K8\3O7=TG,M^!Z-RVSRU1UU<>KM$#3=GYNJ%*[(M&
MDZ5S<J7P1"_"SZ T0K63&R]ANNL17I?(;;IW :? G+M/Y9:0;%6-;'R%YFRU
MPF@MI4%OV=>U;;,M]2G-L]HR[365.LI=;6HM6]G]J:%]97<::OX7A<JS5%=G
MF+79H"G4VBUFX4^XK6JPW"THU6GMHNX0+]>H"SFG+A-ZM)'D!;13$CDSL3+H
M"B9S</91B\PT*,O$9&R,&=P^GX.9K\N9FI*5VS5.?DJO9H)^K'KN62ZT9.1+
MYL1TT74;/6Y4'J ]$X( 0W8;2\OQ&-XVG1=RQ@U7ALB-=P,/$-JY8V-7B\TM
MLU%R:G78X4'BBS+$"%=,O4T(]"++8"2:AK.!B$,,-J5.WO%<AA_&;&J3DHRF
MK*^L%UNEJDHM!PUB%;-?[=,W*;0AV[LQG*<1'O)DT=&G<\QRX:-$W3E%!==1
M%/#Q^[S"SN*0;:E8JZG\F4':FS&N,OMV'(ADR^H*C-Y@3_-:JZ*0J 2%2VS$
M'FY7KOA[4X[L6:'95+V]_+6VNC\I.X6/Y+36LDCQJ[ WJ756T:OIM?;L[,G,
M,&.<B)((&9FV"8,NO*/8$W/2[F])W==@_O,M7V5A:HTF;N.WN*@H?%=C?QIX
ME282>0+/(,N1RUCIYE%2PLHD9!@KT#P'\1[5R;FU7DWMR>*=_,1GY' &W7&%
MEO$QE2D90/.WV/?7S+%:D,;P3^C6(3.;)#N9L]D6;SR,R:SD129MG$41D@9^
M*5REX_;'8$_O&SS\>)].O>JA!7JJ3-7L5:J=NC)%MSN\%X@V5DJSR09G*]AS
MR\,_;NF[QNSEF[)Z ="99)1 B[4R;E-(Y>[ZWG/(J<5Z=C<[-FF?J(X]L:"W
MI\7<?/YRHRDH;=>W56U%2U970LMK.92(QE4P 0.<$O\ %-+9@[*=91#9+OSN
M:MLU-B0VXL2\;+"KN0\P:ZLF;2%N6%D1F&1)3Y97UA:Q1&)M[.\^E&61)5,K
MXXQ;O*J2Z*Z8L7!0@'6-,GNFPF$B*I7$E4JO,J+$5*7^VO2*&]&"@=[R8<<N
MSV,8!DGA!*_ND#8\F/U#<X5'#K*%ZM-^,NJ8QSF.=1*PHCSS'.)B@4></CU1
MCGK>2M4'=.D\PYUP9D+>IBC&6[7;%N1KNW]I:(ZM149D*GV1;&9(TD]&1B4J
MO1,AP=7AKF, Z<H0,X_,DY18G$YU/I5VSU(M!VZ8&HX(@@:H8;QC6U4@#AS5
MX>E0C)P(AQ'@8SA)4Q^L>)C"(B/'7)OLNYI>8;317%D!:0=FVNR5O!=RAR2Y
M0VM*]4FPFN;:#_1LC1L0H <A7D,1'M&'0WZ^QMF58Q(*:[DD$&HV(/:/JW2K
MO%+' I]5R[%1J?4*4L0:YF9&<BMC(35CE,MS<*4O,;Y7VU8(R2EP*  N]Q]=
M,B8UDU>=T B)TV[R(2. N2\"BGS4#!P,G8HMZDK\&?Y(ZKGO1#U?E)=L=A)P
M(EE#;QNAQ<X/P#BLYI=VQ_DN-;B84%!$R;=>67(7I6X<WI1YZG#H3V,+>I*_
M!G^2.MC3_<G:UOY-N;O_ />A.U_[_M#O^?)W7_=F\G^\[&S^'7_.87>_^KQ+
MA! L!#&$0*!8F-,8PCP "E:(&,(B/4  4!$1'J .(CU:^?O:NKWNR3L;S,KS
MC+;E[/RES*1><.D%T-WR^UR=4"*KB,@8P&9T-4S<HOT@$G.$A3AW09:[;)]M
M+0=OM_O1U01+3,/6NUF5$_1]'X/TF0E0/S^E0YH@9J7@/3HB!N'!4@\#!4P>
MD#C+:=R.-D4*8C^A9GVR-9AQP$YD6^<J!8*]8>F/S'IB@YFK:R*J<7"13*F(
M'2 <R92P_(^YV%!L?37("\R?P 8Y!QYGE^R9K5+H]SU$C)1].\C]O[VJIQ]*
MBQLG/]S$;74GW^^4HL#^Z9]LO+/Z4W_RC\0ZKDVG+#+[E-_-B%VZ<@INRJU4
M(1PAT94"4W;%2&(IHJ<0Z5(BSU9)/T/H4D4S\XW3>AL<'@("'M\0_AZOCU7+
ML87[X2^[>;!RNZ+,\H3N&3(9=+HA22K%5KE/213$0 5$4R00$24$ X)D(3@(
ME$PS%_[VST0?W%F]9F/V+UMFOW^E'TFW$?0OK^'UR0M?>NZP?[EUEW_N5'*[
M^O\ ^/\ M^O\^6-Z0C_7(EV(M](MM+ND(_UR)=B+?2+;4SDAB[I%C/*-B[2:
M?0D7I:TBQGE&Q=I-/H2+TQBUI"K?DEO\*^^D7FEW2%6_)+?X5]](O-,9GG_(
M4UV3(^9K:4D?4DO@R?)#2;/^0IKLF1\S6TI(^I)?!D^2&F,@)RH\>N\V(Y^D
M&@&[NJ,/5L@L3D,)3HN<>7RKW4JY# LW$ID4X-4X""R8]0\!$> #Q^6I5KF[
M?#LEHC !?5S&&.LD[PK*B10AV_=+Z&88NQ,LH"9UDP4++VZT23,>D5 YF!CI
M'$"=)J6>Z.HER!M\S#13$Z0+AC:^5TJ8\>!UI2GSC9L'4HD/KDZ(A^RIAQ .
M)R!Q,%:/)(SCG.JN3]S4DBZ522QGMHVQU9V]Y_2D1PUB2(FLCG1Z0ZQA1D\C
MW-\L<W2G%7N))10QC^EINUB2Y%2H]>VW7K3/KZBGCMR[M&E/M^@;7U:Q_K^8
M&)]I]Z_>CO;5JW7<7PID7[%ZBQ8NG,_]4C:A)=^T^K$3]<>W9E/QF,H[?!$2
MYC-H;#&[W<O8%T. %!I5;9"U3-*!DQ.DDET9V]ADU2CTBW >(J*)E,0@0_Y!
MJ@N,A8ZS]R@N0D@D\P;Q<U7N3";=ID5<Q.-ZM85V<778MPISUV<<I8BR::S-
M%0J"D?7*LV4*8(=L"<KJE53S6ZWE,L*MNB8FRWC7#]^BU%B"#<5[WAFPX@DW
MAR@S(F<@2E3;F<'%RX$_67HP,540AMR(.Y+$&%^31G8K/.2,?X39;2\PY#QK
MEZP91M\%0J_37=AO02%>=V>;M#V*C()*<E[.:N10R3IN+^:8JQS?GNQ*D/7>
M#25?X3\VFG/5M?)='H[\A^F''T[/E,BN9B((:[]CK=++OXI,75$OTA@J_P!"
M?)N+5K'4UZE7EQTAG]&=E2O4:2)ZF?[:K5.NRJ.NX!CBB9B)ZKIY<V$5<[N-
MT-(?UV2E,\[F=F/)S8TY/15*">24S9<JX_Y1B3MF6JGB:62[F39W*G%E*1D^
M\Q<;*,)=E16 6B0<-X1H=8O,<M9ES$&7L[;B)SH9*]UV]<F)O%V ;:$I"@6W
MI)CE':-O*Q]$7'#^+XRP0#%W(96DA2I\I4IFKH/F]SK%6DY2E3LQ$1[E1W:Y
MD;E5=Q\/GO<1MXK^WO$+>]Q6Y;9=MUVGR=FR;+3%1N#+=A3LV7]MFO+$_3XU
MVXA:SX%X;EI2$HM.BU[(W6=,8R7L+SOD9Q&1;J_+^9FS76L>Y PGM/KLY3\I
MU^E8KJ,6O.Y!O>4(O=U;MF"6]2430QY2:D22R!AK']-),5(T=4%6.6\C3T*<
MU-8,E)N-BQJF= R_K*FWN-W$[3+!MXS,BA*JWW$;"GV=ZZ3*\48W)*O, ;6E
MIQ>O2C*UVYM&UCC%PD'8IR+!%0'C@.<LI7!R%62);+VP9YAC+"#>QS.W7)N1
M-N%@CI]H>2*_K5?5:2<+%3",IW6V>H,8V=7K9&@BHW;QL.R:"D4$BB+][2N4
M099@IV1)?/"F-L-W3$V*T;[=L4.9N1@\MLXS'Z$FTS/E:1Q-<E&60:;B1&U%
MC*K5D[1"I3T#:XVWTNW/U;-"JM48N_U/=6)I3:5ES-DNW79-]QVZ7+F4:XT7
M0%(W@\"\=7B.@-T@@<%YN-G$0 J1"E[C$2F5*<IB]!UD18^&/,478@Z5?D?%
M6ZT6C$KC:6ZV\1>6GRB8*;&K3Y6UQW!!5JD<?<#NI7)FOSGCEBH1+MLT^]&X
M:BD6?)U;&I=38<C/D,U[[8BL?<2)/?X3[GB3>>3CO;V#ON.*UBK&<56YNYV^
M_0&X^-LITK[$8VEZI*E;X@;TXL>>44<&!<E=XF>N*V=@NJZ52<.1 X66[,+B
M-]V);;;.<HE7>8&QLS>E$. DD8. CH"2(("BAP$C^*<$$.B)P$O#@/#G#,",
M #1$:4Q0,4T>R*8I@ P"4S=(I@$!X@("41 0'JX"/'5=?)U">*V?.\=K )7.
M',P[A\2K)BF*0I)T_.5R)')BF+9KS +$/H\2%Z+J3$G7Q$2E_//&^&:7A6\E
M6E!JD;BCL3:HXK I/R-K7%1JH74K51($*MW8&Q9BSL&AXA:NV!2B%=:Y]\1^
M2?$+=:&SR-B'/U^FV%2+"RNL=<?-G6M=;M-OW;S!=9F#;-.D5/45C]9E#6U#
MLVB?9*'B_&;XQTP>8/L@[9?WZ9K^0C,>G\#Q?C-\8ZC'N(JM<NUCVYUBV0[&
M?K\EFJ1%_$R2(.&3L6>$\NOFO3)"( ?H';=!PGQ'T*B1#=?#AKI2>O/WF8CP
M;W,1W,1Z1]S$3,1,]?2.X[_7'URI9)L!X%*/WB_Z> ?Z..H\87SZ7,*5DE4*
MJG!5B"!R*4V:[T^Q.''<TC(M.$A7Z^]<S=<.X91RDLU3G&S95=DH3F$%4#%!
M\H*"B*U"1E>@(]M$0L.P;QL5&LDP2:L&+5,$FS9LD/.*1)!,I2ID'B!0  ZP
MU#F@[<LF5*VR=L4GL3Q[MW"UO'#A&GT1S6H^RX\;W.3LELL$Y#Q2L=',,CR\
M=)#%0BK KN#@5RO'RG? DB=HWD]<K6MI[*+;5*M1%3Y%C9L=^[618@%IF%R1
M!Z?D;O4A0Q,@DY*376-Y8WM?9Z(M77LVM>4[&-LFN-*!GI"9I&YMJ"<(@R'^
M*:LI)YS$,LJ@ 6YU<);B(?-#M^R;U:P5)4U:@K]5PGU8M4;9CRT2,U%05J8D
MC';D\>#A[ /DW41) C(,2JL5%0.5V'1R(U$O;MM_M>*)562N5B@)PT!C>H8;
MI!*\TD6O_4:ES%BF6,M8N^ \#6:46G4D7S9ATD<T+' HV=+"].FWD-?;Y3\8
M4^P7^_3["K4ZJQRLM8;!*'4)'Q,<B=,BKMV=%)90J)#JIE,)$CFXF#T.L6]^
MRZ]^S.M:$:Y0 8MEC/2 12)-.6V/%D",P1,)GC EYQ'2Q'/?%7[L]#6=R893
MLX^8FUZHUDD( UG@31K3-9<0$?=D"F)3"S84LDYSKM&F>PWG_#>X*&F+#AG(
M5>R'#0$P$!-2%=7<+H1LR,>TE0CG7=#9LHFY&.?LWI2<P0%NY14 >!PT\.H=
M+DV% ZNU3TLCM;4L%JCCN8[!@20%'<3'8S,=Q,?6,L*V+< L4P&K..P8LA,"
MCOKL2&9$H[B8[B9]XQO,K_8]M/9P>=M=.$'B_&;XQTWN5_L>VGLX/.VNG"#Q
M?C-\8ZRY[SW1HT:8PUYSB^/G!P#J$>(=0^UIK\DY':T8]>BUHVUF<7!>4C&=
MGAZ;*6BJ4I9HQ*OX19"D6*C=C6*RQZ8KMS)3#UBR5;M'I#.T"I**IU-%R=F\
MN7PV]NMP>0R1%F?1UO99).2AJ6*>K+#!N2;V:ZT"=@6$G5H3&N1KG7(Y6$I[
MX\A88:$A7C-19%G)K*GI7).;T.-V*55E.W?;=OIU413.F,5]C;4#=?6M?,VD
M$L;L,$0? DE<S$L*.XC.C\-^&FTYC4V=U6PU^JKZS56-\<[%>Q(K>GU]@T;:
MY1^2HVP>>M],B95(UV'0)0@#\9F+MM,]&?9[NO[T6,/]MLNZU]N-YG<F8$PW
MD"SD(6Q7'&E-L4X9) K9%>5E(-HY?.T6Y")D01>N#'>(HID!))-<I$A%(I!'
M8C/L]W7]Z+&'^VV7=6W77$[&A7V%?SA%ZC6N)A@^+(3:%+U^8]SXGX&/D/<]
M%W'<]=Y1]GK[&IV6RU5OT_FM9=MZ^SZ1^:OF*5DZSO3.8'S7ZBB\#\1\AZGJ
M.^L<>6]=5_MH?H>7UDG_ "%-=DR/F:VL<MZZK_;0_0\OK)/^0IKLF1\S6UL9
MH9E>1S*7BG45)-DWD=)QZ\>_:+ (HNF3UL=LZ;J@42B*:Z"JB1P 0$2G'@(#
MUZ@7C&A479M=9N0>9$=,L<YFMM7QM0J3(PTK/RT=<(D[Z+B$G%NZ1^^/$DCD
M'#%@W<H-&$<V70255,=L552P%'U)+X,GR0UQJL4K+U^8;,UF;*7)(VA6!EGD
M:WEB0<X+R50C9I)DYX$66CG"X."D*HB94A3H"J0BIQU*:_8MJKLTC:W[.V(K
M7?K :P%L*8+D-@FU[4*8AP <.6F7>GZB@*!:7=?W6CK[!U#:J17C>:1CGZB\
MU;F'7FPDJUQ$@BYKRL)M56,5-9]H:LO]![0*4!UR.6L45#.-8O.*KXA(.*E<
M:O!L)A**DG$1(]$UGGLHW49R37^R&BZ+Y@V6(HGQX]&)#%,0QBC%MAR:VS>#
M!HG-8@C,C2TW:7\C+VK*$C*WBW2*T@Q?O'";VPRCL'KI '3<KA--<5!*NHNN
M<ZBRRB@OMA*Y@$W+8@MV1FV1<RXSJ%4)DF7;0*\$BZ=S#F7D6#M)$C9*--_:
M]ZP15!FJ8XGYJJZ:2RJJ2;\2WKJO]M#]#R^H/:\?UQ7I+8ZZE<>M0 BS9I><
M.IL[?6>B+B ;\M86[YFL1J B4_S\1\RC,:J7'N2KK[:UJM;>LBHJC(N)U^P?
M0=7:P;>LL&H[E8;6ON39K6EJ<T4VA> G/O)0QE^3JV/MHF4<H[9,4$6;QSU=
M(Y8%0#$42;*J)F 0> ("4Y0$! 0$!#J$!Z];J?)R;&S)IF';%B?B)""/]H%/
M&)0$1]>>WJ8L_P"0IKLF1\S6TI(^I)?!D^2&M#\G]#_@34?U;2_X.9OR6XQ_
MBYH?ZGU_[/\ U?\ 9'7ZLKMD^3)V=V=JFI#XR4QF\8R%KCU)+$]@F:%)2<5(
MB^@W<1,/8MR=61BE8TZS4S!?^QS(.'+<Y#MG+A%7IX_DW]D#-1"+/MOQL_(Q
MAHY+NR3BEWT@\63,NV.^D'BCL%';]T5 BKQVH'2N7!CK*#SCB&IJP7K5YVU/
M?3#W6P3RPX[-9^=/M>(XYQ^#(XT>I\CZ\I^SZDQ/41$=#*O&)ZB(F8B)GJ.Y
MGJ,\#Q'BHL-L<;T4&<1!3]E49CVB!CH91(#/B(Q,B,24#'E,]1D)I'DZ]D""
M\.1/;)B@I7,IW.L 0*@ =+O;(K\PW!YUATJ"1N \0XE >'$ $,TER=.QYO'O
METML>*"JI,G:J9@@% $BB;=4Y# (/.("4Y0$!#@/5U" \!"9<MZZK_;0_0\O
MK8F/),GV>^\T6U[_ "?T/^!-1_5M+_@Y[_);C'^+FA_J?7_^'_9']&0Q:<G/
ML=5:M53[8\4"=1L@<XC *"(F.D0QA$>Z^L1,(CU]?7UB(]>L3'DZ=CRR;@RF
MV3%!A(^?I%YT <1*FDZ433( ]UAU%*4  /$ =0  :FTP]8LOP1M\R36"+]1=
M=I27GJVGY/Z'_ FH_JVE_P ''Y+<8_Q<T/\ 5&O_ /#_ +(_HR$R?)U[(#33
MMJ.V3% HIQ<>X(3O"IS057=R::AP+W9P 3$;I%$0#B/,#B(@  '%WCDQ-G<L
M\B587'3['3=YPKLW&XPLTS2(JS1#URG*+,[,QC7!DIM+NJ+9"5-V(DZ-%(!
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MH+&>KI&4YO=?#B*9"E$?'U>/AZ$)HP7I)3MR5\X'7A/KD5[$1^D7.GY/Z'_
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M<13Z3B7)G#N*68O'**K$_!$Y5E2&***[A):P=CY/9_@;?Y@FD^"])*=N2OG
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M-BE,8I4@*(AH?TRH,HN/,SJM<:FJ$5)HU0S>#BT#5E%Q'JMUTJ^9)J089-9
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M!E;+^U&.N6<\'ERLY2<QU8N4"F*BDQ%/8H3SS5\K%E4.Q;Q*S4\I+-H9,7C
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M7UD NS8K;33;&E5A1LNT=K2:L56=A9UU$W(8U5VFV^ZJQM2E?JU=@RH2K95
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M@ B&:3R)6UXY\@BC;#JJLG:29 Q_?@$ZBC=4A"@)JR <3&, !Q$ XCUCIC'
M8>L67X(V^9)K!%^HNNTI+SU;7&-,C5I)HU342M93IMD"'+]3Z_\ $IB)%*8!
MX5GAQ 0$!UA89$K:*:Y5$;803OGRI0''U^'BFLZ543-U5D>HQ#%, #U@ ]8
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MHS21NE(N#]Y*L&#=2)O$G8EZR^,X:V$R#&O65VC=H14TT)B-Y2Y"K)[?492
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M4QW\#O\ 5='U5\>_=3'?P._U73&.'HTWGU5\>_=3'?P._P!5T?57Q[]U,=_
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MFF,</1IO/JITG[8O_P"+=I_W)H^JG2?MB_\ XMVG_<FF,</1IO/JITG[8O\
M^+=I_P!R:44;[6W"1%T5I11)0!$ARUNS<TP (E$0XPP#PX@(>+V-,9V6C7'*
MWNO(IF4.,V8I>'$J%4MCE4>(@4.:@W@U5C\!$!-S"&YI>)C<"E$0T_JE5?W.
MU_YOK_\ \,Z8SO=&N"^J55_<[7_F^O\ _P ,Z/JE5?W.U_YOK_\ \,Z8SO=&
MN"^J55_<[7_F^O\ _P ,Z/JE5?W.U_YOK_\ \,Z8SO=&N"^J55_<[7_F^O\
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MZ58F159'2."CDC9^NJW3Z4"*)<<7\2?B>QBEV_@[?T]9C5+L;1NZG=KH*8P
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M^( (![/#7R%4/DS.5C1SUA/)&0)X'C^E8.Q_C2Z7AIN>EYT+1$MN3/L& [/
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M <K>?E8MU*B^$D(A)*-'Q6SE\\.''@;\@_'Q<?%S>/#[_#AQZO'U:^9')')
M[FX]3<Y4< S-!HN)+LCRJK3!=,)E&\,(^EL]YVQ?;/B#$S,C$T1)EK;5CN0H
M68KU96T8X=(59&TA;81-]+3\A'-8Z[J]A=ZV=.&UD\!&N0MJ$ENQQ)DAEMG@
MY?=K9Z%+S33D^Y;#]QR/?W^!,59FNE%LM:W+Q45EZG.G=4E8K)EQ[F</+)4<
ME/ZS* QGU;W[+&.L7+T%MD"VQ-5<91R%"8IQ^E+*+)'M61+''34M"5**!)%7
MI):2CJ[-NVR2O0I&1C7(F6()2E-YCS+..LL(V]QCJVQ-N1H.0;CBJXJ1"BRI
M:_D/'\B6)N52D!501YDO7I(Q6<@DF"B1%AYJ2RH=>J,<<;#<YYXY,;D9L/9$
M:6FAW';_ '?:!F/<1%3.1LA8DRU"0%"Q#D*,MT7#W2AOXS(U<R:WG+C!I.&S
M*R5>P-N;,LI*;8O4';5=@+GR4F^;'M;R#";?%<8VIM=97EHZ%'(93W*99;3D
M+1>402Q [P1E:R7Z8HN3+AD:\XY>XI=(W6)LTH>SNU;.1ZQR&NJE(.S,9]2'
M.#CPZ_?YIN'BX^FX</\ 3X^KQZ\YX<./HO8#TAP'K]H.;Q'[_ .KV>&OF]JO
M)09_IV48'< 2QP%<R_![GVEA=Y5J%XNTS>8G:F')-0NUF<IE?@DFK&-GI_\
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MMJI*/1<F-9C)63Z?)TAFDK,/:P[:P;"0H]L7D%N_*,>Y141.]:D4.3FG;.B
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%T:8S_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g851047.jpg
<TEXT>
begin 644 g851047.jpg
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M/W89BS.S6Q*7:GWG%K_==(9>PWN R_B.I4^2Q1FZU8DA]S&**R>"REFNM33
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MNA'!(B4O(IXLDY&_P;IEE:.E5(T_J=&F19@X&5>&#[PG0$/\ M^&OH4V, .
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M*AP=@V1;=+?(URO,G"0)0C&8ND]8K0ZCV)B-W4O/N)%4AG+PPDZ'_P "4Y)
M./\ ^2[VV^C_ ,G:@?\ 5U?:)^EX#P/3:W1X_-T\#B]O?Z/OQL_#VV3;=A3<
M<\SK3<R5&-@V5*O=/I>+X^Q5J/KU<'*+S$<A?)J0=!;7+>R3<@YPQ52,; M
MQ=N59+.XZY6B\,XRGI5;>6Y??KM&VEXIG\OYQSOCFK5:#:N5F3!"V5^7MUSF
M&J(NFE/Q[3XV2<6&\729.0C2'K5=8/I)TLL50R235-=PE#[^!*<DA_R7>VST
M?^3M0/\ J^G\FMD8GY//DVL%7B'R7B'D[L#X\R%7%BNJY=:QM\QTQL]=>AQ
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MC86C6O?A"3_2G<?1^I;;]W^G\FCX0D_TIW'T?J6V_=_I_)IM4_2'T'[O'V^
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MD*0CF6D_-//Y1P0A"+OW#E8I"%.!0W7KZMHXJKH]D*H^T1<FRM4D"E1(HH8
MKA6YRZP ;5.\7L=XQRU>2:^M)&J35U)(O>QVSW%QN-CNOTX-&C1K<X\F#1HT
M:88-&C1IA@T:-&F&#1HT:88B'><@7ZH;T,,P,QD&MP>WFP[:-S%PL]8>0S.+
M<MKGBFV;?EC9!M&0Y25%%M7(.I7Z681L$TCH6.BS*SUALDU,>5B&L#HOD_\
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M@1UG5NMPQP_L4Y2Z8WCZEDV*K%UM]CI,Q8XZV2DC[LS-,QC(3R\I6T)RNR[
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M2:R(B(IE$1$?<OB(B/I'T^O4ZLNL5+1WL&OJMTFQ^-XC]6',M>S<3X.BWO\
M3XL::N65<<RM6G(QA=*XN]>L#H-D!EV*0J*F.02EYZJY$R\0*/ 3G*'S<>/H
MURZ"A6, #X@]0?HOJGWO5\<^G[W$.(<?G]>NN5/Q5B]>B Z6QO057()V 0<*
M4VMG6XHR,D1(?*&C!/Q3*0@$'C]R!2@'H  "-L71Z2I(V IZ;4C%3=1H)E-6
M8,Q4P-%HF,"93,! @&,(F,!0 !,(F$.(B.OR?^$GR<:+:?U.A[:3MGH;+*?.
MC1'(\RH,N%JU\I-0*D5^29R93^U8=D8C3A+R!Q+K*4^G\GF?YADD6;#+NXR*
MB2C,O=E--4'X(5"Q[/8UM)J#X5R^L)+\VVK8ZS-VRR$5CMQ/*7&;KT,1ZH46
MQC6*$=@KP:HI?_F+]R)1$Y#  ' !'@(\.'IU)V2RQC=S,UMXC=:X=O'K2IWB
MGNNQ $2.6'D$#"4RX'/SU?N."93"7AQ-P#TZ:N/L=8^>Y!9-'E$I;IJ-7G%A
M;+U2 50%9.0AB)JBD>.$@J)E44*0XEYQ2J'* @!S .XIS$^+$K'3$4\:8_(D
MXD)<JZ9:76BD6(2#=*$*J4(P"G*50 .4# /-. &#@(!P^M<B^3T.0\G&19!D
MXJERS)7K:*D.8U,597.KYC-6N]144U'E\#MMJR15$='"%B5 =9PSMR^F%3-7
M:05M=5&,U%8L,THIXFAA4K3I %2.2:=P-2%22TK78D[A8##?#+BT1X!>:X(_
MVI1I^7^B_-\^CX9L6_IYK?\ SHT_WNLGD+$^+6E3D%VN-: W7(XB0*JC3*VF
MH4IY=BF<H')&%, '(<Q#AQ^Z*82CZ!'3M=8@Q,5LY,7&&.P$$%A 0I-9 0$$
MS" @/N7Q 0'TAZ?7KZMJ2W*ZT=PJD\UNDD?I?T3]6[P\QS+ V;B1]%O'[[_%
M;7_PS8M#T#>:YQ]7#W4:>O[WYKH^&;%OZ>:Y]_XT:>K[_P":Z<%,Q+BMQ4:Z
MX7QICY9=6&8J*K*TNM***J&;D,8ZAS1@F.<PCQ,81$1'TCQ'5FKXFQ8NZMP+
M8TQ^J"%J=H(@I2ZT<$D2QT8<J2?.C!YB8'.<P$#@4#&,(  F'C 64ZN^.S"_
M>MN%@3\;?T^XWAJ;]S;A?ZP/#[[_ !6POPRXN_3S7/7P^-&GK^]^:^O1\,V+
M?T\US_G1I\_J_HOSZR9,48M'(:[0<:X_\U"G-W -_>96_(@N,RNF*P)^YG,!
M44PY@GX<X2_<\>   4R>*,6IWJL-B8UH!6ZT+8E%D"TRM DJHD:.\D=1,(SF
MG,GSS\P1 1+SC</6/%JR[]\>Y@IYK#>=47'..[?A9+\#PO\ 5?P^]SXL8X,S
M8M'U7FN#^"4:?-Z_Z+\VCX9L6CZKS7/F_IHT^?U?T7Y_F^_K,W#$^+&[:%%#
M&F/T15M-<14%.EUH@G15D2$52/S8P.<FH3[DY#<2F*(@(<!'67L&(\4I0,VJ
MEC+'J:B41)J)G)2JR4Z:A&2YB'(8(L#%,0P 8I@'B @ Z:DN_G1\T ]ZV_I_
M2\%_J\&]9-VX[S;L\?C[?%9G_#-BT/7>:Y\_]-&GS>O^B_-\_P![1\,V+0]=
MYKGS?TT:?/ZOZ+\_S:>%?Q'BE6!A%5<98]445B(Q10YZ563'44.R0,<YS#%B
M8QCF$3&,(\1$1'3?HN*,7.8R4.XQM0%SIV:RHD.K3*TH8J2,FL1%(HFC!$$T
MB !2$#[DI?0 < #0+*=6QCYRZW>L-W-W=\=^_P WCPYF_<=WW@>'WN?%C'_#
M-BW]/-<^_P#&C3U??_-=-NY7?!60:A;*%<K)5IVGWFLS]-MD&YF00;S59M,0
M\@Y^(<+L7C1ZBC)1#]XR559NFSM)-<RC9PBL4BI7M4\3XM7D[L1;&N/U2-K0
M9%N52F5LY4$0BXX_DD@-&"!$^><QN:7@'.,(^L1XW_@FQ9[_ #S7X-<?^;>]
M#SCR'O+K7DO+^[7D_+>3]S.;Y7R?\3Y_#CS/N>/#0"6P;63>VKWK7!O:_?>$
M'ZL+)X#N /TV\?C[?%;F[N4VD;0\_P!<G8J%OL%B:>MP7^-N%UK*YIBQRM8R
MRSN#3)47&/7EIC'=8?V%:\3T@,A$/RPKM1TM W&IW>CN7515Z!M\OXI:H-VB
M%YKH(M&[=H@4TLS.<$&J";= IS <@'."21 .8"$ Y@,8"$ >:#@M&)\6(.JB
M5'&F/T@7M31%<$Z76R LB:.DS"DIS8P.>F)B$,)!XE$Q2B(")0X47S$^+6M-
ML+AMC7'Z"Z46L=)9&EUI-5,X"GP,0Y(P#%, "(<0$/6.A64!M\?,&_FMO-@Q
MMSMV[Z[8 )<;FWFW1XK]/O?=XL1\,V+?T\US_G1I]_A_7?O^C\.CX9L6AZ[S
M7 _^^C3YO7_1=.N4Q'BDE:D5B8RQZ54D$[4*H6E5H#E4+'J&*H4X1G. X& #
M 8!X@8.(:IJN),5+UFNK+8SQ\JLK"1:BJJE+K1U%%#LD3'.<YHP3&,8PB)C"
M/$1'B(\?3H%E) UH]ZZW>MX1?XWC/U>/#F>!OJ\7CZ_IZK-8<S8M#UWFN!^&
M4:?/ZOZ+\^CX9L6_IYKGS_TT:?-Z_P"B_-\^LS4,3XL<-IH5\:X_6%.U61%,
M5*76CB1%*1.1)(HFC!YJ:9/N2$+P*4H  !P -?6>)L6&NTZV-C3'XMTJ_ *I
MH#2ZT*2:JKN9*JH1,8SFE.H5-,IS '$P$* ^@I>#5ELIO'9B!WK7 (N/C>(_
M2/'AS/ =P!Z.FWC][GQ6POPRXM]?OYKG /2(^ZC3T /J'\UT?#-BT?5>:Y\_
M]-&GS>O^B_-\^LI/8GQ:E:Z,@GC7'Y$7+F?*X2)3*V5-<J4.91,%2!& 50$S
MASR<X!YION@X#P$+UXQ-BQK7'"S?&F/T50?P9 42I=:3.!5)N/34*!B1@"!5
M$S&(<./W1#&*/H$=-66SF\?,X\UMYU58_&\!(P&H2!SM]NWK][GQ6POPS8M'
MU7FN#_\ ?1I\_J_HNOGPS8M_3U6_^=&G^]TX;GB7%;>I61PAC3'R*Z41(*)+
M)4NM$424(BH)3IG+& 8IRB "4P#Q ?2 \?3IP-L08G%LV,.,,=B844!$1I-9
M$1$2$XB(^Y?'B/$1$?OCIJ2ZQ76COJ@]ZW2;$=]XC]6',M>Q_P"UO'[W/BQK
M_P"&;%H>N\USYOZ:-/G]7]%^?YM'PRXM]?OYKG ?2 ^ZC3T@'K'\UUFJ/B;%
MCJNMUG&-,?KJB_G"BHK2ZTH<2IS<@FF43&C!$2IIE*0@"/W)"@4/0  %B Q1
MBU6V7INKC6@*(M7%?!LD>F5LR:!58@%%2HD-&"5,%#_=G H!SC?=#Q'0++9#
MK1\\CXK;N:6_2\ /U;_#-DW]]N^O>!X?>Y\5L9\,V+?T\USA]_W4:?/Z@_-?
MG^;4%-QB2-_N"$M4I2O2T>1DY1,Y+98!J4%#J-S%+S'DBW4'B"9N(@3@ AP$
M0$0 >@KS$V+"W:";%QIC\&ZM?GU5$ I=:!)15)W#%24.F$9S3'3*HH4AA#B4
M#F /08W'1.5,>T%A>XAHQHU-9M3/$P,W;5:!00, PIU! R2<>4A@%3[L0,40
MY_W7#G  A\8Y>]'<KTKY/*S1W/\ NXY9FF:97%.V4U5/0UR/23C-(7BGK*#-
M( IFHDCD1Z-RT;MJNC68==H-75&6Y_%7T1A%134U4R"IA>>%A+'W.X:.*HIG
M)U)F92)0 P%P1NQG<7Y)H5;H\%"S5OKK*39M44W+49F/6,F<K5L02\]!PJD;
M[I,_ 2G$! O. 1 0$7_\,V+?T\UO_G1I_O=8-+&.-CXN<OSX\HIGH+< =FJ%
M=%P !.MT@ %AC>?P!(13 ./\P(E]7HUMQUB#$Q6SDQ<88[ 006$!"DUD! 03
M,(" ^Y?$! ?2'I]>OINC5Y-'LC:%5CB.3Y:8DD8RND?<L2HCR*L2NZJMF=8H
MU9MXC0<T<YF*A:^M#$LW==1K$#5!.U))"EF*@DFREF(!L68[\:_^&;%H>@;S
M7./JX>ZC3U_>_-='PS8M_3S7/3ZOY*-/3_\ W=9>AXGQ:ZIM><.<:X_775BT
M3J+*TNM**J'$RG$QSGC!,8P\ XB(CZM5U?$V+%W5N!;&F/U00M3M!$%*76C@
MDB6.C#E23YT8/,3 YSF @<"@8QA  $P\=T%E.KOCYPOP;<+ ^'C[]&_R63?W
MV[Z]X'A][GQ6POPRXM]?OYKG#T^GW4:?-Z_Z+\WSZ/AFQ;^GFN?\Z-/G]7]%
M^?64A\3XM4N=S;*8UQ^=!NVK(MT34RMF30%9F\,L*1!C!*F*IB@93F@'/$ $
MW$0#A=E,3XL3M]6;DQIC\J"\?93+(EI=:!-4Z2<8*1E"!& 4YD^>?F"8!YO.
M-P_FAXM66U[Q]]JVU6XZP6_?>&Y^@862]N=PO]5_#[W/BMA@S-BT?5>:X/X)
M1I\WK_HOS:/AFQ:/JO-<^;^FC3Y_5_1?G^;[^LC>\48M:QL6=MC6@('/9ZVB
M<R5,K29C(K2B1%DC"6, 135((E.4>(&+Q 0X".L_8,1XI2@9M5+&6/4U$HB3
M43.2E5DITU",ES$.0P18&*8A@ Q3 /$! !TU9;L-:/F@$\UM]_UO$?J\>(LF
M[<=YMV>/Q]OBLS_AFQ:'KO-<^?\ IHT^;U_T7YOG^]H^&;%H>N\USYOZ:-/G
M]7]%^?YM/"OXCQ2K PBJN,L>J**Q$8HH<]*K)CJ*'9(&.<YABQ,8QS")C&$>
M(B(CK$5#$^+'#::%?&N/UA3M5D13%2EUHXD12D3D22*)HP>:FF3[DA"\"E*
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M;%AKM.MC8TQ^+=*OP"J: TNM"DFJJ[F2JJ$3&,YI3J%33*<P!Q,!"@/H*7A
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M8)(.)1I9FM@C$S"886SQ\6@VG8HP&.<X)H/2G68G4-SW$8X9.A "KEUN>_\
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M%LX1*,F! ! 0$ $!#@(#Z0$!]8"'S@/J$!] AZ!T%*4A0*0H%*4.!2E  *4
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M.6KE)+W0JS4<NJI;5DIF:P)U5$53<GP >$XGH/6/MQT7T:U'G>VS%&Q/<+1
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M14P568M9M%!<R&KL%;DMW4OOFEZ9N2B<K88Q7;)2S4+"-+=8/QDZPOD*YT'
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M'48\>$0544*DH3D])4R[3G)Q0DIEVE-%$*FFRNM)IJR.L5?VU1Q"I6$U5-4
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M'9RN]]G-?*3[+.]KK/XF?7UCT]L'9RN]]G-1\6'K3T#BQZ?)7V<6+%TPQ_\
M2K%X*?5^_P#1ASUC >/1NK%BZ88_^E6+P4^K]_Z,.>L8#QZ-T/"?K/JDQ"\1
MUCMQ?O/0RS]2R7V"FG&U]D:_B&_U":;EYZ&6?J62^P4TXVOLC7\0W^H35OE#
MY ])L.@=9[%PU:!T8;=8S_CTEI/7.F.0?I-;\%+I10.C#;K&?\>DM)ZYTQR#
M])K?@I=5'"#K'JGQ)XOY_2&%#[I[7^SEB[[!ZCSF#Y0X;Z:EX$?4AGW3VO\
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MTT,N5U#H8-9'SAH5I[,U!(:QUC?1;_D\L1-9ZM0:V0,YOX"5/,&<0CW(QSL
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MK1I45,$8=5<R*5!QM3)/0Z2X?^-1'C;#C_ET]'?LCKZ.M]F;3+R3Q]YLCSA
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M5,L^BTJPQC7D8T]>FJHMK$N58* !WQ4A>)N!CTF4#HRV^;^2$\/I]'H&>DA
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M)SJ>3[DOPUX\SES&185S!Z='43LM!%2PT,M$S,%<5-)!34RQ25"QQ21E@[/
M(FU@NJHVVCM/DT35SY-%5RQ-W)&V;U%?59K3YHD<+/&:',:JOKGJ8:1Y9X9P
MC1)%6&H0*SZ[%)4>B=:ZBA^XM]1CV%@'[ZCBH>'IX7CT_P#X2;EJ3E1Z)UKJ
M*'[BWU&/87^=1Q5^"\?MDW+7AB_>;_.TOJJG'3]!ZQV-B7_#C^SZQ#]C]CU:
MP\' 1%;9+1\(R38,W$I-32R":BRA3R=AEGL[,NQ,NJJ<#OI:0>/5"E,"1%%S
M%1322 B9<QHU0,P4H&8(Q5F4$ZK,H8*Q7@2H9@I(N S 6N;XS'&764HAD171
M)"JET20HSHKD:RJ[1QEU! 8QH2"56QHT:-5Q?!HT:-,,&C1HTPP:-'$.(!Q#
MB/J#YQX>OA^#1Q#B(<0XAZP^<./JX_ATPQ\'U?E+^R&H@["_SJ.*OP7C]LFY
M:E\/J_*7]D-1!V%_G4<5?@O'[9-RUG7][3?/T_JZK$]!ZQV-B1=)]EG>UUG\
M3/J,63'%):;G\0KV?+EDH<XHH#.HT6)<O$87)TB\9.&ZD?8R(-EVHHL#+-RM
M!?G13<.'1&K50CDP&&3M)]EG>UUG\3/K1UW'(!,Z4=2G8VI]UA2OH@EWLUB=
M,F\UCJ$7;.T/=NIE<F*X/(/$SNT7/F(+JK$;(,E4").A=M\^4/J549+! :/,
M$UC44E*.?E=6FKMJV*: :]]39A!/,6V-*\=3)%(NBTDC,F6"T9E*9CD4H1:/
M,:\WBSK+I-<4V5U%-5ML@IDVIE-+3!#4U\4]#%40OO";Z7T;T\?19?2/K'^1
M:/I'55_Z,.>L8#QZ-U\F^F%&_7-X6CK[?^C#GK& \>C=:P\)^L^J3&]7B.L=
MN+]YZ&6?J62^P4TY&GLC7Z.C]F73;O/0RS]2R7V"FG(T]D:_1T?LRZM\H?('
MI-AT#K/8N-?TKY/?[W9/$Y37/-V-&/GZODDUK,%[3A)!2M(LQ<^]@T::'$LB
M:6!,!1\\Y@.?-Q,()#S&_G8@<&!3=#*5\GO][LGB<IJ$;4+N.47 L3UP*"$5
MQFR.0,-G&<&.;%8&CN <2QW 6X.1 00'@J58!<"TU\3Y47V=7DS;0QWR3/T!
M%3W+K;2FI8]GK;&;;;36U>YK1]T7V6VBUM<=)DD>TI95V8EMFN3.0:7NL)LJ
ML2;35V\&Q,977%5K2=SD"78RZNH9 8T^4ACV3GO$H/3CW$,("2ICQG::=(Y"
MKQX2X+2M(AR+J2]H;,ZTZ>EB(HK59NY"177;HJ,U&RR;A%9(JR)A43*4S<QI
M\I#'LG/>)0>MG9/2D5T8Y"(GF]5EEH^ZIQEG=HMW+6NOS4V5!I.N6[HQ&R[>
M)7YC]9)P8J)DD#^4$"\==7R0N8M&J"4,5,><R2!P\L90I50,&$D ,\94C6#P
M@RH1K1@N%&-?IO$)Y,Q@:-95FRJ6%HFBIYUD$E-,A1H*LK2S*P;5:*I9:>0$
MI,1&6.&9 +1:^W:G*0E)E<<0_O;II(NC3B(H2U7CTG\8DTB'R9E%5 <-D"$Y
MQUSBX5*<JKD"KG4(60+OV1U]'6^S-J.];5EEMO%;/.Y'ALMS'F,.61R+7P8!
M#VATG942*/&/N8<[(R3?F@P,HD(&55:**K$37.JF61#OV1U]'6^S-KZ97"V9
M5XN&M42C6#3N&M43BX:J2.I8'B&J42<\9D60L!S.3'6R;*6U2FMEU$=0I21E
M+TL)U3'022T$97@4HI9:1"-6FD>$(Q;=&Z&5GJ./[L35BH^UW/M>]\,B=7Z-
MT,K/4<?W8FK%1]KN?:][X9$Z\:\(O)]D8V0X-U?:,)T_E,<=B&WCB^J9;Y0:
MIU%9OK1>JD_E,<=B&WCB^J9;Y0:IU%9OK1>H'!_G5[4Q/3^K[&%-V]E@NUU8
M\3)K-63H[/\ 4LKW%?6%NWLL%VNK'B9-9JR='9_J65[BOJW2_4.PX#XOE'V<
M%;Z.P'4L5W%#3;Q_\52_:JT^++:<E;Z.P'4L5W%#3;Q_\52_:JT^++:A?D_F
MS[&('!NK[1BJG?&M][6'\)C-*/ZHGZR_]N:3T[XUOO:P_A,9I1_5$_67_MS5
M1WB?.#UAQ)Z?)7V<?;=[73.U[+PR6U1D3H/9.J5_K)ZKMWM=,[7LO#);5&1.
M@]DZI7^LGJQ[V7S^K7 ?%\H^SC+2W163[/O?#E=4U#HI6NH8GN"&JI;HK)]G
MWOARNJ:AT4K74,3W!#0=^OS9[5Q7&-I/LL[VNL_B9]?6/3VP=G*[WV<U\I/L
ML[VNL_B9]?6/3VP=G*[WV<U'Q8>M/0.+'I\E?9Q8L73#'_TJQ>"GU?O_ $8<
M]8P'CT;JQ8NF&/\ Z58O!3ZOW_HPYZQ@/'HW0\)^L^J3$+Q'6.W%^\]#+/U+
M)?8*:<;7V1K^(;_4)IN7GH99^I9+[!33C:^R-?Q#?ZA-6^4/D#TFPZ!UGL7$
M,IK9OM^S+&A8+722,K(Z?3Q'5AJL@\J\F\$LW(D(K(!%G3CY-PF4"E(ZD6#I
MQS"E(=0Y  NHM2O)?8]FYZTQM1R9<JVG"*QA&A)N-A;2F?W08>=F!=1$M>=&
M*F?@0@E6 X)_S0J'^Z#J10.C#;K&?\>DM)ZYTQR#])K?@I=<Q7Z':+YFRRUF
M24,DLS7EFBC-+-(QC8EGFI6AD=B1<LS,2>G&DK-&LAKGD>IRND>1R6>1$,$K
M,6%V:6!HI&)Z2S$GI..,?\"WO:-QBH!SEBHFA7[=V_7E&]=FRRR+)@NU2<$0
MB%7AF2KH_G:?D15F4T0'G&.!@*4BKRI^V*A8ZD+9!NIRL9<KRT_,1$<^B4T'
ML_'L6$-(.)."?N6#D6K*U)/10040C/-EV\@U25(JU,OYJCULEEA;W6%7*BLX
M,C5K.J"#<I3+K"FYA3@BB4YTR&65$O,2*<Y"BH8H&.4!$0Y\X_3K"K6&G:WB
M2?PNE9[Y:IR7I5G*Z+-!,*E=(OI9P#Q4ZR;>5.F9PR0(5!JV*99%FEYL5-9;
MY]IQH7HYHYHA69EEN6(M5^4.2015,XAK):4F#,:H"DJ*V=ZW+Y":4D5&7QL\
MBAHJJ9$:)7OHEHQD5!I?004M'&&GRC/:B45%1F<P:&+\6TNH(#'-EM1$&K@7
MCKIXIE;9RTB3ZDYA9\/LYV^Y@PU%9/;5'(6-9EP51N9D,XZ;O5DV,Z$,562C
M9M*89JF<-R&62>-6[!1<#D7.43"8#/Q?DM,!)HK*%MV6.*:2AR@:=J_#B4AC
M%YW"G@(AQ .=PX"(<> AZPWCBE>P%P]>8NU9&K^1)R*NKY-0\(FQ;N:O'.96
M*6CJ[-M6A_*(R20 X>\':2:R;=VDU(=PDU(N>73OV1U]'6^S-KLJ#0S16LH:
M&JGR3+IY:G+Z&J>8)4,97J8%G:9I9XZ>>>236#25$\*S3M>636+7."31W(JM
MY)ZC**3;F:>.<M3TL#-+#*T4C/#E\TU)$[.C%HX9'$=]FQ#*RCG-C#DZ=MH0
M$+-ST;;[:[>LP=KI3=L>M6/.5$W!,K.N)P9123 @<SRBJAS")A4.;[D"H[AR
M=F#,B(64M21D<6S41-N(J+=UU962A3MT(]@JB67@)=PN5X(*+'%5TQ?QD@MQ
MXJNU!#TSWQWT'K?5*'UE-5U'VNY]KWOAD3KWG0W15Z84IR#*Q%(HURM+&DQL
MHL14J!4JPZ&256%R0PN;Y&T9T?,,E.<GH!&PL=6G19-Q !$Z@3JPZ&60,.@X
M\Y66]DN<\7/YI%"NCD>!A0:K/)ZBMG,H9NV>)*N6JTC6SIC/,C%11,9P9!I)
M,FQR\!D#%YIS:;C\JYLH"S5%AD'*-05CDU&[-LO8K3%E8HG R:C9NRE'!46R
M0AQ(9!- A $H ) ,F7F>I*$#^7J\_1:KW)]JS9(Z/DK=5&TBQ9OVRD7:BJ(/
MFR#M$Y11BRB!DG":A#!S3G*("40$#F 0$##KA:ODCIDF>IR//:_*-9K"(HU1
MJ':6 2>.HI)@B\5$AF<'>7;')U')U DS2Y3FU9EUP"$*F;5-KV65)J>74'1K
MF1^-V8G'G$C][>YM!%NW5RN\L#9N\9OTT)^&K$T47+!<7+8QW Q*3TQ"K"!C
MD!V4#@5,H\"D* 3 IW*F6)6+>0V5,:QTIYZQ<,1GJ+(*Q;A/R[95 5UZ].JO
M6RYN<<%#@VG69?6!$/0!1Z09<P!@^PP[4DMB:@+J/[% -'+QO5XJ,DCMWDF5
M)R0DK%-V,FB94BIP,HB[3.)A PF$2E$(E96Y,'%#UC*36.+;9Z&Y:,WKXL1(
MF+;Z^<S9$ZY$2>?*-; U3/S!()_=E[Y/G 8J)P+Y,WD;1?E,R(M+E&DGXX1%
M&M3552[NZ[]RPYIMJ=1:]RM5&XZ#>QQYCD.G.56ER[._QBHW;&>9F9M6QL(Z
M[:PJ#?BM0C] / XD=B'>EMPOL7"Q#/(L;7)Q)@Q9&A;N12I/3N$&R2)B-G$M
MY*)?"=0@@F#"3<B;T>CTEXR*HBR*["8<(*I+(+VNRJHK)*$4253/)',11)4A
MC$4(8/24Q#&*(>D!'7GNO7)^[CZDQ3E8FM1N1X-PR;OBN:1($=2 (N42+$36
MK<N2,EU%R$4X'1CD90#"4>8<W$ UH:K91S=@J5/'5JW7S'#]!R(N:XX5D(YH
M=PW.)#D>52=0/&+F(8HIJ@M%''T<TQO1Z)BY3,]R62.#2W1F> #F=U4J2TX<
M<WG115!DIJ@[ASHJU$N; #HE-.<VRQA%I#D4T-^::B!7A#6L;HDVO#,3;>8Z
ME5XV%MP]1]8^.;SVC;^ 0^K"GRE-NQ+KQQMKB7BSE-LF5-R]#(=-KU];RCU-
MX_DH=4U/G?*D:MV0G*BFC(P;DWD6R9_) TC"F4$_%8A!*"<X<>;^=N]^NC&1
MD;$]QVN>M*1!FM]9%C&WNBM*-W()ISK!>2@Q1$A3<U=R^9A]R//*03%+KMLJ
MT_T4S98TAS2*EG:0?M?,0:*2Y:X422D4TC6/>PSR&^[P7ZF@TPT?S+5$5?'3
MRD ;&M'<K@V'-#2$0N3T".5S?=QQ-JW>UTSM>R\,EM7[ST,LW4<AW8^L++34
M/84J-*P,K&S<6YMS,S>2B'S628+E",E>(HO&2J[90/2 ?<*CZ1X>L=9J\]#+
M-U'(=V/KLPRLDC*P96&LK*005,:D$$7!!&\$;CT8Z92&",I#*QN""""#JV((
MW$'H(W'&2>]'W/4Z_<%-)ZAT4K74,3W!#2A[T?<]3K]P4TGJ'12M=0Q/<$-6
M'%/(;M3#H'6>Q<8:A_F%I[;V3O"6E#'I[8.SE=[[.:3T/\PM/;>R=X2TH8]/
M;!V<KO?9S5!WD7E#L; <&ZOM&/E@Z3T;K*:\ =Z+G^A3MI!?ZUHL'2>C=937
M@#O1<_T*=M(+_6M6/"3RAZ*8'@O5]IPHO?0RT=1R/=E-9J)^*HWZ"Q[LAK"W
MOH9:.HY'NRFLU$_%4;]!8]V0U/RA\@>DV'0.L]BX:N..C9NO+'XX_P!*(/IA
M>?UL^%K:3XXZ-FZ\L?CC_2B#Z87G];/A:VH'>Q>;U;8LW%NH=JX32WR@U3J*
MS?6B]57/VZG]>N_ )?5,M\H-4ZBLWUHO55S]NI_7KOP"7U#<)/+3LCQ4\%ZO
MM.&C=NBLS^(0[XVTY_YS^Y_T:;%VZ*S/XA#OC;3G_G/[G_1K$._;R5[7PZ!U
MGL7#?J/1B#^@E^U5TGKGQC<>TA_#V>E%1Z,0?T$OVJND]< 1D;B!2F./OD/]
MR0HF,/"/9B/ I0$1X!Z1]&JKPB\GV1@.GJ^T8OL>E-B_ML*Z'S!ZTY#YQX '
MX1$ #UB(!J-%@ODCFBX1\%@O(9ZC/8FR>YA,D.IRGO%FS]A'(@I-5Z-!\AS'
MA)%-JN@5VB+<1,F4RBS-%5JNXN3RTWG2S93H-1LV3L*2N-+ICXDA<&L.FU3M
MK2/)+N7;*"64=MSO(-^'-5!R*Q4EA18+.VCV/<*LS2(D4DD[;6#)))IBN6QK
M+"FDDF998S%J4RRYDDT_++F*4A3K* )S%(4O$"$(4N\"1Y0B2SHDN9N8WAI9
M4CEAHXI133Q3UD%12STM<E=1U+FGBCF5Z61!+. X2/'+R33:12/!22RT^11L
M\-37P2RT]3F<T,M72U%+EM51YA29AE,N59C1(*N>>E>*OAD:"E)C,DX2O:[7
MJZQ,2O0,/ I2MUA9F12AXQE&E?RCV=9&=23\&:" /)!QP+YP]7 ZZPE#GG'A
MK<%A^()SJ>3[DOK6]D]B8=HJUXVRULBP_$$YU/)]R7UJ@[R-*SNSL0MV=BS&
MRD"[,23N\)QTD<<<*+'%&D4:W"QQHJ(H))(55 47))-@-Y)XG"2H]$ZUU%#]
MQ;ZB-L'M%:6VUXOK25A@U;$@G>U%X%.7CSS*)$LC6]10RL45R+],J::J2AS'
M;@4A%$SF$"G*(RYJ/1.M=10_<6^H4; \78T9X&QKDEICVD-<AOT;\@_O;:JP
M:%Q?(N<AVMLX3>65)D28=$7;-6K98J[Q0%&[9N@?BDBD4GLAU>XY=8L/A*;5
MU0#=ME4VUKD67PD7/BQDZ#UBWUXFA=IJ<K]9DY6M5Q6V3R(-$(N"3>H1J;MV
M^?-6":SZ0<%4(QB8X')I.9>$0=.6T2S>*LV3YV5!HLUL19"=9&KDE(R,:RCI
M6 M-AI\L:&?K3%9DI*N.RM7,G5IIPRCEY:#<&4*FFY68M5F[]"0C%TS+L%%%
M'->D[8I5Y/WD)PKBR)^:+LF-A!4(B6;MWS9:4A'2Z15#L#3<2F^BFTH*#M.+
M=O$)!=B]0;*-5==8&HTY1Z[:"S41#U-*SWF9M4'0:\[1>P= A'[&(8H5V/7:
M,V,>!W+N,>V232BFJ$4C,3T@FS!< 4>NO7&E*<JJ7<0"J6IBV#;5NZ60J!)&
M8-IJF*QVB2B&P995DF5MA&_/SRY@ND5#%$U6V7O05!JX^YT[BCD5[PS+5F#6
M[H++L9:<U6OJ2020TKQBKGAWEHT:-:W&_P &C1HTPP:P\_88&J0\A8K1-Q%;
MK\2W,\E9R>DF4/#QC0ABE.ZD).17;,F3<ACD*9=RNDD43% 3 )@ <QI*]9,Y
M%JNQD&C9\S<IBDX:/&Z+ILNF(@(IK-UR*(JD$0 1(H0Q1$ $0] :JVMJMJ:H
M?5.J6!*AK<W6 ()6]K@$$C@0<0;V.K;6L;7!(O;=< @D7X@$&W3CF'9]R\[8
M]Q[@M8R7<8K%%'O6WJH1M@HU.JM]P'9F&8$H9])+Y0MY5QL!9"[+V9E1L=S-
M(E0@L>S["'LMR3<Q=A4;.G/@K+.697(6&[3:[Q)V&M[ET]P_E\?/F-;;0.,5
M\6VI1;'I:0O&P$=8!34I35[#7@MCF[":9L)FDXP-&)D6;'WI;MJ5;L]\"SLK
MI;ZI4)>:QE9;[BNNHU="EWR?P[),96@2$@LZ@'-B@BLEX>O-9QC5YB)866+K
M<+&R3<4$70O%F.-KM;QWD!"Z)V^V6**K(9&3Q71YM"K$KN*V^6[*UM=_0KKN
M)K\?8Y8LE)LT6D0>U34RI6X R\%%&3:+G-KEHZ'.16[2261HN[&E++4NL85J
M^&:XA-0X-,,LCDHDC*;05,S:T1A6.I32K39@*@.SN4[H9R1,P0 U,<E]F92-
MB*-'IU0J7VTINFS"S+)X?5^4O[(:B#L+_.HXJ_!>/VR;EJ7P^K\I?V0U$'87
M^=1Q5^"\?MDW+79+^]IOGZ?U=5C>=!ZQV-B1=)]EG>UUG\3/J*F=E\=,<RXG
MD;]DJYT%PA?J:A3HZK.7Z,;=K*X(X!" MB;)D[ \,8"HHF4<J-40)(NVPJ\Q
MVJ9*5=)]EG>UUG\3/K1^3S92)?HE3%U(I%U71L= 5M87-X5H:NU8IY0KV?KA
MSF)S9QJ!S^272%PY;D !;Q[X5CD1SY.X2OHR9-D"L\>N:FGHPNUH:B+?4U44
M\$0;7U6UXR74F.-DD=)%T6DT1ER6L40F<J^7RB(4-9F18P9A1S K0T%12U<[
M)L]==E.HB91-*LL,<D3[PF^F%'_7-_DBT@U]O_1ASUC >/1NODWQ]^%'X_?L
M_P#@]S$N'^37V_\ 1ASUC >/1NM8>$_6?5)C>KQ'6.W%^\]#+/U+)?8*:<C3
MV1K]'1^S+IMWGH99^I9+[!33D:>R-?HZ/V9=6^4/D#TFPZ!UGL7&OZ5\GO\
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MJ6XLO":(\5LPZU.L.(WXPZ5(),QF0BX>D5""JL"&C<$%7!1N/>N"IX,""<:
MQ<I&&VSPR,-B";P7%-'@M6.-K!Y09*&23N@&.X4.YX/5"2JZBTD11ZFDX/YR
M8>:='R*ZTBYZXU*$%S'S-HKL2^\S.KYG)SD4P=>3534\DIYL[=HK<Q02F!,_
MD^8<2CS3#P'A'+&ZD@;!$LA*YNCL_2+.YO6KN]1J46@D@HG:6!BUU5.*<.40
M<0R9R%4!13RA07(1$A6)&@:C]EIE"%S_ )UFI/$=%R8LU8[7H8\G>H6OS,?3
M(:S3UCA):0;MI5!>1>/Y$'K=K&Q\40B2KU)-W+.VC-D0'7V]<LBS//L\26=U
M6'6J5:+;NTSSYK!2(NTSAZ:J()K1(9*S]M2E-5D::07^//GT^0Z)Z*RT]+#(
M]3%!0NLZTL4=-%29%79C*_<^C,5=EXU4RMH1#EG[GP"3626.FA)$W*9D7'Z%
M1KB"UYIR:J<*Q(HF>TP)3$.5N4IBF T@ @("' =9;'T["3;B[*0LS$S":5M<
M'4/%2;&1*F1>-C@1,J+)=<$@6%%8$O*<P5/)*<T!YAN&D;K@+$[*(C5JGAK;
MI$H-W+US;[9<,;5>4CJK78R(E'[B1/$-@@EI1TN\:LV2OEYF.0CVB[V47,OY
MF1JMKC9J2,/>\XR4728+'B4[6]N\\XJ5<B$82)BGDQCF1D'9&L>BV:F;HNUU
MSR*:3E$CPA'A0>!YWY81P_BK+ILKK,PHZFM+4,,,FSJ(:=0VUK*:C"N8JAV1
MF$SRK97*B)1(J+/ [^M=(<[IL_RK)<RHLL5,TJ*FG$]'4UKE.YLJK,R9XA44
M4*2JK4L4#DM&K-.^P>5Z6KBAF$G\ICCL0V\<7U3+?*#5.HK-]:+U4G\ICCL0
MV\<7U3+?*#5.HK-]:+US0X/\ZO:F.YZ?U?8PINWLL%VNK'B9-9JR='9_J65[
MBOK"W;V6"[75CQ,FLU9.CL_U+*]Q7U;I?J'8<!\7RC[."M]'8#J6*[BAIMX_
M^*I?M5:?%EM.2M]'8#J6*[BAIMX_^*I?M5:?%EM0OR?S9]C$#@W5]HQ53OC6
M^]K#^$QFE']43]9?^W-)Z=\:WWM8?PF,TH_JB?K+_P!N:J.\3YP>L.)/3Y*^
MSC[;O:Z9VO9>&2VJ,B=![)U2O]9/5=N]KIG:]EX9+:HR)T'LG5*_UD]6/>R^
M?U:X#XOE'V<9:6Z*R?9][X<KJFH=%*UU#$]P0U5+=%9/L^]\.5U34.BE:ZAB
M>X(:#OU^;/:N*XQM)]EG>UUG\3/KZQZ>V#LY7>^SFOE)]EG>UUG\3/KZQZ>V
M#LY7>^SFH^+#UIZ!Q8]/DK[.+%BZ88_^E6+P4^K]_P"C#GK& \>C=6+%TPQ_
M]*L7@I]7[_T8<]8P'CT;H>$_6?5)B%XCK';B_>>AEGZEDOL%-.-K[(U_$-_J
M$TW+ST,L_4LE]@IIQM?9&OXAO]0FK?*'R!Z38= ZSV+AJT#HPVZQG_'I+2>N
M=,<@_2:WX*72B@=&&W6,_P"/26D]<Z8Y!^DUOP4NJCA!UCU3XD\7\_I##7RA
M()Q0R4@K:X^B UQK?#IW65\U&.JC@Y8E%G8'A'JB;15&+=JH.A;N#E2<G(1N
M(B*H ,6&3.PQ\7BM"TY :Y4G1CVCIYD)@@W096DCV(<O6,BS\V$4EVQ6"[5J
MB\YPJO"-P=+""JIREW?N3?+,*W*"CB=_F\KZGS$0[QE'*$2<V5A*3=;:O2B<
MR#E0J4>B/N@H9LW6=IF;IJM@3.GYPCKVWQD="R]!AX> )58J,CH5E'5E,B1"
M5]HC52 E#@5 QT0&. 1:J"F<Y3JIG4 YQ.)S<#RNV30"GW+>?2VG-]2A9[4N
M450L) QS*)2:NY1E2BG(5E,D].PBS:)WDTYF(9]6DT5=2NTS9(RV89F"&,11
M<CG<#+K+*DDN:TH+)(L-)5Q[;$XR-#Q;G.]>A<,SE)!=_5[%+Y/62.%=R=)O
MY%,IO<Q54W J\(!UDE&[,RK<#+.G#A-BZ7%)>=;OV1U]'6^S-J#"!I&,NKH9
M/.$<$19Z%Y&LX!<H1#>2-(15H:&D[HP<&<!*O$@!N\.H5-L GY[I(ZJC..*5
M.<[OV1U]'6^S-KM,G)?(-%YBVOW1HIHY(6+UTA+IED-/)K2UZK(["2%PVQ,E
M'&1L:60Q1*%U-'=*C/:8J4[DTES^)4V>50@1RYC-60E8<ID>*)&AJHV3NM8<
MRF4BIKXEJ)V9VCCOH/6^J4/K*:KJ/M=S[7O?#(G5&.^@];ZI0^LIJNH^UW/M
M>]\,B=>M>$7D^R,; \7\_I#%B$Z=7GZ+5>Y/M7I?II4>K;3]G%:LPG3J\_1:
MKW)]J]+]-*CU;:?LXK3XO_$_YN'3^K[&$V0OBN)[5U;Q9'3CLG1V?ZEE>XKZ
M;F0OBN)[5U;Q9'3CLG1V?ZEE>XKZ?&D\E>QL!\7RC[."M]'8#J6*[BAK7:%%
MIE_A9^)N]5KUMCC6NUI^9V*(8RZ)"J29^<*(/D%C-S^H2J-S)*$$"B0Q1* A
ML2M]'8#J6*[BAK"TGV6=[76?Q,^J-'',BQRHDL;Q$/'(H=&',W,C JP\1!&*
M,B2(Z2(KHRV9'4,K D7#*P((\1!&.?EKY.'!5[D+>-57L>,GT=+I,XXD"]+,
M0"2:D3'/#>7@Y[SI42>7<*F!-A+1P 4PE*)2@0"P8R/R<F<:A,+1U,>5W)J1
M8Q2822C'):U.'8).0:J :)G7'F*CD%!*)46LZN*I1#F%Y_W ]ZZQ\<WGM&W\
M A]6%/E*;=B77CC;7#YIR<Z)YJFN<N%!.[D;?+'[D(NY%]@%>D)Z;FG+'AK#
M'+9AH5H]7EF-%W)*P_.T+=SV) -]B%:F._C>&Y\./+<BZS/M^LJ:1#7[$ME:
M.".R-'"4G7O++D X)K^8.TPB)@@E4. *BA(-E4U#% QR'$!F=3>4NRTTA7E:
MR;7H&_L'S)PQ4FX\I:G9D2.$@2\JH1HBXKT@=(.)P3",B3*B(@=R7CQUVPR;
M6Z]:VU6A+/!1%BAWMJ;(.XN;C6<JP<)*1<J!B*M7R"Z)@'@4>($ P"4! P"'
M'4),T\G-@6:AYBR4PL[C259,%GH-:\["3K:YT"&5.4\!.&="U!3^9YL5)1B2
M8 ',2X?<CQK:!:8Z-M)+HEI$\U,A)-!4N("PL&U=A*)\NG>QL9)%IN/- QS)
MT1TER0[31W.FEB!)6DG80WWBRB*3:T4K<+NZT_B PD8<IUM^DXD[&3A,EP#E
M6.4;&,XKD9)MB+':*I 'EH>>>*F)Y3F% X-2\1. B4A"G.7:]%WV[6'$!!Q[
MG*;.'>M(Q@R70GH&T1 )K-VQ$#\7#F&\RYG.2,(*>="3FB0PF#GE 81V'DJ+
M$U9+/ZWF:%>IIM#.RH3],?1Z@@1%1<R1G,9/2"?'FE3("A6@ )C*'\F4"D3-
MJ!UR:6XCW.92<')8WL"$@U;/$$D+'*Q3HJ+I-)5,%4I2O)(%.!%1$Q2NC@',
M$ ,8Q@+K*,_Y6:%AW3HW25H53<QPK,Q6XWC\79B1?APB.[HQ?\;\H=)NGR2F
MJ5&^Z1+*QZ-W<=:=YX[H_!NQV!QAGS"$RA.A'9<QRX4D+=./&;<UP@VKM=LZ
M7;"W539O7C9T)5?*IE)P1^Z.;F%XF P%VG!2T7+7:><Q<E'R3<];K@D7CWK9
MZD<!=S1@$JC554H@)3%, @/ 2B!@$0].O.6^V0[G44WBB>*74XDQ>NXYR>$G
M:I+\UVQ$A7*140F4G*@%%4I2'(W$J@@H"8F AAUK)_A'.E.<*E=XKRA .6J1
M5ESLJK8TC(('\L!%E'$*V5*FB<&JPD5%4"&*B8Q3"4 $8'*7I+1!!FFA-8BH
M;F1174B[@1=1/0SJ1O/RG@&L>.'Y<9Y3?O[16J3=SF JZ=;;MXVM)*+7M;G\
M.GIQZD)_TV>C#Z> 24UQX@(</Y ._OZ+G^A3MI!?ZUKRW,\OYTHKMJ9'(^4Z
MR[CE3':I2=BL[?S58P*HJ 1A/KJ-P,<JJZ2J9VIBJ HH10AN(@$B*WRAFX^)
M")3L,M6K\RBG[*2;DLE?;LWRBS'RGDO*2M;/#G4 Y51!119JX4-P*/._FN=[
M:/E@R.5FCS#+LRR]F8795BJHD-E!U]5X9Q:Q/-@8VZ+[L>FFY2,JD8)64==1
ML+ L!'.BWW\ZS1RCC\6%B1OMOMCT(WOH9:.HY'NRFLU$_%4;]!8]V0UR'CN5
M)K-BK\E!WO%D[ NY&+=LAE*K,L+%'@Y71,F10S"32@9!%#G&#G FL^4*'$
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M;3DKGHKL  @(#[BQ8<. \0'S%#T#Z/1^7AIN8_ 0BI?B A_+5:1](#ZAEEN
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M]0?>X:S67T7TEFK D0IAIADFOF>V.4D;5)*1YT<8O8X(Q:-LS9L];K"9Z"P
M1$R1DE3&YI6YA<$)PPV7_3D*%'APXO4O1][^01_1K@N6CF:#Y''=26S<U)LU
M [7E6O@&L:8=V1G5I5^ S%BZ?G:9$IYU+YM _A-+-))K2 )!1T2ZZ9Q&I$%'
M351*)7,,LD&O7O\ MK)HQ'(;T]=+)5TC+$P[R@A&RN()UC@OW\S,JK8ZR_S
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M(TL9;6I8VD9V2,A[0R)'4,L)UM+I)E$=+3B26IC,<)5T&49E%LVI,P@R:=!
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M9W,3%+)+/T68"+<I@!R!5BF*6 6M'\&_,(OOBL>84W?">%OJ/BO)47;GKO\
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MB36G7+Y;S9DWADF+A257=N ,04&R3 KA1PL!R>21*=3G%YO$('T_E N3KIL
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MDG3YZJZ,1H5'@Z631022YA">'W,\?6XC(TZQJ!(QI"%1A'*<9#/DI&/A)!Y
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M3PB9H5EE$1D#%!+(%L':_'G^ 3<G'Z/^"R[^C_\ C1E'_O'^QPT?P"?DY/\
MBLN__31E'T_A_ECUV&T:\7Y-:/?R'E/^'TOB_P!UXACI/_&OEA_G1T__ /MN
M>]%O_?>+WN<<>?X!/R<?H_X++N/#C_5HRC\_I_3'Z/3Z?1P_MZ/X!-R<?HXX
MLNX\/OYHRC_WC_8X:[#:-/R:T>_D/*>C_P!/I>BUODO$,/\ QKY8?YT=/_\
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MPO+L-] ^[VXGB \0'X3X3T"'$ $/Y0_0( (AQ#T^D?OZ^!^\\FPP   G=Q
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M3#!HT:-,,&C1HTPP:-&C3#!HT:-,,&C1HTPP:-&C3#!HT:-,,&C1HTPP:^<
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KL:-&F&+FC1HTPP:-&C3#!HT:-,,&C1HTPP:-&C3#!HT:-,,&C1HTPQ__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g908649.jpg
<TEXT>
begin 644 g908649.jpg
M_]C_X  02D9)1@ ! 0$!F@&:  #__@!!1$E32S$P.3I;,3A:0E4Q+C$X6D)5
M-#0V,#$N3U544%5473$T.30V7S%?3$504E]0050R7S1#7TQ)3D4N15!3_]L
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M"B8G0T53567#T1E"1$929M3Q1TABI=9GAI>CP?_$ !T! 0 !! ,!
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M4% R?39IBNIJ!K.FU&E$]MS 9>U5\*6L8*N["=CBJR1C=..Y(]*/5%T5=/\
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M@]#MP^IE0&S MKJ%8-U1XP[*?EUT]E>!\UYA@2W%D2Y$AT?CK"[H1US5+ND
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MO"NW44<L.S-'G)8F_+U3!TU2[3;]C4J".:@627:QE4^20$$K'C%2*T>)D2;
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MV_=<7V8[6^N30/5(+IHWYKBJ!29!O6+=ZB,SAT%RDV0Q8AG G3W=>72E*Z.
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MZ:3%E[-B,5E#W[$"E#1)X;&B7KV!1JCM6FV;7NR  ^[4JY!Y("SURPI>G#C
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M\M%IL46\T'FS(;&1D8NB6I4E4"%)E(UY<58?%13])-*I.ML:0;D.$+KL-NX
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M\:V^HO\ PC_]':GWTTK^[_$/]>WSZEIP^0A/[B;_ -YW_$X?(0G]Q-_[SO\
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M/X<_[<\ITGI$M0^LH)EH7=K44XZ^C//M\I_59JFES=G](/1_E=.2_?V;Z_\
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M>?<%,QYO/.DX[<9\V<=L/RXS][./)G[W#'5MTX9\VX*9G\4Z1G\?FA_>^_\
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MDYPI*L9SA6,XSC.<9QSC-Z2XT N.OFR)9-B9N$T) V 9 A*H(0-(V&0IF+:
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M$$DLJ!PY[8)I:G1WQ;4F5:<<?N)%&^U3_MC:OBCG'?B11OM4_P"V-J^*.<[
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MX5\;)\<)/[0]_P D[^:7R1]KQ+\*+Q^H?)*Y]]SGJ.Q!6@=<64_MF;::0?H
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M$*M-*NU33[_"Q=)N=FD8=N5MA6^&W="NT><V3BSG78J-VQLA"(\ZY%:E+M9
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M[7G231OM4_[8VKXHYS.P_1:3ZRKWZ0"^8HWVJ?\ ;&U?%'.9V'Z+2?65>_2
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M'2QB)5)LP-16YW_!,3W9CJ$:G8<K-@V11=A3Y==&3KIU'],0$538-LK5G-P
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MAL2BF4H@P("P4-^S3YLAK#L .T]W\)T@WB X]Z[O<78 *42;'3 A,.=.56R
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MRW_D>\%5_2?G]FGY/FQ^+'NX@53TGV'Z^&? (/']/FQ^+'NX@53TGV'Z^&?
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MP\XY%\:^1\#LNM*6F4MO/:FV>\[C>!4K7]$UY%E?.'8IPQ#?+PI(.+/"@:V
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M(Z)@2*)"0DVA"0JB*)"J*BHJ(J*BHJ9UXZ;<;=:!UHP=:=$'&W&R$VW&S%2
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M69KV)#C#CF$+PC.3#_2%NB3=H!R80#;9,6+:_1F8D*,+80)4J:RB,R),TS>
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MON)""%EY9$>(B1FY2FWGGG9ZVXB6Y#=KV_NH2?86+\>D\0=^N4>CU,EO8[K
M?L*U:E#RRU84T(@R[-"4\_'9<P))OQ)<@7'9<>Q/G3&6W<CXL>40:94ZUV*S
M5C?S>>MCJW!V)=52.<&#+"(DN<FI+4LA7A-@VF)SC;B[4?5'40D*\=6Q5$RC
ML7R.EG8N.'R*:U=;K;G;@5NM9(TM_2&D8@EM/RK6R\RBQS7:*@ 8&F64CZ[[
M<4JNXSY,X'([<?@SX9[GF.^GM"_DMM^H0>)'31?,;,T?K^[8!$*Y\LBI&<B2
M2L./LYA%)X]3S+W@F,RH$Q454L=+RPQF5!>8>RRWE?9QW.^GM"_DMM^H0>8F
M5&?A.NPY(;.3%D)&D-Z@/9O,/(VZ&ILC M)B0Z@,A7+,25%15V"#-BW.)%N,
M%W;PI\5J;$>T.-[6-*9%]AS9N@VZ&T:,"T.-@X.>1@)(J(_<^<KNIFBU##@?
MJ$"Q%X@V>TV+7]Z<1C_)-6 1+ER*>37CL[4Y* F)P=]S[%4@,/QG_*2<95]&
MO*P;.T^*WSH_;NJBO@V\6DK<6!4YQM"\B+'#+9GUPPUWZ%Y2L<:C0GUY1WJU
MQ\/L]^E#JN=<<J># QY@N[V% !9RQRG6@RR16[M"R=B(AEDC8R?7@O.<1C2G
MLN-=S<A?*.[R6<IF'<5DXX-K"2ELQ"T"DJ/V"Y$,>X:FQWNE#16KG&:X%-@1
ME7A7)?N7N^E.U"_=.1V9E2XQ(3L77R'W4_:KMD"1[L#BX6K"^R-)7"LK+#7?
M8QB<<?[U*6U*S] V/-^57OSSXIJ):+3H+<0"RR1TB!:-7W;&#P)Y.4/9>!D7
M!UIKKR%]G;B9%;)#,=]G"59=9?QGLPA7/LWJ%J"7FJURYUJ8@A7[6$&6(+-1
MC&,219F&R0A.J3VJRVYF.^C#K2L]^T[A;2\86A6,=8_)IQDY>\)R<+7$R2[8
M0=&(#;RJ+Y6EXWEB(0'D:%!>%^ 8(.3#+4,25"<RKN_Y:7)RUAK'\/'=G!LL
M/\HD<[B3T;(XP8@C-QQN1 XVI-J%TCN0[LVXIYR9,BX&"*#2K6KKWI3??68/
M]'8?-G<O1&T>SYCX?(YK*]Z4WWUF#_1V'S8W):,5*U=J\8\'7C"G//GO$_)T
MC.5*2G&5=G>XRK'8G.58QGO<*SY.>D$15$LDSWG[Q5XU)40A551$R#>N[V17
MRWULPOT0+]70/JC/$"]66NU"PU>P6L\'K(*$-LR9AD^2AB!<54CY&982_/GO
M,16E/O+2TRE;N%.NJ2VWA2\XQF"=<=1\3J*U+M)73KXW&V!2!+@ )F\#&1X]
MRQR@K[E>)HRW*(Q71TQZ(\IAN=EIZ.ZRW\KCX\9W&'4N)IB^;QU-0=;=7KF)
M-MF2K@7(2JD0&#R<1(DD/D5:0]-!Q55]15B&ZXU-1!A/#7674)<:<E)<>QGE
MLBPC1+X^EM2-<H,.X0,D6]-,/@D@Y3$%S0+C3;*(BF3P)M'6AR5"S33?\5)=
M&4_PI%*]K-L=RN=HO&:CA=^5#?\ 0VK=+NS*NN,27I*GDV$5Q=BQ(/4*MY+)
M?4CU-2M&A]:F:SKHMMF!L4Y@:Q*K$UQ4.-!<B1)<.1%ECQ9IJ?,-MS,9 L8\
M!$GICRE^.IPEO"U5[3>VK=LO0&S:QMN?4]>4H$VU;=?H=+)0?>01)29:<P8D
MA :?\OQ),422<,)<<$-#6I(OP[SN4M6PI=.!:]IM;H]98>C *D!'U\.Q(D.R
MGT#Q<1$2/XQ)=SE<A]2&\+>=5C'?N*4K"48SA./+KKT*KOJY'YY[E(W1B"K"
M6R&VW(;8N\21/DB,DKA%GJ+3*G"D(]&A/QXRDV)QB(]1J>TU"BKRG8)EU*0=
M^N3[T1Z1AZX0K/ (H+=FN%I1'Y0MW2&4:==(LV<(.FW.$6Q;;1L6D$U08ZL&
MIM<"=G@-L#J>%A[&/'AP8Q;6(ZT%)PYL3.;\$[GPF8Z77&H41B1+:81,E1HL
M:-)?=88;;3/*<8[,>3[V.)5Q^VZ3[90OA9?CJGS8_%CW<Q+C[[Y(K[SKRM V
MPVKKAN*VPTV(M,AK(M#38KDVV.0 FX41*V1B)$A@8Q(T>*+[[\I\8[+;"/2G
MSUOR74:$4<?>/UG7CS<<+UC(EWTDT;[5/^V-J^*.<SL/T6D^LJ]^D OF*-]J
MG_;&U?%'.9V'Z+2?65>_2 7S@^B_R_\ 35U]*/B'X4ZX\WY5>_/$")]TPW[(
M@_BI/C_CS?E5[\\0(GW3#?LB#^*D^2?$/&GD54)P+N^*5O+EZ(VCV?,?#Y'-
MB%^B!?JZ!]49YKKEZ(VCV?,?#Y'-B%^B!?JZ!]49Y/M_9^-.A.]?(:4B_P!T
M2H^H;3_6%<?\^;\J??CB 7^Z)4?4-I_K"N/^?-^5/OQR!YSGC3^6W1> ]WQ6
MN9?0;1;FN9M"_)VU:&Z2GJ%ZF12M/I#57-463SLPHQ\XLF\BOG=B?EYMR5XK
M\L9'8==4A,5#>.Q5KNHH94RH&IIM-N9J"@]K58@4B;3&[T*(FQU;/PHT(I7W
MX$QJ>RVR6?G1HC;L*=+G18S(Z2F9EO'(DZ"?N9;4_P!:3J8_M6-\O#G';^'\
MF<X]V<<RJRBC7)9&_-DS1-FC($J:2#BXP^TJ^MZRN,N*29HN]4)+"YPDN,%^
M&2MHCP@F;@OD":' <122+*A/YHH)DK<IDD+)=2HBB5);=9,G];Z>%6^I/@\
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MDKGM[EDJK7SXQ.Z,W[85+(:WWL^04R3K!.LL[7US$CC+R-\?E#I:91JN8FC
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MY'-R.XI*@J#Q"2Y$M=_?)@CL.<L-EG.,M2I%BLN+L16N(Z*.#)O%DPO=I]K
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MV-J^*.<\^R_1A/KVM?'A_*5^9^P/DE5?2CXA^%/V/-^57OSQ)KWI3??68/\
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M2Q$GQ@4)#!@'[ <G&YPJ$8DN*C(;C"HT0?'>S*)$&%YD-PF)#V-]K*\(V-2
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M+VG>F[,2N9LR2)'G2L+8<44]DKB49=F"9)8D9(R"*L-\I+#J':W367"=9O1
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M[Q5'0G>OD-+37W19_L<*^-D^.$G]H>_Y)W\TOB>U]T6?['"OC9/CA)_:'O\
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M*&I 4%5"3PE<XSLV!*BLK'%Q]O9B4N.,M@554S(X[BZ'51,R!'$)M'$ C;<
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M:J^E'Q#\*=<>;\JO?GD?QL=NRCN.S&>VH \=F?-GM*$^W&?X,^;./OXSG')
MQYORJ]^>($3[IAOV1!_%2?)/B'C3R*J$Z>[XI7R9=:>F,:'ZC=E4AICQ*LS2
M:[?3E8QEEC%1N"WR4"/&<7WF.P+-42K_ 'R<X[QP3CL\Z>?2-T-[_$;XZ?:
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M1D7(QXFUC&7()!B1'RM';G+;F$8<;5V*;6E6,*Q7ZS=7W3E/KAZ#$V>,>E3
MQ*+&:P(M&,NOR(;S33>,J!)QC*UJPG&<YQC';C.<XQY>>T9UA]-T<= 8=VB+
M0ZS"B-.)R'M/:EQN,TA:<]@'./V*TYQV]O9Y//RAT8[XFR\C+S+K:@XTZ@.-
MN 6Y0,#S$Q)%R42145%R5%SKE9*5&<:D1RD,/LN(ZR\RKC3K3@*) XVX&DVS
M D0A,20A5$5%14JKY_N8?2@[M^LDHE;LHH+,C%"\ZD0+-*S4Y;XA\>ZQ$4W,
M:EFXHF0MY>)PF$:C0I#:LL)::8RMM?45MIIAIMEEMMEEE+;3332$MM--MX2A
M#;;:<82AM"$X2A"<82A.,)3C&,8QRG)+JUZ=W[I7"K6S!BX$$18(TJ1@19^]
M:?F*'YC-YQD'A><NX9<[,I3G&.]SV]GD[6_]>1TU9SC'ZJ8KRY3_ .A[3V>?
M'W\@<8Q^/.<8_#GF#L6&<,X:.XG8+-:;,MR?!Z8MNBQXB22;#)O6+(@.AI77
M=FV*"VV3KA *$X:ELV)\:XWQHW:F\68CO^(QLT=R-:TO,Z7<%A-/$"O(T4@W
M"VC^R81YXU)YX&8X..$#+0A'/03]S+:G^M)U,?VK&^7BYS#[G[O354^/L'4L
M6W1U[$,;UZB;Z-JZQIQB9*J)38) V/-ID2!;0]$>4+G1)C33LQN5EIY&,L87
MWR$WIV+>C5<)TNIU,..,V^^%"T,6DX1EB@ R!7PDDZ9*EID >4G*0AIF(.A0
MX<-3LF>3CJ<=8BL27$[F['>?FN-@'K'M'A4U1L=B#9O&\IFHCLQ: W%//+2*
MJF?"M(F2F8+!2)*D+8FRVB V;CANR'FX\=IMML2,W'GW6V@%$WF:(N29JDI\
M.5Z_5PED=;42U!*HK%KV%:X] %UHL1S''B;:R2.C;%\KF(D.0\L)7OFM8YV)
ML,;F27C08S<:+%>()\7?M8WJ3>P9-\H)0$L%:M-CI=D'1Y3A <V;K)!4.1*$
M$'8L)^:()QEQ"@YV1#BRD1IJ(\MA$EA[MI=MTMAIQYUM!!E\X[B;1LC!P#)L
ME4!-25M' )M'D16E<%00U7)%LHU[MLN0Q&CODXY)B-S65V#X-&RZTV^VFV-H
M6A?5AUMY8Q$,@6C1PFD'-4D?APX<LJRM'#APXI1PX<.*4<.:*R%Y8,$5+#P1
M*S3A\-V3% B71D4@4?1C&&XD:2;GBQ3"EYSWRWYL^.PTTAQQ2E92EM=<S74]
M @UC11N!7(/RCO:NKL8(99[S7J;"%,M5\.:5 F'2;,F+.*/R3HP/ AC8SSLV
M9(\(C"&$+4G&3[Q;K8JI.?)A4:![_P"'DN(3;DN/!#0K++B&:RY<9I6P4G!5
MYLR 6RUUF;9A^[7E$6VQ1D(KSD=?]IB,J#C4"7<SV@OOM$VVD&!,D"\X@LFD
M9UL#)T=%6IYA7FS^+/NY^,5Q]V-'<E,)BR7&&5R(R7DR$QWU-I4\PF0E#:7L
M,N94WAY+:,.83W^$)PK"<?LKS9_%GW<R2+FB*F>2HB[T5%W]:*B*B]:*B*G!
M4SK#JF2JBY9HJHN2HJ;MVY4545.I4547BBJE4>Z8_P#.(Z\/^>S7O]B%*Y;2
M_>A-K]0D_JKG*1Z"N]+JO4;UTL6>W5>N/RMT:^>C,G; ($/2&DZ3I;:G&&B,
MR,MUM+B<H4M"5)PK'>]O;Y.6:N^V]4R:?9H\?9NO7GW@A%MEEJZUE;CKBXRT
MI0VA)3*E*5G.,83C&<YSGLQC.<XQSGFJFM=Z?_#1D_\ ZC55(BJHJB*J>KOR
M7J2I>#_1(SU?!^J,\48GW3#?LB#^*D^:@3M_4S8P>A>T-=I6B##2I.;M6<92
MI,5K"DYQDIC.,XSC.,XSCMQG&<<5HNV=5IV&9EYV7K[$5RK!6&Y&;I6L,K>;
M)$5K:2Y\I]XIQ"%H4I&%=]A*DYSCLSC.;153)O>G.'I3]E:();_5+AU+UIV5
M/$O[4E?R=[\VKB?K;T%K'JF/_6<YJ96X=2YC24XVCKK.<L/8QC%WK';G.6U=
MF,8^5/+G/WN*FOMM:KB4RN1I.S-?,/LBV$.LNW2M-NMKPISM2M"R>%)5C[^,
MXQG';Y>2JIM!WIS#Z?WF_P"E-)9+ZI<4Z%ZE_JGWI3R7^Z)4?4-I_K"N2!RO
MY7;.JUWVK2D;+U\J,P$LK;SZ;I6LM-./*&^"0XY@GE*%N>#7WB59QE7>J[.W
MO5=CS^K%J3]]'76/_P"]ZQ_VIP*IFYO3GIT_\,$HHED/JEPZEZU_JGWI7[ZZ
M^BC'M=:_C#W,W3Z6U_[7M_""G(^H6V=611I5$G9>OF%N6FSOH0[=*TVI3+Q5
MUQIU.%D\9RVXC.%(7CM2I.<9QG.,XSS-NVSJR04HRV-EZ^=1&M2'Y"F[I6EI
M89P*)(\*[E)/.&V^_6A/?*[,=\I..WMSCMH14V3:9IFFRS3IW$&?W9+56DMI
MS5^Y>JI^3YL?BQ[N(%4])]A^OAGP"#SSXW%J3LQ_Y4==>;'_ -]ZQ^#UKQ'K
M&V=6,V.^/.[+U\VU*-CG(SB[I6DH?;0#AM+6TI1/&'$I<0I"E)SG&%XRG/EQ
MG&*R5-0;TXETI^RM4H)9%ZJ[Q3+<N_UAJCW7-T$#-BD'-Y:9)-T+<;145)(,
ML2I @/<"^93$8>901@91(JMSCOYCJ398>/ $5MMJ+MHE8P79K;4NZ*]3G3+*
M9U]U::?-6'(Q.(<>SS$(JEJEMM80VT_DUAF70[PCP:<=Z2'2Q\F3V^&FS)4E
M3B\]=-A[9U9+KN&8VR]?/N_+5><\&S=*TXOP;1N"ZZOO4$\Y[UMM"EK5V=B4
MIRK.<8QG.&4KLG1IV$\--W[51@<_G.'X!2U4XC!>QC*NSPL2;/?CN>?/V;6<
M^7/X>=2WGDP)+W-Q+@3$LS M]GDCMT&)&8N-@O+RJ1*_<K')((Y2S)5U2V3
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M:^+C$['7:M4[381-=+$BQ8-75BAM@LQTW52L6#65Q'/'XLU0+*Z:UY NH$)
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M+G%HPEI"H3CRRP*+#:9L36$9CCR,M(Q,EZ;#(,Q)8V5KN#LZJN5$F</A(#Q
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M MQ3ZX<IMV= GM=X^Q)B[;7VIZYK:00= S#<EF5 A!AT(K+B2H]?KPTH?,P
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MK,+9;]ZO^M<)9M9@54MWJGONE>JGI<V1J+7,&]=*&MMX[%L6VNF'KC:DT+8
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>APX<4HX<.'%*.'#AQ2CAPX<4HX<.'%*.'#AQ2O_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g952280.jpg
<TEXT>
begin 644 g952280.jpg
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M;2B9W579U2 KMGU%C=G*H0@&;D KF%_9$L!=0'54,S"12BABH4M)GLUURP"
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M3M=A_N"R\4@X>]\!6.4W'M\W[Q_+P^GK-3CXSFY'K_N?X3)C],:/&<W(]?\
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MFW6#4)"-BDFAKM)')9N>V10+<I-RI&N;%2=LFDJM*WH2K;(J4@:VPU#&2V>
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MX:^)2U+FEQ2JX.M3&L3 MC!Z]3(CW)0^"8FS)5UB=O3_ -\IOR@GYS1V]/\
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M.&(YY!CCY<AQQ$,0Z!RX (@ \=40[6-_>Z.Q:MJS?E<]@;0XMLYNV)[C+&\
MR1JF;-N.K*!TVR6!*(T7 )N,QD;'N1L@J-5R].ER0,BNZT&($]\UC XJBHVH
M1K[+1W][%!Z=Z.TT>@>?<=3?2 \0'^O3R#SA[.M(8!&.P85?:\CNN#3S8*R6
M'*2)VF<'$=P-6NK&WDVD.?A-PB<'>[(<H'!1L;$T\N?9PB,1[.9$J59$BR<2
M%BHH[\V8="D%O?1WN%7TLTVRV$B6&V*QK%=I- &F:/DK2RRVLRWD2331&T,0
MC:.>4'ZC=2;22!H+VW1$+[13<A,V+1,DA":VV"JDL;0.41Q-KZX:-<V@D[,L
MZFH8ZQ+]C]Z,UU6%)-LV-4TTX6/0^;I/JUW=-%NKJ:L@J;-\V6P:,E@X4Q+&
M>>1&3NS<_P 1/!,K(R?4AF&1CVKWLN1%NGT8EJG:#?\ .U<[KB-6K>#<V/E0
MH73;G$Y3?LYVT(5#PC>9PW8VDN1VE5MDF.B"MCW!0FA$142HG%4<Z,[*K2JH
MA/8+Z/*;"JMLK9#$A9K.@EP-2A+NDAJ]<WSNKF.31JM%:1Q>;;<G B/UZPS.
M5-4(@F"D(%%4;^Z%,<91=U&9#BK:[[!"Y/512!?/=BJQUHM6I65HH4[FH,<6
MT9*;2<[MP2/*/.UQ0S=H;;;>7.Q6!CGB63,L:EZPU[CS>V*^3GCTY8\!)D$6
MC^,(,P8G:WNR-]O(CJ\';(D)M]G)#JW1>-BSRO<1*+23522_&IKXE8'F#@21
M9[I48%7%NH),>T5P8U# (J"%RTPC:,]GMJZ<,EQR:%;8K]DL?A+I$4M3.R7U
M*H6V\$LEW313:;F0WO;NK01JN96$YF3+)V&(3U]1K9% CSGH%K2L;G=M;I6I
MOLF]P7ANYV_T,T[:3Z[C\@PWH0K<JVSJ:Q-WG526[M7>J73&((\ZPY[<(E+X
MF8R7##G@QP:.^)LE(L%E!N.8E,&EB-PB&YJ%["M9%?W!"85N4V=U*HO>=5I+
M;+<F3<C 'YI<VF%[A8=N&ET0C\(=[B*B=?-%I22+JRI:-=((GB<Z/JB5GI7%
MZ1)N5/M=)NPJU*II%;7-T;-HHY;=I%:\LJ1W;-V$3![89#>6!&%N.KV]J+=/
M=9\KL$4C>?*,K$62O!R6M3,X&88K69K/26SQZ/""9K7 <7$TAO(X4N(+J5H$
M;"EAM97<7B0N1B+O,56(MZ0S9Q1K'8R5QR8D719L2L3&FP9WCEA7:D79>9 N
MQ+*#:JJ#-LLVV9+L6N%N #CP#B' >'.'3P'S<=&M20W][%0#AXZ.TWFYO_2.
MIOZZ:/'[V*_X:.TW_6.IOZZ:\AR"^]Q7?BTW^"NWRJV]T0?OH_\ %6VVC6I/
MC][%?\-':;_K'4W]=-'C][%?\-':;_K'4W]=-.07WN*[\6F_P4Y5;>Z(/WT?
M^*MMM5C]E/W.W9M>J"DGJA3"B)E:VZ2L*47*BJ2D&XM_1QJ81RPGAU51"FHO
M-Z[>IQ)BSXJW@D;$<K;\L463BI'MO:0Q#8+Q^]BO^&CM-_UCJ;^NFH!W&6WV
M*+=E"6FN[^W,[3)W$V&8,L_8T1>[.%Q%<S3..IG-(RR)JD$%M6,2)O<6],\N
MA!)B1V)P$M:=B;@9]KR=[#+:2WO[6>^PV\GM(Y0T\2V32LR9$;HI0D4A5B&V
M<C*CY:K'(FM>[F26WECM[NWCF9<HW-PJ -F#O="74$ C64%AGF-]:IL'94I[
M1<6A\/W$UI:MF7%:,+"84KBKH =FTCMJ5/.ZF [7T='MU'6'9MIR.-RZ..MH
M0&=GRAQE*QJE%<R$R5H&Q 0TJR-=:;L[]3.B;=8^Q_;I>+["=ND2M:7Q::H\
M(^6QW"32=QM%(3MF;UA^>+?7LB7RMY(=*\:YNXDFS>+)E[F.3&N1*6DJ68PT
M]A/B1%&D-MU;0%^>VRR9/;U'KY9N_89V\U[8DQ0BW2*1-#[.+ED3TIR7)@*'
M!K=U[DR(%21N<&UM1KVQO4IDP8?V#;NZZ%V-I[*R0W!H7MMM=K3;KHLEC;^C
MD\N:I[*2VN*)K@*C$)SELU9&N52X^!L\842M_1E.L@-<58F&9]_5P%FD>;1_
M&I)'FU]>.!K:,H;L%HUM89EBA)LT7(QL42>:>-8Q&+>:'GZ]^HC"8E8 *N3*
M\HD).P8 M*Z&20"X8'?J,8D0EBQ=63J_[)]>-H[O=O\ MV0[55]7HGNT]UM.
M[DFNQ9U!7V7U_*J(K*E+8C+K"7N 2AXBDC8'.#77$9 \=IQ<%2H]YRC:'- O
MCK@M7W7AQX!Q#@/#G#IX#YN.JI%<G[#PMM%DNDV^]G95I1ZY))?[1-4.ZR%M
MKPFMB8UK$:?E4F,R;K62IEB>15O X=%WF,+DRF(N*:.-2Q2P&.B8%P[2!O[V
M*   &]':;P   /\ QCJ;'F#V1FG'7%Q.W6X-F</P>\LQ':ZETAM[HB2Z:XN)
M6D1Y)KEVC6*6*"/7*.(X5#AWUI'W;24Q;?E5_;SEIM:%MK""L0BC0*RJD:AB
MZ/(VKFI9R5U1DHVWT:U)\?O8K_AH[3?]8ZF_KIH\?O8K_AH[3?\ 6.IOZZ:Y
MG(+[W%=^+3?X*V^56WNB#]]'_BK;;1K4GQ^]BO\ AH[3?]8ZF_KIH\?O8K_A
MH[3?]8ZF_KIIR"^]Q7?BTW^"G*K;W1!^^C_Q5MMKYS$<<,L@Z0QR$/; !'6I
M?C][%?\ #1VF_P"L=3?UTUP._K8H(" [T=IH@(" AXQU-] ]/_#33D%][BN_
M%IO\%.56WNB#]]'_ (JK)9]Z6\N<]D'NBD&!SD392U3[KX33"5/$.QZV/<L0
M71!75=/V(_#86[)GO^,1.J'M6IG;PWK7!PJR0E09F%@DBQM?2EV#>+NC?9F\
M93$+K?VW9]<@2"@MP5+[/YU!SYS5*5Z6[L;;N;"IEM11%S4OA49>6Z$)G6&3
M%UL9S>(_%75KFK2VM0BYMTA!H<[O'.PGO=\K]S2J_-L*6ZG6>1ZSG67,F^<Z
M-I76>15 PM;%)72'QV^FN#.*]&VQ>/H<\5L9/2K4K4D)<$ZLO'+'*#;+VZ]A
M,E-9K*NKK<CL]IYAE,WVXO\ : QW<M!G?.U(OMWO-7>3?&9IWRN8I0YR*3/#
M[,FI;;*M6JLU GEBU1C(' M$WH"/8*N"SFU2XP;$XPD&$PNZ888$C>%XQBLK
MM9W*37:W$0D,;RJ;@NPU6@R)/$#7L0G*7]FY:2Z= UV)"RL/4JA9HRD.S.YU
MC8)EO.NQSI7E79ZJUASE (6[;6[_ %5N&/-J-E]U/'#(?+Y/1I=,WBFH.;=Q
M*(HO>FNY73*5GF/L;:JY4&XOD-1JW/)P0.P)6-4J;ANRZ6ZQ4)NEN/;YL_FS
MW$:DPLE#3MZV+(J^PI^TWFCK[CU"7"0ZQ%GG3?;4-Q;I*O?38&FD#(@RGC>P
MK7'!4QY8)4"YU9UCV!\8Y4D4*L79*C9Z0-DN=>][MUT9:W9.3,YB18,O;I;(
MFVXDDBLQFEDX3$2^4,=FNLP9I#)2L7IV0*U_$X>Y96_8'5[Y?4C5SK8D:[[F
MHW,XC="GQEX+@5*(]8TA;I=8+>V(2K7P;X*$YEK0TRV8*J]2Q1;)96U-DD>%
M*QZ;TBTH%T=1X)$T<QDF.<R3)/!<2Q30B]$HB5%Q"$Q$V@$0+O.$4O"ZW$K+
MB$8MB3"56Q6P >/5C:.2)'C<P%2Y)@8/E-F^2[/,ZKJ8U0V\C8=^SKT]$K3O
MZ 3.@KM;XWMQCUUH[#L>.(VJ8QQ';NWNLT5DV;6(IVP$Y[6WY9'+X+!K(D"E
MIB\SG368VXIV=M<F=U6S]M-WI7[><IWUMUL4SX!7+;L13V4/JZ2K8G*96P&S
MG;B@MER]5<TKZ82>&3)&M>EQ*EH5L2AH-;VTPUC=4!#JA4F!'Z6+=@[23*63
MT+6V5K)'/(.[U[-\WC=9$WYDE\>D,#0UA)54GB3W;R^(OTOE4 ;DD3EEB.;$
MIL*5,Q62:02AR$X\PUY[>7OL.&U2-SN)4)?&SR L5F]Z1GJ8K=A#Y&IE.3%%
M\84T9NSI,+:D+L>:@BA93"0=@N+,!N(3$Y99=S$9%ZUU'@W))4LL Q>.Z>VL
MXUDN+>:55GCN+>2ZE1N5$1+)%'/&1L)FEVJ;/D:I*MQ;"][MD:XQ*R:%9)V*
M1RQJ61HY$A1@(E+%&9'SUU"E#K"8NAAT-VG=E)W5E[>0W=[GF>Q)M6*>CJ3L
MR5Q=HV S?;!$8^DMN>5='I'.H%N-G-_63%KEB561Z8/<Q6M35"8RNF,$:U4S
M:ES=BW@T*YOL#L\M2PJ31=B:]O%UV$EDDJNM>G7P#)BD:I;0-,;B5>V<V]HH
MPH<37::I9W.V25O4&@+(7ZH'*#1=;(%+@E/<F)L<GG4U;=@PH]JF<?K6YMJ;
M-&K J=^HV611UWP&3*(.5425.B2/$+)B4WOJ1QMI;%*-O2(R369K;G! C*%(
MW+4B<TXLQ9?8CV#611^B8LXV=LB+8]M<40P*G$C1NDAL=-C,";EC.XIX&Z+X
M];34XSF#G.; TN[C#[ 62J..[RBP>'5L6N9BA6=N3-H_/>232Z.XR\#3R&-(
M;-+ );&U*Q0FWM)1$9(KH*^VUPTL;,9=9D"/3'VPCMUC7$[ 2A5UG>=K@LXE
M4NVUF4D*\.L-39D(^6KDIS$4W7V9Z8QB+[GRJ\VH3-$]UM .R"+J)LJ>3"O5
M]6VG.NQ\O9K1;6#E&HY)T]D,$:1->6$P;"GM!'W"6D-CO$6M4WNHH7<ZZFG)
M9*)W5%<32;1DB&2^5P>+2*2Q-,ZIGQ/'7MZ943BY,Y#PC_G5R)1*5&912Q/Q
M*.+#$<1R$!R&MMV7=AA?4JQ$\7-LH<43AGN=S7(U>YR &I%?CEGGJ=S1:E,-
MH@2<GMLY2?D_)L\!3H<3!*CI3*4 8!L%7&[GL=%2P&&UC ]X&U9HA5?QIFA\
M3:E>Z>N)"H;(['T)+:T-YKW)K'>9 Z"C0IR4X+'AU<' [$O')0J.SXY#QL1A
MM9K6"/#L$O[6=)I7FDD@N7,L1)2%0[SRZI6-(GD399&XDG:-HX@D;;UM+(DK
MM<XA:RQF-514DB75?<S$J$7/-F=4.N,HUC#J[EG&]>C6I/C][%?\-':;_K'4
MW]=-'C][%?\ #1VF_P"L=3?UTUQ>07WN*[\6F_P5O<IMO=$'[V/_ !5-!M/T
M^048>?6E;DDDX9FFG&PF)EE%%%XCF8889FTAA@7AACEGGGD(8X8@.60@ ".M
M:$UQ;%%C<O<T9-:+$Z!9$D8$I*?6*G)T]7C@O:H4OC;,1 C'B6,<K<6MP11^
M11="\,+LH2FEHW(T0#CNJZI,G%L<4!9Q)!BU"L2%GGI"' @G-2F-(Q-.0J1[
MG6E%Y&!F8D/_ )BIP#(@W^9F9:JJPV&6Z5&B6$BQ8,W-+*\U2Z-4"97"Y4%?
M+G"N):KD"J0-9+A-WN34\8[-IX,B"'5.\ML48\##EJ<##B46)'E\<Q+22T>W
M[36JWJ-#>-<&5I&9)8XT-HJZMW;ZJ-)K&7,2.R(%A!D(%<W$Y,0@:'M=8P7*
MM'<&8R("5=4!@"Y31>E9RQDW.Q5=6,:Y%;$++2V7M[E'&9?$65$[2['+*--B
MO;;-DZ]Y$L3^Z"T20ZJL#\ST128Y8X)\L,3VYNQQ<UQ:=O,+4YY;#9FQV3A"
M!8?! Y#8\AG44A6)%=H<<WV05FC.<)RV$8'1(K-,;'D)&:I28OQ2)SR<BLT)
MRH%!';%R-47,R7?;:^/SI%T!E(.MHJ7-K:'2>2<MV03:*/$;:"D$AGKHZ28]
M6BS<2UKD>_KEO'''-(WY%D%I\"]5*P['=+H',:ZDJRRHTXH8 KQ=$;42R.I>
M)3Q(H'.8E8[@A-.4#VG.4*U-;+<,#@S[65&WG%1D8:O1]JYLV+::QS6XAL;:
MY@FN(8Y& G@:V@,>$333OM<2+29;;%K:-!"CB>UMI'39EU?3DGQM9(1'AUI-
M'+-&LC;$Q&&(IA\DDC:]V6;+:W\**(U;:P0NRZA8/LQ%YWLWF+<TO#%&X9FS
MR!XA3#'WATHYWCS3('2Q5"A+"T[ Y2*O6I"]X/QJ8T4RIK/5HR21*4K%"9,H
M3FFOQ\1;7XU/X15C['*G;; L=)(%\)BZB$1SOC($D738+'T]();#FF*Q0IS
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M,;TDH-ZK%*!ZNO=CY)"[E$XG=TM^?BGY"H2X\OM61O)PX&XY8\!X#PSO%LW
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M<>-W?V_$5IMXMFX'\)+O#]!-C_ZIFCQ;-P/X27>'Z";'_P!4S6Y/(S_N<O\
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MA_M>RCX39M])Z>@5ICEERS .<_GM]TZO]V=_P54W8RTA))V^%>,W/5_H=>6
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MX189]-Z>WJ58?O48/1=H^CM?.49CV \,XO'<!$.(!G&F7 1#B(<0#)O 1#B
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M[4:]'63] TI3-\---];M6?"+#/IO1X::;ZW:L^$6&?3>GEZFXW][4:]'63]
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M7JJK<@5D7=,TR%,J( TF.&8YJ%@*<%6(L*, 4)2^5EW&GRX<,4H\!P$!^UQ
M0 /G?9-8KH_ 5)4]M+?>#D?Q>[W;B,_XY95Q<=)%FF1R]4)_L2U!QCDY</\
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M1[(]:\>)K,SD#_Q$/5!(/;[_ #QQZ _Q[^7NZPSW^0<<?Z8)!T#_ &>>//\
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M[ZBK!+GFG!3VT"<LB^2(R'B:;@(C@<?AEECR<LBSC<,LL Y@PRRPSQ'(L
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ML)##DT;:U*M9E\OBU?Q.03N<2!IB<+B;6I>Y-*GY7@WL3"T(L<<U;DZ.!O\
M,4J1/AGAD:;F/# ,\1$.&0:Q4\]A*R7FP!)+8ZKFY#&X28^*)79(I?2(^TR+
M"(NCN>A(,,S)1MTI,PCR\31P.1N^0(E!)9W$ H.=*1[* 3(Y0C-.O&;3H=JY
M]<.UA*;A3L-<G61CM(9F$F754_L5ZQV%2A6_;@6LP]3#YQM*B%@1Z?+I/;>&
MX!!"W%DA[@^,MMV\:L'K<;)MOT-MXM;";LO;<56D)D5\N:&*[C9T9NCJFUXW
M 2G.662^)BXK>E!%V#5#@Z2M,S1F,/RPX][2)%C(B6*%*OHY&8XY9A@8.& 8
MCGF&&8X%AG_N8F9@')P SH+',0#,>;#CJ";.W0;;*3D35$+DOZG*IE+ZW(GA
MGCUBV)&(<[.+0XO)T=;W9.D?7%%D#4M?TRAD2.1PE(3W5.H0EJ,E!!N&%0J[
M;)V0=FN3;V*V7VM.L&.(;;7)SN!GE+6\,E?V2XV_-K)WDXOWJ@W/5<G11J1H
MY AA#.RK-NVY)!)*A:XQ7<*"(&QTLM-NY?FT69;B+\O IULZRJNV_6WL[KZ@
M)NV5\DIQ:-KHE-D[D%-@0-V<+#@D]ED2!# K%:D:>2P\(RK[5,%AZ!X4/S.E
M.9U*WZ9Y PR+!S-8'IJ?"V1^=XJ\&-"],XEM4FCZGN-]CK@8D,-P2/;,K_G9
MT:S\L%B%1Q*4$X9APTMB69CEECD69CEACR\\<L,\<L,. #R\\1 ,L<.&6(\O
M( QX98CQX" C2#)MI^YFMR[@EM$Q2Q%4GF-C]D"-*A[9N2D,"CKY7=@UK@S;
M="FDE/8+>RPMU,DC''W:,R%F(C\]C\J+4N+C+8:JD+Q)2-52J2[)*TQ5-%&>
MN]VP9,-X6M8M?MBNW.\\0>&68QJAW6),,K?6CLB\SN"HA8YG&K=4LDCFEN[F
M8' BI-*&:1T9.S)?'FQL4KTS#CECCB9ECGB7GR@P,RPRQ+S'#FS# P0##,<!
M 0S#'(1Q'UW#44Q^]:2EEG3*DXM<-722Y:Z0IW.P*F89[%W>R80W*A18IUTL
MA*!T/D3 E,R<FW 3G)O3XDYN+?@H$G->CQ/K8VQ4]O)8-[UA3VV!G[9 G"6;
MFEK_ "M2Z,;C6=CPJ1S9*.V6,,^&6YB=KG JM83BT@Q%LFU7;^XP<625LTE?
M949+#CY&Y=O=76&Z;KG2=V?MGGE*Q*MY?N?4[?D,99:33U21X7I@XFSJZ+1L
M=EN25W'95O[AV[$)(FC_ *A8E7%?DOX,SPTO<MCZ"8H5*M7T:-&E*-&C1I2J
MEK,O_<TP[H+5J&EY+69:V56?&F1E67FPSV>0VNXY$=A*N\7;"*0^"SRNW#)R
MET^1-O?@#I(E;@1K7EWR2KW<I$G/TOLO>5>TDAN5D,TB9(/#)_"YE-[2KPJ9
MVZ4\RN0./8CJ/W1QZ,53822SH\ZTPUQ^7OZP6AMK="U+5[BB63)?W0]/<K/=
M/1<*! *@58H4(JQR',58HD@JQS%+W .0JA)[H'(4(BA'(3>4*(11B/<O\RTC
M+H;#W3O;WSB44<>\J[!T9P7QEA6XM+D6SG1XIQ;,53<;BWKRH^H4,!2Q&!"D
MMB/.9<#<6LS-(*E4$7=V3^\GF2[TJRJ.Q=O<7S@]$;W9;34RSB1Y,PBDRVC6
M3$(J\%.C"Z[AC)E+EZN/.LRR4K7^BZ5B#%(HD9(8<=;M>HE[@KEERWE;DX5A
M81%:C2"R)5(??%HV0MLPNZK D$[3M?9$)YM_4L%;2$ZW2RJZC2V&QN1R.+]^
MAG[' CE$2B$9CHPALRQ0W++X%!74UU/<X1"W(]][N[^'N,1C:]0]=\V8Z.N?
M?A0K:SCG7OE'E*AA<>^!BGN]C4'LZSMS:<:ES@&_[PC^W)LB;8P[>+0NUXDK
M9+U*2 41"JXS4,M?5DV())-9-(7*PY96U>M$;CV+HS%M<94R7.1S&1NJ-LA<
M8>W MR-0*5I_M3W[V7>VYYMJ&3*]MF<<FD$W93Y% :X<YPHO^A/%RO"NJ=9X
M%N$1OTB6,I<QDY4S<7IZ,1Q."]ZGMH61IG9'=K;,Y:YZWN#;O#?%&X6]XC-K
M3AD)J:Z.R6*Y5.';=[/)7'9Q5U:-^X^%5_5<&VL*VQ=#*T>8E-6RN'.+SUK<
MV)PAR2NUKTWGN2B4FL"Z=]O5K[/$.Y<; K=KW%RQ/;JIZKZ WY.WA5,:9CU@
MVQ5<<WI2G;[7#.YR!5;C)*IM6Y4>F9RB30E^;L5T;;:#ATV1&QQEK<C8QZW\
M5"DI2M[;AU:6M835=DTNR)PFO6R*Q*NYJ\A2AMGJ[@D<E9KME%7L421-C/5\
MLD![).G5EFS\"MM9S8UC(ESHA;%*T1L'LA^XNCJ[2PR7RK;P?;^3%M_/B4S=
M(#*L8W(4T]VGV%<4L;WEMGVYBI8IE)H_)*Y%P/F<NO:O4$CB;JYXLL&?YXG0
M1M>CMO9A+ 4IPF6$3I"30U;M;>+9C,9@$ARF[_)K:CFRUKW3R&OG&6Q.UI"_
M5HO9'H)!'W2.6/0+%%@K]$V2YDOQ[F3FG@2B[B(N=>7! (-83*T,\AAE@1:
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M-Y(#+1_8@'W'_P!NO6#_ #Y_CG_:-'\^?XY_VC43V"L/.7^4-X,B#^(0'_\
MT"J3V/[4C(XE/OR_-X^'OO?_ (5Y,<Z?MP<>:JK,'GZOY?Q\OD[S<=)QU.V]
MR?\ S46</M5[,!\H?Y%UZW_Y\_QS_M&C^?/\<_[1J)[ ^'DD_=%>;_@$'\QU
MYU!NQW;-EGBDXR!&ZVCZ1E[;W_X=>[R'Y4S</'/^I+:0<><!RKV8" \0Z</Z
M#>M_ET<-8N=,W#P_\TMH=/5Y,?)QX_V%Y_Q:];C0G7$.$C,%"Z) 5NQ1^)YS
MD>N+<,00D%=U)TP9"+45CR.U"C$ '++'MW#DCB&*_P 5OG6_]HU#T!<.)/\
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M0%\L0P ,5*<.C1HTI437?=M?;>*U?[9M!>[-T,C>2$MQ4L<>=Y.Y=O<U9:%
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M7?*+.*2(IHZO6]KY8MJ^U=@>+\6*9E,-PW9!8W8-I3G<DT[%&N;(*!?-S+?
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M5C(ZR.HU4!;(K&YSRR&0'.16O<W4-I'M9V*H6"9A2QUB"0,@">8&M_\ 1JL
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MKQ^FKD]&J6C^R5VX5EPQ@5<9!T<^<I#S^9V'269V3BX,1'A7]:CP$>G.5^0
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MGQ-S% W8Y )8I\\"\LE('&<! 0Y+IUYK4?9@+N:U+HK1U-4>![RL!<OS,76
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MZ$W(W5<<61,L0K.<[5@AL=(LFN5-SNU'2RVI:AFSTZ&1RVWYEHFTGR:47&V
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MSL,]KY@(>&JN@#CQX^I65^WS_P _Z]#7$/.'NAH$0X#SA_L'_9Y=8]!W0/\
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M1Q#SA[H:VJNKG31F2DM*A;,S7!G;L<Y"R$@:]-V;D0=F8MQQQ2IBL,L1(<%
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M#S1$1BU55M)UV;(BK8B3HI!/9O"7,NSH\>2I5SO@F7<1#PNV]Q  $0]4S%Q
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M6Y5!+MP3U"%4U9G6'X6A92B22*-M2V_D=PL#'^P5Q?BH.[P^* !Q_'KK,O\
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MEY\<N1ACAQY..( I4[Z-09XPT$^X5P_ %=WU T>,-!/N%</P!7=]0-*5.8]
M_+T?CUH59FV-\L^S)Q*FF30EF(5K&=/FB3X+W)T[:C9$:?,]^P39DEHEYV6
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M,39)>N9I SH7^;M$"0HU649<UF+N]OI$=0JCCXO)I"S=ZQ7GXB>I(=CU"<C
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M$Y!N8AB+M2R-@6N#PTHWMI5ND?R1X/S:F<D1Z]ES<">Z$&#LB*/S4MN2U/\
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M0F/6$/#6>D3+1;E"HEP1FIR'#'(O 4)QY9V1)2P,S2L!2F9XGAF87@)?*SP
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M[2E&C1HTI1HT:-*4:-&C2E&FI+D8K43:6#2+QVJ0,JCM /(L@INTJ\<^[^Z
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M(37\ >) S226HH;$D:1*VM;A-E\5A!$H<SA6J537!HLT-W>MN1JTZ_5W[(Q
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0FC[(Q ^KV7_E[+\YI2O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g984706.jpg
<TEXT>
begin 644 g984706.jpg
M_]C_X  02D9)1@ ! 0$!KP&O  #__@ _1$E32S$P.3I;,3A:0E4Q+C$X6D)5
M-#0V,#$N3U544%5473$T.30V7S%?24Y354Q)3E\T0U],24Y%+D504__; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
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M/;Z)> 62$X)@H05!+WP)W@[XDZ].^!>O>$@CX < [@_^+!54SB<"G*84QZ*
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M-Q#5!G6W9'DM&55SH8J":.**KCK%>$2F2-"BJQDD3:,LVY66-98WR-\4B,%
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MD;,1KD'"UDT/MQFFN"5HTOLU)=U%S<=)(/\ X-/9!2P12 @K,LI36?=NKO\
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MI1PY6ZO&A*CX=YH]X5#O$;(ZQ12%&D/(EI8UD"L6SESF5G&,9AM7>HX>U_\
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M/?%T&>Y6Z;K[1Q('X-[,LKU%F;D;IBIQB0F2TA;Y9ZW)N6APK(YJP[\A9(1
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MD4LL$L<\,CQ30R)+%+&Q22.2-@R2(ZD,KHP#*RD%2 0<C75E5U9'4,CJ596
M*LK#!!!Y$$'!!ZQJ"CA;R)W%PCWS7>RXYXW%Y<5)QH]'L^.7\\FFTCN2NKX
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M%G"5-43U\UC+#A90&=&DIW E*%V;S+T&$" 0N3VXRRM]XNEI\9^YEPJZ'QR
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MXO7YM<%!CXZ?5EL__P ]\?5FY,8QG373742@/S_+ZC&#U^OU"'A^;U!\F *
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MHUEO?2>Z8XLOI_;NLMIQ9DRJ _UW?*M=&H%,4#!WU*Y*R/DS=TQ1$B@$.7J
M&* ^&95[Y?#QZ"/B &_LCT^?H;H/^[,O/!/32O!4PRT\T9VR0SQO%*C>AXY
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M!SF>MJ9JJ8YZ\RSO(YS[6U=4U'244?14=+3TL77T=-!' F?3LB55S[<:X
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M'G\C:.RQ[3",74%)1L6OZDU9=VZK83"14Z[R W"9JS<%4*)2,W"A5U$Q*O\
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M2*)*I' 2*)*$,8BJ9P$JB9C$, E,(9&GV>O99<=NSBF^3,]I1F<[WD=M^2V
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ML</;*=@2&B6Z!@&6)M3W)J:I81GH:4K+-Z))SAH(O:(@1.^/RC!S^,-9W
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M+]7*D1KZA"2U/3)'#;;?N;Q*CBEEJ)ZCK;[,T50+G=)Q<;N595G,9CI:".0
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M554,5--,ICG,4A1,%=<ZW[HUCS1QF&G58Z>BI@=WBU% HBI8 0!N=8E4RR
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MJD*4 $1'-%K+VB>F'4N[J&@H._\ *V^-CF;J0>A*VO9:Y'N@/W"EL.RWHQ]
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MNUYX7F>2KEGIHH;7<IECIY6+BE%1X_0M#'3D]'"7IZV0QXZ29G4LVSXYOO\
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MNU,@9--0LS6,HKSPQ8>(&I6O-LI[@U%(TM,9ND'1R-LRV(W0.?(7'2!PHR
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MXCUR[,9.CI*2+_2IJ>/ECX.&-!C.<850,9&?KY]>L]47N\UG^UW:YU7E;O\
M$UU5/Y6-N[X65^>T;<]>WEU'&OSD:MDS <B")#AZC$23(8/[C%(!@Z_+T'Q]
M0]0S2A3LX.%BMC/<%-&Q1K4I/#:3V$;9L/TP:QFD_30S8O\ X7^<>DO2W_E
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M,BX\FL(++HNB^525]WWHYA^)-/HK?W6<>CXX1$H-&?> .HE\V;=0#YQ#R?4
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M#17>")%\;BD988H2ADECC#+$L6]"(G*X+/)@+Y96,,5(WK#'>>U$YW<;-_\
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*8QC33&,8TU__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g1025011.jpg
<TEXT>
begin 644 g1025011.jpg
M_]C_X  02D9)1@ ! 0$!KP&O  #__@ _1$E32S$P.3I;,3A:0E4Q+C$X6D)5
M-#0V,#$N3U544%5473$T.30V7S%?0T%-55)54U\T0U],24Y%+D504__; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
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M$9Z5860X-BQ0D/W2J4ZC70W<2#RMPU,"H;,>%'%CC+])8X 5!2%*0Z#UE8W
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MFZ2KH^QN.64-2M="]"B]="]"_0&FFFNNFFFA>VOH+TUU -===--0TU    U
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M)<PSUL9>@B">.O4TG,>PV 6B]'"6-D,VAAFHQG5U3735UYPM%8-4S1EFD37
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M/DM^< WAR=',]G2#^TZ3&A5FVKB[:+6]!IT4@1D.<K;R$B=*K0V-'"B&:/3
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M4MY'QU<BJ=:ZF[FR!G4(P!W^P-E:Y[0-)NCJVK)7%/JTN62XAOJ( (; (#[
M(>^HB/L  /R'W]OG\_;YY2,Y@<KKF0DQF8J'4M  2A]02P6JTS=U>[2M0D=>
M[1LAQ)6N599:\X/W1R$W/%IQ66Q^:IA>QM@;$!D49>"CE@GC?MEK68)!":M9
MA+Z98)@"6,OXA;EG?RQC&0ZDDQC&$3&,81,8QA$QC&$3&,81,8QA$QC&$3&,
M81,8QA$QC&$3&,81,8QA$QC&$3&,81,8QA$QC&$3&,81,8QA$QC&$3&,81,8
MQA$QC&$4:7E!B=,7E1\=XFS7D7$./5WW[9-=+N)KP\@WR"1K>05)3V,7+7KD
MR5HH6$*+ C[#*(@RC.VTTK1E+CSB:G<G-J5KFM1M&G]>Y:<V>7%?\$^:/)CQ
MPP!RXOVA17+FTJ+XQE\@EG(6_P :H?6>W*E-9T5ZML4C\#J@Z4IXU)[%45D[
MW+(F8&U+$U\KCY;NLTW[-NJX*;X,^7^<<F.=BM/$*BO#B3150<1N4LRBKLLJ
MBC9G!9M;*Z^Z(?;&2L[BU5))[A&4PJQ43Q(E$?9)JRQQ2R;OYJIB*:QX3RZY
M=<1O(?>_!"H^!4[A?*'E+5G,:@KZ.N&BC/TO9>+?'J!S'[2Y"RBQ+=9DNL:8
M8Y9]:IGZH]:J62D%UEO4O:$^T>5ZMZ=801600#H.OO\ <1^[W$>QZ#L>@['V
M#L>OQS.>.H=:A[=?@'L'0"/MKT'M[!T'M[>WMGEA$QC&$3*-?TA?_P#S%<5>
M_NX-GC_A=-M#W_+YY>4RCU](-0@H\P'&-1N/1:?@FN  UV].XG?K>N,\H1 =
M1 2^D^P;AV&W8Z@'S$0R -HL;MTI,3C%TXZI2GVMR_8'3;:R)V9W;GAFY^5>
MNE4)V>KW1>O&XM)/UOZ*PQ]S\#WR=5=/$6=^'XY=V;X5QSC=IN7QXH8LS7;3
M?2F*MTWTWUVTWTWU@K#KMKOIL ;:[:B AMKL ;:B @( ("&=TYUM3?\ _:.K
MOO\ _5U!_<?<?_RLT_,?OSLG(R@/91I#SSVU*P\_OVP@W/\ UX5?V0WDV+/2
MNW#R9G*2.+/RS.=V<^.>&YXYXYX;GCGADQC&9:A4QC&$3/X*4R9:G/2*R"52
M522:F4IE!6AY"A.?IL4>0>2;KL6<2<7ML6:49KL69IL.F^NVHB&?WQAV9V=G
M;EG\.S_#M^SKEG<78A=V)G9V=G=G9V?EG9V\L[/Y9V\LZIH?2 N,L%X]S'BT
MN@&TLI[C#R>GMEPCE#&8G,GN%TU-9Y'XFTRNA:]F2!I/;$"",SAX)G#CO%U+
ML3&)$_11H:$[*5L>?JIUX\+?)*N^(WD/<:)C%G,M><<K/H28R*XJY4R);M4D
M$N=LEL'34S,6Y'\=?'JSGD[8ED^9)"G+,CC=*HVT-CV_I3UK2RKM[O-FU96M
MTP=_K*WZ_A=HUU*TFJ&302PHPRS&(2!'H<6I+3/,<D*)P:7$HE222I(!2E,$
MA222H(V+/*+,UUYB_C[X1P:I76BX)Q7HN"52]N6SXZ0V#5S&X:@62 2O@:R4
MU7'$3:[?I,4FZ2$2,''[:3I-=4A"[1+KJ0% LZ;;IYJ'.:UDQQ@5*-R&+62C
MEAUVY>N32S36[D5.6,@*5YG(RCKR2#8AJSL1!"5>3TOB>O&&SF@7^G75K49-
MOGS6Q8.]:ZM16ZMWJC@]?P=&C2HX7"7,Y4MA8CI!0&&O%:R=6K)C+V7QQ1Q3
MWX\I4VZ1K4C@E3+D"I.M1+""E218D.+4I5:51IJ:0I3*"=MR5"<XK;4PHXG?
M<LS3;7?38=1 <_3D'%M\?^1GC;@-G7WQ$ME5-J'K"'S"T9OQDN%4>\H4L3A#
M XRN1Z5[)##M#$B_[,:UHI""MF%Q-VU(!<XR,W35*97[)\XGE4C[*5S$D-CT
M@]UVD8BKED'#=OIYC;X)K4QC*5(W&"L-ZZKU5LZV$WPPPQ>V3EP6N4;63@H"
M542.BQP(M<@MWIXQZM?:ZEC6[]N[!CJP2\WZ%^S/RPR8[(4P)I:H\#ZTEN"C
M+5>6)K4,/JQN<;#^'G.;@V8R?1C.8WJMKF$U[(;3EIZC#K6RZYB\<T;S5=IU
MG.6(CI9>1BF>A6PN1V&EEQIW3Q&1N^TLA#?+QFB,&\F/!F>L$=D#5R2K1&1)
M8\T21(E>WO[&6IDCPVI',E*O+<$Z<I,XIR5FA*I%L;]8*4%G%"4&Q6X:Q6>0
M3SCRNL;B;./G .)T9>,H9H'&;)MFY[-F$D6T]!4,X5/!$(K]C9*RWTDTTL-]
M;V)UD3SIL^QYEAC,6U%N!KD[/'U%NF)]JUJM5M79<]B?:T@]2U+%>KV/0'U
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M5W=Z"D[G@EOO%%3]T4MKP4V1*Y&F$K8 XN*MM5-2,UZ3*7U.K82G5(?!C6]
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M>G)9\9&S:/K,AM+%CY,?,,<,0SXC(9+#3-'7BC@KCWXNW4<FAABCBC8^YAC
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MP:_3LBXV<UTPO^Y+<G,T^ R1FST@['I=A*$S5.2B/K9M*V'7X^QO7KSW,?\
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MJ3/6SH28/_PS4>F__1R"RFG[9A6<LOK.?Q@-_O+V(OU8G9O/<,TU<(C'CRQ
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MMF@*6O9IV9;>K*'S]%\'<@@R0,R90YH"]_\ ;%J?"M27MH,V'H?C-CBD- 0
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M]*\$-N1WB1YW5BB)V#5<]06-I;;8B-??8PW1R(:8DD-*T++4;]ZK!#8"0_:
M#.R^6Q7Z0]XV'1;HV3R8V[1[H.WPS6^WJ0G;,<F-#U!N6I-C*.6)BO1L&FNV
M^YFNNOQ2QV](?$$O@^E^_=KR5M:NY6,6=WDP$M/8H^&^['@K.1%V\MY9W;CS
M\+Z#>M3<F";-5J)N[-VY2.SB"Y+X9VR<-1V+[.S\.S_+*<K&:#5SY2_'9:WP
MM85S,X]JSCP 243W8S-#'(SU 6(:@V38R.KP,Z,U[+V3AN AN Z@)1H:;GQB
M=0N;(]7&&RV,RQ!L ;:K8P_M$@2;:B.X!MJH9UBTK8!$O< $-Q 1TV#_ -W;
MJIW\-F,479E,5DL:;>'"_1M4R9_V<;$4;\_RX4_4R>-OMS1R%&XW[U+<%AO_
M 'AD-<JQGCZ]0#L1](?](!U_[P!F0$!^0@/\![R-6<LXQC")C&,(F,8PB8QC
M")C&,(H[?*DNMUKX2VBOIQ5:+8X%/]1:6:]402XGWTQ\<SK@@Q/)IZI,MG3*
MGD;.:Z&,GZV,&L).\I2FE*%D.UVEJ=DUVJ^<.KHXKK[U=*U\:=QV[)+>COF
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M(Y3'&61)=M=O3ZM-D[RA7%#KMZ-.]1TZ'TZ_\T.N7XS["0XR$XS.,Q?D3 G
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MV0PO3BT.:<DQVV<A.)$0^KJ7H!9>A8#OL&FFN@;&;[&;[!KJ&H#OON([;["
M=[;;".VVW>PB(B(Y6LYG-^KAY^N&243!)UTX[TTN 0T#?L6KD+?3MJ7Z1VU
M /W0@1MOWV7J8.X!L.@:;86P;%?PVF[-C*<5.2'99].QUT[$'J3Q14]ZUO*1
M/5E[Q])SL4XX[$<@RUYX"(982,(9(MK]"</3R'5W6\C:DL >OZMUBR588I&:
M&223HKU!IR-9B<#:40AL')$X=DT4HB\<C"4@26%*ECTJB575Q%IS( ELUC<"
MAK!+I2&YY@264,L::VR0OX;JM"U.X/+PE6N0;GZ:';@I#<W74S;8 ["S&H]Z
MZC^.H#_V9G,UOAN%JA,8QA$QC&$3&,81,8QA$QC&$3&,81,8QA$QC&$3&,81
M,8QA$QC&$3&,81,8QA$QC&$3&,81,8QA$QC&$3&,81,8QA$QC&$3,>D/N  '
M\0]A_P 0ZS.,(N(2JOX).4_U.;0N*3!)Z-B_JLICK/("/A[>VVGPG9$LU#7;
MV[  #L0#\,TOG_B]X.V$8>K643'XNZG;"9J[U\O>H*K3F"([?$)3Q]P2M(;A
ML/8>ML,U#VZUZ  S?_&161P>%RXN.5Q&,R3/_P =1K6G;QQR+S1&XNWV<79V
MX;AVX5QUCJ)OVDRM-IV[;9JTC?+Z]L.6P[&W/<XR#C[=<)0)W?N"02 F=V(7
M9W95_P#F=XAK57<3N2,"X8\MN2,2F,PI*Q8S$ZSDUC[.$-F#BZQQ<G+@BMT'
M=CVCZ"8D;GQ;9Y-^,#5J[_7#M_@%&[!5(8Z=O*_'*H>+'';C1>]><D8S8]0J
M8LP3"CK.K-GX@/U:3:,/:FS9W.'>)M\1AL?K)(U*1+<HN^.ZN8Z+4;+'"'D9
M)J6;]+?/ --0'OW_ (#ML.H=>X=:B(ZAUU[= '7W=96;73K7)Y\+/7&_C1P6
M4?+U*]"]/'6*RX5Q[9(9GG&.%O:P\1U?;=K>J(NS3R]VWL-^*CJMC,;O^/R4
MVM[6?4;3ATC-Y39=<Q]K+PXD9<E)ZM?(40QTUJ^39>\TEG,_FKRE[*243+'4
MO1BCW>O,6R[J "'<,I@6<X'B3N4[S9IW3I--]Q+$-5#BW^HE3J(;:_$^.K)$
M0U,TU ![;77Y:VT#MG#AM0K_ *B?J2G_ $<N9.@VUTU$WUJ#-'23'[')S0UT
M$K;8$AQ/JU^(GWVWVU)E?P( /S !_CF6^IV1Y]'<=OAYXX;WN*L\?_?8>V[_
M '?R[^7;_"/$&W6G%2=CW^A70V^XN[D_Y!N.(<^7%^';7-[PP"S=K,W8 \,S
M_<Y'.*#;F)Y!F797^D/C8?7'0LW5,2,4N>-KQ$_78P##1 ML7[J$>_H#X2@D
MO4O4!#;?<0WT#,F>0WD8U"H"2^-+E"AU3_")$YB-02<HQ7OT&VFFZ1B(T,3>
M_>BM,:KU$?V3=2NA')7?3K_S=?\  ,>D/P /X>W^76/T]L <^CO><?QX:UC-
M7G9G\^7>/!UC?R[>.]OCAG;ET;JATSG[???ARZ=L[.W>>)V_K%CB(6]-N!&Y
MU%R\(/P!LSO"3<GW.+\</%"/E10M!BC29\-.9T6U1$E_73-ZGU7ZIEAGP0U3
M&#]HHM0+W$WHM3MMH&X_##X.NQH:Z_TU\PO&),9L3(81R/B)A!&AJS](:7="
M=$1F^I8Z)U/U-U6&Z;[_ !=?AG"2"4P.MM3@U,*'>5KTA^?_ .[;_P \\-RB
MS-!+,U S38.MM# ^)KL'??6VN_JUV#OW]P'_ + Q^4[B'/I;A3D_;WFKP2^?
MMS[3*4.6^.>&;[\<<MP;=>A4_;[SH9GJ[]S=WY%U?R%(>W@.Y@'-Z;LKL_+2
M.+D1_P 0,7=V$YQD-GE_X*K=BBW"RY'&MS"-CC-9%6D[1?5A#OTDJ!3,J[4#
M30#_ %0E;&D[?_%#H>N?-?E(X$.PI]4_)&')C%(;^C1U;)>S_#'3U".JG=RC
MB<E+N(:C\/4\W03!VTU+#;8S34=UW.&1!Z X'B+1QU^L%:D'_:3$U+_C$Z?[
M))OUI&<!A6O7[)>_JTU^X S@CGQYH1Y$W9WI*HW3<X@4IICA6T,5F;IA#8/@
M;&',NQ@D@&^X!IZ@U#U[===CCVN^1^!S6J669O\ >Z[E:Q._+-Y*/9IQ;EN7
MY8'\N_CAF9SY?\-UGZI-!ZT8HW+R-3JII>6A >.>&"UTCQLI<$_'F=G(0;DA
M(W,>J6;GGPS?Q2ZMO)FFM]EFYFA&JN;M+7MZB_B>L#=70U%LF]B]AU%2!(;A
MZ1T'8-]!V[*:N2O'9\^"#/?%-N>R@[=.GT0V;"U!AY^G^V425H]?$,,UZ'O3
M301]A'Y .<">.#?#Q]VVV<N-%*F[;)Q2B*>OH^W_ .I'UCT -R1(&I@"9L.I
M^OI/U'TCJ8 Z:>GK=R\8G QU'457&F!%[:E;D@+>;)&GO7?W]6X-C\EU--U'
M_P!F>;J8:5[ 7MJ =8[]^CX9X-0M>/+^[S-'E_I^&]ED>&?ZG^2X\-YX=W/#
M^&FPSNV1ZY8AW?Z1?#:#L;"WU^"+\^U7O=N8V=V&/NXD)A#N$1W";K"@;QJ7
MLTS6).>II_U8H6Z2LBX#%'>H? +%*O-#<[O?0/A:B)G>^H>GO8.^5EGDG:CL
M49H;J CJ.Q6VINH;!\]1$L=@#8/;L!'OW#V]\C47^(?@8KW(W2U"Y,HD!M__
M $6Q;!2?%WV'4=331-D2C;XQ7I#X1A>Q8Z]B(^H>A#BNWAUXH$B0+-(+^C7P
M#A4!]@W(\IP,/]1>Q9^WUMO6?#.($O42CD_P#?D)F^XZ%#H:_O,;,TFMZ]._
MCDJNU70^.WG@;.KQMYY?PYL[</QSX=Q:W^':SW/5ZL]4L?Y^F/+=%]?F9VY+
M^*;&=8[+\\,/EJ_#N;<,S"7$K/J ?^=_/78/\PQV'X]?Q]O\^LB@'Q0Q1N#3
M]$^6G,R,[BJU5*-B;A!7J=L4'_%Q L6A*&IQ&P .I^XF[; 'IVU$!$1SMXZ+
MY1:[A'?)/RR;A-/^(:+LXD/^NQ.H;@47J&[X@W+-U]8>LW4SX1H /J3!L.NV
MC\[VH./5TF:1_//L]@Q$S?\ 1[98_GY;YX?^+QX;N/T^Z-6.[V7X@*59F=NW
M\_Z9;Q1<FY9G[FP<6SL+M]3\,1L[/'P_)2>E*]ZM1^6VH_S#'8#\A ?YY%"?
MPOYZ->J@8UY+IHKV//U "Y344:7 6D+ WT;:' [+!T5=[: ;\ D@D[WWV#O0
MO4,F41Y7VSZP+/S=IQ^'O0E-K)J0:T "GUV]U.^[<P.'P5@Z]>LOTK"C![#X
MV@][B_4V6#CU]&V@/GEX)]7M,W'+\_U6Q][L[,WP#OR_''CE/Z)-)L<OCOQ%
M='IFX%V'(8[K%B)'=_39V?W?2EX!<2,N7>QV]H=W/GQ*]C(GS8OYBF0%!J:R
MN',R L"B""%4:ES*:H#U%ANN_P!0THRR#@ -Q,(,4;D[ .WP2]=ATUT_.OG'
MF/9$2_0BE^($T6IVW<I!NW3.3LNR]T%.'U=5MJY2% 5J7HJ](JTAH(2M] -
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M6! 1_B+8-0%O/'+OMN$;CG^?/#K>GX=9(XNI-F67AHXNF/7*4G<7+M:/HIU
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M"BJQPW5Q5:BG364V*W/1J>-U21QT6LJ(LM*:J[__ %/_ $L;]Z3Q0?T-9?\
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M#Q_>PY1_K"Y"\O;65<SZ[I&&<CG:P[,@[R]SU^X^V4%CUO8R->GJU"1!W]H
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M(@8V=WH2 K](_(FB2E*MM'@A2KW)<"M$7X+4\83#/YT\6E"N7G,?CU95E5?
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9PB8QC")C&,(F,8PB8QC")C&,(F,8PB__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
